These	O
findings	O
also	O
provide	O
preliminary	O
support	O
for	O
the	O
use	O
of	O
oxytocin	B-I
in	O
the	O
treatment	O
of	O
autism	O
.	O


A	O
6-month	O
retreatment	O
interval	O
was	O
established	O
for	O
this	O
study	O
with	O
a	O
follow-up	O
of	O
12	O
months	O
.	O


Naltrexone	B-I
plasma	O
levels	O
,	O
clinical	O
response	O
and	O
effect	O
on	O
weight	O
in	O
autistic	B-P
children	I-P
.	I-P


There	O
was	O
no	O
relationship	O
between	O
plasma	O
levels	O
and	O
age	O
,	O
level	O
of	O
intellectual	O
functioning	O
,	O
scores	O
on	O
the	O
14	B-P
selected	I-P
Children	I-OUT
's	I-OUT
Psychiatric	I-OUT
Rating	I-OUT
Scale	I-OUT
(	I-OUT
CPRS	I-OUT
)	I-OUT
items	I-OUT
,	I-OUT
Clinical	I-OUT
Global	I-OUT
Impressions	I-OUT
,	I-OUT
Global	I-OUT
Clinical	I-OUT
Consensus	I-OUT
,	I-OUT
and	I-OUT
the	I-OUT
CPRS	I-OUT
hyperactivity	I-OUT
factor	I-OUT
.	I-OUT


Incidence	O
and	O
clinical	O
significance	O
of	O
false-negative	B-P
sextant	I-P
prostate	I-P
biopsies	I-P
.	I-P


Except	O
for	O
initial	O
clinical	O
stage	O
,	O
no	O
differences	O
were	O
noted	O
in	O
the	O
clinical	B-OUT
or	I-OUT
pathological	I-OUT
parameters	I-OUT
,	O
or	O
prostate	B-OUT
specific	I-OUT
antigen	I-OUT
relapse	I-OUT
rates	I-OUT
in	O
patients	O
with	O
negative	O
versus	O
positive	O
repeat	O
biopsies	O
.	O


BACKGROUND	O
Barriers	O
to	O
timely	O
resolution	O
of	O
abnormal	O
cancer	O
screening	O
tests	O
add	O
to	O
cancer	O
health	O
disparities	O
among	O
low-income	B-P
,	I-P
uninsured	I-P
,	I-P
and	I-P
minority	I-P
populations	I-P
.	I-P


RESULTS	O
Time	B-OUT
to	I-OUT
resolution	I-OUT
was	O
significantly	O
shorter	O
in	O
the	O
navigated	O
group	O
(	O
stratified	O
log	O
rank	O
test	O
,	O
P	O
<	O
0.001	O
)	O
.	O


Patients	O
without	O
CR	O
received	O
single-agent	O
crossover	O
therapy	O
at	O
induction	O
doses/schedules	O
until	O
CR	B-OUT
,	I-OUT
disease	I-OUT
progression	I-OUT
(	I-OUT
PD	I-OUT
)	I-OUT
,	I-OUT
or	I-OUT
unacceptable	I-OUT
toxicity	I-OUT
.	I-OUT


Controlling	O
for	O
patient	O
characteristics	O
including	O
performance	O
status	O
,	O
residual	O
tumor	O
size	O
,	O
and	O
tumor	O
stage	O
,	O
there	O
was	O
no	O
statistical	O
difference	O
in	O
a	O
multivariate	O
analysis	O
(	O
HR=1.22	O
;	O
95	O
%	O
CI=0.99-1.52	O
;	O
P=.067	O
)	O
.	O


CONCLUSIONS	B-I
GC	I-I
does	O
not	O
improve	B-OUT
PFS	I-OUT
over	I-I
TC	I-I
as	O
first-line	O
induction	O
chemotherapy	O
in	O
OC	O
.	O


Although	O
favoring	O
TC	B-OUT
,	I-OUT
overall	I-OUT
survival	I-OUT
analyses	O
were	O
limited	O
by	O
the	O
study	O
design	O
and	O
high	O
censoring	O
rates	O
.	O


Graphical	B-OUT
plots	I-OUT
revealed	O
trends	O
towards	O
higher	O
Escort	B-OUT
values	I-OUT
as	O
mean	O
values	O
rose	O
compared	O
with	O
both	O
mini-Wright	B-I
and	O
turbine	B-I
readings	O
for	O
peak	B-OUT
expiratory	I-OUT
flow	I-OUT
rate	I-OUT
and	I-OUT
forced	I-OUT
expiratory	I-OUT
volume	I-OUT
in	I-OUT
one	I-OUT
second	I-OUT
.	I-OUT


Once-daily	O
versus	O
twice-daily	O
intravenous	O
administration	O
of	O
vancomycin	B-I
for	O
infections	B-P
in	I-P
hospitalized	I-P
patients	I-P
.	I-P


The	O
efficacy	O
and	O
toxicity	O
of	O
once-daily	O
(	O
od	O
)	O
versus	O
twice-daily	O
(	O
bd	O
)	O
dosing	O
of	O
vancomycin	B-I
was	O
compared	O
in	O
121	B-P
hospitalized	I-P
patients	I-P
.	I-P


Red	B-OUT
man	I-OUT
syndrome	I-OUT
occurred	O
in	O
7/51	O
(	O
13.7	O
%	O
)	O
and	O
5/52	O
(	O
9.6	O
%	O
)	O
in	O
od	O
and	O
bd	O
groups	O
,	O
respectively	O
.	O


A	O
systems	O
analysis	O
of	O
obstetric	O
triage	O
.	O


RESULTS	O
Results	O
showed	O
that	O
using	O
a	O
triage	O
room	O
and/or	O
standing	O
orders	O
did	O
not	O
significantly	O
decrease	O
length	B-OUT
of	I-OUT
stay	I-OUT
.	I-OUT


The	O
effects	O
of	O
atropine	B-I
and	I-I
metoclopramide	I-I
on	O
the	O
lower	B-OUT
oesophageal	I-OUT
sphincter	I-OUT
pressure	I-OUT
(	I-OUT
LOSP	I-OUT
)	I-OUT
were	O
studied	O
in	O
12	B-P
healthy	I-P
volunteers	I-P
using	I-P
oesophageal	I-P
pressure	I-P
transducers	I-P
.	I-P


injection	O
(	O
P	O
less	O
than	O
0.005	O
)	O
and	O
this	O
change	O
was	O
sustained	O
for	O
60	O
min	O
.	O


OBJECTIVE	O
To	O
examine	O
the	O
predictive	O
validity	O
of	O
symptom	B-OUT
severity	I-OUT
,	I-OUT
cognitive	I-OUT
and	I-OUT
language	I-OUT
measures	I-OUT
taken	O
at	O
ages	O
2	O
and	O
3	O
years	O
to	O
outcome	O
at	O
age	O
7	O
in	O
a	O
sample	B-P
of	I-P
children	I-P
diagnosed	I-P
with	I-P
autism	I-P
at	I-P
age	I-P
2	I-P
.	I-P


CONCLUSIONS	O
The	O
trajectory	O
of	O
autism	O
symptoms	O
over	O
time	O
differed	O
in	O
different	O
domains	O
,	O
suggesting	O
that	O
they	O
may	O
be	O
,	O
at	O
least	O
in	O
part	O
,	O
separable	O
.	O


At	O
this	O
age	O
measures	O
of	O
rate	O
of	O
non-verbal	O
communication	O
might	O
be	O
more	O
informative	O
than	O
scores	O
on	O
standard	O
psychometric	O
tests	O
.	O


When	O
compared	O
with	O
placebo+TRT	B-I
,	O
the	O
TENS+TRT	B-I
group	O
produced	O
earlier	O
and	O
greater	O
reduction	O
of	O
plantarflexor	B-OUT
spasticity	I-OUT
and	O
improvement	B-OUT
in	I-OUT
ankle	I-OUT
dorsiflexion	I-OUT
torque	I-OUT
at	O
week	O
2	O
(	O
P	O
<	O
0.01	O
)	O
.	O


When	O
compared	O
with	O
all	O
3	O
groups	O
,	O
the	O
TENS+TRT	B-I
group	O
showed	O
significantly	O
greater	O
improvement	O
in	O
gait	B-OUT
velocity	I-OUT
(	O
P	O
<	O
0.01	O
)	O
.	O


Risedronate	O
5	O
mg	O
provides	O
effective	O
and	O
well-tolerated	O
therapy	O
for	O
severe	B-P
postmenopausal	I-P
osteoporosis	I-P
,	O
reducing	O
the	O
incidence	O
of	O
vertebral	O
fractures	O
and	O
improving	O
bone	O
density	O
in	O
women	B-P
with	I-P
established	I-P
disease	I-P
.	I-P


Evidence-based	O
use	O
of	O
this	O
drug	O
is	O
increasingly	O
important	O
as	O
trimethoprim-sulfamethoxazole	B-I
resistance	O
among	O
uropathogens	O
increases	O
.	O


Clinical	B-OUT
and	I-OUT
microbiological	I-OUT
cure	I-OUT
rates	I-OUT
at	O
the	O
first	O
follow-up	O
visit	O
were	O
also	O
equivalent	O
between	O
the	O
2	O
groups	O
.	O


In	O
the	O
trimethoprim-sulfamethoxazole	B-I
arm	O
,	O
7	O
of	O
17	O
women	O
(	O
41	O
%	O
)	O
with	O
a	O
trimethoprim-sulfamethoxazole-nonsusceptible	O
isolate	O
had	O
a	O
clinical	B-OUT
cure	I-OUT
compared	O
with	O
84	O
%	O
of	O
women	O
with	O
a	O
trimethoprim-sulfamethoxazole-susceptible	O
isolate	O
(	O
P	O
<	O
.001	O
)	O
.	O


PATIENTS	O
AND	O
METHODS	O
Patients	O
were	O
randomized	O
to	O
21-day	O
cycles	O
of	O
oral	O
capecitabine	B-I
1,250	O
mg/m	O
(	O
2	O
)	O
twice	O
daily	O
on	O
days	O
1	O
to	O
14	O
plus	O
docetaxel	B-I
75	O
mg/m	O
(	O
2	O
)	O
on	O
day	O
1	O
(	O
n	O
=	O
255	O
)	O
or	O
to	O
docetaxel	B-I
100	O
mg/m	O
(	O
2	O
)	O
on	O
day	O
1	O
(	O
n	O
=	O
256	O
)	O
.	O


BACKGROUND	O
In	O
the	O
present	O
study	O
,	O
Interceptor®	B-I
,	I-I
long-lasting	I-I
polyester	I-I
net	I-I
,	I-I
75	I-I
denier	I-I
and	I-I
bursting	I-I
strength	I-I
of	I-I
minimum	I-I
250	I-I
kPa	I-I
coated	I-I
with	I-I
alpha-cypermethrin	I-I
@	I-I
200	I-I
mg/m²	I-I
was	O
evaluated	O
for	O
its	O
efficacy	O
in	O
reducing	O
the	O
mosquito	O
density	O
,	O
blood	O
feeding	O
inhibition	O
and	B-OUT
malaria	I-OUT
incidence	I-P
in	I-P
a	I-P
tribal	I-P
dominated	I-P
malaria	I-P
endemic	I-P
area	I-P
in	I-P
Chhattisgarh	I-P
state	I-P
,	I-P
central	I-P
India	I-P
.	O


METHODS	O
The	O
study	O
was	O
carried	O
out	O
in	O
two	O
phases	O
.	O


RESULTS	B-I
Interceptor	I-I
nets	I-I
were	O
found	B-OUT
effective	I-OUT
in	O
reducing	O
the	B-OUT
density	I-OUT
,	I-OUT
parity	I-OUT
rate	I-OUT
and	I-OUT
blood	I-OUT
feeding	I-OUT
success	I-OUT
rate	I-OUT
of	I-OUT
main	I-OUT
malaria	I-OUT
vector	I-OUT
Anopheles	I-OUT
culicifacies	I-OUT
as	O
compared	O
to	O
that	O
in	B-I
untreated	I-I
net	I-I
and	I-I
no	I-I
net	I-I
villages	I-OUT
.	I-OUT


The	O
nets	O
were	O
found	O
to	O
contain	B-OUT
an	I-OUT
effective	I-OUT
concentration	O
of	O
alpha-cypermethrin	O
against	O
malaria	O
vector	O
after	O
three	O
years	O
of	O
household	O
use	O
.	O


This	O
article	O
presents	O
a	O
randomized	O
controlled	O
study	O
evaluating	O
the	O
effect	O
of	O
a	O
5-month	O
intervention	O
directed	O
toward	O
improving	O
sensory	B-OUT
impairment	I-OUT
,	I-OUT
digestion	I-OUT
,	I-OUT
and	I-OUT
sleep	I-OUT
in	O
46	B-P
children	I-P
with	I-P
autism	I-P
<	I-P
age	I-P
6	I-P
.	I-P


The	O
primary	O
outcome	O
measure	O
was	O
total	B-OUT
operating	I-OUT
time	I-OUT
.	I-OUT


Secondary	O
outcomes	O
were	O
bladder	B-OUT
injury	I-OUT
,	I-OUT
incision-to-delivery	I-OUT
time	I-OUT
,	I-OUT
incision-to-fascial	I-OUT
closure	I-OUT
time	I-OUT
,	I-OUT
estimated	I-OUT
blood	I-OUT
loss	I-OUT
,	I-OUT
postoperative	I-OUT
microhematuria	I-OUT
,	I-OUT
postoperative	I-OUT
pain	I-OUT
,	I-OUT
hospital	I-OUT
days	I-OUT
,	I-OUT
endometritis	I-OUT
,	I-OUT
and	I-OUT
urinary	I-OUT
tract	I-OUT
infection	I-OUT
.	I-OUT


LEVEL	O
OF	O
EVIDENCE	O
I	O
.	O


Significantly	O
higher	O
geometric	B-OUT
mean	I-OUT
titers	I-OUT
against	I-OUT
types	I-OUT
2	I-OUT
and	I-OUT
3	I-OUT
were	O
noted	O
at	O
20	O
months	O
of	O
age	O
for	O
the	O
IPV	B-I
group	O
.	O


Effect	O
of	O
practice	O
on	O
laterality	O
in	O
a	O
mental	B-I
rotation	I-I
task	I-I
.	I-I


BACKGROUND	O
Subclinical	B-OUT
brain	I-OUT
infarct	I-OUT
(	I-OUT
SBI	I-OUT
)	I-OUT
is	O
associated	O
with	O
subsequent	O
stroke	O
and	O
cognitive	O
decline	O
.	O


A	O
total	B-P
of	I-P
227	I-P
subjects	I-P
were	O
randomized	O
to	O
either	O
placebo	B-I
(	O
n	O
=	O
114	O
)	O
or	O
simvastatin	B-I
20	O
mg	O
daily	O
(	O
n	O
=	O
113	O
)	O
.	O


This	O
study	O
assessed	O
invasively	O
the	O
hemodynamics	O
during	O
supine	O
rest	O
and	O
exercise	O
before	O
and	O
after	O
4	O
weeks	O
treatment	O
with	O
30	B-I
mg	I-I
isosorbide	I-I
dinitrate	I-I
(	I-I
ISDN	I-I
)	I-I
or	I-I
placebo	I-I
asymmetrically	O
b.i.d	O
.	O


Dietary	B-I
sulforaphane	I-I
,	O
of	O
recognized	O
low	O
toxicity	O
,	O
was	O
selected	O
for	O
its	O
capacity	O
to	O
reverse	O
abnormalities	O
that	O
have	O
been	O
associated	O
with	O
ASD	O
,	O
including	B-OUT
oxidative	I-OUT
stress	I-OUT
and	I-OUT
lower	I-OUT
antioxidant	I-OUT
capacity	I-OUT
,	I-OUT
depressed	I-OUT
glutathione	I-OUT
synthesis	I-OUT
,	I-OUT
reduced	I-OUT
mitochondrial	I-OUT
function	I-OUT
and	I-OUT
oxidative	I-OUT
phosphorylation	I-OUT
,	I-OUT
increased	I-OUT
lipid	I-OUT
peroxidation	I-OUT
,	I-OUT
and	I-OUT
neuroinflammmation	I-OUT
.	O


One	O
important	O
executive	O
function	O
known	O
to	O
be	O
compromised	O
in	O
autism	B-P
spectrum	I-P
disorder	I-P
(	O
ASD	O
)	O
is	O
related	O
to	O
response	B-OUT
error	I-OUT
monitoring	I-OUT
and	I-OUT
post-error	I-OUT
response	I-OUT
correction	I-OUT
.	I-OUT


Error	O
sensitivity	O
can	O
be	O
readily	O
examined	O
by	O
measuring	O
event-related	B-OUT
potentials	I-OUT
(	I-OUT
ERP	I-OUT
)	I-OUT
associated	O
with	O
responses	O
to	O
errors	O
,	O
the	O
fronto-central	B-OUT
error-related	I-OUT
negativity	I-OUT
(	I-OUT
ERN	I-OUT
)	I-OUT
,	I-OUT
and	I-OUT
the	I-OUT
error-related	I-OUT
positivity	I-OUT
(	I-OUT
Pe	I-OUT
)	I-OUT
.	I-OUT


A	O
prospective	O
,	O
randomized	O
,	O
double-blind	O
study	O
.	O


An	O
experimental	O
model	O
of	O
HPAT	O
axis	O
inhibited	O
by	O
corticosterone	O
(	O
CORT	O
)	O
was	O
established	O
to	O
observe	O
the	O
effect	O
of	O
EB	O
on	O
relevant	O
indices	O
of	O
HPAT	O
axis	O
.	O


CONCLUSION	O
EB	O
could	O
relieve	O
neuroendocrino-immunological	B-OUT
effect	I-OUT
inhibited	O
by	O
exogenous	O
glucocorticoid	O
.	O


Disorder-dissociated	O
effects	O
of	O
fluoxetine	B-I
on	O
brain	O
function	O
of	O
working	O
memory	O
in	O
attention	B-P
deficit	I-P
hyperactivity	I-P
disorder	I-P
and	I-P
autism	I-P
spectrum	I-P
disorder	I-P
.	I-P


CONCLUSIONS	O
The	O
findings	O
show	O
that	O
fluoxetine	O
modulates	O
brain	O
activation	O
during	O
WM	O
in	O
a	O
disorder-specific	O
manner	O
by	O
normalizing	O
task-positive	O
DLPFC	O
dysfunction	B-P
in	I-P
ASD	I-P
boys	O
and	O
enhancing	O
task-negative	O
default	O
mode	O
network	O
(	O
DMN	O
)	O
deactivation	O
in	O
ADHD	O
.	O


Treatment	O
of	O
beta-hemolytic	B-P
streptococcal	I-P
pharyngitis	I-P
with	O
cefaclor	B-I
or	I-I
penicillin	I-I
.	I-I


A	O
study	O
was	O
undertaken	O
to	O
compare	O
the	O
efficacy	O
of	O
cefaclor	B-I
,	O
which	O
is	O
relatively	O
resistant	O
to	O
inactivation	O
by	O
beta-lactamase	O
,	O
with	O
penicillin	O
for	O
eradicating	O
the	O
group	B-P
A	I-P
beta-hemolytic	I-P
streptococcal	I-P
organism	I-P
from	I-P
the	I-P
throats	I-P
of	I-P
93	I-P
patients	I-P
with	I-P
pharyngitis	I-P
.	I-P


This	O
study	O
was	O
carried	O
out	O
to	O
evaluate	O
the	O
effects	B-OUT
of	O
perioperative	O
indomethacin	O
on	B-OUT
intracranial	I-OUT
pressure	I-OUT
(	I-OUT
ICP	I-OUT
)	I-OUT
,	I-OUT
cerebral	I-OUT
blood	I-OUT
flow	I-OUT
(	I-OUT
CBF	I-OUT
)	I-OUT
,	I-OUT
and	I-OUT
cerebral	I-OUT
metabolism	I-OUT
.	I-OUT


Twenty	B-P
patients	I-P
subjected	I-P
to	I-P
craniotomy	I-P
for	I-P
supratentorial	I-P
cerebral	I-P
tumors	I-P
were	O
anesthetized	B-I
with	I-I
thiopental	I-I
,	I-I
fentanyl	I-I
,	I-I
nitrous	I-I
oxide	I-I
,	I-I
and	I-I
isoflurane	I-I
.	I-I


A	O
significant	O
decrease	O
in	O
ICP	B-OUT
from	O
6.5	O
to	O
1.5	O
mm	O
Hg	O
(	O
median	O
)	O
was	O
found	O
after	O
indomethacin	O
administration	O
.	O


We	O
aimed	O
to	O
determine	O
the	O
benefits	O
of	O
regular	B-I
replacement	I-I
of	O
extended	B-I
wear	I-I
RGP	I-I
contact	I-I
lenses	I-I
.	I-I


Hypothermia	O
is	O
a	O
common	O
problem	O
for	O
surgical	B-P
patients	I-P
and	O
can	O
result	O
in	O
many	O
complications	O
.	O


Because	O
few	O
studies	O
compare	O
methods	O
of	O
passive	O
warming	O
,	O
we	O
used	O
an	O
unblinded	O
,	O
prospective	O
,	O
experimental	O
,	O
randomized	O
design	O
to	O
compare	O
the	O
effectiveness	B-OUT
of	O
two	O
passive	O
methods	O
of	O
normothermia	O
management	O
in	O
the	O
postanesthesia	O
care	O
unit	O
(	O
PACU	O
)	O
.	O


We	O
assigned	O
a	O
total	O
of	O
578	B-P
adult	I-P
ambulatory	I-P
surgery	I-P
patients	I-P
to	O
either	O
a	O
control	B-I
group	I-I
that	O
was	O
given	O
two	B-I
folded	I-I
,	I-I
warmed	I-I
cotton	I-I
blankets	I-I
or	I-I
a	I-I
treatment	I-I
group	I-I
that	I-I
was	I-I
given	I-I
a	I-I
warmed	I-I
,	I-I
unfolded	I-I
cotton	I-I
sheet	I-I
and	I-I
cotton	I-I
blanket	I-I
.	I-I


The	O
latter	O
finding	O
is	O
notable	O
as	O
it	O
can	O
be	O
misinterpreted	O
as	O
pain	B-OUT
when	O
methadone	B-I
is	O
used	O
as	O
an	O
analgesic	O
.	O


PURPOSE	O
To	O
determine	O
the	O
effectiveness	O
of	O
the	O
Alleviating	B-I
Depression	I-I
Among	I-I
Patients	I-I
With	I-I
Cancer	I-I
(	I-I
ADAPt-C	I-I
)	I-I
collaborative	I-I
care	I-I
management	I-I
for	O
major	O
depression	O
or	O
dysthymia	O
.	O


PATIENTS	O
AND	O
METHODS	O
Study	B-P
patients	I-P
included	I-P
472	I-P
low-income	I-P
,	I-P
predominantly	I-P
female	I-P
Hispanic	I-P
patients	I-P
with	I-P
cancer	I-P
age	I-P
>	I-P
or=	I-P
18	I-P
years	I-P
with	I-P
major	I-OUT
depression	I-OUT
(	I-P
49	I-P
%	I-P
)	I-P
,	I-P
dysthymia	I-OUT
(	I-P
5	I-P
%	I-P
)	I-P
,	I-P
or	I-P
both	I-P
(	I-P
46	I-P
%	I-P
)	I-P
.	I-P


Increased	O
atrial	O
electromechanical	O
coupling	O
time	O
interval	O
measured	O
by	O
tissue	O
Doppler	O
is	O
accepted	O
as	O
an	O
important	O
factor	O
for	O
prediction	O
of	O
AF	B-OUT
development	I-OUT
in	O
hypertensive	B-P
patients	I-P
.	I-P


RESULTS	B-OUT
Baseline	I-OUT
blood	I-OUT
pressures	I-OUT
,	I-OUT
electrocardiographic	I-OUT
and	I-OUT
echocardiographic	I-OUT
findings	I-OUT
,	I-OUT
and	I-OUT
atrial	I-OUT
electromechanical	I-OUT
coupling	I-OUT
were	O
similar	O
in	O
both	O
groups	O
(	O
p	O
>	O
0.05	O
)	O
.	O


The	O
lowest	O
SaO2	B-OUT
after	O
resuming	O
ventilation	O
and	O
the	O
time	O
from	O
that	O
nadir	O
to	O
an	O
SaO2	O
of	O
97	O
%	O
were	O
also	O
recorded	O
.	O


The	O
SaO2	B-OUT
of	O
patients	O
in	O
the	O
reverse	O
Trendelenburg	O
position	B-OUT
dropped	O
the	O
least	O
and	O
took	O
the	O
shortest	O
time	B-OUT
to	I-OUT
recover	I-OUT
to	O
97	O
%	O
.	O


Silent	O
ischemia	O
is	O
associated	O
with	O
a	O
worse	O
prognosis	O
in	O
patients	O
with	O
stable	O
or	O
unstable	O
angina	O
,	O
survivors	O
of	O
myocardial	O
infarction	O
,	O
and	O
populations	O
at	O
risk	O
for	O
coronary	O
disease	O
.	O


Flutamide-metformin	O
plus	O
ethinylestradiol-drospirenone	O
for	O
lipolysis	B-OUT
and	I-OUT
antiatherogenesis	I-OUT
in	O
young	B-P
women	I-P
with	I-P
ovarian	I-P
hyperandrogenism	I-P
:	I-P
the	O
key	O
role	O
of	O
early	O
,	O
low-dose	O
flutamide	O
.	O


We	O
examined	O
effects	O
of	O
BLT	B-I
on	O
motor	B-OUT
symptoms	I-OUT
,	I-OUT
depression	I-OUT
,	O
and	O
sleep	B-OUT
in	O
PD	O
in	O
a	O
randomized	O
placebo-controlled	B-I
double-blind	O
study	O
in	O
36	B-P
PD	I-P
patients	I-P
,	I-P
using	I-P
Parkinson	I-OUT
's	I-OUT
Disease	I-OUT
Rating	I-OUT
Scale	I-OUT
(	I-OUT
UPDRS	I-OUT
)	I-OUT
I-IV	I-OUT
,	I-OUT
Beck	I-OUT
's	I-OUT
Depression	I-OUT
Inventory	I-OUT
,	I-P
and	I-P
Epworth	I-OUT
Sleepiness	I-OUT
Scale	I-OUT
.	I-OUT


All	O
patients	O
received	O
BLT	B-I
for	O
15	O
days	O
in	O
the	O
morning	O
,	O
30	O
min	O
daily	O
.	O


METHOD	O
In	O
a	O
multisite	O
,	O
randomized	O
clinical	O
trial	O
,	O
extended-release	O
guanfacine	B-I
was	O
compared	O
with	O
placebo	B-I
in	O
children	B-P
with	I-P
ASD	I-P
accompanied	O
by	O
hyperactivity	O
,	O
impulsiveness	O
,	O
and	O
distractibility	O
.	O


A	O
brief	O
cognitive	B-OUT
battery	I-OUT
tapping	I-OUT
working	I-OUT
memory	I-OUT
and	I-OUT
motor	I-OUT
planning	I-OUT
showed	O
no	O
group	O
differences	O
before	O
or	O
after	O
8	O
weeks	O
of	O
treatment	O
.	O


CONCLUSIONS	O
Extended-release	O
guanfacine	O
appears	O
to	O
be	O
safe	O
and	O
effective	O
for	O
reducing	O
hyperactivity	B-OUT
,	I-OUT
impulsiveness	I-OUT
,	I-OUT
and	I-OUT
distractibility	I-OUT
in	O
children	B-P
with	I-P
ASD	I-P
.	I-P


No	O
subjects	O
developed	O
systemic	B-OUT
reactions	I-OUT
.	I-OUT


SETTING	O
Third-level	B-P
referral	I-P
academic	I-P
centers	I-P
,	O
including	O
reproductive	O
biology	O
and	O
genetics	O
laboratories	O
.	O


Retrieved	O
immature	O
oocyte	O
cumulus	O
complexes	O
were	O
cultured	O
for	O
30	O
or	O
36	O
hours	O
in	O
one	O
of	O
six	O
IVM	B-I
culture	I-I
conditions	I-I
containing	I-I
FF-MAS	I-I
(	O
range	O
,	O
0.1-20	O
microM	O
)	O
.	O


A	O
secondary	O
objective	O
was	O
to	O
document	O
the	O
frequency	B-OUT
of	I-OUT
metaphase	I-OUT
II	I-OUT
oocytes	I-OUT
after	O
IVM	O
with	O
FF-MAS	O
supplements	O
.	O


Classification	O
of	O
motor	B-OUT
imagery	I-OUT
performance	I-OUT
in	O
acute	B-P
stroke	I-P
.	I-P


AU-ROC	B-OUT
rose	O
to	O
0.90	O
,	O
but	O
no	B-OUT
virtual	I-OUT
'most	I-OUT
responsible	I-OUT
'	I-OUT
electrode	I-OUT
was	O
observed	O
.	O


SIGNIFICANCE	O
Including	O
only	O
the	O
channels	O
on	O
the	O
unaffected	O
motor	O
cortex	O
is	O
sufficient	O
to	O
train	O
a	O
classifier	O
.	O


As	O
a	O
corollary	O
,	O
the	B-OUT
greater	I-OUT
stem	I-OUT
cell	I-OUT
collection	I-OUT
in	I-I
plerixafor-treated	I-I
patients	O
resulted	O
in	O
the	O
need	O
for	O
significantly	O
fewer	O
days	O
of	O
apheresis	O
to	O
reach	O
minimum	O
and	O
optimum	O
cell	O
doses	O
across	O
all	O
cell	O
count	O
groups	O
.	O


For	O
all	O
CD34	O
(	O
+	O
)	O
cell	O
count	O
groups	B-OUT
,	I-OUT
the	I-OUT
proportion	I-OUT
of	I-OUT
patients	I-OUT
proceeding	I-OUT
to	I-OUT
transplantation	I-OUT
and	I-OUT
the	I-OUT
median	I-OUT
time	I-OUT
to	I-OUT
platelet	I-OUT
and	I-OUT
neutrophil	I-OUT
engraftment	I-OUT
were	O
similar	B-I
in	I-I
the	I-I
plerixafor	I-I
and	I-I
placebo	O
groups	O
.	O


Feasibility	B-OUT
and	I-OUT
effects	I-OUT
of	O
nurse	B-I
run	I-I
clinics	I-I
for	I-P
patients	I-P
with	I-P
epilepsy	I-P
in	I-P
general	I-P
practice	I-P
:	I-P
randomised	O
controlled	O
trial	O
.	O


SUBJECTS	O
251	B-P
patients	I-P
aged	I-P
over	I-P
15	I-P
years	I-P
who	I-P
were	I-P
taking	I-P
anti-epileptic	I-P
drugs	I-P
or	I-P
had	I-P
a	I-P
diagnosis	I-P
of	I-P
epilepsy	I-P
and	I-P
an	I-P
attack	I-P
in	I-P
the	I-P
past	I-P
two	I-P
years	I-P
who	I-P
met	I-P
specified	I-P
inclusion	I-P
criteria	I-P
and	I-P
had	I-P
responded	I-P
to	I-P
a	I-P
questionnaire	I-P
.	I-P


No	O
patients	O
in	O
the	O
"	O
no-closure	O
"	O
group	O
required	O
surgical	O
procedures	O
such	O
as	O
needle	O
aspiration	O
or	O
cyst	O
drainage	O
.	O


BACKGROUND	O
The	O
Western	O
Ontario	O
and	O
McMaster	O
Universities	O
(	O
WOMAC	O
)	O
Osteoarthritis	O
Index	O
is	O
a	O
previously	O
described	O
self-administered	O
questionnaire	O
covering	O
three	O
domains	O
:	O
pain	B-OUT
,	I-OUT
stiffness	I-OUT
and	I-OUT
function	I-OUT
.	I-OUT


DESIGN	O
Prospective	O
,	O
randomized	O
,	O
open-label	O
study	O
.	O


In	O
Group	O
Spinal	O
(	O
S	O
)	O
,	O
10	O
mg	O
of	O
hyperbaric	B-I
tetracaine	I-I
was	O
administered	O
intrathecally	O
.	O


Thereafter	O
,	O
a	O
laryngeal	O
mask	O
airway	O
was	O
inserted	O
and	O
,	O
with	O
spontaneous	O
ventilation	O
,	O
anesthesia	B-I
was	O
maintained	O
by	O
administering	O
isoflurane	B-I
(	O
end-tidal	O
0.7	O
%	O
to	O
1.2	O
%	O
)	O
and	O
70	O
%	O
nitrous	B-I
oxide	I-I
(	I-I
N2O	I-I
)	I-I
in	I-I
oxygen	I-I
.	I-I


MEASUREMENTS	O
AND	O
MAIN	O
RESULTS	O
The	O
two	O
groups	O
were	O
demographically	O
comparable	O
.	O


RA	B-P
patients	I-P
of	I-P
Shen	I-P
deficiency	I-P
and	I-P
cold	I-P
invading	I-P
syndrome	I-P
in	I-P
the	I-P
treatment	I-P
group	I-P
(	I-P
120	I-P
cases	I-P
)	I-P
were	I-P
treated	I-P
with	I-P
BQZD	I-I
and	I-I
MTX	I-I
(	I-I
10	I-I
mg/week	I-I
)	I-I
,	O
while	O
those	O
in	O
the	O
control	B-P
group	I-P
(	I-P
120	I-P
cases	I-P
)	I-P
were	I-P
treated	I-I
with	I-I
MTX	I-I
(	I-I
10	I-I
mg/week	I-I
)	I-I
alone	I-I
.	I-I


RESULTS	O
The	O
total	O
effective	O
rate	O
was	O
80	O
.	O


Hypertension	O
might	O
modify	O
the	O
association	O
between	O
NC	O
and	O
cfPWV	O
.	O


A	O
randomized	O
controlled	O
trial	O
of	O
Hanen	B-I
's	I-I
'More	I-I
Than	I-I
Words	I-I
'	I-I
in	O
toddlers	B-P
with	I-P
early	I-P
autism	I-P
symptoms	I-P
.	I-P


BACKGROUND	O
This	O
randomized	O
controlled	O
trial	O
compared	O
Hanen	B-I
's	I-I
'More	I-I
than	I-I
Words	I-I
'	I-I
(	I-I
HMTW	I-I
)	I-I
,	I-I
a	I-I
parent-implemented	I-I
intervention	I-I
,	O
to	O
a	O
'business	B-I
as	I-I
usual	I-I
'	I-I
control	I-I
group	O
.	O


Children	B-OUT
's	I-OUT
object	I-OUT
interest	I-OUT
,	I-OUT
a	I-OUT
putative	I-OUT
moderator	I-OUT
,	I-I
was	I-I
measured	I-I
at	I-I
Time	I-I
1	I-I
.	I-I


HMTW	B-I
facilitated	I-OUT
communication	I-OUT
in	O
children	O
with	O
lower	O
levels	O
of	O
Time	O
1	O
object	O
interest	O
.	B-P


They	O
were	O
randomly	O
divided	O
into	O
two	O
groups	O
:	O
controls	B-I
(	O
group	O
1	O
)	O
versus	B-I
strict	I-I
sodium	I-I
diet	I-I
(	O
group	O
2	O
;	O
80	O
to	O
100	O
mmol	O
sodium	B-I
daily	O
)	O
.	O


BP	O
treatment	O
was	O
reevaluated	O
at	O
each	O
visit	O
throughout	O
the	O
study	O
.	O


CONCLUSION	O
Low	O
sodium	O
intake	O
in	O
combination	O
with	O
antihypertensive	O
treatment	O
appears	O
to	O
efficiently	O
control	B-OUT
BP	I-OUT
in	O
kidney	B-P
allograft	I-P
recipients	I-P
with	O
hypertension	O
.	O


TRIAL	O
REGISTRATION	O
Current	O
controlled	O
trials	O
-	O
ISRCTN45066244	O
.	O


Plasma	B-OUT
concentrations	I-OUT
of	I-OUT
RU	I-OUT
42633	I-OUT
were	O
similar	O
to	O
those	O
of	O
RU	O
486	O
but	O
concentrations	O
of	O
RU	O
42848	O
and	O
RU	O
42698	O
were	O
much	O
lower	O
.	O


There	O
were	O
no	O
incidences	O
of	O
persistent	O
elevations	O
in	O
serum	B-OUT
transaminases	I-OUT
or	I-OUT
myositis	I-OUT
.	I-OUT


METHODS	O
Twenty-one	B-P
patients	I-P
(	I-P
21	I-P
eyes	I-P
)	I-P
underwent	I-P
PACK-CXL	I-I
treatment	I-I
in	I-I
addition	I-I
to	I-I
antimicrobial	I-I
therapy	I-I
.	I-I


No	O
serious	O
complications	O
occurred	O
in	O
the	B-I
PACK-CXL	I-I
group	O
.	O


Delay	O
in	O
absorption	O
of	O
cephalexin	O
resulted	O
in	O
a	O
decrease	O
in	O
the	O
percentage	O
of	O
T	B-OUT
>	I-OUT
MIC	I-OUT
(	I-OUT
90	I-OUT
)	I-OUT
for	O
certain	O
acid-suppressive	O
regimens	O
and	O
pathogen	O
combinations	O
.	O


Delayed	O
t	B-OUT
(	I-OUT
max	I-OUT
)	I-OUT
associated	O
with	O
acid	O
suppression	O
may	O
result	O
in	O
a	O
diminished	O
T	O
>	O
MIC	O
(	O
90	O
)	O
.	O


Effect	O
of	O
nitazoxanide	B-I
on	O
morbidity	B-OUT
and	I-OUT
mortality	I-OUT
in	O
Zambian	B-P
children	I-P
with	I-P
cryptosporidiosis	I-P
:	I-P
a	O
randomised	O
controlled	O
trial	O
.	O


Secondary	O
endpoints	O
included	O
parasitological	B-OUT
response	I-OUT
by	I-OUT
day	I-OUT
10	I-OUT
and	I-OUT
mortality	I-OUT
at	I-OUT
day	I-OUT
8	I-OUT
.	I-OUT


HIV-seropositive	O
children	O
did	O
not	O
benefit	O
from	O
nitazoxanide	O
.	O


Results	O
support	O
the	O
importance	O
of	O
assessing	O
global	B-OUT
functioning	I-OUT
in	O
addition	O
to	O
symptom	B-OUT
change	I-OUT
and	O
treatment	B-OUT
response	I-OUT
in	O
clinical	O
trials	O
.	O


Patients	O
not	O
fulfilling	O
these	O
criteria	O
should	O
have	O
primary	B-OUT
colostomy	I-OUT
.	I-OUT


Home	B-I
sleep	I-I
studies	I-I
in	O
the	O
assessment	O
of	O
sleep	B-OUT
apnea/hypopnea	I-OUT
syndrome	I-OUT
.	I-OUT


OBJECTIVE	O
To	O
determine	O
the	O
clinical	O
utility	O
of	O
a	O
limited	O
sleep-recording	O
device	O
used	O
unsupervised	O
in	O
the	O
patient	O
's	O
home	O
,	O
compared	O
with	O
in-laboratory	O
,	O
fully	O
supervised	O
polysomnography	O
for	O
the	O
diagnosis	O
of	O
sleep	B-OUT
apnea/hypopnea	I-OUT
syndrome	I-OUT
(	I-OUT
SAHS	I-OUT
)	I-OUT
,	O
and	O
to	O
assess	O
its	O
impact	O
on	O
costs	B-OUT
.	I-OUT


One	O
half	O
of	O
the	O
home	O
studies	O
were	O
randomly	O
assigned	O
to	O
be	O
performed	O
with	O
a	O
sleep	O
technician	O
's	O
set	O
up	O
of	O
the	O
equipment	O
in	O
the	O
patient	O
's	O
home	O
(	O
group	O
1	O
)	O
,	O
and	O
the	O
other	O
half	O
with	O
the	O
patient	O
's	O
own	O
setup	O
of	O
the	O
sleep-recording	O
device	O
(	O
group	O
2	O
)	O
,	O
after	O
an	O
instruction	O
period	O
in	O
the	O
hospital	O
.	O


CONCLUSIONS	O
These	O
results	O
support	O
the	O
acceptability	O
of	O
snowshoeing	O
as	O
a	O
valid	O
means	O
to	O
improve	O
or	O
maintain	O
cardiovascular	B-OUT
endurance	I-OUT
.	I-OUT


The	O
48	B-P
participants	I-P
performed	I-P
a	I-P
visually	I-I
demanding	I-I
air	I-I
traffic	I-I
control	I-I
(	I-I
ATC	I-I
)	I-I
task	I-I
.	I-I


The	O
results	O
show	O
that	O
advance	O
knowledge	O
about	O
the	O
nature	O
of	O
pending	O
tasks	O
led	O
participants	O
to	O
delay	O
visual	O
interruption	O
tasks	O
the	O
longest	O
,	O
which	O
allowed	O
them	O
to	O
avoid	O
intramodal	O
interference	O
and	O
scanning	O
costs	O
associated	O
with	O
performing	O
these	O
tasks	O
concurrently	O
with	O
ATC	O
tasks	O
.	O


Naftidrofuryl	B-I
significantly	O
improved	O
the	O
physiological	B-OUT
function	I-OUT
of	I-OUT
the	I-OUT
liver	I-OUT
cells	I-OUT
as	I-OUT
reflected	I-OUT
by	I-OUT
indocyanine	I-OUT
green	I-OUT
(	I-OUT
ICG	I-OUT
)	I-OUT
clearance	I-OUT
by	O
the	O
liver	O
(	O
t	O
=	O
2.61	O
;	O
p	O
less	O
than	O
or	O
equal	O
to	O
0.02	O
)	O
and	O
also	O
caused	O
a	O
larger	O
fall	O
in	O
raised	O
serum	B-OUT
levels	I-OUT
of	I-OUT
gamma	I-OUT
glutamyl	I-OUT
transpeptidase	I-OUT
(	I-OUT
GGT	I-OUT
)	I-OUT
than	O
did	O
the	O
placebo	B-I
injections	O
.	O


Naftidrofuryl	B-I
,	O
therefore	O
,	O
appears	O
to	O
be	O
of	O
benefit	O
in	O
ethanol-induced	B-P
liver	I-P
damage	I-P
and	O
more	O
extensive	O
long-term	O
trials	O
are	O
suggested	O
in	O
patients	B-P
with	I-P
alcoholic	I-P
liver	I-P
disease	I-P
(	I-P
ALD	I-P
)	I-P
.	I-P


Eighteen	B-P
patients	I-P
of	I-P
colorectal	I-P
cancer	I-P
with	I-P
metastases	I-P
to	I-P
the	I-P
liver	I-P
or	I-P
lung	I-P
or	I-P
of	I-P
unresectable	I-P
hepatoma	I-P
received	O
a	O
24	O
hour	O
continuous	B-I
infusion	I-I
with	I-I
low	I-I
dose	I-I
recombinant	I-I
of	I-I
IL-2	I-I
(	O
mainly	O
8	O
x	O
10	O
(	O
5	O
)	O
JRU/day	O
)	O
for	O
25-40	O
days	O
.	O


Oxygen	O
saturation	O
targets	O
in	O
infants	B-P
with	I-P
bronchiolitis	I-P
(	I-P
BIDS	I-P
)	I-P
:	I-P
a	O
double-blind	O
,	O
randomised	O
,	O
equivalence	O
trial	O
.	O


No	O
evidence	O
exists	O
to	O
support	O
this	O
threshold	O
.	O


The	O
athletes	O
were	O
randomly	O
assigned	O
to	O
2	O
groups	O
:	O
chiropractic	B-I
SMT	I-I
and	I-I
sham	I-I
.	I-I


RESULTS	O
Analysis	O
of	O
grip	B-OUT
strength	I-OUT
data	I-OUT
revealed	O
a	O
statistically	O
significant	O
increase	O
in	O
strength	B-OUT
within	O
the	O
treatment	O
group	O
after	O
the	O
first	O
intervention	O
(	O
6.95	O
%	O
right	O
,	O
12.61	O
%	O
left	O
)	O
as	O
compared	O
with	O
the	O
second	O
(	O
11.53	O
%	O
right	O
,	O
17.02	O
%	O
left	O
)	O
and	O
the	O
third	O
interventions	O
(	O
10.53	O
%	O
right	O
,	O
16.81	O
%	O
left	O
)	O
.	O


Patients	B-P
referred	I-P
for	I-P
coronary	I-P
angiography	I-P
were	O
randomized	O
to	O
very-low-dose	B-I
heparin	I-I
(	O
2,000	O
IU	O
)	O
or	O
low-dose	B-I
heparin	I-I
(	O
5,000	O
IU	O
)	O
.	O


The	O
baseline	O
and	O
procedural	O
characteristics	O
were	O
comparable	O
in	O
both	O
groups	O
.	O


A	O
comparison	O
of	O
urinary	B-OUT
and	I-OUT
sexual	I-OUT
outcomes	I-OUT
in	O
women	B-P
experiencing	I-P
vaginal	I-P
and	I-P
Caesarean	I-P
births	I-P
.	I-P


OBJECTIVE	O
To	O
compare	O
the	O
clinical	O
and	O
psychological	O
effectiveness	O
of	O
the	O
traditional	B-I
British	I-I
antenatal	I-I
visit	I-I
schedule	I-I
(	I-I
traditional	I-I
care	I-I
)	I-I
with	I-I
a	I-I
reduced	I-I
schedule	I-I
of	I-I
visits	I-I
(	I-I
new	I-I
style	I-I
care	I-I
)	I-I
for	O
low	B-P
risk	I-P
women	I-P
,	O
together	O
with	O
maternal	O
and	O
professional	O
satisfaction	O
with	O
care	O
.	O


SUBJECT	O
2794	B-P
women	I-P
at	I-P
low	I-P
risk	I-P
fulfilling	I-P
the	I-P
trial	I-P
's	I-P
inclusion	I-P
criteria	I-P
between	I-P
June	I-P
1993	I-P
and	I-P
July	I-P
1994	I-P
.	I-P


Supplementation	B-I
effect	I-OUT
with	I-I
slow-release	I-I
urea	I-I
in	O
feed	O
blocks	O
for	O
Thai	B-P
beef	I-P
cattle	I-P
--	I-P
nitrogen	I-P
utilization	I-P
,	I-P
blood	I-P
biochemistry	I-P
,	I-P
and	I-P
hematology	I-P
.	I-P


Four	B-P
Thai	I-P
male	I-P
native	I-P
beef	I-P
cattle	I-P
,	I-P
initial	I-P
body	I-P
weight	I-P
(	I-P
BW	I-P
)	I-P
of	I-P
100	I-P
±	I-P
3.0	I-P
kg	I-P
were	O
randomly	O
assigned	O
in	O
a	O
4	O
×	O
4	O
Latin	O
square	O
design	O
to	O
receive	O
four	B-I
dietary	I-I
treatments	I-I
with	I-I
inclusion	I-I
of	I-I
urea	I-I
calcium	I-I
sulphate	I-I
mixture	I-I
(	I-I
U-cas	I-I
)	I-I
in	I-I
feed	I-I
block	I-I
(	O
FB	O
)	O
at	O
0	O
,	O
120	O
,	O
150	O
,	O
and	O
180	O
g/kg	O
dry	O
matter	O
(	O
DM	O
)	O
.	O


Moreover	B-I
,	I-I
supplementation	I-I
of	I-I
U-cas	I-I
in	O
FB	O
at	O
180	O
g/kg	O
DM	O
could	O
reduce	B-OUT
total	I-OUT
N	I-OUT
excretion	I-OUT
(	O
4.1	O
g/day	O
)	O
,	O
as	O
compared	O
to	O
others	O
treatments	O
,	O
while	O
N	O
retention	O
and	O
proportion	O
of	O
N	O
retention	O
to	B-OUT
N	I-OUT
intake	I-OUT
were	O
increased	O
up	O
to	O
6.9	O
g/day	O
and	O
14.9	O
%	O
,	O
respectively	O
.	O


RESULTS	O
The	O
severity	B-OUT
of	I-OUT
negative	I-OUT
symptoms	I-OUT
at	O
the	O
time	O
of	O
assessment	O
was	O
associated	O
with	O
deficits	B-OUT
in	I-OUT
memory	I-OUT
,	I-OUT
verbal	I-OUT
fluency	I-OUT
,	I-OUT
psychomotor	I-OUT
speed	I-OUT
and	I-OUT
executive	I-OUT
function	I-OUT
.	I-OUT


Positive	B-OUT
symptoms	I-OUT
were	O
not	O
associated	O
with	O
cognitive	B-OUT
deficits	I-OUT
.	I-OUT


A	O
doubly	O
multivariate	O
analysis	O
of	O
variance	O
(	O
anova	O
)	O
procedure	O
,	O
including	O
between-group	O
and	O
within-group	O
factors	O
,	O
was	O
implemented	O
.	O


In	O
conclusion	O
,	O
our	O
results	O
show	O
that	O
nutritional	O
intervention	O
with	O
EVOO	B-I
improves	O
antioxidant	O
status	O
in	O
healthy	B-P
elderly	I-P
people	I-P
.	I-P


The	O
aim	O
of	O
the	O
present	O
study	O
was	O
to	O
examine	O
the	O
effects	O
of	O
extremely	O
early	B-I
enteral	I-I
feedings	I-I
on	O
the	O
development	O
in	O
very	B-OUT
low-birthweight	I-OUT
(	I-OUT
VLBW	I-OUT
)	I-OUT
infants	I-OUT
.	I-OUT


MAIN	O
OUTCOME	O
MEASURES	O
Biochemical	B-OUT
[	I-OUT
peak-stimulated	I-OUT
LH	I-OUT
,	I-OUT
estradiol	I-OUT
(	I-OUT
girls	I-OUT
)	I-OUT
,	I-OUT
and	I-OUT
testosterone	I-OUT
(	I-OUT
boys	I-OUT
)	I-OUT
]	I-OUT
and	I-OUT
anthropometric	I-OUT
(	I-OUT
growth	I-OUT
rate	I-OUT
,	I-OUT
bone	I-OUT
age	I-OUT
acceleration	I-OUT
,	I-OUT
pubertal	I-OUT
progression	I-OUT
)	I-OUT
parameters	I-OUT
and	O
safety	B-OUT
were	O
assessed	O
.	O


Sulfasalazine	B-I
decreases	O
acute	O
gastrointestinal	O
complications	O
due	O
to	O
pelvic	O
radiotherapy	O
.	O


Patients	O
were	O
evaluated	O
weekly	O
,	O
and	O
gastrointestinal	B-OUT
toxicities	I-OUT
were	O
graded	O
according	O
to	O
the	O
Late	B-OUT
Effect	I-OUT
of	I-OUT
Normal	I-OUT
Tissue-Subjective	I-OUT
Objective	I-OUT
Management	I-OUT
Analytic	I-OUT
(	I-OUT
LENT-SOMA	I-OUT
)	I-OUT
toxicity	I-OUT
table	I-OUT
during	O
pelvic	O
radiotherapy	O
.	O


This	O
study	O
was	O
undertaken	O
to	O
evaluate	O
the	O
effect	O
of	O
ipratropium	B-I
bromide	I-I
(	I-I
IB	I-I
)	I-I
,	O
an	O
anticholinergic	O
nasal	O
spray	O
,	O
on	O
rhinorrhea	O
in	O
these	O
patients	O
.	O


The	O
relief	B-OUT
in	I-OUT
both	I-OUT
severity	I-OUT
and	I-OUT
duration	I-OUT
of	I-OUT
rhinorrhea	I-OUT
obtained	O
by	O
patients	O
was	O
analyzed	O
using	O
the	O
Wilcoxon	B-OUT
signed-rank	I-OUT
test	I-OUT
and	O
found	O
to	O
be	O
highly	B-OUT
significant	I-OUT
(	O
p	O
<	O
0.001	O
)	O
.	O


A	O
significant	O
difference	O
in	O
the	B-OUT
Fbg	I-OUT
level	I-OUT
was	O
obtained	O
between	O
the	O
2	O
groups	O
.	O


PURPOSE	O
To	O
evaluate	O
the	O
toxicity	B-OUT
and	I-OUT
clinical	I-OUT
outcome	I-OUT
in	O
patients	B-P
with	I-P
locally	I-P
advanced	I-P
cervical	I-P
cancer	I-P
(	I-P
LACC	I-P
)	I-P
treated	O
with	O
whole	B-I
pelvic	I-I
conventional	I-I
radiation	I-I
therapy	I-I
(	O
WP-CRT	O
)	O
versus	O
intensity	B-I
modulated	I-I
radiation	I-I
therapy	I-I
(	O
WP-IMRT	O
)	O
.	O


In	O
the	O
WP-CRT	B-I
arm	O
,	O
13	O
patients	O
had	O
stage	O
IIB	O
disease	O
and	O
9	O
had	O
stage	O
IIIB	O
disease	O
;	O
in	O
the	O
IMRT	B-I
arm	O
,	O
12	O
patients	O
had	O
stage	O
IIB	O
disease	O
and	O
10	O
had	O
stage	O
IIIB	O
disease	O
.	O


GOALS	O
AND	O
BACKGROUND	O
The	O
role	O
of	O
preventive	O
lymphadenectomy	O
has	O
not	O
yet	O
been	O
determined	O
for	O
hepatocellular	B-P
carcinoma	I-P
(	I-P
HCC	I-P
)	I-P
patients	I-P
.	I-P


RESULTS	O
Forty-seven	O
patients	O
(	O
51	O
%	O
)	O
were	O
treated	O
with	O
fibrin	B-I
glue	I-I
and	O
46	O
(	O
49	O
%	O
)	O
were	O
not	O
.	O


We	O
found	O
no	B-OUT
significant	I-OUT
differences	I-OUT
between	O
patients	O
who	O
received	O
fibrin	B-OUT
glue	I-OUT
and	O
those	O
who	O
did	O
not	O
.	O


No	O
improvement	O
on	O
the	O
executive	B-OUT
function	I-OUT
tasks	I-OUT
was	O
seen	O
in	O
any	O
of	O
the	O
groups	O
.	O


Early	O
negativity	O
after	O
the	O
rare	O
non-target	O
(	O
particularly	O
on	O
the	O
right	O
side	O
)	O
was	O
negatively	O
correlated	O
with	O
the	O
HVA/DA	O
ratio	O
.	O


Small	O
changes	O
in	O
ERP	B-OUT
latency	I-OUT
and	I-OUT
distribution	I-OUT
,	O
associated	O
with	O
the	O
neuroleptic	O
action	O
of	O
fenfluramine	B-I
may	O
be	O
partly	O
responsible	O
for	O
a	O
mild	O
improvement	O
of	O
IQ	O
and	O
ACRT	O
performance	O
on	O
medication	O
.	O


CONCLUSIONS	O
All	B-P
patients	I-P
in	I-P
both	I-P
groups	I-P
had	O
an	O
increasing	O
tendency	O
to	O
free	O
radical	O
production	O
during	O
early	O
reperfusion	O
.	O


This	O
study	O
assesses	O
the	O
efficacy	O
of	O
current	O
physiotherapy	O
strategies	O
.	O


There	O
was	O
a	O
significant	O
improvement	O
in	O
shoulder	B-OUT
symptoms	I-OUT
on	I-OUT
Oxford	I-OUT
and	I-OUT
Constant	I-OUT
scores	I-OUT
(	O
P	O
<	O
.001	O
)	O
.	O


The	O
improvement	O
in	O
range	O
of	O
motion	O
was	O
significantly	O
greater	O
in	O
both	O
physiotherapy	B-OUT
groups	I-OUT
over	I-OUT
home	I-OUT
exercises	I-OUT
(	O
P	O
<	O
.001	O
)	O
.	O


HADS	B-OUT
scores	I-OUT
significantly	O
improved	O
during	O
the	O
course	O
of	O
treatment	O
(	O
P	O
<	O
.001	O
)	O
.	O


The	O
improvement	O
in	O
HADS	B-OUT
anxiety	I-OUT
score	I-OUT
was	O
significantly	O
greater	O
in	O
both	O
physiotherapy	O
intervention	O
groups	O
than	O
in	O
home	O
exercises	O
alone	O
.	O


CONCLUSIONS	O
A	O
hospital-based	B-I
exercise	I-I
class	I-I
can	O
produce	O
a	O
rapid	O
recovery	O
from	O
a	O
frozen	B-P
shoulder	I-P
with	O
a	O
minimum	O
number	O
of	O
visits	O
to	O
the	O
hospital	O
and	O
is	O
more	O
effective	O
than	O
individual	O
physiotherapy	O
or	O
a	O
home	O
exercise	O
program	O
.	O


There	O
were	O
significant	O
differences	O
between	O
centres	O
in	O
reduction	O
of	O
cancer	B-OUT
worry	O
from	O
baseline	O
to	O
12	O
months	O
and	O
with	O
the	O
number	O
of	O
women	O
who	O
were	O
recommended	O
to	O
have	O
mammographic	O
surveillance	O
who	O
had	O
not	O
received	O
this	O
.	O


Results	O
differed	O
significantly	O
between	O
centres	O
for	O
doctor	O
's	O
satisfaction	O
with	O
the	O
provision	O
of	O
referral	O
criteria	O
and	O
prescribing	O
information	O
.	O


Prophylaxis	O
was	O
discontinued	O
if	O
the	O
patient	O
experienced	O
a	O
possible	O
or	O
proven	O
fungal	O
infection	O
or	O
a	O
serious	O
toxicity	O
.	O


The	O
risk	O
of	O
discontinuing	O
prophylaxis	O
due	O
to	O
fungal	B-OUT
infection	I-OUT
or	O
toxicity	B-OUT
increased	O
with	O
time	O
in	O
the	O
study	O
and	O
was	O
significantly	O
greater	O
for	O
AMB	O
(	O
P	O
=	O
0.02	O
)	O
.	O


Outcomes	B-OUT
in	O
a	O
nursing	O
home	O
transition	O
case-management	O
program	O
targeting	O
new	B-P
admissions	I-P
.	I-P


(	O
15/11	O
mmHg	O
,	O
p	O
less	O
than	O
0.02	O
)	O
and	O
hypotensive	B-OUT
peak	I-OUT
after	O
20	O
min	O
(	O
57/38	O
mmHg	O
,	O
p	O
greater	O
than	O
0.001	O
)	O
;	O
2	O
)	O
no	O
significant	O
differences	O
for	O
hypotensive	B-OUT
effectiveness	I-OUT
between	O
the	O
two	O
groups	O
,	O
but	O
with	O
SLC	B-I
having	O
a	O
mildly	O
delayed	O
onset	B-OUT
of	I-OUT
action	I-OUT
when	O
compared	O
to	O
SLN	B-I
;	I-I
3	O
)	O
antihypertensive	B-OUT
effect	I-OUT
lasting	O
for	O
about	O
6	O
hours	O
in	O
patients	O
treated	O
with	O
SLC	B-I
and	O
blood	B-OUT
pressure	I-OUT
progressively	O
raising	O
after	O
4	O
hours	O
in	O
patients	O
who	O
received	O
SLN	B-I
;	I-I
4	O
)	O
a	O
significant	O
correlation	O
between	O
blood	B-OUT
pressure	I-OUT
reduction	O
and	O
blood	B-OUT
pressure	I-OUT
before	O
drug	O
administration	O
in	O
both	O
groups	O
;	O
a	O
significant	O
correlation	O
between	O
pretreatment	O
PRA	O
and	O
antihypertensive	O
effect	O
in	O
the	O
SLC	B-I
group	O
.	O


We	O
conclude	O
that	O
both	O
drugs	O
are	O
effective	O
and	O
useful	O
in	O
treating	B-OUT
hypertensive	I-OUT
emergencies	I-OUT
.	I-P


The	O
relative	B-OUT
risk	I-OUT
(	I-OUT
RR	I-OUT
)	I-OUT
of	I-OUT
developing	I-OUT
PIPN	I-OUT
was	O
significantly	O
higher	O
in	O
controls	O
than	O
in	O
vitamin	B-I
E	I-I
group	O
patients	O
(	O
RR=0.3	O
,	O
95	O
%	O
confidence	O
interval	O
(	O
CI	O
)	O
=0.1-0.9	O
)	O
.	O


A	O
double-blind	O
,	O
placebo-controlled	B-I
trial	O
is	O
needed	O
to	O
confirm	O
these	O
results	O
.	O


Factor	B-OUT
VIIc	I-OUT
activity	I-OUT
levels	I-OUT
decreased	O
in	O
both	O
groups	O
with	O
a	O
greater	O
change	O
in	O
the	O
T-group	O
.	O


Further	O
investigation	O
is	O
required	O
to	O
clarify	O
the	O
relative	O
importance	O
of	O
beneficial	O
effects	O
with	O
respect	O
to	O
cardiovascular	O
risk	O
.	O


Serum	B-OUT
norepinephrine	I-OUT
,	I-OUT
epinephrine	I-OUT
,	I-OUT
dopamine	I-OUT
and	I-OUT
ACTH	I-OUT
concentrations	I-OUT
were	O
measured	O
before	O
and	O
after	O
the	O
examination	O
.	O


Wound	B-OUT
infections	I-OUT
occurred	O
in	O
5/32	O
(	O
16	O
per	O
cent	O
)	O
of	O
the	O
cefotaxime	B-I
group	O
and	O
9/31	O
(	O
29	O
per	O
cent	O
)	O
of	O
the	O
cephamandole	B-I
group	O
.	O


There	O
was	O
no	O
difference	O
between	O
the	O
two	O
groups	O
with	O
respect	O
to	O
changes	O
in	O
peak	B-OUT
expiratory	I-OUT
flow	I-OUT
rate	I-OUT
.	I-OUT


Comparison	O
of	O
amiodarone	B-I
and	I-I
disopyramide	I-I
in	O
the	O
control	B-OUT
of	I-OUT
paroxysmal	I-OUT
atrial	I-OUT
fibrillation	I-OUT
and	I-OUT
atrial	I-OUT
flutter	I-OUT
(	O
interim	O
report	O
)	O
.	O


The	O
treatment	O
did	O
not	O
alter	O
outcome	B-OUT
or	O
the	O
duration	B-OUT
of	I-OUT
ICU	I-OUT
stay	I-OUT
.	I-OUT


Heparin	B-I
therapy	I-I
in	O
venous	B-P
thromboembolism	I-P
.	I-P


Patients	B-P
with	I-P
pulmonary	I-P
embolism	I-P
or	I-P
deep	I-P
venous	I-P
thrombosis	I-P
were	O
randomly	O
assigned	O
to	O
receive	O
either	O
intermittent	B-I
or	I-I
continuous	I-I
intravenous	I-I
heparin	I-I
therapy	I-I
.	I-I


Controlling	O
the	O
dose	O
of	O
heparin	O
with	O
coagulation	O
tests	O
resulted	O
in	O
the	O
administration	O
of	O
significantly	O
larger	O
daily	O
doses	O
of	O
heparin	O
with	O
intermittent	O
injections	O
than	O
with	O
continuous	O
infusion	O
.	O


In	O
patients	B-P
with	I-P
a	I-P
high	I-P
risk	I-P
of	I-P
bleeding	I-P
,	O
conventional	B-I
doses	I-I
of	I-I
heparin	I-I
given	O
continuously	O
can	O
reduce	O
the	O
rate	B-OUT
of	I-OUT
hemorrhagic	I-OUT
complications	I-OUT
but	O
will	O
result	O
in	O
more	O
recurrences	O
.	O


Metabolic	O
responses	O
to	O
oral	B-I
surgery	I-I
under	O
local	B-I
anesthesia	I-I
and	O
sedation	O
with	O
intravenous	O
midazolam	B-I
:	I-I
the	O
effects	O
of	O
two	O
different	O
local	B-I
anesthetics	I-I
.	I-I


Ten	O
patients	O
were	O
randomly	O
assigned	O
to	O
receive	O
4.4	B-I
mL	I-I
of	I-I
2	I-I
%	I-I
lidocaine	I-I
with	I-I
1:80,000	I-I
epinephrine	I-I
as	I-I
a	I-I
local	I-I
anesthetic	I-I
and	I-I
10	I-I
were	I-I
given	I-I
4.4	I-I
mL	I-I
of	I-I
3	I-I
%	I-I
prilocaine	I-I
with	I-I
0.03	I-I
IU/mL	I-I
felypressin	I-I
.	I-I


At	O
30	B-OUT
min	I-OUT
potassium	I-OUT
was	O
increased	O
by	O
0.24	O
+/-	O
0.16	O
mmol/L	O
,	O
and	O
glucose	B-OUT
was	O
decreased	O
by	O
0.23	O
+/-	O
0.16	O
mmol/L	O
.	O


Journal	O
of	O
Autism	O
and	O
Developmental	O
Disorders	O
,	O
29	O
,	O
407-418	O
)	O
.	O


The	O
faux	B-I
pas	I-I
is	O
a	O
particular	O
case	O
of	O
a	O
non-intentional	O
action	O
reflecting	O
an	O
involuntary	O
socially	O
inappropriate	O
behavior	O
.	O


METHODS	O
Fifteen	B-P
atopic	I-P
asthmatics	I-P
were	I-P
randomized	I-P
in	I-P
double-blind	I-P
,	I-P
cross-over	I-P
fashion	I-P
to	I-P
receive	I-P
for	I-P
1	I-P
week	I-P
either	I-P
levocetirizine	I-I
5	I-I
mg	I-I
or	I-I
placebo	I-I
.	I-I


RESULTS	O
Baseline	O
mean	B-OUT
+/-	I-OUT
SEM	I-OUT
values	I-OUT
after	O
washout	O
prior	O
to	O
each	O
randomized	O
treatment	O
comparing	O
levocetirizine	B-I
vs	O
placebo	B-I
were	O
not	O
significantly	O
different	O
for	O
prechallenge	O
FEV1	B-OUT
(	O
%	O
predicted	O
)	O
83	O
+/-	O
4	O
vs	O
82	O
+/-	O
4	O
,	O
or	O
AMP	B-OUT
PC20	I-OUT
(	O
mg	O
ml	O
(	O
-1	O
)	O
)	O
45	O
+/-	O
24	O
vs	O
45	O
+/-	O
22	O
,	O
respectively	O
.	O


Further	O
studies	O
are	O
indicated	O
to	O
evaluate	O
the	O
longer-term	O
effects	O
of	O
levocetirizine	B-I
on	O
asthma	B-OUT
exacerbations	I-OUT
.	I-OUT


CONCLUSIONS	O
Since	O
this	O
analysis	O
of	O
reliability	O
,	O
validity	O
,	O
and	O
responsiveness	O
to	O
change	O
did	O
not	O
clearly	O
favour	O
one	O
instrument	O
above	O
the	O
other	O
,	O
the	O
choice	O
between	O
the	O
CRQ	O
and	O
the	O
SGRQ	O
can	O
be	O
based	O
on	O
other	O
considerations	O
such	O
as	O
the	O
required	O
sample	O
size	O
or	O
the	O
availability	O
of	O
reference	O
values	O
.	O


[	O
Maintaining	O
sinus	O
rhythm	O
with	O
quinidine	B-I
and	I-I
amiodarone	I-I
after	I-P
electric	I-P
cardioversion	I-P
]	I-P
.	O


Regional	B-I
ischemic	I-I
preconditioning	I-I
enhances	O
myocardial	B-OUT
performance	O
in	O
off-pump	O
coronary	O
artery	B-P
bypass	I-P
grafting	I-P
.	I-P


IP	O
resulted	O
in	O
a	O
complete	O
recovery	B-OUT
of	I-OUT
the	I-OUT
mean	I-OUT
stroke	I-OUT
volume	I-OUT
index	I-OUT
(	I-OUT
SVI	I-OUT
)	I-OUT
after	O
the	O
operation	O
.	O


In	O
the	O
control	O
subjects	O
,	O
the	O
mean	B-OUT
SVI	I-OUT
showed	O
a	O
significant	B-OUT
reduction	I-OUT
postoperatively	O
(	O
p	O
=	O
0.039	O
)	O
.	O


A	O
randomized	O
controlled	O
trial	O
tested	O
the	O
use	O
of	O
lay	B-I
navigators	I-I
(	I-I
care	I-I
managers	I-I
)	I-I
to	I-I
increase	I-I
cancer	I-OUT
screening	I-OUT
of	I-P
Asian	I-P
and	I-P
Pacific	I-P
Islander	I-P
Medicare	I-P
beneficiaries	I-P
.	I-P


Groups	O
were	O
similar	O
in	O
demographic	B-OUT
characteristics	I-OUT
and	I-OUT
baseline	I-OUT
screening	I-OUT
prevalence	I-OUT
of	I-OUT
breast	I-OUT
,	I-OUT
cervical	I-OUT
,	I-OUT
prostate	I-OUT
,	I-OUT
and	I-OUT
colorectal	I-OUT
cancers	I-OUT
.	I-OUT


In	O
this	O
study	O
seven	B-P
patients	I-P
with	I-P
infantile	I-P
autism	I-P
,	I-P
three	I-P
before	I-P
puberty	I-P
and	I-P
four	I-P
after	I-P
puberty	I-P
,	O
were	O
given	O
a	O
gluten-free	B-I
diet	I-I
.	I-I


Behaviour	B-OUT
was	O
registered	O
before	O
,	O
during	O
and	O
after	O
the	O
period	O
with	O
a	O
gluten-free	B-I
diet	I-I
.	I-I


No	O
connection	O
was	O
observed	O
between	O
gluten	B-OUT
and	I-OUT
behaviour	I-OUT
typical	O
for	O
these	O
patients	O
.	O


A	O
randomized	O
trial	O
of	O
external	B-I
beam	I-I
radiotherapy	I-I
versus	O
cryoablation	B-I
in	O
patients	B-P
with	I-P
localized	I-P
prostate	I-P
cancer	I-P
:	I-P
quality	O
of	O
life	O
outcomes	O
.	O


BACKGROUND	O
A	O
recent	O
randomized	O
trial	O
to	O
compare	O
external	B-I
beam	I-I
radiation	I-I
therapy	I-I
(	I-I
EBRT	I-I
)	I-I
to	O
cryoablation	O
for	O
localized	O
disease	O
showed	O
cryoablation	O
to	O
be	O
noninferior	O
to	O
external	B-I
beam	I-I
EBRT	I-I
in	O
disease	O
progression	O
and	O
overall	O
and	O
disease-specific	O
survival	O
.	O


METHODS	O
From	B-P
December	I-P
1997	I-P
through	I-P
February	I-P
2003	I-P
,	I-P
244	I-P
men	I-P
with	I-P
newly	I-P
diagnosed	I-P
localized	I-P
prostate	I-P
cancer	I-P
were	O
randomly	O
assigned	O
to	O
cryoablation	B-I
or	I-I
EBRT	I-I
(	O
median	O
dose	O
68	O
Gy	O
)	O
.	O


All	O
patients	O
received	O
neoadjuvant	B-I
antiandrogen	I-I
therapy	O
.	O


cryoablation	B-OUT
was	O
associated	O
with	O
more	O
acute	B-OUT
urinary	I-OUT
dysfunction	I-OUT
(	O
mean	O
PCI	O
urinary	O
function	O
cryoablation=69.4	O
;	O
mean	O
EBRT=90.7	O
;	O
P	O
<	O
.001	O
)	O
,	O
which	O
resolved	O
over	O
time	O
.	O


Mean	B-OUT
sexual	I-OUT
function	I-OUT
score	I-OUT
was	O
15	O
points	O
lower	O
at	O
3	O
years	O
for	O
the	O
cryoablation	B-I
group	O
and	O
13	O
%	O
more	O
of	O
the	O
cryoablation	B-I
men	O
said	O
that	O
sexuality	O
was	O
a	O
moderate	O
or	O
big	O
problem	O
.	O


Men	O
who	O
wish	O
to	O
increase	O
their	O
odds	O
of	O
retaining	O
sexual	B-OUT
function	I-OUT
might	O
be	O
counseled	O
to	O
choose	O
EBRT	B-I
over	O
cryoablation	B-I
.	I-I


Analysis	O
of	O
face	B-I
gaze	I-I
in	O
autism	B-P
using	O
"	O
Bubbles	O
"	O
.	O


One	O
of	O
the	O
components	O
of	O
abnormal	O
social	O
functioning	O
in	O
autism	B-P
is	O
an	O
impaired	O
ability	O
to	O
direct	O
eye	O
gaze	O
onto	O
other	O
people	O
's	O
faces	O
in	O
social	O
situations	O
.	O


Here	O
,	O
we	O
investigated	O
the	O
relationship	O
between	O
gaze	B-OUT
onto	I-OUT
the	I-OUT
eye	I-OUT
and	I-OUT
mouth	I-OUT
regions	I-OUT
of	I-OUT
faces	I-OUT
,	O
and	O
the	O
visual	O
information	O
that	O
was	O
present	O
within	O
those	O
regions	O
.	O


BACKGROUND	O
New	O
antimalarial	O
treatments	O
are	O
urgently	O
needed	O
in	O
sub-Saharan	B-P
Africa	I-P
.	I-P


Participants	O
were	O
followed	O
up	O
for	O
1	O
year	O
and	O
received	O
the	O
same	O
preassigned	O
treatment	O
for	O
every	O
new	O
episode	O
of	O
uncomplicated	O
malaria	O
diagnosed	O
during	O
follow-up	O
.	O


Continued	B-OUT
remission	I-OUT
appeared	O
more	O
likely	O
in	O
patients	O
achieving	O
remission	O
earlier	O
in	O
the	O
course	O
of	O
their	O
therapy	O
(	O
0-6	O
months	O
)	O
.	O


Patients	O
with	O
lower	O
RA	O
disease	O
activity	O
were	O
more	O
likely	O
to	O
reach	B-OUT
remission	I-OUT
.	I-OUT


Patients	B-P
>	I-P
or	I-P
=1	I-P
year	I-P
of	I-P
age	I-P
with	I-P
a	I-P
parasite	I-P
density	I-P
>	I-P
or	I-P
=1,000	I-P
asexual	I-P
parasites	I-P
per	I-P
microliter	I-P
were	I-P
enrolled	I-P
in	I-P
this	I-P
study	I-P
.	I-P


Transcutaneous	B-I
electrical	I-I
nerve	I-I
stimulation	I-I
(	I-I
TENS	I-I
)	I-I
has	O
been	O
used	O
to	O
treat	O
chronic	O
pain	O
syndromes	O
and	O
has	O
been	O
reported	O
to	O
be	O
of	O
some	O
utility	O
in	O
the	O
treatment	O
of	O
postsurgical	O
pain	O
.	O


A	O
randomized	O
,	O
blinded	O
,	O
placebo-controlled	B-I
trial	O
was	O
designed	O
to	O
evaluate	O
the	O
utility	O
of	O
TENS	O
after	O
total	B-P
knee	I-P
arthroplasty	I-P
.	I-P


We	O
conclude	O
that	O
there	O
is	O
no	O
utility	O
for	O
TENS	O
in	O
the	O
postoperative	O
management	O
of	O
pain	O
after	O
knee	O
arthroplasty	O
.	O


All	O
participants	O
received	O
either	O
placebo	B-I
or	I-I
caffeine	I-I
(	O
200	O
mg	O
)	O
,	O
while	O
the	O
chewing	B-I
condition	O
also	O
chewed	B-I
on	I-I
a	I-I
tasteless	I-I
and	I-I
odorless	I-I
substance	I-I
for	O
15	O
min	O
each	O
hour	O
.	O


Heart	B-OUT
rate	I-OUT
(	I-OUT
HR	I-OUT
)	I-OUT
,	I-OUT
root	I-OUT
mean	I-OUT
square	I-OUT
of	I-OUT
the	I-OUT
successive	I-OUT
differences	I-OUT
in	I-OUT
R-R	I-OUT
intervals	I-OUT
on	I-OUT
the	I-OUT
ECG	I-OUT
(	I-OUT
RMSSD	I-OUT
)	I-OUT
,	I-OUT
and	I-OUT
preejection	I-OUT
period	I-OUT
(	I-OUT
PEP	I-OUT
)	I-OUT
were	O
simultaneously	O
recorded	O
.	O


Similarly	O
,	O
measures	O
of	O
HR	B-OUT
and	I-OUT
RMSSD	I-OUT
remained	O
the	O
same	B-OUT
between	O
these	O
two	O
conditions	O
;	O
however	O
,	O
PEP	B-OUT
was	O
reduced	O
in	O
the	O
later	O
part	O
of	O
the	O
night	O
in	O
the	O
chewing	B-I
condition	O
compared	O
with	O
a	O
relative	O
increase	O
for	O
placebo	B-I
.	I-I


METHODS	O
This	O
was	O
a	O
multicenter	O
,	O
randomized	O
,	O
double-blind	O
,	O
placebo-controlled	O
study	O
in	O
heparin-resistant	B-P
patients	I-P
undergoing	I-P
cardiac	I-P
surgery	I-P
with	I-P
cardiopulmonary	I-P
bypass	I-P
.	I-P


Fifty-four	B-P
heparin-resistant	I-P
patients	I-P
were	I-P
randomized	I-P
.	I-P


If	O
the	O
activated	O
clotting	O
time	O
remained	O
less	O
than	O
480	O
s	O
,	O
this	O
was	O
considered	O
treatment	O
failure	O
,	O
and	O
2	O
units	O
fresh	O
frozen	O
plasma	O
was	O
transfused	O
.	O


During	O
their	O
hospitalization	O
,	O
48	O
%	O
of	O
patients	O
in	O
the	O
rhAT	B-I
group	O
received	O
fresh	B-OUT
frozen	I-OUT
plasma	I-OUT
,	O
compared	O
with	O
85	O
%	O
of	O
patients	O
in	O
the	O
placebo	B-I
group	O
(	O
P	O
=	O
0.009	O
)	O
.	O


There	O
was	O
no	O
difference	O
between	O
the	O
groups	O
in	O
blood	O
and	O
platelet	O
transfusions	O
.	O


Urinary	B-OUT
excretion	I-OUT
of	O
AVP	O
was	O
suppressed	O
only	O
with	O
the	O
10	O
mg	O
dose	O
from	O
46+/-23	O
to	O
25+/-15	O
fmol	O
min	O
(	O
-1	O
)	O
(	O
P	O
<	O
0.05	O
)	O
without	O
and	O
from	O
410+/-206	O
to	O
181+/-125	O
fmol	O
min	O
(	O
-1	O
)	O
(	O
P	O
<	O
0.05	O
)	O
with	O
stimulation	O
by	O
2.5	O
%	O
saline	O
.	O


Suppression	O
of	O
AVP	O
secretion	O
was	O
observed	O
only	O
at	O
the	O
highest	O
dose	O
level	O
of	O
10	O
mg	O
of	O
asimadoline	O
.	O


RESULTS	O
The	O
incidence	B-OUT
of	I-OUT
DIND	I-OUT
was	O
lower	O
in	O
the	O
pTBA	B-I
group	O
(	O
P=0.30	O
)	O
and	O
fewer	O
patients	O
required	O
therapeutic	O
angioplasty	B-I
to	O
treat	O
DIND	O
(	O
P=0.03	O
)	O
.	O


Four	O
patients	O
had	O
a	O
procedure-related	B-OUT
vessel	I-OUT
perforation	I-OUT
,	O
of	O
which	O
three	O
patients	O
died	O
.	O


Scopolamine-induced	B-P
cognitive	I-P
impairment	I-P
was	I-P
used	I-P
in	I-P
healthy	I-P
men	I-P
to	O
evaluate	O
the	O
central	O
nervous	O
system	O
activity	O
of	O
the	O
new	B-I
cholinomimetic	I-I
SDZ	I-I
ENS-163	I-I
.	I-I


[	B-P
Evaluating	I-P
an	I-P
interactive	I-I
,	I-I
multi-media	I-I
learning	I-I
system	I-I
for	I-P
the	I-P
study	I-P
of	I-P
primary	I-P
open	I-P
angle	I-P
glaucoma	I-P
]	I-P
.	O


OBJECTIVE	O
To	O
compare	O
the	O
insertion	O
characteristics	O
and	O
rate	O
of	O
complications	O
between	O
25-gauge	B-I
Quincke	I-I
and	I-I
24-gauge	I-I
Gertie	I-I
Marx	I-I
needles	I-I
.	O


DESIGN	O
Prospective	O
,	O
randomized	O
study	O
.	O


Antihypertensive	B-OUT
efficacy	I-OUT
of	O
cetamolol	B-I
:	I-I
a	O
dose-titrated	O
study	O
.	O


In	O
general	O
,	O
the	O
changes	B-OUT
in	I-OUT
standing	I-OUT
(	I-OUT
stabilized	I-OUT
)	I-OUT
systolic	I-OUT
and	I-OUT
diastolic	I-OUT
blood	I-OUT
pressure	I-OUT
were	O
similar	O
to	O
those	O
seen	O
in	O
supine	O
measurements	O
.	O


PURPOSE	O
Interferon	O
(	O
IFN	O
)	O
-based	O
adjuvant	O
therapy	O
in	O
melanoma	O
is	O
associated	O
with	O
significant	O
side	O
effects	O
,	O
which	O
necessitates	O
evaluation	O
of	O
health-related	B-OUT
quality	I-OUT
of	I-OUT
life	I-OUT
(	O
HRQOL	O
)	O
.	O


Our	O
trial	O
examined	O
the	O
HRQOL	O
effects	O
of	O
adjuvant	O
pegylated	O
IFN-alpha-2b	O
(	O
PEG-IFN-alpha-2b	O
)	O
versus	O
observation	O
in	O
patients	B-P
with	I-P
stage	I-P
III	I-P
melanoma	I-P
.	I-P


There	O
is	O
an	O
expected	O
negative	O
effect	O
on	O
global	B-OUT
HRQOL	I-OUT
and	O
selected	O
symptoms	O
when	O
patients	O
undergo	O
PEG-IFN-alpha-2b	O
treatment	O
.	O


In	B-P
patients	I-P
admitted	I-P
to	I-P
the	I-P
hospital	I-P
with	I-P
acute	I-P
HF	I-P
,	I-P
both	I-P
ventricles	I-I
were	I-I
evaluated	I-I
by	I-I
echocardiography	I-I
on	I-P
admission	I-P
,	I-P
at	I-P
discharge	I-P
,	I-P
and	I-P
at	I-P
3	I-P
months	I-P
.	I-P


METHODS	O
Safety	O
results	O
are	O
reported	O
for	O
714	B-P
patients	I-P
who	I-P
received	I-P
etanercept	I-I
in	I-P
one	I-P
of	I-P
7	I-P
initial	I-P
trials	I-P
or	I-P
a	I-P
longterm	I-P
extension	I-P
.	I-P


Rates	B-OUT
of	I-OUT
serious	I-OUT
adverse	I-OUT
events	I-OUT
(	O
overall	O
rate=14.8	O
events/100	O
patient-yrs	O
)	O
,	O
serious	B-OUT
infections	I-OUT
(	O
overall	O
rate=4.2	O
events/100	O
patient-yrs	O
)	O
,	O
cancer	B-OUT
(	O
overall	O
rate=1.0	O
events/100	O
patient-yrs	O
)	O
,	O
and	B-OUT
deaths	I-OUT
(	O
overall	O
rate=0.7	O
events/100	O
patient-yrs	O
)	O
were	O
stable	O
each	O
year	O
,	O
through	O
8	O
years	O
of	O
etanercept	O
exposure	O
.	O


Between	B-P
December	I-P
1982	I-P
and	I-P
October	I-P
1986	I-P
,	I-P
131	I-P
patients	I-P
with	I-P
stage	I-P
II-III-IV	I-P
squamous	I-P
cell	I-P
carcinoma	I-P
of	I-P
the	I-P
oropharynx	I-P
or	I-P
oral	I-P
cavity	I-P
were	O
randomized	O
to	O
induction	B-I
chemotherapy	I-I
,	I-I
consisting	I-I
of	I-I
bleomycin	I-I
(	I-I
10	I-I
mg/m2/day	I-I
in	I-I
continuous	I-I
infusion	I-I
from	I-I
day	I-I
1	I-I
to	I-I
day	I-I
5	I-I
)	I-I
,	I-I
methotrexate	I-I
(	I-I
120	I-I
mg/m2	I-I
on	I-I
day	I-I
2	I-I
)	I-I
followed	I-I
by	I-I
folinic	I-I
acid	I-I
,	I-I
5-fluorouracil	I-I
(	I-I
5	I-I
FU	I-I
)	I-I
(	I-I
600	I-I
mg/m2	I-I
on	I-I
day	I-I
2	I-I
)	I-I
,	I-I
and	I-I
cisplatin	I-I
(	I-I
120	I-I
mg/m2	I-I
on	I-I
day	I-I
4	I-I
)	I-I
every	I-I
4	I-I
weeks	I-I
for	I-I
a	I-I
total	I-I
of	I-I
three	I-I
cycles	I-I
followed	I-I
by	I-I
definitive	I-I
locoregional	I-I
treatment	I-I
versus	I-I
locoregional	I-I
treatment	I-I
alone	I-I
.	I-I


A	B-P
total	I-P
of	I-P
116	I-P
patients	I-P
were	I-P
evaluable	I-P
.	I-P


Chemotherapy-related	B-OUT
toxicities	I-OUT
were	O
few	O
and	O
most	O
of	O
them	O
related	O
to	O
cisplatin	O
which	O
was	O
reduced	O
to	O
100	O
mg/m2	O
for	O
35	O
patients	O
.	O


OBJECTIVES	O
Previous	O
uncontrolled	O
studies	O
have	O
suggested	O
an	O
interaction	O
between	O
ticlopidine	B-I
,	O
a	O
major	O
antiplatelet	O
agent	O
,	O
and	O
cyclosporin	B-I
in	O
heart-	O
and	O
kidney-transplant	O
recipients	O
.	O


The	O
aims	O
of	O
this	O
study	O
were	O
to	O
examine	O
in	O
a	O
randomised	O
,	O
double-blind	O
fashion	O
,	O
the	O
possible	O
interaction	O
between	O
cyclosporin	B-I
A	I-I
and	I-I
ticlopidine	I-I
(	O
250	O
mg	O
per	O
day	O
)	O
and	O
the	O
tolerability	O
of	O
this	O
combination	O
in	O
heart-transplant	B-P
recipients	I-P
.	I-P


Adherence	B-OUT
was	O
assessed	O
by	O
3-day	B-OUT
food	I-OUT
records	I-OUT
and	I-OUT
urine	I-OUT
collections	I-OUT
in	I-OUT
children	I-OUT
and	I-OUT
adults	I-OUT
.	I-OUT


Sodium	B-OUT
intake	I-OUT
was	O
significantly	O
lower	O
in	O
the	O
intervention	O
group	O
only	O
in	O
the	O
active	O
participants	O
as	O
compared	O
to	O
dropouts	O
and	O
controls	O
(	O
87	O
vs	O
130	O
and	O
133	O
mmoles/24	O
hr	O
)	O
.	O


There	O
were	O
no	O
significant	O
differences	O
between	O
the	O
groups	O
in	O
height	B-OUT
,	I-OUT
weight	I-OUT
,	I-OUT
or	I-OUT
blood	I-OUT
pressure	I-OUT
.	I-OUT


RESULTS	O
One	B-P
hundred	I-P
twenty	I-P
patients	I-P
were	O
randomly	O
assigned	O
and	O
treated	O
.	O


Although	O
not	O
statistically	O
significant	O
,	O
relative	O
to	O
chemotherapy	O
alone	O
,	O
the	O
risk	B-OUT
of	I-OUT
disease	I-OUT
progression	I-OUT
or	I-OUT
death	I-OUT
was	O
0.66	O
(	O
95	O
%	O
CI	O
,	O
0.38	O
to	O
1.16	O
)	O
among	O
patients	O
treated	O
with	O
bevacizumab-chemotherapy	B-I
and	O
0.72	O
(	O
95	O
%	O
CI	O
,	O
0.42	O
to	O
1.23	O
)	O
among	O
patients	O
treated	O
with	O
bevacizumab-erlotinib	B-I
.	I-I


The	O
toxicity	B-OUT
profile	I-OUT
of	O
the	O
bevacizumab-erlotinib	B-I
combination	I-I
is	O
favorable	O
compared	O
with	O
either	O
chemotherapy-containing	B-I
group	O
.	O


METHODS	O
Thirty-six	B-P
children	I-P
with	I-P
ASD	I-P
,	I-P
ages	I-P
2	I-P
to	I-P
10	I-P
years	I-P
,	I-P
were	I-P
enrolled	I-P
.	I-P


Actigraphy	O
data	O
were	O
collected	O
a	O
second	O
time	O
2	O
weeks	O
after	O
the	O
parent	O
received	O
the	O
randomization	O
assignment	O
and	O
analyzed	O
by	O
using	O
Student	O
's	O
t	O
test	O
.	O


Consecutive	O
2-s	O
epochs	O
of	O
a	O
10-min	B-I
EEG	I-I
record	O
(	O
resting	O
conditions	O
)	O
of	O
F3/C3-F4/C4-P3/01-P4/02	O
were	O
subjected	O
to	O
FFT	O
(	O
Fast	O
Fourier	O
Transform	O
)	O
.	O


Opposite	O
results	O
for	O
the	O
two	O
subgroups	O
were	O
also	O
obtained	O
for	O
the	O
left-right	B-OUT
relations	I-OUT
of	I-OUT
alpha-power	I-OUT
over	O
the	O
anterior	O
regions	O
.	O


Under	O
60	O
mg	O
nimodipine	B-I
both	O
subgroups	O
showed	O
a	O
shift	B-OUT
to	I-OUT
the	I-OUT
left	I-OUT
.	I-OUT


Moreover	O
they	O
suggest	O
a	O
dose	O
dependence	O
of	O
the	O
effect	O
,	O
i.e.	O
,	O
at	O
higher	O
doses	O
nimodipine	B-I
seems	O
to	O
act	O
as	O
a	O
sedative	O
.	O


[	O
Randomized	O
controlled	O
study	O
of	O
OK-432	B-I
in	O
the	O
treatment	O
of	O
cancerous	B-OUT
pleurisy	I-OUT
]	I-OUT
.	O


Also	O
patients	O
with	O
PPD	O
negative	O
skin	O
reaction	O
at	O
the	O
time	O
of	O
beginning	O
of	O
treatment	O
in	O
the	O
OK-432	O
group	O
survived	O
significantly	O
longer	O
than	O
those	O
in	O
the	O
control	O
group	O
(	O
P	O
less	O
than	O
0.001	O
)	O
,	O
but	O
there	O
was	O
no	O
significance	O
between	O
both	O
treatment	O
groups	O
in	O
patients	O
with	O
PPD	O
positive	O
skin	B-OUT
reaction	I-OUT
at	O
the	O
time	O
of	O
beginning	O
of	O
treatment	O
.	O


Correlations	O
between	O
arousals	O
on	O
sleep	B-OUT
tests	I-OUT
and	I-OUT
subjective	I-OUT
tests	I-OUT
were	O
performed	O
.	O


However	O
,	O
fluticasone	O
used	O
at	O
approved	O
doses	O
improves	O
subjective	B-OUT
sleep	I-OUT
in	O
patients	B-P
with	I-P
perennial	I-P
allergic	I-P
rhinitis	I-P
without	O
a	O
change	O
in	O
the	O
apnea/hypopnea	O
index	O
.	O


METHODS	O
Patients	B-P
with	I-P
IBS	I-P
according	I-P
to	I-P
the	I-P
Rome	I-P
II	I-P
criteria	I-P
were	O
randomized	O
to	O
either	O
short	B-I
nurse-based	I-I
or	I-I
a	I-I
long	I-I
multidisciplinary-based	I-I
education	I-I
.	I-I


The	O
effects	O
were	O
evaluated	O
by	O
self-administered	B-I
questionnaires	I-I
at	O
3	O
,	O
6	O
,	O
and	O
12	O
months	O
after	O
baseline	O
,	O
and	O
compared	O
between	O
the	O
groups	O
.	O


However	O
,	O
observational	O
epidemiologic	O
analyses	O
have	O
had	O
limited	O
opportunity	O
to	O
control	O
for	O
confounding	O
bias	O
or	O
to	O
specify	O
aspirin	B-I
doses	O
used	O
.	O


We	O
also	O
attempted	O
to	O
determine	O
whether	O
invasive	O
cancers	O
among	O
aspirin	B-I
users	I-P
were	O
associated	O
with	O
rectal	O
bleeding	O
and	O
early	O
stage	O
at	O
diagnosis	O
.	O


Stage	O
at	O
diagnosis	O
and	O
signs	O
and/or	O
symptoms	O
during	O
presentation	O
were	O
abstracted	O
from	O
medical	O
records	O
.	O


Acute	O
intervention	O
studies	O
in	O
patients	B-P
with	I-P
myocardial	I-P
infarction	I-P
using	O
atenolol	B-I
,	I-I
propranolol	I-I
,	I-I
oxprenolol	I-I
and	O
disopyramide	B-I
phosphate	I-I
.	I-I


In	O
addition	O
,	O
there	O
was	O
no	O
evidence	O
to	O
suggest	O
that	O
either	O
atenolol	B-I
,	O
or	O
propranolol	B-I
reduced	O
the	O
incidence	O
of	B-OUT
'serious	I-OUT
'	I-OUT
ventricular	I-OUT
arrhythmias	I-OUT
in	O
the	O
coronary	O
care	O
unit	O
.	O


In	O
the	O
second	O
study	O
473	B-P
patients	I-P
with	I-P
suspected	I-P
acute	I-P
myocardial	I-P
infarction	I-P
were	O
randomly	O
allocated	O
to	O
treatment	O
with	O
oxprenolol	B-I
,	I-I
disopyramide	I-I
phosphate	I-I
,	I-I
or	I-I
placebo	I-I
.	I-I


SUBJECTS/METHOD	O
In	O
total	O
140	B-P
patients	I-P
(	I-P
36	I-P
men	I-P
,	I-P
104	I-P
women	I-P
)	I-P
,	I-P
aged	I-P
18-60	I-P
years	I-P
and	I-P
body	I-P
mass	I-P
index	I-P
>	I-P
30	I-P
kg/m	I-P
(	I-P
2	I-P
)	I-P
were	I-P
randomized	I-P
and	I-P
93	I-P
patients	I-P
(	I-P
27	I-P
men	I-P
,	I-P
66	I-P
women	I-P
)	I-P
completed	I-P
the	I-P
study	I-P
.	I-P


The	O
patients	O
received	O
regular	O
and	O
individualized	O
counseling	O
by	O
dieticians	O
.	O


Patients	O
were	O
followed	O
up	O
for	O
outcomes	O
of	O
death	B-OUT
,	I-OUT
hepatocellular	I-OUT
carcinoma	I-OUT
and	O
hepatic	B-OUT
decompensation	I-OUT
.	I-OUT


BACKGROUND	O
Evaluating	O
the	O
effectiveness	O
of	O
treatments	O
such	O
as	O
brief	O
alcohol	O
interventions	O
among	O
Hispanics	B-P
is	O
essential	O
to	O
effectively	O
addressing	O
their	O
treatment	O
needs	O
.	O


CONCLUSION	O
As	O
hypothesized	O
,	O
an	O
ethnic	O
match	O
between	O
patient	O
and	O
provider	O
significantly	O
enhanced	O
the	O
effectiveness	B-OUT
of	I-OUT
brief	I-OUT
intervention	I-OUT
among	O
Hispanics	B-P
.	I-P


We	O
describe	O
immunologic	O
findings	O
from	O
a	O
clinical	O
study	O
designed	O
to	O
investigate	O
the	O
safety	O
of	O
iatrogenic	B-I
hookworm	I-I
infection	I-I
in	O
participants	B-P
with	I-P
allergic	I-P
rhinitis	I-P
.	I-P


METHODS	O
As	O
per	O
reference	O
standard	O
,	O
115	B-P
nodules	I-P
were	O
differentiated	O
into	O
nonsolid	O
and	O
part-solid	O
by	O
two	O
radiologists	O
;	O
disagreements	O
were	O
adjudicated	O
by	O
a	O
third	O
radiologist	O
.	O


Diagnosis	O
of	O
a	O
solid	O
component	O
by	O
semiautomatic	O
software	O
depended	O
on	O
the	O
threshold	O
chosen	O
.	O


CONCLUSION	O
Semiautomatic	O
segmentation	O
of	O
subsolid	O
nodules	O
could	O
diagnose	O
part-solid	O
nodules	O
and	O
quantify	O
the	O
solid	O
component	O
similar	O
to	O
human	O
observers	O
.	O


Children	B-P
were	I-P
investigated	I-P
who	I-P
were	I-P
receiving	I-P
glucocorticoid	I-I
treatment	I-I
for	I-P
acute	I-P
lymphoblastic	I-P
leukaemia	I-P
(	I-P
ALL	I-P
)	I-P
.	I-P


RESULTS	O
Glucocorticoid	O
administration	O
for	O
5	O
weeks	O
resulted	O
in	O
significant	O
(	O
P	O
<	O
0.05	O
)	O
increases	O
in	O
BMI	B-OUT
,	I-OUT
leptin	I-OUT
(	I-OUT
corrected	I-OUT
for	I-OUT
BMI	I-OUT
)	I-OUT
and	I-OUT
the	I-OUT
leptin	I-OUT
:	I-OUT
SHBG	I-OUT
ratio	I-OUT
and	I-OUT
lowering	I-OUT
of	I-OUT
SHBG	I-OUT
.	I-OUT


CONCLUSIONS	O
Short-term	O
glucocorticoid	O
treatment	O
has	O
significant	O
effects	O
on	O
BMI	O
,	O
leptin	O
and	O
SHBG	O
.	O


AIM	O
The	O
aims	O
of	O
the	O
present	O
study	O
were	O
to	O
revise	O
the	O
Community	B-I
Re-entry	I-I
Program-Japanese	I-I
version	I-I
and	O
to	O
review	O
the	O
effectiveness	B-OUT
of	O
the	O
revised	O
Program	O
,	O
named	O
the	O
Discharge	B-I
Preparation	I-I
Program	I-I
.	I-I


The	O
Discharge	B-I
Preparation	I-I
Program	I-I
(	I-I
DPP	I-I
)	I-I
was	O
the	O
intervention	B-P
condition	I-P
(	I-P
n	I-P
=	I-P
26	I-P
)	I-P
,	O
and	O
the	O
usual	B-I
rehabilitation	I-I
program	I-I
was	I-I
the	I-I
control	I-I
condition	I-I
(	I-P
n	I-P
=	I-P
23	I-P
)	I-P
.	I-P


RESULTS	O
Significant	O
improvements	O
were	O
found	O
in	O
the	O
score	B-OUT
of	I-OUT
the	I-OUT
'Issues	I-OUT
on	I-OUT
treatment	I-OUT
compliance	I-OUT
'	I-OUT
factor	I-OUT
and	I-OUT
the	I-OUT
score	I-OUT
of	I-OUT
the	I-OUT
'Autistic	I-OUT
life	I-OUT
'	I-OUT
factor	I-OUT
,	O
which	O
are	O
subscales	O
of	O
the	O
Discharge	B-OUT
Difficulty	I-OUT
Scale	I-OUT
,	O
for	O
the	O
DPP	B-I
group	O
,	O
on	O
two-way	O
ANOVA	O
(	O
'Issues	O
on	O
treatment	O
compliance	O
'	O
:	O
F	O
=	O
3.818	O
,	O
P	O
<	O
0.10	O
;	O
'Autistic	O
life	O
'	O
:	O
F	O
=	O
4.155	O
,	O
P	O
<	O
0.05	O
)	O
These	O
factors	O
affected	O
discharge	B-OUT
outcome	I-OUT
.	I-OUT


With	O
regard	O
to	O
the	O
number	B-OUT
of	I-OUT
patients	I-OUT
discharged	I-OUT
in	I-OUT
6	I-OUT
months	I-OUT
after	O
the	O
end	O
of	O
a	O
program	O
,	O
there	O
was	O
no	O
significant	O
difference	O
between	O
both	O
groups	O
.	O


A	O
total	O
of	O
296	B-P
patients	I-P
fulfilling	I-P
the	I-P
International	I-P
Headache	I-P
Society	I-P
diagnostic	I-P
criteria	I-P
for	I-P
migraine	I-P
were	I-P
enrolled	I-P
.	I-P


CM	B-OUT
was	I-OUT
also	I-OUT
significantly	I-OUT
superior	I-OUT
to	I-OUT
EC	I-OUT
during	I-OUT
the	I-OUT
first	I-OUT
attack	I-OUT
for	I-OUT
complete	I-OUT
headache	I-OUT
relief	I-OUT
(	I-OUT
20	I-OUT
vs.	I-OUT
8	I-OUT
%	I-OUT
,	I-OUT
p	I-OUT
=	I-OUT
0.006	I-OUT
)	I-OUT
,	I-OUT
nausea	I-OUT
(	I-OUT
42	I-OUT
vs.	I-OUT
63	I-OUT
%	I-OUT
,	I-OUT
p	I-OUT
=	I-OUT
0	I-OUT
.	I-OUT


The	B-OUT
patients	I-OUT
'	I-OUT
evaluation	I-OUT
was	I-OUT
significant	I-OUT
for	I-OUT
the	I-OUT
first	I-OUT
attack	I-OUT
(	I-OUT
p	I-OUT
=	I-OUT
0.002	I-OUT
)	I-OUT
.	I-OUT


The	B-OUT
global	I-OUT
incidence	I-OUT
of	I-OUT
adverse	I-OUT
events	I-OUT
was	I-OUT
45	I-OUT
%	I-OUT
higher	I-OUT
with	I-OUT
EC	I-OUT
,	I-OUT
though	I-OUT
not	I-OUT
significant	I-OUT
(	I-OUT
32	I-OUT
vs.	I-OUT
22	I-OUT
%	I-OUT
,	I-OUT
p	I-OUT
=	I-OUT
0.075	I-OUT
)	I-OUT
.	I-OUT


Thus	B-OUT
,	I-OUT
CM	I-OUT
is	I-OUT
more	I-OUT
effective	I-OUT
and	I-OUT
has	I-OUT
a	I-OUT
better	I-OUT
gastrointestinal	I-OUT
safety	I-OUT
than	I-OUT
EC	I-OUT
in	I-OUT
the	I-OUT
acute	I-OUT
treatment	I-OUT
of	I-OUT
migraine	I-OUT
attacks	I-OUT
.	I-OUT


The	O
influence	O
of	O
nicotine	B-I
delivered	O
in	O
chewing	B-I
gum	I-I
upon	O
cardiac	O
hemodynamics	O
and	O
conduction	O
has	O
not	O
been	O
well-characterized	O
.	O


CONCLUSIONS	O
These	O
results	O
suggest	O
that	O
nicotine	O
chewing	O
gum	O
increases	O
afterload	B-OUT
and	I-OUT
cardiac	I-OUT
output	I-OUT
.	I-OUT


Isometric	B-OUT
back	I-OUT
extensor	I-OUT
strength	I-OUT
,	I-OUT
spinal	I-OUT
range	I-OUT
of	I-OUT
motion	I-OUT
,	I-OUT
and	I-OUT
scores	I-OUT
for	I-OUT
quality	I-OUT
of	I-OUT
life	I-OUT
were	O
evaluated	O
at	O
baseline	O
and	O
4	O
months	O
.	O


To	O
determine	O
the	O
efficacy	O
of	O
secretin	B-I
,	O
we	O
completed	O
a	O
double-blind	O
,	O
placebo-controlled	B-I
,	O
crossover	O
(	O
3	O
weeks	O
)	O
study	O
in	O
children	B-P
with	I-P
autism/PDD	I-P
and	I-P
various	I-P
GI	I-P
conditions	I-P
using	O
a	O
single	O
dose	O
of	O
intravenous	B-I
porcine	I-I
secretin	I-I
.	I-I


PARTICIPANTS	O
Participants	B-P
(	I-P
n	I-P
=	I-P
1758	I-P
)	I-P
were	I-P
visitors	I-P
to	I-P
the	I-P
QUIT	I-P
website	I-P
who	I-P
were	I-P
based	I-P
in	I-P
the	I-P
United	I-P
Kingdom	I-P
,	I-P
aged	I-P
18	I-P
years	I-P
or	I-P
over	I-P
and	I-P
who	I-P
smoked	I-P
cigarettes	I-P
or	I-P
hand-rolled	I-P
tobacco	I-P
.	O


FINDINGS	O
The	B-P
intervention	I-P
group	I-P
did	O
not	O
differ	O
from	O
the	B-P
control	I-P
group	I-P
on	O
the	B-OUT
primary	I-OUT
outcome	I-OUT
(	O
9.1	O
%	O
versus	O
9.3	O
%	O
;	O
odds	O
ratio	O
=	O
1.02	O
95	O
%	O
confidence	O
interval	O
0.73-1.42	O
)	O
or	O
on	O
any	B-OUT
of	I-OUT
the	I-OUT
secondary	I-OUT
outcomes	I-OUT
.	I-P


BACKGROUND	O
The	O
role	O
of	O
oximes	O
for	O
the	O
treatment	O
of	O
organophosphorus	B-P
pesticide	I-P
poisoning	I-P
has	O
not	O
been	O
conclusively	O
established	O
.	O


All	O
were	O
given	O
a	O
2	O
g	O
loading	O
dose	O
of	O
pralidoxime	B-I
over	O
30	O
min	O
.	O


Analysis	O
was	O
by	O
intention	O
to	O
treat	O
.	O


It	O
is	O
not	O
known	O
whether	O
parenteral	B-I
nutrition	I-I
(	I-I
PN	I-I
)	I-I
administered	O
during	O
bone	B-I
marrow	I-I
transplantation	I-I
(	I-I
BMT	I-I
)	I-I
supports	O
systemic	O
antioxidant	O
status	O
.	O


Plasma	B-OUT
cysteine	I-OUT
concentrations	I-OUT
were	O
unchanged	O
,	O
whereas	O
cystine	O
concentrations	O
increased	O
.	O


There	O
were	O
no	O
differences	O
in	O
other	O
plasma	B-OUT
antioxidants	I-OUT
between	O
groups	O
.	O


BACKGROUND	O
Autism	O
is	O
a	O
complex	O
neurodevelopmental	O
disorder	O
that	O
forms	O
part	O
of	O
a	O
spectrum	O
of	O
related	O
disorders	O
referred	O
to	O
as	O
Autism	O
Spectrum	O
Disorders	O
.	O


Measure	O
of	O
outcome	O
was	O
the	O
Aberrant	B-OUT
Behavior	I-OUT
Checklist-Community	I-OUT
(	I-OUT
ABC-C	I-OUT
)	I-OUT
Rating	I-OUT
Scale	I-OUT
.	I-OUT


CONCLUSION	O
The	O
results	O
of	O
this	O
study	O
show	O
that	O
remifentanil	B-I
1	O
mg/kg	O
is	O
more	O
effective	O
than	O
the	O
combination	O
of	O
lidocaine	B-I
1.5	O
mg/kg	O
and	O
esmolol	B-I
1	O
mg/kg	O
for	O
attenuating	O
the	O
hemodynamic	B-OUT
responses	I-OUT
to	O
rapid	O
sequence	O
intubation	O
.	O


A	O
phase	O
II	O
,	O
randomized	O
,	O
multicenter	O
study	O
evaluating	O
the	O
combination	O
of	O
lapatinib	O
and	O
vinorelbine	O
in	O
women	B-P
with	I-P
ErbB2	I-P
overexpressing	I-P
metastatic	I-P
breast	I-P
cancer	I-P
.	I-P


The	O
primary	O
endpoint	O
was	O
progression-free	B-OUT
survival	I-OUT
(	I-OUT
PFS	I-OUT
)	I-OUT
.	I-OUT


Previous	O
experimental	O
and	O
preclinical	O
studies	O
have	O
shown	O
that	O
a	O
short	O
intervention	O
with	O
enriched	O
enteral	O
nutrition	O
dampens	O
inflammation	O
via	O
stimulation	O
of	O
the	O
autonomic	O
nervous	O
system	O
and	O
thereby	O
reduces	O
postoperative	O
ileus	O
.	O


Patients	B-P
will	O
be	O
allocated	O
either	O
to	O
the	O
intervention	O
group	O
,	O
receiving	B-I
perioperative	I-I
nutrition	I-I
,	O
or	O
to	O
the	O
control	O
group	O
,	O
receiving	B-I
no	I-I
nutrition	I-I
.	I-I


Secondary	O
endpoints	O
include	O
anastomotic	B-OUT
leakage	I-OUT
,	I-OUT
local	I-OUT
and	I-OUT
systemic	I-OUT
inflammation	I-OUT
,	I-OUT
(	I-OUT
aspiration	I-OUT
)	I-OUT
pneumonia	I-OUT
,	I-OUT
surgical	I-OUT
complications	I-OUT
classified	I-OUT
according	I-OUT
to	I-OUT
Clavien-Dindo	I-OUT
,	I-OUT
quality	I-OUT
of	I-OUT
life	I-OUT
,	I-OUT
gut	I-OUT
barrier	I-OUT
integrity	I-OUT
and	I-OUT
time	I-OUT
until	I-OUT
functional	I-OUT
recovery	I-OUT
.	I-OUT


Furthermore	O
,	O
a	O
cost-effectiveness	O
analysis	O
will	O
be	O
performed	O
.	O


Dutch	O
Trial	O
Registry	O
:	O
NTR4670	O
-	O
date	O
of	O
registration	O
:	O
1	O
August	O
2014	O
.	O


DLPFC	O
activation	O
in	O
ASD	O
was	O
associated	O
with	O
increased	O
response	B-OUT
times	I-OUT
for	I-OUT
faces	I-OUT
.	I-OUT


OBJECTIVES	O
This	O
study	O
evaluated	O
the	O
effects	O
of	O
azimilide	B-I
dihydrochloride	I-I
(	I-I
AZ	I-I
)	I-I
on	O
anti-tachycardia	B-OUT
pacing	I-OUT
(	I-OUT
ATP	I-OUT
)	I-OUT
and	O
shock-terminated	B-OUT
events	I-OUT
in	O
patients	B-P
with	I-P
implantable	I-P
cardioverter	I-P
defibrillators	I-P
(	I-P
ICDs	I-P
)	I-P
.	I-P


BACKGROUND	O
Animal	O
studies	O
have	O
shown	O
the	O
effectiveness	O
of	O
AZ	O
for	O
therapy	O
of	O
supraventricular	O
and	O
ventricular	O
tachycardia	O
(	O
VT	O
)	O
.	O


The	O
WBC	O
count	O
in	O
P+EN	O
group	O
was	O
significantly	B-I
lower	O
than	O
that	O
in	O
PN	O
group	O
(	O
5.9	O
±	O
3.0	O
×	O
10⁹/L	O
,	O
6.3	O
±	O
3.2	O
×	O
10⁹/L	O
vs.	O
9.6	O
±	O
3.0	O
×10⁹/L	O
,	O
both	O
P	O
<	O
0.05	O
)	O
,	O
but	O
there	B-OUT
was	I-OUT
no	I-OUT
significant	I-I
difference	I-I
in	I-I
amylase	O
between	O
P+EN	O
group	O
and	O
PN	O
group	O
(	O
211	O
±	O
49	O
U/L	O
,	O
236	O
±	O
52	B-OUT
U/L	I-OUT
vs.	I-OUT
298	I-OUT
±	I-OUT
71	I-OUT
U/L	I-OUT
,	I-OUT
P	I-OUT
>	I-OUT
0.05	I-OUT
)	I-OUT
.	I-OUT


There	B-OUT
was	I-OUT
no	I-OUT
significant	I-OUT
statistical	O
difference	O
in	O
mortality	O
rate	O
among	O
three	O
groups	B-I
.	I-I


The	O
null	O
hypothesis	O
was	O
,	O
therefore	O
,	O
accepted	O
.	O


Further	O
studies	O
using	O
long-term	O
aging	O
procedures	O
should	O
be	O
conducted	O
.	O


Preoperative	O
Local	O
Administration	O
of	O
Morphine	B-I
as	O
an	O
Add-on	O
Therapy	O
in	O
Patients	B-P
Undergoing	I-P
Surgical	I-P
Removal	I-P
of	I-P
an	I-P
Odontogenic	I-P
Maxillary	I-P
Cyst	I-P
.	I-P


A	O
Randomized	O
,	O
Double-Blind	O
Pilot	O
Study	O
.	O


AIMS	O
To	O
evaluate	O
whether	O
a	O
combination	O
of	O
locally	O
administered	O
morphine	B-I
(	O
1	O
mg	O
)	O
and	O
lidocaine	B-I
as	O
part	O
of	O
a	O
multimodal	O
analgesic	O
approach	O
is	O
safe	O
,	O
and	O
whether	O
it	O
improves	O
pain	O
control	O
during	O
the	B-P
first	I-P
24	I-P
hours	I-P
after	I-P
odontogenic	I-P
maxillary	I-P
cyst	I-P
removal	I-P
under	I-P
general	I-P
anesthesia	I-P
compared	O
to	O
local	O
lidocaine	O
alone	O
.	O


Effects	O
of	O
misoprostol	B-OUT
on	O
human	B-P
circulation	I-P
.	I-P


However	O
,	O
vasoconstrictor	O
effects	O
of	O
PGEs	O
have	O
also	O
been	O
noted	O
at	O
selected	O
sites	O
.	O


Twenty	B-P
healthy	I-P
subjects	I-P
participated	I-P
in	O
this	O
double-blind	O
,	O
placebo-controlled	O
,	O
parallel	O
group	O
study	O
.	O


Following	O
a	O
12	O
hour	O
fast	O
,	O
heart	O
rate	O
,	O
arterial	O
blood	O
pressure	O
,	O
light	O
reflex	O
plethysmography	O
of	O
the	O
finger	O
,	O
resting	O
blood	O
flow	O
volume	O
in	O
the	O
lower	O
arm	O
and	O
leg	O
and	O
peripheral	B-OUT
vascular	I-OUT
resistance	I-OUT
were	O
measured	O
at	O
10	O
min	O
.	O


These	O
small	O
changes	O
were	O
not	O
considered	O
to	O
be	O
of	O
clinical	O
importance	O
.	O


Compared	O
with	O
the	O
remaining	O
693	O
patients	O
,	O
subjects	O
with	O
left	B-OUT
ventricular	I-OUT
thrombosis	I-OUT
were	O
older	O
(	O
mean	O
(	O
SD	O
)	O
age	O
:	O
64.6	O
(	O
13.0	O
)	O
v	O
59.8	O
(	O
11.7	O
)	O
years	O
,	O
p	O
<	O
0.005	O
)	O
,	O
and	O
had	O
larger	B-OUT
infarcts	I-OUT
(	O
extent	O
of	O
wall	O
motion	O
asynergy	O
:	O
40.9	O
(	O
11.5	O
)	O
%	O
v	O
24.9	O
(	O
14	O
)	O
%	O
,	O
p	O
<	O
0.001	O
)	O
,	O
greater	O
depression	B-OUT
of	I-OUT
left	I-OUT
ventricular	I-OUT
ejection	I-OUT
fraction	I-OUT
at	I-OUT
S1	I-OUT
(	O
43.3	O
(	O
6.9	O
)	O
%	O
v	O
48.1	O
(	O
6.8	O
)	O
%	O
,	O
p	O
<	O
0.001	O
)	O
,	O
and	O
greater	O
left	B-OUT
ventricular	I-OUT
volumes	I-OUT
at	I-OUT
S1	I-OUT
(	O
end	O
diastolic	O
volume	O
:	O
87	O
(	O
22	O
)	O
v	O
78	O
(	O
18	O
)	O
ml/m	O
(	O
2	O
)	O
,	O
p	O
<	O
0.001	O
;	O
end	O
systolic	O
volume	O
:	O
50	O
(	O
17	O
)	O
v	O
41	O
(	O
14	O
)	O
ml/m	O
(	O
2	O
)	O
,	O
p	O
<	O
0.001	O
)	O
.	O


The	O
prevalence	B-OUT
of	I-OUT
moderate	I-OUT
to	I-OUT
severe	I-OUT
mitral	I-OUT
regurgitation	I-OUT
on	I-OUT
colour	I-OUT
Doppler	I-OUT
at	I-OUT
S1	I-OUT
was	O
greater	O
in	O
patients	O
who	O
had	O
left	B-OUT
ventricular	I-OUT
thrombosis	I-OUT
at	O
any	O
time	O
(	O
10.2	O
%	O
v	O
4.2	O
%	O
,	O
p	O
<	O
0.05	O
)	O
.	O


CONCLUSIONS	O
Left	B-OUT
ventricular	I-OUT
thrombosis	I-OUT
is	O
not	O
reduced	O
,	O
and	O
may	O
even	O
be	O
increased	O
,	O
by	O
early	O
moderate	O
to	O
severe	O
mitral	O
regurgitation	O
after	O
acute	O
myocardial	O
infarction	O
.	O


AIDS	O
Clinical	O
Trials	O
Group	O
Protocol	O
204/Glaxo	O
Wellcome	O
123-014	O
International	O
CMV	O
Prophylaxis	O
Study	O
Group	O
.	O


The	O
intervention	O
paid	O
particular	O
attention	O
to	O
postnatal	O
maternal	O
depression	O
and	O
promoting	O
parenting	O
skills	O
and	O
attachment	O
security	O
,	O
particularly	O
through	O
the	O
use	B-I
of	I-I
video	I-I
during	I-I
home-visits	I-I
.	I-I


A	O
major	O
issue	O
was	O
that	O
of	O
adapting	O
international	O
best	O
practice	O
recommendations	O
with	O
regard	O
to	O
home-visiting	O
programs	O
to	O
the	O
particularities	O
of	O
the	O
existing	O
French	O
social	O
and	O
health	O
care	O
system	O
.	O


The	O
WAIS-III	O
General	O
Ability	O
Index	O
(	O
GAI	O
;	O
Tulsky	O
,	O
Saklofske	O
,	O
Wilkins	O
,	O
&	O
Weiss	O
,	O
2001	O
)	O
is	O
a	O
recently	O
developed	O
,	O
6-subtest	O
measure	O
of	O
global	O
intellectual	O
functioning	O
.	O


The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
develop	O
regression	O
equations	O
to	O
estimate	O
GAI	B-OUT
scores	I-OUT
from	O
demographic	O
variables	O
and	O
WAIS-III	B-OUT
subtest	I-OUT
performance	I-OUT
.	I-OUT


The	O
first	O
group	O
(	O
n=1,200	O
)	O
was	O
used	O
to	O
develop	B-I
the	I-I
formulas	I-I
(	O
i.e.	O
,	O
Development	O
group	O
)	O
and	O
the	O
second	O
(	O
n=1,201	O
)	O
group	O
was	O
used	O
to	O
validate	B-I
the	I-I
prediction	I-I
algorithms	I-I
(	O
i.e.	O
,	O
Validation	O
group	O
)	O
.	O


METHOD	O
The	O
study	O
was	O
a	O
single-blind	O
,	O
randomised	O
,	O
five-treatment	B-I
cross-over	I-I
design	I-I
involving	O
15	B-P
healthy	I-P
volunteers	I-P
.	I-P


Drinking	B-I
water	I-I
and	O
brushing	B-I
with	O
toothpaste	B-I
A	O
.	O


Drinking	B-I
orange	I-I
juice	I-I
.	I-I


4	O
.	O


METHODS	O
Fifty-one	B-P
patients	I-P
participated	I-P
in	I-P
this	I-P
study	I-P
for	I-P
a	I-P
total	I-P
of	I-P
174	I-P
teeth	I-P
.	I-P


In	O
the	O
control	O
group	O
no	B-I
treatment	I-I
was	O
performed	O
.	O


After	O
adjustment	O
for	O
baseline	O
and	O
practice	O
,	O
there	O
was	O
a	O
significant	O
difference	O
at	O
followup	O
between	O
intervention	O
and	O
control	O
practices	O
on	O
the	O
Mini	B-OUT
AQLQ	I-OUT
only	O
(	O
p=0.03	O
)	O
.	O


Estimates	O
for	O
subsequent	O
sample	O
sizes	O
to	O
inform	O
future	O
trials	O
of	O
asthma	O
training	O
were	O
identified	O
.	O


Uterine	O
incision	O
closure	O
at	O
caesarean	O
section	O
:	O
a	O
randomised	O
comparative	O
study	O
of	O
intraperitoneal	B-I
closure	I-I
and	I-I
closure	I-I
after	I-I
temporary	I-I
exteriorisation	I-I
.	I-I


OBJECTIVE	O
To	O
evaluate	O
the	O
influence	O
of	O
exteriorization	O
of	O
uterus	O
during	O
uterine	O
repair	O
on	O
caesarean	O
morbidity	O
.	O


METHODS	O
A	O
randomized	O
comparative	O
study	O
of	O
136	B-P
women	I-P
undergoing	I-P
primary	I-P
caesarean	I-P
delivery	I-P
at	I-P
Havana	I-P
Specialist	I-P
Hospital	I-P
Lagos	I-P
Nigeria	I-P
.	I-P


RESULTS	O
The	O
mean	B-OUT
operative	I-OUT
time	I-OUT
,	I-OUT
estimated	I-OUT
blood	I-OUT
loss	I-OUT
,	I-OUT
transfusion	I-OUT
rate	I-OUT
and	I-OUT
postoperative	I-OUT
anemia	I-OUT
rate	I-OUT
were	O
significantly	O
less	O
in	O
the	O
exteriorized	O
group	O
than	O
the	O
intraperitoneal	O
group	O
(	O
p	O
=	O
0.000	O
,	O
0.009,0.048	O
0.038	O
and	O
0.028	O
respectively	O
)	O
,	O
but	O
not	O
in	O
other	O
outcome	O
measures	O
.	O


CONCLUSION	O
With	O
shorter	O
operative	O
time	O
,	O
less	O
blood	O
loss	O
and	O
similar	O
morbidity	O
profile	O
exteriorization	O
of	O
uterus	O
during	O
caesarean	O
section	O
seems	O
to	O
be	O
preferred	O
except	O
where	O
it	O
is	O
not	O
possible	O
because	O
of	O
adhesions	O
and	O
surgeons	O
inexperience	O
.	O


2	O
.	O


Down	O
syndrome	O
children	O
with	O
Autism	O
Spectrum	O
Disorder	O
displayed	O
more	B-OUT
restricted	I-OUT
repetitive	I-OUT
and	I-OUT
stereotyped	I-OUT
patterns	I-OUT
of	I-OUT
behaviors	I-OUT
,	I-OUT
interests	I-OUT
and	I-OUT
activities	I-OUT
.	I-OUT


OBJECTIVES	O
To	O
examine	O
whether	O
an	O
acute	O
bout	O
of	O
active	B-I
or	I-I
dynamic	I-I
hamstring-stretching	I-I
exercises	I-I
would	O
reduce	O
the	O
amount	O
of	O
muscle	O
damage	O
observed	O
after	O
a	O
strenuous	O
eccentric	O
task	O
and	O
to	O
determine	O
whether	O
the	O
stretching	O
protocols	O
elicit	O
similar	O
responses	O
.	O


Heart	O
rate	O
,	O
core	O
temperature	O
,	O
maximal	O
voluntary	O
isometric	O
contraction	O
,	O
passive	O
hip	O
flexion	O
,	O
passive	O
hamstring	O
stiffness	O
(	O
PHS	O
)	O
,	O
plasma	O
creatine	O
kinase	O
activity	O
,	O
and	O
myoglobin	O
were	O
recorded	O
at	O
prestretching	O
,	O
at	O
poststretching	O
,	O
and	O
every	O
day	O
after	O
the	O
eccentric	O
exercises	O
for	O
5	O
d.	O
RESULTS	O
After	O
stretching	B-I
,	O
the	O
change	B-OUT
in	I-OUT
hip	I-OUT
flexion	I-OUT
was	O
significantly	O
higher	O
in	O
the	O
SAS	B-I
(	O
5°	O
)	O
and	B-I
DAS	I-I
(	O
10.8°	O
)	O
groups	O
than	O
in	O
the	B-I
CON	I-I
(	O
-4.1°	O
)	O
group	O
.	O


Based	O
on	O
those	O
data	O
,	O
a	O
randomised	O
multicentre	O
study	O
was	O
started	O
to	O
explore	O
the	O
risk	O
of	O
an	O
anastomotic	B-OUT
leakage	I-OUT
based	O
upon	O
the	O
surgical	B-I
device	I-I
.	I-I


Perioperative	O
randomisation	O
was	O
to	O
Ethicon™	B-I
PROXIMATE™	I-I
ILS™	I-I
or	I-I
Autosuture™	I-I
Premium	I-I
Plus	I-OUT
CEEA™	I-OUT
.	I-OUT


RESULTS	B-P
Five	I-P
hundred	I-P
twenty-nine	I-P
patients	I-P
were	I-P
randomised	I-P
(	I-OUT
58	I-OUT
%	I-OUT
male	I-OUT
)	I-OUT
.	O


The	O
anastomoses	O
created	B-I
by	I-I
PROXIMATE™	I-OUT
ILS™	O
leaked	O
in	O
25/265	O
(	O
9.4	O
%	O
)	O
anastomoses	B-I
,	I-I
and	I-I
the	I-I
Premium	I-I
Plus	O
CEEA™	O
leaked	O
in	O
19/260	O
(	O
7.3	O
%	O
)	O
,	O
p	O
=	O
.419	O
.	O


CONCLUSION	O
No	B-OUT
difference	I-OUT
in	O
the	O
leak	O
rate	O
could	O
be	O
revealed	O
.	O


Several	O
centres	O
replaced	O
one	O
of	O
the	O
staplers	O
by	O
a	O
new	O
product	O
,	O
and	O
the	O
study	O
was	O
ended	O
before	O
the	O
stipulated	O
number	O
of	O
patients	O
was	O
reached	O
.	O


Four	O
0.4-mg	O
formulations	B-I
with	I-I
different	I-I
in	I-I
vitro	I-I
"	I-I
burst	I-I
times	I-I
"	I-I
and	O
dissolution	B-I
rates	I-I
were	O
administered	O
,	O
with	O
2-week	O
intervals	O
between	O
treatments	O
.	O


OBJECTIVE	O
To	O
evaluate	O
the	O
effect	O
of	O
veno-venous	B-I
continuous	I-I
renal	I-I
replacement	I-I
therapy	I-I
(	I-I
CRRT	I-I
)	I-I
on	O
the	O
plasma	O
levels	O
of	O
endotoxin	O
and	O
cytokines	O
in	O
severely	B-P
burned	I-P
patients	I-P
with	I-P
sepsis	I-P
.	I-P


Maximal	B-OUT
heart	I-OUT
rate	I-OUT
was	O
reduced	O
further	O
by	O
a	O
total	O
daily	O
dose	O
of	O
200	O
mg	O
than	O
by	O
lower	O
doses	O
,	O
but	O
no	O
extra	O
benefit	O
was	O
derived	O
by	O
giving	O
the	O
drug	O
twice	O
daily	O
.	O


DESIGN	O
A	O
randomized	O
,	O
double-blind	O
controlled	O
trial	O
.	O


The	O
incidence	O
of	O
major	B-OUT
bleeding	I-OUT
was	O
1.8	O
%	O
(	O
6	O
of	O
334	O
patients	O
)	O
in	O
the	O
warfarin	O
group	O
and	O
2.1	O
%	O
(	O
7	O
of	O
336	O
patients	O
)	O
in	O
the	O
enoxaparin	O
group	O
(	O
P	O
>	O
0.2	O
)	O
.	O


CONCLUSIONS	O
A	O
postoperative	O
,	O
fixed-dose	O
enoxaparin	B-I
regimen	O
is	O
more	O
effective	O
than	O
adjusted-dose	O
warfarin	B-I
in	O
preventing	O
deep	O
venous	O
thrombosis	O
after	B-P
knee	I-P
arthroplasty	I-P
.	I-P


All	B-I
subjects	I-I
underwent	I-I
assessment	I-I
of	I-I
levels	I-OUT
for	I-OUT
creatinine	I-OUT
,	I-OUT
creatinine	I-OUT
clearance	I-OUT
,	I-OUT
average	I-OUT
pressure	I-OUT
,	I-OUT
total	I-OUT
cholesterol	I-OUT
,	I-OUT
triglyceride	I-OUT
and	I-OUT
fasting	I-OUT
homocysteine	I-OUT
.	I-OUT


In	O
group	O
A	O
,	O
endothelium	O
dependent	O
[	O
(	O
12	O
+/-	O
5	O
)	O
%	O
vs	O
(	O
9	O
+/-	O
5	O
)	O
%	O
,	O
t	O
=	O
2.9	O
,	O
P	O
<	O
0.01	O
]	O
and	O
independent	O
[	O
(	O
18	O
+/-	O
4	O
)	O
%	O
vs	O
(	O
12	O
+/-	O
5	O
)	O
%	O
,	O
t	O
=	O
3.4	O
,	O
P	O
<	O
0.01	O
]	O
vasodilatation	B-OUT
responses	I-OUT
significantly	O
increased	O
after	O
treatment	O
,	O
no	O
significant	O
changes	O
were	O
observed	O
in	O
group	O
B.	O
Endothelium	O
dependent	O
[	O
(	O
9	O
+/-	O
6	O
)	O
%	O
,	O
t	O
=	O
2.8	O
,	O
P	O
<	O
0.01	O
]	O
and	O
independent	O
[	O
(	O
12	O
+/-	O
5	O
)	O
%	O
,	O
t	O
=	O
3.5	O
,	O
P	O
<	O
0.01	O
]	O
vasodilatation	B-OUT
responses	I-OUT
of	O
group	O
A	O
were	O
significantly	O
lower	O
than	O
that	O
of	O
group	O
B	O
after	O
treatment	O
.	O


FINDINGS	O
At	O
the	O
time	O
of	O
analysis	O
,	O
393	O
(	O
96	O
%	O
)	O
patients	O
had	O
died	B-OUT
(	O
ASC	O
132	O
[	O
97	O
%	O
]	O
,	O
ASC	O
plus	O
MVP	O
132	O
[	O
96	O
%	O
]	O
,	O
ASC	O
plus	O
vinorelbine	O
129	O
[	O
95	O
%	O
]	O
)	O
.	O


Exploratory	O
analyses	O
suggested	O
a	O
survival	B-OUT
advantage	I-OUT
for	O
ASC	O
plus	O
vinorelbine	O
compared	O
with	O
ASC	O
alone	O
(	O
HR	O
0.80	O
[	O
0.63-1.02	O
]	O
;	O
p=0.08	O
)	O
,	O
with	O
a	O
median	B-OUT
survival	I-OUT
of	O
9.5	O
months	O
.	O


Child	O
outcomes	O
are	O
reported	O
from	O
baseline	O
to	O
the	O
end	O
of	O
the	O
9-month	O
interventions	O
.	O


CONCLUSIONS	O
These	O
findings	O
support	O
the	O
efficacy	O
of	O
individual-ESI	B-I
compared	O
with	O
group-ESI	B-I
on	O
child	O
outcomes	O
,	O
suggesting	O
the	O
importance	O
of	O
individualized	B-I
parent	I-I
coaching	I-I
in	O
natural	O
environments	O
.	O


METHODS	O
The	O
relationship	O
between	O
the	O
changes	O
of	O
endogenous	O
estrogen	O
and	O
the	O
concentration	O
of	O
cholesteryl	O
ester	O
transfer	O
protein	O
(	O
CETP	O
)	O
in	O
the	O
serum	O
of	O
Chinese	B-P
women	I-P
was	O
investigated	O
.	O


Employment	O
rates	O
are	O
reported	O
in	O
many	O
studies	O
to	O
be	O
very	O
low	O
despite	O
many	O
years	O
of	O
intensive	O
special	O
education	O
services	O
.	O


Specifically	B-OUT
,	I-OUT
21	I-OUT
out	I-OUT
of	I-OUT
24	I-OUT
(	I-OUT
87.5	I-OUT
%	I-OUT
)	I-OUT
treatment	I-OUT
group	I-OUT
participants	I-OUT
acquired	I-OUT
employment	I-OUT
while	I-OUT
1	I-OUT
of	I-OUT
16	I-OUT
(	I-OUT
6.25	I-OUT
%	I-OUT
)	I-OUT
of	I-OUT
control	I-OUT
group	I-OUT
participants	I-OUT
acquired	I-OUT
employment	I-OUT
.	I-OUT


A	O
total	O
of	O
110	B-P
duodenal	I-P
ulcer	I-P
patients	I-P
were	O
studied	O
in	O
a	O
randomized	O
,	O
double-blind	O
,	O
placebo-controlled	O
,	O
multicentre	O
clinical	O
trial	O
.	O


The	O
incidence	O
of	O
side	B-OUT
effects	I-OUT
was	O
less	O
than	O
that	O
presented	O
by	O
the	O
placebo	O
group	O
,	O
possibly	O
due	O
to	O
a	O
greater	O
consumption	O
of	O
antacids	O
in	O
this	O
group	O
.	O


Efficacy	B-OUT
and	I-OUT
safety	I-OUT
of	O
a	O
very-low-protein	B-I
diet	I-I
when	O
postponing	B-P
dialysis	I-P
in	I-P
the	I-P
elderly	I-P
:	I-P
a	O
prospective	O
randomized	O
multicenter	O
controlled	O
study	O
.	O


LIMITATIONS	O
The	O
unblinded	O
nature	O
of	O
the	O
study	O
,	O
exclusion	O
of	O
patients	O
with	O
diabetes	O
,	O
and	O
incomplete	O
enrollment	O
.	O


Fifty-six	B-P
patients	I-P
(	I-P
49	I-P
boys	I-P
,	I-P
7	I-P
girls	I-P
,	I-P
mean	I-P
age	I-P
=	I-P
6.4	I-P
years	I-P
,	I-P
SD	I-P
=	I-P
2.7	I-P
)	I-P
enrolled	I-P
in	I-P
an	I-P
open-label	I-P
trial	I-P
of	I-P
secretin	I-I
,	I-P
during	I-P
which	I-P
they	I-P
received	I-P
one	I-P
injection	I-P
of	I-P
the	I-P
hormone	I-P
(	I-P
2	I-P
IU/kg	I-P
)	I-P
.	I-P


At	O
follow-up	O
,	O
some	O
reported	O
minimal	O
but	O
potentially	O
significant	O
improvements	O
including	O
changes	B-OUT
in	I-OUT
GI	I-OUT
symptoms	I-OUT
,	I-OUT
expressive	I-OUT
and/or	I-OUT
receptive	I-OUT
language	I-OUT
function	I-OUT
,	I-OUT
and	I-OUT
improved	I-OUT
awareness	I-OUT
and	I-OUT
social	I-OUT
interactions	I-OUT
.	I-OUT


Induction	B-I
versus	O
noninduction	B-I
in	O
renal	B-P
transplant	I-P
recipients	I-P
with	I-P
tacrolimus-based	I-P
immunosuppression	I-P
.	I-P


The	O
incidence	B-OUT
of	I-OUT
steroid-sensitive	I-OUT
acute	I-OUT
rejections	I-OUT
was	O
7.9	O
%	O
(	O
induction	O
)	O
and	O
22.2	O
%	O
(	O
noninduction	O
)	O
(	O
P=0.001	O
)	O
.	O


Effectiveness	B-OUT
of	O
the	O
school	B-I
dental	I-I
screening	I-I
programme	I-I
in	O
stimulating	B-OUT
dental	I-OUT
attendance	I-OUT
for	O
children	B-P
in	I-P
need	I-P
of	I-P
treatment	I-P
in	I-P
Northern	I-P
Ireland	I-P
.	I-P


OBJECTIVE	O
To	O
evaluate	O
the	O
effectiveness	O
of	O
school	B-I
dental	I-I
screening	I-I
in	O
promoting	O
dental	B-OUT
attendance	I-OUT
among	O
children	B-P
with	I-P
a	I-P
treatment	I-P
need	I-P
and	O
to	O
examine	O
the	O
relative	O
importance	O
of	O
screening	O
,	O
social	O
class	O
and	O
other	O
factors	O
in	O
dental	B-OUT
attendance	I-OUT
.	I-OUT


The	O
control	O
group	B-I
children	I-I
were	I-I
not	I-I
,	I-I
at	I-I
this	I-I
stage	I-I
,	I-I
screened	I-I
,	O
yet	O
their	O
parents	O
received	O
the	O
same	B-I
questionnaire	I-I
assessing	I-I
dental	I-OUT
attendance	I-OUT
over	I-I
the	I-I
2-month	I-I
period	I-I
.	I-I


In	O
the	O
same	O
period	O
,	O
27.6	O
%	O
of	O
the	O
control	O
group	O
(	O
n=312	O
)	O
claimed	O
attendance	O
.	O


Dose	O
distribution	O
curves	O
in	O
cross-section	O
and	O
midsagittal	O
planes	O
are	O
shown	O
and	O
calculations	O
or	O
equivalent	O
doses	O
at	O
various	O
selected	O
points	O
using	O
Ellis	O
's	O
nominal	O
single-dose	O
formula	O
are	O
tabulated	O
.	O


A	O
Thr-deficient	B-I
basal	I-I
diet	O
(	O
3.1	O
g	O
of	O
Thr/kg	O
of	O
diet	O
)	O
was	O
supplemented	O
with	O
70	B-I
g/kg	I-I
of	I-I
silica	I-I
sand	I-I
(	I-I
control	I-I
)	I-I
or	I-I
high-methoxy	I-I
pectin	I-I
and	I-I
1	I-I
of	I-I
2	I-I
concentrations	I-I
of	I-I
Thr	I-I
(	O
1.8	O
or	O
5.3	O
g/kg	O
of	O
diet	O
;	O
4	O
diets	O
total	O
)	O
,	O
and	O
fed	O
to	O
chicks	B-P
from	I-P
hatch	I-P
to	I-P
d	I-P
16	I-P
posthatch	I-P
.	I-P


Eimeria	B-OUT
maxima	I-OUT
schizonts	I-OUT
were	O
present	O
only	O
in	O
intestinal	O
tissue	O
sampled	O
from	O
infected	O
birds	O
(	O
P	O
<	O
0.01	O
)	O
.	B-OUT


There	O
were	O
no	O
differences	O
due	O
to	O
infection	B-I
or	I-I
Thr	I-I
supplementation	I-I
for	O
cytokine	O
expression	O
in	O
birds	O
fed	O
pectin-containing	O
treatments	O
.	O


The	O
CDAI	O
does	O
not	O
contain	O
an	O
acute-phase	O
reactant	O
component	O
.	O


Disease	B-OUT
activity	I-OUT
states	I-OUT
,	I-OUT
including	I-OUT
remission	I-OUT
,	O
were	O
defined	O
using	O
established	O
cut	O
points	O
;	O
for	O
the	O
DAS28	O
,	O
an	O
alternative	O
cut	O
point	O
of	O
<	O
2.4	O
was	O
also	O
used	O
.	O


Supplementary	O
electrocardiography	B-OUT
(	I-OUT
ECG	I-OUT
)	I-OUT
was	O
performed	O
before	O
and	O
after	O
6-month	O
treatment	O
.	O


MWC	B-OUT
showed	O
a	O
slight	O
,	O
insignificant	O
decrease	O
in	O
both	O
groups	O
.	O


No	O
changes	O
in	O
B-Hb	B-OUT
,	I-OUT
blood	I-OUT
pressure	I-OUT
or	O
pulse	O
were	O
observed	O
during	O
the	O
treatment	O
period	O
.	O


RESULTS	O
The	B-P
two	I-P
groups	I-P
were	I-P
well	I-P
matched	I-P
for	I-P
age	I-P
,	I-P
weight	I-P
,	I-P
and	I-P
other	I-P
factors	I-P
,	O
which	O
could	O
predispose	O
to	O
the	O
development	B-OUT
of	I-OUT
deep	I-OUT
venous	I-OUT
thrombosis	I-OUT
(	I-OUT
DVT	I-OUT
)	I-OUT
and	I-OUT
haemorrhage	I-OUT
.	I-OUT


OBJECTIVE	O
We	O
investigated	O
the	O
use	O
of	O
the	O
bispectral	B-I
index	I-I
for	O
monitoring	O
sedation	B-I
during	O
cardiac	B-OUT
catheterization	I-OUT
.	I-OUT


In	O
66	O
patients	O
,	O
sedation	B-I
was	O
performed	O
without	B-I
use	I-I
of	I-I
the	I-I
bispectral	I-I
index	I-I
,	I-I
while	I-I
the	I-I
index	I-I
was	I-I
used	I-I
in	I-I
the	I-I
other	I-I
60	O
patients	O
.	O


The	O
clinical	B-OUT
evaluation	I-OUT
and	I-OUT
laboratory	I-OUT
tests	I-OUT
were	O
performed	O
before	O
treatment	O
(	O
baseline	O
)	O
and	O
after	O
3	O
and	O
9	O
months	O
of	O
therapy	O
.	O


Proteinuria	B-OUT
reduction	I-OUT
was	O
significantly	O
greater	O
in	O
patients	O
receiving	O
combined	O
therapy	O
in	O
comparison	O
with	O
losartan	O
treatment	O
after	O
3	O
months	O
of	O
therapy	O
(	O
p	O
=	O
0.02	O
)	O
.	O


No	O
significant	O
changes	B-OUT
in	I-OUT
lipids	I-OUT
,	I-OUT
serum	I-OUT
uric	I-OUT
acid	I-OUT
or	I-OUT
protein	I-OUT
levels	I-OUT
were	O
observed	O
.	O


CONCLUSIONS	O
These	O
results	O
indicate	O
that	O
proteinuria	O
is	O
reduced	O
by	O
low	O
doses	O
of	O
losartan	O
or	O
enalapril	O
.	O


The	O
authors	O
describe	O
neuropsychological	O
outcomes	O
in	O
people	B-P
with	I-P
Parkinson	I-P
's	I-P
disease	I-P
(	I-P
PD	I-P
)	I-P
after	I-P
their	I-P
participation	I-P
in	I-P
an	I-P
NIH-sponsored	I-P
,	I-P
randomized	I-P
,	I-P
controlled	I-P
trial	I-P
of	I-P
cognitive-behavioral	I-I
treatment	I-I
for	I-P
depression	I-P
.	I-P


CONCLUSIONS	O
Dual	O
prophylaxis	O
with	O
LMWH	B-I
and	I-I
GCS	I-I
should	O
be	O
recommended	O
for	O
gynecologic	O
cancer	O
patients	O
undergoing	O
major	O
surgery	O
for	O
its	O
better	O
efficacy	B-OUT
than	O
GCS	B-I
.	I-I


Patients	O
with	O
older	O
age	O
and	O
prolonged	O
operation	O
time	O
are	O
at	O
highest	O
risk	O
of	O
developing	O
VTE	B-OUT
post-operatively	I-OUT
.	I-OUT


The	O
purpose	O
of	O
this	O
randomized	O
,	O
double-blind	O
,	O
placebo-controlled	O
study	O
was	O
to	O
investigate	O
the	O
efficacy	O
and	O
tolerability	O
of	O
the	O
active	O
combination	O
in	O
the	O
treatment	O
of	O
post-hemorrhoidectomy	B-P
patients	I-P
.	I-P


Sleep	B-OUT
disturbances	I-OUT
are	O
regarded	O
as	O
a	O
common	O
clinical	O
feature	O
in	O
autistic	B-P
children	I-P
.	I-P


In	O
addition	O
,	O
ZH-fed	O
steers	O
produced	O
a	O
greater	O
(	O
P	O
<	O
0.001	O
)	O
percentage	B-OUT
of	I-OUT
USDA	I-OUT
YG	I-OUT
1	I-OUT
carcasses	I-OUT
(	O
25.9	O
vs.	O
16.2	O
%	O
)	O
and	O
a	O
lesser	O
(	O
P	O
<	O
0.001	O
)	O
percentage	O
of	O
YG	O
4	O
or	O
higher	O
carcasses	O
(	O
1.6	O
vs.	O
6.0	O
%	O
)	O
than	O
steers	O
fed	O
the	O
control	O
diet	B-OUT
.	I-OUT


Postoperative	O
injection	O
of	O
phenylbutazone	B-I
does	O
not	O
influence	O
fibrinolytic	B-OUT
shutdown	I-OUT
.	I-OUT


Fibrinolytic	B-OUT
activity	I-OUT
in	I-OUT
euglobulins	I-OUT
was	O
decreased	O
after	O
the	O
operation	O
in	O
both	O
groups	O
.	O


It	O
can	O
be	O
speculated	O
,	O
however	O
,	O
that	O
the	O
decline	O
of	O
plasminogen	B-OUT
concentration	I-OUT
after	O
surgery	O
in	O
patients	O
receiving	O
this	O
drug	O
was	O
the	O
result	O
of	O
its	O
stimulatory	O
influence	O
on	O
the	O
conversion	O
of	O
plasminogen	O
into	O
plasmin	O
.	O


Risperidone-induced	O
prolactin	B-OUT
elevation	I-OUT
in	O
a	O
prospective	O
study	O
of	O
children	B-P
,	I-P
adolescents	I-P
,	I-P
and	I-P
adults	I-P
with	I-P
mental	I-P
retardation	I-P
and	I-P
pervasive	I-P
developmental	I-P
disorders	I-P
.	I-P


Females	O
may	O
show	O
greater	O
prolactin	B-OUT
elevation	I-OUT
than	O
males	O
.	O


Prolactin	B-OUT
was	O
measured	O
in	O
ng/mL	O
at	O
baseline	O
,	O
once	O
during	O
acute	O
treatment	O
,	O
and	O
once	O
during	O
maintenance	O
.	O


In	O
adults	O
,	O
females	O
showed	O
significantly	O
greater	O
elevations	O
than	O
males	O
.	O


Treatment	O
with	O
omeprazole	B-I
20	O
mg	O
and	O
amoxycillin	B-I
1000	O
mg	O
twice	O
daily	O
for	O
14	O
days	O
altered	O
the	O
normal	O
microflora	O
in	O
the	O
oral	O
,	O
gastric	O
and	O
intestinal	O
tract	O
and	O
antibiotic	O
resistant	O
microorganisms	O
increased	O
in	O
numbers	O
in	O
the	O
intestinal	B-OUT
microflora	I-OUT
.	I-OUT


Cervical	O
spine	O
motion	O
:	O
a	O
fluoroscopic	O
comparison	O
during	O
intubation	B-P
with	O
lighted	O
stylet	O
,	O
GlideScope	O
,	O
and	O
Macintosh	O
laryngoscope	O
.	O


Thus	O
,	O
the	O
Lightwand	O
(	O
Intubating	O
Lighted	O
Stylet	O
)	O
is	O
associated	O
with	O
reduced	O
C-spine	B-OUT
movement	I-OUT
during	O
endotracheal	O
intubation	O
compared	O
with	O
the	O
Macintosh	O
laryngoscope	O
.	O


The	O
Effects	O
of	O
Valsartan	B-I
and	O
Amlodipine	B-I
on	O
the	O
Levels	O
of	O
Irisin	B-I
,	I-I
Adropin	I-I
,	I-I
and	I-I
Perilipin	I-I
.	I-I


Their	O
effect	O
on	O
etiopathogenesis	O
of	O
hypertension	O
is	O
now	O
an	O
area	O
of	O
developing	O
research	O
.	O


The	O
association	O
between	O
hypertension	O
and	O
obesity	O
also	O
suggests	O
the	O
link	O
between	O
antihypertensive	O
agents	O
and	O
energy	O
hemostasis	O
.	O


Risperidone	B-I
and	O
adaptive	B-OUT
behavior	I-OUT
in	O
children	B-P
with	I-P
autism	I-P
.	I-P


METHOD	O
Forty-eight	B-P
children	I-P
(	I-P
5	I-P
years	I-P
to	I-P
16	I-P
years	I-P
,	I-P
5	I-P
months	I-P
)	I-P
who	I-P
showed	I-P
behavioral	I-P
improvement	I-OUT
during	I-P
acute	I-P
treatment	I-P
with	I-P
risperidone	I-I
were	I-I
followed	I-I
for	I-I
6	I-I
months	I-I
and	O
assessed	O
with	O
the	O
Vineland	O
Scales	O
.	O


Lack	O
of	O
efficacy	B-OUT
of	O
citalopram	B-I
in	O
children	B-P
with	I-P
autism	I-P
spectrum	I-P
disorders	I-P
and	I-P
high	I-P
levels	I-P
of	I-P
repetitive	I-P
behavior	I-P
:	I-P
citalopram	I-I
ineffective	O
in	O
children	B-P
with	I-P
autism	I-P
.	I-P


DESIGN	O
National	O
Institutes	O
of	O
Health-sponsored	O
randomized	O
controlled	O
trial	O
.	O


The	O
mean	O
(	O
SD	O
)	O
maximum	O
dosage	O
of	O
citalopram	B-I
hydrobromide	I-I
was	O
16.5	O
(	O
6.5	O
)	O
mg/d	O
by	O
mouth	O
(	O
maximum	O
,	O
20	O
mg/d	O
)	O
.	O


Citalopram	B-I
use	O
was	O
significantly	O
more	O
likely	O
to	O
be	O
associated	O
with	O
adverse	O
events	O
,	O
particularly	O
increased	O
energy	B-OUT
level	I-OUT
,	I-OUT
impulsiveness	I-OUT
,	O
decreased	O
concentration	B-OUT
,	I-OUT
hyperactivity	I-OUT
,	I-OUT
stereotypy	I-OUT
,	I-OUT
diarrhea	I-OUT
,	I-OUT
insomnia	I-OUT
,	I-OUT
and	I-OUT
dry	I-OUT
skin	I-OUT
or	I-OUT
pruritus	I-OUT
.	I-OUT


Challenge	O
exposure	O
of	O
pigs	O
that	O
had	O
been	O
inoculated	O
with	O
the	O
Bartha	O
strain	O
or	O
the	O
inactivated	O
vaccine	O
was	O
followed	O
by	O
clear	O
memory	B-OUT
responses	I-OUT
in	I-OUT
serum	I-OUT
and	I-OUT
in	I-OUT
oropharyngeal	I-OUT
fluid	I-OUT
.	I-OUT


Results	O
of	O
a	O
multicenter	O
,	O
8-week	O
,	O
parallel-group	O
,	O
randomized	O
,	O
double-blind	O
,	O
double-dummy	O
,	O
Phase	O
III	O
clinical	O
trial	O
to	O
evaluate	O
the	O
efficacy	O
and	O
tolerability	O
of	O
amlodipine	B-I
maleate	I-I
versus	I-I
amlodipine	I-I
besylate	I-I
in	O
Korean	B-P
patients	I-P
with	I-P
mild	I-P
to	I-P
moderate	I-P
hypertension	I-P
.	I-P


METHODS	O
This	O
was	O
a	O
multicenter	O
,	O
8-week	O
,	O
parallel-group	O
,	O
randomized	O
,	O
double-blind	O
,	O
double-dummy	O
,	O
Phase	O
III	O
clinical	O
trial	O
.	O


The	O
efficacy	O
of	O
melatonin	B-I
for	O
sleep	O
problems	O
in	O
children	O
with	O
autism	O
,	O
fragile	O
X	O
syndrome	O
,	O
or	O
autism	O
and	O
fragile	O
X	O
syndrome	O
.	O


STUDY	O
OBJECTIVE	O
To	O
determine	O
the	O
efficacy	O
of	O
melatonin	B-I
on	I-P
sleep	I-P
problems	I-P
in	I-P
children	I-P
with	O
autistic	O
spectrum	O
disorder	O
(	O
ASD	O
)	O
and	O
fragile	O
X	O
syndrome	O
(	O
FXS	O
)	O
.	O


Either	O
melatonin	B-I
,	O
3	O
mg	O
,	O
or	O
placebo	B-I
was	O
given	O
to	O
participants	B-P
for	I-P
2	I-P
weeks	I-P
and	O
then	O
alternated	O
for	O
another	O
2	O
weeks	O
.	O


No	B-OUT
adverse	I-OUT
side	I-OUT
effects	I-OUT
attributable	O
to	O
captopril	B-I
were	O
noted	O
,	O
except	O
in	O
one	O
patient	O
in	O
whom	O
proteinuria	B-OUT
developed	O
after	O
seven	O
weeks	O
.	O


A	O
multifactorial	O
strategy	O
of	O
pain	O
management	O
is	O
associated	O
with	O
less	O
pain	O
in	O
scheduled	B-P
vaccination	I-P
of	O
children	B-P
.	I-P


After	O
a	O
pseudo-randomization	O
,	O
usual	B-I
pain	I-I
management	I-I
(	I-I
n	I-I
=	I-I
132	I-I
)	I-I
was	I-I
compared	I-I
to	I-I
a	I-I
multifactorial	I-I
strategy	I-I
(	I-I
n	I-I
=	I-I
107	I-I
)	I-I
associating	I-I
preliminary	I-I
application	I-I
of	I-I
an	I-I
anesthesic	I-I
patch	I-I
,	I-I
preferential	I-I
use	I-I
of	I-I
specified	I-I
vaccines	I-I
,	I-I
child	I-I
education	I-I
by	I-I
the	I-I
parents	I-I
and	I-I
the	I-I
doctor	I-I
,	I-I
parental	I-I
accompaniment	I-I
and	I-I
child	I-I
distraction	I-I
with	I-I
soap	I-I
bubbles	I-I
during	I-I
the	I-I
procedure	I-I
.	I-I


In	O
a	O
double-blind	O
study	O
,	O
24	B-P
Down	I-P
syndrome	I-P
children	I-P
,	I-P
ages	I-P
6	I-P
to	I-P
17	I-P
years	I-P
living	I-P
at	I-P
home	I-P
,	I-P
were	I-P
given	I-P
a	I-P
megadose	I-I
multi-vitamin/mineral	I-I
supplement	I-I
for	I-P
4	I-P
months	I-P
.	I-P


Colchicine	B-I
or	I-I
methotrexate	I-I
has	O
some	O
beneficial	O
effects	O
in	O
the	O
treatment	O
of	O
PBC	O
,	O
and	O
also	O
affects	O
interleukin-1	B-OUT
(	I-OUT
IL-1	I-OUT
)	I-OUT
.	I-OUT


Therefore	O
,	O
we	O
prospectively	O
studied	O
the	O
synthesis	O
of	O
IL-1	B-OUT
beta	I-OUT
by	O
peripheral	O
blood	O
mononuclear	O
cells	O
(	O
PBMC	O
)	O
from	B-P
42	I-P
patients	I-P
with	I-P
PBC	I-P
entered	O
into	O
a	O
randomized	O
,	O
double-blind	O
,	O
double-dummy	O
controlled	O
trial	O
of	O
colchicine	B-I
and	I-I
methotrexate	I-I
.	I-I


For	O
all	O
patients	O
,	O
synthesis	B-OUT
of	I-OUT
IL-1	I-OUT
beta	I-OUT
increased	O
constitutively	O
and	O
in	O
response	O
to	O
immune-mediated	O
stimulants	O
(	O
PHA	O
,	O
IL-2	O
,	O
and	O
mitochondrial	O
antigen	O
)	O
but	O
not	O
the	O
bacterial	O
stimulants	O
LPS	O
or	O
S	O
epidermidis	O
.	O


Patients	B-P
aged	I-P
18-80	I-P
years	I-P
were	I-P
eligible	I-P
for	I-P
enrolment	I-P
if	I-P
they	I-P
had	I-P
stable	I-P
VT	I-P
,	I-P
previous	I-P
myocardial	I-P
infarction	I-P
,	I-P
and	I-P
reduced	I-P
left-ventricular	I-P
ejection	I-P
fraction	I-P
(	I-P
LVEF	I-P
;	I-P
<	I-P
or=50	I-P
%	I-P
)	I-P
.	I-P


Mean	O
follow-up	O
was	O
22.5	O
months	O
(	O
SD	O
9.0	O
)	O
.	O


Family	B-OUT
therapy	I-OUT
was	I-OUT
found	I-OUT
to	I-OUT
be	I-OUT
more	I-OUT
effective	I-OUT
than	I-OUT
individual	I-OUT
therapy	I-OUT
in	O
patients	B-P
whose	I-P
illness	I-P
was	I-P
not	I-P
chronic	I-P
and	I-P
had	I-P
begun	I-P
before	I-P
the	I-P
age	I-P
of	I-P
19	I-P
years	I-P
.	I-P


PURPOSE	O
To	O
compare	O
the	O
efficacy	B-OUT
and	I-OUT
safety	I-OUT
of	O
cutting	B-I
balloon	I-I
angioplasty	I-I
(	I-I
CBA	I-I
)	I-I
versus	I-I
high-pressure	I-I
balloon	I-I
angioplasty	I-I
(	I-I
HPBA	I-I
)	I-I
for	O
the	O
treatment	O
of	O
hemodialysis	B-P
autogenous	I-P
fistula	I-P
stenoses	I-P
resistant	I-P
to	I-P
conventional	I-P
percutaneous	I-P
transluminal	I-P
angioplasty	I-P
(	I-P
PTA	I-P
)	I-P
.	I-P


MATERIALS	O
AND	O
METHODS	O
In	O
a	O
prospective	O
,	O
randomized	O
clinical	O
trial	O
involving	O
patients	B-P
with	I-P
dysfunctional	I-P
,	I-P
stenotic	I-P
hemodialysis	I-P
arteriovenous	I-P
fistulas	I-P
(	I-P
AVFs	I-P
)	I-P
,	O
patients	O
were	O
randomized	O
to	O
receive	O
CBA	B-I
or	O
HPBA	B-I
if	O
conventional	O
PTA	O
had	O
suboptimal	O
results	O
(	O
ie	O
,	O
residual	O
stenosis	O
>	O
30	O
%	O
)	O
.	O


A	O
total	B-P
of	I-P
516	I-P
patients	I-P
consented	I-P
to	I-P
participate	I-P
in	I-P
the	I-P
study	I-P
from	I-P
October	I-P
2008	I-P
to	I-P
September	I-P
2011	I-P
,	I-P
85	I-P
%	I-P
of	I-P
whom	I-P
(	I-P
n	I-P
=	I-P
439	I-P
)	I-P
had	I-P
technically	I-P
successful	I-P
conventional	I-P
PTA	I-P
.	I-P


The	O
remaining	O
71	B-P
patients	I-P
(	I-P
mean	I-P
age	I-P
,	I-P
60	I-P
y	I-P
;	I-P
49	I-P
men	I-P
)	I-P
with	I-P
suboptimal	I-P
PTA	I-P
results	I-P
were	O
eventually	O
randomized	O
:	O
36	O
to	O
the	O
CBA	B-I
arm	O
and	O
35	O
to	O
the	O
HPBA	O
arm	O
.	O


Primary	B-OUT
target	I-OUT
lesion	I-OUT
patency	I-OUT
rates	I-OUT
at	O
6	O
months	O
were	O
66.4	O
%	O
and	O
39.9	O
%	O
for	O
CBA	B-I
and	O
HPBA	B-I
,	O
respectively	O
(	O
P	O
=	O
.01	O
)	O
.	O


For	O
AVF	O
stenoses	O
resistant	O
to	O
conventional	O
PTA	O
,	O
CBA	B-I
may	O
be	O
a	O
better	O
second-line	O
treatment	O
given	O
its	O
superior	O
patency	O
rates	O
.	O


We	O
develop	O
a	O
bivariate	B-OUT
random	I-OUT
effects	I-OUT
model	I-OUT
for	O
such	O
a	O
situation	O
in	O
a	O
2	O
x	O
2	O
crossover	O
design	O
using	O
the	O
natural	B-OUT
log	I-OUT
scale	I-OUT
for	I-OUT
AUC	I-OUT
and	I-OUT
CMAX	I-OUT
that	O
assumes	O
no	O
differential	O
carryover	O
effects	O
and	O
includes	O
components	O
for	O
inter-	O
and	O
intrasubject	O
variability	O
with	O
respect	O
to	O
both	O
formulations	O
.	O


Groups	O
were	O
well	O
matched	O
,	O
and	O
there	O
were	O
no	O
differences	O
between	O
the	O
two	O
methods	O
in	O
surgical	B-OUT
time	I-OUT
or	O
in	O
anesthesia	B-OUT
complications	I-OUT
.	I-OUT


During	O
2	O
years	O
and	O
7	O
months	O
from	O
June	O
,	O
1985	O
to	O
December	O
,	O
1987	O
,	O
a	O
randomized	O
multi-center	O
trial	O
of	O
PVB	B-I
,	I-I
VAB-6	I-I
,	I-I
BVP	I-I
regimen	I-I
(	O
group	O
A	O
)	O
without	B-I
etoposide	I-I
versus	I-I
PEB	I-I
chemotherapy	I-I
(	I-I
bleomycin	I-I
,	I-I
etoposide	I-I
and	I-I
cisplatinum	I-I
)	I-I
(	O
group	O
B	O
)	O
was	O
given	O
to	O
patients	B-P
with	I-P
disseminated	I-P
testicular	I-P
tumors	I-P
.	I-P


Although	O
the	O
incidence	B-OUT
of	I-OUT
myelosuppression	I-OUT
and	I-OUT
alopecia	I-OUT
was	O
significantly	O
higher	O
in	O
group	O
B	O
,	O
neuropathy	B-OUT
was	O
significantly	O
more	O
frequent	O
in	O
group	O
A	O
.	O


Data	O
on	O
repeatability	O
and	O
comparability	O
of	O
different	O
presyncopal	B-I
symptom-limited	I-I
lower	I-I
body	I-I
negative	I-I
pressure	I-I
(	I-I
PSL-LBNP	I-I
)	I-I
exposure	I-I
protocols	I-I
,	O
while	O
scarce	O
,	O
are	O
critical	O
to	O
the	O
interpretation	O
of	O
studies	O
using	O
PSL-LBNP	B-I
methods	O
.	O


In	O
multivariate	O
analyses	O
,	O
greater	O
BMI	O
was	O
significantly	O
associated	O
with	O
higher	B-OUT
PCSM	I-OUT
(	O
for	O
BMI	O
>	O
or	O
=25	O
to	O
<	O
30	O
,	O
hazard	O
ratio	O
[	O
HR	O
]	O
1.52	O
,	O
95	O
%	O
confidence	O
interval	O
[	O
CI	O
]	O
,	O
1.02-2.27	O
,	O
P	O
=	O
.04	O
;	O
for	O
BMI	O
>	O
or	O
=30	O
,	O
HR	O
1.64	O
,	O
95	O
%	O
CI	O
,	O
1.01-2.66	O
,	O
P	O
=	O
.04	O
)	O
.	O


CONCLUSIONS	O
Greater	O
baseline	B-OUT
BMI	I-OUT
is	O
independently	O
associated	O
with	O
higher	O
PCSM	B-OUT
in	O
men	B-P
with	I-P
locally	I-P
advanced	I-P
prostate	I-P
cancer	I-P
.	I-P


Further	O
studies	O
are	O
warranted	O
to	O
evaluate	O
the	O
mechanism	O
(	O
s	O
)	O
for	O
increased	O
cancer-specific	B-OUT
mortality	I-OUT
and	O
to	O
assess	O
whether	O
weight	B-OUT
loss	I-OUT
after	O
prostate	O
cancer	O
diagnosis	O
alters	O
disease	O
course	O
.	O


MATERIAL	O
AND	O
METHODS	O
Forty	B-P
subjects	I-P
with	I-P
chronic	I-P
periodontitis	I-P
and	I-P
presenting	I-P
,	I-P
at	I-P
least	I-P
,	I-P
two	I-P
proximal	I-P
sites	I-P
in	I-P
anterior	I-P
teeth	I-P
(	I-P
upper	I-P
or	I-P
lower	I-P
)	I-P
with	I-P
probing	I-P
depth	I-P
>	I-P
or	I-P
=5	I-P
mm	I-P
were	I-P
selected	I-P
.	I-P


Probing	B-OUT
depth	I-OUT
(	I-OUT
PD	I-OUT
)	I-OUT
,	I-OUT
relative	I-OUT
gingival	I-OUT
margin	I-OUT
level	I-OUT
(	I-OUT
RGML	I-OUT
)	I-OUT
and	I-OUT
relative	I-OUT
attachment	I-OUT
level	I-OUT
(	I-OUT
RAL	I-OUT
)	I-OUT
were	O
registered	O
at	O
five	O
experimental	O
periods	O
:	O
baseline	O
and	O
30	O
,	O
60	O
,	O
90	O
and	O
120	O
days	O
postoperative	O
.	O


At	B-P
baseline	I-P
,	I-P
there	I-P
were	I-P
no	I-P
significant	I-P
differences	I-P
in	I-P
blood	I-OUT
pressure	I-OUT
,	I-OUT
cardiac	I-OUT
output	I-OUT
,	I-OUT
basal	I-OUT
femoral	I-OUT
blood	I-OUT
flow	I-OUT
(	I-OUT
via	I-OUT
Doppler	I-OUT
ultrasound	I-OUT
)	I-OUT
,	I-OUT
vascular	I-OUT
conductance	I-OUT
,	I-OUT
and	I-OUT
vascular	I-OUT
resistance	I-OUT
between	I-P
the	I-P
two	I-P
groups	I-P
.	I-P


No	O
such	O
changes	O
were	O
observed	O
in	O
the	O
control	O
group	O
.	O


METHODS	O
Ninety	B-P
patients	I-P
with	I-P
VBIV	I-OUT
were	I-P
randomly	I-P
divided	I-P
into	I-P
two	I-P
groups	I-P
;	I-P
45	O
patients	O
(	O
the	O
treated	O
group	O
)	O
were	O
treated	O
with	O
YXDM	B-I
and	O
BHI	B-I
intravenous	O
dripping	O
,	O
once	O
a	O
day	O
for	O
14	O
days	O
.	O


Another	B-P
45	I-P
patients	I-P
(	I-P
control	I-P
group	I-P
)	I-P
were	O
treated	O
with	O
Xueshuantong	O
and	O
BHI	O
intravenous	O
dripping	O
,	O
once	O
daily	O
for	O
14	O
days	O
.	O


Plasma	O
pantoprazole	B-I
concentrations	O
were	O
analyzed	O
by	O
liquid	O
chromatography	O
coupled	O
to	O
tandem	O
mass	O
spectrometry	O
(	O
LC-MS-MS	O
)	O
with	O
positive	O
ion	O
electrospray	O
ionization	O
using	O
multiple	O
reactions	O
monitoring	O
(	O
MRM	O
)	O
.	O


Shorter	O
treatment	O
for	O
vaginal	B-P
candidosis	I-P
:	I-P
comparison	O
between	O
single-dose	O
oral	O
fluconazole	B-I
and	O
three-day	O
treatment	O
with	O
local	O
miconazole	B-I
.	I-I


Fluconazole	B-I
is	O
an	O
effective	O
,	O
simple	O
and	O
safe	O
,	O
although	O
slightly	O
expensive	O
,	O
agent	O
for	O
the	O
treatment	O
of	O
vaginal	B-P
candidosis	I-P
.	I-P


Single-dose	B-I
fluconazole	I-I
(	I-I
150	I-I
mg	I-I
)	I-I
administered	I-I
orally	I-I
in	I-I
capsule	I-I
form	I-I
was	I-I
compared	I-I
with	I-I
three-day	I-I
local	I-I
treatment	I-I
with	I-I
miconazole	I-I
pessaries	I-I
in	I-I
the	I-I
treatment	I-I
of	I-I
vaginal	I-I
candidosis	I-I
in	I-I
a	I-I
randomized	I-I
study	I-I
in	I-I
Finland	I-I
.	I-I


OBJECTIVES	O
Reducing	O
unnecessary	O
antibiotic	O
use	O
,	O
particularly	O
among	O
children	O
,	O
continues	O
to	O
be	O
a	O
public	O
health	O
priority	O
.	O


Parents	B-I
received	I-I
educational	I-I
materials	I-I
by	I-I
mail	I-I
and	I-I
in	I-I
primary	I-I
care	I-I
practices	I-I
,	I-I
pharmacies	I-I
,	I-I
and	I-I
child	I-I
care	I-I
settings	I-I
.	I-I


Using	O
health-plan	B-I
data	I-I
,	O
we	O
measured	O
changes	O
in	O
antibiotics	O
dispensed	O
per	O
person-year	O
of	O
observation	O
among	O
children	B-P
who	I-P
were	I-P
aged	I-P
3	I-P
to	I-P
<	I-P
72	I-P
months	I-P
,	I-P
resided	I-P
in	I-P
study	I-P
communities	I-P
,	I-P
and	I-P
were	I-P
insured	I-P
by	I-P
a	I-P
participating	I-P
commercial	I-P
health	I-P
plan	I-P
or	I-P
Medicaid	I-P
.	I-P


RESULTS	O
The	O
data	O
include	O
223,135	B-P
person-years	I-P
of	I-P
observation	I-P
.	I-P


This	O
approach	O
has	O
been	O
tested	O
in	O
a	O
large	O
series	O
of	O
trials	O
since	O
the	O
late	O
70	O
's	O
.	O


A	O
few	O
trials	O
performed	O
randomization	O
between	O
alternating	O
and	O
continuous	O
treatment	O
after	O
a	O
period	O
of	O
initial	B-I
common	I-I
continuous	I-I
therapy	I-I
.	I-I


To	O
ameliorate	O
this	O
weakness	O
,	O
3	O
studies	O
were	O
designed	O
as	O
3-arms	O
approaches	O
using	O
both	O
alternating	O
protocols	O
as	O
continuous	O
control	O
arms	O
.	O


The	O
longer	O
these	O
patients	O
stayed	O
on	O
the	O
continuous	O
protocol	O
the	O
more	O
the	O
study	O
design	O
favoured	O
the	O
alternating	O
therapy	O
.	O


[	B-OUT
Efficacy	I-OUT
and	I-OUT
immune	I-OUT
memory	I-OUT
of	O
plasma-derived	B-I
hepatitis	I-I
B	I-I
vaccine	I-I
11	I-P
years	I-P
after	I-P
primary	I-P
immunization	I-P
]	I-P
.	O


There	O
still	O
existed	O
immune	B-OUT
memory	I-OUT
11	O
years	O
after	O
immunization	O
,	O
but	O
it	O
was	O
significantly	O
weaker	O
than	O
that	O
within	O
the	O
first	O
10	O
years	O
after	O
immunization	O
.	O


Lack	O
of	O
effect	O
of	O
a	O
low-fat	B-I
,	I-I
high-fiber	I-I
diet	I-I
on	O
the	O
recurrence	B-OUT
of	I-OUT
colorectal	I-OUT
adenomas	I-OUT
.	I-OUT


BACKGROUND	O
We	O
tested	O
the	O
hypothesis	O
that	O
dietary	O
intervention	O
can	O
inhibit	O
the	O
development	B-OUT
of	I-OUT
recurrent	I-OUT
colorectal	I-OUT
adenomas	I-OUT
,	O
which	O
are	O
precursors	O
of	O
most	O
large-bowel	O
cancers	O
.	O


Subjects	O
entered	O
the	O
study	O
after	O
undergoing	O
complete	O
colonoscopy	O
and	O
removal	O
of	O
adenomatous	O
polyps	O
;	O
they	O
remained	O
in	O
the	O
study	O
for	O
approximately	O
four	O
years	O
,	O
undergoing	O
colonoscopy	O
one	O
and	O
four	O
years	O
after	O
randomization	O
.	O


Of	O
the	O
958	O
subjects	O
in	O
the	O
intervention	O
group	O
and	O
the	O
947	O
in	O
the	O
control	O
group	O
who	O
completed	O
the	O
study	O
,	O
39.7	O
percent	O
and	O
39.5	O
percent	O
,	O
respectively	O
,	O
had	O
at	O
least	O
one	B-OUT
recurrent	I-OUT
adenoma	I-OUT
;	I-OUT
the	O
unadjusted	B-OUT
risk	I-OUT
ratio	I-OUT
was	O
1.00	O
(	O
95	O
percent	O
confidence	O
interval	O
,	O
0.90	O
to	O
1.12	O
)	O
.	O


A	O
randomized	O
controlled	O
one-year	O
follow-up	O
study	O
of	O
haloperidol	B-I
,	I-I
risperidone	I-I
and	I-I
olanzapine	I-I
.	I-I


CONCLUSION	O
FRCL	B-I
had	O
the	O
action	O
in	O
treating	O
children	O
syncytial	O
viral	O
pneumonia	O
without	O
any	O
adverse	O
reaction	O
,	O
one	O
of	O
its	O
mechanisms	O
might	O
be	O
related	O
to	O
its	O
regulation	O
on	O
immune	O
function	O
.	O


The	O
incidence	O
of	O
extravertebral	O
fractures	O
and	O
of	O
new	O
or	O
progressive	O
vertebral	O
deformity	O
tended	O
to	O
be	O
lower	O
in	O
groups	O
2	O
and	O
3	O
than	O
in	O
group	O
1	O
.	O


STUDY	O
DESIGN	O
Sixty	B-P
subjects	I-P
with	I-P
autism	I-P
were	O
randomly	O
selected	O
and	O
assigned	O
to	O
either	O
treatment	O
or	O
placebo	B-I
group	O
.	O


Subjects	O
in	O
the	O
placebo	B-I
group	O
received	O
normal	B-I
saline	I-I
solution	I-I
.	I-I


Control	O
of	O
the	O
lumbar	O
neutral	O
zone	O
decreases	O
low	B-OUT
back	I-OUT
pain	I-OUT
and	O
improves	B-OUT
self-evaluated	I-OUT
work	I-OUT
ability	I-OUT
:	I-OUT
a	O
12-month	O
randomized	O
controlled	O
study	O
.	O


[	B-P
Complaints	I-P
in	I-P
the	I-P
postoperative	I-P
phase	I-P
related	I-P
to	I-P
anesthetics	I-P
]	I-P
.	O


The	O
second	O
study	O
indicated	O
that	O
balanced	O
anesthesia	O
did	O
not	O
reduce	O
the	O
analgesic	B-OUT
requirement	I-OUT
compared	O
to	O
enflurane	B-I
without	O
alfentanil	B-I
,	O
but	O
lead	O
to	O
a	O
higher	O
incidence	O
of	O
vomiting	B-OUT
.	I-OUT


We	O
used	O
signs	O
of	O
anemia	O
and/or	O
a	O
hemoglobin	O
value	O
less	O
than	O
8	O
g/dL	O
as	O
indications	O
for	O
transfusion	O
.	O


3	O
.	O


5	O
.	O


6	O
.	O


Univariate	O
and	O
multivariable	O
regression	O
analyses	O
identified	O
variables	O
significantly	O
associated	O
with	O
postoperative	O
PRO	O
.	O


Patients	O
with	O
other	O
complications	O
after	O
laparoscopic	O
repair	O
reported	O
more	O
pain	B-OUT
and	I-OUT
less	I-OUT
activity	I-OUT
than	O
those	O
with	O
other	O
complications	O
after	O
open	O
repair	O
(	O
P	O
=	O
.003	O
and	O
P	O
=	O
.009	O
,	O
respectively	O
)	O
.	O


Postoperative	O
neuralgias	O
have	O
a	O
deleterious	O
effect	O
on	O
all	O
patient-reported	O
outcomes	O
.	O


Reduction	B-OUT
of	I-OUT
oral	I-OUT
mucositis	I-OUT
by	O
filgrastim	B-I
(	I-I
r-metHuG-CSF	I-I
)	I-I
in	O
patients	B-P
receiving	I-P
chemotherapy	I-I
.	I-I


Oral	B-OUT
mucositis	I-OUT
was	O
analyzed	O
using	O
the	O
unadjusted	O
chi-square	O
test	O
,	O
and	O
time	B-OUT
to	I-OUT
first	I-OUT
episode	I-OUT
of	I-OUT
mucositis	I-OUT
was	O
analyzed	O
using	O
the	O
stratified	O
log-rank	O
test	O
as	O
well	O
as	O
the	O
Cox	O
proportional	O
hazards	O
regression	O
model	O
.	O


RESULTS	O
In	O
the	O
placebo	O
group	O
,	O
there	O
was	O
no	O
rise	O
in	O
HR	B-OUT
,	I-OUT
SBP	I-OUT
,	I-OUT
DBP	I-OUT
or	I-OUT
RPP	I-OUT
,	O
and	O
there	O
was	O
no	O
difference	O
between	O
the	O
placebo	O
and	O
labetalol	B-I
groups	O
.	O


Computed	B-I
tomography-guided	I-I
percutaneous	I-I
RFT	I-I
of	O
the	O
Gasserian	O
ganglion	O
was	O
performed	O
on	O
80	B-P
patients	I-P
with	I-P
trigeminal	I-P
neuralgia	I-P
.	I-P


METHODS	O
Twenty-nine	B-P
patients	I-P
(	I-P
6	I-P
type	I-P
1	I-P
and	I-P
23	I-P
type	I-P
2	I-P
)	I-P
with	I-P
gastroparesis	I-P
underwent	O
assessments	O
of	O
:	O
(	O
i	O
)	O
gastric	B-OUT
emptying	I-OUT
of	O
a	O
solid/liquid	O
meal	O
using	O
scintigraphy	O
,	O
(	O
ii	O
)	O
glycaemic	O
control	O
(	O
blood	O
glucose	O
at	O
0	O
,	O
30	O
,	O
60	O
,	O
90	O
and	O
120	O
min	O
during	O
the	O
gastric	O
emptying	O
measurement	O
)	O
and	O
(	O
iii	O
)	O
upper	O
gastrointestinal	O
and	O
'meal-related	O
'	O
symptoms	O
(	O
questionnaire	O
)	O
,	O
at	B-P
baseline	I-P
and	I-P
after	I-P
treatment	I-P
with	I-P
KC	I-I
11458	I-I
in	I-P
a	I-P
dose	I-P
of	I-P
8	I-P
mg	I-P
t.d.s.	I-P
,	O
or	B-I
placebo	I-I
for	I-P
8	I-P
days	I-P
.	I-P


RESULTS	O
KC	B-I
11458	I-I
had	O
no	O
statistically	O
significant	O
or	O
clinically	O
relevant	O
effect	O
on	O
gastric	B-OUT
emptying	I-OUT
of	O
either	O
the	O
solid	O
intragastric	O
retention	O
at	O
100	O
min	O
(	O
T100	O
)	O
(	O
P	O
=	O
0.87	O
)	O
or	O
liquid	O
50	O
%	O
emptying	O
time	O
(	O
T50	O
)	O
(	O
P	O
=	O
0.17	O
)	O
components	O
of	O
the	O
meal	O
.	O


The	O
absence	O
of	O
efficacy	O
may	O
relate	O
to	O
an	O
effect	O
of	O
hyperglycaemia	O
.	O


Four	O
different	O
modes	O
of	O
FES	O
were	O
applied	O
in	O
random	O
order	O
:	O
constant	O
stimulation	O
,	O
randomized	O
frequency	O
(	O
mean	O
40	O
Hz	O
)	O
,	O
randomized	O
current	O
amplitude	O
,	O
and	O
randomized	O
pulsewidth	O
(	O
mean	O
250	O
micros	O
)	O
.	O


In	O
randomized	O
trials	O
,	O
stimulation	O
parameters	O
were	O
stochastically	O
modulated	O
every	O
100	O
ms	O
in	O
a	O
range	O
of	O
+/-15	O
%	O
using	O
a	O
uniform	O
probability	O
distribution	O
.	O


There	O
was	O
no	O
significant	O
difference	O
between	O
the	O
fatigue	B-OUT
time	I-OUT
measurements	I-OUT
for	O
the	O
four	O
modes	O
of	O
stimulation	O
.	O


Therefore	O
,	O
our	O
particular	O
method	O
of	O
stochastic	O
modulation	O
of	O
the	O
stimulation	O
parameters	O
,	O
which	O
involved	O
moderate	O
(	O
15	O
%	O
)	O
variations	O
updated	O
every	O
100	O
ms	O
and	O
centered	O
around	O
40	O
Hz	O
,	O
appeared	O
to	O
have	O
no	O
effect	O
on	O
muscle	B-OUT
fatigue	I-OUT
.	I-OUT


There	O
was	O
a	O
strong	O
correlation	O
between	O
maximum	O
force	O
measurements	O
and	O
stimulation	O
order	O
,	O
which	O
was	O
not	O
apparent	O
in	O
the	O
fatigue	B-OUT
time	I-OUT
or	I-OUT
FTI	I-OUT
measurements	I-OUT
.	I-OUT


acetaminophen	B-I
,	I-I
and	I-I
5	I-I
ml	I-I
of	I-I
saline	I-I
,	O
respectively	O
.	O


SETTING	O
Twenty	B-P
pediatric	I-P
endocrine	I-P
centers	I-P
.	I-P


No	B-OUT
AE	I-OUT
led	O
to	O
discontinuation	O
of	O
study	O
drug	O
.	O


INTERVENTION	O
Those	O
assigned	O
to	O
a	O
brief	B-I
motivational	I-I
intervention	I-I
(	I-I
MI	I-I
)	I-I
condition	O
received	O
two	B-I
1-hour	I-I
therapist	I-I
sessions	I-I
following	I-I
assessment	I-I
visits	I-I
,	O
1	O
month	O
apart	O
,	O
focusing	O
on	O
alcohol	O
use	O
and	O
HIV	O
risk-taking	O
.	O


MEASUREMENTS	O
Control	B-I
and	O
MI	B-I
subjects	O
received	O
identical	O
research	O
assessments	O
at	O
baseline	O
,	O
1	O
and	O
6	O
months	O
following	O
study	O
enrollment	O
.	O


FINDINGS	O
Study	B-OUT
retention	I-OUT
was	O
96.8	O
%	O
at	O
6	O
months	O
.	O


These	O
activities	O
were	O
continued	O
for	O
5	O
years	O
.	O


However	O
,	O
more	O
and	O
smaller	O
fibroadenomas	O
were	O
detected	O
in	O
the	O
instruction	O
group	O
than	O
in	O
the	O
control	O
group	O
(	O
P	O
<	O
0.01	O
)	O
.	O


CONCLUSION	O
Intensive	B-OUT
instruction	I-OUT
in	I-OUT
BSE	I-OUT
did	I-OUT
not	I-OUT
seem	I-OUT
to	I-OUT
have	I-OUT
reduced	I-OUT
the	I-OUT
mortality	I-OUT
rate	I-OUT
of	I-OUT
breast	I-OUT
cancer	I-OUT
,	I-OUT
but	I-OUT
more	I-OUT
and	I-OUT
smaller	I-OUT
benign	I-OUT
breast	I-OUT
lumps	I-OUT
could	I-OUT
be	I-OUT
detected	I-OUT
.	I-OUT


Because	O
most	O
NSAIDs	B-I
are	O
weak	O
acids	O
(	O
pKa	O
3-5	O
)	O
and	O
become	O
concentrated	O
in	O
acidic	O
tissues	O
,	O
such	O
as	O
injured	O
and	O
inflamed	O
tissues	O
,	O
we	O
hypothesized	O
that	O
local	O
administration	O
may	O
enhance	O
its	O
analgesic	O
efficacy	O
while	O
lowering	O
the	O
potential	O
for	O
systemic	O
complications	O
.	O


The	O
neural	O
correlates	O
of	O
semantic	O
richness	O
:	O
evidence	O
from	O
an	O
fMRI	O
study	O
of	O
word	O
learning	O
.	O


This	O
pilot	O
study	O
suggests	O
significant	O
additional	O
treatment	O
benefits	O
following	O
a	O
targeted	O
(	O
but	O
relatively	O
non-intensive	O
)	O
dyadic	O
social	O
communication	O
treatment	O
,	O
when	O
compared	O
with	O
routine	O
care	O
.	O


Hepatorenal	O
syndrome	O
.	O


During	O
postoperative	O
observation	O
of	O
up	O
to	O
two	O
years	O
,	O
progressive	O
improvement	O
in	O
hepatic	B-OUT
function	I-OUT
has	O
occurred	O
.	O


DESCRIPTION	O
OF	O
STUDY	O
Fifty-two	B-P
patients	I-P
with	I-P
newly	I-P
diagnosed	I-P
breast	I-P
cancer	I-P
were	O
randomly	O
assigned	O
to	O
one	O
of	O
two	O
treatment	O
arms	O
:	O
usual	B-I
care	I-I
or	O
usual	B-I
care	I-I
plus	I-I
exercise	I-I
.	I-I


All	B-P
participants	I-P
took	O
three	O
gelcaps	O
per	O
day	O
,	O
one	O
at	O
each	O
meal	O
.	O


Selenium	B-I
Treatment	I-I
and	I-I
Chagasic	I-I
Cardiopathy	I-I
(	I-I
STCC	I-I
)	I-I
:	I-I
study	O
protocol	O
for	O
a	O
double-blind	O
randomized	O
controlled	O
trial	O
.	O


The	O
aim	O
of	O
this	O
investigation	O
is	O
to	O
estimate	O
the	O
effect	O
of	O
Se	B-I
treatment	I-I
on	O
prevention	O
of	O
heart	O
disease	O
progression	O
in	O
patients	B-P
with	I-P
chagasic	I-P
cardiopathy	I-P
.	I-P


The	O
following	O
are	O
the	O
primary	O
outcomes	O
to	O
be	O
measured	B-OUT
:	I-OUT
(	I-OUT
1	I-OUT
)	I-OUT
the	I-OUT
trajectories	I-OUT
of	I-OUT
the	I-OUT
left	I-OUT
ventricular	I-OUT
ejection	I-OUT
fraction	I-OUT
in	I-OUT
the	I-OUT
follow-up	I-OUT
period	I-OUT
;	I-OUT
(	I-OUT
2	I-OUT
)	I-OUT
reduction	I-OUT
of	I-OUT
heart	I-OUT
disease	I-OUT
progression	I-OUT
rates	I-OUT
,	I-OUT
with	I-OUT
progression	I-OUT
defined	I-OUT
as	I-OUT
a	I-OUT
10	I-OUT
%	I-OUT
decrease	I-OUT
in	I-OUT
left	I-OUT
ventricular	I-OUT
ejection	I-OUT
fraction	I-OUT
;	I-OUT
and	I-OUT
(	I-OUT
3	I-OUT
)	I-OUT
rate	I-OUT
of	I-OUT
hospital	I-OUT
admissions	I-OUT
attributable	I-OUT
to	I-OUT
dysrhythmia	I-OUT
,	I-OUT
heart	I-OUT
failure	I-OUT
or	I-OUT
stroke	I-OUT
due	I-OUT
to	I-OUT
Chagas	I-OUT
disease	I-OUT
.	O


Both	O
patients	O
and	O
health-care	O
providers	O
will	O
remain	O
blinded	O
to	O
the	O
intervention	O
groups	O
during	O
the	O
5	O
years	O
of	O
follow-up	O
.	O


DISCUSSION	O
If	O
Se	O
treatment	O
reduces	O
the	B-OUT
progression	I-OUT
of	I-OUT
Chagas	I-OUT
cardiopathy	I-OUT
,	O
the	O
inclusion	O
of	O
this	O
micronutrient	O
in	O
the	O
daily	O
diet	O
can	O
improve	O
the	O
therapeutic	O
regimen	O
for	O
this	O
neglected	O
tropical	O
disease	O
at	O
low	O
cost	O
.	O


BACKGROUND	O
Coronary-artery	B-I
bypass	I-I
grafting	I-I
(	I-I
CABG	I-I
)	I-I
and	O
percutaneous	B-I
transluminal	I-I
coronary	I-I
angioplasty	I-I
(	I-I
PTCA	I-I
)	I-I
are	O
alternative	O
methods	O
of	O
revascularization	O
in	O
patients	B-P
with	I-P
coronary	I-P
artery	I-P
disease	I-P
.	I-P


METHODS	O
Patients	B-P
with	I-P
multivessel	I-P
disease	I-P
were	I-P
randomly	I-P
assigned	I-P
to	I-P
an	I-P
initial	I-P
treatment	I-P
strategy	I-P
of	I-P
CABG	I-P
(	I-P
n	I-P
=	I-P
914	I-P
)	I-P
or	I-P
PTCA	I-P
(	I-P
n	I-P
=	I-P
915	I-P
)	I-P
and	O
were	O
followed	O
for	O
an	O
average	O
of	O
5.4	O
years	O
.	O


By	O
five	O
years	O
after	O
study	O
entry	O
,	O
8	O
percent	O
of	O
the	O
patients	O
assigned	O
to	O
CABG	O
had	O
undergone	O
additional	O
revascularization	B-OUT
procedures	I-OUT
,	O
as	O
compared	O
with	O
54	O
percent	O
of	O
those	O
assigned	O
to	O
PTCA	O
;	O
69	O
percent	O
of	O
those	O
assigned	O
to	O
PTCA	O
did	O
not	O
subsequently	O
undergo	O
CABG	O
.	O


METHODS	O
Seventy	B-P
primary	I-P
IgAN	I-P
patients	I-P
were	O
equally	O
randomized	O
into	O
two	O
groups	O
,	O
the	O
treatment	O
group	O
and	O
the	O
control	O
group	O
,	O
they	O
were	O
orally	O
treated	O
with	O
SYN	B-I
Decoction	I-I
(	O
one	O
dose	O
per	O
day	O
)	O
and	O
Losartan	B-I
(	O
50	O
mg	O
per	O
day	O
)	O
respectively	O
for	O
1	O
year	O
.	O


METHODS	O
We	O
therefore	O
conducted	O
a	O
4-month	O
double-blind	O
clinical	O
trial	O
in	O
28	B-P
obese	I-P
[	I-P
mean	I-P
body	I-OUT
mass	I-OUT
index	I-OUT
(	I-OUT
BMI	I-OUT
)	I-OUT
:	I-OUT
40.3	I-P
+/-	I-P
5.7	I-P
kg/m	I-P
(	I-P
2	I-P
)	I-P
]	I-P
,	I-P
insulin-resistant	I-P
[	I-P
homeostasis	I-P
model	I-P
assessment	I-P
-	I-P
insulin	I-P
resistance	I-P
:	I-P
7.6	I-P
+/-	I-P
2.8	I-P
and	I-P
whole	I-P
body	I-P
insulin	I-P
sensitivity	I-P
index	I-P
(	I-P
WBISI	I-P
)	I-P
:	I-P
1.5	I-P
+/-	I-P
0.7	I-P
]	I-P
adolescents	I-P
(	I-P
age	I-P
15.0	I-P
+/-	I-P
1.3	I-P
yr	I-P
)	I-P
randomized	I-P
to	I-P
MET	I-P
(	I-P
n	I-P
=	I-P
15	I-P
,	I-P
dose	I-P
1500	I-P
mg	I-P
daily	I-P
)	I-P
or	I-P
placebo	I-I
(	I-P
n	I-P
=	I-P
13	I-P
)	I-P
.	I-P


METHODS/STUDY	O
DESIGN	O
A	O
pragmatic	O
two-arm	O
parallel	O
cluster	O
randomized	O
controlled	O
trial	O
was	O
designed	O
.	O


The	O
units	O
of	O
allocation	O
are	O
the	O
primary	O
maternal	O
care	O
clinics	O
.	O


Eight	O
weekly	O
sessions	O
were	O
delivered	O
following	O
entry	O
into	O
the	O
study	O
.	O


Clinical	O
support	O
and	O
supervision	O
,	O
delivered	O
mainly	O
by	O
mobile	O
phone	O
,	O
were	O
provided	O
by	O
general	O
physicians	O
and	O
psychiatrists	O
.	O


Secondary	O
outcomes	O
include	B-OUT
measures	I-OUT
of	I-OUT
disability	I-OUT
,	I-OUT
parenting	I-OUT
skills	I-OUT
,	I-OUT
maternal	I-OUT
attitudes	I-OUT
,	I-OUT
health	I-OUT
care	I-OUT
utilization	I-OUT
as	I-OUT
well	I-OUT
as	I-OUT
infant	I-OUT
physical	I-OUT
and	I-OUT
cognitive	I-OUT
development	I-OUT
comprehensively	O
assessed	O
using	O
the	B-OUT
Bayley	I-OUT
's	I-OUT
Scales	I-OUT
.	O


However	O
,	O
in	O
a	O
multi-variate	O
analysis	O
that	O
took	O
into	O
account	B-OUT
disease	I-OUT
extent	I-OUT
,	I-OUT
maintenance	I-OUT
therapy	I-OUT
,	I-OUT
Karnofsky	I-OUT
performance	I-OUT
status	I-OUT
(	I-OUT
PS	I-OUT
)	I-OUT
,	I-OUT
and	I-OUT
absolute	I-OUT
dose-intensity	I-OUT
(	I-OUT
ADI	I-OUT
)	I-OUT
of	I-OUT
anthracycline	I-OUT
given	O
during	O
induction	O
,	O
limited	B-OUT
disease	I-OUT
(	I-OUT
LD	I-OUT
)	I-OUT
and	I-OUT
maintenance	I-OUT
were	O
found	O
to	O
be	O
independent	O
positive	O
predictors	O
of	O
survival	B-OUT
.	I-OUT


CONCLUSION	O
We	O
conclude	O
that	O
maintenance	O
chemotherapy	O
in	O
responding	O
patients	O
is	O
beneficial	O
in	O
SCLC	O
.	O


Socio-demographic	O
,	O
anthropometric	O
,	O
and	O
psychosocial	O
predictors	O
of	O
attrition	O
across	O
behavioral	O
weight-loss	O
trials	O
.	O


Preventing	O
attrition	O
is	O
a	O
major	O
concern	O
in	O
behavioral	O
weight	O
loss	O
intervention	O
studies	O
.	O


For	O
every	O
year	B-OUT
increase	I-OUT
in	I-OUT
education	I-OUT
,	O
the	O
odds	O
of	O
attrition	O
decreased	O
by	O
10	O
%	O
.	O


DESIGN	O
Randomized	O
,	O
controlled	O
trial	O
,	O
with	O
post	O
hoc	O
analysis	O
.	O


SETTING	O
Eight	B-P
sites	I-P
,	I-P
heterogeneous	I-P
for	I-P
sociodemographic	I-P
and	I-P
health	I-P
care	I-P
use	I-P
.	I-P


All	O
children	O
in	O
the	O
INT	O
group	O
had	O
slightly	O
higher	O
rates	B-OUT
of	I-OUT
less	I-OUT
serious	I-OUT
morbidity	I-OUT
.	I-OUT


Tropisetron	B-I
and	I-I
granisetron	I-I
are	O
selective	O
serotonin	O
(	O
5-HT3	O
)	O
antagonists	O
that	O
have	O
been	O
proven	O
effective	O
in	O
the	O
prevention	O
of	O
nausea	B-OUT
and	I-OUT
vomiting	I-OUT
in	O
adults	B-P
and	I-P
children	I-P
receiving	I-P
cancer	I-P
chemotherapy	I-P
.	I-P


INTERVENTIONS	O
Participants	B-I
were	I-I
initially	I-I
randomized	I-I
to	I-I
either	I-I
wait-list	I-I
control	I-I
(	I-I
WLC	I-I
)	I-I
or	I-I
treatment	I-I
groups	I-I
to	I-I
receive	I-I
either	I-I
individualized	I-I
CHM	I-I
decoctions	I-I
or	I-I
a	I-I
therapeutically	I-I
inert	I-I
placebo	I-I
decoction	I-I
.	I-I


Liver	B-OUT
and	I-OUT
renal	I-OUT
function	I-OUT
was	O
measured	O
at	O
0	O
,	O
4	O
,	O
8	O
,	O
and	O
16	O
weeks	O
.	O


CONCLUSIONS	O
the	O
methodology	O
successfully	O
allowed	O
individualized	O
CHM	O
decoctions	O
to	O
be	O
tested	O
rigorously	O
.	O


RESULTS	O
By	O
the	O
end	O
of	O
experiment	O
,	O
the	O
expressions	B-OUT
of	I-OUT
CD3	I-OUT
,	I-OUT
CD68	I-OUT
,	I-OUT
ICAM-1	I-OUT
,	I-OUT
MMP9	I-OUT
,	I-OUT
CD40L	I-OUT
and	I-OUT
tenascin-C	I-OUT
on	O
the	O
plaques	O
were	O
statistically	O
significant	O
lower	O
in	O
the	O
QQG	O
group	O
compared	O
with	O
the	O
control	O
group	O
(	O
P	O
<	O
0.01	O
)	O
.	O


BACKGROUND	O
Fluticasone	B-I
propionate	I-I
,	O
an	O
inhaled	O
corticosteroid	O
with	O
negligible	O
systemic	O
bioavailability	O
via	O
the	O
oral	O
route	O
,	O
is	O
efficacious	O
in	O
the	O
treatment	O
of	O
asthma	B-P
when	O
administered	O
via	O
metered-dose	O
inhaler	O
.	O


Comparison	O
of	O
endotracheal	B-I
and	I-I
peripheral	I-I
intravenous	I-I
adrenaline	I-I
in	O
cardiac	B-P
arrest	I-P
.	I-P


Process	O
evaluation	O
of	O
Healthy	B-I
Bodies	I-I
,	I-I
Healthy	I-I
Souls	I-I
:	I-I
a	I-I
church-based	I-I
health	I-I
intervention	I-I
program	I-I
in	I-P
Baltimore	I-P
City	I-P
.	I-P


The	O
results	O
indicate	O
successful	B-OUT
implementation	I-OUT
of	O
the	O
HBHS	B-I
program	I-I
.	I-I


A	O
sample	O
size	O
of	O
4000	O
is	O
estimated	O
to	O
provide	O
87	O
%	O
power	O
to	O
detect	O
a	O
20	O
%	O
treatment	O
effect	O
.	O


A	B-P
group	I-P
of	I-P
48	I-P
critically	I-P
injured	I-P
patients	I-P
were	O
entered	O
into	O
a	O
prospective	O
,	O
double-blind	O
,	O
placebo-controlled	B-I
trial	O
to	O
evaluate	O
the	O
efficacy	O
of	O
early	B-I
infusion	I-I
of	I-I
PGE1	I-I
for	O
reducing	O
the	O
incidence	B-OUT
of	I-OUT
severe	I-OUT
respiratory	I-OUT
failure	I-OUT
and	I-OUT
mortality	I-OUT
.	I-OUT


In	O
patients	O
who	O
received	O
the	O
full	O
7	O
days	O
of	O
infusion	O
,	O
the	O
plasma	B-OUT
suppressive	I-OUT
activity	I-OUT
remained	O
significantly	O
diminished	O
in	O
the	O
PGE1	O
group	O
--	O
ratio	O
P	O
:	O
C	O
77	O
+/-	O
4	O
%	O
versus	O
61	O
+/-	O
5	O
%	O
(	O
P	O
less	O
than	O
0.04	O
)	O
.	O


(	O
ABSTRACT	O
TRUNCATED	O
AT	O
250	O
WORDS	O
)	O


Psychiatric	B-OUT
assessment	I-OUT
was	O
made	O
with	O
the	O
Hamilton	B-OUT
depression	I-OUT
scale	I-OUT
(	O
HDS	O
)	O
,	O
and	O
unwanted	B-OUT
effects	I-OUT
were	O
measured	O
with	O
the	O
UKU	B-OUT
side-effect	I-OUT
scale	I-OUT
.	I-OUT


None	O
of	O
the	O
patients	O
in	O
the	O
valproate	O
group	O
required	O
ventilation	B-OUT
or	I-OUT
developed	I-OUT
hypotension	I-OUT
,	O
whereas	O
in	O
the	O
diazepam	O
group	O
60	O
%	O
required	O
ventilation	B-OUT
and	O
50	O
%	O
developed	O
hypotension	B-OUT
after	O
starting	O
diazepam	O
infusion	O
.	O


The	O
aim	O
of	O
the	O
Finnish	B-P
Diabetes	I-P
Prevention	O
Study	O
is	O
to	O
assess	O
the	O
efficacy	B-OUT
of	O
an	O
intensive	B-I
diet-exercise	I-I
programme	I-I
in	O
preventing	O
or	O
delaying	O
type	B-OUT
2	I-OUT
diabetes	I-OUT
in	I-P
individuals	I-P
with	I-P
impaired	I-P
glucose	I-P
tolerance	I-P
(	I-P
IGT	I-P
)	I-P
and	O
to	O
evaluate	O
the	O
effect	O
of	O
the	O
programme	O
on	O
the	O
risk	O
factors	O
of	O
atherosclerotic	O
vascular	O
diseases	O
and	O
the	O
incidence	O
of	O
cardiovascular	O
events	O
.	O


A	O
pilot	O
study	O
began	O
in	O
1993	O
,	O
and	O
recruitment	O
ended	O
in	O
1998	O
.	O


RESULTS	O
In	O
25	O
participants	O
,	O
147	O
nodules	O
were	O
present	O
on	O
both	O
examinations	O
(	O
volume	O
:	O
12.0-436.6	O
mm	O
(	O
3	O
)	O
)	O
.	O


This	O
variation	B-OUT
affects	I-OUT
the	I-OUT
classification	I-OUT
of	I-OUT
lung	O
nodules	O
,	O
especially	O
in	O
follow-up	O
examinations	O
.	O


The	O
number	B-OUT
of	I-OUT
patients	I-OUT
presenting	I-OUT
a	I-OUT
level	I-OUT
of	I-OUT
plateau	I-OUT
increased	O
in	O
the	O
active	O
group	O
(	O
from	O
two	O
to	O
four	O
)	O
and	O
decreased	O
in	O
the	O
placebo	O
group	O
(	O
from	O
two	O
to	O
one	O
)	O
.	O


CONCLUSION	O
Liposome-entrapped	O
D.	O
Pteronyssinus	O
vaccination	O
:	O
(	O
i	O
)	O
protects	O
mild	B-P
asthma	I-P
patients	I-P
from	O
the	O
worsening	O
of	O
asthma	O
due	O
to	O
sustained	O
mite	O
exposure	O
;	O
and	O
(	O
ii	O
)	O
reduces	O
the	O
functional	O
and	O
inflammatory	O
changes	O
induced	O
by	O
allergen	O
bronchial	O
provocation	O
.	O


An	O
open	O
,	O
randomized	O
study	O
evaluated	O
the	O
immune	B-OUT
response	I-OUT
and	I-OUT
safety	I-OUT
of	O
two	O
different	O
regimens	O
of	O
diphtheria-tetanus-acellular	B-OUT
pertussis-hepatitis	I-OUT
B-inactivated	I-OUT
poliovirus-Haemophilus	I-OUT
influenzae	I-OUT
type	I-OUT
b	I-OUT
(	I-OUT
DTPa-HBV-IPV-Hib	I-OUT
)	I-OUT
immunization	O
in	O
infants	B-P
primed	I-P
at	I-P
birth	I-P
with	I-P
hepatitis	I-P
B	I-P
vaccine	I-P
.	I-P


Gastric	B-P
ulcer	I-P
treatment	I-P
with	O
intravenous	O
human	B-I
epidermal	I-I
growth	I-I
factor	I-I
:	I-I
a	O
double-blind	O
controlled	O
clinical	O
study	O
.	O


We	O
also	O
prospected	O
an	O
oral	O
use	O
of	O
EGF	B-I
on	O
the	O
basis	O
of	O
our	O
experimental	O
evidence	O
.	O


Indomethacin	B-I
significantly	O
attenuated	O
the	O
antihypertensive	B-OUT
activity	I-OUT
of	O
cilazapril	B-I
.	I-I


4	O
.	O


To	O
investigate	O
this	O
aim	O
,	O
we	O
randomized	O
30	B-P
subjects	I-P
to	O
2.0	B-I
g/d	I-I
ginger	I-I
or	I-I
placebo	I-I
for	I-I
28	I-I
days	I-I
.	I-I


Flexible	B-OUT
sigmoidoscopy	I-OUT
at	O
baseline	O
and	O
day	O
28	O
was	O
used	O
to	O
obtain	O
colon	O
biopsies	O
.	O


The	O
aim	O
of	O
this	O
study	O
was	O
to	O
compare	O
the	O
Cavitron	B-I
ultrasonic	I-I
surgical	I-I
aspirator	I-I
(	I-I
CUSA	I-I
)	I-I
with	I-I
bipolar	I-I
cautery	I-I
(	I-I
BP	I-I
)	I-I
to	I-I
CUSA	I-I
with	I-I
a	I-I
radiofrequency	I-I
coagulator	I-I
[	O
TissueLink	O
(	O
TL	O
)	O
]	O
in	O
terms	O
of	O
efficacy	O
and	O
safety	O
for	O
hepatic	O
transection	O
in	O
living	O
donor	O
liver	O
transplantation	O
.	O


Median	B-OUT
blood	I-OUT
loss	I-OUT
during	I-OUT
liver	I-OUT
transection	I-OUT
was	O
significantly	O
lower	O
in	O
the	O
TL	O
group	O
than	O
in	O
the	O
BP	O
group	O
(	O
195.2	O
+/-	O
84.5	O
versus	O
343.3	O
+/-	O
198.4	O
mL	O
;	O
P	O
=	O
0.023	O
)	O
,	O
and	O
liver	B-OUT
transection	I-OUT
was	O
significantly	O
faster	O
in	O
the	O
TL	O
group	O
than	O
in	O
the	O
BP	O
group	O
(	O
0.7	O
+/-	O
0.2	O
versus	O
0.5	O
+/-	O
0.2	O
cm	O
(	O
2	O
)	O
/minute	O
;	O
P	O
=	O
0.048	O
)	O
.	O


[	B-OUT
No	I-OUT
effect	I-OUT
of	O
spironolactone	B-I
on	O
bulimia	O
nervosa	O
symptoms	O
]	O
.	O


Some	O
case	O
reports	O
mention	O
that	O
Spironolactone	B-I
,	O
a	O
mineral	B-I
corticoid	I-I
antagonist	I-I
and	O
aldosterone	B-I
antagonist	I-I
,	O
reduces	O
binging	B-OUT
in	O
patients	B-P
with	I-P
bulimia	I-P
nervosa	I-P
.	I-P


The	O
results	O
show	O
that	O
the	O
number	B-OUT
of	I-OUT
binges	I-OUT
and	I-OUT
the	I-OUT
scores	I-OUT
on	I-OUT
the	I-OUT
bulimia	I-OUT
scale	I-OUT
decreased	O
somewhat	O
,	O
but	O
this	O
occurred	O
in	O
both	O
groups	O
.	O


Therefore	O
,	O
a	O
treatment	O
with	O
Spironolactone	B-I
seems	O
to	O
have	O
no	B-OUT
effect	I-OUT
on	O
bulimia	O
nervosa	O
symptoms	O
.	O


Influence	O
of	O
SNPs	O
in	O
nutrient-sensitive	B-OUT
candidate	O
genes	B-OUT
and	O
gene-diet	B-OUT
interactions	I-OUT
on	I-OUT
blood	I-OUT
lipids	I-OUT
:	I-OUT
the	O
DiOGenes	B-P
study	I-P
.	I-P


Blood	B-OUT
lipid	I-OUT
response	O
to	O
a	O
given	B-I
dietary	I-I
intervention	I-I
could	O
be	O
determined	O
by	O
the	O
effect	O
of	O
diet	O
,	O
gene	O
variants	O
or	O
gene-diet	O
interactions	O
.	O


In	O
conclusion	O
,	O
we	O
investigated	O
SNP-diet	B-OUT
interactions	I-OUT
for	I-OUT
blood	I-OUT
lipid	I-OUT
profiles	I-OUT
for	O
240	O
SNPs	O
in	O
twenty-four	O
candidate	O
genes	O
,	O
selected	O
for	O
their	O
involvement	O
in	O
lipid	O
metabolism	O
pathways	O
,	O
and	O
identified	O
one	O
significant	O
interaction	B-OUT
between	I-OUT
LPIN1	I-OUT
rs4315495	I-OUT
and	I-OUT
dietary	I-OUT
protein	I-OUT
for	I-OUT
TAG	I-OUT
concentration	I-OUT
.	I-OUT


AIMS	O
Transdermal	B-I
fentanyl	I-I
is	O
a	O
well	O
established	O
treatment	O
for	O
cancer	O
pain	O
.	O


Braced	O
for	O
impact	O
:	O
reducing	O
military	B-P
paratroopers	I-P
'	I-P
ankle	O
sprains	O
using	O
outside-the-boot	B-I
braces	I-I
.	I-I


Children	O
whose	O
parents	O
reported	O
hypercholesterolemia	O
had	O
higher	O
total	B-OUT
and	I-OUT
non-HDL	I-OUT
cholesterol	I-OUT
and	I-OUT
apo	I-OUT
B	I-OUT
levels	I-OUT
than	O
the	O
rest	O
,	O
but	O
these	O
levels	O
were	O
not	O
associated	O
with	O
cardiovascular	O
disease	O
.	O


No	O
modification	O
was	O
found	O
in	O
nonresponders	O
.	O


The	O
REMADHE	O
[	O
Repetitive	O
Education	B-I
and	I-I
Monitoring	I-I
for	O
ADherence	O
for	O
Heart	O
Failure	O
]	O
trial	O
is	O
a	O
long-term	O
randomized	O
,	O
prospective	O
,	O
parallel	O
trial	O
designed	O
to	O
compare	O
intervention	O
with	O
control	B-I
.	I-I


The	O
quality-of-life	B-OUT
questionnaire	I-OUT
score	I-OUT
improved	O
only	O
in	O
the	O
intervention	O
group	O
(	O
P	O
<	O
0.003	O
)	O
.	O


Meropenem	B-I
is	O
as	O
effective	O
as	O
imipenem	B-I
in	O
preventing	O
septic	B-OUT
complications	I-OUT
of	O
patients	O
with	O
severe	O
acute	O
pancreatitis	O
.	O


Treadmill	B-OUT
exercise	I-OUT
tests	I-OUT
and	O
72-hour	B-OUT
electrocardiographic	I-OUT
recordings	I-OUT
were	O
obtained	O
at	O
the	O
end	O
of	O
two	O
2-week	O
treatment	O
periods	O
with	O
sustained-release	B-I
diltiazem	I-I
180	O
mg	O
b.i.d	O
.	O


Episodes	B-OUT
of	I-OUT
asymptomatic	I-OUT
ST	I-OUT
depression	I-OUT
decreased	O
by	O
50	O
%	O
or	O
more	O
in	O
70	O
%	O
of	O
the	O
patients	O
from	O
a	O
median	O
number	O
of	O
4.5	O
(	O
range	O
,	O
0-19	O
)	O
to	O
1.5	O
(	O
range	O
,	O
0-13	O
)	O
(	O
p	O
=	O
0.0001	O
)	O
;	O
their	O
cumulative	B-OUT
duration	I-OUT
also	O
decreased	O
from	O
78.5	O
(	O
range	O
,	O
0-60	O
)	O
to	O
24.5	O
(	O
range	O
,	O
0-411	O
)	O
minutes	O
(	O
p	O
=	O
0.001	O
)	O
.	O


Although	O
less	O
frequent	O
with	O
diltiazem	B-I
administration	O
(	O
45	O
versus	O
54	O
patients	O
,	O
p	O
less	O
than	O
0.03	O
)	O
,	O
exercise-induced	B-OUT
ST	I-OUT
depression	I-OUT
was	O
more	O
often	O
asymptomatic	O
(	O
98	O
%	O
versus	O
72	O
%	O
of	O
patients	O
,	O
p	O
less	O
than	O
0.0001	O
)	O
.	O


INTERVENTIONS	O
Hysteroscopic	B-I
resection	O
of	O
the	O
uterine	O
septum	O
performed	O
with	O
either	O
a	O
26F	B-I
resectoscope	I-I
with	I-I
unipolar	I-I
knife	I-I
(	O
80	O
women	O
,	O
group	O
A	O
)	O
or	O
a	O
5-mm	B-I
diameter	I-I
hysteroscope	I-I
with	I-I
Versapoint	I-I
device	I-I
(	O
80	O
women	O
,	O
group	O
B	O
)	O
.	O


MEASUREMENTS	O
AND	O
MAIN	O
RESULTS	O
Operative	O
parameters	O
(	B-OUT
operative	I-OUT
time	I-OUT
,	I-OUT
fluid	I-OUT
absorption	I-OUT
,	I-OUT
complications	I-OUT
,	I-OUT
need	I-OUT
for	I-OUT
second	I-OUT
intervention	I-OUT
)	I-OUT
and	O
reproductive	O
outcome	O
parameters	O
(	B-OUT
pregnancy	I-OUT
,	I-OUT
abortion	I-OUT
,	I-OUT
term	I-OUT
and	I-OUT
preterm	I-OUT
delivery	I-OUT
,	I-OUT
modality	I-OUT
of	I-OUT
delivery	I-OUT
,	I-OUT
cervical	I-OUT
cerclage	I-OUT
)	I-OUT
were	O
measured	O
.	O


Operative	B-OUT
time	I-OUT
and	I-OUT
fluid	I-OUT
absorption	I-OUT
were	O
significantly	O
greater	O
in	O
group	O
A	O
than	O
in	O
group	O
B	O
(	O
23.4	O
+/-	O
5.7	O
vs	O
16.9	O
+/-	O
4.7	O
minutes	O
and	O
486.4	O
+/-	O
170.0	O
vs	O
222.1	O
+/-	O
104.9	O
mL	O
,	O
respectively	O
)	O
.	O


Quality	B-OUT
of	I-OUT
life	I-OUT
and	I-OUT
fatigue	I-OUT
of	O
patients	B-P
with	I-P
spinal	I-P
bone	I-P
metastases	I-P
under	I-P
combined	I-P
treatment	I-P
with	I-P
resistance	I-I
training	I-I
and	I-I
radiation	I-I
therapy-	I-I
a	O
randomized	O
pilot	O
trial	O
.	O


The	O
Cohen	O
's	O
effect	O
size	O
confirmed	O
the	O
clinically	O
significant	O
improvement	O
of	O
these	O
findings	O
.	O


CONCLUSIONS	B-P
In	I-P
this	O
group	O
of	O
patients	O
we	B-I
were	I-I
able	I-I
to	I-I
show	I-I
that	I-I
guided	I-I
isometric	I-I
resistance	I-I
training	I-I
of	I-I
the	I-I
paravertebral	I-OUT
muscles	I-OUT
can	I-OUT
improve	I-OUT
functional	I-OUT
capacity	I-OUT
,	O
reduce	O
fatigue	B-OUT
and	O
thereby	O
enhance	O
QoL	O
over	O
a	O
6-months	O
period	O
in	O
patients	O
with	O
stable	O
spinal	O
metastases	O
.	O


This	O
study	O
evaluated	O
a	O
manualized	B-I
intervention	I-I
for	I-I
sensory	I-I
difficulties	I-I
for	O
children	B-P
with	I-P
autism	I-P
,	I-P
ages	I-P
4-8	I-P
years	I-P
,	O
using	O
a	O
randomized	O
trial	O
design	O
.	O


Results	O
show	O
that	O
the	O
children	B-P
in	I-P
the	I-P
treatment	I-P
group	I-P
(	I-P
n	I-P
=	I-P
17	I-P
)	I-P
who	O
received	O
30	B-I
sessions	I-I
of	I-I
the	I-I
occupational	I-I
therapy	I-I
intervention	I-I
scored	O
significantly	O
higher	O
(	O
p	O
=	O
0.003	O
,	O
d	O
=	O
1.2	O
)	O
on	O
Goal	B-OUT
Attainment	I-OUT
Scales	I-OUT
(	I-OUT
primary	I-OUT
outcome	I-OUT
)	I-OUT
,	O
and	O
also	O
scored	O
significantly	O
better	O
on	O
measures	O
of	O
caregiver	B-OUT
assistance	I-OUT
in	I-OUT
self-care	I-OUT
(	O
p	O
=	O
0.008	O
d	O
=	O
0.9	O
)	O
and	O
socialization	B-OUT
(	O
p	O
=	O
0.04	O
,	O
d	O
=	O
0.7	O
)	O
than	O
the	O
Usual	B-I
Care	I-I
control	I-I
group	I-P
(	I-P
n	I-P
=	I-P
15	I-P
)	I-P
.	I-P


RESULTS	O
Twenty	B-P
patients	I-P
completed	I-P
the	I-P
study	I-P
.	I-P


The	O
duration	O
of	O
treatment	O
was	O
measured	O
in	O
24	B-P
of	I-P
27	I-P
consecutive	I-P
children	I-P
with	I-P
a	I-P
mean	I-P
age	I-P
of	I-P
24	I-P
months	I-P
(	I-P
5	I-P
to	I-P
75	I-P
)	I-P
following	I-P
posteromedial	I-P
release	I-P
for	I-P
idiopathic	I-P
club	I-P
foot	I-P
.	I-P


Comparison	O
of	O
ketanserin	B-I
and	O
pindolol	B-I
in	O
hypertension	B-P
.	I-P


The	O
antihypertensive	O
effects	O
of	O
ketanserin	B-I
(	O
40	O
mg	O
twice	O
daily	O
)	O
and	O
pindolol	B-I
(	O
5	O
mg	O
twice	O
daily	O
)	O
as	O
monotherapy	O
were	O
compared	O
in	O
a	O
crossover	O
,	O
double-blind	O
trial	O
in	O
17	B-P
patients	I-P
with	I-P
essential	I-P
hypertension	I-P
.	I-P


Both	O
ketanserin	B-I
and	O
pindolol	B-I
decreased	O
supine	B-OUT
systolic	I-OUT
and	I-OUT
diastolic	I-OUT
blood	I-OUT
pressure	I-OUT
significantly	O
(	O
P	O
less	O
than	O
0.01	O
for	O
systolic	B-OUT
and	I-OUT
P	I-OUT
less	O
than	O
0.001	O
for	O
diastolic	O
)	O
when	O
evaluated	O
at	O
the	O
end	O
of	O
the	O
2-month	O
treatment	O
periods	O
.	O


RESULTS	O
Substantial	B-OUT
observer	I-OUT
variation	I-OUT
was	O
found	O
in	O
the	O
rating	O
of	O
sample	O
cases	O
(	O
weighted	O
kappa	O
,	O
0.72	O
;	O
confidence	O
interval	O
,	O
0.68-0.75	O
)	O
and	O
in	O
assigning	O
outcome	B-OUT
based	O
on	O
completed	O
structured	O
interviews	O
(	O
weighted	O
kappa	O
,	O
0.61	O
;	O
confidence	O
interval	O
,	O
0.57-0.64	O
)	O
.	O


This	O
number	O
declined	O
as	O
the	O
trial	O
progressed	O
and	O
coincided	O
with	O
investigator	O
training	O
and	O
feedback	O
from	O
central	O
review	O
.	O


Physical	O
activity	O
for	O
patients	B-P
undergoing	I-P
an	I-P
allogeneic	I-P
hematopoietic	I-P
stem	I-P
cell	I-P
transplantation	I-P
:	I-P
benefits	O
of	O
a	O
moderate	B-I
exercise	I-I
intervention	I-I
.	I-I


CONCLUSION	O
The	O
results	O
show	O
that	O
the	O
training	O
program	O
is	O
feasible	O
and	O
seems	O
to	O
have	O
positive	O
influences	O
on	O
physical	B-OUT
performance	I-OUT
and	I-OUT
quality	I-OUT
of	I-OUT
life	I-OUT
in	O
patients	B-P
undergoing	I-P
an	I-P
allogeneic	I-P
HSCT	I-P
.	I-P


However	O
,	O
further	O
studies	O
are	O
necessary	O
to	O
confirm	O
these	O
results	O
.	O


The	O
modified	O
scale	O
(	B-I
CYBOCS-PDD	I-I
)	I-I
,	O
which	O
contains	O
only	O
the	O
five	B-I
Compulsion	I-I
severity	I-I
items	I-I
(	O
range	O
0-20	O
)	O
,	O
was	O
administered	B-P
to	I-P
172	I-P
medication-free	I-P
children	I-P
(	I-P
mean	I-P
8.2	I-P
+/-	I-P
2.6	I-P
years	I-P
)	I-P
with	I-P
PDD	I-P
(	I-P
autistic	I-P
disorder	I-P
,	I-P
n	I-P
=	I-P
152	I-P
;	I-P
Asperger	I-P
's	I-P
disorder	I-P
,	I-P
n	I-P
=	I-P
6	I-P
;	I-P
PDD	I-P
not	I-P
otherwise	I-P
specified	I-P
,	I-P
n	I-P
=	I-P
14	I-P
)	I-P
participating	I-P
in	I-P
RUPP	I-P
clinical	I-P
trials	I-P
.	I-P


CONCLUSIONS	O
The	O
five-item	O
CYBOCS-PDD	O
is	O
reliable	O
,	O
distinct	O
from	O
other	O
measures	O
of	O
repetitive	O
behavior	O
,	O
and	O
sensitive	O
to	O
change	O
.	O


RESULTS	O
Between	O
1	O
and	O
3	O
years	O
,	O
there	O
were	O
infrequent	O
additional	O
clinical	O
events	O
that	O
were	O
equally	O
distributed	O
between	O
the	O
SES	O
and	O
the	O
BMS	O
group	O
.	O


However	O
,	O
the	O
timing	O
of	O
these	O
events	O
in	O
relation	O
to	O
index	O
event	O
is	O
less	O
clear	O
.	O


From	O
15	O
%	O
to	O
40	O
%	O
of	O
these	O
events	O
occurred	O
beyond	O
30	O
days	O
.	O


Similarly	O
,	O
whereas	O
death	B-OUT
or	I-OUT
MI	I-OUT
increased	O
with	O
higher	O
risk	O
(	O
11	O
%	O
,	O
14	O
%	O
,	O
and	O
23	O
%	O
,	O
respectively	O
)	O
,	O
the	O
proportion	B-OUT
of	I-OUT
patients	I-OUT
with	O
this	O
event	O
beyond	O
30	O
days	O
did	O
not	O
differ	O
in	O
the	O
three	O
strata	O
(	O
22	O
%	O
,	O
20	O
%	O
,	O
and	O
25	O
%	O
,	O
respectively	O
)	O
.	O


Concurrent	B-I
alcohol	I-I
dependence	I-I
(	I-I
AD	I-I
)	I-I
among	O
polysubstance	O
abusers	O
has	O
been	O
associated	O
with	O
negative	O
consequences	O
,	O
although	O
it	O
may	O
not	O
necessarily	O
lead	O
to	O
poor	O
treatment	O
outcomes	O
.	O


Raising	O
a	O
child	B-P
with	I-P
an	I-P
autism	I-P
spectrum	I-P
disorder	I-P
(	I-P
ASD	I-P
)	I-P
is	O
associated	O
with	O
increased	O
family	B-P
chaos	O
and	O
parent	B-P
distress	O
.	O


Successful	O
long-term	O
treatment	O
outcomes	O
are	O
dependent	O
on	O
healthy	O
systemic	O
functioning	O
,	O
but	O
the	O
family	B-OUT
impact	I-OUT
of	I-OUT
treatment	I-OUT
is	O
rarely	O
evaluated	O
.	O


This	O
study	O
assessed	O
the	O
impact	O
of	O
PEERS	B-OUT
on	O
family	B-OUT
chaos	I-OUT
,	I-OUT
parenting	I-OUT
stress	I-OUT
,	I-OUT
and	I-OUT
parenting	I-OUT
self-efficacy	I-OUT
via	O
a	O
randomized	O
,	O
controlled	O
trial	O
.	O


Higher	B-OUT
weekly	I-OUT
contact	I-OUT
hours	I-OUT
and	I-OUT
patient	I-OUT
ratings	I-OUT
of	I-OUT
expressed	I-OUT
emotion	I-OUT
(	I-OUT
EE	I-OUT
)	I-OUT
predicted	O
a	O
negative	O
experience	O
of	O
caregiving	O
.	O


This	O
study	O
is	O
registered	O
with	O
ClinicalTrials.gov	O
,	O
number	O
NCT00242203	O
.	O


The	O
most	O
common	O
grade	O
3-4	O
toxicities	O
were	O
infection	O
(	O
five	O
of	O
60	O
patients	O
in	O
the	O
zoledronic	O
acid	O
group	O
and	O
six	O
of	O
59	O
in	O
the	O
control	O
group	O
)	O
and	O
thrombosis	O
(	O
five	O
of	O
60	O
in	O
the	O
zoledronic	O
acid	O
and	O
two	O
of	O
59	O
in	O
the	O
control	O
group	O
)	O
.	O


RESULTS	O
There	O
was	O
a	O
significantly	O
greater	O
reduction	O
of	O
swelling	B-OUT
from	O
Visit	O
1	O
to	O
Visit	O
2	O
with	O
PN+Dx	O
,	O
and	O
more	O
patients	O
rated	O
the	O
efficacy	B-OUT
of	O
PN+Dx	O
as	O
'very	O
good	O
'	O
or	O
'good	O
'	O
at	O
Visit	O
3	O
(	O
p	O
=	O
0.03	O
)	O
.	O


SETTING	O
University	B-P
teaching	I-P
hospital	I-P
.	I-P


PATIENTS	O
Two	B-P
groups	I-P
(	I-P
control	I-P
group	I-P
[	I-P
group	I-P
1	I-P
]	I-P
and	I-P
hemodiluted	I-P
group	I-P
[	I-P
group	I-P
2	I-P
]	I-P
)	I-P
of	I-P
13	I-P
healthy	I-P
patients	I-P
were	O
studied	O
during	O
a	O
long-term	O
(	O
>	O
4	O
hrs	O
)	O
surgical	O
procedure	O
.	O


MEASUREMENTS	O
AND	O
MAIN	O
RESULTS	O
The	O
albumin	B-OUT
diffusion	I-OUT
space	I-OUT
,	I-OUT
the	I-OUT
colloid	I-OUT
oncotic	I-OUT
pressure	I-OUT
,	I-OUT
the	I-OUT
plasma	I-OUT
albumin	I-OUT
concentration	I-OUT
and	I-OUT
the	I-OUT
electrical	I-OUT
impedance	I-OUT
were	O
measured	O
before	O
(	O
T	O
=	O
10	O
mins	O
)	O
and	O
after	O
(	O
T	O
=	O
60	O
,	O
120	O
,	O
and	O
240	O
mins	O
)	O
hemodilution	O
.	O


Group	B-I
3	I-I
received	I-I
propofol	I-I
2	I-I
mg/kg	I-I
i.v.	I-I
,	O
followed	B-I
by	I-I
propofol	I-I
50	I-I
to	I-I
160	I-I
micrograms/kg/min	I-I
i.v	I-I
.	I-I


to	O
facilitate	O
tracheal	O
intubation	O
and	O
atracurium	B-I
10	O
to	O
20	O
mg	O
i.v	O
.	O


However	O
,	O
the	O
use	O
of	O
enflurane	B-I
versus	O
propofol	B-I
for	O
maintenance	O
of	O
anesthesia	O
did	O
not	O
significantly	O
prolong	O
the	O
time	B-OUT
from	I-OUT
arrival	I-OUT
in	I-OUT
the	I-OUT
recovery	I-OUT
room	I-OUT
to	I-OUT
sitting	I-OUT
,	I-OUT
tolerating	I-OUT
oral	I-OUT
fluids	I-OUT
,	I-OUT
walking	I-OUT
,	I-OUT
or	I-OUT
being	I-OUT
judged	I-OUT
"	I-OUT
fit	I-OUT
for	I-OUT
discharge	I-OUT
.	I-OUT


Maintenance	O
of	O
anesthesia	O
with	O
enflurane	B-I
did	O
not	O
prolong	O
recovery	B-OUT
compared	O
with	O
maintenance	O
with	O
propofol	B-I
,	O
but	O
enflurane	B-I
was	O
associated	O
with	O
increased	O
frequency	B-OUT
of	I-OUT
postoperative	I-OUT
nausea	I-OUT
and	I-OUT
vomiting	I-OUT
.	I-OUT


BACKGROUND	O
Soil-transmitted	O
helminths	O
are	O
among	O
the	O
most	O
prevalent	O
sources	O
of	O
human	O
infections	O
globally	O
.	O


Everolimus	B-I
for	O
subependymal	O
giant	O
cell	O
astrocytoma	O
in	O
patients	B-P
with	I-P
tuberous	I-P
sclerosis	I-P
complex	I-P
:	I-P
2-year	O
open-label	O
extension	O
of	O
the	O
randomised	O
EXIST-1	O
study	O
.	O


METHODS	O
We	O
assessed	O
data	O
from	O
a	O
prospective	O
,	O
open-label	O
extension	O
of	O
a	O
multicentre	O
,	O
phase	O
3	O
,	O
randomised	O
,	O
double-blind	O
,	O
placebo-controlled	B-I
study	O
in	B-P
patients	I-P
with	I-P
tuberous	I-P
sclerosis	I-P
complex	I-P
who	I-P
had	I-P
SEGA	I-P
that	I-P
was	I-P
growing	I-P
and	I-P
needed	I-P
treatment	I-P
.	O


54	O
(	O
49	O
%	O
)	O
patients	O
had	O
a	O
response	O
of	O
50	O
%	O
or	O
greater	O
reduction	B-OUT
in	I-OUT
SEGA	I-OUT
volume	O
(	O
95	O
%	O
CI	O
39·0-58·3	B-OUT
)	I-OUT
,	I-OUT
and	I-OUT
duration	I-OUT
of	I-OUT
response	O
was	O
between	O
2·1	O
and	O
31·1	O
months	O
(	O
median	O
not	B-OUT
reached	I-OUT
)	I-OUT
.	I-OUT


Six	O
(	O
5	O
%	O
)	O
patients	O
withdrew	B-OUT
because	I-OUT
of	I-OUT
adverse	I-OUT
events	O
.	O


STUDY	O
DESIGN	O
A	O
prospective	O
study	O
was	O
performed	O
.	O


METHODS	O
Three	B-P
hundred	I-P
twenty-nine	I-P
patients	I-P
were	O
evaluated	O
.	O


Patients	O
were	O
followed	O
clinically	O
for	O
a	O
minimum	O
of	O
1	O
year	O
.	O


CONCLUSIONS	O
This	O
low	O
0.3	O
%	O
rate	O
is	O
in	O
agreement	O
with	O
recent	O
studies	O
that	O
focus	O
on	O
thromboembolic	B-OUT
disease	I-OUT
.	I-OUT


Given	O
the	O
low	O
incidence	O
,	O
routine	O
screening	O
for	O
asymptomatic	O
thrombi	O
appears	O
unwarranted	O
.	O


In	O
addition	O
,	O
mechanical	O
prophylaxis	O
with	O
graduated	O
compression	O
stockings	O
and	O
pneumatic	O
compression	O
boots	O
is	O
preferable	O
to	O
anticoagulation	O
therapy	O
.	O


A	O
few	O
studies	O
have	O
been	O
conducted	O
that	O
evaluate	O
the	O
effects	O
of	O
risperidone	B-I
on	O
destructive	O
behavior	O
;	O
however	O
,	O
none	O
of	O
these	O
studies	O
have	O
combined	O
objective	O
measures	O
with	O
rating	O
scales	O
to	O
evaluate	O
the	O
effects	O
of	O
risperidone	B-I
on	O
destructive	O
behavior	O
across	O
home	O
and	O
clinical	O
settings	O
.	O


Hemodynamic	B-OUT
responses	I-OUT
were	O
measured	O
,	O
and	O
transesophageal	O
echocardiography	O
(	O
TEE	O
)	O
was	O
used	O
to	O
determine	O
myocardial	O
contractility	O
.	O


This	O
may	O
have	O
applicability	O
to	O
the	O
clinical	O
strategy	O
of	O
permissive	O
hypercapnia	O
and	O
allow	O
the	O
benefit	O
of	O
decreased	O
airway	B-OUT
pressures	I-OUT
to	O
be	O
realized	O
while	O
minimizing	O
the	O
adverse	O
hemodynamic	O
effects	O
of	O
hypercapnic	O
acidosis	O
.	O


METHODS	O
Patients	B-P
in	I-P
REFLEX	I-P
were	O
originally	O
randomized	O
to	O
placebo	B-I
(	I-I
PBO	I-I
)	I-I
+	I-I
methotrexate	I-I
(	I-I
MTX	I-I
;	I-I
PBO-randomized	I-I
)	I-I
or	I-I
RTX	I-I
+	I-I
MTX	I-I
(	I-I
RTX-randomized	I-I
)	I-I
.	I-I


Mean	B-OUT
change	I-OUT
from	I-OUT
baseline	I-OUT
in	I-OUT
PJD	I-OUT
over	O
5	O
years	O
was	O
greater	O
in	B-I
PBO-randomized	I-I
versus	I-I
RTX-randomized	I-I
patients	O
(	O
5.51	O
vs	O
3.21	O
)	O
.	O


Local	B-OUT
septic	I-OUT
complications	I-OUT
occurred	O
in	O
12.5	O
%	O
of	O
patients	O
after	O
pouch-anal	O
anastomosis	O
compared	O
to	O
20.5	O
%	O
after	O
colo-anal	O
anastomosis	O
:	O
stool	B-OUT
frequency	I-OUT
,	O
after	O
pouch-anal	O
anastomosis	O
was	O
3.3	O
per	O
24	O
h	O
compared	O
to	O
5.2	O
per	O
24	O
h	O
after	O
straight	O
anastomosis	O
within	O
the	O
first	O
year	O
after	O
ileostomy	O
closure	O
(	O
p	O
=	O
0.053	O
)	O
;	O
continence	B-OUT
was	O
slightly	O
better	O
in	O
the	O
pouch	O
group	O
(	O
n.s	O
.	O


Weight	O
and	O
lean	O
body	O
mass	O
change	O
with	O
antiretroviral	B-I
initiation	I-I
and	O
impact	O
on	O
bone	O
mineral	O
density	O
.	O


In	O
a	O
double-blind	O
,	O
placebo	B-I
,	O
cross-over	O
study	O
,	O
nine	B-P
healthy	I-P
volunteers	I-P
were	O
given	O
intravenous	B-I
lidocaine	I-I
(	I-I
or	I-I
saline	I-I
)	I-I
to	O
approximate	O
the	O
plasma	O
levels	O
of	O
lidocaine	B-I
achieved	O
during	O
epidural	O
anesthesia	O
for	O
major	B-P
abdominal	I-P
surgery	I-P
.	I-P


The	O
in-hospital	B-OUT
mortality	I-OUT
of	O
257	B-P
patients	I-P
with	I-P
nonanterior	I-P
wall	I-P
AMI	I-P
was	O
similar	O
after	O
PTCA	O
and	O
tPA	O
(	O
3.2	O
%	O
vs	O
3.8	O
%	O
,	O
p	O
=	O
0.82	O
)	O
.	O


Patients	O
were	O
given	O
propranolol	B-I
(	O
160	O
mg	O
daily	O
)	O
,	O
diltiazem	B-I
(	O
360	O
mg	O
daily	O
)	O
and	B-I
placebo	I-I
for	O
2	O
weeks	O
,	O
using	O
a	O
randomized	O
single	O
blind	O
protocol	O
.	O


There	O
was	O
no	O
difference	O
between	O
treatments	O
for	O
evaluations	O
of	O
overall	B-OUT
pain	I-OUT
intensity	I-OUT
,	I-OUT
analgesic	I-OUT
efficacy	I-OUT
,	I-OUT
or	I-OUT
adverse	I-OUT
events	I-OUT
.	I-OUT


Azelnidipine	B-I
and	O
amlodipine	B-I
anti-coronary	O
atherosclerosis	O
trial	O
in	O
hypertensive	B-P
patients	I-P
undergoing	I-P
coronary	I-P
intervention	I-P
by	I-P
serial	I-P
volumetric	I-P
intravascular	I-P
ultrasound	I-P
analysis	I-P
in	I-P
Juntendo	I-P
university	I-P
(	I-P
ALPS-J	I-P
)	I-P
.	O


To	O
confirm	O
this	O
hypothesis	O
,	O
a	O
multicenter	O
randomized	O
trial	O
of	O
CCBs	O
treatment	O
with	O
azelnidipine	B-I
or	O
amlodipine	B-I
will	O
be	O
conducted	O
in	O
hypertensive	B-P
CAD	I-P
patients	I-P
undergoing	I-P
elective	I-P
percutaneous	I-P
coronary	I-P
intervention	I-P
(	I-P
PCI	I-P
)	I-P
.	I-P


Subjects	O
will	O
be	O
randomized	O
to	O
azelnidipine	B-I
or	O
amlodipine	B-I
and	O
observed	O
for	O
48	O
weeks	O
.	O


METHODS	O
A	O
randomized	O
controlled	O
trial	O
,	O
was	O
performed	O
on	O
60	B-P
patients	I-P
undergoing	I-P
PCNL	I-I
.	I-I


They	O
were	O
randomly	O
divided	O
into	O
3	O
groups	O
of	O
20	O
cases	O
each	O
with	O
nephrostomy	B-I
tube	I-I
(	I-I
NT	I-I
)	I-I
and	I-I
temporary	I-I
ureteral	I-I
catheter	I-I
(	I-I
TU	I-I
)	I-I
in	O
group	O
A	O
,	O
only	B-I
TU	I-I
in	O
group	O
B	O
and	O
only	B-I
indwelling	I-I
ureteral	I-I
catheter	I-I
(	I-I
IU	I-I
)	I-I
in	O
group	O
C.	O
Mean	B-P
age	I-P
of	I-P
cases	I-P
were	I-P
43.2	I-P
(	I-P
25-70	I-P
)	I-P
,	I-P
40.1	I-P
(	I-P
25-73	I-P
)	I-P
,	I-P
and	I-P
44	I-P
(	I-P
25-70	I-P
)	I-P
years	I-P
in	I-P
groups	I-P
A	I-P
,	I-P
B	I-P
and	I-P
C	I-P
,	I-P
respectively	I-P
(	O
P	O
=	O
0.6	O
)	O
.	O


When	O
contour	O
spacing	O
was	O
beyond	O
a	O
critical	O
range	O
(	O
about	O
2	O
degrees	O
)	O
,	O
however	O
,	O
the	O
detectability	B-OUT
dropped	O
to	O
chance	O
levels	O
,	O
regardless	O
of	O
the	O
number	O
of	O
colinear	O
lines	O
.	O


Contour	B-OUT
detectability	I-OUT
was	O
found	O
to	O
be	O
a	O
function	O
not	O
only	O
of	O
the	O
relative	O
spacing	O
of	O
contour	O
elements	O
with	O
respect	O
to	O
the	O
noise	O
elements	O
but	O
also	O
of	O
the	O
average	B-OUT
density	I-OUT
of	O
the	O
overall	O
pattern	O
.	O


RESULTS	O
Among	O
those	O
with	O
tumors	O
larger	O
than	O
7	O
cm	O
,	O
the	O
median	B-OUT
overall	I-OUT
survival	I-OUT
in	O
the	O
chemotherapy	B-I
versus	O
CRT	B-I
arm	O
was	O
9.7	O
and	O
13.4	O
months	O
,	O
respectively	O
(	O
p	O
=	O
0.001	O
)	O
.	O


CONCLUSION	O
In	O
patients	B-P
with	I-P
poor	I-P
prognosis	I-P
and	I-P
inoperable	I-P
locally	I-P
advanced	I-P
non-small-cell	I-P
lung	I-P
cancer	I-P
,	O
large	O
tumor	O
size	O
should	O
not	O
be	O
considered	O
a	O
negative	O
predictive	O
factor	O
.	O


Of	O
these	O
,	O
36	B-P
and	I-P
37	I-P
patients	I-P
,	I-P
respectively	I-P
,	I-P
completed	I-P
the	I-P
study	I-P
and	O
were	O
evaluable	O
.	O


A	O
real-time	B-I
polymerase	I-I
chain	I-I
reaction	I-I
assay	I-I
was	O
developed	O
,	O
permitting	O
the	O
comparative	O
determination	O
of	O
hASH1	B-OUT
mRNA	I-OUT
levels	I-OUT
in	O
triplicate	O
in	O
a	O
double-blind	O
pilot	O
study	O
including	O
24	B-P
frozen	I-P
cases	I-P
of	I-P
esthesioneuroblastoma	I-P
and	I-P
poorly	I-P
differentiated	I-P
tumors	I-P
.	I-P


A	O
model	O
for	O
evaluating	O
anticonvulsants	O
.	O


Doses	O
of	O
20	O
mg	O
,	O
and	O
in	O
some	O
cases	O
30	O
mg	O
,	O
per	O
day	O
were	O
compared	O
with	O
placebo	B-I
over	O
predetermined	O
ten-day	O
periods	O
in	O
a	O
double-blind	O
cross-over	O
study	O
.	O


Clobazam	B-I
completely	O
prevented	O
seizures	B-OUT
in	O
most	O
of	O
the	O
patients	O
,	O
and	O
toxic	O
effects	O
were	O
of	O
low	O
frequency	B-OUT
and	I-OUT
severity	I-OUT
.	I-OUT


BACKGROUND	O
The	O
overall	O
effect	O
of	O
prophylactic	O
tamoxifen	O
in	O
women	O
depends	O
on	O
the	O
balance	O
between	O
the	O
effects	O
of	O
the	O
drug	O
,	O
which	O
include	O
preventing	B-OUT
breast	I-OUT
cancer	I-OUT
and	O
altering	O
cardiovascular	B-OUT
risk	I-OUT
.	I-OUT


We	O
administered	O
sivelestat	B-I
to	O
patients	B-P
with	I-P
septic	I-P
acute	I-P
lung	I-P
injury	I-P
(	I-P
ALI	I-P
)	I-P
to	O
examine	O
its	O
usefulness	O
.	O


The	O
primary	O
endpoints	O
in	O
the	O
study	O
were	O
the	O
duration	B-OUT
of	I-OUT
artificial	I-OUT
ventilation	I-OUT
and	I-OUT
pulmonary	I-OUT
oxygenation	I-OUT
ability	I-OUT
,	O
and	O
the	O
secondary	O
endpoints	O
were	O
mortality	B-OUT
and	I-OUT
the	I-OUT
concentrations	I-OUT
of	I-OUT
PMN-E	I-OUT
,	I-OUT
SP-D	I-OUT
,	I-OUT
TNF-alpha	I-OUT
and	I-OUT
IL-8	I-OUT
in	I-OUT
blood	I-OUT
.	I-OUT


Administration	O
of	O
sivelestat	B-I
was	O
found	O
to	O
reduce	O
alveolar	B-OUT
dysfunction	I-OUT
and	O
improve	O
respiratory	B-OUT
function	I-OUT
,	O
and	O
it	O
was	O
suggested	O
that	O
early	O
administration	O
might	O
be	O
useful	O
.	O


Progressive	O
relaxation	O
markedly	O
reduced	O
systolic	B-OUT
blood	I-OUT
pressure	I-OUT
but	O
did	O
not	O
favorably	O
influence	O
performance	O
or	O
affect	O
in	O
response	O
to	O
acute	B-OUT
stress	I-OUT
.	I-OUT


Twenty	B-P
surgeons	I-P
were	I-P
presented	I-P
objects	I-P
in	I-P
a	I-P
random	I-P
order	I-P
,	I-P
with	I-P
participants	I-P
blinded	I-P
as	I-P
to	I-P
their	I-P
identity	I-P
.	I-P


Interpretation	O
of	O
the	O
texture	O
,	O
shape	O
,	O
and	O
consistency	O
of	O
objects	O
can	O
be	O
performed	O
.	O


In	O
some	O
situations	O
,	O
laparoscopic	B-I
instruments	I-I
appear	O
to	O
amplify	O
the	O
haptic	O
information	O
available	O
.	O


Beta-adrenoceptor	O
blockade	O
did	O
not	O
affect	O
the	O
pressor	B-OUT
response	I-OUT
the	I-OUT
cold	I-OUT
.	I-OUT


Transscleral	B-I
cryotherapy	I-I
to	O
the	O
avascular	O
retina	O
was	O
applied	O
to	O
one	B-P
randomly	I-P
selected	I-P
eye	I-P
when	O
there	O
was	O
threshold	O
disease	O
(	O
defined	O
as	O
five	O
or	O
more	O
contiguous	O
or	O
eight	O
cumulative	O
30	O
degree	O
sectors	O
[	O
clock	O
hours	O
]	O
of	O
stage	O
3	O
ROP	O
in	O
zone	O
1	O
or	O
2	O
in	O
the	O
presence	O
of	O
"	O
plus	O
"	O
disease	O
)	O
.	O


Use	O
of	O
a	O
DNAemia	B-I
cut-off	I-I
for	O
monitoring	O
human	O
cytomegalovirus	O
infection	O
reduces	O
the	O
number	B-OUT
of	I-OUT
preemptively	I-OUT
treated	I-OUT
children	I-OUT
and	I-P
young	I-P
adults	I-P
receiving	I-P
hematopoietic	I-P
stem-cell	I-P
transplantation	I-P
compared	O
with	O
qualitative	B-I
pp65	I-I
antigenemia	I-I
.	I-I


Chemotherapy	B-I
is	O
an	O
effective	O
treatment	B-OUT
for	O
primary	O
digestive	O
lymphomas	O
.	O


METHODS	O
Adult	B-P
patients	I-P
who	I-P
underwent	I-P
laparotomy	I-I
for	I-P
bowel	I-P
resection	I-P
scheduled	I-P
for	I-P
opioid-based	I-I
intravenous	I-I
patient-controlled	I-I
analgesia	I-I
received	I-I
oral	I-I
alvimopan	I-I
or	I-I
placebo	I-I
preoperatively	I-P
and	I-P
twice	I-P
daily	I-P
postoperatively	I-P
until	I-P
hospital	I-P
discharge	I-P
or	I-P
for	I-P
7	I-P
postoperative	I-P
days	I-P
.	I-P


This	O
HPLC/MS/MS	O
procedure	O
was	O
used	O
to	O
assess	O
the	O
bioequivalence	O
of	O
cyproheptadine	O
in	O
two	O
cyproheptadine	O
+	O
cobamamide	O
(	O
4	O
mg	O
+	O
1	O
mg	O
)	O
tablet	O
formulations	O
(	O
Cobactin®	O
[	O
cyproheptadine	O
+	O
cobamamide	O
]	O
test	O
formulation	O
supplied	O
from	O
Zambon	O
Laboratórios	O
Farmacêuticos	O
Ltda	O
.	O


METHODS/DESIGN	O
Guided	O
by	O
a	O
multi-level	O
,	O
conceptual	O
framework	O
that	O
emphasizes	O
changes	O
in	O
provider	O
beliefs	O
and	O
organizational	O
characteristics	O
as	O
drivers	O
of	O
improvement	O
in	O
tobacco	O
treatment	O
delivery	O
,	O
the	O
current	O
protocol	O
will	O
use	O
a	O
cluster	O
,	O
randomized	O
design	O
and	O
multiple	O
data	O
sources	O
(	O
patient	O
exit	O
interviews	O
,	O
provider	O
surveys	O
,	O
site	O
observations	O
,	O
chart	O
audits	O
,	O
and	O
semi-structured	O
provider	O
interviews	O
)	O
to	O
study	O
the	O
process	O
of	O
implementing	O
clinical	O
practice	O
guidelines	O
for	O
treating	O
tobacco	O
dependence	O
in	O
18	B-P
public	I-P
dental	I-P
care	I-P
clinics	I-P
in	I-P
New	I-P
York	I-P
City	I-P
.	I-P


BACKGROUND	O
The	O
aim	O
of	O
this	O
study	O
was	O
to	O
evaluate	O
the	O
performance	B-OUT
of	O
a	O
new	O
cuff	B-OUT
pressure	I-OUT
release	I-I
valve	I-I
(	O
CPRV	O
)	O
,	O
in	O
which	O
the	O
release	O
pressure	O
can	O
be	O
adjusted	O
from	O
10	O
to	O
25	O
cmH2O	O
,	O
particularly	O
intended	O
to	O
control	O
pressure	O
in	O
paediatric	B-P
cuffed	I-P
tracheal	I-P
tubes	I-P
and	O
to	O
avoid	O
cuff	O
hyperinflation	O
caused	O
by	O
N2O	O
diffusion	O
.	O


In	O
rating	O
their	O
own	O
behavioral	B-OUT
intentions	I-OUT
,	O
children	O
showed	O
no	O
differences	O
between	O
conditions	O
.	O


It	O
has	O
been	O
claimed	O
that	O
the	O
monitoring	O
of	O
ongoing	O
psychotherapy	O
is	O
of	O
crucial	O
importance	O
for	O
improving	O
the	O
quality	O
of	O
mental	O
health	O
care	O
.	O


DESIGN	O
Randomized	O
,	O
controlled	O
clinical	O
trial	O
.	O


SETTING	O
Outpatient	B-P
physical	I-P
therapy	I-P
department	I-P
of	I-P
a	I-P
large	I-P
military	I-P
medical	I-P
center	I-P
.	I-P


The	O
placebo	B-I
group	I-P
had	O
subtherapeutic	B-I
ultrasound	I-I
to	O
the	O
knee	O
at	O
an	O
intensity	O
of	O
0.1	O
W/cm2	O
with	O
a	O
10	O
%	O
pulsed	O
mode	O
.	O


Both	O
groups	O
were	O
treated	O
at	O
the	O
clinic	O
twice	O
weekly	O
for	O
4	O
weeks	O
.	O


BACKGROUND	O
Molecular	O
markers	O
to	O
predict	O
response	O
to	O
5-fluorouracil	B-I
(	I-I
FU	I-I
)	I-I
-based	I-I
treatment	O
of	O
recurrent	B-P
or	I-P
metastasised	I-P
colorectal	I-P
cancer	I-P
(	I-P
mCRC	I-P
)	I-P
are	O
not	O
established	O
.	O


The	O
aim	O
of	O
this	O
trial	O
was	O
to	O
determine	O
the	O
value	O
of	O
thymidylate	O
synthase	O
(	O
TS	O
)	O
,	O
a	O
key	O
enzyme	O
of	O
DNA	O
synthesis	O
and	O
target	O
of	O
5-FU	O
,	O
to	O
predict	B-OUT
response	I-OUT
to	O
chemotherapy	O
of	O
mCRC	O
.	O


Treatment	O
outcome	O
was	O
best	O
predicted	O
by	O
pretreatment	B-OUT
imitation	I-OUT
,	I-OUT
language	I-OUT
,	I-OUT
and	I-OUT
social	I-OUT
responsiveness	I-OUT
.	I-OUT


insulin	O
.	O


There	O
was	O
an	O
increase	O
in	O
fasting	B-OUT
and	I-OUT
glucagon-stimulated	I-OUT
serum	I-OUT
C-peptide	I-OUT
concentration	I-OUT
during	O
propranolol	O
therapy	O
compared	O
with	O
placebo	O
(	O
p	O
=	O
0.037	O
and	O
p	O
=	O
0.030	O
,	O
respectively	O
)	O
,	O
although	O
this	O
was	O
not	O
reflected	O
by	O
a	O
significant	O
change	O
in	O
serum	B-OUT
insulin	I-OUT
.	I-OUT


The	O
CBT	B-I
model	O
emphasized	O
behavioral	O
experimentation	O
,	O
parent-training	O
,	O
and	O
school	O
consultation	O
.	O


The	O
effects	O
of	O
a	O
multi-component	O
higher-functioning	B-P
autism	I-P
anti-stigma	O
program	O
on	O
adolescent	B-P
boys	I-P
.	I-P


Participants	B-P
were	I-P
seventh-	I-P
,	I-P
eighth-	I-P
and	I-P
ninth-grade	I-P
students	I-P
(	I-P
N	I-P
=	I-P
395	I-P
)	I-P
from	I-P
regular	I-P
classes	I-P
in	I-P
a	I-P
mainstream	I-P
school	I-P
.	I-P


Pharmacodynamic	O
effects	O
on	O
biochemical	B-OUT
markers	I-OUT
of	I-OUT
bone	I-OUT
turnover	I-OUT
and	I-OUT
pharmacokinetics	I-OUT
of	O
the	O
cathepsin	B-I
K	I-I
inhibitor	I-I
,	I-I
ONO-5334	I-I
,	O
in	O
an	O
ascending	O
multiple-dose	O
,	O
phase	O
1	O
study	O
.	O


Multiple	O
dosing	O
with	B-I
ONO-5334	I-I
100	O
mg	O
resulted	O
in	O
considerable	O
suppression	B-OUT
of	I-OUT
bone	I-OUT
resorption	I-OUT
markers	I-OUT
with	O
no	O
appreciable	O
effects	B-OUT
on	I-OUT
bone	I-OUT
formation	I-OUT
markers	I-OUT
(	I-OUT
B-ALP	I-OUT
,	I-OUT
OC	I-OUT
)	I-OUT
or	I-OUT
osteoclast	I-OUT
number	I-OUT
(	I-OUT
TRAP5b	I-OUT
)	I-OUT
.	O


BACKGROUND	O
Tobacco	O
dependence	O
is	O
a	O
chronic	O
,	O
relapsing	O
condition	O
that	O
typically	O
requires	O
multiple	O
quit	O
attempts	O
and	O
extended	O
treatment	O
.	O


Logistic	O
regression	O
results	O
indicated	O
an	O
11.2	O
times	O
higher	O
odds	O
for	O
re-enrollment	O
of	O
the	O
intervention	O
group	O
than	O
the	O
control	O
group	O
(	O
p	O
<	O
.001	O
)	O
.	O


Results	B-OUT
did	I-OUT
not	I-OUT
vary	I-OUT
by	I-OUT
gender	I-OUT
,	I-OUT
race	I-OUT
,	I-OUT
ethnicity	I-OUT
,	I-OUT
or	I-OUT
level	I-OUT
of	I-OUT
education	I-OUT
,	O
however	O
recycled	B-OUT
smokers	I-OUT
were	I-OUT
older	I-OUT
(	O
Mean	O
=	O
45.2	O
;	O
SD	O
=	O
11.7	O
)	O
than	O
smokers	O
who	O
declined	O
a	O
new	O
treatment	O
cycle	O
(	O
Mean	O
=	O
41.8	O
;	O
SD	O
=	O
13.2	O
)	O
;	O
(	O
p	O
=	O
0.013	O
)	O
.	O


BACKGROUND	O
Control	O
of	O
cervical	O
cancer	O
in	O
developing	O
countries	O
has	O
been	O
hampered	O
by	O
a	O
failure	O
to	O
achieve	O
high	O
screening	B-OUT
uptake	I-OUT
.	I-OUT


200	B-P
community	I-P
health	I-P
workers	I-P
were	I-P
randomly	I-P
allocated	I-P
in	I-P
a	I-P
1:1	I-P
ratio	I-P
to	I-P
either	I-P
the	I-P
intervention	I-I
group	I-I
(	I-I
offered	I-I
women	I-I
the	I-I
chance	I-I
to	I-I
self-collect	I-I
a	I-I
sample	I-I
for	I-I
cervical	I-I
screening	I-I
during	I-I
a	I-I
home	I-I
visit	I-I
)	I-I
or	O
the	O
control	B-I
group	I-I
(	I-I
advised	I-I
women	I-I
to	I-I
attend	I-I
a	I-I
health	I-I
clinic	I-I
for	I-I
cervical	I-I
screening	I-I
)	I-I
.	O


FUNDING	O
Instituto	O
Nacional	O
del	O
Cáncer	O
(	O
Argentina	O
)	O
.	O


METHODS	O
Eighty-six	B-P
patients	I-P
consented	O
and	O
were	O
randomly	O
assigned	O
intraoperatively	O
to	O
one	O
of	O
two	O
study	O
groups	O
,	O
and	O
sixty-eight	B-P
of	I-P
them	I-P
completed	I-P
the	I-P
study	I-P
.	I-P


Participating	B-P
institutions	I-P
were	O
asked	O
to	O
send	O
five	B-P
full	I-P
patient	I-P
records	I-P
with	I-P
the	I-P
chemotherapy	I-P
charts	I-P
,	I-P
surgical	I-P
and	I-P
pathology	I-P
reports	I-P
,	I-P
radiation	I-P
treatment	I-P
charts	I-P
,	I-P
treatment	I-P
planning	I-P
calculations	I-P
,	I-P
computed	I-P
tomography	I-P
(	I-P
CT	I-P
)	I-P
scans	I-P
,	I-P
portal	I-P
images	I-P
and	I-P
follow-up	I-P
charts	I-P
.	I-P


All	O
12	O
departments	O
participated	O
.	O


)	O
of	O
4.6	O
Gy	O
.	O


Strictly	B-I
controlled	I-I
isocaloric	I-I
diets	I-I
with	O
36	O
%	O
of	O
energy	O
from	O
test	O
fats	O
were	O
served	O
in	O
random	O
order	O
for	O
3	O
weeks	O
separated	O
by	O
wash-out	O
period	O
(	O
s	O
)	O
.	O


Changes	O
in	O
logarithm	B-OUT
of	I-OUT
minimum	I-OUT
angle	I-OUT
of	I-OUT
resolution	I-OUT
(	I-OUT
logMAR	I-OUT
)	I-OUT
best-corrected	I-OUT
visual	I-OUT
acuity	I-OUT
(	I-OUT
BCVA	I-OUT
)	I-OUT
,	I-OUT
central	I-OUT
macular	I-OUT
thickness	I-OUT
(	I-OUT
CMT	I-OUT
)	I-OUT
shown	I-OUT
by	I-OUT
optical	I-OUT
coherence	I-OUT
tomography-3	I-OUT
were	O
evaluated	O
.	O


RESULTS	O
Baseline	B-OUT
BCVA	I-OUT
(	I-OUT
logMAR	I-OUT
)	I-OUT
and	I-OUT
CMT	I-OUT
were	O
,	O
respectively	O
,	O
0.89	O
+/-	O
0.13	O
and	O
650	O
+/-	O
140	O
microm	O
for	O
the	O
GLP	B-I
group	O
,	O
0.87	O
+/-	O
0.16	O
and	O
690	O
+/-	O
120	O
microm	O
for	O
the	O
IB	B-I
group	O
.	O


OBJECTIVE	O
To	O
evaluate	O
the	O
feasibility	B-OUT
and	I-OUT
outcome	I-OUT
of	O
the	O
step-down	O
approach	O
using	O
either	O
cyclosporin	B-I
A	I-I
(	I-I
CSA	I-I
)	I-I
or	O
methotrexate	B-I
(	I-I
MTX	I-I
)	I-I
as	O
maintenance	O
therapy	O
following	O
6	O
months	O
treatment	O
with	O
these	O
2	O
agents	O
in	O
combination	O
in	O
early	O
,	O
nonerosive	O
rheumatoid	O
arthritis	O
(	O
RA	O
)	O
.	O


RESULTS	O
When	O
being	O
treated	O
with	O
combination	O
therapy	O
,	O
7	B-P
of	I-P
the	I-P
57	I-P
patients	I-P
(	I-P
12.3	I-P
%	I-P
)	I-P
withdrew	I-P
because	O
of	O
adverse	B-OUT
events	I-OUT
.	I-OUT


Of	O
the	O
6	O
CSA	O
patients	O
who	O
completed	O
the	O
trial	O
,	O
4	O
(	O
66.7	O
%	O
)	O
were	O
ACR	O
20	O
%	O
responders	O
,	O
and	O
3	O
(	O
50	O
%	O
)	O
were	O
both	O
ACR	O
50	O
%	O
and	O
ACR	O
70	O
%	O
responders	O
.	O


The	O
treatment	O
was	O
not	O
responsible	O
for	O
severe	O
adverse	B-OUT
events	I-OUT
.	I-OUT


[	O
The	O
equipotency	O
of	O
ropivacaine	B-I
,	I-I
bupivacaine	I-I
and	O
etidocaine	B-I
]	I-I
.	O


The	O
latency	B-OUT
of	I-OUT
analgesia	I-OUT
for	O
the	O
first	O
blocked	O
segment	O
(	O
T	O
12	O
for	O
bupivacaine	O
and	O
ropivacaine	O
and	O
L-1	O
for	O
etidocaine	O
)	O
was	O
6.0	O
min	O
for	O
bupivacaine	B-I
0.75	O
,	O
5.5	O
min	O
for	O
ropivacaine	B-I
1	O
%	O
,	O
and	O
5.2	O
min	O
for	O
etidocaine	B-I
1	O
%	O
,	O
and	O
the	O
highest	O
thoracic	O
dermatome	O
(	O
T	O
5	O
for	O
bupivacaine	B-I
,	O
T	O
4	O
for	O
ropivacaine	B-I
and	O
T	O
7	O
for	O
etidocaine	B-I
)	I-I
was	O
reached	O
after	O
24	O
+/-	O
10	O
,	O
26	O
+/-	O
9	O
,	O
and	O
30	O
+/-	O
18	O
min	O
for	O
bupivacaine	B-I
,	I-I
ropivacaine	I-I
,	O
and	O
etidocaine	B-I
,	O
respectively	O
.	O


The	O
two-segment	B-OUT
regression	I-OUT
time	I-OUT
was	O
199	O
+/-	O
80	O
min	O
for	O
bupivacaine	B-I
,	O
201	O
+/-	O
52	O
min	O
for	O
ropivacaine	B-I
,	O
and	O
174	O
+/-	O
81	O
min	O
for	O
etidocaine	B-I
.	I-I


Its	O
potency	O
is	O
about	O
equal	O
to	O
that	O
of	O
bupivacaine	B-I
and	O
much	O
higher	O
than	O
that	O
of	O
etidocaine	B-I
...	I-I


Patients	O
were	O
examined	O
after	O
52	O
months	O
to	O
assess	O
hernia	B-OUT
recurrence	I-OUT
,	I-OUT
nerve	I-OUT
damage	I-OUT
,	I-OUT
testicular	I-OUT
atrophy	I-OUT
and	I-OUT
patient	I-OUT
satisfaction	I-OUT
.	I-OUT


CONCLUSION	O
Tension-free	O
repair	O
was	O
superior	O
to	O
the	O
non-mesh	O
Shouldice	O
technique	O
.	O


A	O
randomized	O
controlled	O
trial	O
of	O
itraconazole	B-I
versus	I-I
fluconazole	I-I
for	O
the	O
prevention	B-OUT
of	I-OUT
fungal	I-OUT
infections	I-OUT
in	I-P
patients	I-P
with	I-P
haematological	I-P
malignancies	I-P
.	I-P


U.K.	O
Multicentre	O
Antifungal	O
Prophylaxis	O
Study	O
Group	O
.	O


Interestingly	O
,	O
lipopolysaccharide-induced	B-OUT
PBMC	I-OUT
IL-1β	I-OUT
and	I-OUT
TNFα	I-OUT
secretion	I-OUT
increased	I-OUT
from	O
baseline	O
to	O
week	O
12	O
in	O
the	O
SUB	O
group	O
only	O
,	O
despite	O
increases	O
in	O
PBMC	B-OUT
toll-like	I-OUT
receptor	I-OUT
4	I-OUT
(	I-OUT
TLR4	I-OUT
)	I-OUT
mRNA	I-OUT
expression	I-OUT
in	O
the	O
EGG	O
group	O
.	O


The	O
benzodiazepines	O
are	O
typified	O
by	O
a	O
profile	O
of	O
side	O
effects	O
which	O
includes	O
drowsiness	B-OUT
,	I-OUT
ataxia	I-OUT
and	I-OUT
incoordination	I-OUT
.	I-OUT


At	O
all	O
doses	O
up	O
to	O
600	O
mg	O
,	O
Ro	O
15-1788	O
demonstrated	O
none	O
of	O
the	O
classical	O
behavioural	B-OUT
effects	I-OUT
of	O
the	O
benzodiazepines	O
.	O


The	O
mean	B-OUT
Apgar	I-OUT
scores	I-OUT
in	O
the	O
three	O
groups	O
were	O
the	O
same	O
.	O


Effect	O
of	O
enalapril	B-I
on	O
myocardial	O
infarction	O
and	O
unstable	O
angina	O
in	O
patients	B-P
with	I-P
low	I-P
ejection	I-P
fractions	I-P
.	I-P


In	O
each	O
trial	O
there	O
were	O
significant	O
reductions	O
in	O
the	O
number	O
of	O
patients	O
developing	O
myocardial	O
infarction	O
(	O
treatment	O
trial	O
:	O
158	O
placebo	B-I
vs	O
127	O
enalapril	B-I
,	O
p	O
<	O
0.02	O
;	O
prevention	O
trial	O
:	O
204	O
vs	O
161	O
p	O
<	O
0.01	O
)	O
or	O
unstable	O
angina	O
(	O
240	O
vs	O
187	O
p	O
<	O
0.001	O
;	O
355	O
vs	O
312	O
,	O
p	O
<	O
0.05	O
)	O
.	O


California	O
Collaborative	O
Treatment	O
Group	O
.	O


At	O
entry	O
into	O
the	O
study	O
,	O
all	B-P
participants	I-P
had	I-P
sterile	I-P
cultures	I-P
of	I-P
cerebrospinal	I-P
fluid	I-P
,	I-P
blood	I-P
,	I-P
and	I-P
urine	I-P
after	I-P
following	I-P
a	I-P
standardized	I-P
course	I-P
of	I-P
therapy	I-P
for	I-P
culture-proved	I-P
cryptococcal	I-P
meningitis	I-P
.	I-P


The	O
patients	O
were	O
randomly	O
assigned	O
to	O
take	O
either	O
fluconazole	B-I
or	I-I
placebo	I-I
as	O
maintenance	O
therapy	O
.	O


CONCLUSIONS	O
In	O
patients	B-P
with	I-P
AIDS	I-P
,	O
silent	O
persistent	O
infection	O
is	O
common	O
after	O
clinically	O
successful	O
treatment	O
for	O
cryptococcal	O
meningitis	O
.	O


We	O
found	O
that	O
premenstrual	B-OUT
symptomatology	I-OUT
,	O
as	O
well	O
as	O
some	O
measures	B-OUT
of	I-OUT
mood	I-OUT
and	I-OUT
smoking	I-OUT
withdrawal	I-OUT
,	O
were	O
significantly	O
higher	O
during	O
the	O
luteal	O
phase	O
than	O
in	O
the	O
follicular	O
phase	O
.	O


Phase-related	B-OUT
variability	I-OUT
in	O
premenstrual	O
symptomatology	O
[	O
F	O
(	O
3	O
,	O
20	O
)	O
=2.82	O
,	O
p=0.0650	O
)	O
]	O
and	O
urge	B-OUT
to	I-OUT
smoke	I-OUT
[	O
F	O
(	O
2	O
,	O
21	O
)	O
=4.85	O
,	O
p=0.0186	O
)	O
]	O
were	O
associated	O
with	O
relapse	O
.	O


Mean	B-OUT
free	I-OUT
testosterone	I-OUT
and	I-OUT
3alpha-androstanediol	I-OUT
glucuronide	I-OUT
decreased	O
significantly	O
in	O
the	O
group	O
receiving	O
ethinyl	B-I
estradiol/desogestrel	I-I
but	O
not	O
in	O
the	O
ethinyl	B-I
estradiol/levonorgestrel	I-I
group	O
.	O


CONCLUSIONS	O
Treatment	O
of	O
hirsute	O
women	O
with	O
third	B-I
generation	I-I
OCs	I-I
containing	O
desogestrel	B-I
results	O
in	O
a	O
significant	O
increase	O
in	O
sex	B-OUT
hormone-binding	I-OUT
globulin	I-OUT
and	O
decrease	O
in	O
free	B-OUT
testosterone	I-OUT
and	I-OUT
3alpha-androstanediol	I-OUT
glucuronide	I-OUT
.	I-OUT


Both	O
second	B-I
and	I-I
third	I-I
generation	I-I
OCs	I-I
were	O
clinically	O
effective	O
in	O
treating	O
hirsutism	B-P
.	I-P


Comparison	O
of	O
intrathecal	B-I
bupivacaine	I-I
,	I-I
levobupivacaine	I-I
for	O
cesarean	O
section	O
.	O


BACKGROUND	O
Some	O
investigators	O
found	O
a	O
greater	O
incidence	O
of	O
hypotension	O
in	O
patients	B-P
receiving	I-P
intrathecal	I-I
hyperbaric	I-I
solution	I-I
than	I-P
in	I-P
patients	I-P
receiving	I-P
plain	I-P
solution	I-P
for	I-P
cesarean	I-P
section	I-P
.	I-P


The	O
incidence	O
of	O
hypotension	B-OUT
was	O
comparable	O
with	O
Group	O
H	O
=	O
67	O
%	O
,	O
Group	O
B	O
=	O
56	O
%	O
,	O
and	O
Group	O
L	O
=	O
50	O
%	O
.	O


Therefore	O
,	O
Levobupivacaine	B-I
can	O
be	O
an	O
alternative	B-OUT
to	O
bupivacaine	B-I
.	I-I


Effects	O
of	O
20	O
mg	O
rosuvastatin	B-I
on	O
VLDL1-	O
,	O
VLDL2-	O
,	O
IDL-	O
and	O
LDL-ApoB	O
kinetics	O
in	O
type	B-P
2	I-P
diabetes	I-P
.	I-P


Participants	O
,	O
caregivers	O
and	O
those	O
assessing	O
the	O
outcomes	O
were	O
blinded	O
to	O
group	O
assignment	O
.	O


The	O
effects	O
of	O
rosuvastatin	B-I
on	O
the	O
metabolism	O
of	O
triacylglycerol-rich	O
lipoproteins	O
may	O
be	O
beneficial	O
for	O
prevention	O
of	O
atherosclerosis	B-P
in	I-P
type	I-P
2	I-P
diabetic	I-P
patients	I-P
.	I-P


Prospective	O
randomized	O
multicenter	O
trial	O
of	O
sevelamer	B-I
hydrochloride	I-I
and	I-I
calcium	I-I
carbonate	I-I
for	O
the	O
treatment	O
of	O
hyperphosphatemia	B-OUT
in	I-P
hemodialysis	I-P
patients	I-P
in	I-P
Japan	I-P
.	I-P


The	O
dosage	O
of	O
CC	O
was	O
fixed	O
at	O
3.0	O
g/day	O
for	O
the	O
12-week	O
study	O
.	O


Comparison	O
between	O
lithium	B-I
and	I-I
valproate	I-I
in	O
the	O
treatment	O
of	O
acute	B-P
mania	I-P
.	I-P


Understanding	O
long	O
term	O
effects	O
resulting	O
from	O
the	O
cure	O
of	O
this	O
infection	O
is	O
needed	O
to	O
design	O
cancer	O
prevention	O
strategies	O
.	O


At	O
6	O
weeks	O
the	O
quality	B-OUT
of	I-OUT
life	I-OUT
was	O
better	O
in	O
patients	O
who	O
had	O
laparoscopic	O
lymphadenectomy	B-I
(	O
SF-12	O
)	O
.	O


Response	O
to	O
primary	B-I
induction	I-I
chemotherapy	I-I
was	O
relevant	O
for	O
prognosis	O
if	O
a	O
limit	O
of	O
25	O
%	O
tumour	O
cell	O
mass	O
(	O
TCM	O
)	O
reduction	O
was	O
used	O
to	O
separate	O
responders	O
from	O
non-responders	O
.	O


Furthermore	O
,	O
TCM	B-OUT
,	I-OUT
histological	I-OUT
grading	I-OUT
of	I-OUT
myeloma	I-OUT
cells	I-OUT
,	I-OUT
degree	I-OUT
of	I-OUT
bone	I-OUT
marrow	I-OUT
infiltration	I-OUT
,	I-OUT
haemoglobin	I-OUT
,	I-OUT
platelet	I-OUT
counts	I-OUT
,	I-OUT
calcium	I-OUT
,	I-OUT
creatinine	I-OUT
,	I-OUT
albumin	I-OUT
,	I-OUT
beta	I-OUT
2M	I-OUT
,	I-OUT
and	I-OUT
Bence	I-OUT
Jones	I-OUT
proteinuria	I-OUT
correlated	O
to	O
both	O
OAS	O
and	O
TRS	O
.	O


There	O
were	O
no	O
significant	O
differences	O
in	O
complete	B-OUT
response	I-OUT
rates	I-OUT
between	O
patients	O
treated	O
with	O
RT	O
alone	O
or	O
combined	O
chemoradiotherapy	B-I
.	I-I


At	O
3	O
yr	O
follow-up	O
,	O
17.5	O
%	O
of	O
patients	O
in	O
group	O
A	O
were	O
alive	B-OUT
compared	O
to	O
52	O
%	O
in	O
group	O
B	O
and	O
42	O
%	O
in	O
group	O
C	O
(	O
p	O
<	O
0.001	O
)	O
.	O


Dentine	B-OUT
wear	I-OUT
was	O
measured	O
with	O
a	O
profilometer	O
.	O


The	O
primary	O
outcome	O
measure	O
was	O
cardiovascular	B-OUT
mortality	I-OUT
.	I-OUT


Controlling	O
for	O
depression	B-OUT
,	I-OUT
previous	I-OUT
myocardial	I-OUT
infarction	I-OUT
,	I-OUT
low	I-OUT
ejection	I-OUT
fraction	I-OUT
,	I-OUT
decreased	I-OUT
heart	I-OUT
rate	I-OUT
variability	I-OUT
,	I-OUT
and	I-OUT
ventricular	I-OUT
ectopic	I-OUT
beats	I-OUT
had	O
little	O
impact	O
on	O
estimated	O
treatment	O
effect	O
.	O


Predictors	O
of	O
blood	B-OUT
pressure	I-OUT
change	I-OUT
in	O
a	O
series	O
of	O
controlled	O
dietary	O
intervention	O
studies	O
.	O


Three	O
controlled	O
dietary	B-I
intervention	I-I
studies	O
were	O
carried	O
out	O
in	O
1981-1983	B-P
in	I-P
North	I-P
Karelia	I-P
,	I-P
Finland	I-P
,	O
to	O
asses	O
the	O
impact	O
of	O
dietary	O
fat	O
intake	O
modification	O
on	O
blood	B-OUT
pressure	I-OUT
(	I-OUT
BP	I-OUT
)	I-OUT
.	I-OUT


For	O
the	O
present	O
report	O
data	O
from	O
the	O
three	O
studies	O
were	O
pooled	O
for	O
a	O
series	O
of	O
stepwise	O
regression	O
analyses	O
to	O
predict	O
changes	O
in	O
BP	B-OUT
with	O
different	O
dietary	O
changes	O
.	O


A	O
large	O
portion	O
of	O
the	O
difference	O
in	O
cost	B-OUT
was	O
related	O
to	O
the	O
greater	O
frequency	B-OUT
of	I-OUT
outpatient	I-OUT
visits	I-OUT
and	O
the	O
greater	O
resources	B-OUT
used	I-OUT
in	I-OUT
self-care	I-OUT
.	I-OUT


CONCLUSIONS	O
DCCT	B-I
intensive	I-I
therapy	I-I
is	O
more	O
expensive	O
than	O
conventional	O
therapy	O
,	O
but	O
it	O
offers	O
the	O
hope	O
of	O
cost	O
savings	O
as	O
a	O
result	O
of	O
averted	O
complications	O
.	O


The	O
role	O
of	O
adjunctive	B-I
exenatide	I-I
therapy	I-I
in	O
pediatric	B-P
type	I-P
1	I-P
diabetes	I-P
.	I-P


Two	B-I
doses	I-I
of	I-I
exenatide	I-I
(	I-I
1.25	I-I
and	I-I
2.5	I-I
microg	I-I
)	I-I
were	I-I
compared	I-I
with	I-I
insulin	I-I
monotherapy	I-I
.	I-I


This	O
reduction	O
in	O
glucose	B-OUT
excursion	I-OUT
occurs	O
despite	O
reduction	O
in	O
insulin	O
dose	O
.	O


Clinical	O
trials	O
have	O
generally	O
failed	O
to	O
confirm	O
benefits	O
,	O
possibly	O
due	O
to	O
their	O
relatively	O
short	O
duration	O
.	O


Secondary	O
outcomes	O
included	O
heart	B-OUT
failure	I-OUT
,	I-OUT
unstable	I-OUT
angina	I-OUT
,	I-OUT
and	I-OUT
revascularizations	I-OUT
.	I-OUT


Neuroleptics	B-I
and	I-P
depression	I-OUT
.	I-OUT


After	O
4	O
years	O
of	O
study	O
,	O
the	O
gain	B-OUT
in	I-OUT
H-SDSCA	I-OUT
was	O
1.4	O
+	O
or	O
-	O
01	O
in	O
the	O
TOTO	O
group	O
and	O
1.6	O
+	O
or	O
-	O
0.2	O
in	O
the	O
TTOO	O
group	O
leading	O
to	O
a	O
mean	O
height	B-OUT
of	O
-2.0	O
+	O
or	O
-	O
1.0	O
SDS	O
and	O
-2.0	O
+	O
or	O
-	O
0.8	O
SDS	O
,	O
respectively	O
.	O


Both	O
drugs	O
were	O
associated	O
with	O
the	O
topical	O
application	O
of	O
povidone	O
iodine	O
.	O


BACKGROUND	O
Current	O
evidence	O
suggests	O
that	O
a	O
majority	O
of	O
the	O
inherited	O
risks	O
play	O
a	O
major	O
role	O
in	O
glioma	B-P
susceptibility	I-P
,	O
and	O
glioma	O
is	O
due	O
to	O
the	O
co-inheritance	O
of	O
multiple	O
low-risk	O
variants	O
.	O


We	O
then	O
applied	O
three	O
genetic	O
models	O
(	O
dominant	O
,	O
recessive	O
,	O
and	O
additive	O
)	O
using	O
PLINK	O
software	O
to	O
assess	O
the	O
association	O
of	O
each	O
tSNP	O
with	O
glioma	O
risk	O
.	O


The	O
objective	O
of	O
the	O
present	O
study	O
was	O
prospectively	O
and	O
randomly	O
to	O
evaluate	O
the	O
role	O
of	O
L-arginine	B-I
in	O
improving	O
uterine	B-OUT
and	I-OUT
follicular	I-OUT
Doppler	I-OUT
flow	I-OUT
and	O
in	O
improving	O
ovarian	B-OUT
response	I-OUT
to	I-OUT
gonadotrophin	I-OUT
in	O
poor	B-P
responder	I-P
women	I-P
.	I-P


Significant	B-OUT
Doppler	I-OUT
flow	I-OUT
improvement	I-OUT
was	O
obtained	O
in	O
the	O
L-arginine	B-I
supplemented	O
group	O
.	O


Adolescents	O
were	O
more	O
likely	O
to	O
have	B-OUT
headaches	I-OUT
(	O
81.1	O
%	O
,	O
OR	O
1.56	O
(	O
1.36	O
%	O
to	O
1.80	O
%	O
)	O
)	O
and	O
less	O
likely	O
to	O
have	B-OUT
tender	I-OUT
lymph	I-OUT
nodes	I-OUT
,	I-OUT
palpitations	I-OUT
,	I-OUT
dizziness	I-OUT
,	I-OUT
general	I-OUT
malaise	I-OUT
and	I-OUT
pain	I-OUT
,	O
compared	O
to	O
adults	O
.	O


This	O
paper	O
includes	O
secondary	O
(	O
post-results	O
)	O
analysis	O
of	O
data	O
from	O
this	O
trial	O
,	O
but	O
are	O
unrelated	O
to	O
trial	O
outcomes	O
.	O


The	O
influence	O
of	O
dietary	B-I
fibre	I-I
source	I-I
and	O
gender	O
on	O
the	O
postprandial	B-OUT
glucose	I-OUT
and	I-OUT
lipid	I-OUT
response	I-OUT
in	O
healthy	B-P
subjects	I-P
.	I-P


AIM	O
OF	O
THE	O
STUDY	O
To	O
investigate	O
the	O
effects	O
on	O
postprandial	B-OUT
glucose	I-OUT
,	I-OUT
insulin	I-OUT
and	I-OUT
triglyceride	I-OUT
concentrations	I-OUT
of	O
meals	O
enriched	O
with	O
soluble	O
dietary	O
fibres	O
from	O
oats	O
,	O
rye	O
bran	O
,	O
sugar	O
beet	O
fibre	O
or	O
a	O
mixture	O
of	O
these	O
three	O
fibres	O
.	O


METHODS	O
Thirteen	B-P
healthy	I-P
human	I-P
volunteers	I-P
(	I-P
6	I-P
men	I-P
and	I-P
7	I-P
women	I-P
,	I-P
aged	I-P
20-28	I-P
years	I-P
)	I-P
were	O
included	O
in	O
the	O
study	O
.	O


CONCLUSIONS	O
Postprandial	B-OUT
glucose	I-OUT
,	I-OUT
insulin	I-OUT
and	I-OUT
triglyceride	I-OUT
concentrations	I-OUT
are	O
influenced	O
by	O
dietary	B-I
fibre-rich	I-I
meals	I-I
,	O
depending	O
on	O
fibre	O
source	O
,	O
dose	O
of	O
soluble	O
and	O
total	O
fibre	O
and	O
possibly	O
gender	O
.	O


The	O
results	O
of	O
a	O
successful	O
nurse-initiated	B-I
daily	I-I
phone	I-I
calls	I-I
program	I-I
,	O
designed	O
to	O
improve	O
family	O
care	O
giver	O
satisfaction	O
by	O
enhancing	O
the	O
provision	O
of	O
patient-specific	B-I
information	I-I
,	O
are	O
presented	O
.	O


Both	O
groups	O
were	O
given	O
intravenous	B-I
iron	I-I
gluconate	I-I
(	O
125	O
mg	O
)	O
every	O
day	O
for	O
15	O
days	O
.	O


DESIGN	O
Ten	B-P
patients	I-P
(	I-P
mean	I-P
age	I-P
47.7	I-P
yrs	I-P
)	I-P
with	I-P
cognitive	I-P
deficits	I-P
after	I-P
a	I-P
first-ever	I-P
stroke	I-P
participated	I-P
in	O
this	O
single-blind	O
,	O
crossover	O
,	O
and	O
sham-controlled	B-I
experiment	O
.	O


The	O
end	O
points	O
for	O
the	O
study	O
were	O
the	O
clinical	O
outcomes	O
of	O
all	O
patients	O
,	O
and	O
the	O
results	O
of	O
histology	B-OUT
,	O
where	O
appropriate	O
.	O


RESULTS	O
Laparoscopic	O
assessment	O
was	O
correct	O
in	O
all	O
cases	O
in	O
which	O
the	O
appendix	O
was	O
visualized	O
.	O


No	O
patients	O
developed	O
a	O
problem	O
over	O
the	O
10-year	O
follow-up	O
period	O
from	O
having	O
a	O
normal-looking	O
appendix	O
not	O
removed	O
at	O
laparoscopy	O
.	O


Fundamental	B-OUT
frequency	I-OUT
(	I-OUT
F0	I-OUT
)	I-OUT
,	I-OUT
sound	I-OUT
pressure	I-OUT
level	I-OUT
(	I-OUT
SPL	I-OUT
)	I-OUT
and	I-OUT
long-term-average	I-OUT
spectrum	I-OUT
(	I-OUT
LTAS	I-OUT
)	I-OUT
analyses	I-OUT
were	O
made	O
.	O


In	O
one	O
patient	O
this	O
was	O
incapacitating	B-OUT
after	O
10	O
mg	O
and	O
precluded	O
exposure	O
to	O
20	O
mg	O
.	O


hexacetonide	B-I
(	I-I
TH	I-I
)	I-I
and	I-I
i/a	I-I
hyaluronic	I-I
acid	I-I
(	I-I
HA	I-I
)	I-I
in	O
inflammatory	B-P
knee	I-P
osteoarthritis	I-P
.	I-P


There	O
were	O
63	B-P
patients	I-P
(	I-P
24	I-P
male	I-P
,	I-P
39	I-P
female	I-P
,	I-P
mean	I-P
age	I-P
70.5	I-P
years	I-P
)	I-P
with	I-P
bilateral	I-P
symptomatic	I-P
knee	I-P
osteoarthritis	I-P
with	I-P
effusion	I-P
.	I-P


Each	O
was	O
given	O
five	B-I
HA	I-I
injections	I-I
at	I-I
weekly	I-I
intervals	I-I
;	I-I
or	I-I
20	I-I
mg	I-I
TH	I-I
followed	I-I
by	I-I
four	I-I
placebo	I-I
(	I-I
saline	I-I
)	I-I
injections	I-I
.	I-I


The	O
two	B-P
groups	I-P
were	I-P
comparable	I-P
at	I-P
entry	I-P
and	O
no	O
significant	O
differences	O
between	O
the	O
groups	O
developed	O
at	O
any	O
time	O
during	O
the	O
treatment	O
period	O
.	O


However	O
,	O
there	O
was	O
a	O
high	B-P
drop-out	I-P
rate	I-P
and	O
intention	O
to	O
treat	O
analysis	O
failed	O
to	O
demonstrate	O
statistically	O
significant	O
differences	O
between	O
the	O
groups	O
.	O


Results	O
of	O
a	O
phase	O
I/II	O
trial	O
of	O
recombinant	B-I
human	I-I
granulocyte-macrophage	I-I
colony-stimulating	I-I
factor	I-I
in	O
very	B-P
low	I-P
birthweight	I-P
neonates	I-P
:	I-P
significant	O
induction	O
of	O
circulatory	O
neutrophils	O
,	O
monocytes	O
,	O
platelets	O
,	O
and	O
bone	O
marrow	O
neutrophils	O
.	O


In	O
the	O
present	O
study	O
,	O
we	O
sought	O
to	O
determine	O
the	O
safety	O
and	O
biologic	O
response	O
of	O
recombinant	B-I
human	I-I
(	I-I
rhu	I-I
)	I-I
GM-CSF	I-I
in	O
VLBW	O
neonates	O
.	O


Such	O
a	O
pattern	O
is	O
consistent	O
with	O
the	O
role	O
of	O
the	O
left	O
DLPFC	O
in	O
implementing	O
top-down	O
attentional	O
control	O
.	O


The	O
type	O
of	O
second-line	B-I
chemotherapy	I-I
after	O
initial	O
adjuvant	O
or	O
neoadjuvant	O
treatment	O
with	O
a	O
platinum-based	B-I
regimen	I-I
remains	O
largely	O
undefined	O
.	O


In	O
Experiment	O
1	O
,	O
a	O
series	O
of	O
prime-target	O
pairs	O
was	O
presented	O
auditorily	O
,	O
and	O
participants	B-P
were	O
asked	O
to	O
make	O
a	O
lexical	B-I
decision	I-I
on	O
the	O
target	O
word	O
.	O


In	O
Experiment	O
2	O
,	O
participants	B-P
'	I-P
eye	O
movements	O
were	O
monitored	O
when	O
they	O
viewed	O
a	O
visual	B-I
display	I-I
on	I-I
a	I-I
computer	I-I
screen	I-I
while	I-I
listening	I-I
to	I-I
a	I-I
concurrent	I-I
auditory	I-I
input	I-I
.	I-I


Our	O
results	O
provide	O
indirect	O
evidence	O
that	O
reversible	O
changes	O
in	O
the	O
cation-chloride	O
transport	O
system	O
induce	O
modulations	O
of	O
inhibitory	O
neuronal	O
activity	O
at	O
spinal	O
cord	O
level	O
in	O
humans	O
.	O


RESULTS	O
Some	O
89.2	B-P
per	I-P
cent	I-P
of	I-P
patients	I-P
had	I-P
a	I-P
primary	I-P
tumour	I-P
and	I-P
79.7	I-P
per	I-P
cent	I-P
underwent	I-P
surgery	I-I
with	I-P
curative	I-P
intent	I-P
;	I-P
243	I-P
patients	I-P
received	I-P
perioperative	I-OUT
RBC	I-OUT
transfusion	I-OUT
(	I-P
median	I-P
3	I-P
units	I-P
)	I-P
.	I-P


The	O
5-year	B-OUT
overall	I-OUT
survival	I-OUT
rate	I-OUT
of	I-OUT
patients	I-OUT
with	I-OUT
any	I-OUT
type	I-OUT
of	I-OUT
gastrointestinal	I-OUT
cancer	I-OUT
was	O
50.8	O
per	O
cent	O
in	O
the	O
LD	B-P
group	I-P
and	O
45.8	O
per	O
cent	O
in	O
the	O
non-LD	B-P
group	I-P
(	O
P	O
=	O
0.191	O
)	O
.	O


OBJECTIVE	O
To	O
determine	O
the	O
accuracy	O
and	O
clinical	O
value	O
of	O
combining	O
64	B-I
multi-slice	I-I
spiral	I-I
computer	I-I
tomography	I-I
(	I-I
MSCT	I-I
)	I-I
and	I-I
serum	I-I
amyloid	I-I
A	I-I
protein	I-I
(	I-I
SAA	I-I
)	I-I
in	O
the	O
preoperative	B-P
staging	I-P
of	I-P
rectal	I-P
cancer	I-P
.	I-P


In	O
addition	O
,	O
there	O
was	O
statistical	O
difference	O
in	O
the	O
accuracy	B-OUT
of	I-OUT
prediction	I-OUT
to	I-OUT
operative	I-OUT
procedures	I-OUT
between	O
the	O
two	O
groups	O
(	O
94.7	O
%	O
vs.	O
81.7	O
%	O
,	O
P	O
=	O
0.003	O
)	O
.	O


The	O
effect	O
of	O
a	O
single	B-P
dose	I-P
of	I-P
1,000	I-I
mg	I-I
of	I-I
levetiracetam	I-I
on	I-P
essential	I-P
tremor	I-P
was	O
investigated	O
in	O
24	B-P
patients	I-P
in	I-P
a	I-P
double-blind	I-P
,	I-P
placebo-controlled	I-I
trial	I-P
.	I-P


Allogeneic	B-I
marrow	I-I
transplantation	I-I
in	O
patients	B-P
with	I-P
chronic	I-P
myeloid	I-P
leukemia	I-P
in	I-P
the	I-P
chronic	I-P
phase	I-P
:	I-P
a	O
randomized	O
trial	O
of	O
two	O
irradiation	O
regimens	O
.	O


A	O
randomized	O
trial	O
was	O
performed	O
to	O
compare	O
two	O
regimens	O
of	O
total	B-I
body	I-I
irradiation	I-I
in	O
patients	B-P
with	I-P
chronic	I-P
myeloid	I-P
leukemia	I-P
treated	I-P
by	I-P
allogeneic	I-I
marrow	I-I
transplantation	I-I
while	I-P
in	I-P
the	I-P
chronic	I-P
phase	I-P
.	I-P


The	O
4-year	B-OUT
probabilities	I-OUT
of	I-OUT
transplant-related	I-OUT
mortality	I-OUT
were	O
0.24	O
and	O
0.34	O
respectively	O
(	O
P	O
=	O
.13	O
)	O
while	O
the	O
probability	B-OUT
of	I-OUT
moderate	I-OUT
to	I-OUT
severe	I-OUT
acute	I-OUT
graft-versus-host	I-OUT
disease	I-OUT
was	O
0.33	O
for	O
the	O
12.0	O
Gy	O
group	O
and	O
0.44	O
for	O
the	O
15.75	O
Gy	O
group	O
(	O
P	O
=	O
.15	O
)	O
.	O


MANCOVA	O
,	O
ANCOVA	O
and	O
Post	O
Hoc	O
analyses	O
were	O
utilized	O
to	O
test	O
for	O
significant	O
differences	O
among	O
the	O
three	O
groups	O
.	O


OBJECTIVE	O
To	O
compare	O
the	O
analgesic	O
efficacy	O
of	O
rectal	O
administration	O
of	O
Lidocaïne	B-I
gel	I-I
with	I-I
Lidocaïne	I-I
periprostatic	I-I
infiltration	I-I
prior	O
to	O
transrectal	O
ultrasound-guided	O
prostate	O
biopsies	O
.	O


RESULTS	B-P
308	I-P
patients	I-P
were	I-P
included	I-P
in	I-P
this	I-P
trial	I-P
with	I-P
156	I-P
patients	I-P
in	I-P
group	I-P
1	I-P
and	I-P
152	I-P
in	I-P
group	I-P
2	O
.	O


However	B-I
,	I-I
the	I-I
Lidocaïne	I-I
gel	O
,	O
being	O
both	O
safe	O
and	O
simple	O
,	O
tends	O
to	O
maintain	O
a	O
better	O
comfort	O
of	O
the	O
patient	O
30	O
minutes	O
after	O
the	O
end	O
of	O
the	O
biopsies	O
.	O


In	O
the	O
pretreatment	O
state	O
there	O
was	O
good	O
agreement	B-OUT
between	O
the	O
two	O
measures	O
(	O
r2	O
=	O
0.96	O
,	O
SEE	O
0.012	O
g/cm2	O
)	O
.	O


If	O
the	O
formula	O
was	O
used	O
to	O
compute	O
a	O
change	B-OUT
in	I-OUT
total	I-OUT
hip	I-OUT
BMD	I-OUT
,	O
the	O
agreement	B-OUT
between	O
both	O
methods	O
remained	O
good	O
.	O


MAIN	O
OUTCOME	O
MEASURES	O
Clinical	B-OUT
and	I-OUT
instrumental	I-OUT
evaluation	I-OUT
of	I-OUT
postoperative	I-OUT
outcomes	I-OUT
.	I-OUT


METHODS	O
In	O
a	O
prospective	O
,	O
double-blind	O
,	O
randomized	O
controlled	O
trial	B-P
conducted	I-P
in	I-P
a	I-P
tertiary	I-P
maternity	I-P
hospital	I-P
622	I-P
women	I-P
received	O
either	O
400	O
mug	O
of	O
oral	B-I
misoprostol	I-I
or	O
5	O
U	O
of	O
intravenous	B-I
oxytocin	I-I
after	O
delivery	O
of	O
the	O
anterior	O
shoulder	O
or	O
within	O
1	O
min	O
of	O
delivery	O
.	O


METHODS	O
Forty	B-P
children	I-P
between	I-P
the	I-P
ages	I-P
4	I-P
and	I-P
12	I-P
years	I-P
with	I-P
a	I-P
DSM	I-P
IV-TR	I-P
clinical	I-P
diagnosis	I-P
of	I-P
autism	I-P
were	I-P
recruited	I-P
.	I-P


Patients	O
were	O
assessed	O
at	O
baseline	O
and	O
after	O
2	O
,	O
4	O
,	O
6	O
,	O
8	O
and	O
10	O
weeks	O
of	O
starting	O
medication	O
.	O


Cortisol	B-OUT
levels	I-OUT
in	O
patients	B-P
with	I-P
Alzheimer	I-P
's	I-P
disease	I-P
(	I-P
AD	I-P
)	I-P
are	O
relatively	O
unaffected	O
by	O
a	O
challenge	O
with	O
dexamethasone	B-I
(	I-I
DEX	I-I
)	I-I
in	O
vivo	O
.	O


The	O
subjects	O
received	O
a	O
histamine-free	B-I
diet	I-I
also	O
low	O
in	O
allergen	O
24	O
hours	O
before	O
hospitalization	O
and	O
over	O
the	O
whole	O
observation	O
period	O
.	O


We	O
conclude	O
that	O
75	O
mg	O
of	O
pure	O
liquid	O
oral	O
histamine	O
--	O
a	O
dose	O
found	O
in	O
normal	O
meals	O
--	O
can	O
provoke	O
immediate	O
as	O
well	O
as	O
delayed	O
symptoms	O
in	O
50	O
%	O
of	O
healthy	B-P
females	I-P
without	I-P
a	I-P
history	I-P
of	I-P
food	I-P
intolerance	I-P
.	I-P


METHODS	O
Participants	B-P
being	I-P
treated	I-P
were	I-P
recruited	I-P
and	I-P
randomly	I-P
assigned	I-P
to	I-P
two	I-P
groups	I-P
from	I-P
September	I-P
2011-February	I-P
2013	I-P
in	I-P
Taiwan	I-P
.	I-P


Intervention	O
.	O


After	O
completion	O
,	O
the	O
oxygenators	O
were	O
dissected	O
and	O
examined	O
.	O


CONCLUSIONS	O
Although	O
both	O
methods	O
were	O
associated	O
with	O
layering	B-OUT
out	I-OUT
,	I-OUT
agglutination	I-OUT
,	I-OUT
and	I-OUT
clot	I-OUT
formation	I-OUT
,	O
these	O
effects	O
occurred	O
more	O
frequently	O
with	O
administration	O
into	O
the	O
ECMO	O
circuit	O
,	O
particularly	O
in	O
areas	O
of	O
stasis	O
.	O


Between-group	B-OUT
comparisons	I-OUT
revealed	I-OUT
no	I-OUT
significant	I-OUT
differences	I-OUT
in	I-OUT
clinical	I-OUT
outcome	I-OUT
variables	I-OUT
.	I-OUT


In	O
line	O
with	O
earlier	O
investigations	O
,	O
our	O
results	B-OUT
suggest	I-OUT
a	I-OUT
moderate	I-OUT
-	I-OUT
potentially	I-OUT
clinically	I-OUT
relevant	I-OUT
-	I-OUT
treatment	I-OUT
effect	I-OUT
of	I-OUT
prefrontal	I-OUT
10	I-OUT
Hz	I-OUT
rTMS	I-OUT
stimulation	I-OUT
in	I-OUT
chronic	I-OUT
patients	I-OUT
.	I-OUT


Echis	O
carinatus	O
is	O
the	O
most	O
important	O
cause	O
of	O
morbidity	O
and	O
mortality	O
from	O
snake	O
bite	O
in	O
Nigeria	O
and	O
in	O
many	O
other	O
parts	O
of	O
the	O
world	O
.	O


Forty-six	B-P
patients	I-P
with	I-P
systemic	I-P
poisoning	I-P
by	I-P
this	I-P
snake	I-P
were	O
given	O
echis	B-I
antivenom	I-I
made	I-I
either	I-I
by	I-I
the	I-I
South	I-I
African	I-I
Institute	I-I
for	I-I
Medical	I-I
Research	I-I
(	I-I
S.A.I.M.R	I-I
.	I-I


Local	B-OUT
tissue	I-OUT
swelling	I-OUT
was	O
similar	O
in	O
both	O
groups	O
,	O
but	O
local	B-OUT
necrosis	I-OUT
occurred	O
in	O
three	O
patients	O
treated	O
with	O
Behringwerke	B-I
antivenom	I-I
and	O
in	O
none	O
given	O
S.A.I.M.R	O
.	O


Preliminary	O
examination	O
of	O
a	O
cartoon-based	B-I
hostile	I-OUT
attributional	I-OUT
bias	I-OUT
measure	I-OUT
for	O
urban	B-P
African	I-P
American	I-P
boys	I-P
.	I-P


Direct	O
and	O
indirect	O
effects	O
of	O
interdental	B-I
hygiene	I-I
in	O
a	O
clinical	O
trial	O
.	O


fractions	O
)	O
.	O


In	O
both	O
arms	O
of	O
the	O
study	O
,	O
the	O
supraclavicular	O
fossa	O
and	O
axillary	O
apex	O
were	O
treated	O
once	O
daily	O
to	O
50	O
Gy	O
.	O


vs.	O
11	O
%	O
for	O
b.i.d.	O
,	O
p=0.54	O
)	O
.	O


Twelve	B-P
patients	I-P
with	I-P
advanced	I-P
non-small-cell	I-P
lung	I-P
cancer	I-P
(	I-P
NSCLC	I-P
)	I-P
were	O
studied	O
1	O
week	O
before	O
and	O
during	O
22-24	O
h	O
of	O
continuous	B-I
ATP	I-I
infusion	I-I
.	I-I


After	O
an	O
overnight	O
fast	O
,	O
turnover	O
rates	O
of	O
glucose	O
and	O
alanine	O
,	O
and	O
gluconeogenesis	O
from	O
alanine	O
,	O
were	O
determined	O
using	O
primed	O
constant	O
infusions	O
of	O
¿6	B-I
,	I-I
6-	I-I
(	I-I
2	I-I
)	I-I
H	I-I
(	I-I
2	I-I
)	I-I
ğlucose	I-I
and	I-I
¿3-	I-I
(	I-I
13	I-I
)	I-I
Călanine	I-I
.	I-P


INTRODUCTION	O
Conservative	B-I
fluid	I-I
management	I-I
in	O
patients	B-P
with	I-P
acute	I-P
lung	I-P
injury	I-P
(	I-P
ALI	I-P
)	I-P
increases	O
time	O
alive	O
and	O
free	O
from	O
mechanical	B-I
ventilation	I-I
.	I-I


Vascular	B-OUT
pedicle	I-OUT
width	I-OUT
(	I-OUT
VPW	I-OUT
)	I-OUT
is	O
a	O
non-invasive	O
measurement	O
of	O
intravascular	O
volume	O
status	O
.	O


VPW	B-OUT
and	I-OUT
central	I-OUT
venous	I-OUT
pressure	I-OUT
(	I-OUT
CVP	I-OUT
)	I-OUT
or	I-OUT
pulmonary	I-OUT
artery	I-OUT
occlusion	I-OUT
pressure	I-OUT
(	I-OUT
PAOP	I-OUT
)	I-OUT
from	O
the	O
first	O
four	O
study	O
days	O
were	O
correlated	O
.	O


CONCLUSIONS	O
VPW	O
correlates	O
with	O
PAOP	O
better	O
than	B-P
CVP	I-P
in	I-P
patients	I-P
with	I-P
ALI	O
.	O


The	O
principal	O
findings	O
in	O
our	O
study	O
show	O
a	O
strong	O
correlation	O
between	O
PGC-1alpha	B-OUT
and	I-OUT
COX5B	I-OUT
(	O
p	O
<	O
0.001	O
)	O
and	O
between	O
PGC-1alpha	B-OUT
and	I-OUT
MT-CO2	I-OUT
(	O
p=0.017	O
)	O
expression	O
.	O


The	O
PD	O
effects	O
were	O
also	O
assessed	O
according	O
the	O
presence	O
or	O
absence	O
of	O
high	B-OUT
on-treatment	I-OUT
platelet	I-OUT
reactivity	I-OUT
status	I-OUT
.	I-OUT


The	O
PD	O
effects	O
did	O
not	O
vary	O
according	O
the	O
presence	O
or	O
absence	O
of	O
high	O
on-treatment	O
platelet	O
reactivity	O
.	O


RESEARCH	O
DESIGN	O
AND	O
METHODS	O
At	O
31	B-P
weeks	I-P
,	I-P
12	I-P
diet-controlled	I-P
overweight/obese	I-P
women	I-P
with	I-P
GDM	I-P
were	O
randomized	O
to	O
an	O
isocaloric	O
LC/CONV	O
(	O
40	O
%	O
carbohydrate/45	O
%	O
fat/15	O
%	O
protein	O
;	O
n	O
=	O
6	O
)	O
or	O
CHOICE	B-I
(	O
60	O
%	O
/25	O
%	O
/15	O
%	O
;	O
n	O
=	O
6	O
)	O
diet	B-I
.	I-I


All	O
meals	B-I
were	O
provided	O
.	O


Insulin	B-OUT
suppression	I-OUT
of	I-OUT
AT	I-OUT
lipolysis	I-OUT
was	O
improved	O
on	O
CHOICE	O
versus	O
LC/CONV	O
(	O
56	O
vs.	O
31	O
%	O
,	O
P	O
=	O
0.005	O
)	O
,	O
consistent	O
with	O
improved	O
IR	B-OUT
.	I-OUT


The	O
high	O
dose	O
(	O
0.3	O
mM/kg	O
)	O
gadodiamide	B-I
injection	O
in	O
7	O
patients	O
did	O
not	O
shorten	B-OUT
the	I-OUT
T2	I-OUT
value	I-OUT
sufficiently	I-OUT
to	O
overwhelm	O
the	O
T1	B-OUT
shortening	I-OUT
and	I-OUT
leave	I-OUT
pathologic	I-OUT
lesions	I-OUT
hypointense	I-OUT
compared	O
to	O
precontrast	O
studies	O
.	O


Epidural	B-I
morphine	I-I
in	O
the	B-P
elderly	I-P
.	I-P


Postoperative	B-OUT
respiratory	I-OUT
mechanics	I-OUT
,	O
however	O
,	O
were	O
not	O
significantly	O
improved	O
and	O
delayed	B-OUT
respiratory	I-OUT
depression	I-OUT
was	O
observed	O
in	O
one	O
patient	O
.	O


A	O
comparative	O
randomized	O
trial	O
.	O


Twenty-seven	B-P
adolescent	I-P
basketball	I-P
players	I-P
(	I-P
14.7+/-0.5	I-P
years	I-P
;	I-P
Tanner	I-P
stage	I-P
:	I-P
3.5+/-0.5	I-P
)	I-P
were	O
randomly	O
divided	O
into	O
a	O
specialized	B-I
basketball	I-I
training	I-I
group	I-I
(	O
SP	O
,	O
n=10	O
)	O
,	O
a	B-I
mixed	I-I
basketball	I-I
plus	I-I
conditioning	I-I
training	I-I
group	I-I
(	O
MX	O
,	O
n=10	O
)	O
and	B-I
a	I-I
control	I-I
group	I-I
(	O
n=7	O
)	O
.	O


Peak	B-OUT
and	I-OUT
mean	I-OUT
power	I-OUT
output	I-OUT
measured	O
during	O
the	O
Wingate	O
test	O
were	O
also	O
improved	O
by	O
a	O
similar	O
magnitude	O
after	O
SP	O
(	O
21+/-5	O
%	O
)	O
and	O
MX	O
(	O
15+/-6	O
%	O
)	O
.	O


Trunk	B-OUT
muscle	I-OUT
endurance	I-OUT
was	O
equally	O
increased	O
(	O
SP	O
:	O
23+/-4	O
%	O
,	O
MX	O
:	O
25+/-5	O
%	O
)	O
,	O
but	O
arms	B-OUT
endurance	I-OUT
was	O
improved	O
significantly	O
more	O
after	O
MX	O
(	O
50+/-11	O
%	O
)	O
compared	O
to	O
SP	O
(	O
11+/-14	O
%	O
,	O
p	O
<	O
0.05	O
)	O
.	O


Performance	B-OUT
in	O
four	O
basketball	B-OUT
technical	I-OUT
skills	I-OUT
was	O
similarly	O
increased	O
(	O
by	O
17-27	O
%	O
)	O
in	O
both	O
groups	O
,	O
with	O
a	O
tendency	O
for	O
greater	O
improvement	O
of	O
the	O
SP	O
groups	O
in	O
the	O
technical	O
skills	O
of	O
shooting	B-OUT
and	I-OUT
passing	I-OUT
.	I-OUT


single	B-P
doses	I-P
of	I-P
tegaserod	I-I
(	I-P
0.8	I-P
mg	I-P
to	I-P
20	I-P
mg	I-P
)	I-P
or	I-I
placebo	I-I
.	I-I


Baseline	O
values	O
were	O
compared	O
with	O
data	O
collected	O
during	O
the	O
treatment	O
period	O
.	O


RESULTS	O
The	O
proportion	O
of	O
patients	O
with	O
prolongation	B-OUT
of	I-OUT
the	I-OUT
QTc	I-OUT
interval	I-OUT
was	O
the	O
same	O
for	O
placebo	O
and	O
tegaserod	O
,	O
as	O
was	O
the	O
frequency	B-OUT
of	I-OUT
overall	I-OUT
electrocardiographic	I-OUT
abnormalities	I-OUT
.	I-OUT


METHODS	O
AND	O
RESULTS	O
Signal-averaged	B-OUT
electrocardiograms	I-OUT
were	O
obtained	O
from	O
12	B-P
normal	I-P
subjects	I-P
(	I-P
6	I-P
men	I-P
,	I-P
6	I-P
women	I-P
;	I-P
ages	I-P
21	I-P
to	I-P
26	I-P
years	I-P
)	I-P
before	I-P
and	I-P
after	I-P
ingestion	I-P
of	I-P
caffeine	I-I
(	O
5	O
mg/kg	O
body	O
weight	O
)	O
or	O
placebo	B-I
in	O
a	O
randomized	O
,	O
double-blind	O
,	O
crossover	O
fashion	O
.	O


The	O
baseline	O
temperature	O
,	O
final	O
temperature	O
,	O
total	O
time	O
in	O
the	O
operating	O
room	O
,	O
and	O
amount	O
of	O
irrigation	O
fluid	O
used	O
during	O
the	O
procedure	O
were	O
recorded	O
for	O
each	O
patient	O
.	O


A	O
decrease	O
in	O
temperature	B-OUT
was	O
observed	O
in	O
21	O
(	O
72.4	O
%	O
)	O
of	O
the	O
29	O
patients	O
who	O
received	O
warm	B-I
irrigation	I-OUT
fluid	I-OUT
.	I-OUT


XS0601	B-I
also	O
significantly	O
reduced	O
the	O
combined	B-OUT
incidence	I-OUT
of	I-OUT
major	I-OUT
adverse	I-OUT
cardiac	I-OUT
event	I-OUT
(	O
10.4	O
%	O
in	O
the	O
XS0601	O
group	O
vs.	O
22.7	O
%	O
in	O
the	O
placebo	B-I
group	O
,	O
P	O
<	O
0.05	O
)	O
.	O


Body-weight	B-OUT
loss	I-OUT
was	O
significant	O
(	B-I
ENT	I-I
0.8	O
(	O
se	O
0.3	O
)	O
kg	O
,	O
P	O
<	O
0.05	O
;	O
PLA	B-I
1.3	O
(	O
se	O
0.3	O
)	O
kg	O
,	O
P	O
<	O
0.001	O
)	O
,	O
but	O
not	O
different	O
between	O
treatments	O
.	O


We	O
conclude	O
that	O
oral	O
ENT	B-I
administration	O
did	O
not	O
affect	O
food	B-OUT
intake	I-OUT
,	I-OUT
energy	I-OUT
expenditure	I-OUT
or	I-OUT
body	I-OUT
weight	I-OUT
in	O
subjects	B-P
with	I-P
a	I-P
preference	I-P
for	I-P
a	I-P
high-fat	I-P
diet	I-P
experiencing	O
a	O
negative	O
energy	O
and	O
fat	O
balance	O
.	O


We	O
hypothesised	O
that	O
chlorhexidine-alcohol	B-I
would	O
be	O
more	O
effective	O
than	O
povidone	B-I
iodine-alcohol	I-I
as	O
a	O
skin	O
antiseptic	O
to	O
prevent	O
intravascular-catheter-related	O
infections	O
.	O


Throughout	O
gestation	O
,	O
33	B-P
German	I-P
Landrace	I-P
gilts	I-P
were	O
fed	O
high	B-I
(	I-I
HP	I-I
,	I-I
30	I-I
%	I-I
)	I-I
,	I-I
low	I-I
(	I-I
LP	I-I
,	I-I
6.5	I-I
%	I-I
)	I-I
,	I-I
or	I-I
adequate	I-I
(	I-I
AP	I-I
,	I-I
12.1	I-I
%	I-I
)	I-I
protein	I-I
diets	I-I
,	O
which	O
were	O
made	O
isocaloric	O
by	O
adjusting	O
the	O
carbohydrate	O
content	O
.	O


The	B-P
offspring	I-P
were	I-P
cross-fostered	I-P
,	O
and	O
the	O
plasma	B-OUT
cortisol	I-OUT
and	I-OUT
catecholamine	I-OUT
concentrations	I-OUT
of	O
the	O
offspring	B-P
were	O
determined	O
on	O
postnatal	O
d	O
(	O
PND	O
)	O
1	O
and	O
27	O
and	O
under	O
specific	O
challenging	O
conditions	O
:	O
after	O
weaning	O
(	O
PND	O
29	O
)	O
and	O
after	O
ACTH	O
and	O
insulin	O
challenges	O
(	O
PND	O
68	O
and	O
70	O
,	O
respectively	O
)	O
.	O


Maternal	B-OUT
salivary	I-OUT
cortisol	I-OUT
concentrations	I-OUT
increased	O
throughout	O
gestation	O
(	O
P	O
<	O
0.001	O
)	O
and	O
the	O
LP	O
gilts	O
had	O
greater	O
salivary	B-OUT
cortisol	I-OUT
compared	O
with	O
the	O
AP	O
and	O
HP	O
gilts	O
(	O
P	O
<	O
0.05	O
)	O
.	O


No	O
differences	O
between	O
diets	O
were	O
found	O
for	O
cortisol	O
,	O
corticosteroid-binding	O
globulin	O
,	O
and	O
catecholamine	O
concentrations	O
in	O
plasma	O
and	O
for	O
GR	O
binding	O
in	O
hippocampus	O
and	O
hypothalamus	O
in	O
piglets	B-P
at	O
PND	O
1	O
and	O
27	O
.	O


Anesthesia	O
for	O
in	B-P
vitro	I-P
fertilization	I-P
:	I-P
the	O
addition	O
of	O
fentanyl	B-I
to	O
1.5	O
%	O
lidocaine	B-I
.	I-I


Timed	B-OUT
variables	I-OUT
,	I-OUT
such	I-OUT
as	I-OUT
time	I-OUT
to	I-OUT
urination	I-OUT
,	I-OUT
ambulation	I-OUT
,	I-OUT
and	I-OUT
discharge	I-OUT
,	O
were	O
the	O
same	O
for	O
both	O
groups	O
of	O
women	O
.	O


In	O
addition	O
,	O
the	O
narcotic	O
requirements	O
of	O
patients	O
are	O
less	O
in	O
the	O
postanesthesia	O
care	O
unit	O
.	O


Prevention	O
of	O
type	B-P
2	I-P
(	I-P
non-insulin-dependent	I-P
)	I-P
diabetes	I-P
mellitus	I-P
by	O
diet	O
and	O
physical	O
exercise	O
.	O


Blood	B-OUT
pressure	I-OUT
,	I-OUT
lipids	I-OUT
,	I-OUT
and	I-OUT
hyperinsulinaemia	I-OUT
were	O
reduced	O
and	B-OUT
early	I-OUT
insulin	I-OUT
responsiveness	I-OUT
to	I-OUT
glucose	I-OUT
loading	O
preserved	O
.	O


Patients	O
were	O
randomly	O
assigned	O
to	O
one	O
of	O
two	O
treatment	O
groups	O
.	O


The	O
primary	O
endpoint	O
evaluated	O
was	O
SWI	B-OUT
,	O
which	O
was	O
defined	O
as	O
purulent	O
drainage	O
or	O
active	O
wound	O
treatment	O
.	O


Five	B-P
hundred	I-P
ninety-two	I-P
patients	I-P
were	I-P
evaluated	I-P
:	I-P
283	I-P
received	I-P
ampicillin/sulbactam	I-I
and	I-P
309	I-P
received	I-P
cefoxitin	I-I
.	I-I


The	O
incidence	B-OUT
of	I-OUT
wound	I-OUT
infection	I-OUT
among	O
the	O
ampicillin/sulbactam	O
patients	O
was	O
2	O
%	O
and	O
among	O
cefoxitin	O
patients	O
it	O
was	O
7	O
%	O
(	O
p	O
<	O
0.004	O
)	O
.	O


The	O
cefoxitin	O
patients	O
with	O
colon	O
injuries	O
were	O
analyzed	O
(	O
p	O
<	O
0.007	O
)	O
.	O


The	O
major	O
difference	O
between	O
the	O
two	O
groups	O
was	O
an	O
increased	O
incidence	B-OUT
of	I-OUT
enterococcal	I-OUT
infections	I-OUT
in	O
the	O
cefoxitin-treated	O
patients	O
.	O


A	O
comparison	O
of	O
3	O
regimens	O
for	O
protecting	O
contrast-induced	O
nephropathy	O
in	O
patients	B-P
undergoing	I-P
coronary	I-I
procedures	I-I
.	I-I


After	O
adjusting	O
the	O
Mehran	B-OUT
nephropathy	I-OUT
risk	I-OUT
score	I-OUT
,	O
the	O
risk	B-OUT
of	I-OUT
CIN	I-OUT
significantly	O
reduced	O
with	O
sodium	B-I
bicarbonate	I-I
compared	O
with	O
sodium	B-I
chloride	I-I
alone	O
(	O
adjusted	O
risk	O
ratio	O
0.29	O
,	O
P	O
=	O
.043	O
)	O
.	O


Application	O
of	O
either	O
cream	O
produced	O
a	O
very	B-OUT
slight	I-OUT
increase	I-OUT
(	O
less	O
than	O
or	O
equal	O
to	O
0.5	O
log	O
cycle	O
)	O
in	O
the	O
skin	B-OUT
flora	I-OUT
during	O
the	O
first	O
2	O
weeks	O
of	O
treatment	O
.	O


There	O
were	O
no	B-OUT
significant	I-OUT
differences	I-OUT
in	O
the	O
changes	O
occurring	O
between	O
volunteers	O
treated	O
with	O
placebo	O
and	O
those	O
on	O
the	O
steroid	O
formulation	O
.	O


Hb	B-OUT
,	I-OUT
Hct	I-OUT
,	I-OUT
FEP	I-OUT
,	I-OUT
and	I-OUT
ferritin	I-OUT
were	O
similar	O
in	O
both	O
groups	O
with	O
the	O
exception	O
of	O
lower	O
ferritin	O
values	O
at	O
age	O
365	O
d	O
(	O
p	O
less	O
than	O
0.05	O
)	O
in	O
the	O
group	O
fed	O
the	O
nonfortified	O
formula	O
.	O


No	O
infant	O
had	O
hemoglobin	B-OUT
less	O
than	O
100	O
g/L	O
.	O


Co-administration	O
of	O
pethidine	B-I
0.75	I-I
mg	I-I
kg-1	I-I
and	I-I
clonidine	I-I
75	I-I
micrograms	I-I
intrathecally	O
provided	O
good	O
intraoperative	O
anaesthesia	O
for	O
total	B-I
hip	I-I
replacement	I-I
,	O
similar	O
to	O
that	O
obtained	O
using	O
0.5	B-I
%	I-I
isobaric	I-I
bupivacaine	I-I
.	I-I


The	O
primary	O
endpoints	O
were	O
overall	O
survival	B-OUT
and	I-OUT
progression-free	I-OUT
survival	I-OUT
both	O
in	O
the	O
total	O
population	O
and	O
in	O
patients	O
with	O
PD-L1	O
expression	O
on	O
at	O
least	O
50	O
%	O
of	O
tumour	O
cells	O
.	O


FINDINGS	O
Between	B-P
Aug	I-P
28	I-P
,	I-P
2013	I-P
,	I-P
and	I-P
Feb	I-P
27	I-P
,	I-P
2015	I-P
,	I-P
we	I-P
enrolled	I-P
1034	I-P
patients	I-P
:	I-P
345	O
allocated	O
to	O
pembrolizumab	B-I
2	O
mg/kg	O
,	O
346	O
allocated	O
to	O
pembrolizumab	O
10	O
mg/kg	O
,	O
and	O
343	O
allocated	O
to	O
docetaxel	B-I
.	I-I


Likewise	O
,	O
for	O
this	O
patient	O
population	O
,	O
progression-free	B-OUT
survival	I-OUT
was	O
significantly	O
longer	O
with	O
pembrolizumab	B-I
2	O
mg/kg	O
than	O
with	O
docetaxel	B-I
(	O
median	O
5.0	O
months	O
vs	O
4.1	O
months	O
;	O
HR	O
0.59	O
,	O
95	O
%	O
CI	O
0.44-0.78	O
;	O
p=0.0001	O
)	O
and	O
with	O
pembrolizumab	O
10	O
mg/kg	O
than	O
with	O
docetaxel	O
(	O
5.2	O
months	O
vs	O
4.1	O
months	O
;	O
0.59	O
,	O
0.45-0.78	O
;	O
p	O
<	O
0.0001	O
)	O
.	O


INTERPRETATION	O
Pembrolizumab	B-I
prolongs	O
overall	B-OUT
survival	I-OUT
and	O
has	O
a	O
favourable	O
benefit-to-risk	O
profile	O
in	O
patients	B-P
with	I-P
previously	I-P
treated	I-P
,	I-P
PD-L1-positive	I-P
,	I-P
advanced	I-P
non-small-cell	I-P
lung	I-P
cancer	I-P
.	I-P


FUNDING	O
Merck	O
&	O
Co	O
.	O


Bronchoalveolar	O
lavage	O
fluid	O
samples	O
were	O
collected	O
from	O
either	O
the	O
collapsed	O
or	O
the	O
ventilated	O
lung	O
both	O
before	O
one-lung	O
ventilation	O
and	O
30	O
min	O
after	O
re-expansion	O
of	O
the	O
lung	O
.	O


Pre-operative	O
nebulisation	O
of	B-I
budesonide	I-I
may	O
be	O
effective	O
in	O
improving	B-OUT
ventilatory	I-OUT
mechanics	I-OUT
and	I-OUT
reducing	I-OUT
the	I-OUT
inflammatory	I-OUT
response	I-OUT
to	O
one-lung	O
ventilation	O
during	O
thoracic	O
surgery	O
.	O


Clinical	O
evaluation	O
of	O
the	O
speed	B-OUT
and	I-OUT
effectiveness	I-OUT
of	I-OUT
subgingival	I-OUT
calculus	I-OUT
removal	I-OUT
on	O
single-rooted	O
teeth	O
with	O
diamond-coated	B-I
ultrasonic	I-I
tips	I-I
.	I-I


Rett	B-P
syndrome	I-P
:	I-P
randomized	O
controlled	O
trial	O
of	O
L-carnitine	B-I
.	I-I


To	O
investigate	O
whether	O
L-carnitine	B-I
might	O
be	O
of	O
benefit	O
in	O
Rett	O
syndrome	O
,	O
a	O
randomized	O
,	O
placebo-controlled	B-I
,	O
double-blind	O
crossover	O
trial	O
of	O
L-carnitine	B-I
has	O
been	O
completed	O
in	O
35	B-P
subjects	I-P
.	I-P


Outcome	O
was	O
measured	O
by	O
parents/caregivers	O
and	O
at	O
medical	O
follow-up	O
using	O
three	O
established	O
tools	O
:	O
the	B-OUT
Rett	I-OUT
Syndrome	I-OUT
Motor	I-OUT
Behavioral	I-OUT
Assessment	I-OUT
,	I-OUT
the	I-OUT
Hand	I-OUT
Apraxia	I-OUT
Scale	I-OUT
,	I-OUT
and	I-OUT
the	I-OUT
Patient	I-OUT
Well-Being	I-OUT
Index	I-OUT
.	I-OUT


Analysis	O
comparing	O
change	O
between	O
baseline	O
and	O
week	O
8	O
of	O
treatment	O
for	O
L-carnitine	B-I
and	O
the	O
placebo	B-I
showed	O
that	O
both	O
parents/caregivers	O
and	O
medical	O
follow-up	O
detected	O
improvements	O
in	O
the	O
subjects	O
'	O
well-being	B-OUT
.	I-OUT


The	O
bupivacaine	B-I
group	O
had	O
better	O
analgesia	B-OUT
than	O
the	O
control	O
group	O
for	O
the	O
first	O
8	O
hours	O
,	O
after	O
which	O
there	O
was	O
no	O
difference	O
.	O


It	O
is	O
concluded	O
that	O
caudal	O
diamorphine	B-I
gives	O
good	O
postoperative	O
analgesia	O
for	O
perianal	O
operations	O
,	O
particularly	O
when	O
motor	O
blockade	O
is	O
not	O
wanted	O
by	O
the	O
surgeon	O
.	O


Utilization	O
patterns	O
of	O
conventional	B-I
and	I-I
complementary/alternative	I-I
treatments	I-I
in	O
children	B-P
with	I-P
autism	I-P
spectrum	I-P
disorders	I-P
and	I-P
developmental	I-P
disabilities	I-P
in	I-P
a	I-P
population-based	I-P
study	I-P
.	I-P


Variables	O
such	O
as	O
level	B-OUT
of	I-OUT
function	I-OUT
,	I-OUT
immunization	I-OUT
status	I-OUT
,	I-OUT
and	I-OUT
the	I-OUT
presence	I-OUT
of	I-OUT
an	I-OUT
identified	I-OUT
neurogenetic	I-OUT
disorder	I-OUT
were	O
not	O
predictive	O
of	O
CAM	B-I
use	O
.	O


RAB-plate	B-I
versus	O
sliding	B-I
hip	I-I
screw	I-I
for	O
unstable	B-P
trochanteric	I-P
hip	I-P
fractures	I-P
:	I-P
stability	O
of	O
the	O
fixation	O
and	O
modes	B-OUT
of	I-OUT
failure	I-OUT
--	I-OUT
radiographic	I-OUT
analysis	I-P
of	I-P
218	I-P
fractures	I-P
.	I-P


Linear	B-OUT
and	I-OUT
angular	I-OUT
displacements	I-OUT
of	O
the	O
major	O
fragments	O
and	O
implant	B-OUT
migration	I-OUT
into	I-OUT
the	I-OUT
femoral	I-OUT
head	I-OUT
during	O
healing	O
were	O
assessed	O
.	O


Here	O
,	O
we	O
report	O
the	O
prespecified	O
final	O
analysis	O
of	O
this	O
randomized	O
trial	O
.	O


RESULTS	B-P
One	I-P
thousand	I-P
two	I-P
hundred	I-P
five	I-P
patients	I-P
were	O
randomly	O
assigned	O
between	O
1995	O
and	O
2005	O
,	O
602	O
to	B-I
ADT	I-I
alone	O
and	O
603	O
to	B-I
ADT+RT	I-I
.	O


Outcome	O
data	O
were	O
available	O
for	O
89	O
%	O
of	O
enrolled	O
subjects	O
.	O


Comparison	O
of	O
nitinol	B-I
tipless	I-I
stone	I-I
baskets	I-I
in	O
an	O
in	O
vitro	B-OUT
caliceal	O
model	O
.	O


We	O
evaluated	O
the	O
stone	B-P
capture	I-P
rate	I-P
of	I-P
9	I-P
commercially	I-P
available	I-P
tipless	I-I
stone	I-I
baskets	I-I
in	I-P
an	I-P
in	I-P
vitro	I-P
model	I-P
using	O
novice	O
and	O
expert	O
operators	O
.	O


Each	B-P
operator	I-P
performed	I-P
stone	I-I
extraction	I-I
of	I-P
2	I-P
,	I-P
5	I-P
and	I-P
8	I-P
mm	I-P
calculi	I-P
(	O
size	O
determined	O
by	O
digital	O
caliper	O
with	O
3	O
repetitions	O
of	O
each	O
basket	O
.	O


The	O
Zerotip	O
functioned	O
well	O
for	O
2	O
mm	O
calculi	O
in	O
the	O
hands	O
of	O
expert	O
operators	O
(	O
15	O
+/-	O
9	O
seconds	O
)	O
but	O
not	O
novice	O
operators	O
(	O
94	O
+/-	O
95	O
seconds	O
)	O
.	O


The	O
Sur-Catch	O
NT	O
was	O
significantly	O
slower	O
for	O
2	O
mm	O
calculi	O
than	O
the	O
N-Circle	O
(	O
p	O
=	O
0.01	O
)	O
,	O
Dimension	O
(	O
p	O
=.03	O
)	O
,	O
Halo	O
(	O
p	O
=.0005	O
)	O
,	O
Vantage	O
(	O
p	O
=.001	O
)	O
and	O
Zerotip	O
(	O
p	O
=.002	O
)	O
.	O


The	O
Sur-Catch	O
NT	O
had	O
the	O
slowest	B-OUT
stone	I-OUT
capture	I-OUT
rate	I-OUT
for	O
all	O
stone	O
sizes	O
.	O


STUDY	O
DESIGN	O
Cohort	O
study	O
.	O


METHODS	O
Data	O
from	O
a	O
randomized	O
controlled	O
trial	O
with	O
442	B-P
patients	I-P
with	I-P
low	I-P
back	I-P
pain	I-P
were	I-P
used	I-P
.	I-P


The	O
MCIC	B-OUT
of	I-OUT
the	I-OUT
QBPDS	I-OUT
was	O
estimated	O
between	O
17.5	O
to	O
32.9	O
points	O
and	O
8.5	O
to	O
24.6	O
points	O
for	O
(	B-P
sub	I-P
)	I-P
acute	I-P
and	I-P
chronic	I-P
patients	I-P
with	I-P
low	I-P
back	I-P
pain	I-P
.	I-P


Saline	B-I
lung	I-I
lavage	I-I
was	O
performed	O
in	O
33	B-P
healthy	I-P
female	I-P
pigs	I-P
,	I-P
weighing	I-P
52	I-P
+/-	I-P
4.1	I-P
kg	I-P
(	I-P
mean	I-P
+/-	I-P
SD	I-P
)	I-P
,	O
until	O
the	O
Pao2	O
decreased	O
to	O
53	O
+/-	O
8	O
mm	O
Hg	O
.	O


After	O
a	O
stabilization	O
period	O
of	O
60	O
minutes	O
,	O
the	O
animals	O
were	O
randomly	O
assigned	O
to	O
four	B-P
groups	I-P
:	I-P
group	I-P
1	I-P
,	O
pressure-controlled	B-I
ventilation	I-I
(	I-I
PCV	I-I
)	I-I
with	O
a	O
tidal	O
volume	O
of	O
6	O
mL/kg	O
;	O
group	B-P
2	I-P
,	O
PCV	B-I
with	O
a	O
tidal	O
volume	O
of	O
6	O
mL/kg	O
and	O
AV-ECLA	B-I
;	I-I
group	I-P
3	I-P
,	O
HFOV	B-I
;	I-I
group	I-P
4	I-P
,	O
HFOV	B-I
and	I-I
AV-ECLA	I-I
.	I-I


Peak	B-OUT
inspiratory	I-OUT
pressure	I-OUT
was	O
significantly	O
lower	O
in	O
HFOV-treated	O
animals	O
.	O


Less	O
attention	O
has	O
been	O
focused	O
comparing	O
the	O
effectiveness	O
of	O
these	O
inhalational	O
anesthetic	O
agents	O
in	O
neurosurgery	B-P
.	I-P


The	O
present	O
results	O
support	O
the	O
usefulness	O
of	O
infusion	O
of	O
granisetron	B-I
as	O
an	O
administration	O
method	O
during	O
chemotherapy	O
for	O
malignant	O
hemopathy	O
.	O


Reliability	O
analysis	O
showed	O
Cronbach	O
's	O
alpha	O
of	O
the	B-OUT
questionnaire	I-OUT
was	O
0.91	O
.	O


Intraepithelial	O
lymphocytes	O
were	O
characterized	O
by	O
flow	O
cytometry	O
and	O
the	O
gene	O
expression	O
of	O
mucin	O
2	O
(	O
MUC2	O
)	O
,	O
mucin	O
20	O
(	O
MUC20	O
)	O
,	O
β-defensin	O
3	O
,	O
and	O
trefoil	O
factor	O
3	O
(	O
TFF3	O
)	O
was	O
determined	O
by	O
reverse	O
transcription	O
quantitative	O
PCR	O
.	O


The	O
abundance	B-OUT
of	I-OUT
sulfomucins	I-OUT
decreased	O
(	O
P	O
<	O
0.001	B-OUT
)	I-OUT
and	I-OUT
sialomucins	I-OUT
increased	O
with	O
age	O
(	O
P	O
<	O
0.001	O
)	O
,	O
while	O
high	O
dietary	O
ZnO	O
reduced	O
the	O
sulfomucins	O
(	O
P	O
<	O
0.001	O
)	O
and	O
increased	O
the	O
sialomucins	O
(	O
P	O
<	O
0.05	O
)	O
in	O
the	O
crypts	O
.	O


The	O
phenotypes	O
of	O
lymphocytes	O
in	O
the	O
epithelium	O
of	O
the	O
proximal	O
jejunum	O
showed	O
relatively	O
constant	B-OUT
percentages	I-OUT
of	I-OUT
T-cells	I-OUT
,	O
as	O
well	O
as	O
natural	O
killer	O
cells	B-OUT
.	I-OUT


It	O
is	O
concluded	O
that	O
Zn	O
in	O
the	O
form	O
of	O
ZnO	O
appears	O
to	O
have	O
specific	O
effects	O
on	O
the	O
innate	O
and	O
adaptive	O
gut	O
associated	O
immune	B-P
system	I-P
of	O
piglets	O
.	O


CAF-specific	B-OUT
pSMAD2	I-OUT
levels	I-OUT
,	O
however	O
,	O
did	O
not	O
associate	O
with	O
survival	O
outcome	O
.	O


Conversion	O
to	O
complete	O
remission	O
post-ASCT	B-OUT
occurred	O
in	O
30	O
and	O
14	O
%	O
of	O
the	O
amifostine	B-I
and	O
control	O
groups	O
,	O
respectively	O
(	O
P=0.09	O
)	O
.	O


We	O
conclude	O
that	O
amifostine	B-I
can	O
be	O
safely	O
administered	O
prior	O
to	O
high-dose	O
melphalan	O
and	O
significantly	O
reduces	O
the	O
frequency	B-OUT
and	I-OUT
severity	I-OUT
of	I-OUT
therapy-induced	I-OUT
oral	I-OUT
mucositis	I-OUT
.	I-OUT


Participants	B-P
were	I-P
recruited	I-P
from	I-P
two	I-P
academic	I-P
centers	I-P
and	I-P
nine	I-P
oncology	I-P
practices	I-P
,	I-P
which	I-P
were	I-P
members	I-P
of	I-P
NCI	I-P
's	I-P
Community	I-P
Clinical	I-P
Oncology	I-P
Program	I-P
(	I-P
CCOP	I-P
)	I-P
and	I-P
were	I-P
followed	I-P
over	I-P
2	I-P
years	I-P
.	I-P


METHODS	O
AND	O
MATERIALS	O
Fifty	B-P
patients	I-P
were	I-P
randomized	I-P
to	I-P
receive	I-P
conventional	I-I
radiotherapy	I-I
(	I-P
RT	I-P
)	I-P
(	I-P
2-Gy	I-P
fractions	I-P
,	I-P
5	I-P
days	I-P
weekly	I-P
,	I-P
to	I-P
a	I-P
total	I-P
of	I-P
60-74	I-P
Gy	I-P
,	I-P
depending	I-P
on	I-P
the	I-P
tumor	I-P
localization	I-P
and	I-P
TNM	I-P
classification	I-P
)	I-P
and	I-P
carboplatin	I-I
(	I-P
90	I-P
mg/m	I-P
(	I-P
2	I-P
)	I-P
infusion	I-P
once	I-P
per	I-P
week	I-P
before	I-P
RT	I-P
)	I-P
.	O


Similar	O
results	O
were	O
obtained	O
for	O
dysphagia	B-OUT
.	I-OUT


Study	O
protocol	O
:	O
Phase	O
III	O
single-blinded	O
fast-track	O
pragmatic	O
randomised	O
controlled	O
trial	O
of	O
a	O
complex	O
intervention	O
for	O
breathlessness	B-OUT
in	I-OUT
advanced	I-OUT
disease	I-OUT
.	I-OUT


The	O
results	O
will	O
provide	O
evidence	O
of	O
the	O
clinical	B-OUT
and	I-OUT
cost-effectiveness	I-OUT
of	I-OUT
the	I-OUT
service	I-OUT
,	O
informing	O
its	O
longer	O
term	O
development	O
and	O
implementation	O
of	O
the	O
model	O
in	O
other	O
centres	O
nationally	O
and	O
internationally	O
.	O


Little	O
evidence	O
exists	O
on	O
possible	O
predictors	O
of	O
breastfeeding	O
behaviors	O
in	O
the	O
Middle	O
East	O
.	O


CONCLUSIONS	O
The	O
proportion	O
of	O
healthy	B-P
first-time	I-P
mothers	I-P
who	I-P
exclusively	I-P
breastfeed	I-P
in	I-P
Beirut	I-P
is	O
extremely	O
low	O
.	O


Future	O
research	O
and	O
interventions	O
should	O
target	O
different	O
levels	O
of	O
the	O
maternal-child	O
pair	O
's	O
ecosystem	O
.	O


In	O
these	O
patients	O
,	O
response	O
did	B-OUT
not	I-OUT
influence	I-OUT
FFS	I-OUT
except	O
for	O
those	O
with	O
alveolar	O
histology	O
.	O


The	O
Italian	B-P
Study	I-P
Group	I-P
.	I-P


Both	O
drugs	O
were	O
given	O
by	O
subcutaneous	O
route	O
.	O


A	O
Doppler	O
or	O
Duplex	O
Scan	O
diagnosis	O
of	O
DVT	B-OUT
was	O
made	O
in	O
3	O
(	O
0.5	O
%	O
)	O
patients	O
in	O
the	O
enoxaparin	B-I
group	O
(	O
2	O
cases	O
during	O
treatment	O
and	O
1	O
patient	O
at	O
the	O
end	O
of	O
treatment	O
)	O
and	O
in	O
6	O
(	O
1.1	O
%	O
)	O
patients	O
in	O
the	O
calcium	B-I
heparin	I-I
group	O
(	O
5	O
cases	O
during	O
treatment	O
and	O
1	O
,	O
bilateral	O
,	O
after	O
the	O
end	O
of	O
treatment	O
)	O
.	O


CONCLUSION	O
Communication	B-I
skill	I-I
training	I-I
delivered	O
in	O
a	O
computer	O
mediated	O
format	O
had	O
a	O
positive	B-OUT
and	I-OUT
parallel	I-OUT
impact	I-OUT
on	O
both	O
patient	O
and	O
clinician	O
reported	O
use	O
of	O
patient-centered	B-OUT
communication	I-OUT
and	O
in	O
patient	B-OUT
satisfaction	I-OUT
.	I-OUT


OBJECTIVE	O
To	O
examine	O
the	O
effect	O
of	O
waiting	O
times	O
on	O
the	O
health	O
status	O
of	O
patients	B-P
referred	I-P
for	I-P
a	I-P
non-urgent	I-P
rheumatology	I-P
opinion	I-P
.	I-P


Both	O
groups	O
showed	O
significant	O
improvements	O
in	O
mean	B-OUT
[	I-OUT
95	I-OUT
%	I-OUT
confidence	I-OUT
interval	I-OUT
(	I-OUT
CI	I-OUT
)	I-OUT
]	I-OUT
scores	I-OUT
for	I-OUT
pain	I-OUT
:	I-OUT
11	O
(	O
7	O
,	O
16	O
)	O
(	O
P	O
<	O
0.001	O
)	O
;	O
physical	B-OUT
health	I-OUT
status	I-OUT
:	I-OUT
4	O
(	O
2	O
,	O
5	O
)	O
(	O
P	O
<	O
0.001	O
)	O
;	O
mental	B-OUT
health	I-OUT
status	I-OUT
:	I-OUT
2	O
(	O
0.1	O
,	O
4	O
)	O
(	O
P	O
<	O
0.02	O
)	O
;	O
and	O
health	B-OUT
utility	I-OUT
:	I-OUT
0.11	O
(	O
0.07	O
,	O
0.16	O
)	O
(	O
P	O
<	O
0.001	O
)	O
by	O
the	O
end	O
of	O
the	O
15-month	O
period	O
of	O
the	O
study	O
,	O
but	O
there	O
was	O
no	O
significant	O
difference	O
between	O
either	O
arm	O
of	O
the	O
study	O
.	O


It	O
was	O
therefore	O
hypothesized	O
that	O
cognitive	B-I
therapy	I-I
not	O
only	O
reduces	O
panic	O
but	O
also	O
agoraphobia	O
and	O
that	O
it	O
potentiates	O
the	O
effects	O
of	O
exposure	O
in	O
vivo	O
.	O


Two	B-P
groups	I-P
of	I-P
12	I-P
severe	I-P
agoraphobics	I-P
were	I-P
treated	I-P
with	O
4	O
sessions	O
of	O
cognitive	B-I
therapy	I-I
followed	I-I
by	I-I
8	I-I
sessions	I-I
of	I-I
cognitive	I-I
therapy	I-I
combined	I-I
with	I-I
in	I-I
vivo	I-I
exposure	I-I
.	I-I


The	O
initial	O
cognitive	O
therapy	O
produced	O
a	O
significant	O
reduction	O
in	O
panic	B-OUT
frequency	I-OUT
,	O
while	O
associative	O
therapy	O
did	O
not	O
affect	O
panic	O
.	O


Neither	O
cognitive	B-I
therapy	I-I
alone	O
,	O
nor	O
associate	B-I
therapy	I-I
alone	O
significantly	O
reduced	O
depression	B-OUT
,	I-OUT
state	I-OUT
or	I-OUT
trait	I-OUT
anxiety	I-OUT
,	I-OUT
self-rated	I-OUT
agoraphobia	I-OUT
or	I-OUT
behavioral	I-OUT
avoidance	I-OUT
.	I-OUT


Mandibular	B-I
advancement	I-I
splint	I-I
improves	O
indices	O
of	O
obstructive	B-P
sleep	I-P
apnoea	I-P
and	I-P
snoring	I-P
but	O
side	O
effects	O
are	O
common	O
.	O


AIM	O
To	O
assess	O
the	O
efficacy	O
of	O
a	O
mandibular	B-I
advancement	I-I
splint	I-I
(	I-I
MAS	I-I
)	I-I
in	O
the	O
treatment	O
of	O
obstructive	B-OUT
sleep	I-OUT
apnoea	I-OUT
syndrome	I-OUT
(	I-OUT
OSAS	I-OUT
)	I-OUT
.	I-OUT


Treatment	O
over	O
a	O
median	O
of	O
6.5	O
weeks	O
(	O
range	O
2-48	O
)	O
was	O
perceived	O
as	O
beneficial	O
by	O
ten	O
of	O
eleven	O
partners	O
.	O


OBJECTIVE	O
The	O
aim	O
of	O
the	O
study	O
was	O
to	O
investigate	O
whether	O
hydrotalcite	B-I
was	O
comparable	O
to	O
esomeprazole	B-I
,	O
a	O
proton	O
pump	O
inhibitor	O
,	O
in	O
on-demand	O
therapy	O
for	O
non-erosive	B-P
reflux	I-P
disease	I-P
(	I-P
NERD	I-P
)	I-P
.	I-P


Whole	O
pelvic	O
irradiation	B-I
in	O
stage	B-P
I	I-P
endometrial	I-P
carcinoma	I-P
:	I-P
changes	I-OUT
in	I-OUT
numbers	I-OUT
and	I-OUT
reactivities	I-OUT
of	I-OUT
some	I-OUT
blood	I-OUT
lymphocyte	I-OUT
subpopulations	I-OUT
.	I-OUT


The	O
stiffnesses	B-OUT
and	I-OUT
strengths	I-OUT
of	I-OUT
the	I-OUT
osteotomies	I-OUT
fixed	I-OUT
with	O
slotted	B-I
nails	I-I
in	O
10-30	O
degrees	O
torsion	O
were	O
6-8	O
%	O
and	O
the	O
values	O
of	O
non-slotted	O
nails	O
40	O
%	O
of	O
control	O
bone	O
.	O


Clinically	O
,	O
46	B-P
femoral	I-P
shaft	I-P
fractures	I-P
were	I-P
randomized	I-P
to	I-P
treatment	I-P
with	I-P
Gross-Kempf	I-I
nails	I-I
,	I-P
24	I-P
with	I-P
slotted	I-I
nails	I-I
and	I-P
22	I-P
with	I-P
non-slotted	I-I
nails	I-I
.	I-I


Osteosynthesis	O
of	O
femoral	O
shaft	O
fractures	O
using	O
slotted	O
nails	O
has	O
not	O
resulted	O
in	O
healing	O
disturbances	O
,	O
which	O
could	O
be	O
accounted	O
for	O
by	O
the	O
high	O
torsional	O
elasticity	O
of	O
the	O
nail	O
;	O
there	O
seems	O
to	O
be	O
no	O
indication	O
for	O
high-stiffness	O
nails	O
in	O
femoral	B-P
fractures	I-P
.	I-P


Patients	B-P
receiving	I-P
prophylactic	I-P
amnioinfusion	I-I
had	O
a	O
significant	O
decrease	O
in	O
both	O
the	O
frequency	B-OUT
and	I-OUT
severity	I-OUT
of	I-OUT
variable	I-OUT
decelerations	I-OUT
in	I-OUT
the	I-OUT
first	I-OUT
stage	I-OUT
of	I-OUT
labor	I-OUT
(	O
P	O
=	O
.006	O
)	O
and	O
in	O
the	O
average	O
total	O
number	O
of	O
variable	O
decelerations	O
in	O
the	O
first	O
and	O
second	O
stages	O
of	O
labor	O
(	O
P	O
=	O
.01	O
)	O
compared	O
with	O
controls	O
.	O


Pre-	O
and	O
post-testing	O
included	O
standardized	O
and	O
experimental	O
measures	O
of	O
behavior	B-OUT
and	I-OUT
event-related	I-OUT
brain	I-OUT
potentials	I-OUT
(	I-OUT
ERPs	I-OUT
)	I-OUT
,	O
as	O
well	O
as	O
interviews	B-OUT
after	O
training	O
.	O


After	O
training	O
,	O
all	O
participants	O
met	O
behavioral	B-OUT
criteria	I-OUT
for	O
expertise	O
with	O
the	O
specific	O
stimuli	O
on	O
which	O
they	O
received	O
training	O
.	O


Overall	O
,	O
recurrent	B-OUT
hospital	I-OUT
costs	I-OUT
were	O
significantly	O
lower	O
(	O
14	O
%	O
)	O
in	O
the	O
HBI	B-I
group	O
(	O
mean	O
+/-	O
SD	O
,	O
823	O
dollars	O
+/-	O
1642	O
dollars	O
vs	O
960	O
dollars	O
+/-	O
1376	O
dollars	O
per	O
patient	O
per	O
year	O
;	O
P	O
=	O
.045	O
)	O
.	O


However	O
,	O
parental	B-OUT
trait	I-OUT
anxiety	I-OUT
significantly	O
decreased	O
from	O
pre-	O
to	O
post-treatment	O
for	O
parents	O
of	O
treatment	O
responders	O
.	O


Although	O
the	O
operative	O
time	O
for	B-I
retroperitoneoscopic	I-I
laparoscopic	I-I
pyeloplasty	I-I
is	O
significantly	O
longer	O
,	O
the	O
success	O
rate	O
remains	O
the	O
same	O
for	O
both	O
procedures	O
.	O


Electrical	O
sources	O
of	O
P300	O
event-related	O
brain	O
potentials	O
revealed	O
by	O
low	O
resolution	O
electromagnetic	O
tomography	O
.	O


This	O
increase	O
in	O
hilliness	B-OUT
,	O
measured	O
by	O
the	O
GFP	O
,	O
was	O
significant	O
.	O


Patients	O
who	O
satisfy	O
the	O
trial	O
entry	O
criteria	O
are	O
randomised	O
to	O
treatment	O
by	O
coronary	B-I
angioplasty	I-I
or	I-I
coronary	I-I
artery	I-I
bypass	I-I
surgery	I-I
,	O
with	O
prospective	O
stratification	O
into	O
groups	O
with	O
one	O
,	O
two	O
,	O
or	O
three	O
treatment	O
vessels	O
.	O


Randomisation	O
implies	O
an	O
intention	O
to	O
treat	O
the	O
patient	O
by	O
the	O
assigned	O
procedure	O
and	O
the	O
analysis	O
of	O
long	O
term	O
results	O
will	O
include	O
all	O
randomised	O
cases	O
.	O


The	O
major	O
trial	O
end	O
points	O
include	O
death	B-OUT
,	I-OUT
new	I-OUT
myocardial	I-OUT
infarction	I-OUT
,	I-OUT
and	I-OUT
new	I-OUT
coronary	I-OUT
angioplasty	I-OUT
or	I-OUT
coronary	I-OUT
artery	I-OUT
bypass	I-OUT
procedures	I-OUT
.	I-OUT


Removal	B-I
of	I-I
hypertrophied	I-I
anal	I-I
papillae	I-I
and	I-I
fibrous	I-I
anal	I-I
polyps	I-I
increases	O
patient	B-OUT
satisfaction	I-OUT
after	I-P
anal	I-P
fissure	I-P
surgery	I-P
.	I-P


Radiofrequency	B-I
procedure	I-I
is	O
useful	O
in	O
eradication	O
of	O
these	O
concomitant	O
pathologies	O
.	O


On	O
the	O
search	O
for	O
the	O
neurophysiological	B-P
manifestation	I-P
of	I-P
recollective	I-P
experience	I-P
.	I-P


M.E	B-P
.	I-P


These	O
analyses	O
do	O
not	O
support	O
the	O
hypothesis	O
that	O
there	O
is	O
a	O
new	O
component	O
(	O
the	O
"	B-OUT
memory-evoked	I-OUT
shift	I-OUT
"	I-OUT
)	I-OUT
that	O
is	O
a	O
specific	O
manifestation	O
of	O
recollection	O
.	O


As	O
seen	O
from	O
the	O
parents	O
'	O
logs	O
,	O
the	O
median	B-OUT
time	I-OUT
needed	I-OUT
by	I-OUT
the	I-OUT
children	I-OUT
to	I-OUT
fall	I-OUT
asleep	I-OUT
decreased	O
from	O
15	O
minutes	O
(	O
range	O
15	O
to	O
60	O
minutes	O
)	O
to	O
10	O
minutes	O
(	O
range	O
10	O
to	O
15	O
minutes	O
,	O
P	O
=	O
.001	O
)	O
.	O


The	O
number	B-OUT
of	I-OUT
complete	I-OUT
arousals	I-OUT
decreased	O
from	O
5	O
(	O
range	O
1	O
to	O
12	O
)	O
to	O
less	O
than	O
1	O
per	O
night	O
(	O
range	O
0	O
to	O
2	O
)	O
(	O
P	O
=	O
.001	O
)	O
.	O


Total	B-OUT
sleep	I-OUT
time	I-OUT
per	I-OUT
24	I-OUT
hours	I-OUT
increased	O
from	O
5.5	O
hours	O
(	O
range	O
3	O
to	O
8.5	O
hours	O
)	O
to	O
13.0	O
hours	O
(	O
range	O
10	O
to	O
14.5	O
hours	O
,	O
P	O
=	O
.001	O
)	O
.	O


Three-quarters	O
(	O
n	O
=	O
737	O
)	O
were	O
inadequately	O
treated	O
,	O
with	O
blood	B-OUT
pressure	I-OUT
levels	I-OUT
at	O
or	O
above	O
140	O
or	O
90	O
mmHg	O
.	O


Clinician	B-OUT
rating	I-OUT
of	O
severity	O
of	O
the	O
sleep	O
disorder	O
and	O
improvement	O
from	O
baseline	O
,	O
along	O
with	O
caregiver	B-OUT
ratings	I-OUT
of	O
global	O
functioning	O
and	O
family	O
stress	O
were	O
also	O
obtained	O
.	O


Overall	O
,	O
the	O
therapy	O
improved	B-OUT
the	I-OUT
sleep	I-OUT
of	O
47	O
children	O
and	O
was	O
effective	B-OUT
in	I-OUT
reducing	I-OUT
family	I-OUT
stress	I-OUT
.	I-OUT


Basal	B-I
L-arginine	I-I
group	O
=	O
38.75	O
±	O
11.52	O
,	O
final	O
23.32	O
±	O
6.08	O
,	O
p	O
=	O
0.007	O
and	O
basal	B-I
citrulline	I-I
group	O
=	O
41.4	O
±	O
13.47	O
,	O
final	O
23.65	O
±	O
6.74	O
,	O
p	O
=	O
0.007	O
at	O
60-90	O
s.	O
Post-ischemia	B-I
:	I-I
basal	I-I
L-arginine	I-I
36.60	O
±	O
11.51	O
,	O
final	O
18.81	O
±	O
15.13	O
,	O
p	O
=	O
0.004	O
and	B-I
basal	I-I
citrulline	I-I
=	O
49.51	O
±	O
15.17	O
,	O
final	O
27.13	O
±	O
7.87	O
,	O
p	O
=	O
0.003	O
.	O


Levamisole	B-I
versus	I-I
placebo	I-I
as	O
an	O
adjunct	O
to	O
primary	O
therapy	O
of	O
laryngopharyngeal	B-P
epidermoid	I-P
carcinoma	I-P
.	I-P


Randomized	O
prospective	O
study	O
to	O
evaluate	O
child	B-P
abuse	I-OUT
documentation	I-P
in	I-P
the	I-P
emergency	I-P
department	I-P
.	I-P


Hospital	O
and	O
demographic	O
characteristics	O
were	O
similar	O
across	O
intervention	O
groups	O
.	O


OBJECTIVE	O
To	O
evaluate	O
the	O
sensitivity	B-OUT
,	I-OUT
specificity	I-OUT
,	I-OUT
and	I-OUT
acceptability	I-OUT
of	O
TNE	B-I
in	O
diagnosing	O
BE	O
compared	O
with	O
those	O
of	O
SE	B-I
.	I-I


INTERVENTION	O
All	O
patients	O
underwent	O
TNE	B-I
followed	O
by	O
SE	B-I
or	O
the	O
reverse	O
.	O


These	O
include	O
infant	O
illness	O
and	O
maternal	O
responsibilities	O
outside	O
the	O
home	O
,	O
both	O
requiring	O
separation	O
from	O
the	O
mother	O
.	O


To	O
understand	O
better	O
the	O
ability	O
of	O
these	O
pumps	O
to	O
assist	O
women	O
in	O
the	O
maintenance	O
of	O
lactation	O
,	O
the	O
current	O
study	O
was	O
undertaken	O
to	O
evaluate	O
their	O
effects	O
on	O
milk	B-OUT
yield	I-OUT
and	I-OUT
prolactin	I-OUT
and	I-OUT
oxytocin	I-OUT
release	I-OUT
when	O
compared	O
to	O
natural	O
infant	O
suckling	O
.	O


MATERIAL	O
AND	O
METHODS	O
This	O
was	O
a	O
double-blind	O
randomized	O
controlled	O
trial	O
conducted	O
in	O
a	O
tertiary	O
care	O
hospital	O
.	O


A	B-P
total	I-P
of	I-P
174	I-P
patients	I-P
were	I-P
included	I-P
in	I-P
the	I-P
economic	I-P
evaluation	I-P
.	I-P


The	O
incremental	B-OUT
cost-effectiveness	I-OUT
ratio	I-OUT
[	O
95	O
%	O
CI	O
]	O
amounts	O
to	O
minus	O
<	O
euro	O
>	O
78,741.66	O
[	O
-154,987.20	O
;	O
110,486.32	O
]	O
for	O
an	O
additional	O
unit	O
of	O
effect	O
.	O


Given	O
the	O
acceptability	B-OUT
curve	I-OUT
,	O
there	O
is	O
a	O
92.4	O
%	O
chance	O
that	O
the	O
CBT	B-I
,	O
compared	O
with	O
the	O
SET	B-I
,	O
is	O
cost-effective	B-OUT
without	O
the	O
need	O
of	O
additional	O
costs	O
to	O
payers	O
.	O


Serum	B-OUT
vitamin	I-OUT
A	I-OUT
and	I-OUT
25-hydroxyvitamin	I-OUT
D	I-OUT
levels	I-OUT
were	O
not	O
affected	O
.	O


It	O
may	O
be	O
a	O
useful	O
dietary	O
adjunct	O
to	O
lower	O
cholesterol	O
.	O


Although	O
the	O
number	O
of	O
patients	O
studied	O
at	O
our	O
institution	O
was	O
small	O
,	O
administration	O
of	O
1	O
liter	O
intraperitoneally	O
provided	O
consistent	O
IDI	B-OUT
results	O
.	O


The	O
median	O
time	O
to	O
first	O
SRE	B-OUT
was	O
not	O
reached	O
in	O
the	O
intent-to-treat	O
population	O
.	O


CONCLUSIONS	O
Breast	B-P
cancer	I-P
patients	I-P
with	I-P
newly	I-P
diagnosed	I-P
bone	I-P
metastases	I-P
who	O
were	O
treated	O
with	O
zoledronic	B-I
acid	I-I
had	O
a	O
low	O
incidence	O
of	O
SREs	B-OUT
compared	O
with	O
patients	O
who	O
received	O
placebo	B-I
in	O
randomized	O
phase	O
III	O
trials	O
,	O
and	O
pain	O
was	O
decreased	O
from	O
baseline	O
.	O


Thirty-four	B-P
healthy	I-P
young	I-P
women	I-P
were	O
allocated	B-I
to	I-I
12	I-I
consecutive	I-I
cycles	I-I
of	I-I
treatment	I-I
with	I-I
monophasic	I-I
combinations	I-I
of	I-I
:	I-I
20	I-I
micrograms	I-I
ethinyl	I-I
estradiol	I-I
and	I-I
150	I-I
micrograms	I-I
desogestrel	I-I
(	I-I
n	I-I
=	I-I
15	I-I
)	I-I
or	I-I
30	I-I
micrograms	I-I
ethinyl	I-I
estradiol	I-I
and	I-I
75	I-I
micrograms	I-I
gestodene	I-I
(	I-I
n	I-I
=	I-I
19	I-I
)	I-I
.	O


In	O
both	O
groups	O
plasma	B-OUT
levels	I-OUT
of	I-OUT
fibrinogen	I-OUT
and	I-OUT
factor	I-OUT
VII	I-OUT
increased	O
while	O
the	O
capacity	O
of	O
coagulation	O
inhibition	O
was	O
affected	O
by	O
increased	B-OUT
protein	I-OUT
C	I-OUT
and	I-OUT
decreased	I-OUT
protein	I-OUT
S	I-OUT
levels	I-OUT
.	I-OUT


In	O
conclusion	O
,	O
the	O
dynamic	O
balance	O
between	O
generation	O
and	O
resolution	O
of	O
fibrin	O
was	O
undisturbed	O
during	O
treatment	O
with	O
both	O
hormonal	O
compounds	O
and	O
our	O
findings	O
do	O
not	O
provide	O
evidence	O
for	O
increased	O
risk	O
of	O
thrombosis	O
in	O
normal	B-P
women	I-P
.	I-P


BACKGROUND	O
First-generation	O
drug-eluting	O
stents	O
have	O
reduced	O
angiographic	O
and	O
clinical	O
restenosis	O
,	O
but	O
long-term	O
safety	O
remains	O
controversial	O
.	O


The	O
CSF	B-OUT
concentrations	I-OUT
of	I-OUT
neopterin	I-OUT
decreased	O
by	O
63	O
%	O
(	O
from	O
29.6	O
to	O
12.9	O
nmol/l	O
,	O
p	O
<	O
0.01	O
)	O
during	O
zidovudine	B-I
but	O
increased	O
by	O
15	O
%	O
(	O
from	O
22.6	O
to	O
25.9	O
nmol/l	O
,	O
not	O
significant	O
during	O
didanosine	B-I
treatment	O
.	O


These	O
are	O
among	O
the	O
first	O
randomized	O
controlled	O
data	O
to	O
suggest	O
that	O
short-term	B-I
parent-mediated	I-I
interventions	I-I
can	O
have	O
important	O
effects	O
on	O
core	O
impairments	O
in	O
toddlers	B-P
with	I-P
autism	I-P
.	I-P


A	O
sensory	B-I
integration	I-I
therapy	I-I
program	I-I
on	O
sensory	B-P
problems	I-P
for	I-P
children	I-P
with	I-P
autism	I-P
.	I-P


This	O
study	O
was	O
conducted	O
at	O
the	O
Trakya	B-P
University	I-P
Training	I-P
and	I-P
Research	I-P
Center	I-P
for	I-P
Mentally	I-P
and	I-P
Physically	I-P
Handicapped	I-P
Children	I-P
in	I-P
Turkey	I-P
.	I-P


OBJECTIVES	O
We	O
explored	O
whether	O
a	O
successful	O
randomized	O
controlled	O
trial	O
of	O
early	B-I
education	I-I
,	O
the	O
Carolina	O
Abecedarian	O
Project	O
(	O
ABC	O
)	O
,	O
which	O
enrolled	B-P
infants	I-P
from	I-P
1972	I-P
to	I-P
1977	I-P
at	I-P
the	I-P
Frank	I-P
Porter	I-P
Graham	I-P
Child	I-P
Development	I-P
Institute	I-P
in	I-P
Chapel	I-P
Hill	I-P
,	I-P
North	I-P
Carolina	I-P
,	O
improved	O
health	O
outcomes	O
and	O
behaviors	O
by	O
21	O
years	O
of	O
age	O
.	O


We	O
examined	O
the	O
effect	O
of	O
ABC	O
on	O
health	O
outcomes	O
and	O
behavioral	O
risk	O
factors	O
when	B-P
participants	I-P
were	I-P
aged	I-P
21	I-P
years	I-P
,	O
and	O
then	O
explored	O
the	O
mediators	O
of	O
this	O
relationship	O
.	O


These	O
improvements	O
in	O
behaviors	O
were	O
not	O
mediated	O
by	O
IQ	B-OUT
,	I-OUT
math	I-OUT
and	I-OUT
reading	I-OUT
scores	I-OUT
at	O
15	O
years	O
of	O
age	O
,	O
educational	B-OUT
attainment	I-OUT
,	I-OUT
or	I-OUT
health	I-OUT
insurance	I-OUT
.	I-OUT


Purpose	O
of	O
our	O
present	O
prospective	O
study	O
was	O
to	O
evaluate	O
the	O
dose	B-OUT
response	I-OUT
relationship	O
of	O
paclitaxel	O
.	O


The	O
one-year	B-OUT
survival	I-OUT
was	O
37	O
%	O
for	O
group	O
A	O
and	O
44	O
%	O
for	O
group	O
B	O
(	O
P	O
=	O
0.35	O
)	O
.	O


CONCLUSIONS	O
Higher	O
dose	O
paclitaxel	B-I
prolongs	O
the	O
median	O
time	O
to	O
progression	O
but	O
causes	O
more	O
neurotoxicity	O
and	O
leucopenia	O
.	O


Twenty	B-P
nine	I-P
stable	I-P
renal	I-P
transplant	I-P
recipients	I-P
,	I-P
10	I-P
receiving	I-P
cyclosporin	I-I
,	I-I
10	I-I
cyclosporin-prednisolone	I-I
and	I-I
nine	I-I
azathioprine-prednisolone	I-I
were	O
supplemented	O
in	O
a	O
double	O
blind	O
randomization	O
cross-over	O
study	O
with	O
fish	B-I
oil	I-I
and	O
corn	B-I
oil	I-I
for	O
a	O
period	O
of	O
4	O
months	O
each	O
.	O


An	O
increased	O
erythrocyte	O
membrane	O
polyunsaturated	O
fatty	O
acid	O
content	O
might	O
correct	O
the	O
lower	O
erythrocyte	O
deformability	O
in	O
cyclosporin	B-I
treated	O
patients	O
.	O


Effect	O
of	O
n-3	B-I
polyunsaturated	I-I
fatty	I-I
acid	I-I
intake	I-I
on	O
phospholipid	O
fatty	O
acid	O
composition	O
in	O
plasma	O
and	O
erythrocytes	O
.	O


During	O
n-3	B-I
PUFA	I-I
supplementation	I-I
,	O
accumulations	O
of	O
eicosapentaenoic	B-OUT
(	I-OUT
EPA	I-OUT
)	I-OUT
,	I-OUT
docosapentaenoic	I-OUT
(	I-OUT
DPA	I-OUT
)	I-OUT
,	I-OUT
and	I-OUT
docosahexaenoic	I-OUT
(	I-OUT
DHA	I-OUT
)	I-OUT
acids	I-OUT
were	O
marked	O
after	O
2	O
mo	O
with	O
differences	O
among	O
different	O
fractions	O
of	O
plasma	O
and	O
RBCs	O
in	O
further	O
accumulation	O
up	O
to	O
4	O
mo	O
.	O


These	O
data	O
confirm	O
the	O
complex	O
relations	O
among	O
different	B-OUT
fatty	I-OUT
acid	I-OUT
pools	I-OUT
after	O
n-3	B-I
PUFA	I-I
supplementation	I-I
.	I-I


RESULTS	O
For	O
transepidermal	B-OUT
water	I-OUT
loss	I-OUT
,	O
there	O
was	O
a	O
difference	O
of	O
2.3	O
gr/m2/h	O
between	O
MEBO	B-I
,	O
and	O
Flammazine	B-I
,	O
favoring	O
MEBO	B-I
.	I-I


For	O
all	O
secondary	B-OUT
efficacy	I-OUT
parameter	O
results	O
were	O
similar	O
.	O


51	O
%	O
of	O
all	O
carcinomas	O
detected	O
at	O
the	O
first	O
screening	O
were	O
either	O
in	O
situ	O
or	O
invasive	O
with	O
a	O
diameter	O
of	O
10	O
mm	O
or	O
less	O
.	O


INTRODUCTION	O
Atrial	O
defibrillation	O
can	O
be	O
achieved	O
with	O
standard	O
implantable	O
cardioverter	O
defibrillator	O
leads	O
,	O
which	O
has	O
led	O
to	O
the	O
development	O
of	O
combined	O
atrial	O
and	O
ventricular	O
devices	O
.	O


Delivered	B-OUT
energy	I-OUT
at	I-OUT
DFT	I-OUT
was	O
4.2	O
+/-	O
4.1	O
J	O
in	O
the	O
lead	O
configuration	O
and	O
5.0	O
+/-	O
3.7	O
J	O
in	O
the	O
active	B-I
can	I-I
configuration	O
(	O
P	O
=	O
NS	O
)	O
.	O


Peak	B-OUT
current	I-OUT
was	O
32	O
%	O
higher	O
with	O
an	O
active	B-I
can	I-I
(	O
P	O
<	O
0.01	O
)	O
,	O
whereas	O
shock	B-OUT
impedance	I-OUT
was	O
18	O
%	O
lower	O
(	O
P	O
<	O
0.001	O
)	O
.	O


IV	O
.	O


Effects	O
on	O
tyrosine	B-OUT
and	O
phenylalanine	B-OUT
in	I-OUT
plasma	I-OUT
and	I-OUT
urine	I-OUT
.	I-OUT


Plasma	B-OUT
and	I-OUT
urine	I-OUT
concentrations	I-OUT
of	I-OUT
tyrosine	I-OUT
and	I-OUT
phenylalanine	I-OUT
were	O
far	O
higher	B-OUT
in	O
the	O
infants	O
fed	O
F1	O
to	O
F4	O
,	O
especially	O
F2	O
and	O
F4	O
,	O
than	O
in	O
the	O
infants	O
fed	O
BM	O
.	O


Thus	O
,	O
increased	B-OUT
plasma	I-OUT
tyrosine	I-OUT
concentrations	I-OUT
in	O
low-birth-weight	O
infants	O
are	O
related	O
directly	O
both	O
to	O
the	O
quantity	O
and	O
to	O
the	O
quality	O
of	O
the	O
protein	O
in	O
their	O
diets	O
.	O


Impact	O
of	O
vitamin	B-I
D	I-I
supplementation	I-I
on	O
inflammatory	B-OUT
markers	I-OUT
in	O
African	B-P
Americans	I-P
:	I-P
results	O
of	O
a	O
four-arm	O
,	O
randomized	O
,	O
placebo-controlled	O
trial	O
.	O


Of	O
85	B-P
patients	I-P
having	I-P
a	I-P
positive	I-P
culture	I-P
after	I-P
completing	I-P
treatment	I-P
,	O
6	O
(	O
7.1	O
%	O
)	O
were	O
classified	O
as	O
false-positive	O
cultures	O
by	O
a	O
review	O
committee	O
blinded	O
to	O
treatment	O
assignment	O
.	O


Five	O
children	B-P
did	O
not	O
meet	O
learning	O
criteria	O
(	O
low	O
responders	O
)	O
.	O


In	O
Africa	O
,	O
an	O
estimated	O
230	O
million	O
people	O
require	O
preventive	O
chemotherapy	O
.	O


In	O
western	O
Côte	O
d'Ivoire	O
,	O
infections	O
with	O
Schistosoma	O
mansoni	O
are	O
widespread	O
.	O


METHODS/DESIGN	O
We	O
report	O
the	O
study	O
protocol	O
,	O
including	O
ethics	O
statement	O
and	O
insight	O
from	O
a	O
large-scale	O
eligibility	O
survey	O
carried	O
out	O
in	B-P
four	I-P
provinces	I-P
in	I-P
western	I-P
Côte	I-P
d'Ivoire	I-P
.	O


In	B-P
each	I-P
school	I-P
,	I-P
three	I-P
stool	I-P
samples	I-P
are	I-P
being	I-P
collected	I-P
from	I-P
100	I-P
children	I-P
aged	I-P
9-12	I-P
years	I-P
annually	I-P
and	I-P
one	I-P
stool	I-P
sample	I-P
from	I-P
100	I-P
first-year	I-P
students	I-P
at	I-P
baseline	I-P
and	I-P
in	I-P
the	I-P
final	I-P
year	I-P
and	I-P
subjected	I-P
to	I-P
duplicate	I-P
Kato-Katz	I-P
thick	I-P
smears	I-P
.	O


DESIGN	O
We	O
studied	O
the	O
effects	O
of	O
9	O
months	O
of	O
GH	B-I
treatment	I-I
on	O
11betaHSD	O
activity	O
and	O
its	O
relationship	O
with	O
body	B-OUT
composition	I-OUT
and	I-OUT
insulin	I-OUT
sensitivity	I-OUT
in	O
30	B-P
men	I-P
with	I-P
abdominal	I-P
obesity	I-P
,	I-P
aged	I-P
48-66	I-P
years	I-P
,	O
in	O
a	O
randomised	O
,	O
double-blind	O
,	O
placebo-controlled	B-I
trial	O
.	O


METHODS	O
Urinary	B-I
steroid	I-I
profile	I-I
was	I-I
used	I-I
to	I-I
estimate	I-I
11betaHSD	I-OUT
type	I-OUT
1	I-OUT
and	I-OUT
2	I-OUT
(	I-OUT
11betaHSD1	I-OUT
and	I-OUT
11betaHSD2	I-OUT
)	I-OUT
activities	I-OUT
.	I-OUT


Glucose	B-OUT
disposal	I-OUT
rate	I-OUT
(	I-OUT
GDR	I-OUT
)	I-OUT
obtained	I-I
during	I-I
a	I-I
euglycaemic-hyperinsulinaemic	I-I
glucose	I-I
clamp	I-I
was	I-I
used	I-I
to	I-I
assess	I-I
insulin	I-OUT
sensitivity	I-OUT
.	I-OUT


Changes	O
in	O
11betaHSD1	B-OUT
correlated	O
with	O
changes	O
in	O
visceral	B-OUT
fat	I-OUT
mass	I-OUT
between	O
baseline	O
and	O
6	O
weeks	O
.	O


Coenzyme	B-I
Q10	I-I
and	O
exercise	O
training	O
in	O
chronic	B-P
heart	I-P
failure	I-P
.	I-P


AIMS	O
There	O
is	O
evidence	O
that	O
plasma	O
coenzyme	B-OUT
Q	I-OUT
(	I-OUT
10	I-OUT
)	I-OUT
(	I-OUT
CoQ	I-OUT
(	I-OUT
10	I-OUT
)	I-OUT
)	I-OUT
levels	I-OUT
decrease	O
in	O
patients	B-P
with	I-P
advanced	I-P
chronic	I-P
heart	I-P
failure	I-P
(	I-P
CHF	I-P
)	I-P
.	I-P


METHODS	O
Eighteen	B-P
HTs	I-P
aged	I-P
65.7	I-P
±	I-P
9.2	I-P
years	I-P
with	I-P
angiographically	I-P
diagnosed	I-P
unilateral	I-P
RAS	I-P
(	I-P
≥	I-P
60	I-P
%	I-P
)	I-P
were	O
randomized	O
to	O
receive	O
PR-STENT	O
(	O
N=9	O
)	O
or	O
to	B-I
NO-STENT	I-I
(	O
N=9	O
)	O
.	O


RESULTS	B-OUT
Baseline	I-OUT
systolic	I-OUT
BP	I-OUT
and	I-OUT
GFR	I-OUT
values	I-OUT
were	O
not	O
different	O
between	O
groups	O
.	O


The	O
significantly	O
greater	B-OUT
GFR	I-OUT
increase	I-OUT
observed	O
in	O
PR-STENT	O
than	O
in	O
NO-STENT	O
at	O
univariate	O
analysis	O
at	O
the	O
end	O
of	O
follow-up	O
(	O
62.5	O
±	O
19.2	O
vs.	O
42.24	O
±	O
17.6	O
,	O
P	O
<	O
0.02	O
)	O
disappeared	O
after	O
adjustment	O
for	O
confounding	O
factors	O
.	O


TEE	O
was	O
performed	O
for	O
peripheral	O
embolism	O
in	O
two	O
patients	O
,	O
stroke	O
or	O
transient	O
ischemic	O
attack	O
in	O
six	O
,	O
stroke	O
and	O
fever	O
in	O
two	O
,	O
fever	O
in	O
one	O
patient	O
,	O
as	O
a	O
routine	O
postoperative	O
examination	O
in	O
two	O
patients	O
,	O
and	O
for	O
other	O
reasons	O
in	O
seven	O
.	O


Treatment	O
was	O
monitored	O
using	O
TEE	O
.	O


RESULTS	O
There	O
was	O
no	O
difference	O
between	O
patient	O
groups	O
with	O
regard	O
to	O
sex	O
,	O
age	O
,	O
type	O
of	O
prosthesis	O
and	O
time	O
since	O
operation	O
,	O
though	O
anticoagulant	O
status	O
was	O
more	O
often	O
inadequate	O
in	O
group	O
II	O
.	O


CONCLUSIONS	O
Non-obstructive	O
PVT	O
may	O
be	O
asymptomatic	O
in	O
one-third	O
of	O
patients	O
.	O


The	O
study	O
population	O
consists	O
of	O
volunteers	B-P
from	I-P
1100	I-P
eligible	I-P
employees	I-P
of	I-P
a	I-P
Finnish	I-P
insurance	I-P
company	I-P
.	I-P


The	O
primary	O
outcomes	O
of	O
this	O
study	O
are	O
change	B-OUT
in	I-OUT
physical	I-OUT
activity	I-OUT
measured	I-OUT
in	I-OUT
MET	I-OUT
minutes	I-OUT
per	I-OUT
week	I-OUT
,	I-OUT
work	I-OUT
productivity	I-OUT
and	I-OUT
sickness	I-OUT
absence	I-OUT
,	I-OUT
and	I-OUT
healthcare	I-OUT
utilisation	I-OUT
.	I-OUT


CONCLUSIONS	O
Increases	O
in	O
enjoyment	O
partially	O
mediated	O
the	O
positive	O
effect	O
of	O
the	O
LEAP	B-I
intervention	I-I
.	I-I


The	O
results	O
of	O
the	O
releasing	O
factor	O
combined	O
test	O
with	O
arginine	O
vasopressin	O
were	O
compared	O
in	O
the	O
same	O
subjects	O
with	O
a	O
conventional	O
combined	O
test	O
using	O
insulin	O
together	O
with	O
thyrotrophin	O
releasing	O
hormone	O
and	O
luteinising	O
hormone	O
releasing	O
hormone	O
.	O


This	O
new	O
combined	O
releasing	O
factor	O
test	O
appears	O
to	O
be	O
a	O
safe	O
,	O
rapid	O
,	O
and	O
useful	O
test	O
of	O
anterior	O
pituitary	O
function	O
.	O


Measuring	O
the	O
plasticity	O
of	O
social	O
approach	O
:	O
a	O
randomized	O
controlled	O
trial	O
of	O
the	O
effects	O
of	O
the	O
PEERS	B-I
intervention	I-I
on	O
EEG	B-I
asymmetry	I-I
in	O
adolescents	B-P
with	I-P
autism	I-P
spectrum	I-P
disorders	I-P
.	I-P


Adolescents	B-P
with	I-P
ASD	I-P
in	I-P
PEERS	I-I
no	O
longer	O
differed	O
from	O
typically	O
developing	O
adolescents	O
in	O
left-dominant	B-OUT
EEG	I-OUT
asymmetry	I-OUT
at	O
post-test	O
.	O


Epidural	B-I
injections	I-I
are	O
one	O
of	O
the	O
commonly	O
performed	O
nonsurgical	O
interventions	O
in	O
managing	O
central	O
spinal	O
stenosis	O
;	O
however	O
,	O
there	O
has	O
been	O
paucity	O
of	O
literature	O
in	O
reference	O
to	O
efficacy	O
of	O
epidural	B-I
injections	I-I
in	O
managing	O
central	O
spinal	O
stenosis	O
with	O
lumbar	B-I
interlaminar	I-I
epidural	I-I
injections	I-I
.	I-I


OBJECTIVE	O
To	O
assess	O
the	O
effectiveness	O
of	O
lumbar	B-I
interlaminar	I-I
epidural	I-I
injections	I-I
with	I-I
or	I-I
without	I-I
steroids	I-I
in	O
providing	O
effective	O
and	O
long-lasting	O
pain	O
relief	O
with	O
improvement	O
in	O
functional	O
status	O
for	O
the	O
management	O
of	O
chronic	O
low	O
back	O
and	O
lower	O
extremity	O
pain	O
related	O
to	O
lumbar	O
central	O
spinal	O
stenosis	O
.	O


OUTCOMES	O
ASSESSMENT	O
Outcomes	O
were	O
assessed	O
utilizing	O
the	O
numeric	B-OUT
pain	I-OUT
rating	I-OUT
scale	I-OUT
(	I-OUT
NRS	I-OUT
)	I-OUT
and	I-OUT
Oswestry	I-OUT
Disability	I-OUT
Index	I-OUT
(	I-OUT
ODI	I-OUT
)	I-OUT
at	O
3	O
,	O
6	O
,	O
12	O
,	O
18	O
,	O
and	O
24	O
months	O
post	O
treatment	O
.	O


LIMITATIONS	O
Limitations	O
of	O
this	O
trial	O
include	O
lack	O
of	O
placebo	O
control	O
group	O
and	O
treatment	O
of	O
patients	O
with	O
multiple	O
procedures	O
over	O
a	O
period	O
of	O
2	O
years	O
.	O


METHODS	O
From	O
January	B-P
2002	I-P
to	I-P
May	I-P
2008	I-P
,	I-P
168	I-P
patients	I-P
with	I-P
cervical	I-P
vertigo	I-P
were	I-P
randomly	I-P
divided	I-P
into	I-P
treatment	I-P
group	I-P
(	I-P
84	I-P
cases	I-P
)	I-P
and	I-P
the	I-P
control	I-P
group	I-P
(	I-P
84	I-P
cases	I-P
)	I-P
,	I-P
22	I-P
males	I-P
and	I-P
62	I-P
females	I-P
in	I-P
treatment	I-P
group	I-P
;	I-P
24	I-P
males	I-P
and	I-P
60	I-P
females	I-P
in	I-P
control	I-P
group	I-P
.	I-P


The	O
incidence	O
of	O
the	O
disease	O
is	O
rising	O
rapidly	O
in	O
many	O
countries	O
,	O
and	O
there	O
is	O
no	O
generally	O
accepted	O
standard	O
treatment	O
for	O
patients	B-P
with	I-P
unresectable	I-P
disease	I-P
.	I-P


Although	O
many	O
nonrandomized	O
studies	O
have	O
reported	O
tumor	O
responses	O
to	O
anticancer	O
chemotherapy	O
,	O
few	O
have	O
studied	O
palliation	O
and	O
it	O
is	O
not	O
known	O
whether	O
chemotherapy	O
prolongs	O
survival	O
or	O
provides	O
clinically	O
worthwhile	O
palliation	O
with	O
acceptable	O
toxicity	O
when	O
given	O
in	O
addition	O
to	O
ASC	O
.	O


Dose	O
regimen	O
was	O
400	O
mg	O
twice	O
daily	O
from	O
weeks	O
0	O
to	O
eight	O
,	O
increasing	O
to	O
400	O
mg	O
three	O
times	O
a	O
day	O
from	O
weeks	O
nine	O
to	O
24	O
provided	O
that	O
no	O
adverse	O
effects	O
were	O
recorded	O
.	O


For	O
those	O
patients	O
attaining	O
12	O
weeks	O
of	O
treatment	O
an	O
overall	B-OUT
improvement	I-OUT
in	I-OUT
articular	I-OUT
index	I-OUT
and	I-OUT
morning	I-OUT
stiffness	I-OUT
was	O
found	O
.	O


BACKGROUND	O
Smoking	O
is	O
associated	O
with	O
endothelial	O
dysfunction	O
.	O


RESULTS	O
At	O
week	O
24	O
,	O
both	O
donepezil	B-I
groups	O
showed	O
significant	O
improvement	B-OUT
in	I-OUT
cognition	I-OUT
versus	O
placebo	B-I
on	O
the	O
Alzheimer	B-OUT
's	I-OUT
Disease	I-OUT
Assessment	I-OUT
Scale-cognitive	I-OUT
subscale	I-OUT
(	O
mean	O
change	O
from	O
baseline	O
score	O
effect	O
size	O
:	O
donepezil	B-I
5	O
mg/d	O
,	O
-1.90	O
;	O
P=0.001	O
;	O
donepezil	B-I
10	O
mg/d	O
,	O
-2.33	O
;	O
P	O
<	O
0.001	O
)	O
.	O


MATERIAL	O
AND	O
METHODS	O
Two	B-P
hundred	I-P
and	I-P
two	I-P
patients	I-P
were	O
randomized	O
to	O
either	O
the	O
surgical	O
approach	O
(	B-I
total	I-I
laryngectomy	I-I
with	I-I
partial	I-I
pharyngectomy	I-I
and	I-I
neck	I-I
dissection	I-I
,	I-I
followed	I-I
by	I-I
irradiation	I-I
)	I-I
or	I-I
to	I-I
the	I-I
chemotherapy	I-I
arm	I-I
up	I-I
to	I-I
three	I-I
cycles	I-I
of	I-I
induction	I-I
chemotherapy	I-I
(	I-I
cisplatin	I-I
100	O
mg/m	O
(	O
2	O
)	O
day	O
1	O
+	O
5-FU	O
1000	O
mg/m	O
(	O
2	O
)	O
day	O
1-5	O
)	O
followed	O
for	O
complete	O
responders	O
by	O
irradiation	B-I
and	O
otherwise	O
by	O
conventional	B-I
treatment	I-I
.	I-I


CONCLUSION	O
This	O
strategy	O
did	O
not	O
compromise	B-OUT
disease	I-OUT
control	I-OUT
or	I-OUT
survival	I-OUT
(	O
that	O
remained	O
poor	O
)	O
and	O
allowed	O
more	O
than	O
half	O
of	O
the	O
survivors	O
to	O
retain	O
their	O
larynx	O
.	O


Group	O
LM	O
was	O
administered	O
19	O
ml	O
of	O
0.25	B-I
%	I-I
levobupivacaine	I-I
and	I-I
1	I-I
ml	I-I
of	I-I
15	I-I
%	I-I
magnesium	I-I
sulphate	I-I
,	O
while	O
Group	B-I
L	I-I
was	I-I
administered	I-I
20	I-I
ml	I-I
of	I-I
0.25	I-I
%	I-I
levobupivacaine	I-I
for	O
femoral	O
blockade	O
.	O


CONCLUSIONS	O
The	O
addition	O
of	O
magnesium	B-I
to	O
levobupivacaine	O
prolongs	O
the	O
sensory	O
and	O
motor	O
block	O
duration	O
without	O
increasing	O
side	O
effects	O
,	O
enhances	O
the	O
quality	O
of	O
postoperative	O
analgesia	O
and	O
increases	O
patient	O
satisfaction	O
;	O
however	O
,	O
the	O
addition	O
of	O
magnesium	O
delays	O
the	O
time	O
to	O
first	O
mobilisation	O
and	O
decreases	O
rescue	O
analgesic	O
requirements	O
.	O


This	O
article	O
describes	O
the	O
research	O
method	O
used	O
to	O
measure	O
the	O
impact	O
of	O
three	O
alternative	O
models	O
of	O
patient	B-I
counseling	I-I
in	O
the	O
outpatient	B-P
pharmacy	I-P
setting	I-P
.	I-P


The	O
relationship	O
of	O
changes	O
in	O
EORTC	O
QLQ-C30	O
scores	O
to	O
ratings	O
on	O
the	O
Subjective	B-OUT
Significance	I-OUT
Questionnaire	I-OUT
in	O
men	B-P
with	I-P
localized	I-P
prostate	I-P
cancer	I-P
.	I-P


Patients	O
rated	O
their	O
change	O
in	O
physical	B-OUT
functioning	I-OUT
,	I-OUT
emotional	I-OUT
functioning	I-OUT
,	I-OUT
social	I-OUT
functioning	I-OUT
,	I-OUT
and	I-OUT
overall/global	I-OUT
quality	I-OUT
of	I-OUT
life	I-OUT
(	I-OUT
QOL	I-OUT
)	I-OUT
by	I-OUT
completing	I-OUT
a	I-OUT
seven-category	I-OUT
SSQ	I-OUT
at	O
weeks	O
4	O
and	O
7	O
.	O


CONCLUSION	O
The	O
SSQ	B-I
and	O
QLQ-C30	B-I
may	O
measure	O
related	O
concepts	O
that	O
could	O
assist	O
in	O
the	O
interpretation	O
of	O
changes	O
in	O
scores	O
and	O
in	O
the	O
calibration	O
of	O
the	O
QLQ-C30	B-I
.	I-I


CONCLUSION	O
The	O
findings	O
of	O
this	O
present	O
study	O
suggest	O
that	O
there	O
were	O
more	O
satisfactory	O
clinical	B-OUT
outcomes	I-OUT
following	O
the	O
treatment	O
of	O
patients	B-P
with	I-P
ALI	I-P
when	O
NIPPV	O
was	O
delivered	O
using	O
a	O
complex	O
critical	O
care	O
ventilator	O
compared	O
with	O
a	O
conventional	O
mini-ventilator	O
.	O


The	O
results	O
showed	O
that	O
a	O
trend	O
in	O
favour	O
of	O
the	O
buflomedil	O
group	O
in	O
three	O
of	O
the	O
tests	O
became	O
statistically	O
significant	O
in	O
the	O
fourth	O
.	O


Both	O
drugs	O
appeared	O
to	O
be	O
safe	B-OUT
,	O
causing	O
no	O
marked	O
adverse	B-OUT
reactions	I-OUT
.	I-OUT


METHODS	O
Twenty	B-P
consecutive	I-P
patients	I-P
who	I-P
underwent	I-P
sigmoidectomy	I-I
for	I-P
sigmoid	I-P
colon	I-P
cancer	I-P
were	O
prospectively	O
randomized	O
into	O
two	O
groups	O
:	O
the	B-I
"	I-I
ligatures	I-I
group	I-I
"	I-I
,	I-I
in	I-I
which	I-I
bowel	I-I
ligatures	I-I
were	I-I
placed	I-I
,	I-I
3	I-I
,	I-I
5	I-I
,	I-I
10	I-I
cm	I-I
from	I-I
the	I-I
tumor	I-I
proximally	I-I
and	I-I
distally	I-I
before	I-I
dissection	I-I
;	I-I
and	I-I
the	I-I
"	I-I
no	I-I
ligatures	I-I
group	I-I
"	I-I
,	I-I
in	I-I
which	I-I
the	I-I
corresponding	I-I
sites	I-I
were	I-I
ligated	I-I
only	I-I
immediately	I-I
before	I-I
taking	I-I
the	I-I
specimen	I-I
out	I-I
.	I-I


OBJECTIVE	O
This	O
article	O
focuses	O
on	O
patients	O
'	O
clinical	O
and	O
psychosocial	O
experiences	O
with	O
CVC	B-I
self-care	I-I
compared	O
with	O
professionally	B-I
controlled	I-I
CVC	I-I
care	I-I
.	I-I


The	O
intervention	O
group	O
(	O
n	O
=	O
42	O
)	O
was	O
trained	O
to	O
perform	O
CVC	B-I
self-care	I-I
.	I-I


The	O
control	O
group	O
(	O
n	O
=	O
40	O
)	O
followed	O
standard	B-I
CVC	I-I
procedure	I-I
provided	I-I
by	I-I
nurses	I-I
.	I-I


Smokeless	B-I
tobacco	I-I
might	O
be	O
effective	O
as	O
an	O
adjunct	O
for	O
smoking	B-OUT
cessation	I-OUT
.	I-OUT


The	O
study	B-P
enrolled	I-P
263	I-P
healthy	I-P
smokers	I-P
(	I-P
M	I-P
(	I-P
age	I-P
)	I-P
=	I-P
49	I-P
years	I-P
)	I-P
who	I-P
smoked	I-P
a	I-P
mean	I-P
of	I-P
24	I-P
cigarettes/day	I-P
,	I-P
with	I-P
a	I-P
mean	I-P
of	I-P
31	I-P
pack-years	I-P
.	I-P


Smoking	B-OUT
cessation	I-OUT
rates	I-OUT
were	O
statistically	O
significantly	O
better	O
in	O
the	O
smokeless	O
tobacco	O
group	O
than	O
in	O
the	O
control	O
group	O
during	O
the	O
first	O
7	O
weeks	O
.	O


A	O
comparison	O
of	O
the	O
effects	O
of	O
anticholinergic	B-I
and	I-I
beta	I-I
2-agonist	I-I
and	I-I
combination	I-I
therapy	I-I
on	O
respiratory	O
impedance	O
in	O
COPD	B-P
.	I-P


On	O
three	O
trial	O
days	O
,	O
patients	O
inhaled	O
,	O
in	O
random	O
order	O
,	O
40	O
micrograms	O
ipratropium	B-I
bromide	I-I
,	O
200	O
micrograms	O
fenoterol	B-I
hydrobromide	I-I
,	O
or	O
a	B-I
combination	I-I
of	I-I
40	I-I
micrograms	I-I
ipratropium	I-I
and	I-I
100	I-I
micrograms	I-I
fenoterol	I-I
from	O
a	O
powder	O
inhaler	O
,	O
followed	O
by	O
a	O
second	O
dose	O
of	O
the	O
same	O
drug	O
after	O
60	O
min	O
.	O


A	B-OUT
second	I-OUT
dose	I-OUT
of	I-OUT
fenoterol	I-OUT
and	I-OUT
of	I-OUT
the	I-OUT
combination	I-OUT
regimen	I-OUT
resulted	I-OUT
in	I-OUT
a	I-OUT
further	I-OUT
significant	I-OUT
increase	I-OUT
in	I-OUT
FEV1	I-OUT
after	I-OUT
120	I-OUT
min	I-OUT
(	I-OUT
p	I-OUT
less	I-OUT
than	I-OUT
0.05	I-OUT
)	I-OUT
.	I-OUT


The	O
patients	O
were	O
assigned	O
at	O
random	O
to	O
one	O
of	O
the	O
following	O
treatments	O
:	O
1	O
)	O
Defibrotide	B-I
at	I-I
a	I-I
dose	I-I
of	I-I
400	I-I
mg	I-I
b.i.d	I-I
.	I-I


in	B-I
50	I-I
ml	I-I
phleboclysis	I-I
in	I-I
5	I-I
minutes	I-I
(	I-I
n	I-I
=	I-I
108	I-I
)	I-I
;	I-I
2	I-I
)	I-I
calcium	I-I
heparin	I-I
at	I-I
a	I-I
dose	I-I
of	I-I
5000	I-I
IU	I-I
t.i.d	I-I
.	I-I


subcutaneously	B-I
(	I-I
n	I-I
=	I-I
103	I-I
)	I-I
.	O


The	B-I
treatment	I-I
began	I-I
the	I-I
day	I-I
before	I-I
operation	I-I
and	I-I
continued	I-I
on	I-I
average	I-I
up	I-I
to	I-I
the	I-I
eighth	I-I
day	I-I
for	I-I
the	I-I
Defibrotide	I-I
group	I-I
.	I-I


Statistically	O
significant	O
(	O
p	O
less	O
than	O
0.01	O
)	O
was	O
the	O
difference	O
in	O
postoperative	B-OUT
bleeding	I-OUT
evaluated	I-OUT
with	O
particular	O
attention	O
in	O
patients	O
of	O
advanced	O
age	O
.	O


)	O
with	O
those	O
of	O
celecoxib	B-I
200	I-I
mg	I-I
o.d	I-I
.	I-I


Secondary	O
outcome	O
variables	O
included	O
OA	B-OUT
pain	I-OUT
in	I-OUT
the	I-OUT
target	I-OUT
joint	I-OUT
,	I-OUT
patient	I-OUT
's	I-OUT
and	I-OUT
physician	I-OUT
's	I-OUT
global	I-OUT
assessments	I-OUT
of	I-OUT
disease	I-OUT
activity	I-OUT
,	I-OUT
Short	I-OUT
Arthritis	I-OUT
assessment	I-OUT
Scale	I-OUT
(	I-OUT
SAS	I-OUT
)	I-OUT
total	I-OUT
score	I-OUT
,	I-OUT
rescue	I-OUT
medication	I-OUT
use	I-OUT
,	I-OUT
and	I-OUT
safety	I-OUT
and	I-OUT
tolerability	I-OUT
.	I-OUT


As	O
the	O
coefficient	O
of	O
variation	O
(	O
VC	O
)	O
of	O
measured	O
blood	B-OUT
glucose	I-OUT
continuously	O
increased	O
the	O
best	O
time	O
of	O
a	O
steady	O
state	O
was	O
between	O
90	O
and	O
130	O
min	O
after	O
beginning	O
the	O
infusion	O
(	O
mean	O
VC	O
8.9	O
%	O
)	O
.	O


A	O
comparison	O
of	O
dorsal	B-I
and	I-I
volar	I-I
resting	I-I
hand	I-I
splints	I-I
in	O
the	O
reduction	O
of	O
hypertonus	B-P
.	I-P


Ten	B-P
adults	I-P
with	I-P
hypertonic	I-P
wrist	I-P
flexors	I-P
volunteered	I-P
as	I-P
subjects	I-P
in	O
an	O
experiment	O
comparing	O
the	O
effectiveness	O
of	O
dorsal	B-I
and	I-I
volar	I-I
resting	I-I
hand	I-I
splints	I-I
in	O
the	O
reduction	O
of	O
abnormal	B-OUT
muscle	I-OUT
tone	I-OUT
.	I-OUT


Results	O
demonstrated	O
no	B-OUT
significant	I-OUT
differences	I-OUT
between	O
the	O
volar	B-I
and	I-I
dorsal	I-I
splints	I-I
in	O
reducing	O
hypertonus	B-OUT
.	I-OUT


Testing	O
three	O
different	O
cancer	O
genetics	O
registry	O
recruitment	O
methods	O
with	O
Hispanic	B-P
cancer	I-P
patients	I-P
and	I-P
their	I-P
family	I-P
members	I-P
previously	I-P
registered	I-P
in	I-P
local	I-P
cancer	I-P
registries	I-P
in	I-P
Texas	I-P
.	I-P


Nasotracheal	B-I
intubation	I-I
under	I-I
curve-tipped	I-I
suction	I-I
catheter	I-I
guidance	O
reduces	O
epistaxis	B-P
.	I-P


BACKGROUND	O
Nasotracheal	B-I
intubation	I-I
(	I-I
NTI	I-I
)	I-I
has	O
greater	O
potential	O
for	O
trauma	O
of	O
nasopharyngeal	O
mucosa	O
than	O
orotracheal	O
intubation	O
.	O


The	O
present	O
study	O
investigated	O
the	O
success	B-OUT
rate	I-OUT
of	O
NTI	O
and	O
frequency	O
of	O
nasal	O
bleeding	O
using	O
a	O
curve-tipped	B-I
suction	I-I
catheter	I-I
(	I-I
CTSC	I-I
)	I-I
to	I-I
guide	O
nasotracheal	O
tube	O
advancement	O
.	O


The	O
curved	O
tip	O
was	O
directed	O
ventrally	O
.	O


PATIENTS	O
AND	O
METHODS	O
Patients	B-P
were	I-P
younger	I-P
than	I-P
55	I-P
years	I-P
and	I-P
had	I-P
at	I-P
least	I-P
one	I-P
adverse	I-P
prognostic	I-P
factor	I-P
.	I-P


The	O
3-year	B-OUT
survival	I-OUT
rate	I-OUT
did	O
not	O
differ	O
between	O
sequential	O
chemotherapy	O
and	O
autotransplantation	O
,	O
at	O
71	O
%	O
(	O
95	O
%	O
confidence	O
interval	O
,	O
64	O
%	O
to	O
78	O
%	O
)	O
and	O
69	O
%	O
(	O
95	O
%	O
confidence	O
interval	O
,	O
62	O
%	O
to	O
76	O
%	O
)	O
,	O
respectively	O
(	O
P	O
=	O
.60	O
,	O
relative	O
risk	O
=	O
1.11	O
)	O
.	O


Clofarabine	B-I
±	I-I
fludarabine	I-I
with	O
once	O
daily	O
i.v	O
.	B-I


We	O
found	O
pronounced	O
synergy	O
between	O
each	O
nucleoside	O
and	O
the	O
alkylator	O
but	O
even	O
more	O
enhanced	O
cytotoxic	O
synergy	O
when	O
the	O
nucleoside	O
analogs	O
were	O
combined	O
prior	O
to	O
exposing	O
the	O
cells	O
to	O
Bu	O
.	O


Forty-two	B-P
patients	I-P
had	I-P
AML	I-P
:	I-P
14	I-P
were	I-P
induction	I-P
failures	I-P
,	I-P
8	I-P
in	I-P
first	I-P
chemotherapy-refractory	I-P
relapse	I-P
,	I-P
7	I-P
in	I-P
untreated	I-P
relapse	I-P
,	I-P
3	I-P
in	I-P
second	I-P
or	I-P
subsequent	I-P
relapse	I-P
,	I-P
4	I-P
were	I-P
in	I-P
second	I-P
complete	I-P
remission	I-P
(	I-P
CR	I-P
)	I-P
,	I-P
and	I-P
3	I-P
in	I-P
second	I-P
CR	I-P
without	I-P
platelet	I-P
recovery	I-P
(	I-P
CRp	I-P
)	I-P
,	I-P
2	I-P
were	I-P
in	I-P
high-risk	I-P
CR1	I-P
.	I-P


Twenty	O
of	O
the	O
42	O
AML	O
patients	O
and	O
5	O
of	O
9	O
CML	O
patients	O
are	O
alive	O
with	B-OUT
a	I-OUT
projected	I-OUT
median	I-OUT
overall	I-OUT
survival	I-OUT
(	O
OS	O
)	O
of	O
23	O
months	B-OUT
.	I-OUT


Marrow	B-OUT
and	I-OUT
blood	I-OUT
(	I-OUT
T	I-OUT
cell	I-OUT
)	I-OUT
chimerism	O
studies	O
at	O
day	O
+100	O
revealed	O
that	O
both	O
in	O
the	O
lower-dose	O
Clo	O
groups	O
(	O
groups	O
1+2	O
)	O
and	O
the	O
higher-dose	O
Clo	O
groups	O
(	O
groups	O
3+4	O
)	O
,	O
the	O
patients	O
had	B-OUT
a	I-OUT
median	I-OUT
of	I-OUT
100	I-OUT
%	I-OUT
donor	I-OUT
(	I-OUT
T	I-OUT
cell	I-OUT
)	I-OUT
-derived	I-OUT
DNA	O
.	O


In	O
the	O
first	O
100	O
days	O
,	O
1	O
patient	B-OUT
died	I-OUT
of	I-OUT
pneumonia	I-OUT
,	O
and	O
1	B-OUT
of	I-OUT
liver	I-OUT
GVHD	O
.	O


This	O
double-blind	O
and	O
placebo-controlled	B-I
clinical	O
trial	O
in	O
autistic	B-P
children	I-P
had	O
three	O
objectives	O
:	O
(	O
a	O
)	O
to	O
replicate	O
earlier	O
findings	O
that	O
haloperidol	B-I
administration	O
is	O
associated	O
with	O
a	O
significant	O
reduction	O
of	O
behavioral	B-OUT
symptoms	I-OUT
;	I-OUT
(	O
b	O
)	O
to	O
further	O
assess	O
its	O
safety	B-OUT
when	O
given	O
on	O
a	O
short-term	O
basis	O
;	O
and	O
(	O
c	O
)	O
to	O
assess	O
whether	O
it	O
has	O
an	O
effect	B-OUT
on	I-OUT
discrimination	I-OUT
learning	I-OUT
.	I-OUT


OBJECTIVE	O
To	O
compare	O
the	O
duration	B-OUT
of	O
spinal	O
block	O
with	O
5	B-I
%	I-I
prilocaine	I-I
and	I-I
2	I-I
%	I-I
mepivacaine	I-I
in	O
short	B-P
procedures	I-P
for	I-P
transurethral	I-P
resection	I-P
and	O
to	O
assess	B-OUT
possible	I-OUT
complications	I-OUT
in	O
the	O
immediate	O
postoperative	O
period	O
.	O


The	O
proportion	O
of	O
chronic	O
liver	O
disease	O
associated	O
with	O
the	O
pre-core	B-P
mutant	I-P
of	I-P
hepatitis	I-P
B	I-P
virus	I-P
(	I-P
HBV	I-P
)	I-P
infection	I-P
is	O
increasing	O
,	O
particularly	O
in	O
Mediterranean	B-P
Europe	I-P
and	I-P
in	I-P
Asia	I-P
.	I-P


Pre-core	O
mutant	O
chronic	O
hepatitis	O
B	O
infection	O
usually	O
proceeds	O
to	O
serious	O
liver	O
disease	O
.	O


The	O
efficacy	O
and	O
safety	O
of	O
tesaglitazar	B-I
(	O
0.5	O
and	O
1	O
mg	O
)	O
and	O
pioglitazone	B-I
(	O
15	O
,	O
30	O
and	O
45	O
mg	O
)	O
were	O
compared	O
in	O
a	O
24-week	O
,	O
randomised	O
,	O
double-blind	O
study	O
in	O
1,707	B-P
patients	I-P
with	I-P
type	I-P
2	I-P
diabetes	I-P
mellitus	I-P
.	I-P


A	O
randomised	O
controlled	O
comparison	O
between	O
stimulating	B-I
and	I-I
standard	I-I
catheters	I-I
for	O
lumbar	B-OUT
plexus	I-OUT
block	I-OUT
.	I-OUT


The	O
aim	O
of	O
this	O
randomised	O
,	O
prospective	O
,	O
blinded	O
study	O
was	O
to	O
evaluate	O
if	O
stimulating	B-I
catheters	I-I
can	O
decrease	O
the	O
minimum	B-OUT
effective	I-OUT
anaesthetic	I-OUT
volume	I-OUT
in	O
50	O
%	O
of	O
patients	B-P
during	I-P
lumbar	I-P
plexus	I-P
block	I-P
using	O
mepivacaine	B-I
1.5	O
%	O
compared	O
with	O
standard	B-I
catheters	I-I
.	I-I


Modest	O
clinical	O
benefits	O
were	O
achieved	O
with	O
both	O
PLC	B-I
and	O
NTX	B-I
,	O
with	O
marginally	O
better	O
overall	O
results	O
following	O
NTX	O
,	O
and	O
degree	O
of	O
improvement	O
appeared	O
to	O
be	O
related	O
to	O
plasma	O
chemical	O
profiles	O
.	O


Massively	O
elevated	O
levels	O
of	O
beta-endorphin	B-OUT
were	O
observed	O
in	O
all	O
children	B-P
with	O
assays	O
using	O
C-terminal	O
antibody	O
but	O
not	O
with	O
an	O
N-terminal	O
antibody	O
assay	O
.	O


The	O
best	O
clinical	O
responders	O
exhibited	O
the	O
clearest	O
normalization	O
of	O
the	O
elevated	O
plasma	B-OUT
chemistries	I-OUT
,	O
especially	O
in	O
C-terminal-beta-endorphin	O
and	O
serotonin	O
.	O


At	O
baseline	O
,	O
the	O
children	O
's	O
PUFA	O
(	O
n-3	O
and	O
n-6	O
)	O
,	O
vitamin	B-OUT
and	I-OUT
mineral	I-OUT
levels	I-OUT
were	O
low	O
,	O
but	O
they	O
improved	O
significantly	O
in	O
the	O
group	O
treated	O
with	O
n-3	O
,	O
vitamins	B-I
and	I-I
minerals	I-I
(	O
P=0·0005	O
)	O
.	O


After	O
adding	O
postoperative	O
delayed	B-OUT
ischemic	I-OUT
neurological	I-OUT
deficits	I-OUT
to	O
the	O
model	O
,	O
only	O
worsened	O
National	B-OUT
Institutes	I-OUT
of	I-OUT
Health	I-OUT
Stroke	I-OUT
Scale	I-OUT
score	I-OUT
,	I-OUT
Barthel	I-OUT
Activities	I-OUT
of	I-OUT
Daily	I-OUT
Living	I-OUT
index	I-OUT
,	I-OUT
and	I-OUT
discharge	I-OUT
destination	I-OUT
(	O
home	O
versus	O
other	O
)	O
remained	O
independently	O
associated	O
with	O
fever	O
.	O


)	O
ondansetron	B-I
in	O
chemotherapy-naive	B-P
patients	I-P
who	I-P
received	I-P
moderately	I-I
emetogenic	I-I
chemotherapy	I-I
.	I-I


ondansetron	B-I
(	O
n	O
=	O
543	O
)	O
.	O


Prophylactic	B-I
corticosteroids	I-I
were	I-I
allowed	I-I
.	I-I


Because	O
the	O
two	O
antiemetic	O
regimens	O
exhibited	O
equivalent	O
efficacies	O
,	O
additional	O
factors	O
such	O
as	O
convenience	O
and	O
cost	O
of	O
therapy	O
should	O
be	O
considered	O
.	O


There	O
was	O
a	O
main	O
effect	O
of	B-OUT
stimulus	I-OUT
temperature	I-OUT
on	I-OUT
pain	I-OUT
ratings	I-OUT
,	O
but	O
no	B-OUT
main	I-OUT
effect	I-OUT
of	I-OUT
condition	I-OUT
(	O
p	O
=	O
0.32	O
)	O
,	O
nor	B-OUT
a	I-OUT
condition	I-OUT
x	I-OUT
temperature	I-OUT
interaction	I-OUT
(	O
p	O
=	O
0.31	B-P
)	I-P
.	I-P


Again	O
,	O
there	O
was	O
no	B-OUT
main	I-OUT
effect	I-OUT
of	I-OUT
condition	I-OUT
on	I-OUT
heat	I-OUT
pain	I-OUT
threshold	I-OUT
(	O
p	O
=	O
0.17	O
)	O
,	O
nor	O
on	B-OUT
cold	I-OUT
pain	I-OUT
threshold	I-OUT
(	O
p	O
=	O
0.65	O
)	O
,	O
nor	O
on	O
any	O
of	O
the	B-OUT
secondary	I-OUT
measures	I-OUT
(	O
p	O
<	O
0.56	O
for	O
all	O
)	O
.	O


Efficient	O
tetanus	B-I
toxoid	I-I
immunization	I-I
on	O
vitamin	B-OUT
D	I-OUT
supplementation	I-P
.	I-P


RESULTS	O
During	O
vitamin	O
D	O
supplementation	O
the	O
median	B-OUT
25-hydroxyvitamin	I-OUT
D	I-OUT
serum	I-OUT
concentration	I-OUT
increased	O
to	O
80.3	O
nM	O
,	O
which	O
as	O
expected	O
decreased	O
in	O
the	O
placebo	O
group	O
to	O
29.1	O
nM	O
during	O
the	O
ultraviolet-deprived	O
winter	O
months	O
.	O


Study	O
power	O
was	O
fixed	O
as	O
80	O
%	O
with	O
5	O
%	O
cutoff	O
point	O
(	O
p	O
<	O
0.05	O
)	O
for	O
statistical	O
significance	O
.	O


Quality	B-OUT
of	I-OUT
life	I-OUT
equally	I-OUT
improved	O
after	O
both	O
techniques	O
.	O


However	O
,	O
the	O
trial	O
failed	O
to	O
detect	O
differences	O
in	B-OUT
P-QOL	I-OUT
scores	I-OUT
and	I-OUT
complication	I-OUT
rates	I-OUT
between	O
the	O
groups	O
.	O


Moreover	O
,	O
GA+AA	O
carriers	O
were	O
more	O
likely	O
to	O
attain	O
the	B-OUT
target	I-OUT
fasting	I-OUT
and	I-OUT
2-h	I-OUT
glucose	I-OUT
level	I-OUT
(	O
Plog	O
rank=0.0091	O
and	O
0.007	O
,	O
respectively	O
)	O
.	O


RESULTS	O
There	O
were	O
significantly	O
more	O
responders	O
in	O
the	O
acarbose-treated	O
group	O
compared	O
with	O
the	O
placebo	O
group	O
(	O
20/24	O
patients	O
vs.	O
10/19	O
patients	O
;	O
p	O
<	O
0.05	O
)	O
.	O


CONCLUSIONS	O
The	O
findings	O
of	O
this	O
study	O
suggest	O
that	O
the	O
addition	O
of	O
acarbose	B-I
to	O
sulphonylurea/insulin	B-I
combination	I-I
therapy	I-I
can	O
improve	O
glycaemic	B-OUT
control	I-OUT
in	O
type	B-P
2	I-P
diabetic	I-P
patients	I-P
.	I-P


This	O
involved	O
two	B-I
anthelmintic-treatment	I-I
levels	I-I
(	I-I
treated	I-I
vs.	I-I
non-treated	I-I
)	I-I
,	I-I
two	I-I
supplementary	I-I
nutrition	I-I
levels	I-I
(	I-I
protein-energy	I-I
supplementation	I-I
yes/no	I-I
)	I-I
and	I-I
three	I-I
genotypes	I-I
:	I-I
indigenous	I-I
Menz	I-I
(	I-P
n=40	I-P
)	I-P
,	I-P
50	I-P
%	I-P
Awassi	I-I
x	I-I
50	I-P
%	I-P
Menz	I-I
crosses	I-I
(	I-P
n=38	I-P
)	I-P
and	I-P
75	I-P
%	I-P
Awassi	I-P
x	I-P
25	I-P
%	I-P
Menz	I-P
crosses	I-P
(	I-P
n=31	I-P
)	I-P
.	I-P


Supplemented	O
sheep	O
were	O
offered	O
a	O
concentrate	B-I
mix	I-I
daily	I-I
on	O
an	O
individual	O
basis	O
.	O


Anthelmintic-treated	B-I
sheep	I-I
were	I-I
drenched	I-I
with	I-I
fenbendazole	I-I
against	I-I
nematodes	I-I
and	I-I
with	I-I
triclabendazole	I-I
against	I-I
trematodes	I-I
.	I-I


A	O
randomised	O
prospective	O
study	O
comparing	O
the	O
new	O
vacuum	O
extractor	O
policy	O
with	O
forceps	O
delivery	O
.	O


SETTING	O
Four	B-P
district	I-P
general	I-P
hospitals	I-P
in	I-P
the	I-P
West	I-P
Midlands	I-P
.	I-P


MAIN	O
OUTCOME	O
MEASURES	O
Delivery	B-OUT
success	I-OUT
rate	I-OUT
,	I-OUT
maternal	I-OUT
perineal	I-OUT
and	I-OUT
vaginal	I-OUT
injuries	I-OUT
,	I-OUT
maternal	I-OUT
anaesthetic	I-OUT
requirements	I-OUT
,	I-OUT
neonatal	I-OUT
scalp	I-OUT
and	I-OUT
facial	I-OUT
injuries	I-OUT
.	I-OUT


However	O
,	O
more	O
women	O
in	O
the	O
vacuum	O
extractor	O
group	O
were	O
delivered	O
vaginally	O
(	O
98	O
%	O
)	O
than	O
in	O
the	O
forceps	O
group	O
(	O
96	O
%	O
)	O
.	O


Further	O
studies	O
are	O
required	O
to	O
assess	O
neonatal	O
morbidity	O
adequately	O
.	O


Smoothing	O
affects	O
the	O
individualized	O
net	O
trough-to-peak	B-OUT
ratios	I-OUT
in	O
an	O
unpredictable	O
way	O
and	O
should	O
therefore	O
be	O
avoided	O
.	O


The	B-I
InsuPatch	I-I
(	I-I
IP	I-I
)	I-I
is	O
a	O
novel	O
insulin	O
infusion	O
site	O
warming	O
device	O
developed	O
to	O
accelerate	O
insulin	O
action	O
by	O
increasing	O
blood	O
flow	O
to	O
the	O
area	O
of	O
insulin	O
absorption	O
.	O


Due	O
to	O
observed	O
higher	B-OUT
Cu/Zn	I-OUT
ratio	I-OUT
,	O
it	O
is	O
suggested	O
to	O
test	O
blood	O
levels	O
of	O
Zn	O
and	O
Cu	O
in	O
all	O
autistic	O
children	O
and	O
give	O
them	O
a	O
Zn	O
supplement	O
if	O
needed	O
.	O


Combined	B-I
typhoid	I-I
fever	I-I
and	I-I
hepatitis	I-I
A	I-I
vaccine	I-I
:	I-I
comparison	O
of	O
immunogenicity	B-OUT
and	I-OUT
safety	I-OUT
to	O
concomitant	O
monovalent	O
vaccine	O
over	O
3	O
years	O
.	O


Seroconversion	B-OUT
and	I-OUT
seroprotection	I-OUT
rates	I-OUT
and	I-OUT
geometric	I-OUT
mean	I-OUT
antibody	I-OUT
concentrations	I-OUT
were	O
measured	O
at	O
14	O
and	O
28	O
days	O
,	O
1	O
,	O
2	O
,	O
and	O
3	O
years	O
postvaccination	O
,	O
and	O
28	O
days	O
after	O
the	O
booster	O
dose	O
.	O


Vi	B-OUT
seroprotection	I-OUT
rates	I-OUT
(	O
>	O
or	O
=	O
1	O
microg/mL	O
)	O
of	O
85.2	O
%	O
and	O
84.9	O
%	O
after	O
28	O
days	O
fell	O
to	O
32.1	O
%	O
and	O
35.6	O
%	O
after	O
3	O
years	O
,	O
increasing	O
to	O
67.3	O
%	O
and	O
69.8	O
%	O
after	O
the	O
booster	O
dose	O
.	O


A	O
randomised	O
trial	O
comparing	O
holmium	B-I
laser	I-I
enucleation	I-I
versus	O
transurethral	B-I
resection	I-I
in	O
the	O
treatment	B-P
of	I-P
prostates	I-P
larger	I-P
than	I-P
40	I-P
grams	I-P
:	I-P
results	O
at	O
2	O
years	O
.	O


Continence	B-OUT
and	I-OUT
potency	I-OUT
data	I-OUT
were	O
also	O
recorded	O
.	O


Self-management	B-I
improvement	I-I
program	I-I
combined	I-I
with	I-I
community	I-I
involvement	I-I
in	O
Thai	B-P
hypertensive	I-P
population	I-P
:	I-P
an	O
action	O
research	O
.	O


MATERIAL	O
AND	O
METHOD	O
Forty-four	B-P
subjects	I-P
,	I-P
aged	I-P
35	I-P
to	I-P
59-year-old	I-P
,	I-P
with	I-P
hypertension	I-P
in	I-P
Nakhon	I-P
Pathom	I-P
Province	I-P
,	I-P
Thailand	I-P
,	O
were	O
randomly	O
allocated	O
to	O
either	O
an	O
experimental	B-I
group	I-I
(	O
n	O
=	O
22	O
)	O
or	O
a	O
control	B-I
group	I-I
(	O
n	O
=	O
20	O
)	O
.	O


CONCLUSION	O
The	O
program	O
applied	O
social	B-I
cognitive	I-I
theory	I-I
(	I-I
SCT	I-I
)	I-I
to	O
promote	O
self-management	B-I
techniques	I-I
,	O
increased	O
the	O
health	B-OUT
promoting	I-OUT
behavior	I-OUT
among	O
hypertensive	O
people	O
.	O


Effectiveness	B-OUT
of	O
written	O
guidelines	O
on	O
the	O
appropriateness	O
of	O
thromboprophylaxis	B-I
prescriptions	I-I
for	I-P
medical	I-P
patients	I-P
:	I-P
a	O
prospective	O
randomized	O
study	O
.	O


Using	B-OUT
specific	I-OUT
forms	I-OUT
did	O
not	B-OUT
improve	I-OUT
under-prescription	I-OUT
of	I-OUT
anticoagulants	I-OUT
.	O


A	O
little	O
over	O
60	O
%	O
of	O
the	O
patients	O
who	O
met	O
guideline	O
criteria	O
for	O
thromboprophylaxis	O
were	B-OUT
prescribed	I-OUT
anticoagulants	I-OUT
in	O
both	O
intervention	O
and	O
control	O
wards	O
,	O
either	O
at	O
baseline	O
or	O
after	O
intervention	O
.	O


Patients	B-P
with	I-P
schizophrenia	I-P
experience	O
higher	O
rates	O
of	O
obesity	O
as	O
well	O
as	O
related	O
morbidity	O
and	O
mortality	O
than	O
the	O
general	O
population	O
does	O
.	O


Given	O
preclinical	O
studies	O
revealing	O
the	O
role	O
of	O
the	O
endogenous	O
opioid	O
systems	O
in	O
human	O
appetite	O
and	O
the	O
potential	O
of	O
antipsychotic	O
medications	O
to	O
interfere	O
with	O
this	O
system	O
,	O
we	O
hypothesized	O
that	O
opioid	O
antagonists	O
may	O
be	O
beneficial	O
in	O
arresting	O
antipsychotic-associated	B-OUT
weight	I-OUT
gain	I-OUT
and	O
promoting	O
further	O
weight	B-OUT
loss	I-OUT
in	O
women	O
with	O
schizophrenia	O
.	O


In	O
the	O
present	O
study	O
,	O
24	B-P
overweight	I-P
women	I-P
with	I-P
a	I-P
diagnosis	I-P
of	I-P
schizophrenia	I-P
or	I-P
schizoaffective	I-P
disorder	I-P
were	O
randomized	O
to	O
placebo	B-I
or	I-I
naltrexone	I-I
(	I-I
NTX	I-I
)	I-I
25	O
mg/d	O
for	O
8	O
weeks	O
.	O


These	O
data	O
support	O
the	O
need	O
to	O
further	O
investigate	O
the	O
role	O
of	O
D2	O
blockade	O
in	O
reducing	O
food	B-OUT
reward-based	I-OUT
overeating	I-OUT
.	I-OUT


Following	O
a	O
non-randomized	O
study	O
suggesting	O
that	O
desmopressin	B-I
acetate	I-I
(	I-I
desmopressin	I-I
)	I-I
reduced	O
blood	O
product	O
requirements	O
in	O
these	O
patients	O
,	O
we	O
conducted	O
a	O
double-blind	O
,	O
placebo-controlled	B-I
randomized	O
trial	O
of	O
desmopressin	B-I
(	O
0.3	O
micrograms/kg	O
,	O
i.	O
v.	O
)	O
in	O
92	B-P
patients	I-P
with	I-P
overt	I-P
bleeding	I-P
and	I-P
a	I-P
prolonged	I-P
bleeding	I-P
time	I-P
.	I-P


BACKGROUND	O
Acute	O
diarrhoea	O
is	O
a	O
frequent	O
problem	O
in	O
children	B-P
with	I-P
heavy	I-P
economic	I-P
burden	I-P
for	I-P
families	I-P
and	I-P
society	I-P
.	I-P


AIM	O
To	O
test	O
the	O
efficacy	O
of	O
a	O
new	O
synbiotic	B-I
formulation	I-I
containing	I-I
Lactobacillus	I-I
paracasei	I-I
B21060	I-I
,	I-I
arabinogalactan	I-I
and	I-I
xilooligosaccharides	I-I
in	O
children	B-P
with	I-P
acute	I-P
diarrhoea	I-P
.	I-P


Furthermore	O
,	O
even	O
daily	O
administration	O
of	O
azithromycin	B-I
to	O
chronically	O
infected	O
cats	O
was	O
ineffective	B-OUT
in	I-OUT
clearing	I-OUT
infection	I-OUT
.	I-OUT


OBJECTIVES	O
According	O
to	O
the	O
proposed	O
interference	O
of	O
N-acetylcysteine	B-I
(	I-I
NAC	I-I
)	I-I
with	O
pathophysiologic	O
processes	O
of	O
autistic	O
disorders	O
(	O
ADs	O
)	O
,	O
we	O
aimed	O
to	O
assess	O
the	B-OUT
effectiveness	I-OUT
and	I-OUT
safety	I-OUT
of	O
NAC	B-I
as	O
an	O
adjunct	O
to	O
risperidone	B-I
in	O
the	O
treatment	O
of	O
ADs	O
in	O
a	O
randomized	O
,	O
double-blind	O
,	O
clinical	O
trial	O
.	O


The	O
main	O
outcome	O
was	O
mean	B-OUT
decrease	I-OUT
in	I-OUT
the	I-OUT
ABC-C	I-OUT
irritability	I-OUT
subscale	I-OUT
score	I-OUT
from	O
baseline	O
at	O
5	O
and	O
10	O
weeks	O
.	O


Follow-up	O
data	O
were	O
collected	O
from	O
the	O
general	O
practitioners	O
.	O


Overall	O
,	O
changes	B-OUT
in	I-OUT
pulmonary	I-OUT
drug	I-OUT
prescription	I-OUT
during	O
6	O
months	O
of	O
follow-up	O
were	O
infrequent	O
(	O
n	O
=	O
53	O
,	O
13.7	O
%	O
;	O
among	O
new	O
cases	O
of	O
COPD	O
,	O
15	O
(	O
17.9	O
%	O
)	O
out	O
of	O
84	O
)	O
.	O


The	O
average	O
drop	B-OUT
in	I-OUT
intraocular	I-OUT
pressure	I-OUT
attributable	O
to	O
ALT	B-I
was	O
6.6	O
mmHg	O
.	O


A	O
single-blind	O
study	O
compared	O
the	O
effectiveness	O
of	O
glutaraldehyde-treated	B-I
polymerized	I-I
ragweed	I-I
with	O
nonpolymerized	B-I
monomeric	I-I
ragweed	I-I
.	I-I


Nineteen	B-P
ragweed-sensitive	I-P
patients	I-P
were	I-P
randomized	I-P
into	I-P
2	I-P
groups	I-P
;	I-P
10	I-P
received	I-P
the	I-P
polymerized	I-I
form	I-I
and	I-P
9	I-P
received	I-P
the	I-P
monomeric	I-I
form	I-I
.	I-I


Pretreatment	O
levels	O
of	O
antigen	O
E	O
--	O
specific	O
IgE	O
and	O
blocking	O
antibody	O
activity	O
were	O
similar	O
in	O
both	O
groups	O
.	O


After	O
1	O
year	O
of	O
treatment	O
,	O
no	O
consistent	O
decrease	O
in	O
postseasonal	B-OUT
specific	I-OUT
IgE	I-OUT
rise	I-OUT
could	O
be	O
shown	O
in	O
either	O
group	O
.	O


Both	O
groups	O
experienced	O
symptomatic	B-OUT
improvement	I-OUT
with	O
treatment	O
.	O


However	O
,	O
health	O
deciders	O
need	O
reliable	O
data	O
on	O
which	O
to	O
base	O
future	O
policies	O
concerning	O
this	O
.	O


These	O
results	O
show	O
that	O
the	B-OUT
pre-hospital	I-OUT
thrombolytic	I-OUT
strategy	I-OUT
in	I-OUT
patients	I-OUT
with	I-OUT
suspected	I-OUT
myocardial	I-OUT
infarction	I-OUT
is	I-OUT
both	I-OUT
effective	I-OUT
and	I-OUT
safe	I-OUT
when	I-OUT
performed	I-OUT
by	I-OUT
well-equipped	I-OUT
well-staffed	I-OUT
mobile	I-OUT
emergency	I-OUT
units	I-OUT
.	I-OUT


Parietal	B-OUT
cell	I-OUT
density	I-OUT
in	O
duodenal	B-P
ulcer	I-P
patients	I-P
after	I-P
short-term	I-P
treatment	I-P
with	I-P
cimetidine	I-I
and	I-I
antacids	I-I
.	I-I


In	O
Study	O
1	O
,	O
the	O
authors	O
found	O
that	O
in	O
the	O
made-in-the-U.S.	B-I
scenario	I-I
condition	O
,	O
European	B-P
Americans	I-P
were	I-P
more	I-P
accurate	I-P
than	I-P
were	I-P
Asian	I-P
Americans	I-P
in	O
their	O
retrospective	B-OUT
frequency	I-OUT
judgments	I-OUT
of	I-OUT
emotions	I-OUT
.	I-OUT


Forty	B-P
patients	I-P
had	I-P
both	I-P
their	I-P
trachea	I-P
and	I-P
oesophagus	I-P
intubated	I-I
,	O
each	O
patient	O
was	O
studied	O
twice	O
.	O


Auscultation	B-OUT
of	I-OUT
the	I-OUT
epigastrium	I-OUT
,	O
right	O
and	O
left	O
axilla	O
is	O
more	O
reliable	O
than	O
auscultation	O
of	O
the	O
chest	O
,	O
and	O
the	O
anaesthetist	B-P
's	I-P
feeling	I-P
when	I-P
he	I-P
squeezes	I-P
the	I-P
bag	I-P
.	I-P


We	O
conclude	O
that	O
auscultation	O
of	O
epigastrium	O
,	O
right	O
and	O
left	O
axilla	O
,	O
are	O
recommended	O
.	O


Poor	O
self-rated	O
health	O
is	O
not	O
associated	O
with	O
a	O
high	O
total	O
allostatic	O
load	O
in	O
type	B-P
2	I-P
diabetic	I-P
patients	I-P
--	I-P
but	I-P
high	O
blood	O
pressure	O
is	O
.	O


METHODS	O
The	O
subjects	B-P
included	I-P
in	I-P
the	I-P
study	I-P
came	I-P
from	I-P
a	I-P
randomized	I-P
,	I-P
controlled	I-P
trial	I-P
of	I-P
type	I-P
2	I-P
diabetes	I-P
.	I-P


EXPERIMENTAL	O
DESIGN	O
The	O
LCS6	O
genotype	O
was	O
assayed	O
by	O
real-time	B-I
PCR	I-I
in	I-I
DNA	I-I
extracted	I-I
from	I-I
whole	I-I
blood	I-I
(	I-I
n	I-I
=	I-I
2,834	I-I
)	I-I
and	I-I
compared	I-I
with	I-I
paired	I-I
tumor	I-I
tissue	I-I
(	O
n	O
=	O
977	O
)	O
.	O


G-allele	B-OUT
carriers	I-OUT
were	O
significantly	O
more	O
frequent	O
in	B-P
Caucasians	I-P
versus	I-P
other	I-P
races	I-P
(	O
χ	O
(	O
2	O
)	O
test	O
,	O
P	O
<	O
0.0001	O
)	O
.	O


The	O
observational	O
analysis	O
showed	O
a	O
significant	O
difference	B-OUT
in	I-OUT
survival	I-OUT
between	O
transfused	O
and	O
non-transfused	O
patients	O
(	O
59.6	O
versus	O
72.9	O
per	O
cent	O
;	O
P	O
<	O
0.001	O
)	O
.	O


Local	B-OUT
recurrences	I-OUT
were	O
more	O
frequent	O
in	O
transfused	O
than	O
non-transfused	O
patients	O
(	O
11.9	O
versus	O
7.6	O
per	O
cent	O
;	O
P	O
=	O
0.09	O
)	O
.	O


CONCLUSION	O
Leucocyte	O
depletion	O
of	O
perioperative	B-I
transfused	I-I
blood	I-I
has	O
no	O
effect	O
on	O
long-term	B-OUT
survival	I-OUT
and/or	I-OUT
cancer	I-OUT
recurrence	I-OUT
.	I-OUT


OBJECTIVE	O
Our	O
aim	O
was	O
to	O
evaluate	O
the	O
effectiveness	O
of	O
5	B-I
%	I-I
lidocaine	I-I
(	I-I
ELA-Max	I-I
)	I-I
cream	I-I
applied	O
after	O
erbium	B-I
:	I-I
yttrium-aluminum-garnet	I-I
(	I-I
Er	I-I
:	I-I
YAG	I-I
)	I-I
laser	I-I
ablation	I-I
of	O
the	O
stratum	O
corneum	O
.	O


Full-face	O
laser	O
resurfacing	O
was	O
performed	O
,	O
and	O
visual	B-OUT
analog	I-OUT
pain	I-OUT
scores	I-OUT
(	I-OUT
0	I-OUT
to	I-OUT
10	I-OUT
)	I-OUT
were	O
recorded	O
during	O
each	O
of	O
2	O
passes	O
.	O


A	O
total	O
of	B-P
920	I-P
patients	I-P
will	I-P
be	I-P
accrued	I-P
from	I-P
33	I-P
institutions	I-P
within	I-P
5	I-P
years	I-P
.	I-P


This	O
natural	O
history	O
information	O
is	O
important	O
when	O
considering	O
prophylactic	O
treatment	O
for	O
MS	B-OUT
at	O
the	O
time	O
of	O
a	O
first	O
acute	O
onset	O
of	O
optic	O
neuritis	O
.	O


BACKGROUND	O
Prophylactic	B-I
cranial	I-I
irradiation	I-I
in	O
patients	B-P
with	I-P
small-cell	I-P
lung	I-P
cancer	I-P
decreases	O
the	O
overall	O
rate	B-OUT
of	I-OUT
brain	I-OUT
metastases	I-OUT
without	O
an	O
effect	O
on	O
overall	B-OUT
survival	I-OUT
.	I-OUT


It	O
has	O
been	O
suggested	O
that	O
this	O
treatment	O
may	O
increase	O
neuropsychological	B-OUT
syndromes	I-OUT
and	I-OUT
brain	I-OUT
abnormalities	I-OUT
indicated	O
by	O
computed	O
tomography	O
scans	O
.	O


IMPLICATIONS	O
The	O
results	O
of	O
the	O
trial	O
favor	O
,	O
at	O
present	O
,	O
the	O
indication	O
of	O
prophylactic	O
cranial	O
irradiation	O
for	O
patients	B-P
who	I-P
are	I-P
in	I-P
complete	I-P
remission	I-P
.	I-P


Population	O
pharmacokinetic/pharmacodynamic	O
analysis	O
of	O
the	O
DPP-4	B-I
inhibitor	I-I
linagliptin	I-I
in	O
Japanese	B-P
patients	I-P
with	I-P
type	I-P
2	I-P
diabetes	I-P
mellitus	I-P
.	I-P


RESULTS	O
Nonlinear	O
PK	O
of	O
linagliptin	O
in	O
T2DM	O
patients	O
were	O
well	O
described	O
by	O
a	O
2-compartment	O
model	O
assuming	O
concentration-dependent	O
binding	O
to	O
DPP-4	O
in	O
the	O
central	O
and	O
peripheral	O
compartment	O
.	O


Plasma	B-OUT
DPP-4	I-OUT
inhibition	I-OUT
was	O
integrated	O
in	O
the	O
model	O
by	O
relating	O
the	O
model-predicted	O
DPP-4	O
occupancy	O
with	O
linagliptin	B-I
linearly	O
to	O
DPP-4	O
inhibition	O
.	O


Data	O
were	O
analyzed	O
by	O
using	O
two-sample	O
t	O
tests	O
,	O
chi-square	O
methods	O
,	O
and	O
Fisher	O
's	O
exact	O
test	O
.	O


No	O
adverse	B-OUT
events	I-OUT
or	I-OUT
side	I-OUT
effects	I-OUT
were	O
reported	O
,	O
and	O
all	O
patients	O
who	O
entered	O
the	O
study	O
completed	O
it	O
.	O


During	O
maintenance	O
therapy	O
with	O
interferon	B-I
alfa-2b	I-I
,	O
no	O
significant	O
differences	O
in	O
the	O
occurrence	B-OUT
of	I-OUT
relapse	I-OUT
have	O
yet	O
been	O
seen	O
compared	O
to	O
patients	B-P
on	I-P
no	I-P
maintenance	I-P
therapy	I-P
.	I-P


The	O
effects	O
of	O
both	O
the	O
early	O
and	O
the	O
late	O
block	O
in	O
UKALL	O
X	O
alone	O
have	O
been	O
reported	O
previously	O
.	O


OBJECTIVE	O
We	O
aimed	O
to	O
investigate	O
the	O
effects	O
of	O
the	B-I
Oxymizer	I-I
on	I-OUT
endurance	I-OUT
time	I-OUT
in	O
comparison	O
to	O
a	B-I
conventional	I-I
nasal	I-I
cannula	I-I
(	I-I
CNC	I-I
)	I-I
.	O


Furthermore	O
,	O
there	O
was	O
a	O
positive	O
correlation	O
(	O
r	O
=	O
0.427	O
,	O
p	O
=	O
0.002	O
)	O
between	B-OUT
the	I-OUT
O2	I-OUT
flow	I-OUT
rate	I-OUT
and	I-OUT
improvements	I-OUT
in	I-OUT
the	I-OUT
constant	I-OUT
work	I-OUT
rate	I-OUT
test	O
,	O
showing	O
greater	O
improvements	O
in	O
favor	O
of	B-I
the	I-I
Oxymizer	I-I
in	O
patients	O
with	O
a	O
higher	O
demand	O
for	O
O2	O
(	O
≥	O
4	O
liters/min	O
)	O
.	O


DESIGN	O
Paired	O
randomized	O
controlled	O
trial	O
.	O


Tetracaine/adrenaline/cocaine	B-I
for	O
local	B-P
anesthesia	I-P
.	I-P


Buprenorphine	B-I
alone	O
and	O
in	O
combination	O
with	O
naloxone	B-I
in	O
non-dependent	B-P
humans	I-P
.	I-P


This	O
study	O
evaluated	O
the	O
effects	O
of	O
concurrent	O
naloxone	B-I
on	O
the	O
opioid	B-OUT
agonist	I-OUT
effects	I-OUT
of	O
buprenorphine	B-I
,	O
a	O
mixed	O
agonist-antagonist	O
marketed	O
as	O
an	O
analgesic	O
and	O
under	O
development	O
as	O
a	O
treatment	O
for	O
drug	O
abuse	O
.	O


Thus	O
,	O
a	O
combination	O
product	O
of	O
buprenorphine	B-I
and	O
naloxone	O
may	O
have	O
lower	O
abuse	B-OUT
liability	I-OUT
than	O
buprenorphine	B-I
alone	O
.	O


Participants	O
were	O
assessed	O
using	O
a	O
baseline	O
written	O
pretest	B-OUT
of	I-OUT
ACLS	I-OUT
knowledge	I-OUT
.	I-OUT


On	O
the	O
Megacode	B-OUT
performance	I-OUT
test	I-OUT
,	O
the	O
video-based	B-I
,	I-I
low-	I-I
,	I-I
and	I-I
high-fidelity	I-I
groups	I-I
performed	O
significantly	O
better	O
than	O
the	O
control	B-I
group	I-I
(	O
p	O
=	O
0.028	O
,	O
p	O
<	O
0.001	O
,	O
p	O
=	O
0.019	O
)	O
.	O


We	O
advocate	O
the	O
use	O
of	O
a	O
more	O
cost-effective	O
all-polyethylene	B-I
tibial	I-I
component	I-I
in	O
elderly	B-P
patients	I-P
(	I-P
>	I-P
70	I-P
years	I-P
old	I-P
)	I-P
who	O
are	O
not	O
likely	O
to	O
need	O
the	O
versatility	O
of	O
exchange	O
of	O
a	O
modular	O
polyethylene	O
insert	O
because	O
of	O
wear	O
.	O


Enhanced	O
induction	B-OUT
of	O
apoptosis	O
in	O
lung	B-P
adenocarcinoma	I-P
after	O
preoperative	O
chemotherapy	O
with	O
tegafur	B-I
and	O
uracil	B-I
(	O
UFT	O
)	O
.	O


One	O
group	O
received	O
UFT	O
600	O
mg/day	O
preoperatively	O
for	O
7	O
consecutive	O
days	O
and	O
a	O
control	O
group	O
received	O
no	B-I
chemotherapy	I-I
or	I-I
radiotherapy	I-I
.	I-I


ORG	B-I
2766	I-I
treatment	I-I
(	O
20	O
mg	O
per	O
day	O
during	O
4	O
weeks	O
)	O
was	O
associated	O
with	O
an	O
increased	O
amount	O
and	O
an	O
improved	O
quality	O
of	O
the	O
social	O
interaction	O
of	O
the	O
autistic	B-P
children	I-P
with	O
a	O
familiar	O
experimenter	O
.	O


The	O
data	O
supported	O
the	O
notion	O
of	O
a	O
stimulating	O
effect	O
of	O
ORG	B-I
2766	I-I
on	O
social	O
interaction	O
.	O


This	O
study	O
is	O
a	O
prospective	O
assessment	O
of	O
anti-Xa	B-OUT
levels	I-OUT
in	O
patients	B-P
on	I-P
long-term	I-P
therapy	I-P
for	I-P
acute	I-P
venous	I-P
thromboembolism	I-P
who	I-P
have	I-P
active	I-P
cancer	I-P
.	I-P


Patients	O
were	O
followed	O
for	O
bleeding	B-OUT
and	I-OUT
recurrent	I-OUT
venous	I-OUT
thromboembolism	I-OUT
.	I-OUT


At	O
follow-up	O
,	O
the	O
CBT	B-I
group	O
tended	O
to	O
be	O
more	O
likely	O
to	O
have	O
experienced	O
3	O
months	O
of	O
seizure	B-OUT
freedom	I-OUT
(	O
odds	O
ratio	O
3.125	O
,	O
p	O
=	O
0.086	O
)	O
.	O


A	O
community-based	B-P
,	O
double-blind	O
,	O
randomized	O
trial	O
of	O
praziquantel	B-I
was	O
carried	O
out	O
in	O
an	B-P
area	I-P
of	I-P
Zambia	I-P
endemic	I-P
for	I-P
schistosomiasis	I-P
.	I-P


However	O
,	O
there	O
were	O
no	O
significant	O
differences	O
,	O
between	O
the	O
two	O
groups	O
,	O
in	O
the	O
prevalences	O
of	O
these	O
symptoms	O
of	O
morbidity	B-OUT
.	I-OUT


It	O
therefore	O
appears	O
that	O
once-yearly	O
treatment	O
of	O
children	B-P
,	I-P
in	I-P
this	I-P
and	I-P
similar	I-P
endemic	I-P
areas	I-P
,	O
is	O
sufficient	O
to	O
reduce	O
schistosomiasis	O
morbidity	O
to	O
,	O
and	O
maintain	O
it	O
at	O
,	O
a	O
tolerable	O
level	O
.	O


Stentless	B-I
(	I-P
Freestyle	I-P
,	I-P
Toronto	I-P
,	I-P
n	I-P
=	I-P
106	I-P
)	I-P
or	I-P
conventional	I-I
biological	I-I
aortic	I-I
valves	I-I
(	I-P
Carpentier-Edwards	I-P
,	I-P
n	I-P
=	I-P
74	I-P
)	I-P
were	I-P
evaluated	I-P
prospectively	O
.	O


These	O
results	O
obtained	O
with	O
the	O
LNH-84	O
regimen	O
demonstrate	O
that	O
this	O
therapeutic	O
scheme	O
is	O
an	O
effective	O
treatment	O
for	O
aggressive	O
ML	O
.	O


Those	O
factors	O
include	O
being	O
of	O
African-American	B-P
race	I-P
,	O
having	O
a	O
preoperative	O
intraocular	O
pressure	O
of	O
20	O
mm	O
Hg	O
or	O
more	O
on	O
maximum	O
tolerated	O
medications	O
,	O
and	O
being	O
on	O
two	O
or	O
more	O
medications	O
preoperatively	O
.	O


Those	B-P
with	I-P
significant	I-P
improvement	I-P
of	I-P
urticaria	I-P
activity	I-P
score	I-P
under	I-P
fexofenadine	I-I
at	I-P
180	I-P
mg	I-P
were	O
included	O
in	O
the	O
CIU	O
group	O
.	O


METHODS	O
In	O
the	O
current	O
investigation	O
,	O
changes	O
in	O
autonomic	O
tone	O
associated	O
with	O
long-term	O
administration	O
of	O
an	O
angiotensin-converting	O
enzyme	O
inhibitor	O
were	O
measured	O
using	O
spectral	O
analysis	O
of	O
heart	O
rate	O
variability	O
in	O
13	B-P
patients	I-P
with	I-P
congestive	I-P
heart	I-P
failure	I-P
who	O
were	O
enrolled	O
in	O
a	O
double-blind	O
randomized	O
placebo-controlled	B-I
trial	O
of	O
the	O
angiotensin-converting	B-I
enzyme	I-I
inhibitor	I-I
zofenopril	I-I
.	I-I


The	O
primary	O
outcome	O
measure	O
was	O
average	B-OUT
wrist	I-OUT
pain	I-OUT
during	I-OUT
the	I-OUT
past	I-OUT
week	I-OUT
,	O
measured	O
using	O
a	O
visual	O
analog	O
scale	O
(	O
VAS	O
)	O
.	O


Secondary	O
outcome	O
measures	O
were	O
grip	B-OUT
strength	I-OUT
and	I-OUT
functional	I-OUT
ability	I-OUT
.	I-OUT


Measurements	O
were	O
performed	O
at	O
baseline	O
and	O
after	O
4	O
weeks	O
.	O


CONCLUSION	O
Prefabricated	O
wrist	B-I
working	I-I
splints	I-I
are	O
highly	O
effective	O
in	O
reducing	O
wrist	O
pain	O
after	O
4	O
weeks	O
of	O
splint	O
wearing	O
in	O
RA	B-P
patients	I-P
with	I-P
wrist	I-P
arthritis	I-P
.	I-P


We	O
conclude	O
that	O
a	O
20-week	O
parent	O
education	O
programme	O
including	O
skills	O
training	O
for	O
parents	B-P
of	I-P
young	I-P
children	I-P
with	I-P
autistic	I-P
disorder	I-P
provides	O
significant	O
improvements	O
in	O
child	B-OUT
adaptive	I-OUT
behaviour	I-OUT
and	I-OUT
symptoms	I-OUT
of	I-OUT
autism	I-OUT
for	O
low-functioning	B-P
children	I-P
.	I-P


CONCLUSIONS	O
Although	O
mechanisms	O
remain	O
unclear	O
,	O
a	O
group-based	B-I
psychosocial	I-I
intervention	I-I
program	I-I
for	O
women	B-P
with	I-P
coronary	I-P
heart	I-P
disease	I-P
may	O
prolong	O
lives	O
independent	O
of	O
other	O
prognostic	O
factors	O
.	O


The	O
aim	O
of	O
this	O
study	O
was	O
to	O
compare	O
the	O
pharmacodynamic	O
response	O
to	O
a	O
neuroactive	B-I
steroid	I-I
,	I-I
pregnanolone	I-I
,	O
before	O
and	O
during	O
different	O
hormonal	O
settings	O
of	O
postmenopausal	B-I
hormone	I-I
replacement	I-I
therapy	I-I
(	I-I
HRT	I-I
)	I-I
,	O
using	O
natural	B-I
progesterone	I-I
.	I-I


During	O
treatment	O
with	O
either	O
E	B-I
(	I-I
2	I-I
)	I-I
alone	I-I
or	I-I
E	I-I
(	I-I
2	I-I
)	I-I
+progesterone	I-I
the	O
response	O
in	O
saccadic	B-OUT
eye	I-OUT
movement	I-OUT
parameters	I-OUT
and	O
in	O
self-rated	B-OUT
sedation	I-OUT
to	O
pregnanolone	O
was	O
enhanced	O
compared	O
to	O
pretreatment	O
values	O
.	O


In	O
conclusion	O
,	O
during	O
treatment	O
with	O
either	O
E	B-I
(	I-I
2	I-I
)	I-I
alone	I-I
,	I-I
or	I-I
E	I-I
(	I-I
2	I-I
)	I-I
+progesterone	I-I
,	I-I
pregnanolone	I-OUT
sensitivity	I-OUT
was	O
increased	O
.	O


The	O
intent-to-treat	O
(	O
ITT	O
)	O
analysis	O
initially	O
involved	O
all	O
patients	O
randomized	O
to	B-I
lopinavir/ritonavir	I-I
monotherapy	I-I
(	O
n	O
=	O
83	O
)	O
,	O
and	O
then	O
focused	O
on	O
patients	O
who	O
had	O
an	O
HIV	O
RNA	O
<	O
50	O
copies/mL	O
at	O
week	O
48	O
(	O
n	O
=	O
56	O
)	O
.	O


Participants	O
attended	O
90	O
%	O
of	O
laboratory-based	O
training	O
sessions	O
,	O
found	O
VR-JIT	B-I
easy	I-OUT
to	I-OUT
use	I-OUT
and	O
enjoyable	B-OUT
,	O
and	O
they	O
felt	O
prepared	B-OUT
for	I-OUT
future	I-OUT
interviews	I-OUT
.	I-OUT


OBJECTIVE	O
To	O
compare	O
bipolar	B-I
with	O
the	O
conventional	B-I
monopolar	I-I
transurethral	I-I
resection	I-I
of	I-I
the	I-I
prostate	I-I
(	I-I
TURP	I-I
)	I-I
for	O
blood	O
loss	O
and	O
speed	O
of	O
resection	O
.	O


The	O
decrease	O
in	B-OUT
blood	I-OUT
haemoglobin	I-OUT
concentration	I-OUT
during	O
the	O
day	O
of	O
surgery	O
was	O
smaller	O
in	O
the	O
bipolar	O
group	O
(	O
5.5	O
%	O
vs	O
9.6	O
%	O
P	O
<	O
0.001	O
)	O
.	O


PATIENTS	O
AND	O
METHODS	O
A	B-P
total	I-P
of	I-P
90	I-P
eyes	I-P
of	I-P
90	I-P
patients	I-P
with	I-P
primary	I-P
open-angle	I-P
glaucoma	I-P
or	I-P
pseudoexfoliative	I-P
glaucoma	I-P
underwent	I-P
deep	I-P
sclerectomy	I-P
.	I-P


Increased	O
repetitive	O
behaviours	O
and	O
prolactin	O
responsivity	O
to	O
oral	O
m-chlorophenylpiperazine	B-I
in	O
adults	B-P
with	I-P
autism	I-P
spectrum	I-P
disorders	I-P
.	I-P


There	O
is	O
evidence	O
that	O
abnormalities	O
exist	O
in	O
the	O
serotonin	O
(	O
5-HT	O
)	O
system	O
in	O
autism	O
spectrum	O
patients	O
.	O


In	O
each	O
patient	O
a	O
euglycaemic	O
glucose	O
clamp	O
with	O
simultaneous	O
indirect	O
calorimetry	O
allowed	O
us	O
to	O
determine	O
whole	B-OUT
body	I-OUT
glucose	I-OUT
disposal	I-OUT
and	O
substrate	B-OUT
oxidation	I-OUT
.	I-OUT


The	O
aging	O
motor	O
system	O
as	O
a	O
model	O
for	O
plastic	O
changes	O
of	O
GABA-mediated	O
intracortical	O
inhibition	O
and	O
their	O
behavioral	O
relevance	O
.	O


Double-pulse	B-I
transcranial	I-I
magnetic	I-I
stimulation	I-I
(	I-I
dpTMS	I-I
)	I-I
was	I-I
used	I-I
to	I-I
examine	I-I
inhibition	I-I
by	I-I
means	I-I
of	I-I
short-interval	I-I
intracortical	I-I
inhibition	I-I
(	I-I
SICI	I-I
)	I-I
of	I-I
the	I-I
contralateral	I-I
primary	I-I
motor	I-I
cortex	I-I
in	O
a	O
sample	O
of	O
64	B-P
healthy	I-P
right-handed	I-P
human	I-P
subjects	I-P
covering	I-P
a	I-P
wide	I-P
range	I-P
of	I-P
the	I-P
adult	I-P
lifespan	I-P
(	I-P
age	I-P
range	I-P
20-88	I-P
years	I-P
,	I-P
mean	I-P
47.6	I-P
±	I-P
20.7	I-P
,	I-P
34	I-P
female	I-P
)	I-P
.	I-OUT


Declining	B-OUT
resting-state	I-OUT
inhibition	I-OUT
was	O
associated	O
with	O
weakened	O
event-related	O
modulation	O
of	O
inhibition	O
.	O


[	B-I
Propofol	I-I
infusion	O
for	O
the	O
maintenance	O
of	O
short-term	B-P
anesthesia	I-OUT
]	I-OUT
.	O


Coverage	O
efficiency	O
was	O
calculated	O
as	O
coverage	B-I
of	I-I
children	I-I
per	I-I
bednet	I-I
owned	I-I
.	I-I


In	O
multivariable	O
analysis	O
,	O
having	O
a	O
child	B-P
under	I-P
5	I-P
years	I-P
of	I-P
age	I-P
was	O
the	O
only	O
variable	O
associated	O
with	O
bednet	O
use	O
(	O
OR	O
9.10	O
;	O
p=0.001	O
)	O
,	O
yielding	O
a	O
99	O
%	O
likelihood	O
of	O
using	O
a	O
bednet	O
(	O
95	O
%	O
CI	O
96.4	O
to	O
99.9	O
%	O
)	O
versus	O
82	O
%	O
(	O
95	O
%	O
CI	O
72.2	O
to	O
88.4	O
%	O
)	O
in	O
households	O
without	O
young	O
children	O
.	O


Challenges	O
and	O
potential	O
solutions	O
to	O
meeting	O
accrual	O
goals	O
in	O
a	O
Phase	O
II	O
chemoprevention	O
trial	O
for	O
prostate	B-P
cancer	I-P
.	I-P


Screening	B-I
logs	I-I
were	O
reviewed	O
to	O
identify	O
trends	O
as	O
well	O
as	O
patient	O
,	O
protocol	O
and	O
infrastructure	O
-related	O
barriers	O
impacting	O
accrual	O
and	O
revisions	O
to	O
protocol	O
implemented	O
.	O


METHOD	O
The	O
sample	O
comprised	O
24	B-P
children	I-P
(	I-P
19	I-P
boys	I-P
;	I-P
5	I-P
girls	I-P
)	I-P
who	I-P
met	I-P
American	I-P
Psychiatric	I-P
Association	I-P
,	I-P
Diagnostic	I-P
and	I-P
Statistical	I-P
Manual	I-P
of	I-P
Mental	I-P
Disorders	I-P
,	I-P
4th	I-P
ed	I-P
.	I-P


Parents	O
noted	O
significant	O
declines	O
in	O
inattentive	B-OUT
and	I-OUT
oppositional	I-OUT
behavior	I-OUT
,	O
and	O
improvements	O
in	O
social	B-OUT
skills	I-OUT
.	I-OUT


No	O
exacerbation	B-OUT
of	I-OUT
stereotypies	I-OUT
was	O
noted	O
,	O
and	O
side	B-OUT
effects	I-OUT
were	O
similar	O
to	O
those	O
seen	O
in	O
typically	O
developing	O
children	O
with	O
ADHD	O
.	O


Dose	O
response	O
was	O
primarily	O
linear	O
in	O
the	O
dose	O
range	O
studied	O
.	O


All	O
patients	B-P
received	O
total	B-I
abdominal	I-I
hysterectomy	I-I
and	I-I
bilateral	I-I
salpingo-oophorectomy	I-I
plus	I-I
complementary	I-I
radium	I-I
therapy	I-I
on	I-I
the	I-I
vaginal	I-I
stump	I-I
.	I-I


After	O
the	O
conventional	O
treatment	O
,	O
patients	O
were	O
randomly	O
allocated	O
to	O
adjuvant	B-I
hormone	I-I
therapy	I-I
or	I-I
no	I-I
further	I-I
treatment	I-I
.	I-I


The	O
effect	O
of	O
meal	O
ingestion	O
and	O
meal	O
composition	O
on	O
the	O
CV	O
responses	O
to	O
orthostasis	O
are	O
unknown	O
.	O


Cardiac	B-OUT
output	I-OUT
(	I-OUT
CO	I-OUT
)	I-OUT
,	I-OUT
forearm	I-OUT
blood	I-OUT
flow	I-OUT
(	I-OUT
FABF	I-OUT
)	I-OUT
heart	I-OUT
rate	I-OUT
(	I-OUT
HR	I-OUT
)	I-OUT
and	I-OUT
blood	I-OUT
pressure	I-OUT
(	I-OUT
BP	I-OUT
)	I-OUT
were	O
measured	O
before	O
and	O
during	O
LBSP	O
while	O
fasted	O
and	O
after	O
eating	B-I
HC	I-I
and	I-I
HF	I-I
meals	I-I
.	I-I


Both	O
meals	O
resulted	O
in	O
a	O
fall	O
in	O
total	B-OUT
peripheral	I-OUT
resistance	I-OUT
but	O
only	O
HC	O
led	O
to	O
a	O
significant	O
fall	O
in	O
BP	B-OUT
(	O
p	O
<	O
0.05	O
)	O
.	O


The	B-OUT
joint	I-OUT
distribution	I-OUT
of	I-OUT
costs	I-OUT
and	I-OUT
QALY	I-OUT
benefits	I-OUT
indicates	O
that	O
the	O
probability	O
of	O
simvastatin	B-OUT
being	I-OUT
cost-effective	I-OUT
for	O
willingness-to-pay	O
thresholds	O
of	O
£20,000	O
and	O
£30,000	O
is	O
86	O
%	O
and	O
83	O
%	O
,	O
respectively	O
.	O


This	O
provides	O
an	O
opportunity	O
to	O
impart	O
lifestyle	O
advice	O
.	O


The	O
additional	O
value	O
of	O
a	O
night	B-I
splint	I-I
to	I-I
eccentric	I-I
exercises	I-I
in	O
chronic	B-P
midportion	I-P
Achilles	I-P
tendinopathy	I-P
:	I-P
a	O
randomised	O
controlled	O
trial	O
.	O


DESIGN	O
Randomized	O
and	O
placebo-controlled	B-I
study	O
.	O


RESULTS	O
The	O
duration	B-OUT
of	I-OUT
hypoxemia	I-OUT
(	I-OUT
transcutaneous	I-OUT
partial	I-OUT
pressure	I-OUT
of	I-OUT
O2	I-OUT
<	O
6.6	O
kPa	O
(	O
<	O
50	O
mm	O
Hg	O
)	O
and/or	O
arterial	B-OUT
blood	I-OUT
oxygen	I-OUT
saturation	I-OUT
<	O
80	O
%	O
)	O
during	O
treatment	O
procedures	O
was	O
significantly	O
longer	O
in	O
the	O
saline	O
group	O
(	O
mean	O
82	O
vs	O
36	O
seconds	O
,	O
P	O
=	O
.001	O
)	O
and	O
distress	O
quantified	O
by	O
a	O
novel	O
behavioral	O
scoring	O
method	O
was	O
much	O
higher	O
.	O


The	O
effects	O
of	O
feeding	O
diets	O
with	O
different	O
milliequivalents	O
(	O
meq	O
)	O
of	O
dietary	O
[	B-I
(	I-I
Na+	I-I
+	I-I
K+	I-I
)	I-I
-	I-I
(	I-I
Cl-	I-I
+	I-I
SO4=	I-I
)	I-I
]	I-I
to	O
dairy	B-P
cows	I-P
during	I-P
the	I-P
last	I-P
seven	I-P
weeks	I-P
of	I-P
pregnancy	I-P
on	O
their	O
acid-base	O
status	O
and	O
calcium	O
mobilisation	O
rate	O
around	O
parturition	O
were	O
studied	O
.	O


Changes	O
in	O
meq	O
of	O
dietary	B-OUT
[	I-OUT
(	I-OUT
Na+	I-OUT
+	I-OUT
K+	I-OUT
)	I-OUT
-	I-OUT
(	I-OUT
Cl-	I-OUT
+	I-OUT
SO4=	I-OUT
)	I-OUT
]	I-OUT
were	O
achieved	O
by	O
adding	O
KCl	B-I
,	I-I
K2SO4	I-I
and	I-I
(	I-I
NH4	I-I
)	I-I
2SO4	I-I
(	I-I
anion	I-I
diet	I-I
)	I-I
or	I-I
K2CO3	I-I
(	I-I
cation	I-I
diet	I-I
)	I-I
to	O
basal	O
concentrates	O
.	O


Visual	B-OUT
acuity	I-OUT
was	O
decreased	O
to	O
0.9	O
+/-	O
0.23	O
in	O
the	O
Crazy	O
lens	O
group	O
as	O
compared	O
with	O
1.2	O
+/-	O
0.13	O
in	O
the	O
clear	B-I
lens	I-I
group	O
.	O


Contrast	B-OUT
sensitivity	I-OUT
was	O
significantly	O
reduced	O
in	O
a	O
photopic	O
condition	O
with	O
and	O
without	O
glare	O
and	O
in	O
a	O
scotopic	O
condition	O
without	O
glare	O
.	O


CONCLUSIONS	O
Special-effect	B-I
contact	I-I
lenses	I-I
were	O
associated	O
with	O
a	O
reduction	O
of	O
many	O
visual	B-OUT
functions	I-OUT
,	O
including	O
visual	B-OUT
acuity	I-OUT
and	I-OUT
contrast	I-OUT
sensitivity	I-OUT
.	I-OUT


The	O
initial	O
dose	O
of	O
sertraline	B-I
was	O
50	O
mg/day	O
with	O
increases	O
of	O
50	O
mg/day	O
every	O
3	O
weeks	O
permitted	O
after	O
the	O
fourth	O
week	O
of	O
treatment	O
(	O
dosing	O
was	O
flexible	O
up	O
to	O
a	O
maximum	O
of	O
200	O
mg/day	O
)	O
.	O


RESULTS	O
In	O
intent-to-treat	O
endpoint	O
analyses	O
of	O
203	O
of	O
the	O
patients	O
,	O
significantly	O
more	O
of	O
the	O
134	B-P
patients	I-P
given	I-P
sertraline	I-I
(	O
N=71	O
[	O
53	O
%	O
]	O
)	O
than	O
of	O
the	O
69	B-P
patients	I-P
receiving	I-P
placebo	I-I
(	O
N=20	O
[	O
29	O
%	O
]	O
)	O
were	O
considered	O
responders	O
according	O
to	O
their	O
CGI	B-OUT
improvement	I-OUT
scores	I-OUT
at	O
the	O
end	O
of	O
treatment	O
.	O


Analysis	O
of	O
covariance	O
showed	O
superiority	O
of	O
sertraline	B-I
over	O
placebo	B-I
on	O
all	O
primary	O
and	O
secondary	O
efficacy	B-OUT
measures	I-OUT
.	I-OUT


The	O
use	O
of	B-I
BCG	I-I
administered	O
intraperitoneally	O
in	O
a	B-P
randomized	I-P
study	I-P
of	I-P
patients	I-P
with	I-P
gastric	I-P
,	I-P
pancreatic	I-P
and	I-P
colorectal	I-P
cancer	I-P
proved	O
of	O
no	B-OUT
benefit	I-OUT
.	O


On	O
the	O
other	O
hand	O
,	O
when	B-I
BCG	I-I
was	O
given	O
orally	O
in	O
a	B-P
randomized	I-P
study	I-P
of	I-P
patients	I-P
with	I-P
resectable	I-P
cancer	I-P
of	I-P
the	I-P
colon	I-P
and	O
in	O
nonrandomized	O
consecutive	O
studies	O
of	B-P
patients	I-P
with	I-P
malignant	I-P
melanoma	I-P
and	I-P
stage	I-P
IV	I-P
carcinoma	I-P
of	I-P
the	I-P
breast	I-OUT
survival	I-OUT
was	O
increased	O
.	O


Lumbar	B-I
epidural	I-I
anesthesia	I-I
with	I-I
20	I-I
ml	I-I
of	I-I
either	I-I
3	I-I
%	I-I
2-chloroprocaine	I-I
(	I-I
C	I-I
)	I-I
,	I-I
1.5	I-I
%	I-I
lidocaine	I-I
(	I-I
L	I-I
)	I-I
,	I-I
or	I-I
1.5	I-I
%	I-I
mepivacaine	I-I
(	I-I
M	I-I
)	I-I
with	I-I
epinephrine	I-I
was	O
studied	O
in	O
84	B-P
outpatients	I-P
undergoing	I-P
surgery	I-P
(	I-P
extracorporeal	I-P
shock	I-P
wave	I-P
lithotripsy	I-P
(	I-P
ESWL	I-P
]	I-P
.	I-P


In	O
contrast	O
to	O
previous	O
understanding	O
,	O
mepivacaine	O
produces	O
significantly	O
longer	O
anesthesia	O
and	O
recovery	O
times	O
and	O
may	O
not	O
be	O
optimal	O
for	O
outpatient	O
epidural	O
use	O
.	O


The	B-OUT
amount	I-OUT
of	I-OUT
glucose	I-OUT
infused	I-OUT
at	I-OUT
steady-state	I-OUT
to	O
maintain	B-OUT
stable	I-OUT
blood	I-OUT
glucose	I-OUT
[	O
90	O
mg/dl	O
(	O
4.95	O
mmol/l	O
)	O
]	O
was	O
used	O
to	O
calculate	O
several	O
indices	O
of	O
insulin	O
sensitivity	O
.	O


Age	O
,	O
sex	O
,	O
and	O
body	O
mass	O
index	O
were	O
matched	O
among	O
groups	O
.	O


Of	O
note	O
,	O
when	O
compared	O
with	O
omega-3	O
fatty	O
acids	O
,	O
fenofibrate	O
therapy	O
decreased	O
fasting	B-OUT
insulin	I-OUT
(	O
P=0.023	O
)	O
and	O
increased	O
plasma	B-OUT
adiponectin	I-OUT
(	O
P=0.002	O
)	O
and	O
insulin	B-OUT
sensitivity	I-OUT
(	O
P=0.015	O
)	O
.	O


PATIENTS	O
AND	O
METHODS	O
Fifteen	B-P
patients	I-P
with	I-P
mouth	I-P
leak	I-P
complaining	I-P
of	I-P
mouth	I-P
dryness	I-P
and	I-P
nasal	I-P
obstruction	I-P
underwent	O
two	B-I
consecutive	I-I
overnight	I-I
polysomnographies	I-I
,	I-I
one	I-I
with	I-I
a	I-I
chinstrap	I-I
,	I-I
in	I-I
random	I-I
order	I-I
.	I-I


The	O
arousal	B-OUT
index	I-OUT
was	O
significantly	O
higher	O
during	O
leak	O
periods	O
,	O
and	O
its	O
changes	O
correlated	O
positively	O
with	O
changes	O
in	O
mouth	B-OUT
leak	I-OUT
.	I-OUT


The	O
characteristics	O
of	O
the	O
VACs	O
,	O
including	O
the	O
sites	O
,	O
procedures	O
,	O
and	O
lengths	O
,	O
were	O
similar	O
in	O
both	O
groups	O
.	O


No	O
significant	O
difference	O
in	O
the	O
rate	B-OUT
of	I-OUT
catheter	I-OUT
colonization	I-OUT
was	O
observed	O
between	O
the	O
groups	O
(	O
14.6	O
%	O
vs	O
26.2	O
%	O
,	O
P	O
=	O
0.1371	O
)	O
.	O


The	O
ASD	B-P
group	I-P
recognised	O
a	O
similar	O
number	O
of	O
to-be-forgotten	B-OUT
words	I-OUT
as	O
the	O
TD	O
group	O
,	O
but	O
significantly	O
fewer	O
to-be-learned	B-OUT
words	I-OUT
.	I-OUT


This	O
deficit	B-OUT
was	O
only	O
evident	B-OUT
in	I-OUT
Remember	I-OUT
responses	I-OUT
that	O
reflect	O
autonoetic	B-OUT
awareness	I-OUT
,	I-OUT
or	I-OUT
episodic	I-OUT
memory	I-OUT
,	I-OUT
and	I-OUT
not	I-OUT
Know	I-OUT
responses	I-OUT
.	I-OUT


The	O
presence	O
of	O
CHF	O
clinical	O
features	O
was	O
an	O
important	O
determinant	O
of	O
plasma	O
vWf	O
concentrations	O
.	O


The	O
ET-1	B-OUT
and	I-OUT
its	I-OUT
receptor	I-OUT
genes	I-OUT
were	O
expressed	O
in	O
the	O
right	O
and	O
left	O
ventricles	O
of	O
control	O
and	O
T	O
(	O
3	O
)	O
-treated	O
broilers	O
at	O
12	O
,	O
28	O
and	O
49	O
days	O
of	O
age	O
.	O


Group	O
I	O
consisted	O
of	O
15	B-P
patients	I-P
with	I-P
Forrest	I-P
IB	I-P
and	O
Group	O
II	O
consisted	O
of	O
30	B-P
patients	I-P
with	I-P
Forrest	I-P
II	I-P
.	I-P


Two	O
regimens	O
were	O
randomly	O
allocated	O
to	O
all	O
patients	O
within	O
half	O
an	O
hour	O
after	O
the	O
endoscopic	O
procedure	O
:	O
1	O
)	O
somatostatin-UCB	B-I
250	O
mcg	O
i.v	O
.	O


infusion	O
for	O
72	O
h.	O
RESULTS	O
In	O
Group	O
I	O
,	O
although	O
mean	B-OUT
blood	I-OUT
transfusion	I-OUT
requirements	I-OUT
(	O
no	O
.	O


CONCLUSIONS	O
Somatostatin	B-I
is	O
more	O
effective	B-OUT
than	O
ranitidine	O
in	O
controlling	O
acute	B-OUT
non-variceal	I-OUT
gastrointestinal	I-OUT
bleeding	I-OUT
in	O
patients	O
with	O
Forrest	O
IB	O
bleeding	O
activity	O
.	O


EULAR	B-P
Sjogren	I-P
's	I-P
Syndrome	I-P
Disease	I-P
Activity	I-P
Index	I-P
(	I-P
ESSDAI	I-P
)	I-P
is	I-P
sensitive	I-P
to	I-P
show	I-P
efficacy	I-OUT
of	I-P
rituximab	I-I
treatment	I-I
in	I-P
a	I-P
randomised	I-P
controlled	I-P
trial	I-P
.	I-P


Virologic	B-OUT
success	I-OUT
(	O
HIV-1	O
RNA	O
<	O
50	O
copies/mL	O
)	O
was	O
maintained	O
at	O
week	O
96	O
(	O
84	O
%	O
vs	O
82	O
%	O
,	O
difference	O
+2.7	O
%	O
,	O
95	O
%	O
CI	O
:	O
-2.9	O
%	O
to	O
8.3	O
%	O
)	O
.	O


Median	B-OUT
changes	I-OUT
in	I-OUT
serum	I-OUT
creatinine	I-OUT
(	O
mg/dL	O
)	O
at	O
week	O
96	O
were	O
similar	O
to	O
week	O
48	O
.	O


This	O
subtype	O
of	O
diabetes	O
is	O
known	O
as	O
ketosis-prone	O
type	O
2	O
diabetes	O
(	O
KPDM	O
)	O
.	O


P	O
=	O
NS	O
despite	O
a	O
fourfold	O
increase	O
in	O
free	B-OUT
fatty	I-OUT
acid	I-OUT
(	I-OUT
FFA	I-OUT
)	I-OUT
levels	I-OUT
(	O
0.4	O
+/-	O
0.3	O
to	O
1.8	O
+/-	O
1.1	O
mmol/l	O
,	O
P	O
<	O
0.01	O
)	O
during	O
the	O
48-h	O
intralipid	B-I
infusion	I-I
;	I-I
the	O
response	B-OUT
to	I-OUT
AIR	I-OUT
(	I-OUT
arg	I-OUT
)	I-OUT
stimulation	I-OUT
,	O
as	O
well	O
as	O
changes	O
in	O
insulin	B-OUT
and	I-OUT
C-peptide	I-OUT
levels	I-OUT
,	O
were	O
similar	O
among	O
obese	O
patients	O
with	O
KPDM	O
,	O
patients	O
with	O
ketosis-resistant	O
type	O
2	O
diabetes	O
,	O
and	O
nondiabetic	O
control	O
subjects	O
.	O


After	O
five	O
years	O
this	O
difference	O
was	O
no	O
longer	O
statistically	O
significant	O
and	O
children	B-P
who	I-P
presented	I-P
anti-HBsAg	I-OUT
concentrations	I-OUT
below	I-OUT
10	I-OUT
mUI/ml	I-OUT
received	O
an	O
additional	O
booster	O
dose	O
which	O
stimulated	O
the	O
antibody	B-OUT
concentration	I-OUT
to	I-OUT
exceed	I-OUT
100	I-OUT
mIU/ml	I-OUT
in	I-OUT
all	O
cases	O
.	O


Patients	O
were	O
randomised	O
to	O
receive	O
either	O
four	O
or	O
eight	O
courses	O
of	O
cytotoxic	B-I
chemotherapy	I-I
with	I-I
cyclophosphamide	I-I
,	I-I
vincristine	I-I
and	I-I
etoposide	I-I
and	O
also	O
randomised	O
to	O
receive	O
,	O
on	O
disease	O
progression	O
,	O
either	O
second	B-I
line	I-I
chemotherapy	I-I
(	I-I
methotrexate	I-I
and	I-I
doxorubicin	I-I
)	I-I
or	I-I
symptomatic	I-I
treatment	I-I
only	I-I
.	I-I


MATERIALS	O
AND	O
METHODS	O
Testing	O
was	O
done	O
using	O
a	O
Questionnaire	O
in	O
a	O
"	O
True/False	O
"	O
format	O
.	O


Results	O
were	O
analysed	O
using	O
a	O
Student	O
's	O
t	O
test	O
analysis	O
.	O


The	O
students	O
taught	O
on	O
an	O
integrated	O
course	O
showed	O
a	O
much	O
greater	O
range	B-OUT
of	I-OUT
results	I-OUT
.	I-OUT


CONCLUSIONS	O
Dietary	B-I
PUFA	I-I
supplementation	I-I
markedly	O
potentiates	O
baroreflex	O
function	O
and	O
enhances	O
heart	B-OUT
rate	I-OUT
variability	I-OUT
in	O
patients	B-P
with	I-P
stable	I-P
congestive	I-P
heart	I-P
failure	I-P
.	I-P


The	O
study	O
consisted	O
of	O
23	B-P
patients	I-P
(	I-P
13	I-P
females	I-P
and	I-P
10	I-P
males	I-P
)	I-P
with	I-P
a	I-P
bilateral	I-P
maxillary	I-P
deficiency	I-P
.	I-P


Comparison	O
of	O
neurocognitive	B-OUT
functioning	I-OUT
in	O
children	B-P
previously	I-P
randomly	I-P
assigned	I-P
to	I-P
intrathecal	I-I
methotrexate	I-I
compared	O
with	O
triple	B-I
intrathecal	I-I
therapy	I-I
for	O
the	O
treatment	O
of	O
childhood	B-P
acute	I-P
lymphoblastic	I-P
leukemia	I-P
.	I-P


PATIENTS	O
AND	O
METHODS	O
In	O
this	O
multisite	O
study	O
,	O
171	B-P
children	I-P
with	I-P
standard-risk	I-P
ALL	I-P
,	I-P
age	I-P
1	I-P
to	I-P
9.99	I-P
years	I-P
at	I-P
diagnosis	I-P
,	I-P
previously	I-P
randomly	I-P
assigned	I-P
to	I-P
IT	I-I
methotrexate	I-I
(	I-P
n	I-P
=	I-P
82	I-P
)	I-P
or	I-P
to	I-P
triple	I-I
IT	I-I
therapy	I-I
(	I-P
n	I-P
=	I-P
89	I-P
)	I-P
on	I-P
CCG	I-P
1952	I-P
,	I-P
underwent	I-P
neurocognitive	I-P
evaluation	I-P
by	I-P
a	I-P
licensed	I-P
psychologist	I-P
at	I-P
a	I-P
mean	I-P
of	I-P
5.9	I-P
years	I-P
after	I-P
random	I-P
assignment	I-P
.	I-P


Likewise	O
,	O
19.5	B-P
%	I-P
of	I-P
children	I-P
in	I-P
the	I-P
IT	I-I
methotrexate	I-I
group	I-P
had	O
a	O
Processing	B-OUT
Speed	I-OUT
Index	I-OUT
score	I-OUT
in	O
the	O
below-average	O
range	O
compared	O
with	O
6.9	O
%	O
in	O
the	O
triple	B-I
IT	I-I
therapy	I-I
group	I-I
(	O
P	O
=	O
.02	O
)	O
.	O


The	O
Breast	O
Cancer	O
Prevention	O
Trial	O
is	O
the	O
largest	O
breast	O
cancer	O
prevention	O
study	O
ever	O
undertaken	O
.	O


Administered	O
by	O
the	O
National	O
Surgical	O
Adjuvant	O
Breast	O
and	O
Bowel	O
Project	O
,	O
it	O
is	O
the	O
first	O
trial	O
seeking	O
to	O
demonstrate	O
whether	O
a	O
drug	O
,	O
tamoxifen	B-I
,	O
can	O
prevent	B-P
breast	I-P
cancer	I-P
in	I-P
high-risk	I-P
women	I-P
.	I-P


Furthermore	O
,	O
patients	B-P
with	I-P
CHF	I-P
are	O
often	O
on	O
numerous	O
pharmacological	O
agents	O
for	O
their	O
comorbidities	O
.	O


INTERVENTIONS	O
Single-dose	O
intranasal	O
administration	O
of	O
oxytocin	B-I
(	I-I
24	I-I
IU	I-I
)	I-I
and	O
placebo	B-I
.	I-I


In	O
our	O
previous	O
case-control	O
study	O
using	O
the	O
same	O
psychological	O
task	O
,	O
when	O
making	O
decisions	O
about	O
social	O
information	O
with	O
conflicting	O
verbal	O
and	O
nonverbal	O
contents	O
,	O
participants	O
with	O
ASD	O
made	O
judgments	O
based	O
on	O
nonverbal	O
contents	O
less	O
frequently	O
with	O
longer	O
time	O
and	O
could	O
not	O
induce	O
enough	O
activation	O
in	O
the	O
medial	O
prefrontal	O
cortex	O
.	O


DESIGN	O
Prospective	O
,	O
randomized	O
,	O
parallel	O
,	O
single-blind	O
(	O
investigator	O
)	O
,	O
placebo-controlled	B-I
,	O
multicenter	O
clinical	O
trial	O
.	O


Secondary	O
:	O
muscle	B-OUT
stiffness	I-OUT
(	I-OUT
101-point	I-OUT
numeric	I-OUT
rating	I-OUT
scale	I-OUT
)	I-OUT
,	I-OUT
lateral	I-OUT
trunk	I-OUT
flexibility	I-OUT
(	I-OUT
fingertip-floor	I-OUT
distance	I-OUT
)	I-OUT
,	I-OUT
and	I-OUT
Roland-Morris	I-OUT
Disability	I-OUT
Questionnaire	I-OUT
over	O
3	O
days	O
of	O
treatment	O
and	O
2	O
days	O
of	O
follow-up	O
.	O


Assessment	O
of	O
safety	B-OUT
and	I-OUT
clinical	I-OUT
efficacy	I-OUT
over	O
a	O
1-month	O
period	O
included	O
timed	O
tests	O
of	O
gait	B-OUT
and	I-OUT
bradykinesia	I-OUT
,	I-OUT
Unified	I-OUT
Parkinson	I-OUT
's	I-OUT
Disease	I-OUT
Rating	I-OUT
Scale	I-OUT
(	I-OUT
UPDRS	I-OUT
)	I-OUT
,	I-OUT
and	I-OUT
additional	I-OUT
clinical	I-OUT
,	I-OUT
neuropsychological	I-OUT
,	I-OUT
and	I-OUT
neurophysiologic	I-OUT
measures	I-OUT
.	I-OUT


Various	O
large	B-I
volume	I-I
cuffed	I-I
endotracheal	I-I
tubes	I-I
were	O
studied	O
,	O
including	O
Portex	B-I
Profile	I-I
,	I-I
Searle	I-I
Sensiv	I-I
,	I-I
Mallinkrodt	I-I
Hi-Lo	I-I
,	O
and	O
Lanz	B-I
.	I-I


This	O
impairment	O
of	O
tracheal	B-OUT
mucosal	I-OUT
blood	I-OUT
flow	I-OUT
is	O
an	O
important	O
factor	O
in	O
tracheal	B-OUT
morbidity	I-OUT
associated	O
with	O
intubation	O
.	O


Combination	B-I
therapy	I-I
cleared	O
all	O
AK	O
lesions	O
only	O
after	O
the	O
first	O
course	O
,	O
while	B-I
PDT	I-I
and	I-I
imiquimod	I-I
therapy	I-I
cleared	O
41.7	O
%	O
and	O
66.7	O
%	O
of	O
AK	O
lesions	O
after	O
the	O
first	O
course	O
,	O
respectively	O
.	O


Most	B-P
Japanese	I-P
AK	I-P
lesions	I-P
can	O
be	O
satisfactorily	O
treated	O
with	O
either	B-I
PDT	I-I
or	I-I
imiquimod	I-I
monotherapy	I-I
.	O


If	O
a	O
negative	O
pressure	O
drainage	O
system	O
is	O
to	O
be	O
used	O
,	O
a	O
low	O
pressure	O
suction	O
drain	O
should	O
be	O
used	O
in	O
preference	O
to	O
a	O
high	O
pressure	O
system	O
.	O


BACKGROUND	O
In	O
the	O
BIGPRO	O
1	O
trial	O
,	O
one	O
year	O
of	O
treatment	O
with	O
metformin	B-I
in	O
non-diabetic	B-P
obese	I-P
subjects	I-P
with	I-P
a	I-P
central	I-P
fat	I-P
distribution	I-P
had	O
no	O
significant	O
effect	O
on	O
fasting	O
plasma	O
triglyceride	O
concentration	O
or	O
on	O
blood	O
pressure	O
despite	O
a	O
decrease	O
in	O
weight	O
,	O
fasting	O
plasma	O
insulin	O
and	O
glucose	O
concentrations	O
.	O


CONCLUSIONS	O
The	O
consistency	O
of	O
the	O
two	O
BIGPRO	O
trials	O
supports	O
the	O
conclusion	O
that	O
metformin	B-I
affects	O
several	O
cardiovascular	O
risk	O
factors	O
favourably	O
in	O
non-diabetic	B-P
subjects	I-P
with	I-P
a	I-P
central	I-P
fat	I-P
distribution	I-P
.	I-P


CCT	B-I
and	O
tDCS	B-I
were	O
applied	O
for	O
10	O
consecutive	O
workdays	O
.	O


METHODS	O
A	O
10-month	O
three-armed	O
cluster-randomized	O
controlled	O
trial	O
compared	O
DCM	B-I
and	O
VPM	B-I
with	O
control	O
.	O


RESULTS	O
Changes	O
in	O
the	O
BARS	B-OUT
score	I-OUT
did	O
not	O
differ	O
significantly	O
between	O
the	O
DCM	O
and	O
the	O
control	O
group	O
or	O
between	O
the	O
VPM	O
and	O
the	O
control	O
group	O
after	O
10	O
months	O
.	O


BACKGROUND	O
Seizures	O
occur	O
in	O
1	O
to	O
2	O
percent	O
of	O
neonates	B-P
admitted	I-P
to	I-P
an	I-P
intensive	I-P
care	I-P
unit	I-P
.	I-P


CONCLUSIONS	O
Phenobarbital	B-I
and	O
phenytoin	B-I
are	O
equally	O
but	O
incompletely	O
effective	O
as	O
anticonvulsants	B-OUT
in	O
neonates	B-P
.	I-P


Patients	O
were	O
evaluated	O
clinically	O
for	O
48	O
weeks	O
after	O
initiation	O
of	O
therapy	O
.	O


A	O
prospective	O
,	O
randomized	O
,	O
controlled	O
study	O
on	O
cefotiam	B-I
.	I-I


Administration	O
of	O
cefotiam	B-I
was	O
randomized	O
for	O
patients	B-P
undergoing	I-P
major	I-P
craniotomies	I-P
.	I-P


Excluded	B-P
were	I-P
contaminated	I-P
cases	I-P
,	I-P
operations	I-P
with	I-P
a	I-P
transnasal-transsphenoidal	I-P
approach	I-P
,	I-P
shunt-operations	I-P
and	I-P
patients	I-P
with	I-P
any	I-P
other	I-P
preoperative	I-P
infection	I-P
or	I-P
antibiotic	I-I
therapy	I-I
.	I-I


Outpatients	B-P
were	I-P
excluded	I-P
due	I-P
to	I-P
difficulties	I-P
in	I-P
obtaining	I-P
sufficient	I-P
clinical	I-P
information	I-P
.	I-P


With	B-P
regard	I-P
to	I-P
age	I-P
,	I-P
sex	I-P
,	I-P
diagnosis	I-P
and	I-P
the	I-P
site	I-P
of	I-P
te	I-P
trepanation	I-P
,	I-P
control	I-I
patients	I-I
(	I-P
n	I-P
=	I-P
355	I-P
)	I-P
and	I-P
cefotiam	I-P
treated	I-P
patients	I-P
(	I-P
n	I-P
=	I-P
356	I-P
)	I-P
were	I-P
shown	I-P
to	I-P
be	I-P
comparable	I-P
.	I-P


Thus	O
it	O
was	O
concluded	O
that	O
a	O
single	O
dose	O
of	O
cefotiam	O
significantly	O
reduces	O
post-operative	B-OUT
deep	I-OUT
wound	I-OUT
infection	I-OUT
.	I-OUT


Group	O
S	O
presented	O
an	O
increase	O
(	O
P	O
<	O
0.05	O
)	O
in	O
total	B-OUT
cholesterol	I-OUT
,	I-OUT
LDL	I-OUT
and	I-OUT
LDL	I-OUT
:	I-OUT
HDL	I-OUT
ratio	I-OUT
,	O
whilst	O
HDL	B-OUT
diminished	O
(	O
P	O
=	O
0.03	O
)	O
.	O


Quality	B-OUT
of	I-OUT
sleep	I-OUT
was	O
also	O
improved	O
with	O
desmopressin	B-I
versus	O
placebo	B-I
(	O
statistically	O
significant	O
for	O
one	O
of	O
the	O
two	O
parameters	O
evaluated	O
)	O
.	O


We	O
have	O
developed	O
novel	B-I
molecular	I-I
methods	I-I
using	O
a	O
stool	O
sample	O
,	O
which	O
contains	O
intact	O
sloughed	O
colon	O
cells	O
,	O
to	O
quantify	O
colonic	O
gene	O
expression	O
profiles	O
.	O


In	O
this	O
study	O
,	O
our	O
goal	O
was	O
to	O
identify	O
diagnostic	O
gene	O
sets	O
(	O
combinations	O
)	O
for	O
the	O
noninvasive	O
classification	O
of	O
different	O
phenotypes	O
.	O


Hair	O
analysis	O
and	O
biophysical	O
properties	O
of	O
the	O
skin	O
were	O
assessed	O
before	O
treatment	O
and	O
at	O
weeks	O
2	O
,	O
4	O
and	O
6	O
after	O
the	O
therapy	O
.	O


Regarding	O
comparison	O
of	O
the	O
biophysical	O
properties	O
of	O
the	O
skin	O
,	O
there	O
was	O
no	O
statistically	O
significant	O
difference	O
in	O
the	O
assessments	O
,	O
except	O
for	O
the	O
increase	O
determined	O
during	O
the	O
second	O
week	O
in	O
the	O
erythema	B-OUT
index	I-OUT
in	O
the	O
laser-treated	O
areas	O
.	O


Topical	B-I
PUVA	I-I
,	I-I
etretinate	I-I
,	O
and	O
combined	B-I
PUVA	I-I
and	I-I
etretinate	I-I
for	O
palmoplantar	O
pustulosis	O
:	O
comparison	O
of	O
therapeutic	B-OUT
efficacy	I-OUT
and	O
the	O
influences	O
of	O
tonsillar	B-OUT
and	I-P
dental	I-P
focal	I-P
infections	I-P
.	I-P


UVA-control	O
sites	O
failed	O
to	O
be	O
cleared	B-OUT
within	O
12	O
weeks	O
.	O


Tonsillar	B-OUT
focal	I-OUT
infection	I-OUT
(	I-OUT
TFI	I-OUT
)	I-OUT
and	I-OUT
dental	I-OUT
focal	I-OUT
infection	I-OUT
(	I-OUT
DFI	I-OUT
)	I-OUT
were	O
found	O
in	O
6/20	O
and	O
17/20	O
patients	O
,	O
respectively	O
.	O


METHODS	O
We	O
evaluated	O
the	O
effects	B-OUT
of	O
calcitriol	B-I
(	I-I
1alpha,25-dihydroxyvitamin	I-I
D3	I-I
)	I-I
on	O
bone	B-OUT
mineral	I-OUT
density	I-OUT
(	I-OUT
BMD	I-OUT
)	I-OUT
in	O
76	B-P
patients	I-P
(	I-P
26	I-P
men	I-P
and	I-P
50	I-P
women	I-P
)	I-P
with	I-P
cirrhosis	I-P
who	O
were	O
assigned	O
randomly	B-I
to	I-I
receive	I-I
calcitriol	I-I
(	I-I
0.5	I-I
mg	I-I
twice	I-I
per	I-I
day	I-I
)	I-I
or	I-I
not	I-I
.	I-I


The	O
median	O
(	O
25th	O
and	O
75th	O
percentiles	O
)	O
annual	O
change	O
in	O
BMD	B-OUT
was	O
-0.5	O
(	O
-1.8	O
,	O
1.3	O
%	O
)	O
in	O
the	O
treated	O
group	O
and	O
-1.5	O
(	O
-3.8	O
,	O
-0.7	O
%	O
)	O
in	O
the	O
control	B-P
group	I-P
.	I-P


Starting	B-OUT
from	I-OUT
an	I-OUT
equivalent	I-OUT
baseline	I-OUT
of	I-OUT
correct	I-OUT
answers	I-OUT
to	I-OUT
a	I-OUT
specially	I-OUT
designed	I-OUT
multiple-choice	I-OUT
questionnaire	I-OUT
(	I-OUT
47	I-OUT
%	I-OUT
in	I-OUT
the	I-OUT
counselor	I-OUT
group	I-OUT
and	I-OUT
45	I-OUT
%	I-OUT
in	I-OUT
the	I-OUT
computer	I-OUT
group	I-OUT
)	I-OUT
both	I-OUT
groups	I-OUT
showed	I-OUT
a	I-OUT
highly	I-OUT
significant	I-OUT
and	I-OUT
similar	I-OUT
increase	I-OUT
(	I-OUT
reaching	I-OUT
84	I-OUT
%	I-OUT
in	I-OUT
the	I-OUT
counselor	I-OUT
group	I-OUT
and	I-OUT
85	I-OUT
%	I-OUT
in	I-OUT
the	I-OUT
computer	I-OUT
group	I-OUT
)	I-OUT
.	I-OUT


The	O
computer	O
program	O
under	O
evaluation	O
can	O
successfully	O
educate	O
individuals	O
considering	O
genetic	O
testing	O
for	O
CF	O
.	O


Ninety-one	B-P
female	I-P
bulimic	I-P
outpatients	I-P
received	O
lithium	B-I
carbonate	I-I
or	I-I
placebo	I-I
on	O
a	O
random	O
basis	O
,	O
after	O
being	O
separated	O
into	O
depressed	B-P
and	I-P
nondepressed	I-P
subgroups	O
,	O
in	O
an	O
8-week	O
double-blind	O
trial	O
.	O


However	O
,	O
depression	B-OUT
and	I-OUT
other	I-OUT
psychopathologies	I-OUT
decreased	O
with	O
improvement	O
in	O
bulimic	B-OUT
behavior	I-OUT
.	I-OUT


Secondly	O
,	O
to	O
quantify	O
pathological	O
fractures	O
after	O
combined	O
treatment	O
.	O


23.3	O
%	O
of	O
the	O
patients	O
in	O
group	O
A	O
and	O
30.0	O
%	O
of	O
the	O
patients	O
in	O
group	O
B	O
had	O
pathological	B-OUT
fractures	I-OUT
,	O
no	O
fracture	O
was	O
assigned	O
to	O
intervention	O
,	O
and	O
no	O
difference	O
between	O
groups	O
after	O
3	O
and	O
6	O
months	O
was	O
observed	O
(	O
p	O
=	O
0.592	O
and	O
p	O
=	O
0.604	O
)	O
.	O


CONCLUSIONS	O
Our	O
trial	O
demonstrated	O
that	O
resistance	B-I
training	I-I
concomitant	I-I
to	I-I
RT	I-I
can	O
improve	O
bone	B-OUT
density	I-OUT
in	O
spinal	O
bone	O
metastases	O
.	O


Randomized	O
,	O
controlled	O
trial	O
of	O
an	O
intervention	B-I
for	O
toddlers	B-P
with	I-P
autism	I-P
:	I-P
the	O
Early	O
Start	O
Denver	O
Model	O
.	O


OBJECTIVE	O
To	O
conduct	O
a	O
randomized	O
,	O
controlled	O
trial	O
to	O
evaluate	O
the	O
efficacy	B-OUT
of	O
the	O
Early	B-I
Start	I-I
Denver	I-I
Model	I-I
(	I-I
ESDM	I-I
)	I-I
,	O
a	O
comprehensive	O
developmental	O
behavioral	O
intervention	O
,	O
for	O
improving	O
outcomes	O
of	O
toddlers	B-P
diagnosed	I-P
with	I-P
autism	I-P
spectrum	I-P
disorder	I-P
(	I-P
ASD	I-P
)	I-P
.	I-P


The	O
purpose	O
of	O
this	O
investigation	O
was	O
to	O
determine	O
:	O
(	O
1	O
)	O
Is	O
positioning	O
with	O
the	O
unaffected	O
lung	O
in	O
the	O
dependent	O
lateral	O
position	O
related	O
to	O
increased	O
arterial	O
blood	O
saturation	O
levels	O
and	O
decreased	O
blood	O
pressure	O
,	O
pulse	O
and	O
respiration	O
?	O
(	O
2	O
)	O
What	O
is	O
the	O
relationship	O
between	O
the	O
dependent	O
variables	O
--	O
oxygenation	O
saturation	O
levels	O
,	O
blood	O
pressure	O
,	O
pulse	O
and	O
respiration	O
--	O
and	O
the	O
independent	O
variables	O
--	O
body	O
position	O
and	O
time	O
in	O
the	O
position	O
?	O
Thirty-nine	B-P
patients	I-P
with	I-P
unilateral	I-P
lung	I-P
pathology	I-P
were	O
positioned	B-I
on	I-I
their	I-I
sides	I-I
with	I-I
the	I-I
unaffected	I-I
lung	I-I
down	I-I
,	I-I
on	I-I
their	I-I
sides	I-I
with	I-I
the	I-I
affected	I-I
lung	I-I
down	I-I
,	I-I
and	I-I
also	I-I
in	I-I
semi-Fowler	I-I
's	I-I
position	I-I
.	I-I


Delavirdine	O
is	O
a	O
nonnucleoside	O
reverse	O
transcriptase	O
inhibitor	O
with	O
in	O
vitro	O
activity	O
against	O
human	B-OUT
immunodeficiency	I-OUT
virus	I-OUT
type	I-OUT
1	I-OUT
(	I-P
HIV-1	I-P
)	I-P
that	O
is	O
currently	O
being	O
evaluated	O
in	O
combination	O
regimens	O
with	O
various	O
nucleoside	O
analogs	O
,	O
including	O
didanosine	O
.	O


Tissue	O
samples	O
from	O
93	B-P
de	I-P
novo	I-P
diffuse	I-P
large	I-P
B-cell	I-P
lymphoma	I-P
patients	I-P
seen	I-P
between	I-P
1995	I-P
and	I-P
2009	I-P
randomly	I-P
receiving	I-P
either	I-P
standard	I-I
combination	I-I
chemotherapy	I-I
(	I-I
CHOP	I-I
,	I-P
n=48	I-P
)	I-P
or	I-I
the	I-I
identical	I-I
program	I-I
with	I-I
rituximab	I-I
(	I-P
n=45	I-P
)	I-P
were	O
subtyped	O
using	O
an	O
investigational	O
immunohistochemical	O
(	O
IHC	O
)	O
based	O
tissue	O
microarray	O
(	O
TMA	O
)	O
and	O
contrasted	O
to	O
the	O
approximately	O
corresponding	O
categories	O
as	O
defined	O
either	O
by	O
Hans	O
and	O
associates	O
using	O
a	O
three	O
marker	O
panel	O
into	O
germinal	O
or	O
non-germinal	O
centre	O
subtypes	O
or	O
by	O
Choi	O
and	O
colleagues	O
with	O
two	O
additional	O
antibodies	O
into	O
germinal	O
centre	O
(	O
GCB	O
)	O
or	O
activated	O
B-cells	O
(	O
ABC	O
)	O
.	O


Each	O
of	O
these	O
primary	O
subdivisions	O
was	O
further	O
evaluated	B-OUT
for	I-OUT
expression	I-OUT
of	I-OUT
BCL2	I-OUT
and	I-OUT
LMO2	I-OUT
both	O
of	O
which	O
are	O
recognised	O
to	O
predicate	O
response	O
.	O


Nevertheless	O
not	O
even	O
a	O
small	O
difference	O
could	O
be	O
demonstrated	O
in	O
the	O
presence	O
of	O
the	O
anti	O
CD	O
20	O
monoclonal	O
antibody	O
.	O


The	O
purpose	O
of	O
this	O
trial	O
is	O
to	O
explore	O
the	O
effect	O
of	O
two	O
different	O
potentially	O
important	O
design	O
features	O
on	O
clinical	B-OUT
reasoning	I-OUT
skills	I-OUT
and	I-OUT
the	I-OUT
student	I-OUT
experience	I-OUT
.	I-OUT


Additionally	O
a	O
15-item	B-OUT
self-reported	I-OUT
evaluation	I-OUT
is	O
completed	O
for	O
each	O
VP	B-I
,	O
based	O
on	O
a	O
widely	O
used	O
EViP	O
tool	O
.	O


Our	O
power	O
calculations	O
indicate	O
a	B-P
sample	I-P
size	I-P
of	I-P
112	I-P
is	I-P
required	I-P
for	O
both	O
primary	O
outcomes	O
.	O


DISCUSSION	O
This	O
trial	O
will	O
provide	O
robust	O
evidence	O
to	O
support	O
the	O
effectiveness	O
of	O
different	O
designs	O
of	O
virtual	O
patients	O
,	O
based	O
on	O
student	B-OUT
performance	I-OUT
and	I-OUT
evaluation	I-OUT
.	I-OUT


Between	O
1	O
year	O
and	O
7.5	O
years	O
,	O
three	O
breasts	O
with	O
smooth	B-OUT
and	I-OUT
textured	I-OUT
implants	I-OUT
contracted	I-OUT
and	I-OUT
one	I-OUT
with	I-OUT
a	I-OUT
textured	I-OUT
implant	I-OUT
softened.The	I-OUT
patients	O
reported	O
on	O
a	O
Visual	B-OUT
Analogue	I-OUT
Scale	I-OUT
(	O
1	O
to	O
10	O
)	O
the	O
impact	O
of	O
the	O
augmentation	O
on	O
their	O
quality	B-OUT
of	I-OUT
life	I-OUT
to	O
be	O
9	O
+/-	O
1	O
.	O


Four	O
patients	O
preferred	O
the	O
breast	O
with	O
the	O
smooth	O
prosthesis	O
,	O
three	O
preferred	O
the	O
breast	O
with	O
the	O
textured	O
prosthesis	O
,	O
and	O
the	O
others	O
found	O
both	O
breasts	O
equal	O
.	O


The	O
majority	O
of	O
the	O
patients	O
preferred	B-OUT
the	I-OUT
smooth	I-OUT
implants	I-OUT
.	I-OUT


Auditory	B-I
integration	I-I
training	I-I
and	I-I
a	I-I
control	I-I
treatment	I-I
were	O
provided	O
for	O
16	B-P
children	I-P
with	I-P
autism	I-OUT
in	O
a	O
crossover	O
experimental	O
design	O
.	O


No	B-OUT
differences	I-OUT
were	O
detected	O
on	O
teacher-rated	B-OUT
measures	I-OUT
.	I-OUT


Children	B-OUT
's	I-OUT
IQs	I-OUT
and	I-OUT
language	I-OUT
comprehension	I-OUT
did	I-OUT
not	I-OUT
increase	I-OUT
,	O
but	O
adaptive/social	B-OUT
behavior	I-OUT
scores	I-OUT
and	I-OUT
expressive	I-OUT
language	I-OUT
quotients	I-OUT
decreased	I-OUT
.	I-OUT


Mean	B-OUT
adherence	I-OUT
rates	I-OUT
based	O
on	O
self-reports	O
were	O
also	O
significantly	O
better	O
(	O
P	O
<	O
0.001	O
)	O
with	O
MF-DPI	O
400	O
microg	O
QD	O
PM	O
(	O
97.2	O
%	O
)	O
than	O
with	O
MF-DPI	O
200	O
microg	O
twice-daily	O
(	O
95.3	O
%	O
)	O
.	O


CONCLUSION	O
Mean	O
adherence	B-OUT
rates	I-OUT
were	O
greater	O
with	O
a	O
once-daily	O
dosing	O
regimen	O
of	O
MF-DPI	B-I
than	O
with	O
a	O
twice-daily	O
dosing	O
regimen.This	O
trial	O
was	O
completed	O
prior	O
to	O
the	O
ISMJE	O
requirements	O
for	O
trial	O
registration	O
.	O


PATIENTS	O
AND	O
METHODS	O
Between	B-P
January	I-P
1983	I-P
and	I-P
February	I-P
1989	I-P
,	I-P
a	I-P
total	I-P
of	I-P
165	I-P
patients	I-P
with	I-P
carcinoma	I-P
of	I-P
the	I-P
uterine	I-P
cervix	I-P
was	I-P
entered	I-P
in	I-P
a	I-P
prospective	I-P
randomized	I-P
study	I-P
concerning	I-P
the	I-P
point	I-P
A	I-P
dose	I-I
of	I-I
HDR	I-I
therapy	I-I
(	I-I
6	I-I
Gy/fraction	I-I
vs	I-I
7.5	I-I
Gy/fraction	I-I
)	I-I
and	I-I
external	I-I
irradiation	I-I
dose	I-I
at	I-I
Department	I-I
of	I-I
Radiation	I-I
Therapy	I-I
,	I-P
The	I-P
Center	I-P
for	I-P
Adult	I-P
Diseases	I-P
,	I-P
Osaka	I-P
.	I-P


In	O
each	O
stage	O
,	O
5-year	B-OUT
survival	I-OUT
rates	I-OUT
in	O
groups	O
A	O
and	O
B	O
were	O
100	O
%	O
,	O
93	O
%	O
in	O
stage	O
I	O
,	O
82	O
%	O
and	O
85	O
%	O
in	O
stage	O
II	O
,	O
62	O
%	O
and	O
52	O
%	O
in	O
stage	O
II	O
and	O
22	O
%	O
and	O
31	O
%	O
in	O
stage	O
IV	O
,	O
respectively	O
.	O


There	O
were	O
no	O
statistically	O
significant	O
differences	O
among	O
these	O
survival	O
curves	O
in	O
each	O
stage	O
.	O


BACKGROUND	O
Even	O
though	O
there	O
is	O
research	O
demonstrating	O
a	O
positive	O
relationship	O
between	O
leisure	O
participation	O
and	O
the	O
two	O
constructs	O
of	O
quality	B-OUT
of	I-OUT
life	I-OUT
and	I-OUT
stress	I-OUT
reduction	O
,	O
current	O
conceptualisation	O
of	O
leisure	O
as	O
a	O
contributor	O
to	O
quality	O
of	O
life	O
is	O
limited	O
.	O


RESULTS	O
There	O
was	O
a	O
significant	O
decrease	O
in	O
overall	O
scores	O
of	O
stress	B-OUT
levels	I-OUT
for	O
participants	O
over	O
the	O
course	O
of	O
the	O
study	O
and	O
there	O
was	O
a	O
significant	O
increase	O
in	O
the	O
four	O
factors	O
of	O
quality	B-OUT
of	I-OUT
life	I-OUT
that	O
were	O
measured	O
(	B-OUT
satisfaction	I-OUT
,	I-OUT
independence	I-OUT
,	I-OUT
competence	I-OUT
and	I-OUT
social	I-OUT
interaction	I-OUT
)	I-OUT
as	O
well	O
as	O
the	O
total	B-OUT
score	I-OUT
for	I-OUT
quality	I-OUT
of	I-OUT
life	I-OUT
from	O
baseline	O
to	O
the	O
end	O
of	O
the	O
intervention	O
12	O
months	O
later	O
.	O


[	O
The	O
effect	O
of	O
indobufen	B-I
on	O
aortocoronary	B-P
bypass	I-P
patency	I-P
after	O
1	O
week	O
and	O
after	O
1	O
year	O
]	O
.	O


METHODS	O
Two	O
consecutive	O
same	O
day	O
colonoscopies	B-I
were	O
performed	O
in	O
183	B-P
patients	I-P
.	I-P


Miss	B-OUT
rates	I-OUT
are	O
low	O
for	O
adenomas	O
>	O
or	O
=	O
1	O
cm	O
.	O


Combination	O
CT	O
and	O
Tc-MIBI	O
SPECT	O
for	O
28	O
NPC	O
patients	O
with	O
congruent	O
results	O
showed	O
the	O
same	O
sensitivity	B-OUT
,	I-OUT
specificity	I-OUT
,	I-OUT
and	I-OUT
accuracy	I-OUT
of	O
100	O
%	O
,	O
96	O
%	O
,	O
and	O
96	O
%	O
,	O
respectively	O
,	O
as	O
FDG-PET	B-I
for	O
differentiating	O
recurrent	O
or	O
residual	O
NPC	O
from	O
benign	O
lesions	O
.	O


CONCLUSIONS	O
In	O
detecting	O
recurrent	B-OUT
or	I-OUT
residual	I-OUT
NPC	I-OUT
,	O
FDG-PET	B-I
is	O
the	O
best	O
tool	O
.	O


However	O
,	O
combined	O
use	O
of	O
CT	B-I
and	I-I
Tc-MIBI	I-I
SPECT	I-I
can	O
result	O
in	O
the	O
same	O
accuracy	B-OUT
as	O
FDG-PET	B-I
.	I-I


Oral	O
ganciclovir	B-I
and	I-I
valacyclovir	I-I
reduce	O
the	O
incidence	O
of	O
cytomegalovirus	B-OUT
(	I-OUT
CMV	I-OUT
)	I-OUT
disease	I-OUT
after	I-P
renal	I-P
transplantation	I-P
(	I-P
RTx	I-P
)	I-P
.	I-P


Our	O
study	O
was	O
designed	O
to	O
compare	O
the	O
efficacy	B-OUT
,	I-OUT
costs	I-OUT
,	I-OUT
and	I-OUT
safety	I-OUT
of	O
oral	O
ganciclovir	B-I
and	I-I
valacyclovir	I-I
in	O
the	O
prophylaxis	O
of	O
CMV	O
disease	O
over	O
the	O
first	O
6	O
months	O
after	O
RTx	O
.	O


The	O
patients	O
were	O
monitored	O
by	O
CMV-nested	O
PCR	O
in	O
whole	O
blood	O
.	O


Thirty-six	O
out	O
of	O
38	O
(	O
94.7	O
%	O
)	O
recipients	O
were	O
CMV-seropositive	B-OUT
.	I-OUT


Treatment	B-OUT
failure	I-OUT
(	I-OUT
death	I-OUT
,	I-OUT
graft	I-OUT
loss	I-OUT
,	I-OUT
CMV	I-OUT
disease	I-OUT
,	I-OUT
or	I-OUT
withdrawal	I-OUT
from	I-OUT
study	I-OUT
)	I-OUT
occurred	O
in	O
14.3	O
%	O
,	O
0	O
%	O
and	O
66.7	O
%	O
in	O
the	O
GAN	O
,	O
VAL	O
,	O
and	O
C	O
groups	O
,	O
respectively	O
(	O
P=0.014	O
,	O
GAN	O
vs	O
C	O
;	O
P=0.001	O
,	O
VAL	O
vs	O
C	O
;	O
P=NS	O
,	O
GAN	O
vs	O
VAL	O
)	O
.	O


The	O
average	B-OUT
CMV-associated	I-OUT
costs	I-OUT
per	I-OUT
patient	I-OUT
(	O
in	O
2001	O
euros	O
)	O
were	O
2,449+/-1,178	O
,	O
2,485+/-581	O
,	O
and	O
4,259+/-4,616	O
in	O
the	O
GAN	O
,	O
VAL	O
,	O
and	O
C	O
groups	O
,	O
respectively	O
.	O


Ganciclovir	O
and	O
valacyclovir	O
were	O
well	B-OUT
tolerated	I-OUT
,	O
with	O
ganciclovir	O
having	O
had	O
to	O
be	O
withdrawn	O
shortly	O
in	O
one	O
patient	O
only	O
because	O
of	O
thrombocytopenia	O
.	O


This	O
study	O
evaluated	O
peginterferon	B-I
alfa-2a	I-I
for	O
60	O
wk	O
,	O
alone	O
or	O
in	O
combination	O
with	O
lamivudine	O
.	O


Five	O
patients	O
demonstrated	O
a	O
>	O
90	O
%	O
decrease	O
in	O
HBsAg	B-OUT
concentration	I-OUT
at	O
week	O
60	O
,	O
including	O
3	O
with	O
undetectable	O
HBV	B-OUT
DNA	I-OUT
at	O
week	O
84	O
and	O
a	O
fourth	O
who	O
met	O
criteria	O
for	O
SVR	B-OUT
.	I-OUT


Here	O
,	O
we	O
report	O
a	O
randomized	O
double-blind	O
,	O
placebo-controlled	B-I
trial	O
that	O
examined	O
the	O
neural	O
and	O
behavioral	O
effects	O
of	O
a	O
single	O
dose	O
of	O
intranasal	B-I
oxytocin	I-I
on	O
emotion	O
recognition	O
in	O
individuals	B-P
with	I-P
Asperger	I-P
syndrome	I-P
(	I-P
AS	I-P
)	I-P
,	O
a	O
clinical	O
condition	O
characterized	O
by	O
impaired	O
eye	O
gaze	O
and	O
facial	O
emotion	O
recognition	O
.	O


Our	O
data	O
suggest	O
that	O
the	O
amygdala	O
,	O
together	O
with	O
functionally	O
associated	O
cortical	O
areas	O
mediate	O
the	O
positive	O
effect	O
of	O
oxytocin	B-I
on	O
social	B-OUT
cognitive	I-OUT
functioning	I-OUT
in	O
AS	O
.	O


This	O
study	O
aimed	O
to	O
examine	O
the	O
relationship	O
between	O
both	O
MSL	B-I
and	O
MDSL	B-I
on	O
age	O
and	O
ADL	O
in	B-P
elderly	I-P
subjects	I-P
.	I-P


Fifty-seven	B-P
elderly	I-P
females	I-P
who	I-P
live	I-P
independently	I-P
(	I-P
age	I-P
74.8±5.6	I-P
years	I-P
)	I-P
were	I-P
recruited	I-P
.	I-I


DESIGN	O
Randomized	O
,	O
masked	O
clinical	O
trial	O
.	O


PARTICIPANTS	O
Eighteen	B-P
subjects	I-P
(	I-P
mean	I-P
age	I-P
,	I-P
29.5±11.0	I-P
years	I-P
)	I-P
allergic	I-P
to	I-P
grass	I-P
pollen	I-P
.	O


MAIN	O
OUTCOME	O
MEASURES	B-OUT
Bulbar	I-OUT
conjunctival	I-OUT
hyperemia	I-OUT
,	I-OUT
ocular	I-OUT
surface	I-OUT
temperature	I-OUT
,	I-OUT
and	I-OUT
ocular	I-OUT
symptoms	I-OUT
repeated	O
before	O
and	O
every	O
10	O
minutes	O
after	O
treatment	O
for	O
1	O
hour	O
.	O


RESULTS	B-OUT
Bulbar	I-OUT
conjunctival	I-OUT
hyperemia	I-OUT
and	I-OUT
ocular	I-OUT
symptoms	I-OUT
decreased	O
and	O
temperature	O
recovered	O
to	O
baseline	O
faster	O
with	B-I
nonpharmaceutical	I-I
treatments	I-I
compared	O
with	B-I
no	I-I
treatment	I-I
(	O
P	O
<	O
0.05	O
)	O
.	O


Artificial	O
tears	O
combined	O
with	B-I
CC	O
reduced	B-OUT
hyperemia	I-OUT
more	O
than	O
other	O
treatments	O
(	O
P	O
<	O
0.05	O
)	O
.	O


CONCLUSIONS	O
After	O
controlled	O
exposure	O
to	O
grass	O
pollen	O
,	O
CC	O
and	O
AT	O
treatment	O
showed	O
a	O
therapeutic	O
effect	O
on	O
the	O
signs	O
and	B-P
symptoms	I-P
of	I-P
allergic	I-P
conjunctivitis	I-P
.	O


RESULTS	O
The	O
frequency	B-OUT
of	O
H.	B-OUT
pylori	I-OUT
infection	I-OUT
was	O
significantly	O
lower	O
in	O
the	O
filling	B-I
group	I-P
compared	O
with	O
the	O
nonfilling	B-P
group	I-P
(	O
53.7	O
and	O
78.8	O
%	O
,	O
respectively	O
;	O
P	O
<	O
0.001	O
)	O
.	O


The	O
eradication	B-OUT
rates	I-OUT
in	O
the	O
CT	B-I
,	I-I
QT	I-I
,	I-I
and	I-I
LT	I-I
groups	O
were	O
65.5	O
,	O
67.0	O
,	O
and	O
58.6	O
%	O
,	O
respectively	O
,	O
in	O
the	O
intention-to-treat	O
(	O
ITT	O
)	O
analysis	O
and	O
69.6	O
,	O
70.7	O
,	O
and	O
62.2	O
%	O
,	O
respectively	O
,	O
in	O
the	O
per-protocol	O
(	O
PP	O
)	O
analysis	O
.	O


It	O
has	O
been	O
shown	O
previously	O
that	O
alopecia	O
areata	O
can	O
be	O
treated	O
with	O
dinitrochlorobenzene	B-I
(	I-I
DNCB	I-I
)	I-I
and	O
other	O
contact	B-I
allergens	I-I
.	I-I


None	B-OUT
of	O
those	O
treated	O
with	O
croton	B-I
oil	I-I
regrew	I-OUT
hair	I-OUT
when	O
treated	O
later	O
with	O
DNCB	B-I
.	I-I


METHODS	O
Patients	B-P
aged	I-P
25	I-P
to	I-P
74	I-P
years	I-P
attending	I-P
community	I-P
pharmacies	I-P
with	I-P
a	I-P
prescription	I-P
for	I-P
at	I-P
least	I-P
1	I-P
drug	I-P
indicated	I-P
for	I-P
CVD	I-P
or	I-P
CV	I-P
risk	I-P
factors	I-P
were	O
randomized	O
to	O
2	O
groups	O
:	O
an	O
intervention	B-I
group	I-I
that	I-I
received	I-I
pharmaceutical	I-I
care	I-I
,	I-I
which	I-I
was	I-I
provided	I-I
by	I-I
specially	I-I
trained	I-I
pharmacists	I-I
working	I-I
in	I-I
collaboration	I-I
with	I-I
physicians	I-I
,	O
and	O
a	O
control	B-I
group	I-I
that	I-I
received	I-I
usual	I-I
care	I-I
(	I-I
routine	I-I
dispensing	I-I
counseling	I-I
)	I-I
and	I-I
verbal	I-I
and	I-I
written	I-I
counseling	I-I
regarding	I-I
CVD	I-I
prevention	I-I
.	I-I


TC	B-OUT
was	O
measured	O
by	O
the	O
pharmacist	O
during	O
the	O
study	O
visit	O
using	O
the	O
enzymatic	B-OUT
dry	I-OUT
method	I-OUT
.	I-OUT


The	O
I	O
group	O
was	O
divided	O
into	O
subgroups	O
based	O
on	O
baseline	O
behaviour	O
and	O
risk	O
factor	O
status	O
.	O


Assessment	O
of	O
airway	O
responsiveness	O
by	O
bronchoprovocation	O
and	O
bronchodilatation	O
tests	O
is	O
important	O
in	O
the	O
diagnostic	O
work-up	O
protocol	O
of	O
bronchial	B-P
asthma	I-P
and	O
it	O
would	O
be	O
convenient	O
to	O
undertake	O
both	O
tests	O
on	O
the	O
same	O
occasion	O
.	O


INTRODUCTION	O
Activation	O
of	O
the	O
phosphatidylinositol-3-kinase	B-I
(	I-I
PI3K	I-I
)	I-I
and/or	O
mitogen-activated	B-I
protein	I-I
kinase	I-I
(	I-I
MAPK	I-I
)	I-I
pathways	O
results	O
in	O
anti-estrogen	B-OUT
resistance	I-OUT
in	O
vitro	O
,	O
but	O
a	O
biomarker	O
with	O
clinical	O
validity	O
to	O
predict	O
intrinsic	O
resistance	O
has	O
not	O
been	O
identified	O
.	O


METHODS	O
We	O
recollected	O
primary	B-P
tumor	I-P
tissue	I-P
from	I-P
patients	I-P
who	I-P
participated	I-P
in	I-P
a	I-P
randomized	I-P
trial	I-P
of	I-P
adjuvant	I-I
tamoxifen	I-I
(	I-I
1-3	I-I
years	I-I
)	I-I
versus	I-I
observation	I-I
.	I-I


In	O
systemically	O
untreated	O
breast	O
cancer	O
patients	O
,	O
p-p70S6K	O
was	O
associated	O
with	O
a	O
decreased	B-OUT
risk	I-OUT
for	I-OUT
recurrence	I-OUT
.	O


BACKGROUND	O
Practice	B-P
nurses	I-P
play	O
an	O
increasingly	O
important	O
role	O
in	O
the	O
prevention	O
of	O
cardiovascular	O
diseases	O
but	O
we	O
do	O
not	O
have	O
evidence	O
about	O
the	O
accuracy	B-OUT
of	O
their	O
cardiovascular	O
risk	O
assessments	O
during	O
real	O
practice	O
consultations	O
.	O


Elderly	B-P
patients	I-P
(	O
OR	O
1.1	O
,	O
95	O
%	O
CI	O
1.0-1.1	O
)	O
,	O
male	B-P
patients	I-P
(	I-P
vs.	I-P
female	I-P
OR	O
3.1	O
,	O
95	O
%	O
CI	O
1.2-7.3	O
)	O
,	O
and	O
smoking	B-P
patients	I-P
(	I-P
vs.	I-P
non-smoking	I-P
OR	O
3.8	O
,	O
95	O
%	O
CI	O
1.7-8.9	O
)	O
were	O
more	O
likely	O
to	O
have	O
their	O
cardiovascular	B-OUT
risk	I-OUT
miscalculated	I-OUT
.	I-OUT


CONCLUSIONS	O
The	O
overall	O
standard	O
of	O
accuracy	O
of	O
cardiovascular	B-I
risk	I-I
assessment	I-I
by	O
trained	B-P
practice	I-P
nurses	I-P
in	I-P
actual	I-P
practice	I-P
is	O
high	O
.	O


Predictors	O
of	O
local	O
adverse	O
effects	O
caused	O
by	O
topical	O
tretinoin	B-I
cream	O
0·1	O
%	O
in	O
the	B-P
Veterans	I-P
Affairs	I-P
Topical	I-P
Tretinoin	I-P
Chemoprevention	I-P
trial	I-P
.	O


Univariate	O
and	O
multivariate	O
logistic	O
regression	O
models	O
were	O
used	O
to	O
examine	O
the	O
associations	O
between	O
baseline	O
characteristics	O
and	O
local	O
adverse	O
effects	O
.	O


The	O
concurrent	O
use	O
of	O
other	O
topical	O
medications	O
may	O
worsen	O
irritation	O
caused	O
by	O
tretinoin	O
.	O


The	O
clinical	O
and	O
biochemical	O
effects	O
of	O
propofol	B-I
infusion	O
with	B-I
and	I-I
without	I-I
EDTA	I-I
for	O
maintenance	O
anesthesia	O
in	O
healthy	B-P
children	I-P
undergoing	I-P
ambulatory	I-P
surgery	I-P
.	I-P


Propofol	B-I
with	I-I
EDTA	I-I
produced	O
no	O
significant	O
effects	O
on	O
clinical	B-OUT
efficacy	I-OUT
or	I-OUT
renal	I-OUT
function	I-OUT
.	I-OUT


IMPLICATIONS	O
The	O
addition	O
of	O
EDTA	O
does	O
not	O
alter	O
the	O
clinical	O
profile	O
of	O
propofol	O
in	O
pediatric	B-P
ambulatory	I-P
surgical	I-P
patients	I-P
.	I-P


One	B-P
hundred	I-P
and	I-P
fifty-five	I-P
patients	I-P
were	I-P
randomized	I-P
,	I-P
144	I-P
were	I-P
evaluable	I-P
for	I-P
safety	I-P
and	I-P
142	I-P
for	I-P
response	I-P
.	I-P


FM	O
comprised	O
fludarabine	B-I
(	O
20	O
mg/m	O
(	O
2	O
)	O
i.v	O
.	O


)	O
,	O
days	O
1-5	O
,	O
plus	O
mitoxantrone	B-I
(	O
10	O
mg/m	O
(	O
2	O
)	O
i.v	O
.	O


These	O
findings	O
were	O
not	O
as	O
evident	O
when	O
outcomes	O
where	O
clozapine	O
was	O
not	O
clearly	O
superior	O
(	B-OUT
psychotic	I-OUT
symptoms	I-OUT
,	I-OUT
weight	I-OUT
gain	I-OUT
)	I-OUT
were	O
examined	O
.	O


In	O
a	O
double	O
blind	O
randomized	O
study	O
,	O
branched-chain	B-I
amino	I-I
acids	I-I
and	O
placebo	B-I
(	I-I
casein	I-I
)	I-I
were	O
compared	O
as	O
a	O
treatment	O
for	O
chronic	B-P
hepatic	I-P
encephalopathy	I-P
in	I-P
cirrhosis	I-P
.	I-P


Based	O
primarily	O
on	O
the	O
beneficial	O
effect	O
of	O
gabapentin	O
on	O
acquired	O
pendular	O
nystagmus	O
(	O
APN	O
)	O
,	O
a	O
GABAergic	O
mechanism	O
in	O
controlling	O
nystagmus	O
has	O
been	O
hypothesised	O
.	O


However	O
,	O
as	O
gabapentin	O
is	O
not	O
a	O
selective	O
GABAergic	O
agent	O
,	O
vigabatrin	O
,	O
a	O
"	O
pure	O
"	O
GABAergic	O
medication	O
,	O
and	O
gabapentin	O
,	O
were	O
compared	O
in	O
a	O
single	O
blind	O
cross	O
over	O
trial	O
in	O
eight	B-P
patients	I-P
with	I-P
definite	I-P
multiple	I-P
sclerosis	I-P
.	I-P


Neuro-ophthalmological	O
and	O
electro-oculographic	O
(	O
EOG	O
)	O
evaluations	O
were	O
performed	O
four	O
and	O
three	O
times	O
,	O
respectively	O
.	O


Treatment	O
efficacy	B-OUT
was	O
based	O
on	O
improving	O
visual	B-OUT
acuity	I-OUT
and	O
EOG	B-OUT
indices	I-OUT
(	I-OUT
amplitude	I-OUT
or	I-OUT
frequency	I-OUT
of	I-OUT
nystagmus	I-OUT
,	I-OUT
or	I-OUT
both	I-OUT
)	I-OUT
by	O
at	O
least	O
50	O
%	O
of	O
pretreatment	O
values	O
.	O


Three	B-P
out	I-P
of	I-P
eight	I-P
patients	I-P
dropped	I-P
out	I-P
due	I-P
to	I-P
adverse	I-OUT
effects	I-OUT
.	I-OUT


If	O
diastolic	B-OUT
blood	I-OUT
pressure	I-OUT
was	O
not	O
adequately	O
controlled	O
(	O
less	O
than	O
85	O
mm	O
Hg	O
)	O
after	O
four	O
weeks	O
of	O
monotherapy	O
,	O
1	O
mg	O
of	O
polythiazide	B-I
was	O
added	O
to	O
the	O
daily	O
regimen	O
.	O


There	O
were	O
no	O
statistically	O
significant	O
differences	O
between	O
the	O
drug	O
groups	O
for	O
the	O
measured	O
variables	O
in	O
either	O
the	O
parallel	O
or	O
crossover	O
phase	O
of	O
the	O
study	O
.	O


In	O
each	O
study	O
,	O
samples	O
were	O
collected	O
in	O
a	O
subset	O
of	O
patients	O
;	O
a	O
new	O
cohort	O
was	O
enrolled	O
each	O
year	O
.	O


Exercise	B-I
training	I-I
prevented	O
an	O
increase	O
in	O
leptin	O
levels	O
during	O
the	O
study	O
period	O
.	O


LIMITATIONS	O
Single-center	O
nonblinded	O
trial	O
.	O


The	O
Palindrome	B-I
catheter	O
required	O
less	O
thrombolysis	B-OUT
and	O
achieved	O
higher	O
blood	B-OUT
flow	I-OUT
rates	I-OUT
than	O
the	O
HemoStar	B-I
catheter	O
.	O


Patients	O
in	O
each	O
group	O
showed	O
an	O
increase	O
in	O
total	B-OUT
white	I-OUT
blood	I-OUT
cell	I-OUT
(	I-OUT
WBC	I-OUT
)	I-OUT
count	I-OUT
.	I-OUT


Of	O
119	B-P
eligible	I-P
patients	I-P
,	O
115	O
(	O
96.6	O
%	O
)	O
attained	O
complete	O
remission	O
by	O
treatment	O
with	O
prednisone	B-I
(	I-I
PRD	I-I
)	I-I
plus	I-I
vincristine	I-I
(	I-I
VCR	I-I
)	I-I
or	I-I
vindesine	I-I
(	I-I
VDS	I-I
)	I-I
.	I-I


After	O
preventive	O
central	O
nervous	O
system	O
(	O
CNS	O
)	O
therapy	O
including	O
18	B-I
Gy	I-I
cranial	I-I
irradiation	I-I
and	O
three	O
doses	O
of	O
intrathecal	B-I
methotrexate	I-I
(	I-I
MTX	I-I
)	I-I
,	O
the	O
patients	O
were	O
assigned	O
randomly	O
to	O
the	O
two	O
maintenance	O
chemotherapies	O
,	O
Regimen	O
A	O
and	O
Regimen	O
B	O
.	O


Regimen	O
A	O
(	O
intermittent	O
regimen	O
)	O
consisted	O
of	O
PRD	B-I
(	O
120	O
mg/m2/day	O
by	O
mouth	O
for	O
5	O
days	O
)	O
plus	B-I
6-mercaptopurine	I-I
(	I-I
6MP	I-I
)	I-I
(	O
175	O
mg/m2/day	O
by	O
mouth	O
for	O
5	O
days	O
)	O
plus	B-I
VCR	I-I
(	I-I
2.0	I-I
mg/m2	O
intravenously	O
)	O
alternating	B-I
biweekly	I-I
with	I-I
MTX	I-I
(	O
225	O
mg/m2	O
intravenously	O
)	O
.	O


The	O
CCR	B-OUT
rates	I-OUT
in	O
Regimen	O
A	O
and	O
B	O
were	O
75.1	O
%	O
+/-	O
5.8	O
%	O
(	O
mean	O
+/-	O
1	O
SE	O
)	O
and	O
49.7	O
%	O
+/-	O
7.3	O
%	O
(	O
P	O
less	O
than	O
0.01	O
)	O
at	O
4	O
years	O
,	O
and	O
72.1	O
%	O
+/-	O
6.3	O
%	O
and	O
49.7	O
%	O
+/-	O
7.3	O
%	O
(	O
P	O
less	O
than	O
0.05	O
)	O
at	O
5	O
years	O
,	O
respectively	O
.	O


In	O
Regimen	O
B	O
,	O
CNS	B-OUT
and	I-OUT
testicular	I-OUT
relapses	I-OUT
increased	O
after	O
3	O
years	O
of	O
CCR	O
.	O


STEPP	O
analyses	O
showed	O
little	O
effect	O
of	O
chemotherapy	O
for	O
tumors	O
with	O
high	O
levels	B-OUT
of	I-OUT
ER	I-OUT
expression	I-OUT
(	O
P	O
=	O
0.07	O
)	O
,	O
or	O
for	O
the	O
cohort	O
with	O
one	O
positive	O
node	O
(	O
P	O
=	O
0.03	O
)	O
.	O


BACKGROUND	O
Tubulointerstitial	O
injury	O
is	O
a	O
major	O
feature	O
of	O
diabetic	O
nephropathy	O
and	O
an	O
important	O
predictor	O
of	O
renal	O
dysfunction	O
.	O


Before	O
PTF	O
administration	O
,	O
baseline	O
parameters	O
were	O
similar	O
in	O
both	O
groups	O
of	O
patients	O
with	O
DM	O
.	O


The	O
primary	O
end	O
point	O
is	O
the	O
occurrence	B-OUT
of	I-OUT
cardiovascular	I-OUT
death	I-OUT
or	I-OUT
nonfatal	I-OUT
myocardial	I-OUT
infarction	I-OUT
through	I-OUT
postoperative	I-OUT
day	I-OUT
30	I-OUT
.	I-OUT


Enhancing	O
the	O
self-esteem	B-OUT
of	O
inpatient	B-P
alcoholics	I-P
.	I-P


Ambulatory	B-OUT
activity	I-OUT
was	O
corrected	O
for	O
body	O
height	O
.	O


BACKGROUND	O
Swirling	O
flow	O
,	O
organized	O
in	O
vortices	O
,	O
contributes	O
to	O
adequate	O
left	O
ventricular	O
function	O
.	O


The	O
anterior	B-OUT
component	I-OUT
of	I-OUT
these	I-OUT
visualized	I-OUT
vortices	I-OUT
was	O
analyzed	O
,	O
due	O
to	O
its	O
higher	O
significance	O
in	O
the	O
cardiac	O
cycle	O
,	O
following	O
early	O
filling	O
(	O
V1	O
)	O
and	O
atrial	O
contraction	O
(	O
V2	O
)	O
.	O


These	O
differences	O
may	O
be	O
related	O
to	O
varying	O
roles	O
of	O
vortices	B-OUT
in	O
different	O
periods	O
of	O
the	O
cardiac	O
cycle	O
.	O


Randomized	O
trial	O
of	O
early	B-I
developmental	I-I
intervention	I-I
on	O
outcomes	O
in	O
children	B-P
after	I-P
birth	I-OUT
asphyxia	I-OUT
in	O
developing	O
countries	O
.	O


Intervention	B-P
infants	I-P
received	O
a	O
parent-implemented	B-I
EDI	I-I
delivered	O
with	O
home	O
visits	O
by	O
parent	O
trainers	O
every	O
other	O
week	O
for	O
3	O
years	O
starting	O
the	O
first	O
month	O
after	O
birth	O
.	O


RESULTS	O
MDI	B-OUT
was	O
higher	O
in	O
the	O
EDI	O
(	O
102.6	O
±	O
9.8	O
)	O
compared	O
with	O
the	O
control	O
resuscitated	O
children	O
(	O
98.0	O
±	O
14.6	O
,	O
1-sided	O
P	O
=	O
.0202	O
)	O
,	O
but	O
there	O
was	O
no	O
difference	O
between	O
groups	O
in	O
the	O
nonresuscitated	O
children	O
(	O
100.1	O
±	O
10.7	O
vs	O
97.7	O
±	O
10.4	O
,	O
P	B-OUT
=	I-OUT
.1392	I-OUT
)	I-OUT
.	I-OUT


MDI	B-OUT
and	I-OUT
Psychomotor	I-OUT
Development	I-OUT
Index	O
scores	O
of	O
both	B-P
nonresuscitated	I-P
and	I-P
resuscitated	O
infants	O
were	O
within	O
normal	O
range	O
,	O
independent	O
of	O
early	O
intervention	O
.	O


Oxidative	O
DNA	O
damage	O
measured	O
in	O
human	O
lymphocytes	O
:	O
large	O
differences	O
between	O
sexes	O
and	O
between	O
countries	O
,	O
and	O
correlations	O
with	O
heart	O
disease	O
mortality	O
rates	O
.	O


Importantly	O
,	O
the	O
clinical	O
and	O
immunological	O
effects	O
of	O
SIT	O
were	O
not	O
affected	O
by	O
intervention	O
with	O
steroids	O
administered	O
with	O
vitamin	O
D	O
(	O
3	O
)	O
.	O


RESULTS	O
Between	B-P
April	I-P
2005	I-P
and	I-P
February	I-P
2006	I-P
,	I-P
a	I-P
total	I-P
of	I-P
918	I-P
patients	I-P
were	I-P
enrolled	I-P
.	I-P


However	O
,	O
the	O
cecal	B-OUT
intubation	I-OUT
time	I-OUT
was	O
shorter	O
in	O
the	O
CF-240I	O
group	O
(	O
5.75	O
+/-	O
3.18	O
vs	O
6.26	O
+/-	O
3.30	O
min	O
,	O
P	O
=	O
0.02	O
)	O
.	O


ELISA	B-OUT
showed	O
that	O
autologous	B-P
SCT	I-P
patients	I-P
with	I-P
breast	I-P
cancer	I-P
who	O
received	O
GM-CSF	O
had	O
a	O
better	O
response	B-OUT
to	O
influenza	B-OUT
A	I-OUT
(	O
P	O
<	O
.05	O
)	O
and	O
B	B-OUT
(	O
P	O
<	O
.01	O
)	O
.	O


GM-CSF	B-I
appears	O
to	O
improve	O
the	O
response	B-OUT
to	I-OUT
influenza	I-OUT
vaccination	I-OUT
in	O
some	O
groups	O
of	O
SCT	B-P
patients	I-P
,	O
but	O
only	O
to	O
a	O
limited	O
extent	O
.	O


Multisite	O
,	O
double-blind	O
,	O
placebo-controlled	B-I
trial	O
of	O
porcine	B-I
secretin	I-I
in	O
autism	B-P
.	I-P


OBJECTIVE	O
To	O
examine	O
the	O
efficacy	B-OUT
of	O
intravenous	O
porcine	B-I
secretin	I-I
for	O
the	O
treatment	B-OUT
of	O
autistic	B-OUT
disorder	I-OUT
.	I-OUT


Subjects	B-P
were	O
assigned	O
to	O
gain	B-I
weight	I-I
(	O
approximately	O
4	O
kg	O
)	O
(	O
n=35	O
)	O
or	O
to	O
maintain	B-I
weight	I-I
(	O
n=8	O
)	O
.	O


Endothelial	B-OUT
function	I-OUT
(	I-OUT
brachial	I-OUT
artery	I-OUT
flow-mediated	I-OUT
dilation	I-OUT
[	I-OUT
FMD	I-OUT
]	I-OUT
)	I-OUT
was	O
measured	O
at	O
baseline	O
,	O
after	O
fat	O
gain	O
(	O
8	O
weeks	O
)	O
,	O
and	O
after	O
weight	O
loss	O
(	O
16	O
weeks	O
)	O
for	O
fat	O
gainers	O
and	O
at	O
baseline	O
and	O
follow-up	O
(	O
8	O
weeks	O
)	O
for	O
weight	O
maintainers	O
.	O


Body	O
composition	O
was	O
measured	O
by	O
dual-energy	O
X-ray	O
absorptiometry	O
and	O
abdominal	O
computed	O
tomographic	O
scans	O
.	O


(	O
Fat	O
Gain	O
and	O
Cardiovascular	O
Disease	O
Mechanisms	O
;	O
NCT00589498	O
)	O
.	O


The	O
Phase	O
1	O
single	O
round	O
of	O
DMSA	B-I
led	O
to	O
a	O
dramatic	O
normalization	B-OUT
of	I-OUT
RBC	I-OUT
glutathione	I-OUT
in	O
almost	O
all	O
cases	O
,	O
and	O
greatly	O
improved	O
abnormal	B-OUT
platelet	I-OUT
counts	I-OUT
,	O
suggesting	O
a	O
significant	O
decrease	O
in	O
inflammation	B-OUT
.	I-OUT


Biodistribution	O
of	O
three	O
photosensitizers	B-I
in	O
dogs	B-P
with	I-P
spontaneous	I-P
tumors	I-P
.	I-P


No	O
differences	O
were	O
found	O
in	O
thermal	B-OUT
sensitivity	I-OUT
(	O
esophagus	O
(	O
p=0.67	O
)	O
and	O
duodenum	B-OUT
(	O
p=0.17	O
)	O
)	O
,	O
sensory	B-OUT
response	I-OUT
to	I-OUT
electrical	I-OUT
stimulation	I-OUT
(	O
esophagus	O
(	O
p=0.57	O
)	O
and	O
duodenum	B-OUT
(	O
p=0.52	O
)	O
)	O
or	O
induced	B-OUT
somatic	I-OUT
referred	I-OUT
pain	I-OUT
areas	I-OUT
(	O
esophagus	O
(	O
p=0.75	O
)	O
and	O
duodenum	O
(	O
p=0.51	O
)	O
)	O
.	O


OBJECTIVE	O
To	O
study	O
the	O
immunomodulatory	O
effect	O
of	O
the	O
histamine	O
receptor	O
antagonist	O
,	O
ranitidine	O
,	O
in	O
patients	B-P
admitted	I-P
to	I-P
the	I-P
intensive	I-P
care	I-P
unit	I-P
after	I-P
severe	I-P
head	I-P
injury	I-P
.	I-P


SETTING	O
Surgical	O
intensive	O
care	O
unit	O
of	O
a	O
university	B-P
Level	I-P
I	I-P
trauma	I-P
center	I-P
.	I-P


PATIENTS	O
Twenty	B-P
patients	I-P
admitted	I-P
with	I-P
a	I-P
Glasgow	I-P
Coma	I-P
Scale	I-P
score	I-P
of	I-P
<	I-P
10	I-P
who	O
were	O
enrolled	O
as	O
part	O
of	O
a	O
prospective	O
,	O
multicenter	O
trial	O
to	O
assess	O
the	O
impact	O
of	O
multiple	O
risk	O
factors	O
and	O
ranitidine	O
prophylaxis	O
on	O
the	O
development	O
of	O
stress-related	O
upper	O
gastrointestinal	O
bleeding	O
.	O


CONCLUSION	O
This	O
study	O
demonstrates	O
an	O
immunostimulatory	O
effect	O
of	O
the	O
histamine-2-receptor	O
antagonist	O
,	O
ranitidine	O
,	O
both	O
at	O
the	O
cellular	O
and	O
mediator	O
levels	O
in	O
patients	B-P
after	I-P
head	I-P
injury	I-P
.	I-P


We	O
argue	O
that	O
the	O
DSM-IV	O
criteria	O
for	O
sexual	O
arousal	O
disorder	O
are	O
in	O
need	O
of	O
revision	O
.	O


SUBJECTS	O
A	B-P
total	I-P
of	I-P
36	I-P
obese	I-P
nondiabetic	I-P
volunteers	I-P
with	I-P
hyperinsulinemia	I-P
(	I-P
10	I-P
males/26	I-P
females	I-P
,	I-P
aged	I-P
34-65	I-P
y	I-P
,	I-P
BMI	I-P
28-43	I-P
kg/m	I-P
(	I-P
2	I-P
)	I-P
,	I-P
fasting	I-P
insulin	I-P
12-45	I-P
mU/l	I-P
)	I-P
.	I-P


RESULTS	O
After	O
16	O
weeks	O
,	O
weight	B-OUT
loss	I-OUT
was	O
similar	O
in	O
response	O
to	O
each	O
diet	O
;	O
the	O
overall	O
decrease	O
was	O
7.9+/-0.6	O
kg	O
(	O
P	O
<	O
0.001	O
)	O
,	O
of	O
which	O
6.8+/-0.5	O
kg	O
was	O
fat	O
(	O
P	O
<	O
0.001	O
)	O
.	O


After	O
16	O
weeks	O
,	O
the	O
TEF	B-OUT
was	O
not	O
reduced	O
in	O
either	O
dietary	O
group	O
.	O


There	O
was	O
no	O
change	O
in	O
TEE	B-OUT
after	O
16	O
weeks	O
.	O


RESULTS	O
The	O
two	O
intervention	O
groups	O
demonstrated	O
significant	O
decreases	O
in	O
parent-reported	B-OUT
anxiety	I-OUT
symptoms	I-OUT
at	O
follow-up	O
and	O
a	O
significant	O
increase	O
in	O
the	O
child	O
's	O
ability	O
to	O
generate	O
positive	O
strategies	O
in	O
an	O
anxiety-provoking	O
situation	O
.	O


OBJECTIVE	O
To	O
observe	O
therapeutic	O
effect	O
of	O
small	B-I
needle-knife	I-I
comprehensive	I-I
therapy	I-I
on	O
pain	B-OUT
and	I-OUT
lumbar	I-OUT
flexion	I-OUT
range	I-OUT
in	O
the	O
chronic	B-P
nonspecific	I-P
low	I-P
back	I-P
pain	I-P
patient	I-P
.	I-P


RESULTS	O
After	O
treatment	O
,	O
the	O
pain	B-OUT
and	I-OUT
the	I-OUT
lumbar	I-OUT
flexion	I-OUT
range	I-OUT
were	O
significantly	O
improved	O
in	O
the	O
two	O
groups	O
;	O
and	O
after	O
treatment	O
,	O
the	O
VAS	B-OUT
score	I-OUT
and	I-OUT
the	I-OUT
lumbar	I-OUT
flexion	I-OUT
range	I-OUT
were	O
(	O
1.60	O
+/-	O
0.38	O
)	O
points	O
and	O
(	O
65.76	O
+/-	O
15.11	O
)	O
cm	O
in	O
the	O
needle-knife	B-I
group	O
and	O
(	O
4.59	O
+/-	O
1.09	O
)	O
points	O
and	O
(	O
53.74	O
+/-	O
15.13	O
)	O
cm	O
in	O
the	O
physiotherapy	O
group	O
,	O
respectively	O
,	O
the	O
needle-knife	B-I
group	O
being	O
significantly	O
better	O
than	O
the	O
physiotherapy	O
group	O
(	O
P	O
<	O
0.01	O
)	O
.	O


OBJECTIVES	O
To	O
(	O
1	O
)	O
determine	O
the	O
efficacy	O
of	O
venlafaxine	B-I
XR	I-I
for	O
the	O
treatment	O
of	O
pain	B-P
(	I-P
secondary	I-P
aim	I-P
)	I-P
in	I-P
individuals	I-P
with	I-P
spinal	I-P
cord	I-P
injury	I-P
(	I-P
SCI	I-P
)	I-P
enrolled	I-P
in	I-P
a	I-P
randomized	I-P
controlled	I-P
trial	I-P
(	I-P
RCT	I-P
)	I-P
on	I-P
the	I-P
efficacy	I-P
of	I-P
venlafaxine	I-I
XR	I-P
for	I-P
major	I-P
depressive	I-P
disorder	I-P
(	I-P
MDD	I-P
)	I-P
(	O
primary	O
aim	O
)	O
;	O
and	O
(	O
2	O
)	O
test	O
the	O
hypothesis	O
that	O
venlafaxine	B-I
XR	O
would	O
be	O
effective	O
for	O
both	O
neuropathic	O
and	O
nociceptive	O
pain	O
.	O


PARTICIPANTS	O
Individuals	B-P
(	I-P
N=123	I-P
)	I-P
with	I-P
SCI	I-P
and	I-P
major	I-P
depression	I-P
between	I-P
18	I-P
and	I-P
64	I-P
years	I-P
of	I-P
age	I-P
,	I-P
at	I-P
least	I-P
1	I-P
month	I-P
post-SCI	I-P
who	I-P
also	I-P
reported	I-P
pain	I-P
.	I-P


INTERVENTION	O
Twelve-week	O
trial	O
of	O
venlafaxine	B-I
XR	I-I
versus	I-I
placebo	I-I
using	I-I
a	I-I
flexible	I-I
titration	I-I
schedule	I-I
.	I-I


OUTCOME	O
MEASURES	O
A	O
0-to-10	B-OUT
numeric	I-OUT
rating	I-OUT
scale	I-OUT
for	I-OUT
pain	I-OUT
,	I-OUT
pain	I-OUT
interference	I-OUT
items	I-OUT
of	I-OUT
the	I-OUT
Brief	I-OUT
Pain	I-OUT
Inventory	I-OUT
;	I-OUT
30	O
%	O
and	O
50	O
%	O
responders	O
.	O


RESULTS	O
The	O
effect	O
of	O
venlafaxine	B-I
XR	I-I
on	O
neuropathic	O
pain	O
was	O
similar	O
to	O
that	O
of	O
placebo	B-I
.	I-I


Its	O
usefulness	O
for	O
treating	O
central	O
neuropathic	O
pain	O
is	O
likely	O
to	O
be	O
limited	O
.	O


The	O
post	O
supplementation	O
trials	O
involved	O
supplementation	O
with	O
either	O
maltodextrin	O
or	O
sodium	O
bicarbonate	O
in	O
a	O
double-blind	O
,	O
crossover	O
design	O
,	O
creating	O
four	O
study	O
conditions	B-I
(	I-I
placebo	I-I
with	I-I
maltodextrin	I-I
;	I-I
placebo	I-I
with	I-I
sodium	I-I
bicarbonate	I-I
;	I-I
beta-alanine	I-I
with	I-I
maltodextrin	I-I
;	I-I
beta-alanine	I-I
with	I-I
sodium	I-I
bicarbonate	I-OUT
)	I-OUT
.	I-OUT


Pentoxifylline	B-I
therapy	O
in	O
HIV	B-P
seropositive	I-P
subjects	I-P
with	I-P
elevated	I-P
TNF	I-P
.	I-P


Tumor	O
necrosis	O
factor-alpha	O
(	O
TNF-alpha	O
)	O
is	O
thought	O
to	O
induce	O
cachexia	O
in	O
subjects	O
infected	O
with	O
human	O
immunodeficiency	O
virus	O
(	O
HIV	O
)	O
,	O
and	O
it	O
has	O
been	O
suggested	O
that	O
HIV-seropositive	B-P
patients	I-P
would	O
benefit	O
from	O
treatment	O
with	O
pentoxifylline	B-I
,	O
a	O
known	O
suppressor	O
of	O
TNF-alpha	O
production	O
.	O


Furthermore	O
,	O
pentoxifylline	O
treatment	O
did	O
not	O
influence	O
the	O
weight	B-OUT
,	I-OUT
temperature	I-OUT
,	I-OUT
well	I-OUT
being	I-OUT
,	I-OUT
or	I-OUT
tiredness	I-OUT
of	I-OUT
the	I-OUT
subjects	I-OUT
.	I-OUT


Prehydration	O
alone	O
is	O
sufficient	O
to	O
prevent	O
contrast-induced	O
nephropathy	O
after	O
day-only	B-P
angiography	I-P
procedures	I-P
--	I-P
a	I-P
randomised	O
controlled	O
trial	O
.	O


METHODS	O
Sixty-five	B-P
day-only	I-P
patients	I-P
with	I-P
renal	I-P
impairment	I-P
(	I-P
mean	I-P
serum	I-P
creatinine	I-P
concentration	I-P
0.16+/-0.03	I-P
mmol/l	I-P
)	I-P
due	I-P
to	I-P
undergo	I-P
coronary	I-P
or	I-P
peripheral	I-P
angiography	I-P
and/or	I-P
stenting	I-P
were	O
randomly	O
assigned	O
to	O
IV	B-I
NAC	I-I
300	I-I
or	I-I
600	I-I
mg	O
immediately	O
before	O
and	O
after	O
the	O
procedure	O
or	O
IV	O
fluid	O
alone	O
.	O


Tinidazole	B-I
and	I-I
metronidazole	I-I
in	O
hepatic	B-P
amoebiasis	I-P
.	I-P


Effects	O
of	O
aerobic	B-I
exercise	I-I
on	O
cognition	O
and	O
hippocampal	O
volume	O
in	O
Alzheimer	B-P
's	I-P
disease	I-P
:	I-P
study	O
protocol	O
of	O
a	O
randomized	O
controlled	O
trial	O
(	O
The	O
FIT-AD	O
trial	O
)	O
.	O


METHODS/DESIGN	O
This	O
pilot	O
randomized	O
controlled	O
trial	O
will	O
investigate	O
the	O
effects	O
of	O
a	O
6-month	O
,	O
individualized	O
,	O
moderate-intensity	B-I
cycling	I-I
intervention	I-I
(	O
20	O
to	O
50	O
minutes	O
per	O
session	O
,	O
3	O
times	O
a	O
week	O
)	O
on	O
cognition	O
and	O
hippocampal	O
volume	O
in	O
community-dwelling	B-P
older	I-P
adults	I-P
with	I-P
mild-to-moderate	I-P
Alzheimer	I-P
's	I-P
disease	I-P
.	I-P


Hippocampal	B-OUT
volume	I-OUT
will	O
be	O
measured	O
by	O
magnetic	O
resonance	O
imaging	O
at	O
baseline	O
and	O
6	O
and	O
12	O
months	O
.	O


No	O
other	O
plasma	B-OUT
free	I-OUT
essential	I-OUT
fatty	I-OUT
acid	I-OUT
changed	I-OUT
during	O
the	O
trial	O
,	O
although	O
the	O
HDL	B-OUT
:	I-OUT
cholesterol	I-OUT
increased	I-OUT
slightly	I-OUT
but	O
non-significantly	B-OUT
with	O
an	O
increase	B-OUT
in	O
EPA	B-OUT
and	I-OUT
DHA	I-OUT
.	I-OUT


Manipulation	O
of	O
afferent	O
inputs	O
may	O
temporarily	O
modulate	O
dystonic	O
spasms	O
.	O


A	O
randomized	O
controlled	O
trial	O
to	O
improve	O
colon	B-I
cancer	I-I
screening	I-I
in	O
rural	B-P
family	I-P
medicine	I-P
:	I-P
an	O
Iowa	O
Research	O
Network	O
(	O
IRENE	O
)	O
study	O
.	O


RESULTS	O
This	B-P
study	I-P
enrolled	I-P
743	I-P
patients	I-P
.	I-P


CRC	B-OUT
screening	I-OUT
was	O
completed	B-OUT
by	O
17.8	O
%	O
in	O
the	O
usual	O
care	O
group	O
,	O
20.5	O
%	O
in	O
the	O
chart	O
reminder	O
group	O
,	O
56.5	O
%	O
in	O
the	O
mailed	O
education/FIT	O
group	O
,	O
and	O
57.2	O
%	O
in	O
the	O
mailed	O
education/FIT	O
plus	O
phone	O
call	O
group	O
.	O


We	O
found	O
no	O
effect	O
from	O
the	O
chart	O
reminder	O
compared	O
with	O
usual	O
care	O
(	O
odds	O
ratio	O
[	O
OR	O
]	O
,	O
1.2	O
;	O
95	O
%	O
confidence	O
interval	O
[	O
CI	O
]	O
,	O
0.7-2.0	O
)	O
;	O
and	O
a	O
beneficial	B-OUT
effect	I-OUT
from	O
the	O
mailed	O
education/FIT	O
(	O
OR	O
,	O
6.0	O
;	O
95	O
%	O
CI	O
,	O
3.7-9.6	O
)	O
and	O
the	O
mailed	O
education/FIT	O
plus	O
phone	O
call	O
(	O
OR	O
,	O
6.2	O
;	O
95	O
%	O
CI	O
,	O
3.8-9.9	O
)	O
.	O


Both	O
FIT	B-OUT
and	I-OUT
colonoscopy	I-OUT
rates	I-OUT
increased	I-OUT
significantly	O
in	O
both	O
mailed	O
education	O
groups	O
.	O


There	O
were	O
no	O
serious	O
adverse	O
events	O
.	O


Intercellular	B-OUT
adhesion	I-OUT
molecule-1	I-OUT
concentration	I-OUT
(	O
ng/mL	O
)	O
rose	O
by	O
51.2	O
in	O
the	O
placebo	O
group	O
,	O
rose	O
slightly	O
(	O
by	O
10.6	O
)	O
in	O
the	O
low-dose	O
allopurinol	B-I
group	O
,	O
but	O
fell	O
in	O
the	O
high-dose	O
group	O
(	O
by	O
2.6	O
;	O
difference	O
between	O
groups	O
P=0.012	O
,	O
Kruskal-Wallis	O
test	O
)	O
.	O


CONCLUSIONS	O
Consistent	O
with	O
previously	O
published	O
efficacy	O
results	O
,	O
these	O
data	O
suggest	O
that	O
150	O
mg/m	O
(	O
2	O
)	O
qw	O
3/4	O
may	O
represent	O
the	O
most	O
clinically	O
efficacious	O
nab-paclitaxel	O
dosing	O
regimen	O
for	O
patients	B-P
with	I-P
no	I-P
previous	I-P
chemotherapy	I-P
for	I-P
MBC	I-P
.	I-P


A	O
phase	O
III	O
trial	O
confirming	O
these	O
results	O
would	O
be	O
necessary	O
and	O
prudent	O
before	O
widespread	O
adoption	O
of	O
the	O
150	O
mg/m	O
(	O
2	O
)	O
dose	O
in	O
clinical	O
practice	O
.	O


Within	O
a	O
multicentric	O
study	O
of	O
several	B-P
Social	I-P
Pediatric	I-P
Centers	I-P
(	I-P
SPCs	I-P
)	I-P
and	I-P
further	I-P
clinics/institutions	I-P
in	I-P
Germany	I-P
,	O
it	O
has	O
been	O
established	O
as	O
a	O
group	B-I
parenting	I-I
training	I-I
(	I-P
3-7	I-P
families	I-P
per	I-P
training	I-P
)	I-P
.	O


We	O
studied	O
137	B-P
women	I-P
and	O
treatments	O
were	O
found	O
to	O
be	O
equivalent	O
for	O
onset	O
,	O
duration	O
and	O
quality	O
of	O
block	O
.	O


This	O
study	O
examined	O
the	O
impact	O
of	O
oxytocin	B-I
on	O
repetitive	B-OUT
behaviors	I-OUT
in	O
15	B-P
adults	I-P
with	I-P
autism	I-P
or	I-P
Asperger	I-P
's	I-P
disorder	I-P
via	O
randomized	O
double-blind	O
oxytocin	B-I
and	I-I
placebo	I-I
challenges	O
.	O


OBJECTIVE	O
To	O
evaluate	O
the	O
safety	B-OUT
and	I-OUT
tolerability	I-OUT
of	O
a	O
single	B-I
subconjunctival	I-I
(	I-I
SCJ	I-I
)	I-I
or	O
intravitreal	B-I
(	I-I
IVT	I-I
)	I-I
injection	I-I
of	O
an	O
ophthalmic	O
sirolimus	B-I
formulation	O
in	O
eyes	O
with	O
diabetic	O
macular	O
edema	O
(	O
DME	O
)	O
.	O


DESIGN	O
Randomized	O
,	O
open-label	O
,	O
dose-escalating	O
phase	O
I	O
study	O
.	O


Secondary	O
end	O
points	O
were	B-OUT
changes	I-OUT
in	I-OUT
BCVA	I-OUT
and	I-OUT
retinal	I-OUT
thickness	I-OUT
.	O


After	O
4	O
weeks	O
,	O
'responders	O
'	O
to	O
treatment	O
(	B-OUT
diastolic	I-OUT
blood	I-OUT
pressure	I-OUT
reduced	O
to	O
less	O
than	O
or	O
equal	O
to	O
90	O
mmHg	O
or	O
by	O
greater	O
than	O
or	O
equal	O
to	O
10	O
mmHg	O
)	O
were	O
kept	O
on	O
monotherapy	B-I
and	O
checked	O
at	O
4-weekly	O
intervals	O
for	O
another	O
3	O
months	O
.	O


At	O
the	O
end	O
of	O
the	O
first	O
month	O
,	O
54.2	O
%	O
of	O
the	O
subjects	O
were	O
responders	O
to	O
clonidine	B-I
and	O
41.5	O
%	O
were	O
responders	O
to	O
the	O
placebo	B-I
(	O
P	O
less	O
than	O
0.05	O
for	O
both	O
groups	O
)	O
.	O


Peak	B-OUT
VO2	I-OUT
was	O
20.4	O
+/-	O
3.2	O
and	O
21.2	O
+/-	O
3.1	O
ml/min/kg	O
,	O
respectively	O
,	O
for	O
those	O
administered	O
the	O
placebo	B-I
and	O
the	O
drug	O
,	O
and	O
anaerobic	B-OUT
threshold	I-OUT
was	O
13.1	O
+/-	O
2.1	O
and	O
14.0	O
+/-	O
2.0	O
ml/min/kg	O
.	O


Although	O
the	O
overall	B-OUT
survival	I-OUT
probability	I-OUT
for	O
5	O
years	O
did	O
not	O
differ	O
between	O
the	O
SPG	O
and	O
control	O
groups	O
,	O
in	O
264	B-P
patients	I-P
with	I-P
curatively	I-P
resected	I-P
cancer	I-P
,	O
the	O
probability	O
to	O
5	O
year	O
survival	O
and	O
to	O
recurrence	B-OUT
in	O
the	O
sizofiran-administered	O
patients	O
was	O
better	O
than	O
in	O
the	O
controls	O
.	O


Control	O
of	O
perioperative	O
hypertension	B-OUT
during	O
coronary	B-I
artery	I-I
surgery	I-I
.	I-I


Both	O
the	O
anesthesiologists	O
and	O
the	O
recovery	O
room	O
nurses	O
rated	O
remifentanil	O
better	O
with	O
respect	O
to	O
level	B-OUT
of	I-OUT
consciousness	I-OUT
.	I-OUT


Analgesics	B-OUT
were	O
required	O
earlier	O
in	O
patients	O
receiving	O
remifentanil	O
;	O
median	O
time	O
0.5	O
vs	O
1.08	O
hr	O
,	O
P	O
<	O
0.001	O
.	O


Dose-response	O
relationship	O
of	O
complementary	B-I
radiotherapy	I-I
following	O
four	O
cycles	O
of	O
combination	B-I
chemotherapy	I-I
in	O
intermediate-stage	O
Hodgkin	B-P
's	I-P
disease	I-P
.	I-P


CONCLUSION	O
Our	O
results	O
strongly	O
suggest	O
that	O
there	O
is	O
no	O
relevant	O
radiotherapy	B-OUT
dose	I-OUT
effect	I-OUT
in	O
the	O
range	O
between	O
20	O
Gy	O
and	O
40	O
Gy	O
in	O
IF/BF	O
and	O
EF/IF	O
after	O
4	O
months	O
of	O
modern	B-P
polychemotherapy	I-I
in	I-P
patients	I-P
with	I-P
intermediate-stage	I-P
HD	I-P
.	I-P


Relapse	O
patterns	O
indicate	O
that	O
patients	O
destined	O
to	O
relapse	O
need	O
more	O
systemic	O
,	O
rather	O
than	O
local	O
,	O
treatment	O
.	O


All	O
analyses	O
were	O
by	O
intention	O
to	O
treat	O
.	O


There	O
were	O
fewer	O
falls	B-OUT
(	O
n=196	O
,	O
7·80/1000	O
patient-days	O
vs	O
n=380	O
,	O
13·78/1000	O
patient-days	O
,	O
adjusted	O
rate	O
ratio	O
0·60	O
[	O
robust	O
95	O
%	O
CI	O
0·42-0·94	O
]	O
,	O
p=0·003	B-OUT
)	I-OUT
,	I-OUT
injurious	I-OUT
falls	O
(	O
n=66	O
,	O
2·63/1000	O
patient-days	O
vs	O
131	O
,	O
4·75/1000	O
patient-days	O
,	O
0·65	O
[	O
robust	O
95	O
%	O
CI	O
0·42-0·88	O
]	O
,	O
p=0·006	B-OUT
)	I-OUT
,	O
and	O
fallers	O
(	O
n=136	O
[	O
8·38	O
%	O
]	O
vs	O
n=248	O
[	O
12·51	O
%	O
]	O
adjusted	O
odds	O
ratio	O
0·55	O
[	O
robust	O
95	O
%	O
CI	O
0·38	O
to	O
0·81	O
]	O
,	O
p=0·003	O
)	O
in	O
the	O
intervention	O
compared	O
with	O
the	O
control	O
group	O
.	O


Indomethacin	B-I
did	O
not	O
reduce	O
the	O
frequency	B-OUT
of	I-OUT
dose	I-OUT
reductions	I-OUT
for	I-OUT
toxic	I-OUT
side-effects	I-OUT
and	O
did	O
not	O
permit	O
the	O
administration	B-OUT
of	I-OUT
higher	I-OUT
interferon	I-OUT
doses	I-OUT
.	I-OUT


Blood	B-OUT
pressure	I-OUT
reduction	I-OUT
was	O
significant	O
in	O
these	O
all	B-P
groups	I-P
and	O
no	O
differences	O
were	O
observed	O
in	O
blood	O
pressure	O
reduction	O
among	O
the	O
groups	O
.	O


For	O
the	O
320	O
patients	O
who	O
completed	O
the	O
DAN-PSSsex	O
,	O
alfuzosin	O
treatment	O
was	O
associated	O
with	O
a	O
significant	O
improvement	O
in	O
the	O
mean	B-OUT
change	I-OUT
from	I-OUT
baseline	I-OUT
in	I-OUT
erectile	I-OUT
function	I-OUT
on	O
day	O
29	O
compared	O
with	O
placebo	O
(	O
P=0.02	O
)	O
.	O


For	O
patients	O
with	O
ED	O
at	O
baseline	O
,	O
a	O
marginal	O
improvement	O
in	O
erectile	B-OUT
function	I-OUT
was	O
demonstrated	O
with	O
alfuzosin	O
treatment	O
(	O
P=0.09	O
vs	O
placebo	O
)	O
.	O


For	O
patients	O
with	O
EjD	O
at	O
baseline	O
,	O
the	O
mean	O
change	O
from	O
baseline	O
in	O
ejaculatory	B-OUT
function	I-OUT
with	O
alfuzosin	O
was	O
comparable	O
to	O
that	O
with	O
placebo	O
.	O


Young	B-P
adults	I-P
with	I-P
sickle	I-P
cell	I-P
disease	I-P
(	I-P
SCD	I-P
)	I-P
are	O
often	O
stigmatized	O
when	O
they	O
seek	O
care	O
for	O
pain	O
.	O


A	O
pilot	O
randomised	O
controlled	O
trial	O
of	O
cognitive	B-I
behavioural	I-I
therapy	I-I
for	O
antenatal	B-P
depression	I-P
.	I-P


We	O
studied	O
101	B-P
adult	I-P
patients	I-P
with	I-P
newly	I-P
detected	I-P
bronchial	I-P
asthma	I-P
who	I-P
were	I-P
without	I-P
inhaled	I-P
steroid	I-P
or	I-P
any	I-P
regular	I-P
pharmacological	I-P
treatment	I-P
for	I-P
their	I-P
asthma	I-P
.	I-P


The	O
drugs	O
were	O
given	O
with	O
a	O
Turbuhaler	B-I
dry	I-I
powder	I-I
inhaler	I-I
.	I-I


The	O
low	O
dose	O
may	O
not	O
be	O
enough	O
to	O
suppress	O
asthmatic	O
inflammation	O
despite	O
good	B-OUT
clinical	I-OUT
primary	I-OUT
response	I-OUT
.	I-OUT


Sunbathing	B-OUT
and	I-OUT
sunbed	I-OUT
use	I-OUT
increased	O
with	O
age	O
.	O


Families	O
in	O
the	O
target	O
treatment	O
group	O
were	O
given	O
2	O
hours	O
of	O
therapy	B-I
and	I-I
coaching	I-I
each	O
week	O
in	O
an	O
intervention	O
emphasizing	O
social-interaction	B-I
and	I-I
the	I-I
parent-child	I-I
relationship	I-I
.	I-I


A	O
replication	O
and	O
extension	O
of	O
the	O
PEERS	B-I
intervention	I-I
:	I-I
examining	O
effects	O
on	O
social	B-OUT
skills	I-OUT
and	O
social	B-OUT
anxiety	I-OUT
in	O
adolescents	B-P
with	I-P
autism	I-P
spectrum	I-P
disorders	I-P
.	I-P


PEERS	B-I
focuses	O
on	O
improving	O
friendship	B-OUT
quality	I-OUT
and	O
social	B-OUT
skills	I-OUT
among	O
adolescents	B-P
with	I-P
higher-functioning	I-P
ASD	I-P
.	I-P


[	O
Prevention	O
of	O
migraine	B-OUT
with	O
flunarizine	B-I
and	O
acetylsalicylic	B-I
acid	I-I
.	I-I


After	O
clinical	O
exclusion	O
of	O
symptomatic	O
headache	O
4	O
weeks	O
were	O
documented	O
by	O
means	O
of	O
a	O
migraine	O
diary	O
.	O


If	O
the	O
response	O
to	O
one	O
is	O
insufficient	O
the	O
other	O
substance	O
should	O
be	O
tried	O
.	O


Double	O
hearing	O
protection	O
and	O
speech	O
intelligibility-room	O
for	O
improvement	O
.	O


Much	O
of	O
the	O
research	O
that	O
spurred	O
the	O
introduction	O
of	O
foam	O
earplugs	O
indicated	O
little	O
change	O
in	O
speech	O
intelligibility	O
in	O
persons	O
with	O
normal	O
hearing	O
.	O


METHODS	O
Therefore	O
,	O
we	O
exposed	O
patients	B-P
with	I-P
mild	I-P
asthma	I-P
to	O
2	B-I
weeks	I-I
of	I-I
repeated	I-I
low-dose	I-I
allergen	I-I
,	I-I
with	I-I
concomitant	I-I
inhaled	I-I
steroid	I-I
or	I-I
placebo	I-I
treatment	I-I
.	I-I


The	O
ECM	O
proteins	O
in	O
asthmatics	O
were	O
also	O
compared	O
with	O
a	O
normal	O
control	O
group	O
.	O


Effect	O
of	O
esomeprazole	B-I
triple	I-I
therapy	I-I
on	O
eradication	B-OUT
rates	I-OUT
of	I-OUT
Helicobacter	I-OUT
pylori	I-OUT
,	I-OUT
gastric	I-OUT
ulcer	I-OUT
healing	I-OUT
and	I-OUT
prevention	I-OUT
of	I-OUT
relapse	I-OUT
in	O
gastric	B-P
ulcer	I-P
patients	I-P
.	I-P


OBJECTIVES	O
To	O
compare	O
esomeprazole-based	B-I
triple	O
therapy	O
with	O
esomeprazole	O
alone	O
for	O
the	O
eradication	B-OUT
of	I-OUT
Helicobacter	I-OUT
pylori	I-OUT
(	I-OUT
H.	I-OUT
pylori	I-OUT
)	I-OUT
,	I-OUT
healing	I-OUT
of	I-OUT
ulcer	I-OUT
and	I-OUT
prevention	I-OUT
of	I-OUT
relapse	I-OUT
in	O
H.	O
pylori-related	O
gastric	O
ulcer	O
(	O
GU	O
)	O
diseases	O
.	O


METHODS	O
In	O
this	O
double-blind	O
study	O
,	O
401	B-P
H.	I-P
pylori-positive	I-P
patients	I-P
with	I-P
more	I-P
than	I-P
or	I-P
equal	I-P
to	I-P
two	I-P
GUs	I-P
were	O
randomized	O
to	O
:	O
esomeprazole	B-I
(	O
20	O
mg	O
)	O
twice	O
daily	O
(	O
bid	O
)	O
and	O
amoxicillin	B-I
(	O
1000	O
mg	O
)	O
bid	O
and	O
clarithromycin	B-I
(	O
500	O
mg	O
)	O
bid	O
(	O
EAC	O
)	O
for	O
1	O
week	O
,	O
followed	O
by	O
placebo	B-I
for	O
3	O
weeks	O
(	O
EAC	O
and	O
placebo	O
)	O
;	O
EAC	O
for	O
1	O
week	O
,	O
followed	O
by	O
esomeprazole	B-I
(	O
20	O
mg	O
)	O
once	O
daily	O
(	O
E20	O
)	O
for	O
3	O
weeks	O
(	O
EAC	O
and	O
E20	O
)	O
;	O
or	O
esomeprazole	B-I
(	O
20	O
mg	O
)	O
bid	O
and	O
placebo	B-I
antimicrobials	I-I
for	O
1	O
week	O
,	O
followed	O
by	O
E20	O
for	O
3	O
weeks	O
(	O
E20	O
bid	O
and	O
E20	O
)	O
.	O


Quantitative	O
analysis	O
of	O
this	O
effect	O
of	O
the	O
instruments	O
used	O
was	O
performed	O
on	O
20	B-P
freshly	I-P
extracted	I-P
,	I-P
non-periodontally	I-P
involved	I-P
,	I-P
large	I-P
human	I-P
molars	I-P
.	I-P


The	O
second	O
study	O
involved	O
two	O
treatment	O
groups	O
,	O
ultrasonic	B-I
scaler	I-I
alone	I-I
and	I-I
hand	I-I
instruments	I-I
,	O
each	O
allocated	O
with	O
20	O
teeth	O
(	O
small	O
root	O
fragments	O
)	O
.	O


The	O
level	O
of	O
significance	O
was	O
set	O
at	O
p	O
<	O
or=0.05	O
.	O


In	O
thyrotoxicosis	O
,	O
trough	B-OUT
levels	I-OUT
of	I-OUT
propranolol	I-OUT
and	I-OUT
nadolol	I-OUT
were	O
significantly	O
inversely	O
correlated	O
with	O
derived	B-OUT
creatinine	I-OUT
clearance	I-OUT
values	I-OUT
.	I-OUT


Motion	O
aftereffects	O
with	O
horizontally	O
moving	O
sound	O
sources	O
in	O
the	O
free	O
field	O
.	O


Handling	O
characteristics	O
were	O
judged	O
by	O
the	O
surgeons	O
to	O
be	O
superior	O
for	O
BP	B-I
.	I-I


Strip	B-I
use	I-I
(	I-I
peroxide	I-I
or	I-I
placebo	I-I
)	I-I
was	O
for	O
30	O
minutes	O
,	O
twice	O
daily	O
for	O
2	O
weeks	O
,	O
while	O
dentifrice	O
use	O
was	O
at	O
least	O
twice	O
daily	O
for	O
12	O
weeks	O
.	O


Between-group	O
comparisons	O
demonstrated	O
significant	O
(	O
P	O
<	O
0.0001	O
)	O
reductions	O
in	O
yellowness	B-OUT
and	I-OUT
redness	I-OUT
,	O
and	O
increased	O
brightness	B-OUT
favoring	I-OUT
the	O
peroxide	O
strip	O
group	O
.	O


BACKGROUND	O
Promising	O
results	O
with	O
hyperbaric	B-I
therapy	I-I
for	O
children	B-P
with	I-P
autism	I-P
have	O
been	O
reported	O
,	O
but	O
most	O
involved	O
the	O
use	O
of	O
only	O
mild	O
pressure	O
with	O
oxygen	O
supplementation	O
.	O


To	O
address	O
the	O
need	O
for	O
improved	O
educational	O
outcomes	O
,	O
a	O
previously	O
tested	O
consultation	O
intervention	O
called	O
the	O
Collaborative	B-I
Model	I-I
for	I-I
Promoting	I-I
Competence	I-I
and	I-I
Success	I-I
(	I-I
COMPASS	I-I
;	I-I
Ruble	O
,	O
Dalrymple	O
,	O
&	O
McGrew	O
,	O
2010	O
;	O
Ruble	O
,	O
Dalrymple	O
,	O
&	O
McGrew	O
,	O
2012	O
)	O
was	O
evaluated	O
in	O
a	O
2nd	O
randomized	O
controlled	O
trial	O
,	O
with	O
the	O
addition	B-P
of	I-P
a	I-P
web-based	I-P
group	I-P
.	I-P


METHOD	O
Forty-nine	B-P
teacher-child	I-P
dyads	I-P
were	O
randomized	O
into	O
1	B-I
of	I-I
3	I-I
groups	I-I
:	I-I
(	I-I
1	I-I
)	I-I
a	I-I
placebo	I-I
control	I-I
(	I-I
PBO	I-I
)	I-I
group	I-I
,	I-I
(	I-I
2	I-I
)	I-I
COMPASS	I-I
followed	I-I
by	I-I
face-to-face	I-I
(	I-I
FF	I-I
)	I-I
coaching	I-I
sessions	I-I
,	I-I
and	I-I
(	I-I
3	I-I
)	I-I
COMPASS	I-I
followed	I-I
by	I-I
web-based	I-I
(	I-I
WEB	I-I
)	I-I
coaching	I-I
sessions	I-I
.	I-I


CONCLUSIONS	O
A	O
27-month	O
course	O
of	O
EDTA	O
chelation	O
therapy	O
retards	O
the	O
progression	O
of	O
diabetic	O
nephropathy	B-P
in	I-P
type	I-P
2	I-P
diabetic	I-P
patients	I-P
with	I-P
high-normal	I-P
body	I-P
lead	I-P
burdens	O
.	O


BACKGROUND	O
Improved	O
endothelial	O
function	O
may	O
contribute	O
to	O
the	O
beneficial	O
effects	O
of	O
cholesterol	O
lowering	O
therapy	O
in	O
patients	B-P
with	I-P
coronary	I-P
artery	I-P
disease	I-P
(	I-P
CAD	I-P
)	I-P
,	O
but	O
results	O
of	O
the	O
effect	O
of	O
statin	O
therapy	O
on	O
endothelial	O
function	O
are	O
disparate	O
in	O
these	O
patients	O
.	O


Cardiopulmonary	B-I
exercise	I-I
testing	O
was	O
performed	O
at	O
baseline	O
and	O
after	O
10	O
weeks	O
.	O


METHODS	O
Between	B-P
July	I-P
,	I-P
1995	I-P
,	I-P
and	I-P
December	I-P
,	I-P
2003	I-P
,	I-P
167	I-P
patients	I-P
were	I-P
enrolled	I-P
from	I-P
27	I-P
Japanese	I-P
hospitals	I-P
and	O
randomly	O
assigned	O
to	O
TH	O
(	O
n=82	O
)	O
or	O
LTA	O
(	O
n=85	O
)	O
.	O


This	O
study	O
is	O
registered	O
with	O
,	O
number	O
NCT00149266	O
.	O


The	O
hazard	B-OUT
ratio	I-OUT
of	I-OUT
death	I-OUT
for	I-OUT
LTA	I-OUT
compared	O
with	O
TH	O
was	O
1.36	O
(	O
0.89-2.08	O
,	O
p=0.92	O
)	O
.	O


Three	O
patients	O
died	B-OUT
in	O
hospital	O
after	O
LTA	O
but	O
none	O
after	O
TH	O
.	O


Comparison	O
of	O
the	O
effectiveness	B-OUT
of	I-OUT
fennel	I-OUT
and	I-OUT
mefenamic	I-OUT
acid	I-OUT
on	O
pain	O
intensity	O
in	O
dysmenorrhoea	B-P
.	I-P


METHODS	O
We	O
conducted	O
a	O
randomized	O
controlled	O
trial	O
at	O
a	O
tertiary	O
care	O
medical	O
center	O
.	O


CLINICAL	O
TRIAL	O
REGISTRACTION	O
ClinicalTrials.gov	O
,	O
www.clinicaltrials.gov	O
,	O
NCT01076062	O
.	O


BACKGROUND	O
In	O
stressful	O
conditions	O
,	O
increasing	O
blood	O
glucose	O
concentrations	O
are	O
closely	O
related	O
to	O
an	O
increase	O
in	O
catecholamines	O
and	O
cortisol	O
release	O
.	O


Clonidine	O
,	O
a	O
centrally	O
acting	O
alpha	O
(	O
2	O
)	O
-adrenoceptor	O
agonist	O
,	O
has	O
neuroendocrine	O
effects	O
,	O
including	O
inhibition	O
of	O
sympathoadrenal	O
activity	O
.	O


METHODS	O
After	O
randomization	O
,	O
patients	O
were	O
premedicated	O
with	O
clonidine	B-I
or	I-I
flunitrazepam	I-I
(	O
control	O
)	O
.	O


infusion	O
to	O
maintain	O
blood	O
glucose	O
in	O
the	O
range	O
5.5-11.1	O
mmol	O
litre	O
(	O
-1	O
)	O
.	O


Effectiveness	O
of	O
a	O
fundamental	B-I
motor	I-I
skill	I-I
intervention	I-I
for	O
4-year-old	B-P
children	I-P
with	I-P
autism	I-P
spectrum	I-P
disorder	I-P
:	I-P
A	O
pilot	O
study	O
.	O


A	O
wait-list	B-I
control	I-I
experimental	O
design	O
was	O
employed	O
to	O
investigate	O
the	O
effectiveness	O
of	O
a	O
fundamental	B-I
motor	I-I
skill	I-I
intervention	I-I
at	O
improving	O
the	O
motor	B-OUT
skills	I-OUT
,	I-OUT
adaptive	I-OUT
behavior	I-OUT
,	I-OUT
and	I-OUT
social	I-OUT
skills	I-OUT
of	O
4-year-old	B-P
children	I-P
with	I-P
autism	I-P
spectrum	I-P
disorder	I-P
(	I-P
experimental	I-P
n	I-P
=	I-P
5	I-P
,	I-P
control	I-P
n	I-P
=	I-P
4	I-P
)	I-P
;	I-P
the	O
impact	O
of	O
intervention	O
intensity	O
was	O
also	O
explored	O
.	O


The	O
experimental	O
group	O
significantly	O
improved	B-OUT
their	I-OUT
object	I-OUT
manipulation	I-OUT
and	I-OUT
overall	I-OUT
motor	I-OUT
scores	O
from	O
pre-	O
to	O
post-intervention	B-I
.	O


All	O
operations	O
were	O
performed	O
through	O
a	O
posterolateral	O
approach	O
.	O


Measurements	O
were	O
also	O
made	O
to	O
compare	O
the	O
preoperative	B-OUT
plan	I-OUT
with	O
the	O
actual	B-OUT
amount	I-OUT
of	I-OUT
bone	I-OUT
removed	I-OUT
.	I-OUT


The	O
current	O
study	O
investigated	O
the	O
extent	O
to	O
which	O
the	O
lag	O
effect	O
on	O
the	O
durability	B-OUT
of	I-OUT
memory-based	I-OUT
automaticity	I-OUT
is	O
due	O
to	O
interference	O
or	O
to	O
the	O
loss	O
of	O
memory	O
strength	O
with	O
time	O
.	O


Participants	B-P
repeatedly	O
practiced	O
alphabet	B-I
subtraction	I-I
items	I-I
in	I-I
short	I-I
lag	I-I
and	I-I
long	I-I
lag	I-I
conditions	I-I
.	I-I


In	O
both	O
groups	O
,	O
IL-6	B-OUT
and	I-OUT
TNF-alpha	I-OUT
levels	I-OUT
remained	O
low	O
throughout	O
the	O
study	O
period	O
.	O


Circadian	O
changes	O
in	O
the	O
pharmacokinetics	B-OUT
of	O
oral	B-P
ketoprofen	I-I
.	I-I


The	O
time	B-OUT
to	I-OUT
reach	I-OUT
peak	I-OUT
concentration	I-OUT
was	O
much	O
longer	O
after	O
drug	O
administration	O
at	O
01.00	O
hours	O
(	O
135	O
+/-	O
16.7	O
min	O
)	O
than	O
at	O
07.00	O
(	O
73.1	O
+/-	O
14.1	O
min	O
)	O
,	O
13.00	O
(	O
75	O
+/-	O
16.5	O
min	O
)	O
or	O
19.00	O
hours	O
(	O
82.5	O
+/-	O
12.7	O
min	O
)	O
[	O
p	O
less	O
than	O
0.05	O
]	O
.	O


The	O
elimination	B-OUT
half-life	I-OUT
was	O
significantly	O
longer	O
after	O
administration	O
at	O
01.00	O
hours	O
than	O
after	O
19.00	O
hours	O
(	O
p	O
less	O
than	O
0.05	O
)	O
,	O
while	O
the	O
total	B-OUT
clearance	I-OUT
was	O
lowest	O
at	O
07.00	O
hours	O
.	O


Results	O
from	O
the	O
Nutritional	O
Prevention	O
of	O
Cancer	O
Trial	O
conducted	O
among	O
individuals	O
at	O
high	O
risk	O
of	O
nonmelanoma	O
skin	O
cancer	O
continue	O
to	O
demonstrate	O
that	O
selenium	B-I
supplementation	I-I
is	O
ineffective	O
at	O
preventing	B-OUT
basal	I-OUT
cell	I-OUT
carcinoma	I-OUT
and	O
that	O
it	O
increases	O
the	O
risk	B-OUT
of	I-OUT
squamous	I-OUT
cell	I-OUT
carcinoma	I-OUT
and	I-OUT
total	I-OUT
nonmelanoma	I-OUT
skin	I-OUT
cancer	I-OUT
.	I-OUT


Bilateral	B-I
venography	I-I
was	O
performed	O
in	O
all	O
patients	O
on	O
day	O
seven	O
after	O
operation	O
,	O
and	O
showed	O
an	O
overall	O
deep	O
vein	O
thrombosis	O
incidence	O
of	O
16	O
%	O
.	O


The	O
visiting	O
doctors	O
had	O
not	O
suspected	O
deep	O
vein	O
thrombosis	O
in	O
any	O
of	O
the	O
patients	O
.	O


This	O
may	O
have	O
been	O
because	O
postoperative	B-OUT
painful	I-OUT
and	I-OUT
swollen	I-OUT
legs	I-OUT
effectively	O
masked	O
any	O
signs	O
and	O
symptoms	O
of	O
deep	O
vein	O
thrombosis	O
.	O


The	O
high	O
subclinical	O
frequency	O
of	O
deep	O
vein	O
thrombosis	O
indicates	O
the	O
importance	O
of	O
improving	O
thromboprophylaxis	O
in	O
order	O
to	O
further	O
minimise	O
the	O
occurrence	O
of	O
deep	O
vein	O
thrombosis	O
and	O
the	O
risk	O
of	O
thromboembolic	O
complications	O
.	O


At	O
two	O
years	O
the	O
mean	O
cholesterol	B-OUT
level	I-OUT
was	O
highest	O
in	O
the	O
Aza	B-I
plus	I-I
MP	I-I
group	O
,	O
6.8	O
mmol/L	O
and	O
lowest	O
in	O
the	O
group	O
receiving	O
triple	B-I
therapy	I-I
,	O
5.8	O
mmol/L	O
(	O
P	O
=	O
ns	O
)	O
.	O


Among	O
sulindac-treated	B-I
patients	I-P
who	O
did	O
not	O
develop	O
adenomas	O
(	O
"	O
responders	O
"	O
)	O
,	O
4	O
(	O
33	O
%	O
)	O
were	O
homozygous	B-OUT
for	I-OUT
E158K	I-OUT
and	O
2	O
(	O
17	O
%	O
)	O
were	O
homozygous	B-OUT
for	I-OUT
E308G	I-OUT
variant	I-OUT
alleles	I-OUT
.	I-OUT


Effects	O
of	O
ORG-2766	B-I
on	O
brain	O
event-related	O
potentials	O
of	O
autistic	B-P
children	I-P
.	I-P


In	O
visual	O
and	O
auditory	O
oddball	O
paradigms	O
(	O
with	O
task	O
and	O
nontask	O
conditions	O
)	O
,	O
standard	O
(	O
80	O
%	O
)	O
,	O
target	O
(	O
10	O
%	O
)	O
,	O
and	O
unexpected	O
novel	O
stimuli	O
(	O
10	O
%	O
)	O
were	O
presented	O
.	O


This	O
study	O
showed	O
no	O
significant	O
effects	O
of	O
secretin	O
on	O
children	B-P
with	I-P
autism	I-P
.	I-P


OBJECTIVE	O
To	O
ensure	O
that	O
generic	O
warfarin	O
products	O
can	O
be	O
safely	O
interchanged	O
with	O
Coumadin	O
.	O


METHODS	O
Multiple	O
n-of-1	O
randomized	O
,	O
double-blind	O
,	O
crossover	O
trials	O
switched	O
outpatients	B-P
(	I-P
N	I-P
=	I-P
7	I-P
)	I-P
between	O
a	O
generic	B-I
warfarin	I-I
formulation	I-I
(	I-I
Apo-warfarin	I-I
)	I-I
and	I-I
Coumadin	I-I
over	I-I
30	I-I
weeks	I-I
.	I-I


Inter-	O
and	O
intrapatient	O
differences	O
between	O
generic	O
warfarin	B-I
and	O
Coumadin	B-I
were	O
compared	O
,	O
and	O
overall	O
study	O
patient	O
results	O
were	O
compared	O
with	O
those	O
of	O
a	O
Coumadin	O
control	O
group	O
.	O


CONCLUSIONS	O
It	O
appears	O
that	O
patients	O
can	O
safely	B-OUT
and	I-OUT
effectively	I-OUT
switch	I-OUT
between	O
generic	O
warfarin	B-I
and	O
Coumadin	B-I
.	I-I


They	O
were	O
randomly	O
allocated	O
to	O
one	O
of	O
three	O
groups	O
(	O
n	O
=	O
40	O
for	O
each	O
)	O
:	O
saline	B-I
(	O
as	O
a	O
control	O
)	O
,	O
granisetron	B-I
20	O
micrograms/kg	O
,	O
and	O
granisetron	B-I
40	O
micrograms/kg	O
.	O


The	O
adverse	B-OUT
events	I-OUT
in	O
the	O
granisetron	O
groups	O
were	O
similar	O
to	O
those	O
in	O
the	O
control	O
group	O
.	O


during	O
anesthesia	O
appears	O
to	O
be	O
a	O
simple	B-OUT
,	I-OUT
effective	I-OUT
,	I-OUT
and	I-OUT
safe	I-OUT
method	I-OUT
for	O
preventing	O
postoperative	B-OUT
nausea	I-OUT
and	I-OUT
vomiting	I-OUT
.	I-OUT


OBJECTIVE	O
Primary	O
prophylaxis	O
against	O
Pneumocystis	O
carinii	O
pneumonia	O
(	O
PCP	O
)	O
for	O
patients	B-P
with	I-P
HIV	I-P
infection	I-P
has	O
been	O
recommended	O
by	O
the	O
Centers	O
for	O
Disease	O
Control	O
and	O
Prevention	O
.	O


METHODS	O
A	B-P
total	I-P
of	I-P
121	I-P
HIV-infected	I-P
patients	I-P
with	I-P
CD4+	I-P
cell	I-P
counts	I-P
<	I-P
or	I-P
=	I-P
200	I-P
x	I-P
10	I-P
(	I-P
6	I-P
)	I-P
/l	I-P
or	I-P
an	I-P
AIDS	I-P
diagnosis	I-P
were	O
enrolled	O
in	O
a	O
controlled	O
study	O
of	O
aerosolized	B-I
pentamidine	I-I
as	O
primary	O
PCP	O
prophylaxis	O
.	O


Patients	O
were	O
randomly	O
assigned	O
to	O
treatment	O
(	O
n	O
=	O
61	O
)	O
with	O
aerosolized	B-I
pentamidine	I-I
once	O
every	O
month	O
or	O
to	O
no	B-I
treatment	I-I
(	O
n	O
=	O
60	O
)	O
.	O


Intermediate	O
accuracy	B-OUT
scores	I-OUT
indicated	O
that	O
participants	O
could	O
match	O
one	O
of	O
the	O
samples	O
but	O
not	O
both	O
of	O
them	O
.	O


The	O
safety	O
evaluation	O
was	O
not	O
masked	O
for	O
potentially	O
deployed	O
participants	O
,	O
who	O
were	O
therefore	O
not	O
included	O
in	O
the	O
safety	O
analysis	O
for	O
comparison	O
between	O
the	O
vaccine	O
doses	O
and	O
placebo	O
,	O
but	O
were	O
pooled	O
with	O
the	O
non-deployed	O
group	O
to	O
compare	O
immunogenicity	O
.	O


Participants	O
were	O
followed	O
up	O
for	O
6	O
months	O
.	O


Comparison	O
of	O
arch	O
dimension	O
changes	O
in	O
1-phase	O
vs	O
2-phase	O
treatment	O
of	O
Class	B-P
II	I-P
malocclusion	I-P
.	I-P


This	O
was	O
a	O
prospective	O
randomized	O
clinical	O
trial	O
conducted	O
in	O
the	O
Department	B-P
of	I-P
Orthodontics	I-P
at	I-P
the	I-P
University	I-P
of	I-P
Florida	I-P
between	I-P
1990	I-P
and	I-P
2003	I-P
.	I-P


A	O
placebo-controlled	B-I
double-blind	O
study	O
]	O
.	O


Melatonin	B-I
significantly	O
improved	B-OUT
sleep	I-OUT
latency	I-OUT
(	O
by	O
an	O
average	O
of	O
47	O
min	O
)	O
and	O
total	B-OUT
sleep	I-OUT
(	O
by	O
an	O
average	O
of	O
52	O
min	O
)	O
compared	O
to	O
placebo	B-I
,	O
but	O
not	O
number	O
of	O
night	O
wakenings	O
.	O


The	O
typical	O
side-effects	O
of	O
anti-serotonin	B-OUT
drugs	I-OUT
,	O
especially	O
sedation	B-OUT
or	I-OUT
dizziness	I-OUT
and	I-OUT
hyperorexia	I-OUT
were	O
hardly	O
observed	O
.	O


RESULTS	O
When	O
including	O
all	O
follow-up	O
variables	O
,	O
there	O
were	O
three	O
groups	O
:	O
(	O
1	O
)	O
Thirty-seven	O
children	O
with	O
male	O
predominance	O
,	O
familial	O
history	O
of	O
epilepsy	O
,	O
simple	O
febrile	O
convulsions	O
,	O
massive	O
myoclonus	O
,	O
tonic-clonic	O
fits	O
.	O


These	O
patients	O
met	O
the	O
major	O
characteristics	O
of	O
Lennox-Gastaut	O
syndrome	O
.	O


Within	O
MAE	O
groups	O
combined	O
,	O
clinical	O
and	O
EEG	O
risk	O
factors	O
for	O
mental	O
retardation	O
could	O
be	O
identified	O
.	O


[	O
A	O
clinical	O
trial	O
of	O
ultrasound-guided	B-I
facet	I-I
joint	I-I
block	I-I
in	O
the	O
lumbar	O
spine	O
to	O
treat	O
facet	B-P
joint	I-P
related	I-P
low	I-P
back	I-P
pain	I-P
]	I-P
.	O


VAS	B-OUT
score	I-OUT
,	I-OUT
puncture	I-OUT
time	I-OUT
and	I-OUT
one-time	I-OUT
puncture	I-OUT
success	I-OUT
rate	I-OUT
(	O
%	O
)	O
were	O
recorded	O
.	O


There	O
were	O
8	O
,	O
9	O
,	O
9	O
,	O
and	O
9	O
patients	O
in	O
US	O
group	O
obtaining	O
a	O
reduction	B-OUT
in	O
VAS	B-OUT
scores	I-OUT
>	O
or	O
=	O
3	O
at	O
30	O
min	O
,	O
1	O
d	O
,	O
2	O
d	O
and	O
6	O
weeks	O
after	O
the	O
procedure	O
respectively	O
,	O
while	O
the	O
numbers	O
of	O
such	O
patients	O
were	O
5	O
,	O
6	O
,	O
5	O
,	O
5	O
in	O
B	O
group	O
(	O
P	O
>	O
0.05	O
)	O
.	O


Women	O
selecting	O
this	O
treatment	O
were	O
assigned	O
to	O
a	O
group	O
that	O
received	O
both	O
mail	B-I
and	I-I
telephone	I-I
reminders	I-I
or	O
to	O
a	O
second	O
group	O
that	O
received	O
only	B-I
a	I-I
scheduled	I-I
appointment	I-I
at	I-I
the	I-I
time	I-I
of	I-I
the	I-I
previous	I-I
injection	I-I
.	I-I


Informed	O
consent	O
were	O
given	O
by	O
all	O
patients	O
.	O


After	O
2	O
weeks	O
of	O
placebo	B-I
run-in	O
period	O
,	O
105	B-P
patients	I-P
with	I-P
mild	I-P
or	I-P
moderate	I-P
essential	I-P
hypertension	I-P
were	O
randomized	O
to	O
receive	O
either	O
enalapril	B-I
(	O
10	O
mg	O
per	O
day	O
)	O
or	B-I
indapamide	I-I
(	O
2.5	O
mg	O
per	O
day	O
)	O
for	O
8	O
weeks	O
.	O


No	O
significant	O
difference	O
(	O
all	O
P	O
values	O
>	O
0.05	O
)	O
was	O
found	O
in	O
baseline	O
data	O
between	O
the	O
two	O
groups	O
.	O


CONCLUSIONS	O
Enalapril	B-I
and	I-I
indapamide	I-I
are	O
both	O
similarly	O
effective	O
in	O
reducing	O
peripheral	B-OUT
arterial	I-OUT
blood	I-OUT
pressure	I-OUT
.	I-OUT


Moreover	O
,	O
enalapril	B-I
is	O
more	O
effective	O
in	O
reducing	O
central	B-OUT
systolic	I-OUT
pressure	I-OUT
and	I-OUT
augmentation	I-OUT
index	I-OUT
than	O
indapamide	B-I
.	I-I


Dietary	B-I
factors	I-I
may	O
influence	O
benign	O
fibrocystic	O
breast	O
conditions	O
,	O
but	O
little	O
is	O
known	O
of	O
their	O
association	O
with	O
fibroadenomas	O
.	O


We	O
examined	O
possible	O
associations	O
between	O
a	O
broad	O
spectrum	O
of	O
circulating	O
biomarkers	B-OUT
of	I-OUT
dietary	I-OUT
intake	I-OUT
and	O
risk	O
of	O
fibroadenomas	O
.	O


Conditional	B-OUT
logistic	I-OUT
regression	I-OUT
was	O
used	O
to	O
estimate	B-OUT
adjusted	I-OUT
odds	I-OUT
ratios	I-OUT
(	I-OUT
OR	I-OUT
)	I-OUT
and	O
95	B-OUT
%	I-OUT
CI	I-OUT
.	I-OUT


Fenoterol	B-I
(	I-I
FNT	I-I
)	I-I
,	I-I
ipratropium	I-I
bromide	I-I
(	I-I
IB	I-I
)	I-I
,	I-I
and	I-I
placebo	I-I
were	O
administered	O
respectively	O
to	O
children	O
in	O
the	O
different	O
groups	O
by	O
means	O
of	O
metered	O
dose	O
inhalers	O
(	O
MDI	O
)	O
with	O
spacers	O
,	O
using	O
doses	O
of	O
3	O
puffs	O
every	O
hour	O
,	O
for	O
4	O
hours	O
.	O


The	O
same	O
test	O
was	O
also	O
applied	O
to	O
the	O
independent	O
samples	O
for	O
determining	O
the	O
superiority	O
of	O
one	O
treatment	O
,	O
FNT	B-I
or	I-I
IB	I-I
,	O
over	O
the	O
other	O
.	O


Significant	O
bronchodilator	O
effect	O
was	O
obtained	O
in	B-P
infants	I-P
with	I-P
AW	I-P
when	O
repeated	O
doses	O
of	B-I
FNT	I-I
or	I-I
IB	I-I
were	O
administered	O
with	O
MDI	O
and	O
spacers	O
.	O


CONCLUSIONS	O
C-reactive	O
protein	O
and	O
a	O
family	O
history	O
of	O
myocardial	O
infarction	O
were	O
positively	O
associated	O
with	O
subsequent	B-OUT
venous	I-OUT
thrombosis	I-OUT
.	I-OUT


These	O
findings	O
should	O
be	O
confirmed	O
by	O
further	O
investigations	O
.	O


RESULTS	O
The	O
mean	B-OUT
total	I-OUT
operating	I-OUT
times	I-OUT
(	O
standard	O
error	O
of	O
the	O
mean	O
)	O
when	O
the	O
hand-sewn	O
and	O
the	O
stapled	O
methods	O
were	O
used	O
were	O
214	O
(	O
4	O
)	O
minutes	O
and	O
217	O
(	O
3.4	O
)	O
minutes	O
,	O
respectively	O
(	O
p	O
=	O
not	O
significant	O
[	O
NS	O
]	O
)	O
.	O


METHODS	O
Adverse	O
ocular	O
events	O
reported	O
by	O
clinician	O
investigators	O
were	O
listed	O
using	O
terms	O
modified	O
from	O
the	O
COSTART	O
dictionary	O
.	O


The	O
primary	O
efficacy	O
measure	O
was	O
pain-free	B-OUT
status	I-OUT
at	I-OUT
2	I-OUT
hours	I-OUT
postdose	I-OUT
.	I-OUT


The	O
most	O
commonly	O
reported	O
adverse	B-OUT
events	I-OUT
(	O
all	O
with	O
incidence	O
of	O
5	O
%	O
or	O
less	O
)	O
among	O
patients	O
receiving	O
rizatriptan	B-I
were	O
dry	B-OUT
mouth	I-OUT
,	I-OUT
dizziness	I-OUT
,	I-OUT
asthenia/fatigue	I-OUT
,	I-OUT
nausea	I-OUT
,	I-OUT
and	I-OUT
somnolence	I-OUT
.	I-OUT


PATIENTS	O
AND	O
METHODS	O
The	B-P
randomized	I-P
,	I-P
three-arm	I-P
trial	I-P
recruited	I-P
patients	I-P
in	I-P
stages	I-P
IIB	I-P
and	I-P
IIIA	I-P
with	I-P
risk	I-P
factors	I-P
and	I-P
stages	I-P
IIIB	I-P
and	I-P
IV	I-P
.	I-P


Differences	B-OUT
in	I-OUT
survival	I-OUT
were	O
not	O
significant	O
in	O
sequential	O
analysis	O
.	O


CONCLUSION	O
Combined	O
with	O
local	O
irradiation	O
,	O
BEACOPP	B-I
in	O
one	O
or	O
both	O
variants	O
shows	O
superior	O
disease	O
control	O
compared	O
with	O
COPP/ABVD	B-I
,	O
with	O
acceptable	O
acute	O
toxicity	O
.	O


PSK	B-I
may	O
suppress	O
CD57	O
(	O
+	O
)	O
T	O
cells	O
to	O
improve	O
survival	O
of	O
advanced	B-P
gastric	I-P
cancer	I-P
patients	I-P
.	I-P


CONCLUSION	O
The	O
present	O
findings	O
suggest	O
that	O
PSK	B-I
improves	O
overall	O
survival	O
of	O
stage	B-P
III	I-P
gastric	I-P
cancer	I-P
patients	I-P
partly	O
by	O
inhibiting	O
CD57	O
(	O
+	O
)	O
T	O
cells	O
,	O
a	O
proven	O
poor	O
prognostic	O
factor	O
in	O
advanced	O
gastric	O
cancer	O
.	O


The	O
immune	O
test	O
confirmed	O
that	O
the	O
rHA	O
protein	O
vaccine	O
could	O
also	O
induce	O
high	O
neutralizing	O
antibodies	O
,	O
and	O
the	O
AIV	O
challenge	O
test	O
proved	O
that	O
the	O
rHA	O
protein-based	O
vaccine	O
could	O
prevent	O
the	O
corresponding	O
infection	O
.	O


This	O
trial	O
is	O
registered	O
with	O
the	O
Iranian	O
Clinical	O
Trials	O
Registry	O
(	O
IRCT1138901151556N10	O
;	O
www.irct.ir	O
)	O
.	O


The	O
aim	O
of	O
the	O
present	O
trial	O
was	O
to	O
evaluate	O
the	O
effects	O
of	O
IFN-alpha	B-I
administered	O
as	O
an	O
adjuvant	B-I
of	I-I
HBV	I-I
vaccine	I-I
in	O
healthy	B-P
unvaccinated	I-P
individuals	I-P
.	I-P


Radial	B-I
artery	I-I
was	I-I
cannulated	I-I
for	I-OUT
arterial	I-OUT
blood	I-OUT
pressure	I-OUT
(	I-OUT
ABP	I-OUT
)	I-OUT
monitoring	I-OUT
and	I-OUT
blood	I-OUT
sampling	I-I
and	I-I
Swan-Ganz	I-I
catheter	I-I
was	I-I
position	I-I
in	I-I
the	I-I
pulmonary	I-I
artery	I-I
via	I-I
right	I-I
internal	I-I
jugular	I-I
vein	I-I
under	I-I
local	I-I
anesthesia	I-I
.	I-OUT


RESULTS	B-OUT
SVRI	I-OUT
,	I-OUT
MAP	I-OUT
,	I-OUT
HR	I-OUT
in	I-OUT
group	I-OUT
N	O
increased	O
significantly	O
at	O
T1	O
,	O
T2	O
,	O
T4	O
compared	O
with	O
group	O
S	O
(	O
p	O
<	O
0.05	B-OUT
)	I-OUT
.	I-OUT


BACKGROUND	O
AND	O
PURPOSE	O
A	O
low-affinity	O
,	O
use-dependent	O
N-Methyl-D-Aspartate	B-I
(	I-I
NMDA	I-I
)	I-I
antagonist	I-I
AR-R15896AR	I-I
has	O
neuroprotective	O
properties	O
in	O
animal	B-P
models	I-P
of	I-P
ischaemic	I-P
stroke	I-P
.	I-P


However	O
,	O
active	O
treatment	O
produced	O
more	O
side	B-OUT
effects	I-OUT
than	O
placebo	B-I
,	O
thus	O
indicating	O
safety	O
concerns	O
and	O
tolerability	O
issues	O
for	O
use	O
in	O
high	O
doses	O
in	O
an	O
acute	O
stroke	O
population	O
.	O


Our	O
goal	O
was	O
to	O
evaluate	O
retrograde	O
bone	O
marrow	O
cell	O
delivery	O
in	O
patients	B-P
with	I-P
either	I-P
ischemic	I-P
heart	I-P
failure	I-P
(	I-P
IHF	I-P
)	I-P
or	I-P
nonischemic	I-P
heart	I-P
failure	I-P
(	I-P
NIHF	I-P
)	I-P
.	I-P


Similarly	O
,	O
24	O
subjects	O
were	O
randomized	O
to	O
the	O
nonischemic	O
BMAC	O
group	O
and	O
6	O
to	O
the	O
nonischemic	O
control	O
group	O
.	O


On	O
the	O
basis	O
of	O
this	O
trial	O
and	O
the	O
safety	O
of	O
retrograde	O
coronary	O
sinus	O
infusion	O
,	O
there	O
are	O
three	O
other	O
trials	O
under	O
way	O
using	O
this	O
route	O
of	O
delivery	O
.	O


Repeated	O
doses	O
of	O
porcine	B-I
secretin	I-I
in	O
the	O
treatment	O
of	O
autism	B-P
:	I-P
a	O
randomized	O
,	O
placebo-controlled	O
trial	O
.	O


Aortic	B-I
valve	I-I
replacement	I-I
.	I-I


The	B-P
patients	I-P
were	I-P
selected	I-P
that	I-P
those	I-P
with	I-P
narrow	I-P
aortic	I-P
roots	I-P
were	I-P
over-represented	I-I
.	I-I


The	B-OUT
clinical	I-OUT
improvement	I-OUT
was	O
striking	O
,	O
although	O
the	B-OUT
number	I-OUT
of	I-OUT
patients	I-OUT
still	I-OUT
incapacitated	I-OUT
was	O
relatively	O
large	O
in	O
patients	O
with	O
the	O
small	B-I
L-K	I-I
valves	I-I
(	O
Nos	O
.	O


14	O
&	O
16	B-OUT
)	I-OUT
.	I-OUT


RESULTS	O
The	O
rate	B-OUT
of	I-OUT
malabsorption	I-OUT
was	O
84	O
%	O
for	O
sorbitol	B-I
,	O
36	O
%	O
for	O
fructose	B-I
and	O
12	O
%	O
for	O
xylitol	B-I
(	O
p	O
<	O
0.01	O
for	O
sorbitol	B-I
versus	I-I
fructose	I-I
and	I-I
xylitol	I-I
)	I-I
.	O


The	O
Beck	B-OUT
Depression	I-OUT
Inventory	I-OUT
(	I-OUT
BDI	I-OUT
)	I-OUT
,	I-OUT
the	I-OUT
Hamilton	I-OUT
Depression	I-OUT
Rating	I-OUT
Scale	I-OUT
(	I-OUT
HDRS	I-OUT
)	I-OUT
and	O
a	O
synoptic	O
table	O
were	O
used	O
to	O
score	O
depressive	B-OUT
symptoms	I-OUT
.	I-OUT


There	O
were	O
intervals	O
of	O
4	O
weeks	O
without	O
medication	O
between	O
the	O
treatment	O
periods	O
.	O


A	O
2-year	O
randomized	O
,	O
controlled	O
trial	O
.	O


INTRODUCTION	O
The	O
present	O
study	O
is	O
aimed	O
at	O
investigating	O
possible	O
predictors	O
of	O
response	O
to	O
ziprasidone	O
in	O
a	O
sample	O
of	O
patients	B-P
with	I-P
mixed	I-P
depressive	I-P
state	I-P
.	I-P


The	O
perioperative	O
use	O
of	O
glucocorticoids	O
has	O
been	O
advocated	O
as	O
a	O
method	O
to	O
improve	O
postoperative	O
outcomes	O
.	O


The	O
primary	O
outcome	O
was	O
the	B-OUT
incidence	I-OUT
of	I-OUT
low	I-OUT
cardiac	I-OUT
output	I-OUT
syndrome	I-OUT
(	O
standardized	O
score	O
)	O
or	O
death	O
36	O
hours	O
postoperatively	O
.	O


However	O
,	O
the	O
incidence	B-OUT
of	I-OUT
low	I-OUT
cardiac	I-OUT
output	I-OUT
syndrome	I-OUT
was	O
46	O
%	O
(	O
17/37	O
)	O
in	O
the	O
single-dose	O
and	O
38	O
%	O
(	O
15/39	O
)	O
in	O
the	O
2-dose	O
methylprednisolone	O
groups	O
(	O
P	O
=	O
.51	O
)	O
.	O


Inotropic	B-OUT
requirement	I-OUT
,	I-OUT
duration	I-OUT
of	I-OUT
mechanical	I-OUT
ventilation	I-OUT
,	I-OUT
intensive	I-OUT
care	I-OUT
unit	I-OUT
,	I-OUT
and	I-OUT
hospital	O
stay	O
did	O
not	O
differ	O
between	O
the	O
2	O
groups	O
.	O


BACKGROUND	O
There	O
is	O
increasing	O
evidence	O
that	O
dietary	O
factors	O
may	O
play	O
a	O
role	O
in	O
the	O
production	O
,	O
metabolism	O
,	O
and	O
bioavailability	O
of	O
sex	O
hormones	O
and	O
their	O
impact	O
on	O
target	O
tissues	O
.	O


Serum	B-OUT
hormone-binding	I-OUT
globulin	I-OUT
levels	I-OUT
increased	O
in	O
41.4	O
%	O
of	O
women	O
in	O
the	O
experimental	O
group	O
compared	O
with	O
37.5	O
%	O
of	O
women	O
in	O
the	O
placebo	B-I
group	O
.	O


BACKGROUND	O
No	O
studies	O
have	O
been	O
published	O
comparing	O
the	O
U-	B-I
and	I-I
H-type	I-I
methods	I-I
of	I-I
the	I-I
TVT	I-I
SECUR	I-I
(	I-I
TVT-S	I-I
)	I-I
procedure	I-I
.	I-I


DESIGN	O
,	O
SETTING	O
,	O
AND	O
PARTICIPANTS	O
Women	B-P
with	I-P
urodynamic	I-P
SUI	I-P
were	I-P
enrolled	I-P
in	O
this	O
12-mo	O
multicenter	O
randomized	O
study	O
.	O


Patients	O
'	O
satisfaction	B-OUT
and	O
complications	B-OUT
were	O
evaluated	O
.	O


Subjective	B-OUT
cure	I-OUT
rates	I-OUT
were	O
77.1	O
%	O
for	O
the	O
U-type	O
method	O
and	O
75.7	O
%	O
for	O
the	O
H-type	O
method	O
(	O
p=0.786	O
)	O
.	O


However	O
,	O
QOL	B-OUT
and	O
treatment	B-OUT
satisfaction	I-OUT
favored	O
the	O
U-type	B-I
method	I-I
.	I-I


BACKGROUND	O
The	O
efficacy	B-OUT
of	O
nebulized	O
corticosteroids	B-I
in	O
the	O
prevention	O
of	O
exacerbation	O
of	O
chronic	B-P
obstructive	I-P
pulmonary	I-P
disease	I-P
(	I-P
COPD	I-P
)	I-P
has	O
been	O
poorly	O
studied	O
.	O


OBJECTIVE	O
To	O
evaluate	O
the	O
efficacy	B-OUT
and	O
tolerability	B-OUT
of	O
nebulized	B-I
flunisolide	I-I
(	O
1	O
mg	O
)	O
+	B-I
salbutamol/ipratropium	I-I
bromide	I-I
(	O
1,875/375	O
microg	O
)	O
b.i.d	O
.	O


The	O
main	O
outcome	O
was	O
the	O
frequency	B-OUT
of	I-OUT
severe	I-OUT
exacerbations	I-OUT
over	O
a	O
6-month	O
period	O
.	O


In	O
the	O
placebo	B-I
group	O
,	O
scores	O
were	O
higher	O
than	O
in	O
the	O
flunisolide	B-I
group	O
but	O
nonsignificant	O
for	O
dyspnea	B-OUT
,	I-OUT
cough	I-OUT
,	I-OUT
sputum	I-OUT
amount	I-OUT
and	I-OUT
purulence	I-OUT
.	I-OUT


Observational	B-I
learning	I-I
and	O
the	O
formation	O
of	O
classes	O
of	O
reading	O
skills	O
by	O
individuals	B-P
with	I-P
autism	I-P
and	I-P
other	I-P
developmental	I-P
disabilities	I-P
.	I-P


However	O
,	O
based	O
on	O
observing	O
a	O
model	O
,	O
none	O
of	O
the	O
participants	O
demonstrated	O
full	O
stimulus	B-OUT
classes	I-OUT
.	I-OUT


When	O
full	O
stimulus	O
classes	O
did	O
not	O
occur	O
from	O
observing	O
a	O
model	O
,	O
participants	O
named	O
the	O
model	O
's	O
pictures	O
,	O
read	O
the	O
model	O
's	O
printed	O
words	O
,	O
or	O
matched	O
the	O
model	O
's	O
pictures	O
and	O
words	O
.	O


A	O
comparison	O
of	O
the	O
effects	O
of	O
(	B-I
-	I-I
)	I-I
-hyoscine	I-I
and	I-I
amylobarbitone	I-I
sodium	I-I
on	O
measurements	O
of	O
post-rotational	B-P
turning	I-P
sensation	I-P
and	I-P
nystagmus	I-OUT
.	I-OUT


A	O
randomized	O
comparison	O
of	O
acyclovir	B-I
and	I-I
vidarabine	I-I
.	I-I


We	O
conclude	O
that	O
acyclovir	B-I
is	O
better	O
than	O
vidarabine	B-I
for	O
the	O
treatment	O
of	O
varicella-zoster	O
infection	O
in	O
immunocompromised	B-P
patients	I-P
.	I-P


Behavioral	B-OUT
response	I-OUT
variables	I-OUT
,	I-OUT
salivary	I-OUT
cortisol	I-OUT
concentration	I-OUT
,	I-OUT
WBC	I-OUT
count	I-OUT
,	I-OUT
and	I-OUT
serum	I-OUT
concentrations	I-OUT
of	I-OUT
glucose	I-OUT
,	I-OUT
prolactin	I-OUT
,	I-OUT
haptoglobin	I-OUT
,	I-OUT
and	I-OUT
C-reactive	I-OUT
protein	I-OUT
were	O
analyzed	O
.	O


CONCLUSIONS	O
AND	O
CLINICAL	O
RELEVANCE	O
sDAP	O
appeared	O
to	O
affect	O
behavioral	B-OUT
and	I-OUT
neuroendocrine	I-OUT
perioperative	I-OUT
stress	I-OUT
responses	I-OUT
by	O
modification	O
of	O
lactotropic	O
axis	O
activity	O
.	O


Use	O
of	O
sDAP	B-I
in	O
a	O
clinical	O
setting	O
may	O
improve	O
the	O
recovery	B-OUT
and	O
welfare	O
of	O
dogs	B-P
undergoing	I-P
surgery	I-P
.	I-P


Repeated	O
triple	B-I
dye	I-I
application	I-I
was	O
considered	O
least	B-OUT
acceptable	I-OUT
by	O
staff	O
and	O
parents	O
and	O
had	O
the	O
longest	B-OUT
attachment	I-OUT
time	I-OUT
.	I-OUT


Etomidate	B-I
with	I-I
or	I-I
without	I-I
flumazenil	I-I
anesthesia	I-I
for	O
stem	O
cell	O
transplantation	O
in	O
autistic	B-P
children	I-P
.	I-P


METHODS	O
Forty	B-P
autistic	I-P
children	I-P
aged	I-P
2-12	I-P
,	I-P
who	I-P
were	I-P
scheduled	I-P
for	I-P
stem	I-P
cell	I-P
transplantation	I-P
via	I-P
lumbar	I-P
puncture	I-P
under	I-P
anesthesia	I-P
,	O
were	O
randomized	O
for	O
a	O
double-blind	O
study	O
.	O


The	O
children	O
were	O
randomly	O
assigned	O
to	O
two	O
groups	O
:	O
the	B-I
flumazenil	I-I
group	I-I
(	O
group	O
F	O
,	O
n=20	O
)	O
and	O
the	B-I
etomidate	I-I
group	I-I
(	O
group	O
E	O
,	O
n=20	O
)	O
.	O


Five	O
patients	O
complained	O
of	O
pain	B-OUT
on	I-OUT
the	I-OUT
site	I-OUT
of	I-OUT
injection	I-OUT
.	I-OUT


CONCLUSIONS	O
Etomidate	B-I
resulted	O
in	O
stable	O
hemodynamic	B-OUT
responses	I-OUT
and	O
relatively	O
less	O
adverse	B-OUT
effects	I-OUT
,	O
and	O
flumazenil	B-I
antagonized	O
the	O
anesthetic	B-OUT
effect	I-OUT
of	O
etomidate	O
;	O
thus	O
,	O
etomidate	O
with	O
flumazenil	O
is	O
suitable	O
for	O
performing	O
stem	O
cell	O
transplantation	O
in	O
autistic	B-P
children	I-P
.	I-P


The	O
primary	O
outcome	O
was	O
a	O
composite	B-OUT
of	I-OUT
death	I-OUT
from	I-OUT
cardiovascular	I-OUT
causes	I-OUT
,	I-OUT
aborted	I-OUT
cardiac	I-OUT
arrest	I-OUT
,	I-OUT
or	I-OUT
hospitalization	I-OUT
for	I-OUT
the	I-OUT
management	I-OUT
of	I-OUT
heart	I-OUT
failure	I-OUT
.	I-OUT


)	O
.	O


The	O
school-age	B-P
children	I-P
were	O
randomly	O
assigned	O
to	O
a	O
study	O
or	O
control	O
group	O
,	O
and	O
the	O
preschool	B-P
children	I-P
served	O
as	O
their	O
own	O
controls	O
.	O


Also	O
,	O
the	O
school-age	O
group	O
,	O
in	O
pre-	O
and	O
posttesting	O
,	O
demonstrated	O
that	O
the	O
SCRPA	B-I
curriculum	O
increased	O
knowledge	B-OUT
and	I-OUT
skills	I-OUT
in	O
the	O
study	O
group	O
,	O
changes	O
not	O
found	O
in	O
the	O
control	O
group	O
.	O


The	O
aim	O
of	O
the	O
present	O
study	O
was	O
to	O
evaluate	O
the	O
protective	O
effect	O
of	O
broccoli	B-I
intake	O
in	O
smokers	B-P
and	I-P
nonsmokers	I-P
.	I-P


Strand	B-OUT
breaks	I-OUT
decreased	O
significantly	O
after	O
the	O
broccoli	O
diet	O
in	O
smokers	O
as	O
well	O
as	O
in	O
nonsmokers	O
(	O
-22.2	O
%	O
;	O
P	O
<	O
0.0001	O
)	O
,	O
whereas	O
oxidized	B-OUT
purines	I-OUT
decreased	O
significantly	O
only	O
in	O
smokers	O
(	O
-51.0	O
%	O
;	O
P	O
<	O
0.0001	O
)	O
.	O


Broccoli	B-I
intake	O
did	O
not	O
modify	O
HDAC	B-OUT
activity	I-OUT
and	I-OUT
IGF-I	I-OUT
serum	I-OUT
levels	I-OUT
.	I-OUT


OBJECTIVE	O
To	O
evaluate	O
the	O
therapeutic	O
effect	O
of	O
Compound	B-I
Xuanju	I-I
Capsule	O
on	O
type	O
III	O
prostatitis	O
.	O


RESULTS	O
All	B-P
the	I-P
242	I-P
patients	I-P
completed	I-P
the	I-P
treatment	I-P
.	I-P


Randomized	O
controlled	O
trial	O
:	O
Multimodal	B-I
Anxiety	I-I
and	I-I
Social	I-I
Skill	I-I
Intervention	I-I
for	O
adolescents	B-P
with	I-P
autism	I-P
spectrum	I-P
disorder	I-P
.	I-P


These	O
findings	O
suggest	O
MASSI	B-I
is	O
a	O
feasible	B-OUT
treatment	O
program	O
and	O
further	O
evaluation	O
is	O
warranted	O
.	O


GM-CSF	B-I
had	O
to	O
be	O
reduced	O
or	O
suspended	O
in	O
50	O
%	O
of	O
patients	O
because	O
of	O
toxicity	B-OUT
.	I-OUT


METHODS	O
This	O
is	O
a	O
secondary	O
analysis	O
of	O
all	B-P
patients	I-P
with	I-P
mechanical	I-P
ventilation	I-P
(	I-P
N	I-P
=	I-P
104	I-P
)	I-P
previously	I-P
enrolled	I-P
in	I-P
a	I-P
randomized	I-P
controlled	I-P
trial	I-P
of	I-P
early	I-P
occupational	I-P
and	I-P
physical	I-P
therapy	I-P
vs	I-P
conventional	I-P
therapy	I-P
,	I-P
which	I-P
evaluated	I-P
the	I-P
end	I-P
point	I-P
of	I-P
functional	I-OUT
independence	I-OUT
.	I-OUT


Early	O
mobilization	O
also	O
significantly	O
reduced	O
insulin	B-OUT
requirements	I-OUT
to	O
achieve	B-OUT
similar	I-OUT
glycemic	I-OUT
goals	I-OUT
as	O
compared	O
with	O
control	O
patients	O
(	O
0.07	O
units/kg/d	O
vs	O
0.2	O
units/kg/d	O
,	O
P	O
<	O
.001	O
)	O
.	O


Mean	B-OUT
postoperative	I-OUT
intraocular	I-OUT
pressure	I-OUT
was	O
12.2	O
mmHg	O
in	O
group	O
1	O
,	O
and	O
13.7	O
mmHg	O
in	O
group	O
2	O
(	O
P	O
=	O
0.16	O
)	O
.	O


CONCLUSION	O
For	O
this	O
population	O
of	O
low-risk	B-P
patients	I-P
,	O
there	O
was	O
no	O
significant	O
difference	O
in	O
outcome	O
after	O
applications	O
of	O
a	O
single	O
intraoperative	O
dose	O
of	O
beta	B-I
radiation	I-I
.	I-I


MATERIAL	O
AND	O
METHODS	O
Using	O
impressions	O
made	O
from	O
a	O
stainless	O
steel	O
complete-crown	O
master	O
die	O
,	O
9	B-P
stone	I-P
cast	I-P
replicas	I-P
were	I-P
fabricated	I-P
,	I-P
numbered	I-P
,	I-P
and	I-P
distributed	I-P
into	I-P
8	I-P
ceramic	I-P
ZrO	I-P
(	I-P
2	I-P
)	I-P
CAD/CAM	I-P
system	I-P
groups	I-P
(	I-P
Lava	I-P
Frame	I-P
0.3	I-P
and	I-P
0.5	I-P
,	I-P
IPS	I-P
e.max	I-P
ZirCAD	I-P
,	I-P
VITA	I-P
YZ	I-P
,	I-P
Procera	I-P
AllZircon	I-P
,	I-P
Digizon	I-P
,	I-P
DC	I-P
Zircon	I-P
,	I-P
and	I-P
Cercon	I-P
Base	I-P
)	I-P
and	I-P
to	I-P
a	I-P
lithium	I-P
disilicate	I-P
glass-ceramic	I-P
control	I-P
group	I-P
(	I-P
IPS	I-P
e.max	I-P
Press	I-P
)	I-P
using	I-P
a	I-P
simple	I-P
computer-generated	I-P
randomization	I-P
method	I-P
.	I-P


Translucency	B-OUT
was	O
measured	O
by	O
the	O
direct	O
transmission	O
method	O
with	O
a	O
digital	O
photoradiometer	O
mounted	O
in	O
a	O
dark	O
chamber	O
.	O


The	O
light	O
source	O
was	O
a	O
150-W	O
halogen	O
lamp	O
beam	O
.	O


Measurements	O
were	O
repeated	O
3	O
times	O
for	O
each	O
specimen	O
.	O


Data	O
obtained	O
were	O
analyzed	O
using	O
1-way	O
ANOVA	O
and	O
the	O
Bonferroni	O
multiple	O
comparison	O
test	O
(	O
alpha=.05	O
)	O
.	O


RESULTS	O
Among	O
ZrO	O
(	O
2	O
)	O
copings	O
,	O
Lava	O
(	O
0.3	O
mm	O
and	O
0.5	O
mm	O
thick	O
)	O
showed	O
the	O
highest	O
(	O
P	O
<	O
.05	O
)	O
values	B-OUT
of	I-OUT
translucency	I-OUT
measured	O
as	O
light	O
flow	O
units	O
(	O
3.572	O
+	O
or	O
-	O
018	O
x	O
10	O
(	O
3	O
)	O
lx	O
and	O
3.181	O
+	O
or	O
-	O
0.13	O
x	O
10	O
(	O
3	O
)	O
lx	O
,	O
respectively	O
)	O
.	O


A	O
Pearson	O
r	O
correlation	O
indicated	O
the	O
REEDA	O
score	O
was	O
associated	O
with	O
a	O
laceration	B-OUT
and	I-OUT
not	I-OUT
with	I-OUT
infant	I-OUT
weight	I-OUT
.	I-OUT


PURPOSE	O
Vasomotor	B-OUT
symptoms	I-OUT
are	O
common	O
adverse	O
effects	O
of	O
antiestrogen	B-I
hormone	I-I
treatment	I-I
in	O
conventional	O
breast	O
cancer	O
care	O
.	O


Recent	O
studies	O
suggest	O
acupuncture	B-I
may	O
be	O
effective	O
in	O
reducing	O
vasomotor	B-OUT
symptoms	I-OUT
in	O
menopausal	B-P
women	I-P
.	I-P


These	O
changes	O
were	O
similar	O
in	O
both	O
groups	O
,	O
indicating	O
that	O
acupuncture	B-I
was	O
as	O
effective	O
as	O
venlafaxine	B-I
.	I-I


It	O
is	O
a	O
safe	O
,	O
effective	O
and	O
durable	O
treatment	O
for	O
vasomotor	O
symptoms	O
secondary	O
to	O
long-term	O
antiestrogen	B-I
hormone	I-I
use	O
in	O
patients	B-P
with	I-P
breast	I-P
cancer	I-P
.	I-P


METHODS/DESIGN	O
The	O
Staged	B-P
Nutrition	I-P
and	I-P
Activity	I-P
Counseling	I-P
(	I-P
SNAC	I-P
)	I-P
study	I-P
is	O
a	O
randomized	O
clustered	O
design	O
clinical	O
trial	O
that	O
will	O
investigate	O
the	O
effectiveness	O
and	O
efficacy	O
of	O
a	O
multi-component	B-I
lifestyle	I-I
intervention	I-I
on	O
cardiovascular	B-P
disease	I-P
risk	I-P
factors	I-P
and	I-P
vascular	I-P
function	I-P
in	I-P
patients	I-P
at	I-P
risk	I-P
in	I-P
primary	I-P
care	I-P
.	I-P


DISCUSSION	O
The	O
design	O
features	O
of	O
our	O
trial	O
,	O
and	O
the	O
practical	O
problems	O
(	O
and	O
solutions	O
)	O
associated	O
with	O
implementing	O
these	O
design	O
features	O
,	O
particularly	O
those	O
that	O
result	O
in	O
potential	O
delay	O
between	O
recruitment	O
,	O
baseline	O
data	O
collection	O
,	O
randomization	O
,	O
intervention	O
,	O
and	O
assessment	O
will	O
be	O
discussed	O
.	O


Clomiphene	B-I
citrate	I-I
(	O
100	O
mg/day	O
)	O
on	O
cycle	O
days	O
3-7	O
of	O
the	O
second	O
cycle	O
in	O
both	O
groups	O
.	O


Efficacy	B-OUT
and	I-OUT
safety	I-OUT
of	O
sildenafil	B-I
in	O
Asian	B-P
males	I-P
with	I-P
erectile	I-P
dysfunction	I-P
and	I-P
cardiovascular	I-P
risk	I-P
.	I-P


In	O
addition	O
,	O
sildenafil-treated	B-I
subjects	O
were	O
more	O
satisfied	B-OUT
with	O
treatment	O
and	O
had	O
a	O
higher	O
intercourse	B-OUT
success	I-OUT
rate	I-OUT
.	I-OUT


Intervention	O
was	O
unopposed	B-I
micronized	I-I
17beta-estradiol	I-I
versus	I-I
placebo	I-I
.	I-I


Measurements	O
were	O
made	O
using	O
high-resolution	O
B-mode	B-I
ultrasonography	I-I
to	O
measure	O
carotid	B-OUT
artery	I-OUT
IMT	I-OUT
at	O
baseline	O
and	O
every	O
6	O
months	O
on-trial	O
.	O


We	O
varied	O
the	O
direction	O
and	O
magnitude	O
of	O
the	O
perturbations	O
,	O
as	O
well	O
as	O
the	O
prior	O
knowledge	O
of	O
perturbation	O
direction	O
.	O


in	O
tibialis	O
anterior	O
and	O
rectus	O
femoris	O
)	O
.	O


During	O
the	O
4-year	O
follow-up	O
period	O
there	O
were	O
no	O
significant	O
differences	O
in	O
the	O
progression	B-OUT
rates	I-OUT
(	I-OUT
appearance	I-OUT
of	I-OUT
metastases	I-OUT
in	I-OUT
bone	I-OUT
scan	I-OUT
)	I-OUT
between	O
the	O
therapy	O
groups	O
.	O


The	O
high	O
risk	O
of	O
complications	O
associated	O
with	O
estrogens	O
and	O
radiotherapy	O
has	O
to	O
be	O
taken	O
into	O
consideration	O
in	O
the	O
selection	O
of	O
treatment	O
.	O


Transesophageal	B-I
echocardiography	I-I
in	O
quantification	O
of	O
emboli	O
during	O
femoral	O
nailing	O
:	O
reamed	B-I
versus	O
unreamed	B-I
techniques	O
.	O


We	O
quantified	O
the	O
embolic	O
load	O
to	O
the	O
lungs	O
created	O
with	O
two	O
different	O
techniques	O
of	O
femoral	B-I
nailing	I-I
.	I-I


Eleven	B-P
patients	I-P
with	I-P
12	I-P
traumatic	I-P
femur	I-P
fractures	I-P
were	O
randomized	O
to	O
reamed	B-I
(	O
7	O
fractures	O
)	O
and	O
unreamed	B-I
(	O
5	O
fractures	O
)	O
groups	O
.	O


Intramedullary	O
nailing	O
was	O
with	O
the	O
AO/ASIF*	O
universal	O
reamed	B-I
or	O
unreamed	B-I
nail	I-I
.	I-I


The	O
duration	O
of	O
each	O
level	O
of	O
embolic	O
phenomena	O
(	O
zero	O
,	O
moderate	O
,	O
severe	O
)	O
was	O
used	O
to	O
determine	O
total	O
embolic	O
load	O
with	O
various	O
steps	O
(	O
fracture	O
manipulation	O
,	O
proximal	O
portal	O
opening	O
,	O
reaming	O
,	O
and	O
nail	O
passage	O
)	O
.	O


Manual	O
grading	O
of	O
emboli	B-OUT
correlated	O
highly	B-OUT
with	O
software	O
quantification	O
.	O


Our	O
data	O
confirm	O
the	O
presence	O
and	O
similarity	O
of	O
emboli	B-OUT
generation	I-OUT
with	I-OUT
both	I-OUT
methods	I-OUT
of	I-OUT
intramedullary	I-OUT
nailing	I-OUT
.	I-OUT


Working	O
well	O
with	O
a	O
disability	B-P
:	I-P
health	I-I
promotion	I-I
as	O
a	O
means	O
to	O
employment	O
.	O


Data	O
were	O
analyzed	O
with	O
repeated-measures	O
ANOVA	O
.	O


Control-group	B-I
participants	O
also	O
experienced	O
significantly	O
lower	B-OUT
rates	I-OUT
of	I-OUT
limitation	I-OUT
,	O
but	O
pre-	B-OUT
to	I-OUT
postdifferences	I-OUT
were	O
less	O
dramatic	O
,	O
F	O
(	O
1	O
,	O
308	O
)	O
=	O
4.19	O
,	O
p	O
=	O
.006	O
.	O


MSL-109	B-I
adjuvant	I-I
therapy	I-I
for	O
cytomegalovirus	B-P
retinitis	I-P
in	I-P
patients	I-P
with	I-P
acquired	I-P
immunodeficiency	I-P
syndrome	I-P
:	I-P
the	O
Monoclonal	O
Antibody	O
Cytomegalovirus	O
Retinitis	O
Trial	O
.	O


The	B-P
Studies	I-P
of	I-P
Ocular	I-P
Complications	I-P
of	I-P
AIDS	I-P
Research	I-P
Group	I-P
.	I-P


The	O
mortality	B-OUT
difference	O
was	O
not	O
explained	O
by	O
differences	O
in	O
baseline	O
variables	O
or	O
in	O
concurrent	O
antiretroviral	O
therapy	O
.	O


CONCLUSIONS	O
Intravenous	O
MSL-109	B-I
,	O
60	O
mg	O
every	O
2	O
weeks	O
,	O
appeared	O
to	O
be	O
ineffective	B-OUT
adjuvant	O
therapy	O
for	O
CMV	O
retinitis	O
.	O


Promoting	O
imitation	O
in	O
young	B-P
children	I-P
with	I-P
autism	I-P
:	I-P
a	O
comparison	O
of	O
reciprocal	B-I
imitation	I-I
training	I-I
and	O
video	B-I
modeling	I-I
.	I-I


The	O
11-beta-hydroxysteroid	O
dehydrogenase	O
type	O
1	O
inhibitor	O
INCB13739	B-I
improves	O
hyperglycemia	B-OUT
in	I-P
patients	I-P
with	I-P
type	I-P
2	I-P
diabetes	I-P
inadequately	I-P
controlled	I-P
by	I-P
metformin	I-P
monotherapy	I-P
.	I-P


RESEARCH	O
DESIGN	O
AND	O
METHODS	O
This	O
double-blind	O
placebo-controlled	B-I
paralleled	O
study	O
randomized	O
302	B-P
patients	I-P
with	I-P
type	I-P
2	I-P
diabetes	I-P
(	I-P
mean	I-P
A1C	I-P
8.3	I-P
%	I-P
)	I-P
on	I-P
metformin	I-I
monotherapy	I-I
(	I-P
mean	I-P
1.5	I-P
g/day	I-P
)	I-P
to	O
receive	O
one	O
of	O
five	O
INCB13739	B-I
doses	I-I
or	I-I
placebo	I-I
once	O
daily	O
for	O
12	O
weeks	O
.	O


The	O
primary	O
end	O
point	O
was	O
the	O
change	B-OUT
in	I-OUT
A1C	I-OUT
at	I-OUT
study	I-OUT
end	I-OUT
.	I-OUT


Total	B-OUT
cholesterol	I-OUT
,	I-OUT
LDL	I-OUT
cholesterol	I-OUT
,	I-OUT
and	I-OUT
triglycerides	I-OUT
were	O
all	O
significantly	O
decreased	O
in	O
hyperlipidemic	O
patients	O
.	O


Evaluation	O
of	O
asthma	O
knowledge	O
and	O
quality	O
of	O
life	O
in	O
Hungarian	B-P
asthmatics	I-P
.	I-P


Patients	O
'	O
QoL	O
,	O
asthma	O
knowledge	O
was	O
assessed	O
twice	O
,	O
once	O
before	O
and	O
after	O
the	O
education	B-I
seminar	I-I
,	O
education	O
was	O
only	O
provided	O
for	O
the	O
intervention	O
group	O
.	O


In	O
inhaler-use	O
technique	O
,	O
we	O
could	O
not	O
find	O
significant	O
changes	O
neither	O
in	O
the	O
intervention	O
nor	O
in	O
the	O
control	O
group	O
.	O


The	O
effects	O
of	O
14	O
weeks	O
of	O
Kata	B-I
techniques	I-I
training	I-I
on	O
stereotypic	O
behaviors	O
of	O
children	B-P
with	I-P
autism	I-P
spectrum	I-P
disorders	I-P
(	I-P
ASD	I-P
)	I-P
were	O
investigated	O
.	O


Comparison	O
of	O
prostate-specific	B-I
antigen	I-I
corrected	I-I
for	I-I
total	I-I
prostate	I-I
volume	I-I
and	I-I
transition	I-I
zone	I-I
volume	I-I
in	O
a	O
population-based	B-P
screening	I-P
study	I-P
.	I-P


A	O
receiver	O
operating	O
characteristic	O
(	O
ROC	O
)	O
curve	O
analysis	O
was	O
done	O
of	O
sensitivity	O
and	O
specificity	O
of	O
biopsy	O
indications	O
through	O
PSA	B-I
and	I-I
PSA	I-I
corrected	I-I
for	I-I
the	I-I
volumes	I-I
measured	I-I
with	O
transrectal	O
ultrasound	O
.	O


The	O
discriminatory	O
potential	O
of	O
the	O
corrected	O
PSA	B-OUT
value	I-OUT
is	O
better	O
at	O
predicting	O
the	O
results	O
of	O
needle	O
biopsy	O
of	O
the	O
prostate	O
when	O
compared	O
with	O
PSA	O
alone	O
.	O


The	O
role	O
of	O
NO	O
was	O
investigated	O
by	O
administering	O
N	B-I
(	I-I
G	I-I
)	I-I
-nitro-l-arginine	I-I
methyl	I-I
ester	I-I
hydrochloride	I-I
(	I-I
L-NAME	I-I
,	O
20	O
mM	O
)	O
,	O
an	O
NO	B-I
synthase	I-I
inhibitor	I-I
or	O
Ringer	B-I
's	I-I
solution	I-I
(	O
control	O
site	O
)	O
,	O
via	O
intradermal	O
microdialysis	O
(	O
protocol	O
1	O
;	O
n=7	O
)	O
.	O


Cutaneous	B-OUT
vascular	I-OUT
conductance	I-OUT
(	I-OUT
CVC	I-OUT
)	I-OUT
was	O
calculated	O
from	O
the	O
ratio	O
of	O
SkBF	O
to	O
mean	O
arterial	O
blood	O
pressure	O
.	O


Evaluation	O
of	O
these	O
management	O
strategies	O
has	O
the	O
potential	O
to	O
improve	O
patient	O
care	O
,	O
health-related	O
quality	O
of	O
life	O
,	O
and	O
the	O
cost-effectiveness	O
of	O
CHD	O
investigation	O
.	O


In	O
the	O
group	O
of	O
Futraful	B-I
alone	O
the	O
survival	B-OUT
and	I-OUT
disease-free	I-OUT
rate	I-OUT
were	O
improved	O
in	O
three	O
years	O
after	O
operation	O
,	O
especially	O
marked	O
in	O
patients	B-P
with	I-P
the	I-P
advanced	I-P
stage	I-P
.	I-P


The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
determine	O
the	O
change	O
in	O
fibularis	O
longus	O
and	O
soleus	O
activation	O
following	O
tibiofibular	B-I
joint	I-I
manipulation	I-I
in	O
individuals	B-P
with	I-P
CAI	I-P
.	I-P


Pulmonary	B-OUT
function	I-OUT
and	I-OUT
exhaled	I-OUT
NO	I-OUT
were	O
measured	O
at	O
every	O
visit	O
.	O


There	O
have	O
been	O
impressive	O
advances	O
in	O
endoscopic	O
procedures	O
during	O
recent	O
years	O
,	O
and	O
there	O
is	O
an	O
emerging	O
trend	O
that	O
the	O
number	O
of	O
procedures	O
is	O
increasing	O
in	O
parallel	O
with	O
these	O
.	O


Recent	O
developments	O
in	O
medical	O
simulation	O
seem	O
promising	O
with	O
regard	O
to	O
the	O
possibility	O
of	O
"	O
training	O
out	O
"	O
undesirable	O
parts	O
of	O
the	O
learning	O
curve	O
outside	O
the	O
operating	O
room	O
.	O


This	O
,	O
the	O
largest	O
ever	O
study	O
of	O
nutritional	O
support	O
after	O
hip	O
fracture	O
,	O
shows	O
that	O
their	O
employment	O
significantly	O
reduced	O
patients	B-OUT
'	I-OUT
risk	I-OUT
of	I-OUT
dying	I-OUT
in	O
the	O
acute	O
trauma	O
unit	O
;	O
an	O
effect	O
that	O
persisted	O
at	O
4	O
month	O
follow-up	O
.	O


Measures	O
included	O
changes	O
in	O
professionally	O
completed	O
Childhood	B-OUT
Autism	I-OUT
Rating	I-OUT
Scale	I-OUT
(	I-OUT
CARS	I-OUT
)	I-OUT
,	I-OUT
hand	I-OUT
muscle	I-OUT
testing	I-OUT
,	I-OUT
and	I-OUT
modified	I-OUT
clinical	I-OUT
global	I-OUT
impression	I-OUT
(	I-OUT
CGI	I-OUT
)	I-OUT
forms	I-OUT
;	I-OUT
parent	I-OUT
completed	I-OUT
Autism	I-OUT
Treatment	I-OUT
Evaluation	I-OUT
Checklist	I-OUT
(	I-OUT
ATEC	I-OUT
)	I-OUT
,	I-OUT
treatment	I-OUT
adherence	I-OUT
measurement	I-OUT
(	I-OUT
TAM	I-OUT
)	I-OUT
,	I-OUT
frequency	I-OUT
and	I-OUT
intensity	I-OUT
of	I-OUT
side	I-OUT
effect	I-OUT
rating	I-OUT
(	I-OUT
FISER	I-OUT
)	I-OUT
/global	I-OUT
rating	I-OUT
of	I-OUT
side	I-OUT
effect	I-OUT
burden	I-OUT
(	I-OUT
GRSEB	I-OUT
)	I-OUT
/patient	I-OUT
report	I-OUT
of	I-OUT
incidence	I-OUT
of	I-OUT
side	I-OUT
effects	I-OUT
(	I-OUT
PRISE	I-OUT
)	I-OUT
forms	I-OUT
;	I-OUT
and	I-OUT
lab	I-OUT
testing	I-OUT
.	I-OUT


Oral	O
PPIs	B-I
alone	O
were	O
effective	O
and	O
economical	O
as	O
prophylaxis	O
against	O
GI	O
complications	O
.	O


At	O
10	B-OUT
years	I-OUT
,	I-OUT
the	I-OUT
LRC	O
rates	O
were	B-I
38.0	I-I
%	I-I
(	O
C-HART	O
)	O
versus	B-I
26.0	I-I
%	I-I
(	O
HART	O
,	O
P=.002	B-OUT
)	I-OUT
.	I-OUT


Intravenous	B-I
flecainide	I-I
versus	I-I
verapamil	I-I
for	O
acute	O
conversion	O
of	O
paroxysmal	B-P
atrial	I-P
fibrillation	I-P
or	I-P
flutter	I-P
to	I-P
sinus	I-P
rhythm	I-P
.	I-P


Thus	O
,	O
23	O
of	O
32	O
patients	O
(	O
72	O
%	O
)	O
with	O
AF	O
and	O
none	O
of	O
7	O
with	O
AFI	O
converted	O
to	O
sinus	B-OUT
rhythm	I-OUT
after	O
treatment	O
with	O
flecainide	O
.	O


Transient	B-OUT
adverse	I-OUT
effects	I-OUT
were	O
noted	O
in	O
10	O
patients	O
(	O
26	O
%	O
)	O
after	O
flecainide	O
.	O


Verapamil	B-I
appears	O
to	O
be	O
of	O
no	O
use	O
for	O
conversion	B-OUT
of	I-OUT
AF	I-OUT
or	I-OUT
AFI	I-OUT
to	O
sinus	O
rhythm	O
.	O


The	O
absolute	O
bioavailability	O
reaches	O
24	O
%	O
probably	O
due	O
to	O
a	O
first-pass	O
effect	O
.	O


This	O
metabolite	B-OUT
is	O
detected	O
in	O
plasma	O
in	O
concentrations	O
ten	O
times	O
lower	O
than	O
the	O
parent	O
compound	O
.	O


Forty-one	B-P
migraine	I-P
subjects	I-P
(	I-P
26	I-P
males	I-P
,	I-P
15	I-P
females	I-P
)	I-P
,	I-P
mean	I-P
age	I-P
36	I-P
+/-	I-P
2	I-P
years	I-P
(	I-P
range	I-P
36-39	I-P
years	I-P
)	I-P
,	I-P
and	I-P
20	I-P
healthy	I-P
control	I-P
subjects	I-P
(	I-P
14	I-P
males	I-P
,	I-P
six	I-P
females	I-P
)	I-P
,	I-P
mean	I-P
age	I-P
36	I-P
+/-	I-P
2	I-P
years	I-P
(	I-P
range	I-P
36-39	I-P
years	I-P
)	I-P
were	O
randomized	O
(	O
double-blind	O
)	O
to	O
receiving	O
sumatriptan	B-I
(	I-I
group	I-I
A	I-I
)	I-I
or	I-I
placebo	I-I
(	I-I
group	I-I
B	I-I
)	I-I
.	I-I


Our	O
data	O
show	O
that	O
succinate	B-I
sumatriptan	I-I
can	O
be	O
used	O
with	O
safety	O
in	O
patients	B-P
without	I-P
hypertension	I-P
and	I-P
other	I-P
cardiovascular	I-P
disease	I-P
.	I-P


Future	O
studies	O
among	O
subjects	B-P
diagnosed	I-P
with	I-P
an	I-P
ASD	I-P
should	O
further	O
explore	O
the	O
pharmacokinetics	O
of	O
glutathione	O
supplementation	O
and	O
evaluate	O
the	O
potential	O
effects	O
of	O
glutathione	O
supplementation	O
upon	O
clinical	O
symptoms	O
.	O


All	O
60	B-P
patients	I-P
were	O
then	O
assigned	O
to	O
1	O
of	O
3	O
groups	O
according	O
to	O
demand	O
for	O
treatment	O
.	O


The	O
current	O
study	O
involved	O
a	O
randomized	O
controlled	O
trial	O
of	O
Group	B-I
Stepping	I-I
Stones	I-I
Triple	I-I
P	I-I
(	I-I
GSSTP	I-I
)	I-I
for	O
a	O
mixed-disability	B-P
group	I-P
.	I-P


Results	O
among	O
participants	O
were	O
similar	O
despite	O
children	O
's	O
differing	O
impairments	O
.	O


We	O
evaluated	O
a	O
new	O
prognostic	B-I
classification	I-I
incorporating	O
additional	O
information	O
from	O
inflammatory	O
markers	O
.	O


The	O
effect	O
of	O
eradication	O
of	O
Helicobacter	O
pylori	O
upon	O
the	O
duodenal	B-OUT
ulcer	I-OUT
recurrence	I-OUT
--	I-OUT
a	I-OUT
24	O
month	O
follow-up	O
study	O
.	O


OBJECTIVE	O
Our	O
study	O
was	O
designed	O
to	O
examine	O
the	O
efficacy	O
of	O
stepwise	B-I
hook	I-I
extension	I-I
technique	I-I
for	I-I
radiofrequency	I-I
ablation	I-I
(	I-I
RFA	I-I
)	I-I
therapy	I-I
of	O
hepatocellular	B-P
carcinoma	I-P
in	O
a	O
randomized	O
controlled	O
study	O
.	O


METHOD	O
Twenty	B-P
patients	I-P
with	I-P
hepatocellular	I-P
carcinoma	I-P
measuring	I-P
<	I-P
25	I-P
mm	I-P
were	O
divided	O
randomly	O
into	O
two	O
equal	O
groups	O
.	O


The	O
diameters	B-OUT
of	I-OUT
RFA-induced	I-OUT
lesions	I-OUT
were	O
not	O
significantly	O
different	O
between	O
the	O
groups	O
(	O
group	O
1	O
:	O
27	O
,	O
range	O
23-37	O
mm	O
;	O
group	O
2	O
:	O
23	O
,	O
0-42	O
mm	O
)	O
.	O


Processing	O
familiar	O
and	O
unfamiliar	O
auditory	O
stimuli	O
during	B-P
general	I-P
anesthesia	I-P
.	I-P


Because	O
the	O
process	O
for	O
learning	O
new	O
or	O
unfamiliar	O
stimuli	O
(	O
elaboration	O
)	O
in	O
particular	O
may	O
be	O
impaired	O
under	B-P
general	I-P
anesthesia	I-P
,	O
more	O
memory	O
priming	O
was	O
expected	O
for	O
familiar	O
than	O
for	O
unfamiliar	O
material	O
.	O


aureus	O
,	O
and	O
to	O
a	O
minor	O
degree	O
diphtheroids	O
(	O
Corynebacterium	O
species	O
)	O
.	O


Proteus	O
mirabilis	O
,	O
Escherichia	O
coli	O
and	O
micrococci	O
.	O


There	O
was	O
a	O
significant	B-OUT
quantitative	I-OUT
diminished	I-OUT
growth	I-OUT
(	O
P	O
less	O
than	O
0.05	O
)	O
of	O
bacteria	O
in	O
the	O
group	O
of	O
patients	O
treated	O
with	O
PVP-I	B-I
compared	O
to	O
the	O
control	O
group	O
.	O


Side	O
effects	O
were	O
minimal	O
and	O
similar	O
between	O
both	O
active	O
medication	O
and	B-I
placebo	I-I
.	O


[	B-I
Therapy	I-I
of	O
metastatic	B-P
endocrine	I-P
tumors	I-P
of	I-P
the	I-P
gastrointestinal	I-P
tract	I-P
]	I-P
.	I-P


The	O
influence	O
of	O
fidelity	B-OUT
of	I-OUT
implementation	I-OUT
on	O
teacher-student	B-OUT
interaction	I-OUT
quality	I-OUT
in	O
the	O
context	O
of	O
a	O
randomized	O
controlled	O
trial	O
of	O
the	O
Responsive	B-I
Classroom	I-I
approach	I-I
.	I-I


In	O
addition	O
,	O
teachers	B-OUT
completed	I-OUT
self-report	I-OUT
measures	I-OUT
of	I-OUT
FOI	I-OUT
,	I-OUT
the	I-OUT
Classroom	I-OUT
Practices	I-OUT
Teacher	I-OUT
Survey	I-OUT
and	I-OUT
Classroom	I-OUT
Practices	I-OUT
Frequency	I-OUT
Survey	I-OUT
,	O
at	O
the	O
end	O
of	O
the	O
school	O
year	O
.	B-OUT


In	O
turn	O
,	O
FOI	O
related	O
to	O
greater	O
improvement	O
in	B-OUT
teacher-student	I-OUT
interaction	I-OUT
quality	I-OUT
,	O
β=0.52	O
,	O
p=.001	O
,	O
R2=.32	O
.	O


Xylitol	B-I
for	O
prevention	O
of	O
acute	B-P
otitis	I-P
media	I-P
.	I-P


Group	O
A	O
received	O
Jessner	B-I
's	I-I
solution	I-I
peel	I-I
,	O
group	O
B	O
received	O
trichloroacetic	B-I
acid	I-I
peel	I-I
20	I-I
%	I-I
,	O
and	O
group	O
C	O
received	O
topical	B-I
hydroquinone	I-I
2	I-I
%	I-I
and	I-I
kojic	I-I
acid	I-I
.	I-I


The	O
statistical	O
analysis	O
was	O
done	O
through	O
one-way	O
anova	O
followed	O
by	O
least	O
significant	O
difference	O
(	O
LSD	O
)	O
.	O


CONCLUSION	O
Trichloroacetic	B-I
acid	I-I
20	I-I
%	I-I
showed	O
better	O
results	O
than	O
Jessner	B-I
's	I-I
solution	I-I
as	O
peeling	O
agent	O
and	O
hydroquinone	B-I
2	I-I
%	I-I
with	I-I
kojic	I-I
acid	I-I
as	O
a	O
topical	O
agent	O
in	O
the	O
treatment	B-OUT
of	I-OUT
melasma	I-OUT
.	I-OUT


At	O
the	O
end	O
of	O
the	O
study	O
,	O
71	O
%	O
in	O
the	O
fluvoxamine	O
group	O
and	O
69	O
%	O
in	O
the	O
clomipramine	O
group	O
were	O
responders	O
(	O
>	O
or=	O
50	O
%	O
decrease	O
in	O
17-item	B-OUT
HAMD	I-OUT
total	I-OUT
score	I-OUT
)	I-OUT
.	O


Analyses	O
reveal	O
that	O
olanzapine	B-I
shows	O
a	O
greater	O
clinical	B-OUT
cost	I-OUT
effectiveness	I-OUT
,	O
as	O
well	O
as	O
a	O
greater	O
functional	B-OUT
cost	I-OUT
effectiveness	I-OUT
,	O
than	O
haloperidol	B-I
,	O
and	O
that	O
functional	B-OUT
outcomes	I-OUT
,	O
in	O
particular	O
,	O
show	O
promise	O
as	O
important	O
measures	O
of	O
effectiveness	O
.	O


Functional	O
outcomes	O
can	O
help	O
differentiate	O
medications	O
and	O
can	O
be	O
used	O
to	O
help	O
demonstrate	O
the	O
cost	B-OUT
effectiveness	I-OUT
of	O
atypical	O
agents	O
.	O


When	O
comparing	O
olanzapine	B-I
with	O
haloperidol	B-I
,	O
cost	B-OUT
savings	I-OUT
are	O
seen	O
throughout	O
the	O
treatment	O
period	O
(	O
1	O
year	O
)	O
,	O
with	O
physical	B-OUT
functioning	I-OUT
most	O
highly	O
affected	O
over	O
time	O
.	O


Gabapentin	B-I
might	O
also	O
reduce	O
postoperative	B-OUT
pain	I-OUT
.	I-OUT


Gabapentin	B-I
reduced	O
the	O
need	O
for	O
additional	O
postoperative	B-OUT
pain	I-OUT
treatment	I-OUT
(	O
PCA	O
boluses	O
of	O
50	O
microg	O
of	O
fentanyl	O
)	O
by	O
40	O
%	O
during	O
the	O
first	O
20	O
postoperative	O
hours	O
.	O


METHOD	O
Data	B-P
were	I-P
collected	I-P
over	I-P
a	I-P
23-week	I-P
period	I-P
,	I-P
from	I-P
4:00	I-P
PM	I-P
to	I-P
midnight	I-P
,	O
and	O
resulted	O
in	O
446	B-P
patients	I-P
being	I-P
recruited	I-P
into	I-P
the	I-P
study	I-P
(	I-P
90	I-P
%	I-P
of	I-P
those	I-P
who	I-P
screened	I-P
positive	I-P
)	I-P
and	O
randomized	O
to	O
three	O
conditions	O
following	O
a	O
two-stage	O
process	O
:	O
screened	B-I
only	I-I
(	O
n	O
=	O
147	O
)	O
,	O
assessed	B-I
(	O
n	O
=	O
152	O
)	O
,	O
and	O
received	B-I
intervention	I-I
(	O
n	O
=	O
147	O
)	O
.	O


RESULTS	O
At	O
3-month	O
follow-up	O
,	O
both	O
groups	O
showed	O
significant	O
decreases	O
in	O
the	O
proportion	O
who	O
were	O
positive	O
for	O
at-risk	O
drinking	O
,	O
the	O
primary	O
outcome	O
variable	O
.	O


Patients	O
were	O
allocated	O
at	O
random	O
to	O
receive	O
a	O
daily	O
bedtime	O
dose	O
of	O
either	O
1	O
ketoprofen	B-I
tablet	O
or	O
1	O
indomethacin	B-I
suppository	I-I
plus	O
the	O
dummy	O
of	O
the	O
other	O
formulation	O
for	O
a	O
period	O
of	O
3	O
weeks	O
.	O


Sixteen	B-P
schizophrenia	I-P
patients	I-P
with	I-P
predominantly	I-P
negative	I-P
symptoms	I-P
on	I-P
stable	I-P
antipsychotic	I-P
medication	I-P
were	O
treated	O
with	O
20	B-I
Hz	I-I
rTMS	I-I
(	O
90	O
%	O
of	O
motor	O
threshold	O
,	O
2000	O
stimuli	O
per	O
session	O
)	O
over	O
ten	O
days	O
within	O
2	O
weeks	O
with	O
six	O
weeks	O
follow-up	O
.	O


Sham	B-OUT
rTMS	I-OUT
showed	O
a	O
trend	O
for	O
improvement	B-OUT
over	I-OUT
time	I-OUT
on	O
positive	B-OUT
and	I-OUT
negative	I-OUT
subscales	I-OUT
of	I-OUT
PANSS	I-OUT
and	I-OUT
MADRS	I-OUT
.	I-OUT


[	O
Observation	O
on	O
therapeutic	O
effect	O
of	O
acupuncture	B-I
on	O
early	B-P
peripheral	I-P
facial	I-P
paralysis	I-P
]	I-P
.	O


NSAID	O
ionisation	O
in	O
the	O
management	O
of	O
soft-tissue	B-OUT
rheumatism	I-OUT
:	I-OUT
role	O
played	O
by	O
the	O
drug	O
,	O
electrical	B-OUT
stimulation	I-OUT
and	I-OUT
suggestion	I-OUT
.	I-OUT


The	O
mean	B-OUT
improvement	I-OUT
rate	I-OUT
from	O
baseline	O
at	O
month	O
12	O
in	O
International	B-OUT
Prostate	I-OUT
Symptom	I-OUT
Score	I-OUT
and	I-OUT
the	I-OUT
maximal	I-OUT
urinary	I-OUT
flow	I-OUT
rate	I-OUT
was	O
similar	O
in	O
the	O
2	O
groups	O
.	O


Visual	B-I
field	I-I
progression	I-I
was	I-I
analyzed	I-I
using	I-I
repeated	I-I
measures	I-I
models	I-I
.	I-I


However	O
,	O
at	O
the	O
8-year	O
follow-up	O
examination	O
,	O
substantial	O
worsening	B-OUT
(	I-OUT
>	I-OUT
or	I-OUT
=3	I-OUT
dB	I-OUT
)	I-OUT
of	I-OUT
MD	I-OUT
from	I-OUT
baseline	I-OUT
was	O
found	O
in	O
21.3	O
%	O
and	O
25.5	O
%	O
of	O
the	O
initial	O
surgery	O
and	O
initial	O
medicine	O
groups	O
,	O
respectively	O
.	O


Initial	B-I
surgery	I-I
led	O
to	O
less	O
VF	B-OUT
progression	I-OUT
than	O
initial	B-I
medicine	I-I
in	O
subjects	B-P
with	I-P
advanced	I-P
VF	I-P
loss	I-P
at	I-P
baseline	I-P
,	O
whereas	O
subjects	B-P
with	I-P
diabetes	I-P
had	O
more	O
VF	B-OUT
loss	I-OUT
over	O
time	O
if	O
treated	O
initially	O
with	O
surgery	O
.	O


Effects	O
of	O
nifedipine	B-I
and	O
nitrendipine	B-I
on	O
insulin	B-OUT
secretion	I-OUT
in	O
obese	B-P
patients	I-P
.	I-P


Terazosin	B-I
and	I-I
enalapril	I-I
had	O
a	O
comparable	O
effect	O
on	O
resting	B-OUT
BP	I-OUT
,	I-OUT
reducing	I-OUT
systolic	I-OUT
(	I-OUT
SBP	I-OUT
)	I-OUT
and	I-OUT
diastolic	I-OUT
(	I-OUT
DBP	I-OUT
)	I-OUT
blood	I-OUT
pressure	I-OUT
from	O
159.5	O
+/-	O
13.9/101.6	O
+/-	O
8.8	O
mm	O
Hg	O
during	O
placebo	O
by	O
7.8	O
%	O
/6.7	O
%	O
and	O
by	O
11.3	O
%	O
/10.2	O
%	O
,	O
respectively	O
.	O


(	O
ABSTRACT	O
TRUNCATED	O
AT	O
250	O
WORDS	O
)	O


Nicotine	B-I
infusion	O
acutely	O
impairs	O
insulin	O
sensitivity	O
in	O
type	B-P
2	I-P
diabetic	I-P
patients	I-P
but	O
not	O
in	O
healthy	O
subjects	O
.	O


OBJECTIVES	O
The	O
aim	O
of	O
this	O
study	O
was	O
to	O
examine	O
if	O
an	O
acute	O
nicotine	B-I
infusion	O
alters	O
insulin	O
sensitivity	O
to	O
a	O
similar	O
degree	O
in	O
type	O
2	O
diabetic	O
patients	O
as	O
in	O
healthy	O
control	O
subjects	O
.	O


DESIGN	O
.	O


SUBJECTS	O
Six	B-P
male	I-P
and	I-P
female	I-P
type	I-P
2	I-P
diabetic	I-P
patients	I-P
[	I-P
DM2	I-P
;	I-P
age	I-P
54	I-P
+/-	I-P
10	I-P
(	I-P
mean	I-P
+/-	I-P
SD	I-P
)	I-P
years	I-P
;	I-P
body	I-P
mass	I-P
index	I-P
(	I-P
BMI	I-P
)	I-P
25.6	I-P
+/-	I-P
2.9	I-P
kg	I-P
m	I-P
(	I-P
-2	I-P
)	I-P
]	I-P
treated	I-P
with	I-P
diet	I-P
or	I-P
one	I-P
oral	I-P
hypoglycaemic	I-P
agent	I-P
and	I-P
six	I-P
age-	I-P
and	I-P
BMI-matched	I-P
control	I-P
subjects	I-P
(	I-P
Ctr	I-P
)	I-P
.	I-P


Only	O
minor	O
differences	O
were	O
seen	O
in	O
FFA	B-OUT
levels	I-OUT
,	I-OUT
pulse	I-OUT
rates	I-OUT
and	I-OUT
blood	I-OUT
pressure	I-OUT
.	I-OUT


These	O
results	O
show	O
that	O
diabetic	O
subjects	O
are	O
particularly	O
susceptible	O
to	O
the	O
detrimental	O
effects	O
of	O
nicotine	B-I
.	O


MRI	O
assessed	B-OUT
lesion	I-OUT
volume	I-OUT
,	I-OUT
atrophy	I-OUT
,	I-OUT
and	I-OUT
the	I-OUT
presence	I-OUT
of	I-OUT
iron-labeled	I-OUT
CD34	I-OUT
(	I-OUT
+	I-OUT
)	I-OUT
cells	I-OUT
reinjected	O
on	O
day	O
6	O
.	O


Their	O
results	O
were	O
detected	O
by	O
the	O
revised	B-OUT
Chinese	I-OUT
version	I-OUT
of	I-OUT
Psycho-Educational	I-OUT
Profile	I-OUT
for	I-OUT
autistic	I-OUT
and	I-OUT
developmentally	I-OUT
disabled	I-OUT
children	I-OUT
(	I-OUT
C-PEP	I-OUT
)	I-OUT
.	I-OUT


Peripheral	O
opioid	O
receptors	O
have	O
been	O
found	O
in	O
inflamed	O
synovia	O
and	O
the	O
analgesic	O
effect	O
of	O
intra-articularly	O
administered	O
morphine	B-I
after	O
arthroscopic	O
knee	O
surgery	O
has	O
been	O
proven	O
.	O


Piritramide	B-OUT
consumption	I-OUT
was	O
identical	O
in	O
both	O
groups	O
(	O
19.7	O
+/-	O
16	O
mg	O
vs.	O
19.8	O
+/-	O
19	O
mg	O
)	O
.	O


Seventy-seven	B-P
individuals	I-P
(	I-P
19	I-P
men	I-P
,	I-P
58	I-P
women	I-P
;	I-P
age	I-P
,	I-P
30-55	I-P
years	I-P
)	I-P
were	O
randomly	O
allocated	O
to	O
one	O
of	O
three	O
groups	B-P
;	I-P
two	I-P
groups	I-P
completed	I-I
30	I-I
minutes	I-I
of	I-I
accumulated	I-I
walking	I-I
with	I-I
either	I-I
monthly	I-I
or	I-I
weekly	I-I
telephone	I-I
support	I-I
;	I-I
the	I-P
third	I-I
group	I-I
(	I-I
control	I-I
)	I-I
performed	I-I
stretching	I-I
exercises	I-I
.	O


However	O
,	O
at	O
the	O
end	O
of	O
the	O
intervention	O
,	O
there	O
was	O
a	O
decrease	O
in	B-OUT
PWV	I-OUT
(	O
P	O
<	O
.001	O
)	O
accompanied	O
by	O
an	O
increase	O
in	B-OUT
NOx	I-OUT
(	O
P	O
<	O
.001	O
)	O
,	O
with	O
changes	O
maintained	O
4	O
months	O
post-intervention	O
.	O


A	O
lifestyle	O
approach	O
to	O
meeting	O
current	B-I
physical	I-I
activity	I-I
guidelines	O
results	O
in	O
favorable	O
alterations	O
in	O
arterial	O
function	O
in	B-P
overweight	I-P
individuals	I-P
.	O


The	O
score	B-OUT
of	I-OUT
childhood	I-OUT
autism	I-OUT
rating	I-OUT
scale	I-OUT
(	I-OUT
CARS	I-OUT
)	I-OUT
and	O
clinical	B-OUT
efficacy	I-OUT
in	O
both	O
groups	O
were	O
observed	O
before	O
and	O
after	O
treatment	O
.	O


Muscle	B-OUT
CreaT	I-OUT
gene	I-OUT
expression	I-OUT
does	O
not	O
appear	O
to	O
be	O
affected	O
by	O
vegetarianism	B-P
.	I-P


STUDY	O
OBJECTIVE	O
To	O
compare	O
reduction	O
of	O
pain	O
after	O
laparoscopy	O
for	O
ablation	B-I
or	O
excision	B-I
of	O
endometriosis	O
.	O


In	O
some	O
limited	O
areas	O
such	O
as	O
deep	O
dyspareunia	O
,	O
excision	B-I
is	O
more	O
effective	O
than	O
ablation	B-I
.	I-I


METHODS	O
Forty-nine	B-P
community-based	I-P
pediatricians	I-P
at	I-P
8	I-P
practices	I-P
participated	I-P
in	I-P
a	I-P
cluster-randomized	I-P
trial	I-P
.	I-P


Practices	O
were	O
then	O
given	O
access	O
to	O
an	O
ADHD	B-I
Internet	I-I
portal	I-I
that	O
allowed	O
parents	O
,	O
teachers	O
,	O
and	O
pediatricians	O
to	O
input	O
information	O
(	O
eg	O
,	O
rating	O
scales	O
)	O
about	O
patients	O
,	O
after	O
which	O
information	O
was	O
scored	O
,	O
interpreted	O
,	O
and	O
formatted	O
in	O
a	O
report	O
style	O
that	O
was	O
helpful	O
for	O
assessment	O
and	O
treatment	O
of	O
patients	O
with	O
ADHD	O
.	O


CONCLUSION	O
A	B-I
quality	I-I
improvement	I-I
intervention	I-I
that	O
can	O
be	O
widely	O
disseminated	O
by	O
using	O
Internet-based	B-I
information	I-I
technology	I-I
significantly	O
improved	O
the	O
quality	O
of	O
ADHD	O
care	O
in	O
community-based	B-P
pediatric	I-P
settings	I-P
.	I-P


A	O
multicenter	O
study	O
on	O
the	O
use	O
of	O
pulsed	B-I
low-intensity	I-I
direct	I-I
current	I-I
for	O
healing	O
chronic	B-OUT
stage	I-OUT
II	I-OUT
and	I-OUT
stage	I-OUT
III	I-OUT
decubitus	I-OUT
ulcers	I-OUT
.	I-OUT


Forty-three	B-P
patients	I-P
were	I-P
selected	I-P
for	I-P
the	I-P
experimental	I-P
group	I-P
,	I-P
and	I-P
31	I-P
control	I-P
subjects	I-P
used	I-P
the	I-P
sham	I-I
instrument	I-I
(	I-I
placebo	I-I
group	I-I
)	I-I
.	I-I


The	O
growth	O
of	O
fibroblasts	O
and	O
keratinocytes	O
may	O
be	O
enhanced	O
by	O
pulsed	B-I
low-intensity	I-I
direct	I-I
current	I-I
due	O
to	O
changes	O
in	O
calcium	B-OUT
homeostasis	I-OUT
.	I-OUT


0	O
microg/mL	O
by	O
using	O
computer-assisted	O
target-controlled	O
infusion	O
to	O
3	B-P
groups	I-P
of	I-P
healthy	I-P
male	I-P
patients	I-P
:	I-P
Control	I-I
(	I-I
n	I-I
=	I-I
35	I-I
)	I-I
,	I-I
2.5	I-I
microg/kg	I-I
Clonidine	I-I
(	I-I
n	I-I
=	I-I
36	I-I
)	I-I
,	I-I
and	I-I
5.0	I-I
microg/kg	I-I
Clonidine	I-I
(	I-I
n	I-I
=	I-I
36	I-I
)	I-I
groups	I-I
.	I-I


The	O
EC50	B-OUT
in	O
the	O
2.5	O
and	O
5.0	O
microg/kg	O
clonidine	O
groups	O
was	O
significantly	O
smaller	O
than	O
that	O
in	O
the	O
Control	O
group	O
(	O
P	O
<	O
0.001	O
)	O
.	O


We	O
tested	O
whether	O
combined	B-I
treatment	I-I
(	I-I
COMB	I-I
)	I-I
with	I-I
risperidone	I-I
and	I-I
parent	I-I
training	I-I
(	I-I
PT	I-I
)	I-I
in	O
behavior	O
management	O
is	O
superior	O
to	O
medication	O
alone	O
(	O
MED	O
)	O
in	O
improving	O
severe	B-OUT
behavioral	I-OUT
problems	I-OUT
in	O
children	B-P
with	I-P
PDDs	I-P
.	I-P


The	O
participants	O
received	O
risperidone	B-I
monotherapy	I-I
from	O
0.5	O
to	O
3.5	O
mg/day	O
(	O
with	O
switch	O
to	O
aripiprazole	B-I
if	O
risperidone	B-I
was	O
ineffective	O
)	O
.	O


Parents	O
in	O
the	O
COMB	O
group	O
(	O
n	O
=	O
75	O
;	O
60.5	O
%	O
)	O
received	O
a	O
mean	O
of	O
10.9	O
PT	O
sessions	O
.	O


The	O
effect	O
of	O
food	O
was	O
studied	O
in	O
an	O
open	O
crossover	O
design	O
with	O
a	O
1-week	O
washout	O
period	O
.	O


Twelve	O
subjects	O
received	O
150	B-I
mg	I-I
YM17E	I-I
in	O
both	O
the	O
fasted	O
and	O
post-prandial	O
states	O
.	O


Of	O
these	O
,	O
62	B-P
took	I-P
part	I-P
in	I-P
the	I-P
treatment	I-P
program	I-P
and	I-P
43	I-P
served	I-P
as	I-P
controls	I-P
.	I-P


The	O
weight	B-OUT
difference	I-OUT
between	O
the	O
treatment	O
and	O
control	O
group	O
at	O
the	O
18-month	O
follow-up	O
was	O
highly	O
significant	O
(	O
p	O
<	O
0.001	O
)	O
.	O


In	O
all	O
six	O
cases	O
in	O
the	O
nonstoma	O
group	O
,	O
reoperations	B-OUT
were	O
necessary	O
.	O


The	O
study	O
was	O
stopped	O
after	O
34	O
patients	O
were	O
included	O
.	O


A	O
meta-analysis	O
of	O
the	O
available	O
data	O
confirmed	O
the	O
value	O
of	O
a	O
protective	O
ostomy	O
for	O
patients	B-P
undergoing	I-P
low	I-P
anterior	I-P
resection	I-P
.	I-P


This	O
prospective	O
,	O
randomized	O
study	O
compares	O
,	O
for	O
the	O
first	O
time	O
,	O
measured	O
blood	O
loss	O
at	O
conization	O
and	O
within	O
24	O
hours	O
after	O
using	O
either	O
the	O
cold	B-I
knife	I-I
technique	I-I
or	I-I
the	I-I
carbon	I-I
dioxide	I-I
laser	I-I
scalpel	I-I
.	I-I


Prospective	O
randomized	O
evaluation	O
of	O
diode-laser	O
and	O
cryotherapy	O
in	O
prethreshold	B-OUT
retinopathy	I-OUT
of	I-P
prematurity	I-P
.	I-P


METHODS	O
AND	O
MEASURES	O
Thirty	B-P
subjects	I-P
were	O
pretested	O
(	O
baseline	O
)	O
for	O
normalized	O
H-reflex	B-OUT
(	O
defined	O
as	O
the	O
ratio	O
of	O
maximum	O
H-reflex	O
[	O
Hmax	O
]	O
to	O
maximum	O
direct	O
motor	O
response	O
[	O
Mmax	O
]	O
)	O
and	O
peak	B-OUT
plantar	I-OUT
flexion	I-OUT
torque	I-OUT
.	I-OUT


BACKGROUND	O
Microvascular	O
obstruction	O
(	O
MVO	O
)	O
secondary	O
to	O
ischaemic-reperfusion	O
injury	O
is	O
an	O
important	O
but	O
underappreciated	O
determinant	O
of	O
short-	O
and	O
longer-term	O
outcome	O
following	O
percutaneous	B-I
coronary	I-I
intervention	I-I
(	I-I
PCI	I-I
)	I-I
treatment	O
of	O
ST-elevation	O
myocardial	O
infarction	O
(	O
STEMI	O
)	O
.	O


Several	O
small	O
studies	O
have	O
demonstrated	O
a	O
reduction	O
in	O
the	O
degree	O
of	O
MVO	B-OUT
utilising	O
a	O
variety	O
of	O
vasoactive	B-I
agents	I-I
,	I-I
with	I-I
adenosine	I-I
and	I-I
sodium	I-I
nitroprusside	I-I
(	I-I
SNP	I-I
)	I-I
being	O
most	O
evaluated	O
.	O


The	O
study	O
aims	O
to	O
recruit	O
240	B-P
patients	I-P
(	I-P
powered	I-P
at	I-P
80	I-P
%	I-P
to	I-P
detect	I-P
a	I-P
5	I-P
%	I-P
absolute	I-P
reduction	I-P
in	I-P
IS	I-P
)	I-P
.	I-P


In	O
a	O
previously	O
reported	O
trial	O
to	O
prevent	O
delirium	O
,	O
we	O
randomized	O
patients	B-P
undergoing	I-P
hip	I-OUT
fracture	I-OUT
repair	I-OUT
under	I-P
spinal	I-I
anesthesia	I-I
to	I-I
light	I-I
(	I-I
BIS	I-I
>	I-I
80	I-I
)	I-I
or	I-I
deep	I-I
(	I-I
BIS	I-I
approximately	I-I
50	I-I
)	I-I
sedation	I-I
.	I-I


However	O
,	O
among	O
patients	O
with	O
serious	O
comorbidities	O
(	O
Charlson	O
score	O
>	O
4	O
)	O
,	O
1-year	B-OUT
mortality	I-OUT
was	O
reduced	O
in	O
the	O
light	B-I
(	O
22.2	O
%	O
)	O
vs	O
deep	B-I
(	O
43.6	O
%	O
)	O
sedation	B-I
group	O
(	O
hazard	O
ratio	O
[	O
HR	O
]	O
,	O
0.43	O
;	O
95	O
%	O
confidence	O
interval	O
,	O
0.19-0.97	O
;	O
P	O
=	O
0.04	O
)	O
during	O
spinal	O
anesthesia	O
.	O


Paraesthesia	O
during	O
the	O
needle-through-needle	B-I
and	O
the	O
double	B-I
segment	I-I
technique	I-I
for	O
combined	B-P
spinal	I-P
epidural	I-P
anaesthesia	I-P
.	I-P


The	O
efficacy	O
of	O
the	O
bladder	B-I
neck	I-I
plication	I-I
stitch	I-I
technique	I-I
in	O
promoting	O
an	O
earlier	O
return	O
of	O
continence	O
was	O
prospectively	O
evaluated	O
in	O
158	B-P
patients	I-P
who	I-P
underwent	I-P
RARP	I-P
for	I-P
clinically	I-P
localized	I-P
prostate	I-P
cancer	I-P
by	I-P
a	I-P
single	I-P
surgeon	I-P
at	I-P
our	I-P
institute	I-P
from	I-P
March	I-P
2012	I-P
to	I-P
January	I-P
2013	I-P
.	I-P


Recovery	B-OUT
from	I-OUT
incontinence	I-OUT
at	O
1	O
,	O
3	O
,	O
and	O
6	O
months	O
were	O
observed	O
in	O
22	O
(	O
27.8	O
%	O
)	O
,	O
42	O
(	O
53.2	O
%	O
)	O
,	O
and	O
57	O
(	O
72.2	O
%	O
)	O
patients	O
,	O
respectively	O
,	O
treated	O
with	O
,	O
and	O
23	O
(	O
29.1	O
%	O
)	O
,	O
47	O
(	O
59.5	O
%	O
)	O
,	O
and	O
59	O
(	O
74.7	O
%	O
)	O
patients	O
,	O
respectively	O
,	O
treated	O
without	O
the	O
bladder	B-I
neck	I-I
plication	I-I
stitch	I-I
,	O
with	O
no	O
significant	O
difference	O
in	O
time	O
to	O
recovery	O
from	O
incontinence	O
between	O
the	O
two	O
groups	O
.	O


CONCLUSIONS	O
This	O
study	O
suggests	O
that	O
for	O
patients	B-P
ar	I-P
substantial	I-P
risk	I-P
for	I-P
systemic	I-P
metastases	I-P
,	O
it	O
is	O
preferable	O
to	O
give	O
a	O
12-week	O
course	O
of	O
chemotherapy	B-I
followed	O
by	O
radiation	B-I
therapy	I-I
,	O
rather	O
than	O
radiation	B-I
therapy	I-I
followed	I-I
by	I-I
chemotherapy	I-I
.	I-I


OBJECTIVES	O
To	O
analyze	O
the	O
effect	O
of	O
differing	O
diet	O
on	O
the	O
acid	O
load	O
content	O
on	O
bone	B-OUT
metabolism	I-OUT
.	I-OUT


METHODS	O
We	O
studied	O
the	O
distribution	O
of	O
a	O
Web-based	B-I
and	I-I
a	I-I
print-delivered	I-I
version	I-I
of	I-I
the	I-I
Active	I-I
Plus	I-I
intervention	I-I
in	O
a	O
clustered	O
randomized	O
controlled	O
trial	O
(	O
RCT	O
)	O
.	O


The	O
baseline	O
(	O
printed	O
or	O
Web-based	O
)	O
results	O
were	O
analyzed	O
using	O
ANOVA	O
and	O
chi-square	O
tests	O
to	O
establish	O
the	O
differences	O
in	O
user	O
characteristics	O
between	O
both	O
intervention	O
groups	O
.	O


We	O
used	O
logistic	O
regression	O
analyses	O
to	O
study	O
the	O
interaction	O
between	O
the	O
user	B-OUT
characteristics	I-OUT
and	O
the	O
delivery	O
mode	O
in	O
the	O
prediction	O
of	O
dropout	B-OUT
rate	I-OUT
within	O
the	O
intervention	O
period	O
.	O


In	O
this	O
work	O
,	O
we	O
analysed	O
the	O
frequency	O
of	O
peripheral	O
blood	O
lymphocyte	O
subsets	O
in	O
10	B-P
Chinese	I-P
patients	I-P
with	I-P
histologically	I-P
proven	I-P
CAHB	I-P
and	I-P
seven	I-P
healthy	I-P
Chinese	I-P
individuals	I-P
.	I-P


The	O
CD4/CD8	B-OUT
ratios	I-OUT
were	O
significantly	O
reduced	O
(	O
P	O
<	O
0.01	O
)	O
in	O
the	O
10	O
patients	O
with	O
chronic	O
hepatitis	O
B	O
,	O
compared	O
with	O
those	O
of	O
the	O
controls	O
,	O
owing	O
to	O
a	O
significant	O
increase	O
in	O
the	O
number	B-OUT
of	I-OUT
CD8+	I-OUT
cells	I-OUT
(	O
P	O
<	O
0.005	O
)	O
.	O


The	O
cumulative	O
proportions	O
of	O
the	O
children	O
with	O
complete	B-OUT
resolution	I-OUT
of	I-OUT
their	I-OUT
enlarged	I-OUT
livers	I-OUT
at	O
48	O
,	O
96	O
,	O
168	O
or	O
336	O
and	O
504	O
h	O
after	O
commencement	O
of	O
treatment	O
were	O
significantly	O
higher	O
in	O
those	O
treated	O
with	O
CQ	B-I
plus	I-I
chlorpheniramine	I-I
(	I-I
CQCP	I-I
)	I-I
than	O
in	O
the	O
other	O
two	O
treatment	O
groups	O
(	O
with	O
P-values	O
of	O
0.02	O
,	O
0.001	O
,	O
0.00000	O
and	O
0.00002	O
,	O
respectively	O
)	O
.	O


Aztreonam	B-I
versus	I-I
gentamicin	I-I
for	O
short-term	O
prophylaxis	O
in	O
biliary	B-P
and	I-P
gastric	I-P
surgery	I-P
.	I-P


MATERIALS	O
AND	O
METHODS	O
Patients	B-P
undergoing	I-P
MMS	I-I
were	O
prospectively	O
randomized	O
to	O
have	O
their	O
tissue	B-I
margins	I-I
oriented	I-I
using	I-I
light	I-I
scoring	I-I
using	I-I
a	I-I
scalpel	I-I
versus	I-I
marking	I-I
them	I-I
using	I-I
a	I-I
gentian	I-I
violet	I-I
marker	I-I
.	I-I


RESULTS	O
Data	B-P
were	I-P
analyzed	I-P
for	I-P
101	I-P
tumors	I-P
.	I-P


RESULTS	O
All	O
randomized	O
participants	O
(	O
n	O
=	O
146	O
)	O
were	O
included	O
in	O
the	O
intention-to-treat	O
generalized	O
estimating	O
equations	O
analysis	O
(	O
72	O
in	O
intervention	O
and	O
74	O
in	O
control	O
group	O
)	O
.	O


No	O
treatment	O
effect	O
was	O
found	O
on	O
the	O
primary	O
outcomes	B-OUT
body	I-OUT
weight	I-OUT
(	O
β	O
=	O
0.49	O
kg	O
,	O
95	O
%	O
CI	O
:	O
-0.15-1.12	B-OUT
)	I-OUT
,	I-OUT
physical	I-OUT
performance	I-OUT
(	O
β	O
=	O
0.15	O
points	O
,	O
95	O
%	O
CI	O
:	O
-0.33-0.64	O
)	O
and	B-OUT
handgrip	I-OUT
strength	I-OUT
(	O
β	O
=	O
0.49	O
kg	O
,	O
95	O
%	O
CI	O
:	O
-0.62-1.60	O
)	O
.	O


Placebo-controlled	B-I
clinical	O
trial	O
evaluating	O
9.5	O
%	O
hydrogen	B-I
peroxide	I-I
high-adhesion	I-I
whitening	I-I
strips	I-I
.	I-I


Mean	B-OUT
±	I-OUT
SE	I-OUT
between-group	O
differences	O
in	O
Ab*	O
were	O
-0.6	O
±	O
0.16	O
,	O
-0.8	O
±	O
0.15	O
,	O
-1.6	O
±	O
0.19	O
,	O
and	O
-1.9	O
±	O
0.20	O
at	O
Days	O
4	O
,	O
7	O
,	O
15	O
,	O
and	O
21	O
,	O
respectively	O
.	O


The	O
risk	O
of	O
a	O
recurrence	B-OUT
(	O
adjusted	O
for	O
initial	O
CD4	O
cell	O
count	O
)	O
was	O
3.25	O
times	O
higher	O
in	O
the	O
pentamidine	B-I
group	O
(	O
P	O
<	O
0.001	O
,	O
95	O
percent	O
confidence	O
interval	O
,	O
1.72	O
to	O
6.16	O
)	O
.	O


There	O
were	O
19	O
serious	O
bacterial	B-OUT
infections	I-OUT
in	O
the	O
trimethoprim-sulfamethoxazole	O
group	O
and	O
38	O
in	O
the	O
pentamidine	O
group	O
.	O


OBJECTIVE	O
To	O
compare	O
the	O
clinical	O
efficacy	O
of	O
alginate	O
drug	O
Geviskon	B-I
and	O
aluminum-magnesium	B-I
antacids	I-I
to	O
relieve	O
symptoms	O
of	O
esophageal	O
,	O
extraesophageal	O
syndrome	O
and	O
functional	O
dyspepsia	O
at	O
3	O
and	O
7	O
days	O
of	O
study	O
in	O
patients	B-P
with	I-P
GERD	I-P
elderly	I-P
.	I-P


CONCLUSION	O
The	O
clinical	O
features	O
Geviskon	O
the	O
frequency	O
and	O
timing	O
of	O
relief	O
of	O
symptoms	O
of	O
esophageal	B-OUT
,	I-OUT
extraesophageal	I-OUT
syndrome	I-OUT
,	I-OUT
functional	I-OUT
dyspepsia	I-OUT
with	I-P
GERD	I-P
in	I-P
the	I-P
older	I-P
age	I-P
groups	I-P
is	O
higher	O
than	O
that	O
of	O
antacids	O
.	O


To	O
determine	O
whether	O
increased	O
sorafenib	B-I
doses	O
cause	O
incremental	O
increases	O
in	O
blood	B-OUT
pressure	I-OUT
(	I-OUT
BP	I-OUT
)	I-OUT
,	O
we	O
measured	O
12-h	O
ambulatory	O
BP	O
in	O
41	B-P
normotensive	I-P
advanced	I-P
solid	I-P
tumor	I-P
patients	I-P
in	O
a	O
randomized	O
dose-escalation	O
study	O
.	O


These	O
findings	B-P
in	I-P
normotensive	I-P
patients	I-P
suggest	I-OUT
BP	O
is	O
a	O
complex	O
pharmacodynamic	O
biomarker	O
of	O
VEGF	O
inhibition	O
.	O


Patients	O
have	O
intrinsic	O
differences	O
in	O
sensitivity	O
to	O
sorafenib	O
's	O
BP-elevating	O
effects	O
.	O


Neuromuscular	O
transmission	O
was	O
allowed	O
to	O
recover	O
spontaneously	O
.	O


[	B-P
Medical	I-P
safety	I-P
and	I-P
staff	I-P
mental	I-P
health	I-P
]	I-P
.	O


Several	O
studies	O
have	O
reported	O
that	O
most	O
adverse	O
events	O
are	O
due	O
to	O
errors	O
of	O
hospital	O
staff	O
,	O
and	O
emphasized	O
the	O
necessity	O
of	O
promoting	O
countermeasures	O
against	O
medical	O
errors	O
.	O


The	O
SEM	O
model	O
constructed	O
in	O
this	O
study	O
suggested	O
that	O
one	O
of	O
the	O
potential	O
root	O
causes	O
was	O
sleep	B-OUT
disturbance	I-OUT
.	I-OUT


Specific	B-I
immunoglobulin	I-I
for	O
treatment	O
of	O
whooping	B-P
cough	I-P
.	I-P


The	O
main	O
study	O
group	O
consisted	O
of	O
47	B-P
children	I-P
with	I-P
less	I-P
than	I-P
or	I-P
equal	I-P
to	I-P
14	I-P
days	I-P
of	I-P
disease	I-P
before	I-P
therapy	I-P
.	I-P


We	O
found	O
that	O
early	O
treatment	O
was	O
important	O
,	O
since	O
the	O
effect	O
on	O
duration	B-OUT
of	I-OUT
whoops	I-OUT
was	O
most	O
pronounced	O
when	O
disease	O
duration	O
before	O
treatment	O
was	O
less	O
than	O
or	O
equal	O
to	O
7	O
days	O
.	O


METHOD	O
The	O
study	O
was	O
a	O
between-subjects	O
design	O
(	B-I
mindfulness	I-I
intervention	I-I
vs	O
control	B-I
)	I-I
with	O
difference	O
between	O
number	O
of	O
most	O
and	O
least	O
chosen	O
stimulus	O
selections	O
on	O
an	O
over-selectivity	O
task	O
as	O
the	O
dependent	O
measure	O
.	O


340	B-P
cases	I-P
of	I-P
hookworm	I-P
infection	I-P
,	I-P
196	I-P
cases	I-P
of	I-P
ascariasis	I-P
and	I-P
178	I-P
cases	I-P
of	I-P
trichuriasis	I-P
were	I-P
treated	I-P
with	I-P
an	I-I
anthelmintic	I-I
,	I-I
oxibendazole	I-I
,	I-I
15mg/kg.d	I-I
x	I-I
3d	I-I
;	I-I
102	I-I
,	I-I
70	I-I
and	I-I
66	I-I
cases	I-I
of	I-I
respective	I-I
infections	I-I
were	I-I
treated	I-I
with	I-I
pyrantel	I-I
10mg/kg.d	I-I
x	I-I
3d	I-I
and	I-I
108	I-I
,	I-I
74	I-I
and	I-I
63	I-I
cases	I-I
took	I-I
placebo	I-I
for	I-I
comparison	I-I
and	I-I
as	I-I
control	I-I
under	I-I
double-blind	I-I
observations	I-I
.	I-I


Re-examinations	O
of	O
the	O
stool	O
were	O
performed	O
after	O
the	O
treatment	O
.	O


Among	O
the	O
cases	O
treated	O
with	O
oxibendazole	O
,	O
the	O
egg	B-OUT
negative	I-OUT
conversion	I-OUT
rates	I-OUT
of	I-OUT
hookworm	I-OUT
,	I-OUT
Ascaris	I-OUT
and	I-OUT
Trichuris	I-OUT
were	O
70.3-80.6	O
%	O
,	O
92.5-97.8	O
and	O
67.0-71.0	O
%	O
respectively	O
.	O


METHODS	O
From	O
September	B-P
1996	I-P
to	I-P
October	I-P
1998	I-P
,	I-P
we	I-P
randomly	I-P
allocated	I-P
49	I-P
legs	I-P
to	I-P
compression	I-I
sclerotherapy	I-I
and	I-P
49	I-P
legs	I-P
to	I-P
ambulatory	I-I
phlebectomy	I-I
.	I-I


CONCLUSION	O
Our	O
results	O
show	O
that	O
ambulatory	B-I
phlebectomy	I-I
is	O
an	O
effective	O
therapy	O
for	O
varicose	O
veins	O
of	O
the	O
leg	O
.	O


PATIENTS	O
AND	O
METHODS	O
A	O
cohort	O
study	O
was	O
conducted	O
on	O
two	B-P
matched	I-P
groups	I-P
of	I-P
30	I-P
children	I-P
referred	I-P
to	I-P
our	I-P
ED	I-P
between	I-P
2010	I-P
and	I-P
2011	I-P
.	I-P


Why	O
are	O
there	O
sometimes	O
concreteness	B-OUT
effects	I-OUT
in	I-OUT
memory	I-OUT
for	O
prose	O
?	O
Four	B-P
experiments	I-P
explored	O
on-line	O
encoding	O
strategies	O
and	O
memory	B-P
for	I-P
high	I-P
imagery	I-P
and	I-P
low	I-P
imagery	I-P
texts	I-P
.	I-P


Expanded	O
blastocysts	O
were	O
vitrified	O
in	O
a	O
solution	O
containing	B-I
6	I-I
M	I-I
ethylene	I-I
glycol	I-I
,	I-I
0.6	I-I
M	I-I
trehalose	I-I
and	I-I
2	I-I
%	I-I
(	I-I
wt/vol	I-I
)	I-I
polyethylene	I-I
glycol	I-I
in	I-I
10	I-I
%	I-I
HEPES-buffered	I-I
PZM-5	I-I
.	O


After	O
warming	O
,	O
cryoprotective	O
agents	O
were	O
removed	O
using	O
a	O
single	O
step	B-OUT
.	I-OUT


In	O
Experiment	O
1	O
,	O
the	O
embryos	O
vitrified	O
by	O
the	B-I
MVAC	I-I
or	I-I
CT	O
and	O
fresh	O
embryos	O
without	O
vitrification	O
(	O
Control	O
)	O
were	O
used	O
.	O


BACKGROUND	O
Medication	O
errors	O
are	O
an	O
important	O
public	O
health	O
concern	O
,	O
and	O
poor	O
understanding	O
of	O
medication	O
labels	O
are	O
a	O
root	O
cause	O
.	O


CONCLUSION	O
The	O
study	O
demonstrated	O
that	O
olopatadine	B-I
is	O
effective	O
and	O
safe	O
in	O
preventing	O
and	O
treating	O
ocular	B-OUT
itching	I-OUT
and	I-OUT
hyperemia	I-OUT
associated	O
with	O
acute	B-P
allergic	I-P
conjunctivitis	I-P
and	O
is	O
more	O
effective	O
and	O
more	O
comfortable	O
than	O
ketorolac	B-I
.	I-I


The	O
incidence	B-OUT
of	I-OUT
grade	I-OUT
>	I-OUT
or	I-OUT
=	I-OUT
2	I-OUT
graft-versus-host	I-OUT
disease	I-OUT
was	O
similar	O
in	O
each	O
group	O
(	O
11/25	O
[	O
44	O
%	O
]	O
in	O
the	O
PTX	B-I
group	O
v	O
12/26	O
[	O
46	O
%	O
]	O
in	O
the	O
control	O
group	O
)	O
.	O


In	O
conclusion	O
,	O
our	O
study	O
failed	O
to	O
show	O
a	O
prophylactic	O
effect	O
of	O
PTX	B-I
in	O
transplant-related	O
toxicities	O
after	O
BMT	O
.	O


Post	O
hoc	O
analysis	O
looking	O
at	O
the	O
3	O
core	O
symptoms	O
of	O
autism	O
,	O
that	O
is	O
,	O
social	B-OUT
interaction	I-OUT
,	I-OUT
communication	I-OUT
,	I-OUT
and	I-OUT
stereotyped	I-OUT
behaviors	I-OUT
,	O
revealed	O
a	O
significant	O
improvement	O
of	O
the	O
social	B-OUT
interaction	I-OUT
score	I-OUT
after	O
6	O
months	O
of	O
active	O
treatment	O
.	O


However	O
,	O
there	O
are	O
no	O
reports	O
on	O
adapalene	B-I
gel	I-I
for	O
the	O
treatment	O
of	O
pityriasis	B-P
versicolor	I-P
.	I-P


In	O
order	O
to	O
assess	O
the	O
risk	O
of	O
pneumonia	O
,	O
dehydration	O
,	O
and	O
death	O
associated	O
with	O
videofluoroscopic	B-I
evidence	O
of	O
aspiration	B-P
following	I-P
stroke	I-P
,	I-P
the	I-P
clinical	I-P
records	I-P
of	I-P
26	I-P
patients	I-P
with	I-P
aspiration	I-P
and	I-P
33	I-P
randomly	I-P
selected	I-P
,	I-P
case-matched	I-P
,	I-P
dysphagic	I-P
controls	I-P
without	I-P
videofluoroscopic	I-P
evidence	I-P
of	I-P
aspiration	I-OUT
were	I-P
reviewed	I-P
.	I-P


The	O
odds	O
ratio	O
for	O
death	B-OUT
was	O
9.2	O
times	O
greater	O
for	O
those	O
aspirating	O
thickened	O
liquids	O
or	O
more	O
solid	O
consistencies	O
compared	O
with	O
those	O
who	O
did	O
not	O
aspirate	O
or	O
who	O
aspirated	O
thin	O
liquids	O
only	O
(	O
p	O
=	O
0.01	O
)	O
.	O


Glucocorticoids	B-I
are	O
used	O
in	O
an	O
attempt	O
to	O
reduce	O
brain	O
edema	O
secondary	O
to	O
head	O
injury	O
.	O


Since	O
the	O
excretion	B-OUT
of	I-OUT
cortisol	I-OUT
in	I-OUT
urine	I-OUT
reflects	O
the	O
production	O
rate	O
closely	O
and	O
is	O
not	O
influenced	O
by	O
liver	O
function	O
and	O
barbiturates	O
,	O
the	O
results	O
in	O
group	O
2	O
show	O
that	O
the	O
endogenous	O
production	O
of	O
steroids	O
is	O
an	O
adequate	O
reaction	O
to	O
severe	O
head	O
injury	O
.	O


Exogenous	O
glucocorticoids	B-I
are	O
thus	O
unlikely	O
to	O
have	O
any	O
more	O
beneficial	O
effects	O
than	O
endogenous	O
cortisol	B-I
.	I-I


We	O
studied	O
,	O
if	O
menses	B-OUT
were	O
affected	O
in	O
the	O
treatment	O
groups	O
,	O
up	O
to	O
36	O
months	O
after	O
randomization	O
.	O


OBJECTIVE	O
Little	O
is	O
known	O
about	O
the	O
neuropsychological	O
effects	O
of	O
risperidone	B-I
in	O
children	B-P
with	I-P
pervasive	I-P
developmental	I-P
disorders	I-P
.	I-P


Management	O
of	O
unstable	B-P
angina	I-P
at	I-P
rest	I-P
by	O
verapamil	B-I
.	I-I


1	O
.	O


The	O
Affected	O
side	O
was	O
assessed	O
using	O
Brunnstrom	B-OUT
recovery	I-OUT
stage	I-OUT
(	I-OUT
BRS	I-OUT
)	I-OUT
and	I-OUT
Fugl-Meyer	I-OUT
assessment	I-OUT
(	I-OUT
FMA	I-OUT
)	I-OUT
whereas	O
the	O
less-affected	O
side	O
was	O
evaluated	O
by	O
Minnesota	B-OUT
manual	I-OUT
dexterity	I-OUT
test	I-OUT
(	I-OUT
MMDT	I-OUT
)	I-OUT
,	I-OUT
Purdue	I-OUT
peg	I-OUT
board	I-OUT
test	I-OUT
(	I-OUT
PPBT	I-OUT
)	I-OUT
and	I-OUT
Manual	I-OUT
Muscle	I-OUT
Testing	I-OUT
(	I-OUT
MMT	I-OUT
)	I-OUT
.	I-OUT


RESULTS	O
Postintervention	O
,	O
the	O
less-affected	O
side	O
of	O
experimental	O
group	O
demonstrated	O
significant	O
improvement	B-OUT
for	I-OUT
MMDT	I-OUT
(	O
P	O
=	O
0.003	O
)	O
,	O
PPBT	B-OUT
(	O
P	O
=	O
0.01	O
)	O
and	O
MMT	B-OUT
(	O
P	O
<	O
0.001	O
to	O
0.043	O
)	O
in	O
comparison	O
to	O
the	O
control	O
group	O
.	O


For	O
the	O
seven	O
round	O
group	O
,	O
the	O
degree	O
of	O
improvement	B-OUT
on	O
the	O
assessment	B-OUT
measures	I-OUT
could	O
be	O
partially	O
explained	O
by	O
a	O
regression	O
analysis	O
based	O
on	O
excretion	B-OUT
of	I-OUT
toxic	I-OUT
metals	I-OUT
and	I-OUT
changes	I-OUT
in	I-OUT
glutathione	I-OUT
(	O
adjusted	O
R2	O
of	O
0.28-0.75	O
,	O
p	O
<	O
0.02	O
in	O
all	O
cases	O
)	O
.	O


The	O
assessment	O
measures	O
correlated	O
reasonably	O
with	O
one	O
another	O
at	O
the	O
beginning	O
of	O
the	O
study	O
(	O
r	O
=	O
0.60-0.87	O
)	O
and	O
even	O
better	O
at	O
the	O
end	O
of	O
the	O
study	O
(	O
r	O
=	O
0.63-0.94	O
)	O
.	O


Thirteen	B-P
children	I-P
with	I-P
autism	I-P
between	I-P
the	I-P
ages	I-P
of	I-P
three	I-P
and	I-P
six	I-P
received	O
daily	O
treatment	O
according	O
to	O
the	O
methodology	O
for	O
5	O
months	O
.	O


Evaluation	O
of	O
AMSA	B-I
in	O
children	B-P
with	I-P
acute	I-P
leukemia	I-P
.	I-P


A	O
Pediatric	O
Oncology	O
Group	O
study	O
.	O


Children	B-P
with	I-P
ALL	I-P
were	O
randomized	O
between	O
Regimens	O
I	O
and	O
II	O
(	O
31	O
and	O
36	O
evaluable	O
patients	O
,	O
respectively	O
)	O
.	O


However	O
,	O
the	O
high	O
incidence	B-OUT
of	I-OUT
severe	I-OUT
,	I-OUT
life-threatening	I-OUT
,	I-OUT
or	I-OUT
fatal	I-OUT
infections	I-OUT
meant	O
that	O
the	O
quality	B-OUT
and	I-OUT
quantity	I-OUT
of	I-OUT
responses	I-OUT
and	I-OUT
survival	I-OUT
was	O
not	O
commensurate	O
with	O
the	O
toxicity	B-OUT
,	O
and	O
that	O
it	O
would	O
be	O
difficult	O
to	O
incorporate	O
this	O
drug	O
into	O
combination	O
chemotherapy	O
with	O
other	O
myelosuppressive	O
agents	O
.	O


Experience	O
and	O
perception	O
of	O
bodily	O
symptoms	O
therefore	O
play	O
an	O
important	O
role	O
in	O
social	O
anxiety	O
.	O


Half	O
of	O
the	O
participants	B-I
heard	I-I
their	I-I
heart	I-I
sounds	I-I
first	I-I
via	I-I
headphones	I-I
and	I-I
then	I-I
via	I-I
loudspeakers	I-I
which	I-I
were	I-I
also	I-I
audible	I-I
to	I-I
observers	I-I
.	I-I


These	O
effects	O
were	O
in	O
excess	O
of	O
actual	B-OUT
heart	I-OUT
rate	I-OUT
differences	I-OUT
.	I-OUT


Falls	O
lead	O
to	O
significant	O
morbidity	B-OUT
and	I-OUT
mortality	I-OUT
in	O
persons	B-P
older	I-P
than	I-P
65	I-P
years	I-P
of	I-P
age	I-P
.	I-P


Impaired	O
proprioception	O
may	O
be	O
a	O
contributing	O
factor	O
to	O
falls	O
,	O
and	O
this	O
may	O
be	O
influenced	O
by	O
the	O
level	O
of	O
habitual	O
physical	O
activity	O
.	O


Antifibrinolytic	B-I
therapy	I-I
for	O
prevention	O
of	O
hemorrhage	O
during	O
surgery	B-P
of	I-P
the	I-P
thyroid	I-P
gland	I-P
.	I-P


There	O
were	O
no	O
toxic	B-OUT
effects	I-OUT
.	I-OUT


Secondary	O
caries	O
formation	O
in	O
vitro	O
around	O
glass	B-P
ionomer-lined	I-P
amalgam	I-P
and	I-P
composite	I-P
restorations	I-P
.	I-P


BACKGROUND	O
Postoperative	O
nausea	O
and	O
vomiting	O
(	O
PONV	O
)	O
is	O
still	O
a	O
common	O
and	O
major	O
complication	O
for	O
surgical	B-P
patients	I-P
,	O
which	O
may	O
delay	O
post-anesthetic	O
care	O
unit	O
discharge	O
,	O
prolong	O
hospital	O
stay	O
and	O
thus	O
increase	O
the	O
cost	O
of	O
hospitalization	O
.	O


However	O
,	O
expenses	O
and	O
side	O
effects	O
of	O
these	O
agents	O
have	O
also	O
been	O
a	O
concern	O
for	O
clinical	O
doctors	O
.	O


RESULTS	O
In	O
episodic	O
migraine	O
,	O
the	O
preferred	O
HIT-6	B-I
and	O
MSQ	B-I
algorithms	I-I
explained	O
22	O
%	O
and	O
25	O
%	O
of	O
the	O
variance	O
(	O
R	O
(	O
2	O
)	O
)	O
in	O
the	O
training	O
samples	O
,	O
respectively	O
,	O
and	O
had	O
similar	O
prediction	O
errors	O
(	O
root	O
mean	O
square	O
errors	O
of	O
0.30	O
)	O
.	O


The	O
preferred	O
HIT-6	B-I
and	I-I
MSQ	I-I
algorithms	O
will	O
be	O
useful	O
in	O
estimating	O
health-state	O
utilities	O
in	O
migraine	O
trials	O
in	O
which	O
no	O
preference-based	O
measure	O
is	O
present	O
.	O


Salivary	O
testosterone	O
and	O
immunoglobulin	O
A	O
were	O
increased	O
by	O
resistance	B-I
training	I-I
in	O
adults	B-P
with	I-P
Down	I-P
syndrome	I-P
.	I-P


All	B-P
participants	I-P
had	I-P
medical	I-P
approval	I-P
for	I-P
participation	I-P
in	I-P
physical	I-P
activity	I-P
.	I-P


Resistance	O
training	O
significantly	O
increased	O
salivary	B-OUT
IgA	I-OUT
concentration	I-OUT
(	O
P=0.0120	O
;	O
d=0.94	O
)	O
and	O
testosterone	B-OUT
levels	I-OUT
(	O
P=0.0088	O
;	O
d=1.57	O
)	O
in	O
the	O
exercising	O
group	O
.	O


APPLICATION	O
The	O
present	O
experiment	O
suggests	O
that	O
the	O
creation	O
of	O
distance	O
estimation	O
training	O
should	O
begin	O
with	O
a	O
careful	O
analysis	O
of	O
the	O
transfer	O
task	O
,	O
and	O
that	O
distance	O
estimation	O
training	O
programs	O
should	O
explicitly	O
teach	O
trainees	B-P
that	I-P
their	I-P
training	I-P
will	O
not	O
generalize	O
to	O
all	O
distance	O
estimation	O
tasks	O
.	O


BACKGROUND	O
The	O
aim	O
of	O
this	O
paper	O
is	O
to	O
present	O
our	O
experience	O
concerning	O
cooperation	O
in	O
the	O
treatment	O
of	O
Slovak	B-P
patients	I-P
with	I-P
differentiated	I-P
thyroid	I-P
cancer	I-P
in	I-P
Slovak	I-P
and	I-P
Czech	I-P
hospitals	I-P
.	I-P


Then	B-P
they	I-P
were	I-P
sent	I-P
to	I-P
the	I-P
Department	I-P
of	I-P
Nuclear	I-P
Medicine	I-P
in	I-P
Ostrava	I-P
in	I-P
the	I-P
Czech	I-P
Republic	I-P
.	I-P


After	O
3-6	O
months	O
some	O
patients	O
were	O
examined	O
by	O
means	O
of	O
diagnostic	B-OUT
whole	I-OUT
body	I-OUT
scintigraphy	I-OUT
after	O
application	O
of	O
300	O
MBq	O
131I	O
.	O


Generally	O
we	O
have	O
very	O
good	B-OUT
treatment	I-OUT
results	I-OUT
.	I-OUT


Our	O
collaboration	O
also	O
successfully	O
continues	O
after	O
entrance	O
of	O
the	O
Slovak	O
Republic	O
and	O
the	O
Czech	O
Republic	O
to	O
the	O
European	O
Union	O
in	O
2004	O
.	O


The	O
treatment	O
results	O
were	O
very	O
similar	O
to	O
therapeutic	O
results	O
in	O
our	O
patients	O
from	O
the	O
Czech	O
Republic	O
.	O


RESULTS	O
At	O
enrollment	O
,	O
minority	B-P
patients	I-P
had	O
significantly	O
more	O
pain	B-OUT
than	O
their	O
white	O
counterparts	O
(	O
6.0	O
vs	O
5.0	O
,	O
P	O
=	O
0.05	O
)	O
.	O


At	O
follow-up	O
,	O
minorities	O
in	O
the	O
control	O
group	O
continued	O
to	O
have	O
more	O
pain	B-OUT
(	O
6.4	O
vs	O
4.7	O
,	O
P	O
=	O
0.01	O
)	O
,	O
whereas	O
in	O
the	O
experimental	O
group	O
,	O
disparities	O
were	O
eliminated	O
(	O
4.0	O
vs	O
4.3	O
,	O
P	O
=	O
0.71	O
)	O
.	O


Venous	B-OUT
plasma	I-OUT
potassium	I-OUT
and	I-OUT
lactic	I-OUT
acid	I-OUT
were	O
also	O
not	O
affected	O
by	O
digoxin-induced	B-I
skeletal	O
muscle	O
Na	O
(	O
+	O
)	O
-K	O
(	O
+	O
)	O
-ATPase	O
blockade	O
.	O


BACKGROUND	O
AND	O
AIM	O
Adjuvant	B-I
locoregional	I-I
chemotherapy	I-I
has	O
been	O
shown	O
to	O
be	O
useful	O
to	O
prevent	O
recurrence	O
after	O
curative	O
resection	O
of	O
hepatocellular	O
carcinoma	O
(	O
HCC	O
)	O
in	O
some	O
retrospective	O
studies	O
.	O


A	O
non-randomised	O
controlled	B-I
study	O
design	O
comprising	B-P
an	I-P
intervention	I-I
group	I-I
(	I-P
n=48	I-P
)	I-P
and	I-P
comparator	I-I
(	I-I
no	I-I
intervention	I-I
)	I-I
group	I-P
(	I-P
n=28	I-P
)	I-P
was	I-P
used	I-P
to	O
evaluate	O
the	O
effects	O
of	O
the	O
intervention	O
on	O
child	B-OUT
behaviour	I-OUT
(	I-OUT
Eyberg	I-OUT
Child	I-OUT
Behaviour	I-OUT
Inventory	I-OUT
;	I-OUT
parent-set	I-OUT
goals	I-OUT
)	I-OUT
and	O
parenting	B-OUT
efficacy	I-OUT
and	I-OUT
satisfaction	I-OUT
(	I-OUT
Parents	I-OUT
Sense	I-OUT
of	I-OUT
Competence	I-OUT
Scale	I-OUT
)	I-OUT
at	O
post-intervention	O
and	O
six-month	O
follow-up	O
.	O


Findings	O
suggest	O
this	O
is	O
a	O
promising	O
intervention	B-I
for	I-I
parents	I-I
of	O
a	O
child	O
with	O
a	O
disability	O
that	O
is	O
likely	O
to	O
be	O
less	O
resource	O
intensive	O
to	O
service	O
providers	O
than	O
individually	O
delivered	O
interventions	O
.	O


We	O
developed	O
a	O
telemedicine	O
system	O
for	O
remote	O
guidance	O
of	O
emergency	O
airway	O
management	O
called	O
the	O
Tele-Airway	B-I
Management	I-I
System	I-I
(	O
TAMS	O
)	O
.	O


However	O
,	O
a	O
larger	O
study	O
will	O
be	O
required	O
to	O
determine	O
non-superiority	O
or	O
equivalence	O
.	O


A	O
multiple	O
regression	O
analysis	O
did	O
not	O
provide	O
any	O
comprehensibility	O
in	O
the	O
relationship	O
between	O
masticatory	B-OUT
performance	I-OUT
and	I-OUT
the	I-OUT
variables	I-OUT
of	I-OUT
chewing	I-OUT
experience	I-OUT
.	I-OUT


Cilomilast	B-I
(	I-I
Ariflo	I-I
)	I-I
,	O
a	O
new	O
oral	B-I
phosphodiesterase-4	I-I
selective	I-I
inhibitor	I-I
,	O
improves	O
lung	B-OUT
function	I-OUT
in	O
chronic	O
obstructive	O
pulmonary	O
disease	O
(	O
COPD	O
)	O
.	O


Compared	O
with	O
placebo	B-I
,	O
analysis	O
of	O
variance	O
(	O
ANOVA	O
)	O
of	O
the	O
change	O
from	O
baseline	O
showed	O
that	O
cilomilast	B-I
did	O
not	O
alter	O
any	O
sputum	B-OUT
endpoint	I-OUT
or	I-OUT
FEV1	I-OUT
.	I-OUT


In	O
addition	O
,	O
by	O
Poisson	O
analysis	O
,	O
comparison	O
of	O
cell	O
counts	O
analyzed	O
as	O
a	O
ratio	O
of	O
active	O
to	O
placebo	O
demonstrated	O
reductions	B-OUT
of	I-OUT
CD8+	I-OUT
(	O
48	O
%	O
p	O
<	O
0.01	O
)	O
and	O
CD68+	B-OUT
(	O
47	O
%	O
p	O
=	O
0.001	O
)	O
cells	O
.	O


During	O
the	O
5-8	O
week	O
treatment	O
,	O
three	O
novel	O
probes	O
were	O
administered	O
to	O
determine	O
mastery	B-OUT
of	I-OUT
joint	I-OUT
attention	I-OUT
skills	I-OUT
.	I-OUT


Results	O
revealed	O
that	O
children	O
randomized	O
to	O
the	O
joint	B-I
attention	I-I
group	O
were	O
more	O
likely	O
to	O
acknowledge	B-OUT
the	I-OUT
probe	I-OUT
and	I-OUT
engage	I-OUT
in	I-OUT
shared	I-OUT
interactions	I-OUT
between	O
intervener	O
and	O
probe	O
upon	O
termination	O
of	O
intervention	O
.	O


140	B-P
patients	I-P
with	I-P
a	I-P
threatening	I-P
premature	I-P
birth	I-P
at	I-P
the	I-P
greater	I-P
than	I-P
or	I-P
equal	I-P
to	I-P
24-less	I-P
than	I-P
37	I-P
week	I-P
of	I-P
gestation	I-P
were	O
in	O
this	O
study	O
randomly	O
treated	O
with	O
hexoprenalin	B-I
or	I-I
salbutamol	I-I
.	I-I


The	O
current	O
exploratory	O
study	O
suggests	O
that-within	O
an	O
RCT	O
design-RLAI	O
and	O
oral	O
SGAs	O
are	O
equally	O
effective	B-OUT
and	O
have	O
similar	B-OUT
safety	I-OUT
profiles	I-OUT
in	O
patients	B-P
in	O
the	O
early	O
phase	O
of	O
SS	O
disorders	O
.	O


[	O
Intraoperative	O
continuous	O
epidural	O
block	O
influences	O
postoperative	O
changes	O
in	O
breathing	O
pattern	O
and	O
thoracoabdominal	O
movement	O
associated	O
with	O
upper	O
abdominal	O
surgery	O
]	O
.	O


Furthermore	O
,	O
there	O
were	O
identical	O
shortening	O
of	O
inspiratory	B-OUT
time	I-OUT
and	I-OUT
prolongation	I-OUT
of	I-OUT
duty	I-OUT
ratio	I-OUT
(	O
inspiratory	O
time/duration	O
of	O
a	O
breath	O
)	O
in	O
the	O
two	O
groups	O
.	O


Oral	O
health	O
impacts	O
on	O
daily	O
living	O
related	O
to	O
four	O
different	O
treatment	O
protocols	O
for	O
chronic	B-P
periodontitis	I-P
.	I-P


BACKGROUND	O
Patients	B-P
with	I-P
Raynaud	I-P
's	I-P
syndrome	I-P
have	O
abnormal	O
digital	O
vasoconstriction	O
,	O
which	O
may	O
be	O
secondary	O
to	O
impaired	O
synthesis	O
of	O
,	O
or	O
impaired	O
sensitivity	O
to	O
,	O
nitric	O
oxide	O
.	O


A	B-I
similar	I-I
procedure	I-I
was	I-I
done	I-I
simultaneously	I-I
on	I-I
the	I-I
other	I-I
arm	I-I
with	I-I
KY	I-I
jelly	I-I
only	I-I
(	I-I
placebo	I-I
)	I-I
.	O


No	O
adverse	O
effects	O
were	O
reported	O
.	O


[	O
Potentials	O
of	O
monocular	B-I
augmented	I-I
reality	I-I
technology	I-I
in	O
automobile	O
production	O
]	O
.	O


Data	O
are	O
presented	O
to	O
the	O
dominant	O
eye	O
on	O
a	O
semi-transparent	O
mirror	O
using	O
a	O
head-mounted	O
display	O
(	O
HMD	O
)	O
unit	O
that	O
works	O
with	O
retinal	O
laser	O
technology	O
.	O


In	O
this	O
study	O
the	O
potential	O
benefits	O
and	O
drawbacks	O
of	O
this	O
new	O
AR	B-I
technology	I-I
were	O
evaluated	O
.	O


Half	O
of	O
the	O
participants	O
complained	O
about	O
deficiencies	O
concerning	O
the	O
ergonomic	B-OUT
hardware	I-OUT
design	I-OUT
of	O
the	O
AR	O
system	O
.	O


DESIGN	O
Prospective	O
,	O
randomized	O
multicenter	O
study	O
.	O


Moreover	O
,	O
it	O
allows	O
operative	O
procedures	O
to	O
be	O
performed	O
with	O
the	O
new	O
bipolar	O
instruments	O
.	O


PATIENTS	O
Women	B-P
undergoing	I-P
controlled	I-P
ovarian	I-P
stimulation	I-P
for	I-P
assisted	I-P
conception	I-P
were	O
randomized	O
to	O
receive	O
LA	B-I
according	I-I
to	I-I
"	I-I
short	I-I
"	I-I
or	I-I
"	I-I
ultrashort	I-I
"	I-I
protocols	I-I
.	I-I


Each	O
patient	O
was	O
thus	O
her	O
own	O
control	O
.	O


Neither	O
5	B-I
FU	I-I
infusion	I-I
combination	O
appears	O
to	O
significantly	O
alter	B-OUT
the	I-OUT
dismal	I-OUT
prognosis	I-OUT
of	O
advanced	O
upper	O
gastrointestinal	O
neoplasms	O
.	O


Two	B-P
study	I-P
groups	I-P
were	I-P
randomly	I-P
formed	I-P
:	I-P
enamel	I-P
blocks	I-P
brushed	I-P
with	I-P
(	I-P
a	I-P
)	I-P
the	I-I
Gantrez-NNP	I-I
combination	I-I
and	I-I
(	I-I
b	I-I
)	I-I
conventional	I-I
toothpaste	I-I
,	I-P
for	I-P
1	I-P
minute	I-P
once	I-P
daily	I-P
for	I-P
4	I-P
weeks	I-P
,	I-P
then	I-P
rinsed	I-I
with	I-I
distilled	I-I
water	I-I
and	I-I
placed	I-I
in	I-I
thymol	I-I
solution	I-I
.	I-I


Influenza	O
and	O
pneumococcal	O
vaccination	B-I
as	O
a	O
model	O
to	O
assess	O
C-reactive	O
protein	O
response	O
to	O
mild	B-P
inflammation	I-P
.	I-P


Static	B-I
stretching	I-I
is	O
widely	O
applied	O
in	O
various	O
disciplines	O
.	O


In	O
addition	O
,	O
DPT	B-OUT
and	I-OUT
stiffness	I-OUT
were	O
significantly	O
lower	O
after	O
300	O
seconds	O
than	O
after	O
20-second	B-I
stretching	I-I
(	O
p	O
<	O
0.05	O
)	O
,	O
and	O
SLR	B-OUT
increased	O
significantly	O
after	O
all	O
stretching	B-I
durations	O
(	O
p	O
<	O
0.05	O
)	O
.	O


Thirty	B-P
alpacas	I-P
,	I-P
all	I-P
positive	I-P
for	I-P
Chorioptes	I-P
sp	I-P
.	I-P


Group	O
A	O
received	O
a	O
single	O
topical	O
administration	O
of	O
a	O
0.5	O
%	O
formulation	O
of	O
eprinomectin	B-I
at	O
the	O
dose	O
rate	O
of	O
500mug/kg	O
.	O


Group	O
B	O
received	O
three	O
subcutaneous	O
administrations	O
at	O
14	O
days	O
interval	O
of	O
a	O
1	O
%	O
formulation	O
of	O
ivermectin	B-I
at	O
the	O
dose	O
rate	O
of	O
400mug/kg	O
.	O


The	O
eprinomectin	B-I
protocol	O
employed	O
in	O
Study	O
2	O
,	O
consisting	O
of	O
four	O
weekly	O
topical	O
administrations	O
at	O
the	O
dose	O
rate	O
of	O
500mug/kg	O
of	O
body	O
weight	O
,	O
proved	O
highly	O
effective	O
at	O
reducing	O
the	O
Chorioptes	B-OUT
mite	I-OUT
burden	I-OUT
in	I-P
alpacas	I-P
.	I-P


With	O
respect	O
to	O
other	O
drug	O
use	O
,	O
fewer	O
women	O
than	O
men	O
reported	O
using	B-OUT
sedatives	I-OUT
and	O
tested	O
positive	O
for	O
sedatives	B-OUT
at	I-OUT
intake	I-OUT
.	I-OUT


Men	O
and	O
women	O
experienced	O
comparable	O
improvement	O
during	O
the	O
course	O
of	O
treatment	O
and	O
follow-up	O
.	O


Of	O
576	B-P
patients	I-P
with	I-P
non-Q-wave	I-P
acute	I-P
myocardial	I-P
infarction	I-P
enrolled	I-P
in	I-P
the	I-P
Diltiazem	I-P
Reinfarction	I-P
Study	I-P
,	I-P
246	I-P
(	I-P
43	I-P
%	I-P
)	I-P
had	I-P
1	I-P
or	I-P
more	I-P
episodes	I-P
of	I-P
angina	I-P
at	I-P
rest	I-P
or	I-P
with	I-P
minimal	I-P
effort	I-P
during	I-P
10.5	I-P
days	I-P
of	I-P
treatment	I-P
with	I-P
either	I-P
diltiazem	I-I
(	I-P
90	I-P
mg	I-P
every	I-P
6	I-P
hours	I-P
)	I-P
or	I-I
placebo	I-I
.	I-I


Reinfarction	B-OUT
(	O
12.2	O
%	O
vs	O
3.6	O
%	O
,	O
p	O
less	O
than	O
0.0001	O
)	O
or	O
death	B-OUT
(	O
6.1	O
%	O
vs	O
1.5	O
%	O
,	O
p	O
=	O
0.003	O
)	O
was	O
more	O
likely	O
to	O
occur	O
within	O
2	O
weeks	O
of	O
randomization	O
in	O
patients	O
with	O
postinfarction	O
angina	O
than	O
in	O
those	O
without	O
angina	O
.	O


Based	O
on	O
serial	O
electrocardiographic	O
data	O
,	O
115	O
of	O
the	O
246	O
patients	O
with	O
angina	O
had	O
transient	O
ST-T	B-OUT
changes	O
and	O
131	O
did	O
not	O
.	O


PURPOSE	O
Limited	O
robust	O
randomised	O
controlled	O
trials	O
investigating	O
fruit	B-OUT
and	I-OUT
vegetable	I-OUT
(	I-OUT
F	I-OUT
&	I-OUT
V	I-OUT
)	I-OUT
intake	I-OUT
in	O
people	B-P
at	I-P
risk	I-P
of	I-P
cardiovascular	I-P
disease	I-P
(	I-P
CVD	I-P
)	I-P
exist	O
.	O


RESULTS	O
Compliance	O
to	O
target	O
numbers	O
and	O
types	O
of	O
F	O
&	O
V	O
was	O
broadly	O
met	O
and	O
verified	O
by	O
dietary	O
records	O
,	O
and	O
plasma	B-OUT
and	I-OUT
urinary	I-OUT
biomarkers	I-OUT
.	I-OUT


BACKGROUND	O
Keratosis	B-P
pilaris	I-P
(	O
KP	O
)	O
is	O
a	O
common	O
condition	O
of	O
follicular	O
plugging	O
with	O
variable	O
erythema	O
.	O


MATERIALS	O
AND	O
METHODS	B-P
Sixteen	I-P
Korean	I-P
patients	I-P
were	I-P
treated	I-P
with	I-P
FCR™	I-P
on	I-P
both	I-P
upper	I-P
arms	I-P
for	I-P
five	I-P
sessions	I-P
at	I-P
2-week	I-P
intervals	I-OUT
.	I-OUT


PURPOSE	O
The	O
purpose	O
of	O
the	O
present	O
study	O
was	O
to	O
investigate	O
the	O
effects	O
of	O
resistance	B-I
and	I-I
endurance	I-I
training	I-I
on	O
serum	B-OUT
adiponectin	I-OUT
and	I-OUT
insulin	I-OUT
resistance	I-OUT
index	I-OUT
(	I-OUT
SI	I-OUT
)	I-OUT
in	O
healthy	B-P
men	I-P
.	I-P


The	B-I
experimental	I-I
groups	I-I
performed	I-I
either	I-I
endurance	I-I
or	I-I
resistance	I-I
training	I-I
3	I-I
days	I-I
a	I-I
week	I-I
for	I-I
12	I-I
weeks	I-I
.	I-I


Participants	O
engaged	O
in	O
a	O
pretest	O
roleplay	O
with	O
an	O
actress	O
playing	O
a	O
drinking	O
pregnant	O
woman	O
.	O


Both	O
groups	O
then	O
engaged	O
in	O
a	O
post-test	O
roleplay	O
similar	O
to	O
the	O
pretest	O
.	O


INTRODUCTION	O
Gingival	O
overgrowth	O
associated	O
with	O
immunosuppression	O
following	O
liver	O
transplantation	O
is	O
a	O
commonly	O
recognized	O
clinical	O
problem	O
.	O


Gingival	B-OUT
overgrowth	I-OUT
was	O
assessed	O
in	O
a	O
blinded	O
fashion	O
and	O
scored	O
in	O
a	O
previously	O
validated	O
manner	O
.	O


Treatment	O
with	O
recombinant	B-I
interleukin	I-I
2	I-I
prevented	O
the	O
postoperative	O
fall	O
in	O
both	O
natural	B-OUT
killer	I-OUT
and	I-OUT
lymphokine-activated	I-OUT
killer	I-OUT
cell	I-OUT
cytotoxicity	I-OUT
,	O
clearly	O
demonstrated	O
in	O
the	O
control	O
group	O
.	O


These	O
combined	O
effects	O
may	O
have	O
important	O
consequences	O
in	O
controlling	O
metastatic	O
dissemination	O
of	O
tumor	O
during	O
the	O
vulnerable	O
perioperative	O
period	O
.	O


A	O
double-blind	O
,	O
placebo-controlled	O
study	O
was	O
designed	O
to	O
assess	O
critically	O
the	O
effects	O
of	O
naltrexone	B-I
on	O
behavioral	B-OUT
symptoms	I-OUT
and	O
learning	B-OUT
in	O
autistic	B-P
children	I-P
,	O
and	O
its	O
safety	O
.	O


This	O
is	O
a	O
preliminary	O
report	O
on	O
18	B-P
children	I-P
,	I-P
ages	I-P
3.08	I-P
to	I-P
7.99	I-P
years	I-P
,	I-P
who	I-P
completed	I-P
this	I-P
ongoing	I-P
study	I-P
.	I-P


Subjects	O
were	O
randomly	O
assigned	O
to	O
naltrexone	B-I
or	I-I
placebo	I-I
and	I-I
received	I-I
daily	I-I
doses	I-I
over	I-I
a	I-I
period	I-I
of	I-I
21	I-I
days	I-I
.	I-I


Inhibin	O
A	O
is	O
down-regulated	O
during	O
chemotherapy	B-I
in	O
patients	B-P
with	I-P
breast	I-P
cancer	I-P
.	I-P


BACKGROUND	O
Inhibins	O
are	O
dimeric	O
glycoproteins	O
,	O
composed	O
of	O
an	O
alpha-subunit	O
(	O
INH-α	O
)	O
and	O
one	O
of	O
two	O
possible	O
beta-subunits	O
(	O
βA	O
or	O
βB	O
)	O
,	O
with	O
substantial	O
roles	O
in	O
human	O
reproduction	O
and	O
in	O
endocrine-responsive	O
tumours	O
.	O


Cell	O
death	O
after	O
treatment	O
with	O
chemotherapy	B-I
is	O
exerted	O
by	O
activation	O
of	O
apoptosis	O
,	O
and	O
the	O
p53	O
protein	O
has	O
been	O
shown	O
to	O
actively	O
participate	O
in	O
this	O
process	O
.	O


Therapy	B-OUT
response	I-OUT
was	O
obtained	O
for	O
38	B-P
patients	I-P
with	I-P
clinically	I-P
evaluable	I-P
disease	I-P
after	I-P
initial	I-P
surgery	I-P
.	I-P


A	O
significant	O
difference	O
in	O
relapse-free	B-OUT
survival	I-OUT
in	O
favour	O
of	O
paclitaxel/cisplatin	B-I
chemotherapy	I-I
was	O
found	O
(	O
P	O
=	O
0.001	O
)	O
.	O


We	O
did	O
not	O
observe	O
an	O
association	O
between	O
TP53	B-OUT
tumour	I-OUT
status	I-OUT
and	O
prognosis	B-OUT
for	O
patients	O
who	O
received	O
paclitaxel/cisplatin	B-I
combination	O
treatment	O
,	O
indicating	O
that	O
the	O
effect	O
of	O
this	O
therapy	O
is	O
not	O
influenced	O
by	O
this	O
parameter	O
.	O


RESULTS	O
Most	O
patients	O
in	O
both	O
study	O
groups	O
showed	O
high	O
adherence	B-OUT
to	O
raloxifene	B-I
at	O
the	O
3-month	O
visit	O
:	O
56.3	O
%	O
vs	O
62.7	O
%	O
for	O
groups	O
A	O
and	O
B	O
,	O
respectively	O
;	O
this	O
proportion	O
at	O
the	O
12-month	O
visit	O
was	O
47.4	O
%	O
(	O
P=0.15	O
)	O
and	O
52.5	O
%	O
(	O
P=0.02	O
)	O
,	O
respectively	O
.	O


At	O
baseline	O
,	O
"	B-OUT
pain/discomfort	I-OUT
"	I-OUT
was	O
the	O
dimension	O
showing	O
the	O
highest	O
percentage	O
of	O
women	O
reporting	O
problems	O
:	O
86.4	O
%	O
vs	O
83.2	O
%	O
in	O
groups	O
A	O
and	O
B	O
,	O
respectively	O
(	O
P=0.22	O
)	O
.	O


HRQOL	B-OUT
improved	O
in	O
both	O
groups	O
throughout	O
the	O
study	O
,	O
with	O
an	O
overall	O
mean	O
increment	O
in	O
the	O
EuroQoL	B-OUT
visual	I-OUT
analog	I-OUT
scale	I-OUT
(	I-OUT
EQ	I-OUT
VAS	I-OUT
)	I-OUT
of	O
9.2	O
at	O
12	O
months	O
(	O
P	O
<	O
0.01	O
)	O
.	O


Lithium	B-I
plus	I-I
early	I-I
morning	I-I
sleep	I-I
deprivation	I-I
produced	O
a	O
quicker	O
response	B-OUT
than	O
lithium	O
with	O
the	O
control	O
sleep	O
deprivation	O
,	O
and	O
the	O
response	B-OUT
was	O
sustained	O
for	O
at	O
least	O
30	O
days	O
.	O


Temporal	O
discounting	O
:	O
the	O
differential	O
effect	O
of	O
proximal	O
and	O
distal	O
consequences	O
on	O
confession	B-I
decisions	I-I
.	I-I


Consistent	O
with	O
this	O
hypothesis	O
,	O
Experiment	O
1	O
showed	O
that	O
participants	B-P
(	I-P
N	I-P
=	I-P
81	I-P
)	I-P
altered	O
how	O
frequently	O
they	O
admitted	B-OUT
to	I-OUT
criminal	I-OUT
and	I-OUT
unethical	I-OUT
behaviors	I-OUT
during	O
an	O
interview	O
to	O
avoid	O
a	O
proximal	O
consequence	O
even	O
though	O
doing	O
so	O
increased	O
their	O
risk	O
of	O
incurring	O
a	O
distal	B-OUT
consequence	I-OUT
.	I-OUT


In	O
MRI	B-I
,	O
superficial	B-OUT
brain	I-OUT
retraction	I-OUT
deficits	I-OUT
(	O
P	O
<	O
0.001	O
)	O
and	O
ischemic	B-OUT
lesions	I-OUT
in	O
the	O
territory	O
of	O
the	O
ruptured	B-OUT
aneurysm	I-OUT
(	O
P=0.025	O
)	O
were	O
more	O
frequent	O
in	O
the	O
surgical	O
group	O
.	O


Kaplan-Meier	O
analysis	O
(	O
mean+/-SD	O
follow-up	O
39+/-18	O
months	O
)	O
revealed	O
equal	O
survival	B-OUT
in	O
both	O
treatment	O
groups	O
.	O


No	O
late	B-OUT
rebleedings	I-OUT
have	O
occurred	O
.	O


The	O
long-term	O
efficacy	O
of	O
endovascular	O
treatment	O
in	O
preventing	O
rebleeding	B-OUT
remains	O
open	O
.	O


Measures	O
included	O
out-of-pocket	B-OUT
pharmaceutical	I-OUT
expenditures	I-OUT
,	I-OUT
excess	I-OUT
expenditures	I-OUT
on	I-OUT
pads	I-OUT
or	I-OUT
tampons	I-OUT
,	I-OUT
the	I-OUT
value	I-OUT
of	I-OUT
time	I-OUT
missed	I-OUT
from	I-OUT
paid	I-OUT
work	I-OUT
and	I-OUT
home	I-OUT
management	I-OUT
activities	I-OUT
,	I-OUT
and	I-OUT
health	I-OUT
utility	I-OUT
.	I-OUT


BACKGROUND	O
Previous	O
research	O
has	O
suggested	O
that	O
music	B-I
therapy	I-I
may	O
facilitate	O
skills	B-OUT
in	O
areas	O
typically	O
affected	O
by	O
autism	B-P
spectrum	I-P
disorders	I-P
such	O
as	O
social	B-OUT
interaction	I-OUT
and	I-OUT
communication	I-OUT
.	I-OUT


This	O
study	O
evaluated	O
whether	O
a	O
combined	B-I
strategy	I-I
of	I-I
phosphorus-restricted	I-I
diet	I-I
and	I-I
phosphate-binding	I-I
therapy	I-I
can	O
reduce	O
the	O
risk	B-OUT
of	I-OUT
all-cause	I-OUT
mortality	I-OUT
and/or	I-OUT
dialysis	I-OUT
initiation	I-OUT
by	O
attenuating	O
coronary	B-OUT
artery	I-OUT
calcification	I-OUT
(	I-OUT
CAC	I-OUT
)	I-OUT
progression	I-OUT
in	O
non-dialysis	B-P
CKD	I-P
patients	I-P
.	I-P


End-points	O
were	B-OUT
death	I-OUT
for	I-OUT
any	I-OUT
cause	I-OUT
and	I-OUT
initiation	I-OUT
of	I-OUT
dialysis	I-OUT
.	O


Accelerated	B-OUT
progression	I-OUT
(	O
annual	O
CAC	O
increase	O
>	O
75th	O
percentile	O
of	O
the	O
study	O
cohort	O
)	O
increased	O
the	B-OUT
risk	I-OUT
of	I-OUT
all-cause	I-OUT
mortality	I-OUT
and	I-OUT
composite	I-OUT
end-point	I-OUT
(	O
p	O
=	O
0.01	O
)	O
independently	O
of	O
the	O
use	O
of	O
sevelamer	O
.	O


Future	O
studies	O
should	O
investigate	O
the	O
role	O
of	O
serum	O
phosphorus	O
,	O
the	O
usefulness	O
of	O
a	O
phosphorus-restricted	O
diet	O
,	O
and	O
the	O
appropriateness	O
of	O
current	O
normal	O
ranges	O
of	O
serum	O
phosphorus	O
concentration	O
in	O
relation	O
to	O
events	O
in	O
non-dialyzed	O
CKD	O
patients	O
.	O


Number	O
of	O
presentations	B-I
of	I-I
the	I-I
standard	I-I
never	O
affected	O
the	O
proportion	B-OUT
of	I-OUT
identifications	I-OUT
of	I-OUT
the	I-OUT
standard	I-OUT
when	O
it	O
was	O
presented	O
,	O
nor	O
other	O
features	O
of	O
the	O
temporal	O
generalization	O
gradients	O
observed	O
.	O


The	O
topiramate	B-I
and	O
placebo	B-I
groups	O
did	O
not	O
differ	O
on	O
sex	O
,	O
level	O
of	O
education	O
,	O
premorbid	O
intelligence	O
,	O
methadone	O
dose	O
,	O
or	O
illicit	O
drug	O
use	O
.	O


Topiramate	B-I
had	O
no	O
effects	O
on	O
visual	B-OUT
processing	I-OUT
,	I-OUT
other	I-OUT
measures	I-OUT
of	I-OUT
psychomotor	I-OUT
function	I-OUT
,	I-OUT
risk-taking	I-OUT
,	I-OUT
self-control	I-OUT
,	I-OUT
Sternberg	I-OUT
working	I-OUT
memory	I-OUT
,	I-OUT
free	I-OUT
recall	I-OUT
,	I-OUT
and	I-OUT
metamemory	I-OUT
.	I-OUT


Assigned	O
group	O
was	O
the	O
major	O
predictor	O
of	O
change	O
in	O
calcium	B-OUT
intake	I-OUT
.	I-OUT


The	O
effects	O
of	O
acute	O
administration	O
per	O
os	O
of	O
30	O
mg	O
camazepam	B-I
and	O
the	O
same	O
dose	O
of	O
temazepam	B-I
,	O
were	O
compared	O
with	O
placebo	B-I
in	O
8	B-P
young	I-P
male	I-P
volunteers	I-P
,	I-P
fully	I-P
adapted	I-P
to	I-P
the	I-P
laboratory	I-P
environment	I-P
by	I-P
6	I-P
nights	I-P
of	I-P
adaptation	I-P
.	I-P


METHODS	O
In	O
this	O
single-center	O
,	O
randomized	O
controlled	O
study	O
,	O
women	B-P
were	O
assigned	O
to	O
a	O
multiphasic	B-I
pill	I-I
,	I-I
a	I-I
lower-dose	I-I
monophasic	I-I
pill	I-I
,	I-I
a	I-I
higher-dose	I-I
monophasic	I-I
pill	I-I
,	I-I
or	I-I
nonsteroidal	I-I
contraception	I-I
.	I-I


CONCLUSION	O
This	O
multiphasic	B-I
pill	I-I
more	O
closely	O
resembled	O
the	O
lower-dose	O
monophasic	B-I
pill	I-I
than	O
the	O
higher-dose	O
monophasic	B-I
pill	I-I
in	O
its	O
suppression	B-OUT
of	I-OUT
follicular	I-OUT
development	I-OUT
.	I-OUT


Logistic	O
regression	O
analyses	O
showed	O
that	O
no	O
having	O
creation	O
a	O
pleural	B-I
tent	I-I
procedure	O
was	O
the	O
most	O
significant	O
predictive	O
factor	O
of	O
the	O
occurrence	B-OUT
and	I-OUT
duration	I-OUT
of	I-OUT
prolonged	I-OUT
air	I-OUT
leaks	I-OUT
.	I-OUT


CONCLUSIONS	O
Pleural	O
tent	O
creation	O
after	O
upper	O
lobectomy	O
is	O
a	O
simple	B-OUT
and	I-OUT
safe	I-OUT
procedure	I-OUT
that	O
reduces	O
the	O
duration	B-OUT
of	I-OUT
air	I-OUT
leaks	I-OUT
and	O
the	O
hospital	B-OUT
stay	I-OUT
costs	I-OUT
.	I-OUT


BACKGROUND	O
Previous	O
research	O
has	O
identified	O
a	O
high	O
risk	O
of	O
gastric	O
carcinoma	O
as	O
well	O
as	O
a	O
high	O
prevalence	O
of	O
cancer	O
precursor	O
lesions	O
in	O
rural	B-P
populations	I-P
living	I-P
in	I-P
the	I-P
province	I-P
of	I-P
Nariño	I-P
,	I-P
Colombia	I-P
,	I-P
in	I-P
the	I-P
Andes	I-P
Mountains	I-P
.	O


RESULTS	O
All	O
three	O
basic	O
interventions	O
resulted	O
in	O
statistically	O
significant	O
increases	O
in	O
the	B-OUT
rates	I-OUT
of	I-OUT
regression	I-OUT
:	I-OUT
Relative	O
risks	O
were	O
4.8	O
(	O
95	O
%	O
confidence	O
interval	O
[	O
CI	O
]	O
=	O
1.6-14.2	O
)	O
for	O
anti-H.	O
pylori	O
treatment	O
,	O
5	O
.	O


Median	B-OUT
remedication	I-OUT
times	I-OUT
with	O
both	O
doses	O
of	O
ibuprofen	B-I
arginate	I-I
were	O
similar	O
to	O
those	O
with	O
both	O
doses	O
of	O
ibuprofen	O
,	O
ranging	O
from	O
4.0	O
to	O
5.2	O
hours	O
.	O


The	O
impact	O
of	O
different	O
doses	O
of	O
medroxyprogesterone	B-I
acetate	I-I
on	O
mood	B-OUT
symptoms	I-OUT
in	O
sequential	B-I
hormonal	I-I
therapy	I-I
.	I-I


The	O
end	B-OUT
points	I-OUT
were	O
survival	B-OUT
and	I-OUT
time	I-OUT
to	I-OUT
treatment	I-OUT
failure	I-OUT
(	I-OUT
TTF	I-OUT
)	I-OUT
.	I-OUT


Pethidine	B-I
versus	I-I
tramadol	I-I
for	O
pain	B-OUT
relief	I-OUT
during	I-P
labor	I-P
.	I-P


Group	O
1	O
received	O
100	O
mg	O
pethidine	B-I
;	I-I
group	O
2	O
,	O
100	O
mg	O
tramadol	B-I
,	O
intramuscularly	O
.	O


Alternative	O
voice	O
after	O
laryngectomy	B-I
using	O
a	O
sound-producing	B-I
voice	I-I
prosthesis	I-I
.	I-I


RESULTS	O
The	O
current	O
prototype	O
seems	O
beneficial	O
in	O
female	B-P
laryngectomees	I-P
with	I-P
a	I-P
hypotonic	I-P
PE	I-P
segment	I-P
only	O
.	O


Pitch	B-OUT
regulation	I-OUT
of	O
this	O
prosthetic	O
voice	O
is	O
possible	O
,	O
yet	O
limited	O
.	O


The	O
aR	O
is	O
a	O
procedure	O
dependent	O
on	O
the	O
cooperation	O
of	O
the	O
patient	O
,	O
whereas	O
IOS	O
is	O
measured	O
regardless	O
from	O
the	O
breathing	O
activities	O
of	O
the	O
patient	O
.	O


RESULTS	O
The	O
complete	B-OUT
resistance	I-OUT
showed	O
neither	O
in	O
the	O
basic	O
measurement	O
(	O
aR	O
0,38	O
+/-	O
0,14	O
kPa/l/s	O
;	O
IOS	O
0,38	O
+/-	O
0,11	O
kPa/l/s	O
)	O
nor	O
in	O
the	O
control	O
solution	O
(	O
aR	O
0,38	O
+/-	O
0,14	O
;	O
IOS	O
0,39	O
+/-	O
0,14	O
)	O
nor	O
after	O
application	O
of	O
the	O
allergenic	O
solution	O
(	O
15	O
min	O
:	O
aR	O
0,69	O
+/-	O
0,27	O
;	O
IOS	O
0,77	O
+/-	O
0,42	O
;	O
30	O
min	O
:	O
aR	O
0,65	O
+/-	O
0,29	O
;	O
IOS	O
0,6	O
+/-	O
0,38	O
)	O
a	O
significant	O
difference	O
between	O
the	O
two	O
methods	O
.	O


The	O
results	O
of	O
the	O
measurement	B-OUT
of	I-OUT
aR	I-OUT
and	I-OUT
IOS	I-OUT
after	O
the	O
allergenic	O
solution	O
showed	O
a	O
positive	O
correlation	B-OUT
(	O
15	O
min	O
:	O
r	O
=	O
0,63	O
,	O
p	O
<	O
0,01	O
;	O
30	O
min	O
:	O
r	O
=	O
0,67	O
,	O
p	O
<	O
0,01	O
)	O
.	O


We	O
found	O
by	O
means	O
of	O
clinic	O
and	O
measurement	O
methods	O
in	O
the	O
aR	O
of	O
7	B-P
patients	I-P
a	I-P
positive	I-P
reaction	I-OUT
,	I-P
within	I-P
7	I-P
patient	I-P
a	I-P
negative	I-P
reaction	I-OUT
,	I-P
3	I-P
patients	I-P
had	I-P
a	I-P
unspecific	I-OUT
nasal	I-OUT
hyperreactivity	I-OUT
.	I-OUT


After	O
taking	O
take	O
135	O
mg	O
of	O
isoflavones	B-I
daily	O
for	O
1	O
week	O
,	O
the	O
women	O
in	O
the	O
study	O
group	O
were	O
assigned	O
to	O
the	O
equol-producing	O
(	O
EP	O
)	O
or	O
the	O
non-EP	O
group	O
according	O
to	O
the	O
presence	O
or	O
absence	O
of	O
equol	O
in	O
their	O
urine	O
.	O


Measurements	O
were	O
made	O
for	O
1	B-I
minute	I-I
before	I-I
and	I-I
after	I-I
0.4	I-I
mL	I-I
of	I-I
water	I-I
was	I-I
instilled	I-I
into	I-I
the	I-I
oropharynx	I-I
.	I-I


9	O
(	O
1.5	O
)	O
,	O
respectively	O
)	O
.	O


CONCLUSION	O
These	O
data	O
suggest	O
that	O
airway	O
protection	O
is	O
compromised	O
in	O
the	O
prone	O
sleeping	O
position	O
during	O
active	O
sleep	O
,	O
even	O
in	O
healthy	O
infants	O
exposed	O
to	O
minute	O
pharyngeal	O
fluid	O
volumes	O
of	O
0.4	O
mL	O
.	O


The	O
reduction	O
in	O
airway	B-OUT
protective	I-OUT
reflexes	I-OUT
when	O
in	O
the	O
prone	O
position	O
and	O
in	O
active	O
sleep	O
may	O
be	O
the	O
mechanism	O
for	O
the	O
increased	O
risk	O
of	O
SIDS	O
in	O
the	O
prone	O
position	O
.	O


We	O
aimed	O
to	O
assess	O
endobronchial	B-I
ultrasound-guided	I-I
transbronchial	I-I
needle	I-I
aspiration	I-I
as	O
an	O
initial	O
investigation	O
technique	O
for	O
patients	B-P
with	I-P
suspected	I-P
lung	I-P
cancer	I-P
.	I-P


FINDINGS	O
Between	O
June	O
10	O
,	O
2008	O
,	O
and	O
July	O
4	O
,	O
2011	O
,	O
we	O
randomly	B-P
allocated	I-P
133	I-P
patients	I-P
to	I-P
treatment	I-P
:	I-P
66	I-P
to	I-P
EBUS-TBNA	I-P
and	I-P
67	I-P
to	I-P
CDS	I-P
(	O
one	O
later	O
withdrew	O
consent	O
)	O
.	O


One	O
patient	O
in	O
each	O
group	O
had	B-OUT
a	I-OUT
pneumothorax	I-OUT
from	O
a	O
CT-guided	O
biopsy	O
sample	O
;	O
the	O
patient	O
from	O
the	O
CDS	O
group	B-OUT
needed	I-OUT
intercostal	I-OUT
drainage	I-OUT
and	O
was	O
admitted	O
to	O
hospital	O
.	O


Both	O
therapies	O
were	O
well	B-OUT
tolerated	I-OUT
.	I-OUT


Clindamycin	B-I
was	O
found	O
to	O
be	O
more	O
effective	B-OUT
than	O
cefoxitin	O
in	O
eradicating	B-OUT
the	I-OUT
offending	I-OUT
anaerobic	I-OUT
pathogens	I-OUT
from	I-OUT
the	I-OUT
site	I-OUT
of	I-OUT
infection	I-OUT
.	I-OUT


METHODS	O
To	O
investigate	O
the	O
effect	O
of	O
exposure	O
to	O
nitrogen	B-I
dioxide	I-I
(	I-I
NO2	I-I
)	I-I
on	O
nasal	O
airways	O
resistance	O
(	O
NAR	O
)	O
and	O
inflammatory	O
mediators	O
in	O
nasal	O
lavage	O
fluid	O
,	O
eight	B-P
subjects	I-P
with	I-P
a	I-P
history	I-P
of	I-P
seasonal	I-P
allergic	I-P
rhinitis	I-P
,	I-P
who	I-P
were	I-P
tested	I-P
out	I-P
of	I-P
season	I-P
,	O
were	O
exposed	O
in	O
a	O
randomized	O
single-blind	O
,	O
crossover	O
study	O
to	O
either	O
air	B-I
or	O
400	O
ppb	O
NO2	B-I
for	O
6	O
hours	O
.	O


Another	B-P
group	I-P
of	I-P
eight	I-P
subjects	I-P
with	I-P
a	I-P
history	I-P
of	I-P
seasonal	I-P
allergic	I-P
rhinitis	I-P
were	O
also	O
randomized	O
to	O
exposure	O
to	O
air	O
or	O
400	O
ppb	O
NO2	B-I
for	O
6	O
hours	O
and	O
then	O
challenged	O
with	O
allergen	O
,	O
before	O
evaluation	O
for	O
changes	B-OUT
in	I-OUT
NAR	I-OUT
and	I-OUT
changes	I-OUT
in	I-OUT
ECP	I-OUT
,	I-OUT
MCT	I-OUT
,	I-OUT
MPO	I-OUT
,	I-OUT
and	I-OUT
IL-8	I-OUT
in	I-OUT
nasal	I-OUT
lavage	I-OUT
fluid	I-OUT
.	I-OUT


CONCLUSIONS	O
These	O
results	O
suggest	O
that	O
acute	O
exposure	O
to	O
NO2	B-I
at	O
concentrations	O
found	O
at	O
the	O
curbside	O
in	O
heavy	O
traffic	O
during	O
episodes	O
of	O
pollution	O
,	O
may	O
"	O
prime	O
"	O
eosinophils	O
for	O
subsequent	O
activation	O
by	O
allergen	O
in	O
individuals	O
with	O
a	O
history	O
of	O
seasonal	O
allergic	O
rhinitis	O
.	O


PURPOSE	O
To	O
evaluate	O
the	O
efficacy	B-OUT
and	I-OUT
tolerability	I-OUT
of	O
dofequidar	B-I
plus	I-I
cyclophosphamide	I-I
,	I-I
doxorubicin	I-I
,	I-I
and	I-I
fluorouracil	I-I
(	I-I
CAF	I-I
)	I-I
therapy	I-I
in	O
comparison	O
with	O
CAF	B-I
alone	I-I
,	O
in	O
patients	B-P
with	I-P
advanced	I-P
or	I-P
recurrent	I-P
breast	I-P
cancer	I-P
.	I-P


PATIENTS	O
AND	O
METHODS	O
In	O
this	O
randomized	O
,	O
double-blind	O
,	O
placebo-controlled	B-I
trial	O
,	O
patients	O
were	O
treated	O
with	O
six	O
cycles	O
of	O
CAF	B-I
therapy	I-I
:	I-I
28	O
days/cycle	B-I
,	I-I
with	I-I
doxorubicin	I-I
(	I-I
25	I-I
mg/m2	I-I
)	I-I
and	I-I
fluorouracil	I-I
(	I-I
500	I-I
mg/m2	I-I
)	I-I
administered	I-I
on	I-I
days	I-I
1	I-I
and	I-I
8	I-I
and	I-I
cyclophosphamide	I-I
(	I-I
100	I-I
mg	I-I
orally	I-I
[	I-I
PO	I-I
]	I-I
)	I-I
administered	I-I
on	I-I
day	I-I
1	I-I
through	I-I
14	I-I
.	I-I


Patients	O
received	O
dofequidar	B-I
(	I-I
900	I-I
mg	I-I
PO	I-I
)	I-I
30	O
minutes	O
before	O
each	O
dose	O
of	O
doxorubicin	B-I
.	I-I


There	O
was	O
a	O
trend	O
for	O
prolonged	B-OUT
progression-free	I-OUT
survival	I-OUT
(	I-OUT
PFS	I-OUT
;	I-OUT
median	O
241	O
days	O
for	O
CAF	O
v	O
366	O
days	O
for	O
dofequidar	O
+	O
CAF	O
;	O
P	O
=	O
.145	O
)	O
.	O


III	O
:	O
Continued	B-I
lifestyle	I-I
intervention	I-I
combined	I-I
with	I-I
the	I-I
same	I-I
drugs	I-I
as	I-I
in	I-I
phase	I-I
II	I-I
and	I-I
in	I-I
addition	I-I
pravastatin	I-I
or	I-I
placebo	I-I
.	I-I


SETTING	O
Fifty-four	B-P
general	I-P
practice	I-P
surgeries	I-P
in	I-P
Norway	I-P
.	I-P


MAIN	O
OUTCOME	O
MEASURES	O
Recurrence	B-OUT
rate	I-OUT
,	I-OUT
vision	I-OUT
,	I-OUT
and	I-OUT
complications	I-OUT
.	I-OUT


RESULTS	O
Uveitis	B-OUT
recurrence	I-OUT
was	I-OUT
reduced	I-OUT
in	O
implanted	O
eyes	O
from	O
62	O
%	O
(	O
during	O
the	O
1-year	O
preimplantation	O
period	O
)	O
to	O
4	O
%	O
,	O
10	O
%	O
,	O
and	O
20	O
%	O
during	O
the	O
1-	O
,	O
2-	O
,	O
and	O
3-year	O
postimplantation	O
periods	O
,	O
respectively	O
,	O
for	O
the	O
0.59-mg	O
dose	O
group	O
(	O
P	O
<	O
.01	O
)	O
and	O
from	O
58	O
%	O
to	O
7	O
%	O
,	O
17	O
%	O
,	O
and	O
41	O
%	O
,	O
respectively	O
,	O
for	O
the	O
2.1-mg	O
dose	O
group	O
(	O
P	O
<	O
.01	O
)	O
.	O


APPLICATION	O
TO	O
CLINICAL	O
PRACTICE	O
The	O
FA	O
implant	O
provides	O
an	O
alternative	O
therapy	O
for	O
prolonged	O
control	O
of	O
inflammation	O
in	O
noninfectious	O
posterior	O
uveitis	O
.	O


From	B-P
1989	I-P
to	I-P
1997	I-P
,	I-P
68	I-P
patients	I-P
diagnosed	I-P
with	I-P
previously	I-P
untreated	I-P
PMBCL	I-P
,	I-P
aged	I-P
18-65	I-P
years	I-P
and	I-P
negative	I-P
for	I-P
immunodeficiency	I-P
virus	I-P
test	I-P
,	O
were	O
considered	O
candidates	O
to	O
receive	O
either	B-I
conventional	I-I
chemotherapy	I-I
with	I-I
CEOP-Bleo	I-I
(	I-I
cyclophosphamide	I-I
750	I-I
mg/m	I-I
(	I-I
2	I-I
)	I-I
,	I-I
vincristine	I-I
1.4	I-I
mg/m	I-I
(	I-I
2	I-I
)	I-I
,	I-I
prednisone	I-I
40	I-I
mg/m	I-I
(	I-I
2	I-I
)	I-I
,	I-I
epirubicin	I-I
70	I-I
mg/m	I-I
(	I-I
2	I-I
)	I-I
,	I-I
and	I-I
bleomycin	I-I
10	I-I
mg/m	I-I
(	I-I
2	I-I
)	I-I
)	I-I
or	I-I
mega	I-I
CEOP-Bleo	I-I
(	I-I
cyclophosphamide	I-I
1000	I-I
mg/m	I-I
(	I-I
2	I-I
)	I-I
,	I-I
epirubicin	I-I
120	I-I
mg/m	I-I
(	I-I
2	I-I
)	I-I
,	I-I
vincristine	I-I
,	I-I
prednisone	I-I
,	I-I
and	I-I
bleomycin	I-I
at	I-I
the	I-I
same	I-I
doses	I-I
)	I-I
every	I-I
21	I-I
days	I-I
for	I-I
six	I-I
cycles	I-I
,	I-I
followed	I-I
by	I-I
radiotherapy	I-I
to	I-I
the	I-I
mediastinum	I-I
with	I-I
the	I-I
mantle	I-I
technique	I-I
(	I-I
35-45	I-I
Gy	I-I
,	I-I
mean	I-I
38	I-I
Gy	I-I
)	I-I
.	I-I


Complete	B-OUT
response	I-OUT
(	I-OUT
CR	I-OUT
)	I-OUT
rates	I-OUT
were	O
not	O
statistically	O
different	O
:	O
64	O
%	O
[	O
95	O
percent	O
confidence	B-OUT
interval	I-OUT
(	I-OUT
CI	I-OUT
)	I-OUT
:	I-OUT
58	O
percent	O
to	O
70	O
percent	O
]	O
for	O
conventional	O
arm	O
vs	O
81	O
percent	O
(	O
95	O
CI	O
:	O
77-86	O
percent	O
)	O
in	O
the	O
intensive	O
group	O
(	O
p=0.2	O
)	O
.	O


The	B-OUT
international	I-OUT
prognostic	I-OUT
index	I-OUT
was	O
not	O
useful	O
to	O
define	O
clinical	O
risk	O
in	O
this	O
selected	O
group	O
of	O
patients	O
.	O


Patients	O
with	O
pleural	O
or	O
pericardial	O
effusion	O
are	O
considered	O
at	O
high	O
risk	O
for	O
failure	O
with	O
the	O
actual	O
programs	O
of	O
treatment	O
and	O
probably	O
will	O
be	O
considered	O
for	O
experimental	O
therapeutic	O
approaches	O
.	O


TRIAL	O
REGISTRATION	O
NCT00759434	O
Clinicaltrials.gov	O
.	O


In	O
fully	O
and	O
partially	O
evaluable	O
patients	B-P
with	I-P
a	I-P
68-month	I-P
median	I-P
follow-up	I-P
,	O
treatment	B-OUT
failures	I-OUT
have	O
occurred	O
in	O
27	O
%	O
of	O
172	B-P
receiving	I-P
CMFVP	I-I
and	O
47	O
%	O
of	O
186	B-P
women	I-P
given	I-P
L-PAM	I-I
(	O
p	O
=	O
0.002	O
)	O
.	O


BACKGROUND	O
Afatinib	O
is	O
an	O
oral	O
,	O
irreversible	O
ErbB	O
family	O
blocker	O
that	O
has	O
shown	O
activity	O
in	O
epidermal	O
growth	O
factor	O
receptor	O
(	O
EGFR	O
)	O
-mutated	O
lung	O
cancer	O
.	O


Most	O
common	O
grade	O
≥3	B-OUT
drug-related	I-OUT
AEs	I-OUT
(	O
DRAEs	O
)	O
were	B-OUT
rash/acne	I-OUT
(	O
18	O
%	O
versus	O
8.3	B-OUT
%	I-OUT
)	I-OUT
,	I-OUT
diarrhea	I-OUT
(	O
14.8	O
%	O
versus	O
0	O
%	O
)	O
,	O
and	B-OUT
stomatitis/mucositis	I-OUT
(	O
11.5	O
%	O
versus	O
0	O
%	O
)	O
with	O
afatinib	O
and	O
cetuximab	O
,	O
respectively	O
.	O


CDP571	B-I
,	O
a	O
humanized	O
monoclonal	O
antibody	O
to	O
tumour	O
necrosis	O
factor-alpha	O
,	O
for	O
steroid-dependent	O
Crohn	O
's	O
disease	O
:	O
a	O
randomized	O
,	O
double-blind	O
,	O
placebo-controlled	B-I
trial	O
.	O


CONCLUSIONS	O
CDP571	B-I
was	O
ineffective	O
for	O
sparing	B-OUT
steroids	I-OUT
in	O
patients	B-P
with	I-P
steroid-dependent	I-P
Crohn	I-P
's	I-P
disease	I-P
.	I-P


Effects	O
of	O
supervised	B-I
exercise	I-I
therapy	I-I
in	O
patients	B-P
receiving	I-P
radiotherapy	I-I
for	I-P
breast	I-P
cancer	I-P
.	I-P


CONCLUSION	O
Patients	B-P
receiving	I-P
radiotherapy	I-I
for	I-P
breast	I-P
cancer	I-P
may	O
benefit	O
in	O
physical	O
and	O
psychological	O
aspects	O
from	O
supervised	B-I
moderate-intensity	I-I
exercise	I-I
therapy	I-I
.	I-I


The	O
outcome	O
of	O
patients	B-P
with	I-P
rectal	I-P
cancer	I-P
treated	I-P
by	I-P
abdominoperineal	I-I
or	I-I
anterior	I-I
resection	I-I
,	I-I
with	I-I
or	I-I
without	I-I
preoperative	I-I
radiotherapy	I-I
,	O
was	O
assessed	O
to	O
detect	O
any	O
differences	O
attributable	O
to	O
the	O
operative	O
method	O
and	O
interactions	O
between	O
radiotherapy	O
and	O
type	O
of	O
surgery	O
.	O


Sphincter-saving	B-I
procedures	I-I
appear	O
to	O
have	O
no	O
adverse	O
effects	O
on	O
outcome	O
of	O
rectal	B-P
cancer	I-P
,	O
but	O
the	O
optimum	O
use	O
of	O
radiotherapy	O
is	O
still	O
to	O
be	O
defined	O
.	O


The	O
treatment	O
lasted	O
12	O
weeks	O
.	O


Based	O
on	O
the	O
results	O
of	O
this	O
study	O
,	O
it	O
is	O
suggested	O
that	O
routine	O
administration	O
of	O
antidepressants	B-OUT
and	I-OUT
antianxiety	I-OUT
drugs	O
should	O
be	O
carried	O
out	O
in	O
senile	B-P
hypertensive	I-P
patients	I-P
complicating	O
with	O
depression	O
or	O
anxiety	O
.	O


Few	O
adverse	B-OUT
events	I-OUT
were	O
noted	O
.	O


Dopexamine	B-I
has	O
no	O
additional	O
benefit	O
in	O
high-risk	B-P
patients	I-P
receiving	I-P
goal-directed	I-I
fluid	I-I
therapy	I-I
undergoing	I-I
major	I-I
abdominal	I-I
surgery	I-I
.	I-I


In	O
this	O
study	O
,	O
we	O
assessed	O
the	O
effects	O
of	B-I
low-dose	I-I
dopexamine	I-I
on	O
morbidity	O
after	B-I
major	I-I
abdominal	I-I
surgery	I-I
in	I-P
patients	I-P
who	I-P
were	I-P
at	I-P
increased	I-P
risk	I-P
by	I-P
virtue	I-P
of	I-P
a	I-P
reduced	I-P
AT	O
.	O


Patients	O
were	O
given	O
a	O
250-mL	O
bolus	B-I
of	I-I
Voluven	I-I
(	I-I
6	I-I
%	I-I
hydroxyethyl	I-I
starch	I-I
130/0.4	I-I
in	I-I
0.9	I-I
%	I-I
sodium	I-I
chloride	I-I
)	I-I
until	O
the	O
stroke	O
volume	O
no	O
longer	O
increased	O
by	O
10	O
%	O
,	O
then	O
received	O
either	B-I
dopexamine	I-I
(	O
0.5	O
μg	O
·	O
kg	O
(	O
-1	O
)	O
·	O
min	B-I
(	I-I
-1	I-I
)	I-I
)	I-I
or	O
saline	O
0.9	O
%	O
for	O
24	O
hours	O
.	O


There	O
was	O
no	O
significant	O
reduction	B-OUT
in	I-OUT
morbidity	O
on	O
any	O
measured	O
postoperative	B-OUT
day	I-OUT
.	I-OUT


CONCLUSION	O
With	O
the	O
effective	B-I
use	I-I
of	I-I
goal-directed	I-I
fluid	I-I
therapy	I-P
in	I-P
elective	I-P
surgical	I-P
patients	O
,	O
the	O
routine	B-I
use	I-I
of	I-I
dopexamine	O
does	O
not	O
confer	O
an	O
additional	O
clinical	O
benefit	O
.	O


METHODS	O
A	B-P
total	I-P
of	I-P
20	I-P
patients	I-P
(	I-P
2-18	I-P
years	I-P
)	I-P
fasted	I-I
for	I-P
14	I-P
h	I-P
(	I-P
22.00-12.00	I-P
h	I-P
)	I-P
on	I-P
two	I-P
occasions	I-P
as	O
part	O
of	O
a	O
randomized	O
cross-over	O
study	O
.	O


RESULTS	O
BG	O
was	O
related	O
to	O
age	B-OUT
and	I-OUT
body	I-OUT
mass	I-OUT
index	I-OUT
on	O
treatment	O
but	O
no	O
subject	O
became	O
hypoglycaemic	O
on	O
or	O
off	O
therapy	O
prior	O
to	O
07.00	O
h.	O
Five	O
children	O
(	O
aged	O
3	O
,	O
4	O
,	O
7	O
,	O
8	O
and	O
11	O
years	O
)	O
were	O
hypoglycaemic	B-OUT
between	O
07.00	O
and	O
12.00	O
h	O
off	O
treatment	O
.	O


Noradrenaline	B-OUT
levels	I-OUT
were	O
reduced	O
in	O
patients	B-P
with	I-P
PHDC-	I-P
.	I-P


Patients	B-P
with	I-P
PHD	I-P
have	O
altered	O
sympathetic	B-OUT
nerve	I-OUT
activity	I-OUT
.	I-OUT


Statistically	O
significant	O
differences	O
were	O
found	O
between	O
TIMP	B-I
and	O
TOT	B-I
when	O
measuring	O
their	O
effects	O
on	O
perceived	B-OUT
exertion	I-OUT
and	I-OUT
perceived	I-OUT
fatigue	I-OUT
.	I-OUT


Development	O
,	O
description	O
,	O
and	O
acceptability	O
of	O
a	O
small-group	B-I
,	I-I
behavioral	I-I
intervention	I-I
to	O
prevent	O
HIV	O
and	O
hepatitis	O
C	O
virus	O
infections	O
among	O
young	B-P
adult	I-P
injection	I-P
drug	I-P
users	I-P
.	I-P


Minimal	O
evidence	O
of	O
contamination	B-OUT
was	O
found	O
.	O


The	O
proportions	B-OUT
of	O
depressed	B-OUT
(	O
p	O
<	O
0.01	O
)	O
and	O
anxious	B-OUT
(	O
p=0.04	O
)	O
patients	O
were	O
also	O
smaller	O
in	O
the	O
group	O
who	O
were	O
operated	O
on	O
.	O


aureus	O
exopolysaccharides	O
;	O
and	O
inactivated	O
,	O
unencapsulated	O
Staph	O
,	O
aureus	O
and	O
Streptococcus	O
spp	O
.	O


METHODS	O
The	O
study	O
was	O
conducted	O
with	O
21	B-P
children	I-P
with	I-P
Autism	I-P
Spectrum	I-P
Disorder	I-P
diagnoses	I-P
,	O
randomly	O
allocated	O
into	O
two	O
groups	O
,	O
who	B-I
received	I-I
the	I-I
same	I-I
short-term	I-I
intervention	I-I
types	I-I
(	I-I
6	I-I
weeks	I-I
with	I-I
the	I-I
mother	I-I
and	I-I
6	I-I
weeks	I-I
with	I-I
the	I-I
support	I-I
of	I-I
an	I-I
educational	I-I
software	I-I
program	I-I
)	I-I
.	I-I


Stapled	B-I
mucosectomy	I-I
for	O
acute	O
thrombosed	O
circumferentially	O
prolapsed	O
piles	O
:	O
a	O
prospective	O
randomized	O
comparison	O
with	O
conventional	B-I
haemorrhoidectomy	I-I
.	I-I


Although	O
postoperative	B-OUT
stay	I-OUT
and	I-OUT
in-hospital	I-OUT
analgesia	I-OUT
were	O
the	O
same	O
,	O
patients	B-P
from	O
the	O
stapled	B-I
group	I-I
reported	O
significantly	O
more	O
pain	O
at	O
discharge	O
.	O


However	O
,	O
by	O
2	O
weeks	O
the	O
conventional	B-I
group	I-I
reported	O
significantly	O
higher	B-OUT
pain	I-OUT
scores	I-OUT
particularly	O
on	O
passing	O
stool	O
.	O


CONCLUSION	O
Stapled	B-I
mucosectomy	I-I
for	O
acute	O
thrombosed	O
circumferential	O
piles	O
is	O
feasible	O
and	O
may	O
result	O
in	O
less	B-OUT
pain	I-OUT
,	O
a	O
more	O
rapid	O
resolution	O
of	O
symptoms	O
and	O
an	O
earlier	O
return	O
to	O
work	O
compared	O
with	O
a	O
conventional	B-I
procedure	I-I
.	I-I


The	O
Pain	O
Course	O
:	O
a	O
randomised	O
controlled	O
trial	O
of	O
a	O
clinician-guided	B-I
Internet-delivered	I-I
cognitive	I-I
behaviour	I-I
therapy	I-I
program	I-I
for	I-P
managing	I-P
chronic	I-P
pain	I-P
and	I-P
emotional	I-P
well-being	I-P
.	I-P


Overall	O
,	O
the	O
clinician	O
spent	O
a	O
total	B-OUT
mean	I-OUT
time	I-OUT
of	O
81.54	O
minutes	O
(	O
SD	O
30.91	O
minutes	O
)	O
contacting	O
participants	O
during	O
the	O
program	O
.	O


The	O
results	O
appear	O
better	O
than	O
those	O
reported	O
in	O
iCBT	B-I
studies	O
to	O
date	O
and	O
provide	O
support	O
for	O
the	O
potential	O
of	O
clinician-guided	B-I
iCBT	I-I
in	O
the	O
treatment	O
of	O
disability	B-OUT
,	I-OUT
anxiety	I-OUT
,	I-OUT
and	I-OUT
depression	I-OUT
for	I-OUT
people	I-OUT
with	I-OUT
chronic	I-OUT
pain	I-OUT
.	I-OUT


CONCLUSION	O
Improvements	O
to	O
whole	O
body	O
insulin	O
sensitivity	O
after	O
short-term	B-I
aerobic	I-I
exercise	I-I
training	O
are	O
due	O
to	O
gains	O
in	O
peripheral	O
,	O
not	O
heptic	O
insulin	O
sensitivity	O
.	O


Supplementation	B-I
with	I-I
iron	I-I
and	I-I
riboflavin	I-I
enhances	O
dark	O
adaptation	O
response	O
to	O
vitamin	B-I
A-fortified	I-I
rice	I-I
in	O
iron-deficient	B-P
,	I-P
pregnant	I-P
,	I-P
nightblind	I-P
Nepali	I-P
women	I-P
.	I-P


OBJECTIVE	O
The	O
objective	O
was	O
to	O
assess	O
the	O
effect	O
of	O
supplemental	B-I
iron	I-I
and	I-I
riboflavin	I-I
on	O
pupillary	O
threshold	O
(	O
PT	O
)	O
and	O
plasma	O
retinol	O
in	O
nightblind	O
,	O
pregnant	B-P
Nepali	I-P
women	I-P
given	I-P
vitamin	I-P
A-fortified	I-P
rice	I-P
.	I-P


CONCLUSIONS	O
Iron	O
deficiency	O
may	O
limit	O
the	O
efficacy	O
of	O
vitamin	B-I
A	I-I
to	O
normalize	O
dark	O
adaptation	O
in	O
pregnant	B-P
Nepali	I-P
women	I-P
.	I-P


METHODS	O
Sixty	B-P
patients	I-P
aged	I-P
18	I-P
years	I-P
or	I-P
older	I-P
with	I-P
unresectable	I-P
upper	I-P
abdominal	I-P
cancers	I-P
were	O
randomized	O
into	O
two	O
groups	O
to	O
receive	O
USCPN	O
.	O


Subjects	O
were	O
assessed	O
for	O
the	B-OUT
pain	I-OUT
relief	I-OUT
using	O
Numerical	O
rating	O
scale	O
(	O
NRS	O
)	O
to	O
assess	O
their	O
pain	O
relief	O
.	O


RESULTS	O
Baseline	O
parameters	O
being	O
comparable	O
(	O
P	O
>	O
0.05	O
)	O
,	O
the	O
site	O
of	O
drug	O
injections	O
(	O
single	O
or	O
double	O
needle	O
)	O
had	O
no	O
bearing	O
on	O
the	O
onset	O
of	B-OUT
pain	I-OUT
relief	I-OUT
and	I-OUT
patient	I-OUT
satisfaction	I-OUT
scores	I-OUT
(	O
P	O
>	O
0.05	B-OUT
)	I-OUT
.	I-OUT


Pain	B-OUT
relief	I-OUT
during	O
follow-up	O
visits	O
was	O
comparable	O
between	O
the	O
two	O
groups	O
(	O
P	O
>	O
0.05	O
)	O
.	O


CONCLUSIONS	O
Minor	B-OUT
RMT	I-OUT
changes	I-OUT
during	O
rTMS	B-I
treatment	O
do	O
not	O
necessarily	O
suggest	O
the	O
need	O
for	O
systematic	O
re-examination	O
of	O
the	O
RMT	O
for	O
safety	O
and	O
efficacy	O
issues	O
.	O


PURPOSE	O
The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
compare	O
the	O
efficacies	B-OUT
of	O
0.3	O
%	O
ofloxacin	O
eyedrops	O
,	O
when	O
given	O
twice-a-day	O
(	O
BID	O
)	O
versus	O
four-times-a-day	O
(	O
QID	O
)	O
,	O
for	O
the	O
treatment	O
of	O
external	O
ocular	O
disease	O
.	O


There	O
was	O
a	O
significant	O
decrease	O
in	O
clinical	B-OUT
scores	I-OUT
in	O
the	O
BID	O
and	O
QID	O
groups	O
by	O
days	O
3	O
to	O
5	O
(	O
2.6-3.0	O
points	O
)	O
and	O
a	O
further	O
decrease	O
by	O
day	O
11	O
(	O
4.3-5.0	O
points	O
)	O
.	O


There	O
was	O
no	O
significant	O
difference	O
between	O
the	O
two	O
groups	O
at	O
any	O
time	O
interval	O
.	O


In	O
study	O
II	O
,	O
normalized	O
MEG-X	B-I
test	O
results	O
(	O
ranging	O
from	O
<	O
or	O
=	O
4	O
to	O
120	O
microg/L	O
)	O
were	O
virtually	O
identical	O
to	O
the	O
standard	O
test	O
results	O
(	O
mean	O
difference	O
:	O
-1.9	O
microg/L	O
;	O
95	O
%	O
confidence	O
interval	O
[	O
CI	O
]	O
:	O
-5.3	O
;	O
1.5	O
microg/L	O
)	O
.	O


Groups	O
did	O
not	O
differ	O
significantly	O
(	O
p	O
>	O
0.49	O
)	O
with	O
respect	O
to	O
this	O
outcome	O
.	O


There	O
were	O
no	O
significant	O
differences	O
between	O
the	O
three	O
groups	O
with	O
respect	O
to	O
requirements	B-OUT
for	I-OUT
supplemental	I-OUT
pain	I-OUT
medications	I-OUT
in	O
the	O
recovery	O
room	O
,	O
incidence	B-OUT
of	I-OUT
postoperative	I-OUT
vomiting	I-OUT
,	I-OUT
or	I-OUT
length	I-OUT
of	I-OUT
time	I-OUT
spent	I-OUT
in	I-OUT
the	I-OUT
recovery	I-OUT
room	I-OUT
.	I-OUT


CONCLUSION	O
Topical	O
bupivacaine	B-I
decreases	O
postoperative	O
pain	O
scores	O
significantly	O
compared	O
with	O
placebo	B-I
in	O
women	O
undergoing	O
laparoscopic	O
tubal	O
sterilization	O
with	O
silastic	O
bands	O
.	O


The	B-OUT
AF	I-OUT
frequency	I-OUT
decreased	O
similarly	O
in	O
both	O
groups	O
,	O
and	O
there	O
was	O
no	O
significant	O
difference	O
in	O
the	O
primary	O
endpoint	O
between	O
the	O
two	O
groups	O
.	O


A	O
simplified	O
4-site	O
economical	O
intradermal	O
post-exposure	O
rabies	B-I
vaccine	I-I
regimen	I-P
:	I-P
a	O
randomised	O
controlled	O
comparison	O
with	O
standard	O
methods	O
.	O


PDE5	O
inhibition	O
,	O
by	O
blocking	O
degradation	O
of	O
nitric	O
oxide	O
second-messenger	O
cyclic	O
guanosine	O
monophosphate	O
,	O
might	O
be	O
beneficial	O
.	O


In	O
the	O
sildenafil	O
group	O
only	O
,	O
at	O
6	O
months	O
and	O
1	O
year	O
,	O
LV	B-OUT
ejection	I-OUT
fraction	I-OUT
,	I-OUT
early	I-OUT
diastolic	I-OUT
tissue	I-OUT
Doppler	I-OUT
velocities	I-OUT
(	I-OUT
E	I-OUT
'	I-OUT
)	I-OUT
at	I-OUT
the	I-OUT
mitral	I-OUT
lateral	I-OUT
(	O
from	O
4.62	O
to	O
5.20	O
and	O
5.19	O
m/s	O
)	O
and	O
septal	B-OUT
(	O
from	O
4.71	O
to	O
5.23	O
and	O
5.24	O
m/s	O
)	O
annuli	B-OUT
significantly	I-OUT
increased	O
,	O
whereas	O
the	O
ratio	O
of	O
early	O
transmitral	O
(	O
E	O
)	O
to	O
E	O
'	O
lateral	O
decreased	O
(	O
from	O
13.1	O
to	O
9.8	O
to	O
9.4	O
)	O
(	O
P	O
<	O
0.01	O
)	O
.	O


CITATION	O
Krenk	O
L	O
;	O
Jennum	O
P	O
;	O
Kehlet	O
H.	O
Postoperative	O
sleep	O
disturbances	O
after	O
zolpidem	O
treatment	O
in	O
fast-track	O
hip	O
and	O
knee	O
replacement	O
.	O


Furthermore	O
,	O
the	O
addition	O
of	O
protein	B-I
to	I-I
a	I-I
carbohydrate	I-I
supplement	I-I
will	O
enhance	O
the	O
insulin	O
response	O
of	O
a	O
carbohydrate	O
supplement	O
.	O


Nine	B-P
trained	I-P
cyclists	I-P
exercised	O
on	O
3	O
separate	O
occasions	O
at	O
intensities	O
that	O
varied	O
between	O
45	O
%	O
and	O
75	O
%	O
VO2max	O
for	O
3	O
h	O
and	O
then	O
at	O
85	O
%	O
VO2max	O
until	O
fatigued	O
.	O


Carbohydrate	O
supplementation	O
significantly	O
increased	O
time	B-OUT
to	I-OUT
exhaustion	I-OUT
(	O
carbohydrate	O
19.7	O
+/-	O
4.6	O
min	O
vs.	O
placebo	O
12.7	O
+/-	O
3.1	O
min	O
)	O
,	O
while	O
the	O
addition	O
of	O
protein	O
enhanced	O
the	O
effect	O
of	O
the	O
carbohydrate	O
supplement	O
(	O
carbohydrate-protein	O
26.9	O
+/-	O
4.5	O
min	O
,	O
p	O
<	O
.05	O
)	O
.	O


This	O
study	O
investigated	O
differences	O
between	O
the	O
symptoms	O
associated	O
with	O
either	O
adjuvant	B-I
tamoxifen	I-I
or	I-I
exemestane	I-I
.	I-I


Symptoms	O
were	O
common	O
in	O
both	O
groups	O
.	O


Aerobic	B-I
exercise	I-I
improves	O
self-reported	B-OUT
sleep	I-OUT
and	I-OUT
quality	I-OUT
of	I-OUT
life	I-OUT
in	O
older	B-P
adults	I-P
with	I-P
insomnia	I-P
.	I-P


Ten	B-P
dogs	I-P
were	I-P
anesthetized	I-P
with	I-P
sevoflurane	I-I
and	I-P
nine	I-P
dogs	I-P
were	I-P
anesthetized	I-P
with	I-P
isoflurane	I-I
.	I-I


Eighteen	O
dogs	O
were	O
instrumented	O
with	O
a	O
dorsal	O
pedal	O
arterial	O
catheter	O
,	O
and	O
one	O
dog	O
had	O
a	O
femoral	O
arterial	O
catheter	O
.	O


Treadmill	B-I
exercise	I-I
testing	I-I
with	O
measurement	O
of	O
expired	B-OUT
gas	I-OUT
exchange	I-OUT
and	I-OUT
respiratory	I-OUT
flow	I-OUT
was	O
performed	O
before	O
ablation	O
and	O
4	O
weeks	O
after	O
pacemaker	O
implantation	O
,	O
with	O
the	O
pacemaker	O
programmed	O
to	O
both	O
the	O
fixed-rate	O
VVI	O
and	O
rate-modulating	O
minute	O
ventilation	O
VVIR	O
pacing	O
modes	O
in	O
random	O
sequence	O
.	O


The	O
primary	O
outcome	O
is	O
change	B-OUT
in	I-OUT
6-minute	I-OUT
walk	I-OUT
distance	I-OUT
immediately	O
following	O
intervention	O
.	O


Measurements	O
of	O
exercise	B-OUT
capacity	I-OUT
,	I-OUT
physical	I-OUT
activity	I-OUT
,	I-OUT
symptoms	I-OUT
and	I-OUT
quality	I-OUT
of	I-OUT
life	I-OUT
will	O
be	O
taken	O
at	O
baseline	O
,	O
immediately	O
following	O
the	O
intervention	O
and	O
at	O
12	O
months	O
,	O
by	O
a	O
blinded	O
assessor	O
.	O


Other	O
aspects	O
of	O
therapy	O
were	O
constant	O
.	O


These	O
observations	O
need	O
to	O
be	O
confirmed	O
by	O
blind-controlled	O
studies	O
in	O
larger	O
numbers	O
of	O
patients	O
with	O
mild	O
as	O
well	O
as	O
severe	O
respiratory	O
involvement	O
.	O


We	O
postulated	O
that	O
this	O
drug	O
might	O
reduce	O
mortality	O
in	O
patients	B-P
at	I-P
high	I-P
risk	I-P
of	I-P
death	I-P
after	O
myocardial	O
infarction	O
because	O
of	O
impaired	O
ventricular	O
function	O
,	O
irrespective	O
of	O
whether	O
they	O
had	O
ventricular	O
arrhythmias	O
.	O


Intention-to-treat	O
and	O
on-treatment	O
analyses	O
were	O
done	O
.	O


INTERPRETATION	O
Our	O
findings	O
do	O
not	O
support	O
the	O
systematic	O
prophylactic	O
use	O
of	O
amiodarone	B-I
in	O
all	O
patients	O
with	O
depressed	O
left-ventricular	O
function	O
after	O
myocardial	O
infarction	O
.	O


A	O
continuous	O
score	O
that	O
represents	O
the	O
residual	O
difference	O
between	O
these	O
two	O
components	O
was	O
derived	O
that	O
only	O
requires	O
measurement	O
of	O
medial	O
E	O
:	O
e	O
'	O
and	O
s	O
'	O
.	O


Before	O
treatment	O
,	O
TSAb	B-OUT
ranging	O
from	O
170	O
to	O
1529	O
%	O
was	O
present	O
in	O
28/29	O
patients	O
and	O
reached	O
significantly	O
low	O
levels	O
at	O
the	O
end	O
of	O
treatment	O
whatever	O
its	O
duration	O
.	O


End-treatment	B-OUT
TSAb	I-OUT
values	I-OUT
,	O
when	O
low	O
(	O
less	O
than	O
350	O
%	O
)	O
or	O
negative	O
did	O
not	O
correlate	O
with	O
later	O
evolution	O
:	O
in	O
these	O
39	O
patients	O
,	O
relapse	B-OUT
rate	I-OUT
was	O
41	O
%	O
.	O


The	O
mean	B-OUT
hemoglobin	I-OUT
and	I-OUT
hematocrit	I-OUT
were	O
similar	O
in	O
the	O
two	O
groups	O
until	O
the	O
third	O
trimester	O
but	O
thereafter	O
were	O
higher	O
(	O
p	O
<	O
0.05	O
)	O
in	O
the	O
hematinic	O
group	O
.	O


AIM	O
This	O
study	O
was	O
carried	O
out	O
to	O
determine	O
the	O
effect	O
of	O
injection	O
duration	O
on	O
bruising	O
and	O
pain	O
following	O
the	O
administration	O
of	O
the	O
subcutaneous	O
injection	O
of	O
heparin	B-I
.	I-I


BACKGROUND	O
Although	O
different	O
methods	O
to	O
prevent	O
bruising	O
and	O
pain	O
following	O
the	O
subcutaneous	O
injection	O
of	O
heparin	B-I
have	O
been	O
widely	O
studied	O
and	O
described	O
,	O
the	O
effect	O
of	O
injection	O
duration	O
on	O
the	O
occurrence	O
of	O
bruising	O
and	O
pain	O
is	O
little	O
documented	O
.	O


Data	O
were	O
analysed	O
using	O
chi-square	O
test	O
,	O
Mann-Whitney	O
U	O
,	O
Wilcoxon	O
signed	O
ranks	O
tests	O
and	O
correlation	O
.	O


Indobufen	B-I
was	O
also	O
able	O
to	O
reduce	O
platelet	B-OUT
adhesiveness	I-OUT
and	O
to	O
lengthen	O
bleeding	B-OUT
time	I-OUT
,	O
especially	O
when	O
the	O
higher	O
dosage	O
was	O
used	O
.	O


The	O
Steward	O
recovery	O
score	O
was	O
also	O
recorded	O
every	O
five	O
minutes	O
during	O
the	O
first	O
20	O
minutes	O
postoperatively	O
and	O
then	O
every	O
10	O
to	O
15	O
minutes	O
.	O


Groups	O
were	O
similar	O
regarding	O
patient	O
characteristics	O
,	O
depth	O
of	O
anaesthesia	O
,	O
sufentanil	O
total	O
dose	O
,	O
anaesthesia	O
duration	O
(	O
D	O
:	O
349.1	O
+/-	O
19.1	O
min	O
;	O
I	O
:	O
349.2	O
+/-	O
22.9	O
min	O
)	O
,	O
haemodynamic/respiratory	O
parameters	O
,	O
and	O
surgical	O
conditions	O
(	O
assessed	O
by	O
a	O
bleeding	O
score	O
)	O
.	O


Full	B-OUT
recovery	I-OUT
also	O
occurred	O
earlier	O
in	O
the	O
D	O
group	O
(	B-OUT
D	I-OUT
:	I-OUT
22.1	I-OUT
+/-	I-OUT
3.1	I-OUT
min	I-OUT
vs	I-OUT
I	I-OUT
:	I-OUT
37.6	I-OUT
+/-	I-OUT
4.0	I-OUT
min	I-OUT
,	I-OUT
P	I-OUT
<	I-OUT
0.005	I-OUT
for	I-OUT
stating	I-OUT
name	I-OUT
)	I-OUT
.	O


The	O
proportion	O
of	O
patients	O
(	O
95	O
%	O
CI	O
)	O
achieving	B-OUT
a	I-OUT
therapeutic	I-OUT
glycaemic	I-OUT
response	I-OUT
(	O
HbA	O
(	O
1c	O
)	O
<	O
7	O
%	O
)	O
:	O
43.8	O
%	O
(	O
34.8	O
,	O
49.6	O
)	O
(	O
SAXA-MET	O
)	O
vs.	O
35.0	O
%	O
(	O
29.0	O
,	O
43.8	O
)	O
(	O
MET-UP	O
)	O
.	O


These	O
patients	O
were	O
allocated	O
at	O
random	O
to	O
two	O
groups	O
,	O
one	B-I
of	I-I
which	I-I
was	I-I
given	I-I
treatment	I-I
for	I-I
8	I-I
days	I-I
and	I-I
the	I-I
other	I-I
for	I-I
15	I-I
days	I-I
.	I-I


No	O
significant	O
differences	B-OUT
in	I-OUT
mortality	I-OUT
,	I-OUT
morbidity	I-OUT
or	I-OUT
incapacity	I-OUT
for	I-OUT
work	I-OUT
could	O
be	O
detected	O
during	O
the	O
three-month	O
period	O
of	O
follow-up	O
.	O


When	O
compared	O
with	O
the	O
baseline	O
values	O
,	O
all	O
measured	O
variables	O
at	O
60	O
months	O
improved	O
significantly	O
(	O
p	O
<	O
0.0001	O
)	O
.	O


The	O
results	O
therefore	O
might	O
provide	O
a	O
more	O
appropriate	O
frame	O
of	O
reference	O
for	O
interpretation	O
of	O
the	O
responses	B-OUT
to	I-OUT
symptom-limited	I-OUT
ramp	I-OUT
incremental	I-OUT
cycle	I-OUT
ergometry	I-OUT
in	O
sedentary	B-P
subjects	I-P
;	I-P
i.e	O
.	O


Measures	O
collected	O
1	O
week	O
before	O
and	O
4	O
weeks	O
after	O
infusion	O
included	O
autism	B-OUT
symptoms	I-OUT
,	I-OUT
language	I-OUT
skills	I-OUT
,	I-OUT
and	I-OUT
problem	I-OUT
behaviors	I-OUT
,	I-OUT
gathered	I-OUT
from	I-OUT
parents	I-OUT
,	I-OUT
teachers	I-OUT
,	I-OUT
and	I-OUT
investigators	I-OUT
,	O
who	O
were	O
all	O
blind	O
to	O
treatment	O
.	O


The	O
current	O
study	O
sought	O
to	O
address	O
these	O
issues	O
by	O
examining	O
how	O
individual	O
differences	O
in	O
alcohol	O
consequences	O
influence	O
outcomes	O
of	O
a	O
laboratory-based	B-I
computerized	I-I
intervention	I-I
.	I-I


INTERVENTIONS	O
Total	B-I
laparoscopic	I-I
hysterectomy	I-I
for	I-I
benign	I-I
pathology	I-I
.	I-I


Statistical	O
differences	O
were	O
found	O
between	O
groups	O
concerning	O
uterine	B-OUT
weight	I-OUT
,	I-OUT
operating	I-OUT
time	I-OUT
,	I-OUT
and	I-OUT
drop	I-OUT
in	I-OUT
hemoglobin	I-OUT
level	I-OUT
.	I-OUT


MEASUREMENTS	O
Self-reported	B-OUT
Physical	I-OUT
function	I-OUT
,	I-OUT
physical	I-OUT
performance	I-OUT
tests	I-OUT
,	I-OUT
health	I-OUT
care	I-OUT
utilization	I-OUT
,	I-OUT
and	I-OUT
health	I-OUT
behaviors	I-OUT
.	I-OUT


The	O
number	B-OUT
of	I-OUT
hospitalized	I-OUT
participants	I-OUT
increased	O
by	O
69	O
%	O
among	O
the	O
controls	O
and	O
decreased	O
by	O
38	O
%	O
in	O
the	O
intervention	O
group	O
(	O
P	O
=	O
.083	O
)	O
.	O


CONCLUSIONS	O
This	O
project	O
provides	O
evidence	O
that	O
a	O
community-based	O
collaboration	O
with	O
primary	O
care	O
providers	O
can	O
improve	B-OUT
function	I-OUT
and	I-OUT
reduce	I-OUT
inpatient	I-OUT
utilization	I-OUT
in	O
chronically	B-P
ill	I-P
older	I-P
adults	I-P
.	I-P


We	O
analyzed	O
17	O
health	O
behaviors	O
of	O
those	O
who	O
attended	O
the	O
first	O
session	O
and	O
those	O
who	O
did	O
not	O
.	O


Thus	O
,	O
we	O
found	O
neither	O
"	O
favorable	O
"	O
nor	O
"	O
unfavorable	O
"	O
selection	O
bias	O
in	O
the	O
use	O
of	O
these	O
preventive	O
services	O
.	O


Prevention	O
of	O
subsequent	O
exercise-induced	B-OUT
periinfarct	I-OUT
ischemia	I-OUT
by	O
emergency	B-I
coronary	I-I
angioplasty	I-I
in	O
acute	B-P
myocardial	I-P
infarction	I-P
:	I-P
comparison	O
with	O
intracoronary	B-I
streptokinase	I-I
.	I-I


These	O
results	O
suggest	O
further	O
application	O
of	O
coronary	B-I
angioplasty	I-I
in	O
the	O
management	O
of	O
acute	B-P
myocardial	I-P
infarction	I-P
.	I-P


Results	O
The	O
daytime	B-OUT
systolic/diastolic	I-OUT
ABP	I-OUT
response	I-OUT
to	O
HCT	O
was	O
4.9	O
[	O
95	O
%	O
confidence	O
interval	O
(	O
CI	O
)	O
1.2-8.6	O
]	O
/3.6	O
(	O
1.0-6.2	O
)	O
mmHg	O
for	O
men	O
and	O
12.9	O
(	O
9.2-16.6	O
)	O
/6.3	O
(	O
3.7-8.8	O
)	O
mmHg	O
for	O
women	O
.	O


The	O
night-time	B-OUT
systolic/diastolic	I-OUT
response	I-OUT
to	O
HCT	B-I
was	O
5.0	O
(	O
0.6-9.4	O
)	O
/2.7	O
[	O
(	O
-0.4	O
)	O
-5.7	O
]	O
mmHg	O
for	O
men	O
and	O
11.5	O
(	O
7.1-16.0	O
)	O
/5.7	O
(	O
2.6-8.8	O
)	O
mmHg	O
for	O
women	O
,	O
and	O
to	O
LIS	B-I
was	O
18.7	O
(	O
14.2-22.1	O
)	O
/15.4	O
(	O
12.4-18.5	O
)	O
mmHg	O
for	O
men	O
and	O
3.5	O
[	O
(	O
-1.0	O
)	O
-7.9	O
]	O
/2.3	O
[	O
(	O
-0.8	O
)	O
-5.4	O
]	O
mmHg	O
for	O
women	O
.	O


Overall	O
,	O
individual	O
or	O
total	O
lignans	O
or	O
proanthocyanidins	O
were	O
not	O
associated	O
with	O
colorectal	B-OUT
adenoma	I-OUT
recurrence	I-OUT
.	I-OUT


The	O
effects	O
of	O
physical	B-I
and	I-I
emotional	I-I
status	I-I
on	O
adherence	O
to	O
a	O
low-fat	B-I
dietary	I-I
pattern	I-I
in	O
the	O
Women	O
's	O
Health	O
Initiative	O
.	O


Additional	O
findings	O
included	O
that	O
a	O
10	O
%	O
increase	O
in	O
physical	B-OUT
functioning	I-OUT
increased	O
session	B-OUT
attendance	I-OUT
by	O
0.4	O
%	O
(	O
P	O
<	O
.001	O
)	O
and	O
a	O
10	O
%	O
increase	O
in	O
mental	B-OUT
health	I-OUT
predicted	O
a	O
decrease	O
in	O
percent	O
energy	B-OUT
from	I-OUT
fat	I-OUT
of	O
0.3	O
%	O
(	O
P	O
<	O
.001	O
)	O
.	O


Dependent	O
measures	O
were	O
parent	O
and	O
teacher	O
Clinical	B-OUT
Global	I-OUT
Impressions	I-OUT
(	I-OUT
CGI	I-OUT
)	I-OUT
and	O
Naltrexone	B-OUT
Side	I-OUT
Effects	I-OUT
Rating	I-OUT
Scale	I-OUT
(	I-OUT
SE	I-OUT
)	I-OUT
,	I-OUT
Conners	I-OUT
Parent	I-OUT
Impulsivity/Hyperactivity	I-OUT
Factor	I-OUT
,	I-OUT
Teacher	I-OUT
Hyperactivity	I-OUT
Factor	I-OUT
,	O
laboratory	O
CGI	O
,	O
and	O
analysis	O
of	O
videotaped	O
behavior	O
.	O


Administering	O
naltrexone	B-I
was	O
a	O
challenge	O
.	O


BACKGROUND	O
Although	O
indomethacin	B-I
is	O
effective	O
in	O
preventing	O
heterotopic	B-OUT
ossification	I-OUT
(	I-OUT
HO	I-OUT
)	I-OUT
after	O
primary	B-P
total	I-P
hip	I-P
arthroplasty	I-P
,	O
side	B-OUT
effects	I-OUT
are	O
frequently	O
observed	O
.	O


HO	B-OUT
was	I-OUT
graded	I-OUT
according	O
to	O
the	O
1-year	O
postoperative	O
radiographs	O
according	O
to	O
the	O
Brooker	O
classification	O
.	O


INTERPRETATION	O
The	O
prophylactic	O
effect	O
of	O
rofecoxib	B-I
for	O
7	O
days	O
in	O
preventing	O
heterotopic	O
ossification	O
after	O
primary	O
total	O
hip	O
arthroplasty	O
is	O
comparable	O
to	O
the	O
effect	O
of	O
indomethacin	B-I
given	O
for	O
7	O
days	O
.	O


A	O
randomized	O
controlled	O
trial	O
of	O
acellular	B-I
diphtheria/pertussis/tetanus	I-I
(	I-I
ADPT	I-I
)	I-I
freeze-dried	I-I
and	I-I
liquid	I-I
vaccines	I-I
in	I-P
infants	I-P
was	I-P
conducted	I-P
in	I-P
a	I-P
peri-urban	I-P
community	I-P
(	I-P
Ashaiman	I-P
)	I-P
in	I-P
southern	I-P
Ghana	I-P
.	I-P


The	O
acellular	O
vaccines	O
produced	O
significantly	O
fewer	O
local	B-OUT
and	I-OUT
systemic	I-OUT
reactions	I-OUT
.	I-OUT


Geometric	B-OUT
mean	I-OUT
titres	I-OUT
(	I-OUT
GMTs	I-OUT
)	I-OUT
,	O
measured	O
by	O
ELISA	B-OUT
,	O
to	O
pertussis	B-OUT
toxin	I-OUT
(	I-OUT
PT	I-OUT
)	I-OUT
and	I-OUT
filamentous	I-OUT
haemagglutinin	I-OUT
(	I-OUT
FHA	I-OUT
)	I-OUT
were	O
significantly	O
higher	O
in	O
the	O
acellular	B-I
vaccine	I-I
groups	O
than	O
in	O
the	O
whole-cell	B-I
DPT	I-I
(	I-I
WCDPT	I-I
)	I-I
group	O
.	O


Twelve	O
months	O
after	O
primary	O
vaccination	O
,	O
GMTs	B-OUT
to	I-OUT
PT	I-OUT
in	O
the	O
freeze-dried	O
,	O
liquid	O
ADPT	O
groups	O
and	O
the	O
WCDPT	O
group	O
have	O
fallen	O
from	O
56.23	O
,	O
62.63	O
and	O
44.97	O
ELISA	O
U/ml	O
to	O
6.08	O
,	O
6.18	O
and	O
11.30	O
ELISA	O
U/ml	O
,	O
respectively	O
.	O


In	O
this	O
comparative	O
controlled	O
trial	O
,	O
the	O
ADPT	B-I
vaccines	I-I
were	O
more	O
immunogenic	B-OUT
,	O
with	O
less	B-OUT
local	I-OUT
and	I-OUT
systemic	I-OUT
reactions	I-OUT
,	O
than	O
the	O
WCDPT	B-I
vaccine	I-I
but	O
there	O
was	O
a	O
considerable	O
drop	O
in	O
antibody	B-OUT
titres	I-OUT
in	O
all	O
the	O
vaccine	O
groups	O
12	O
months	O
after	O
primary	O
vaccination	O
.	O


Each	O
item	O
was	O
rated	O
as	O
to	O
the	O
seriousness	O
of	O
the	O
pathology	O
it	O
would	O
represent	O
if	O
manifested	O
by	O
either	O
a	O
boy	O
child	O
,	O
girl	O
child	O
,	O
boy	O
adolescent	O
,	O
or	O
girl	O
adolescent	O
,	O
with	O
one-fourth	O
of	O
the	O
raters	O
assigned	O
to	O
each	O
condition	O
.	O


They	O
were	O
demonstrated	O
to	O
have	O
satisfactoy	O
reliability	O
and	O
convergent	O
validity	O
and	O
to	O
have	O
the	O
psychophysical	O
characteristics	O
of	O
a	O
prothetic	O
continuum	O
.	O


Dental	B-I
prophylaxis	I-I
decreases	I-P
the	I-P
risk	I-P
of	I-P
esophageal	I-OUT
cancer	I-OUT
in	I-P
males	I-P
;	I-P
a	I-P
nationwide	I-P
population-based	I-P
study	I-P
in	I-P
Taiwan	I-P
.	I-P


Paracetamol	B-I
reduces	O
postoperative	O
pain	B-OUT
and	I-OUT
rescue	I-OUT
analgesic	I-OUT
demand	I-OUT
after	O
robot-assisted	B-I
endoscopic	I-I
thyroidectomy	I-I
by	I-I
the	I-I
transaxillary	I-I
approach	I-I
.	I-I


This	O
clinical	O
trial	O
was	O
conducted	O
to	O
determine	O
if	O
repeated	O
intravenous	B-I
paracetamol	I-I
could	O
decrease	O
postoperative	O
pain	O
and	O
rescue	O
analgesic	O
requirements	O
after	O
robot-assisted	B-I
endoscopic	I-I
thyroidectomy	I-I
via	O
the	O
transaxillary	B-I
approach	I-I
.	I-I


Both	O
groups	O
completed	O
a	O
multiple-choice	O
test	O
based	O
on	O
the	O
aforementioned	O
passage	O
.	O


Within-subject	O
analyses	O
examined	O
the	O
association	O
between	O
the	O
presence	O
of	O
IEDs	O
and	O
changes	O
in	O
attention-deficit/hyperactivity	B-OUT
disorder	I-OUT
(	I-OUT
ADHD	I-OUT
)	I-OUT
symptoms	I-OUT
.	I-OUT


Fluctuations	O
in	O
the	O
presence	O
of	O
epileptiform	O
discharges	O
within	O
individual	O
children	O
with	O
a	O
developmental	O
disability	O
syndrome	O
may	O
be	O
associated	O
with	O
fluctuations	O
in	O
ADHD	O
symptomatology	O
,	O
even	O
in	O
the	O
absence	O
of	O
clinical	O
seizures	O
.	O


Validation	O
of	O
an	O
FFQ	O
for	O
evaluation	O
of	O
EPA	B-OUT
and	I-OUT
DHA	I-OUT
intake	I-OUT
.	I-OUT


Intakes	O
of	O
marine	B-I
food	I-I
products	I-I
and	O
EPA	B-I
and	O
DHA	B-I
were	O
estimated	O
by	O
FFQ	O
on	O
the	O
basis	O
of	O
consumption	O
of	O
marine	B-I
food	I-I
products	I-I
in	O
the	O
last	O
month	O
.	O


All	O
subjects	B-P
participated	O
in	O
a	O
crossover	O
study	O
of	O
2	O
randomly	O
scheduled	O
15-day	B-I
study	I-I
periods	I-I
during	I-I
which	I-I
250	I-I
mg	I-I
theophylline	I-I
twice	I-I
daily	I-I
or	I-I
matching	I-I
placebo	I-I
was	I-I
used	I-I
.	I-I


CONCLUSIONS	O
Prolonged	O
use	O
of	O
theophylline	O
has	O
a	O
sustained	O
effect	O
on	O
cardiovascular	B-OUT
,	I-OUT
metabolic	I-OUT
,	I-OUT
and	I-OUT
symptom	I-OUT
responses	I-OUT
to	O
hypoglycemia	O
in	O
patients	B-P
with	I-P
type	I-P
1	I-P
diabetes	I-P
and	I-P
hypoglycemia	I-P
unawareness	I-P
.	I-P


FINDINGS	O
At	O
10	O
years	O
,	O
674	O
(	O
83	O
%	O
)	O
of	O
809	O
patients	O
allocated	O
endovascular	O
coiling	O
and	O
657	O
(	O
79	O
%	O
)	O
of	O
835	O
patients	O
allocated	O
neurosurgical	O
clipping	O
were	O
alive	O
(	O
odds	O
ratio	O
[	O
OR	O
]	O
1·35	O
,	O
95	O
%	O
CI	O
1·06-1·73	O
)	O
.	O


[	O
Late	O
cardiac	B-OUT
toxicity	I-OUT
in	O
Hodgkin	O
's	O
disease	O
.	O


Apparent	B-OUT
phalangeal	I-OUT
ultrasound	I-OUT
transmission	I-OUT
velocity	I-OUT
(	I-OUT
APU	I-OUT
)	I-OUT
was	O
assessed	O
as	O
parameter	O
of	O
bone	O
quality	O
independent	O
of	O
BMD	O
.	O


APU	B-OUT
decreased	O
during	O
the	O
first	O
6	O
months	O
of	O
treatment	O
,	O
but	O
had	O
returned	O
to	O
its	O
baseline	O
value	O
after	O
24	O
months	O
and	O
remained	O
unchanged	O
throughout	O
the	O
rest	O
of	O
the	O
study	O
.	O


Thereby	O
,	O
GH	B-I
shows	O
a	O
triphasic	O
action	O
on	O
BMD	B-OUT
:	I-OUT
an	O
initial	O
decrease	O
in	O
BMD	B-OUT
during	O
the	O
1st	O
year	O
,	O
followed	O
by	O
a	O
continuous	O
increase	O
in	O
BMD	B-OUT
with	O
buildup	O
of	O
a	O
stable	O
plateau	O
after	O
60	O
months	O
.	O


After	O
the	O
10	O
and	O
15	O
mg/hr	O
infusions	O
of	O
diltiazem	B-I
,	O
mean	O
+/-	O
SD	O
elimination	O
half-life	O
was	O
6.8	O
+/-	O
1.8	O
and	O
6.9	O
+/-	O
1.5	O
hours	O
,	O
volume	O
of	O
distribution	O
was	O
411	O
+/-	O
151.8	O
and	O
299	O
+/-	O
70.8	O
I	O
,	O
and	O
systemic	O
clearance	O
was	O
42	O
+/-	O
12.4	O
and	O
31	O
+/-	O
8.3	O
l/hr	O
,	O
respectively	O
.	O


Mean	B-OUT
+/-	I-OUT
SD	I-OUT
Emax	I-OUT
(	O
maximum	O
percent	O
reduction	O
in	O
heart	O
rate	O
from	O
baseline	O
)	O
and	O
EC50	B-OUT
(	O
plasma	O
diltiazem	O
concentration	O
that	O
achieves	O
half	O
Emax	O
)	O
were	O
52	O
+/-	O
17	O
%	O
and	O
110	O
+/-	O
84	O
ng/ml	O
,	O
respectively	O
.	O


A	O
relation	O
between	O
plasma	O
diltiazem	O
concentration	O
and	O
percent	O
change	O
in	O
systolic	B-OUT
blood	I-OUT
pressure	I-OUT
(	I-OUT
SBP	I-OUT
)	I-OUT
or	I-OUT
diastolic	I-OUT
blood	I-OUT
pressure	I-OUT
(	I-OUT
DBP	I-OUT
)	I-OUT
from	O
baseline	O
was	O
not	O
observed	O
(	O
mean	O
+/-	O
SD	O
r2	O
,	O
SBP/DBP	O
:	O
0.35	O
+/-	O
0.24/0.36	O
+/-	O
0.2	O
)	O
.	O


There	O
were	O
no	O
untoward	O
side	O
effects	O
observed	O
.	O


Thirty	B-P
patients	I-P
scheduled	I-P
for	I-P
aortic	I-P
valve	I-P
replacement	I-P
were	I-P
included	I-P
.	I-P


The	O
patients	O
were	O
randomized	O
to	O
group	O
I	O
(	B-I
creatine	I-I
phosphate	I-I
)	I-I
or	O
group	O
II	O
(	B-I
control	I-I
)	I-I
.	O


Postoperative	O
hemodynamic	B-OUT
evaluation	I-OUT
revealed	O
no	O
significant	O
differences	O
between	O
the	O
groups	O
.	O


The	O
effect	O
of	O
a	O
culture-specific	B-I
education	I-I
program	I-I
to	I-I
promote	I-I
breastfeeding	I-I
among	I-P
Vietnamese	I-P
women	I-P
in	I-P
Sydney	I-P
.	I-P


To	O
counteract	O
this	O
trend	O
,	O
a	O
language	B-I
and	I-I
culture	I-I
specific	I-I
education	I-I
program	O
was	O
developed	O
.	O


Pulsed	B-I
electromagnetic	I-I
fields	I-I
for	O
postmenopausal	B-P
osteoporosis	I-P
and	I-P
concomitant	I-P
lumbar	I-P
osteoarthritis	I-P
in	I-P
southwest	I-P
China	I-P
using	O
proximal	B-OUT
femur	I-OUT
bone	I-OUT
mineral	I-OUT
density	I-OUT
as	O
the	O
primary	O
endpoint	O
:	O
study	O
protocol	O
for	O
a	O
randomized	O
controlled	O
trial	O
.	O


METHODS	O
The	O
effects	O
of	O
captopril	B-I
(	O
12.5	O
mg	O
and	O
25	O
mg	O
)	O
and	O
enalapril	B-I
(	O
5	O
mg	O
and	O
10	O
mg	O
)	O
administered	O
during	O
7-day	O
periods	O
on	O
electroencephalogram	B-OUT
(	I-OUT
EEG	I-OUT
)	I-OUT
,	I-OUT
cognitive	I-OUT
functions	I-OUT
,	I-OUT
and	I-OUT
subjective	I-OUT
assessments	I-OUT
were	O
investigated	O
in	O
healthy	B-P
males	I-P
.	I-P


Enalapril	B-I
did	O
not	O
alter	O
subjective	B-OUT
ratings	I-OUT
.	I-OUT


Patients	O
were	O
assessed	O
by	O
a	O
third-year	O
resident	O
of	O
psychiatry	O
at	O
baseline	O
and	O
after	O
2	O
,	O
4	O
,	O
6	O
and	O
8	O
weeks	O
of	O
starting	O
medication	O
.	O


=	O
1.68	O
,	O
P	O
=	O
0.002	O
;	O
F	O
=	O
8.21	O
,	O
d.f	O
.	O


Community-based	B-I
treatment	I-I
for	O
opioid	B-P
dependent	I-P
offenders	I-P
:	I-P
a	O
pilot	O
study	O
.	O


CONCLUSION	O
Findings	O
support	O
primary	B-I
care	I-I
OST	O
feasibility	O
for	O
a	O
community-supervised	O
offender	O
sample	O
.	O


Once-daily	O
versus	O
twice-daily	O
lamivudine	B-I
,	I-I
in	I-I
combination	I-I
with	I-I
zidovudine	I-I
and	I-I
efavirenz	I-I
,	O
for	O
the	O
treatment	O
of	O
antiretroviral-naive	B-P
adults	I-P
with	I-P
HIV	I-P
infection	I-P
:	I-P
a	O
randomized	O
equivalence	B-OUT
trial	O
.	O


regimens	O
were	O
equivalent	O
(	O
HIV-1	O
RNA	O
level	O
<	O
400	O
copies/mL	O
,	O
178	O
[	O
64	O
%	O
]	O
of	O
278	O
vs.	O
174	O
[	O
63	O
%	O
]	O
of	O
276	O
;	O
treatment	O
difference	O
,	O
1	O
%	O
[	O
95	O
%	O
CI	O
,	O
-7.1	O
%	O
to	O
8.9	O
%	O
]	O
;	O
HIV-1	O
RNA	O
level	O
<	O
50	O
copies/mL	O
,	O
165	O
[	O
59	O
%	O
]	O
of	O
278	O
vs.	O
168	O
[	O
61	O
%	O
]	O
of	O
276	O
;	O
treatment	O
difference	O
,	O
1.7	O
%	O
[	O
95	O
%	O
CI	O
,	O
-9.7	O
%	O
to	O
6.6	O
%	O
]	O
)	O
.	O


Once	O
portal	B-OUT
hypertension	I-OUT
occurred	O
,	O
all	O
subjects	O
on	O
TG	O
were	O
changed	O
to	O
MP	O
.	O


The	O
participants	O
were	O
randomly	O
assigned	O
to	O
1	O
of	O
3	O
interventions	O
in	O
which	B-I
margarines	I-I
fortified	I-I
with	I-I
either	I-I
10	I-I
weight	I-I
percent	I-I
ALA	I-I
,	I-I
EPA	I-I
,	I-I
or	I-I
DHA	I-I
ethyl	I-I
esters	I-I
replaced	O
their	O
normal	O
spread	O
for	O
6	O
wk	O
.	O


ALA	O
did	O
not	O
increase	B-OUT
erythrocyte	I-OUT
EPA	I-OUT
or	O
the	B-OUT
omega-3	I-OUT
index	I-OUT
.	O


DESIGN	O
This	O
was	O
a	O
prospective	O
,	O
randomized	O
,	O
placebo-controlled	B-I
trial	O
in	O
21	B-P
patients	I-P
aged	I-P
35	I-P
+/-	I-P
11	I-P
y	I-P
(	I-P
x	I-P
+/-	I-P
SD	I-P
)	I-P
with	I-P
burns	I-P
on	I-P
45	I-P
+/-	I-P
21	I-P
%	I-P
of	I-P
their	I-P
body	I-P
surface	I-P
area	I-P
.	I-P


OBJECTIVE	O
To	O
evaluate	O
two	O
solutions	O
,	O
lactated	B-I
Ringer	I-I
's	I-I
(	I-I
LR	I-I
)	I-I
and	I-I
a	I-I
balanced	I-I
salt	I-I
solution	I-I
(	O
BSS	O
Plus	O
,	O
Alcon	O
Laboratories	O
,	O
Ft.	O
Worth	O
,	O
TX	O
)	O
,	O
compared	O
with	O
normal	O
saline	B-I
solution	I-I
(	I-I
NSS	I-I
)	I-I
,	O
for	O
ocular	O
irrigation	O
in	O
healthy	B-P
adult	I-P
volunteers	I-P
with	I-P
and	I-P
without	I-P
the	I-P
Morgan	I-P
therapeutic	I-P
lens	I-P
(	I-P
MTL	I-P
)	I-P
.	I-P


Exclusion	O
criteria	O
included	O
the	O
use	O
of	O
analgesics	O
within	O
four	O
hours	O
of	O
the	O
study	O
.	O


Following	O
randomization	O
and	O
prior	O
to	O
any	O
intervention	O
,	O
baseline	O
discomfort	B-OUT
scores	I-OUT
were	O
obtained	O
by	O
means	O
of	O
a	O
verbally	O
administered	O
,	O
horizontal	O
,	O
100-mm	O
,	O
unnumbered	O
analog	O
discomfort	O
scale	O
.	O


A	O
global	O
evaluation	O
to	O
assess	O
the	O
method	O
of	O
irrigation	O
and	O
the	O
solutions	O
used	O
for	O
irrigation	O
was	O
completed	O
by	O
both	O
the	O
physician	O
blinded	O
to	O
the	O
treatment	B-P
groups	I-P
and	I-P
the	I-P
volunteers	I-P
.	I-P


RESULTS	O
Sixty-three	B-P
volunteers	I-P
were	I-P
recruited	I-P
into	I-P
the	I-P
study	I-P
,	I-P
with	I-P
61	I-P
entered	I-P
in	I-P
the	I-P
final	I-P
analysis	I-P
.	I-P


Analysis	O
of	O
the	O
global	O
evaluations	O
for	O
each	O
group	O
revealed	O
no	O
difference	O
in	O
the	O
distributions	O
of	O
physician	B-OUT
and	I-OUT
volunteer	I-OUT
scores	I-OUT
.	I-OUT


The	O
secondary	O
events	O
during	O
the	O
first	O
14	O
days	O
also	O
revealed	O
no	O
benefit	O
of	O
dalteparin	B-I
compared	O
with	O
aspirin	B-I
:	I-I
symptomatic	I-OUT
cerebral	I-OUT
haemorrhage	I-OUT
6/224	O
versus	O
4/225	O
;	O
symptomatic	B-OUT
and	I-OUT
asymptomatic	I-OUT
cerebral	I-OUT
haemorrhage	I-OUT
26/224	O
versus	O
32/225	O
;	O
progression	B-OUT
of	I-OUT
symptoms	I-OUT
within	I-OUT
the	I-OUT
first	I-OUT
48	I-OUT
hours	I-OUT
24/224	O
versus	O
17/225	O
;	O
and	O
death	O
21/224	O
versus	O
16/225	O
.	O


This	O
prevalence	O
was	O
higher	O
than	O
in	O
other	O
countries	O
.	O


Using	O
one	O
definition	O
,	O
the	O
prevalence	O
of	O
low	O
RF	B-OUT
profile	I-OUT
increased	O
from	O
3.8	O
%	O
(	O
3.1-4.5	O
)	O
in	O
1984-1986	O
to	O
6.7	O
%	O
(	O
6.1-7.3	O
)	O
in	O
2003-2006	O
;	O
using	O
another	O
definition	O
,	O
the	O
results	O
were	O
5.9	O
%	O
(	O
5.1-6.8	O
)	O
and	O
9.7	O
%	O
(	O
9.0-10.5	O
)	O
,	O
respectively	O
.	O


Thus	O
,	O
in	O
order	O
to	O
obtain	O
a	O
prompt	O
improvement	O
,	O
the	O
association	O
of	O
local	O
therapy	O
acting	O
on	O
the	O
genital	O
epithelium	O
to	O
the	O
systemic	O
treatment	O
should	O
be	O
considered	O
.	O


SUBJECTS	O
AND	O
METHODS	O
In	O
a	O
randomized	O
,	O
double	O
blind	O
,	O
controlled	O
with	O
placebo	B-I
study	O
,	O
27	B-P
women	I-P
with	I-P
climacteric	I-P
symptoms	I-P
and	I-P
atrophic	I-P
vaginitis	I-P
were	O
treated	O
for	O
4	O
months	O
with	O
HT	B-I
plus	I-I
vaginal	I-I
estriol	I-I
0.5	I-I
mg/day	I-I
(	O
group	O
E	O
)	O
or	O
placebo	B-I
(	O
group	O
P	O
)	O
.	O


Papanicolaou	B-OUT
smear	I-OUT
showed	I-OUT
reactive	I-OUT
or	I-OUT
reparative	I-OUT
changes	I-OUT
and	I-OUT
karyopyknotic	I-OUT
index	I-OUT
exhibited	I-OUT
a	I-OUT
significant	I-OUT
increase	I-OUT
in	I-OUT
superficial	I-OUT
cells	I-OUT
in	I-OUT
both	I-OUT
groups	I-OUT
and	I-OUT
at	I-OUT
the	I-OUT
end	I-OUT
of	I-OUT
the	I-OUT
study	I-OUT
.	I-OUT


Weekly	B-OUT
urine	I-OUT
drug	I-OUT
screens	I-OUT
measured	O
opioid	O
use	O
.	O


Anhedonia	B-OUT
was	O
defined	O
to	O
be	O
present	O
if	O
the	O
participants	O
reported	O
having	O
suffered	O
a	O
major	O
loss	O
of	O
interest	O
during	O
the	O
previous	O
month	O
.	O


The	O
risk	O
of	O
any	O
hospitalization	O
for	O
AF	O
[	O
hazard	O
ratio	O
(	O
95	O
%	O
confidence	O
interval	O
)	O
0.626	O
(	O
0.546-0.719	O
)	O
]	O
and	O
duration	O
of	O
hospital	B-OUT
stay	I-OUT
were	O
significantly	O
reduced	O
by	O
dronedarone	B-I
(	O
P	O
<	O
0.0001	O
vs.	O
placebo	B-I
)	I-I
.	O


Hospitalization	B-OUT
burden	I-OUT
was	O
significantly	O
reduced	O
across	O
all	O
levels	O
of	O
care	O
(	O
P	O
<	O
0.05	O
)	O
.	O


In	O
both	O
study	O
and	O
control	O
groups	O
before	O
and	O
after	O
treatment	O
the	O
mean	B-OUT
vaginal	I-OUT
pH	I-OUT
was	O
in	O
the	O
range	O
of	O
4.3-4.6	O
.	O


The	O
influence	O
of	O
other	O
organisms	O
appeared	O
to	O
be	O
negligible	O
.	O


When	O
pleasantness	O
ratings	O
of	O
scent	O
were	O
covaried	O
,	O
physiological	B-OUT
changes	I-OUT
in	I-OUT
temperature	I-OUT
and	I-OUT
heart	I-OUT
rate	I-OUT
did	O
not	O
differ	O
based	O
on	O
scent	O
exposure	O
,	O
but	O
mood	B-OUT
ratings	I-OUT
differed	O
by	O
scent	O
condition	O
.	O


We	O
used	O
multiple	O
linear	O
and	O
logistic	O
models	O
to	O
regress	O
lesion	O
risk	O
and	O
intima-media	O
thickness	O
on	O
work-related	B-OUT
stress	I-OUT
scores	I-OUT
from	O
a	O
questionnaire	O
administered	O
at	O
an	O
18-month	O
follow-up	O
examination	O
.	O


Among	O
women	B-P
,	I-P
stress	I-OUT
was	O
not	O
related	O
to	O
the	O
prevalence	B-OUT
of	I-OUT
lesions	I-OUT
or	I-OUT
intima-media	I-OUT
thickness	I-OUT
.	I-OUT


These	O
findings	O
suggest	O
that	O
men	B-P
with	I-P
greater	I-P
work-related	I-OUT
stress	I-OUT
are	O
at	O
increased	O
risk	O
for	O
atherosclerotic	B-OUT
disease	I-OUT
.	I-OUT


Women	O
in	O
this	O
age	O
group	O
may	O
be	O
protected	O
from	O
such	O
effects	O
,	O
or	O
current	O
work-place	O
questionnaires	O
may	O
not	O
accurately	O
assess	O
stress	O
in	O
women	O
.	O


Children	O
were	O
randomly	O
assigned	O
to	O
the	O
Experimental	O
group	O
,	O
with	O
vitamin	B-I
A-fortified	I-I
cooking	I-I
oil	I-I
ration	O
;	O
to	O
Control-1	O
group	O
with	O
unfortified	B-I
cooking	I-I
oil	I-I
ration	I-I
;	I-I
and	O
to	O
Control-2	O
group	O
without	B-I
cooking	I-I
oil	I-I
ration	I-I
.	I-I


Determinants	O
of	O
post-intervention	O
serum	O
retinol	O
concentration	O
included	O
baseline	O
serum	O
retinol	O
concentration	O
,	O
caregiver	O
's	O
education	O
,	O
receipt	O
of	O
high-dose	O
vitamin	O
A	O
capsule	O
,	O
interaction	O
between	O
consumption	O
of	O
vitamin	O
A-fortified	O
cooking	O
oil	O
and	O
of	O
other	O
vitamin	O
A-rich	O
foods	O
,	O
and	O
between	O
households	O
purchasing	O
cooking	O
oil	O
and	O
food	O
expenditure	O
.	O


Intake	O
of	O
vitamin	B-I
A-fortified	I-I
cooking	I-I
oil	I-I
combined	O
with	O
vitamin	O
A-rich	O
foods	O
was	O
necessary	O
to	O
increase	O
serum	B-OUT
retinol	I-OUT
concentration	I-OUT
.	I-OUT


It	O
is	O
recommended	O
to	O
vigorously	O
promote	O
the	O
consumption	O
of	O
vitamin	B-I
A-fortified	I-I
cooking	I-I
oil	I-I
together	O
with	O
other	O
vitamin	O
A-rich	O
sources	O
to	O
sustain	O
the	O
prevention	B-OUT
and	O
control	B-OUT
of	O
vitamin	O
A	O
deficiency	B-OUT
.	I-OUT


The	O
ability	O
to	O
predict	O
the	O
effect	O
of	O
anthelmintic	O
treatment	O
on	O
milk	O
production	O
depends	O
on	O
the	O
level	O
of	O
parasitism	O
quantified	O
by	O
an	O
ELISA	O
measuring	O
milk	B-OUT
antibodies	I-OUT
against	O
O.	O
ostertagi	O
,	O
and	O
reported	O
as	O
optical	B-OUT
density	I-OUT
ratios	I-OUT
(	I-OUT
ODRs	I-OUT
)	I-OUT
.	O


Twenty-six	B-P
pupils	I-P
(	I-P
12	I-P
boys	I-P
and	I-P
14	I-P
girls	I-P
)	I-P
of	I-P
a	I-P
special	I-P
needs	I-P
school	I-P
participated	I-P
in	O
therapeutic	B-I
riding	I-I
.	I-I


A	O
quality	O
improvement	O
process	O
cycle	O
will	O
introduce	O
the	O
neonatal	O
resuscitation	O
protocol	O
.	O


This	O
blood	O
volume	O
was	O
removed	O
in	O
the	O
fluid	O
resuscitation	O
study	O
to	O
create	O
a	O
model	O
of	O
acute	O
blood	O
loss	O
.	O


Using	O
data	O
from	O
a	O
large	O
randomized	O
trial	O
,	O
we	O
explored	O
the	O
prognostic	O
value	O
of	O
clinical	O
variables	O
,	O
measured	O
at	O
hospital	O
admission	O
for	O
acute	O
heart	O
failure	O
,	O
to	O
determine	O
whether	O
a	O
few	O
selected	O
variables	O
were	O
inferior	O
to	O
an	O
extended	O
data	O
set	O
.	O


However	O
,	O
predictive	O
models	O
were	O
of	O
only	O
moderate	B-OUT
accuracy	I-OUT
,	O
especially	O
for	O
outcomes	B-OUT
that	I-OUT
included	I-OUT
nonfatal	I-OUT
events	I-OUT
.	I-OUT


OBJECTIVE	O
To	O
determine	O
whether	O
moxifloxacin	B-I
penetrates	O
the	O
uterine	O
tissue	O
and	O
accumulates	O
at	O
levels	O
sufficient	O
to	O
eradicate	B-OUT
the	I-OUT
major	I-OUT
pathogens	I-OUT
causing	O
pelvic	B-P
inflammatory	I-P
disease	I-P
(	I-P
PID	I-P
)	I-P
.	I-P


Moxifloxacin	B-OUT
accumulated	I-OUT
in	I-OUT
uterine	I-OUT
tissue	I-OUT
and	I-OUT
concentrations	I-OUT
were	O
highest	O
1	O
hour	O
after	O
infusion	O
in	O
both	O
plasma	O
and	O
tissue	O
.	O


Twenty-five	O
patients	O
were	O
attributed	O
to	O
the	O
coma	O
type	O
,	O
which	O
is	O
a	O
progredient	O
coma	O
lasting	O
several	O
days	O
.	O


Patients	O
with	O
psychotic	O
reactions	O
or	O
abnormal	O
psychiatric	O
behaviour	O
(	O
3/38	O
)	O
and	O
one	O
patient	O
who	O
died	B-OUT
after	O
alcohol	O
intake	O
were	O
excluded	O
from	O
the	O
analysis	O
.	O


Patients	O
who	O
received	O
MOF-Strep	O
experienced	O
substantially	O
greater	O
vomiting	B-OUT
and	I-OUT
hematologic	I-OUT
toxicity	I-OUT
than	O
patients	B-P
who	I-P
received	I-P
FU	O
+	O
HU	O
(	O
p	O
less	O
than	O
0.001	O
)	O
.	O


RESULTS	O
The	O
score	B-OUT
of	I-OUT
symptom	I-OUT
was	O
lower	O
in	O
titanoreine	B-I
group	O
(	O
4.4	O
)	O
than	O
that	O
in	O
the	O
control	O
group	O
(	O
6.1	O
)	O
24	O
hours	O
after	O
PPH	O
(	O
P	O
<	O
0.05	O
)	O
,	O
but	O
no	O
significant	O
difference	O
in	O
symptom	B-OUT
grade	I-OUT
was	O
found	O
between	O
the	O
two	O
groups	O
6	O
days	O
and	O
12	O
days	O
after	O
PPH	O
(	O
P	O
>	O
0.05	O
)	O
.	O


CONCLUSIONS	O
Titanoreine	B-I
can	O
effectively	O
relieve	B-OUT
the	O
early	O
postoperative	O
symptoms	O
after	O
PPH	O
.	O


Our	O
double-blind	O
,	O
placebo-controlled	B-I
clinical	O
trial	O
was	O
designed	O
to	O
test	O
the	O
efficacy	O
of	O
beta-carotene	B-I
in	O
raising	O
CD4	O
counts	O
in	O
HIV-infected	B-P
patients	I-P
.	I-P


The	O
aim	O
of	O
this	O
study	O
was	O
to	O
examine	O
the	O
effects	O
of	O
2	O
in-season	O
short-term	B-I
sprint	I-I
and	I-I
power	I-I
training	I-I
protocols	I-I
on	O
vertical	O
countermovement	O
jump	O
height	O
(	O
with	O
or	O
without	O
arms	O
)	O
,	O
sprint	O
(	O
Sprint-15m	O
)	O
speed	O
,	O
and	O
agility	O
(	O
Agility-15m	O
)	O
speed	O
in	O
male	B-P
elite	I-P
junior	I-P
soccer	I-P
players	I-P
.	I-P


Twenty	B-P
highly	I-P
trained	I-P
soccer	I-P
players	I-P
(	I-P
age	I-P
18.3	I-P
+/-	I-P
0.6	I-P
years	I-P
,	I-P
height	I-P
177	I-P
+/-	I-P
4	I-P
cm	I-P
,	I-P
body	I-P
mass	I-P
71.4	I-P
+/-	I-P
6.9	I-P
kg	I-P
,	I-P
sum	I-P
skinfolds	I-P
48.1	I-P
+/-	I-P
11.4	I-P
mm	I-P
)	I-P
,	I-P
members	I-P
of	I-P
a	I-P
professional	I-P
soccer	I-P
academy	I-P
,	O
were	O
randomly	O
allocated	O
to	O
either	O
a	O
CONTRAST	O
(	O
n	O
=	O
10	O
)	O
or	O
SPRINT	O
(	O
n	O
=	O
10	O
)	O
group	O
.	O


A	O
time	O
x	O
training	O
group	O
effect	O
was	O
found	O
for	O
Sprint-15m	O
performance	O
with	O
the	O
CONTRAST	O
group	O
showing	O
significantly	O
better	O
scores	O
than	O
the	O
SPRINT	O
group	O
(	O
7.23	O
+/-	O
0.18	O
vs.	O
7.09	O
+/-	O
0.20	O
m.s	O
,	O
p	O
<	O
0.01	O
)	O
.	O


We	O
found	O
significant	O
correlations	O
between	O
FMRP	B-OUT
levels	I-OUT
and	O
contrast	O
sensitivity	O
at	O
low	O
spatial	O
and	O
high	O
temporal	O
frequencies	O
,	O
perceptual	O
integration	O
,	O
and	O
motion	O
perception	O
.	O


This	O
pattern	O
of	O
data	O
is	O
reminiscent	O
to	O
that	O
observed	O
in	O
patients	B-P
with	O
Fragile	O
X	O
Syndrome	O
(	O
FXS	O
)	O
.	O


BACKGROUND	O
Almost	O
one	O
third	O
of	O
women	B-P
suffer	O
continuous	O
lower	O
back	O
pain	O
during	O
labour	O
.	O


Participants	B-P
will	I-P
be	I-P
recruited	I-P
from	I-P
two	I-P
major	I-P
maternity	I-P
hospitals	I-P
in	I-P
Australia	I-P
.	I-P


Baseline	O
demographic	O
and	O
clinical	O
characteristics	O
will	O
be	O
analysed	O
for	O
comparability	O
between	O
groups	O
.	O


Weight	B-OUT
loss	I-OUT
maintenance	I-OUT
in	O
overweight	B-P
subjects	I-P
on	O
ad	B-I
libitum	I-I
diets	I-I
with	O
high	O
or	O
low	O
protein	O
content	O
and	O
glycemic	O
index	O
:	O
the	O
DIOGENES	O
trial	O
12-month	O
results	O
.	O


Average	B-OUT
weight	I-OUT
regain	I-OUT
over	O
the	O
12-month	O
intervention	O
period	O
was	O
3.9	O
(	O
95	O
%	O
CI	O
3.0-4.8	O
)	O
kg	O
.	O


Subjects	O
on	O
the	O
HP	O
diets	O
regained	B-OUT
less	I-OUT
weight	I-OUT
than	O
subjects	O
on	O
the	O
LP	O
diets	O
.	O


There	O
were	O
no	O
clinically	O
relevant	O
differences	O
in	O
changes	O
in	O
cardiometabolic	O
risk	O
factors	O
among	O
diet	O
groups	O
.	O


The	O
treatment	O
for	O
4	O
weeks	O
wasas	O
one	O
session	O
,	O
and	O
2	O
sessions	O
were	O
required	O
in	O
the	O
three	O
groups	O
.	O


At	O
the	O
end	O
of2	O
sessions	O
of	O
treatment	O
,	O
the	O
clinical	B-OUT
efficacy	I-OUT
and	I-OUT
adverse	I-OUT
reactions	I-OUT
were	O
compared	O
among	O
the	O
three	O
groups	O
.	O


0	O
%	O
(	O
11/50	O
)	O
in	O
the	O
forlax	O
group	O
(	O
both	O
P	O
<	O
0	O
.	O


CONCLUSION	O
the	O
combined	B-I
therapy	I-I
of	I-I
acupoint	I-I
embedding	I-I
and	I-I
forlax	I-I
achieves	O
the	O
better	O
clinical	O
efficacy	O
on	O
diabetic	B-P
constipation	I-P
and	O
constipation	B-OUT
symptom	I-OUT
scores	I-OUT
as	O
compared	O
with	O
the	O
simple	B-I
acupoint	I-I
embedding	I-I
therapy	I-I
and	O
the	O
oral	B-I
administration	I-I
of	I-I
forlax	I-I
the	O
short-term	O
efficacy	O
of	O
the	O
simple	O
acupoint	O
embedding	O
therapy	O
is	O
not	O
different	O
significantly	O
from	O
the	O
simple	O
forlax	O
medication	O
,	O
but	O
the	O
long-term	O
efficacy	O
and	O
safety	O
are	O
better	O
than	O
those	O
of	O
simple	O
forlax	O
medicaiton	O
.	O


The	O
efficacy	O
of	O
sublingual	B-I
immunotherapy	I-I
for	O
respiratory	O
allergy	O
is	O
not	O
affected	O
by	O
different	O
dosage	O
regimens	O
in	O
the	O
induction	O
phase	O
.	O


AIM	O
OF	O
THE	O
STUDY	O
To	O
determine	O
whether	O
different	O
induction	O
regimens	O
affect	O
the	O
outcome	O
of	O
sublingual	B-I
immunotherapy	I-I
.	I-I


Forty-three	B-P
subjects	I-P
were	O
allocated	O
to	O
sublingual	B-I
immunotherapy	I-I
,	I-I
with	I-I
three	I-I
different	I-I
induction	I-I
protocols	I-I
(	I-I
8-	I-I
,	I-I
15-	I-I
and	I-I
20-day	I-I
,	I-I
respectively	I-I
)	I-I
.	O


Symptom	B-OUT
and	I-OUT
medication	I-OUT
scores	I-OUT
,	I-OUT
skin	I-OUT
test	I-OUT
results	I-OUT
and	I-OUT
(	I-OUT
in	I-OUT
asthmatic	I-OUT
patients	I-OUT
)	I-OUT
FEV1	I-OUT
values	I-OUT
were	O
monitored	O
for	O
two	O
years	O
.	O


Two	B-P
hundred	I-P
and	I-P
twenty-nine	I-P
adult	I-P
patients	I-P
with	I-P
differentiated	I-P
thyroid	I-P
cancer	I-P
requiring	I-P
radioiodine	I-P
WBS	I-P
were	I-P
studied	I-P
.	I-P


Of	O
the	O
discordant	O
scans	O
,	O
8	O
(	O
4	O
%	O
)	O
had	O
superior	O
scans	O
after	O
recombinant	B-I
human	I-I
TSH	I-I
administration	I-I
,	O
and	O
17	O
(	O
8	O
%	O
)	O
had	O
superior	O
scans	O
after	O
thyroid	O
hormone	O
withdrawal	O
(	O
P	O
=	O
0.108	O
)	O
.	O


In	O
conclusion	O
,	O
recombinant	B-I
human	I-I
TSH	I-I
administration	I-I
is	O
a	O
safe	O
and	O
effective	O
means	O
of	O
stimulating	O
radioiodine	O
uptake	O
and	O
serum	O
Tg	O
levels	O
in	O
patients	B-P
undergoing	I-P
evaluation	I-P
for	I-P
thyroid	I-P
cancer	I-P
persistence	I-P
and	I-P
recurrence	I-P
.	I-P


CONCLUSION	B-P
In	I-P
patients	I-P
with	I-P
active	I-P
RA	I-P
in	I-P
whom	I-P
the	I-P
response	I-I
to	I-I
MTX	I-P
has	I-P
been	I-P
inadequate	I-P
,	O
the	O
addition	B-I
of	I-I
tofacitinib	I-I
at	O
a	O
dosage	O
≥3	O
mg	O
twice	O
daily	O
showed	O
sustained	O
efficacy	O
and	O
a	O
manageable	O
safety	O
profile	O
over	O
24	O
weeks	O
.	O


Decreased	O
insula-dACC	O
rsFC	O
may	O
index	O
overlapping	O
circuitry	O
associated	O
with	O
smoking	O
and	O
SZ	O
.	O


BACKGROUND	O
Rye	B-I
bread	I-I
contributes	O
an	O
important	O
part	O
of	O
the	O
whole	O
grain	O
intake	O
in	O
the	O
Scandinavian	B-P
diet	O
.	O


CONCLUSIONS	O
The	O
present	O
study	O
demonstrated	O
that	O
ferulic	O
acid	O
from	O
rye	O
bran	O
is	O
bioavailable	O
and	O
that	O
the	O
urinary	O
concentration	O
of	O
ferulic	O
acid	O
reflects	O
the	O
dietary	O
intake	O
of	O
this	O
hydroxycinnamic	O
acid	O
.	O


Blood	B-OUT
isoflavone	I-OUT
concentrations	I-OUT
were	O
measured	O
at	O
the	O
end	O
of	O
the	O
study	O
.	O


Several	O
hypotheses	O
are	O
discussed	O
,	O
highlighting	O
the	O
selective	O
nature	O
of	O
the	O
effect	O
of	O
soy	O
consumption	O
in	O
the	O
population	O
.	O


The	O
cholesterol-lowering	O
effect	O
during	O
the	O
run-in	O
period	O
may	O
be	O
explained	O
by	O
the	O
"	O
regression	O
to	O
the	O
mean	O
effect	O
"	O
and	O
by	O
other	O
factors	O
related	O
to	O
study	O
participation	O
,	O
mainly	O
nutrient	O
displacement	O
induced	O
by	O
the	O
protein	B-I
supplement	I-I
.	I-I


The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
compare	O
the	O
functional	O
and	O
radiological	O
result	O
of	O
two	O
different	O
positions	O
of	O
the	O
wrist	O
in	O
a	O
plaster	B-I
cast	I-I
following	O
Colles	O
'	O
fracture	O
.	O


For	O
this	O
prospective	O
study	O
,	O
each	O
of	O
50	B-P
patients	I-P
with	I-P
type	I-P
A	I-P
2.2	I-P
,	I-P
A	I-P
3.3	I-P
,	I-P
C	I-P
1.2	I-P
or	I-P
C	I-P
2.2	I-P
(	I-P
AO	I-P
classification	I-P
)	I-P
fractures	I-P
of	I-P
the	I-P
radius	I-P
was	O
randomly	O
assigned	O
to	O
one	O
of	O
two	O
groups	O
.	O


At	O
review	O
2-7	O
years	O
after	O
the	O
accidents	O
,	O
the	O
two	O
groups	O
were	O
compared	O
with	O
reference	O
to	O
symptoms	B-OUT
,	I-OUT
range	I-OUT
of	I-OUT
motion	I-OUT
at	I-OUT
the	I-OUT
wrist	I-OUT
,	I-OUT
power	I-OUT
of	I-OUT
first	I-OUT
closure	I-OUT
and	I-OUT
radiographic	I-OUT
appearance	I-OUT
.	I-OUT


DESIGN	O
DELTA-1	O
was	O
based	O
on	O
a	O
randomized	O
,	O
blinded	O
,	O
crossover	O
experimental	O
design	O
.	O


RESULTS	O
DELTA-1	O
was	O
able	O
to	O
provide	O
a	O
standardized	O
diet	O
that	O
met	O
nutrient	B-OUT
specifications	I-OUT
across	O
4	O
field	O
centers	O
over	O
24	O
weeks	O
of	O
participant	O
feeding	O
spanning	O
a	O
total	O
of	O
8	O
months	O
.	O


APPLICATIONS	O
Prestudy	O
chemical	O
validation	O
of	O
menus	O
and	O
continuous	O
sampling	O
and	O
assay	O
of	O
diets	O
throughout	O
the	O
study	O
are	O
essential	O
to	O
standardize	O
experimental	O
diets	O
and	O
to	O
ensure	O
that	O
nutrient	O
target	O
goals	O
are	O
met	O
and	O
maintained	O
throughout	O
a	O
controlled	O
multicenter	O
feeding	O
study	O
.	O


Symptom	B-OUT
scores	I-OUT
,	I-OUT
peak	I-OUT
flow	I-OUT
rates	I-OUT
,	I-OUT
spirometry	I-OUT
,	I-OUT
and	I-OUT
beta-agonist	I-OUT
frequency	I-OUT
were	O
closely	O
monitored	O
.	O


The	O
average	O
dose	O
of	O
prednisone	O
during	O
the	O
placebo-treatment	B-I
period	O
was	O
11.97	O
mg/day	O
compared	O
to	O
8.37	O
mg/day	O
while	O
subjects	O
were	O
taking	O
MTX	B-I
.	I-I


Complications	B-OUT
from	I-OUT
MTX	I-OUT
were	O
mild	O
and	O
included	O
anorexia	B-OUT
,	I-OUT
alopecia	I-OUT
,	I-OUT
and	I-OUT
stomatitis	I-OUT
.	I-OUT


Low-dose	O
MTX	B-I
significantly	O
reduced	O
the	O
steroid	B-OUT
requirement	I-OUT
in	O
this	O
group	O
of	O
subjects	B-P
with	I-P
steroid-dependent	I-P
asthma	I-P
.	I-P


It	O
was	O
designed	O
as	O
an	O
open-label	O
,	O
multicenter	O
,	O
randomized	O
,	O
comparative	O
study	O
involving	O
104-week	O
oral	O
treatment	O
with	O
1	B-I
of	I-I
the	I-I
3	I-I
drugs	I-I
(	I-I
aripiprazole	I-I
,	I-I
blonanserin	I-I
,	I-I
and	I-I
paliperidone	I-I
)	I-I
in	O
patients	B-P
with	I-P
schizophrenia	I-P
aged	I-P
20	I-P
years	I-P
or	I-P
over	I-P
who	I-P
required	I-P
antipsychotic	I-I
medication	I-I
or	I-P
switching	I-P
of	I-P
the	I-P
current	I-P
medication	I-P
to	I-P
others	I-P
for	I-P
reasons	I-P
such	I-P
as	I-P
lack	I-P
of	I-P
efficacy	I-P
and	I-P
intolerability	I-P
.	I-P


The	O
aim	O
of	O
the	O
present	O
investigation	O
was	O
to	O
compare	O
the	O
efficacy	O
of	O
a	O
low-dose	B-I
antacid	I-I
(	I-I
Maalox	I-I
70	I-I
,	O
280	O
mmol/day	O
)	O
with	O
that	O
of	O
the	O
H2-receptor	B-I
antagonist	I-I
cimetidine	I-I
(	I-I
Tagamet	I-I
,	O
200	O
mg	O
three	O
times	O
daily	O
and	O
400	O
mg/day	O
)	O
after	O
14	O
and	O
28	O
days	O
in	O
the	O
treatment	O
of	O
duodenal	B-P
ulcer	I-P
.	I-P


The	O
two	B-P
treatment	I-P
groups	I-P
were	O
matched	O
for	O
age	O
,	O
sex	O
,	O
drinking	O
and	O
smoking	O
habits	O
,	O
and	O
drug	O
use	O
.	O


METHODS	O
Forty-eight	B-P
patients	I-P
with	I-P
SSc	I-P
were	O
assigned	O
randomly	O
to	O
the	O
multifaceted	B-I
oral	I-I
health	I-I
intervention	I-I
or	O
usual	B-I
dental	I-I
care	I-I
control	O
group	O
.	O


Evaluations	O
were	O
at	O
baseline	O
,	O
3-	O
,	O
and	O
6-months	O
.	O


Compared	O
to	O
the	O
control	O
group	O
,	O
the	O
intervention	O
group	O
showed	O
a	O
significant	O
and	O
larger	O
reduction	B-OUT
in	I-OUT
GI	I-OUT
score	I-OUT
by	O
8	O
%	O
at	O
6	O
months	O
(	O
p=0.0007	O
)	O
.	O


CONCLUSIONS	O
Results	O
support	O
the	O
use	B-I
of	I-I
adaptive	I-I
devices	I-I
and	I-I
orofacial	I-I
exercise	I-I
to	O
improve	B-OUT
gingival	I-OUT
health	I-OUT
in	I-P
adults	I-P
with	I-P
SSc	O
when	O
compared	O
to	O
use	B-I
of	I-I
manual	I-I
toothbrushing	I-I
and	I-I
finger-held	I-I
flossing	I-I
.	O


All	B-P
had	I-P
been	I-P
paced	I-P
for	I-P
complete	I-P
or	I-P
Mobitz	I-P
II	I-P
heart	I-P
block	I-P
.	I-P


Double	O
blind	O
cross	O
over	O
study	O
was	O
performed	O
comparing	O
exercise	B-OUT
capacity	I-OUT
,	I-OUT
measuring	I-OUT
distance	I-OUT
walked	I-OUT
on	I-OUT
a	I-OUT
6-min	I-OUT
walking	I-OUT
test	I-OUT
and	O
time	B-OUT
taken	I-OUT
to	I-OUT
climb	I-OUT
two	I-OUT
flights	I-OUT
of	I-OUT
stairs	I-OUT
;	I-OUT
and	O
symptoms	B-OUT
,	O
evaluated	O
by	O
an	O
activity	B-OUT
of	I-OUT
daily	I-OUT
living	I-OUT
questionnaire	I-OUT
,	O
in	O
atrioventricular	B-I
synchronous	I-I
and	I-I
ventricular	I-I
pacing	I-I
.	I-I


Both	O
drugs	O
were	O
equally	O
effective	O
as	O
measured	O
by	O
the	O
Hamilton	B-OUT
Rating	I-OUT
Scale	I-OUT
for	I-OUT
Depression	I-OUT
,	O
the	O
overall	B-OUT
assessment	I-OUT
of	I-OUT
efficacy	I-OUT
and	O
the	O
Zung	B-OUT
Self-rating	I-OUT
Scale	I-OUT
,	O
and	O
clearly	O
superior	O
to	O
placebo	O
;	O
there	O
were	O
no	O
significant	O
differences	O
between	O
the	O
2	O
active	O
drugs	O
.	O


The	O
purpose	O
of	O
the	O
study	O
was	O
to	O
explore	O
a	O
low-cost	B-I
intervention	I-I
that	O
targets	O
an	O
increasingly	O
common	O
developmental	O
disorder	O
.	O


The	O
results	O
suggest	O
that	O
PlayWisely	O
can	O
improve	O
recognition	B-OUT
,	I-OUT
brain	I-OUT
region	I-OUT
agility	I-OUT
,	I-OUT
phonemic	I-OUT
awareness	I-OUT
,	I-OUT
letter	I-OUT
recognition	I-OUT
,	I-OUT
and	I-OUT
early	I-OUT
memory	I-OUT
skills	I-OUT
in	O
ASD	O
.	O


It	O
was	O
observed	O
by	O
the	O
parents	O
,	O
coaches	O
,	O
and	O
study	O
investigators	O
that	O
the	O
children	O
who	O
were	O
less	O
than	O
3	O
years	O
of	O
age	O
showed	O
improvements	O
in	O
autism	B-OUT
symptoms	I-OUT
;	I-OUT
however	O
,	O
the	O
group	O
was	O
too	O
small	O
to	O
reach	O
statistical	O
significance	O
.	O


Metformin	B-I
does	O
not	O
enhance	O
ovulation	O
induction	O
in	O
clomiphene	B-P
resistant	I-P
polycystic	I-P
ovary	I-P
syndrome	I-P
in	O
clinical	O
practice	O
.	O


The	O
primary	O
outcomes	O
were	O
restoration	B-OUT
of	I-OUT
spontaneous	I-OUT
menses	I-OUT
,	I-OUT
ovulation	I-OUT
induction	I-OUT
(	I-OUT
spontaneous	I-OUT
or	I-OUT
clomiphene	I-OUT
induced	I-OUT
)	I-OUT
and	I-OUT
pregnancy	I-OUT
.	I-OUT


RESULTS	O
Twelve	B-P
women	I-P
completed	I-P
the	I-P
metformin	I-I
arm	I-P
and	I-P
14	I-P
the	I-P
placebo	I-I
arm	I-P
.	I-P


Assessment	B-P
of	I-P
the	I-P
pain	I-P
of	I-P
blood-sugar	I-P
testing	I-P
:	I-P
a	I-P
randomised	I-P
controlled	I-P
trial	I-P
.	I-P


Success	O
rates	O
were	O
the	O
same	O
.	O


Prophylactic	B-I
training	I-I
for	O
the	O
prevention	O
of	O
radiotherapy-induced	O
trismus	O
-	O
a	O
randomised	O
study	O
.	O


There	O
was	O
a	O
significant	O
mean	O
difference	O
in	B-OUT
MIO	I-OUT
from	O
baseline	O
to	O
week	O
6	O
(	O
3	O
mm	O
,	O
p	O
=	O
0.018	O
)	O
,	O
and	O
month	O
6	O
(	O
2.7	O
mm	O
,	O
p	O
=	O
0.040	O
)	O
,	O
for	O
patients	O
receiving	O
3D	O
conformal	O
radiotherapy	O
.	O


PURPOSE	O
To	O
evaluate	O
the	O
suppressive	O
effect	O
of	O
intravenous	O
dezocine	B-I
on	O
fentanyl-induced	O
cough	B-OUT
during	O
the	O
induction	O
of	O
general	O
anesthesia	O
.	O


The	O
injection	O
time	O
of	O
fentanyl	O
was	O
less	O
than	O
2	O
s	O
in	O
all	O
patients	O
.	O


We	O
aimed	O
to	O
compare	O
the	O
effects	O
of	O
different	O
concentrations	O
of	O
preincisional	O
peritonsillar	B-I
levobupivacaine	I-I
(	O
0.25	O
%	O
and	O
0.5	O
%	O
)	O
infiltration	O
on	O
postoperative	B-OUT
pain	I-OUT
and	I-OUT
bleeding	I-OUT
in	O
a	O
placebo-controlled	B-I
design	O
.	O


There	O
was	O
no	O
difference	O
between	O
groups	O
in	O
terms	O
of	O
fever	B-OUT
,	I-OUT
dysphagia	I-OUT
,	I-OUT
nausea-vomiting	I-OUT
,	I-OUT
hemorrhage	I-OUT
.	I-OUT


To	O
measure	O
hemodynamic	O
parameters	O
and	O
ShvO2	O
,	O
mixed	O
venous	O
,	O
and	O
arterial	O
lactate	O
concentrations	O
during	O
enflurane	B-I
and	I-I
isoflurane	I-I
anesthesia	I-I
.	I-I


INTERVENTIONS	O
After	O
placement	O
of	O
catheters	O
in	O
the	O
pulmonary	O
artery	O
,	O
radial	O
artery	O
,	O
peripheral	O
and	O
right	O
hepatic	O
vein	O
,	O
one	O
hour	O
postoperatively	O
either	O
enflurane	B-I
or	I-I
isoflurane	I-I
was	O
applied	O
at	O
different	O
minimum	O
alveolar	O
concentration	O
(	O
MAC	O
)	O
of	O
0.5	O
,	O
1.0	O
,	O
and	O
1.5	O
in	O
a	O
randomized	O
order	O
.	O


This	O
decrease	O
in	O
ShvO2	B-OUT
reflected	O
an	O
increase	O
in	O
splanchnic	B-OUT
O2	I-OUT
extraction	I-OUT
with	O
enflurane	B-I
;	I-I
in	O
contrast	O
to	O
isoflurane	B-I
.	I-I


Transurethral	B-I
resection	I-I
was	O
repeated	O
5	O
to	O
6	O
weeks	O
later	O
to	O
evaluate	O
the	O
residual	O
tumor	O
rate	O
.	O


OBJECTIVE	O
Bisphosphonates	B-I
are	O
effective	O
treatment	O
for	O
osteoporosis	O
but	O
have	O
been	O
associated	O
with	O
gastrointestinal	O
(	O
GI	O
)	O
mucosal	O
injury	O
.	O


Endoscopy	B-I
and	O
evaluator-blind	O
assessments	O
of	O
the	O
esophageal	O
,	O
gastric	O
,	O
and	O
duodenal	O
mucosa	O
were	O
performed	O
at	O
baseline	O
and	O
on	O
Days	O
8	O
and	O
15	O
.	O


RESULTS	O
Overall	O
,	O
gastric	B-OUT
ulcers	I-OUT
>	O
or	O
=	O
3	O
mm	O
were	O
observed	O
in	O
18	O
(	O
6.0	O
%	O
)	O
of	O
300	O
evaluable	O
subjects	O
in	O
the	O
risedronate	B-I
group	O
and	O
36	O
(	O
12.1	O
%	O
)	O
of	O
297	O
in	O
the	O
alendronate	O
group	O
during	O
treatment	O
(	O
p	O
=	O
0.013	O
)	O
.	O


On	O
Day	O
8	O
,	O
the	O
incidences	B-OUT
of	I-OUT
gastric	I-OUT
ulcers	I-OUT
in	O
the	O
risedronate	B-I
and	O
alendronate	B-I
groups	O
were	O
3.6	O
%	O
and	O
6.6	O
%	O
,	O
respectively	O
(	O
p	O
=	O
0.133	O
)	O
,	O
and	O
on	O
Day	O
15	O
,	O
they	O
were	O
3.3	O
%	O
and	O
8.7	O
%	O
(	O
p	O
=	O
0.008	O
)	O
.	O


Effects	O
of	O
a	O
fish-oil	B-I
and	I-I
vegetable-oil	I-I
formula	I-I
on	O
aggregation	O
and	O
ethanolamine-containing	O
lysophospholipid	B-OUT
generation	I-OUT
in	O
activated	O
human	O
platelets	O
and	O
on	O
leukotriene	B-OUT
production	I-OUT
in	O
stimulated	O
neutrophils	O
.	O


The	O
effects	O
of	O
consuming	O
a	O
liquid	B-I
formula	I-I
containing	I-I
either	I-I
fish	I-I
oil	I-I
enriched	I-I
in	I-I
omega-3	I-I
fatty	I-I
acids	I-I
or	I-I
vegetable	I-I
oil	I-I
enriched	I-I
in	I-I
oleic	I-I
acid	I-I
was	O
evaluated	O
in	O
20	B-P
male	I-P
subjects	I-P
randomly	O
allocated	O
into	O
two	B-I
groups	I-I
over	I-I
a	I-I
42-d	I-I
period	I-I
.	I-I


No	O
such	O
alterations	O
in	O
the	O
formation	O
of	O
lipoxygenase	O
products	O
were	O
found	O
with	O
the	O
vegetable	B-I
oil	I-I
treatment	I-I
.	I-I


Patients	B-I
received	I-I
a	I-I
5	I-I
mg	I-I
kg	I-I
(	I-I
-1	I-I
)	I-I
bolus	I-I
of	I-I
magnesium	I-I
sulphate	I-I
followed	I-I
by	I-I
a	I-I
500	I-I
mg	I-I
h	I-I
(	I-I
-1	I-I
)	I-I
infusion	I-I
or	I-I
saline	I-I
in	O
the	O
same	O
volumes	O
for	O
24	O
h.	O
Time	B-OUT
to	I-OUT
first	I-OUT
pain	I-OUT
,	I-OUT
analgesic	I-OUT
request	I-OUT
,	I-OUT
return	I-OUT
of	I-OUT
motor	I-OUT
function	I-OUT
,	I-OUT
visual	I-OUT
analogue	I-OUT
pain	I-OUT
and	I-OUT
sedation	I-OUT
scores	I-OUT
were	O
evaluated	O
every	O
4	O
h	O
during	O
the	O
24	O
h	O
postoperative	O
period	O
.	O


Data	O
were	O
expressed	O
as	O
mean	O
+/-	O
SD	O
,	O
with	O
P	O
<	O
0.05	O
being	O
considered	O
significant	O
.	O


RESULTS	O
Vital	B-OUT
signs	I-OUT
were	O
stable	O
during	O
spinal	O
anaesthesia	O
and	O
postoperative	O
period	O
.	O


When	O
compared	O
to	O
the	O
control	O
group	O
,	O
time	B-OUT
to	I-OUT
analgesic	I-OUT
need	I-OUT
was	O
increased	O
and	O
total	B-OUT
analgesic	I-OUT
consumption	I-OUT
was	O
reduced	O
in	O
the	O
magnesium	O
group	O
(	O
meperidine	O
consumption	O
60.0	O
+/-	O
73.1	O
mg	O
control	O
group	O
,	O
31.8	O
+/-	O
30.7	O
mg	O
magnesium	O
group	O
,	O
P	O
=	O
0.02	O
)	O
.	O


Incidences	O
of	O
hypercalcemia	B-OUT
,	I-OUT
hyperphosphatemia	I-OUT
,	I-OUT
and	I-OUT
elevated	I-OUT
calcium-phosphorus	I-OUT
product	I-OUT
levels	I-OUT
were	O
not	O
significantly	O
different	O
between	O
groups	O
.	O


Post-operative	B-OUT
hospital	I-OUT
stay	I-OUT
,	I-OUT
post-operative	I-OUT
morbidity	I-OUT
,	I-OUT
readmission	I-OUT
rate	I-OUT
,	I-OUT
and	I-OUT
in-hospital	I-OUT
mortality	I-OUT
were	O
recorded	O
.	O


FT	O
surgery	O
had	O
a	O
better	O
protective	O
role	O
with	O
respect	O
to	O
the	O
post-operative	O
immune	O
system	O
compared	O
with	O
traditional	O
peri-operative	O
care	O
.	O


At	O
the	O
second	O
assessment	O
,	O
all	O
3	O
PGY	O
classes	O
were	O
still	O
significantly	O
differentiable	O
by	O
technical	B-OUT
skills	I-OUT
,	I-OUT
with	I-OUT
no	I-OUT
difference	I-OUT
in	I-OUT
error	I-OUT
rate	I-OUT
.	I-OUT


Pre-transplant	O
pharmacokinetic	O
profiling	O
and	O
tacrolimus	B-OUT
requirements	I-OUT
post-transplant	I-OUT
.	I-OUT


if	O
the	O
pre-transplant	O
C	O
(	O
2	O
)	O
level	O
was	O
≤20	O
ng/mL	O
,	O
0.1	O
mg/kg	O
b.d	O
.	O


if	O
the	O
C	O
(	O
2	O
)	O
level	O
was	O
21-59	O
ng/mL	O
or	O
0.05	O
mg/kg	O
b.d	O
.	O


Subsequent	O
dosing	O
in	O
both	O
groups	O
was	O
based	B-I
upon	I-I
tacrolimus	I-I
trough	O
level	O
monitoring	B-P
.	I-P


Women	O
with	O
a	O
positive	O
HPV	B-I
test	I-I
and	O
a	O
normal	O
Pap	B-I
test	I-I
result	O
were	O
offered	O
a	O
second	O
HPV	B-I
test	I-I
at	O
least	O
1	O
year	O
later	O
,	O
and	O
those	O
who	O
were	O
found	O
to	O
be	O
persistently	O
infected	O
with	O
the	O
same	O
high-risk	O
type	O
of	O
HPV	O
were	O
then	O
offered	O
colposcopy	O
with	O
cervical	O
biopsy	O
.	O


Women	O
with	O
persistent	O
HPV	O
infection	O
remained	O
at	O
high	O
risk	O
for	O
grade	O
2	O
or	O
3	O
lesions	O
or	O
cancer	O
after	O
referral	O
for	O
colposcopy	O
.	O


It	O
may	O
therefore	O
be	O
concluded	O
that	O
it	O
is	O
feasible	O
to	O
achieve	O
significant	O
use	O
of	O
conventional	O
toothbrushes	O
and	O
toothpastes	O
,	O
with	O
consequent	O
major	O
and	O
sustained	O
improvements	O
in	O
plaque	O
control	O
and	O
gingival	O
health	O
in	O
a	O
disadvantaged	O
population	O
hitherto	O
often	O
considered	O
as	O
not	O
amenable	O
to	O
conventional	O
oral	O
hygiene	O
for	O
cultural	O
or	O
economic	O
reasons	O
.	O


Those	O
assigned	O
to	O
PACT	O
were	O
also	O
given	O
treatment	O
as	O
usual	O
.	O


This	O
study	O
is	O
registered	O
as	O
an	O
International	O
Standard	O
Randomised	O
Controlled	O
Trial	O
,	O
number	O
ISRCTN58133827	O
.	O


At	O
the	O
13-month	O
endpoint	O
,	O
the	O
severity	B-OUT
of	I-OUT
symptoms	I-OUT
was	O
reduced	O
by	O
3.9	O
points	O
(	O
SD	O
4.7	O
)	O
on	O
the	O
ADOS-G	O
algorithm	O
in	O
the	O
group	O
assigned	O
to	O
PACT	O
,	O
and	O
2.9	O
(	O
3.9	O
)	O
in	O
the	O
group	O
assigned	O
to	O
treatment	O
as	O
usual	O
,	O
representing	O
a	O
between-group	O
effect	O
size	O
of	O
-0.24	O
(	O
95	O
%	O
CI	O
-0.59	O
to	O
0.11	O
)	O
,	O
after	O
adjustment	O
for	O
centre	O
,	O
sex	O
,	O
socioeconomic	O
status	O
,	O
age	O
,	O
and	O
verbal	O
and	O
non-verbal	O
abilities	O
.	O


A	O
comparative	O
study	O
of	O
methyldopa	B-I
and	O
labetalol	B-I
in	O
the	O
treatment	O
of	O
hypertension	B-OUT
.	I-OUT


The	O
effects	O
of	O
isotonic	B-I
training	I-I
(	I-I
5BX	I-I
programme	I-I
)	I-I
and	I-I
isometric	I-I
training	I-I
(	I-I
a	I-I
programme	I-I
of	I-I
isometric	I-I
exercises	I-I
working	I-I
all	I-I
major	I-I
groups	I-I
of	I-I
muscles	I-I
)	I-I
were	O
compared	O
with	B-I
a	I-I
control	I-I
group	I-I
with	O
no	O
specific	O
workout	O
.	O


Both	O
isotonic	B-I
and	I-I
isometric	I-I
training	I-I
resulted	O
in	O
significant	B-OUT
cardiovascular	I-OUT
improvement	I-OUT
but	O
seemed	O
inadequate	O
to	O
improve	O
vital	B-OUT
capacity	I-OUT
and	I-OUT
flow	I-OUT
rates	I-OUT
.	I-OUT


It	O
is	O
concluded	O
that	O
such	O
isotonic	B-I
or	I-I
isometric	I-I
training	I-I
of	O
thrice	O
a	O
week	O
for	O
ten	O
weeks	O
,	O
requiring	O
no	O
equipment	O
,	O
less	O
time	O
and	O
space	O
can	O
be	O
promoted	O
to	O
improve	O
physical	B-OUT
fitness	I-OUT
.	I-OUT


SETTING	O
The	O
study	O
was	O
conducted	O
in	O
air	B-P
and	I-P
land	I-P
emergency	I-P
medical	I-P
services	I-P
and	I-P
2	I-P
trauma	I-P
centers	I-P
serving	I-P
a	I-P
population	I-P
of	I-P
4	I-P
million	I-P
people	I-P
.	I-P


Randomization	O
compliance	O
was	O
96	O
%	O
(	O
109/113	O
)	O
.	O


Initial	B-OUT
head	I-OUT
scans	I-OUT
scored	O
3	O
or	O
higher	O
by	O
Marshall	O
classification	O
for	O
12	O
HSD	O
and	O
11	O
NS	O
patients	O
.	O


OBJECTIVE	O
Although	O
most	O
cases	O
of	O
epistaxis	O
are	O
managed	O
conservatively	O
,	O
occasionally	O
they	O
can	O
progress	O
to	O
significant	O
hemorrhage	O
requiring	O
more	O
involved	O
management	O
or	O
surgery	O
.	O


Should	O
this	O
fail	O
,	O
patients	O
then	O
proceed	O
with	O
surgical	O
clipping	O
.	O


A	O
controlled	O
,	O
randomized	O
,	O
double-blind	O
trial	O
to	O
evaluate	O
the	O
effect	O
of	O
a	O
supplement	B-I
of	I-I
cocoa	I-I
husk	I-I
that	I-I
is	I-I
rich	I-I
in	I-I
dietary	I-I
fiber	I-I
on	O
colonic	B-OUT
transit	I-OUT
in	O
constipated	B-P
pediatric	I-P
patients	I-P
.	I-P


Our	O
aim	O
with	O
this	O
pilot	O
study	O
was	O
to	O
evaluate	O
if	O
fiber	O
supplementation	O
is	O
beneficial	O
for	O
the	O
treatment	O
of	O
children	B-P
with	I-P
idiopathic	I-OUT
chronic	I-OUT
constipation	I-OUT
.	I-OUT


After	O
screening	O
,	O
the	O
patients	O
were	O
randomly	O
allocated	O
to	O
receive	O
,	O
for	O
a	O
period	O
of	O
4	O
weeks	O
,	O
either	O
a	O
cocoa	B-I
husk	I-I
supplement	I-I
or	I-I
placebo	I-I
plus	I-I
standardized	I-I
toilet	I-I
training	I-I
procedures	I-I
.	I-I


RESULTS	O
Fifty-six	B-P
chronically	I-P
constipated	I-P
children	I-P
were	I-P
randomly	I-P
assigned	I-P
into	I-P
the	I-P
study	I-P
,	I-P
but	I-P
only	I-P
48	I-P
children	I-P
completed	I-P
it	I-P
.	I-P


The	O
total	B-OUT
transit	I-OUT
time	I-OUT
decreased	O
by	O
45.4	O
+/-	O
38.4	O
hours	O
in	O
the	O
cocoa	O
husk	O
group	O
and	O
by	O
8.7	O
+/-	O
28.9	O
hours	O
in	O
the	O
placebo	O
group	O
(	O
-38.1	O
hours	O
)	O
.	O


In	O
the	O
case	O
of	O
the	O
right	O
colon	O
,	O
changes	B-OUT
in	I-OUT
transit	I-OUT
time	I-OUT
also	O
were	O
significant	O
between	O
groups	O
.	O


We	O
also	O
observed	O
a	O
reduction	O
in	O
the	O
percentage	O
of	O
patients	O
who	O
reported	O
hard	O
stools	O
(	B-OUT
hard	I-OUT
scybalous	I-OUT
or	I-OUT
pebble-like	I-OUT
stools	I-OUT
)	I-OUT
,	O
although	O
this	O
reduction	O
was	O
significantly	O
greater	O
in	O
the	O
cocoa	O
husk	O
group	O
.	O


BACKGROUND	O
High-sensitivity	B-I
C-reactive	I-I
protein	I-I
(	I-I
hsCRP	I-I
)	I-I
is	O
associated	O
with	O
adverse	O
cardiovascular	O
outcomes	O
in	O
acute	B-P
coronary	I-P
syndromes	I-P
(	I-P
ACS	I-P
)	I-P
.	I-P


The	O
ability	O
to	O
formulate	O
recommendations	O
regarding	O
clinical	O
use	O
of	O
hsCRP	B-I
is	O
limited	O
by	O
a	O
paucity	O
of	O
data	O
regarding	O
several	O
key	O
issues	O
.	O


A	O
comparative	O
analysis	O
of	O
the	O
effects	O
of	O
the	O
fixed	O
combination	B-I
of	I-I
timolol	I-I
and	I-I
dorzolamide	I-I
versus	O
latanoprost	B-I
plus	I-I
timolol	I-I
on	O
ocular	B-OUT
hemodynamics	I-OUT
and	I-OUT
visual	I-OUT
function	I-OUT
in	O
patients	B-P
with	I-P
primary	I-P
open-angle	I-P
glaucoma	I-P
.	I-P


Effects	O
of	O
vicarious	B-I
reinforcement	I-I
in	I-P
normal	I-P
and	I-P
severely	I-P
disturbed	I-P
children	I-P
.	I-P


However	O
,	O
comparisons	O
of	O
TORS	B-I
and	O
RT	B-I
in	O
a	O
non-randomized	O
fashion	O
are	O
susceptible	O
to	O
bias	O
.	O


The	O
goal	O
of	O
this	O
randomized	O
phase	O
II	O
study	O
is	O
to	O
compare	O
QOL	B-OUT
,	I-OUT
functional	I-OUT
outcomes	I-OUT
,	I-OUT
toxicity	I-OUT
profiles	I-OUT
,	I-OUT
and	I-OUT
survival	I-OUT
following	O
primary	B-I
RT	I-I
(	I-I
±	I-I
chemotherapy	I-I
)	I-I
vs.	I-I
TORS	I-I
(	I-I
±	I-I
adjuvant	I-I
[	I-I
chemo	I-I
]	I-I
RT	I-I
)	I-I
in	O
patients	O
with	O
OPSCC	O
.	O


However	O
,	O
most	O
studies	O
evaluate	O
low	O
sodium	O
diet	O
,	O
while	O
little	O
is	O
known	O
about	O
the	O
effects	O
of	O
interventions	O
to	O
improve	O
adherence	O
and	O
knowledge	O
of	O
patients	O
about	O
diet	O
content	O
.	O


Comparison	O
of	O
sedative	B-I
drugs	I-I
under	O
peribulbar	O
or	O
topical	O
anesthesia	O
during	O
phacoemulsification	B-P
.	I-P


BACKGROUND	O
AND	O
OBJECTIVE	O
To	O
compare	O
dexmedetomidine	B-I
and	I-I
midazolam+fentanyl	I-I
sedation	I-I
primarily	O
based	O
on	O
patient	O
satisfaction	O
during	O
phacoemulsification	O
under	O
topical	O
and	O
peribulbar	O
anesthesia	O
.	O


Patients	O
were	O
divided	O
into	O
four	B-P
groups	I-P
(	I-P
20	I-P
patients	I-P
for	I-P
each	I-P
)	I-P
:	I-P
dexmedetomidine	I-I
and	I-I
topical	I-I
anesthesia	I-I
,	I-I
dexmedetomidine	I-I
and	I-I
peribulbar	I-I
anesthesia	I-I
,	I-I
midazolam+fentanyl	I-I
and	I-I
topical	I-I
anesthesia	I-I
,	O
and	O
midazolam+fentanyl	B-I
and	I-I
peribulbar	I-I
anesthesia	I-I
.	I-I


Operative	O
and	O
recovery	O
times	O
were	O
recorded	O
.	O


RESULTS	O
In	O
the	O
midazolam+fentanyl	B-I
groups	O
,	O
better	O
patient	B-OUT
and	I-OUT
surgeon	I-OUT
satisfaction	I-OUT
scores	I-OUT
were	O
obtained	O
(	O
P	O
<	O
.005	O
)	O
,	O
verbal	B-OUT
pain	I-OUT
scale	I-OUT
scores	I-OUT
were	O
significantly	O
lower	O
(	O
P	O
<	O
.001	O
)	O
,	O
and	O
patients	O
needed	O
less	O
postoperative	B-OUT
analgesia	I-OUT
.	I-OUT


Studies	O
have	O
shown	O
that	O
half	O
of	O
patients	B-P
who	I-P
had	I-P
no	I-P
pre-discharge	I-P
contact	I-P
with	I-P
outpatient	I-P
services	I-P
do	O
not	O
keep	O
their	O
first	O
outpatient	O
appointment	O
.	O


The	O
treatment	O
group	O
participates	O
in	O
the	O
Post-Discharge	B-OUT
Network	I-OUT
Coordination	I-OUT
Program	I-OUT
.	I-OUT


This	O
randomized	O
controlled	O
trial	O
was	O
designed	O
to	O
demonstrate	O
whether	O
an	O
implementation	B-I
intention	I-I
intervention	I-I
involving	O
the	O
completion	O
of	O
a	O
simple	O
self-administered	B-I
questionnaire	I-I
linking	O
the	O
intention	B-I
of	I-I
taking	I-I
medication	I-I
with	I-I
a	I-I
particular	I-I
time	I-I
,	I-I
place	I-I
,	I-I
and	I-I
other	I-I
activity	I-I
can	O
improve	O
AED	B-I
treatment	O
schedule	O
adherence	O
.	O


The	O
effects	O
of	O
moderate	B-I
to	I-I
vigorous	I-OUT
aerobic	I-I
exercise	I-I
on	O
the	O
sleep	B-P
need	I-P
of	I-P
sedentary	I-P
young	I-P
adults	I-P
.	I-P


RESULTS	O
At	O
basal	O
conditions	O
there	O
were	O
no	O
significant	O
differences	O
between	O
groups	O
.	O


CONCLUSIONS	B-I
Oral	I-I
magnesium	O
supplementation	O
improves	B-OUT
the	I-OUT
metabolic	I-OUT
profile	I-OUT
and	I-OUT
blood	I-OUT
pressure	I-P
of	I-P
MONW	I-P
individuals	I-P
.	O


Time	B-OUT
spent	I-OUT
in	I-OUT
the	I-OUT
neonatal	I-OUT
intensive	I-OUT
care	I-OUT
unit	I-OUT
did	O
not	O
differ	O
between	O
groups	O
.	O


Neither	O
the	O
number	B-OUT
of	I-OUT
infants	I-OUT
requiring	I-OUT
intermittent	I-OUT
positive	I-OUT
pressure	I-OUT
ventilation	I-OUT
or	I-OUT
duration	I-OUT
of	I-OUT
O2-	I-OUT
treatment	I-OUT
,	I-OUT
nor	I-OUT
number	I-OUT
of	I-OUT
infants	I-OUT
with	I-OUT
respiratory	I-OUT
distress	I-OUT
syndrome	I-OUT
differed	O
between	O
groups	O
.	O


We	O
did	O
not	O
find	O
any	O
difference	O
in	O
the	O
outcome	O
of	O
the	O
VLBW	B-P
infants	I-P
when	I-P
the	I-P
hypertensive	I-P
mother	I-P
had	I-P
been	I-P
treated	I-P
with	I-P
either	I-P
hydralazine	I-I
or	I-P
labetalol	I-I
.	I-I


This	O
randomized	O
prospective	O
study	O
evaluates	O
the	O
need	O
for	O
hip	O
restrictions	O
following	O
a	O
modified	O
anterolateral	O
procedure	O
.	O


The	B-P
early	I-P
group	I-P
had	I-P
no	I-I
flexion	I-I
or	I-I
car	I-I
riding	I-I
restrictions	I-I
.	I-I


No	O
incidents	O
of	O
dislocation	B-OUT
occurred	O
.	O


They	O
also	O
drove	B-OUT
earlier	O
(	O
P=.02	O
)	O
.	O


One	O
hundred	O
patients	O
received	O
1	B-I
gm	I-I
of	I-I
erythromycin	I-I
base	I-I
by	O
mouth	O
per	O
day	O
for	O
4	O
weeks	O
,	O
followed	O
by	O
333	O
mg/day	O
for	O
8	O
weeks	O
,	O
plus	O
placebo	B-I
for	I-I
tetracycline	I-I
.	I-I


Furthermore	O
,	O
the	O
combination	O
could	O
facilitate	O
this	O
determination	O
in	O
72	O
%	O
(	O
35/49	O
)	O
,	O
significantly	O
better	O
than	O
CA19-9	O
alone	O
(	O
P	O
=	O
0.004	O
)	O
.	O


Comparative	O
effects	O
of	O
valsartan	B-I
versus	O
amlodipine	B-I
on	O
left	O
ventricular	O
mass	O
and	O
reactive	O
oxygen	O
species	O
formation	O
by	O
monocytes	O
in	O
hypertensive	B-P
patients	I-P
with	I-P
left	I-P
ventricular	I-P
hypertrophy	I-P
.	I-P


In	O
addition	O
,	O
CRP	O
,	O
plasma	O
renin	O
activity	O
,	O
plasma	O
aldosterone	O
,	O
and	O
traditional	O
risk	O
factors	O
were	O
assessed	O
.	O


Formation	B-OUT
of	I-OUT
ROS	I-OUT
by	I-OUT
monocytes	I-OUT
was	O
reduced	B-OUT
to	I-OUT
a	I-OUT
greater	I-OUT
extent	I-OUT
with	O
valsartan	B-I
than	O
with	O
amlodipine	B-I
(	O
28	O
%	O
vs.	O
2	O
%	O
,	O
n	O
=	O
50	O
,	O
p	O
<	O
0.01	O
)	O
.	O


Valsartan	B-I
but	O
not	O
amlodipine	B-I
reduced	I-OUT
CRP	I-OUT
levels	I-OUT
.	I-OUT


METHODS	O
Forty	B-P
cases	I-P
with	I-P
respiration	I-P
and	I-P
cardiac	I-P
arrest	I-P
in	I-P
the	I-P
department	I-P
of	I-P
critical	I-P
care	I-P
medicine	I-P
were	I-P
randomly	I-P
divided	I-P
into	O
low	B-I
VT	I-I
ventilation	I-I
group	I-I
and	I-I
conventional	I-I
VT	I-I
group	I-I
.	I-I


In	O
all	O
the	O
patients	O
in	B-OUT
both	I-OUT
groups	I-OUT
barotrauma	O
did	O
not	O
occur	O
.	O


SETTING	O
University	O
laboratory	O
.	O


MAIN	O
OUTCOME	O
MEASURES	O
Knee	B-OUT
range	I-OUT
of	I-OUT
motion	I-OUT
(	I-OUT
ROM	I-OUT
)	I-OUT
,	I-OUT
stretch	I-OUT
perception	I-OUT
,	I-OUT
pressure	I-OUT
pain	I-OUT
threshold	I-OUT
(	I-OUT
PPT	I-OUT
)	I-OUT
and	I-OUT
subjective	I-OUT
pain	I-OUT
intensity	I-OUT
.	I-OUT


Effect	O
of	O
marine	B-I
oils	I-I
supplementation	I-I
on	O
coagulation	O
and	O
cellular	O
activation	O
in	O
whole	O
blood	O
.	O


The	O
concentration	B-OUT
of	I-OUT
prothrombin	I-OUT
fragment	I-OUT
1	I-OUT
+	I-OUT
2	I-OUT
was	O
reduced	O
25	O
%	O
(	O
P	O
<	O
0.05	O
)	O
after	O
whale	O
oil	O
supplementation	O
.	O


The	O
LPS-induced	B-OUT
tissue	I-OUT
factor	I-OUT
activity	I-OUT
in	I-OUT
monocytes	I-OUT
was	O
reduced	O
to	O
a	O
significant	O
degree	O
only	O
in	O
the	O
seal/CLO	O
group	O
(	O
34	O
%	O
)	O
and	O
whale	O
oil	O
group	O
(	O
35	O
%	O
)	O
(	O
P	O
<	O
0.05	O
)	O
.	O


The	O
most	O
dramatic	O
change	O
in	O
thromboxane	B-OUT
B2	I-OUT
in	O
LPS-stimulated	O
blood	O
was	O
seen	O
after	O
whale	O
oil	O
intake	O
with	O
44	O
%	O
reduction	O
(	O
P	O
<	O
0.01	O
)	O
.	O


CONCLUSION	O
The	O
results	O
from	O
our	O
study	O
indicate	O
that	O
injecting	O
subcutaneous	O
buffered	O
lidocaine	B-I
before	O
intradermal	O
injection	O
of	O
(	O
99m	O
)	O
Tc-SC	O
for	O
breast	O
lymphoscintigraphy	O
significantly	O
decreases	O
patient	B-OUT
pain	I-OUT
without	O
interfering	O
with	O
lymph	B-OUT
node	I-OUT
visualization	I-OUT
.	I-OUT


Operative	O
data	O
and	O
complications	O
were	O
recorded	O
,	O
and	O
patients	O
were	O
followed	O
up	O
through	O
a	O
structured	O
pro	O
forma	O
protocol	O
.	O


METHOD	O
the	O
research	O
sample	O
consisted	O
of	O
11	B-P
mothers	I-P
of	I-P
children	I-P
diagnosed	I-P
,	I-P
according	I-P
to	I-P
the	I-P
criteria	I-P
established	I-P
by	I-P
the	I-P
DSM	I-P
IVtr	I-P
(	I-P
APA	I-P
,	I-P
2002	I-P
)	I-P
,	I-P
with	I-P
autism	I-P
(	I-P
six	I-P
)	I-P
and	I-P
with	I-P
Asperger	I-P
Syndrome	I-P
(	I-P
five	I-P
)	I-P
and	I-P
who	I-P
were	I-P
seen	I-P
at	I-P
the	I-P
Investigation	I-P
Laboratory	I-P
of	I-P
Global	I-P
Developmental	I-P
Disorders	I-P
of	I-P
the	I-P
Federal	I-P
University	I-P
of	I-P
São	I-P
Paulo	I-P
.	O


The	O
better	O
scores	O
observed	O
for	O
the	O
TG	O
is	O
probably	O
related	O
to	O
the	O
effectiveness	O
of	O
direct	O
intervention	O
,	O
and	O
not	O
to	O
the	O
lack	O
of	O
attention	O
of	B-P
parents	I-P
in	O
the	B-I
OG	I-I
in	O
recognizing	O
behavioral	O
changes	O
in	O
their	O
children	O
.	O


Seventy-three	B-P
patients	I-P
with	I-P
advanced	I-P
UGIA	I-P
were	I-P
randomised	I-P
to	O
receive	O
45	B-I
mg/m2	I-I
docetaxel	I-I
or	I-I
180	I-I
mg/m2	I-I
irinotecan	I-I
with	I-I
5-FU/leucovorin	I-I
.	I-I


All	O
baseline	O
marker	O
levels	O
,	O
except	O
CA72-4	O
,	O
correlated	O
with	O
time	B-OUT
to	I-OUT
progression	I-OUT
and	O
survival	B-OUT
.	I-OUT


Early	O
changes	O
generally	O
failed	O
to	O
provide	O
accurate	O
information	O
for	O
tumour	O
response	O
and	O
survival	O
.	O


A	O
formula	O
that	O
provides	O
12.5	O
mg/L	O
of	O
zinc	O
permits	O
positive	B-OUT
zinc	I-OUT
balance	I-OUT
and	I-OUT
zinc	I-OUT
retention	I-OUT
similar	O
to	O
in	O
utero	O
rates	O
.	O


An	B-I
exposure	I-I
prevention	I-I
rating	I-I
method	I-I
for	O
intervention	O
needs	O
assessment	O
and	O
effectiveness	O
evaluation	O
.	O


Validation	O
studies	O
are	O
needed	O
as	O
a	O
next	O
step	O
.	O


This	O
assessment	O
method	O
complements	O
quantitative	O
exposure	O
assessment	O
with	O
an	O
upstream	O
prevention	O
focus	O
.	O


We	O
planned	O
analyses	O
of	O
mature	O
overall	O
survival	O
data	O
in	O
the	O
intention-to-treat	O
population	B-P
after	O
209	O
(	O
LUX-Lung	O
3	O
)	O
and	O
237	O
(	O
LUX-Lung	O
6	O
)	O
deaths	O
.	O


FINDINGS	O
Median	O
follow-up	O
in	O
LUX-Lung	O
3	O
was	O
41	O
months	O
(	O
IQR	O
35-44	O
)	O
;	O
213	O
(	O
62	O
%	O
)	O
of	O
345	B-P
patients	I-P
had	O
died	O
.	O


In	O
both	O
trials	O
,	O
the	O
most	O
common	O
afatinib-related	O
grade	B-OUT
3-4	I-OUT
adverse	I-OUT
events	I-OUT
were	O
rash	B-OUT
or	I-OUT
acne	I-OUT
(	O
37	O
[	O
16	O
%	O
]	O
of	O
229	B-P
patients	I-P
in	I-P
LUX-Lung	I-P
3	I-P
and	O
35	O
[	O
15	O
%	O
]	O
of	O
239	B-P
patients	I-P
in	I-P
LUX-Lung	I-P
6	O
)	O
,	O
diarrhoea	B-OUT
(	O
33	O
[	O
14	O
%	O
]	O
and	O
13	O
[	O
5	O
%	O
]	O
)	O
,	O
paronychia	B-OUT
(	O
26	O
[	O
11	O
%	O
]	O
in	O
LUX-Lung	O
3	O
only	O
)	O
,	O
and	O
stomatitis	B-OUT
or	I-OUT
mucositis	I-OUT
(	O
13	O
[	O
5	O
%	O
]	O
in	O
LUX-Lung	O
6	O
only	O
)	O
.	O


It	O
has	O
not	O
been	O
studied	O
in	O
combination	O
with	O
2-CP	B-I
.	I-I


Tomato	B-I
paste	I-I
rich	I-I
in	I-I
lycopene	I-I
protects	O
against	O
cutaneous	B-OUT
photodamage	I-OUT
in	O
humans	B-P
in	I-P
vivo	I-P
:	I-P
a	O
randomized	O
controlled	O
trial	O
.	O


Comparing	O
the	O
effectiveness	B-OUT
of	O
peer	B-I
mentoring	I-I
and	O
student	B-I
mentoring	I-I
in	O
a	O
35-week	O
fitness	O
program	O
for	O
older	B-P
adults	I-P
.	I-P


To	O
investigate	O
the	O
applicability	B-OUT
and	O
effectiveness	B-OUT
of	O
a	O
peer-mentored	B-I
exercise	I-I
program	I-I
,	O
this	O
study	O
compared	O
the	O
retention	B-OUT
and	I-OUT
participation	I-OUT
rates	I-OUT
,	O
and	O
physical	B-OUT
improvements	I-OUT
of	O
older	B-P
adults	I-P
trained	I-I
by	I-I
peer	I-I
mentors	I-I
(	I-I
PM	I-I
)	I-I
to	I-I
a	I-I
group	I-I
trained	I-I
by	I-I
young	I-I
qualified	I-I
student	I-I
mentors	I-I
(	I-I
SM	I-I
)	I-I
.	I-I


Pre-	O
,	O
midterm-	O
and	O
post-training	B-OUT
assessments	I-OUT
of	I-OUT
fitness	I-OUT
were	O
completed	O
and	B-OUT
rates	I-OUT
of	I-OUT
participation	I-OUT
and	I-OUT
retention	I-OUT
were	O
documented	O
.	O


Twelve	B-P
healthy	I-P
male	I-P
volunteers	I-P
received	O
a	O
constant	B-I
30-min	I-I
infusion	I-I
of	I-I
either	I-I
1	I-I
g	I-I
of	I-I
imipenem	I-I
plus	I-I
1	I-I
g	I-I
of	I-I
cilastatin	I-I
or	I-I
1	I-I
g	I-I
of	I-I
meropenem	I-I
.	I-I


Pharmacokinetic	O
parameters	O
were	O
based	O
on	O
an	O
open	O
two-compartment	B-I
model	I-I
and	I-I
a	I-I
noncompartmental	I-I
technique	I-I
.	I-I


The	O
volumes	O
of	O
distribution	O
at	O
steady	O
state	O
of	O
imipenem	O
and	O
meropenem	O
were	O
15.3	O
+/-	O
3.3	O
and	O
18.6	O
+/-	O
3.0	O
liters/70	O
kg	O
,	O
respectively	O
,	O
and	O
the	O
mean	O
renal	O
clearances	O
per	O
1.73	O
m2	O
were	O
85.6	O
+/-	O
17.6	O
and	O
144.6	O
+/-	O
26.0	O
ml/min	O
,	O
respectively	O
.	O


Both	B-P
antibiotics	I-P
were	I-P
well	I-P
tolerated	I-P
in	I-P
this	I-P
single-dose	I-P
administration	I-P
study	I-P
.	I-P


After	O
1	O
and	O
6	O
h	O
the	O
median	O
SBAs	B-OUT
for	O
imipenem	O
and	O
meropenem	O
,	O
were	O
409	O
and	O
34.9	O
and	O
97.9	O
and	O
5.8	O
,	O
respectively	O
,	O
against	O
Staphylococcus	O
aureus	O
,	O
19.9	O
and	O
4.4	O
and	O
19.4	O
and	O
4.8	O
,	O
respectively	O
,	O
against	O
Pseudomonas	O
aeruginosa	O
,	O
34.3	O
and	O
2.2	O
and	O
232	O
and	O
15.5	O
,	O
respectively	O
,	O
against	O
Enterobacter	O
cloacae	O
,	O
and	O
13.4	O
and	O
2.25	O
and	O
90.7	O
and	O
7.9	O
,	O
respectively	O
,	O
against	O
Proteus	O
mirabilis	O
.	O


BACKGROUND	O
Ageing	O
with	O
visual	O
impairment	O
is	O
associated	O
with	O
a	O
high	O
degree	O
of	O
disability	O
whereby	O
age-related	O
macular	O
degeneration	O
in	O
particular	O
causes	O
dependence	O
in	O
activities	B-OUT
of	I-OUT
daily	I-OUT
living	I-OUT
(	I-OUT
ADL	I-OUT
)	I-OUT
even	O
at	O
an	O
early	O
stage	O
.	O


CONCLUSION	O
The	O
health-promotion	B-I
programme	I-I
seems	O
to	O
have	O
slowed	O
down	O
the	O
disablement	B-OUT
process	I-OUT
among	O
elderly	B-P
with	I-P
decreased	I-P
vision	I-P
by	O
enabling	O
them	O
to	O
maintain	O
their	O
ADL	B-OUT
level	I-OUT
and	O
by	O
reducing	B-OUT
self-reported	I-OUT
health	I-OUT
problems	I-OUT
for	O
at	O
least	O
28	O
months	O
following	O
intervention	O
.	O


DESIGN	O
Patients	O
in	O
this	O
randomized	O
,	O
double-blind	O
,	O
vehicle-controlled	O
study	O
applied	O
5	B-I
%	I-I
imiquimod	I-I
cream	I-I
or	I-I
vehicle	I-I
to	I-I
AK	I-OUT
lesions	I-OUT
3	I-I
times	I-I
per	I-I
week	I-I
for	I-I
a	I-I
maximum	I-I
of	I-I
12	I-I
weeks	I-I
or	I-I
until	I-I
lesions	I-I
had	I-I
resolved	I-I
.	I-I


A	O
statistical	O
comparison	O
of	O
the	O
pharmacokinetic	B-OUT
parameters	I-OUT
did	O
not	O
demonstrate	O
bioequivalence	O
of	O
the	O
two	O
products	O
.	O


The	O
antibody	B-OUT
level	I-OUT
in	O
either	O
group	O
were	O
low	O
throughout	O
the	O
15-day	O
study	O
period	O
.	O


The	O
geometric	B-OUT
mean	I-OUT
titer	I-OUT
(	I-OUT
GMT	I-OUT
)	I-OUT
values	I-OUT
ranged	O
from	O
group	O
0.027-0.117	O
IU	O
ml	O
(	O
-1	O
)	O
in	O
the	O
Erig	O
group	O
and	O
from	O
0.029	O
to	O
0.072	O
IU	O
ml	O
(	O
-1	O
)	O
in	O
the	O
PHT-Erig	O
.	O


The	O
increased	O
purity	O
,	O
the	O
heat-treatment	O
step	O
introduced	O
in	O
the	O
manufacturing	O
process	O
of	O
PHT-Erig	O
,	O
and	O
the	O
good	O
clinical	O
results	O
substantiate	O
the	O
use	O
of	O
this	O
new	O
generation	O
,	O
purified	O
equine	O
F	O
(	O
ab	O
'	O
)	O
2	O
preparation	O
in	O
the	O
post-exposure	O
prophylaxis	O
of	O
rabies	O
.	O


OBJECTIVE	O
To	O
examine	O
the	O
adhesion	B-OUT
prevention	I-OUT
effects	I-OUT
of	O
2	O
types	O
of	O
fibrin	B-I
sealant	I-I
after	I-I
laparoscopic	I-I
myomectomy	I-I
(	I-I
LM	I-I
)	I-I
.	I-I


No	B-OUT
bilateral	I-OUT
adnexal	I-OUT
adhesions	I-OUT
were	O
observed	O
in	O
the	O
3	O
groups	O
.	O


The	O
effectiveness	O
of	O
educational	B-I
interventions	I-I
to	O
enhance	O
the	O
adoption	B-OUT
of	I-OUT
fee-based	I-OUT
arsenic	I-OUT
testing	I-OUT
in	I-P
Bangladesh	I-P
:	I-P
a	O
cluster	O
randomized	O
controlled	O
trial	O
.	O


Randomly	B-P
selected	I-P
households	I-P
(	I-P
N	I-P
=	I-P
452	I-P
)	I-P
were	O
divided	O
into	O
three	B-I
interventions	I-I
implemented	I-I
by	I-I
community	I-I
workers	I-I
:	I-I
1	I-I
)	I-I
fee-based	I-I
As	I-I
testing	I-I
with	I-I
household	I-I
education	I-I
(	I-I
HE	I-I
)	I-I
;	I-I
2	I-I
)	I-I
fee-based	I-I
As	I-I
testing	I-I
with	I-I
household	I-I
education	I-I
and	I-I
a	I-I
local	I-I
media	I-I
campaign	I-I
(	I-I
HELM	I-I
)	I-I
;	I-I
and	I-I
3	I-I
)	I-I
fee-based	I-I
As	I-I
testing	I-I
alone	I-I
(	I-I
Control	I-I
)	I-I
.	I-I


The	O
fee	O
for	O
the	O
As	O
test	O
was	O
US	O
$	O
0.28	O
,	O
higher	O
than	O
the	O
cost	O
of	O
the	O
test	O
(	O
US	O
$	O
0.16	O
)	O
.	O


In	O
conclusion	O
,	O
fee-based	B-OUT
As	I-OUT
testing	I-OUT
with	I-I
household	I-OUT
education	I-OUT
is	I-OUT
effective	I-OUT
in	I-OUT
the	I-OUT
increasing	I-OUT
demand	I-OUT
for	I-OUT
As	I-OUT
testing	I-OUT
in	I-P
rural	I-P
Bangladesh	I-P
.	I-P


METHODS	O
We	O
administered	O
a	O
double-blind	O
placebo-controlled	B-I
trial	O
of	O
fluoxetine	B-I
to	O
35	B-P
patients	I-P
with	I-P
restricting-type	I-P
anorexia	I-P
nervosa	I-P
.	I-P


These	O
surveys	O
suggested	O
that	O
engaging	O
supervisors	O
in	O
a	O
dialogue	O
about	O
tolerance	O
might	O
improve	B-OUT
their	I-OUT
willingness	I-OUT
to	I-OUT
use	I-OUT
the	I-OUT
EAP	I-OUT
.	I-OUT


This	O
training	O
adopted	O
a	O
cognitive	O
mapping	O
technique	O
to	O
help	O
improve	O
supervisor	O
responsiveness	O
.	O


There	O
were	O
42	B-P
patients	I-P
in	I-P
the	I-P
experimental	I-P
group	I-P
,	I-P
including	I-P
16	I-P
males	I-P
and	I-P
26	I-P
females	I-P
,	I-P
ranging	I-P
in	I-P
age	I-P
from	I-P
41	I-P
to	I-P
63	I-P
years	I-P
,	I-P
with	I-P
an	I-P
average	I-P
of	I-P
(	I-P
53.62	I-P
+/-	I-P
6.53	I-P
)	I-P
years	I-P
;	I-P
the	I-P
disease	I-P
course	I-P
ranged	I-P
from	I-P
8	I-P
to	I-P
24	I-P
months	I-P
,	I-P
with	I-P
an	I-P
average	I-P
of	I-P
(	I-P
10.35	I-P
+/-	I-P
6.42	I-P
)	I-P
months	I-P
.	I-P


PATIENTS	O
AND	O
METHODS	O
Two	B-P
hundred	I-P
eighty-eight	I-P
cancer	I-P
patients	I-P
,	I-P
referred	I-P
to	I-P
complementary	I-P
therapy	I-P
services	I-P
with	I-P
clinical	I-P
anxiety	I-P
and/or	I-P
depression	I-P
,	O
were	O
allocated	O
randomly	O
to	O
a	O
course	O
of	O
aromatherapy	B-I
massage	I-I
or	I-I
usual	I-I
supportive	I-I
care	I-I
alone	I-I
.	I-I


CONCLUSION	O
Aromatherapy	B-I
massage	I-I
does	O
not	O
appear	O
to	O
confer	O
benefit	B-OUT
on	O
cancer	B-P
patients	I-P
'	I-P
anxiety	I-OUT
and/or	I-OUT
depression	I-OUT
in	O
the	O
long-term	O
,	O
but	O
is	O
associated	O
with	O
clinically	O
important	O
benefit	B-OUT
up	O
to	O
2	O
weeks	O
after	O
the	O
intervention	O
.	O


METHODS	O
A	O
cluster	O
randomized	O
field	O
trial	O
was	O
conducted	O
among	B-P
2968	I-P
Bangladeshi	I-P
rural	I-P
children	I-P
6-36	I-P
months	I-P
old	I-P
.	O


CONCLUSIONS	O
Oral	O
dexamethasone	O
therapy	O
does	O
not	O
affect	O
the	O
clinical	B-OUT
course	I-OUT
of	O
children	B-P
hospitalized	I-P
with	I-P
bronchiolitis	I-P
and	O
therefore	O
can	O
not	O
be	O
recommended	O
in	O
this	O
clinical	O
situation	O
.	O


METHODS	O
Three	B-P
hundred	I-P
cases	I-P
of	I-P
VVC	I-P
were	I-P
recruited	I-P
.	I-P


Eradication	B-OUT
rate	I-OUT
of	O
3	O
day	O
,	O
6	O
day	O
and	O
7	O
day	O
miconazole	B-I
courses	O
for	O
uncomplicated	O
VVC	O
at	O
day	O
35	O
was	O
93.8	O
%	O
,	O
95.3	O
%	O
,	O
and	O
89.8	O
%	O
,	O
respectively	O
(	O
P	O
>	O
0.05	O
)	O
.	O


Preliminary	O
findings	O
from	O
a	O
prospective	O
,	O
randomized	O
trial	O
of	O
two	O
palatal	B-I
operations	I-I
for	O
sleep-disordered	O
breathing	O
.	O


METHODS	O
Twenty	B-P
patients	I-P
with	I-P
mild	I-P
SDB	I-P
for	I-P
whom	I-P
conservative	I-P
treatment	I-P
failed	I-P
were	O
identified	O
and	O
consecutively	O
enrolled	O
into	O
an	O
institutional	O
review	O
board-approved	O
surgical	O
protocol	O
.	O


Patients	O
not	O
achieving	O
satisfactory	O
improvement	O
in	O
their	O
condition	O
were	O
crossed	O
over	O
to	O
the	O
alternative	B-I
surgical	I-I
therapy	I-I
for	I-I
attempted	I-I
salvage	I-I
.	I-I


Six	O
of	O
the	O
RFAP	B-I
patients	O
(	O
60	O
%	O
)	O
achieved	O
a	O
satisfactory	O
resolution	O
of	O
their	O
snoring	B-OUT
,	O
and	O
4	O
failed	O
and	O
were	O
salvaged	O
with	O
LAUP	B-I
.	I-I


Effectiveness	O
of	O
education	O
for	O
gastric	B-P
cancer	I-P
patients	I-P
:	I-P
a	O
controlled	O
prospective	O
trial	O
comparing	O
interactive	B-I
vs.	I-I
lecture-based	I-I
programs	I-I
.	I-I


The	O
outcomes	O
were	O
patients	B-OUT
'	I-OUT
disease-related	I-OUT
knowledge	I-OUT
,	I-OUT
active	I-OUT
coping	I-OUT
with	I-OUT
illness	I-OUT
,	I-OUT
and	I-OUT
quality	I-OUT
of	I-OUT
life	I-OUT
(	I-OUT
QoL	I-OUT
)	I-OUT
at	O
the	O
end	O
of	O
their	O
stay	O
and	O
6	O
and	O
12	O
months	O
thereafter	O
.	O


METHODS	O
In	O
this	O
study	O
,	O
88	B-P
patients	I-P
6-17	I-P
years	I-P
of	I-P
age	I-P
,	I-P
with	I-P
ADHD	I-P
and	I-P
ASD	I-P
,	O
were	O
treated	O
with	O
1.2	O
mg/kg/day	O
atomoxetine	B-I
for	O
20	O
weeks	O
as	O
follow-up	O
of	O
an	O
8	O
week	O
double-blind	O
placebo-controlled	B-I
period	O
.	O


Subjective	O
effects	O
of	O
,	O
and	O
preference	O
for	O
,	O
ethanol	B-I
and	I-I
diazepam	I-I
vs.	I-I
placebo	I-I
were	O
measured	O
using	O
a	O
choice	O
procedure	O
.	O


Diazepam	B-I
produced	O
sedative-like	B-OUT
effects	I-OUT
in	O
both	O
choosers	O
and	O
non-choosers	O
,	O
but	O
markedly	O
decreased	B-OUT
Anxiety	I-OUT
and	I-OUT
increased	I-OUT
Friendliness	I-OUT
in	O
choosers	O
only	O
.	O


Amoxicillin/metronidazole/omeprazole/clarithromycin	O
:	O
a	O
new	O
,	O
short	O
quadruple	O
therapy	B-P
for	I-P
Helicobacter	I-OUT
pylori	I-OUT
eradication	I-OUT
.	I-OUT


BACKGROUND	O
Triple	O
therapy	O
regimens	O
including	O
two	O
antibiotics	O
plus	O
acid	O
suppression	O
have	O
become	O
the	O
new	O
standard	O
therapy	O
in	O
Helicobacter	O
pylori	O
eradication	O
because	O
of	O
success	O
rates	O
of	O
about	O
90	O
%	O
.	O


Each	O
of	O
the	O
four	O
drugs	O
was	O
given	O
for	O
5	O
days	O
.	O


A	O
multicenter	O
,	O
open-label	O
study	O
of	O
vernakalant	O
for	O
the	O
conversion	O
of	O
atrial	B-P
fibrillation	I-P
to	O
sinus	O
rhythm	O
.	O


BACKGROUND	O
The	O
efficacy	B-OUT
and	I-OUT
safety	I-OUT
of	O
vernakalant	O
,	O
a	O
relatively	O
atrial-selective	O
antiarrhythmic	O
agent	O
,	O
in	O
converting	O
atrial	B-OUT
fibrillation	I-OUT
(	I-OUT
AF	I-OUT
)	I-OUT
to	O
sinus	B-OUT
rhythm	I-OUT
(	I-OUT
SR	I-OUT
)	I-OUT
were	O
evaluated	O
in	O
this	O
multicenter	B-P
,	I-P
open-label	I-P
study	I-P
of	I-P
patients	I-P
with	I-P
AF	I-P
lasting	I-P
>	I-P
3	I-P
hours	I-P
and	I-P
<	I-P
or	I-P
=45	I-P
days	I-P
(	O
RCT	O
no	O
.	O


NCT00281554	O
)	O
.	O


METHODS	O
Adult	B-P
patients	I-P
with	I-P
AF	I-P
and	I-P
an	I-P
indication	I-P
for	I-P
conversion	I-P
to	I-P
SR	I-OUT
received	I-I
a	I-I
10-minute	I-I
intravenous	I-I
infusion	I-I
of	I-I
vernakalant	I-I
(	I-I
3	I-I
mg/kg	I-I
)	I-I
.	I-I


If	B-I
after	I-I
a	I-I
15-minute	I-I
observation	I-I
period	I-I
AF	I-I
was	I-I
present	I-I
,	I-I
a	I-I
second	I-I
10-minute	I-I
infusion	I-I
of	I-I
intravenous	I-I
vernakalant	I-I
(	I-I
2	I-I
mg/kg	I-I
)	I-I
was	I-I
given	I-I
.	I-I


CONCLUSIONS	O
Vernakalant	O
rapidly	O
converted	O
recent-onset	O
AF	O
to	O
SR	O
,	O
was	O
well	O
tolerated	O
,	O
and	O
may	O
be	O
a	O
valuable	O
therapeutic	O
alternative	O
for	O
reestablishing	O
SR	O
in	O
patients	B-P
with	I-P
recent-onset	I-P
AF	I-P
.	I-P


Prospective	O
randomized	O
trial	O
of	O
an	O
anterior	O
surface	O
modified	O
prolate	O
intraocular	O
lens	O
.	O


PURPOSE	O
We	O
compare	O
the	O
contrast	B-OUT
sensitivity	I-OUT
obtained	O
with	O
an	O
anterior	O
surface	O
modified	O
prolate	O
intraocular	O
lens	O
with	O
the	O
contrast	O
sensitivity	O
obtained	O
with	O
a	O
standard	O
spherical	O
intraocular	O
lens	O
.	O


Further	O
analyses	O
on	O
appropriately	O
powered	O
subsets	O
are	O
needed	O
to	O
determine	O
the	O
prognostic	O
and	O
predictive	O
significance	O
of	O
MET	O
in	O
vemurafenib-treated	O
melanoma	O
.	O


No	B-OUT
significant	O
group	O
differences	O
were	O
found	O
on	O
other	O
aspects	O
of	O
parent-child	B-OUT
interaction	I-OUT
or	I-OUT
on	I-OUT
child	I-OUT
play	I-OUT
behavior	I-OUT
.	I-OUT


Implementation	O
of	O
VIPP-AUTI	B-I
in	O
clinical	O
practice	O
is	O
facilitated	O
by	O
the	O
use	O
of	O
a	O
detailed	O
manual	O
and	O
a	O
relatively	O
brief	O
training	O
of	O
interveners	O
.	O


RESULTS	O
After	O
the	O
intervention	O
period	O
,	O
the	O
diabetes	B-I
specific	I-I
formula	I-I
resulted	O
in	O
a	O
significantly	O
lower	O
postprandial	B-OUT
rise	I-OUT
in	I-OUT
blood	I-OUT
glucose	I-OUT
concentrations	I-OUT
at	O
0.5	O
hour	O
(	O
P	O
<	O
0.05	O
)	O
and	O
1	O
hour	O
(	O
P	O
<	O
0.01	O
)	O
;	O
significantly	O
lower	O
peak	B-OUT
height	I-OUT
of	I-OUT
plasma	I-OUT
glucose	I-OUT
(	O
P	O
=	O
0.05	O
)	O
;	O
significantly	O
lower	O
plasma	B-OUT
insulin	I-OUT
concentrations	I-OUT
at	O
0.5	O
hour	O
(	O
P	O
<	O
0.01	O
)	O
,	O
1	O
hour	O
(	O
P	O
<	O
0.01	O
)	O
and	O
2	O
hours	O
(	O
P	O
<	O
0.01	O
)	O
;	O
and	O
a	O
significantly	O
lower	O
plasma	B-OUT
insulin	I-OUT
peak	I-OUT
compared	O
to	O
controls	O
;	O
both	O
OGTT	O
and	O
a	O
standard	O
test	O
meal	O
(	O
P	O
<	O
0.05	O
)	O
.	O


On	O
top	O
of	O
this	O
,	O
the	O
insulin	B-OUT
sensitivity	I-OUT
(	I-OUT
HOMA-IS	I-OUT
)	I-OUT
was	O
significantly	O
improved	O
and	O
may	O
therefore	O
directly	O
improve	O
the	O
impact	O
on	O
long	O
term	O
complications	O
.	O


Monitoring	O
acute	O
effects	O
on	O
athletic	O
performance	O
with	O
mixed	O
linear	O
modeling	O
.	O


We	O
used	O
mixed	O
linear	O
modeling	O
of	O
log-transformed	O
swim	O
time	O
to	O
quantify	O
effects	B-OUT
on	I-OUT
performance	I-OUT
in	O
training	O
versus	O
competition	O
,	O
in	O
morning	O
versus	O
evening	O
swims	O
,	O
and	O
with	O
use	O
of	O
caffeine	O
.	O


RESULTS	O
Most	O
effects	B-OUT
were	O
clear	O
,	O
owing	O
to	O
the	O
high	O
reliability	O
of	O
performance	B-OUT
times	I-OUT
in	I-OUT
training	I-OUT
and	I-OUT
competition	I-OUT
(	O
typical	O
errors	O
of	O
0.9	O
%	O
and	O
0.8	O
%	O
,	O
respectively	O
)	O
.	O


Performance	B-OUT
time	I-OUT
improved	O
linearly	O
by	O
0.8	O
%	O
per	O
4	O
wk	O
.	O


OBJECTIVE	O
To	O
compare	O
efficacy	O
between	O
double-dose	O
methotrexate	B-I
and	O
single-dose	O
methotrexate	B-I
for	O
treatment	O
of	O
tubal	O
ectopic	O
pregnancy	O
(	O
EP	O
)	O
.	O


Serum	O
human	O
chorionic	O
gonadotropin	O
(	O
β-hCG	O
)	O
levels	O
were	O
followed	O
until	O
negative	O
.	O


Receiver	O
operative	O
characteristics	O
showed	O
that	O
higher	O
cut-off	O
levels	O
of	B-OUT
β-hCG	I-OUT
and	I-OUT
gestational	I-OUT
mass	I-OUT
diameter	I-OUT
were	O
associated	O
with	B-OUT
successful	I-OUT
outcome	I-OUT
in	O
group	O
1	O
.	O


Among	O
participants	O
with	O
initial	O
β-hCG	O
of	O
3600-5500	O
mIU/mL	O
,	O
the	B-OUT
success	I-OUT
rate	I-OUT
was	O
higher	O
in	O
group	O
1	O
(	O
P=0.03	O
)	O
.	O


BACKGROUND	O
Myocardial	B-I
contrast	I-I
echocardiography	I-I
may	O
be	O
more	O
versatile	O
than	O
perfusion	B-I
scintigraphy	I-I
for	O
identifying	O
the	O
presence	O
and	O
extent	O
of	O
perfusion	O
defects	O
after	O
MI	O
.	O


The	O
accuracy	O
of	O
MCE	B-I
was	O
assessed	O
for	O
detection	O
of	O
segments	O
and	O
patients	O
with	O
moderate	O
and	O
severe	O
sestamibi-SPECT	O
defects	O
,	O
as	O
well	O
as	O
for	O
detection	O
of	O
patients	O
with	O
extensive	O
perfusion	O
defects	O
(	O
>	O
12	O
%	O
of	O
left	O
ventricle	O
)	O
.	O


Thematic	O
qualitative	O
analysis	O
of	O
the	O
parent	O
interviews	O
showed	O
that	O
the	O
parent-child	O
relationship	O
grew	O
stronger	O
.	O


CONCLUSION	O
FCMT	B-I
improves	O
social	O
interactions	O
in	O
the	O
home	O
and	O
community	O
and	O
the	O
parent-child	O
relationship	O
,	O
but	O
not	O
language	O
skills	O
or	O
general	O
social	O
responsiveness	O
.	O


In	O
addition	O
,	O
a	O
general	O
enhancement	O
of	O
the	O
activation	B-OUT
state	I-OUT
of	I-OUT
T	I-OUT
lymphocytes	I-OUT
was	O
observed	O
.	O


We	O
compared	O
the	O
efficacy	O
of	O
pretreatment	O
with	O
thiopental	B-I
0.25	O
mg/kg	O
and	O
0.5	O
mg/kg	O
and	O
lidocaine	B-I
40	O
mg	O
after	O
venous	O
occlusion	O
for	O
prevention	O
of	O
propofol-induced	B-OUT
pain	I-OUT
.	I-OUT


Propofol	B-I
was	O
administered	O
after	O
release	O
of	O
venous	O
occlusion	O
.	O


We	O
therefore	O
suggest	O
routine	O
pretreatment	O
with	O
thiopental	B-I
0.5	O
mg/kg	O
along	O
with	O
venous	O
occlusion	O
for	O
1	O
min	O
for	O
prevention	O
of	O
pain	B-OUT
associated	O
with	O
propofol	O
injection	O
.	O


Pretreatment	O
with	O
thiopental	B-I
0.25	O
mg/kg	O
and	O
0.5	O
mg/kg	O
after	O
manual	O
venous	O
occlusion	O
for	O
1	O
min	O
effectively	O
attenuated	O
pain	B-OUT
associated	O
with	O
propofol	O
injection	O
.	O


Solutions	O
were	O
used	O
for	O
skin	O
disinfection	O
before	O
catheter	O
insertion	O
(	O
2	O
consecutive	O
30-second	O
applications	O
separated	O
by	O
a	O
period	O
sufficiently	O
long	O
to	O
allow	O
for	O
dryness	O
)	O
and	O
then	O
as	O
single	O
applications	O
during	O
subsequent	O
dressing	O
changes	O
(	O
every	O
72	O
hours	O
,	O
or	O
earlier	O
if	O
soiled	O
or	O
wet	O
)	O
.	O


Independent	O
risk	O
factors	O
for	O
catheter	B-OUT
colonization	I-OUT
were	O
catheter	O
insertion	O
into	O
the	O
jugular	O
vein	O
(	O
adjusted	O
relative	O
risk	O
,	O
2.01	O
;	O
95	O
%	O
confidence	O
interval	O
,	O
1.24-3.24	O
)	O
and	O
use	O
of	O
povidone-iodine	B-I
(	O
adjusted	O
relative	O
risk	O
,	O
1.87	O
;	O
95	O
%	O
confidence	O
interval	O
,	O
1.18-2.96	O
)	O
.	O


Objective	O
parameters	O
were	O
used	O
to	O
evaluate	O
therapeutical	O
effects	O
.	O


AIM	O
To	O
compare	O
the	O
immediate	O
restoration	O
of	O
single	B-I
implants	I-I
in	O
the	O
esthetic	O
zones	O
performed	O
on	O
implants	O
placed	O
immediately	O
after	O
tooth	O
extraction	O
or	O
8	O
weeks	O
later	O
(	O
immediate	O
replacement	B-I
vs.	O
immediate	O
restoration	B-I
)	I-I
.	O


The	B-P
patients	I-P
were	I-P
randomly	I-P
divided	I-P
into	O
two	O
groups	O
:	O
in	O
the	O
test	O
group	O
patients	O
received	O
implants	B-I
placed	I-I
and	I-I
restored	I-I
(	O
non-occlusal	O
loading	O
)	O
at	O
the	O
time	O
of	O
tooth	O
extraction	O
;	O
in	O
the	O
control	O
group	O
implants	B-I
were	I-I
placed	I-I
8	O
weeks	O
after	B-I
tooth	I-I
extraction	I-I
and	I-I
immediately	I-I
restored	I-I
.	I-I


The	O
following	O
parameters	O
were	O
evaluated	O
at	O
the	O
moment	O
of	O
provisional	O
restoration	O
(	O
within	O
48	O
h	O
after	O
implant	O
placement	O
)	O
and	O
at	O
the	O
2	O
years	O
follow-up	O
visit	O
:	O
marginal	B-OUT
bone	I-OUT
resorption	I-OUT
,	I-OUT
papilla	I-OUT
index	I-OUT
,	I-OUT
position	I-OUT
of	I-OUT
the	I-OUT
mucosal	I-OUT
margin	I-OUT
.	I-OUT


dosing	O
.	O


This	O
study	O
evaluates	O
the	O
effectiveness	O
of	O
an	O
intervention	O
package	O
including	O
a	O
discrete	B-I
trial	I-I
program	I-I
(	I-I
Rapid	I-I
Motor	I-I
Imitation	I-I
Antecedent	I-I
Training	I-I
(	O
Tsiouri	O
and	O
Greer	O
,	O
J	O
Behav	O
Educat	O
12:185-206	O
,	O
2003	O
)	O
combined	B-I
with	I-I
parent	I-I
education	I-I
for	I-I
eliciting	O
first	O
words	O
in	O
children	B-P
with	I-P
ASD	I-P
who	I-P
had	I-P
little	I-P
or	I-P
no	I-P
spoken	I-P
language	I-P
.	I-P


Evaluation	O
of	O
the	O
approach	O
includes	O
specific	O
intervention	O
targets	O
and	O
functional	B-OUT
spoken	I-OUT
language	I-OUT
outcomes	I-OUT
(	I-OUT
Tager-Flusberg	I-OUT
et	I-OUT
al.	I-OUT
,	O
J	B-OUT
Speech	I-OUT
Lang	I-OUT
Hear	I-OUT
Res	I-OUT
52:643-652	I-OUT
,	I-OUT
2009	I-OUT
)	I-OUT
.	I-OUT


Why	O
distinctive	B-I
information	I-I
reduces	O
false	B-OUT
memories	I-OUT
:	I-OUT
evidence	O
for	O
both	O
impoverished	B-P
relational-encoding	I-P
and	I-P
distinctiveness	I-P
heuristic	I-P
accounts	I-P
.	I-P


When	O
participants	B-P
were	I-P
given	I-P
inclusion	I-I
recall	I-I
instructions	I-I
to	I-I
report	I-I
studied	I-I
items	I-I
as	I-I
well	I-I
as	I-I
related	I-I
items	I-I
,	O
they	O
still	O
reported	B-OUT
critical	I-OUT
lures	I-OUT
less	O
often	O
after	O
picture	O
encoding	O
than	O
they	O
did	O
after	O
word	O
encoding	O
.	O


As	O
the	O
impoverished	O
relational-encoding	O
account	O
suggests	O
,	O
critical	B-OUT
lures	I-OUT
appear	O
less	O
likely	O
to	O
come	O
to	O
mind	O
after	O
picture	B-I
encoding	I-I
than	O
they	O
do	O
after	O
word	B-I
encoding	I-I
.	I-I


There	O
were	O
no	O
complications	B-OUT
in	O
the	O
4-hour	O
group	O
.	O


There	O
were	O
no	O
statistically	O
significant	O
differences	O
between	O
the	O
two	O
groups	O
on	O
any	O
of	O
the	O
other	O
study	O
variables	O
.	O


A	O
study	O
was	O
undertaken	O
to	O
determine	O
whether	O
changes	O
in	O
arterial	O
oxygen	O
tension	O
affect	O
levels	O
of	O
exhaled	O
NO	O
in	O
humans	B-P
.	I-P


Exhaled	B-OUT
NO	I-OUT
was	O
measured	O
with	O
a	O
chemiluminescence	O
detector	O
from	O
end	O
expiratory	O
single	O
breath	O
exhalation	O
.	O


RESULTS	O
A	O
dose-dependent	O
change	O
in	O
exhaled	B-OUT
NO	I-OUT
during	O
graded	B-OUT
oxygen	I-OUT
breathing	I-OUT
was	O
observed	O
(	O
p	O
=	O
0.0012	O
)	O
.	O


Stress	O
measures	O
were	O
administered	O
3	O
months	O
after	O
surgery	O
and	O
at	O
the	O
first	O
visit	O
after	O
the	O
visual	O
acuity	O
(	O
VA	O
)	O
assessment	O
done	O
at	O
12	O
months	O
of	O
age	O
.	O


Inflammatory	O
response	O
in	O
humans	B-P
exposed	I-P
to	I-P
2.0	I-P
ppm	I-P
nitrogen	I-I
dioxide	I-I
.	I-I


In	O
the	O
BL	O
,	O
NO2	B-OUT
exposure	I-OUT
caused	O
increases	O
in	O
polymorphonuclear	B-OUT
neutrophils	I-OUT
(	I-OUT
PMNs	I-OUT
)	I-OUT
,	I-OUT
interleukin	I-OUT
6	I-OUT
(	I-OUT
IL-6	I-OUT
)	I-OUT
,	I-OUT
IL-8	I-OUT
,	I-OUT
alpha1-antitrypsin	I-OUT
,	I-OUT
and	I-OUT
tissue	I-OUT
plasminogen	I-OUT
activator	I-OUT
,	O
and	O
decreases	O
in	O
epithelial	B-OUT
cells	I-OUT
.	I-OUT


In	O
the	O
BAL	O
,	O
there	O
were	O
no	O
NO2-induced	O
changes	O
in	O
either	O
cell	B-OUT
numbers	I-OUT
or	I-OUT
soluble	I-OUT
mediators	I-OUT
.	I-OUT


On	O
the	O
other	O
hand	O
,	O
alveolar	O
macrophages	O
from	O
BAL	O
showed	O
a	O
decrease	O
in	O
the	O
ability	O
to	O
phagocytose	B-OUT
unopsonized	I-OUT
Candida	I-OUT
albicans	I-OUT
and	O
a	O
decrease	O
in	O
superoxide	B-OUT
production	I-OUT
.	I-OUT


METHODS	O
This	O
randomized	O
,	O
double	O
blind	O
,	O
placebo	B-I
controlled	O
study	O
compares	O
outcome	O
measures	O
in	O
26	B-P
patients	I-P
with	I-P
chronic	I-P
neck	I-P
pain	I-P
(	I-P
WAD-II	I-P
chronic	I-P
)	I-P
subsequent	I-P
to	I-P
a	I-P
motor	I-P
vehicle	I-P
accident	I-P
.	I-P


OBJECTIVE	O
To	O
investigate	O
the	O
impact	O
of	O
nasal	O
irrigation	O
with	O
isotonic	B-I
or	I-I
hypertonic	I-I
sodium	I-I
chloride	I-I
solution	I-I
on	O
mucociliary	O
clearance	O
time	O
in	O
patients	B-P
with	I-P
allergic	I-P
rhinitis	I-P
,	I-P
acute	I-P
sinusitis	I-P
and	I-P
chronic	I-P
sinusitis	I-P
.	I-P


The	O
results	O
before	O
and	O
after	O
irrigation	O
were	O
compared	O
using	O
the	O
Wilcoxon	O
t-test	O
.	O


The	O
baseline	O
characteristics	O
were	O
balanced	O
among	O
the	O
groups	O
[	O
mean	O
HbA1c	O
8.2	O
%	O
(	O
67	O
mmol/mol	O
)	O
,	O
BMI	O
32.2	O
kg/m	O
(	O
2	O
)	O
]	O
.	O


The	B-OUT
primary	I-OUT
endpoint	I-OUT
was	I-OUT
change	O
from	O
baseline	O
in	O
HbA1c	O
at	O
week	O
18	O
.	O


BACKGROUND	O
Colon	O
cancer	O
is	O
curable	O
by	O
surgery	O
,	O
but	O
cure	O
rate	O
depends	O
on	O
the	O
extent	O
of	O
disease	O
.	O


In	O
EMDA	B-I
,	O
or	O
iontophoresis	O
,	O
a	O
low-intensity	O
electric	O
current	O
is	O
applied	O
over	O
the	O
skin	O
to	O
deliver	O
medication	O
into	O
body	O
tissues	O
.	O


Immediately	O
before	O
and	O
after	O
the	O
five	O
treatment	O
sessions	O
and	O
7	O
days	O
after	O
treatment	O
ended	O
,	O
both	O
patient	O
and	O
physician	O
measured	O
the	O
degree	B-OUT
of	I-OUT
pain	I-OUT
using	O
a	O
categoric	O
scale	O
(	O
no	O
pain	O
,	O
slight	O
pain	O
,	O
intermediate	O
pain	O
,	O
strong	O
pain	O
,	O
and	O
very	O
strong	O
pain	O
)	O
and	O
evaluated	O
pain	B-OUT
intensity	I-OUT
using	O
the	O
Scott	O
and	O
Huskisson	O
Visual	O
Analogue	O
Scale	O
(	O
VAS	O
)	O
.	O


No	O
patient	O
reported	O
any	O
adverse	B-OUT
effects	I-OUT
during	O
treatment	O
.	O


Weight	B-OUT
loss	I-OUT
of	O
10	O
%	O
or	O
more	O
of	O
initial	O
body	O
weight	O
was	O
observed	O
in	O
6	O
of	O
10	O
women	O
in	O
the	O
comprehensive	O
group	O
at	O
12	O
months	O
.	O


METHODS	O
The	O
patients	B-P
were	I-P
24	I-P
children	I-P
undergoing	I-P
tonsillectomy	I-I
and	I-P
adenoidectomy	I-I
.	I-I


CONCLUSIONS	O
Gas	O
extraction	O
decreased	O
the	O
level	B-OUT
of	I-OUT
exposure	I-OUT
by	O
up	O
to	O
94	O
%	O
,	O
achieving	O
levels	O
that	O
were	O
below	O
the	O
recommended	O
limits	O
and	O
greatly	O
reducing	O
occupational	B-OUT
risk	I-OUT
.	I-OUT


per	O
day	O
.	O


A	O
total	O
of	O
24	B-P
patients	I-P
were	I-P
recruited	I-P
to	I-P
the	I-P
study	I-P
;	I-P
ten	I-P
received	I-P
cyclosporin	I-I
with	I-I
blood	I-I
transfusions	I-I
(	I-I
BT	I-I
)	I-I
(	I-P
group	I-P
1	I-P
)	I-P
,	I-P
14	I-P
received	I-P
BT	I-I
alone	I-I
(	I-P
group	I-P
2	I-P
)	I-P
.	O


TRIAL	O
REGISTRATION	O
ClinicalTrials	O
(	O
NCT	O
)	O
:	O
NCT00512122	O
.	O


METHODS	O
Twenty	B-P
moderate	I-P
to	I-P
severe	I-P
persistent	I-P
asthmatics	I-P
completed	O
a	O
randomized	O
double-blind	O
crossover	O
study	O
.	O


The	O
risk	O
of	O
significant	B-OUT
neoplasia	I-OUT
(	I-OUT
carcinoma	I-OUT
or	I-OUT
adenoma	I-OUT
with	I-OUT
villous	I-OUT
structure	I-OUT
,	I-OUT
severe	I-OUT
dysplasia	I-OUT
,	I-OUT
or	I-OUT
diameter	I-OUT
>	I-OUT
10	I-OUT
mm	I-OUT
)	I-OUT
was	O
5.2	O
%	O
(	O
2.3-8.1	O
%	O
)	O
and	O
8.6	O
%	O
(	O
3.8-13.3	O
%	O
)	O
after	O
48	O
months	O
and	O
8.6	O
%	O
(	O
4.2-13.0	O
%	O
)	O
and	O
17.4	O
%	O
(	O
7.6-27.2	O
%	O
)	O
after	O
96	O
months	O
.	O


Extending	O
the	O
surveillance	O
to	O
8	O
years	O
also	O
tended	O
to	O
increase	O
the	O
risk	O
more	O
in	O
the	O
group	O
being	O
examined	O
every	O
4	O
years	O
,	O
but	O
reduction	O
of	O
the	O
number	O
of	O
surveillance	O
examinations	O
by	O
more	O
than	O
50	O
%	O
and	O
a	O
probable	O
reduction	O
of	O
complications	O
from	O
surveillance	O
examinations	O
themselves	O
may	O
justify	O
a	O
recommendation	O
for	O
the	O
longest	O
interval	O
.	O


Exposure	O
to	O
lead	O
impairs	O
cognitive	O
development	O
in	O
young	B-P
children	I-P
,	O
but	O
the	O
benefits	O
of	O
lowering	O
blood	O
lead	O
pharmacologically	O
are	O
not	O
clear	O
.	O


RESULTS	O
A	O
total	O
of	O
83	B-P
patients	I-P
were	O
eligible	O
for	O
safety	O
and	O
efficacy	O
analyses	O
.	O


The	O
median	B-OUT
OS	I-OUT
was	O
similar	O
in	O
the	O
S-1+paclitaxel	O
and	O
S-1+cisplatin	O
groups	O
(	O
16	O
vs	O
17	O
months	O
;	O
P=0.84	O
)	O
.	O


The	O
incidence	B-OUT
of	I-OUT
grade	I-OUT
3	I-OUT
or	I-OUT
higher	I-OUT
haematological	I-OUT
toxicity	I-OUT
was	O
19.0	O
%	O
with	O
S-1+paclitaxel	O
and	O
19.5	O
%	O
with	O
S-1+cisplatin	B-I
.	I-I


While	O
hand-excavated	O
,	O
bur-excavated	O
and	O
air-abraded	O
carious	O
dentin	O
surfaces	O
were	O
covered	O
with	O
a	O
residual	B-OUT
smear	I-OUT
layer	I-OUT
,	O
sono-abrasion	O
with	O
patent	O
dentinal	O
tubules	O
completely	O
removed	O
the	O
smear	O
layer	O
.	O


At	O
60°·s-1	O
,	O
there	O
were	O
significant	B-OUT
increments	I-OUT
in	I-OUT
IR	I-OUT
strength	I-OUT
and	I-OUT
the	I-OUT
ER/IR	I-OUT
ratio	O
in	O
both	O
shoulders	O
.	O


Moreover	O
,	O
the	O
absence	O
of	O
land-based	O
strength	O
training	O
,	O
from	O
16	O
to	O
32	O
weeks	O
,	O
revealed	B-OUT
a	I-OUT
reduction	I-OUT
in	I-OUT
the	I-OUT
ER/IR	I-OUT
ratio	I-OUT
values	O
in	O
both	O
shoulders	O
.	O


Our	O
findings	O
suggest	O
that	O
young	O
swimmers	O
'	O
coaches	O
should	B-I
use	I-I
dry-land	I-I
strength	I-I
training	I-I
protocols	I-I
,	O
and	O
that	O
it	O
is	O
recommended	O
that	O
these	O
should	O
be	O
conducted	O
on	O
a	O
regular	O
basis	O
(	O
during	O
the	O
whole	O
season	O
)	O
.	O


Patient	O
access	O
to	O
audiotapes	B-I
of	O
clinical	O
interviews	O
promotes	O
factual	B-OUT
retention	I-OUT
but	O
does	O
not	O
reliably	O
reduce	O
psychological	B-OUT
distress	I-OUT
and	O
may	O
be	O
actively	O
unhelpful	O
in	O
some	O
subgroups	O
of	O
patients	O
.	O


CGM-measured	B-OUT
hypoglycemia	I-OUT
over	O
a	O
24-h	O
span	O
is	O
highly	O
associated	O
with	B-OUT
SH	I-OUT
the	O
following	O
day	O
(	O
P	O
<	O
0.001	O
)	O
,	O
but	O
the	B-OUT
PPV	I-OUT
is	O
low	O
.	O


Yet	O
,	O
sleep	O
withdrawal	O
even	O
if	O
only	O
partial	O
,	O
has	O
a	O
negative	O
influence	O
on	O
performance	O
,	O
particularly	O
when	O
the	O
type	O
of	O
exercise	O
requires	O
good	O
psychomotor	O
performance	O
The	O
purpose	O
of	O
the	O
present	O
study	O
was	O
to	O
investigate	O
whether	O
the	O
intake	O
of	O
a	O
hypnotic	O
drug	O
would	O
have	O
negative	O
effects	O
on	O
physical	O
performance	O
capacity	O
.	O


Feasibility	O
of	O
an	O
obesity	B-I
intervention	I-I
for	O
paediatric	O
primary	O
care	O
targeting	O
parenting	B-P
and	I-P
children	I-P
:	I-P
Helping	I-P
HAND	I-P
.	I-P


BACKGROUND	O
The	O
primary	O
care	O
setting	O
offers	O
the	O
opportunity	O
to	O
reach	O
children	B-P
and	I-P
parents	I-P
to	O
encourage	O
healthy	O
lifestyle	O
behaviours	O
,	O
and	O
improve	O
weight	O
status	O
among	O
children	O
.	O


Intervention	O
group	O
attended	O
monthly	B-I
sessions	I-I
and	I-I
self-selected	I-I
child	I-I
behaviours	I-I
and	I-I
parenting	I-I
practices	I-I
to	O
change	O
.	O


There	O
was	O
20	O
%	O
attrition	O
from	B-I
Helping	I-I
HAND	I-I
(	O
attended	O
<	O
4/6	O
sessions	O
)	O
.	O


Families	O
self-selected	O
4.35	O
(	O
SD	O
1.75	O
)	O
behaviours	O
to	O
target	O
during	O
the	O
6-month	O
programme	O
and	O
each	O
of	O
the	O
seven	O
behaviours	O
was	O
selected	O
by	O
45-80	O
%	O
of	O
the	O
families	O
.	O


Intervention	O
group	O
viewed	O
14.9	O
(	O
SE	O
2.3	B-OUT
)	I-OUT
h/week	I-OUT
of	I-OUT
TV	I-OUT
post	O
intervention	O
versus	O
control	O
group	O
23.3	O
(	O
SE	O
2.4	O
)	O
h/week	O
(	O
P	O
<	O
0.05	O
)	O
.	O


CONCLUSION	O
Helping	O
HAND	O
is	O
feasible	O
,	O
due	O
to	O
low	O
attrition	O
,	O
good	O
programme	O
attendance	O
,	O
and	O
clinically	O
relevant	O
improvements	O
in	O
some	O
child	O
and	O
parenting	O
behaviours	O
.	O


METHODS	O
A	O
pilot	O
multinational	O
,	O
multicentre	O
,	O
randomized	O
,	O
active-controlled	O
,	O
parallel	O
group	O
open-label	O
study	O
has	O
been	O
conducted	O
in	O
a	O
group	B-P
of	I-P
patients	I-P
with	I-P
progressive	I-P
chronic	I-P
renal	I-P
failure	I-P
(	I-P
creatinine	I-P
clearance	I-P
20-45	I-P
ml/min	I-P
)	I-P
either	I-P
with	I-P
or	I-P
without	I-P
proteinuria	I-P
and	I-P
hypertension	I-P
.	I-P


RESULTS	O
Serum	B-OUT
creatinine	I-OUT
increased	O
in	O
all	O
three	O
groups	O
(	O
mean	O
change	O
within	O
a	O
group	O
:	O
11	O
micromol/l	O
in	O
group	O
1	O
,	O
P=	O
0.045	O
;	O
9	O
micromol/l	O
in	O
group	O
2	O
,	O
P=	O
0.030	O
;	O
15	O
micromol/l	O
in	O
group	O
3	O
,	O
P=	O
0.0006	O
)	O
.	O


A	O
live	B-I
oral	I-I
cholera	I-I
vaccine	I-I
developed	I-I
from	I-I
a	I-I
non-toxigenic	I-I
Vibrio	I-I
cholerae	I-I
O1	I-I
El	I-I
Tor	I-I
strain	I-I
VA1.3	I-I
was	O
tested	O
in	O
a	O
double-blind	O
randomized	O
placebo	B-I
controlled	O
study	O
for	O
safety	O
and	O
immunogenicity	O
in	O
304	B-P
men	I-P
aged	I-P
between	I-P
16	I-P
and	I-P
50	I-P
years	I-P
from	I-P
Kolkata	I-P
,	I-P
India	I-P
.	I-P


Pharmacokinetics	B-OUT
and	I-OUT
relative	I-OUT
bioavailability	I-OUT
of	O
prajmalium	B-I
bitartrate	I-I
after	O
single	O
oral	O
dosing	O
.	O


One	B-P
subject	I-P
was	I-P
identified	I-P
to	I-P
be	I-P
a	I-P
poor	I-OUT
metabolizer	I-OUT
.	I-OUT


The	O
extent	O
of	O
vertebral	O
deformity	O
was	O
measured	O
by	O
a	O
vertebral	O
index	O
as	O
well	O
as	O
height	O
.	O


All	O
patients	O
received	O
melphalan	B-I
and	O
prednisone	B-I
daily	O
for	O
4	O
days	O
every	O
4	O
weeks	O
as	O
the	O
primary	O
chemotherapy	O
for	O
their	O
disease	O
.	O


There	O
was	O
an	O
improvement	O
of	B-OUT
IIEF	I-OUT
score	I-OUT
for	O
all	O
domains	O
in	O
Cappra	O
(	O
®	O
)	O
group	O
compared	O
with	O
placebo	O
group	O
.	O


The	O
influence	O
of	O
beta-adrenoceptor	B-I
blockade	O
on	O
left	B-P
ventricular	I-P
function	I-P
.	I-P


In	O
particular	O
,	O
it	O
resulted	O
in	O
less	B-OUT
catheter	I-OUT
placement	I-OUT
without	I-OUT
a	I-OUT
wire	I-OUT
(	O
P=.01	O
)	O
,	O
shorter	B-OUT
time	I-OUT
to	I-OUT
proper	I-OUT
catheter	I-OUT
positioning	I-OUT
(	O
P=.045	O
)	O
and	O
use	B-OUT
of	I-OUT
oblique	I-OUT
digital	I-OUT
subtraction	I-OUT
angiography	I-OUT
(	O
P=.035	O
)	O
.	O


Survey	O
respondents	O
valued	O
the	O
experience	O
.	O


Stearoyl-coenzyme	B-OUT
A	O
desaturase	O
1	O
(	O
SCD1	O
)	O
content	O
was	O
decreased	O
with	O
DIWL	O
(	O
-19.5	O
±	O
8.5	O
%	O
,	O
p	B-OUT
<	I-OUT
0.05	I-OUT
)	I-OUT
,	I-OUT
but	I-OUT
increased	I-OUT
with	I-OUT
EX	I-OUT
(	I-OUT
19.6	I-OUT
±	I-OUT
7.4	I-OUT
%	I-OUT
,	O
p	O
<	O
0.05	O
)	O
.	O


Effect	O
of	O
macronutrient	B-I
composition	O
of	O
the	O
diet	O
on	O
the	O
regulation	B-OUT
of	I-OUT
lipolysis	I-OUT
in	I-OUT
adipose	I-OUT
tissue	I-OUT
at	O
rest	O
and	O
during	O
exercise	O
:	O
microdialysis	O
study	O
.	O


During	O
exercise	O
,	O
the	O
HFD	B-I
promotes	O
higher	B-OUT
lipolysis	I-OUT
in	I-OUT
adipose	I-OUT
tissue	I-OUT
and	O
this	O
is	O
associated	O
with	O
a	O
higher	O
catecholamine	O
response	O
and	O
lower	O
insulinemia	O
.	O


A	O
total	O
of	O
19	O
patients	O
received	O
WAD	B-I
,	O
the	O
remaining	O
20	O
acting	O
as	O
a	O
control	B-I
group	I-I
.	I-I


The	O
difference	O
in	O
median	O
percentage	O
change	O
between	O
D	O
and	O
C	O
was	O
statistically	O
significant	O
[	O
-4.0	O
(	O
D	O
)	O
vs.	O
4.7	O
(	O
C	O
)	O
;	O
P	O
=	O
0.005	O
,	O
n	O
=	O
39	O
]	O
.	O


Serum-induced	B-OUT
cellular	I-OUT
invasion	I-OUT
of	I-OUT
MIA-Paca-2	I-OUT
cells	I-OUT
in	O
response	O
to	O
patient	O
serum	O
was	O
studied	O
using	O
a	O
Boyden	O
chamber	O
assay	O
in	O
30	O
patients	O
(	O
14	O
WAD	O
and	O
16	O
C	O
)	O
.	O


One-year	O
results	O
from	O
the	O
phase	O
III	O
investigation	B-I
of	I-I
the	I-I
KeraVision	I-I
Intacs	I-I
.	I-I


In	O
a	O
substudy	O
,	O
89	O
%	O
eyes	O
(	O
58	O
of	O
65	O
)	O
varied	O
within	O
+/-	O
0.50	O
D	O
over	O
the	O
course	O
of	O
a	O
day	O
.	O


Although	O
the	O
electrophysiologic	O
changes	O
induced	O
by	O
these	O
antiarrhythmic	O
agents	O
contributed	O
to	O
facilitating	O
pacing-induced	O
termination	O
,	O
neither	O
tachycardia	B-OUT
cycle	I-OUT
length	I-OUT
nor	I-OUT
action	I-OUT
potential	I-OUT
duration	I-OUT
were	O
useful	O
predictors	O
of	O
the	O
ability	O
of	O
pacing	O
to	O
terminate	O
atrial	O
flutter	O
.	O


Primary	O
endpoint	O
was	O
cTFC	B-OUT
after	I-OUT
PCI	I-OUT
.	I-OUT


Mean	B-P
age	I-P
of	I-P
patients	I-P
was	I-P
58.8±10	I-P
years	I-P
.	I-P


cTFC	B-OUT
before	O
angioplasty	O
was	O
significantly	O
lower	O
in	O
ticagrelor	O
than	O
in	O
clopidogrel	O
(	O
81.1±29.4	O
vs.	O
95.1±17.5	O
frames	O
respectively	O
,	O
p=0.01	O
)	O
.	O


After	O
angioplasty	O
there	O
were	O
no	O
differences	O
between	O
ticagrelor	O
and	O
clopidogrel	B-OUT
in	I-OUT
cTFC	O
(	O
24.6±9.3	O
vs.	O
27.0±13.4	O
frames	O
respectively	O
,	O
p=0.62	B-OUT
)	I-OUT
;	I-OUT
MBG	O
grade	O
3	O
was	O
present	O
in	O
76.4	O
vs.	O
69.4	O
%	O
of	O
patients	O
,	O
respectively	O
(	B-OUT
p=0.41	I-OUT
)	I-OUT
.	I-OUT


Pregabalin	B-I
IR	I-I
can	O
be	O
taken	O
with	O
or	O
without	O
food	O
.	O


METHODS	O
This	O
was	O
a	O
24-week	O
,	O
randomized	O
,	O
double-blind	O
,	O
parallel	O
group	O
,	O
multi-center	O
study	B-P
.	I-P


NCT00784550	O
.	O


Since	B-P
1977	I-P
,	I-P
31	I-P
patients	I-P
were	I-P
entered	I-P
in	I-P
a	I-P
randomized	I-P
,	I-P
prospective	I-P
study	I-P
testing	I-P
the	I-P
efficacy	I-P
of	I-P
adjuvant	I-I
chemotherapy	I-I
after	I-P
aggressive	I-P
local	I-P
treatment	I-P
of	I-P
high-grade	I-P
sarcomas	I-P
of	I-P
the	I-P
head	I-P
,	I-P
neck	I-P
,	I-P
breast	I-P
,	I-P
and	I-P
trunk	I-P
(	I-P
excluding	I-P
retroperitoneal	I-P
sarcomas	I-P
)	I-P
.	I-P


We	O
therefore	O
investigated	O
the	O
time	O
course	O
of	O
subjective	O
and	O
objective	O
measures	O
of	O
nasal	B-OUT
affection	I-OUT
after	O
steroid	O
administration	O
in	O
patients	B-P
with	I-P
allergic	I-P
rhinitis	I-P
following	O
specific	O
allergen	O
challenge	O
.	O


A	O
single	O
dose	O
of	O
either	O
betamethasone	B-I
(	I-I
60	I-I
mg	I-I
)	I-I
,	I-I
methylprednisolone	I-I
(	I-I
400	I-I
mg	I-I
)	I-I
or	I-I
placebo	I-I
was	O
given	O
intravenously	O
,	O
5	O
min	O
after	O
intranasal	O
allergen	O
provocation	O
.	O


However	O
,	O
after	O
150	O
min	O
,	O
nasal	B-OUT
airflow	I-OUT
was	O
21	O
%	O
rsp	O
.	O


Itching	B-OUT
,	O
a	O
pathophysiologically	O
complex	O
sensation	O
,	O
is	O
favourably	O
influenced	O
by	O
steroids	O
within	O
10	O
min	O
,	O
therefore	O
presumably	O
via	O
nongenomic	O
mechanisms	O
.	O


METHODS	O
Seventy-six	B-P
patients	I-P
with	I-P
esophageal	I-P
gastric	I-P
carcinoma	I-P
were	O
randomly	O
divided	O
into	O
two	O
groups	O
,	O
the	O
FZYLG	B-I
group	I-P
and	O
the	O
control	B-I
group	I-I
.	I-I


The	O
tumor	O
tissue	O
in	O
both	O
groups	O
was	O
resected	O
and	O
cell	B-OUT
cycle	I-OUT
and	O
apoptosis	B-OUT
rate	I-OUT
as	O
well	O
as	O
NF-kappa	O
B	O
were	O
determined	O
by	O
flowcytometry	O
.	O


No	O
difference	O
was	O
demonstrated	O
in	O
pain	B-OUT
severity	I-OUT
between	O
active	B-I
and	I-I
sham	I-I
TENS	I-I
groups	O
but	O
the	O
active	B-I
TENS	I-I
group	O
required	O
slightly	O
less	O
analgesia	O
.	O


Because	O
oral	B-I
contraceptives	I-I
(	O
OCs	O
)	O
may	O
reduce	O
the	O
active	B-OUT
androgen	I-OUT
level	I-OUT
,	O
hormonal	O
therapy	O
with	O
OCs	O
has	O
been	O
used	O
successfully	O
to	O
treat	O
patients	B-P
with	I-P
acne	I-P
,	O
although	O
this	O
treatment	O
has	O
previously	O
not	O
been	O
studied	O
in	O
placebo-controlled	O
trials	O
.	O


In	O
the	O
investigator	B-OUT
's	I-OUT
global	I-OUT
assessment	I-OUT
,	O
93.7	O
%	O
of	O
the	O
active	O
treatment	O
group	O
versus	O
65.4	O
%	O
of	O
the	O
placebo	O
group	O
were	O
rated	O
as	O
improved	O
at	O
the	O
end	O
of	O
the	O
study	O
(	O
p	O
<	O
0.001	O
)	O
.	O


We	O
used	O
continuous	O
intraluminal	O
esophageal	O
and	O
tracheal	O
pH	O
monitoring	O
probes	O
to	O
investigate	O
the	O
effect	O
of	O
ranitidine	B-I
on	O
the	O
incidence	O
of	O
GER	B-OUT
and	I-OUT
tracheal	I-OUT
aspiration	I-OUT
in	O
80	B-P
adult	I-P
patients	I-P
undergoing	I-P
thoracotomy	I-P
.	I-P


The	O
study	O
was	O
placebo-controlled	B-I
,	O
randomized	O
,	O
and	O
double-blinded	O
.	O


In	O
the	O
therapy	O
group	O
,	O
52	O
%	O
of	O
all	O
specimens	O
were	O
sterile	O
,	O
in	O
the	O
control	O
group	O
only	O
25	O
%	O
.	O


Systemic	B-OUT
administration	I-OUT
of	I-OUT
antibiotics	I-OUT
,	O
e.g	O
.	O


Patients	B-P
with	I-P
acute	I-P
myelogenous	I-P
leukemia	I-P
in	I-P
relapse	I-P
who	I-P
were	I-P
ineligible	I-P
for	I-P
further	I-P
anthracycline	I-I
therapy	I-I
either	I-P
because	I-P
they	I-P
were	I-P
judged	I-P
to	I-P
be	I-P
anthracycline	I-I
resistant	I-P
or	I-P
had	I-P
received	I-P
the	I-P
maximum	I-P
doses	I-P
were	O
randomized	O
to	O
receive	O
high-dose	O
cytarabine	B-I
(	O
3	O
g/m2	O
every	O
12	O
hours	O
for	O
6	O
days	O
)	O
or	O
amsacrine	B-I
(	O
75	O
mg/m2	O
daily	O
for	O
7	O
days	O
)	O
.	O


The	O
cost	O
effectiveness	O
analysis	O
(	B-OUT
cost	I-OUT
per	I-OUT
quality-adjusted	I-OUT
life	I-OUT
year	I-OUT
;	I-OUT
QALY	I-OUT
)	I-OUT
was	O
derived	O
from	O
a	O
multi-centre	O
,	O
two-arm	O
,	O
parallel	O
group	O
,	O
assessor-blind	O
,	O
randomised	O
controlled	O
trial	O
which	O
took	O
place	O
in	O
18	B-P
trauma	I-P
centres	I-P
in	I-P
the	I-P
United	I-P
Kingdom	I-P
.	I-P


These	O
were	O
greater	O
than	O
£30,000	O
.	O


Compared	O
with	B-I
locking-plate	I-I
fixation	I-I
,	I-I
K-wire	I-I
fixation	O
is	O
a	O
'cost	O
saving	O
'	O
intervention	O
,	O
with	O
similar	O
health	O
benefits	O
.	O


Results	O
suggest	O
that	O
the	O
allocation	O
to	O
an	O
individualized	O
,	O
comprehensive	O
,	O
home-based	O
cardiac	O
rehabilitation	O
program	O
provided	O
more	O
advantageous	O
outcomes	O
.	O


These	O
findings	O
suggest	O
that	O
an	O
individualized	O
,	O
comprehensive	O
,	O
home-based	O
cardiac	O
rehabilitation	O
program	O
improves	O
risk	B-OUT
factor	I-OUT
profiles	I-OUT
and	I-OUT
work	I-OUT
resumption	I-OUT
patterns	I-OUT
for	O
patients	B-P
following	I-P
PCI	I-P
.	I-P


Patients	B-OUT
'	I-OUT
postoperative	I-OUT
pain	I-OUT
,	I-OUT
anxiety	I-OUT
,	I-OUT
blood	I-OUT
pressure	I-OUT
(	I-OUT
BP	I-OUT
)	I-OUT
,	I-OUT
heart	I-OUT
rate	I-OUT
(	I-OUT
HR	I-OUT
)	I-OUT
and	I-OUT
oxygen	I-OUT
saturation	I-OUT
were	I-OUT
also	I-OUT
studied	I-OUT
as	I-OUT
stress	I-OUT
markers	I-OUT
.	I-OUT


PATIENTS	O
Thirty	B-P
patients	I-P
admitted	I-P
to	I-P
the	I-P
intensive	I-P
care	I-P
unit	I-P
who	I-P
had	I-P
a	I-P
thermodilution	I-P
pulmonary	I-P
artery	I-P
catheter	I-P
in	I-P
place	I-P
.	I-P


OUTCOME	O
MEASURES	O
Thermodilution	B-OUT
cardiac	I-OUT
output	I-OUT
measurements	I-OUT
.	I-OUT


which	O
produced	O
a	O
95	O
%	O
confidence	O
interval	O
from	O
-0.539	O
to	O
-0.083	O
.	O


To	O
ensure	O
accurate	O
comparisons	O
between	O
consecutive	O
cardiac	O
output	O
measurements	O
,	O
the	O
researchers	O
recommend	O
that	O
the	O
position	O
in	O
which	O
the	O
cardiac	O
output	O
measurements	O
are	O
performed	O
be	O
documented	O
and	O
the	O
cardiac	O
output	O
measurements	O
be	O
conducted	O
in	O
a	O
uniform	O
position	O
.	O


OBJECTIVE	O
To	O
compare	O
the	O
impact	O
of	O
1000-microgram	O
self-administered	B-I
vaginal	I-I
misoprostol	I-I
versus	O
self-administered	B-I
vaginal	I-I
placebo	I-I
at	O
home	O
on	O
preoperative	O
cervical	O
ripening	O
in	O
both	O
premenopausal	B-P
and	I-P
postmenopausal	I-P
women	I-P
prior	I-P
to	I-P
outpatient	I-P
resectoscopy	I-P
.	I-P


Values	O
are	O
given	O
as	O
median	B-OUT
(	I-OUT
range	I-OUT
)	I-OUT
or	I-OUT
n	I-OUT
(	I-OUT
%	I-OUT
)	I-OUT
.	I-OUT


Values	O
are	O
given	O
as	O
median	O
(	O
range	O
)	O
.	O


(	O
d	O
)	O
Occurrence	B-OUT
of	I-OUT
adverse	I-OUT
effects	I-OUT
in	O
the	O
two	O
treatment	O
groups	O
.	O


Awareness	O
of	O
the	O
role	O
of	O
context	O
was	O
assessed	O
using	O
a	O
behavioral	B-I
task	I-I
and	O
explicit	B-I
questions	I-I
.	I-I


Experiment	O
2	O
used	O
a	O
modified	B-I
training	I-I
protocol	I-I
that	O
promoted	O
attention	O
to	O
context	O
cues	O
.	O


All	O
patients	O
developed	O
granulocyte	B-OUT
nadirs	I-OUT
below	O
100/cu	O
mm	O
.	O


By	O
actuarial	O
analysis	O
,	O
the	O
median	B-OUT
duration	I-OUT
of	I-OUT
granulocytopenia	I-OUT
,	O
less	O
than	O
1000/cu	O
mm	O
,	O
was	O
16.0	O
days	O
in	O
the	O
lithium	B-I
group	O
and	O
24.6	O
days	O
in	O
the	O
no-lithium	B-I
group	O
,	O
p	O
=	O
0.013	O
.	O


Despite	O
the	O
shortened	B-OUT
duration	I-OUT
of	I-OUT
neutropenia	I-OUT
,	O
the	O
incidence	O
of	O
infections	O
and	O
the	O
rate	O
of	O
remission	O
were	O
not	O
affected	O
.	O


In	O
this	O
double-blind	O
,	O
randomized	O
,	O
cross-over	O
study	O
,	O
20	B-P
adult	I-P
patients	I-P
with	I-P
reversible	I-P
chronic	I-P
airway	I-P
obstruction	I-P
(	I-P
intrinsic	I-P
asthma	I-P
or	I-P
COPD	I-P
)	I-P
inhaled	O
single	O
doses	O
of	O
formoterol	B-I
9	I-I
microg	I-I
or	I-I
salbutamol	I-I
100	I-I
microg	I-I
(	I-I
group	I-I
A	I-I
)	I-I
or	I-I
formoterol	I-I
18	I-I
microg	I-I
or	I-I
salbutamol	I-I
200	I-I
microg	I-I
(	I-I
group	I-I
B	I-I
)	I-I
.	I-I


BACKGROUND	O
Preoperative	O
oral	B-I
rehydration	I-OUT
solution	I-I
(	I-I
ORS	I-I
)	I-I
prevents	O
hypovolemia	B-OUT
.	I-OUT


Anesthesia	O
was	O
maintained	O
with	O
propofol	B-I
and	O
remifentanil	B-OUT
,	O
and	O
rocuronium	B-I
0.6	O
mg	O
x	O
kg	O
(	O
-1	O
)	O
was	O
administrated	O
.	O


CONCLUSIONS	O
Preoperative	O
oral	O
rehydration	O
possibly	O
increases	O
circulating	O
blood	O
volume	O
,	O
and	O
shortens	O
the	O
duration	O
of	B-OUT
rocuronium	I-OUT
effect	I-OUT
.	O


Positive	O
effects	O
of	O
methylphenidate	B-I
on	O
inattention	B-OUT
and	I-P
hyperactivity	I-OUT
in	I-P
pervasive	I-P
developmental	I-P
disorders	I-P
:	I-P
an	O
analysis	O
of	O
secondary	O
measures	O
.	O


METHODS	O
Sixty-six	B-P
children	I-P
(	I-P
mean	I-P
age	I-P
7.5	I-P
y	I-P
)	I-P
with	I-P
autistic	I-P
disorder	I-P
,	I-P
Asperger	I-P
's	I-P
disorder	I-P
,	I-P
and	I-P
PDD	I-P
not	I-P
otherwise	I-P
specified	I-P
,	O
were	O
randomized	O
to	O
varying	O
sequences	O
of	O
placebo	B-I
and	I-I
three	I-I
different	I-I
doses	I-I
of	I-I
methylphenidate	I-I
during	O
a	O
4-week	O
blinded	O
,	O
crossover	O
study	O
.	O


The	O
difference	O
in	O
proportions	O
,	O
TISSEEL	O
VH	O
S/D	O
minus	O
TISSEEL	O
VH	O
,	O
was	O
1.4	O
%	O
with	O
a	O
standard	O
error	O
of	O
3.70	O
%	O
.	O


The	O
safety	O
profile	O
of	O
TISSEEL	O
VH	O
S/D	O
was	O
very	O
similar	O
to	O
that	O
of	O
currently	O
licensed	O
TISSEEL	O
VH	O
as	O
assessed	O
by	O
the	O
safety	O
endpoints	O
.	O


Statistical	O
analysis	O
was	O
performed	O
to	O
compare	O
the	O
DNA	O
copy	O
numbers	O
of	O
the	O
three	O
groups	O
.	O


Groups	B-P
were	I-P
divided	I-P
according	I-P
to	I-P
whether	I-P
they	I-P
would	I-P
receive	I-P
the	I-P
Ivanissevich	I-I
technique	I-I
(	I-P
n	I-P
=	I-P
55	I-P
)	I-P
,	I-P
Tauber	I-I
's	I-I
technique	I-I
(	I-P
n	I-P
=	I-P
51	I-P
)	I-P
or	I-P
subinguinal	I-I
sclerotherapy	I-I
(	I-P
n	I-P
=	I-P
49	I-P
)	I-P
.	I-P


CONCLUSIONS	B-I
Gemcitabine	I-I
plus	I-I
erlotinib	I-I
is	O
more	O
effective	O
than	B-I
gemcitabine	I-I
alone	I-I
for	O
treating	B-P
metastatic	I-P
pancreatic	I-P
cancer	I-P
patients	I-P
,	I-P
especially	I-P
those	I-P
with	I-P
EGFR	I-P
mutations	I-P
.	O


Cefprozil	B-I
versus	I-I
penicillin	I-I
V	I-I
in	O
treatment	O
of	O
streptococcal	B-P
tonsillopharyngitis	I-P
.	I-P


Tamsulosin	O
Investigator	O
Group	O
.	O


METHODS	O
This	O
trial	O
extended	O
a	O
13-week	O
,	O
Phase	O
III	O
multicenter	O
placebo-controlled	O
,	O
double-blind	O
outpatient	O
trial	O
for	O
an	O
additional	O
40	O
weeks	O
.	O


Clinically	O
significant	O
orthostatic	B-OUT
hypotension	I-OUT
was	O
not	O
observed	O
.	O


OBJECTIVE	O
To	O
describe	O
the	O
authors	O
'	O
experience	O
of	O
conducting	O
a	O
clinical	O
drug	O
trial	O
in	O
children	B-P
with	I-P
Asperger	I-P
Syndrome	I-P
,	O
including	O
the	O
pitfalls	O
encountered	O
and	O
lessons	O
learnt	O
.	O


RESULTS	O
Mean	B-OUT
baseline	I-OUT
values	I-OUT
for	O
the	O
three	O
co-primary	O
endpoints	O
ranged	O
from	O
62.52	O
to	O
70.14	O
mm	O
.	O


There	O
was	O
an	O
initial	O
increase	O
in	O
heart	B-OUT
rate	I-OUT
in	O
the	O
nicardipine	B-I
group	O
,	O
but	O
the	O
rise	O
was	O
only	O
moderate	O
(	O
3	O
beats/min	O
supine	O
p	O
=	O
0.3219	O
,	O
and	O
7	O
beats/min	O
standing	O
,	O
p	O
=	O
0.0203	O
)	O
at	O
the	O
end	O
of	O
the	O
24	O
weeks	O
.	O


Overall	O
,	O
in	O
comparison	O
with	O
propranolol	B-I
,	O
nicardipine	O
was	O
effective	O
,	O
well-tolerated	O
and	O
safe	O
to	O
use	O
in	O
the	O
monotherapy	O
of	O
mild	O
or	O
moderate	O
essential	O
hypertension	O
.	O


CONCLUSIONS	O
In	O
patients	O
with	O
ISR	O
,	O
an	O
oral	O
adjunctive	O
sirolimus	O
treatment	O
with	O
an	O
intensified	O
loading	O
regimen	O
before	O
coronary	O
intervention	O
resulted	O
in	O
a	O
significant	O
improvement	O
in	O
the	O
angiographic	B-OUT
parameters	I-OUT
of	I-OUT
restenosis	I-OUT
.	I-OUT


Enteral	O
nutrition	O
with	O
eicosapentaenoic	B-I
acid	I-I
,	I-I
gamma-linolenic	I-I
acid	I-I
,	I-I
and	I-I
antioxidants	I-I
reduces	O
alveolar	O
inflammatory	O
mediators	O
and	O
protein	O
influx	O
in	B-P
patients	I-P
with	I-P
acute	I-P
respiratory	I-P
distress	I-P
syndrome	I-P
.	I-P


INTERVENTIONS	O
A	O
total	O
of	O
43	O
of	O
67	O
evaluable	O
patients	O
randomly	O
received	O
either	O
EPA+GLA	B-I
or	I-I
an	I-I
isonitrogenous	I-I
,	I-I
isocaloric	I-I
standard	I-I
diet	I-I
that	O
was	O
tube	O
fed	O
at	O
a	O
minimum	O
caloric	O
delivery	O
of	O
75	O
%	O
of	O
basal	O
energy	O
expenditure	O
times	O
1.33	O
for	O
at	O
least	O
4	O
to	O
7	O
days	O
.	O


Additional	O
controlled	O
studies	O
are	O
needed	O
to	O
confirm	O
these	O
findings	O
.	O


Large	B-OUT
(	I-OUT
C1	I-OUT
)	I-OUT
and	I-OUT
small	I-OUT
artery	I-OUT
elasticity	I-OUT
(	I-OUT
C2	I-OUT
)	I-OUT
were	O
measured	O
by	O
pulse	O
contour	O
analysis	O
of	O
the	O
radial	O
artery	O
.	O


TRIAL	O
REGISTRATION	O
ClinicalTrials.gov	O
Identifier	O
NCT01174225	O
.	O


A	O
randomized	O
breast-feeding	B-I
promotion	I-I
intervention	O
did	O
not	O
reduce	O
child	O
obesity	O
in	O
Belarus	B-P
.	I-P


The	O
experimental	O
intervention	O
led	O
to	O
a	O
large	O
increase	O
in	O
exclusive	B-OUT
breast-feeding	I-OUT
at	I-OUT
3	I-OUT
mo	I-OUT
(	O
43.3	O
%	O
vs.	O
6.4	O
%	O
,	O
P	O
<	O
0.001	O
)	O
and	O
a	O
significantly	O
higher	O
prevalence	O
of	O
any	O
breast-feeding	O
throughout	O
infancy	O
.	O


Effects	O
of	O
halothane	B-I
and	O
isoflurane	B-I
on	O
transient	B-OUT
renal	I-OUT
dysfunction	I-OUT
associated	O
with	O
infrarenal	O
aortic	O
cross-clamping	O
.	O


Induction	O
of	O
anesthesia	B-I
consisted	O
of	O
midazolam	B-I
,	I-I
fentanyl	I-I
,	I-I
and	I-I
pancuronium	I-I
.	I-I


Both	O
medication	O
adherence	O
and	O
AA	O
meeting	O
attendance	O
evidenced	O
direct	O
and	O
independent	O
influences	O
on	O
abstinent	O
outcome	O
:	O
medication	O
adherence	O
showed	O
a	O
small	O
direct	O
influence	O
,	O
and	O
AA	O
meeting	O
attendance	O
showed	O
a	O
much	O
larger	O
,	O
independent	O
influence	O
.	O


The	O
mean	O
duration	B-OUT
for	I-OUT
obtaining	I-OUT
good	I-OUT
contractions	I-OUT
was	O
shorter	O
in	O
the	O
propranolol	B-I
group	O
in	O
both	O
the	O
first	O
and	O
second	O
day	O
of	O
induction	O
The	O
mean	O
interval	O
between	O
the	O
beginning	O
of	O
induction	O
until	O
the	O
beginning	O
of	O
active	O
phase	O
at	O
the	O
first	O
day	O
of	O
induction	O
was	O
shorter	O
in	O
the	O
propranolol	B-I
group	O
.	O


METHODS	O
Background	O
infusions	O
were	O
saline	B-I
,	I-I
or	I-I
GLP-1	I-I
at	O
0.3	O
or	O
0.9	O
pmol/	O
kg/min	O
on	O
separate	O
days	O
in	O
random	O
order	O
.	O


Interdigestive	B-OUT
fundus	I-OUT
motility	I-OUT
was	O
recorded	O
by	O
barostat	O
(	O
maximum	O
capacity	O
of	O
intragastric	O
bag	O
1200	O
ml	O
)	O
during	O
basal	O
and	O
peptide	O
periods	O
of	O
60	O
minutes	O
each	O
.	O


Thereafter	O
stepwise	O
isobaric	O
distensions	O
were	O
performed	O
with	O
ongoing	O
peptide	O
infusion	O
,	O
and	O
gastric	B-OUT
sensation	I-OUT
was	O
scored	O
.	O


It	O
allows	O
the	O
stomach	O
to	O
afford	O
a	O
larger	O
volume	O
without	O
increase	B-OUT
in	I-OUT
sensation	I-OUT
.	I-OUT


Fentanyl	B-I
supplementation	O
to	O
inhalation	B-P
anaesthesia	I-P
.	I-P


The	O
mean	B-OUT
arterial	I-OUT
pressures	I-OUT
and	I-OUT
pulse	I-OUT
rates	I-OUT
were	O
not	O
significantly	O
different	O
in	O
each	O
group	O
throughout	O
the	O
course	O
of	O
the	O
operation	O
.	O


Systematic	B-I
approach	I-I
to	O
benign	B-P
paroxysmal	I-P
positional	I-P
vertigo	I-P
in	I-P
the	I-P
elderly	I-P
.	I-P


This	O
study	O
has	O
2	O
parts	O
.	O


In	O
the	O
first	O
part	O
,	O
patients	O
were	O
randomly	O
assigned	O
to	O
1	O
of	O
2	O
groups	O
:	O
the	B-I
CRM	I-I
and	I-I
avoidance	I-I
(	I-I
no	I-I
treatment	I-I
)	I-I
.	I-I


Patients	O
were	O
evaluated	O
1	O
month	O
after	O
the	O
first	O
visit	O
.	O


CONCLUSION	O
A	O
combination	O
of	O
CRM	O
and	O
VR	O
improves	O
BPPV	B-OUT
in	I-P
the	I-P
elderly	I-P
.	I-P


OBJECTIVE	O
To	O
perform	O
a	O
comparative	O
assessment	O
of	O
the	O
efficacy	O
of	O
total	B-I
occlusive	I-I
ionic	I-I
silver-containing	I-I
dressing	I-I
(	I-I
TOISD	I-I
)	I-I
combination	I-I
vs	I-I
no	I-I
dressing	I-I
after	O
colorectal	B-P
surgery	I-P
.	I-P


The	B-OUT
odds	I-OUT
ratio	I-OUT
(	I-OUT
OR	I-OUT
)	I-OUT
of	O
patients	O
with	O
wounds	O
in	O
the	O
control	O
group	O
was	O
4.1	O
(	O
95	O
%	O
CI	O
is	O
1.884	O
,	O
8.964	O
)	O
more	O
likely	O
to	O
be	O
contaminated	O
with	O
bacteria	O
compared	O
with	O
wounds	O
covered	O
with	O
occlusive	O
ionic	O
silver-containing	O
dressing	O
.	O


CONCLUSION	O
TOISD	O
was	O
found	O
to	O
be	O
effective	O
in	O
reducing	B-OUT
bacterial	I-OUT
colonisation	I-OUT
on	O
the	O
surgical	O
site	O
compared	O
with	O
no	O
dressing	O
.	O


Aripiprazole	B-I
as	O
well	O
as	O
risperidone	O
lowered	B-OUT
ABC	I-OUT
scores	I-OUT
during	O
2	O
months	O
.	O


OBJECTIVES	O
To	O
report	O
results	O
from	O
a	O
preplanned	O
analysis	O
of	O
data	O
from	O
the	O
first	O
year	O
of	O
the	O
3-year	O
SPINART	O
study	O
,	O
which	O
compares	O
routine	O
prophylaxis	O
with	O
on-demand	O
treatment	O
with	B-I
sucrose-formulated	I-I
recombinant	I-I
FVIII	I-I
(	I-I
rFVIII-FS	I-I
)	I-I
.	O


CONCLUSIONS	O
Routine	O
prophylaxis	O
with	B-I
rFVIII-FS	I-I
leads	O
to	O
a	O
significant	O
reduction	O
in	O
bleeding	O
as	O
compared	O
with	O
on-demand	O
treatment	O
.	O


Adverse	O
events	O
were	O
consistent	O
with	O
the	O
established	B-I
rFVIII-FS	I-I
safety	O
profile	O
.	O


Randomized	O
,	O
controlled	O
,	O
crossover	O
trial	O
of	O
methylphenidate	B-I
in	O
pervasive	O
developmental	O
disorders	O
with	O
hyperactivity	O
.	O


OBJECTIVES	O
To	O
determine	O
the	O
efficacy	O
and	O
safety	O
of	O
methylphenidate	B-I
hydrochloride	I-I
in	I-P
children	I-P
with	O
pervasive	O
developmental	O
disorders	O
and	O
hyperactivity	O
.	O


This	O
study	O
examined	O
the	O
feasibility	O
and	O
safety	O
of	O
deliberate	O
mild	O
hypothermia	O
and	O
rewarming	O
.	O


In	O
addition	O
to	O
the	O
need	O
for	O
determining	O
whether	O
deliberate	O
mild	O
hypothermia	O
confers	O
cerebral	O
protection	O
in	O
humans	O
,	O
the	O
potential	O
risks	O
of	O
the	O
therapy	O
need	O
to	O
be	O
further	O
characterized	O
.	O


METHODS	O
AND	O
RESULTS	O
A	B-P
total	I-P
of	I-P
122	I-P
(	I-P
qDES	I-P
66	I-P
,	I-P
BMS	I-P
56	I-P
)	I-P
patients	I-P
were	O
enrolled	O
into	O
the	O
IVUS	O
substudy	O
.	O


All	O
IVUS	O
images	O
(	O
immediately	O
after	O
the	O
procedure	O
and	O
at	O
6-month	O
follow-up	O
)	O
were	O
analyzed	O
at	O
an	O
independent	O
core	O
laboratory	O
in	O
a	O
blind	O
manner	O
.	O


At	O
baseline	O
,	O
qDES	B-I
achieved	O
stent	B-OUT
expansion	I-OUT
similar	O
to	O
BMS	O
.	O


Prostamol	B-I
Uno	I-I
(	I-I
PU	I-I
)	I-I
efficacy	I-OUT
and	O
safety	B-OUT
were	O
studied	O
in	O
a	O
multicenter	B-P
,	I-P
open-population	I-P
,	O
randomized	O
and	O
comparative	O
trial	O
.	O


The	O
first	O
contribution	O
is	O
a	O
new	O
red	B-I
lesion	I-I
candidate	I-I
detection	I-I
system	I-I
based	O
on	O
pixel	O
classification	O
.	O


The	O
detected	O
candidate	O
objects	O
are	O
classified	O
using	O
all	O
features	O
and	O
a	O
k-nearest	O
neighbor	O
classifier	O
.	O


When	O
determining	O
whether	O
an	O
image	O
contains	O
red	B-OUT
lesions	I-OUT
the	O
system	O
achieves	O
a	O
sensitivity	B-OUT
of	O
100	O
%	O
at	O
a	O
specificity	O
of	O
87	O
%	O
.	O


INTERVENTIONS	B-P
Patients	I-P
with	I-P
symptomatic	I-P
VMA/VMT	I-P
were	O
randomly	O
assigned	O
(	O
2:1	O
or	O
3:1	O
in	O
study	O
TG-MV-006	O
and	O
study	O
TG-MV-007	O
,	O
respectively	O
)	O
to	O
receive	O
a	O
single	O
intravitreal	O
injection	O
of	B-I
ocriplasmin	I-I
,	O
125	O
μg	O
,	O
or	B-I
placebo-injected	I-I
vehicle	I-I
(	I-I
placebo	I-I
)	I-I
.	O


MAIN	O
OUTCOMES	O
AND	O
MEASURES	B-OUT
Mean	I-OUT
changes	I-OUT
between	I-OUT
baseline	I-OUT
and	I-OUT
6-month	I-OUT
follow-up	I-OUT
NEI	I-OUT
VFQ-25	I-OUT
composite	I-OUT
and	I-OUT
subscale	I-OUT
scores	I-OUT
and	O
the	B-OUT
proportion	I-OUT
of	I-OUT
patients	I-OUT
with	I-OUT
a	I-OUT
clinically	I-OUT
meaningful	I-OUT
change	I-OUT
(	I-OUT
≥5	I-OUT
points	I-OUT
)	I-OUT
in	I-OUT
scores	I-OUT
.	O


BACKGROUND	O
A	O
smooth	O
,	O
cohesive	O
,	O
24-mg/mL	O
hyaluronic	B-I
acid	I-I
(	I-I
HA	I-I
)	I-I
gel	I-I
with	O
uniform	O
consistency	O
,	O
even	O
flow	O
characteristics	O
,	O
and	O
extended	O
duration	O
was	O
designed	O
for	O
injection	O
into	O
the	O
mid	O
to	O
deep	O
dermis	O
.	O


METHODS	O
&	O
MATERIALS	O
This	O
double-blind	O
study	O
at	O
three	B-P
centers	I-P
enrolled	I-P
60	I-P
subjects	I-P
,	I-P
injected	I-P
with	I-P
both	I-P
products	I-P
,	I-P
randomly	I-P
assigned	I-P
to	I-P
left	I-P
or	I-P
right	I-P
nasolabial	I-P
fold	I-P
.	I-P


Ninety-five	O
percent	O
of	O
the	O
injections	O
were	O
considered	O
easy	O
or	O
very	O
easy	O
;	O
a	O
greater	O
percentage	O
of	O
HA+lidocaine	O
injections	O
were	O
rated	O
very	O
easy	O
.	O


The	O
combination	O
of	O
EEN	B-I
and	I-I
rhubarb	I-I
significantly	O
reduced	O
the	O
values	O
of	O
APACHE	B-OUT
II	I-OUT
scores	I-OUT
.	I-OUT


Combination	O
therapies	O
significantly	O
reduced	O
abnormally	O
higher	O
white	B-OUT
blood	I-OUT
cell	I-OUT
(	I-OUT
WBC	I-OUT
)	I-OUT
counts	I-OUT
and	I-OUT
levels	I-OUT
of	I-OUT
plasma	I-OUT
CRP	I-OUT
and	I-OUT
IL-6	I-OUT
,	O
but	O
increased	O
the	O
levels	B-OUT
of	I-OUT
plasma	I-OUT
IL-11	I-OUT
.	I-OUT


Thrombus	O
aspiration	O
reduces	O
microvascular	B-OUT
obstruction	I-OUT
after	O
primary	B-P
coronary	I-P
intervention	I-P
:	I-P
a	O
myocardial	O
contrast	O
echocardiography	O
substudy	O
of	O
the	O
REMEDIA	O
Trial	O
.	O


METHODS	O
A	O
total	B-P
of	I-P
25	I-P
patients	I-P
were	I-P
randomized	I-P
to	I-P
be	I-P
pretreated	I-P
with	I-P
thrombus	I-I
aspiration	I-I
before	I-I
PCI	I-I
of	I-I
the	I-I
culprit	I-I
lesion	I-I
and	I-I
25	I-P
received	I-P
standard	I-I
PCI	I-I
.	I-I


Regional	B-OUT
wall	I-OUT
motion	I-OUT
score	I-OUT
index	I-OUT
(	I-OUT
WMSI	I-OUT
)	I-OUT
,	I-OUT
contrast	I-OUT
score	I-OUT
index	I-OUT
(	I-OUT
CSI	I-OUT
)	I-OUT
,	I-OUT
endocardial	I-OUT
length	I-OUT
of	I-OUT
wall	I-OUT
motion	I-OUT
abnormality	I-OUT
(	I-OUT
WML	I-OUT
)	I-OUT
and	I-OUT
contrast	I-OUT
defect	I-OUT
(	I-OUT
CDL	I-OUT
)	I-OUT
,	I-OUT
end-diastolic	I-OUT
and	I-OUT
end-systolic	I-OUT
left	I-OUT
ventricular	I-OUT
(	I-OUT
LV	I-OUT
)	I-OUT
volumes	I-OUT
,	I-OUT
and	I-OUT
ejection	I-OUT
fraction	I-OUT
were	O
calculated	O
.	O


In	O
the	O
overall	O
study	O
population	O
,	O
the	O
extent	B-OUT
of	I-OUT
MO	I-OUT
significantly	O
correlated	O
with	O
temporal	O
changes	O
in	O
LV	B-OUT
volumes	I-OUT
.	I-OUT


Thus	O
,	O
the	O
beneficial	O
effect	O
of	O
thrombus	O
aspiration	O
occurs	O
at	O
the	O
microvascular	O
level	O
,	O
but	O
additional	O
mechanisms	O
may	O
play	O
a	O
role	O
in	O
influencing	O
the	O
final	O
extent	O
of	O
MO	B-OUT
,	O
which	O
strictly	O
correlates	O
with	O
post-infarct	O
LV	B-OUT
remodeling	I-OUT
.	I-OUT


OBJECTIVE	O
To	O
study	O
the	O
relation	O
between	O
moderate	O
coronary	O
dissections	O
,	O
coronary	O
flow	O
velocity	O
reserve	O
(	O
CFVR	O
)	O
,	O
and	O
long	O
term	O
outcome	O
.	O


Patients	B-P
with	I-P
severe	I-P
dissections	I-P
(	I-P
n	I-P
=	I-P
128	I-P
)	I-P
or	I-P
without	I-P
available	I-P
reference	I-P
vessel	I-P
CFVR	I-P
(	I-P
n	I-P
=	I-P
139	I-P
)	I-P
were	I-P
excluded	I-P
.	I-P


RESULTS	O
Following	O
balloon	O
angioplasty	O
,	O
there	O
was	O
no	O
difference	O
in	O
CFVR	B-OUT
between	O
the	O
two	O
groups	O
.	O


RESULTS	O
Median	O
PFS	B-OUT
was	O
4.7	O
and	O
4.3	O
months	O
for	O
arms	O
A	O
and	O
B	O
,	O
respectively	O
(	O
6-month	O
PFS	O
,	O
27.3	O
%	O
versus	O
30.9	O
%	O
)	O
.	O


OBJECTIVES	O
The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
evaluate	O
the	O
relationship	O
of	O
baseline	O
pulse	O
pressure	O
and	O
mean	O
arterial	O
pressure	O
to	O
mortality	O
in	O
patients	B-P
with	I-P
left	I-P
ventricular	I-P
dysfunction	I-P
.	I-P


Higher	B-OUT
mean	I-OUT
arterial	I-OUT
pressure	I-OUT
was	O
associated	O
with	O
higher	O
heart	O
rate	O
,	O
lower	O
calcium	B-I
channel	I-I
blocker	I-I
and	O
digoxin	B-I
use	O
and	O
lower	O
New	O
York	O
Heart	O
Association	O
functional	O
class	O
.	O


Fifty	B-P
sedentary	I-P
males	I-P
were	O
randomly	O
divided	O
into	O
five	O
groups	O
.	O


Early	O
combination	O
disease-modifying	O
antirheumatic	B-I
drug	I-I
therapy	I-I
and	O
tight	O
disease	O
control	O
improve	O
long-term	B-OUT
radiologic	I-OUT
outcome	I-OUT
in	O
patients	B-P
with	I-P
early	I-P
rheumatoid	I-P
arthritis	I-P
:	I-P
the	O
11-year	O
results	O
of	O
the	O
Finnish	O
Rheumatoid	O
Arthritis	O
Combination	O
Therapy	O
trial	O
.	O


INTRODUCTION	O
Early	O
treatment	O
of	O
rheumatoid	B-P
arthritis	I-P
(	I-P
RA	I-P
)	I-P
has	O
been	O
shown	O
to	O
retard	O
the	O
development	B-OUT
of	I-OUT
joint	I-OUT
damage	I-OUT
for	O
a	O
period	O
of	O
up	O
to	O
5	O
years	O
.	O


The	O
aim	O
of	O
this	O
study	O
was	O
to	O
evaluate	B-OUT
the	I-OUT
radiologic	I-OUT
progression	I-OUT
beyond	O
that	O
time	O
in	O
patients	B-P
with	I-P
early	I-P
RA	I-P
initially	I-P
treated	I-P
with	I-P
a	I-P
combination	I-P
of	I-P
three	I-I
disease-modifying	I-I
antirheumatic	I-I
drugs	I-I
(	I-I
DMARDs	I-I
)	I-I
or	I-P
a	I-P
single	I-I
DMARD	I-I
.	I-I


After	O
2	O
years	O
,	O
the	O
drug-treatment	O
strategy	O
became	O
unrestricted	O
,	O
but	O
still	O
targeted	O
remission	O
.	O


These	O
results	O
suggest	O
that	O
impaired	O
metabolism	O
of	O
BK	O
induced	O
by	O
ACE	O
inhibitors	O
may	O
relate	O
to	O
the	O
manifestation	O
of	O
cough	O
in	O
hypertensive	B-P
patients	I-P
receiving	I-P
ACE	I-P
inhibitors	I-P
.	I-P


2	B-P
,	I-P
270	I-P
pigs	I-P
(	I-P
PIC	I-P
Line	I-P
327	I-P
×	I-P
1050	I-P
;	I-P
initially	I-P
46.5	I-P
kg	O
)	O
were	O
allotted	B-I
a	I-I
corn-soybean	I-I
meal-based	I-I
diet	I-I
or	O
diets	O
with	O
20	O
or	O
40	O
%	O
of	O
a	O
9.4	O
%	O
oil	B-I
DDGS	I-I
(	I-I
29.4	I-I
%	I-I
CP	O
,	O
19.6	B-I
%	I-I
ADF	O
,	O
and	O
34.5	B-I
%	I-I
NDF	O
;	O
as-fed	O
basis	O
)	O
or	O
a	O
12.1	B-I
%	I-I
oil	I-I
DDGS	I-I
(	O
28.5	O
%	O
CP	O
,	O
17.6	O
%	O
ADF	O
,	O
and	O
31.4	O
%	O
NDF	O
;	O
as-fed	O
basis	O
)	O
.	O


Increasing	B-I
DDGS	I-I
increased	O
(	O
linear	O
,	O
P	O
<	O
0.01	B-OUT
)	I-OUT
jowl	I-OUT
IV	O
and	O
tended	O
(	O
linear	O
,	O
P	O
<	O
0.07	O
)	O
to	O
increase	B-OUT
G	O
:	O
F.	O
Regardless	O
of	O
source	B-OUT
,	I-OUT
HCW	I-OUT
and	I-OUT
carcass	I-OUT
yield	I-OUT
decreased	O
(	O
linear	O
,	O
P	O
<	O
0.05	O
)	O
as	O
DDGS	O
increased	O
.	O


On	O
day	O
5	O
a	O
single	O
dose	O
of	O
either	O
drug	O
was	O
given	O
.	O


All	O
families	O
were	O
compared	O
at	O
pre-	O
and	O
post-treatment	O
on	O
formal	O
dependent	O
measures	O
.	O


Carbon	B-I
dioxide	I-I
insufflation	I-I
in	O
open-chamber	O
cardiac	O
surgery	O
:	O
a	O
double-blind	O
,	O
randomized	O
clinical	O
trial	O
of	O
neurocognitive	O
effects	O
.	O


OBJECTIVE	O
The	O
aims	O
of	O
this	O
study	O
were	O
first	O
to	O
analyze	O
neurocognitive	B-OUT
outcomes	I-OUT
of	O
patients	B-P
after	I-P
open-chamber	I-P
cardiac	I-P
surgery	I-P
to	O
determine	O
whether	O
carbon	B-I
dioxide	I-I
pericardial	I-I
insufflation	I-I
reduces	O
incidence	O
of	O
neurocognitive	B-OUT
decline	I-OUT
(	O
primary	O
end	O
point	O
)	O
as	O
measured	O
6	O
weeks	O
postoperatively	O
and	O
second	O
to	O
assess	O
the	O
utility	O
of	O
carbon	B-I
dioxide	I-I
insufflation	I-I
in	O
cardiac	O
chamber	O
deairing	O
as	O
assessed	O
by	O
transesophageal	O
echocardiography	O
.	O


METHODS	O
A	O
multicenter	O
,	O
prospective	O
,	O
double-blind	O
,	O
randomized	O
,	O
controlled	O
trial	O
compared	O
neurocognitive	O
outcomes	O
in	O
patients	B-P
undergoing	I-P
open-chamber	I-P
(	I-P
left-sided	I-P
)	I-P
cardiac	I-P
surgery	I-P
who	I-P
were	I-P
assigned	I-P
carbon	I-I
dioxide	I-I
insufflation	I-I
or	I-I
placebo	I-I
(	I-P
control	I-P
group	I-P
)	I-P
in	I-P
addition	I-P
to	I-P
standardized	I-P
mechanical	I-P
deairing	I-P
maneuvers	I-P
.	I-P


The	B-P
most	I-P
important	I-P
factor	I-P
is	I-P
atheromatous	I-P
vascular	I-P
disease	I-P
.	I-P


Data	B-P
for	I-P
prostate	I-P
cancer	I-P
were	I-P
obtained	I-P
from	I-P
the	I-P
ERSPC	I-P
central	I-P
database	I-P
.	I-P


Incidence	B-OUT
of	I-OUT
LSPC	I-OUT
was	O
2.4	O
%	O
,	O
2.7	O
%	O
,	O
2.2	O
%	O
and	O
2.6	O
%	O
in	O
the	O
first	O
,	O
second	O
,	O
third	O
and	O
fourth	O
round	O
,	O
respectively	O
.	O


CONCLUSIONS	O
Cancer	B-OUT
detection	I-OUT
rate	I-OUT
was	O
stable	O
during	O
the	O
three	O
screening	B-I
rounds	O
.	O


Thirty-three	B-P
eligible	I-P
women	I-P
were	O
randomized	O
to	O
double-blind	O
treatment	O
and	O
administered	O
3.75	B-I
mg	I-I
of	I-I
depot	I-I
leuprolide	I-I
or	I-I
a	I-I
placebo	I-I
once	O
a	O
month	O
for	O
3	O
months	O
.	O


Outcome	O
measures	O
were	O
the	O
DSRs	B-OUT
and	I-OUT
the	I-OUT
17-item	I-OUT
Hamilton	I-OUT
Depression	I-OUT
Rating	I-OUT
Scale	I-OUT
(	I-OUT
HAM-D17	I-OUT
)	I-OUT
.	I-OUT


Depression	B-OUT
symptoms	I-OUT
were	O
at	O
clinical	O
levels	O
premenstrually	O
in	O
the	O
PMS	O
and	O
PME	O
groups	O
;	O
following	O
treatment	O
they	O
remitted	O
in	O
the	O
PMS	O
group	O
but	O
not	O
in	O
the	O
PME	O
leuprolide	B-I
subjects	O
.	O


Twenty-four	B-P
Helicobacter	I-P
pylori-negative	I-P
subjects	I-P
were	O
randomized	O
to	O
treatment	O
with	O
ibuprofen	B-I
or	I-I
ibuprofen-arginate	I-I
(	O
each	O
600	O
mg/6	O
hr	O
during	O
3	O
days	O
)	O
.	O


Biopsies	O
were	O
taken	O
from	O
the	O
gastric	O
antrum	O
and	O
corpus	O
for	O
determination	O
of	O
prostaglandin	O
E2	O
(	O
PGE2	O
)	O
by	O
ELISA	B-I
and	O
cyclooxygenase	O
(	O
COX-1	O
and	O
COX-2	O
)	O
and	O
nitric	O
oxide	O
synthase	O
(	O
eNOS	O
and	O
iNOS	O
)	O
by	O
western	O
blot	O
.	O


COX-1	B-OUT
,	I-OUT
COX-2	I-OUT
,	I-OUT
eNOS	I-OUT
,	I-OUT
and	I-OUT
iNOS	I-OUT
were	O
detectable	O
in	O
all	O
subjects	O
.	O


COX-2	O
was	O
higher	O
in	O
corpus	O
than	O
antrum	O
and	O
it	O
increased	O
after	O
ibuprofen	O
treatment	O
.	O


There	O
were	O
no	O
significant	O
differences	O
between	O
ibuprofen	O
and	O
ibuprofen-arginate	O
in	O
PGE2	O
,	O
or	O
enzymes	O
.	O


This	O
first-in-human	O
study	O
investigated	O
the	O
safety	O
,	O
pharmacokinetics	O
and	O
pharmacogenomics	O
of	O
single	O
and	O
multiple	O
doses	O
of	O
selisistat	B-I
in	O
healthy	B-P
male	I-P
and	I-P
female	I-P
subjects	I-P
.	I-P


Steady-state	B-OUT
plasma	I-OUT
concentrations	I-OUT
were	O
achieved	O
within	O
4	O
days	O
of	O
repeated	O
dosing	O
.	O


There	O
were	O
no	O
trends	O
in	O
clinical	O
laboratory	O
parameters	O
or	O
vital	O
signs	O
.	O


Furthermore	O
,	O
the	O
effect	O
of	O
shearing	O
on	O
thermoregulative	B-OUT
responses	I-OUT
in	O
sheep	O
has	O
not	O
been	O
adequately	O
studied	O
under	O
temperate	B-P
environmental	I-P
conditions	I-P
.	I-P


Physiological	O
responses	O
,	O
such	O
as	O
water	B-OUT
turnover	I-OUT
,	I-OUT
surface	I-OUT
temperature	I-OUT
,	I-OUT
and	I-OUT
rectal	I-OUT
temperature	I-OUT
,	I-OUT
as	I-OUT
well	I-OUT
as	I-OUT
drinking	I-OUT
behavior	I-OUT
of	I-OUT
sheep	I-OUT
were	O
also	O
evaluated	O
.	O


Once	O
versus	O
thrice	O
daily	B-I
gentamicin	I-I
in	O
patients	B-P
with	I-P
serious	I-P
infections	I-P
.	I-P


BACKGROUND	O
Total	B-I
parenteral	I-I
nutrition	I-I
(	I-I
TPN	I-I
)	I-I
supplemented	I-I
with	I-I
glutamine	I-I
(	I-I
GLN	I-I
)	I-I
has	O
been	O
reported	O
to	O
be	O
effective	O
for	O
patients	B-P
with	I-P
bone	I-P
marrow	I-P
transplantation	I-P
(	I-P
BMT	I-P
)	I-P
.	I-P


The	O
primary	O
end	O
point	O
of	O
death	B-OUT
,	I-OUT
myocardial	I-OUT
infarction	I-OUT
,	I-OUT
or	I-OUT
target	I-OUT
vessel	I-OUT
revascularization	I-OUT
(	I-OUT
TVR	I-OUT
)	I-OUT
was	O
analyzed	O
as	O
time-to-first	O
event	O
within	O
9	O
months	O
of	O
the	O
index	O
PCI	B-I
.	I-I


There	O
was	O
also	O
a	O
control	O
group	O
that	O
just	O
filled	O
in	O
the	O
study	O
questionnaire	O
but	B-I
did	I-I
not	I-I
receive	I-I
an	I-I
educational	I-I
intervention	I-I
.	I-I


No	O
differences	O
in	O
the	O
amount	O
of	O
knowledge	B-OUT
increase	O
were	O
found	O
between	O
three	O
interventions	O
tested	O
.	O


The	O
educational	O
brochure	O
seems	O
to	O
represent	O
the	O
most	O
convenient	O
and	O
least	O
costly	O
method	O
to	O
increase	O
knowledge	B-OUT
about	O
breast	O
cancer	O
and	O
screening	O
among	O
women	O
who	O
present	O
for	O
screening	O
mammography	O
.	O


Pulse	B-I
versus	I-I
continuous	I-I
terbinafine	I-I
for	O
onychomycosis	B-P
:	I-P
a	O
randomized	O
,	O
double-blind	O
,	O
controlled	O
trial	O
.	O


The	O
primary	O
outcome	O
measure	O
was	O
mycological	B-OUT
cure	I-OUT
of	I-OUT
the	I-OUT
target	I-OUT
toenail	I-OUT
at	I-OUT
18	I-OUT
months	I-OUT
.	I-OUT


Effect	O
of	O
acute	B-I
exercise	I-I
on	O
executive	B-OUT
function	I-OUT
in	O
children	B-P
with	I-P
attention	I-P
deficit	I-P
hyperactivity	I-P
disorder	I-P
.	I-P


Thus	O
,	O
the	O
use	O
of	O
concentrate	O
of	O
factor	B-OUT
IX	I-OUT
in	O
this	O
trial	O
,	O
as	O
well	O
as	O
potentiating	O
intravascular	B-OUT
coagulation	I-OUT
,	O
was	O
inadequate	O
as	O
replacement	O
for	O
the	O
clotting	O
factor	O
deficiencies	O
.	O


Drug	B-OUT
strength	I-OUT
ratings	I-OUT
peaked	O
at	O
2	O
min	O
(	O
first	O
time	O
point	O
)	O
and	O
definite	O
subjective	O
effects	O
were	O
no	O
longer	O
present	O
at	O
approximately	O
20	O
min	O
after	O
inhalation	O
.	O


Dose-related	O
increases	O
were	O
observed	O
on	B-OUT
questionnaire	I-OUT
measures	I-OUT
of	I-OUT
mystical-type	I-OUT
experience	I-OUT
(	I-OUT
Mysticism	I-OUT
Scale	I-OUT
)	I-OUT
and	I-OUT
subjective	I-OUT
effects	I-OUT
associated	I-OUT
with	I-OUT
classic	I-OUT
serotonergic	I-OUT
(	I-OUT
5-HT2	I-OUT
(	I-OUT
A	I-OUT
)	I-OUT
)	I-OUT
hallucinogens	I-OUT
(	I-OUT
Hallucinogen	I-OUT
Rating	I-OUT
Scale	I-OUT
)	I-OUT
.	I-I


Participant	B-P
narratives	O
indicated	O
intense	O
experiences	O
characterized	O
by	O
disruptions	O
in	O
vestibular	O
and	O
interoceptive	O
signals	O
(	O
e.g.	B-OUT
,	O
change	B-OUT
in	I-OUT
spatial	I-OUT
orientation	I-OUT
,	I-OUT
pressure	I-OUT
on	I-OUT
the	I-OUT
body	I-OUT
)	I-OUT
and	O
unusual	O
and	O
sometimes	O
recurring	O
themes	O
across	O
sessions	O
such	O
as	O
revisiting	O
childhood	O
memories	O
,	O
cartoon-like	O
imagery	O
,	O
and	O
contact	O
with	O
entities	O
.	O


Patients	B-P
also	O
received	O
a	O
low-sodium	B-I
(	I-I
40	I-I
mmol/day	I-I
)	I-I
diet	I-I
and	I-I
the	I-I
aldosterone	I-I
antagonist	I-I
,	I-I
potassium	I-I
canrenoate	I-I
(	O
100	O
mg	O
b.i.d.	O
)	O
.	O


The	O
results	O
of	O
this	O
study	O
indicate	O
that	O
torasemide	B-I
is	O
suitable	O
for	O
the	O
treatment	O
of	O
sodium	O
retention	O
in	O
patients	B-P
with	I-P
cirrhosis	I-P
and	I-P
ascites	I-P
.	I-P


RESULTS	O
Seventeen	O
of	O
20	O
(	O
85	O
%	O
)	O
women	O
in	O
the	O
control	O
group	O
developed	O
preeclampsia	B-OUT
,	O
whereas	O
9	O
of	O
20	O
(	O
45	O
%	O
)	O
in	O
the	O
treatment	O
group	O
developed	O
preeclampsia	B-OUT
.	I-OUT


CONCLUSIONS	O
It	O
seems	O
likely	O
that	O
Ozagrel	B-I
Hydrochloride	I-I
could	O
be	O
used	O
for	O
the	O
prevention	B-OUT
of	I-OUT
preeclampsia	I-OUT
in	I-P
high-risk	I-P
pregnant	I-P
women	I-P
.	I-P


BACKGROUND	O
An	O
oral	B-I
formulation	I-I
of	I-I
ganciclovir	I-I
(	I-I
GCV	I-I
)	I-I
was	O
recently	O
approved	O
for	O
the	O
prevention	O
of	O
cytomegalovirus	O
disease	O
in	O
solid	O
organ	O
transplant	O
recipients	O
.	O


This	O
study	O
was	O
designed	O
to	O
determine	O
the	O
bioavailability	O
of	O
GCV	B-I
and	O
to	O
test	O
a	O
dosing	O
algorithm	O
in	O
transplant	B-P
and	I-P
dialysis	I-P
patients	I-P
with	I-P
different	I-P
levels	I-P
of	I-P
renal	I-P
function	I-P
.	I-P


Drug	O
dosing	O
was	O
established	O
by	O
the	O
following	O
algorithm	O
based	O
on	O
calculated	O
creatinine	O
clearance	O
(	O
CrCl	O
)	O
:	O
CrCl	O
=	O
[	O
(	O
140-age	O
)	O
x	O
body	O
weight	O
]	O
/	O
(	O
72	O
x	O
Cr	O
)	O
x	O
0.85	O
for	O
women	O
that	O
is	O
,	O
CrCl	O
>	O
50	O
ml/min	O
,	O
1000	O
mg	O
every	O
8	O
hr	O
;	O
CrCl	O
of	O
25-50	O
ml/min	O
,	O
1000	O
mg	O
every	O
24	O
hr	O
;	O
CrCl	O
of	O
10-24	O
ml/	O
min	O
,	O
500	O
mg	O
every	O
day	O
;	O
CrCl	O
<	O
10	O
ml/min	O
(	O
or	O
on	O
dialysis	O
)	O
,	O
500	O
mg	O
every	O
other	O
day	O
after	O
dialysis	O
.	O


Absolute	B-OUT
bioavailability	I-OUT
,	O
for	O
the	O
nine	O
patients	O
so	O
analyzed	O
,	O
was	O
7.2+/-2.4	O
%	O
.	O


Stage	O
II/FH	O
patients	O
also	O
had	O
either	O
zero	O
or	O
2000	O
cGy	O
irradiation	O
(	O
RT	O
)	O
postoperatively	O
and	O
Stage	O
III/FH	O
patients	O
either	O
1000	O
or	O
2000	O
cGy	O
.	O


CA	B-OUT
was	I-OUT
poorly	I-OUT
tolerated	I-OUT
in	O
7	O
patients	O
and	O
CC	O
in	O
2	O
(	O
NS	O
)	O
.	O


A	O
large	O
effect	B-OUT
size	I-OUT
was	O
also	O
observed	O
(	O
partial	O
η	O
(	O
2	O
)	O
=.39	O
)	O
.	O


INTERVENTIONS	O
Each	O
head	B-P
trauma	I-P
patient	I-P
requiring	O
rapid-sequence	O
intubation	O
who	O
met	O
the	O
inclusion	O
criteria	O
received	O
standard	O
rapid-sequence	B-I
intubation	I-I
maneuvers	I-I
and	O
lidocaine	B-I
(	O
1	O
mg/kg	O
)	O
IV	O
.	O


No	O
patient	O
in	O
either	O
group	O
experienced	O
emesis	B-OUT
or	I-OUT
significant	I-OUT
dysrhythmias	I-OUT
.	I-OUT


Concurrent	O
training	B-I
enhances	O
athletes	O
'	O
cardiovascular	B-P
and	I-P
cardiorespiratory	I-P
measures	O
.	O


Integrated	B-I
CE	I-I
in	O
women	O
discernibly	O
reduced	O
systolic	B-OUT
and	I-OUT
diastolic	I-OUT
BP	I-OUT
(	O
-13.2	O
%	O
and	O
-12.6	O
%	O
,	O
respectively	O
)	O
,	O
increased	O
estimated	O
[	O
latin	O
capital	O
V	O
with	O
dot	O
above	B-OUT
]	I-OUT
o2max	I-OUT
(	O
22.9	O
%	O
)	O
,	O
and	O
produced	O
a	O
trend	O
toward	O
reduced	O
resting	B-OUT
HR	I-OUT
(	O
-2.4	O
%	O
)	O
.	O


We	O
used	O
logistic	O
regression	O
models	O
to	O
assess	O
factors	O
that	O
are	O
associated	O
with	O
inadequate	B-I
FSG	I-I
(	O
defined	O
as	O
a	O
study	O
in	O
which	O
the	O
depth	O
of	O
insertion	O
of	O
FSG	O
was	O
<	O
50	O
cm	O
or	O
visual	O
inspection	O
was	O
limited	O
to	O
<	O
90	O
%	O
of	O
the	O
mucosal	O
surface	O
but	O
without	O
detection	O
of	O
a	O
polyp	O
or	O
mass	O
)	O
.	O


Obesity	B-OUT
(	O
BMI	O
>	O
30	O
kg/m	O
(	O
2	O
)	O
)	O
was	O
associated	O
with	O
reduced	O
odds	O
(	O
OR	O
=	O
0.67	O
;	O
95	O
%	O
CI	O
:	O
0.62-0.72	O
)	O
.	O


Veterans	O
Administration	O
Cooperative	O
Study	O
on	O
Treatment	O
of	O
Alcoholic	O
Cirrhosis	O
with	O
Ascites	O
.	O


We	O
identified	O
three	O
risk	O
groups	O
:	O
Group	B-P
1	I-P
had	I-P
normal	I-P
or	I-P
mildly	I-P
abnormal	I-P
results	I-P
on	I-P
liver-function	I-P
tests	I-P
,	I-P
Group	I-P
2	I-P
had	I-P
more	I-P
severe	I-P
liver	I-P
dysfunction	I-P
or	I-P
previous	I-P
complications	I-P
,	I-P
and	I-P
Group	I-P
3	I-P
had	I-P
severe	I-P
prerenal	I-P
azotemia	I-P
without	I-P
kidney	I-P
disease	I-P
.	I-P


For	O
the	O
patients	O
who	O
received	O
the	O
medical	O
treatment	O
and	O
those	O
who	O
received	O
the	O
surgical	O
treatment	O
combined	O
,	O
the	O
median	O
survival	O
times	O
were	O
1093	O
days	O
in	O
Group	O
1	O
,	O
222	O
days	O
in	O
Group	O
2	O
,	O
and	O
37	O
days	O
in	O
Group	O
3	O
(	O
P	O
less	O
than	O
or	O
equal	O
to	O
0.01	O
)	O
for	O
all	O
comparisons	O
)	O
.	O


However	O
,	O
survival	B-OUT
was	O
closely	O
related	O
to	O
the	O
severity	O
of	O
the	O
illness	O
at	O
the	O
time	O
of	O
randomization	O
and	O
was	O
not	O
altered	O
by	O
shunting	O
.	O


Pouch	B-I
versus	I-I
esophagojejunostomy	I-OUT
after	O
total	B-P
gastrectomy	I-OUT
:	I-OUT
a	I-P
randomized	I-P
clinical	I-P
trial	I-P
.	I-P


Preliminary	O
findings	O
of	O
the	O
minimally-invasive	B-I
surgery	I-I
plus	I-I
rtPA	I-I
for	O
intracerebral	B-OUT
hemorrhage	I-OUT
evacuation	I-OUT
(	I-P
MISTIE	I-P
)	I-P
clinical	O
trial	O
.	O


RESULTS	O
Average	B-OUT
aspiration	I-OUT
of	I-OUT
clots	I-OUT
for	O
all	O
patients	O
randomized	O
to	O
surgery	O
plus	O
rtPA	O
was	O
20	O
%	O
of	O
mean	O
initial	O
clot	O
size	O
.	O


After	O
acute	O
treatment	O
phase	O
(	O
aspiration	O
plus	O
rtPA	O
)	O
,	O
clot	B-OUT
was	I-OUT
reduced	I-OUT
an	O
average	O
of	O
46	O
%	O
.	O


CONCLUSION	O
There	O
is	O
tentative	O
indication	O
that	O
minimally-invasive	O
surgery	O
plus	O
rtPA	O
shows	O
greater	B-OUT
clot	I-OUT
resolution	I-OUT
than	O
traditional	O
medical	O
management	O
.	O


Clinical	O
and	O
prognostic	O
significance	O
of	O
serum	O
magnesium	O
concentration	O
in	O
patients	B-P
with	I-P
severe	I-P
chronic	I-P
congestive	I-P
heart	I-P
failure	I-P
:	I-P
the	O
PROMISE	O
Study	O
.	O


BACKGROUND	O
Low	O
heart	O
rate	O
ischemia	O
,	O
as	O
detected	O
by	O
Holter	O
ambulatory	O
electrocardiographic	O
monitoring	O
,	O
suggests	O
that	O
reduced	O
coronary	O
flow	O
is	O
the	O
major	O
factor	O
leading	O
to	O
ischemia	O
.	O


CONCLUSIONS	O
The	O
results	O
suggest	O
that	O
increased	O
neural	B-OUT
tone	I-OUT
at	O
the	O
time	O
of	O
the	O
ischemic	O
event	O
may	O
play	O
a	O
role	O
in	O
reducing	O
coronary	O
perfusion	O
leading	O
to	O
silent	O
ischemia	O
.	O


Epo-b	B-I
(	O
30000	O
IU	O
once	O
weekly	O
)	O
was	O
initiated	O
in	O
patients	O
with	O
Hb	O
<	O
11	O
g/dl	O
and	O
continued	O
until	O
Hb	O
≥12	O
g/dl	O
was	O
reached	O
.	O


RESULTS	O
Eighty-two	B-P
patients	I-P
were	I-P
enrolled	I-P
;	I-P
41	I-P
(	I-P
50	I-P
%	I-P
)	I-P
patients	I-P
in	I-P
group	I-P
A	I-P
and	I-P
41	I-P
(	I-P
50	I-P
%	I-P
)	I-P
patients	I-P
in	I-P
group	I-P
B	I-P
were	I-P
evaluated	I-P
.	I-P


CONCLUSION	O
These	O
data	O
suggest	O
that	O
IV	O
ceftriaxone	B-I
followed	O
by	O
oral	O
cefditoren	B-I
pivoxil	I-I
is	O
highly	O
effective	B-OUT
and	O
well-tolerated	B-OUT
for	O
the	O
treatment	O
of	O
acute	O
pyelonephritis	O
,	O
even	O
for	O
uropathogens	O
with	O
a	O
high	O
proportion	O
of	O
quinolone-resistant	O
strains	O
.	O


METHODS	O
In	O
a	O
prospective	O
clinical	O
trial	O
,	O
43	B-P
ankles	I-P
(	I-P
30	I-P
patients	I-P
)	I-P
with	I-P
radiographic	I-P
Kellgren	I-P
Lawrence	I-P
grade	I-P
III	I-P
OA	I-P
were	O
randomized	O
to	O
receive	O
three	B-I
intra-articular	I-I
HA	I-I
injections	I-I
,	O
with	O
one-week	O
interval	O
of	O
or	O
exercise	B-I
therapy	I-I
for	O
six	O
weeks	O
.	O


Randomized	O
,	O
comparative	O
study	O
of	O
the	O
efficacy	B-OUT
and	O
safety	B-OUT
of	O
artesunate	B-I
plus	I-I
amodiaquine	I-I
,	O
administered	O
as	O
a	O
single	O
daily	O
intake	O
versus	O
two	O
daily	O
intakes	O
in	O
the	O
treatment	O
of	O
uncomplicated	B-P
falciparum	I-P
malaria	I-P
.	I-P


RESULTS	O
Three-hundred	B-P
and	I-P
sixteen	I-P
patients	I-P
were	I-P
included	I-P
in	I-P
the	I-P
study	I-P
.	I-P


The	O
adequate	B-OUT
responses	I-OUT
to	I-OUT
treatment	I-OUT
were	O
similar	O
for	O
the	O
two	O
treatment	O
regimens	O
on	O
D14	O
,	O
PCR-corrected	O
(	O
99,4	O
%	O
in	O
the	O
one-daily	O
intake	O
group	O
versus	O
99,3	O
%	O
in	O
the	O
comparative	O
group	O
)	O
.	O


Rivaroxaban	B-I
versus	I-I
warfarin	I-I
in	O
nonvalvular	B-P
atrial	I-P
fibrillation	I-P
.	I-P


BACKGROUND	O
The	O
use	O
of	O
warfarin	B-I
reduces	O
the	O
rate	B-OUT
of	I-OUT
ischemic	I-OUT
stroke	I-OUT
in	O
patients	B-P
with	I-P
atrial	I-P
fibrillation	I-P
but	O
requires	O
frequent	O
monitoring	O
and	O
dose	O
adjustment	O
.	O


METHODS	O
Forty	B-P
premenopausal	I-P
women	I-P
with	I-P
large	I-P
,	I-P
symptomatic	I-P
leiomyomata	I-P
were	O
randomized	O
to	O
receive	B-I
either	I-I
5	I-I
or	I-I
10	I-I
mg	I-I
of	I-I
mifepristone	I-I
daily	I-I
for	I-I
6	I-I
months	I-I
in	I-I
an	I-I
open-label	I-I
study	I-I
.	I-I


Uterine	O
volume	O
was	O
measured	O
at	O
bimonthly	O
intervals	O
by	O
sonography	O
.	O


Leiomyoma-related	B-OUT
symptoms	I-OUT
were	O
comparably	O
reduced	O
in	O
both	O
groups	O
.	O


No	O
atypical	B-OUT
hyperplasia	I-OUT
was	O
noted	O
.	O


Although	O
final	O
blood	B-OUT
pressures	I-OUT
(	I-OUT
systolic/diastolic	I-OUT
)	I-OUT
were	O
significantly	O
lower	O
in	O
the	O
strict-treatment	O
group	O
compared	O
with	O
the	O
mild-treatment	O
group	O
(	O
135.9/74.8	O
vs.	O
145.6/78.1	O
mmHg	O
;	O
p	O
<	O
0.001	O
)	O
,	O
the	O
incidence	O
of	O
the	O
primary	O
endpoint	O
was	O
similar	O
in	O
the	O
two	O
groups	O
(	O
86	O
patients	O
in	O
each	O
group	O
;	O
p=0.99	O
)	O
.	O


Blood	B-OUT
plasma	I-OUT
levels	I-OUT
of	O
the	O
drugs	O
were	O
measured	O
.	O


Patients	B-P
who	I-P
were	I-P
identified	I-P
as	I-P
requiring	I-P
pedicled	I-P
flap	I-P
reconstruction	I-P
were	I-P
potential	I-P
candidates	I-P
for	I-P
the	I-P
study	I-P
.	I-P


Fifty-six	O
patients	O
were	O
assigned	O
to	O
5	O
days	O
of	O
perioperative	B-I
antibiotic	I-I
prophylaxis	I-I
.	I-I


Wound	B-OUT
infection	I-OUT
developed	O
in	O
14	O
(	O
25	O
%	O
)	O
of	O
these	O
patients	O
(	O
P	O
greater	O
than	O
.05	O
)	O
.	O


Randomized	O
controlled	O
trial	O
of	O
education	O
and	O
feedback	O
for	O
implementation	O
of	O
guidelines	O
for	O
acute	O
low	O
back	O
pain	O
.	O


PARTICIPANTS	O
Fourteen	B-P
physician	I-P
groups	I-P
with	I-P
120	I-P
primary	I-P
care	I-P
physician	I-P
and	I-P
associate	I-P
practitioners	I-P
from	I-P
2	I-P
group	I-P
model	I-P
HMO	I-P
practices	I-P
.	I-P


The	O
patient	B-I
education	I-I
component	I-I
included	I-I
written	I-I
and	I-I
videotaped	I-I
materials	I-I
on	I-I
the	I-I
care	I-I
of	I-I
low	I-I
back	I-I
pain	I-I
.	I-I


MAIN	O
RESULTS	O
The	O
clinician	B-I
intervention	I-I
was	O
associated	O
with	O
an	O
absolute	O
increase	O
in	O
guideline-consistent	B-OUT
behavior	I-OUT
of	O
5.4	O
%	O
in	O
the	O
intervention	O
group	O
versus	O
a	O
decline	O
of	O
2.7	O
%	O
in	O
the	O
control	O
group	O
(	O
P	O
=.04	O
)	O
.	O


Weekly	O
docetaxel	B-I
with	O
or	O
without	O
gemcitabine	B-I
as	O
second-line	B-I
chemotherapy	I-I
in	O
paclitaxel-pretreated	B-I
patients	I-P
with	I-P
metastatic	I-P
breast	I-P
cancer	I-P
:	I-P
a	O
randomized	O
phase	O
II	O
study	O
conducted	O
by	O
the	O
Hellenic	O
Co-Operative	O
Oncology	O
Group	O
.	O


Differences	O
in	O
change	O
over	O
time	O
and	O
between	O
the	O
intervention	O
and	O
control	O
group	O
were	O
analyzed	O
by	O
repeated	O
measures	O
and	O
the	O
association	O
between	O
characteristics	O
of	O
children	O
and	O
families	O
with	O
improved	O
outcome	O
by	O
multivariate	O
analysis	O
of	O
variance	O
.	O


METHODS	O
Reanalysis	O
of	O
the	O
prediction	B-I
model	I-I
for	O
the	O
risk	O
of	O
developing	O
POAG	O
using	O
the	O
same	O
baseline	O
variables	O
(	O
age	O
,	O
IOP	O
,	O
CCT	O
,	O
VCDR	O
,	O
and	O
PSD	O
)	O
except	O
that	O
IOP	O
was	O
adjusted	O
for	O
CCT	O
using	O
correction	O
formulae	O
.	O


The	B-P
participants	I-P
were	I-P
primary	I-P
antenatal	I-P
care	I-P
providers	I-P
--	I-P
family	I-P
physicians	I-P
,	I-P
obstetricians	I-P
,	I-P
and	I-P
midwives	I-P
--	I-P
from	I-P
four	I-P
diverse	I-P
communities	I-P
in	I-P
Ontario	I-P
.	I-P


There	O
was	O
no	O
statistically	O
significant	O
difference	O
between	O
any	O
of	O
the	O
treatment	O
arms	O
with	O
respect	O
to	O
disease-free	B-OUT
survival	I-OUT
or	I-OUT
3-year	I-OUT
survival	I-OUT
(	O
P	O
>	O
0.54	O
and	O
P	O
>	O
or=	O
0.09	O
for	O
all	O
pairwise	O
comparisons	O
)	O
,	O
schedules	O
(	O
dose	O
level	O
1/2	O
vs.	O
3/4	O
;	O
P	O
=	O
0.46	O
and	O
P	O
=	O
0.5	O
)	O
,	O
or	O
dose	O
of	O
IL-2	O
administered	O
(	O
dose	O
level	O
1/3	O
vs.	O
2/4	O
;	O
P	O
=	O
0.99	O
and	O
P	O
=	O
0.1	O
)	O
.	O


Future	O
adjuvant	O
trials	O
in	O
this	O
setting	O
are	O
not	O
likely	O
to	O
include	O
IL-2	B-I
in	O
view	O
of	O
the	O
clinical	B-OUT
efficacy	I-OUT
and	I-OUT
favorable	I-OUT
toxicity	I-OUT
profiles	O
of	O
selected	O
multitargeted	O
kinase	O
inhibitors	O
.	O


[	O
Effects	O
of	O
early	O
acupuncture	B-I
on	O
motor	O
function	O
of	O
the	O
limb	O
in	O
the	O
severe	B-P
head	I-P
injury	I-P
patients	I-P
]	I-P
.	O


METHODS	O
Ninety-six	B-P
patients	I-P
were	O
randomly	O
divided	O
into	O
an	O
observation	O
group	O
and	O
a	O
control	O
group	O
,	O
48	B-P
cases	I-P
in	I-P
each	I-P
group	I-P
.	I-P


The	O
patient	O
in	O
the	O
control	O
group	O
were	O
treated	O
by	O
routine	B-I
treatment	I-I
of	I-I
neurosurgical	I-I
operation	I-I
and	I-I
drug	I-I
treatment	I-I
(	I-I
Mannitol	I-I
,	I-I
Citioline	I-I
Sodium	I-I
,	I-I
Cefeazidime	I-I
,	I-I
etc.	I-I
)	I-I
.	I-I


CONCLUSION	O
Early	O
acupuncture	B-I
can	O
improve	O
the	O
limb	O
motor	O
function	O
in	O
the	O
severe	B-P
head	I-P
injury	I-P
patients	I-P
.	I-P


Eighteen	B-P
children	I-P
with	I-P
ASD	I-P
were	O
assessed	O
with	O
pretreatment	O
and	O
posttreatment	O
measures	O
on	O
the	O
Walker-McConnell	B-OUT
Scale	I-OUT
(	I-OUT
WMS	I-OUT
)	I-OUT
and	I-OUT
the	I-OUT
MGH	I-OUT
YouthCare	I-OUT
Social	I-OUT
Competence	I-OUT
Development	I-OUT
Scale	I-OUT
.	I-OUT


We	O
aimed	O
to	O
see	O
whether	O
the	O
pentasaccharide	B-I
fondaparinux	I-I
,	O
the	O
first	O
drug	O
of	O
a	O
new	O
class	O
of	O
synthetic	B-I
antithrombotic	I-I
agents	I-I
,	O
could	O
reduce	O
this	O
risk	O
to	O
a	O
greater	O
extent	O
than	O
other	O
available	O
treatments	O
.	O


METHODS	O
In	O
a	O
double-blind	O
study	O
,	O
we	B-P
randomly	I-P
assigned	I-P
2275	I-P
consecutive	I-P
patients	I-P
aged	I-P
18	I-P
years	I-P
or	I-P
older	I-P
who	I-P
were	I-P
undergoing	I-P
elective	I-P
hip-replacement	I-P
surgery	I-P
to	I-P
receive	I-P
postoperative	I-P
subcutaneous	I-P
injections	I-P
of	I-P
either	I-P
2.5	I-I
mg	I-I
fondaparinux	I-I
once	I-I
daily	I-I
or	I-I
30	I-I
mg	I-I
enoxaparin	I-I
twice	I-P
daily	I-P
.	I-P


The	O
relative	O
reduction	O
in	O
risk	B-OUT
was	O
26.3	O
%	O
(	O
95	O
%	O
CI	O
-10.8	O
to	O
52.8	O
,	O
p=0.099	O
)	O
.	O


OBJECTIVE	O
To	O
determine	O
the	O
clinical	O
and	O
economic	O
effects	O
of	O
granulocyte	B-I
macrophage	I-I
colony-stimulating	I-I
factor	I-I
(	I-I
GM-CSF	I-I
)	I-I
as	O
adjunct	O
therapy	O
in	O
relapsed	B-P
or	I-P
refractory	I-P
Hodgkin	I-P
disease	I-P
.	I-P


SETTING	O
A	O
tertiary	B-P
referral	I-P
center	I-P
.	I-P


PATIENTS	O
Twenty-four	B-P
patients	I-P
(	I-P
twelve	I-P
of	I-P
whom	I-P
were	I-P
controls	I-P
)	I-P
treated	I-P
with	I-P
high-dose	I-I
chemotherapy	I-I
and	I-P
autologous	I-I
bone	I-I
marrow	I-I
transplantation	I-I
.	I-I


"	O
The	O
purposes	O
of	O
this	O
study	O
were	O
to	O
examine	O
the	O
influence	O
of	O
ultrasound	O
on	O
the	O
transdermal	O
delivery	O
of	O
ketoprofen	O
in	O
humans	O
and	O
to	O
compare	O
the	O
concentrations	O
found	O
after	O
continuous	O
and	O
pulsed	O
application	O
.	O


The	O
ultrasound	O
head	O
was	O
moved	O
over	O
a	O
10-cm2	O
area	O
using	O
small	O
,	O
continuous	O
,	O
circular	O
movements	O
.	O


Biopsies	O
of	O
adipose	O
tissue	O
and	O
synovial	O
tissue	O
were	O
taken	O
during	O
surgery	O
to	O
evaluate	B-OUT
the	I-OUT
local	I-OUT
penetration	I-OUT
of	I-OUT
the	I-OUT
drug	I-OUT
.	I-OUT


RESULTS	O
The	O
concentration	B-OUT
of	I-OUT
ketoprofen	I-OUT
in	O
plasma	O
was	O
negligible	O
in	O
all	O
3	O
groups	O
.	O


BACKGROUND	O
Plasma	O
triglyceride	O
concentration	O
has	O
been	O
an	O
inconsistent	O
independent	O
risk	O
factor	O
for	O
coronary	O
heart	O
disease	O
,	O
perhaps	O
because	O
of	O
the	O
metabolic	O
heterogeneity	O
among	O
VLDL	O
particles	O
,	O
the	O
main	O
carriers	O
of	O
triglycerides	O
in	O
plasma	O
.	O


After	O
12	O
months	O
this	O
successful	O
outcome	O
was	O
improved	O
slightly	O
further	O
.	O


METHODS	O
A	O
randomized	O
,	O
single-blind	O
,	O
controlled	O
trial	O
was	O
conducted	O
in	O
30	B-P
non-diabetic	I-P
patients	I-P
with	I-P
hypertension	I-P
over	O
a	O
period	O
of	O
9	O
weeks	O
to	O
evaluate	O
the	O
effect	O
of	O
a	O
device	B-I
that	I-I
helps	I-I
to	I-I
slow	I-OUT
breathing	I-OUT
(	I-I
Resperate	I-I
)	I-I
on	O
BP	B-OUT
and	I-OUT
quality	I-OUT
of	I-OUT
life	I-OUT
(	I-OUT
QoL	I-OUT
)	I-OUT
.	I-OUT


Efficacy	B-OUT
and	I-OUT
safety	I-OUT
of	O
recombinant	B-I
human	I-I
nerve	I-I
growth	I-I
factor	I-I
in	O
patients	B-P
with	I-P
diabetic	I-P
polyneuropathy	I-P
:	I-P
A	O
randomized	O
controlled	O
trial	O
.	O


Administration	O
of	O
rhNGF	B-I
was	O
safe	O
,	O
with	O
few	O
adverse	B-OUT
events	I-OUT
attributed	O
to	O
treatment	O
apart	O
from	O
injection	O
site	B-OUT
pain/hyperalgesia	I-OUT
and	I-OUT
other	I-OUT
pain	I-OUT
syndromes	I-OUT
.	I-OUT


Exceptions	O
were	O
the	O
global	B-OUT
symptom	I-OUT
assessment	I-OUT
(	O
P	O
=.03	O
)	O
and	O
2	O
of	O
32	O
comparisons	O
within	O
the	O
PBQ	O
,	O
which	O
showed	O
a	O
modest	O
but	O
significant	O
benefit	O
of	O
rhNGF	B-I
(	O
P	O
=.05	O
for	O
severity	O
of	O
pain	O
in	O
the	O
legs	O
and	O
P	O
=.003	O
for	O
6-month	O
symptoms	O
in	O
the	O
feet	O
and	O
legs	O
)	O
.	O


CONCLUSION	O
Unlike	O
previous	O
phase	O
2	O
trials	O
,	O
this	O
phase	O
3	O
clinical	O
trial	O
failed	O
to	O
demonstrate	O
a	O
significant	O
beneficial	O
effect	O
of	O
rhNGF	O
on	O
diabetic	O
polyneuropathy	O
.	O


JAMA	O
.	O


We	O
designed	O
a	O
randomized	O
trial	O
to	O
assess	O
whether	O
the	O
early	B-I
withdrawal	I-I
of	I-I
cyclosporine	I-I
(	I-I
CsA	I-I
)	I-I
followed	I-I
by	I-I
the	I-I
initiation	I-I
of	I-I
everolimus	I-I
(	I-I
Evr	I-I
)	I-I
monotherapy	I-I
in	O
de	B-P
novo	I-P
liver	I-P
transplantation	I-P
(	I-P
LT	I-P
)	I-P
patients	I-P
would	O
result	O
in	O
superior	O
renal	O
function	O
compared	O
to	O
a	O
CsA-based	O
immunosuppression	O
protocol	O
.	O


The	O
1-year	B-OUT
freedom	I-OUT
from	I-OUT
efficacy	I-OUT
failure	I-OUT
in	O
Evr	B-I
group	O
was	O
75	O
%	O
versus	O
69.2	O
%	O
in	O
CsA	B-I
group	O
,	O
p	O
=	O
0.36	O
.	O


PURPOSE	O
We	O
conducted	O
a	O
prospective	O
randomized	O
controlled	O
study	O
to	O
evaluate	O
the	O
effect	O
of	O
micronized	B-I
flavonoid	I-I
fractions	I-I
(	I-I
MFF	I-I
)	I-I
on	O
pain	B-OUT
after	I-P
hemorrhoidectomy	I-P
.	I-P


CONCLUSION	O
Using	O
MFF	B-I
after	I-P
hemorrhoidectomy	I-P
reduced	O
the	O
severity	B-OUT
of	I-OUT
pain	I-OUT
and	I-OUT
intramuscular	I-OUT
analgesic	I-OUT
requirement	I-OUT
.	I-OUT


Divergence	B-OUT
in	O
student	B-P
and	I-P
educator	I-P
conceptual	I-P
structures	I-P
during	O
auscultation	B-P
training	I-P
.	I-P


The	O
groups	O
'	O
diagnostic	O
accuracy	O
,	O
however	O
,	O
did	O
not	O
differ	O
significantly	O
on	O
the	O
post-test	O
,	O
retention	O
test	O
or	O
transfer	O
test	O
items	O
(	O
p	O
>	O
0.12	O
)	O
.	O


The	O
number	B-OUT
of	I-OUT
harvested	I-OUT
lymph	I-OUT
nodes	I-OUT
was	O
similar	O
(	O
median	O
,	O
LH	B-I
13	O
[	O
IQR	O
,	O
10-16	O
]	O
vs	O
OH	B-I
12	O
[	O
IQR	O
,	O
11-13	O
]	O
;	O
P	O
=	O
0.67	O
)	O
.	O


Further	O
studies	O
are	O
required	O
to	O
assess	O
the	O
long-term	B-OUT
safety	I-OUT
.	I-OUT


Pulmonary	O
vein	O
re-isolation	O
for	O
atrial	B-P
fibrillation	I-P
using	O
duty-cycled	B-I
phased	I-I
radiofrequency	I-I
ablation	I-I
:	I-I
safety	O
and	O
efficacy	O
of	O
a	O
primary	B-I
2:1	I-I
bipolar/unipolar	I-I
ablation	I-I
mode	I-I
.	I-I


Significant	O
shorter	O
procedure	O
and	O
fluoroscopy	O
times	O
compared	O
with	O
a	O
primary	O
4:1	O
ablation	O
mode	O
during	O
repeat	O
PVI	O
are	O
mainly	O
attributed	O
to	O
a	O
lower	O
incidence	O
of	O
acutely	O
reconnected	O
PVs	O
within	O
the	O
first	O
30	O
min	O
.	O


METHODS	O
AND	O
RESULTS	O
Forty-eight	B-P
patients	I-P
with	I-P
unexplained	I-P
syncope	I-P
and	I-P
negative	I-P
passive	I-P
head-up	I-P
tilt	I-P
at	I-P
70	I-P
degrees	I-P
for	I-P
40	I-P
min	I-P
,	I-P
and	I-P
14	I-P
healthy	I-P
controls	I-P
underwent	O
glyceryl	B-I
trinitrate	I-I
head-up	I-I
tilt	I-I
and	I-I
isoprenaline	I-I
head-up	I-I
tilt	I-I
(	O
maximum	O
dose	O
5	O
microg	O
x	O
min	O
(	O
-1	O
)	O
)	O
one	O
week	O
apart	O
in	O
random	O
order	O
.	O


Side-effects	B-OUT
prevented	O
completion	O
of	O
the	O
test	O
in	O
68	O
%	O
.	O


No	B-OUT
difference	I-OUT
in	I-OUT
efficacy	I-OUT
was	O
seen	O
among	O
patients	O
who	O
received	O
montelukast	B-I
and	O
the	O
group	O
given	O
a	O
placebo	B-I
.	I-I


RESULTS	O
The	O
ESDM	B-I
group	O
exhibited	O
greater	O
improvements	O
in	O
autism	B-OUT
symptoms	I-OUT
,	I-OUT
IQ	I-OUT
,	I-OUT
language	I-OUT
,	I-OUT
and	I-OUT
adaptive	I-OUT
and	I-OUT
social	I-OUT
behaviors	I-OUT
than	O
the	O
community	O
intervention	O
group	O
.	O


CONCLUSIONS	O
This	O
was	O
the	O
first	O
trial	O
to	O
demonstrate	O
that	O
early	O
behavioral	O
intervention	O
is	O
associated	O
with	B-OUT
normalized	I-OUT
patterns	I-OUT
of	I-OUT
brain	I-OUT
activity	I-OUT
,	O
which	O
is	O
associated	O
with	B-OUT
improvements	I-OUT
in	I-OUT
social	I-OUT
behavior	I-OUT
,	O
in	B-P
young	I-P
children	I-P
with	I-P
autism	I-P
spectrum	I-P
disorder	I-P
.	O


Areas	O
of	O
secondary	O
hyperalgesia	O
,	O
heat	O
pain	O
detection	O
thresholds	O
,	O
and	O
painfulness	O
of	O
stimulation	O
with	O
45	O
degrees	O
C	O
for	O
1	O
min	O
(	O
long	O
thermal	O
stimulation	O
)	O
were	O
quantified	O
.	O


A	O
randomized	O
comparative	O
study	O
of	O
surgical	B-I
adjuvant	I-I
chemotherapy	I-I
using	O
dl-leucovorin	B-I
(	I-I
dl-LV	I-I
)	I-I
and	I-I
5-fluorouracil	I-I
(	I-I
5-FU	I-I
)	I-I
(	I-I
FL-therapy	I-I
)	I-I
with	I-I
CDDP	I-I
,	I-I
5-FU	I-I
,	I-I
and	I-I
dl-LV	I-I
(	I-I
PFL-therapy	I-I
)	I-I
was	O
conducted	O
.	O


These	O
data	O
suggest	O
that	O
PFL-therapy	B-I
and	O
FL-therapy	B-I
seem	O
to	O
be	O
possible	O
and	O
promising	O
surgical	B-I
adjuvant	I-I
therapies	I-I
for	O
advanced	B-OUT
colorectal	I-OUT
carcinoma	I-OUT
.	I-OUT


An	O
evaluation	O
method	O
providing	O
confidence	O
intervals	O
applied	O
to	O
radioimmunoassay	B-I
.	I-I


The	O
order	O
of	O
the	O
single	B-I
tubes	I-I
in	O
each	O
assay	O
run	O
is	O
randomized	O
.	O


A	O
polynomial	O
is	O
fitted	O
to	O
untransformed	O
data	O
(	O
y	O
=	O
counts	O
per	O
minute	O
;	O
x	O
=	O
concentration	O
of	O
curve.A	O
confidence	O
interval	O
is	O
calculated	O
for	O
each	O
sample	O
,	O
taking	O
into	O
account	O
the	O
variance	O
of	O
the	O
standard	O
curve	O
and	O
that	O
of	O
the	O
actual	O
duplicate	O
assay	O
jointly	O
.	O


In	O
vivo	O
study	O
was	O
conducted	O
according	O
to	O
a	O
single-center	O
,	O
randomized	O
,	O
single-dose	O
,	O
laboratory-blinded	O
,	O
2	O
Way	O
,	O
Cross-Over	O
Study	O
with	O
a	O
washout	O
period	O
of	O
10	O
days	O
.	O


DESIGN	O
Double-blinded	O
,	O
prospective	O
,	O
randomized	O
,	O
controlled	O
clinical	O
trial	O
.	O


For	O
14	O
days	O
,	O
patients	O
recorded	O
pain	B-OUT
levels	I-OUT
twice	I-OUT
daily	I-OUT
using	O
a	O
visual	B-OUT
analogue	I-OUT
scale	I-OUT
.	I-OUT


Mean	B-OUT
CL	I-OUT
was	O
43.7	O
(	O
±8.9	O
)	O
mm	O
.	O


CONCLUSION	O
This	O
study	O
shows	O
that	B-P
in	I-P
twin	I-P
pregnancies	I-P
,	O
age	O
,	O
use	O
of	O
ART	O
and	O
having	O
delivered	O
term	O
in	O
a	O
previous	O
pregnancy	O
has	O
an	O
association	O
with	B-OUT
CL	O
.	O


Effects	O
of	O
interaction	O
of	O
RRR-alpha-tocopheryl	B-I
acetate	I-I
and	I-I
fish	I-I
oil	I-I
on	O
low-density-lipoprotein	O
oxidation	O
in	O
postmenopausal	B-P
women	I-P
with	I-P
and	I-P
without	I-P
hormone-replacement	I-I
therapy	I-I
.	I-I


The	O
independent	O
effect	B-OUT
of	O
fish	O
oil	O
was	O
also	O
assessed	O
.	O


Amphotericin	B-I
B	I-I
in	I-P
children	I-P
with	I-P
malignant	I-P
disease	I-P
:	I-P
a	O
comparison	O
of	O
the	O
toxicities	O
and	O
pharmacokinetics	O
of	O
amphotericin	B-I
B	I-I
administered	I-I
in	I-I
dextrose	I-I
versus	I-I
lipid	I-I
emulsion	I-I
.	I-I


Blood	O
samples	O
were	O
collected	O
up	O
to	O
24	O
h	O
after	O
administration	O
of	O
the	O
first	O
dose	O
,	O
and	O
the	O
concentration	B-OUT
of	I-OUT
AmB	I-OUT
in	I-OUT
plasma	I-OUT
was	O
analyzed	O
by	O
a	O
high-performance	O
liquid	O
chromatography	O
assay	O
.	O


h-1	O
.	O


kg-1	O
)	O
was	O
significantly	O
lower	O
(	O
P	O
<	O
0.005	O
)	O
than	O
the	O
CL	O
of	O
AmB	B-I
in	I-I
lipid	I-I
emulsion	I-I
(	O
0.062	O
+/-	O
0	O
.	O


The	O
steady-state	B-OUT
volume	I-OUT
of	I-OUT
distribution	I-OUT
for	I-OUT
AmB	I-OUT
in	O
dextrose	O
(	O
0.83	O
+/-	O
0.33	O
liter	O
.	O


Although	O
AmB	B-OUT
in	I-OUT
lipid	I-OUT
emulsion	I-OUT
is	O
apparently	O
cleared	O
faster	O
and	O
distributes	O
more	O
widely	O
than	O
AmB	B-OUT
in	I-OUT
dextrose	I-OUT
,	O
this	O
study	O
did	O
not	O
reveal	O
any	O
significant	O
advantage	O
with	O
respect	O
to	O
safety	B-OUT
and	I-OUT
tolerance	I-OUT
in	O
the	O
administration	O
of	O
AmB	B-I
in	I-I
lipid	I-I
emulsion	I-I
compared	O
to	O
its	O
administration	O
in	O
dextrose	B-I
in	O
children	B-P
with	I-P
malignant	I-P
disease	I-P
.	I-P


METHODS	O
Consecutively	B-P
listed	I-P
candidates	I-P
for	I-P
elective	I-P
bypass	I-P
were	O
randomly	O
assigned	O
to	O
either	O
off-pump	B-I
or	I-I
on-pump	I-I
techniques	I-I
(	I-P
n	I-P
=	I-P
107	I-P
)	I-P
.	O


The	O
probiotic	O
group	O
showed	O
the	O
better	O
scores	O
on	B-OUT
overall	I-OUT
PAC-SYM	I-OUT
(	O
P=0.013	O
)	O
,	O
PAC-SYM	B-OUT
subscales	I-OUT
of	I-OUT
abdominal	I-OUT
symptoms	I-OUT
(	O
P=0.043	O
)	O
and	O
rectal	O
symptoms	O
(	O
P=0.031	O
)	O
,	O
and	O
PAC-QOL	O
satisfaction	O
subscale	O
(	O
P=0.037	O
)	O
in	O
comparison	O
with	O
the	O
placebo	O
group	O
.	O


A	O
comparison	O
of	O
the	O
effectiveness	O
and	O
patient	O
tolerance	O
of	O
oral	O
sodium	O
phosphate	O
,	O
castor	O
oil	O
,	O
and	O
standard	O
electrolyte	O
lavage	O
for	O
colonoscopy	B-P
or	I-P
sigmoidoscopy	I-P
preparation	I-P
.	I-P


For	O
endoscopic	B-OUT
recurrence	I-OUT
(	O
Rutgeerts	O
score	O
≥i2	O
)	O
at	O
6	O
months	O
,	O
patients	O
stepped-up	O
to	O
thiopurine	O
,	O
fortnightly	B-I
adalimumab	I-I
with	I-I
thiopurine	I-I
,	O
or	O
weekly	O
adalimumab	O
.	O


Analysis	O
included	O
all	O
patients	O
who	O
received	O
at	O
least	O
one	O
dose	O
of	O
study	O
drug	O
.	O


FUNDING	O
AbbVie	O
,	O
Gutsy	O
Group	O
,	O
Gandel	O
Philanthropy	O
,	O
Angior	O
Foundation	O
,	O
Crohn	O
's	O
Colitis	O
Australia	O
,	O
and	O
the	O
National	O
Health	O
and	O
Medical	O
Research	O
Council	O
.	O


We	O
treated	O
patients	B-P
with	I-P
coronary	I-P
artery	I-P
disease	I-P
with	O
sulfasalazine	B-I
,	I-I
an	I-I
inhibitor	I-I
of	I-I
NFκB	I-I
,	I-I
and	I-I
placebo	I-I
in	I-I
a	I-I
randomized	I-I
,	I-I
double-blind	I-I
,	I-I
crossover	I-I
study	I-I
design	I-I
.	I-OUT


Dose	O
increments	O
were	O
given	O
at	O
20	O
min	O
intervals	O
with	O
measurements	O
being	O
made	O
15	O
min	O
after	O
each	O
dose	O
.	O


This	O
study	O
clearly	O
shows	O
that	O
a	O
pretreatment	O
with	O
a	O
conventional	O
dose	O
of	O
formoterol	B-I
,	I-I
salmeterol	I-I
,	I-I
or	I-I
oxitropium	I-I
bromide	I-I
does	O
not	O
preclude	O
the	O
possibility	O
of	O
inducing	O
a	O
further	O
bronchodilation	B-OUT
with	O
salbutamol	B-I
in	O
patients	B-P
suffering	I-P
from	I-P
partially	I-P
reversible	I-P
chronic	I-P
obstructive	I-P
pulmonary	I-P
disease	I-P
.	I-P


Peripheral	B-OUT
arterial	I-OUT
blood	I-OUT
oxygenation	I-OUT
decreased	O
to	O
78.9	O
+/-	O
8.7	O
%	O
(	O
mean	O
+/-	O
SD	O
)	O
ranging	O
from	O
52	O
%	O
-90	O
%	O
.	O


Further	O
studies	O
are	O
needed	O
to	O
optimize	O
the	O
clinical	O
practice	O
of	O
IV	B-I
opioid	I-I
treatment	I-I
to	O
prevent	O
serious	O
complications	O
.	O


Event-free	B-OUT
survival	I-OUT
after	O
1	O
year	O
was	O
higher	O
in	O
the	O
bypass	O
group	O
(	O
71.4	O
%	O
vs.	O
52.3	O
%	O
;	O
P	O
=	O
0.02	O
)	O
due	O
to	O
a	O
lower	O
target	O
lesion	O
revascularization	O
rate	O
.	O


BACKGROUND	O
Insulin-like	O
growth	O
factors	O
(	O
IGF-1	O
and	O
IGF-2	O
)	O
bind	O
to	O
the	O
IGF-1	O
receptor	O
(	O
IGF-1R	O
)	O
,	O
increasing	O
cell	B-OUT
proliferation	I-OUT
and	O
survival	B-OUT
.	I-OUT


Ganitumab	B-I
is	O
a	O
monoclonal	O
IgG1	O
antibody	O
that	O
blocks	O
IGF-1R	O
.	O


We	O
analysed	O
overall	B-OUT
survival	I-OUT
as	O
one	O
of	O
our	O
secondary	O
endpoints	O
.	O


The	O
convergence	O
of	O
cervical	O
and	O
trigeminal	O
afferents	O
on	O
second-order	O
neurons	O
in	O
the	O
trigeminocervical	O
nucleus	O
may	O
refer	O
pain	O
from	O
the	O
upper	O
cervical	O
spine	O
into	O
the	O
head	O
and	O
face	O
.	O


Forty-five	B-P
(	I-P
45	I-P
)	I-P
female	I-P
subjects	I-P
,	I-P
between	I-P
the	I-P
ages	I-P
of	I-P
18	I-P
and	I-P
40	I-P
years	I-P
,	O
were	O
randomly	O
assigned	O
to	O
three	O
groups	O
consisting	O
of	O
the	O
no-treatment	B-I
control	I-I
,	I-P
the	I-P
treatment-control	I-I
(	I-I
table	I-I
stabilization	I-I
)	I-I
,	I-I
and	I-I
the	I-I
experimental	I-I
(	I-I
PostureJac	I-I
)	I-I
group	I-I
.	I-I


The	O
results	O
indicated	O
that	O
the	O
PostureJac	B-I
group	I-P
was	O
superior	O
to	O
the	O
no-treatment	B-P
control	I-P
(	I-P
p=.001	I-P
)	I-P
and	I-P
the	I-P
treatment-control	I-P
(	I-P
p=.004	I-P
)	I-P
groups	I-P
in	O
terms	O
of	O
increasing	O
endurance	B-OUT
of	I-OUT
the	I-OUT
deep	I-OUT
cervical	I-OUT
flexors	I-OUT
.	I-OUT


Consequently	O
,	O
the	O
PostureJac	B-I
may	O
be	O
a	O
useful	O
therapeutic	O
tool	O
in	O
the	O
management	O
of	O
cervicogenic	B-OUT
headache	I-OUT
and	I-OUT
mechanical	I-OUT
neck	I-OUT
pain	I-OUT
.	I-OUT


Low-intensity	B-I
exercise	I-I
and	O
reduction	O
of	O
the	B-OUT
risk	I-OUT
for	I-OUT
falls	I-OUT
among	I-P
at-risk	I-P
elders	I-P
.	I-P


The	O
2	O
groups	O
were	O
compared	O
with	O
chi2	O
test	O
for	O
independence	O
of	O
categorical	O
variables	O
.	O


Wilcoxon	O
rank	O
sum	O
test	O
was	O
used	O
for	O
continuous	O
variables	O
.	O


CONCLUSION	O
The	O
study	O
confirmed	O
the	O
high	O
activity	O
of	O
gemcitabine-taxane	B-I
combinations	I-I
in	O
MBC	O
.	O


Split-dose	O
paclitaxel	B-I
had	O
similar	O
activity	B-OUT
and	O
toxicity	B-OUT
to	O
the	O
3-weekly	O
administration	O
.	O


Randomized	B-I
controlled	I-I
trials	I-I
are	O
the	O
gold	O
standard	O
for	O
the	O
evaluation	O
of	O
new	O
therapies	O
and	O
surgical	O
procedures	O
and	O
as	O
such	O
require	O
strict	O
attention	O
to	O
study	O
design	O
and	O
statistical	O
analysis	O
.	O


The	O
primary	O
endpoint	O
was	O
a	O
composite	B-OUT
of	I-OUT
major	I-OUT
macrovascular	I-OUT
and	I-OUT
microvascular	I-OUT
disease	I-OUT
.	I-OUT


The	O
effects	O
of	O
active	O
treatment	O
on	O
outcomes	O
were	O
estimated	O
in	O
subgroups	B-P
according	I-P
to	I-P
age	I-P
:	I-P
below	I-P
65	I-P
,	I-P
65-74	I-P
and	I-P
at	I-P
least	I-P
75	I-P
years	I-P
.	I-P


There	O
are	O
no	O
controlled	O
studies	O
evaluating	O
these	O
interventions	O
as	O
adjuncts	O
to	O
facilitate	O
completion	O
of	O
painful	O
procedures	O
in	O
the	O
pediatric	O
emergency	O
department	O
(	O
ED	O
)	O
.	O


METHODS	O
Eligible	B-P
children	I-P
between	I-P
6	I-P
and	I-P
18	I-P
years	I-P
of	I-P
age	I-P
(	I-P
N	I-P
=	I-P
240	I-P
)	I-P
presenting	I-P
to	I-P
the	I-P
ED	I-P
for	I-P
laceration	I-P
repair	I-P
were	O
randomly	O
assigned	O
to	O
an	O
intervention	O
or	O
control	O
arm	O
.	O


Those	O
assigned	O
to	O
the	O
intervention	O
arm	O
were	O
given	O
a	O
choice	O
of	O
age-appropriate	B-I
distracters	I-I
during	O
laceration	O
repair	O
.	O


In	O
parallel	O
,	O
the	O
maximal	B-OUT
metabolic	I-OUT
effect	I-OUT
of	I-OUT
glibenclamide	I-OUT
tended	O
to	O
be	O
higher	O
with	O
enalapril	B-I
(	O
GIR	O
(	O
max	O
)	O
5.2	O
+/-	O
1.9	O
vs	O
4.1	O
+/-	O
1.3	O
mg	O
kg	O
(	O
-1	O
)	O
min	O
(	O
-1	O
)	O
;	O
p	O
=	O
0.19	O
)	O
.	O


However	O
,	O
the	O
total	B-OUT
metabolic	I-OUT
effect	I-OUT
of	I-OUT
glibenclamide	I-OUT
was	O
almost	O
identical	O
between	O
volunteers	O
taking	O
enalapril	B-I
or	I-I
placebo	I-I
(	O
AUC	O
GIR	O
(	O
0-600	O
)	O
1267	O
+/-	O
334	O
vs	O
1286	O
+/-	O
249	O
mg	O
kg	O
(	O
-1	O
)	O
,	O
ns	O
)	O
.	O


BACKGROUND	O
Neurobiological	O
research	O
has	O
implicated	O
the	O
dopamine	O
and	O
serotonin	O
systems	O
in	O
the	O
pathogenesis	O
of	O
autism	B-P
.	I-P


Open-label	O
reports	O
suggest	O
that	O
the	O
serotonin2A-dopamine	B-I
D2	I-I
antagonist	I-I
risperidone	I-I
may	O
be	O
safe	O
and	O
effective	O
in	O
reducing	O
the	O
interfering	O
symptoms	O
of	O
patients	B-P
with	I-P
autism	I-P
.	I-P


Nizatidine	B-I
versus	O
ranitidine	B-I
in	O
the	O
treatment	O
of	O
peptic	O
ulcer	O
disease	O
:	O
report	O
on	O
the	O
Dutch	O
investigation	O
as	O
part	O
of	O
a	O
European	B-P
multicentre	I-P
trial	I-P
.	I-P


Oat	B-I
ingestion	I-I
reduces	O
systolic	O
and	O
diastolic	O
blood	O
pressure	O
in	O
patients	B-P
with	I-P
mild	I-P
or	I-P
borderline	I-P
hypertension	I-P
:	I-P
a	O
pilot	O
trial	O
.	O


OBJECTIVES	O
We	O
assessed	O
the	O
short-term	O
antihypertensive	O
effects	O
of	O
soluble	B-I
fiber-rich	I-I
whole	I-I
oat	I-I
cereals	I-I
when	O
added	O
to	O
a	O
standard	O
American	O
diet	O
.	O


In	O
addition	O
,	O
multiple	O
assessments	O
of	O
insulin	O
sensitivity	O
were	O
conducted	O
.	O


RESULTS	O
The	O
oat	O
cereal	O
group	O
experienced	O
a	O
7.5	O
mm	O
Hg	O
reduction	O
in	O
SBP	B-OUT
(	O
P	O
&	O
lt.01	O
)	O
and	O
a	O
5.5	O
mm	O
Hg	O
reduction	O
in	O
DBP	B-OUT
(	O
P	O
&	O
lt.02	O
)	O
,	O
while	O
there	O
was	O
virtually	O
no	O
change	O
in	O
either	O
SBP	O
or	O
DBP	O
in	O
the	O
control	O
group	O
.	O


Although	O
exercise	O
may	O
be	O
used	O
by	O
some	O
to	O
decrease	O
distress	O
,	O
little	O
is	O
known	O
about	O
how	O
it	O
may	O
contribute	O
to	O
stress	O
management	O
(	O
SM	O
)	O
among	O
patients	B-P
receiving	I-P
chemotherapy	I-P
.	I-P


This	O
study	O
provides	O
support	O
for	O
including	O
an	O
exercise	B-OUT
component	I-OUT
in	O
SM	O
interventions	O
for	O
cancer	B-P
patients	I-P
receiving	I-P
chemotherapy	I-P
(	O
clinicaltrials.gov	O
identifier	O
:	O
NCT00740038	O
)	O
.	O


The	O
primary	O
efficacy	O
endpoint	O
was	O
the	O
sum	B-OUT
of	I-OUT
pain	I-OUT
intensity	I-OUT
difference	I-OUT
(	I-OUT
SPID	I-OUT
)	I-OUT
over	I-OUT
30	I-OUT
min	I-OUT
post-administration	I-OUT
.	I-OUT


Does	O
aerobic	B-I
training	I-I
lead	O
to	O
a	O
more	O
active	B-OUT
lifestyle	I-OUT
and	I-OUT
improved	I-OUT
quality	I-OUT
of	I-OUT
life	I-OUT
in	O
patients	B-P
with	I-P
chronic	I-P
heart	I-P
failure	I-P
?	O
BACKGROUND	O
Due	O
to	O
dyspnea	O
and	O
fatigue	O
,	O
patients	B-P
with	I-P
chronic	I-P
heart	I-P
failure	I-P
(	I-P
CHF	I-P
)	I-P
are	O
often	O
restricted	O
in	O
the	O
performance	O
of	O
everyday	O
activities	O
,	O
which	O
gradually	O
may	O
lead	O
to	O
hypoactivity	O
.	O


Changes	O
in	O
level	O
of	O
everyday	O
PA	O
were	O
related	O
to	O
changes	O
in	O
peak	B-OUT
Vo	I-OUT
(	I-OUT
2	I-OUT
)	I-OUT
(	O
r=0.58	O
,	O
P=0.01	O
)	O
and	O
knee	B-OUT
extension	I-OUT
strength	I-OUT
(	O
r=0.48	O
,	O
P=0.05	O
)	O
.	O


However	O
,	O
correlations	O
between	O
training-related	O
changes	O
in	O
parameters	O
suggest	O
that	O
aerobic	O
training	O
has	O
the	O
potential	O
to	O
increase	O
levels	O
of	O
everyday	B-OUT
PA	I-OUT
in	O
CHF	O
.	O


In	O
20	O
operations	O
,	O
19	B-P
children	I-P
were	I-P
randomized	I-P
to	I-P
heparin-coated	I-I
(	I-I
group	I-I
HC	I-I
,	I-I
n	I-I
=	I-I
10	I-I
)	I-I
or	I-I
standard	I-I
(	I-I
group	I-I
C	I-I
,	I-I
n	I-I
=	I-I
10	I-I
)	I-I
bypass	I-I
circuits	I-I
.	I-I


Heparin-coated	B-I
CPB	I-I
circuits	I-I
improve	O
the	O
biocompatibility	O
of	O
CPB	O
during	O
heart	O
surgery	O
in	O
the	O
paediatric	B-P
patient	I-P
population	O
,	O
as	O
reflected	O
by	O
significantly	O
reduced	O
levels	O
of	O
circulating	O
complement	O
factors	O
and	O
interleukin-6	O
.	O


CONCLUSIONS	O
Low	O
dialysate	O
sodium	O
concentrations	O
significantly	B-OUT
decreased	I-OUT
systolic	I-OUT
BP	O
and	O
ameliorated	B-OUT
intradialytic	I-OUT
hypertension	I-OUT
.	O


Routine	O
administration	O
of	O
intravenous	O
esmolol	O
before	O
ECT	O
may	O
cause	O
a	O
decrease	O
in	O
ictal	B-OUT
regularity	I-OUT
.	I-OUT


Careful	O
consideration	O
should	O
be	O
given	O
to	O
the	O
potential	O
benefits	O
of	O
esmolol	O
versus	O
the	O
deleterious	O
effect	O
on	O
the	O
electrophysiologic	O
process	O
.	O


BACKGROUND	O
Cool	B-I
dialysate	I-I
is	O
often	O
recommended	O
for	O
prevention	O
of	O
intra-dialytic	O
hypotensive	O
episodes	O
in	O
maintenance	B-P
hemodialysis	I-P
(	I-P
HD	I-P
)	I-P
patients	I-P
.	I-P


TRIAL	O
REGISTRATION	O
Clinicaltrials.gov	O
Identifier	O
--	O
NCT02064153	O
.	O


METHODS	O
&	O
PROCEDURES	O
In	O
a	O
single-blind	O
RCT	O
design	O
,	O
88	B-P
children	I-P
with	I-P
pragmatic	I-P
and	I-P
social	I-P
communication	I-P
needs	I-P
aged	I-P
5	I-P
;	I-P
11-10	I-P
;	I-P
8	I-P
,	I-P
recruited	I-P
from	I-P
UK	I-P
speech	I-P
and	I-P
language	I-P
therapy	I-P
services	I-P
,	O
were	O
randomly	O
assigned	O
in	O
a	O
2:1	O
ratio	O
to	O
SCIP	B-I
or	O
to	O
treatment-as-usual	B-I
.	I-I


The	O
daily	B-OUT
pain	I-OUT
response	I-OUT
was	I-OUT
assessed	I-OUT
using	I-OUT
a	I-OUT
visual	I-OUT
analogue	I-OUT
scale	I-OUT
card	I-OUT
in	I-I
19	I-I
patients	I-I
who	I-I
received	I-I
at	I-I
least	I-I
2	I-I
weeks	I-I
of	I-I
the	I-I
drug	I-I
,	I-I
16	I-I
of	I-I
whom	I-I
were	I-I
crossed-over	I-I
to	I-I
receive	I-I
the	I-I
alternate	I-I
agent	I-I
.	I-I


Comparing	O
the	O
mean	B-OUT
individual	I-OUT
daily	I-OUT
pain	I-OUT
scores	I-OUT
for	O
each	O
phase	O
of	O
study	O
,	O
5	O
patients	O
(	O
31	O
%	O
)	O
had	O
significantly	O
less	O
pain	B-OUT
while	O
receiving	O
mexiletine	B-I
compared	O
with	O
their	O
response	O
to	O
placebo	B-I
,	O
5	O
patients	O
(	O
31	O
%	O
)	O
had	O
significantly	O
less	O
pain	B-OUT
while	O
receiving	O
placebo	B-I
,	O
and	O
no	O
difference	O
was	O
noted	O
in	O
6	O
patients	O
(	O
38	O
%	O
)	O
.	O


Crossover	B-OUT
and	I-OUT
multivariate	I-OUT
analyses	I-OUT
for	O
repeated	O
measures	O
showed	O
no	O
apparent	O
difference	O
in	O
the	O
response	O
to	O
mexiletine	B-I
versus	O
placebo	B-I
.	I-I


Elevated	O
thromboxane	O
levels	O
are	O
associated	O
with	O
a	O
number	O
of	O
disease	O
states	O
,	O
including	O
dermal	O
pressure	O
ulcers	O
.	O


When	O
dazmegrel	B-I
was	I-I
orally	I-I
administered	I-I
to	I-I
greyhound	I-I
dogs	I-I
wearing	I-I
leg	I-I
casts	I-I
,	O
it	O
resulted	O
in	O
a	O
sparring	O
effect	O
on	O
the	O
skin	O
areas	O
of	O
potential	O
pressure	O
ulcer	O
development	O
.	O


Trimetazidine	O
European	O
Multicenter	O
Study	O
Group	O
.	O


1	O
.	O


Reproducibility	O
of	O
exercise	O
performance	O
was	O
verified	O
during	O
a	O
3	O
week	O
run-in	O
placebo	O
washout	O
period	O
.	O


With	O
both	O
drugs	O
there	O
was	O
a	O
trend	O
to	O
decreased	O
ischaemic	B-OUT
episodes	I-OUT
in	O
the	O
46	O
%	O
patients	O
who	O
experienced	O
ambulatory	O
ischaemia	O
on	O
Holter	O
monitoring	O
.	O


(	O
ABSTRACT	O
TRUNCATED	O
AT	O
250	O
WORDS	O
)	O


PURPOSE	O
Cure	O
rates	O
for	O
localized	O
high-risk	O
prostate	O
cancers	O
(	O
PCa	O
)	O
and	O
some	O
intermediate-risk	O
PCa	O
are	O
frequently	O
suboptimal	O
with	O
local	O
therapy	O
.	O


For	B-P
the	I-P
first	I-P
12	I-P
weeks	I-P
,	I-P
patients	I-P
were	I-P
randomly	I-P
assigned	I-P
to	I-P
LHRHa	I-I
versus	I-I
LHRHa	I-I
plus	I-I
AA	I-I
.	I-I


METHOD	O
The	O
target	B-P
population	I-P
was	I-P
300	I-P
control	I-P
and	I-P
300	I-P
test	I-P
subjects	I-P
across	I-P
three	I-P
sites	I-P
in	I-P
the	I-P
UK	I-P
,	I-P
but	I-P
recruitment	I-P
difficulties	I-P
resulted	I-P
in	I-P
only	I-P
125	I-P
patients	I-P
being	I-P
evaluable	I-P
.	I-P


CONCLUSION	O
Evaluation	O
of	O
wound	B-OUT
progress	I-OUT
is	O
clearly	O
difficult	O
.	O


Making	O
interpretation	O
more	O
objective	O
removed	O
that	O
bias	O
and	O
did	O
not	O
demonstrate	O
a	O
significant	O
advantage	O
for	O
the	O
test	O
dressing	O
.	O


Blinded	O
assessments	O
may	O
miss	O
finer	O
nuances	O
of	O
wound	B-OUT
progression	I-OUT
,	O
but	O
are	O
likely	O
to	O
be	O
more	O
accurate	O
.	O


INTRODUCTION	O
Methotrexate	B-I
(	I-I
MTX	I-I
)	I-I
has	O
been	O
shown	O
to	O
modify	O
infliximab	B-I
pharmacokinetics	O
in	O
rheumatoid	O
arthritis	O
.	O


We	O
investigated	O
the	O
above	O
objective	O
in	O
patients	B-P
enrolled	I-P
in	I-P
WRIST	I-P
.	I-P


After	O
the	O
intervention	O
and	O
at	O
follow-up	O
,	O
three	O
vessel	O
segments	O
were	O
individually	O
analyzed	O
with	O
quantitative	O
coronary	O
angiography	O
:	O
1	O
)	O
the	O
"	O
stent	O
,	O
"	O
2	O
)	O
the	O
"	O
radiation	O
ribbon	O
,	O
"	O
and	O
3	O
)	O
the	O
"	O
ribbon+margin	O
"	O
segment	O
(	O
including	O
5	O
mm	O
on	O
either	O
end	O
of	O
the	O
injured	O
or	O
radiation-ribbon	O
segment	O
)	O
.	O


RESULTS	O
(	O
192	O
)	O
Ir	O
reduced	O
recurrent	B-OUT
restenosis	I-OUT
(	O
23.7	O
%	O
vs.	O
60.7	O
%	O
,	O
p	O
<	O
0.001	O
)	O
and	O
the	O
length	B-OUT
of	I-OUT
recurrent	I-OUT
restenosis	I-OUT
(	O
8.99	O
+/-	O
4.34	O
mm	O
vs.	O
17.54	O
+/-	O
10.48	O
mm	O
,	O
p	O
<	O
0.001	O
)	O
at	O
follow-up	O
compared	O
to	O
placebo	O
.	O


This	O
association	O
differs	O
depending	O
on	O
how	O
QOL	O
is	O
defined	O
and	O
measured	O
,	O
with	O
stronger	O
relations	O
observed	O
with	O
life	O
satisfaction	O
and	O
mental	O
well-being	O
among	O
those	O
diagnosed	O
with	O
MDD	O
.	O


The	O
lack	O
of	O
association	O
between	O
depression	O
and	O
physical	O
well-being	O
may	O
be	O
explained	O
by	O
participants	B-P
'	I-P
subjective	O
interpretation	O
of	O
physical	O
well-being	O
after	O
SCI	O
and	O
their	O
expectations	O
and	O
perceptions	O
of	O
improved	O
physical	O
health-related	O
QOL	O
based	O
on	O
the	O
use	O
of	O
assistive	O
technology	O
.	O


Very	O
few	O
infants	O
developed	O
iron	B-OUT
deficiency	I-OUT
anaemia	I-OUT
in	O
either	O
group	O
but	O
there	O
was	O
a	O
tendency	O
for	O
serum	B-OUT
ferritin	I-OUT
levels	I-OUT
to	O
fall	O
between	O
6	O
and	O
18	O
months	O
of	O
age	O
in	O
both	O
groups	O
.	O


Length	O
of	O
procedure	O
times	O
and	O
adolescent	O
reactions	O
were	O
also	O
recorded	O
to	O
inform	O
clinical	O
utility	O
.	O


Effects	O
of	O
topical	B-I
boswellic	I-I
acid	I-I
on	O
photo	B-P
and	I-P
age-damaged	I-P
skin	I-P
:	I-P
clinical	I-OUT
,	I-OUT
biophysical	I-OUT
,	I-OUT
and	I-OUT
echographic	I-OUT
evaluations	I-OUT
in	O
a	O
double-blind	O
,	O
randomized	O
,	O
split-face	O
study	O
.	O


Osteopontin	B-I
is	O
a	O
prognostic	O
factor	O
for	O
survival	B-OUT
of	O
acute	B-P
myeloid	I-P
leukemia	I-P
patients	I-P
.	I-P


DESIGN	O
Prospective	O
randomized	O
study	O
.	O


INTERVENTIONS	O
After	O
a	O
6-hr-period	O
of	O
protective	B-I
conventional	I-I
mechanical	I-I
ventilation	I-I
,	O
patients	O
were	O
submitted	O
to	O
three	B-I
1-hr	I-I
periods	I-I
of	I-I
high-frequency	I-I
oscillatory	I-I
ventilation	I-I
(	O
+5	O
,	O
+10	O
,	O
+15	O
)	O
in	O
a	O
randomized	O
order	O
,	O
with	O
a	O
mean	O
airway	O
pressure	O
level	O
determined	O
by	O
adding	O
5	B-I
,	I-I
10	I-I
,	I-I
or	I-I
15	I-I
cm	I-I
H2O	I-I
to	O
the	O
mean	O
airway	O
pressure	O
recorded	O
during	O
conventional	O
mechanical	O
ventilation	O
.	O


High-frequency	O
oscillatory	O
ventilation	O
did	O
not	B-OUT
improve	I-OUT
oxygenation	I-OUT
whatever	O
the	O
mean	O
airway	O
pressure	O
level	O
.	O


The	O
patient	B-P
experience	I-P
of	O
community	B-I
hospital	I-I
--	I-I
the	I-I
process	I-I
of	I-I
care	I-I
as	O
a	O
determinant	O
of	O
satisfaction	O
.	O


AIMS	O
AND	O
OBJECTIVES	O
We	O
report	O
findings	O
from	O
a	O
qualitative	O
study	O
to	O
identify	O
patient	B-P
views	I-P
of	I-P
community	I-I
hospital	I-I
care	I-I
.	I-I


The	O
formal	B-OUT
,	I-OUT
or	I-OUT
'hard	I-OUT
'	I-OUT
,	I-OUT
process	I-OUT
of	I-OUT
rehabilitation	I-OUT
was	O
not	O
well	O
understood	O
by	O
patients	O
.	O


CONCLUSIONS	O
We	O
identify	O
a	O
model	O
of	O
community	O
hospital	O
care	O
that	O
incorporates	O
technical	O
aspects	O
of	O
rehabilitation	O
within	O
a	O
human	O
approach	O
that	O
is	O
welcomed	O
by	O
patients	B-P
.	I-P


Recommendations	O
are	O
made	O
about	O
the	O
appropriate	O
scope	O
of	O
qualitative	O
findings	O
in	O
the	O
context	O
of	O
trials	O
and	O
about	O
techniques	O
to	O
access	O
patient	B-P
views	O
in	O
areas	O
where	O
they	O
have	O
difficulty	O
in	O
expressing	O
critical	O
impressions	O
.	O


BACKGROUND	O
Mirror	B-I
therapy	I-I
(	I-I
MT	I-I
)	I-I
and	I-I
mesh	I-I
glove	I-I
(	I-I
MG	I-I
)	I-I
afferent	I-I
stimulation	I-I
may	O
be	O
effective	O
in	O
reducing	O
motor	O
impairment	O
after	O
stroke	O
.	O


Secondary	O
outcomes	O
included	O
kinematic	B-OUT
parameters	I-OUT
for	I-OUT
motor	I-OUT
control	I-OUT
and	O
the	O
Motor	B-OUT
Activity	I-OUT
Log	I-OUT
and	O
ABILHAND	B-OUT
Questionnaire	I-OUT
for	I-OUT
daily	I-OUT
function	I-OUT
.	I-OUT


Subjects	B-P
were	I-P
1,504	I-P
police	I-P
trainees	I-P
(	I-P
85	I-P
%	I-P
male	I-P
,	I-P
15	I-P
%	I-P
female	I-P
)	I-P
with	I-P
an	I-P
ethnic	I-P
distribution	I-P
of	I-P
82	I-P
%	I-P
white	I-P
,	I-P
16	I-P
%	I-P
African	I-P
American	I-P
,	I-P
and	I-P
2	I-P
%	I-P
other	I-P
.	I-P


Randomised	O
Phase	O
I/II	O
trial	O
assessing	O
the	O
safety	B-OUT
and	O
efficacy	B-OUT
of	O
radiolabelled	B-I
anti-carcinoembryonic	I-I
antigen	I-I
I	I-I
(	I-I
131	I-I
)	I-I
KAb201	I-I
antibodies	O
given	O
intra-arterially	O
or	O
intravenously	O
in	O
patients	B-P
with	I-P
unresectable	I-P
pancreatic	I-P
adenocarcinoma	I-P
.	I-P


However	O
the	O
drawback	O
is	O
the	O
accompanying	O
systemic	O
toxicity	O
,	O
which	O
targeted	O
treatments	O
may	O
overcome	O
.	O


One	O
patient	O
was	O
still	O
alive	O
at	O
the	O
time	O
of	O
this	O
analysis	O
.	O


MATERIALS	O
AND	O
METHODS	O
The	O
study	O
was	O
performed	O
on	O
90	B-P
ASA	I-P
class	I-P
I-II	I-P
urologic	I-P
patients	I-P
during	I-P
extracorporeal	I-I
shock	I-I
wave	I-I
lithotripsy	I-I
.	I-I


As	O
expected	O
,	O
older	O
patients	O
had	O
more	O
co-morbidity	B-OUT
.	I-OUT


Children	B-P
with	I-P
persistent	I-P
conduct	I-P
problems	I-P
who	I-P
dropout	I-P
of	I-P
treatment	I-P
.	I-P


We	O
report	O
two	O
studies	O
focusing	O
on	O
the	O
treatment	O
process	O
and	O
the	O
dropout	B-OUT
rate	I-OUT
of	I-OUT
children	I-OUT
with	I-P
persistent	I-P
conduct	I-P
problems	I-P
presenting	I-P
to	I-P
a	I-P
community	I-P
mental	I-P
health	I-P
service	I-P
,	O
using	O
a	O
prospective	O
design	O
.	O


Dropout	B-OUT
occurred	O
significantly	O
less	O
frequently	O
in	O
the	O
CBT	B-I
group	O
.	O


The	O
dropout	O
group	O
was	O
associated	O
with	O
mothers	B-P
who	I-P
were	I-P
younger	I-OUT
and	I-OUT
less	I-OUT
educated	I-OUT
,	O
a	O
poorer	B-OUT
rating	I-OUT
by	I-OUT
the	I-OUT
clinicians	I-OUT
at	O
the	O
last	O
meeting	O
,	O
parental	B-OUT
dissatisfaction	I-OUT
with	I-OUT
the	I-OUT
treatment	I-OUT
service	I-OUT
and	O
perception	B-OUT
that	I-OUT
the	I-OUT
treatment	I-OUT
was	O
less	O
organised	O
and	O
having	O
less	O
behavioural	O
tasks	O
.	O


Initial	O
IH	O
in	O
early	O
CRVO	O
may	O
be	O
a	O
first	O
treatment	O
option	O
in	O
patients	O
anxious	O
about	O
IVI	O
.	O


The	O
mean	B-OUT
numbers	I-OUT
of	I-OUT
doses	I-OUT
of	I-OUT
droperidol	I-OUT
were	O
0.8+/-0.9	O
and	O
0.3+/-0.6	O
(	O
P	O
<	O
.05	O
)	O
,	O
respectively	O
.	O


Effect	O
of	O
propranolol	B-I
on	O
facial	O
scanning	O
in	O
autism	B-P
spectrum	I-P
disorder	I-P
:	I-P
a	O
preliminary	O
investigation	O
.	O


BACKGROUND	O
Autism	B-P
spectrum	I-P
disorder	I-P
(	I-P
ASD	I-P
)	I-P
is	O
a	O
neurodevelopmental	O
disorder	O
characterized	O
by	O
social	O
communication	O
impairments	O
and	O
restricted	O
,	O
repetitive	O
behaviors	O
.	O


It	O
has	O
been	O
previously	O
hypothesized	O
that	O
abnormalities	O
in	O
facial	O
scanning	O
,	O
such	O
as	O
reduced	O
eye	O
contact	O
or	O
increased	O
mouth	O
fixation	O
,	O
contribute	O
to	O
social	O
communication	O
deficits	O
in	O
ASD	O
.	O


In	O
addition	O
,	O
previous	O
reports	O
have	O
suggested	O
elevated	O
stress	O
and	O
anxiety	O
in	O
ASD	O
,	O
symptoms	O
that	O
are	O
believed	O
to	O
impact	O
facial	O
scanning	O
patterns	O
.	O


Students	B-P
spent	O
an	O
average	O
of	O
59.1	O
minutes	O
per	O
week	O
outdoors	O
while	O
attending	O
school	O
and	O
35.5	O
minutes	O
during	O
peak	B-OUT
sun	I-OUT
exposure	I-OUT
.	I-OUT


The	O
Coping	O
Cat	O
program	O
for	O
children	B-P
with	I-P
anxiety	I-P
and	I-P
autism	I-P
spectrum	I-P
disorder	I-P
:	I-P
a	O
pilot	O
randomized	O
controlled	O
trial	O
.	O


Those	O
in	O
mastectomy	O
group	O
received	O
further	O
excision	O
or	O
radiotherapy	B-I
for	O
locoregional	O
recurrence	O
and	O
when	O
local	O
treatments	O
had	O
been	O
exhausted	O
or	O
metastatic	O
disease	O
diagnosed	O
they	O
received	O
tamoxifen	B-I
.	I-I


Both	O
drugs	O
were	O
administered	O
in	O
association	O
with	O
spironolactone	B-I
(	O
200	O
mg/day	O
)	O
in	O
28	B-P
nonazotemic	I-P
cirrhotic	I-P
patients	I-P
with	I-P
controlled	I-P
ascites	I-P
.	I-P


No	O
changes	O
in	O
serum	B-OUT
parameters	I-OUT
were	O
induced	O
by	O
either	O
treatment	O
.	O


Two	O
episodes	O
of	O
hepatic	B-OUT
encephalopathy	I-OUT
occurred	O
in	O
the	O
torasemide	B-I
group	O
.	O


Magnetic	O
resonance	O
angiography	O
for	O
monitoring	O
prophylactic	O
endoscopic	O
treatment	O
of	O
high	O
risk	O
esophageal	O
varices	O
.	O


We	O
evaluated	O
portal	O
hemodynamics	O
using	O
magnetic	O
resonance	O
angiography	O
(	O
MRA	O
)	O
in	O
these	O
two	O
forms	O
of	O
treatment	O
.	O


PATIENTS	O
AND	O
METHODS	O
The	O
study	O
was	O
carried	O
out	O
in	O
50	B-P
cirrhotic	I-P
patients	I-P
.	I-P


MRA	O
was	O
performed	O
to	O
identify	O
the	O
hepatofugal	O
supply	O
vein	O
selectively	O
for	O
esophageal	B-P
varices	I-P
.	I-P


H.	B-OUT
pylori	I-OUT
infection	I-OUT
was	O
cured	B-OUT
in	O
10	O
(	O
55.6	O
%	O
)	O
patients	O
with	O
the	O
second-line	B-I
regimen	I-I
.	I-I


Activity	O
of	O
the	O
supplementary	O
motor	O
area	O
may	O
be	O
inferred	O
from	O
movement-related	B-I
potentials	I-I
(	I-I
MRPs	I-I
)	I-I
which	O
are	O
associated	O
with	O
the	O
preparation	O
and	O
execution	O
of	O
voluntary	O
,	O
or	O
internally	O
determined	O
movements	O
.	O


For	O
non-cued	B-I
movements	O
,	O
abnormalities	O
in	O
MRPs	O
for	O
Parkinson	O
's	O
disease	O
subjects	O
consisted	O
of	O
delayed	B-OUT
MRP	I-OUT
onset	I-OUT
and	I-OUT
peak	I-OUT
times	I-OUT
,	O
and	O
prolonged	O
cortical	O
activity	O
following	O
movement	O
.	O


One-year	O
follow-up	O
of	O
the	O
outcome	O
of	O
a	O
randomized	O
controlled	O
trial	O
of	O
a	O
home-based	B-I
intervention	I-I
programme	I-I
for	O
children	B-P
with	I-P
autism	I-P
and	I-P
developmental	I-P
delay	I-P
and	O
their	O
families	O
.	O


The	O
primary	O
outcome	O
variable	O
was	B-OUT
self-reported	I-OUT
access	I-OUT
to	I-OUT
post-release	I-OUT
medical	I-OUT
care	I-OUT
.	O


Pain	B-OUT
score	I-OUT
at	O
18	O
hours	O
was	O
lower	O
in	O
0.5	B-I
%	I-I
bupivacaine	I-I
group	O
compared	O
with	O
0.25	B-I
%	I-I
bupivacaine	I-I
group	O
(	O
p	O
=	O
0.001	O
)	O
.	O


CONCLUSION	O
FNB	B-I
with	I-I
0.5	I-I
%	I-I
bupivacaine	I-I
provided	O
longer	O
time	O
to	O
first	O
analgesic	O
and	O
lower	O
narcotic	O
requirements	O
after	O
patellar	O
tendon	O
graft	O
ACL	O
reconstruction	O
when	O
compared	O
to	O
0.25	B-I
%	I-I
bupivacaine	I-I
.	I-I


The	O
percentage	B-OUT
of	I-OUT
cancers	I-OUT
with	I-OUT
negative	I-OUT
margins	I-OUT
was	O
statistically	O
significantly	O
greater	O
in	O
patients	O
treated	O
with	O
neoadjuvant	B-I
therapy	I-I
than	O
those	O
treated	O
with	O
immediate	B-I
surgery	I-I
alone	I-I
(	O
69	O
%	O
vs.	O
42	O
%	O
,	O
respectively	O
)	O
.	O


After	O
six	O
months	O
of	O
NHT	O
therapy	O
the	O
proportion	B-OUT
of	I-OUT
patients	I-OUT
with	I-OUT
pathological	I-OUT
stage	I-OUT
B	I-OUT
(	O
67	O
%	O
vs.	O
36	O
%	O
,	O
respectively	O
)	O
and	O
negative	B-OUT
margins	I-OUT
was	O
greater	O
than	O
after	O
3	O
months	O
(	O
92	O
%	O
vs.	O
42	O
%	O
,	O
respectively	O
)	O
.	O


After	O
baseline	O
screening	O
,	O
subjects	B-P
with	I-P
FXS	I-P
(	I-P
n	I-P
=	I-P
49	I-P
)	I-P
underwent	O
a	O
1-week	B-I
placebo	I-I
lead-in	I-I
and	I-I
then	I-I
were	I-I
randomized	I-I
to	I-I
study	I-I
drug	I-I
or	I-I
placebo	I-I
for	I-I
a	I-I
4-week	I-I
period	I-I
.	I-I


PURPOSE	O
This	O
study	O
compares	O
the	O
effects	O
of	O
neutral	B-I
temperature	I-I
,	I-I
cold	I-I
and	I-I
ice-slush	I-I
beverages	I-I
,	I-I
with	I-I
and	I-I
without	I-I
0.5	I-I
%	I-I
menthol	I-I
on	O
cycling	B-OUT
performance	I-OUT
,	I-OUT
core	I-OUT
temperature	I-OUT
(	I-OUT
Tco	I-OUT
)	I-OUT
and	I-OUT
stress	I-OUT
responses	I-OUT
in	O
a	O
tropical	O
climate	O
(	O
hot	O
and	O
humid	O
conditions	O
)	O
.	O


RESULTS	B-OUT
Both	I-OUT
the	I-OUT
beverage	I-OUT
aroma	O
(	B-OUT
P	I-OUT
<	I-OUT
0.02	I-OUT
)	I-OUT
and	I-OUT
beverage	I-OUT
temperature	O
(	B-OUT
P	I-OUT
<	I-OUT
0.02	I-OUT
)	I-OUT
had	I-OUT
significant	I-OUT
and	I-OUT
positive	I-OUT
effects	O
on	O
performance	O
,	O
which	O
was	O
considerably	B-I
better	I-I
with	I-I
ice-slush	I-I
than	I-I
with	I-I
a	I-I
neutral	I-I
temperature	O
beverage	O
,	O
whatever	B-I
the	O
aroma	O
(	B-I
P	I-I
<	I-I
0.002	I-I
)	I-I
,	I-I
and	I-I
with	I-I
menthol	I-I
vs	I-I
non-menthol	O
(	O
P	O
<	O
0.02	O
)	O
.	O


Barriers	O
to	O
high	B-OUT
blood	I-OUT
pressure	I-OUT
(	O
HBP	O
)	O
care	O
and	O
control	O
have	O
been	O
reported	O
in	O
the	O
literature	O
for	O
>	O
30	O
years	O
.	O


Few	O
reports	O
on	O
barriers	O
,	O
however	O
,	O
have	O
focused	O
on	O
the	O
young	B-P
black	I-P
man	I-P
with	I-P
HBP	I-P
,	O
the	O
age/sex/race	O
group	O
with	O
the	O
highest	O
rates	O
of	O
early	O
severe	O
and	O
complicated	O
HBP	O
and	O
the	O
lowest	O
rates	O
of	O
awareness	O
,	O
treatment	O
,	O
and	O
control	O
.	O


Low	B-OUT
alcoholism	I-OUT
risk	I-OUT
and	I-OUT
employment	I-OUT
were	O
identified	O
as	O
significant	O
predictors	O
of	O
compliance	O
with	O
HBP	O
medication-taking	O
behavior	O
.	O


Comprehensive	B-I
interventions	I-I
are	O
needed	O
to	O
address	O
socioeconomic	O
and	O
lifestyle	O
issues	O
as	O
well	O
as	O
other	O
barriers	O
to	O
care	O
and	O
treatment	O
,	O
if	O
HBP	O
care	O
is	O
to	O
be	O
salient	O
and	O
effective	O
in	O
this	O
high	B-P
risk	I-P
group	I-P
.	I-P


We	O
studied	O
the	O
correlation	O
between	O
response	O
to	O
fluvoxamine	B-I
and	O
serotonin	O
transporter	O
gene	O
promoter	O
region	O
polymorphism	O
(	O
5-HTTLPR	O
)	O
.	O


Behavioral	B-OUT
assessments	I-OUT
were	O
obtained	O
before	O
and	O
at	O
12	O
weeks	O
of	O
treatment	O
.	O


However	O
,	O
with	O
respect	O
to	O
language	B-OUT
use	I-OUT
,	O
a	O
significant	O
effectiveness	O
was	O
noted	O
in	O
the	O
s	O
allele	O
.	O


Warfarin	B-I
is	O
an	O
established	O
treatment	O
for	O
prevention	O
of	O
ischaemic	O
stroke	O
in	O
patients	B-P
with	I-P
atrial	I-P
fibrillation	I-P
,	O
but	O
the	O
value	O
of	O
this	O
agent	O
relative	O
to	O
aspirin	O
in	O
unclear	O
.	O


SPAF-II	O
aims	O
to	O
address	O
this	O
issue	O
and	O
also	O
to	O
assess	O
the	O
differential	O
effects	O
of	O
the	O
two	O
treatments	O
according	O
to	O
age	O
.	O


The	O
primary	B-OUT
event	I-OUT
rate	I-OUT
per	I-OUT
year	I-OUT
was	O
3.6	O
%	O
with	O
warfarin	B-I
and	O
4.8	O
%	O
with	O
aspirin	B-I
(	O
RR	O
0.73	O
,	O
p	O
=	O
0.39	O
)	O
.	O


In	O
this	O
older	O
group	O
,	O
the	O
rate	B-OUT
of	I-OUT
all	I-OUT
stroke	I-OUT
with	I-OUT
residual	I-OUT
deficit	I-OUT
(	O
ischaemic	O
or	O
haemorrhagic	O
)	O
was	O
4.3	O
%	O
per	O
year	O
with	O
aspirin	B-I
and	O
4.6	O
%	O
per	O
year	O
with	O
warfarin	B-I
(	O
RR	O
1.1	O
)	O
.	O


Patient	O
age	O
and	O
the	O
inherent	O
risk	O
of	O
thromboembolism	O
should	O
be	O
considered	O
in	O
the	O
choice	O
of	O
antithrombotic	O
prophylaxis	O
for	O
patients	O
with	O
atrial	O
fibrillation	O
.	O


BACKGROUND	O
The	O
late	O
hemodynamic	O
effects	O
of	O
preserving	O
the	O
papillary	O
muscles	O
during	O
mitral	B-I
valve	I-I
replacement	I-I
have	O
not	O
been	O
evaluated	O
.	O


Early	O
after	O
surgery	O
,	O
the	O
No	O
Pres	O
group	O
had	O
lower	B-OUT
ejection	I-OUT
fractions	I-OUT
and	I-OUT
stroke	I-OUT
work	I-OUT
indexes	I-OUT
(	O
P	O
<	O
.05	O
by	O
repeated-measures	O
[	O
rm	O
]	O
ANOVA	O
)	O
than	O
the	O
Pres	O
group	O
did	O
at	O
similar	O
end-diastolic	O
volume	O
indexes	O
.	O


The	O
No	O
Pres	O
group	O
had	O
similar	O
cardiac	B-OUT
indexes	I-OUT
after	O
exercise	O
because	O
heart	B-OUT
rate	I-OUT
increased	I-OUT
(	O
P	O
<	O
.005	O
by	O
rm	O
ANOVA	O
)	O
.	O


Relaxation	B-I
and	I-I
imagery	I-I
and	I-I
cognitive-behavioral	I-I
training	I-I
reduce	O
pain	B-OUT
during	O
cancer	O
treatment	O
:	O
a	O
controlled	O
clinical	O
trial	O
.	O


Few	O
controlled	O
clinical	O
trials	O
of	O
psychological	O
interventions	O
for	O
cancer	B-OUT
pain	I-OUT
relief	I-OUT
exist	O
in	O
spite	O
of	O
frequent	O
support	O
for	O
their	O
importance	O
as	O
adjuncts	O
to	O
medical	O
treatment	O
.	O


This	O
study	O
compared	O
oral	O
mucositis	O
pain	O
levels	O
in	O
4	B-P
groups	I-P
of	I-P
cancer	I-P
patients	I-P
receiving	I-P
bone	I-P
marrow	I-P
transplants	I-P
(	I-P
BMT	I-P
)	I-P
:	I-P
(	I-P
1	I-P
)	I-P
treatment	I-I
as	I-I
usual	I-I
control	I-I
,	I-I
(	I-I
2	I-I
)	I-I
therapist	I-I
support	I-I
,	I-I
(	I-I
3	I-I
)	I-I
relaxation	I-I
and	I-I
imagery	I-I
training	I-I
,	I-I
and	I-I
(	I-I
4	I-I
)	I-I
training	I-I
in	I-I
a	I-I
package	I-I
of	I-I
cognitive-behavioral	I-I
coping	I-I
skills	I-I
which	I-I
included	I-I
relaxation	I-I
and	I-I
imagery	I-I
.	I-I


Results	O
confirmed	O
our	O
hypothesis	O
that	O
patients	O
who	O
received	O
either	O
relaxation	O
and	O
imagery	O
alone	O
or	O
patients	O
who	O
received	O
the	O
package	O
of	O
cognitive-behavioral	O
coping	O
skills	O
would	O
report	O
less	O
pain	B-OUT
than	O
patients	O
in	O
the	O
other	O
2	O
groups	O
.	O


Average	B-OUT
visual	I-OUT
analogue	I-OUT
scale	I-OUT
(	I-OUT
VAS	I-OUT
)	I-OUT
report	I-OUT
of	I-OUT
pain	I-OUT
within	O
the	O
therapist	O
support	O
group	O
was	O
not	O
significantly	O
lower	O
than	O
the	O
control	O
group	O
(	O
P	O
=	O
0.103	O
)	O
nor	O
significantly	O
higher	O
than	O
the	O
training	O
groups	O
.	O


The	B-I
trial	I-I
ended	I-I
with	I-I
a	I-I
4-week	I-I
drug-free	I-I
period	I-I
.	I-I


The	O
treatment	O
group	O
complete	B-OUT
effective	I-OUT
and	O
partial	B-OUT
effective	I-OUT
were	O
10	O
%	O
and	O
35	O
%	O
difference	O
.	O


We	O
then	B-P
selected	I-P
10	I-P
representative	I-P
patients	I-P
from	I-P
this	I-P
group	I-P
and	I-P
generated	I-I
proton	I-I
SBRT	I-I
treatment	I-P
plans	I-P
,	O
using	O
the	O
identical	O
dose	O
of	O
50Gy	O
in	O
4	O
fractions	O
,	O
and	O
assessed	O
potential	O
differences	O
in	O
CW	O
dose	O
between	O
the	O
2	O
plans	O
.	O


Light-for-gestational	B-OUT
age	I-OUT
(	I-OUT
LGA	I-OUT
)	I-OUT
was	O
suspected	O
if	O
the	O
estimated	O
birth-weight	O
was	O
less	O
than	O
85	O
%	O
of	O
the	O
expected	O
mean	O
birthweight	O
.	O


Data	O
collection	O
was	O
not	O
blinded	O
;	O
however	O
,	O
analysis	O
was	O
conducted	O
by	O
a	O
statistician	O
blinded	O
to	O
practice	O
allocation	O
.	O


Secondary	B-OUT
-	I-OUT
resource	I-OUT
use	I-OUT
and	I-OUT
costs	I-OUT
,	I-OUT
patient	I-OUT
safety	I-OUT
(	I-OUT
deaths	I-OUT
and	I-OUT
emergency	I-OUT
hospital	I-OUT
admissions	I-OUT
within	O
7	O
days	O
of	O
index	O
request	O
,	O
and	O
A	O
&	O
E	O
attendance	O
within	O
28	O
days	O
)	O
,	O
health	O
status	O
and	O
experience	O
of	O
care	O
.	O


Triage	O
appeared	O
safe	O
,	O
and	O
no	O
differences	O
in	O
patient	O
health	O
status	O
were	O
observed	O
.	O


NT	O
was	O
somewhat	B-I
less	I-I
acceptable	O
to	O
patients	O
than	O
GPT	O
or	O
UC	O
.	O


CONCLUSIONS	O
Introducing	O
GPT	O
or	O
NT	O
was	O
associated	O
with	O
a	O
redistribution	O
of	O
primary	O
care	O
workload	O
for	O
patients	O
requesting	O
same-day	O
consultations	O
,	O
and	O
at	O
similar	O
cost	O
to	O
UC	O
.	O


n-6-propylthiouracil	O
(	O
PROP	O
)	O
bitter	O
taste	O
phenotype	O
may	O
be	O
a	O
potential	O
risk	O
factor	O
for	O
non-adherence	O
to	O
oral	O
NRT	O
products	O
due	O
to	O
their	O
bitter	O
taste	O
.	O


Japanese	B-P
Urothelial	I-P
Cancer	I-P
Research	I-P
Group	I-P
.	I-P


RESULTS	O
Of	O
the	O
88	O
eligible	O
patients	O
,	O
four	O
treated	O
with	O
S-MEC	B-I
therapy	I-I
and	O
two	O
treated	O
with	O
I-MEC	B-I
therapy	O
showed	O
CR	O
.	O


The	O
response	B-OUT
rate	I-OUT
with	I-OUT
I-MEC	I-OUT
therapy	I-OUT
was	O
significantly	O
higher	O
than	O
that	O
with	O
M-VAC	B-I
therapy	O
(	O
P	O
=	O
0.02	O
)	O
.	O


CONCLUSION	O
MEC	B-I
therapy	I-I
used	O
in	O
this	O
study	O
is	O
promising	O
in	O
terms	O
of	O
the	O
antitumor	B-OUT
effects	I-OUT
.	I-OUT


PATIENTS	O
AND	O
METHODS	O
Patients	B-P
with	I-P
mutant	I-P
KRAS	I-P
metastatic	I-P
adenocarcinoma	I-P
of	I-P
the	I-P
colon	I-P
or	I-P
rectum	I-P
refractory	I-P
to	I-P
fluoropyrimidine-	I-I
and	I-I
oxaliplatin-based	I-I
chemotherapy	I-I
were	O
randomized	O
1	O
:	O
1	O
:	O
1	O
to	O
receive	O
intravenous	B-I
FOLFIRI	I-I
plus	I-I
conatumumab	I-I
10	I-I
mg/kg	I-I
(	I-I
Arm	I-I
A	I-I
)	I-I
,	I-I
ganitumab	I-I
12	I-I
mg/kg	I-I
(	I-I
Arm	I-I
B	I-I
)	I-I
,	I-I
or	I-I
placebo	I-I
(	O
Arm	O
C	O
)	O
Q2W	O
.	O


A	O
prospective	O
randomised	O
comparison	O
of	O
the	O
dynamic	B-I
hip	I-I
screw	I-I
and	I-P
the	I-P
gamma	I-I
locking	I-I
nail	I-I
.	I-I


Beneficial	O
effect	O
of	O
etidronate	B-I
therapy	I-I
in	O
chronically	B-P
hospitalized	I-P
,	I-P
disabled	I-P
patients	I-P
with	I-P
stroke	I-P
.	I-P


Duration	B-P
of	I-P
hospitalization	I-P
was	I-P
more	I-P
than	I-P
1	I-P
year	I-P
because	I-P
of	I-P
insufficiency	I-P
of	I-P
nursing	I-P
homes	I-P
.	I-P


Our	O
study	O
showed	O
that	O
immobilization-induced	O
hypercalcemia	O
and	O
25-hydroxyvitamin	O
D	O
deficiency	O
contribute	O
to	O
reduced	O
bone	O
mineral	O
density	O
(	O
BMD	O
)	O
.	O


This	O
study	O
was	O
designed	O
to	O
address	O
the	O
possibility	O
that	O
treatment	O
with	O
etidronate	B-I
may	O
reduce	O
the	O
bone	O
resorption	O
and	O
lower	O
the	O
incidence	O
of	O
fractures	O
in	O
elderly	B-P
patients	I-P
who	I-P
are	I-P
chronically	I-P
hospitalized	I-P
and	I-P
disabled	I-P
as	I-P
a	I-P
result	I-P
of	I-P
hemiparesis	I-P
after	I-P
stroke	I-P
.	I-P


In	O
the	O
etidronate	B-I
group	O
,	O
serum	B-OUT
calcium	I-OUT
and	I-OUT
urinary	I-OUT
deoxypyridinoline	I-OUT
levels	I-OUT
decreased	O
significantly	O
during	O
the	O
study	O
period	O
,	O
whereas	O
the	O
levels	O
in	O
the	O
placebo	B-I
group	O
were	O
increased	O
.	O


BACKGROUND	O
Levosimendan	B-I
,	O
a	O
novel	O
calcium	O
sensitiser	O
,	O
improves	O
cardiac	O
performance	O
and	O
symptoms	O
without	O
increasing	O
oxygen	O
consumption	O
,	O
and	O
decreases	O
the	O
mortality	O
of	O
patients	B-P
with	I-P
low-output	I-P
heart	I-P
failure	I-P
.	I-P


A	O
sensitivity	O
analysis	O
on	O
dosage	B-OUT
of	I-OUT
drug	I-OUT
and	I-OUT
duration	I-OUT
of	I-OUT
survival	I-OUT
was	O
performed	O
.	O


BACKGROUND	O
Suboptimal	O
vitamin	O
D	O
status	O
is	O
prevalent	O
in	O
HIV-infected	B-P
patients	I-P
and	O
associated	O
with	O
increased	O
risk	B-OUT
of	I-OUT
disease	I-OUT
severity	I-OUT
and	I-OUT
morbidity	I-OUT
.	I-OUT


RESULTS	O
Fifty-eight	B-P
subjects	I-P
enrolled	I-P
(	I-P
67	I-P
%	I-P
male	I-P
,	I-P
85	I-P
%	I-P
African	I-P
American	I-P
and	I-P
64	I-P
%	I-P
BHIV	I-P
)	I-P
and	I-P
50	I-P
completed	I-P
with	I-P
no	I-P
safety	I-OUT
concerns	I-OUT
.	I-OUT


In	O
unadjusted	O
analyses	O
,	O
there	O
were	O
no	O
differences	O
between	O
randomization	O
groups	O
at	O
baseline	O
;	O
at	O
3	O
,	O
6	O
and	O
12	O
months	O
,	O
25	O
(	O
OH	O
)	O
D	O
was	O
higher	O
with	O
supplementation	O
than	O
baseline	O
and	O
higher	O
than	O
with	O
placebo	O
(	O
P	O
<	O
0.05	O
)	O
.	O


In	O
adjusted	O
mixed	O
models	O
,	O
in	O
the	O
supplementation	O
group	O
,	O
the	O
fixed	O
effect	O
of	O
25	B-OUT
(	I-OUT
OH	I-OUT
)	I-OUT
D	I-OUT
was	O
higher	O
(	O
P	O
<	O
0.001	O
)	O
.	O


Lambs	O
were	O
fed	O
until	O
the	O
average	O
BW	O
of	O
each	O
pen	O
reached	O
a	O
target	O
BW	O
(	O
55.4	O
kg	O
for	O
wethers	O
and	O
50.0	O
kg	O
for	O
ewes	O
)	O
,	O
at	O
which	O
time	O
the	O
entire	O
pen	O
of	O
lambs	O
was	O
slaughtered	O
.	O


The	O
relationships	O
between	O
baseline	B-I
PTX3	I-I
levels	I-I
or	O
their	O
changes	O
over	O
time	O
and	O
mortality	O
were	O
evaluated	O
with	O
multivariable	O
Cox	O
proportional	O
hazard	O
models	O
including	O
clinical	O
factors	O
,	O
high	O
sensitivity	O
C-reactive	O
protein	O
(	O
hsCRP	O
)	O
,	O
and	O
N-terminal	O
pro	O
brain	O
natriuretic	O
peptide	O
(	O
NT-proBNP	O
)	O
.	O


Three-month	O
changes	O
in	O
PTX3	O
were	O
associated	O
with	O
fatal	B-OUT
events	I-OUT
after	O
adjustment	O
for	O
hsCRP	O
or	O
NT-proBNP	O
.	O


CONCLUSION	O
In	O
two	O
independent	O
clinical	O
trials	O
that	O
enrolled	O
patients	B-P
with	I-P
chronic	I-P
HF	I-P
,	O
PTX3	B-I
was	O
consistently	O
associated	O
with	O
outcomes	O
.	O


BACKGROUND	O
This	O
study	O
was	O
performed	O
as	O
a	O
substudy	O
analysis	O
of	O
a	O
randomized	O
trial	O
comparing	O
conventional	B-I
open	I-I
esophagectomy	I-I
[	O
open	O
surgical	O
technique	O
(	O
OE	O
)	O
]	O
by	O
thoracotomy	B-I
and	I-I
laparotomy	I-I
with	O
minimally	B-I
invasive	I-I
esophagectomy	I-I
[	I-I
minimally	I-I
invasive	I-I
procedure	I-I
(	I-I
MIE	I-I
)	I-I
]	I-I
by	I-I
thoracoscopy	I-I
and	I-I
laparoscopy	I-I
.	I-I


Moreover	O
,	O
significant	O
differences	O
in	O
the	O
prolactin	B-OUT
levels	I-OUT
at	O
168	O
h	O
after	O
surgery	O
imply	O
that	O
the	O
stress	B-OUT
response	I-OUT
is	O
better	O
preserved	O
in	O
the	O
MIE	B-I
group	O
.	O


It	O
is	O
known	O
that	O
the	O
parahippocampal	O
cortex	O
is	O
involved	O
in	O
object-place	O
associations	O
in	O
spatial	O
learning	O
,	O
but	O
it	O
remains	O
unknown	O
whether	O
activity	O
within	O
this	O
region	O
is	O
modulated	O
by	O
affective	O
signals	O
during	O
navigation	O
.	O


A	O
day	O
before	O
scanning	O
,	O
participants	B-P
undertook	I-P
an	I-P
active	I-P
object	I-P
location	I-P
memory	I-P
task	I-P
within	I-P
a	I-P
virtual	I-P
house	I-P
in	I-P
which	I-P
each	I-P
room	I-P
was	I-P
associated	I-P
with	I-P
a	I-P
different	I-P
schedule	I-P
of	I-P
task-irrelevant	I-P
emotional	I-P
events	I-P
.	I-P


Our	O
results	O
showed	O
that	O
parahippocampal	B-OUT
activity	I-OUT
was	O
significantly	O
enhanced	O
bilaterally	O
when	O
participants	B-P
viewed	O
images	O
of	O
a	O
room	O
in	O
which	O
they	O
had	O
previously	O
encountered	O
negatively	O
arousing	O
events	O
.	O


We	O
conclude	O
that	O
such	O
automatic	B-OUT
enhancement	I-OUT
of	I-OUT
place	I-OUT
representations	I-OUT
by	O
aversive	O
emotional	O
events	O
serves	O
as	O
an	O
important	O
adaptive	O
mechanism	O
for	O
avoiding	O
future	O
threats	O
.	O


Paracetamol	B-I
and	O
opioid	O
pathways	O
:	O
a	O
pilot	O
randomized	O
clinical	O
trial	O
.	O


They	O
were	O
administered	O
intravenous	B-I
paracetamol	I-I
(	I-I
APAP	I-I
1	I-I
g	I-I
)	I-I
or	I-I
saline	I-I
(	I-I
placebo	I-I
,	I-I
pl	I-I
)	I-I
followed	O
at	O
100	O
min	O
with	O
IV	B-I
naloxone	I-I
(	I-I
Nal	I-I
8	I-I
mg	I-I
)	I-I
or	I-I
saline	I-I
,	O
every	O
week	O
for	O
4	O
weeks	O
.	O


AUC	B-OUT
(	O
90-150	O
)	O
is	O
not	O
significantly	O
different	O
.	O


This	O
pilot	O
study	O
shows	O
for	O
the	O
first	O
time	O
in	O
human	B-P
volunteers	I-P
that	O
naloxone	B-I
does	O
not	O
inhibit	B-OUT
paracetamol	I-OUT
antinociception	I-OUT
,	O
suggesting	O
no	O
significant	O
implication	O
of	O
the	O
opioid	O
system	O
in	O
paracetamol	B-I
mechanism	O
of	O
action	O
:	O
this	O
needs	O
be	O
confirmed	O
on	O
a	O
larger	O
number	O
of	O
subjects	O
.	O


Retinal	O
lesions	O
placed	O
with	O
diode	B-I
lasers	I-I
are	O
deeper	O
than	O
similar	O
argon	B-I
laser	I-I
lesions	O
,	O
and	O
it	O
is	O
not	O
known	O
whether	O
this	O
difference	O
could	O
influence	O
the	O
response	B-OUT
to	O
ablative	B-I
therapy	I-I
.	I-I


A	O
prospective	O
assessment	O
of	O
late	O
changes	O
in	O
breast	O
appearance	O
in	O
559	B-P
patients	I-P
after	I-P
tumour	I-I
excision	I-I
and	I-I
radiotherapy	I-I
for	I-P
early	I-P
breast	I-P
cancer	I-P
noted	O
a	O
strong	O
association	O
with	O
breast	O
size	O
.	O


During	O
the	O
sleep-deprivation	B-I
day	O
,	O
both	O
mean	O
24-h	O
blood	B-OUT
pressure	I-OUT
and	O
mean	O
24-h	O
heart	B-OUT
rate	O
were	O
higher	O
in	O
comparison	O
with	O
those	O
recorded	O
during	O
the	O
routine	O
workday	O
,	O
the	O
difference	O
being	O
more	O
pronounced	O
during	O
the	O
nighttime	O
(	O
P	O
<	O
.01	O
)	O
.	O


Urinary	B-OUT
excretion	I-OUT
of	I-OUT
norepinephrine	I-OUT
showed	O
a	O
significant	O
increase	O
at	O
night	O
during	O
sleep	B-I
deprivation	I-I
(	O
P	O
<	O
.05	O
)	O
.	O


STUDY	O
DESIGN	O
AND	O
METHODS	B-P
A	I-P
total	I-P
of	I-P
108	I-P
iron-deficient	I-P
patients	I-P
were	O
randomly	O
assigned	O
to	O
two	O
groups	O
:	O
Group	O
C	B-I
(	I-I
control	I-I
)	I-I
or	O
Group	O
IE	B-I
(	I-I
200	I-I
mg	I-I
of	I-I
iron	I-I
sucrose	I-I
intravenously	I-I
over	I-I
1	I-I
hr	I-I
and	I-I
3000	I-I
IU	I-I
of	I-I
rHuEPO-β	I-I
subcutaneously	O
during	O
the	O
operation	O
and	O
during	O
the	O
postoperative	O
period	O
if	O
the	O
hemoglobin	O
[	O
Hb	O
]	O
level	O
was	O
70-80	O
g/L	O
)	O
.	O


One	O
or	O
2	O
units	O
of	O
blood	O
were	O
transfused	O
to	O
patients	O
in	O
both	O
groups	O
according	O
to	O
postoperative	O
Hb	O
level	O
(	O
between	O
60	O
and	O
70	O
g/L	O
or	O
betweeen	O
50	O
and	O
60	O
g/L	O
,	O
respectively	B-OUT
)	I-OUT
.	I-OUT


Perioperative	B-OUT
laboratory	I-OUT
and	I-OUT
clinical	I-OUT
outcomes	I-OUT
(	I-OUT
Hb	I-OUT
,	I-OUT
iron	I-OUT
variables	I-OUT
,	I-OUT
postoperative	I-OUT
bleeding	I-OUT
amount	I-OUT
,	I-OUT
and	I-OUT
number	I-OUT
of	I-OUT
units	I-OUT
of	I-OUT
RBCs	I-OUT
transfused	I-OUT
and	I-OUT
incidences	I-OUT
)	I-OUT
were	O
documented	O
.	O


Two-hundred	B-P
patients	I-P
were	O
randomized	O
into	O
2	B-I
groups	I-I
to	I-I
receive	I-I
heparinized	I-I
(	I-I
group	I-I
H	I-I
,	I-I
n	I-I
=	I-I
100	I-I
)	I-I
or	I-I
nonheparinized	I-I
(	I-I
group	I-I
S	I-I
,	I-I
n	I-I
=	I-I
100	I-I
)	I-I
flush	I-I
solutions	I-I
.	I-I


Randomised	O
,	O
parallel-group	O
,	O
multicentre	O
,	O
multinational	O
phase	O
2	O
study	O
comparing	O
edoxaban	B-I
,	O
an	O
oral	O
factor	B-I
Xa	I-I
inhibitor	I-I
,	O
with	O
warfarin	B-I
for	O
stroke	B-P
prevention	I-P
in	I-P
patients	I-P
with	I-P
atrial	I-P
fibrillation	I-P
.	I-P


There	O
were	O
no	O
significant	O
differences	O
in	B-OUT
hepatic	I-OUT
enzyme	I-OUT
elevations	I-OUT
or	I-OUT
bilirubin	I-OUT
values	I-OUT
among	O
the	O
groups	O
.	O


In	O
contrast	O
,	O
the	B-I
edoxaban	I-I
bid	O
regimens	O
were	O
associated	O
with	O
more	B-OUT
bleeding	I-OUT
than	I-I
warfarin	I-I
.	O


OBJECTIVE	O
To	O
compare	O
the	O
efficacy	O
of	O
meloxicam	B-I
and	I-I
a	I-I
glucosamine-chondroitin	I-I
(	I-I
Glu-Ch	I-I
)	I-I
supplement	I-I
in	O
the	O
management	O
of	O
feline	B-OUT
osteoarthritis	I-OUT
(	I-OUT
OA	I-OUT
)	I-OUT
.	O


Cats	B-P
over	I-P
eight	I-P
years	I-P
of	I-P
age	I-P
with	I-P
clinical	I-P
signs	I-P
of	I-P
chronic	I-P
OA	I-P
were	I-P
assigned	I-P
to	I-P
one	I-P
of	I-P
two	I-P
groups	I-P
and	O
Glu-Ch	B-I
or	I-I
meloxicam	I-I
was	O
administered	O
orally	O
for	O
70	O
days	O
,	O
followed	O
by	O
a	O
placebo	B-I
until	O
day	O
98	O
.	O


Pre-treatment	O
disease	B-OUT
scores	I-OUT
were	O
significantly	O
higher	O
in	O
the	O
meloxicam	B-I
group	O
for	O
owner	B-OUT
mobility	I-OUT
(	O
p=0.01	O
)	O
and	O
veterinary	B-OUT
lameness	I-OUT
(	O
p=0.02	O
)	O
.	O


About	B-P
40	I-P
children	I-P
between	I-P
the	I-P
ages	I-P
three	I-P
and	I-P
11	I-P
years	I-P
(	I-P
inclusive	I-P
)	I-P
with	I-P
a	I-P
DSM	I-P
IV	I-P
clinical	I-P
diagnosis	I-P
of	I-P
autism	I-P
and	I-P
who	I-P
were	I-P
outpatients	I-P
from	I-P
a	I-P
specialty	I-P
clinic	I-P
for	I-P
children	I-P
were	I-P
recruited	I-P
.	I-P


Patients	O
were	O
randomly	O
allocated	O
to	O
piracetam	B-I
+	I-I
risperidone	I-I
(	I-I
Group	I-I
A	I-I
)	I-I
or	I-I
placebo	I-I
+	I-I
risperidone	I-I
(	O
Group	O
B	O
)	O
for	O
a	O
10-week	O
,	O
double-blind	O
,	O
placebo-controlled	O
study	O
.	O


Patients	O
were	O
assessed	O
at	O
baseline	O
and	O
after	O
2	O
,	O
4	O
,	O
6	O
,	O
8	O
and	O
10	O
weeks	O
of	O
starting	O
medication	O
.	O


The	O
measure	O
of	O
the	O
outcome	O
was	O
the	O
Aberrant	B-OUT
Behavior	I-OUT
Checklist-Community	I-OUT
(	I-OUT
ABC-C	I-OUT
)	I-OUT
Rating	I-OUT
Scale	I-OUT
(	I-OUT
total	I-OUT
score	I-OUT
)	I-OUT
.	I-OUT


The	O
ABC-C	B-OUT
Rating	I-OUT
Scale	I-OUT
scores	I-OUT
improved	O
with	O
piracetam	O
.	O


=	O
1	O
,	O
P	O
=	O
0.02	O
)	O
.	O


Recent	O
animal	O
models	O
suggest	O
that	O
enteral	B-I
feeding	I-I
(	I-I
TEN	I-I
)	I-I
compared	O
to	O
parenteral	B-I
nutrition	I-I
(	I-I
TPN	I-I
)	I-I
improves	O
resistance	O
to	O
infection	O
.	O


Seventy-five	B-P
patients	I-P
with	I-P
an	I-P
abdominal	I-P
trauma	I-P
index	I-P
(	I-P
ATI	I-P
)	I-P
greater	I-P
than	I-P
15	I-P
and	I-P
less	I-P
than	I-P
40	I-P
were	I-P
randomized	I-P
at	I-P
initial	I-I
laparotomy	I-I
to	I-P
receive	I-I
either	I-I
TEN	I-I
(	I-I
Vivonex	I-I
TEN	I-I
)	I-I
or	I-I
TPN	I-I
(	I-I
Freamine	I-I
HBC	I-I
6.9	I-I
%	I-I
and	I-I
Trophamine	I-I
6	I-I
%	I-I
)	I-I
;	I-I
both	I-P
regimens	I-P
contained	I-P
2.5	I-P
%	I-P
fat	I-P
,	I-P
33	I-P
%	I-P
branched	I-P
chain	I-P
amino	I-P
acids	I-P
,	I-P
and	I-P
had	I-P
a	I-P
calorie	I-P
to	I-P
nitrogen	I-P
ratio	I-P
of	I-P
150:1	I-P
.	I-P


TEN	B-I
was	O
delivered	O
via	O
a	O
needle	O
catheter	O
jejunostomy	O
.	O


Infections	B-OUT
developed	O
in	O
5	O
(	O
17	O
%	O
)	O
of	O
the	O
TEN	B-I
patients	O
compared	O
to	O
11	O
(	O
37	O
%	O
)	O
of	O
the	O
TPN	B-I
group	O
.	O


The	O
primary	O
outcome	O
measure	O
was	O
headache	B-OUT
intensity	I-OUT
.	I-OUT


RESULTS	B-OUT
Headache	I-OUT
intensity	I-OUT
showed	O
significant	O
main	O
effects	O
of	O
period	O
(	O
before	O
vs.	O
after	O
therapy	O
,	O
p	O
=	O
0.02	O
)	O
and	O
group	O
(	O
biofeedback	O
vs.	O
control	O
groups	O
,	O
p	O
=	O
0.42	O
)	O
and	O
a	O
significant	O
period	O
×	O
group	O
interaction	B-OUT
(	I-OUT
p	I-OUT
<	I-OUT
0.001	I-OUT
)	I-OUT
.	O


[	B-OUT
Folic	I-OUT
acid	I-OUT
deficiency	I-OUT
in	O
pregnant	B-P
women	I-P
in	I-P
Switzerland	I-P
]	I-P
.	O


Postoperative	B-OUT
pain	I-OUT
was	O
assessed	O
for	O
24	O
hr	O
using	O
an	O
objective	B-OUT
pain	I-OUT
score	I-OUT
.	I-OUT


Groups	O
II	O
,	O
III	O
and	O
IV	O
were	O
comparable	O
with	O
regards	O
to	O
duration	B-OUT
of	I-OUT
postoperative	I-OUT
analgesia	I-OUT
and	I-OUT
total	I-OUT
analgesic	I-OUT
consumption	I-OUT
(	O
P	O
>	O
0.05	O
)	O
.	O


Incidence	O
of	O
nausea	B-OUT
and	I-OUT
vomiting	I-OUT
were	O
comparable	O
in	O
all	O
four	O
groups	O
.	O


No	O
significant	O
alteration	O
in	O
vital	B-OUT
signs	I-OUT
or	O
any	O
other	O
adverse	O
effects	O
were	O
observed	O
.	O


Experimentally	O
induced	O
pain	O
can	O
be	O
attenuated	O
by	O
concomitant	O
heterotopic	O
nociceptive	O
stimuli	O
(	O
counterirritation	O
)	O
.	O


The	B-OUT
temporal	I-OUT
dynamics	I-OUT
of	I-OUT
adenosine-induced	I-OUT
dyspnea	I-OUT
and	I-OUT
RIII	I-OUT
inhibition	I-OUT
differed	O
(	O
immediate	O
onset	O
followed	O
by	O
a	O
slow	O
decrease	O
for	O
dyspnea	O
,	O
slower	O
onset	O
for	O
RIII	O
inhibition	O
)	O
.	O


RESULTS	O
All	O
patients	B-OUT
underwent	I-OUT
NCE	I-I
4D	I-I
MRA	I-OUT
without	I-OUT
any	I-OUT
difficulty	I-OUT
.	O


Among	B-P
seven	I-P
patients	I-P
with	I-P
patent	I-P
DAVFs	I-P
,	O
all	O
cases	O
showed	O
an	B-OUT
early	I-OUT
visualization	I-OUT
of	I-OUT
the	I-OUT
transverse	I-OUT
sinus	I-OUT
on	I-I
NCE	I-I
4D	I-I
MRA	I-I
.	O


Except	O
for	O
one	O
case	O
,	O
the	O
type	O
of	O
DAVF	O
of	B-I
NCE	I-I
4D	I-I
MRA	I-I
was	O
agreed	O
with	O
that	O
of	O
reference	O
standard	O
study	O
.	B-OUT


CONCLUSION	O
NCE	O
4D	O
MRA	O
with	O
STAR	O
tagging	O
and	O
VFA	O
sampling	O
is	O
technically	O
and	O
clinically	O
feasible	O
and	O
represents	O
a	O
promising	O
technique	O
for	O
assessment	O
of	O
DAVF	O
in	O
the	O
transverse	O
sinus	O
.	O


Further	O
technical	O
developments	O
should	O
aim	O
at	O
improvements	O
of	O
spatial	O
and	O
temporal	O
coverage	O
.	O


Airway	B-OUT
management	I-OUT
training	I-I
using	O
the	O
laryngeal	B-I
mask	I-I
airway	I-I
:	I-I
a	O
comparison	O
of	O
two	O
different	O
training	O
programmes	O
.	O


A	O
randomized	O
,	O
open-label	O
,	O
multicenter	O
study	O
was	O
undertaken	O
to	O
compare	O
the	O
effects	O
of	O
oral	B-I
contraceptives	I-I
(	I-I
OC	I-I
)	I-I
containing	I-I
100	I-I
micrograms	I-I
levonorgestrel	I-I
(	I-I
LNG	I-I
)	I-I
/20	I-I
micrograms	I-I
ethinyl	I-I
estradiol	I-I
(	I-I
EE	I-I
)	I-I
(	I-I
Aless/Loette	I-I
)	I-I
and	O
1000	B-I
micrograms	I-I
norethindrone	I-I
acetate	I-I
(	I-I
NETA	I-I
)	I-I
/20	I-I
micrograms	I-I
EE	I-I
(	I-I
Loestrin	I-I
Fe	I-I
1/20	I-I
)	I-I
on	O
menstrual	O
cycle	O
control	O
over	O
four	O
cycles	O
of	O
use	O
.	O


A	O
total	O
of	O
84	B-P
evaluable	I-P
women	I-P
provided	I-P
274	I-P
cycles	I-P
of	I-P
exposure	I-P
in	I-P
the	I-P
LNG/EE	I-P
group	I-P
,	I-P
and	I-P
89	I-P
women	I-P
provided	I-P
289	I-P
cycles	I-P
of	I-P
exposure	I-P
in	I-P
the	I-P
NETA/EE	I-P
group	I-P
.	I-P


The	O
occurrence	B-OUT
of	I-OUT
bleeding	I-OUT
and/or	I-OUT
spotting	I-OUT
was	O
significantly	O
lower	O
in	O
cycles	O
2	O
and	O
3	O
in	O
the	O
LNG/EE	B-P
group	I-P
(	O
41.7	O
%	O
and	O
34.8	O
%	O
,	O
respectively	O
)	O
compared	O
with	O
the	O
NETA/EE	O
group	O
(	O
62.3	O
%	O
and	O
56.3	O
%	O
;	O
p	O
<	O
0.05	O
)	O
.	O


The	O
primary	O
efficacy	O
variable	O
was	B-OUT
mean	I-OUT
diurnal	I-OUT
intraocular	I-OUT
pressure	I-OUT
(	I-OUT
IOP	I-OUT
)	I-OUT
at	O
day	O
29	O
.	O


The	O
most	O
frequently	O
reported	O
adverse	O
event	B-OUT
was	I-OUT
conjunctival	I-OUT
hyperaemia	I-OUT
with	O
an	O
incidence	O
of	O
41	O
%	O
(	O
30/73	O
)	O
,	O
40	O
%	O
(	O
29/73	O
)	O
,	O
14	O
%	O
(	O
10/73	O
)	O
and	O
40	O
%	O
(	O
31/78	O
)	O
in	O
the	O
PG324	O
0.01	O
%	O
,	O
PG324	O
0.02	O
%	O
,	O
latanoprost	B-I
and	I-I
AR-13324	O
0.02	O
%	O
groups	O
,	O
respectively	O
.	O


CONCLUSIONS	O
In	O
this	O
short-term	O
study	O
,	O
the	O
fixed-dose	O
combination	B-I
of	I-I
AR-13324	O
0.02	O
%	O
and	O
latanoprost	O
0.005	O
%	O
in	O
PG324	O
Ophthalmic	O
Solution	O
provides	O
clinically	O
and	O
statistically	B-OUT
superior	I-OUT
ocular	I-OUT
hypotensive	I-OUT
efficacy	O
relative	O
to	O
its	O
individual	O
active	O
components	O
at	O
the	O
same	O
concentrations	O
.	B-OUT


Four	O
patients	O
in	O
the	O
combined	O
treatment	O
arm	O
experienced	B-OUT
manageable	I-OUT
complications	I-OUT
,	I-OUT
no	I-OUT
complications	I-OUT
occurred	O
after	O
brachytherapy	O
alone	O
.	O


In	O
this	O
pilot	O
study	O
,	O
we	O
tested	O
the	O
effects	O
of	O
a	O
novel	O
intervention	O
(	B-I
JASPER	I-I
,	I-I
Joint	I-I
Attention	I-I
Symbolic	I-I
Play	I-I
Engagement	I-I
and	I-I
Regulation	I-I
)	I-I
on	O
3	B-P
to	I-P
5	I-P
year	I-P
old	I-P
,	I-P
minimally	I-P
verbal	I-P
children	I-P
with	I-P
autism	I-P
who	I-P
were	I-P
attending	I-P
a	I-P
non-public	I-P
preschool	I-P
.	I-P


On	O
achievement	O
of	O
"	B-OUT
optimal	I-OUT
cosmetic	I-OUT
result	I-OUT
"	I-OUT
(	O
baseline	O
)	O
,	O
patients	O
were	O
followed	O
up	O
for	O
6	O
months	O
;	O
bilateral	O
retreatment	O
with	O
Perlane	B-I
was	O
offered	O
at	O
6	O
or	O
9	O
months	O
after	O
baseline	O
.	O


According	O
to	O
investigator-based	B-OUT
Wrinkle	I-OUT
Severity	I-OUT
Rating	I-OUT
Scale	I-OUT
assessments	I-OUT
at	O
6	O
and	O
9	O
months	O
after	O
baseline	O
,	O
Perlane	B-I
was	O
superior	B-OUT
in	O
50.0	O
percent	O
and	O
48.8	O
percent	O
of	O
patients	O
,	O
respectively	O
,	O
whereas	O
Zyplast	B-I
was	O
superior	B-OUT
in	O
10.3	O
percent	O
and	O
14.0	O
percent	O
of	O
patients	O
,	O
respectively	O
(	O
p	O
<	O
0.0004	O
)	O
.	O


"	B-OUT
Optimal	I-OUT
cosmetic	I-OUT
result	I-OUT
"	I-OUT
was	O
achieved	O
with	O
a	O
smaller	B-OUT
volume	I-OUT
of	O
Perlane	B-I
than	O
Zyplast	B-I
(	O
mean	O
,	O
1.2	O
ml	O
versus	O
2.1	O
ml	O
)	O
.	O


Perlane	B-I
has	O
acceptable	O
long-term	B-OUT
safety	I-OUT
and	O
offers	O
a	O
longer-lasting	O
aesthetic	B-OUT
improvement	I-OUT
than	O
Zyplast	B-I
.	I-I


24	B-P
gallstone	I-P
patients	I-P
were	O
treated	O
with	O
cicloxilic	B-I
acid	I-I
,	O
an	O
agent	O
endowed	O
with	O
choleretic	O
activity	O
,	O
at	O
the	O
dose	O
of	O
240	O
mg/day	O
for	O
1	O
month	O
.	O


Bile	B-OUT
lipid	I-OUT
composition	I-OUT
was	O
determined	O
and	O
the	O
saturation	O
index	O
calculated	O
before	O
and	O
after	O
treatment	O
,	O
on	O
samples	O
collected	O
by	O
duodenal	O
siphonage	O
after	O
caerulein	O
stimulation	O
,	O
in	O
both	O
groups	O
.	O


RESULTS	O
The	O
consumption	O
of	O
L.	B-I
plantarum	I-I
CECT	I-I
7315/7316	I-I
during	O
3	O
months	O
after	O
influenza	B-I
vaccination	I-I
increased	O
the	O
levels	B-OUT
of	I-OUT
influenza-specific	I-OUT
IgA	I-OUT
and	I-OUT
IgG	I-OUT
antibodies	I-OUT
.	I-OUT


Moreover	O
,	O
a	O
trend	O
towards	O
an	O
increase	O
in	O
influenza-specific	B-OUT
IgM	I-OUT
antibodies	I-OUT
was	O
also	O
observed	O
.	O


The	O
need	O
for	O
chemotherapy	B-I
after	O
prolonged	B-P
complete	I-P
remission	I-P
in	I-P
acute	I-P
leukemia	I-P
of	I-P
childhood	I-P
.	I-P


Custom	O
tray	O
application	O
of	O
peroxide	B-I
gel	I-I
as	O
an	O
adjunct	O
to	O
scaling	B-I
and	I-I
root	I-I
planing	I-I
in	O
the	O
treatment	B-P
of	I-P
periodontitis	I-P
:	I-P
results	O
of	O
a	O
randomized	O
controlled	O
trial	O
after	O
six	O
months	O
.	O


OBJECTIVE	O
Scaling	B-I
and	I-I
root	I-I
planing	I-I
(	I-I
SRP	I-I
)	I-I
is	O
the	O
primary	O
non-surgical	O
treatment	O
for	O
periodontitis	O
,	O
but	O
its	O
effectiveness	O
is	O
limited	O
.	O


Ten	O
weeks	O
following	O
SRP	B-I
,	O
mean	B-OUT
PPD	I-OUT
decreases	O
were	O
0.77	O
mm	O
for	O
the	O
test	O
group	O
and	O
0.13	O
mm	O
for	O
the	O
control	O
,	O
and	O
mean	B-OUT
BI	I-OUT
reductions	O
were	O
0.14	O
for	O
the	O
test	O
group	O
and	O
0.00	O
for	O
the	O
control	O
.	O


Vaccinees	B-I
were	I-I
bled	I-I
immediately	I-I
prior	I-I
to	I-I
each	I-I
vaccination	I-I
,	I-I
and	I-I
again	I-I
at	I-I
3-	I-I
and	I-I
12-month	I-I
follow-up	I-I
.	I-I


This	O
effect	O
was	O
seen	O
only	O
during	O
supine	O
sleep	O
and	O
non-rapid	O
eye	O
movement	O
sleep	O
and	O
was	O
absent	O
in	O
non-supine	O
sleep	O
,	O
rapid	O
eye	O
movement	O
sleep	O
,	O
and	O
during	O
periods	O
of	O
wakefulness	O
.	O


Thoracic	B-OUT
fluid	I-OUT
content	I-OUT
index	I-OUT
and	I-OUT
left	I-OUT
ventricular	I-OUT
hemodynamics	I-OUT
measured	O
by	O
impedance	O
cardiography	O
showed	O
no	O
response	O
to	O
sleeping	O
angle	O
.	O


The	O
changes	O
in	O
Cheyne-Stokes	O
apneas	O
are	O
not	O
related	O
to	O
changes	O
in	O
lung	O
congestion	O
and	O
left	O
ventricular	O
hemodynamics	O
.	O


MATERIALS	O
AND	O
METHODS	O
Patients	O
were	O
randomized	O
to	O
music	B-I
,	I-I
guided	I-I
imagery	I-I
,	I-I
or	I-I
usual	I-I
care	I-I
after	O
completing	O
a	O
baseline	B-I
questionnaire	I-I
.	I-I


Effects	O
of	O
fish	B-I
oil	I-I
supplementation	I-I
on	O
markers	O
of	O
the	O
metabolic	O
syndrome	O
.	O


STUDY	O
DESIGN	O
A	B-P
total	I-P
of	I-P
78	I-P
boys	I-P
age	I-P
13-15	I-P
years	I-P
with	I-P
a	I-P
mean	I-P
body	I-P
fat	I-P
percentage	I-P
of	I-P
30	I-P
%	I-P
+/-9	I-P
%	I-P
were	O
randomly	O
assigned	O
to	O
consume	O
fish	B-I
oil	I-I
(	O
providing	O
1.5	O
g	O
of	O
n-3	O
long-chain	B-I
polyunsaturated	I-I
fatty	I-I
acid/day	I-I
)	I-I
or	I-I
vegetable	I-I
oil	I-I
(	I-I
control	I-I
)	I-I
for	O
16	O
weeks	O
.	O


No	O
association	O
was	O
seen	O
between	O
RBC	B-OUT
EPA	I-OUT
and	I-OUT
plasma	I-OUT
TAG	I-OUT
concentration	I-OUT
or	I-OUT
insulin	I-OUT
sensitivity	I-OUT
.	I-OUT


All	O
the	O
patients	O
were	O
evaluated	O
for	O
toxicity	B-OUT
and	I-OUT
survival	I-OUT
according	O
to	O
the	O
as-treated	O
principle	O
.	O


RESULTS	O
With	O
a	O
median	O
follow-up	O
of	O
26.3	O
months	O
(	O
range	O
3-74.6	O
months	O
)	O
,	O
59	O
%	O
of	O
patients	O
in	O
the	O
cisplatin	O
arm	O
completed	O
the	O
planned	O
concurrent	O
chemoradiation	O
treatment	O
,	O
compared	O
to	O
73	O
%	O
in	O
the	O
carboplatin	O
arm	O
.	O


Forty-two	O
percent	O
of	O
cisplatin	O
patients	O
completed	O
the	O
3	B-OUT
cycles	I-OUT
of	I-OUT
adjuvant	I-OUT
therapy	I-OUT
compared	O
to	O
70	O
%	O
in	O
the	O
carboplatin	O
group	O
.	O


The	O
3	B-OUT
year	I-OUT
overall	I-OUT
survival	I-OUT
rates	I-OUT
were	O
77.7	O
%	O
and	O
79.2	O
%	O
for	O
cisplatin	O
and	O
carboplatin	O
groups	O
,	O
respectively	O
(	O
p=0.9884	O
)	O
(	O
HR	O
0.83	O
,	O
95	O
%	O
CI	O
:	O
0.63-1.010	O
)	O
.	O


METHODS	O
Fifty	B-P
women	I-P
between	I-P
16	I-P
and	I-P
24	I-P
weeks	I-P
of	I-P
pregnancy	I-P
were	I-P
recruited	I-P
at	I-P
Tygerberg	I-P
and	I-P
Paarl	I-P
Hospitals	I-P
,	I-P
Western	I-P
Cape	I-P
,	I-P
South	I-P
Africa	I-P
.	I-P


Twenty-six	B-P
women	I-P
were	I-P
randomized	I-P
to	I-P
a	I-P
10-week	I-I
exercise	I-I
program	I-I
and	I-I
24	I-P
were	I-P
randomized	I-P
as	I-P
controls	I-I
.	I-I


Pain	B-OUT
intensity	I-OUT
(	O
P=0.76	O
)	O
and	O
functional	B-OUT
ability	I-OUT
(	O
P=0.29	O
)	O
were	O
comparable	O
between	O
the	O
groups	O
on	O
study	O
entry	O
.	O


In	O
the	O
control	O
group	O
,	O
there	O
were	O
no	O
significant	O
changes	O
in	O
pain	B-OUT
intensity	I-OUT
(	O
P=0.89	O
)	O
or	O
functional	B-OUT
ability	I-OUT
(	O
P=0.70	O
)	O
at	O
the	O
end	O
of	O
the	O
study	O
.	O


CONCLUSION	O
A	O
specific	B-I
exercise	I-I
program	I-I
decreased	O
back	O
pain	O
intensity	O
and	O
increased	O
functional	O
ability	O
during	O
pregnancy	B-P
in	I-P
South	I-P
African	I-P
women	I-P
with	I-P
lumbar	I-P
and	I-P
pelvic	I-P
girdle	I-P
pain	I-P
.	I-P


BACKGROUND	O
The	O
increasing	O
prevalence	O
of	O
type	O
2	O
diabetes	O
poses	O
a	O
major	O
public	O
health	O
challenge	O
.	O


Secondary	O
endpoints	O
include	O
all-cause	B-OUT
mortality	I-OUT
,	I-OUT
development	I-OUT
of	I-OUT
renal	I-OUT
and	I-OUT
visual	I-OUT
impairment	I-OUT
,	I-OUT
peripheral	I-OUT
neuropathy	I-OUT
,	I-OUT
health	I-OUT
service	I-OUT
costs	I-OUT
,	I-OUT
self-reported	I-OUT
quality	I-OUT
of	I-OUT
life	I-OUT
,	I-OUT
functional	I-OUT
status	I-OUT
and	I-OUT
health	I-OUT
utility	I-OUT
.	I-OUT


DISCUSSION	O
ADDITION-Cambridge	O
is	O
conducted	O
in	O
a	O
defined	O
high-risk	O
group	O
accessible	O
through	O
primary	O
care	O
.	O


This	O
study	O
was	O
performed	O
to	O
investigate	O
the	O
analgesic	B-OUT
effect	I-OUT
of	O
lidocaine	B-I
and	I-I
a	I-I
combination	I-I
of	I-I
lidocaine	I-I
and	I-I
ketamine	I-I
following	O
epidural	O
administration	O
in	O
dromedary	B-P
camels	I-P
.	I-P


There	O
was	O
,	O
however	O
,	O
no	O
significant	O
difference	O
in	O
distribution	B-OUT
of	I-OUT
allele	I-OUT
genotypes	I-OUT
between	I-OUT
all	I-OUT
lung	I-OUT
cancer	I-OUT
cases	I-OUT
and	I-OUT
the	I-OUT
controls	I-OUT
,	O
nor	O
among	O
histological	O
types	O
for	O
the	O
cases	O
.	O


METHODS	O
On	O
six	O
occasions	O
,	O
1	O
to	O
3	O
days	O
apart	O
within	O
15	O
days	O
,	O
199	B-P
patients	I-P
with	I-P
elbow	I-P
epicondylitis	I-P
received	O
40	O
mA-minutes	O
of	O
either	O
active	O
or	O
placebo	B-I
treatment	O
.	O


RESULTS	O
Dexamethasone	B-I
produced	O
a	O
significant	O
23-mm	O
improvement	O
on	O
the	O
100-mm	B-OUT
patient	I-OUT
visual	I-OUT
analog	I-OUT
scale	I-OUT
ratings	I-OUT
,	O
compared	O
with	O
14	O
mm	O
for	O
placebo	B-I
at	O
2	O
days	O
and	O
24	O
mm	O
compared	O
with	O
19	O
mm	O
at	O
1	O
month	O
.	O


DESIGN/INTERVENTION	O
A	O
statewide	O
survey	O
of	O
all	B-P
primary	I-P
care	I-P
clinicians	I-P
serving	I-P
children	I-P
addressed	O
their	O
self-reported	O
sun	B-OUT
protection	I-OUT
advocacy	I-OUT
practices	I-OUT
.	I-OUT


Thus	O
,	O
both	O
the	O
degenerative	O
and	O
vascular	O
type	O
of	O
dementia	O
exhibited	O
a	O
therapeutic	O
benefit	O
that	O
could	O
be	O
objectified	O
at	O
the	O
neurophysiological	O
level	O
by	O
EEG	O
mapping	O
in	O
an	O
improvement	O
of	O
vigilance	O
.	O


It	O
is	O
metabolized	O
by	O
CYP2B6	O
to	O
its	O
active	O
metabolite	O
hydroxybupropion	O
,	O
yet	O
alterations	O
in	O
CYP2B6	O
activity	O
have	O
little	O
impact	O
on	O
bupropion	B-OUT
plasma	I-OUT
levels	I-OUT
.	I-OUT


Furthermore	O
,	O
less	O
than	O
10	O
%	O
of	O
a	O
bupropion	B-I
dose	O
is	O
excreted	O
as	O
urinary	O
bupropion	B-I
and	O
its	O
characterized	O
metabolites	O
hydroxybupropion	O
,	O
threohydrobupropion	O
,	O
and	O
erythrohydrobupropion	O
,	O
suggesting	O
that	O
alternative	O
metabolic	O
pathways	O
may	O
exist	O
.	O


In	O
42	B-P
healthy	I-P
volunteers	I-P
,	O
CYP2C19*2	O
(	O
a	O
reduced	O
activity	O
allele	O
)	O
was	O
associated	O
with	O
higher	O
bupropion	B-I
area	O
under	O
the	O
plasma	O
concentration-time	O
curve	O
(	O
AUC	O
)	O
,	O
but	O
similar	O
hydroxybupropion	O
AUC	O
.	O


Genotype	O
had	O
a	O
significant	O
influence	O
on	O
both	O
behavioral	B-OUT
and	I-OUT
neuronal	I-OUT
measures	I-OUT
of	I-OUT
social	I-OUT
processing	I-OUT
.	I-OUT


OT	O
seems	O
to	O
modulate	O
this	O
effect	O
by	O
enhancing	O
activation	B-OUT
differences	I-OUT
between	O
allele	B-P
groups	I-P
,	O
which	O
suggests	O
an	O
interaction	O
between	O
genetic	B-OUT
makeup	I-OUT
and	O
OT	B-OUT
availability	I-OUT
on	O
fusiform	B-OUT
gyrus	I-OUT
activation	I-OUT
.	I-OUT


The	B-OUT
30-day	I-OUT
mortality	I-OUT
did	O
not	O
differ	O
between	O
group	O
A	O
(	O
17.3	O
%	O
)	O
and	O
group	O
B	O
(	O
13.4	O
%	O
;	O
p=0.78	B-OUT
)	I-OUT
.	I-OUT


Intra-	O
and	O
postoperative	B-I
IABP	O
support	O
was	O
required	O
by	O
13	O
patients	O
(	O
21	O
%	O
)	O
in	O
group	B-OUT
A	I-OUT
.	I-OUT


Effect	O
of	O
micronutrient	B-I
supplement	I-I
on	O
health	B-OUT
and	I-OUT
nutritional	I-OUT
status	I-OUT
of	O
schoolchildren	B-P
:	I-P
study	O
design	O
.	O


The	O
power	O
of	O
the	O
outcome	O
variables	O
ranged	O
from	O
74	O
%	O
to	O
100	O
%	O
and	O
was	O
adequate	O
for	O
successful	O
pairing	O
.	O


OBJECTIVE	O
To	O
compare	O
the	O
efficacy	O
of	O
an	O
acupuncture	B-I
regimen	I-I
for	O
persistent	B-P
allergic	I-P
rhinitis	I-P
(	I-P
PER	I-P
)	I-P
,	O
aimed	O
at	O
improving	O
a	O
patient	O
's	O
mind	O
or	O
Shen	O
in	O
Traditional	B-I
Chinese	I-I
Medicine	I-I
,	O
to	O
that	O
of	O
a	O
second-generation	B-I
Hi-receptor	I-I
antagonist	I-I
,	I-I
cetirizine	I-I
hydrochloride	I-I
.	I-I


After	O
a	O
1-week	O
preparatory	O
screening	O
period	O
,	O
240	B-P
eligible	I-P
participants	I-P
with	I-P
PER	I-P
will	O
be	O
randomized	O
to	O
receive	O
acupuncture	B-I
or	I-I
pharmacotherapy	I-I
(	O
1:1	O
)	O
for	O
4	O
weeks	O
with	O
a	O
4-week	O
follow-up	O
.	O


The	O
results	O
were	O
assessed	O
by	O
the	O
survival	B-OUT
time	I-OUT
and	I-OUT
quality	I-OUT
of	I-OUT
survival	I-OUT
.	I-OUT


PURPOSE	O
To	O
investigate	O
the	O
efficacy	O
and	O
safety	O
of	O
zoledronic	B-I
acid	I-I
for	O
the	O
treatment	O
of	O
bone	O
metastases	O
from	O
breast	O
cancer	O
.	O


An	O
SRE	O
was	O
defined	O
as	O
pathologic	O
fracture	O
,	O
spinal	O
cord	O
compression	O
,	O
and	O
radiation	O
or	O
surgery	O
to	O
bone	O
.	O


Secondary	O
end	O
points	O
included	O
percentage	O
of	O
patients	O
with	O
at	O
least	O
one	O
SRE	O
,	O
time-to-first	O
SRE	O
,	O
and	O
Andersen-Gill	O
multiple-event	O
analysis	O
.	O


The	O
percentage	B-OUT
of	I-OUT
patients	I-OUT
with	I-OUT
at	I-OUT
least	I-OUT
one	I-OUT
SRE	I-OUT
(	I-OUT
excluding	I-OUT
HCM	I-OUT
)	I-OUT
was	I-OUT
significantly	I-OUT
reduced	I-OUT
by	O
20	O
%	O
by	O
zoledronic	O
acid	O
(	O
29.8	O
%	O
v	O
49.6	O
%	O
for	O
placebo	O
;	O
P	O
=	O
.003	O
)	O
.	O


CONCLUSION	O
Zoledronic	B-I
acid	I-I
significantly	O
reduced	O
skeletal	O
complications	O
compared	O
with	O
placebo	B-I
across	O
multiple	O
end	O
points	O
in	O
Japanese	B-P
women	I-P
with	I-P
bone	I-P
metastases	I-P
from	I-P
breast	I-P
cancer	I-P
.	I-P


The	O
effect	O
of	O
case	B-I
management	I-I
on	O
the	O
costs	B-OUT
of	I-OUT
health	I-OUT
care	I-OUT
for	O
enrollees	O
in	O
Medicare	O
Plus	O
Choice	O
plans	O
:	O
a	O
randomized	O
trial	O
.	O


CONCLUSIONS	O
This	O
study	O
provides	O
no	O
statistically	O
significant	O
evidence	O
that	O
social	O
work-oriented	O
case	O
management	O
reduces	O
the	O
use	O
or	O
the	O
cost	B-OUT
of	I-OUT
health	I-OUT
care	I-OUT
for	O
high-risk	O
older	O
people	O
.	O


Ginkgo	O
biloba	O
has	O
been	O
reported	O
to	O
affect	O
the	O
neurotransmitter	O
system	O
and	O
to	O
have	O
antioxidant	O
properties	O
that	O
could	O
impact	O
the	O
pathogenesis	O
of	O
Autism	B-P
Spectrum	I-P
Disorder	I-P
.	I-P


None	O
of	O
the	O
5	O
subscales	O
of	O
ABC-C	B-OUT
rating	I-OUT
scale	I-OUT
showed	O
significant	O
differences	O
between	O
the	O
two	O
groups	O
.	O


The	O
quality	O
of	O
these	O
randomized	O
controlled	O
trials	O
was	O
scored	O
.	O


This	O
trial	O
protocol	O
is	O
aimed	O
to	O
test	O
the	O
SCION-PAIN	O
program	O
,	O
a	O
multi	O
modular	O
structured	O
intervention	O
to	O
improve	O
self	O
management	O
in	O
cancer	B-P
patients	I-P
with	I-P
pain	I-P
.	I-P


METHODS	O
240	B-P
patients	I-P
with	I-P
diagnosed	I-P
malignancy	I-P
and	I-P
pain	I-P
>	I-P
3	I-P
days	I-P
and	I-P
average	I-P
pain	I-P
>	I-P
or=	I-P
3/10	I-P
will	I-P
participate	I-P
in	I-P
a	I-P
cluster	I-P
randomized	I-P
trial	I-P
on	I-P
18	I-P
wards	I-P
in	I-P
2	I-P
German	I-P
university	I-P
hospitals	I-P
.	I-P


TRIAL	O
REGISTRATION	O
ClinicalTrials	O
NCT00779597	O
.	O


Joint	O
study	O
of	O
extracranial	O
arterial	O
occlusion	O
.	O


Each	O
group	O
received	O
identical	O
dietary	O
instructions	O
.	O


Alkalinized	B-I
lidocaine	I-I
and	I-I
heparin	I-I
provide	O
immediate	O
relief	O
of	O
pain	B-OUT
and	O
urgency	O
in	O
patients	B-P
with	I-P
interstitial	I-P
cystitis	I-P
.	I-P


CONCLUSIONS	O
The	O
combination	O
of	O
alkalinized	O
lidocaine	O
and	O
heparin	O
provides	O
up	O
to	O
12	O
hours	O
of	O
relief	O
from	O
urgency	B-OUT
and	I-OUT
pain	I-OUT
associated	O
with	O
IC	O
.	O


Paclitaxel	B-I
administered	O
as	O
a	O
single	O
agent	O
or	O
in	O
combination	O
with	O
cisplatin	B-I
has	O
been	O
shown	O
to	O
be	O
a	O
potentially	O
new	O
useful	O
agent	O
for	O
the	O
treatment	O
of	O
NSCLC	O
.	O


RESULTS	O
Compared	O
with	O
the	O
cisplatin-only	O
arm	O
,	O
there	O
was	O
a	O
9	O
%	O
improvement	O
(	O
95	O
%	O
confidence	O
interval	O
,	O
0	O
%	O
to	O
19	O
%	O
)	O
in	O
overall	B-OUT
response	I-OUT
rate	I-OUT
for	O
the	O
paclitaxel/cisplatin	B-I
arm	O
(	O
17	O
%	O
v	O
26	O
%	O
,	O
respectively	O
;	O
P=.028	O
)	O
.	O


The	O
study	O
had	O
a	O
cross-over	O
,	O
placebo-controlled	O
design	O
consisting	O
of	O
4	O
d	O
separated	O
by	O
>	O
or	O
=	O
1	O
wk	O
.	O


There	O
was	O
no	O
significant	O
difference	O
in	O
the	O
maximal	B-OUT
percent	I-OUT
fall	I-OUT
in	I-OUT
FEV1	I-OUT
from	I-OUT
baseline	I-OUT
between	O
LTD4	O
(	O
mean	O
+/-	O
SEM	O
,	O
49.5	O
+/-	O
4.4	O
%	O
fall	O
)	O
and	O
methacholine	O
(	O
mean	O
+/-	O
SEM	O
,	O
55.9	O
+/-	O
3.4	O
%	O
fall	O
)	O
(	O
p	O
=	O
0.11	O
)	O
.	O


Behavioral	B-I
parent	I-I
training	I-I
to	O
address	O
sleep	B-OUT
disturbances	I-OUT
in	O
young	B-P
children	I-P
with	I-P
autism	I-P
spectrum	I-P
disorder	I-P
:	I-P
a	O
pilot	O
trial	O
.	O


Each	O
participant	O
was	O
individually	O
administered	O
a	O
5-session	O
program	O
delivered	O
over	O
the	O
8-week	O
study	O
.	O


Results	O
supported	O
the	O
feasibility	B-OUT
of	O
the	O
manualized	O
parent	O
training	O
program	O
and	O
the	O
comparison	O
program	O
.	O


One	O
of	O
the	O
objectives	O
of	O
Childrens	O
Cancer	O
Study	O
Group	O
(	O
CCSG	O
)	O
study	O
141	O
(	O
CCG-141	O
)	O
was	O
to	O
determine	O
the	O
frequency	B-OUT
of	O
occult	B-OUT
testicular	I-OUT
leukemia	I-OUT
(	I-OUT
TL	I-OUT
)	I-OUT
after	O
3	O
years	O
of	O
disease-free	B-OUT
survival	I-OUT
(	I-OUT
DFS	I-OUT
)	I-OUT
and	O
to	O
retreat	O
boys	B-P
with	I-P
occult	I-P
TL	I-P
to	O
prolong	O
their	O
subsequent	O
DFS	O
.	O


Of	O
the	O
494	B-P
boys	I-P
entered	I-P
on	I-P
study	I-P
,	O
255	O
(	O
51.6	O
%	O
)	O
were	O
in	O
complete	O
continuous	O
remission	O
(	O
CCR	O
)	O
3	O
years	O
after	O
entering	O
remission	O
and	O
an	O
additional	O
eight	O
were	O
in	O
CCR	O
3	O
years	O
after	O
localized	O
extramedullary	O
relapse	O
and	O
retreatment	O
;	O
263	B-P
boys	I-P
were	I-P
eligible	I-P
for	I-P
testicular	I-I
biopsy	I-I
.	I-I


Of	O
the	O
26	O
boys	O
who	O
did	O
not	O
undergo	O
biopsy	B-I
,	O
21	O
(	O
80.8	O
%	O
)	O
remained	O
in	O
CCR	O
;	O
two	O
(	O
7.7	O
%	O
)	O
developed	B-OUT
isolated	I-OUT
overt	I-OUT
TL	I-OUT
.	I-OUT


The	O
HER2	B-OUT
status	I-OUT
was	O
analyzed	O
by	O
three	O
different	O
approaches	O
:	O
local	B-I
and	I-I
central	I-I
evaluation	I-I
using	I-I
immunohistochemistry	I-I
combined	I-I
with	I-I
in	I-I
situ-hybridization	I-I
as	O
well	O
as	O
evaluation	B-I
of	I-I
HER2	I-OUT
mRNA	I-OUT
expression	I-OUT
using	I-I
kinetic	I-I
RT-PCR	I-I
from	I-I
formalin-fixed	I-I
,	I-I
paraffin-embedded	I-I
(	I-I
FFPE	I-I
)	I-I
tissue	I-I
samples	I-I
using	O
a	O
predefined	O
cutoff	O
.	O


HER2	B-OUT
overexpression/amplification	I-OUT
was	O
observed	O
in	O
37.3	O
%	O
(	O
91/244	O
)	O
and	O
17.9	O
%	O
(	O
41/229	O
)	O
of	O
the	O
informative	O
samples	O
in	O
the	O
local	O
and	O
central	O
evaluations	O
,	O
respectively	O
.	O


We	O
observed	O
a	O
highly	O
significant	O
correlation	B-OUT
between	I-OUT
central	I-OUT
HER2	I-OUT
expression	I-OUT
and	I-OUT
HER2	I-OUT
status	I-OUT
measured	I-OUT
by	I-OUT
kinetic	I-OUT
RT-PCR	I-OUT
(	O
r	O
=	O
0.856	O
,	O
P	O
<	O
0.0001	O
)	O
and	O
an	O
overall	O
agreement	O
of	O
95.6	O
%	O
(	O
κ	O
statistic	O
,	O
0.862	O
,	O
CI	O
0.77-0.94	O
)	O
.	O


Further	O
,	O
central	B-OUT
HER2	I-OUT
as	I-OUT
well	I-OUT
as	I-OUT
HER2	I-OUT
mRNA	I-OUT
expression	I-OUT
were	I-OUT
predictors	I-OUT
for	I-OUT
a	I-OUT
pathological	I-OUT
complete	I-OUT
response	I-OUT
after	I-OUT
neoadjuvant	I-OUT
anthracycline/taxane-based	I-OUT
primary	I-OUT
chemotherapy	I-OUT
in	O
a	O
univariate	O
binary	O
logistic	O
regression	O
analysis	O
(	O
OR	O
3.29	O
,	O
P	O
=	O
0.002	O
;	O
OR	O
2.65	O
,	O
P	O
=	O
0.004	O
)	O
.	O


The	B-OUT
predictive	I-OUT
value	I-OUT
could	O
be	O
confirmed	O
for	O
the	B-OUT
central	I-OUT
HER2	I-OUT
status	I-OUT
by	O
multivariate	O
analysis	O
(	O
OR	O
3.04	O
,	O
P	O
=	O
0.027	O
)	O
.	O


Cooperative	B-P
Group	I-P
of	I-P
Study	I-P
and	I-P
Treatment	I-P
of	I-P
Multiple	I-P
Myeloma	I-P
.	I-P


A	O
single-center	O
open	O
label	O
randomized	O
trial	O
of	O
the	O
safety	B-OUT
and	I-OUT
efficacy	I-OUT
of	O
the	O
use	O
of	O
sirolimus	B-I
versus	I-I
azathioprine	I-I
in	O
one-haplotype	B-P
living	I-P
related	I-P
kidney	I-P
transplant	I-P
recipients-preliminary	I-P
results	O
.	O


FINDINGS	O
Two	B-P
patients	I-P
were	I-P
excluded	I-P
from	I-P
group	I-P
B	I-P
after	I-P
randomisation	I-P
.	I-P


INTERPRETATION	O
Autologous	B-I
implantation	I-I
of	I-I
bone	I-I
marrow-mononuclear	I-I
cells	I-I
could	O
be	O
safe	B-OUT
and	I-OUT
effective	I-OUT
for	O
achievement	O
of	O
therapeutic	B-OUT
angiogenesis	I-OUT
,	O
because	O
of	O
the	O
natural	O
ability	O
of	O
marrow	O
cells	O
to	O
supply	O
endothelial	O
progenitor	O
cells	O
and	O
to	O
secrete	O
various	O
angiogenic	O
factors	O
or	O
cytokines	O
.	O


Analysis	O
is	O
by	O
intention	O
to	O
treat	O
.	O


This	O
finding	O
offers	O
surgeons	O
,	O
for	O
now	O
,	O
enhanced	O
flexibility	O
in	O
planning	O
revascularization	O
.	O


Condylomata	O
acuminata	O
(	O
CA	O
)	O
caused	O
by	O
human	O
papillomavirus	O
(	O
HPV	O
)	O
is	O
a	O
common	O
sexually	O
transmitted	O
disease	O
with	O
half	O
a	O
million	O
new	O
cases	O
diagnosed	O
in	O
the	O
United	O
States	O
per	O
year	O
and	O
the	O
annual	O
increase	O
in	O
incidence	O
in	O
China	O
.	O


Ibopamine	B-I
is	O
a	O
dopaminergic	O
and	O
adrenergic	O
receptor	O
agonist	O
,	O
which	O
is	O
active	O
in	O
the	O
treatment	O
of	O
congestive	O
heart	O
failure	O
.	O


No	O
influence	O
on	O
heart	B-OUT
rhythm	I-OUT
was	O
noted	O
.	O


The	O
mean	O
number/hr	O
.	O


Given	O
the	O
widespread	O
use	O
of	O
MDMA	B-I
,	O
our	O
lack	O
of	O
knowledge	O
raises	O
concerns	O
.	O


Release	B-OUT
of	I-OUT
cortisol	I-OUT
but	O
not	O
of	O
prolactin	B-OUT
after	O
dexfenfluramine	B-I
administration	O
was	O
significantly	O
reduced	O
in	O
both	O
groups	O
of	O
ecstasy	O
users	O
compared	O
with	O
the	O
controls	O
.	O


Analyses	O
of	O
covariance	O
showed	O
that	O
likely	O
confounding	O
variables	O
including	O
recent	O
exposure	O
to	O
ecstasy	O
,	O
psychosocial	O
profiles	O
and	O
use	O
of	O
other	O
drugs	O
did	O
not	O
explain	O
the	O
differences	O
found	O
between	O
the	O
groups	O
.	O


CONCLUSIONS	O
These	O
results	O
provide	O
further	O
evidence	O
that	O
use	O
of	O
ecstasy	O
may	O
be	O
associated	O
with	O
impairment	B-OUT
of	I-OUT
memory	I-OUT
and	I-OUT
of	I-OUT
serotonergic	I-OUT
function	I-OUT
.	I-OUT


The	O
interventions	O
consisted	O
of	O
packets	B-I
of	I-I
green	I-I
tea	I-I
,	I-I
black	I-I
tea	I-I
,	I-I
caffeinated	I-I
water	I-I
,	I-I
or	I-I
placebo	I-I
.	O


Patients	B-P
received	I-P
oral	I-I
esomeprazole	I-I
40	I-I
mg	I-I
(	I-I
n	I-I
=	I-I
220	I-I
)	I-I
or	I-I
20	I-I
mg	I-I
(	I-I
n	I-I
=	I-I
226	I-I
)	I-I
or	I-I
placebo	I-I
(	I-I
n	I-I
=	I-I
229	I-I
)	I-I
once	I-I
daily	I-I
for	I-I
4	I-I
wk	I-I
.	I-I


Secondary	O
outcomes	O
included	O
resolution	B-OUT
of	I-OUT
sleep	I-OUT
disturbances	I-OUT
,	I-OUT
sleep	I-OUT
quality	I-OUT
measured	I-OUT
by	I-OUT
the	I-OUT
Pittsburgh	I-OUT
Sleep	I-OUT
Quality	I-OUT
Index	I-OUT
(	I-OUT
PSQI	I-OUT
)	I-OUT
questionnaire	I-OUT
,	I-OUT
and	I-OUT
work	I-OUT
productivity	I-OUT
measured	I-OUT
by	I-OUT
the	I-OUT
Work	I-OUT
Productivity	I-OUT
and	I-OUT
Activity	I-OUT
Impairment	I-OUT
Questionnaire	I-OUT
.	I-OUT


CONCLUSIONS	O
Esomeprazole	O
reduced	O
nighttime	O
heartburn	O
and	O
GERD-related	O
sleep	O
disturbances	O
and	O
improved	O
sleep	O
quality	O
and	O
work	O
productivity	O
.	O


OBJECTIVES	O
To	O
assess	B-OUT
and	I-OUT
compare	I-OUT
the	I-OUT
effectiveness	I-OUT
of	O
3	B-I
%	I-I
diclofenac	I-I
sodium	I-I
associated	O
with	O
2.5	B-I
%	I-I
hyaluronic	I-I
acid	I-I
and	I-I
of	I-I
5	I-I
%	I-I
5-Fluorouracil	I-I
for	O
the	O
treatment	O
of	O
actinic	O
keratosis	O
,	O
as	O
well	O
as	O
the	O
patient	O
's	O
degree	O
of	O
satisfaction	O
and	O
tolerability	O
.	O


There	O
was	O
a	O
high	O
degree	O
of	O
satisfaction	O
in	O
both	O
groups	O
(	O
73	O
%	O
in	O
the	O
diclofenac	B-I
sodium	O
group	O
and	O
77	O
%	O
in	O
the	O
5-Fluorouracil	B-I
group	O
;	O
p=0.827	O
)	O
.	O


At	O
the	O
time	O
of	O
enrollment	O
,	O
patients	O
were	O
stratified	O
according	O
to	O
diabetes	O
status	O
.	O


Among	O
diabetic	O
patients	O
randomized	O
to	O
tirofiban	O
(	O
n=560	O
)	O
,	O
the	O
incidence	B-OUT
of	I-OUT
death	I-OUT
,	I-OUT
myocardial	I-OUT
infarction	I-OUT
(	I-OUT
MI	I-OUT
)	I-OUT
,	I-OUT
or	I-OUT
urgent	I-OUT
TVR	I-OUT
at	O
30	O
days	O
was	O
6.2	O
%	O
,	O
and	O
among	O
those	O
randomized	O
to	O
abciximab	O
(	O
n=557	O
)	O
it	O
was	O
5.4	O
%	O
(	O
hazard	O
ratio	O
[	O
HR	O
]	O
1.16	O
;	O
P=0.540	O
)	O
.	O


At	O
6	O
months	O
,	O
the	O
composite	O
of	O
death	B-OUT
,	I-OUT
MI	I-OUT
,	I-OUT
or	I-OUT
any	I-OUT
TVR	I-OUT
occurred	O
in	O
15.7	O
%	O
and	O
in	O
16.9	O
%	O
of	O
tirofiban	O
and	O
abciximab	O
patients	O
,	O
respectively	O
(	O
HR	O
0.93	O
;	O
P=0.610	O
)	O
.	O


The	O
1-year	B-OUT
mortality	I-OUT
was	O
2.1	O
%	O
in	O
the	O
tirofiban	O
group	O
and	O
2.9	O
%	O
in	O
the	O
abciximab	O
group	O
(	O
HR	O
0.74	O
;	O
P=	O
0.436	O
)	O
.	O


This	O
study	O
evaluated	O
a	O
tailored	B-I
intervention	I-I
to	O
promote	B-I
sun	I-I
protection	I-I
in	O
parents	B-P
and	I-P
their	I-P
children	I-P
,	O
hypothesizing	O
that	O
the	O
tailored	O
intervention	O
would	O
lead	O
to	O
improved	B-OUT
skin	I-OUT
cancer	I-OUT
prevention	I-OUT
behaviors	I-OUT
compared	O
to	O
generic	O
materials	O
.	O


Eleven	B-P
subjects	I-P
using	I-P
insulin	I-I
plus	I-I
10	I-P
mg	I-P
glyburide	I-I
before	O
breakfast	O
had	O
lower	O
mean	O
fasting	O
glucose	O
at	O
10-16	O
weeks	O
than	O
10	O
subjects	O
using	O
insulin	O
with	O
placebo	B-I
(	O
mean	O
+/-	O
SEM	O
;	O
5.9	O
+/-	O
0.3	O
versus	O
7.5	O
+/-	O
0.7	O
mmol/L	O
;	O
p	O
less	O
than	O
0.05	O
)	O
,	O
and	O
had	O
a	O
greater	O
decrement	O
of	O
glycosylated	B-OUT
hemoglobin	I-OUT
from	O
baseline	O
values	O
(	O
1.3	O
+/-	O
0.1	O
versus	O
0.8	O
+/-	O
0.2	O
%	O
A1	O
,	O
p	O
less	O
than	O
0.05	O
)	O
.	O


These	O
data	O
support	O
this	O
form	O
of	O
combined	O
therapy	O
as	O
one	O
option	O
for	O
treating	O
obese	B-P
persons	I-P
with	I-P
type	I-P
2	I-P
diabetes	I-P
no	O
longer	O
responsive	O
to	O
oral	O
therapy	O
alone	O
.	O


The	O
reductions	O
in	O
FEV1	B-OUT
and	I-OUT
FVC	I-OUT
were	O
comparable	O
and	O
were	O
not	O
symptomatic	O
.	O


Study	O
patients	O
were	O
insulin	O
deficient	O
as	O
shown	O
by	O
low	O
baseline	B-OUT
C	I-OUT
peptide	I-OUT
values	I-OUT
(	I-OUT
0.43	I-OUT
+/-	O
0.05	O
nmol/L	O
)	O
.	O


BACKGROUND	O
Late-life	B-P
depression	I-P
is	O
associated	O
with	O
high	B-OUT
rates	I-OUT
of	I-OUT
morbidity	I-OUT
,	I-OUT
premature	I-OUT
mortality	I-OUT
,	I-OUT
disability	I-OUT
,	I-OUT
functional	I-OUT
decline	I-OUT
,	I-OUT
caregiver	I-OUT
burden	I-OUT
and	I-OUT
increased	I-OUT
health	I-OUT
care	I-OUT
costs	I-OUT
.	I-OUT


DISCUSSION	O
The	O
current	O
health	B-OUT
,	I-OUT
social	I-OUT
and	I-OUT
economic	I-OUT
costs	I-OUT
of	O
late-life	O
depression	O
make	O
prevention	O
imperative	O
from	O
a	O
public	O
health	O
perspective	O
.	O


The	O
main	O
results	O
are	O
expected	O
to	O
be	O
available	O
in	O
2017	O
.	O


Randomized	O
comparison	O
of	O
the	O
efficacy	B-OUT
and	I-OUT
safety	I-OUT
of	O
zotarolimus-eluting	B-I
stents	I-I
vs.	O
sirolimus-eluting	B-I
stents	I-I
for	O
percutaneous	B-P
coronary	I-P
intervention	I-P
in	I-P
chronic	I-P
total	I-P
occlusion	I-P
--	I-P
CAtholic	I-P
Total	I-P
Occlusion	I-P
Study	I-P
(	I-P
CATOS	I-P
)	I-P
trial	I-P
.	I-P


There	O
were	O
no	O
significant	O
between-group	O
differences	O
in	O
the	B-OUT
rate	I-OUT
of	I-OUT
TVF	O
(	O
10.0	O
%	O
vs.	O
17.5	O
%	O
;	O
P=0.168	O
)	O
nor	O
in	O
the	O
rate	O
of	O
ST	O
(	O
0.0	O
%	O
vs.	O
1.3	O
%	O
;	O
P=0.316	O
)	O
during	O
the	O
12-month	O
clinical	O
follow-up	O
.	O


After	O
each	O
study	O
phase	O
the	O
glomerular	B-OUT
filtration	I-OUT
rate	I-OUT
(	I-OUT
GFR	I-OUT
)	I-OUT
and	I-OUT
renal	I-OUT
plasma	I-OUT
flow	I-OUT
(	I-OUT
RPF	I-OUT
)	I-OUT
were	O
determined	O
.	O


In	O
the	O
combination	O
phase	O
,	O
RPF	B-OUT
increased	O
by	O
123	O
+/-	O
36	O
mL/min	O
(	O
P	O
<	O
0.01	O
)	O
.	O


CONCLUSION	O
The	O
use	O
of	O
abciximab	O
in	O
the	O
organization	O
phase	O
for	O
pPCI	O
results	O
in	O
signs	B-OUT
of	I-OUT
early	I-OUT
recanalization	I-OUT
of	I-OUT
the	I-OUT
infarct-related	I-OUT
artery	I-OUT
and	O
a	O
subsequent	O
improved	O
myocardial	B-OUT
tissue	I-OUT
reperfusion	I-OUT
.	I-OUT


FINDINGS	O
240	B-P
eligible	I-P
patients	I-P
were	I-P
recruited	I-P
from	I-P
six	I-P
Australian	I-P
centres	I-P
between	I-P
Sept	I-P
30	I-P
,	I-P
2005	I-P
,	I-P
and	I-P
Nov	I-P
19	I-P
,	I-P
2009	I-P
.	I-P


39	O
patients	O
(	O
32	O
%	O
)	O
in	O
the	O
standard	O
diagnosis	O
group	O
and	O
18	O
(	O
15	O
%	O
)	O
in	O
the	O
biomarker	O
diagnosis	O
group	O
received	O
empirical	O
antifungal	O
treatment	O
(	O
difference	O
17	O
%	O
,	O
95	O
%	O
CI	O
4-26	O
;	O
p=0·002	O
)	O
.	O


This	O
approach	O
is	O
an	O
effective	O
strategy	O
for	O
the	O
management	O
of	O
invasive	O
aspergillosis	O
in	B-P
high-risk	I-P
haematology	I-P
patients	I-P
.	O


MPIS	B-OUT
and	I-OUT
forced	I-OUT
expiratory	I-OUT
volume	I-OUT
in	I-OUT
1	I-OUT
second	I-OUT
(	I-OUT
FEV	I-OUT
(	I-OUT
1	I-OUT
)	I-OUT
)	I-OUT
were	O
recorded	O
before	O
administering	O
study	O
medication	O
and	O
thereafter	O
,	O
hourly	O
for	O
4	O
hours	O
.	O


Deliberate	B-OUT
hypotension	I-OUT
in	O
patients	B-P
with	I-P
intracranial	I-P
arteriovenous	I-P
malformations	I-P
:	I-P
esmolol	I-I
compared	O
with	O
isoflurane	B-I
and	I-I
sodium	I-I
nitroprusside	I-I
.	I-I


Although	O
esmolol	B-I
may	O
be	O
used	O
as	O
a	O
primary	O
hypotensive	O
agent	O
,	O
the	O
potential	O
for	O
marked	B-OUT
myocardial	I-OUT
depression	I-OUT
must	O
be	O
recognized	O
.	O


Treatment	O
of	O
acute	O
asthma	O
.	O


The	O
results	O
were	O
similar	O
when	O
the	O
patients	O
were	O
divided	O
in	O
accord	O
with	O
the	O
degree	O
of	O
respiratory	B-OUT
obstruction	I-OUT
(	O
baseline	O
FEV1	O
<	O
30	O
percent	O
of	O
predicted	O
)	O
and	O
theophylline	B-OUT
level	I-OUT
at	O
30	O
min	O
of	O
treatment	O
(	O
placebo	O
group	O
patients	O
with	O
theophylline	B-I
level	O
<	O
10	O
mg/L	O
vs	O
aminophylline	B-I
group	O
patients	O
with	O
theophylline	O
level	O
>	O
or	O
=	O
10	O
mg/L	O
)	O
.	O


Bifidobacteria	B-OUT
were	I-OUT
analysed	I-OUT
by	I-I
a	I-I
direct	I-I
PCR	I-I
method	I-I
in	I-I
fecal	I-I
samples	I-I
from	I-I
mothers	I-I
at	O
30-35	O
weeks	O
of	O
gestation	O
and	O
from	O
infants	O
at	O
1	O
month	O
of	O
age	O
and	O
from	O
breast-milk	B-I
samples	I-I
1	I-I
month	I-I
post-partum	I-I
.	I-I


Allergic	B-P
mothers	I-P
had	O
significantly	O
lower	O
amounts	O
of	O
bifidobacteria	B-OUT
in	O
breast-milk	O
compared	O
with	O
non-allergic	O
mothers	O
[	O
median	O
1.3	O
x	O
10	O
(	O
3	O
)	O
bacterial	O
cells/mL	O
(	O
IQR	O
22.4-3.0	O
x	O
10	O
(	O
3	O
)	O
)	O
vs.	O
5.6	O
x	O
10	O
(	O
3	O
)	O
bacterial	O
cells/mL	O
(	O
1.8	O
x	O
10	O
(	O
3	O
)	O
-1.8	O
x	O
10	O
(	O
4	O
)	O
)	O
,	O
respectively	O
,	O
(	O
P=0.004	O
)	O
]	O
,	O
and	O
their	O
infants	O
had	O
concurrently	O
lower	O
counts	O
of	O
bifidobacteria	B-OUT
in	I-OUT
feces	I-OUT
[	O
3.9	O
x	O
10	O
(	O
8	O
)	O
bacterial	O
cells/g	O
(	O
IQR	O
6.5	O
x	O
10	O
(	O
6	O
)	O
-1.5	O
x	O
10	O
(	O
9	O
)	O
)	O
in	O
infants	O
of	O
allergic	O
mothers	O
,	O
vs.	O
2.5	O
x	O
10	O
(	O
9	O
)	O
bacterial	O
cells/g	O
(	O
6.5	O
x	O
10	O
(	O
8	O
)	O
-3.2	O
x	O
10	O
(	O
10	O
)	O
)	O
in	O
infants	O
of	O
non-allergic	O
mothers	O
,	O
P=0.013	O
]	O
.	O


Cognitive	O
effects	O
of	O
lithium	B-I
carbonate	I-I
and	I-I
haloperidol	I-I
in	O
treatment-resistant	B-P
aggressive	I-P
children	I-P
.	I-P


[	B-I
Closure	I-I
of	I-I
persistent	I-OUT
foramen	I-OUT
ovale	I-OUT
-	O
the	O
last	O
closure	O
?	O
]	O
.	O


Effect	O
of	O
VX-770	B-I
in	O
persons	B-P
with	I-P
cystic	I-P
fibrosis	I-P
and	I-P
the	I-P
G551D-CFTR	I-P
mutation	I-P
.	I-P


None	O
of	O
the	O
subjects	O
withdrew	O
from	O
the	O
study	O
.	O


OBJECTIVE	O
To	O
compare	O
thermal	B-I
welding	I-I
tonsillectomy	I-I
(	I-I
TWT	I-I
)	I-I
with	I-I
bipolar	I-I
electrocautery	I-I
tonsillectomy	I-I
(	I-I
BET	I-I
)	I-I
procedure	I-I
.	I-I


Intraoperative	B-OUT
bleeding	I-OUT
,	I-OUT
operative	I-OUT
time	I-OUT
,	I-OUT
postoperative	I-OUT
pain	I-OUT
,	I-OUT
complication	I-OUT
rates	I-OUT
,	I-OUT
and	I-OUT
return	I-OUT
to	I-OUT
normal	I-OUT
diet	I-OUT
were	O
evaluated	O
.	O


Primary	B-OUT
hemorrhage	I-OUT
occurred	O
in	O
1	O
subject	O
of	O
the	O
BET	B-I
group	O
.	O


Results	O
held	O
across	O
formats	O
and	O
suggest	O
that	O
parent	O
management	O
training	O
can	O
provide	O
an	O
effective	B-OUT
intervention	I-OUT
for	I-OUT
parents	I-OUT
of	I-OUT
a	I-OUT
child	I-OUT
with	I-OUT
Asperger	I-OUT
syndrome	I-OUT
.	I-OUT


Improving	O
peer	B-OUT
engagement	I-OUT
of	O
children	B-P
with	I-P
autism	I-P
on	I-P
the	I-P
school	I-P
playground	I-P
:	I-P
a	O
randomized	O
controlled	O
trial	O
.	O


This	O
prolongation	O
was	O
not	O
associated	O
with	O
a	O
significant	O
reduction	O
in	O
the	O
total	B-OUT
cost	I-OUT
per	O
surviving	O
infant	O
(	O
tocolysis	O
,	O
$	O
38,593	O
+/-	O
$	O
40,887	O
versus	O
bed	O
rest	O
,	O
$	O
43,158	O
+/-	O
$	O
37,116	O
;	O
p	O
=	O
0.445	O
)	O
.	O


Patients	B-P
with	I-P
advanced	I-P
cancer	I-P
and	I-P
their	I-P
closest	I-P
relative	I-P
were	I-P
recruited	I-P
from	I-P
medical	I-P
,	I-P
surgical	I-P
,	I-P
and	I-P
oncological	I-P
departments	I-P
.	I-P


A	O
total	O
of	O
65.9	O
%	O
of	O
the	O
families	O
declined	O
participation	B-OUT
.	I-OUT


METHODS	O
Review	O
the	O
design	O
considerations	O
for	O
clinical	O
trials	O
in	O
children	B-P
with	I-P
autistic	I-P
disorder	I-P
accompanied	I-P
by	I-P
severe	I-P
tantrums	I-P
,	I-P
aggressive	I-P
and/or	I-P
self-injurious	I-P
behaviors	I-P
.	I-P


These	O
design	O
considerations	O
include	O
the	O
definition	O
of	O
inclusion	O
criteria	O
that	O
are	O
relevant	O
to	O
clinical	O
practice	O
and	O
matching	O
study	O
design	O
to	O
the	O
goal	O
of	O
evaluating	O
short-	O
and	O
long-term	O
effects	O
.	O


Vaginal	B-I
electrical	I-I
stimulation	I-I
of	I-I
the	I-I
pelvic	I-I
floor	I-I
:	I-I
a	O
randomized	O
feasibility	O
study	O
in	O
urinary	B-P
incontinent	I-P
elderly	I-P
women	I-P
.	I-P


Twenty-four	B-P
women	I-P
treated	I-P
with	I-P
ES	I-I
and	I-P
11	I-P
women	I-P
treated	I-P
with	I-P
Kegel	I-I
exercises	I-I
completed	O
the	O
8-week	O
study	O
program	O
.	O


RESULTS	O
No	O
significant	O
improvement	O
in	O
objective	O
outcome	O
variables	O
was	O
observed	O
in	O
the	O
population	O
treated	O
with	O
ES	B-I
compared	O
with	O
the	O
population	O
treated	O
with	O
KE	B-I
(	O
with	O
29.2	O
%	O
vs.	O
36.4	O
%	O
of	O
the	O
women	O
showing	O
objective	O
improvement	O
in	O
measured	B-OUT
urinary	I-OUT
leakage	I-OUT
)	I-OUT
.	O


CONCLUSIONS	O
Although	O
the	O
number	O
of	O
enrolled	O
women	O
was	O
very	O
small	O
this	O
study	O
shows	O
that	O
:	O
1	O
.	O


RESULTS	O
There	O
was	O
a	O
significant	B-OUT
improvement	I-OUT
in	I-OUT
knowledge	I-OUT
about	I-OUT
schizophrenia	I-OUT
in	O
the	O
experimental	O
group	O
and	O
a	O
significant	B-OUT
difference	I-OUT
in	I-OUT
symptom	I-OUT
scores	I-OUT
and	I-OUT
functioning	I-OUT
at	O
9	O
months	O
after	O
discharge	O
.	O


Children	B-P
were	O
matched	O
on	O
CA	O
,	O
IQ	O
,	O
and	O
autistic	O
symptoms	O
before	O
being	O
randomly	O
assigned	O
to	O
LEGO	B-I
or	O
SULP	B-I
.	I-I


Therapy	O
occurred	O
for	O
1	B-P
h/week	I-P
over	I-P
18	I-P
weeks	I-P
.	I-P


The	O
incidence	O
of	O
adverse	B-OUT
events	I-OUT
(	I-OUT
rise	I-OUT
in	I-OUT
serum	I-OUT
creatinine	I-OUT
and	I-OUT
fall	I-OUT
in	I-OUT
serum	I-OUT
potassium	I-OUT
,	I-OUT
loss	I-OUT
of	I-OUT
appetite	I-OUT
and	I-OUT
shivering	I-OUT
,	I-OUT
rigor	I-OUT
and	I-OUT
fever	I-OUT
during	I-OUT
infusion	I-OUT
indicative	I-OUT
of	I-OUT
renal	I-OUT
,	I-OUT
GIT	I-OUT
and	I-OUT
infusion	I-OUT
related	I-OUT
toxicities	I-OUT
respectively	I-OUT
)	I-OUT
was	O
similar	O
in	O
the	O
three	O
groups	O
.	O


Soluble	B-I
intercellular	I-I
adhesion	I-I
molecule-1	I-I
in	O
primary	B-P
biliary	I-P
cirrhosis	I-P
:	I-P
effect	O
of	O
ursodeoxycholic	B-I
acid	I-I
and	O
immunosuppressive	B-I
therapy	I-I
.	I-I


Further	O
reductions	O
were	O
achieved	O
by	O
adding	O
prednisone	B-I
and	I-I
azathioprine	I-I
.	I-I


RESULTS	O
Results	O
of	O
the	O
promoter	O
methylation	O
of	O
MGMT	O
genes	O
showed	O
that	O
methylation	O
rate	O
was	O
20.00	O
%	O
in	O
the	O
treatment	O
group	O
and	O
46.67	O
%	O
in	O
the	O
control	O
group	O
(	O
P	O
<	O
0.05	O
)	O
.	O


The	O
toxic/adverse	B-OUT
reactions	I-OUT
were	O
milder	O
in	O
the	O
treatment	O
group	O
than	O
in	O
the	O
control	O
group	O
(	O
P	O
<	O
0.01	O
)	O
.	O


ATRA	B-I
has	O
no	O
overall	O
effect	O
on	O
treatment	O
outcomes	O
in	O
this	O
group	O
of	O
patients	O
.	O


The	O
blood	O
from	O
40	B-P
aspirin-naïve	I-P
volunteers	I-P
with	I-P
at	I-P
least	I-P
one	I-P
cardiovascular	I-P
risk	I-P
factor	I-P
was	O
preincubated	O
in	O
vitro	O
with	B-I
verbascoside	I-I
(	O
1	O
and	O
2	O
mg/dL	O
)	O
and	B-I
aspirin	I-I
(	O
100	O
μM	O
)	O
.	O


As	O
compared	O
to	O
reference	O
,	O
preincubation	O
with	O
verbascoside	O
resulted	O
in	O
a	O
significant	B-OUT
inhibition	I-OUT
of	I-OUT
adenosine	I-OUT
diphosphate	I-OUT
(	I-OUT
ADP	I-OUT
)	I-OUT
and	I-OUT
arachidonic	I-OUT
acid	I-OUT
(	I-OUT
AA	I-OUT
)	I-OUT
-induced	I-OUT
PA	O
(	O
p	O
<	O
0.01	O
for	O
both	B-I
)	I-I
.	I-I


Whereas	O
the	O
results	O
of	O
the	O
treatment	O
were	O
nearly	O
identical	O
in	O
both	O
groups	O
of	O
treatment	O
with	O
badly	O
differentiated	O
carcinomas	O
,	O
a	O
significant	O
improvement	O
could	O
be	O
achieved	O
by	O
the	O
initial	O
local	O
treatment	O
of	O
well	O
and	O
moderately	O
differentiated	O
malignancies	O
.	O


Effectiveness	O
of	O
a	O
clinical	B-I
intervention	I-I
in	O
improving	O
pain	O
control	O
in	O
outpatients	B-P
with	I-P
cancer	I-P
treated	I-P
by	I-P
radiation	I-I
therapy	I-I
.	I-I


Results	O
showed	O
that	O
the	O
experimental	O
group	O
patients	O
decreased	O
their	O
pain	O
levels	O
more	O
than	O
the	O
control	O
group	O
patients	O
did	O
over	O
time	O
.	O


Each	O
person	O
shall	O
receive	O
therapy	B-I
in	O
an	O
out-patient	O
setting	O
in	O
groups	O
of	O
3-4	O
.	O


Of	O
these	O
12	O
,	O
one	O
was	O
lost	O
to	O
follow-up	O
and	O
four	O
did	O
not	O
receive	O
brachytherapy	B-I
because	O
they	O
were	O
unfit	O
,	O
had	O
extension	O
into	O
the	O
cardia	O
or	O
had	O
mainly	O
extrinsic	O
compression	O
.	O


A	B-P
total	I-P
of	I-P
480	I-P
subjects	I-P
aged	I-P
28-75	I-P
were	I-P
enrolled	I-P
in	I-P
this	I-P
study	I-P
from	I-P
September	I-P
2005-December	I-P
2005	I-P
from	I-P
six	I-P
hospitals	I-P
in	I-P
different	I-P
Chinese	I-P
regions	I-P
.	I-P


The	O
results	O
of	O
this	O
study	O
have	O
shown	O
that	O
interactions	O
among	O
homocysteine	O
metabolism	O
gene	O
polymorphisms	O
lead	O
to	O
dramatic	O
elevations	O
in	O
the	O
folate	O
deficiency	O
risk	O
.	O


A	O
double-blind	O
placebo-controlled	O
study	O
examined	O
the	O
effect	O
of	O
a	O
single	O
dose	O
of	O
synthetic	B-I
human	I-I
secretin	I-I
on	O
aberrant	B-OUT
behavior	I-OUT
.	I-OUT


By	O
parent	O
and	O
teacher	O
report	O
,	O
the	O
majority	O
of	O
change	O
occurred	O
either	O
on	O
the	O
placebo	B-I
trial	O
or	O
reflected	O
deterioration	O
subsequent	O
to	O
secretin	B-I
infusion	O
.	O


BACKGROUND	O
GS-9620	B-I
is	O
a	O
novel	O
oral	O
agonist	O
of	O
Toll-like	O
receptor	O
7	O
(	O
TLR7	O
)	O
in	O
development	O
for	O
the	O
treatment	O
of	O
chronic	O
viral	O
hepatitis	O
.	O


RESULTS	O
GS-9620	B-I
was	O
well-absorbed	B-OUT
and	I-OUT
well-tolerated	I-OUT
in	O
oral	O
doses	O
up	O
to	O
12	O
mg	O
.	O


Previous	O
investigators	O
have	O
demonstrated	O
enhanced	O
detection	O
of	O
atrial	B-OUT
defects	I-OUT
by	O
the	O
dye-dilution	O
technique	O
after	O
delivery	O
of	O
contrast	O
medium	O
into	O
the	O
inferior	O
rather	O
than	O
the	O
superior	O
vena	O
cava	O
.	O


Precordial	O
echocardiography	O
combined	O
with	O
femoral	O
contrast	O
delivery	O
was	O
significantly	O
more	O
sensitive	B-OUT
than	O
cardiac	O
catheterization	O
for	O
assessment	B-OUT
of	I-OUT
patent	I-OUT
foramen	I-OUT
ovale	I-OUT
(	O
8	O
of	O
21	O
patients	O
vs.	O
2	O
of	O
21	O
patients	O
,	O
p	O
<	O
0.05	O
)	O
.	O


Antihypertensive	B-I
therapy	I-I
resulted	O
in	O
significant	O
blood	B-OUT
pressure	I-OUT
reduction	I-OUT
(	O
p	O
less	O
than	O
.01	O
)	O
.	O


Risperidone	B-I
improves	O
behavioral	B-OUT
symptoms	I-OUT
in	O
children	B-P
with	I-P
autism	I-P
in	O
a	O
randomized	O
,	O
double-blind	O
,	O
placebo-controlled	B-I
trial	O
.	O


One	B-P
hundred	I-P
seventy-seven	I-P
women	I-P
aged	I-P
41	I-P
+/-	I-P
8	I-P
(	I-P
mean	I-P
+/-	I-P
SD	I-P
)	I-P
years	I-P
,	I-P
referred	I-P
for	I-P
evaluation	I-P
of	I-P
excessive	I-P
uterine	I-P
bleeding	I-P
,	I-P
were	I-P
enrolled	I-P
in	O
an	O
open-label	O
randomized	O
trial	O
to	O
evaluate	O
the	O
efficacy	O
of	O
local	B-I
anesthesia	I-I
before	O
hysteroscopy	B-OUT
in	I-P
an	I-P
outpatient	I-P
population	I-P
.	I-P


The	O
patients	O
underwent	O
hysteroscopy	B-OUT
and	I-I
endometrial	I-I
biopsy	I-I
with	I-I
paracervical	I-I
block	I-I
by	I-I
10	I-I
mL	I-I
of	I-I
1	I-I
%	I-I
mepivacaine	I-I
hydrochloride	I-I
solution	I-I
(	O
n	O
=	O
87	O
)	O
or	O
no	B-I
local	I-I
anesthesia	I-I
(	O
n	O
=	O
90	O
)	O
and	O
assessed	O
lower	O
abdominal	O
and	O
pelvic	O
pain	O
according	O
to	O
a	O
10-point	O
linear	O
analog	O
scale	O
.	O


METHOD	O
Thirty-nine	B-P
subjects	I-P
(	I-P
intent	I-P
to	I-P
treat	I-P
;	I-P
5-19	I-P
years	I-P
old	I-P
;	I-P
IQ	I-P
>	I-P
35	I-P
)	I-P
had	I-P
autism	I-P
diagnosed	I-P
according	I-P
to	I-P
DSM-IV	I-P
and	I-P
ICD-10	I-P
criteria	I-P
using	I-P
the	I-P
Autism	I-P
Diagnostic	I-P
Interview-Revised	I-P
and	I-P
the	I-P
Autism	I-P
Diagnostic	I-P
Observation	I-P
Schedule-Generic	I-P
.	I-P


However	O
,	O
in	O
the	O
amantadine-treated	B-I
group	O
there	O
were	O
statistically	O
significant	O
improvements	O
in	O
absolute	O
changes	O
in	O
clinician-rated	O
ABC-CVs	B-OUT
for	I-OUT
hyperactivity	I-OUT
(	O
amantadine	O
-6.4	O
versus	O
placebo	O
-2.1	O
;	O
p	O
=	O
.046	O
)	O
and	O
inappropriate	B-OUT
speech	I-OUT
(	O
-1.9	O
versus	O
0.4	O
;	O
p	O
=	O
.008	O
)	O
.	O


CONCLUSIONS	O
Parents	O
did	O
not	O
report	O
statistically	O
significant	O
behavioral	B-OUT
change	I-OUT
with	O
amantadine	O
.	O


The	O
design	O
of	O
these	O
and	O
similar	O
drug	O
trials	O
in	O
children	B-P
with	I-P
autistic	I-P
disorder	I-P
must	O
take	O
into	O
account	O
the	O
possibility	O
of	O
a	O
large	O
placebo	O
response	O
.	O


[	O
Does	O
urapidil	B-I
attenuate	O
the	O
hypertensive	B-OUT
response	I-OUT
to	I-OUT
tracheal	I-OUT
intubation	I-OUT
at	I-P
the	I-P
time	I-P
of	I-P
general	I-P
anesthesia	I-P
?	O
]	O
.	O


Economic	B-OUT
data	I-OUT
included	I-OUT
health	I-OUT
,	I-OUT
education	I-OUT
and	I-OUT
social	I-OUT
services	I-OUT
,	I-OUT
childcare	I-OUT
,	I-OUT
parental	I-OUT
productivity	I-OUT
losses	I-OUT
and	I-OUT
informal	I-OUT
care	I-OUT
.	O


TRIAL	O
REGISTRATION	O
Current	O
Controlled	O
Trials	O
ISRCTN58133827	O
.	O


First	O
,	O
bivariate	O
analysis	O
,	O
using	O
anova	O
for	O
continuous	O
variables	O
and	O
Chi-square	O
test	O
for	O
categorical	O
variables	O
,	O
was	O
performed	O
to	O
identify	O
possible	O
predictors	O
of	O
eltrombopag	O
dose	O
(	O
P	O
<	O
0.05	O
)	O
.	O


Ordinal	O
logistic	O
model	O
identified	O
several	O
predictors	O
of	O
eltrombopag	O
dose	O
.	O


Early	O
selection	O
of	O
the	O
optimal	O
eltrombopag	O
dose	O
expedites	O
the	O
initiation	O
of	O
antiviral	O
therapy	O
.	O


We	O
conducted	O
a	O
controlled	O
,	O
randomized	O
trial	O
with	O
enoxaparin	O
in	O
the	O
treatment	O
of	O
established	O
deep	O
vein	O
thrombosis	O
.	O


METHODS	O
In	O
a	O
multicenter	O
trial	O
,	O
we	O
compared	O
fixed-dose	O
subcutaneous	O
enoxaparin	B-I
,	O
given	O
twice	O
daily	O
,	O
with	O
adjusted-dose	O
intravenous	O
unfractionated	B-I
heparin	I-I
(	I-I
UFH	I-I
)	I-I
given	O
by	O
continuous	O
intravenous	O
infusion	O
for	O
the	O
initial	O
10	O
days	O
of	O
treatment	O
of	O
patients	B-P
with	I-P
proximal	I-P
vein	I-P
thrombosis	I-P
.	I-P


RESULTS	O
There	B-P
were	I-P
67	I-P
patients	I-P
in	I-P
each	I-P
group	I-P
.	I-P


Thus	O
,	O
our	O
study	O
confirmed	O
,	O
with	O
the	O
use	O
of	O
enoxaparin	B-I
,	O
other	O
observations	O
that	O
low-molecular-weight	B-I
heparin	I-I
provides	O
a	O
real	O
therapeutic	O
advance	O
in	O
the	O
treatment	O
of	O
deep	B-P
vein	I-P
thrombosis	I-P
.	I-P


Measurement	O
of	O
health-related	B-OUT
quality	I-OUT
of	I-OUT
life	I-OUT
in	O
multiple	B-P
myeloma	I-P
.	I-P


Nordic	O
Myeloma	O
Study	O
Group	O
.	O


524	B-P
(	I-P
90.2	I-P
%	I-P
)	I-P
of	I-P
581	I-P
patients	I-P
enrolled	I-P
in	I-P
the	I-P
NMSG	I-P
4/90	I-P
completed	I-P
the	I-P
first	I-P
questionnaire	I-P
,	I-P
and	I-P
484	I-P
(	I-P
83.3	I-P
%	I-P
)	I-P
completed	I-P
all	I-P
questionnaires	I-P
given	I-P
to	I-P
them	I-P
.	I-P


Validity	O
was	O
shown	O
by	O
(	O
1	O
)	O
the	O
ability	O
of	O
the	O
scales	O
to	O
discriminate	O
clearly	O
between	O
patients	O
differing	O
in	O
clinical	O
status	O
as	O
defined	O
by	O
pretreatment	O
W.H.O	O
.	O


The	B-OUT
results	I-OUT
demonstrate	I-OUT
that	I-OUT
the	I-OUT
QLQ-C30	I-OUT
is	I-OUT
a	I-OUT
reliable	I-OUT
and	I-OUT
valid	I-OUT
instrument	I-OUT
for	I-OUT
the	I-OUT
measurement	I-OUT
of	I-OUT
quality	I-OUT
of	I-OUT
life	I-OUT
in	I-OUT
these	I-OUT
patients	I-OUT
.	I-OUT


Environmental	O
enrichment	O
as	O
an	O
effective	O
treatment	O
for	O
autism	B-OUT
:	I-OUT
a	O
randomized	O
controlled	O
trial	O
.	O


Given	O
the	O
sensorimotor	O
deficits	O
in	O
most	O
children	B-P
with	I-P
autism	I-P
,	O
we	O
attempted	O
to	O
translate	O
that	O
approach	O
to	O
their	O
treatment	O
.	O


Indeed	O
,	O
42	O
%	O
of	O
the	O
enriched	O
group	O
and	O
only	O
7	O
%	O
of	O
the	O
control	O
group	O
had	O
what	O
we	O
considered	O
to	O
be	O
a	O
clinically	O
significant	O
improvement	O
of	O
5	O
points	O
on	O
that	O
scale	O
.	O


Sensorimotor	O
enrichment	O
also	O
produced	O
a	O
clear	B-OUT
improvement	I-OUT
in	I-OUT
cognition	I-OUT
,	O
as	O
determined	O
by	O
their	O
Leiter-R	O
Visualization	O
and	O
Reasoning	O
scores	O
.	O


Environmental	O
enrichment	O
therefore	O
appears	O
to	O
be	O
effective	O
in	O
ameliorating	B-OUT
some	I-OUT
of	I-OUT
the	I-OUT
symptoms	I-OUT
of	I-OUT
autism	I-OUT
in	O
children	O
.	O


The	O
study	O
took	O
place	O
in	O
four	B-P
intervention	I-P
and	I-P
six	I-P
control	I-P
neighborhoods	I-P
in	I-P
Seattle	I-P
.	I-P


Particularly	O
in	O
patients	B-P
with	I-P
prolonged	I-P
neutropenia	I-P
,	O
subsequent	O
adaptation	O
of	O
such	O
a	O
regimen	O
will	O
be	O
the	O
rule	O
rather	O
than	O
exception	O
.	O


Calcium	B-I
channel	I-I
blocker	I-I
inhibition	I-I
of	I-I
AGE	I-I
and	I-I
RAGE	I-I
axis	O
limits	O
renal	B-OUT
injury	I-OUT
in	O
nondiabetic	B-P
patients	I-P
with	I-P
stage	I-P
I	I-P
or	I-P
II	I-P
chronic	I-P
kidney	I-P
disease	I-P
.	I-P


BACKGROUND	O
There	O
is	O
a	O
growing	O
body	O
of	O
evidence	O
that	O
advanced	O
glycation	O
end	O
products	O
(	O
AGE	O
)	O
and	O
their	O
receptor	O
(	O
RAGE	O
)	O
system	O
are	O
implicated	O
in	O
chronic	O
kidney	O
disease	O
(	O
CKD	O
)	O
.	O


We	O
have	O
previously	O
found	O
that	O
a	O
long-acting	O
calcium	B-I
channel	I-I
blocker	I-I
,	I-I
azelnidipine	I-I
,	I-I
but	I-I
not	I-I
amlodipine	I-I
,	O
improves	O
renal	B-OUT
injury	I-OUT
in	O
CKD	O
patients	O
.	O


HYPOTHESIS	O
We	O
hypothesized	O
that	O
azelnidipine	B-I
treatment	O
could	O
limit	O
renal	O
injury	O
partly	O
by	O
blocking	O
the	O
AGE-RAGE	B-OUT
axis	I-OUT
.	I-OUT


OBJECTIVES	O
To	O
determine	O
the	O
efficacy	O
of	O
2	O
distinct	O
6-week	O
robot-assisted	B-I
reaching	I-I
programs	I-I
compared	O
with	O
an	O
intensive	O
conventional	B-I
arm	I-I
exercise	I-I
program	I-I
(	O
ICAE	O
)	O
for	O
chronic	B-OUT
,	I-OUT
stroke-related	I-OUT
upper-extremity	I-OUT
(	I-OUT
UE	I-OUT
)	I-OUT
impairment	O
.	O


DESIGN	O
Randomized	O
controlled	O
trial	O
,	O
single-blinded	O
,	O
with	O
12-week	O
follow-up	O
.	O


CONCLUSIONS	B-OUT
Chronic	I-OUT
UE	O
deficits	O
because	O
of	O
stroke	B-OUT
are	O
responsive	O
to	O
intensive	O
motor	O
task	O
training	O
.	O


Isometric	B-I
contractions	I-I
reduce	O
plantar	B-OUT
flexor	I-OUT
moment	I-OUT
,	I-OUT
Achilles	I-OUT
tendon	I-OUT
stiffness	I-OUT
,	I-OUT
and	I-OUT
neuromuscular	I-OUT
activity	I-OUT
but	O
remove	O
the	O
subsequent	O
effects	O
of	O
stretch	O
.	O


Second	O
,	O
the	O
subjects	O
performed	O
six	B-I
8-s	I-I
maximal	I-I
voluntary	I-I
isometric	I-I
contractions	I-I
(	I-I
MVICs	I-I
)	I-I
before	I-I
repeating	I-I
the	I-I
passive	I-I
and	I-I
active	I-I
trials	I-I
.	I-I


Use	O
of	O
antecedent	B-I
aerobic	I-I
exercise	I-I
to	O
reduce	O
maladaptive	B-OUT
and	I-OUT
stereotypic	I-OUT
behaviors	I-OUT
of	O
adults	B-P
with	I-P
both	I-P
autism	I-P
and	I-P
mental	I-P
retardation	I-P
is	O
supported	O
.	O


There	O
were	O
no	O
significant	O
differences	O
in	O
the	O
logarithm	O
of	O
the	O
heart	B-OUT
rate	I-OUT
,	I-OUT
recovery	I-OUT
time	I-OUT
or	I-OUT
quality	I-OUT
of	I-OUT
recovery	I-OUT
between	O
the	O
three	O
induction	O
groups	O
.	O


Treatment	B-I
involved	I-I
12	I-I
weekly	I-I
group	I-I
sessions	I-I
and	I-I
was	I-I
compared	I-I
with	I-I
a	I-I
waiting	I-I
list	I-I
condition	I-I
.	I-I


Discussion	O
focuses	O
on	O
the	O
implications	O
for	O
the	O
use	O
of	O
cognitive	O
behaviour	O
therapy	O
with	O
HFA	B-P
children	I-P
,	O
for	O
theory	O
of	O
mind	O
research	O
and	O
for	O
further	O
research	O
on	O
the	O
treatment	O
components	O
.	O


Among	O
the	O
552	B-P
participants	I-P
who	I-P
completed	I-P
the	I-P
follow-up	I-P
examination	I-P
,	I-P
94	I-P
stopped	I-P
treatment	I-P
early	I-P
.	I-P


DESIGN	O
A	O
prospective	O
,	O
investigator-masked	O
,	O
randomized	O
,	O
controlled	O
comparative	O
study	O
involving	O
36	B-P
eyes	I-P
of	I-P
34	I-P
patients	I-P
with	I-P
functioning	I-P
filtering	I-P
blebs	I-P
who	I-P
were	I-P
to	I-P
undergo	I-P
cataract	I-P
surgery	I-P
.	I-P


The	O
main	O
outcome	O
measure	O
was	O
antibiotic	B-OUT
concentration	I-OUT
measured	O
by	O
chromatographic	O
separation	O
and	O
mass	O
spectrometry	O
of	O
aqueous	O
samples	O
obtained	O
during	O
surgery	O
.	O


With	O
combined	O
topical	O
and	O
oral	O
therapy	O
,	O
significantly	O
more	O
ofloxacin	O
was	O
measured	O
than	O
ciprofloxacin	O
(	O
3.84	O
microg/mL	O
vs	O
0.35	O
microg/mL	O
[	O
P	O
<	O
.001	O
]	O
)	O
.	O


A	O
randomized	O
double-blind	O
clinical	O
trial	O
of	O
griseofulvin	B-I
treatment	O
.	O


The	O
role	O
of	O
the	O
MA-sensitive	O
chemotaxis	O
in	O
rheumatoid	O
arthritis	O
could	O
thus	O
be	O
elucidated	O
by	O
a	O
clinical	O
trial	O
of	O
griseofulvin	B-I
treatment	O
.	O


Moreover	O
,	O
the	O
placebo-treated	B-I
patients	O
showed	O
more	O
improvement	B-OUT
than	O
the	O
griseofulvin-treated	B-I
patients	O
.	O


It	O
is	O
therefore	O
suggested	O
that	O
the	O
MA-sensitive	O
chemotaxis	O
plays	O
a	O
reparative	O
role	O
in	O
the	O
inflammatory	O
lesions	O
of	O
rheumatoid	O
arthritis	O
.	O


The	O
effects	O
of	O
the	O
angiotensin-converting	B-I
enzyme	I-I
lisinopril	I-I
were	O
compared	O
with	O
those	O
of	O
the	O
calcium	B-I
antagonist	I-I
nifedipine	I-I
in	O
162	B-P
non-insulin-dependent	I-P
diabetic	I-P
hypertensive	I-P
patients	I-P
for	O
a	O
24-week	O
period	O
.	O


Fasting	B-OUT
and	I-OUT
post-prandial	I-OUT
plasma	I-OUT
glucose	I-OUT
,	I-OUT
glycosylated	I-OUT
haemoglobin	I-OUT
and	I-OUT
plasma	I-OUT
lipids	I-OUT
appeared	O
to	O
be	O
unaffected	O
by	O
either	O
agent	O
.	O


Finally	O
,	O
both	O
lisinopril	B-I
and	O
nifedipine	B-I
showed	O
a	O
similar	O
antihypertensive	B-OUT
effect	I-OUT
in	O
these	O
patients	O
which	O
was	O
not	O
associated	O
with	O
significant	O
differences	O
in	O
plasma	O
glucose	O
,	O
insulin	O
or	O
lipid	O
concentrations	O
.	O


This	O
conflict	O
may	O
inhibit	O
people	B-P
's	I-P
response	O
to	O
the	O
advantageous	O
but	O
unfair	O
outcomes	O
.	O


In	O
further	O
accordance	O
with	O
our	O
line	O
of	O
reasoning	O
,	O
the	O
effect	O
is	O
particularly	O
pronounced	O
among	O
those	O
who	O
adhere	O
to	O
a	O
prosocial	O
orientation	O
or	O
who	O
have	O
adopted	O
a	O
prosocial	O
mindset	O
and	O
is	O
not	O
observed	O
among	O
those	O
with	O
proself	O
orientations	O
or	O
mindsets	O
.	O


Thirty	O
minutes	O
after	O
rectal	O
administration	O
of	O
midazolam	B-I
,	O
patients	O
showed	O
a	O
decrease	O
in	O
both	O
systolic	B-OUT
and	I-OUT
diastolic	I-OUT
blood	I-OUT
pressure	I-OUT
and	I-OUT
heart	I-OUT
rate	I-OUT
.	I-OUT


Demographic	B-P
,	I-P
antepartum	I-P
,	I-P
and	I-P
intrapartum	I-P
characteristics	I-P
were	I-P
similar	I-P
between	I-P
the	I-P
groups	I-P
.	I-P


Hemoglobin	B-OUT
difference	I-OUT
before	I-OUT
and	I-OUT
after	I-OUT
delivery	I-OUT
,	I-OUT
need	I-OUT
for	I-OUT
second	I-OUT
or	I-OUT
third	I-OUT
uterotonic	I-OUT
agent	I-OUT
,	I-OUT
and	I-OUT
all	I-OUT
measured	I-OUT
neonatal	I-OUT
variables	I-OUT
including	I-OUT
birth	I-OUT
weights	I-OUT
,	I-OUT
and	I-OUT
umbilical	I-OUT
cord	I-OUT
pH	I-OUT
were	O
similar	O
between	O
the	O
groups	O
.	O


These	O
results	O
suggest	O
that	O
intrapleural	O
instillation	O
using	O
a	O
combination	O
of	O
anti-cancer	B-I
agent	I-I
and	I-I
immunopotentiator	I-I
is	O
an	O
effective	O
treatment	O
for	O
malignant	O
pleurisy	O
.	O


Cardiac	O
tamponade	O
secondary	O
to	O
cancer	O
is	O
a	O
life-threatening	O
complication	O
requiring	O
immediate	O
treatment	O
.	O


It	O
was	O
considered	O
that	O
local	O
instillation	O
of	O
anti-cancer	B-I
agents	I-I
with	O
pericardial	B-I
drainage	I-I
was	O
a	O
useful	O
therapeutic	O
modality	O
for	O
malignant	O
pericarditis	O
.	O


Topical	B-I
retapamulin	I-I
ointment	I-I
(	O
1	O
%	O
,	O
wt/wt	O
)	O
twice	O
daily	O
for	O
5	O
days	O
versus	O
oral	O
cephalexin	B-I
twice	O
daily	O
for	O
10	O
days	O
in	O
the	O
treatment	O
of	O
secondarily	B-P
infected	I-P
dermatitis	I-P
:	I-P
results	O
of	O
a	O
randomized	O
controlled	O
trial	O
.	O


BACKGROUND	O
New	O
antibacterial	O
agents	O
with	O
activity	O
against	O
pathogenic	O
strains	O
resistant	O
to	O
established	O
antibiotics	O
are	O
needed	O
to	O
treat	O
patients	B-P
with	I-P
secondarily	I-P
infected	I-P
dermatitis	I-P
(	I-P
SID	I-P
)	I-P
.	I-P


OBJECTIVE	O
We	O
sought	O
to	O
determine	O
the	O
clinical	O
safety	O
and	O
efficacy	O
of	O
topical	B-I
retapamulin	I-I
ointment	I-I
1	O
%	O
versus	O
oral	O
cephalexin	B-I
for	O
the	O
treatment	O
of	O
SID	O
.	O


Microbiologic	B-OUT
success	I-OUT
rates	I-OUT
at	O
follow-up	O
were	O
87.2	O
%	O
for	O
retapamulin	B-I
and	O
91.8	O
%	O
for	O
cephalexin	B-I
.	I-I


The	O
antidepressant	B-I
venlafaxine	I-I
(	O
150	O
mg	O
daily	O
)	O
and	O
the	O
dopamine	B-I
agonist	I-I
pramipexole	I-I
(	O
1.5	O
mg	O
daily	O
)	O
were	O
evaluated	O
in	O
the	O
second	O
study	O
.	O


Secondary	O
measures	O
included	O
assessments	B-OUT
of	I-OUT
cocaine	I-OUT
craving	I-OUT
and	I-OUT
psychiatric	I-OUT
functioning	I-OUT
.	I-OUT


There	O
were	O
trends	O
for	O
BE	B-OUT
levels	I-OUT
to	O
become	O
reduced	O
in	O
the	O
pentoxifylline	B-I
group	O
during	O
the	O
first	O
4	O
weeks	O
of	O
treatment	O
and	O
for	O
Addiction	B-OUT
Severity	I-OUT
Index	I-OUT
(	I-OUT
ASI	I-OUT
)	I-OUT
drug	O
composite	O
scores	O
to	O
be	O
lower	O
in	O
the	O
pentoxyfylline	B-I
group	O
at	O
end-point	O
compared	O
to	O
the	O
placebo	O
group	O
.	O


Significant	O
within-group	O
reductions	O
in	O
reported	O
cocaine	B-OUT
use	I-OUT
and	I-OUT
craving	I-OUT
were	O
found	O
for	O
all	O
treatment	O
groups	O
,	O
but	O
none	O
of	O
the	O
active	O
medications	O
were	O
superior	O
to	O
placebo	B-I
on	O
these	O
measures	O
.	O


Exercise	O
echocardiography	O
demonstrates	O
biventricular	O
systolic	O
dysfunction	O
and	O
reveals	O
decreased	O
left	O
ventricular	O
contractile	O
reserve	O
in	O
children	B-P
after	I-P
tetralogy	I-P
of	I-P
Fallot	I-P
repair	I-P
.	I-P


METHODS	O
Twenty-nine	B-P
children	I-P
(	I-P
age	I-P
range	I-P
,	I-P
5-18	I-P
years	I-P
)	I-P
with	I-P
repaired	I-P
TOF	I-P
and	I-P
44	I-P
healthy	I-P
controls	I-P
were	O
prospectively	O
evaluated	O
.	O


RESULTS	O
Children	B-P
with	I-P
repaired	I-P
TOF	I-P
had	O
dilated	O
right	O
ventricles	O
(	O
RV	O
end-diastolic	O
volume	O
index	O
=	O
153	O
±	O
37.3	O
mL/m	O
(	O
2	O
)	O
)	O
but	O
normal	O
ejection	O
fractions	O
as	O
measured	O
on	O
magnetic	O
resonance	O
imaging	O
(	O
LV	O
ejection	O
fraction	O
=	O
59.3	O
±	O
6.2	O
%	O
,	O
RV	O
ejection	O
fraction	O
=	O
50.2	O
±	O
8.5	O
%	O
)	O
and	B-OUT
normal	I-OUT
serum	I-OUT
neurohormonal	I-OUT
markers	I-OUT
.	O


Detailed	O
resting	O
echocardiography	O
detected	B-OUT
abnormal	I-OUT
ventricular	I-OUT
function	I-OUT
,	O
worst	O
in	O
the	O
right	O
ventricle	O
and	O
RV	O
outflow	O
tract	O
.	O


The	B-OUT
LV	I-OUT
force-frequency	I-OUT
curves	I-OUT
of	O
patients	O
were	O
attenuated	O
,	O
with	O
an	O
early	O
plateau	O
and	O
inadequate	O
increase	O
of	O
isovolumic	O
contraction	O
.	O


Recording	B-I
blocks	I-I
consisted	I-I
of	I-I
targets	I-I
preceded	I-I
by	I-I
randomized	I-I
sequences	I-I
of	I-I
standards	I-I
and	I-I
by	I-I
sequences	I-I
of	I-I
standards	I-I
that	I-I
included	I-I
a	I-I
predictive	I-I
sequence	I-I
signaling	I-I
the	I-I
occurrence	I-I
of	I-I
a	I-I
subsequent	I-I
target	I-I
event	I-I
.	I-I


METHODS	O
Patients	B-P
(	I-P
n=766	I-P
)	I-P
,	I-P
aged	I-P
18	I-P
to	I-P
65	I-P
years	I-P
inclusive	I-P
,	I-P
with	I-P
current	I-P
manic	I-P
or	I-P
mixed	I-P
episodes	I-P
were	I-P
initially	I-P
randomized	I-P
(	O
4:1	O
)	O
to	O
flexibly-dosed	O
paliperidone	B-I
ER	I-I
(	O
3-12	O
mg/day	O
)	O
or	O
olanzapine	B-I
(	O
5-20	O
mg/day	O
;	O
3-week	O
acute	O
treatment	O
phase	O
)	O
;	O
responders	O
continued	O
the	O
same	O
treatment	O
(	O
12-week	O
continuation	O
phase	O
)	O
.	O


Time	B-OUT
to	I-OUT
recurrence	I-OUT
of	I-OUT
any	I-OUT
mood	I-OUT
symptoms	I-OUT
was	O
significantly	O
longer	O
with	O
paliperidone	B-I
ER	I-I
than	O
placebo	O
(	O
p=0.017	O
;	O
based	O
on	O
weighted	O
Z-test	O
at	O
0.0198	O
significance	O
level	O
;	O
hazard	O
ratio	O
[	O
placebo	O
:	O
paliperidone	O
ER	O
;	O
unweighted	O
95	O
%	O
confidence	O
interval	O
]	O
:	O
1.43	O
[	O
1.03	O
;	O
1.98	O
]	O
)	O
;	O
the	O
difference	O
was	O
significant	O
for	O
preventing	O
recurrence	B-OUT
of	I-OUT
manic	I-OUT
,	O
but	O
not	O
depressive	O
,	O
symptoms	O
.	O


LIMITATIONS	O
Responder-enriched	O
design	O
prevents	O
extrapolation	O
of	O
data	O
to	B-P
patients	I-P
not	I-P
previously	I-P
stabilized	I-P
on	I-P
paliperidone	I-I
ER	I-I
.	I-I


All	B-P
patients	I-P
received	I-P
the	I-P
Spectron	I-I
EF	I-I
stem	I-I
.	I-I


Effect	O
of	O
camel	B-I
milk	I-I
on	O
thymus	O
and	O
activation-regulated	O
chemokine	O
in	O
autistic	B-P
children	I-P
:	I-P
double-blind	O
study	O
.	O


Measures	O
included	O
changes	O
in	O
professionally	O
completed	O
CARS	B-OUT
score	I-OUT
and	I-OUT
blood	I-OUT
samples	I-OUT
for	I-OUT
TARC	I-OUT
serum	I-OUT
level	I-OUT
were	O
taken	O
before	O
and	O
after	O
milk	O
consumption	O
of	O
500	O
ml	O
per	O
day	O
in	O
children	O
's	O
regular	O
daily	O
diet	O
.	O


We	O
aimed	O
to	O
assess	O
effectiveness	B-OUT
and	I-OUT
safety	I-OUT
of	O
all	O
four	O
treatments	O
.	O


This	O
trial	O
is	O
registered	O
at	O
http	O
:	O
//isrctn.org	O
,	O
number	O
ISRCTN54285094	O
.	O


Patients	B-P
,	I-P
aged	I-P
18-50	I-P
years	I-P
,	O
were	O
randomly	O
assigned	O
to	O
placebo	B-I
(	O
n=102	O
)	O
,	O
laquinimod	B-I
0.3	O
mg	O
a	O
day	O
(	O
n=98	O
)	O
,	O
or	O
0.6	O
mg	O
a	O
day	O
(	O
n=106	O
)	O
.	O


Brain	B-OUT
MRI	I-OUT
scans	I-OUT
and	I-OUT
clinical	I-OUT
assessments	I-OUT
were	O
done	O
at	O
week	O
-4	O
,	O
baseline	O
,	O
and	O
monthly	O
from	O
week	O
12	O
to	O
week	O
36	O
.	O


FINDINGS	O
Compared	O
with	O
placebo	O
,	O
treatment	O
with	O
laquinimod	O
0.6	O
mg	O
per	O
day	O
showed	O
a	O
40.4	O
%	O
reduction	O
of	O
the	O
baseline	O
adjusted	O
mean	O
cumulative	B-OUT
number	I-OUT
of	I-OUT
GdE	I-OUT
lesions	I-OUT
per	I-OUT
scan	I-OUT
on	O
the	O
last	O
four	O
scans	O
(	O
simple	O
means	O
4.2	O
[	O
SD	O
9.2	O
]	O
vs	O
2.6	O
[	O
5.3	O
]	O
,	O
p=0.0048	O
)	O
;	O
treatment	O
with	O
0.3	O
mg	O
per	O
day	O
showed	O
no	O
significant	O
effects	O
(	O
3.9	O
[	O
5.5	O
]	O
vs	O
placebo	O
,	O
p=0.6740	O
)	O
.	O


BACKGROUND	O
Volunteer	B-I
befriending	I-I
promoted	O
remission	B-P
of	I-P
chronic	I-P
depression	I-P
when	O
clinical	O
and	O
other	O
treatment	O
variables	O
were	O
controlled	O
.	O


This	O
knowledge	O
might	O
profitably	O
be	O
incorporated	O
into	O
the	O
evaluation	O
of	O
existing	O
treatments	O
.	O


Most	O
clinicians	O
attribute	O
this	O
phenomenon	O
to	O
an	O
acute	O
and	O
transient	O
increase	O
in	O
catecholamine	O
release	O
,	O
but	O
other	O
mechanisms	O
such	O
as	O
neurogenic	O
hypertension	O
or	O
activation	O
of	O
the	O
renin-angiotensin-aldosterone	O
system	O
have	O
also	O
been	O
proposed	O
.	O


A	O
comparative	O
evaluation	O
of	O
calcium	B-I
hydroxide	I-I
and	I-I
zinc	I-I
oxide	I-I
eugenol	I-I
used	I-I
as	I-I
root	I-OUT
canal	I-OUT
filling	I-OUT
materials	I-OUT
in	O
primary	B-P
molars	I-P
is	O
presented	O
.	O


The	O
authors	O
aimed	O
to	O
identify	O
the	O
effect	O
of	O
home-based	B-I
nursing	I-I
pulmonary	I-I
rehabilitation	I-I
on	O
fatigue	O
,	O
activities	O
of	O
daily	O
living	O
(	O
ADL	O
)	O
and	O
quality	O
of	O
life	O
(	O
QOL	O
)	O
in	O
patients	B-P
with	I-P
COPD	I-P
.	I-P


Independent	O
and	O
paired	O
t-tests	O
,	O
chi-squared	O
tests	O
and	O
covariance	O
analysis	O
were	O
used	O
to	O
analysing	O
data	O
.	O


Nineteen	O
patients	O
underwent	O
primary	B-I
rhytidectomies	I-I
;	I-I
two	O
underwent	O
secondary	B-I
face	I-I
lifts	I-I
.	I-I


Temporary	B-OUT
weakness	I-OUT
of	I-OUT
the	I-OUT
buccal	I-OUT
branch	I-OUT
of	I-OUT
the	I-OUT
facial	I-OUT
nerve	I-OUT
occurred	O
in	O
2	O
patients	O
on	O
the	O
side	O
of	O
the	O
more	O
extensive	O
surgery	O
.	O


No	O
discernible	O
differences	O
in	O
facial	O
halves	O
were	O
noted	O
again	O
.	O


Differences	B-OUT
between	I-OUT
facial	I-OUT
sides	I-OUT
on	O
the	O
6-	O
and	O
12-month	O
postoperative	O
photographs	O
were	O
not	O
detectable	O
.	O


All	O
procedures	O
are	O
lacking	O
in	O
their	O
improvement	B-OUT
of	I-OUT
midface	I-OUT
ptosis	I-OUT
and	I-OUT
the	I-OUT
nasolabial	I-OUT
folds	I-OUT
.	I-OUT


The	O
left	O
eye	O
served	O
as	O
a	O
control	O
without	O
administration	O
.	O


Eyes	O
treated	O
with	O
latanoprost	O
,	O
stored	O
both	O
at	O
4	O
degrees	O
C	O
and	O
30	O
degrees	O
C	O
,	O
achieved	O
statistically	B-OUT
significantly	I-OUT
lower	I-OUT
mean	I-OUT
IOPs	I-OUT
than	O
untreated	O
eyes	O
at	O
all	O
time	O
points	O
,	O
except	O
at	O
21	O
hours	O
treated	O
by	O
the	O
drug	O
stored	O
at	O
30	O
degrees	O
C.	O
We	O
subtracted	O
the	O
IOP	O
of	O
eyes	O
receiving	O
latanoprost	O
from	O
the	O
IOP	O
of	O
untreated	O
eyes	O
for	O
each	O
time	O
point	O
to	O
evaluate	O
the	O
efficacy	B-OUT
of	O
the	O
eye	O
drops	O
(	O
delta	O
IOP	O
)	O
.	O


Randomized	O
clinical	O
trial	O
of	O
behavioral	O
intervention	O
and	O
nutrition	O
education	O
to	O
improve	O
caloric	O
intake	O
and	O
weight	O
in	O
children	B-P
with	I-P
cystic	I-P
fibrosis	I-P
.	I-P


PARTICIPANTS	O
Seventy-nine	B-P
children	I-P
aged	I-P
4	I-P
to	I-P
12	I-P
years	I-P
below	I-P
the	I-P
40th	I-P
percentile	I-P
for	I-P
weight	I-P
for	I-P
age	I-P
were	I-P
recruited	I-P
.	I-P


MAIN	O
OUTCOME	O
MEASURES	O
Primary	O
outcomes	O
were	O
changes	O
from	O
pretreatment	O
to	O
posttreatment	O
in	O
caloric	B-OUT
intake	I-OUT
and	I-OUT
weight	I-OUT
gain	I-OUT
.	I-OUT


To	O
assess	O
physiologic	B-OUT
effects	I-OUT
,	O
practitioners	O
and	O
subjects	O
wore	O
cardiorespiratory	B-OUT
monitors	I-OUT
to	I-OUT
assess	I-OUT
respiratory	I-OUT
rate	I-OUT
(	I-OUT
RR	I-OUT
)	I-OUT
,	I-OUT
heart	I-OUT
rate	I-OUT
(	I-OUT
HR	I-OUT
)	I-OUT
and	I-OUT
heart	I-OUT
rate	I-OUT
variability	I-OUT
(	I-OUT
HRV	I-OUT
)	I-OUT
throughout	O
the	O
4	O
10-minute	O
study	O
periods	O
:	O
Baseline	O
(	O
both	O
practitioner	B-I
and	I-I
subjects	I-I
read	I-I
neutral	I-I
material	I-I
)	I-I
;	I-I
non-tactile-LKM	O
(	B-I
subjects	I-I
read	I-I
while	I-I
the	I-I
practitioner	I-I
practiced	I-I
LKM	I-I
while	I-I
pretending	I-I
to	I-I
read	I-I
)	I-I
;	I-I
tactile-LKM	O
(	B-I
subjects	I-I
rested	I-I
while	I-I
the	I-I
practitioner	I-I
practiced	I-I
LKM	I-I
while	I-I
lightly	I-I
touching	I-I
the	I-I
subject	I-I
on	I-I
arms	I-I
,	I-I
shoulders	I-I
,	I-I
hands	I-I
,	I-I
feet	I-I
,	I-I
and	I-I
legs	I-I
)	I-I
;	I-I
Post-Intervention	O
Rest	O
(	B-I
subjects	I-I
rested	I-I
;	I-I
the	I-I
practitioner	I-I
read	I-I
)	I-I
.	O


Despite	O
blinding	O
,	O
subjects	O
'	O
VAS	B-OUT
scores	I-OUT
improved	O
from	O
baseline	O
to	O
post-intervention	O
for	O
stress	B-OUT
(	O
5.5	O
vs.	O
2.2	O
)	O
,	O
relaxation	B-OUT
(	O
3.8	O
vs.	O
8.8	O
)	O
and	O
peacefulness	B-OUT
(	O
3.8	O
vs.	O
9.0	O
,	O
P	O
<	O
0.05	O
for	O
all	O
comparisons	O
)	O
.	O


RESULTS	O
Recruitment	B-P
led	I-P
to	I-P
22	I-P
patients	I-P
in	I-P
group	I-P
1	I-P
and	I-P
25	I-P
patients	I-P
in	I-P
group	I-P
2	I-P
.	I-P


The	O
rate	B-OUT
of	I-OUT
visualized	I-OUT
EBSLN	I-OUT
was	O
higher	O
in	O
group	O
1	O
(	O
66	O
%	O
vs	O
21	O
%	O
;	O
P	O
=	O
.003	O
)	O
.	O


In	O
both	O
groups	O
,	O
there	O
was	O
no	O
difference	O
in	O
median	B-OUT
total	I-OUT
RSI	I-OUT
score	I-OUT
before	O
surgery	O
or	O
at	O
3	O
weeks	O
and	O
3	O
months	O
after	O
surgery	O
.	O


DESIGN	O
A	O
prospective	O
,	O
randomised	O
study	O
.	O


RESULTS	O
A	O
pool	B-P
of	I-P
108	I-P
patients	I-P
was	O
randomly	O
divided	O
into	O
two	O
groups	O
.	O


Circulating	B-I
blood	I-I
B	I-I
cells	I-I
in	O
multiple	B-P
myeloma	I-P
:	I-P
analysis	O
and	O
relationship	O
to	O
circulating	O
clonal	O
cells	O
and	O
clinical	O
parameters	O
in	O
a	O
cohort	O
of	O
patients	B-P
entered	I-P
on	I-P
the	I-P
Eastern	I-P
Cooperative	I-P
Oncology	I-P
Group	I-P
phase	I-P
III	I-P
E9486	I-P
clinical	I-P
trial	I-P
.	I-P


10	B-P
adolescent	I-P
or	I-P
adult	I-P
subjects	I-P
with	I-P
high-functioning	I-P
autism	I-P
or	I-P
Asperger-syndrome	I-P
were	I-P
included	I-P
in	I-P
the	I-P
investigation	I-P
.	I-P


The	O
training	O
was	O
conducted	O
for	O
five	O
weeks	O
,	O
consisting	O
of	O
two	O
hours	O
training	O
a	O
week	O
.	O


The	O
trained	O
individuals	O
improved	O
significantly	O
on	O
the	O
affect	B-OUT
recognition	I-OUT
task	I-OUT
,	O
but	O
not	O
on	O
any	O
other	O
measure	O
.	O


To	O
the	O
patients	O
of	O
trial	O
group	O
,	O
oral	O
administration	O
of	O
WTC	B-I
was	O
given	O
additionally	O
with	O
4	O
capsules	O
,	O
3	O
times	O
a	O
day	O
for	O
consecutive	O
3	O
months	O
.	O


RESULTS	O
sCD44v6	B-OUT
was	O
significantly	O
positive	O
correlated	O
with	O
the	O
degree	B-OUT
of	I-OUT
cancer	I-OUT
cell	I-OUT
differentiation	I-OUT
,	I-OUT
infiltration	I-OUT
and	I-OUT
lymph	I-OUT
node	I-OUT
metastasis	I-OUT
;	I-OUT
(	O
2	O
)	O
Level	B-OUT
of	I-OUT
sCD44v6	I-OUT
was	O
the	O
highest	O
in	O
patients	B-P
of	I-P
blood	I-P
stasis	I-P
type	I-P
,	O
as	O
compared	O
with	O
that	O
in	O
the	O
patients	B-P
of	I-P
Pi-deficiency	I-P
type	I-P
or	I-P
of	I-P
damp-heat	I-P
type	I-P
,	O
the	O
difference	O
was	O
significant	O
;	O
(	O
3	O
)	O
After	O
ending	O
treatment	O
,	O
level	B-OUT
of	I-OUT
sCD44v6	I-OUT
in	O
the	O
trial	O
group	O
was	O
significantly	O
lower	O
than	O
that	O
in	O
the	O
control	O
group	O
.	O


SAM	O
participate	O
in	O
the	O
development	O
of	O
diabetic	O
macroangiopathy	O
and	O
microangiopathy	O
.	O


One	O
group	O
(	B-I
FDTV	I-I
)	I-I
received	O
2/180	O
mg	O
once	O
a	O
day	O
;	O
the	O
other	O
group	O
received	O
T	B-I
2	O
mg	O
once	O
a	O
day	O
.	O


However	O
,	O
VCAM-1	B-OUT
presented	O
a	O
significantly	O
greater	O
reduction	O
(	O
p	O
=	O
0.022	O
)	O
in	O
the	O
trandolapril-verapamil	B-I
group	O
.	O


RESULTS	O
There	O
were	O
no	O
significant	O
differences	O
in	O
birth	B-OUT
weight	I-OUT
,	I-OUT
treatment	I-OUT
with	I-OUT
antibiotics	I-OUT
,	I-OUT
and	I-OUT
the	I-OUT
starting	I-OUT
time	I-OUT
of	I-OUT
breast-feeding	I-OUT
among	O
the	O
three	O
groups	O
.	O


each	B-I
)	I-I
on	I-I
D	I-I
-5	I-I
and	I-I
on	I-I
D	I-I
-2.5	I-I
,	I-I
prior	I-I
to	I-I
PGF	I-I
(	I-I
2α	I-I
)	I-I
,	I-I
on	I-I
D	I-I
0	I-I
(	I-I
2PPG	I-I
)	I-I
.	O


Assessment	O
of	O
paravalvular	O
aortic	O
regurgitation	O
after	O
transcatheter	B-I
aortic	I-I
valve	I-I
replacement	I-I
:	I-I
intra-core	O
laboratory	O
variability	O
.	O


A	O
consortium	B-P
of	I-P
echocardiography	I-P
core	I-P
laboratory	I-P
directors	I-P
was	O
formed	O
to	O
evaluate	O
the	O
echocardiographic	B-I
images	I-I
and	O
to	O
grade	O
PAR	B-OUT
and	O
central	O
and	O
total	O
aortic	O
regurgitation	O
in	O
a	O
randomly	B-P
chosen	I-P
subset	I-P
of	I-P
the	I-P
randomized	I-P
patients	I-P
in	I-P
the	I-P
PARTNER	I-P
IIB	I-P
trial	I-P
using	I-P
a	I-P
multiwindow	I-P
,	I-P
multiparametric	I-P
approach	I-P
.	I-P


Using	O
the	O
four-class	O
grading	O
scheme	O
the	B-OUT
weighted	I-OUT
κ	I-OUT
statistic	I-OUT
for	I-OUT
PAR	I-OUT
was	O
0.481	O
(	O
95	O
%	O
confidence	O
limits	O
,	O
0.367	O
,	O
0.595	O
)	O
.	O


Similar	O
results	O
were	O
seen	O
for	B-OUT
central	I-OUT
and	I-OUT
total	I-OUT
aortic	I-OUT
regurgitation	I-OUT
assessments	O
.	O


A	O
multiparametric	O
approach	O
is	O
advocated	O
,	O
and	O
other	O
echocardiographic	O
methods	O
for	O
assessing	O
PAR	O
deserve	O
further	O
study	O
.	O


Patients	B-I
were	I-I
titrated	I-I
to	I-I
tapentadol	I-I
PR	I-I
300	I-I
mg/day	I-I
over	I-I
3	I-I
weeks	I-I
.	O


RESULTS	O
In	O
the	O
per-protocol	O
population	O
(	B-OUT
n	I-OUT
=	I-OUT
288	I-OUT
)	I-OUT
,	I-OUT
the	I-OUT
effectiveness	I-I
of	I-I
tapentadol	O
PR	O
was	O
clinically	O
and	O
statistically	B-I
comparable	I-I
to	I-I
tapentadol	I-I
PR/pregabalin	O
based	O
on	B-OUT
the	I-OUT
change	I-OUT
in	I-OUT
pain	O
intensity	O
from	O
randomization	O
to	O
final	O
evaluation	O
(	O
LOCF	O
;	O
LSMD	O
[	O
95	O
%	O
CI	O
]	O
,	O
-0.066	O
[	O
-0.57	O
,	O
0.43	O
]	O
;	O
P	O
<	O
0.0001	O
for	B-OUT
noninferiority	I-OUT
)	I-OUT
.	I-OUT


The	B-P
3,583	I-P
men	I-P
in	I-P
the	I-P
CARE	I-P
trial	I-P
also	O
showed	O
a	O
reduction	O
in	O
risk	B-OUT
,	O
but	O
the	O
magnitude	O
tended	O
to	O
be	O
less	O
.	O


Pravastatin	B-I
improved	O
plasma	B-OUT
lipids	I-OUT
similarly	O
in	O
men	B-P
and	I-P
women	I-P
.	I-P


The	O
results	O
of	O
a	O
multicenter	O
,	O
randomized	O
trial	O
on	O
the	O
effect	O
of	O
intravenous	B-I
administration	I-I
of	I-I
gamma	I-I
globulin	I-I
(	I-I
IVGG	I-I
)	I-I
plus	I-I
aspirin	I-I
versus	I-I
aspirin	I-I
alone	I-I
upon	O
coronary	O
aneurysm	O
formation	O
show	O
a	O
decrease	O
in	O
coronary	B-OUT
aneurysm	I-OUT
formation	I-OUT
from	O
the	O
usual	O
20	O
%	O
-30	O
%	O
to	O
3	O
%	O
.	O


The	O
percentage	O
of	O
depression	B-OUT
for	I-OUT
ST-segment	I-OUT
was	O
lower	O
for	O
diltiazem	B-I
when	O
compared	O
with	O
placebo	B-I
(	O
p	O
<	O
0.05	O
)	O
and	O
the	O
percentage	O
of	O
patients	O
that	O
reach	O
higher	O
stages	O
in	O
the	O
ergometric	O
test	O
was	O
significantly	O
better	O
for	O
diltiazem	B-I
.	I-I


PURPOSE	O
The	O
aim	O
of	O
this	O
study	O
was	O
to	O
determine	O
if	O
local	O
injection	O
of	O
bupivacaine	B-I
after	O
hemorrhoidal	O
banding	O
causes	O
a	O
decrease	B-OUT
in	I-OUT
pain	I-OUT
and	I-OUT
in	I-OUT
the	I-OUT
incidence	I-OUT
of	I-OUT
associated	I-OUT
symptoms	I-OUT
.	I-OUT


In	O
patients	O
receiving	O
bupivacaine	B-I
compared	O
with	O
no	O
injection	O
,	O
within	O
30	O
minutes	O
postbanding	O
there	O
was	O
a	O
significant	O
reduction	B-OUT
in	I-OUT
pain	I-OUT
graded	O
by	O
the	O
patient	O
(	O
P	O
=	O
0.000002	O
)	O
and	O
by	O
the	O
nurse	O
(	O
P	O
=	O
0.000005	O
)	O
and	O
a	O
significant	O
reduction	O
in	O
incidence	B-OUT
of	I-OUT
nausea	I-OUT
(	O
P	O
=	O
0.01	O
)	O
and	O
shaking	O
(	O
P	O
=	O
0.008	O
)	O
.	O


In	O
a	O
randomized	O
controlled	O
trial	O
,	O
the	O
effectiveness	B-OUT
of	O
a	O
polymeric	B-I
surgical	I-I
sealant	I-I
(	I-I
CoSeal	I-I
)	I-I
was	O
compared	B-I
to	I-I
Gelfoam/thrombin	I-I
for	I-I
managing	I-I
anastomotic	I-OUT
bleeding	I-OUT
after	I-I
implantation	I-I
of	I-I
Dacron	I-I
grafts	I-I
during	I-I
aortic	I-I
reconstruction	I-I
for	I-I
nonruptured	I-I
aneurysms	I-I
.	I-I


These	O
results	O
support	O
the	O
use	O
of	O
this	O
novel	O
sealant	O
for	O
the	O
intraoperative	B-P
management	I-P
of	I-P
anastomotic	I-P
bleeding	I-P
during	I-P
aortic	I-P
reconstruction	I-P
procedures	I-P
.	I-P


Overall	O
,	O
the	O
follow-up	O
outcome	O
is	O
far	O
from	O
reassuring	O
,	O
whatever	O
the	O
type	O
of	O
treatment	O
.	O


Comparison	O
of	O
the	O
efficacy	O
of	O
fluoxetine	B-I
alone	I-I
vs.	I-I
fluoxetine	I-I
plus	I-I
local	I-I
lidocaine	I-I
ointment	I-I
in	O
the	O
treatment	O
of	O
premature	B-P
ejaculation	I-P
.	I-P


CONCLUSION	O
The	B-I
combination	I-I
of	I-I
resistive	I-I
underwater	I-I
exercises	I-I
and	I-I
interferential	I-I
current	I-I
therapy	I-I
is	O
a	O
potentially	O
valuable	O
treatment	O
for	O
patients	B-P
with	I-P
juvenile	I-P
idiopathic	I-P
arthritis	I-P
.	I-P


Thirty-seven	B-P
children	I-P
between	I-P
3	I-P
and	I-P
11	I-P
years	I-P
of	I-P
age	I-P
with	I-P
a	I-P
diagnosis	I-P
of	I-P
autism	I-P
and/or	I-P
pervasive	I-P
developmental	I-P
disorder	I-P
were	O
gender	O
and	O
age	O
matched	O
and	O
randomly	O
assigned	O
to	O
receive	B-I
either	I-I
placebo	I-I
or	I-I
dimethylglycine	I-I
for	I-I
4	I-I
weeks	I-I
.	I-I


Women	O
in	O
the	O
intervention	O
arm	O
were	O
also	O
more	O
likely	O
to	O
take	B-OUT
their	I-OUT
infant	I-OUT
to	I-OUT
the	I-OUT
clinic	I-OUT
within	I-OUT
the	I-OUT
first	I-OUT
week	I-OUT
of	I-OUT
life	I-OUT
(	O
risk	O
ratio	O
1.10	O
;	O
95	O
%	O
CI	O
:	O
1.04-1.18	O
)	O
.	O


This	O
trial	O
could	O
inform	O
national	O
primary	O
healthcare	O
reengineering	O
strategies	O
in	O
favour	O
of	O
home	O
visits	O
.	O


Severity	O
of	O
symptoms	O
was	O
rated	O
using	O
the	O
CARS	O
(	O
Childhood	O
Autism	O
Rating	O
Scale	O
)	O
.	O


Outcome	O
measures	O
included	O
Communication	B-OUT
and	I-OUT
Symbolic	I-OUT
Behavior	I-OUT
Scale	I-OUT
(	I-OUT
CSBS	I-OUT
)	I-OUT
,	I-OUT
Ritvo	I-OUT
Real-life	I-OUT
Rating	I-OUT
Scale	I-OUT
,	I-OUT
weekly	I-OUT
Global	I-OUT
Rating	I-OUT
Scale	I-OUT
(	I-OUT
GBRS	I-OUT
)	I-OUT
by	O
parents	O
and	O
teachers	O
,	O
and	O
daily	O
log	O
of	O
gastrointestinal	O
symptoms	O
.	O


CONCLUSIONS	O
A	O
single	O
dose	O
of	O
intravenous	O
human	B-I
secretin	I-I
is	O
not	O
effective	O
in	O
changing	O
behaviour	O
and	O
communication	O
in	O
children	O
with	O
ASD	O
when	O
compared	O
to	O
placebo	B-I
.	I-I


Aerobic	O
fitness	O
is	O
associated	O
with	O
white	B-OUT
matter	I-OUT
integrity	I-OUT
(	I-OUT
WMI	I-OUT
)	I-OUT
in	O
adults	O
as	O
measured	O
by	O
diffusion	B-OUT
tensor	I-OUT
imaging	I-OUT
(	I-OUT
DTI	I-OUT
)	I-OUT
.	O


Increasing	O
the	O
dialysate	O
Na+	B-I
concentration	O
decreases	O
hypotensive	O
episodes	O
.	O


During	O
a	O
9	O
week	O
period	O
,	O
the	O
patients	O
were	O
on	O
a	O
standard	B-I
Na+	I-I
dialysate	I-I
(	O
Na+	O
=	O
140	O
meq/L	O
)	O
basal	O
period	O
(	O
B	O
)	O
;	O
9	O
%	O
(	O
Na+	O
=	O
149	O
meq/L	O
)	O
linear	B-I
(	O
L	O
)	O
;	O
step	O
drop	O
(	O
S	O
)	O
;	O
and	O
exponential	O
drop	O
(	O
E	O
)	O
.	O


Serum	B-OUT
Na+	I-OUT
levels	I-OUT
were	O
significantly	O
higher	O
predialysis	O
and	O
postdialysis	O
for	O
those	O
patients	O
on	O
Na+	B-I
modeling	I-I
.	I-I


Parenteral	B-I
amino	I-I
acid	I-I
and	O
metabolic	O
acidosis	O
in	O
premature	B-P
infants	I-P
.	I-P


BACKGROUND	O
Aggressive	B-I
parenteral	I-I
nutrition	I-I
(	I-I
PN	I-I
)	I-I
including	I-I
amino	I-I
acids	I-I
is	O
recommended	O
for	O
low-birth-weight	B-P
infants	I-P
to	O
prevent	O
energy	O
and	O
protein	O
deficit	O
.	O


Their	O
impact	O
on	O
acid-base	O
homeostasis	O
has	O
not	O
been	O
examined	O
.	O


Temporal	O
expectation	O
in	O
focal	B-P
hand	I-P
dystonia	I-P
.	I-P


During	O
the	O
'dark	O
'	O
interval	O
,	O
subjects	O
were	O
asked	O
to	O
indicate	O
when	O
the	O
movement	O
represented	O
in	O
the	O
video	O
reached	O
its	O
end	O
by	O
clicking	O
on	O
the	O
space	O
bar	O
of	O
the	O
keyboard	O
.	O


Our	O
findings	O
suggest	O
an	O
alteration	O
of	O
the	O
writing	O
movement	O
representation	O
at	O
a	O
central	O
level	O
and	O
are	O
consistent	O
with	O
the	O
view	O
that	O
dystonia	O
is	O
not	O
a	O
purely	O
motor	O
disorder	O
,	O
but	O
it	O
also	O
involves	O
non-motor	O
(	O
sensory	O
,	O
cognitive	O
)	O
aspects	O
related	O
to	O
movement	O
processing	O
and	O
planning	O
.	O


These	O
symptoms	O
have	O
to	O
be	O
attributed	O
to	O
a	O
neuronal	O
degeneration	O
.	O


This	O
objective	O
improvement	O
was	O
associated	O
with	O
a	O
subjective	O
improvement	O
.	O


A	O
single-bout	O
of	O
exercise	B-I
produced	O
increases	O
in	O
STARS	B-OUT
and	I-OUT
SRF	I-OUT
mRNA	I-OUT
and	I-OUT
decreases	I-OUT
in	I-OUT
MRTF-A	I-OUT
mRNA	I-OUT
with	I-OUT
both	I-OUT
ECC	I-OUT
and	I-OUT
CONC	I-OUT
exercise	I-OUT
,	O
but	O
with	O
an	O
enhanced	O
response	O
occurring	O
following	O
ECC	B-I
exercise	I-I
.	I-I


Prolonged	O
ECC	O
and	O
CONC	O
training	O
equally	O
stimulated	O
muscle	O
hypertrophy	O
and	O
produced	O
increases	O
in	O
MRTF-A	B-OUT
protein	I-OUT
of	O
125	O
%	O
and	O
99	O
%	O
,	O
respectively	O
(	O
P	O
<	O
0.001	O
)	O
.	O


No	O
changes	O
occurred	O
for	O
total	B-OUT
SRF	I-OUT
protein	I-OUT
.	I-OUT


This	O
study	O
showed	O
that	O
the	O
two	O
combinations	O
of	O
0.5	O
%	O
timolol	B-I
maleate	I-I
and	O
2	O
%	O
pilocarpine	B-I
HCl	I-I
compared	O
in	O
this	O
study	O
were	O
equally	O
effective	O
in	O
reducing	O
intraocular	B-OUT
pressure	I-OUT
.	I-OUT


The	O
mean	O
decrease	O
in	O
mean	B-OUT
daily	I-OUT
intraocular	I-OUT
pressure	I-OUT
was	O
29.3	O
%	O
for	O
Fotil	O
,	O
and	O
26.0	O
%	O
for	O
Timpilo	O
.	O


In	O
general	O
,	O
adverse	B-OUT
events	I-OUT
were	O
similar	O
in	O
both	O
study	O
groups	O
.	O


In	O
patients	O
with	O
no	O
contraindication	O
to	O
beta-blockers	O
,	O
these	O
drugs	O
appeared	O
to	O
be	O
safe	O
.	O


The	O
occlusal	O
surface	O
was	O
ground	O
flat	O
and	O
the	O
teeth	O
were	O
sectioned	O
mesio-distally	O
.	O


The	O
resulting	O
size	O
of	O
the	O
occlusal	O
opening	O
was	O
1.0	O
mm	O
,	O
1.4	O
mm	O
,	O
1.6	O
mm	O
and	O
1.8	O
mm	O
for	O
Groups	O
A	O
,	O
B	O
,	O
C	O
,	O
and	O
D	O
,	O
respectively	O
.	O


Supplemental	B-OUT
consumption	I-OUT
of	I-OUT
metamizol	I-OUT
was	O
significantly	O
lower	O
(	O
P	O
<	O
0.05	O
)	O
in	O
Group	O
3	O
than	O
in	O
Group	O
1	O
during	O
the	O
first	O
6	O
h	O
after	O
surgery	O
.	O


morphine	B-I
was	O
more	O
effective	O
for	O
treatment	O
of	O
pain	B-OUT
after	O
laparoscopic	B-P
cholecystectomy	I-P
.	I-P


This	O
study	O
aimed	O
to	O
determine	O
whether	O
intravenous	B-I
lipid	I-I
emulsion	I-I
could	O
improve	O
recovery	O
profiles	O
from	O
isoflurane	B-I
anaesthesia	I-I
in	O
adult	B-P
patients	I-P
undergoing	I-P
laparoscopic	I-P
cholecystectomy	I-P
.	I-P


Sixty-six	B-P
patients	I-P
were	I-P
enrolled	I-P
.	I-P


In	O
conclusion	O
,	O
intravenous	O
lipid	B-I
emulsion	I-I
may	O
effectively	O
improve	O
the	O
recovery	B-OUT
time	I-OUT
and	O
quality	O
from	O
isoflurane	B-I
anaesthesia	I-I
for	O
laparoscopic	O
cholecystectomy	O
.	O


OBJECTIVES	O
This	O
study	O
intended	O
to	O
determine	O
the	O
effect	O
of	O
varying	O
degrees	O
of	O
lossy	B-I
Joint	I-I
Photographic	I-OUT
Experts	I-I
Group	I-I
(	I-I
JPEG	I-I
)	I-I
compression	I-I
on	O
detection	B-OUT
of	I-OUT
coronary	I-OUT
angiographic	I-OUT
features	I-OUT
.	I-OUT


Caution	O
is	O
warranted	O
in	O
the	O
interpretation	O
of	O
coronary	B-I
angiograms	I-I
that	O
have	O
been	O
subjected	O
to	O
lossy	O
JPEG	B-I
compression	I-I
beyond	O
a	O
ratio	O
of	O
6:1	O
.	O


PARTICIPANTS	O
100	B-P
neurosurgical	I-P
patients	I-P
and	I-P
40	I-P
patients	I-P
with	I-P
leukaemia	I-P
who	I-P
required	I-P
chemotherapy	I-P
.	I-P


INTERVENTIONS	O
Neurosurgical	O
patients	O
'	O
hands	B-I
and	I-I
forearms	I-I
were	I-I
covered	I-I
for	I-I
15	I-I
minutes	I-I
with	I-I
a	I-I
carbon	I-I
fibre	I-I
heating	I-I
mitt	I-I
.	I-I


Patients	O
were	O
assigned	O
randomly	O
to	O
active	B-I
warming	I-I
at	I-I
52	I-I
degrees	I-I
C	I-I
or	I-I
passive	I-I
insulation	I-I
(	O
heater	O
not	O
activated	O
)	O
.	O


OBJECTIVE	O
To	O
assess	O
the	O
efficacy	B-OUT
and	I-OUT
tolerability	I-OUT
of	O
second-line	O
sequential	O
administration	O
of	O
erlotinib	B-I
and	I-I
docetaxel	I-I
in	O
advanced	O
NSCLC	O
.	O


There	O
was	O
no	O
significant	O
difference	O
in	O
response	B-OUT
rates	I-OUT
(	O
p=0.784	O
)	O
.	O


METHODS	O
We	O
prospectively	O
evaluated	O
the	O
association	O
between	O
baseline	B-P
BMI	I-P
and	I-P
the	I-P
risk	I-P
of	I-P
incident	I-OUT
distal	I-OUT
adenoma	I-OUT
(	I-P
1,213	I-P
cases	I-P
)	I-P
,	I-P
recurrent	I-OUT
adenoma	I-OUT
(	I-P
752	I-P
cases	I-P
)	I-P
,	I-P
and	I-P
incident	I-OUT
colorectal	I-OUT
cancer	I-OUT
(	I-P
966	I-P
cases	I-P
)	I-P
among	I-P
men	I-P
and	I-P
women	I-P
,	I-P
ages	I-P
55	I-P
to	I-P
74	I-P
years	I-P
,	I-P
randomly	I-P
assigned	I-P
to	I-P
receive	I-P
flexible	I-I
sigmoidoscopy	I-I
screening	I-I
as	I-P
part	I-P
of	I-P
the	I-P
Prostate	I-P
,	I-P
Lung	I-P
,	I-P
Colorectal	I-P
,	I-P
and	I-P
Ovarian	I-P
Cancer	I-P
Screening	I-P
Trial	I-P
.	I-P


Radiotherapy	B-I
in	O
the	O
head	O
and	O
neck	O
region	O
and	O
chemotherapy	B-I
might	O
give	O
rise	O
to	O
oral	O
mucositis	O
which	O
is	O
a	O
severe	O
and	O
painful	O
inflammation	O
.	O


A	O
number	O
of	O
studies	O
have	O
attempted	O
to	O
evaluate	O
the	O
effect	O
of	O
low-power	B-I
laser	I-I
on	I-I
radiotherapy-	I-OUT
and	O
chemotherapy-induced	B-OUT
mucositis	I-OUT
.	I-OUT


OBJECTIVE	O
To	O
determine	O
predictors	O
of	O
shunt-dependent	B-OUT
hydrocephalus	I-OUT
and	I-OUT
functional	I-OUT
outcomes	I-OUT
after	O
aneurysmal	O
SAH	O
.	O


RESULTS	O
Ultimately	O
,	O
147	O
patients	O
(	O
31.2	O
%	O
)	O
required	O
a	O
ventriculoperitoneal	O
shunt	O
(	O
VPS	O
)	O
in	O
our	O
series	O
.	O


On	O
multivariate	O
analysis	O
,	O
intraventricular	B-OUT
hemorrhage	I-OUT
and	I-OUT
intraparenchymal	I-OUT
hemorrhage	I-OUT
were	O
independent	O
risk	O
factors	O
for	O
shunt	B-OUT
dependency	I-OUT
(	O
P	O
<	O
.05	O
)	O
.	O


The	O
fictional	O
narrative	O
was	O
constructed	O
to	O
match	O
the	O
summary	O
in	O
content	O
and	O
length	O
.	O


For	O
two	O
themes	O
,	O
there	O
was	O
no	O
statistically	O
significant	O
difference	O
in	O
recall	B-OUT
between	O
the	O
arms	O
.	O


CONCLUSIONS	O
Physicians	B-P
exposed	O
to	O
a	O
narrative	O
about	O
opioid	B-I
guidelines	I-I
were	O
more	O
likely	O
to	O
recall	O
guideline	O
content	O
at	O
1	O
hour	O
than	O
those	O
exposed	O
to	O
a	O
summary	O
of	O
the	O
guidelines	O
.	O


BACKGROUND	O
We	O
performed	O
short-term	B-I
neoadjuvant	I-I
chemotherapy	I-I
(	I-I
s-NAC	I-I
)	I-I
to	O
examine	O
whether	O
anticancer	O
drugs	O
can	O
change	O
the	O
proliferative	O
ability	O
of	O
cancer	O
cells	O
in	O
gastric	B-P
cancer	I-P
patients	I-P
.	I-P


Patients	O
were	O
classed	O
into	O
four	O
groups	O
:	O
Group	B-P
F	I-P
,	I-P
16	I-P
cases	I-P
who	I-P
received	I-P
a	I-P
single	I-P
administration	I-P
of	I-P
5-fluorouracil	I-I
(	I-I
5-FU	I-I
)	I-I
;	I-I
Group	I-P
C	I-P
,	I-P
15	I-P
cases	I-P
who	I-P
received	I-P
a	I-P
single	I-P
administration	I-P
of	I-P
cis-diamminedichloroplatinum	I-I
(	I-I
CDDP	I-I
;	I-I
cisplatin	I-I
)	I-I
;	I-I
Group	I-P
FC	I-P
,	I-P
16	I-P
cases	I-P
who	I-P
received	I-P
both	I-P
5-FU+CDDP	I-I
;	I-I
and	O
a	B-P
Control	I-P
group	I-P
,	I-P
16	I-P
cases	I-P
who	I-P
did	I-P
not	I-I
receive	I-I
chemotherapy	I-I
.	I-I


We	O
reviewed	O
neoadjuvant	O
biopsy	O
tissue	O
and	O
gastric	O
cancer	O
tissue	O
delivered	O
by	O
operation	O
in	O
these	O
cases	O
.	O


The	O
TUNEL	O
method	O
and	O
immunohistochemistry	O
with	O
an	O
anti-MIB-1	O
antibody	O
were	O
used	O
to	O
evaluate	O
cellular	B-OUT
apoptosis	I-OUT
and	I-OUT
proliferative	I-OUT
ability	I-OUT
,	O
respectively	O
.	O


The	O
AI	B-OUT
of	O
gastric	B-OUT
cancer	I-OUT
tissue	I-OUT
in	O
Group	O
FC	O
was	O
significantly	O
higher	O
than	O
in	O
the	O
other	O
groups	O
(	O
P	O
<	O
0.01	O
)	O
.	O


In	O
addition	O
,	O
after	O
s-NAC	B-I
operation	O
there	O
was	O
a	O
significant	O
inhibition	O
of	O
proliferative	B-OUT
potency	I-OUT
and	O
an	O
induction	O
of	O
apoptosis	B-OUT
in	O
Group	O
FC	O
.	O


Design	O
and	O
subject	O
characteristics	O
in	O
the	O
federally-funded	O
citalopram	B-I
trial	O
in	O
children	B-P
with	I-P
pervasive	I-P
developmental	I-P
disorders	I-P
.	I-P


Subjects	B-P
in	I-P
this	I-P
trial	I-P
were	I-P
slightly	I-P
older	I-P
and	I-P
more	I-P
likely	I-P
to	I-P
have	I-P
complaints	I-P
of	I-OUT
repetitive	I-OUT
behavior	I-OUT
than	O
participants	O
in	O
RUPP	O
trials	O
.	O


The	O
14	B-P
preschool	I-P
special	I-P
education	I-P
teachers	I-P
were	O
randomly	O
assigned	O
to	O
one	O
of	O
three	O
groups	O
:	O
(	O
1	O
)	O
symbolic	B-I
play	I-I
then	I-I
joint	I-I
attention	I-I
intervention	I-I
,	O
(	O
2	O
)	O
joint	B-I
attention	I-I
then	I-I
symbolic	I-I
intervention	I-I
,	O
and	O
(	O
3	O
)	O
wait-list	B-I
control	I-I
period	I-I
then	I-I
further	I-I
randomized	I-I
to	I-I
either	I-I
group	I-I
1	I-I
or	I-I
group	I-I
2	I-I
.	I-I


RESULTS	O
Before	O
PCI	O
,	O
no	O
increase	O
in	O
the	O
percentage	B-OUT
of	I-OUT
patient	I-OUT
with	I-OUT
TIMI	I-OUT
flow	I-OUT
better	O
than	O
TIMI-2	O
was	O
observed	O
by	O
the	O
treatment	O
of	O
tirofiban	B-I
(	O
69.3	O
%	O
vs	O
78.9	O
%	O
,	O
P	O
=	O
0.10	O
)	O
.	O


While	O
after	O
PCI	O
,	O
significant	O
increase	O
in	O
the	O
percentage	B-OUT
of	I-OUT
patient	I-OUT
with	I-OUT
TIMI	I-OUT
flow	I-OUT
better	O
than	O
TIMI-2	O
was	O
manifested	O
in	O
the	O
tirofiban	B-I
group	O
(	O
96.0	O
%	O
vs	O
100.0	O
%	O
,	O
P	O
=	O
0.04	O
)	O
.	O


There	O
were	O
0	O
and	O
4	O
major	B-OUT
adverse	I-OUT
cardiovascular	I-OUT
events	I-OUT
(	I-OUT
MACE	I-OUT
)	I-OUT
within	O
30	O
days	O
observed	O
in	O
the	O
tirofiban	B-I
group	O
and	O
the	O
control	O
group	O
(	O
0.0	O
%	O
vs	O
5.3	O
%	O
,	O
P	O
=	O
0.05	O
)	O
.	O


No	O
difference	O
between	O
the	O
two	O
groups	O
was	O
found	O
in	O
the	O
bleeding	B-OUT
complications	I-OUT
within	O
30	O
days	O
including	O
the	O
mild	B-OUT
hemorrhage	I-OUT
(	O
5	O
vs	O
4	O
cases	O
,	O
P	O
=	O
0.75	O
)	O
,	O
severe	B-OUT
hemorrhage	I-OUT
(	O
2	O
vs	O
1	O
cases	O
,	O
P	O
=	O
0.56	O
)	O
or	O
severe	B-OUT
thrombocytopenia	I-OUT
(	O
2	O
vs	O
0	O
cases	O
,	O
P	O
=	O
0.49	O
)	O
.	O


Few	O
studies	O
have	O
explored	O
the	O
joint	O
association	O
of	O
circulating	O
vitamin	O
D	O
levels	O
with	O
VDR	O
polymorphisms	O
.	O


We	O
observed	O
a	O
significant	O
interaction	O
between	O
circulating	O
25	B-OUT
(	I-OUT
OH	I-OUT
)	I-OUT
D	I-OUT
levels	I-OUT
and	I-OUT
the	I-OUT
VDR	I-OUT
FokI	I-OUT
genotype	I-OUT
(	O
pinteraction	O
<	O
0.05	O
)	O
.	O


Men	O
with	O
the	O
less	O
functional	O
FokI	O
ff	O
genotype	O
(	O
14	O
%	O
in	O
the	O
European-descent	O
population	O
of	O
this	O
cohort	O
)	O
are	O
more	O
susceptible	O
to	O
this	O
cancer	O
in	O
the	O
presence	O
of	O
low	O
25	O
(	O
OH	O
)	O
D	O
status	O
.	O


The	O
Italian	B-P
Tamoxifen	I-I
Prevention	I-P
Study	I-P
.	I-P


The	O
primary	O
analysis	O
of	O
the	O
population	O
for	O
survival	B-OUT
was	O
by	O
intention	O
to	O
treat	O
.	O


INTERPRETATION	O
Treatment	O
with	O
gefitinib	B-I
was	O
not	O
associated	O
with	O
significant	O
improvement	O
in	O
survival	B-OUT
in	O
either	O
coprimary	O
population	O
.	O


Three	O
valid	O
straylight	B-OUT
measurements	I-OUT
were	O
taken	O
on	O
each	O
eye	O
before	O
and	O
a	O
few	O
minutes	O
after	O
lens	O
insertion	O
,	O
when	O
lens	O
stabilization	O
had	O
occurred	O
.	O


RESULTS	O
The	O
subjects	O
'	O
mean	B-OUT
straylight	I-OUT
values	I-OUT
were	O
0.90	O
+/-	O
0.09	O
at	O
baseline	O
and	O
0.95	O
+/-	O
0.10	O
with	O
the	O
clear	O
Optima	O
38	O
CL	O
.	O


Differences	O
in	O
straylight	B-OUT
between	O
baseline	O
(	O
without	O
CL	O
)	O
and	O
with	O
the	O
clear	O
CL	O
in	O
place	O
were	O
neither	O
statistically	O
significant	O
(	O
p	O
=	O
0.066	O
)	O
nor	O
was	O
there	O
a	O
significant	O
difference	O
between	O
baseline	O
and	O
the	O
amber	O
CL	O
(	O
p	O
=	O
0.052	O
)	O
.	O


Differences	O
in	O
straylight	O
with	O
the	O
clear	O
CL	O
compared	O
with	O
the	O
grey-green	O
CL	O
were	O
also	O
statistically	O
different	O
from	O
zero	O
(	O
p	O
=	O
0.002	O
)	O
showing	O
an	O
increased	O
straylight	B-OUT
value	I-OUT
for	O
the	O
tinted	O
CL	O
.	O


This	O
difference	O
between	O
the	O
tinted	O
CL	O
could	O
suggest	O
a	O
wavelength	O
dependence	O
of	O
straylight	O
values	O
,	O
although	O
this	O
should	O
be	O
investigated	O
further	O
by	O
controlling	O
for	O
pupil	O
size	O
and	O
subjects	O
'	O
pigmentation	O
,	O
as	O
well	O
as	O
by	O
using	O
neutral	O
density	O
filters	O
.	O


The	O
basic	O
intervention	O
was	O
a	O
one-time	B-I
e-mail	I-I
reminder	I-I
highlighting	I-I
six	I-I
HF-specific	I-I
clinical	I-I
recommendations	I-I
.	I-I


PRINCIPAL	O
FINDINGS	O
Both	O
the	O
basic	O
and	O
the	O
augmented	O
interventions	O
greatly	O
increased	O
the	O
practice	B-OUT
of	I-OUT
evidence-based	I-OUT
care	I-OUT
,	O
according	O
to	O
patient	O
records	O
,	O
in	O
the	O
areas	O
of	O
patient	O
assessment	O
and	O
instructions	O
about	O
HF	O
disease	O
management	O
.	O


OBJECTIVE	O
To	O
study	O
the	O
symptomatology	O
of	O
early	B-P
hemorrhoids	I-P
and	O
to	O
compare	O
injection	B-I
sclerotherapy	I-I
(	I-I
IS	I-I
)	I-I
with	I-I
electrocoagulation	I-I
(	I-I
EC	I-I
)	I-I
in	O
the	O
management	O
outcome	O
of	O
early	O
haemorrhoids	O
with	O
respect	O
to	O
pain	B-OUT
during	I-OUT
the	I-OUT
procedure	I-OUT
,	I-OUT
reduction	I-OUT
in	I-OUT
bleeding	I-OUT
per	I-OUT
rectum	I-OUT
,	O
and	O
overall	B-OUT
patient	I-OUT
satisfaction	I-OUT
score	I-OUT
.	I-OUT


BACKGROUND	O
Tailored	O
nutrition	O
interventions	O
have	O
been	O
shown	O
to	O
be	O
more	O
effective	O
than	O
non-tailored	O
materials	O
in	O
changing	O
dietary	O
behaviours	O
,	O
particularly	O
fat	O
intake	O
and	O
fruit	O
and	O
vegetable	O
intake	O
.	O


RESULTS	O
The	O
TF	B-I
group	O
reported	O
a	O
significantly	O
greater	O
increase	O
in	O
fruit	B-OUT
intake	I-OUT
(	O
0.3	O
serves/d	O
P	O
=	O
0.031	O
)	O
in	O
comparison	O
to	O
GE	O
and	O
the	O
C	O
group	O
.	O


All	O
three	O
intervention	O
groups	O
showed	O
a	O
reduction	O
in	O
total	B-OUT
saturated	I-OUT
fat	I-OUT
intake	I-OUT
.	I-OUT


(	O
ABSTRACT	O
TRUNCATED	O
AT	O
250	O
WORDS	O
)	O


Peripheral	B-OUT
muscle	I-OUT
strength	I-OUT
was	O
evaluated	O
using	O
dynamometry	O
and	O
spirometry	O
.	O


The	O
magnesium	B-I
bolus	O
did	O
not	O
produce	O
significant	O
sedation	B-OUT
or	O
appreciably	O
reduce	O
muscle	B-OUT
strength	I-OUT
.	I-OUT


Radiation	O
and	O
contrast	O
agent	O
doses	O
reductions	O
by	O
using	O
80-kV	O
tube	O
voltage	O
in	O
coronary	O
computed	O
tomographic	O
angiography	O
:	O
a	O
comparative	O
study	O
.	O


Each	O
coronary	O
segment	O
was	O
evaluated	O
for	O
image	B-OUT
quality	I-OUT
on	O
a	O
4-point	O
scale	O
.	O


RESULTS	O
Compared	O
with	O
the	O
120-kV	O
group	O
,	O
effective	B-OUT
dose	I-OUT
and	I-OUT
amount	I-OUT
of	I-OUT
contrast	I-OUT
agent	I-OUT
in	O
the	O
80-kV	B-I
group	O
were	O
decreased	O
by	O
57.8	O
%	O
and	O
30.5	O
%	O
(	O
effective	O
dose:2.7	O
±	O
0.5	O
vs.	O
6.4	O
±	O
1.3	O
mSv	O
;	O
amount	O
of	O
contrast	O
agent:57.1	O
±	O
3.2	O
vs.	O
82.1	O
±	O
6.1	O
mL	O
;	O
both	O
p	O
<	O
0.0001	O
)	O
,	O
respectively	B-OUT
.	I-OUT


Our	B-P
center	I-P
initiated	I-P
such	I-P
a	I-P
trial	I-P
in	I-P
January	I-P
2011	I-P
,	I-P
following	I-P
subjects	I-P
randomized	I-P
to	I-P
LESS-DN	I-I
versus	I-I
LDN	I-I
from	I-P
surgery	I-P
through	I-P
5	I-P
years	I-P
postdonation	I-P
.	I-P


Operative	B-P
parameters	I-P
(	I-OUT
overall	I-OUT
time	I-OUT
,	I-OUT
time	I-OUT
to	I-OUT
extraction	I-OUT
,	I-OUT
warm	I-OUT
ischemia	I-OUT
time	I-OUT
,	I-OUT
blood	I-OUT
loss	I-OUT
)	I-OUT
were	I-P
similar	I-P
between	I-P
groups	I-P
.	I-P


LDN	B-I
and	I-I
LESS-DN	O
offer	O
similar	B-OUT
recovery	I-OUT
and	I-OUT
satisfaction	I-OUT
after	O
donation	O
.	O


BACKGROUND	O
Primary	B-P
biliary	I-P
cholangitis	I-P
(	I-P
formerly	I-P
called	I-P
primary	I-P
biliary	I-P
cirrhosis	I-P
)	I-P
can	O
progress	O
to	O
cirrhosis	O
and	O
death	O
despite	O
ursodiol	O
therapy	O
.	O


The	O
rate	O
of	B-OUT
serious	I-OUT
adverse	I-OUT
events	I-OUT
was	O
16	O
%	O
in	O
the	O
5-10-mg	O
group	O
,	O
11	O
%	O
in	O
the	O
10-mg	O
group	O
,	O
and	O
4	O
%	O
in	O
the	O
placebo	O
group	O
.	O


The	O
participants	O
expressed	O
satisfaction	O
with	O
the	O
programme	O
.	O


We	O
studied	O
clinical	O
efficiency	O
and	O
IFN-inducing	O
activity	O
of	O
anaferon	B-I
in	O
chronic	B-P
recurrent	I-P
genital	I-P
herpes	I-P
with	I-P
high	I-P
incidence	I-P
of	I-P
relapses	I-P
.	I-P


Randomized	O
controlled	O
trial	O
of	O
the	O
focus	O
parent	O
training	O
for	O
toddlers	B-P
with	I-P
autism	I-P
:	I-P
1-year	O
outcome	O
.	O


As	O
lateral	B-P
humeral	I-P
epicondylitis	I-P
(	I-P
tennis	I-P
elbow	I-P
)	I-P
is	O
a	O
similar	O
chronic	O
tendon	O
lesion	O
,	O
30	B-P
patients	I-P
with	I-P
both	I-P
clinical	I-P
and	I-P
thermographic	I-P
evidence	I-P
of	I-P
tennis	I-P
elbow	I-P
were	O
randomly	B-I
allocated	I-I
to	I-I
receive	I-I
either	I-I
active	I-I
or	I-I
inactive	I-I
PEMF	I-I
therapy	I-I
.	I-I


RATIONALE	O
Subjects	O
who	O
view	O
experimental	O
procedures	O
as	O
worthwhile	O
are	O
more	O
likely	O
to	O
participate	O
in	O
clinical	O
trials	O
and	O
comply	O
with	O
study	O
procedures	O
.	O


Designing	O
studies	O
that	O
consider	O
the	O
consumer	O
's	O
perspective	O
will	O
help	O
to	O
forge	O
a	O
better	O
alliance	O
between	O
participants	O
and	O
researchers	O
.	O


OBJECTIVE	O
Participant	O
satisfaction	O
is	O
seldom	O
assessed	O
in	O
pharmacological	O
research	O
.	O


In	O
this	O
paper	O
,	O
we	O
report	O
on	O
parent	O
satisfaction	O
in	O
a	O
randomized	O
clinical	O
trial	O
in	O
children	B-P
with	I-P
autistic	I-P
disorder	I-P
and	I-P
severely	I-P
disruptive	I-P
behavior	I-P
.	I-P


The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
compare	O
apical	B-I
seal	I-I
of	O
five	O
different	O
root	B-I
canal	I-I
sealers	I-I
.	I-I


Sixty	B-P
roots	I-P
of	I-P
maxillary	I-P
central	I-P
incisors	I-P
were	O
cleansed	O
and	O
shaped	O
and	O
randomly	O
assigned	O
to	O
one	O
of	O
six	O
groups	O
of	O
ten	O
roots	O
each	O
.	O


The	O
roots	O
,	O
except	O
for	O
the	O
apical	O
2	O
mm	O
,	O
were	O
coated	O
with	O
two	O
layers	O
of	O
nail	O
polish	O
.	O


The	O
roots	O
were	O
stained	O
with	O
india	O
ink	O
,	O
decalcified	O
,	O
dehydrated	O
,	O
and	O
then	O
placed	O
in	O
methylsalicylate	O
to	O
make	O
them	O
transparent	O
.	O


Healthcare	B-OUT
cost	I-OUT
differences	I-OUT
between	O
sustained	O
quitters	O
and	O
a	O
sample	O
of	O
community-dwelling	O
smokers	O
,	O
matched	O
to	O
these	O
quitters	O
on	O
the	O
basis	O
of	O
health	O
services	O
use	O
around	O
the	O
time	O
trial	O
participant	O
enrolled	O
and	O
by	O
demographics	O
,	O
were	O
also	O
examined	O
.	O


By	O
that	O
quarter	O
,	O
continuous	O
sustained	O
quitters	O
cost	B-OUT
$	O
541	O
(	O
p	O
<	O
0.001	O
)	O
less	O
than	O
continuing	O
smokers	O
.	O


DESIGN	O
,	O
SETTING	O
,	O
AND	O
PARTICIPANTS	O
According	O
to	O
a	O
randomized	O
double-blind	O
design	O
,	O
11	B-P
healthy	I-P
subjects	I-P
(	I-P
controls	I-P
)	I-P
and	I-P
12	I-P
hypertensive	I-P
inpatients	I-P
(	I-P
mean	I-P
age	I-P
,	I-P
38.9	I-P
and	I-P
40.4	I-P
yr	I-P
,	I-P
respectively	I-P
)	I-P
received	O
1-h	B-I
iv	I-I
infusion	I-I
of	I-I
beta-endorphin	I-I
(	I-I
250	I-I
mug/h	I-I
)	I-I
and	I-I
,	I-I
on	I-I
another	I-I
occasion	I-I
,	I-I
the	I-I
same	I-I
infusion	I-I
protocol	I-I
preceded	I-I
by	I-I
the	I-I
opioid	I-I
antagonist	I-I
naloxone	I-I
(	I-I
8	I-I
mg	I-I
)	I-I
.	I-I


These	O
hemodynamic	B-OUT
and	I-OUT
hormonal	I-OUT
responses	I-OUT
to	O
beta-endorphin	O
in	O
hypertensive	O
patients	O
were	O
significantly	O
(	O
P	O
<	O
0.0001	O
)	O
greater	O
than	O
in	O
controls	O
but	O
were	O
annulled	O
in	O
all	O
individuals	O
when	O
naloxone	O
preceded	O
beta-endorphin	O
infusion	O
.	O


The	B-OUT
intensity	I-OUT
of	I-OUT
pain	I-OUT
was	I-OUT
scored	I-OUT
based	I-OUT
on	I-OUT
10-point	I-OUT
VAS	I-OUT
before	I-OUT
and	I-OUT
after	I-OUT
treatment	I-OUT
for	I-OUT
up	I-OUT
to	I-OUT
24	I-OUT
h	I-OUT
postoperatively	I-OUT
.	I-OUT


RESULTS	O
At	O
the	O
6	O
,	O
12	O
and	O
24	O
h	O
postoperative	O
intervals	O
after	O
drug	O
administration	B-OUT
,	I-OUT
the	I-OUT
intensity	I-OUT
of	O
pain	O
was	O
significantly	O
lower	O
in	O
the	O
experimental	O
groups	B-I
than	I-I
in	I-I
the	O
placebo	O
group	B-I
(	I-I
P	I-I
<	I-I
0.01	I-I
)	I-I
.	O


Tramadol	O
was	O
significantly	O
less	O
effective	B-I
(	I-I
P	I-I
<	I-I
0.05	I-I
)	I-I
than	I-I
Naproxen	O
,	O
and	O
Novafen	O
that	O
were	O
similar	O
to	O
each	O
other	O
(	O
P	O
>	O
0.05	O
)	O
.	O


Times	B-OUT
were	O
recorded	O
to	O
awakening	O
and	O
tracheal	O
extubation	O
.	O


Time	B-OUT
to	I-OUT
awakening	I-OUT
did	O
not	O
differ	O
significantly	O
.	O


In	O
conclusion	O
,	O
patients	B-P
undergoing	I-P
CABG	I-P
and	O
who	O
were	O
anaesthetized	O
with	O
fentanyl	B-I
and	O
propofol	B-I
needed	O
mechanical	B-OUT
ventilatory	I-OUT
support	I-OUT
for	O
a	O
significantly	O
longer	O
time	O
than	O
those	O
receiving	O
alfentanil	B-I
or	O
sufentanil	B-I
and	O
propofol	B-I
.	I-I


Immunogenicity	B-OUT
and	I-OUT
safety	I-OUT
were	O
evaluated	O
for	O
up	O
to	O
10	O
months	O
.	O


The	O
proportion	B-OUT
of	I-OUT
vaccine	I-OUT
high	I-OUT
responders	I-OUT
was	O
higher	O
in	O
the	O
experimental	O
group	O
(	O
n	O
=	O
48	O
)	O
than	O
among	O
controls	O
(	O
n	O
=	O
49	O
;	O
48.8	O
%	O
vs	O
25.0	O
%	O
;	O
P	O
=	O
.02	O
)	O
at	O
9	O
months	O
.	O


TRIAL	O
REGISTRATION	O
ClinicalTrials.gov	O
identifier	O
:	O
NCT00562939	O
.	O


The	O
interactions	O
of	O
"	O
testing	O
conditions	O
"	O
,	O
"	O
adhesive-composite	O
combination	O
"	O
and	O
"	O
tooth	O
substrate	O
"	O
with	O
"	O
marginal	O
adaptation	O
"	O
were	O
evaluated	O
by	O
two-way	O
ANOVA	O
.	O


OBJECTIVE	O
To	O
evaluate	O
the	O
efficacy	O
and	O
safety	O
of	O
aripiprazole	B-I
versus	O
placebo	B-I
in	O
preventing	O
relapse	O
of	O
irritability	B-OUT
symptoms	I-OUT
associated	O
with	O
autistic	B-P
disorder	I-P
in	I-P
pediatric	I-P
patients	I-P
.	I-P


Kaplan-Meier	B-OUT
relapse	I-OUT
rates	I-OUT
at	O
week	O
16	O
were	O
35	O
%	O
for	O
aripiprazole	O
and	O
52	O
%	O
for	B-I
placebo	I-I
(	O
hazard	O
ratio	O
[	O
HR	O
]	O
=	O
0.57	O
;	O
number	O
needed	O
to	O
treat	O
[	O
NNT	O
]	O
=	O
6	O
)	O
.	O


CONCLUSION	O
Malnutrition	B-OUT
was	O
highly	O
prevalent	O
in	O
this	O
setting	O
of	O
patients	O
.	O


min	O
plus	O
paclitaxel	B-I
225	O
mg/m2	O
on	O
day	O
1	O
.	O


RESULTS	O
Of	O
141	B-P
patients	I-P
enrolled	I-P
,	O
83	O
%	O
were	O
randomly	O
assigned	O
after	O
chemotherapy	O
to	O
qdRT	B-I
(	O
n	O
=	O
59	O
)	O
or	O
HART	B-I
(	O
n	O
=	O
60	O
)	O
.	O


Grade	B-OUT
>	I-OUT
or	I-OUT
=	I-OUT
3	I-OUT
toxicities	I-OUT
included	O
esophagitis	O
in	O
14	O
v	O
nine	B-P
patients	I-P
,	O
and	O
pneumonitis	O
in	O
0	O
v	O
6	O
patients	O
for	O
HART	B-I
and	O
qdRT	B-I
,	O
respectively	O
.	O


Data	O
of	O
the	O
playroom	O
observation	O
pointed	O
to	O
an	O
activating	B-OUT
influence	I-OUT
of	O
Org	O
2766	O
,	O
as	O
revealed	O
by	O
a	O
significant	O
decrease	O
of	O
stereotypic	B-OUT
behavior	I-OUT
and	O
significant	O
increases	O
in	O
"	B-OUT
change	I-OUT
toys	I-OUT
,	I-OUT
"	I-OUT
"	I-OUT
locomote	I-OUT
,	I-OUT
"	I-OUT
and	I-OUT
"	I-OUT
talk	I-OUT
.	I-OUT


"	B-OUT
Checklist	O
ratings	O
did	O
not	O
show	O
significant	O
changes	O
.	O


OBJECTIVE	O
One	O
type	O
of	O
test	O
commonly	O
used	O
to	O
examine	O
auditory	B-P
processing	I-P
disorders	I-P
(	I-P
APD	I-P
)	I-P
is	O
the	O
low-pass	B-I
filtered	I-I
speech	I-I
test	I-I
(	O
LPFST	O
)	O
,	O
of	O
which	O
there	O
are	O
various	O
versions	O
.	O


Adult	B-P
participants	I-P
performed	O
significantly	O
better	O
on	O
the	O
UCAST-FW	B-OUT
in	O
comparison	O
to	O
the	O
child	B-P
participants	I-P
.	I-P


Defibrillation	B-OUT
or	I-OUT
cardio	I-OUT
version	I-OUT
was	O
needed	O
in	O
7.14	O
%	O
patients	O
in	O
group	O
I	O
and	O
28.57	O
%	O
patients	O
in	O
group	O
II	O
(	O
P=0.078	O
)	O
.	O


BACKGROUND	O
It	O
has	O
been	O
suggested	O
that	O
the	O
use	O
of	O
adjunctive	B-I
hyperbaric	I-I
oxygen	I-I
therapy	I-I
improves	O
the	O
healing	O
of	O
diabetic	B-OUT
foot	I-OUT
ulcers	I-OUT
,	O
and	O
decreases	O
the	O
risk	O
of	O
lower	B-OUT
extremity	I-OUT
amputations	I-OUT
.	I-OUT


Patients	O
receive	O
hyperbaric	B-I
oxygen	I-I
therapy	I-I
every	O
day	O
for	O
6	O
weeks	O
during	O
the	O
treatment	O
phase	O
and	O
are	O
provided	O
ongoing	B-I
wound	I-I
care	I-I
and	O
weekly	O
assessments	O
.	O


The	O
decision	O
to	O
amputate	O
is	O
made	O
by	O
a	O
vascular	O
surgeon	O
.	O


DISCUSSION	O
The	O
results	O
of	O
this	O
study	O
will	O
provide	O
detailed	O
information	O
on	O
the	O
efficacy	O
of	O
hyperbaric	B-I
oxygen	I-I
therapy	I-I
for	O
the	O
treatment	O
of	O
non-healing	B-P
ulcers	I-P
of	I-P
the	I-P
lower	I-P
limb	I-P
.	I-P


TRIAL	O
REGISTRATION	O
ClinicalTrials.gov	O
Identifier	O
:	O
NCT00621608	O
.	O


Nepafenac	B-I
for	O
epiretinal	B-P
membrane	I-P
surgery	I-P
.	I-P


Best	O
evidence	O
in	O
critical	O
care	O
medicine	O
.	O


Steroids	B-I
to	O
prevent	O
post-extubation	B-OUT
airway	I-OUT
obstruction	I-OUT
in	O
adult	B-P
critically	I-P
ill	I-P
patients	I-P
.	I-P


Short-term	O
effects	O
of	O
systemic	O
antibiotics	B-I
during	O
periodontal	B-P
healing	I-P
.	I-P


DESIGN	O
A	O
cross-sectional	O
survey	O
of	O
women	B-P
in	I-P
the	I-P
18th	I-P
week	I-P
of	I-P
pregnancy	I-P
.	I-P


Among	O
the	O
Pakistanis	O
a	O
correlation	O
was	O
found	O
between	O
the	B-I
dietary	I-I
intake	I-I
of	I-I
margarine	I-I
,	O
the	O
main	O
source	O
of	B-I
vitamin	I-I
D	I-I
in	O
the	O
diet	O
,	O
and	O
the	O
concentration	O
of	O
25-hydroxyvitamin	O
D3	O
in	O
serum	O
,	O
r	O
=	O
0.48	O
(	O
P	O
=	O
0.01	O
)	O
.	O


The	O
Pakistani	O
women	O
had	O
a	O
lower	B-OUT
intake	I-OUT
of	I-OUT
calcium	I-OUT
than	O
the	O
Norwegians	O
(	O
median	O
793	O
vs	O
1134	O
mg/day	O
,	O
P	O
<	O
0.001	O
)	O
.	O


Median	B-OUT
PFS	I-OUT
[	O
10.1	O
versus	O
10.3	O
months	O
;	O
hazard	O
ratio	O
(	O
HR	O
)	O
0.98	O
;	O
log-rank	O
P	O
=	O
0.38	O
]	O
and	O
OS	B-OUT
(	O
19.9	O
versus	O
30.0	O
months	O
;	O
HR	O
0.663	O
;	O
log-rank	O
P	O
=	O
0.21	O
)	O
were	O
comparable	O
in	O
both	O
arms	O
.	O


CONCLUSION	O
In	O
this	O
randomised	O
trial	O
,	O
no	O
differences	O
in	O
the	O
efficacy	O
study	O
end	O
points	O
were	O
observed	O
between	O
the	O
two	O
treatment	O
arms	O
.	O


Visual	B-I
Assessment	I-I
of	I-I
Relative	I-I
Apical	I-I
Sparing	I-I
Pattern	I-I
Is	O
More	O
Useful	O
Than	O
Quantitative	O
Assessment	O
for	O
Diagnosing	O
Cardiac	O
Amyloidosis	O
in	O
Borderline	B-P
or	I-P
Mildly	I-P
Increased	I-P
Left	I-P
Ventricular	I-P
Wall	I-P
Thickness	I-P
.	I-P


CONCLUSIONS	O
Visual	O
identification	O
of	B-I
RapSP-LS	I-I
is	O
useful	O
in	O
terms	O
of	O
added	B-OUT
diagnostic	I-OUT
value	I-OUT
compared	O
with	O
quantitative	O
calculation	O
of	B-I
RapLSI	I-I
.	O


DESIGN	O
Randomized	O
,	O
placebo-controlled	O
,	O
double-blinded	O
study	O
.	O


PATIENTS	O
44	B-P
women	I-P
between	I-P
18	I-P
and	I-P
70	I-P
years	I-P
of	I-P
age	I-P
,	I-P
who	I-P
were	I-P
surgical	I-P
candidates	I-P
for	I-P
laparoscopic	I-P
cholecystectomy	I-P
.	I-P


Sleepiness	B-OUT
was	O
assessed	O
by	O
the	O
Karolinska	O
Sleepiness	O
Scale	O
.	O


Three	B-P
patients	I-P
did	I-P
not	I-P
complete	I-P
the	I-P
study	I-P
.	I-P


CONCLUSIONS	O
The	O
use	O
of	O
10mg	O
of	O
IV	O
melatonin	B-I
administered	O
during	O
laparoscopic	O
cholecystectomy	O
did	O
not	O
affect	O
postoperative	B-OUT
pain	I-OUT
or	I-OUT
use	I-OUT
of	I-OUT
analgesic	I-OUT
medication	I-OUT
.	I-OUT


Concomitant	O
immunosuppression	O
may	O
affect	O
the	O
mycophenolate	B-OUT
mofetil	I-OUT
exposure	O
.	O


Mean	B-OUT
baseline	I-OUT
plasma	I-OUT
OPN	I-OUT
was	O
46	O
ng/ml	O
(	O
range	O
22.6	O
to	O
290	O
)	O
which	O
did	O
not	O
differ	O
from	O
normal	O
levels	O
.	B-OUT


However	O
,	O
our	O
finding	O
of	O
elevated	B-OUT
mean	I-OUT
OPN	I-OUT
plasma	I-OUT
level	I-OUT
around	O
the	O
time	O
of	O
recurrence	O
warrants	O
further	O
study	O
.	O


TRIAL	O
REGISTRATION	O
NCT00002864	O
,	O
http	O
:	O
//clinicaltrials.gov/show/NCT00002864	O
.	O


A	O
comparison	O
of	O
laser-assisted	B-I
drug	I-I
delivery	I-I
at	O
two	O
output	O
energies	O
for	O
enhancing	B-P
the	I-P
delivery	I-OUT
of	I-OUT
topically	I-OUT
applied	I-OUT
LMX-4	I-OUT
cream	I-OUT
prior	I-P
to	I-P
venipuncture	I-I
.	I-I


OBJECTIVE	O
It	O
has	O
been	O
proposed	O
that	O
a	O
deficit	O
of	O
adenosinergic	O
activity	O
could	O
contribute	O
to	O
the	O
pathophysiology	O
of	O
schizophrenia	O
.	O


Patients	B-P
were	I-P
randomly	I-P
allocated	I-P
(	O
17	O
patients	O
in	O
each	O
group	O
)	O
to	O
risperidone	B-I
(	O
6	O
mg/day	O
)	O
or	O
haloperidol	B-I
15	O
mg/day	O
or	O
clozapine	B-I
(	O
300	O
mg/day	O
)	O
.	O


Compared	O
with	O
placebo	O
,	O
conivaptan	O
at	O
20	O
and	O
40	O
mg	O
significantly	O
reduced	O
pulmonary	B-OUT
capillary	I-OUT
wedge	I-OUT
pressure	I-OUT
(	O
-2.6+/-0.7	O
,	O
-5.4+/-0.7	O
,	O
and	O
-4.6+/-0.7	O
mm	O
Hg	O
for	O
placebo	O
and	O
20	O
and	O
40	O
mg	O
groups	O
,	O
respectively	O
;	O
P	O
<	O
0.05	O
)	O
and	O
right	B-OUT
atrial	I-OUT
pressure	I-OUT
(	O
-2.0+/-0.4	O
,	O
-3.7+/-0.4	O
,	O
and	O
-3.5+/-0.4	O
mm	O
Hg	O
for	O
placebo	O
and	O
20	O
and	O
40	O
mg	O
groups	O
,	O
respectively	O
;	O
P	O
<	O
0.05	O
)	O
during	O
the	O
3-	O
to	O
6-hour	O
interval	O
after	O
intravenous	O
administration	O
.	O


METHODS	O
This	O
study	O
was	O
a	O
prospective	O
,	O
double-blinded	O
,	O
8-wk	O
trial	O
.	O


RESULTS	O
Subjects	O
displayed	O
a	O
strong	O
implicit	O
preference	O
for	O
whites	O
over	O
blacks	O
(	O
P	O
<	O
.0001	O
)	O
and	O
associated	O
"	B-OUT
medically	I-OUT
cooperative	I-OUT
"	I-OUT
with	O
whites	O
over	O
blacks	O
(	O
P	O
<	O
.0001	O
)	O
.	O


There	O
was	O
no	O
significant	O
difference	O
in	O
the	O
rate	B-OUT
of	I-OUT
recommendation	I-OUT
for	I-OUT
TKR	I-OUT
when	O
the	O
patient	O
was	O
black	O
(	O
47	O
%	O
)	O
versus	O
white	O
(	O
38	O
%	O
)	O
(	O
P	O
=	O
.439	O
)	O
,	O
and	O
neither	O
implicit	O
nor	O
explicit	O
racial	O
biases	O
predicted	O
differential	O
treatment	O
recommendations	O
by	O
race	O
(	O
all	O
P	O
>	O
.06	O
)	O
.	O


Although	O
participants	O
were	O
more	O
likely	O
to	O
recommend	B-OUT
TKR	I-OUT
when	O
completing	O
the	O
implicit	O
association	O
test	O
before	O
the	O
decision	O
,	O
patient	O
race	O
was	O
not	O
significant	O
in	O
the	O
association	O
(	O
P	O
=	O
.960	O
)	O
.	O


Does	O
watching	O
a	O
video	O
on	O
third	B-I
molar	I-I
surgery	I-I
increase	O
patients	B-P
'	I-P
anxiety	I-P
level	I-P
?	O
OBJECTIVE	O
To	O
identify	O
the	O
effects	O
of	O
watching	B-I
live	I-I
taping	I-I
of	I-I
third	I-I
molar	I-I
removal	I-I
on	O
patients	B-P
'	I-P
anxiety	I-P
levels	I-P
before	O
and	O
after	O
extraction	O
.	O


Regression	O
analyses	O
revealed	O
inverse	O
associations	O
of	O
FEV	B-OUT
(	I-OUT
1	I-OUT
)	I-OUT
and	O
FEV	B-OUT
(	I-OUT
1	I-OUT
)	I-OUT
/FVC	I-OUT
ratio	I-OUT
with	O
IL-5	B-OUT
(	O
P	O
<	O
0.05	O
)	O
in	O
men	O
and	O
with	O
IL-5	B-OUT
(	O
P	O
=	O
0.01	O
)	O
,	O
IL-6	B-OUT
(	O
P	O
<	O
0.001	O
)	O
,	O
IFN-gamma	B-OUT
(	O
P	O
=	O
0.034	O
)	O
and	O
serum	B-OUT
cotinine	I-OUT
(	O
P	O
<	O
0.001	O
)	O
in	O
women	O
.	O


Better	O
emotional	B-OUT
coping	I-OUT
behaviours	I-OUT
were	O
also	O
revealed	O
by	O
some	O
changes	O
in	O
personality	O
traits	O
in	O
the	O
intervention	O
group	O
.	O


The	O
relationship	O
between	O
two	O
indices	O
was	O
linear	O
in	O
each	O
subject	O
,	O
and	O
the	O
correlation	O
coefficient	O
was	O
0.83	O
when	O
evaluated	O
using	O
whole	O
data	O
.	O


Overall	B-OUT
survival	I-OUT
was	O
59	O
%	O
in	O
the	O
control	O
and	O
69	O
in	O
the	O
infusion	O
group	O
(	O
p	O
=	O
0.048	O
)	O
.	O


Domperidone	B-I
,	I-I
metoclopramide	I-I
,	I-I
and	I-I
placebo	I-I
.	I-I


Renal	O
function	O
was	O
studied	O
in	O
18	B-P
patients	I-P
with	I-P
Type	I-P
1	I-P
diabetes	I-P
mellitus	I-P
.	I-P


All	B-P
were	I-P
participating	I-P
in	I-P
the	I-P
Canadian-European	I-P
randomized	I-P
placebo-controlled	I-I
cyclosporin	I-I
trial	I-P
in	I-P
newly	I-P
diagnosed	I-P
Type	I-P
1	I-P
diabetic	I-P
patients	I-P
,	O
nine	O
being	O
randomized	O
to	O
placebo	B-I
,	O
and	O
nine	O
to	O
cyclosporin	B-I
A	I-I
.	I-I


When	O
corrected	O
for	O
differences	O
in	O
blood	O
glucose	O
control	O
it	O
appeared	O
that	O
in	O
three	O
out	O
of	O
nine	O
patients	O
glomerular	B-OUT
filtration	I-OUT
rate	I-OUT
had	O
not	O
completely	O
returned	O
to	O
the	O
reference	O
range	O
of	O
the	O
placebo	B-I
group	O
.	O


We	O
conclude	O
that	O
the	O
nephrotoxic	O
side-effects	O
of	O
cyclosporin	B-I
A	I-I
treatment	O
for	O
1	O
year	O
are	O
reversible	O
.	O


Failure	O
rates	O
were	O
higher	O
among	O
HIV-infected	B-P
persons	I-P
treated	O
with	O
thrice-weekly	O
intensive	O
phase	O
therapy	O
.	O


Continuous	O
glucose	O
monitoring	O
in	O
acute	B-P
coronary	I-P
syndrome	I-P
.	I-P


RESULTS	O
We	O
observed	O
a	O
statistically	O
significant	O
difference	O
in	O
the	B-OUT
mean	I-OUT
time	I-OUT
for	I-OUT
achieving	I-OUT
normoglycemia	I-OUT
,	O
favoring	O
the	O
conventional	O
group	O
with	O
a	O
P	O
=	O
0.02	O
.	O


The	O
time	B-OUT
difference	I-OUT
in	I-OUT
scaling	I-OUT
between	O
the	O
product	O
and	O
placebo	O
side	O
was	O
not	O
significant	O
.	O


This	O
study	O
found	O
that	O
SofScale	B-I
is	O
safe	O
to	O
gingival	B-OUT
tissues	I-OUT
and	O
does	O
not	O
promote	O
tooth	B-OUT
sensitivity	I-OUT
.	I-OUT


To	O
evaluate	O
the	O
role	O
of	O
hydroxyurea	B-I
(	I-I
HU	I-I
)	I-I
for	O
the	O
outcome	O
of	O
IFN	B-I
therapy	I-I
,	O
we	O
conducted	O
a	O
randomized	O
trial	O
to	O
compare	B-I
the	I-I
combination	I-I
of	I-I
IFN	I-I
and	I-I
HU	I-I
vs	I-I
HU	I-I
monotherapy	I-I
(	I-I
CML-study	I-I
II	I-I
)	I-I
.	I-I


In	O
all	O
,	O
340	B-P
patients	I-P
were	I-P
Ph/BCR-ABL	I-P
positive	I-P
and	I-P
evaluable	I-P
.	I-P


Duration	B-OUT
of	I-OUT
chronic	I-OUT
phase	I-OUT
was	O
55	O
months	O
for	O
IFN/HU	O
and	O
41	O
months	O
for	O
HU	O
(	O
P	O
<	O
0.0001	O
)	O
.	O


Primary	B-P
care	I-P
physicians	I-P
(	I-P
113	I-P
)	I-P
participated	I-P
in	I-P
a	I-P
randomized	I-P
controlled	I-P
trial	I-P
to	I-P
evaluate	I-P
an	I-P
online	I-P
CME	I-P
series	I-P
.	I-P


Physicians	O
who	O
viewed	O
the	O
seminars	O
were	O
significantly	O
more	O
likely	O
to	O
recommend	B-OUT
guideline-consistent	I-OUT
care	I-OUT
to	O
patients	O
in	O
the	O
vignettes	O
.	O


For	O
some	O
guidelines	O
there	O
were	O
no	O
group	O
differences	O
.	O


Upon	O
completion	O
of	O
lung	O
resection	O
,	O
a	O
catheter	O
was	O
placed	O
in	O
the	O
proximal	O
paraphrenic	O
tissue	O
on	O
the	O
pericardial	O
surface	O
.	O


After	O
an	O
initial	O
phase	O
of	O
recovery	O
of	O
5	O
days	O
all	O
patients	O
underwent	O
ultrasonographic	B-I
assessment	O
of	O
diaphragmatic	O
motion	O
followed	O
by	O
lung	O
function	O
testing	O
with	O
and	O
without	O
induced	O
phrenic	O
nerve	O
palsy	O
.	O


CONCLUSIONS	O
Our	O
results	O
show	O
that	O
phrenic	O
nerve	O
palsy	O
causes	O
a	O
significant	O
impairment	O
of	B-OUT
dynamic	I-OUT
lung	I-OUT
volumes	I-OUT
during	O
the	O
early	O
postoperative	O
period	O
after	B-I
pneumonectomy	I-I
.	O


Descriptive	B-OUT
statistics	I-OUT
of	I-OUT
DRE-outcome	I-OUT
per	I-OUT
PSA-range	I-OUT
were	O
used	O
to	O
determine	O
the	O
observer	O
variability	O
of	O
six	O
examiners	O
.	O


CONCLUSIONS	O
Three	O
of	O
six	O
examiners	O
considered	O
DRE	B-OUT
significantly	O
more	O
often	O
suspicious	O
than	O
the	O
others	O
.	O


INTRODUCTION	O
Delusions	O
may	O
arise	O
from	O
abnormalities	O
in	O
emotional	O
perception	O
.	O


Second	O
,	O
delusional	O
patients	O
took	O
significantly	O
longer	O
than	O
both	O
other	O
groups	O
to	O
correctly	B-OUT
classify	I-OUT
neutral	I-OUT
words	I-OUT
in	O
both	O
affective	O
classification	O
tasks	O
.	O


Effects	O
of	O
alcohol	B-I
on	O
the	O
pharmacokinetics	B-OUT
of	O
morphine	B-I
sulfate	I-I
and	O
naltrexone	B-I
hydrochloride	I-I
extended	O
release	O
capsules	O
.	O


No	O
drug	B-OUT
interaction	I-OUT
was	O
found	O
between	O
morphine	O
in	O
MS-sNT	O
and	O
4	O
%	O
or	O
20	O
%	O
alcohol	O
.	O


The	O
treatment	O
effect	O
on	O
child	B-OUT
initiation	I-OUT
of	I-OUT
joint	I-OUT
attention	I-OUT
increased	O
with	O
increasing	O
level	B-OUT
of	I-OUT
sociability	I-OUT
at	O
baseline	O
,	O
whereas	O
nonverbal	B-OUT
IQ	I-OUT
and	I-OUT
expressive	I-OUT
language	I-OUT
had	O
no	O
moderating	O
effect	O
.	O


Clinical	O
trial	O
registration	O
information	O
--	O
Joint	O
Attention	O
Intervention	O
and	O
Young	O
Children	O
With	O
Autism	O
;	O
http	O
:	O
//clinicaltrials.gov/	O
;	O
NCT00378157	O
.	O


DC	B-I
provided	O
superior	O
palliation	B-OUT
and	O
was	O
well	O
tolerated	B-OUT
by	O
an	O
essentially	B-P
geriatric	I-P
population	I-P
.	I-P


Our	O
primary	O
objective	O
was	O
to	O
compare	O
whether	O
tinzaparin	B-I
and	O
dalteparin	B-I
differentially	O
accumulate	O
in	O
HD	B-P
patients	I-P
.	I-P


Two	O
minutes	O
before	O
the	O
venepuncture	B-I
,	O
in	O
the	O
intervention	O
arm	O
,	O
40	O
babies	O
received	O
5	O
ml	O
of	O
EBM	O
,	O
while	O
41	O
babies	O
in	O
control	O
group	O
received	O
5	B-I
ml	I-I
of	I-I
distilled	I-I
water	I-I
(	I-I
DW	I-I
)	I-I
as	I-I
placebo	I-I
.	I-I


This	O
has	O
implications	O
for	O
e-learning	B-I
design	O
in	O
medicine	O
and	O
other	O
disciplines	O
.	O


DESIGN	O
AND	O
METHODS	O
This	O
was	O
a	O
multicenter	B-P
prospective	I-P
trial	I-P
in	I-P
77	I-P
SAA	I-P
patients	I-P
treated	I-P
with	I-P
horse	I-I
ALG	I-I
(	I-I
15	I-I
mg/kg/day	I-I
day1-5	I-I
)	I-I
and	I-I
CyA	I-I
(	I-I
5	I-I
mg/kg/day	I-I
day	I-I
1-180	I-I
)	I-I
.	I-I


RESULTS	O
At	O
day	O
+120	O
responses	B-OUT
were	O
classified	O
as	O
absent	B-OUT
,	I-OUT
partial	I-OUT
,	O
and	O
complete	B-OUT
in	O
12	O
,	O
22	O
,	O
and	O
4	O
patients	O
in	O
group	O
A	O
and	O
in	O
23	O
,	O
7	O
,	O
and	O
9	O
patients	O
in	O
group	O
B	O
(	O
p=0.001	O
)	O
.	O


A	O
study	O
in	O
ASA	B-P
I	I-P
and	I-P
II	I-P
patients	I-P
.	I-P


Traditionally	O
,	O
this	O
information	O
has	O
been	O
collected	O
with	O
paper	O
and	O
pencil	O
.	O


One	O
solution	O
that	O
addresses	O
many	O
of	O
these	O
barriers	O
is	O
the	O
adoption	B-I
of	I-I
computerized	I-I
screening	I-I
for	I-I
symptom	I-I
and	I-I
quality-of-life	I-I
information	I-I
.	I-I


We	O
intend	O
to	O
build	O
on	O
our	O
work	O
by	O
using	O
the	O
survey	O
platform	O
in	O
other	O
modalities	O
while	O
ensuring	O
that	O
the	O
patient	O
's	O
preferences	O
are	O
considered	O
at	O
all	O
times	O
.	O


Effects	O
of	O
iron	B-I
on	O
the	O
pharmacokinetics	B-OUT
of	I-OUT
paracetamol	I-OUT
in	I-OUT
saliva	I-OUT
.	I-OUT


A	O
communication-based	B-I
intervention	I-I
for	O
nonverbal	B-P
children	I-P
with	O
autism	O
:	O
what	O
changes	O
?	O
Who	O
benefits	O
?	O
OBJECTIVE	O
This	O
article	O
examines	O
the	O
form	O
and	O
function	O
of	O
spontaneous	O
communication	O
and	O
outcome	O
predictors	O
in	O
nonverbal	B-P
children	I-P
with	I-P
autism	I-P
following	I-P
classroom-based	I-I
intervention	I-I
(	I-I
Picture	I-I
Exchange	I-I
Communication	I-I
System	I-I
[	I-I
PECS	I-I
]	I-I
training	I-I
)	I-I
.	O


Canine	B-P
parvoviral	I-P
enteritis	I-P
continues	O
to	O
cause	O
significant	O
morbidity	O
and	O
mortality	O
in	O
dogs	B-P
worldwide	O
,	O
and	O
efficacious	O
antiviral	B-I
therapies	I-I
are	O
lacking	O
.	O


A	O
double-blind	O
,	O
placebo-controlled	O
challenge	O
trial	O
was	O
performed	O
in	O
beagle	B-P
pups	I-P
(	I-P
8-9	I-P
weeks	I-P
)	I-P
;	I-P
clinical	O
signs	O
,	O
body	O
weight	O
,	O
hematologic	O
parameters	O
,	O
and	O
mortality	O
were	O
monitored	O
for	O
a	O
period	O
of	O
14	O
days	O
after	O
challenge	O
.	O


All	O
five	O
dogs	O
in	O
the	O
placebo	O
group	O
developed	O
fulminating	B-OUT
enteritis	I-OUT
with	I-OUT
typical	I-OUT
clinical	I-OUT
signs	I-OUT
and	I-OUT
died	I-OUT
within	O
10	O
days	O
post-inoculation	O
(	O
or	O
6	O
days	O
post-treatment	O
)	O
.	O


INTRODUCTION	O
This	O
preliminary	O
study	O
aimed	O
to	O
investigate	O
the	O
effects	O
of	O
the	O
probiotic	B-I
Saccharomyces	I-I
boulardii	I-I
on	O
proinflammatory	O
and	O
anti-inflammatory	O
cytokines	O
in	O
patients	B-P
with	I-P
diarrhea-dominant	I-P
irritable	I-P
bowel	I-P
syndrome	I-P
(	I-P
IBS-D	I-P
)	I-P
.	I-P


RESULTS	O
Thirty-seven	B-P
patients	I-P
received	I-P
S.	I-I
boulardii	I-I
and	I-P
35	I-P
patients	I-P
received	I-P
the	I-P
placebo	I-I
.	I-I


No	O
serious	O
adverse	O
events	O
were	O
found	O
in	O
either	O
group	O
.	O


CONCLUSION	O
S.	B-I
boulardii	I-I
with	O
ispaghula	O
husk	O
was	O
superior	O
to	O
placebo	O
with	O
ispaghula	O
husk	O
in	O
improving	O
the	O
cytokine	O
profile	O
,	O
histology	O
,	O
and	O
quality	O
of	O
life	O
of	B-P
patients	I-P
with	I-P
IBS-D	I-P
.	O


These	O
preliminary	O
results	O
need	O
to	O
be	O
confirmed	O
in	O
a	O
well-powered	O
trial	O
.	O


There	O
was	O
also	O
a	O
significant	B-OUT
difference	I-OUT
in	I-OUT
Lip	I-OUT
levels	I-OUT
between	O
the	O
control	O
and	O
cirrhosis	O
group	O
and	O
the	O
control	O
and	O
HCC	O
groups	O
(	O
all	O
P	O
<	O
0.001	O
)	O
.	O


There	O
were	O
also	O
differences	B-OUT
in	I-OUT
Cho/Lip	O
between	O
the	O
control	O
and	O
cirrhosis	O
groups	O
,	O
the	O
control	O
and	O
HCC	O
groups	O
,	O
and	O
the	O
cirrhosis	O
and	O
HCC	O
groups	O
(	O
all	O
P	O
<	O
0.001	O
)	O
.H-MRS	O
followed	O
by	O
the	O
analysis	O
with	O
LCModel	O
can	O
be	O
used	O
to	O
measure	B-OUT
changes	I-OUT
in	I-OUT
hepatic	I-OUT
metabolite	I-OUT
levels	O
in	O
patients	O
with	O
liver	O
cirrhosis	O
secondary	O
to	O
chronic	O
hepatitis	O
B	O
and	O
HCC	O
.	O


Thus	O
,	O
H-MRS	O
may	O
be	O
helpful	O
in	O
monitoring	O
HCC	O
and	O
liver	O
cirrhosis	O
development	O
.	O


Experimental	B-I
group	I-I
(	I-I
n	I-I
=	I-I
15	I-I
)	I-I
received	I-I
a	I-I
topical	I-I
application	I-I
of	I-I
doxymycine	I-I
and	I-I
controls	I-I
(	I-I
n	I-I
=	I-I
16	I-I
)	I-I
received	I-I
calcii	I-I
gluconase	I-I
in	I-I
the	I-I
same	I-I
manner	I-I
.	I-I


Medications	B-I
were	I-I
covered	I-I
by	I-I
isobutyl	I-I
cyanoacrylate	I-I
(	I-I
Iso-Dent	I-I
)	I-I
.	I-I


Left	B-OUT
ventricular	I-OUT
time	I-OUT
intervals	I-OUT
were	O
obtained	B-OUT
by	O
means	O
of	O
carotid	B-OUT
thermistor	I-OUT
plethysmography	I-OUT
.	I-OUT


Alinidine	B-I
increased	O
both	O
total	B-OUT
exercise	I-OUT
duration	I-OUT
from	O
246.7	O
+/-	O
120.7	O
to	O
346.6	O
+/-	O
114.1	O
s	O
(	O
p	O
less	O
than	O
0.05	O
)	O
and	O
time	B-OUT
to	I-OUT
0.1-mV	I-OUT
ST	I-OUT
segment	I-OUT
depression	I-OUT
from	O
98.3	O
+/-	O
53	O
to	O
187.2	O
+/-	O
105	O
s	O
(	O
p	O
less	O
than	O
0.05	O
)	O
.	O


Similarly	O
the	O
drug	O
induced	B-OUT
a	I-OUT
reduction	I-OUT
of	I-OUT
the	I-OUT
rate-pressure	I-OUT
product	I-OUT
and	O
of	O
the	O
extent	B-OUT
of	I-OUT
ischemic	I-OUT
ST	I-OUT
segment	I-OUT
depression	I-OUT
during	O
exercise	O
.	O


Estradiol	B-OUT
,	I-OUT
prolactin	I-OUT
and	I-OUT
cortisol	I-OUT
,	I-OUT
and	I-OUT
a	I-OUT
single	I-OUT
measure	I-OUT
of	I-OUT
IL-6	I-OUT
were	O
assayed	O
.	O


RESULTS	O
In	O
the	O
analyses	O
of	O
time	O
to	B-OUT
PPMD	I-OUT
recurrence	I-OUT
,	I-OUT
poor	I-OUT
sleep	I-OUT
quality	I-OUT
,	O
but	O
none	O
of	O
the	O
hormones	O
,	O
was	O
associated	O
with	B-OUT
PPMD	I-OUT
recurrence	I-OUT
(	O
p	O
<	O
.05	O
)	O
after	O
controlling	O
for	O
medication	O
assignment	O
.	O


CONCLUSIONS	O
Poor	O
sleep	O
quality	O
across	O
the	O
first	O
17	O
weeks	O
post-delivery	O
increases	O
the	O
risk	O
for	O
recurrent	O
PPMD	O
among	B-P
women	I-P
with	I-P
a	I-P
history	I-P
of	I-P
MDD	I-P
.	O


Transthoracic	B-I
echocardiography	I-I
with	I-I
myocardial	I-I
velocity	I-I
imaging	I-I
and	I-I
right	I-I
heart	I-I
catheterization	I-I
were	O
performed	O
in	O
33	B-P
patients	I-P
with	I-P
pulmonary	I-P
hypertension	I-P
.	I-P


Measured	B-OUT
IVRTs	I-OUT
were	O
significantly	B-OUT
longer	I-OUT
in	O
patients	O
with	O
pulmonary	O
hypertension	O
than	O
in	O
control	O
subjects	O
.	O


The	O
basal	B-OUT
segment	I-OUT
IVRT	I-OUT
'	I-OUT
corrected	O
for	O
heart	B-OUT
rate	I-OUT
correlates	O
well	O
with	O
the	O
invasive	O
PAP	O
measurement	O
and	O
,	O
therefore	O
,	O
can	O
be	O
used	O
to	O
predict	O
systolic	B-OUT
PAP	I-OUT
.	I-OUT


Two	O
preplanned	O
comparisons	O
were	O
made	O
:	O
(	O
a	O
)	O
Spinal	B-I
manipulative	I-I
therapy	I-I
(	I-I
SMT	I-I
)	I-I
combined	I-I
with	I-I
trunk	I-I
strengthening	I-I
exercises	I-I
(	I-I
TSE	I-I
)	I-I
vs.	I-I
SMT	I-I
combined	I-I
with	I-I
trunk	I-I
stretching	I-I
exercises	I-I
,	I-I
and	I-I
(	O
b	O
)	O
SMT	B-I
combined	I-I
with	I-I
TSE	I-I
vs.	I-I
nonsteroidal	I-I
anti-inflammatory	I-I
drug	I-I
(	I-I
NSAID	I-I
)	I-I
therapy	I-I
combined	I-I
with	I-I
TSE	I-I
.	I-I


The	O
trial	O
evaluated	O
therapies	O
in	O
combination	O
only	O
and	O
was	O
not	O
designed	O
to	O
test	O
the	O
individual	O
treatment	O
components	O
.	O


RESULTS	O
Individual	O
group	O
comparisons	O
after	O
5	O
and	O
11	O
wk	O
of	O
intervention	O
on	O
all	O
three	B-OUT
main	I-OUT
outcome	I-OUT
measures	I-OUT
did	O
not	O
reveal	O
any	O
clear	O
clinically	O
important	O
or	O
statistically	O
significant	O
differences	O
.	O


PURPOSE	O
To	O
evaluate	O
the	O
safety	O
and	O
efficacy	O
of	O
initial	O
treatment	O
with	O
imatinib	B-I
mesylate	I-I
800	O
mg/d	O
(	O
400	O
mg	O
twice	O
daily	O
)	O
versus	O
400	O
mg/d	O
in	O
patients	B-P
with	I-P
newly	I-P
diagnosed	I-P
chronic	I-P
myeloid	I-P
leukemia	I-P
in	I-P
chronic	I-P
phase	I-P
.	I-P


PURPOSE	O
To	O
determine	O
the	O
efficacy	B-OUT
and	O
safety	B-OUT
of	O
subconjunctival	B-I
5-	I-I
fluorouracil	I-I
injections	I-I
after	O
trabeculectomy	O
in	O
patients	B-P
with	I-P
poor	I-P
prognoses	I-P
,	I-P
to	I-P
determine	I-P
risk	I-P
factors	I-P
for	I-P
surgical	I-P
failure	I-P
and	I-P
to	I-P
examine	I-P
the	I-P
relationship	I-P
of	I-P
intraocular	I-OUT
pressure	I-OUT
and	I-OUT
visual	I-OUT
function	I-OUT
.	I-OUT


In	O
123	B-P
patients	I-P
(	O
per	O
protocol	O
set	O
)	O
,	O
those	O
remaining	O
free	O
from	O
PAF/PAFL	B-OUT
after	O
the	O
treatment	O
were	O
3.1	O
%	O
on	O
placebo	B-I
,	O
7.7	O
%	O
on	O
25	O
mg/BID	O
,	O
9.4	O
%	O
on	O
50	O
mg/BID	O
,	O
and	O
39.4	O
%	O
on	O
100	O
mg/BID	O
of	O
flecainide	B-I
.	I-I


One	O
of	O
the	O
2	O
controlled	O
preventive	O
trials	O
within	O
the	O
Oslo	O
Study	O
was	O
a	O
non-drug	O
trial	O
on	O
the	O
effect	B-OUT
of	I-OUT
diet	I-OUT
and	I-OUT
smoking	I-OUT
intervention	I-OUT
on	O
coronary	O
heart	O
disease	O
in	O
1232	B-P
middleaged	I-P
,	I-P
normotensive	I-P
,	I-P
healthy	I-P
men	I-P
.	I-P


Some	O
of	O
the	O
most	O
important	O
items	O
:	O
personality	O
,	O
motivation	O
,	O
diet	O
history	O
,	O
bodyweight	O
,	O
blood	O
lipids	O
and	O
blood	O
sugar	O
anti-smoking	O
advice	O
given	O
individually	O
to	O
all	O
smokers	O
in	O
the	O
intervention	O
group	O
advice	O
that	O
smoking	O
cessation	O
was	O
expected	O
to	O
be	O
of	O
special	O
importance	O
for	O
those	O
with	O
elevated	O
blood	O
lipids	O
.	O


METHODS	O
This	O
was	O
an	O
open-label	O
,	O
randomized	O
,	O
three-period	O
crossover	O
study	O
in	O
healthy	B-P
male	I-P
volunteers	I-P
(	I-P
n=12	I-P
)	I-P
.	I-P


DESIGN	O
The	O
design	O
was	O
a	O
randomized	O
,	O
double-blind	O
,	O
controlled	O
crossover	O
trial	O
.	B-P


The	O
primary	O
outcome	O
was	B-OUT
insulin	I-OUT
sensitivity	I-OUT
assessed	I-OUT
by	I-OUT
using	I-OUT
the	I-OUT
Matsuda	I-OUT
method	I-OUT
from	I-OUT
an	I-OUT
oral-glucose-tolerance	I-OUT
test	I-OUT
.	O


CONCLUSIONS	B-I
Supplementation	I-I
with	I-I
a	I-I
blend	I-I
of	I-I
KS	I-I
oil	I-I
is	O
associated	O
with	O
decreased	B-OUT
insulin	I-OUT
sensitivity	I-OUT
.	O


Randomized	O
clinical	O
trial	O
comparing	O
systemic	O
interferon	B-I
with	O
diathermocoagulation	B-I
in	O
primary	B-P
multiple	I-P
and	I-P
widespread	I-P
anogenital	I-P
condyloma	I-P
.	I-P


Effect	O
of	O
a	O
vitamin/mineral	B-I
supplement	I-I
on	O
children	B-P
and	I-P
adults	I-P
with	I-P
autism	I-P
.	I-P


For	O
the	O
other	O
three	O
assessment	O
tools	O
the	O
difference	O
between	O
treatment	O
group	O
and	O
placebo	O
group	O
was	O
not	O
statistically	O
significant.Regression	O
analysis	O
revealed	O
that	O
the	O
degree	O
of	O
improvement	O
on	O
the	O
Average	B-OUT
Change	I-OUT
of	I-OUT
the	I-OUT
PGI-R	I-OUT
was	O
strongly	O
associated	O
with	O
several	O
biomarkers	O
(	O
adj	O
.	O


The	O
alternative	O
scenario	O
analysis	O
showed	O
that	O
the	O
probability	B-OUT
of	I-OUT
cost-effectiveness	I-OUT
increased	I-OUT
over	O
the	O
range	O
of	O
threshold	O
values	O
used	O
if	O
the	O
cost	O
perspective	O
was	O
restricted	O
to	O
formal	O
healthcare	O
.	O


CONCLUSIONS	O
A	O
multifaceted	O
,	O
psychosocial	O
intervention	O
programme	O
was	O
found	O
unlikely	O
to	O
be	O
cost-effective	B-OUT
from	O
a	O
societal	O
perspective	O
.	O


SUBJECTS	O
AND	O
METHODS	O
Medically	B-P
(	I-I
oral	I-I
pyridostigmine	I-I
)	I-I
well-controlled	I-P
adult	I-P
patients	I-P
with	I-P
myasthenia	I-P
gravis	I-P
who	I-P
were	I-P
posted	I-P
for	I-P
thymectomy	I-I
,	O
were	O
randomly	O
divided	O
into	O
two	O
groups	O
.	O


By	O
giving	O
the	O
morning	O
dose	O
of	O
pyridostigmine	B-I
(	O
Group	O
2	O
)	O
,	O
an	O
identical	O
intubating	O
dose	O
of	O
vecuronium	B-I
showed	O
relative	B-OUT
resistance	I-OUT
(	O
peak	O
effect-97	O
%	O
T1	O
suppression	O
)	O
and	O
delayed	B-OUT
onset	I-OUT
time	I-OUT
(	O
198	O
sec	O
approx.	O
)	O
.	O


Evidence	O
supports	O
a	O
connection	O
among	O
dietary	B-I
sodium	I-I
,	O
the	O
rennin-angiotensin	O
system	O
,	O
and	O
myocardial	O
function	O
.	O


Thirteen	B-P
healthy	I-P
volunteers	I-P
(	I-P
aged	I-P
38.6	I-P
+/-	I-P
4	I-P
years	I-P
)	I-P
entered	O
a	O
2	O
week	O
crossover	O
design	O
study	O
(	O
week	O
1	O
,	O
high	B-I
sodium	I-I
diet	I-I
[	I-I
HS	I-I
]	I-I
>	O
200	O
mmol	O
Na/day	O
;	O
week	O
2	O
,	O
low	B-I
sodium	I-I
diet	I-I
[	I-I
LS	I-I
]	I-I
,	O
<	O
10	O
mmol	O
Na/day	O
)	O
to	O
investigate	O
the	O
influence	O
of	O
dietary	O
sodium	O
and	O
Ang	O
II	O
on	O
myocardial	O
relaxation	O
and	O
renal	B-OUT
blood	I-OUT
flow	I-OUT
(	I-OUT
RBF	I-OUT
)	I-OUT
.	I-OUT


It	O
is	O
important	O
to	O
consider	O
dietary	B-I
sodium	I-I
intake	O
when	O
assessing	O
diastolic	B-OUT
function	I-OUT
.	I-OUT


The	O
population	O
pharmacokinetic	B-OUT
(	I-OUT
PK	I-OUT
)	I-OUT
profile	I-OUT
of	O
oral	B-I
clonidine	I-I
was	O
characterized	O
in	O
newborns	B-P
with	I-P
neonatal	I-P
abstinence	I-P
syndrome	I-P
,	O
and	O
significant	O
covariates	O
affecting	O
its	O
PK	O
parameters	O
were	O
identified	O
.	O


METHODS	O
Patients	B-P
were	I-P
eligible	I-P
if	I-P
they	I-P
had	I-P
stage	I-P
I-IIIB	I-P
NSCLC	I-P
,	I-P
unsuitable	I-P
for	I-P
curative	I-P
therapy	I-P
,	I-P
or	I-P
stage	I-P
IV	I-P
with	I-P
a	I-P
PET-detected	I-P
extracranial	I-P
solitary	I-P
metastasis	I-P
.	I-P


METHODOLOGY	O
One	B-P
hundred	I-P
and	I-P
ninety-three	I-P
(	I-P
193	I-P
)	I-P
H.	I-P
pylori-positive	I-P
patients	I-P
were	O
randomly	O
assigned	O
to	O
one	O
of	O
the	O
following	O
7-day	O
treatments	O
:	O
Group	B-P
A	I-P
(	I-P
N	I-P
=	I-P
64	I-P
)	I-P
:	I-P
amoxicillin	I-I
,	I-I
clarithromycin	I-I
and	I-I
rabeprazole	I-I
;	I-I
Group	I-P
B	I-P
(	I-P
N	I-P
=	I-P
64	I-P
)	I-P
:	I-P
tinidazole	I-I
,	I-I
clarithromycin	I-I
and	I-I
ranitidine	I-I
bismuth	I-I
citrate	I-I
;	I-I
Group	I-P
C	I-P
(	I-P
N	I-P
=	I-P
65	I-P
)	I-P
:	I-P
tinidazole	I-I
,	I-I
clarithromycin	I-I
and	I-I
rabeprazole	I-I
Eradication	O
was	O
assessed	O
by	O
13C-Urea	O
Breath	O
Test	O
6-8	O
weeks	O
after	O
the	O
end	O
of	O
the	O
therapy	O
.	O


No	O
significant	O
difference	O
in	O
eradication	B-OUT
rates	I-OUT
was	O
observed	O
among	O
the	O
three	O
groups	O
both	O
in	O
intention	O
to	O
treat	O
analysis	O
and	O
in	O
per	O
protocol	O
analysis	O
.	O


A	B-I
sham	I-I
and	I-I
an	I-I
active	I-I
ITD	I-I
were	O
used	O
for	O
1	O
min	O
each	O
in	O
a	O
randomized	O
order	O
,	O
first	O
on	O
a	O
facemask	B-I
and	O
then	O
on	O
an	O
ETT	B-I
.	I-I


CONCLUSIONS	O
Use	O
of	O
an	O
active	B-I
ITD	I-I
attached	I-I
to	I-I
a	I-I
facemask	I-I
or	I-I
an	I-I
ETT	I-I
resulted	O
in	O
a	O
significantly	O
lower	O
negative	B-OUT
intratracheal	I-OUT
pressure	I-OUT
during	O
the	O
decompression	O
phase	O
of	O
active	O
compression-decompression	O
cardiopulmonary	O
resuscitation	O
when	O
compared	O
with	O
controls	O
.	O


The	O
results	O
were	O
compared	O
with	O
a	O
group	B-P
of	I-P
normal	I-P
deliveries	I-P
in	I-P
which	I-P
analgesia	I-OUT
was	I-P
achieved	I-P
with	I-P
pethidine	I-I
.	I-I


Both	O
medicaments	O
excerted	O
an	O
identical	B-OUT
analgetic	I-OUT
efficiency	I-OUT
.	I-OUT


A	O
comparison	O
of	O
human	O
papillomavirus	O
testing	O
of	O
clinician-collected	B-I
and	I-I
self-collected	I-I
samples	I-I
during	O
follow-up	O
after	O
screen-and-treat	O
.	O


However	O
,	O
because	O
cryotherapy	O
is	O
not	O
100	O
%	O
effective	O
,	O
follow-up	O
is	O
needed	O
after	O
treatment	O
to	O
detect	O
post-treatment	O
failures	O
.	O


HPV	O
testing	O
using	O
self-collected	B-I
vaginal	I-I
specimens	I-I
may	O
be	O
useful	O
in	O
primary	O
screening	O
but	O
performs	O
poorly	O
for	O
detecting	O
post-treatment	B-OUT
failures	I-OUT
.	I-OUT


Program	B-OUT
fidelity	I-OUT
was	O
measured	O
through	O
video	B-I
coding	I-I
and	O
use	O
of	O
a	O
checklist	O
.	O


In	O
classrooms	O
with	O
moderate	O
fidelity	B-OUT
,	I-OUT
students	I-OUT
in	I-OUT
Structured	I-OUT
Teaching	I-OUT
experienced	I-OUT
a	O
greater	O
gain	O
than	O
students	B-P
in	I-P
Strategies	I-OUT
for	I-OUT
Teaching	I-OUT
based	I-OUT
on	I-OUT
Autism	I-OUT
Research	I-OUT
(	O
10.1	O
vs.	O
4.4	O
points	O
)	O
.	O


The	O
results	O
suggest	O
significant	O
variability	O
in	O
implementation	O
of	O
evidence-based	O
practices	O
,	O
even	O
with	O
supports	O
,	O
and	O
also	O
suggest	O
the	O
need	O
to	O
address	O
challenging	O
issues	O
related	O
to	O
implementation	O
measurement	O
in	O
community	O
settings	O
.	O


A	O
prospective	O
,	O
randomized	O
,	O
comparative	O
trial	O
of	O
a	O
COX-2	B-I
selective	I-I
nonsteroidal	I-I
anti-inflammatory	I-I
drug	I-I
versus	I-I
placebo	I-I
in	O
inguinal	B-P
herniorrhaphy	I-P
patients	I-P
.	I-P


METHODS	O
A	O
prospective	O
,	O
randomized	O
,	O
blinded	O
,	O
placebo-controlled	B-I
trial	O
was	O
conducted	O
in	O
adults	B-P
undergoing	I-P
elective	I-P
,	I-P
outpatient	I-P
,	I-P
unilateral	I-P
inguinal	I-P
herniorrhaphy	I-P
.	I-P


Pain	B-OUT
outcomes	O
were	O
assessed	O
,	O
including	O
pain	B-OUT
intensity	I-OUT
(	O
1-10	O
visual-analogue	O
scale	O
)	O
and	O
the	O
use	O
of	O
hydrocodone	O
bitartrate	O
.	O


Statistics	O
are	O
mean	O
+/-	O
standard	O
deviation	O
.	O


In	O
addition	O
,	O
COX-2-treated	O
patients	O
had	O
less	O
difficulty	O
coughing	B-OUT
on	O
postoperative	O
day	O
1	O
.	O


These	O
results	O
suggest	O
that	O
multimodal	O
pain	O
therapy	O
with	O
COX-2	O
inhibitors	O
may	O
have	O
a	O
role	O
in	O
outpatient	B-P
inguinal	I-P
hernia	I-P
repair	I-P
.	I-P


Drug	O
effects	O
were	O
monitored	O
with	B-I
behavior	I-I
checklists	I-I
rated	I-I
by	I-I
parents	I-I
and	I-I
teachers	I-I
,	I-I
and	I-I
ethological	I-I
playroom	I-I
observations	I-I
.	I-I


Single-use	O
plaque	O
removal	O
efficacy	B-OUT
of	O
three	B-P
power	I-I
toothbrushes	I-I
.	I-I


A	O
prospective	O
randomized	O
trial	O
in	O
sepsis	O
and	O
double	O
organic	O
failure	O
should	O
be	O
projected	O
.	O


METHODS	O
In	O
a	O
randomized	O
double-blind	O
crossover	O
study	O
balanced	O
to	O
order	O
,	O
17	B-P
metabolic	I-P
syndrome	I-P
(	I-P
MetS	I-P
)	I-P
and	I-P
15	I-P
healthy	I-P
subjects	I-P
inhaled	I-I
filtered	I-I
air	I-I
(	I-I
FA	I-I
)	I-I
or	I-I
DE	I-I
exposure	I-I
in	I-P
two-hour	I-P
sessions	I-P
on	I-P
different	I-P
days	I-P
with	I-P
a	I-P
minimum	I-P
2-week	I-P
washout	I-P
period	I-P
.	I-P


We	O
performed	O
multiplex	O
cytokine	O
assay	O
to	O
measure	O
the	O
changes	O
in	O
the	O
systemic	O
inflammatory	O
cytokines	O
,	O
and	O
endothelial	O
adhesion	O
molecules	O
(	O
n=15	O
)	O
.	O


Effectiveness	O
of	O
erythromycin	B-I
in	O
the	O
treatment	O
of	O
acute	B-P
bronchitis	I-P
.	I-P


CONCLUSIONS	O
Erythromycin	B-I
is	O
effective	O
in	O
significantly	O
reducing	O
lost	O
time	O
from	O
work	O
,	O
but	O
it	O
is	O
not	O
effective	O
in	O
reducing	O
cough	O
or	O
other	O
symptoms	O
in	O
patients	B-P
with	I-P
acute	I-P
bronchitis	I-P
,	O
regardless	O
of	O
the	O
outcome	O
of	O
the	O
M	O
pneumoniae	O
antibody	O
test	O
.	O


Significant	O
(	B-OUT
p	I-OUT
<	I-OUT
0.05	I-OUT
)	I-OUT
HDL	I-OUT
cholesterol	I-OUT
increased	I-OUT
(	I-OUT
14.6	I-OUT
%	I-OUT
)	I-OUT
and	I-OUT
triglycerides	I-OUT
decreased	I-OUT
(	O
19	O
%	O
)	O
in	O
the	O
training	O
group	O
but	O
changes	O
of	O
all	O
these	O
lipids	O
were	O
insignificant	O
in	O
the	O
control	O
group	O
over	O
the	O
3	O
months	B-OUT
.	I-OUT


We	O
studied	O
the	O
effects	O
after	O
single	O
doses	O
of	O
niguldipine	B-I
(	O
0.3	O
,	O
0.6	O
,	O
and	O
0.9	O
mg	O
intravenously	O
;	O
8	O
and	O
16	O
mg	O
orally	O
)	O
and	O
nifedipine	B-I
(	O
2	O
mg	O
intravenously	O
;	O
20	O
mg	O
orally	O
)	O
in	O
healthy	B-P
male	I-P
volunteers	I-P
in	O
randomized	O
placebo-controlled	B-I
experiments	O
.	O


Total	B-OUT
peripheral	I-OUT
resistance	I-OUT
(	I-OUT
TPR	I-OUT
)	I-OUT
,	I-OUT
heart	I-OUT
rate-corrected	I-OUT
electromechanical	I-OUT
systole	I-OUT
(	I-OUT
QS2c	I-OUT
)	I-OUT
,	O
and	O
preejection	B-OUT
period	I-OUT
(	I-OUT
PEPc	I-OUT
)	I-OUT
were	O
assessed	O
noninvasively	O
.	O


We	O
conclude	O
that	O
the	O
vasodilatory	B-OUT
effects	I-OUT
of	O
dihydropyridines	B-I
may	O
(	O
as	O
for	O
nifedipine	B-I
)	I-I
or	O
may	O
not	O
(	O
as	O
for	O
niguldipine	B-I
)	I-I
be	O
associated	O
with	O
changes	O
that	O
are	O
suggestive	O
of	O
negative	B-OUT
inotropic	I-OUT
effects	I-OUT
,	O
and	O
that	O
this	O
difference	O
is	O
detectable	O
by	O
noninvasive	O
methods	O
in	O
healthy	B-P
subjects	I-P
.	I-P


Results	O
indicate	O
that	O
,	O
while	B-P
individuals	I-P
with	I-P
autism	I-P
may	O
have	O
the	O
ability	O
to	O
think	O
about	O
reputation	O
,	O
a	O
reduced	O
expectation	O
of	O
reciprocal	O
behavior	O
from	O
others	O
may	O
reduce	O
the	O
degree	O
to	O
which	O
they	B-OUT
engage	I-OUT
in	O
reputation	O
management	O
.	O


The	O
comparison	O
involved	O
randomly	O
assigning	O
150	B-P
outpatients	I-P
with	I-P
major	I-P
depression	I-P
to	I-P
a	I-P
treatment	I-P
focused	I-P
exclusively	I-P
on	I-P
the	I-P
behavioral	I-OUT
activation	I-OUT
(	I-OUT
BA	I-OUT
)	I-OUT
component	I-OUT
of	I-OUT
CT	I-OUT
,	O
a	O
treatment	O
that	O
included	O
both	O
BA	B-I
and	I-I
the	I-I
teaching	I-I
of	I-I
skills	I-I
to	I-I
modify	I-I
automatic	I-OUT
thoughts	I-OUT
(	I-OUT
AT	I-OUT
)	I-OUT
,	I-I
but	I-I
excluding	I-I
the	I-I
components	I-I
of	I-I
CT	I-I
focused	I-I
on	I-I
core	I-OUT
schema	I-OUT
,	I-I
or	I-I
the	I-I
full	I-I
CT	I-I
treatment	I-I
.	I-I


BACKGROUND	O
Parkinson	O
's	O
disease	O
(	O
PD	O
)	O
is	O
a	O
chronic	O
neurodegenerative	O
disorder	O
with	O
limited	O
knowledge	O
about	O
the	O
normal	O
function	O
and	O
effects	O
of	O
non-pharmacological	B-I
therapies	I-I
on	O
the	O
hypothalamic-pituitary-adrenal	B-OUT
(	I-OUT
HPA	I-OUT
)	I-OUT
axis	I-OUT
.	I-OUT


SETTING	O
AND	O
INTERVENTIONS	O
Forty-five	B-P
women	I-P
and	I-P
men	I-P
,	I-P
aged	I-P
50-79	I-P
years	I-P
,	I-P
were	I-P
recruited	I-P
.	I-P


Twenty-nine	B-P
of	I-P
them	I-P
were	I-P
blindly	I-P
randomised	I-P
to	I-P
tactile	I-I
massage	I-I
(	I-I
TM	I-I
)	I-I
and	I-P
16	I-P
of	I-P
them	I-P
to	I-P
the	I-P
control	I-I
group	I-P
,	I-P
rest	I-I
to	I-I
music	I-I
(	I-I
RTM	I-I
)	I-I
.	I-I


CONCLUSIONS	O
Diurnal	B-OUT
salivary	I-OUT
cortisol	I-OUT
rhythm	I-OUT
was	O
normal	O
.	O


No	O
associations	O
were	O
seen	O
between	O
salivary	B-OUT
cortisol	I-OUT
concentration	I-OUT
and	O
clinical	O
and/or	O
pharmacological	O
characteristics	O
.	O


The	O
estimated	O
reduction	B-OUT
in	I-OUT
mean	I-OUT
post-treatment	I-OUT
eggs	I-OUT
per	I-OUT
gram	I-OUT
of	I-OUT
feces	I-OUT
relative	O
to	O
placebo	B-I
was	O
63	O
%	O
(	O
95	O
%	O
CI	O
30-81	O
%	O
)	O
for	O
triple	O
mebendazole	B-I
,	O
75	O
%	O
(	O
47-88	O
%	O
)	O
for	O
single	O
albendazole	B-I
,	O
and	O
88	O
%	O
(	O
58-97	O
%	O
)	O
for	O
triple	O
albendazole	B-I
.	I-I


Individual	B-OUT
and	I-OUT
total	I-OUT
fecal	I-OUT
SCFA	I-OUT
excretion	I-OUT
,	I-OUT
weight	I-OUT
,	I-OUT
and	I-OUT
moisture	I-OUT
were	O
higher	O
than	O
those	O
for	O
habitual	O
diets	O
when	O
either	O
fiber	O
diet	O
was	O
consumed	O
.	O


Cost	O
effectiveness	O
of	O
training	O
incontinent	B-P
elderly	I-P
in	I-P
nursing	I-P
homes	I-P
:	I-P
a	O
randomized	O
clinical	O
trial	O
.	O


The	O
training	O
program	O
lasted	O
three	O
months	O
,	O
and	O
a	O
22-week	O
follow-up	O
period	O
examined	O
the	O
durability	O
of	O
the	O
treatment	O
effect	O
.	O


The	O
therapy	O
became	O
effective	O
after	O
six	O
weeks	O
of	O
training	O
.	O


RESULTS	O
The	O
high-dependence	O
group	O
showed	O
slowed	B-OUT
reaction	I-OUT
time	I-OUT
and	O
reduced	B-OUT
early	I-OUT
processing	I-OUT
negativity	I-OUT
and	O
peak	B-OUT
N1	I-OUT
amplitude	I-OUT
to	O
location-relevant	O
nontarget	O
stimuli	O
.	O


The	B-P
subjects	I-P
included	I-P
132	I-P
patients	I-P
randomized	I-P
to	I-P
the	I-P
study	I-P
,	I-P
of	I-P
whom	I-P
123	I-P
started	I-P
one	I-P
of	I-P
the	I-P
treatment	I-P
programs	I-P
.	I-P


They	B-P
had	I-P
all	I-P
had	I-P
at	I-P
least	I-P
6	I-P
months	I-P
of	I-P
chronic	I-P
LBP	I-P
.	I-P


The	O
results	O
presented	O
here	O
are	O
based	O
on	O
data	O
collected	O
4	O
months	O
following	O
treatment	O
,	O
which	O
shows	O
an	O
86	O
%	O
response	O
rate	O
.	O


The	O
results	O
show	O
that	O
4	O
months	O
after	O
treatment	O
,	O
the	O
intensive	O
multidisciplinary	O
program	O
is	O
superior	O
to	O
the	O
less	O
intensive	O
programs	O
in	O
terms	O
of	O
return-to-work	O
rate	O
,	O
health-care	O
contacts	O
,	O
pain	O
and	O
disability	O
scores	O
,	O
and	O
staying	O
physically	O
active	O
.	O


High-calcium	B-I
milk	I-I
prevents	O
overweight	O
and	O
obesity	O
among	O
postmenopausal	B-P
women	I-P
.	I-P


Sixty	B-P
women	I-P
were	I-P
qualified	I-P
to	I-P
participate	I-P
in	O
the	O
study	O
.	O


The	O
difference	O
in	O
infectious	B-OUT
complications	I-OUT
between	O
groups	O
1	O
and	O
3	O
was	O
statistically	O
highly	O
significant	O
(	O
p	O
<	O
0.01	O
)	O
and	O
between	O
groups	O
2	O
and	O
3	O
it	O
was	O
significant	O
(	O
p	O
<	O
0.05	O
)	O
.	O


Randomized	O
trial	O
of	O
fenretinide	B-I
in	O
superficial	B-P
bladder	I-P
cancer	I-P
using	O
DNA	O
flow	O
cytometry	O
as	O
an	O
intermediate	O
end	O
point	O
.	O


This	O
figure	O
was	O
48.9	O
%	O
in	O
the	O
fenretinide	B-I
arm	O
and	O
41.9	O
%	O
in	O
the	O
control	O
arm	O
(	O
odds	O
ratio	O
,	O
1.16	O
;	O
95	O
%	O
confidence	O
interval	O
,	O
0.44-3.07	O
)	O
.	O


Dietary	B-I
supplementation	I-I
of	I-I
glutamine	I-I
prevents	O
intestinal	O
dysfunction	O
and	O
atrophy	O
in	O
weanling	O
piglets	O
,	O
but	O
the	O
underlying	O
mechanism	O
(	O
s	O
)	O
are	O
largely	O
unknown	O
.	O


1	O
,	O
we	O
obtained	O
small	B-P
intestine	I-P
from	I-P
28-d-old	I-P
pigs	I-P
weaned	I-P
at	I-P
21	I-P
d	I-P
of	I-P
age	I-P
and	I-P
from	I-P
age-matched	I-P
suckling	I-P
piglets	I-P
.	I-P


At	O
d	O
28	O
,	O
we	O
collected	O
small	O
intestine	O
for	O
biochemical	O
and	O
morphological	O
measurements	O
and	O
microarray	O
analysis	O
of	O
gene	B-OUT
expression	I-OUT
using	O
the	O
Operon	O
Porcine	O
Genome	O
Oligo	O
set	O
.	O


Early	O
weaning	O
resulted	O
in	O
increased	O
(	O
52-346	O
%	O
)	O
expression	B-OUT
of	I-OUT
genes	I-OUT
related	I-OUT
to	I-OUT
oxidative	I-OUT
stress	I-OUT
and	I-OUT
immune	I-OUT
activation	I-OUT
but	O
decreased	O
(	O
35-77	O
%	O
)	O
expression	B-OUT
of	I-OUT
genes	I-OUT
related	I-OUT
to	I-OUT
macronutrient	I-OUT
metabolism	I-OUT
and	O
cell	B-OUT
proliferation	I-OUT
in	I-OUT
the	I-OUT
gut	I-OUT
.	I-OUT


Dietary	B-I
glutamine	I-I
supplementation	I-I
increased	O
intestinal	B-OUT
expression	I-OUT
(	I-OUT
120-124	I-OUT
%	I-OUT
)	I-OUT
of	I-OUT
genes	I-OUT
that	O
are	O
necessary	O
for	O
cell	O
growth	O
and	O
removal	B-OUT
of	I-OUT
oxidants	I-OUT
,	O
while	O
reducing	O
(	O
34-75	O
%	O
)	O
expression	B-OUT
of	I-OUT
genes	I-OUT
that	O
promote	O
oxidative	B-OUT
stress	I-OUT
and	I-OUT
immune	I-OUT
activation	I-OUT
.	I-OUT


Dietary	B-I
iron	I-I
exposures	O
were	O
estimated	O
from	O
a	O
food	O
frequency	O
questionnaire	O
.	O


Treatment	O
of	O
acute	B-P
otitis	I-P
media	I-P
in	I-P
children	I-P
under	I-P
2	I-P
years	I-P
of	I-P
age	I-P
.	I-P


Diarrhea	B-OUT
and	I-OUT
diaper-area	I-OUT
dermatitis	I-OUT
were	O
more	O
common	O
among	O
children	O
who	O
received	O
amoxicillin-clavulanate	B-I
.	I-I


Effect	O
of	O
aliskiren	B-I
on	O
proteinuria	B-OUT
in	O
non-diabetic	B-P
chronic	I-P
kidney	I-P
disease	I-P
:	I-P
a	O
double-blind	O
,	O
crossover	O
,	O
randomised	O
,	O
controlled	O
trial	O
.	O


The	O
study	O
consisted	O
of	O
five	O
treatment	O
periods	O
.	O


The	O
patients	O
were	O
randomly	O
assigned	O
to	O
receive	B-I
aliskiren	I-I
(	O
150	O
mg	B-I
)	I-I
,	I-I
aliskiren	I-I
(	O
300	O
mg	B-I
)	I-I
,	I-I
perindopril	I-I
(	O
5	O
mg	B-I
)	I-I
,	I-I
perindopril	I-I
(	O
10	O
mg	O
)	O
or	B-I
placebo	I-I
.	O


The	O
potential	O
of	O
the	O
aldose	O
reductase	O
inhibitor	O
tolrestat	B-I
to	O
ameliorate	O
definite	O
diabetic	O
autonomic	O
neuropathy	O
(	O
DAN	O
)	O
,	O
as	O
defined	O
by	O
standard	O
cardiovascular	O
autonomic	O
function	O
tests	O
,	O
was	O
evaluated	O
in	O
35	B-P
patients	I-P
over	O
a	O
period	O
of	O
2	O
years	O
,	O
with	O
repeated	O
measurements	O
at	O
3-month	O
intervals	O
.	O


Three	O
of	O
35	O
patients	O
on	O
tolrestat	B-I
(	O
8.6	O
%	O
)	O
developed	O
high	B-OUT
transaminases	I-OUT
levels	I-OUT
(	O
more	O
than	O
threefold	O
the	O
upper	O
normal	O
limit	O
)	O
and	O
were	O
withdrawn	O
from	O
the	O
study	O
.	O


In	O
conclusion	O
,	O
tolrestat	B-I
improved	O
autonomic	B-OUT
nervous	I-OUT
system	I-OUT
function	I-OUT
in	O
patients	B-P
with	I-P
definite	I-P
DAN	I-P
,	O
in	O
comparison	O
to	O
baseline	O
and	O
placebo	O
.	O


Chemotherapy	B-I
for	O
operable	B-P
gastric	I-P
cancer	I-P
:	I-P
results	O
of	O
the	O
Dutch	O
randomised	O
FAMTX	O
trial	O
.	O


In	O
case	O
of	O
progressive	O
disease	O
(	O
PD	O
)	O
after	O
two	O
courses	O
,	O
patients	O
were	O
operated	O
upon	O
as	O
soon	O
as	O
possible	O
.	O


The	O
standard	O
surgical	O
procedure	O
was	O
a	O
limited	O
lymphadenectomy	O
(	O
D1	O
)	O
with	O
staging	O
biopsy	O
of	O
the	O
para-aortic	O
lymph	O
nodes	O
.	O


More	O
active	O
regimens	O
than	O
FAMTX	B-I
are	O
required	O
for	O
future	O
randomised	O
trials	O
.	O


SETTING	O
AND	O
PARTICIPANTS	O
Participants	B-P
included	I-P
87	I-P
newly	I-P
postmenopausal	I-P
women	I-P
with	I-P
status	I-P
post	I-P
chemotherapy	I-P
,	I-P
recruited	I-P
from	I-P
a	I-P
breast	I-P
cancer	I-P
clinic	I-P
in	I-P
an	I-P
academic	I-P
medical	I-P
center	I-P
.	I-P


For	O
the	O
modified	B-I
ITT	I-I
sample	I-I
,	I-I
desvenlafaxine	I-I
(	I-I
n	I-I
=	O
208	O
)	O
and	O
placebo	O
(	B-OUT
n	I-OUT
=	I-OUT
102	I-OUT
)	I-OUT
,	I-OUT
baseline	I-OUT
HAM-D₁₇	O
scores	O
were	B-OUT
23.8	I-OUT
and	I-OUT
23.9	I-OUT
;	I-OUT
the	O
SDS	O
baseline	O
scores	O
were	O
20.1	O
and	O
20.8	O
.	O


Between-group	O
differences	O
on	O
the	O
SDS	O
narrowly	O
missed	O
statistical	O
significance	O
in	O
the	O
ITT	O
population	O
alone	O
,	O
but	O
the	O
totality	O
of	O
data	O
suggests	O
functional	O
improvements	O
with	O
active	O
treatment	O
.	O


Cardiovascular	O
risk	O
is	O
increased	O
in	O
GH	O
deficiency	O
(	O
GHD	O
)	O
.	O


We	O
investigated	O
in	O
healthy	B-P
nonobese	I-P
males	I-P
the	O
effect	O
of	O
the	O
GH	O
receptor	O
antagonist	O
pegvisomant	B-I
in	O
different	O
metabolic	O
conditions	O
.	O


fed	O
,	O
conditions	O
.	O


DESIGN	O
A	O
prospective	O
,	O
randomized	O
trial	O
.	O


METHODS	O
Two	B-P
hundred	I-P
two	I-P
patients	I-P
with	I-P
PPLs	I-P
and	I-P
positive	I-P
EBUS	I-P
findings	I-P
were	I-P
enrolled	I-P
.	I-P


They	O
were	O
randomly	O
classified	O
into	O
two	O
groups	O
.	O


Concerning	O
the	O
three	O
different	O
techniques	O
,	O
TBNA	O
showed	O
the	O
highest	B-OUT
diagnostic	I-OUT
yield	I-OUT
(	O
62.5	O
%	O
)	O
in	O
comparison	O
to	O
TBB	O
(	O
48.9	O
%	O
)	O
and	O
to	O
BW	O
(	O
19.8	O
%	O
)	O
.	O


CONCLUSIONS	O
Applying	O
TBNA	O
to	O
EBUS-guided	O
CDPs	O
further	O
increased	O
the	O
diagnostic	B-OUT
yield	I-OUT
of	O
PPLs	O
without	O
additional	O
risk	O
.	O


RESULTS	O
9	O
patients	O
were	O
classified	O
as	B-OUT
rich	I-OUT
(	O
none	O
had	O
received	O
placebo	O
,	O
3	O
low-dose	O
teriparatide	O
,	O
and	O
6	O
high-dose	O
teriparatide	O
)	O
.	O


9	O
patients	O
were	O
classified	O
as	B-OUT
intermediate	I-OUT
(	O
1	O
had	O
received	O
placebo	O
,	O
5	O
low-dose	O
,	O
and	O
3	O
high-dose	O
)	O
.	O


The	O
results	O
must	O
therefore	O
be	O
interpreted	O
with	O
caution	O
.	O


Moreover	O
,	O
teriparatide	B-I
appeared	O
to	O
improve	B-OUT
early	I-OUT
callus	I-OUT
formation	I-OUT
in	I-P
distal	I-P
radial	I-P
fractures	I-P
.	I-P


A	O
comparison	O
of	O
single-dose	B-I
versus	O
conventional-dose	B-I
antibiotic	I-I
treatment	I-I
of	O
bacteriuria	B-P
in	I-P
elderly	I-P
women	I-P
.	I-P


It	O
is	O
concluded	O
that	O
there	O
may	O
be	O
a	O
place	O
for	O
the	O
use	O
of	O
single-dose	B-I
antibiotic	I-I
therapy	I-I
for	O
the	O
treatment	O
of	O
selected	B-P
elderly	I-P
women	I-P
with	I-P
bacteriuria	I-P
,	O
but	O
larger	O
studies	O
are	O
needed	O
.	O


We	O
evaluated	O
a	O
5-day	O
'live-in	O
'	O
intervention	O
using	O
a	O
double-blind	O
randomized	O
control	O
trial	O
.	O


Parameters	B-OUT
of	I-OUT
liver	I-OUT
function	I-OUT
,	I-OUT
taste	I-OUT
acuity	I-OUT
,	I-OUT
dark	I-OUT
adaptation	I-OUT
and	I-OUT
of	I-OUT
zinc	I-OUT
and	I-OUT
vitamin	I-OUT
A	I-OUT
metabolism	I-OUT
were	O
followed	O
for	O
six	O
weeks	O
.	O


OBJECTIVE	O
To	O
compare	O
laparoscopically	B-I
assisted	I-I
vaginal	I-I
hysterectomy	I-I
(	I-I
LAVH	I-I
)	I-I
and	I-I
total	I-I
abdominal	I-I
hysterectomy	I-I
(	I-I
TAH	I-I
)	I-I
in	O
patients	B-P
with	I-P
uterine	I-P
fibroids	I-P
.	I-P


METHODS	O
Randomisation	O
between	O
LAVH	B-I
and	I-I
TAH	I-I
.	I-I


RESULTS	O
Median	B-OUT
uterine	I-OUT
weight	I-OUT
was	O
400	O
g	O
in	O
both	O
LAVH	B-I
and	O
TAH	B-I
group	O
.	O


The	O
additive	O
analgesic	O
efficacy	O
of	O
acetaminophen	B-I
,	O
1000	O
mg	O
,	O
and	O
codeine	B-I
,	O
60	O
mg	O
,	O
in	O
dental	B-P
pain	I-P
.	I-P


In	O
a	O
double-blind	O
,	O
randomized	O
,	O
single-dose	O
trial	O
the	O
analgesic	O
contribution	O
of	O
acetaminophen	B-I
,	I-I
1000	I-I
mg	I-I
,	I-I
and	I-I
codeine	I-I
,	I-I
60	I-I
mg	I-I
,	O
was	O
determined	O
.	O


The	O
effectiveness	O
of	O
single-dose	O
metronidazole	B-I
therapy	O
for	O
patients	B-P
and	I-P
their	I-P
partners	I-P
with	I-P
bacterial	I-P
vaginosis	I-P
.	I-P


Forty-two	B-P
children	I-P
with	I-P
the	I-P
diagnosis	I-P
of	I-P
autism	I-P
were	O
randomized	O
to	O
one	O
of	O
two	O
groups	O
in	O
this	O
double-blind	O
cross-over	O
trial	O
.	O


All	O
children	O
were	O
evaluated	O
at	O
weeks	O
1	O
,	O
3	O
,	O
6	O
,	O
9	O
,	O
and	O
12	O
with	O
standardized	O
assessments	B-OUT
of	I-OUT
language	I-OUT
,	I-OUT
behavior	I-OUT
,	I-OUT
and	I-OUT
autism	I-OUT
symptomatology	I-OUT
.	I-OUT


Human	O
platelet	O
response	O
to	O
three	O
salicylate	B-I
dosage	O
forms	O
.	O


No	O
relationship	O
was	O
found	O
between	O
the	O
maximum	O
observed	O
plasma	B-OUT
ASA	I-OUT
level	I-OUT
and	I-OUT
the	I-OUT
maximum	I-OUT
effect	I-OUT
.	I-OUT


Siblings	B-P
of	I-P
children	I-P
with	I-P
a	I-P
disability	I-P
are	O
an	O
at	O
risk	O
group	O
for	O
emotional	O
and	O
behavioral	O
problems	O
.	O


This	O
study	O
evaluated	O
an	O
intervention	O
to	O
promote	O
the	O
emotional	O
and	O
behavioral	O
functioning	O
of	O
siblings	B-P
of	I-P
children	I-P
with	I-P
disabilities	I-P
and	I-P
chronic	I-P
health	I-P
conditions	I-P
.	I-P


The	O
primary	O
outcome	O
was	O
siblings	O
'	O
emotional	B-OUT
and	I-OUT
behavioral	I-OUT
functioning	I-OUT
.	I-OUT


Siblings	O
were	O
followed-up	O
immediately	O
after	O
the	O
intervention	O
and	O
at	O
3-months	O
.	O


The	O
aim	O
of	O
this	O
study	O
was	O
to	O
assess	O
the	O
accuracy	B-OUT
of	O
pelvic	O
radiotherapy	B-I
during	O
a	O
trial	O
of	O
blocked	O
radiotherapy	O
at	O
the	O
Royal	O
Marsden	O
Hospital	O
,	O
UK	B-P
.	I-P


Field	B-OUT
placement	I-OUT
errors	I-OUT
(	I-OUT
FPEs	I-OUT
)	I-OUT
were	O
calculated	O
by	O
comparing	O
field	O
centres	O
of	O
each	O
film	O
with	O
a	O
designated	O
point	O
of	O
interest	O
.	O


Data	O
was	O
evaluated	O
to	O
calculate	O
the	O
overall	B-OUT
treatment	I-OUT
simulator	I-OUT
differences	I-OUT
,	I-OUT
the	I-OUT
number	I-OUT
of	I-OUT
error	I-OUT
free	I-OUT
treatments	I-OUT
,	I-OUT
and	I-OUT
mean	I-OUT
treatment-simulator	I-OUT
position	I-OUT
and	O
to	O
evaluate	B-OUT
the	I-OUT
role	I-OUT
of	I-OUT
systematic	I-OUT
versus	I-OUT
random	I-OUT
errors	I-OUT
.	I-OUT


Oral	O
S-adenosylmethionine	B-I
was	O
tolerated	B-OUT
to	O
the	O
same	O
extent	O
as	O
placebo	O
.	O


Three-year-survival	B-OUT
rate	I-OUT
of	O
histologically	O
confirmed	O
non-curatively	O
resected	O
colon	O
carcinoma	O
patients	O
was	O
higher	O
in	O
the	O
group	O
receiving	O
regimen	B-I
C	I-I
than	O
in	O
regimen	B-I
D.	I-I
But	O
no	O
significant	O
difference	O
was	O
found	O
among	O
the	O
other	O
groups	O
.	O


METHODS	O
After	O
a	O
4-week	O
washout	O
period	O
,	O
patients	B-P
whose	I-P
untreated	I-P
daytime	I-P
diastolic	I-P
ambulatory	I-P
BP	I-P
averaged	I-P
>	I-P
or	I-P
=	I-P
85	I-P
mm	I-P
Hg	I-P
were	O
randomized	O
to	O
be	O
treated	O
according	O
to	O
their	O
ambulatory	B-I
or	I-I
home	I-I
BP	I-I
.	I-I


RESULTS	O
Ninety-eight	B-P
patients	I-P
completed	I-P
the	I-P
study	I-P
.	I-P


At	O
the	O
end	O
of	O
the	O
study	O
,	O
the	O
systolic/diastolic	B-OUT
differences	I-OUT
between	I-OUT
ambulatory	I-OUT
(	O
n	O
=	O
46	O
)	O
and	O
home	O
(	O
n	O
=	O
52	O
)	O
BP	B-OUT
groups	O
in	O
home	B-OUT
,	I-OUT
daytime	I-OUT
ambulatory	I-OUT
,	I-OUT
night-time	I-OUT
ambulatory	I-OUT
,	I-OUT
and	I-OUT
24-h	I-OUT
ambulatory	I-OUT
BP	I-OUT
changes	I-OUT
averaged	O
2.6/2.6	O
mm	O
Hg	O
,	O
0.6/1.7	O
mm	O
Hg	O
,	O
1.0/1.4	O
mm	O
Hg	O
,	O
and	O
0.6/1.5	O
mm	O
Hg	O
,	O
respectively	O
(	O
P	O
range	O
.06	O
to	O
.75	O
)	O
A	O
nonsignificant	O
trend	O
to	O
more	O
intensive	O
drug	O
therapy	O
in	O
the	O
ambulatory	B-OUT
BP	I-OUT
group	O
and	O
a	O
nonsignificant	O
trend	O
to	O
larger	O
share	O
of	O
patients	O
reaching	O
(	O
57.7	O
%	O
v	O
43.5	O
%	O
,	O
P	O
=	O
.16	O
)	O
the	O
target	O
pressure	O
in	O
the	O
home	O
BP	O
group	O
was	O
observed	O
due	O
to	O
the	O
3.8	O
mm	O
Hg	O
difference	O
in	O
ambulatory	B-OUT
and	I-OUT
home	I-OUT
diastolic	I-OUT
BP	I-OUT
at	O
randomization	O
.	O


Culturally	O
and	O
linguistically	O
appropriate	O
interventions	O
are	O
necessary	O
to	O
increase	O
hepatitis	B-OUT
B	I-OUT
knowledge	I-OUT
,	I-OUT
serologic	I-OUT
testing	I-OUT
,	O
and	O
vaccination	B-OUT
among	O
Cambodian	O
Americans	O
.	O


Our	O
findings	O
reveal	O
the	O
value	O
of	O
qualitative	O
exploration	O
to	O
providing	O
cultural	O
context	O
to	O
biomedical	O
information	O
--	O
a	O
formula	O
for	O
effective	O
health	O
promotion	O
and	O
practice	O
.	O


CONCLUSIONS	O
The	O
percentage	O
of	O
adjudicated	O
PMI	B-OUT
events	I-OUT
is	O
driven	O
by	O
the	O
MI-definition	O
criteria	O
and	O
biomarker	O
type	O
.	O


The	O
study	O
used	O
200	O
microg	O
inhaled	O
salbutamol	B-I
and	O
500	O
microg	O
inhaled	B-I
terbutaline	I-I
.	I-I


ME-609	B-I
(	I-I
Xerese	I-I
,	I-I
Xerclear	I-I
)	I-I
is	O
a	O
combination	O
of	O
5	O
%	O
acyclovir	B-I
and	O
1	O
%	O
hydrocortisone	B-I
developed	O
for	O
the	O
topical	O
treatment	O
of	O
HSL	O
.	O


In	O
patients	O
with	O
ulcerative	O
lesions	O
,	O
healing	B-OUT
times	I-OUT
were	O
reduced	O
in	O
the	O
ME-609	O
and	O
acyclovir	O
groups	O
compared	O
with	O
placebo	O
(	O
P	O
<	O
.01	O
for	O
both	O
)	O
.	O


Animal	O
studies	O
with	O
SSRI	O
's	O
suggest	O
that	O
serotonergic	O
modulation	O
alters	O
methamphetamine	B-I
's	I-I
behavioral	I-OUT
effects	I-OUT
.	I-OUT


Primary	O
care-based	O
ambulatory	B-OUT
opioid	I-OUT
detoxification	I-OUT
:	I-OUT
the	O
results	O
of	O
a	O
clinical	O
trial	O
.	O


PATIENTS	O
Injection	B-P
drug	I-P
users	I-P
(	I-P
IDUs	I-P
)	I-P
seeking	I-P
substance	I-P
abuse	I-P
treatment	I-P
between	I-P
the	I-P
ages	I-P
of	I-P
18	I-P
and	I-P
50	I-P
years	I-P
who	I-P
were	I-P
addicted	I-P
to	I-P
opioids	I-P
(	I-P
e.g.	I-P
,	O
heroin	B-P
)	I-P
and	I-P
not	I-P
currently	I-P
in	I-P
drug	I-P
treatment	I-P
.	I-P


In	O
the	O
clonidine	B-I
plus	I-I
naltrexone	I-I
protocol	O
,	O
clonidine	O
was	O
administered	O
and	O
naltrexone	B-I
was	O
administered	O
in	O
increasing	O
doses	O
over	O
five	O
days	O
.	O


DESIGN	O
A	O
prospective	O
nonrandomized	O
clinical	O
trial	O
.	O


For	O
FPV	B-I
1,400	O
mg	O
BID	O
plus	O
RTV	B-I
100	O
mg	O
BID	O
,	O
the	O
values	B-OUT
for	I-OUT
plasma	I-OUT
amprenavir	I-OUT
(	I-OUT
APV	I-OUT
)	I-OUT
area	I-OUT
under	I-OUT
the	I-OUT
concentration-time	I-OUT
profile	I-OUT
over	I-OUT
the	I-OUT
dosing	I-OUT
interval	I-OUT
(	I-OUT
tau	I-OUT
)	I-OUT
at	I-OUT
steady	I-OUT
state	I-OUT
[	O
AUC	O
(	O
0-tau	O
)	O
]	O
,	O
maximum	B-OUT
concentration	I-OUT
of	I-OUT
drug	I-OUT
in	I-OUT
plasma	I-OUT
(	I-OUT
C	I-OUT
(	I-OUT
max	I-OUT
)	I-OUT
)	I-OUT
,	I-OUT
and	I-OUT
plasma	I-OUT
concentration	I-OUT
at	I-OUT
the	I-OUT
end	I-OUT
of	I-OUT
tau	I-OUT
at	I-OUT
steady	I-OUT
state	I-OUT
(	I-OUT
C	I-OUT
(	I-OUT
tau	I-OUT
)	I-OUT
)	I-OUT
were	O
54	O
,	O
81	O
,	O
and	O
26	O
%	O
higher	O
,	O
respectively	O
,	O
and	O
the	O
values	B-OUT
for	I-OUT
plasma	I-OUT
RTV	I-OUT
AUC	I-OUT
(	I-OUT
0-tau	I-OUT
)	I-OUT
,	I-OUT
C	I-OUT
(	I-OUT
max	I-OUT
)	I-OUT
,	I-OUT
and	I-OUT
C	I-OUT
(	I-OUT
tau	I-OUT
)	I-OUT
were	O
49	O
%	O
higher	O
,	O
71	O
%	O
higher	O
,	O
and	O
11	O
%	O
lower	O
,	O
respectively	O
,	O
than	O
those	O
for	O
FPV	B-I
700	O
mg	O
BID	O
plus	O
RTV	O
100	O
mg	O
BID	O
.	O


This	O
prospective	O
randomized	O
trial	O
was	O
conducted	O
to	O
compare	O
the	O
efficacy	O
of	O
cytokine	B-I
removal	I-I
between	I-I
online	I-I
hemodiafiltration	I-I
(	I-I
HDF	I-I
)	I-I
,	I-I
which	I-I
combines	I-I
convective	I-I
and	I-I
diffusive	I-I
solute	I-I
removal	I-I
,	I-I
and	I-I
high-flux	I-I
hemodialysis	I-I
(	I-I
HD	I-I
)	I-I
.	O


In	O
conclusion	O
,	O
online	O
HDF	O
in	O
sepsis-related	O
AKI	O
could	O
provide	O
significantly	B-OUT
better	I-OUT
removal	I-OUT
of	I-OUT
VEGF	I-OUT
and	O
other	O
cytokines	O
and	O
these	O
were	O
associated	B-OUT
with	I-OUT
better	O
renal	O
outcome	O
than	O
high-flux	O
HD	O
.	O


This	O
feature	O
of	O
their	O
behavior	O
is	O
extremely	O
important	O
for	O
many	O
real-world	O
monitoring	O
tasks	O
that	O
require	O
sustained	O
attention	O
for	O
long	O
time	O
periods	O
.	O


RESULTS	O
For	O
VACT2	O
,	O
median	B-OUT
time	I-OUT
to	I-OUT
good	I-OUT
or	I-OUT
excellent	I-OUT
PGART	I-OUT
response	I-OUT
was	O
6	O
,	O
5	O
,	O
4	O
,	O
and	O
3	O
days	O
for	O
acetaminophen	B-I
,	I-I
celecoxib	I-I
,	I-I
rofecoxib	I-I
12.5	O
mg	O
,	O
and	O
rofecoxib	B-I
25	O
mg	O
(	O
COX-2	O
inhibitors	O
vs	O
acetaminophen	B-I
,	O
p	O
<	O
or=0.035	O
;	O
rofecoxib	B-I
25	O
mg	O
vs	O
celecoxib	B-I
,	O
p=0.01	O
)	O
.	O


There	O
was	O
no	O
significant	O
difference	O
between	O
treatment	O
groups	O
in	O
the	O
percentage	O
of	O
patients	O
who	O
experienced	O
a	O
clinical	B-OUT
adverse	I-OUT
experience	I-OUT
(	I-OUT
AE	I-OUT
)	I-OUT
.	I-OUT


There	O
was	O
a	O
more	O
rapid	O
and	O
greater	O
response	B-OUT
with	O
rofecoxib	O
25	O
mg	O
than	O
celecoxib	B-I
200	O
mg.	O
Rofecoxib	B-I
12.5	O
mg	O
demonstrated	O
greater	O
efficacy	B-OUT
than	O
celecoxib	B-I
200	O
mg	O
over	O
the	O
first	O
6	O
days	O
,	O
and	O
was	O
similar	O
over	O
6	O
weeks	O
.	O


All	O
study	O
medications	O
were	O
generally	O
well	B-OUT
tolerated	I-OUT
.	I-OUT


During	O
two	O
consecutive	O
periods	O
of	O
2	O
days	O
,	O
patients	O
received	O
active	B-I
drugs	I-I
or	O
placebo	B-I
in	O
a	O
randomized	O
order	O
.	O


After	O
placebo	B-I
,	O
the	O
tests	O
always	O
were	O
positive	O
,	O
and	O
the	O
ECG	B-OUT
changes	I-OUT
occurred	O
at	O
the	O
same	O
+/-	O
1	O
dose	O
of	O
ergometrine	B-I
in	O
10	O
cases	O
,	O
showing	O
good	B-OUT
reproducibility	I-OUT
.	I-OUT


After	O
nicorandil	B-I
,	O
the	O
tests	O
were	O
negative	O
in	O
nine	O
patients	O
and	O
positive	O
for	O
a	O
higher	O
or	O
lower	O
dose	O
of	O
ergometrine	B-I
in	O
three	O
and	O
one	O
patient	O
,	O
respectively	O
(	O
p	O
=	O
0.0034	O
vs.	O
placebo	B-I
)	I-I
.	O


Such	O
embolic	O
signals	O
are	O
common	O
after	O
carotid	O
endarterectomy	O
,	O
and	O
their	O
frequency	O
predicts	O
risk	O
of	O
stroke	O
recurrence	O
.	O


METHODS	O
AND	O
RESULTS	O
Patients	B-P
undergoing	I-P
carotid	I-P
endarterectomy	I-P
were	O
randomized	O
in	O
a	O
double-blind	O
manner	O
between	O
L-arginine	B-I
(	I-P
n=14	I-P
)	I-P
,	O
GSNO	B-I
(	I-P
n=14	I-P
)	I-P
,	O
or	O
placebo	B-I
(	I-P
n=14	I-P
)	I-P
administered	O
intravenously	O
for	O
90	O
minutes	O
,	O
starting	O
30	O
minutes	O
after	O
skin	O
closure	O
.	O


The	B-OUT
reduction	I-OUT
in	I-OUT
the	I-OUT
signals	I-OUT
persisted	O
at	O
the	O
24-hour	O
recording	O
.	O


In	O
a	O
randomized	O
clinical	O
trial	O
,	O
87	B-P
patients	I-P
with	I-P
inoperable	I-P
,	I-P
extensive	I-P
non-small	I-P
cell	I-P
lung	I-P
cancer	I-P
(	I-P
NSCLC	I-P
)	I-P
were	O
randomized	O
to	O
receive	O
either	O
combination	B-I
chemotherapy	I-I
(	I-I
cisplatin	I-I
at	O
70	O
mg/m2	O
intravenously	O
[	O
i.v	O
.	O


]	O
on	O
day	O
1	O
and	O
etoposide	B-I
at	O
100	O
mg/m2	O
i.v	O
.	O


on	O
day	O
1	O
and	O
200	O
mg/m2	O
orally	O
on	O
days	O
2	O
and	O
3	O
)	O
or	O
symptomatic	B-I
treatment	I-I
.	I-I


There	O
was	O
a	O
poor	O
correlation	O
between	O
microscopy	O
and	O
culture	O
of	O
the	O
bile	O
for	O
bacteria	B-OUT
and	O
there	O
was	O
no	O
increase	O
in	O
sepsis	B-OUT
when	O
bacteria	O
were	O
observed	O
on	O
microscopy	O
.	O


METHODS	O
Children	B-P
(	I-P
N	I-P
=	I-P
128	I-P
)	I-P
with	I-P
autism	I-P
or	I-P
PDD-NOS	I-P
(	I-P
DSM-4	I-P
criteria	I-P
)	I-P
aged	I-P
2	I-P
years	I-P
8	I-P
months	I-P
to	I-P
5	I-P
years	I-P
11	I-P
months	I-P
and	I-P
recruited	I-P
from	I-P
5	I-P
disability	I-P
agencies	I-P
in	I-P
4	I-P
US	I-P
states	I-P
were	I-P
randomized	I-P
in	O
two	O
1-year	O
cohorts	O
.	O


Home	O
consultants	O
administered	O
the	O
intervention	O
with	O
fidelity	O
.	O


ADOS	O
findings	O
must	O
be	O
interpreted	O
cautiously	O
because	O
results	O
do	O
not	O
align	O
with	O
clinical	O
experience	O
.	O


Stage	O
1	O
of	O
the	O
trial	O
saw	O
72	B-P
Danish	I-P
children	I-P
(	I-P
aged	I-P
4	I-P
years	I-P
to	I-P
10	I-P
years	I-P
11	I-P
months	I-P
)	I-P
assigned	I-P
to	I-P
diet	I-P
(	I-P
A	I-P
)	I-P
or	I-P
non-diet	I-I
(	I-P
B	I-P
)	I-P
groups	I-P
by	I-P
stratified	I-P
randomisation	I-P
.	I-P


Surpassing	O
of	O
predefined	O
statistical	O
thresholds	O
as	O
evidence	O
of	O
improvement	O
in	O
group	O
A	O
at	O
12	O
months	O
sanctioned	O
the	O
re-assignment	O
of	O
group	O
B	O
participants	O
to	O
active	O
dietary	O
treatment	O
.	O


Further	O
studies	O
are	O
required	O
to	O
ascertain	O
potential	O
best-	O
and	O
non-responders	O
to	O
intervention	O
.	O


The	O
aim	O
of	O
this	O
study	O
was	O
to	O
elucidate	O
the	O
effect	O
of	O
treatment	O
with	O
nebivolol	B-I
on	O
the	O
metabolic	B-OUT
state	I-OUT
of	I-OUT
oxidative	I-OUT
stress	I-OUT
,	O
and	O
antioxidant	O
status	O
markers	O
in	O
patients	B-P
with	I-P
cardiac	I-P
syndrome-X	I-P
(	I-P
CSX	I-P
)	I-P
,	O
additionally	O
,	O
to	O
compare	O
with	O
the	O
effect	O
of	O
metoprolol	B-I
treatment	I-I
.	I-I


INTRODUCTION	O
Our	O
objective	O
was	O
to	O
evaluate	O
the	O
effects	O
of	O
a	O
highly	O
filled	O
light-cured	B-I
sealant	I-I
(	I-I
HFLCS	I-I
)	I-I
on	O
the	O
shear	O
bond	O
strength	O
and	O
bond	O
failure	O
site	O
of	O
metal	O
and	O
ceramic	O
brackets	O
bonded	O
with	O
resin-modified	O
glass	O
ionomer	O
cement	O
(	O
RMGIC	O
)	O
.	O


In	O
groups	O
1	O
and	O
3	O
,	O
the	O
brackets	O
were	O
bonded	O
directly	O
to	O
etched	O
enamel	O
surfaces	O
;	O
in	O
groups	O
2	O
and	O
4	O
,	O
the	O
etched	O
enamel	O
was	O
covered	O
with	O
HFLCS	B-I
(	I-I
Pro	I-I
Seal	I-I
,	I-I
Reliance	I-I
Orthodontic	I-I
Products	I-I
,	I-I
Itasca	I-I
,	I-I
Ill	I-I
)	I-I
.	I-I


Pretreatment	O
with	O
HFLCS	B-OUT
did	I-OUT
not	I-OUT
cause	I-OUT
a	I-OUT
statistically	I-OUT
significant	I-OUT
change	I-OUT
in	I-OUT
the	I-OUT
shear	I-OUT
bond	I-OUT
values	I-OUT
of	I-OUT
either	I-OUT
metal	I-OUT
or	I-OUT
ceramic	I-OUT
brackets	I-OUT
(	O
P	O
=	O
0.38	O
)	O
.	O


Shear	B-OUT
bond	I-OUT
values	I-OUT
of	I-OUT
the	I-OUT
ceramic	I-OUT
brackets	I-OUT
were	O
higher	O
than	O
those	O
of	O
the	O
metal	O
brackets	O
independent	O
of	O
HFLCS	O
application	O
(	O
P	O
<	O
0.001	O
)	O
.	O


CONCLUSIONS	O
HFLCS	O
application	O
on	O
enamel	O
etched	O
with	O
37	O
%	O
phosphoric	O
acid	O
did	O
not	O
affect	O
the	O
bond	O
strength	O
values	O
and	O
the	O
bond	O
failure	O
modes	O
of	O
metal	O
and	O
ceramic	O
brackets	O
bonded	O
with	O
RMGIC	O
.	O


Sexual	B-OUT
function	I-OUT
was	O
assessed	O
using	O
a	O
standardized	O
questionnaire	O
[	O
Female	O
Sexual	O
Function	O
Index	O
(	O
FSFI	O
)	O
]	O
.	O


RESULTS	O
Forty-nine	B-P
women	I-P
were	I-P
included	I-P
in	I-P
the	I-P
EE30/LNG150	I-I
group	I-P
and	I-P
48	I-P
in	I-P
the	I-P
EE20/LNG100	I-I
group	I-P
.	I-P


EE30/LNG150	B-I
group	O
presented	O
54	O
%	O
and	O
67	O
%	O
decreases	O
of	O
total	B-OUT
testosterone	I-OUT
and	I-OUT
free	I-OUT
androgen	I-OUT
index	I-OUT
,	O
respectively	O
,	O
with	O
statistical	O
significance	O
.	O


CONCLUSIONS	O
EE30/LNG150	B-I
decreased	O
plasma	O
androgen	O
levels	O
,	O
but	O
there	O
was	O
no	O
impairment	O
in	O
sexual	O
desire	O
,	O
on	O
the	O
other	O
hand	O
,	O
sexual	O
desire	O
score	O
increased	O
with	O
EE20/LNG100	B-I
formulation	O
.	O


RESULTS	O
Preoperative	O
patient	O
characteristics	O
and	O
operative	O
parameters	O
were	O
similar	O
in	O
three	O
groups	O
.	O


Patients	B-P
who	I-P
met	I-P
remission	I-P
criteria	I-P
at	I-P
2	I-P
consecutive	I-P
weekly	I-P
visits	I-P
during	I-P
6	I-P
to	I-P
12	I-P
weeks	I-P
of	I-P
open-label	I-P
olanzapine	I-I
treatment	I-P
were	O
randomly	O
assigned	O
to	O
olanzapine	B-I
or	O
placebo	B-I
treatment	O
for	O
48	O
weeks	O
.	O


Olanzapine-treated	B-I
patients	O
also	O
experienced	O
longer	O
time	B-OUT
to	I-OUT
depressive	I-OUT
symptomatic	I-OUT
relapse	I-OUT
(	O
85	O
versus	O
22	O
days	O
,	O
p=0.001	O
)	O
and	O
manic	B-OUT
symptomatic	I-OUT
relapse	I-OUT
(	O
too	O
few	O
relapses	O
to	O
calculate	O
versus	O
42	O
days	O
,	O
p	O
<	O
0.001	O
)	O
than	O
did	O
placebo-treated	O
patients	O
.	O


OBJECTIVES	O
To	O
test	O
experimentally	O
whether	O
a	O
psychological	B-I
intervention	I-I
reduces	O
depression-related	O
symptoms	O
and	O
markers	O
of	O
inflammation	O
among	O
cancer	B-P
patients	I-P
and	O
to	O
test	O
one	O
mechanism	O
for	O
the	O
intervention	O
effects	O
.	O


Depression	O
and	O
inflammation	O
are	O
common	O
among	O
cancer	B-P
patients	I-P
.	I-P


CALLISTO	O
was	O
a	O
12-month	O
,	O
prospective	O
,	O
multicenter	B-P
,	O
open-label	O
study	O
.	O


The	O
aim	O
of	O
this	O
study	O
was	O
to	O
further	O
validate	O
the	O
impact	O
of	O
α-SMA	O
expression	O
and	O
stromal	O
density	O
in	O
resectable	B-P
pancreatic	I-P
cancer	I-P
patients	I-P
treated	I-P
with	I-I
adjuvant	I-I
gemcitabine	I-I
compared	I-P
with	I-P
untreated	I-P
patients	I-P
.	O


This	O
significant	O
influence	O
was	O
restricted	O
to	O
patients	O
who	O
received	O
no	O
adjuvant	O
therapy	O
.	O


6.9	O
%	O
)	O
of	O
initial	O
body	B-OUT
weight	I-OUT
vs	O
3.2	O
%	O
(	O
3.7	O
%	O
)	O
in	O
the	O
placebo	B-I
group	O
(	O
P	O
<	O
0.0001	O
)	O
.	O


A	O
follow-up	O
was	O
conducted	O
12	O
months	O
later	O
(	O
mean	O
age	O
=	O
35	O
months	O
)	O
.	O


However	O
,	O
the	O
present	O
pilot	O
study	O
was	O
compromised	O
by	O
several	O
factors	O
:	O
a	O
reliance	O
on	O
parental	O
report	O
to	O
measure	O
language	O
,	O
non-matching	O
of	O
the	O
groups	O
on	O
initial	O
IQ	O
,	O
and	O
a	O
lack	O
of	O
systematic	O
checking	O
regarding	O
the	O
implementation	O
of	O
the	O
parent	O
training	O
intervention	O
.	O


The	O
neutrophil	B-OUT
nadir	I-OUT
was	O
similar	O
with	O
and	O
without	O
priming	O
(	O
mean	O
+/-	O
SD	O
,	O
490	O
+/-	O
310/microL	O
v	O
550	O
+/-	O
350/microL	O
,	O
respectively	O
;	O
P	O
=.2	O
)	O
;	O
however	O
,	O
on	O
day	O
16	O
the	O
mean	O
neutrophil	B-OUT
count	I-OUT
was	O
higher	O
(	O
mean	O
+/-	O
SD	O
,	O
1030	O
+/-	O
580/microL	O
v	O
690	O
+/-	O
370/microL	O
,	O
P	O
=.004	O
)	O
,	O
and	O
the	O
proportion	O
of	O
patients	O
with	O
a	O
neutrophil	B-OUT
count	I-OUT
less	O
than	O
500/microL	O
was	O
lower	O
after	O
priming	O
than	O
before	O
(	O
six	O
of	O
35	O
or	O
17	O
.	O


Episodes	O
of	O
fever	B-OUT
and	I-OUT
neutropenia	I-OUT
were	O
not	O
observed	O
.	O


On	O
day	O
16	O
,	O
a	O
higher	O
mean	O
neutrophil	B-OUT
count	I-OUT
and	O
a	O
lower	O
proportion	O
of	O
patients	O
with	O
severe	O
(	O
<	O
500/microL	O
)	O
neutropenia	B-OUT
were	O
observed	O
.	O


In	O
Treatment	O
B	O
,	O
C	O
,	O
D	O
or	O
E	O
,	O
subjects	O
received	B-I
Tong	I-I
Xin	I-I
Luo	I-I
,	I-I
Nao	I-I
Xin	I-I
Tong	I-I
,	I-I
Guan	I-I
Mai	I-I
Ning	I-I
or	I-I
Yin	I-I
Xing	I-I
Ye	O
for	O
7	O
days	O
and	O
a	O
single	O
dose	O
of	O
20	B-I
mg	I-I
simvastatin	I-I
on	O
Day	O
7	O
.	O


3	O
.	O


An	B-I
internet-based	I-I
cognitive-behavioural	I-I
training	I-I
for	O
acute	B-P
tinnitus	I-P
:	I-P
secondary	O
analysis	O
of	O
acceptance	O
in	O
terms	O
of	O
satisfaction	O
,	O
trial	O
attrition	O
and	O
non-usage	O
attrition	O
.	O


This	O
study	O
analyses	O
Internet-based	B-I
training	I-I
regarding	O
acceptance	O
and	O
attrition	O
in	O
a	O
trial	O
on	O
minimal-contact	B-P
interventions	I-P
for	I-P
acute	I-P
tinnitus	I-P
.	I-P


Whenever	O
possible	O
,	O
we	O
give	O
information	O
on	O
other	O
forms	O
of	O
training	O
for	O
comparison	O
.	O


The	O
same	O
was	O
true	O
for	O
the	O
analysis	O
of	O
protocols	O
.	O


In	O
a	O
survival	B-OUT
analysis	I-OUT
,	O
the	O
difference	O
between	O
the	O
two	O
response	O
curves	O
was	O
significant	O
by	O
the	O
log-rank	O
test	O
(	O
P	O
=	O
0.04	O
)	O
,	O
with	O
the	O
no	O
incentive	O
group	O
having	O
a	O
shorter	O
time	O
to	O
response	O
than	O
the	O
incentive	B-I
group	I-I
.	I-I


Ursodeoxycholic	B-I
acid	I-I
has	O
no	O
influence	O
on	O
function	O
after	O
restorative	O
proctocolectomy	B-OUT
in	O
ulcerative	B-P
colitis	I-P
.	I-P


CONCLUSIONS	O
We	O
conclude	O
that	O
ursodeoxycholic	B-I
acid	I-I
given	O
over	O
4	O
weeks	O
had	O
no	O
influence	O
on	O
functional	B-OUT
score	I-OUT
or	I-OUT
bowel	I-OUT
frequency	I-OUT
after	O
restorative	O
proctocolectomy	O
for	O
U.C	B-OUT
.	I-OUT


Future	O
studies	O
with	O
longer	O
treatment	O
duration	O
and	O
larger	O
sample	O
size	O
are	O
needed	O
to	O
further	O
explore	O
the	O
potential	O
role	O
of	B-I
rosiglitazone	I-I
in	O
improving	O
cognitive	O
function	O
in	B-P
patients	I-P
with	I-P
schizophrenia	I-P
.	O


While	O
the	O
N170	O
was	O
predominant	O
in	O
the	O
right	O
hemisphere	O
in	O
TD	O
and	O
ADHD	O
,	O
children	B-P
with	I-P
ASD	I-P
(	I-P
ASD/ASD+ADHD	I-P
)	I-P
showed	O
a	O
bilateral	O
distribution	O
.	O


In	O
addition	O
,	O
children	B-P
with	I-P
ASD	I-P
demonstrated	O
altered	O
response	B-OUT
to	I-OUT
gaze	I-OUT
direction	I-OUT
on	O
P1	O
latency	O
and	O
no	O
sensitivity	B-OUT
to	I-OUT
gaze	I-OUT
direction	I-OUT
on	O
midline-N170	O
amplitude	O
compared	O
to	O
TD	O
and	O
ADHD	O
.	O


This	O
study	O
follows	O
40	B-P
children	I-P
who	I-P
were	I-P
participants	I-P
in	I-P
a	I-P
randomized	I-P
controlled	I-P
early	I-P
intervention	I-P
trial	I-P
(	I-P
Kasari	I-P
et	I-P
al	I-P
.	I-P


Polydioxanone	B-I
sternal	I-I
sutures	I-I
for	O
prevention	O
of	O
sternal	O
dehiscence	O
.	O


Conventional	B-I
in	I-I
vitro	I-I
fertilization	I-I
versus	O
intracytoplasmic	B-I
sperm	I-I
injection	I-I
in	I-P
patients	I-P
with	I-P
borderline	I-P
semen	I-P
:	I-P
a	O
randomized	O
study	O
using	O
sibling	O
oocytes	O
.	O


In	O
2	B-P
patients	I-P
,	O
there	O
was	O
no	O
fertilization	O
after	O
either	O
IVF	B-I
(	O
0/6	O
oocytes	O
)	O
or	O
ICSI	B-I
(	O
0/9	O
oocytes	O
)	O
.	O


METHODS	O
Two	B-P
hundred	I-P
seven	I-P
consecutive	I-P
coronary	I-P
artery	I-P
bypass	I-P
patients	I-P
(	I-P
mean	I-P
age	I-P
62	I-P
+/-	I-P
11	I-P
years	I-P
)	I-P
were	O
randomized	O
to	O
receive	O
sotalol	B-I
alone	I-I
(	O
80	O
mg	O
twice	O
daily	O
for	O
5	O
days	O
starting	O
from	O
the	O
morning	O
of	O
the	O
first	O
postoperative	O
day	O
)	O
(	O
group	O
S	O
)	O
,	O
magnesium	B-I
alone	I-I
(	O
1.5	O
g	O
daily	O
for	O
6	O
days	O
starting	O
in	O
the	O
operating	O
room	O
just	O
before	O
cardiopulmonary	O
bypass	O
)	O
(	O
group	O
M	O
)	O
,	O
both	B-I
pharmacologic	I-I
agents	I-I
at	I-I
the	I-I
same	I-I
dosages	I-I
(	O
group	O
S+M	O
)	O
,	O
or	B-I
no	I-I
antiarrhythmic	I-I
agents	I-I
(	O
group	O
CTR	O
)	O
.	O


All	B-P
patients	I-P
with	I-P
an	I-P
ejection	I-P
fraction	I-P
less	I-P
than	I-P
0.40	I-P
were	I-P
excluded	I-P
.	I-P


RESULTS	O
The	O
incidence	B-OUT
of	I-OUT
postoperative	I-OUT
AF	I-OUT
was	O
11.8	O
%	O
(	O
6/51	O
)	O
in	O
the	O
S	O
group	O
,	O
14.8	O
%	O
(	O
8/54	O
)	O
in	O
the	O
M	O
group	O
,	O
1.9	O
%	O
(	O
1/52	O
)	O
in	O
the	O
S+M	O
group	O
,	O
and	O
38	O
%	O
(	O
19/50	O
)	O
in	O
the	O
CTR	O
group	O
.	O


Additionally	O
study	O
was	O
done	O
to	O
determine	O
if	O
the	O
use	O
of	O
topical	B-I
anesthetic	I-I
decreased	O
the	O
pain	B-OUT
of	O
needle	O
insertion	O
with	O
the	O
P-ASA	O
injection	O
.	O


METHODS	O
Four	B-P
hundred	I-P
ninety	I-P
six	I-P
home	I-P
,	I-P
hospital	I-P
,	I-P
and	I-P
hospice	I-P
nurses	I-P
participated	I-P
in	I-P
a	I-P
one-day	I-I
workshop	I-I
or	I-I
two	I-I
half-day	I-I
workshops	I-I
on	I-I
cancer	I-I
pain	I-I
assessment	I-I
and	I-I
management	I-I
.	I-I


Eighty-six	B-I
nurses	I-I
served	I-I
as	I-I
controls	I-I
.	I-P


[	O
Validity	O
of	O
cardiotocography	B-I
in	O
the	O
detection	O
of	O
umbilical	B-OUT
cord	I-OUT
complications	I-OUT
]	I-OUT
.	O


Inter-	O
and	O
intra-observer	O
variability	O
were	O
also	O
examined	O
.	O


RESULTS	O
Reliability	B-OUT
52	O
%	O
,	O
ppv	B-OUT
52	O
%	O
,	O
npv	B-OUT
52	O
%	O
,	O
sensitivity	B-OUT
46	O
%	O
,	O
specificity	B-OUT
58	O
%	O
.	O


The	O
intraobserver	B-OUT
variability	I-OUT
was	O
25	O
%	O
.	O


Working	O
memory	O
and	O
cognitive	O
flexibility-training	O
for	O
children	B-P
with	I-P
an	I-P
autism	I-P
spectrum	I-P
disorder	I-P
:	I-P
a	O
randomized	O
controlled	O
trial	O
.	O


There	O
is	O
an	O
urgent	O
need	O
for	O
effective	O
interventions	O
,	O
but	O
in	O
spite	O
of	O
the	O
increasing	O
research	O
focus	O
on	O
computerized	O
cognitive	O
training	O
,	O
this	O
has	O
not	O
been	O
studied	O
in	O
ASD	O
.	O


The	O
main	O
factors	O
were	O
two	O
sources	O
of	O
dietary	O
CP	O
and	O
four	O
levels	O
of	O
RPLM	O
.	O


Steers	O
fed	O
diets	O
containing	O
SBM-U	O
had	O
12	O
%	O
less	O
(	O
P	O
<	O
.10	O
)	O
fat	B-OUT
thickness	I-OUT
than	O
those	O
fed	O
diets	O
containing	O
SBM	O
.	O


Sixty-four	B-P
healthy	I-P
volunteers	I-P
(	I-P
aged	I-P
40	I-P
to	I-P
65	I-P
years	I-P
)	I-P
,	I-P
selected	I-P
on	I-P
the	I-P
basis	I-P
of	I-P
fulfilling	I-P
the	I-P
ICD-10	I-P
F48.0	I-P
criteria	I-P
for	I-P
neurasthenia	I-P
,	O
were	O
assigned	O
randomly	O
to	O
four	O
equal	O
dosing	O
groups	O
,	O
receiving	O
80	O
,	O
160	O
,	O
or	O
320	O
mg	O
of	O
the	O
combination	O
b.i.d	O
.	O


Assessments	O
were	O
performed	O
on	O
the	O
day	O
before	O
dosing	O
,	O
and	O
again	O
at	O
Days	O
1	O
,	O
30	O
,	O
and	O
90	O
at	O
1	O
hour	O
after	O
the	O
morning	O
dose	O
and	O
1	O
hour	O
after	O
the	O
afternoon	O
dose	O
.	O


The	O
treatments	O
were	O
well	B-OUT
tolerated	I-OUT
by	O
all	O
volunteers	O
.	O


There	O
were	O
also	O
several	O
supporting	O
changes	O
from	O
other	O
assessments	O
,	O
including	O
an	O
advantage	O
of	O
320	O
mg	O
over	O
placebo	B-I
on	O
the	O
global	O
score	O
from	O
the	O
Symptom	O
Checklist-90-revised	O
(	O
SCL-90-R	O
)	O
at	O
Day	O
90	O
.	O


PURPOSE	O
The	O
aim	O
was	O
to	O
determine	O
the	O
efficacy	O
of	O
two	B-I
artificial	I-I
eye-drop	I-I
formulations	I-I
by	O
analysing	O
the	O
lower	O
tear	O
film	O
meniscus	O
volume	O
through	O
a	O
commercial	O
high-resolution	O
spectral-domain	O
optical	O
coherence	O
tomographer	O
.	O


Volume	O
was	O
calculated	O
from	O
the	O
local	O
area	O
obtained	O
from	O
tomograms	O
considering	O
a	O
regular	O
distribution	O
of	O
the	O
tear	O
meniscus	O
across	O
the	O
eyelid	O
.	O


High	O
resolution	O
imaging	O
of	O
lower	O
tear	O
film	O
meniscus	O
with	O
clinical	O
optical	O
coherence	O
tomography	O
systems	O
provides	O
useful	O
measures	B-OUT
of	I-OUT
tear	I-OUT
volume	O
.	O


Drug-drug	O
interaction	O
study	O
of	O
ACT-178882	O
,	O
a	O
new	O
renin	O
inhibitor	O
,	O
and	O
diltiazem	O
in	O
healthy	B-P
subjects	I-P
.	I-P


METHODS	O
In	O
this	O
open-label	O
,	O
two-way	O
crossover	O
,	O
drug-drug	O
interaction	O
study	O
,	O
healthy	B-P
young	I-P
male	I-P
subjects	I-P
received	O
treatments	O
A	O
and	O
B	O
in	O
a	O
randomized	O
fashion	O
.	O


Serial	O
blood	O
samples	O
for	O
the	O
measurement	O
of	O
ACT-178882	O
were	O
drawn	O
pre-dose	O
and	O
up	O
to	O
120	O
h	O
post-dose	O
during	O
treatment	O
A	O
and	O
pre-dose	O
ACT-178882	O
and	O
up	O
to	O
240	O
h	O
post-dose	O
during	O
treatment	O
B.	O
Trough	B-OUT
blood	I-OUT
samples	I-OUT
for	O
the	O
measurement	O
of	O
diltiazem	O
were	O
taken	O
on	O
days	O
1-5	O
of	O
dosing	O
during	O
treatment	B-OUT
B	I-OUT
.	I-OUT


In	O
the	O
presence	O
of	O
diltiazem	O
these	O
values	O
were	O
43.5	O
(	O
36.8-51.4	O
)	O
ng/mL	O
and	O
918	O
(	O
781-1078	O
)	O
ng·h/mL	O
,	O
respectively	B-OUT
.	I-OUT


The	B-OUT
median	I-OUT
time	I-OUT
to	I-OUT
Cmax	I-OUT
(	O
tmax	O
)	O
for	O
ACT-178882	O
was	O
prolonged	O
from	O
3.5	O
to	O
5.0	O
h	O
by	O
diltiazem	O
whereas	O
its	B-OUT
apparent	I-OUT
terminal	I-OUT
half-life	I-OUT
(	O
t½	O
)	O
was	O
unaffected	O
by	O
diltiazem	O
,	O
22.9	O
and	O
24.2	O
h	O
for	O
treatments	O
A	O
and	O
B	O
,	O
respectively	O
.	O


One	O
(	O
7.1	O
%	O
)	O
and	O
3	O
(	O
21.3	O
%	O
)	O
of	O
14	O
subjects	B-OUT
reported	I-OUT
an	I-OUT
adverse	O
event	O
during	O
treatment	O
A	O
and	O
B	O
,	O
respectively	B-OUT
,	O
with	O
headache	O
being	O
the	O
most	O
frequently	O
reported	O
,	O
with	O
three	O
events	O
.	O


METHODS	O
The	O
authors	O
randomly	B-P
selected	I-P
subjects	I-P
for	I-P
cavity	I-P
preparation	I-P
with	I-P
conventional	I-I
air	I-I
turbine/bur	I-I
dental	I-I
surgery	I-I
or	I-I
an	I-I
Er	I-I
,	I-I
Cr	I-I
:	I-I
YSGG	I-I
laser-powered	I-I
system	I-I
using	I-P
a	I-P
split-mouth	I-P
design	I-P
.	I-P


Sixty-seven	B-P
subjects	I-P
completed	I-P
the	I-P
study	I-P
.	I-P


CHF	O
STAT	O
Investigators	O
.	O


Patients	O
will	O
be	O
assigned	O
to	O
receive	O
either	O
amiodarone	B-I
or	I-I
placebo	I-I
.	I-I


All	O
patients	O
will	O
receive	O
vasodilator	O
therapy	O
,	O
unless	O
they	O
find	O
it	O
intolerable	O
.	O


This	O
sample	O
size	O
will	O
allow	O
for	O
the	O
detection	O
of	O
a	O
33	O
%	O
decrease	O
in	O
2-year	B-OUT
mortality	I-OUT
(	O
20	O
%	O
vs	O
30	O
%	O
)	O
in	O
the	O
treated	O
patients	O
compared	O
with	O
those	O
in	O
the	O
placebo	O
group	O
,	O
with	O
a	O
power	O
of	O
0.90	O
and	O
a	O
2-sided	O
alpha	O
level	O
of	O
0.05	O
.	O


(	O
ABSTRACT	O
TRUNCATED	O
AT	O
250	O
WORDS	O
)	O


Lipid	B-OUT
variables	I-OUT
were	O
compared	O
with	O
a	O
primary	O
focus	O
on	O
LDL-C	B-OUT
and	O
with	O
secondary	O
focuses	O
on	O
the	O
percentage	O
of	O
patients	O
who	O
reached	O
the	O
LDL-C	B-OUT
targets	O
and	O
changes	O
in	O
the	O
levels	B-OUT
of	I-OUT
RLP-C	I-OUT
(	O
remnant	O
like	O
particle	O
cholesterol	O
)	O
and	O
sd-LDL-C	B-OUT
,	O
two	O
characteristic	O
atherogenic	O
risks	O
of	O
DM	O
.	O


METHODS	O
Of	O
197	B-P
patients	I-P
with	I-P
differentiated	I-P
papillary	I-P
thyroid	I-P
carcinoma	I-P
,	O
49	O
underwent	O
total	O
thyroidectomy	O
alone	O
,	O
and	O
148	O
underwent	O
total	B-I
thyroidectomy	I-I
plus	I-I
CND	I-I
.	I-I


Hypocalcemic	B-OUT
symptoms	I-OUT
,	I-OUT
serum	I-OUT
calcium	I-OUT
,	I-OUT
and	I-OUT
parathyroid	I-OUT
hormone	I-OUT
(	I-OUT
PTH	I-OUT
)	I-OUT
levels	I-OUT
were	O
compared	O
among	O
the	O
groups	O
.	O


CONCLUSIONS	O
Compared	O
with	O
total	O
thyroidectomy	O
alone	O
,	O
CND	O
significantly	O
increases	O
the	O
rate	O
of	O
postoperative	B-OUT
hypocalcemia	I-OUT
,	O
which	O
can	O
be	O
prevented	O
by	O
routine	O
postoperative	O
supplementation	O
with	O
oral	O
calcium	O
and	O
vitamin	O
D	O
.	O


Sublingual	O
administration	O
of	O
certain	O
buffered	B-I
propranolol	I-I
may	O
improve	O
the	O
rate	O
and	O
extent	O
of	O
absorption	O
compared	O
to	O
oral	O
administration	O
.	O


Based	O
on	O
this	O
model	O
,	O
the	O
quantity	O
of	O
drug	B-OUT
absorbed	I-OUT
via	I-OUT
buccal/sublingual	I-OUT
mucosa	O
was	B-OUT
estimated	I-OUT
.	O


The	O
modified	O
ACAT	O
model	O
provided	O
a	O
useful	O
approach	O
to	O
describe	O
sublingual	O
absorption	O
of	O
propranolol	O
and	O
clearly	O
demonstrated	O
an	O
improvement	B-I
of	I-I
absorption	I-I
of	O
Promptol™	O
.	O


Medium	O
correlations	O
were	O
found	O
for	O
the	O
oscillatory	B-OUT
parameters	I-OUT
and	I-OUT
Raw	I-OUT
,	O
whereas	O
for	O
tc-PO2	B-OUT
and	I-OUT
Raw	I-OUT
the	O
correlation	O
was	O
markedly	O
lower	O
.	O


Overall	O
evaluation	O
showed	O
that	O
bodyplethysmography	B-I
and	O
the	O
polyfrequent	B-I
oscillation	I-I
method	I-I
(	O
reactance	O
or	O
resonance	O
frequency	O
)	O
are	O
comparably	O
sensitive	O
.	O


Healthy	B-P
normotensive	I-P
undergraduates	I-P
(	I-P
66	I-P
women	I-P
,	I-P
68	I-P
men	I-P
)	I-P
who	I-P
either	I-P
did	I-P
or	I-P
did	I-P
not	I-P
report	I-P
prior	I-P
experience	I-P
with	I-P
pain	I-OUT
from	I-P
submerging	I-P
a	I-P
limb	I-P
in	I-P
cold	I-P
water	I-P
were	I-P
enrolled	I-P
.	I-P


Analysis	O
of	O
variance	O
revealed	O
a	O
main	O
effect	O
of	O
expectation	O
(	O
p	O
<	O
.05	O
)	O
,	O
such	O
that	O
participants	O
in	O
the	O
placebo	O
expectation	O
group	O
reported	O
less	B-OUT
pain	I-OUT
.	O


Association	O
of	O
PML-RAR	O
alpha	O
fusion	O
mRNA	O
type	O
with	O
pretreatment	O
hematologic	B-OUT
characteristics	I-OUT
but	O
not	O
treatment	O
outcome	O
in	O
acute	B-P
promyelocytic	I-P
leukemia	I-P
:	I-P
an	O
intergroup	O
molecular	O
study	O
.	O


Among	O
221	O
PML-RAR	O
alpha-positive	O
cases	O
,	O
there	O
were	O
82	O
S-form	O
cases	O
(	O
37	O
%	O
)	O
,	O
121	O
L-form	O
cases	O
(	O
55	O
%	O
)	O
,	O
and	O
18	O
V-form	O
cases	O
(	O
8	O
%	O
)	O
.	O


There	O
were	O
no	O
differences	O
between	O
S-form	O
and	O
L-form	O
cases	O
in	O
either	O
CR	B-OUT
rate	I-OUT
(	O
79	O
%	O
v	O
69	O
%	O
;	O
P	O
=	O
.14	O
)	O
or	O
disease	B-OUT
free	I-OUT
survival	I-OUT
distribution	I-OUT
(	O
multivariate	O
analysis	O
adjusting	O
for	O
the	O
association	O
of	O
S-form	O
type	O
and	O
higher	O
WBC	O
count	O
;	O
P	O
=	O
.40	O
)	O
.	O


We	O
conclude	O
that	O
the	O
S-form	O
type	O
is	O
associated	O
with	O
previously-identified	O
adverse	O
risk	O
WBC	O
parameters	O
but	O
that	O
the	O
identification	O
of	O
the	O
S-form	O
or	O
L-form	O
type	O
of	O
PML-RAR	O
alpha	O
mRNA	O
,	O
per	O
se	O
,	O
does	O
not	O
predict	O
clinical	O
outcome	O
or	O
add	O
to	O
the	O
value	O
of	O
an	O
increased	O
WBC	O
count	O
as	O
a	O
negative	O
prognostic	O
indicator	O
in	O
APL	B-P
patients	I-P
.	I-P


Estrogen	B-I
therapy	I-I
for	O
severe	B-P
persistent	I-P
depressions	I-P
in	I-P
women	I-P
.	I-P


Possible	O
physiological	O
mechanisms	O
are	O
discussed	O
.	O


The	O
risk-benefit	B-OUT
ratio	I-OUT
for	O
estrogen	B-I
therapy	I-I
of	O
depression	B-OUT
in	O
these	O
patients	O
was	O
judged	O
to	O
be	O
favorable	B-OUT
.	I-OUT


Loss	O
of	O
bone	B-OUT
mineral	I-OUT
density	I-OUT
after	O
antiretroviral	B-I
therapy	I-I
initiation	I-I
,	O
independent	O
of	O
antiretroviral	O
regimen	O
.	O


This	O
result	O
provides	O
the	O
first	O
evidence	O
for	O
the	O
activation	O
of	O
object-based	B-OUT
representations	I-OUT
during	O
visual	B-I
search	I-I
task	I-I
performance	I-I
and	O
further	O
supports	O
the	O
notion	O
that	O
both	O
excitatory	B-OUT
and	I-OUT
inhibitory	I-OUT
guidance	I-OUT
mechanisms	I-OUT
are	O
involved	O
in	O
target	O
location	O
in	O
visual	O
search	O
.	O


TRIAL	O
REGISTRATION	O
clinicaltrials.gov	O
Identifier	O
:	O
NCT00017953	O
.	O


In	O
this	O
study	O
,	O
we	O
examined	O
whether	O
posterior	O
ERP	O
components	O
associated	O
with	O
identity	O
processing	O
(	O
P2	O
,	O
N250	O
and	O
face-N400	O
)	O
and	O
components	O
associated	O
with	O
early-stage	O
face	O
processing	O
(	O
P1	O
and	O
N170	O
)	O
are	O
atypical	O
in	O
ASD	O
.	O


Effects	B-P
of	I-P
brain-penetrating	I-I
ACE	I-I
inhibitors	I-I
on	I-P
Alzheimer	I-OUT
disease	I-OUT
progression	I-OUT
.	I-OUT


Each	B-I
cycle	I-I
consisted	I-I
of	I-I
21	I-I
days	I-I
of	I-I
active	I-I
treatment	I-I
,	I-I
followed	I-I
by	I-I
7	I-I
days	I-I
without	I-I
treatment	I-I
.	I-I


Both	O
treatments	O
were	O
associated	O
with	O
small	O
changes	O
in	O
systolic	B-OUT
BP	I-OUT
and	I-OUT
diastolic	I-OUT
BP	I-OUT
(	O
DBP	O
)	O
,	O
but	O
only	O
the	O
within-group	O
change	O
in	O
DBP	B-OUT
for	O
the	O
OC	O
group	O
was	O
statistically	O
significant	O
(	O
p	O
=	O
.04	O
)	O
.	O


Between-treatment	O
comparisons	O
of	O
third	O
treatment	O
cycle	O
mean	O
values	O
were	O
performed	O
by	O
analysis	O
of	O
covariance	O
(	O
baseline	O
values	O
as	O
covariate	O
)	O
.	O


Patients	O
evaluated	O
the	O
severity	O
of	O
seasonal	B-OUT
allergic	I-OUT
rhinitis	I-OUT
symptoms	I-OUT
daily	O
for	O
2	O
weeks	O
according	O
to	O
a	O
4-point	O
scale	O
(	O
0	O
=	O
absent	O
,	O
1	O
=	O
mild	O
,	O
2	O
=	O
moderate	O
,	O
3	O
=	O
severe	O
)	O
.	O


CONCLUSIONS	O
This	O
study	O
confirmed	O
that	O
a	O
220-microgram	O
dose	O
of	O
triamcinolone	O
acetonide	O
aqueous	O
nasal	O
spray	O
,	O
administered	O
once	O
daily	O
for	O
2	O
weeks	O
,	O
is	O
well	O
tolerated	O
and	O
reduces	B-OUT
effectively	I-OUT
the	I-OUT
severity	I-OUT
of	I-OUT
symptoms	I-OUT
of	I-OUT
seasonal	I-OUT
allergic	I-OUT
rhinitis	I-OUT
due	I-OUT
to	I-OUT
ragweed	I-OUT
.	I-OUT


Short-term	O
GHQ	B-OUT
success	I-OUT
was	O
determined	O
by	O
a	O
return	O
to	O
a	O
normal	O
GHQ	B-OUT
score	I-OUT
(	O
<	O
5	O
)	O
or	O
a	O
reduction	O
of	O
>	O
or	O
=50	O
%	O
after	O
the	O
two	O
visits	O
.	O


RESULTS	O
Patients	O
with	O
short-term	O
GHQ	O
success	O
were	O
more	O
likely	O
to	O
show	O
mid-term	B-OUT
GHQ	I-OUT
success	I-OUT
(	O
p	O
<	O
.001	O
)	O
,	O
marginally	O
less	O
likely	O
to	O
die	B-OUT
of	I-OUT
any	I-OUT
causes	I-OUT
(	O
p	O
=	O
.087	O
)	O
,	O
less	O
likely	O
to	O
die	B-OUT
of	I-OUT
cardiac	I-OUT
causes	I-OUT
(	O
p	O
=	O
.043	O
)	O
,	O
less	O
likely	O
to	O
be	O
readmitted	B-OUT
for	O
any	O
reason	O
(	O
p	O
<	O
.001	O
)	O
and	O
for	O
cardiac	O
reasons	O
(	O
p	O
<	O
.001	O
)	O
,	O
and	O
less	O
likely	O
to	O
have	O
high	B-OUT
depression	I-OUT
(	O
p	O
<	O
.001	O
)	O
and	O
anxiety	B-OUT
(	O
p	O
<	O
.001	O
)	O
at	O
1-year	O
than	O
patients	O
with	O
short-term	O
unsuccessful	O
GHQ	B-OUT
outcomes	I-OUT
.	I-OUT


To	O
determine	O
the	O
effectiveness	O
of	O
nicotinic	O
acid	O
in	O
dyslipidemic	B-P
patients	I-P
with	I-P
non-insulin-dependent	I-P
diabetes	I-P
mellitus	I-P
,	I-P
13	I-P
patients	I-P
were	I-P
treated	I-P
in	I-P
a	I-P
randomized	I-P
crossover	I-P
trial	I-P
.	I-P


Compared	O
with	O
the	O
control	O
period	O
,	O
nicotinic	B-I
acid	I-I
therapy	O
reduced	O
the	O
plasma	B-OUT
total	I-OUT
cholesterol	I-OUT
level	I-OUT
by	O
24	O
%	O
,	O
plasma	B-OUT
triglyceride	I-OUT
level	I-OUT
by	O
45	O
%	O
,	O
very-low-density	B-OUT
lipoprotein	I-OUT
cholesterol	I-OUT
level	I-OUT
by	O
58	O
%	O
,	O
and	O
low-density	B-OUT
lipoprotein	I-OUT
cholesterol	I-OUT
level	I-OUT
by	O
15	O
%	O
,	O
and	O
it	O
increased	O
the	O
high-density	B-OUT
lipoprotein	I-OUT
cholesterol	I-OUT
level	I-OUT
by	O
34	O
%	O
.	O


However	O
,	O
nicotinic	B-I
acid	I-I
therapy	O
resulted	O
in	O
the	O
deterioration	B-OUT
of	I-OUT
glycemic	I-OUT
control	I-OUT
,	O
as	O
evidenced	O
by	O
a	O
16	O
%	O
increase	O
in	O
mean	B-OUT
plasma	I-OUT
glucose	I-OUT
concentrations	I-OUT
,	O
a	O
21	O
%	O
increase	O
in	O
glycosylated	B-OUT
hemoglobin	I-OUT
levels	I-OUT
,	O
and	O
the	O
induction	O
of	O
marked	B-OUT
glycosuria	I-OUT
in	O
some	O
patients	O
.	O


Sublingual	O
administration	O
of	O
micronized	B-I
estradiol	I-I
and	I-I
progesterone	I-I
,	O
with	O
and	O
without	O
micronized	B-I
testosterone	I-I
:	I-I
effect	O
on	O
biochemical	B-P
markers	I-P
of	I-P
bone	I-OUT
metabolism	I-P
and	I-OUT
bone	I-OUT
mineral	I-OUT
density	I-OUT
.	I-OUT


Data	O
were	O
analyzed	O
via	O
a	O
repeated	O
measures	O
analysis	O
of	O
variance	O
and	O
a	O
Student	O
's	O
t	O
test	O
(	O
alpha=0.05	O
)	O
.	O


Bone-specific	B-OUT
alkaline	I-OUT
phosphatase	I-OUT
decreased	O
(	O
p	O
<	O
0.05	O
)	O
by	O
-14.3	O
+/-	O
4.1	O
%	O
in	O
the	O
HRT	B-I
alone	O
group	O
and	O
by	O
-8.2	O
+/-	O
4.6	O
%	O
in	O
the	O
HRT	B-I
+	I-I
T	I-I
group	O
.	O


Deoxypyridinoline	O
levels	B-OUT
decreased	O
significantly	O
in	O
the	O
HRT	B-I
alone	I-I
and	O
HRT	B-I
+	I-I
T	I-I
groups	O
,	O
-	O
14.4	O
+/-	O
6.8	O
%	O
and	O
-26.9	O
+/-	O
7.6	O
%	O
,	O
respectively	O
.	O


Total	B-OUT
hip	I-OUT
bone	I-OUT
mineral	I-OUT
density	I-OUT
was	O
maintained	O
in	O
the	O
HRT	B-I
alone	I-I
group	O
(	O
+0.4	O
+/-	O
0.4	O
%	O
)	O
and	O
increased	O
(	O
p	O
<	O
0.05	O
)	O
in	O
the	O
HRT	B-I
+	I-I
T	I-I
group	O
(	O
+	O
1.8	O
+/-	O
0.5	O
%	O
)	O
.	O


Although	O
the	O
addition	O
of	O
testosterone	O
to	O
HRT	B-I
for	O
1	O
year	O
did	O
not	O
result	O
in	O
added	O
benefit	O
to	O
the	O
spine	B-OUT
bone	I-OUT
mineral	I-OUT
density	I-OUT
,	O
it	O
did	O
result	O
in	O
a	O
significant	O
increase	O
in	O
hip	B-OUT
bone	I-OUT
mineral	I-OUT
density	I-OUT
.	I-OUT


OBJECTIVES	O
To	O
compare	O
2	O
short-term	O
,	O
community	B-I
caregiver	I-I
training	I-I
interventions	I-I
for	O
preschool-aged	B-P
children	I-P
with	I-P
Autism	I-P
Spectrum	I-P
Disorder	I-P
who	I-P
had	I-P
low	I-P
resources	I-P
.	I-P


Although	O
the	O
median	B-OUT
duration	I-OUT
of	I-OUT
response	I-OUT
was	I-OUT
long	I-OUT
in	O
both	O
treatment	O
arms	O
(	O
combination	O
,	O
19	O
months	O
versus	O
alternating	O
,	O
21	O
months	O
)	O
,	O
the	O
median	O
overall	B-OUT
survival	I-OUT
in	O
both	O
groups	O
was	O
not	O
definitely	O
prolonged	O
(	O
22	O
versus	O
24	O
months	O
,	O
respectively	O
)	O
.	O


Between	B-P
May	I-P
1988	I-P
and	I-P
June	I-P
2000	I-P
,	I-P
698	I-P
children	I-P
were	I-P
treated	I-P
in	I-P
the	I-P
Medical	I-P
Research	I-P
Council	I-P
acute	I-P
myeloid	I-P
leukemia	I-P
10	I-P
and	I-P
12	I-P
trials	I-P
.	I-P


METHODS	O
This	O
study	O
is	O
a	O
randomised	O
,	O
double-blind	O
,	O
parallel-group	O
,	O
fesoterodine-controlled	B-I
study	O
in	O
patients	B-P
with	I-P
continuous	I-P
OAB	I-P
symptoms	I-P
for	I-P
≥	I-P
3	I-P
months	I-P
,	I-P
daily	I-P
mean	I-P
voiding	I-P
frequency	I-P
(	I-P
DMVF	I-P
)	I-P
≥	I-P
8	I-P
,	I-P
and	I-P
daily	I-P
mean	I-P
urgency	I-P
or	I-P
urgency	I-P
incontinence	I-P
frequency	I-P
≥	O
2	O
.	O


The	O
primary	O
efficacy	O
end-point	B-OUT
was	I-OUT
the	I-OUT
difference	I-OUT
in	O
DMVF	O
at	O
12	O
weeks	O
.	O


The	O
other	O
six	O
secondary	O
end-points	O
and	O
variables	O
for	O
safety	O
analysis	O
showed	O
no	O
difference	O
between	O
the	O
two	B-I
groups	I-I
.	I-I


RESULTS	O
During	O
trial	O
1	O
,	O
there	O
was	O
a	O
-0.6	O
+/-	O
0.3	O
mmol	O
l-1	O
(	O
mean	O
+/-	O
SE	O
)	O
change	B-OUT
in	I-OUT
lactate	I-OUT
.	I-OUT


A	O
similar	O
comparison	O
during	O
trial	O
2	O
revealed	O
a	O
1.8	O
+/-	O
0.3	O
mmol.l-1	O
increase	O
in	O
lactate	B-OUT
,	O
signifying	O
a	O
workload	O
above	O
LSS	O
and	O
therefore	O
confirming	O
trial	O
1	O
as	O
the	O
maximum	O
LSS	O
(	O
MLSS	O
)	O
.	O


METHODS	O
One	B-P
hundred	I-P
patients	I-P
were	I-P
randomized	I-P
into	I-P
2	I-P
groups	I-P
to	I-P
undergo	I-P
percutaneous	I-I
transmitral	I-I
commissurotomy	I-I
(	I-I
PTMC	I-I
)	I-I
by	I-P
means	I-I
of	I-I
the	I-I
Inoue	I-I
balloon	I-I
technique	I-I
(	I-I
IBMC	I-I
,	I-I
n	I-I
=	I-I
49	I-I
)	I-I
or	I-I
metallic	I-I
commissurotomy	I-I
(	I-I
PMMC	I-I
,	I-I
n	I-I
=	I-I
51	I-I
)	I-I
.	I-I


Compared	O
to	O
the	O
placebo	B-I
condition	O
,	O
the	O
results	O
showed	O
a	O
decrease	O
in	O
behavior	B-OUT
problems	I-OUT
at	O
the	O
1	O
1/2	O
and	O
2	O
month	O
assessment	O
periods	O
and	O
a	O
slight	O
loss	O
of	O
these	O
benefits	O
at	O
the	O
3	O
and	O
4	O
month	O
assessment	O
periods	O
.	O


This	O
study	O
tested	O
the	O
effect	O
of	O
a	O
method	O
of	O
facilitating	B-I
prelinguistic	I-I
communication	I-I
on	O
parents	B-OUT
'	I-OUT
responsivity	I-OUT
and	I-OUT
children	I-OUT
's	I-OUT
communication	I-OUT
and	I-OUT
productive	I-OUT
language	I-OUT
development	I-OUT
.	I-OUT


The	O
method	O
involved	O
Responsivity	B-I
education	I-I
for	I-I
the	I-I
parents	I-I
and	I-P
Prelinguistic	I-I
Milieu	I-I
Teaching	I-I
for	I-I
the	I-I
children	I-I
(	I-I
RPMT	I-I
)	I-I
.	I-I


Measures	O
on	O
child	O
's	O
anxiety	O
using	O
the	O
Spence	B-OUT
Child	I-OUT
Anxiety	I-OUT
Scale	I-OUT
--	I-OUT
Child	I-OUT
(	I-OUT
SCAS-C	I-OUT
)	I-OUT
and	O
the	O
Clinical	B-OUT
Global	I-OUT
Impression-Severity	I-OUT
scale	I-OUT
(	I-OUT
CGI	I-OUT
--	I-OUT
S	I-OUT
)	I-OUT
were	O
administered	O
at	O
pre-	O
,	O
post-treatment	O
,	O
and	O
follow-ups	O
(	O
3-	O
and	O
6-month	O
)	O
.	O


Findings	O
from	O
the	O
present	O
study	O
suggest	O
factors	O
such	O
as	O
regular	B-I
sessions	I-I
in	I-I
a	I-I
structured	I-I
setting	I-I
,	I-I
consistent	I-I
therapists	I-I
,	I-I
social	I-I
exposure	I-I
and	O
the	O
use	O
of	O
autism-friendly	B-I
strategies	I-I
are	O
important	O
components	O
of	O
an	O
effective	O
framework	O
in	O
the	O
management	O
of	O
anxiety	O
in	O
children	B-P
and	I-P
adolescents	I-P
with	I-P
ASD	I-P
.	I-P


In	O
the	O
recipients	O
of	O
all	O
five	O
vaccine	O
dosages	O
,	O
no	O
influence	O
of	O
sex	O
and	O
age	O
was	O
found	O
on	O
the	O
anti-HBs	B-OUT
conversion	I-OUT
rates	I-OUT
.	I-OUT


AIMS	O
The	O
nursing-led	B-I
inpatient	I-I
unit	I-I
is	O
designed	O
to	O
substitute	O
for	O
a	O
period	O
of	O
care	O
in	O
acute	O
hospital	O
wards	O
and	O
to	O
improve	O
patient	O
outcome	O
prior	O
to	O
discharge	O
to	O
the	O
community	O
.	O


Clinical	B-OUT
outcome	I-OUT
was	O
measured	O
using	O
Barthel	B-OUT
Index	I-OUT
,	O
a	O
functional	O
status	O
measure	O
.	O


METHODS	O
A	B-P
group	I-P
of	I-P
3-	I-P
to	I-P
10-year-old	I-P
children	I-P
with	I-P
autism	I-P
were	O
randomized	O
in	O
a	O
double-blind	O
fashion	O
to	O
receive	O
a	O
supplement	B-I
containing	O
200	O
mg	O
of	O
DHA	B-I
or	O
a	O
placebo	B-I
for	O
6	O
months	O
.	O


The	O
parents	O
and	O
the	O
investigator	O
completed	O
the	O
Clinical	O
Global	O
Impressions-Improvement	O
scale	O
to	O
rate	O
changes	O
in	O
core	O
symptoms	O
of	O
autism	O
after	O
3	O
and	O
6	O
months	O
.	O


Our	O
results	O
may	O
have	O
been	O
limited	O
by	O
inadequate	O
sample	O
size	O
.	O


We	O
believe	O
that	O
the	O
video	B-I
assisted	I-I
thoracoscopy	I-I
(	I-I
VATS	I-I
)	I-I
is	O
the	O
best	O
treatment	O
possible	O
because	O
it	O
allows	O
us	O
to	O
treat	O
the	O
ruptured	O
bleb	O
radically	O
avoiding	O
any	O
recurrence	O
.	O


Clinical	O
benefit	O
with	O
docetaxel	B-I
plus	I-I
fluorouracil	I-I
and	I-I
cisplatin	I-I
compared	O
with	O
cisplatin	B-I
and	I-I
fluorouracil	I-I
in	O
a	O
phase	O
III	O
trial	O
of	O
advanced	B-P
gastric	I-P
or	I-P
gastroesophageal	I-P
cancer	I-P
adenocarcinoma	I-P
:	I-P
the	O
V-325	O
Study	O
Group	O
.	O


The	O
addition	O
of	O
D	B-I
to	O
CF	B-I
not	O
only	O
significantly	O
improved	O
clinical	O
benefit	O
but	O
also	O
improved	O
quality	B-OUT
of	I-OUT
life	I-OUT
,	I-OUT
time	I-OUT
to	I-OUT
progression	I-OUT
,	I-OUT
and	I-OUT
overall	I-OUT
survival	I-OUT
compared	O
with	O
CF	B-I
.	I-I


One	O
way	O
to	O
cope	O
with	O
chemotherapy-related	O
symptom	O
distress	O
is	O
through	O
the	O
use	O
of	O
distraction	O
.	O


Evaluation	O
of	O
the	O
intervention	O
indicated	O
that	O
women	B-P
thought	O
the	O
head	O
mounted	O
device	O
was	O
easy	O
to	O
use	O
,	O
they	O
experienced	O
no	O
cybersickness	B-OUT
,	O
and	O
100	O
%	O
would	O
use	O
VR	O
again	O
.	O


A	O
double-blind	O
placebo-controlled	O
trial	O
of	O
zonisamide	B-I
(	I-I
zonegran	I-I
)	I-I
in	O
the	O
treatment	O
of	O
essential	B-OUT
tremor	I-OUT
.	I-OUT


We	O
performed	O
a	O
double-blind	O
placebo-controlled	O
randomized	O
trial	O
to	O
evaluate	O
the	O
efficacy	B-OUT
and	O
tolerability	B-OUT
of	O
zonisamide	B-I
(	I-I
ZNS	I-I
)	I-I
,	O
an	O
antiepileptic	O
agent	O
,	O
in	O
treating	O
ET	B-OUT
.	I-OUT


On	O
the	O
CGI-C	O
,	O
60	O
%	O
(	O
n	O
=	O
6	O
)	O
of	O
patients	O
in	O
the	O
ZNS	O
group	O
felt	O
that	O
their	O
tremor	B-OUT
was	O
unchanged	O
,	O
while	O
the	O
remaining	O
patients	O
felt	O
that	O
their	O
tremor	B-OUT
was	O
"	O
minimally	O
improved	O
.	O


Participants	O
in	O
the	O
intervention	B-I
and	O
control	B-I
conditions	O
did	O
not	O
differ	O
significantly	O
in	O
terms	O
of	O
any	O
measure	O
of	O
sex	B-OUT
risk	I-OUT
behavior	I-OUT
examined	O
.	O


None	O
of	O
the	O
measures	O
of	O
parent	O
behavior	O
and	O
family	O
processes	O
derived	O
from	O
data	O
at	O
baseline	O
of	O
the	O
FOF	O
study	O
predicted	O
whether	O
participants	O
engaged	O
in	O
high-risk	B-OUT
sex	I-OUT
.	I-OUT


Among	O
measures	O
derived	O
from	O
data	O
collected	O
at	O
long-term	O
follow-up	O
,	O
however	O
,	O
having	O
ever	O
met	O
criteria	O
for	O
substance	O
abuse	O
or	O
dependence	O
predicted	O
greater	O
likelihood	O
of	O
high-risk	B-OUT
sexual	I-OUT
behavior	I-OUT
,	O
and	O
being	O
married	O
or	O
being	O
in	O
a	O
romantic	O
relationship	O
was	O
associated	O
with	O
lower	O
likelihood	O
of	O
high-risk	B-OUT
sexual	I-OUT
behavior	I-OUT
.	I-OUT


Time	B-OUT
per	I-OUT
day	I-OUT
with	I-OUT
glucose	I-OUT
levels	I-OUT
in	O
the	O
range	O
of	O
71-180	O
mg/dl	O
increased	O
significantly	O
(	O
P	O
=	O
0.02	O
)	O
from	O
baseline	O
to	O
12	O
months	O
.	O


Besides	O
this	O
transformation	O
the	O
effects	O
of	O
prompts	O
will	O
be	O
examined	O
.	O


Information	O
about	O
pupils	B-OUT
'	I-OUT
smoking	I-OUT
status	I-OUT
and	O
other	O
factors	O
related	O
to	O
smoking	O
will	O
be	O
obtained	O
using	O
a	O
web-based	O
questionnaire	O
.	O


Expectations	O
are	O
that	O
pupils	O
receiving	O
tailored	O
advice	O
will	O
be	O
less	O
likely	O
to	O
smoke	O
after	O
24	O
months	O
in	O
contrast	O
to	O
pupils	O
in	O
the	O
control	O
condition	O
.	O


Its	O
effects	O
on	O
bone	B-OUT
in	O
vivo	O
are	O
unknown	O
,	O
although	O
beta	O
receptor	O
sites	O
have	O
been	O
found	O
on	O
osteoblasts	O
.	O


Two	O
patients	O
who	O
received	O
phenoxymethylpenicillin	B-I
and	O
two	O
given	O
doxycycline	B-I
subsequently	O
developed	O
major	O
manifestations	O
of	O
Lyme	B-OUT
borreliosis	I-OUT
;	I-OUT
these	O
did	O
not	O
occur	O
in	O
patients	O
receiving	O
azithromycin	B-I
.	I-I


Although	O
azithromycin	B-I
has	O
been	O
shown	O
to	O
be	O
effective	O
in	O
the	O
treatment	O
of	O
erythema	O
migrans	O
,	O
further	O
studies	O
will	O
be	O
needed	O
to	O
determine	O
the	O
optimal	O
dosage	O
and	O
duration	O
of	O
therapy	O
.	O


A	O
unicenter	O
,	O
single-blind	O
,	O
randomized	O
study	O
was	O
conducted	O
on	O
283	B-P
patients	I-P
with	I-P
active	I-P
duodenal	I-P
ulcer	I-P
to	I-P
compare	I-P
possible	I-P
factors	I-P
that	I-P
may	I-P
affect	I-P
healing	I-P
and	I-P
relapse	I-P
in	I-P
patients	I-P
treated	I-P
with	I-P
a	I-P
potent	I-P
antisecretory	I-I
agent	I-I
,	I-I
cimetidine	I-I
,	I-P
or	I-P
a	I-P
site-protective	I-P
and	I-P
cytoprotective	I-P
agent	I-P
,	I-P
sucralfate	I-I
.	I-I


Furthermore	O
,	O
in	O
cimetidine-	B-I
but	O
not	O
sucralfate-healed	B-I
patients	O
,	O
early	O
ulcer	O
relapse	O
(	O
within	O
6	O
mo	O
)	O
was	O
associated	O
with	O
short	O
duration	B-OUT
of	I-OUT
illness	I-OUT
,	O
short	O
remission	B-OUT
period	I-OUT
,	I-OUT
long	I-OUT
symptomatic	I-OUT
spell	I-OUT
,	I-OUT
and	I-OUT
reluctance	I-OUT
to	I-OUT
give	I-OUT
up	I-OUT
smoking	I-OUT
.	I-OUT


We	O
conclude	O
that	O
smoking	O
adversely	O
affects	O
duodenal	O
ulcer	O
healing	O
by	O
cimetidine	B-I
and	O
hastens	O
subsequent	O
relapse	O
,	O
and	O
that	O
sucralfate	B-I
overcomes	O
the	O
adverse	O
effect	O
of	O
smoking	O
on	O
healing	O
as	O
encountered	O
with	O
cimetidine	B-I
,	O
and	O
results	O
in	O
a	O
subsequent	O
remission	O
period	O
double	O
that	O
of	O
cimetidine	B-I
.	I-I


In	O
both	O
groups	O
,	O
ISDN-mediated	B-OUT
dilation	I-OUT
is	O
unaffected	O
by	O
the	O
treatment	O
.	O


As	O
a	O
marker	O
of	O
oxidative	O
stress	O
,	O
allopurinol	O
significantly	O
reduced	B-OUT
malondialdehyde	I-OUT
.	I-OUT


Moreover	O
,	O
myeloperoxidase	B-OUT
levels	I-OUT
were	O
reduced	O
by	O
the	O
treatment	O
with	O
allopurinol	O
(	O
56.1	O
+/-	O
3.4	O
ng/ml	O
vs.	O
44.4	O
+/-	O
2.4	O
ng/ml	O
,	O
P	O
<	O
0.05	O
)	O
but	O
there	O
were	O
no	O
change	O
in	O
the	O
placebo	O
group	O
.	O


Bilateral	B-OUT
circumference	I-OUT
measurements	O
were	O
done	O
for	O
evaluation	O
of	O
the	O
edema	O
.	O


RESULTS	O
Symptoms	O
were	O
decreased	O
in	O
all	O
three	O
groups	O
(	O
p	O
<	O
0.05	O
)	O
.	O


CONCLUSION	B-I
Kinesio	I-I
Taping	I-I
(	I-I
®	I-I
)	I-I
Application	O
along	B-I
with	I-I
CDT	O
may	O
have	O
a	O
better	O
effect	O
on	O
decreasing	B-OUT
lymphedema	I-OUT
which	O
can	O
stimulate	O
the	O
reduction	B-OUT
of	I-OUT
edema	O
for	O
long	O
term	O
effects	O
.	O


OBJECT	O
Stable	O
hemodynamics	O
,	O
normocapnia	O
,	O
and	O
adequate	O
pain	O
relief	O
are	O
considered	O
important	O
factors	O
in	O
the	O
reduction	O
of	O
neurological	O
complications	O
in	O
pediatric	B-P
patients	I-P
undergoing	I-P
encephaloduroarteriomyosynangiosis	I-I
(	I-I
EDAMS	I-I
)	I-I
operations	I-P
for	I-P
the	I-P
treatment	I-P
of	I-P
moyamoya	I-P
disease	I-P
.	I-P


Patients	O
in	O
the	O
control	O
group	O
did	O
not	O
receive	O
NB	O
.	O


For	O
delirious	B-OUT
awakening	I-OUT
,	O
the	O
odds	O
ratio	O
in	O
the	O
control	O
group	O
was	O
4.9	O
compared	O
with	O
the	O
NB	O
group	O
.	O


Pain	B-OUT
and	I-OUT
analgesic	I-OUT
requirement	I-OUT
were	O
higher	O
in	O
the	O
control	O
patients	O
than	O
in	O
the	O
NB-treated	O
patients	O
during	O
the	O
postanesthesia	O
care	O
unit	O
stay	O
.	O


CONCLUSIONS	O
The	O
use	O
of	O
skull	O
block	O
during	O
EDAMS	O
surgery	O
provided	O
easy	O
hemodynamic	B-OUT
control	I-OUT
,	I-OUT
calm	I-OUT
awakening	I-OUT
,	I-OUT
and	I-OUT
better	I-OUT
pain	I-OUT
relief	I-OUT
and	O
may	O
be	O
related	O
to	O
the	O
reduced	O
postoperative	B-OUT
morbidity	I-OUT
.	I-OUT


Objective	B-OUT
regression	I-OUT
(	O
CR	O
+	O
PR	O
)	O
was	O
observed	O
in	O
58	O
%	O
of	O
group	O
A	O
and	O
75	O
%	O
of	O
group	O
B	O
,	O
with	O
CR	O
in	O
11	O
%	O
and	O
23	O
%	O
,	O
respectively	O
.	O


Participants	B-P
were	I-P
randomly	I-P
assigned	I-P
to	I-P
treatment	I-I
and	I-I
control	I-I
groups	I-I
and	O
repeated	O
measures	O
MANCOVA	O
was	O
used	O
to	O
detect	O
differences	O
in	O
pain	B-OUT
and	I-OUT
power	I-OUT
over	O
a	B-I
4-day	I-I
period	I-I
of	I-I
time	I-I
.	I-I


Comparison	O
was	O
made	O
with	O
a	O
delayed	B-I
treatment	I-I
control	I-I
group	I-I
(	I-I
DTC	I-I
)	I-I
.	O


In	O
this	O
more	O
homogeneous	O
subgroup	O
,	O
the	O
10-year	B-OUT
survival	I-OUT
rates	I-OUT
(	O
and	O
standard	O
errors	O
)	O
were	O
for	O
RDL	O
,	O
60	O
%	O
(	O
+/-	O
7	O
%	O
)	O
and	O
for	O
EXT	O
,	O
74	O
%	O
(	O
+/-	O
6	O
%	O
)	O
(	O
P	O
value	O
for	O
comparison	O
of	O
survival	O
curves	O
=	O
0.13	O
)	O
.	O


In	O
patients	O
from	O
this	O
subgroup	O
with	O
central-medial	O
tumors	O
,	O
comprising	O
62	O
%	O
of	O
the	O
total	O
,	O
survival	B-OUT
after	O
RDL	O
at	O
10	O
years	O
was	O
60	O
%	O
(	O
+/-	O
8	O
%	O
)	O
,	O
and	O
after	O
EXT	O
86	O
%	O
(	O
+/-	O
6	O
%	O
)	O
(	O
P	O
=	O
0.025	O
)	O
.	O


Altered	O
peripheral	B-OUT
vasodilator	I-OUT
profile	I-OUT
of	O
nitroglycerin	O
during	O
long-term	O
infusion	O
of	O
N-acetylcysteine	O
.	O


Oral	O
bioavailability	O
of	O
moxifloxacin	B-I
after	I-P
Roux-en-Y	I-I
gastric	I-I
bypass	I-I
surgery	I-I
.	I-I


This	O
may	O
suggest	O
a	O
higher	O
enterohepatic	O
recirculation	B-I
of	I-P
moxifloxacin	I-P
after	I-P
gastric	O
bypass	O
.	O


In	O
four	O
cases	O
(	O
12.9	O
%	O
)	O
the	O
sentinel	O
lymph	O
node	O
was	O
the	O
only	O
site	O
of	O
metastasis	O
,	O
all	O
of	O
them	O
being	O
detected	O
by	O
association	B-OUT
of	I-OUT
hematoxylin	I-OUT
and	I-OUT
eosin	I-OUT
and	I-OUT
immunohistochemical	I-OUT
examination	I-OUT
.	I-OUT


There	O
was	O
no	O
aberrant	O
lymph	B-OUT
drainage	I-OUT
that	O
would	O
alter	O
resection	O
margins	O
in	O
patients	O
studied	O
.	O


The	O
antihypertensive	B-OUT
efficacies	O
of	O
lisinopril	B-I
and	O
captopril	B-I
were	O
compared	O
using	O
office	O
sphygmomanometry	O
and	O
24-h	O
ambulatory	O
blood	O
pressure	O
monitoring	O
.	O


Recombinant	B-I
human	I-I
erythropoietin	I-I
.	I-I


If	O
prescribers	O
complied	O
with	O
current	O
guidelines	O
,	O
microscopy	O
would	O
give	O
rise	O
to	O
lower	O
average	O
costs	B-OUT
per	O
patient	O
correctly	O
treated	O
than	O
RDTs	B-I
in	O
areas	O
of	O
both	O
high	O
and	O
low	O
transmission	O
.	O


Neo-ALTTO	B-I
(	I-I
Neoadjuvant	I-I
Lapatinib	I-I
and/or	I-I
Trastuzumab	I-I
Treatment	O
Optimisation	O
)	O
enrolled	O
455	B-P
women	I-P
with	I-P
invasive	I-P
human	I-P
epidermal	I-P
growth	I-P
factor	I-P
receptor	I-P
2	I-P
(	I-P
HER2	I-P
)	I-P
-positive	I-P
breast	I-P
cancer	I-P
and	O
compared	O
rates	O
of	O
pathologic	O
complete	O
response	O
(	O
pCR	O
)	O
to	O
neoadjuvant	B-I
lapatinib	I-I
,	I-I
trastuzumab	I-I
,	I-I
and	I-I
their	I-I
combination	I-I
.	I-I


The	O
early	O
metabolic	B-OUT
effects	I-OUT
of	O
the	O
anti-HER2	B-I
therapies	I-I
on	O
the	O
primary	O
tumors	O
and	O
their	O
predictive	O
values	O
for	O
pCR	O
were	O
assessed	B-P
in	I-P
a	I-P
subset	I-P
of	I-P
patients	I-P
.	I-P


METHODS	O
Eighty-six	B-P
patients	I-P
underwent	I-P
(	I-I
18	I-I
)	I-I
F-FDG	I-I
PET/CT	I-I
at	O
baseline	O
and	O
weeks	O
2	O
and	O
6	O
of	O
anti-HER2	B-I
treatment	I-I
.	I-I


A	O
controlled	O
crossover	O
trial	O
of	O
fenfluramine	B-I
in	O
autism	B-P
.	I-P


RESULTS	O
TB1	O
(	O
containing	O
ginseng	O
leaf	O
,	O
cistanche	O
,	O
fleeceflower	O
root	O
,	O
immature	O
bitter	O
orange	O
,	O
rhubarb	O
,	O
etc	O
)	O
could	O
improve	O
various	O
symptoms	B-OUT
of	I-OUT
aging	I-OUT
,	O
and	O
had	O
the	O
effect	O
in	O
regulating	B-OUT
immune	I-OUT
and	I-OUT
endocrinal	I-OUT
function	I-OUT
,	I-OUT
scavenging	I-OUT
free	I-OUT
radicals	I-OUT
and	I-OUT
adjusting	I-OUT
coli	I-OUT
flora	I-OUT
.	I-OUT


VDMV	B-I
achieved	O
PIP	B-OUT
and	O
PEEP	B-OUT
closest	O
to	O
that	O
targeted	O
and	O
significantly	O
lower	O
variation	O
in	O
all	O
measured	O
parameters	O
(	O
p	O
<	O
0.001	O
)	O
other	O
than	O
with	O
PIP	O
.	O


SIB	O
delivered	O
TV	B-OUT
and	O
MV	B-OUT
over	O
twice	O
that	O
delivered	O
by	O
VDMV	B-I
and	O
Neopuff	B-I
.	I-I


No	O
correlation	B-OUT
with	I-OUT
intellectual	I-OUT
ability	I-OUT
was	O
found	O
at	O
any	O
of	O
these	O
sites	O
.	O


CONCLUSIONS	O
Therapeutic	O
steady	O
state	O
concentrations	O
of	O
roflumilast	O
and	O
its	O
N-oxide	O
do	O
not	O
alter	O
the	O
disposition	B-OUT
of	I-OUT
the	I-OUT
CYP3A	I-OUT
substrate	I-OUT
midazolam	I-OUT
in	O
healthy	B-P
subjects	I-P
.	I-P


This	O
parent-mediated	O
intervention	O
has	O
previously	O
been	O
shown	O
to	O
significantly	O
increase	O
responsive	O
parental	O
communication	O
(	O
Siller	O
et	O
al	O
.	O


in	O
J	O
Autism	O
Dev	O
Disord	O
43:540-555	O
,	O
2013a	O
)	O
.	O


One	B-P
hundred	I-P
twenty-two	I-P
chemotherapy-naive	I-P
patients	I-P
with	I-P
histologically	I-P
confirmed	I-P
colorectal	I-P
adenocarcinoma	I-P
were	O
entered	O
into	O
a	O
randomized	O
trial	O
comparing	O
infusional	B-I
fluorouracil	I-I
(	I-I
FU	I-I
)	I-I
versus	I-I
cisplatin	I-I
(	I-I
CDDP	I-I
)	I-I
and	I-I
FU	I-I
.	I-I


There	O
were	O
no	O
significant	O
differences	O
in	O
either	O
the	O
duration	B-OUT
of	I-OUT
response	I-OUT
(	O
median	O
,	O
6	O
and	O
4.7	O
months	O
for	O
CDDP/FU	B-I
and	O
FU	B-I
groups	O
,	O
respectively	O
)	O
or	O
survival	B-OUT
(	O
median	O
10	O
,	O
and	O
12	O
months	O
,	O
respectively	O
)	O
.	O


METHODS	O
In	O
the	O
surgery	B-I
setting	O
,	O
a	O
total	O
of	O
381	B-P
patients	I-P
were	I-P
randomised	I-P
to	I-P
chemotherapy	I-I
(	I-P
C	I-P
,	I-P
192	I-P
patients	I-P
)	I-P
or	I-P
no	I-I
chemotherapy	I-I
(	I-P
NoC	I-P
,	I-P
189	I-P
patients	I-P
)	I-P
.	I-P


C	O
was	O
three	O
3-weekly	O
cycles	O
of	O
cisplatin/vindesine	B-I
,	I-I
mitomycin/ifosfamide/cisplatin	I-I
,	I-I
mitomycin/vinblastine/cisplatin	I-I
or	I-I
vinorelbine/cisplatin	I-I
.	I-I


RESULTS	O
Chemotherapy	B-I
was	O
given	O
before	O
surgery	B-I
in	O
3	O
%	O
of	O
patients	O
whilst	O
97	O
%	O
received	O
adjuvant	B-I
chemotherapy	I-I
.	I-I


198	O
(	O
52	O
%	O
)	O
of	O
patients	O
have	O
died	O
,	O
but	O
there	O
is	O
currently	O
no	O
evidence	O
of	O
a	O
benefit	B-OUT
in	I-OUT
overall	I-OUT
survival	I-OUT
to	O
the	O
C	O
group	O
:	O
HR	O
1.02	O
(	O
95	O
%	O
CI	O
0.77-1.35	O
)	O
,	O
P	O
=	O
0.90	O
)	O
.	O


No	O
beneficial	O
effects	O
of	O
CCB	B-I
treatment	O
on	O
clinical	B-OUT
events	I-OUT
were	O
observed	O
during	O
the	O
2-year	O
study	O
follow-up	O
.	O


No	B-OUT
significant	I-OUT
difference	I-OUT
was	I-OUT
found	I-OUT
concerning	I-OUT
plasma	I-OUT
levels	I-OUT
of	I-OUT
P	I-OUT
(	I-OUT
578	I-OUT
+/-	I-OUT
477	I-OUT
ng/ml	I-OUT
compared	I-OUT
with	I-OUT
646	I-OUT
+/-	I-OUT
457	I-OUT
ng/ml	I-OUT
,	I-OUT
p	I-OUT
greater	I-OUT
than	I-OUT
0.05	I-OUT
)	I-OUT
.	I-OUT


Metal	B-OUT
release	I-OUT
and	I-OUT
metal	I-OUT
allergy	I-OUT
after	O
total	B-I
hip	I-I
replacement	I-I
with	I-I
resurfacing	I-I
versus	I-I
conventional	I-I
hybrid	I-I
prosthesis	I-I
.	I-I


BACKGROUND	O
Metal-on-metal	B-I
(	I-I
MOM	I-I
)	I-I
total	I-I
hip	I-I
arthroplasties	I-I
were	O
reintroduced	O
because	O
of	O
the	O
problems	O
with	O
osteolysis	O
and	O
aseptic	O
loosening	O
related	O
to	O
polyethylene	O
wear	O
of	O
early	O
metal-on-polyethylene	O
(	O
MOP	O
)	O
arthroplasties	O
.	O


METHODS	O
A	O
mixed-methods	O
randomized	O
controlled	O
trial	O
(	B-I
intervention	I-I
(	I-I
INT	I-I
)	I-I
vs.	I-I
waitlist	I-I
(	I-I
WL	I-I
)	I-I
)	I-I
was	O
conducted	O
with	O
patients	B-P
suffering	I-P
from	I-P
FMS	I-P
.	I-P


Complete	O
data	O
from	O
T0	O
to	O
T2	O
were	O
available	O
for	O
43	B-P
patients	I-P
.	I-P


A	O
randomised	O
comparison	O
of	O
the	O
self-pressurised	O
air-QTM	O
intubating	O
laryngeal	B-I
airway	O
with	O
the	O
LMA	B-I
Unique™	I-I
in	I-P
children	I-P
.	O


The	O
interventions	O
were	O
either	O
a	O
commercially	B-I
available	I-I
weighted	I-I
blanket	I-I
or	I-I
otherwise	I-I
identical	I-I
usual	I-I
weight	I-I
blanket	I-I
(	O
control	O
)	O
,	O
introduced	O
at	O
bedtime	O
;	O
each	O
was	O
used	O
for	O
a	O
2-week	O
period	O
before	O
crossover	O
to	O
the	O
other	O
blanket	O
.	O


However	O
,	O
the	O
weighted	B-I
blanket	I-I
was	O
favored	O
by	O
children	O
and	O
parents	O
,	O
and	O
blankets	O
were	O
well	B-OUT
tolerated	I-OUT
over	O
this	O
period	O
.	O


Acipimox	B-I
was	O
well	O
tolerated	B-OUT
,	O
and	O
could	O
be	O
a	O
useful	O
addition	O
to	O
the	O
drugs	O
available	O
for	O
the	O
treatment	O
of	O
patients	B-P
with	I-P
hypertriglyceridaemia	I-P
.	I-P


The	O
incidence	B-OUT
of	I-OUT
diarrhoea	I-OUT
during	O
therapy	O
was	O
higher	O
for	O
patients	B-P
treated	I-P
with	I-P
cefdinir	I-I
(	I-P
17	I-P
%	I-P
)	I-P
than	I-P
for	I-P
patients	I-P
treated	I-P
with	I-P
cefprozil	I-I
(	I-P
6	I-P
%	I-P
)	I-P
(	O
P	O
<	O
0.01	O
)	O
,	O
but	O
most	O
cases	O
were	O
mild	O
and	O
did	O
not	O
lead	O
to	O
discontinuation	O
of	O
treatment	O
.	O


Subgroup	O
results	O
were	O
consistent	O
.	O


Palmar-plantar	B-OUT
erythrodysesthesia	I-OUT
(	O
48	O
%	O
versus	O
2	O
%	O
)	O
,	O
stomatitis	B-OUT
(	O
22	O
%	O
versus	O
15	O
%	O
)	O
and	O
mucositis	B-OUT
(	O
23	O
%	O
versus	O
13	O
%	O
)	O
were	O
more	O
often	O
associated	O
with	O
PLD	B-I
than	O
doxorubicin	B-I
.	I-I


Eleven	B-P
patients	I-P
were	O
excluded	O
from	O
analysis	O
and	O
another	O
5	O
patients	O
were	O
excluded	O
from	O
response	O
analysis	O
.	O


The	O
levels	O
of	O
the	O
systolic	B-OUT
and	I-OUT
diastolic	I-OUT
pressures	I-OUT
at	O
entry	O
were	O
not	O
predictive	O
of	O
the	O
dose	O
of	O
nifedipine	B-I
required	O
for	O
effective	B-OUT
blood	I-OUT
pressure	I-OUT
control	O
.	O


The	O
neuropeptide	B-I
oxytocin	I-I
has	O
been	O
shown	O
to	O
promote	O
face	O
processing	O
and	O
modulate	O
brain	O
activity	O
in	O
healthy	B-P
adults	I-P
.	I-P


The	O
efficacy	O
was	O
assessed	O
by	O
serial	O
Holter	B-OUT
monitoring	I-OUT
.	I-OUT


The	B-OUT
total	I-OUT
symptom	I-OUT
score	I-OUT
significantly	O
decreased	O
in	O
all	O
active	O
groups	O
compared	O
with	B-I
placebo	I-I
(	O
-18.8	O
%	O
for	O
placebo	O
patients	O
;	O
-71.9	O
%	O
,	O
P	O
=	O
0.0022	O
for	O
20	O
μg	O
;	O
-75.6	O
%	O
,	O
P	O
=	O
0.0007	O
for	O
80	O
μg	O
;	O
-81.8	O
%	O
,	O
P	O
=	O
0.0009	O
for	O
160	O
μg	O
;	O
-78.3	O
%	O
,	O
P	O
=	O
0.0003	O
for	O
320	B-OUT
μg	I-OUT
)	I-OUT
.	O


METHODS	O
cluster-RCT	B-I
designed	O
to	O
compare	O
stroke	B-P
patient	I-P
referrals	I-P
by	I-P
Emergency	I-I
Medical	I-I
Service	I-I
(	I-I
EMS	I-I
)	I-I
and	I-P
Emergency	I-P
Room	I-P
(	I-P
ER	I-P
)	I-P
health	I-P
professionals	I-P
trained	I-P
in	I-P
the	I-P
ECP	I-I
,	I-P
with	I-P
those	I-P
of	I-P
non-trained	I-P
EMS	I-P
and	I-P
ER	I-P
controls	I-P
.	I-P


This	O
randomized	O
,	O
double-blind	O
,	O
triple-dummy	O
,	O
parallel-groups	O
study	O
compared	O
rizatriptan	B-I
5	I-I
mg	I-I
,	I-I
rizatriptan	I-I
10	I-I
mg	I-I
,	I-I
sumatriptan	I-I
100	I-I
mg	I-I
,	I-I
and	I-I
placebo	I-I
in	O
1268	B-P
outpatients	I-P
treating	I-P
a	I-P
single	I-P
migraine	I-P
attack	I-P
.	I-P


The	O
prophylactic	B-OUT
effect	I-OUT
of	O
valproate	B-I
on	O
glyceryltrinitrate	B-OUT
induced	I-OUT
migraine	I-OUT
.	I-OUT


Median	B-OUT
peak	I-OUT
headache	I-OUT
intensity	I-OUT
was	O
1	O
(	O
range	O
0-9	O
)	O
after	O
valproate	B-I
compared	O
to	O
4.5	O
(	O
range	O
0-8	O
)	O
after	O
placebo	B-I
(	O
P	O
=	O
0.120	O
)	O
.	O


METHODS	O
This	O
randomized	O
,	O
multinational	O
,	O
open-label	O
trial	O
included	O
subjects	B-P
treated	I-P
for	I-P
T2DM	I-P
with	I-P
metformin	I-I
±	I-I
sulphonylurea	I-I
,	I-P
who	I-P
had	I-P
glycated	I-P
haemoglobin	I-P
(	I-P
HbA1c	I-P
)	I-P
levels	I-P
of	I-P
7.5-12	I-P
%	I-P
.	O


Subjects	O
were	O
assigned	O
to	O
24	B-I
weeks	I-I
of	I-I
insulin	I-I
glargine	I-I
,	O
titrated	O
to	O
target	O
fasting	O
plasma	O
glucose	O
of	O
4.0-5.5	B-I
mmol/L	I-I
or	I-I
liraglutide	I-I
,	O
escalated	O
to	O
the	O
highest	O
approved	O
clinical	O
dose	O
of	O
1.8	O
mg	O
daily	O
.	O


The	O
mean	O
(	O
s.d	O
.	O


RESULTS	O
As	O
the	O
drop-out	O
rate	O
after	O
crossover	O
was	O
high	O
(	O
17	O
of	O
79	O
patients	O
[	O
22	O
%	O
]	O
)	O
,	O
we	O
analyzed	O
the	O
trial	O
as	O
a	O
parallel	O
clinical	O
trial	O
,	O
using	O
data	O
of	O
the	O
first	O
half	O
of	O
the	O
crossover	O
phase	O
only	O
.	O


The	O
response	O
to	O
cardiopulmonary	B-I
exercise	I-I
(	I-I
CPX	I-I
)	I-I
in	O
patients	B-P
with	I-P
heart	I-P
failure	I-P
(	I-P
HF	I-P
)	I-P
with	I-P
normal	I-P
left	I-P
ventricular	I-P
(	I-P
LV	I-P
)	I-P
ejection	I-P
fractions	I-P
(	I-P
EFs	I-P
)	I-P
is	O
not	O
well	O
characterized	O
.	O


All	O
patients	O
were	O
evaluated	O
with	O
echocardiography	B-I
and	O
a	O
standardized	B-I
CPX	I-I
test	I-I
as	O
part	O
of	O
the	O
trial	O
.	O


There	O
was	O
no	O
significant	O
difference	O
in	O
the	O
use	B-OUT
of	I-OUT
beta	I-OUT
blockers	I-OUT
or	I-OUT
the	I-OUT
incidence	I-OUT
of	I-OUT
coronary	I-OUT
artery	I-OUT
disease	I-OUT
.	I-OUT


The	O
VE/VCO	B-OUT
(	I-OUT
2	I-OUT
)	I-OUT
ratios	I-OUT
for	O
the	O
2	O
groups	O
were	O
abnormal	O
and	O
comparable	O
(	O
32	O
2	O
+/-	O
7.5	O
vs	O
34.0	O
+/-	O
8.3	O
,	O
p	O
=	O
0.3	O
,	O
diastolic	O
HF	O
vs	O
systolic	O
HF	O
)	O
.	O


In	O
conclusion	O
,	O
the	O
CPX	B-OUT
response	I-OUT
in	O
patients	O
with	O
diastolic	O
HF	O
and	O
systolic	O
HF	O
is	O
markedly	O
abnormal	O
and	O
indistinguishable	O
with	O
regard	O
to	O
peak	B-OUT
VO	I-OUT
(	I-OUT
2	I-OUT
)	I-OUT
and	I-OUT
ventilation	I-OUT
despite	O
marked	O
differences	O
in	O
the	O
LV	O
EF	O
.	O


BACKGROUND	O
The	O
results	O
of	O
open	O
pilot	O
studies	O
suggest	O
that	O
the	O
serotonin-1A	B-I
(	I-I
5-HT1A	I-I
)	I-I
receptor	I-I
agonist	I-I
buspirone	I-I
might	O
be	O
effective	O
in	O
social	O
phobia	O
.	O


The	O
ORR	B-OUT
was	O
better	O
with	O
the	O
longer	O
regimens	O
(	O
arm	O
A	O
,	O
56.9	O
%	O
;	O
B	O
,	O
64	O
%	O
;	O
and	O
C	O
,	O
47.6	O
%	O
;	O
P	O
:	O
=.06	O
)	O
and	O
was	O
41	O
%	O
after	O
second-line	O
FEC	B-I
100	O
.	O


CONCLUSION	O
In	O
MBC	O
,	O
longer	O
epirubicin-based	O
regimens	O
are	O
better	O
in	O
terms	O
of	O
response	B-OUT
duration	I-OUT
and	I-OUT
TTP	I-OUT
.	I-OUT


RESULTS	O
All	O
NT	B-I
201	I-I
and	I-I
BTXCo	I-I
doses	O
achieved	O
a	O
statistically	O
significant	O
reduction	B-OUT
of	I-OUT
the	I-OUT
compound	I-OUT
muscle	I-OUT
action	I-OUT
potential	I-OUT
M-wave	I-OUT
amplitude	I-OUT
in	O
the	B-OUT
EDB	I-OUT
muscle	I-OUT
.	I-OUT


CONCLUSIONS	O
NT	B-I
201	I-I
is	O
effective	O
and	O
safe	O
in	O
inducing	O
the	O
desired	O
paretic	O
effect	O
.	O


DESIGN	O
Field	O
experiment	O
,	O
two-way	O
analysis	O
of	O
variance	O
with	O
one	O
between	O
group	B-P
(	I-I
short-	I-I
versus	I-I
long-stay	I-I
)	I-I
and	I-P
one	I-P
repeated	I-P
measures	I-P
factor	I-P
(	I-P
admission	I-P
,	I-P
then	I-P
12	I-P
,	I-P
18	I-P
,	I-P
24	I-P
,	I-P
30	I-P
and	I-P
36	I-P
months	I-P
post-admission	I-P
)	I-P
.	O


SUBJECTS	B-P
n	I-P
=	I-P
81	I-P
;	I-P
mean	I-P
age	I-P
11	I-P
months	I-P
;	I-P
79	I-P
contribute	I-P
longitudinal	I-P
data	I-P
;	I-P
44	I-P
every	I-P
measurement	I-P
.	I-P


SS	B-I
discharged	I-I
immediately	I-I
(	O
mean	O
18	O
days	O
)	O
for	B-I
standard	I-I
Health	I-I
Service	I-I
care	I-I
at	I-I
home	I-I
for	O
6	O
months	O
plus	B-I
high-energy	I-I
supplement	I-I
(	O
3.31	O
MJ	O
with	O
20.6	O
g	O
protein	O
daily	O
)	O
for	O
first	O
3	O
months	O
.	O


Weight	B-OUT
advantage	I-OUT
peaked	O
at	O
12	O
and	O
18	O
months	O
,	O
length	O
later	O
at	O
18	O
and	O
24	O
months	O
.	O


Although	O
in	O
the	O
long-term	O
both	O
groups	O
move	O
towards	O
expected	O
levels	O
in	O
their	O
home	O
community	O
,	O
a	O
significant	O
advantage	O
maintained	O
for	O
approximately	O
2	O
years	O
is	O
developmentally	O
advantageous	O
during	O
the	O
critical	O
time	O
after	O
weaning	O
.	O


BACKGROUND	O
Effective	O
pharmacotherapies	O
to	O
treat	O
methamphetamine	O
(	O
MA	O
)	O
dependence	O
have	O
not	O
been	O
identified	O
,	O
and	O
behavioral	O
therapies	O
are	O
marginally	O
effective	O
.	O


The	O
study	O
also	O
is	O
evaluating	O
improvements	O
in	O
health	B-OUT
and	I-OUT
functional	I-OUT
outcomes	I-OUT
during	O
and	O
after	O
the	O
protocol	O
.	O


The	O
WOMAC	B-OUT
score	I-OUT
at	O
three	O
,	O
six	O
,	O
and	O
twelve	O
months	O
did	O
not	O
differ	O
significantly	O
between	O
the	O
piriformis	O
fossa	O
and	O
trochanteric	O
nailing	O
groups	O
.	O


MATERIAL	O
AND	O
METHOD	O
A	O
randomized	O
,	O
double	O
blind	O
,	O
controlled	O
trial	O
on	O
46	B-P
adults	I-P
ASA	I-P
I-II	I-P
,	I-P
undergoing	I-P
elective	I-P
gynecological	I-P
or	I-P
general	I-P
surgery	I-P
with	I-P
balanced	I-P
general	I-P
anesthesia	I-P
was	O
performed	O
.	O


RESULTS	O
The	O
heart	B-OUT
rate	I-OUT
and	I-OUT
blood	I-OUT
pressure	I-OUT
were	O
taken	O
at	O
0	O
,	O
1	O
,	O
2	O
,	O
3	O
,	O
4	O
,	O
5	O
,	O
6	O
,	O
7	O
,	O
8	O
,	O
9	O
,	O
10	O
,	O
15	O
,	O
20	O
,	O
25	O
,	O
and	O
30	O
min	O
after	O
the	O
injection	O
.	O


There	O
was	O
no	O
significant	O
difference	O
in	O
blood	B-OUT
pressure	I-OUT
between	O
groups	O
and	O
no	O
side	O
effects	O
occurred	O
.	O


Platinum-based	B-I
chemotherapy	I-I
is	O
often	O
a	O
first-line	O
treatment	O
.	O


CONCLUSIONS	O
Pemetrexed-cisplatin	B-I
compared	O
with	O
placebo-cisplatin	O
did	O
not	O
significantly	O
improve	O
survival	B-OUT
for	O
the	O
intent-to-treat	O
population	O
.	O


All	O
but	O
six	O
of	O
the	O
women	O
continued	O
to	O
breast-feed	O
for	O
>	O
or	O
=	O
12	O
mo	O
.	O


The	O
aim	O
of	O
this	O
study	O
was	O
to	O
test	O
the	O
ability	O
of	O
PapCone®	B-I
versus	I-I
the	I-I
conventional	I-I
sampling	I-I
method	I-I
(	I-I
Ayre	I-I
's	I-I
spatula	I-I
plus	I-I
cytobrush	I-I
)	I-I
to	O
collect	O
ectocervical	O
and	O
glandular	O
cells	O
.	O


Measurements	B-I
of	I-I
American	I-OUT
Urological	I-OUT
Association	I-OUT
symptom	I-OUT
score	I-OUT
,	I-OUT
peak	I-OUT
urine	I-OUT
flow	I-OUT
rate	I-OUT
and	I-I
prostate	I-OUT
specific	I-OUT
antigen	I-OUT
(	I-OUT
PSA	I-OUT
)	I-OUT
are	I-I
often	I-I
followed	I-I
over	I-I
time	I-I
in	I-I
urological	I-I
management	I-I
.	I-I


IIT	B-I
increased	O
circulating	B-OUT
GH	I-OUT
(	O
P	O
=	O
0.04	O
)	O
and	O
lowered	O
bioavailable	B-OUT
IGF-I	I-OUT
(	O
P	O
=	O
0.002	O
)	O
.	O


The	O
physostigmine	O
patch	O
application	O
in	O
doses	O
of	O
30	O
mg	O
and	O
60	O
mg	O
apparently	O
did	O
not	O
lead	O
to	O
physostigmine	B-OUT
plasma	I-OUT
concentrations	I-OUT
that	O
were	O
sufficient	O
to	O
compensate	O
for	O
cholinergic	O
deficiencies	O
in	O
affected	O
brain	O
areas	O
and	O
produce	O
clinical	O
benefits	O
.	O


PURPOSE	O
To	O
investigate	O
the	O
injection	O
frequency	O
and	O
visual	O
acuity	O
(	O
VA	O
)	O
outcomes	O
with	O
combination	O
therapy	O
(	B-I
ranibizumab	I-I
plus	I-I
verteporfin	I-I
photodynamic	I-I
therapy	I-I
,	I-I
PDT	I-I
)	I-I
versus	O
monotherapy	O
(	B-I
ranibizumab	I-I
)	I-I
.	O


Ranibizumab	B-I
was	O
administered	O
3	O
times	O
monthly	O
followed	O
by	O
'as	O
needed	O
'	O
to	O
month	O
12	O
based	O
on	O
predetermined	O
vision/anatomical	O
criteria	O
.	O


Randomized	O
trial	O
of	O
liberal	B-I
versus	I-I
restrictive	I-I
guidelines	I-I
for	I-I
red	I-I
blood	I-I
cell	I-I
transfusion	I-I
in	O
preterm	B-P
infants	I-P
.	I-P


INTERVENTION	O
The	O
infants	O
were	O
assigned	O
randomly	O
to	O
either	O
the	O
liberal-	B-I
or	I-I
the	I-I
restrictive-transfusion	I-I
group	O
.	O


Cortical	B-OUT
bone	I-OUT
dimensions	I-OUT
were	O
evaluated	B-OUT
by	I-OUT
digital	I-OUT
x-ray	I-OUT
radiogrammetry	I-OUT
of	O
the	O
metacarpal	O
bones	O
every	O
6	O
months	O
.	O


Total	O
bone	O
width	O
did	O
not	O
change	O
significantly	O
(	O
0.68	O
%	O
,	O
CI	O
-1.17	O
to	O
2.57	O
%	O
;	O
not	O
significant	O
(	O
NS	O
)	O
)	O
.	O


CONCLUSIONS	O
Cortical	O
bone	O
reacts	O
promptly	O
to	O
reinstitution	O
of	O
GH	O
beyond	O
the	O
attainment	O
of	B-OUT
final	I-OUT
height	I-OUT
by	I-OUT
increasing	I-OUT
the	O
cortical	O
thickness	O
through	O
endosteal	B-OUT
bone	I-OUT
growth	I-OUT
.	I-OUT


The	O
effects	O
of	O
candesartan	B-I
on	O
diabetes	B-OUT
glomerulopathy	I-OUT
:	I-OUT
a	O
double-blind	O
,	O
placebo-controlled	B-I
trial	O
.	O


METHODS	O
In	O
this	O
double-blind	O
,	O
placebo-controlled	O
study	O
,	O
we	O
randomly	O
assigned	O
5362	B-P
patients	I-P
who	I-P
had	I-P
not	I-P
been	I-P
treated	I-P
with	I-P
clopidogrel	I-P
to	I-P
receive	I-P
either	I-P
cangrelor	I-I
or	I-I
placebo	I-I
at	I-P
the	I-P
time	I-P
of	I-P
PCI	I-P
,	I-P
followed	I-P
by	I-P
600	I-I
mg	I-I
of	I-I
clopidogrel	I-I
.	I-I


RESULTS	O
The	O
primary	B-OUT
end	I-OUT
point	I-OUT
occurred	I-P
in	I-P
185	I-P
of	I-P
2654	I-P
patients	I-P
receiving	I-P
cangrelor	I-I
(	I-P
7.0	I-P
%	I-P
)	I-P
and	I-P
in	I-P
210	I-P
of	I-P
2641	I-P
patients	I-P
receiving	I-P
placebo	I-I
(	I-P
8.0	I-P
%	I-P
)	I-P
(	O
odds	O
ratio	O
in	O
the	O
cangrelor	O
group	O
,	O
0.87	O
;	O
95	O
%	O
confidence	O
interval	O
[	O
CI	O
]	O
,	O
0.71	O
to	O
1.07	O
;	O
P=0.17	O
)	O
(	O
modified	O
intention-to-treat	O
population	O
adjusted	O
for	O
missing	O
data	O
)	O
.	O


The	O
SPS3	B-I
experience	O
]	O
.	O


21	B-P
were	O
assigned	O
at	O
random	O
to	O
the	O
MI	B-I
group	I-P
and	O
27	B-P
to	O
the	O
AI	B-I
group	I-P
.	I-P


RESULTS	O
In	O
the	O
MI	O
,	O
23.8	O
%	O
were	O
abstinent	B-OUT
at	O
15	O
days	O
;	O
the	O
same	O
percentage	O
at	O
one	O
month	O
and	O
3	O
months	O
;	O
19	O
%	O
at	O
6	O
months	O
;	O
and	O
14.3	O
%	O
remained	O
abstinent	B-OUT
after	I-OUT
a	I-OUT
year	I-OUT
.	I-OUT


After	O
the	O
procedure	O
the	O
mean	B-OUT
minimal	I-OUT
luminal	I-OUT
diameter	I-OUT
in	O
the	O
conventional	B-I
group	O
was	O
2.34	O
+/-	O
0.46	O
mm	O
versus	O
2.90	O
+/-	O
0.41	O
mm	O
in	O
the	O
stented	B-I
group	O
(	O
P	O
<	O
.0001	O
)	O
.	O


The	O
6-month	O
angiographic	O
follow-up	O
showed	O
a	O
mean	B-OUT
minimal	I-OUT
luminal	I-OUT
diameter	I-OUT
of	O
1.57	O
+/-	O
0.74	O
mm	O
in	O
the	O
conventional	O
group	O
versus	O
1.93	O
+/-	O
0.85	O
mm	O
in	O
the	O
stented	O
group	O
(	O
P	O
=.009	O
)	O
and	O
a	O
mean	B-OUT
diameter	I-OUT
stenosis	I-OUT
of	O
44.7	O
%	O
+/-	O
25.0	O
%	O
versus	O
35.5	O
%	O
+/-	O
26.5	O
%	O
(	O
P	O
=.036	O
)	O
.	O


OBJECTIVE	O
To	O
determine	O
clinical	B-OUT
,	I-OUT
enzymatic	I-OUT
,	I-OUT
and	I-OUT
microbiologic	I-OUT
effects	I-OUT
of	O
controlled-release	O
localized	O
administration	O
of	O
minocycline	B-I
on	O
dogs	B-P
with	I-P
periodontitis	I-P
.	I-P


CONCLUSIONS	O
AND	O
CLINICAL	O
RELEVANCE	O
Increased	B-OUT
peptidase	I-OUT
activity	I-OUT
is	O
correlated	O
with	O
the	O
progression	O
of	O
periodontitis	B-P
in	I-P
dogs	I-P
.	I-P


Treatment	O
with	O
minocycline	B-I
,	O
using	O
a	O
localized	O
delivery	O
system	O
,	O
was	O
effective	O
in	O
dogs	O
for	O
at	O
least	O
13	O
weeks	O
after	O
cessation	O
of	O
drug	O
administration	O
.	O


BACKGROUND	O
Patients	B-P
with	I-P
chronic	I-P
heart	I-P
failure	I-P
complain	O
of	O
breathlessness	O
and	O
fatigue	O
on	O
exercise	O
.	O


METHODS	O
Twelve	B-P
patients	I-P
with	I-P
stable	I-P
chronic	I-P
heart	I-P
failure	I-P
and	I-P
10	I-P
matched	I-P
controls	I-P
underwent	O
repeated	O
assessment	O
of	O
airways	O
resistance	O
using	O
impulse	O
oscillometry	B-I
and	I-I
peak	I-I
exercise	I-I
testing	I-I
with	I-I
metabolic	I-I
gas	I-I
exchange	I-I
after	O
receiving	O
nebulized	B-I
saline	I-I
as	I-I
placebo	I-I
or	O
combined	B-I
salbutamol	I-I
and	I-I
ipratropium	I-I
bromide	I-I
in	O
a	O
double-blind	O
crossover	O
randomized	O
fashion	O
.	O


The	O
slope	O
relating	O
symptoms	O
to	O
ventilation	B-OUT
(	O
ie	O
,	O
Borg/VE	O
)	O
was	O
significantly	O
reduced	O
in	O
the	O
patients	O
after	O
bronchodilators	O
(	O
17	O
%	O
+/-8	O
%	O
,	O
P	O
<	O
.05	O
)	O
.	O


The	O
relationship	O
between	O
the	O
improvement	O
in	O
VT	O
and	O
reduction	O
in	O
gradient	O
of	O
the	O
Borg/VE	B-OUT
slope	I-OUT
was	O
significant	O
(	O
r=.40	O
,	O
P	O
<	O
.05	O
)	O
.	O


CONCLUSIONS	O
Nebulized	O
bronchodilators	O
improve	O
airways	B-OUT
resistance	I-OUT
,	I-OUT
lung	I-OUT
reactance	I-OUT
,	I-OUT
and	I-OUT
peak	I-OUT
tidal	I-OUT
volume	I-OUT
during	O
exercise	O
in	O
chronic	O
heart	O
failure	O
but	O
do	O
not	O
increase	O
peak	O
exercise	O
capacity	O
.	O


For	O
example	O
,	O
in	O
the	O
early	O
phase	O
of	O
hypertension	O
,	O
diuretics	O
usually	O
worsen	O
the	O
metabolic	B-OUT
equilibrium	I-OUT
.	I-OUT


The	O
results	O
show	O
that	O
the	O
antihypertensive	B-OUT
effect	I-OUT
of	O
the	O
two	O
drugs	O
was	O
the	O
same	O
(	O
both	O
caused	O
a	O
more	O
than	O
10	O
%	O
decrease	O
in	O
systolic	B-OUT
and	I-OUT
diastolic	I-OUT
blood	I-OUT
pressure	I-OUT
)	I-OUT
.	O


The	O
two	O
groups	O
had	O
a	O
similar	O
3-year	B-OUT
disease-free	I-OUT
survival	I-OUT
,	I-OUT
progression	I-OUT
free	I-OUT
survival	I-OUT
,	I-OUT
and	I-OUT
overall	I-OUT
survival	I-OUT
,	O
i.e	O
.	O


OBJECTIVE	O
To	O
assess	O
whether	O
three-dimensional	B-I
imaging	I-I
of	I-I
the	I-I
Achilles	I-I
tendon	I-I
by	I-I
ultrasonographic	I-I
tissue	I-I
characterisation	I-I
(	I-I
UTC	I-I
)	I-I
can	O
differentiate	O
between	O
symptomatic	O
and	O
asymptomatic	O
tendons	O
.	O


UTC	O
categorises	O
four	O
different	O
echotypes	B-OUT
that	O
represent	O
(	O
I	O
)	O
highly	B-OUT
stable	I-OUT
;	I-OUT
(	O
II	O
)	O
medium	B-OUT
stable	I-OUT
;	I-OUT
(	O
III	O
)	O
highly	B-OUT
variable	I-OUT
and	O
(	O
IV	O
)	O
constantly	B-OUT
low	I-OUT
intensity	O
and	O
variable	O
distribution	O
.	O


The	O
percentages	O
of	O
echo-types	B-OUT
were	O
calculated	O
,	O
and	O
the	O
maximum	O
tendon	B-OUT
thickness	I-OUT
was	O
measured	O
.	O


The	O
mean	O
maximum	O
tendon	B-OUT
thickness	I-OUT
was	O
9.2	O
mm	O
in	O
the	O
symptomatic	O
group	O
and	O
6.8	O
mm	O
in	O
the	O
asymptomatic	O
group	O
(	O
p	O
<	O
0.001	O
)	O
.	O


Before	O
the	O
skin	O
incision	O
performed	O
after	O
anesthesia	O
induction	O
,	O
we	O
performed	O
ilioinguinal	B-I
iliohypogastric	I-I
block	I-I
(	O
group	O
C	O
given	O
saline	B-I
and	O
group	O
P	O
and	O
DB	B-I
given	O
levobupivacaine	B-I
)	I-I
.	O


CONCLUSION	O
The	O
results	O
demonstrated	O
that	O
chemotherapy	B-I
but	O
not	O
radiotherapy	B-I
results	O
in	O
significant	O
increase	O
in	O
the	O
trace	B-OUT
elements	I-OUT
levels	I-OUT
and	I-OUT
antioxidant	I-OUT
activities	I-OUT
in	O
blood	O
serum	O
of	O
cervical	B-P
cancer	I-P
patients	I-P
.	I-P


Analysis	O
was	O
per	O
protocol	O
.	O


Median	B-OUT
(	I-OUT
IQR	I-OUT
)	I-OUT
attacks	I-OUT
of	I-OUT
aura	I-OUT
were	O
reduced	O
from	O
3.2	O
(	O
1.0-5.0	O
)	O
per	O
12	O
weeks	O
on	O
placebo	B-I
to	O
1.0	O
(	O
0-3.0	O
)	O
on	O
tonabersat	O
(	O
p=0.01	O
)	O
,	O
whereas	O
the	O
other	O
primary	O
outcome	O
measure	O
,	O
median	B-OUT
migraine	I-OUT
headache	I-OUT
days	I-OUT
with	I-OUT
or	I-OUT
without	I-OUT
aura	I-OUT
,	O
was	O
not	O
significantly	O
different	O
between	O
placebo	B-I
and	O
tonabersat	B-I
groups	O
(	O
3.0	O
days	O
in	O
each	O
group	O
;	O
p=0.09	O
)	O
.	O


The	O
results	O
support	O
the	O
theory	O
that	O
auras	O
are	O
caused	O
by	O
CSD	O
and	O
that	O
this	O
phenomenon	O
is	O
not	O
involved	O
in	O
attacks	O
without	O
aura	O
.	O


To	O
explore	O
the	O
steady-state	O
pharmacokinetic	O
profile	O
after	O
coadministration	O
of	O
galantamine	B-I
and	I-I
risperidone	I-I
,	O
an	O
open-label	O
,	O
randomized	O
,	O
single-center	O
,	O
two-way	O
crossover	O
drug-drug	O
interaction	O
study	O
was	O
conducted	O
in	O
16	B-P
healthy	I-P
elderly	I-P
subjects	I-P
,	I-P
ages	I-P
60	I-P
years	I-P
and	I-P
older	I-P
.	I-P


The	O
results	O
showed	O
that	O
risperidone	B-I
,	O
when	O
administered	O
with	O
galantamine	B-I
,	O
did	O
not	O
change	O
the	O
bioavailability	B-OUT
of	O
galantamine	B-I
at	O
steady	O
state	O
.	O


TXB2	B-OUT
was	I-OUT
measured	I-OUT
in	I-OUT
serum	I-OUT
from	O
blood	O
allowed	O
to	O
clot	O
at	O
37	O
degrees	O
C.	O
2	O
.	O


Serum	B-OUT
TXB2	I-OUT
remained	I-OUT
low	I-OUT
,	O
whereas	O
PG	B-OUT
synthesis	I-OUT
recovered	I-OUT
within	O
6	O
h.	O
3	O
.	O


Better	O
effects	O
on	O
the	O
pathological	O
results	O
of	O
the	O
cervix	B-OUT
and	O
the	O
mRNA	B-OUT
expression	I-OUT
of	I-OUT
hTERT	I-OUT
were	O
obtained	O
in	O
the	O
treatment	O
group	O
after	O
treatment	O
(	O
P	O
<	O
0.05	O
)	O
.	O


However	O
,	O
beyond	O
safety	B-OUT
and	I-OUT
efficacy	I-OUT
,	O
the	O
delivery	O
system	O
or	O
vehicle	O
used	O
in	O
topical	O
treatment	O
formulations	O
is	O
equally	O
important	O
in	O
affecting	O
patient	B-OUT
satisfaction	I-OUT
,	I-OUT
tolerability	I-OUT
,	I-OUT
and	I-OUT
subsequent	I-OUT
treatment	I-OUT
compliance	I-OUT
and	O
hence	O
clinical	B-OUT
resolution	I-OUT
of	O
active	O
disease	O
.	O


SUMMARY	O
OF	O
BACKGROUND	O
DATA	O
An	O
obvious	O
gap	O
exists	O
in	O
knowledge	O
concerning	O
long-term	O
efficacy	O
and	O
cost-effectiveness	O
of	O
manipulative	O
treatment	O
methods	O
.	O


Sixty-seven	B-P
patients	I-P
with	I-P
bacterial	I-P
vaginosis	I-P
(	I-P
BV	I-P
)	I-P
,	I-P
50	I-P
with	I-P
intermediate	I-P
flora	I-P
and	I-P
42	I-P
with	I-P
normal	I-P
vaginal	I-P
flora	I-P
were	I-P
enrolled	I-P
in	O
this	O
double-blind	O
study	O
.	O


The	O
study	O
demonstrated	O
a	B-OUT
cure	I-OUT
rate	O
of	O
nearly	O
80	O
%	O
;	O
i.e.	O
,	O
32	O
%	O
of	O
the	O
women	O
could	O
restore	O
normal	O
vaginal	O
flora	O
and	O
47	B-OUT
%	I-OUT
had	I-OUT
improved	I-OUT
Nugent	I-OUT
score	I-OUT
,	O
whereas	O
20	O
%	O
of	O
the	O
subjects	O
did	O
not	O
clear	O
BV	O
in	O
the	O
first	O
follow-up	O
(	O
after	O
8	O
days	O
treatment	O
)	O
.	O


Effect	O
of	O
delayed	B-I
cord	I-I
clamping	I-I
on	O
iron	B-OUT
stores	I-OUT
in	O
infants	B-P
born	I-P
to	I-P
anemic	I-P
mothers	I-P
:	I-P
a	O
randomized	O
controlled	O
trial	O
.	O


The	O
groups	O
were	O
comparable	O
for	O
maternal	O
age	O
,	O
parity	O
,	O
weight	O
and	O
supplemental	O
iron	O
intake	O
,	O
infant	O
s	O
birth	O
weight	O
,	O
gestation	O
and	O
sex	O
.	O


RESULTS	O
There	O
were	O
no	O
significant	O
differences	O
between	O
the	O
two	O
groups	O
with	O
regard	O
to	O
the	O
temporospatial	O
variables	O
of	O
velocity	B-OUT
,	I-OUT
cadence	I-OUT
,	I-OUT
step	I-OUT
length	I-OUT
,	I-OUT
and	I-OUT
stride	I-OUT
length	I-OUT
at	O
any	O
tested	O
time	O
point	O
.	O


BACKGROUND	O
Long-term	O
care	O
hospitals	O
are	O
Medicare	O
providers	O
of	O
postacute	B-P
care	I-P
that	O
have	O
a	B-P
mean	I-P
length	I-P
of	I-P
stay	I-P
of	I-P
25	I-P
days	I-P
or	I-P
more	I-P
.	I-P


Multivariable	O
survey-logistic	O
regression	O
analyses	O
were	O
performed	O
to	O
assess	O
predictors	O
and	O
probability	O
of	O
the	O
outcome	O
.	O


All	O
predictors	O
were	O
significantly	O
(	O
P	O
<	O
.01	O
)	O
associated	O
with	O
a	B-OUT
hospitalization	I-OUT
of	I-OUT
32	I-OUT
days	I-OUT
or	I-OUT
longer	I-OUT
;	I-OUT
having	O
a	O
tracheostomy	O
was	O
the	O
strongest	O
predictor	O
(	O
odds	O
ratio	O
,	O
4.74	O
)	O
.	O


Heat-exercise	B-P
performance	I-P
of	I-P
pyridostigmine-treated	I-I
subjects	I-P
wearing	I-P
chemical	I-P
protective	I-P
clothing	I-P
.	I-P


[	O
Long-term	O
treatment	O
of	O
cerebrovascular	O
changes	O
in	O
the	O
elderly	B-P
(	O
author	O
's	O
transl	O
)	O
]	O
.	O


Cost-effectiveness	B-OUT
of	O
a	O
telephone-delivered	B-I
intervention	I-I
for	I-I
physical	I-I
activity	I-I
and	I-I
diet	I-I
.	I-I


Economic	B-OUT
outcomes	I-OUT
were	O
assessed	O
using	O
a	O
state-transition	O
Markov	O
model	O
,	O
which	O
predicted	O
the	O
progress	O
of	O
participants	O
through	O
five	O
health	O
states	O
relating	O
to	O
physical	O
activity	O
and	O
dietary	O
improvement	O
,	O
for	O
ten	O
years	O
after	O
recruitment	O
.	O


Comparing	O
Telephone	B-I
Counselling	I-I
outcomes	O
to	O
existing	B-I
practice	I-I
(	I-I
Real	I-I
Control	I-I
)	I-I
,	O
the	O
intervention	O
was	O
found	O
to	O
be	O
cost-effective	B-OUT
(	O
$	O
29,375	O
per	O
quality	O
adjusted	O
life	O
year	O
gained	O
)	O
.	O


Usual	B-I
Care	I-I
(	I-I
brief	I-I
intervention	I-I
)	I-I
compared	O
to	O
existing	B-I
practice	I-I
(	I-I
Real	I-I
Control	I-I
)	I-I
was	O
also	O
cost-effective	B-OUT
(	O
$	O
12,153	O
per	O
quality	O
adjusted	O
life	O
year	O
gained	O
)	O
.	O


TRIAL	O
REGISTRATION	O
This	O
paper	O
uses	O
data	O
collected	O
in	O
a	O
previous	O
clinical	O
trial	O
registered	O
at	O
the	O
Australian	O
Clinical	O
Trials	O
Registry	O
,	O
Australian	O
New	O
Zealand	O
Clinical	O
Trials	O
Registry	O
:	O
Anzcrt.org.au	O
ACTRN012607000195459	O
.	O


These	O
results	O
do	O
not	O
support	O
the	O
empirical	O
addition	O
of	O
vancomycin	O
to	O
initial	O
antibiotic	O
therapy	O
in	O
cancer	B-P
patients	I-P
with	I-P
fever	I-P
and	I-P
granulocytopenia	I-P
.	I-P


Fifty-two	O
percent	O
of	O
the	O
patients	O
would	O
take	O
warfarin	B-I
for	O
an	O
absolute	O
decrease	O
in	O
stroke	B-OUT
risk	I-OUT
of	O
1	O
%	O
over	O
2	O
years	O
.	O


The	O
method	O
used	O
to	O
elicit	O
the	O
patients	O
'	O
MCIDs	B-OUT
can	O
have	O
a	O
clinically	O
important	O
effect	O
on	O
patient	O
responses	O
.	O


These	O
findings	O
may	O
stem	O
from	O
the	O
unrealistic	O
assumption	O
that	O
all	O
players	O
are	O
equal	O
:	O
in	O
reality	O
individuals	O
are	O
expected	O
to	O
vary	O
in	O
the	O
power	O
with	O
which	O
they	O
can	O
punish	O
defectors	O
.	O


Defecting	O
players	O
were	O
most	O
likely	O
to	O
switch	O
to	O
cooperation	O
if	O
the	O
partner	O
cooperated	O
:	O
adding	O
punishment	B-I
yielded	O
no	O
additional	O
benefit	O
and	O
,	O
under	O
some	O
circumstances	O
,	O
increased	O
the	O
chance	O
that	O
the	O
partner	O
would	O
both	O
defect	O
and	O
retaliate	O
against	O
the	O
punisher	O
.	O


Our	O
findings	O
show	O
that	O
,	O
in	O
a	O
two-player	B-I
game	I-I
,	O
cooperation	B-OUT
begets	O
cooperation	O
and	O
that	O
punishment	O
does	O
not	O
seem	O
to	O
yield	O
any	O
additional	O
benefits	O
.	O


Further	O
work	O
should	O
explore	O
whether	O
strong	O
punishers	O
might	O
prevail	O
in	O
multi-player	O
games	O
.	O


The	O
mean	O
follow-up	O
period	O
was	O
10.8	O
years	O
(	O
range	O
,	O
ten	O
to	O
twelve	O
years	O
)	O
.	O


The	O
patients	O
were	O
assessed	O
clinically	O
and	O
radiographically	O
with	O
the	B-OUT
rating	I-OUT
system	I-OUT
of	I-OUT
the	I-OUT
Knee	I-OUT
Society	I-OUT
and	O
with	O
the	B-OUT
Western	I-OUT
Ontario	I-OUT
and	I-OUT
McMaster	I-OUT
Universities	I-OUT
Osteoarthritis	I-OUT
Index	I-OUT
(	I-OUT
WOMAC	I-OUT
)	I-OUT
score	I-OUT
at	O
three	O
months	O
,	O
one	O
year	O
,	O
and	O
annually	O
thereafter	O
.	O


The	B-OUT
Kaplan-Meier	I-OUT
survivorship	I-OUT
with	I-OUT
revision	I-OUT
as	O
the	O
end	O
point	O
at	O
10.8	O
years	O
was	O
98.8	O
%	O
(	O
95	O
%	O
confidence	O
interval	O
[	O
CI	O
]	O
,	O
0.96	O
to	O
1.00	O
)	O
in	O
the	B-I
computernavigated	I-I
total	I-I
knee	I-I
arthroplasty	I-I
group	O
and	O
99.2	O
%	O
(	O
95	O
%	O
CI	O
,	O
0.96	O
to	O
1.00	O
)	O
in	O
the	B-I
conventional	I-I
total	I-I
knee	I-I
arthroplasty	I-I
group	O
.	O


CONCLUSIONS	O
Our	O
data	O
demonstrated	O
no	O
difference	O
in	O
clinical	O
function	O
or	O
alignment	O
and	O
survivorship	O
of	O
the	O
components	O
between	O
the	B-P
knees	I-P
that	I-P
underwent	I-I
computer-navigated	I-I
total	I-I
knee	I-I
arthroplasty	I-I
and	I-P
those	I-P
that	I-P
underwent	I-I
conventional	I-I
total	I-I
knee	I-I
arthroplasty	I-I
.	O


Comparison	O
of	O
the	O
therapeutic	O
effects	O
of	O
epoetin	B-I
zeta	I-I
to	I-I
epoetin	I-I
alfa	I-I
in	O
the	O
maintenance	B-P
phase	I-P
of	I-P
renal	I-P
anaemia	I-P
treatment	I-P
.	I-P


OBJECTIVE	O
To	O
evaluate	O
the	O
therapeutic	O
efficacy	O
and	O
safety	O
of	O
epoetin	B-I
zeta	I-I
,	O
compared	O
with	O
epoetin	B-I
alfa	I-I
,	O
in	O
maintaining	O
target	O
haemoglobin	O
(	O
Hb	O
)	O
concentrations	O
in	O
patients	B-P
with	I-P
anaemia	I-P
and	I-P
chronic	I-P
kidney	I-P
disease	I-P
(	I-P
CKD	I-P
)	I-P
maintained	I-P
on	I-P
haemodialysis	I-P
.	I-P


Patients	O
had	O
received	O
epoetin	B-I
for	O
>	O
or	O
=	O
3	O
months	O
upon	O
study	O
entry	O
and	O
had	O
achieved	O
a	O
target	O
Hb	O
level	O
of	O
10.5-12.5	O
g/dL	O
with	O
a	O
stable	O
epoetin	B-I
dose	O
.	O


RESULTS	O
In	B-P
total	I-P
,	I-P
313	I-P
patients	I-P
were	I-P
randomized	I-P
to	O
receive	O
epoetin	B-I
zeta	I-I
(	O
n	O
=	O
155	O
)	O
or	O
epoetin	B-I
alfa	I-I
(	O
n	O
=	O
158	O
)	O
;	O
146	O
and	O
145	O
patients	O
(	O
respectively	O
)	O
switched	O
treatment	O
after	O
12	O
weeks	O
.	O


Patients	O
underwent	O
minor	O
nominal	O
dose	O
adjustments	O
during	O
treatment	O
crossover	O
.	O


AE	O
profile	O
was	O
similar	O
for	O
both	O
products	O
;	O
the	O
most	O
commonly	O
reported	O
AEs	O
were	O
infections	B-OUT
and	I-OUT
infestations	I-OUT
(	O
in	O
26.5	O
%	O
of	O
patients	O
receiving	O
epoetin	O
zeta	O
and	O
23.6	O
%	O
receiving	O
epoetin	O
alfa	O
)	O
.	O


The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
evaluate	O
and	O
compare	O
laparoscopic	B-I
treatment	I-I
for	O
stage	B-P
I	I-P
endometrial	I-P
cancer	I-P
with	O
the	O
traditional	B-I
transabdominal	I-I
approach	I-I
.	O


The	O
main	O
outcomes	O
studied	O
were	O
operative	B-OUT
time	I-OUT
,	I-OUT
blood	I-OUT
loss	I-OUT
,	I-OUT
blood	I-OUT
transfusion	I-OUT
,	I-OUT
intraoperative	I-OUT
complications	I-OUT
,	I-OUT
postoperative	I-OUT
complications	I-OUT
,	I-OUT
duration	I-OUT
of	I-OUT
hospital	I-OUT
stay	I-OUT
,	I-OUT
and	I-OUT
number	I-OUT
of	I-OUT
lymph	I-OUT
nodes	I-OUT
obtained	O
.	O


Only	O
six	O
adverse	B-OUT
events	I-OUT
,	O
all	O
of	O
which	O
were	O
mild	O
or	O
moderate	O
in	O
intensity	O
and	O
occurred	O
in	O
four	O
diclofenac	B-I
recipients	O
,	O
were	O
observed	O
in	O
the	O
study	O
.	O


A	O
trend	O
towards	O
better	O
tolerability	B-OUT
results	I-OUT
for	O
oxaprozin	B-I
compared	O
with	O
diclofenac	B-I
was	O
also	O
noted	O
.	O


Ondansetron	B-I
has	O
similar	O
clinical	B-OUT
efficacy	I-OUT
against	O
both	O
nausea	B-OUT
and	O
vomiting	B-OUT
.	I-OUT


The	O
relative	O
risks	O
of	O
0.67	O
and	O
0.74	O
were	O
clinically	O
similar	O
and	O
the	O
difference	O
between	O
them	O
did	O
not	O
reach	O
statistical	O
significance	O
.	O


Enhanced	O
pitch	O
sensitivity	O
in	O
individuals	B-P
with	I-P
autism	I-P
:	I-P
a	O
signal	O
detection	O
analysis	O
.	O


In	O
both	O
tasks	O
,	O
the	O
obtained	O
psychometric	O
functions	O
revealed	O
higher	B-OUT
pitch	I-OUT
sensitivity	I-OUT
for	O
subjects	O
with	O
autism	O
,	O
with	O
a	O
more	O
pronounced	O
advantage	O
over	O
control	O
participants	O
in	O
the	O
categorization	B-OUT
task	I-OUT
.	I-OUT


However	O
,	O
residual	O
tumor	O
is	O
present	O
immediately	O
after	O
the	O
procedure	O
in	O
approximately	O
20	O
to	O
40	O
%	O
of	O
cases	O
.	O


METHODS	O
Twenty	B-P
patients	I-P
received	O
three	O
cycles	O
of	O
C	B-I
&	I-I
D	I-I
followed	O
by	O
imiquimod	B-I
5	I-I
%	I-I
or	I-I
vehicle	I-I
cream	I-I
once	I-I
daily	I-I
for	O
1	O
month	O
as	O
adjunctive	B-I
therapy	I-I
.	I-I


The	O
primary	O
end	O
point	O
was	O
the	O
frequency	O
of	O
residual	O
tumor	O
.	O


The	O
secondary	O
end	O
points	O
included	O
the	O
time	O
to	O
heal	O
and	O
cosmetic	O
appearance	O
.	O


These	O
preliminary	O
results	O
suggest	O
that	O
further	O
studies	O
to	O
investigate	O
imiquimod	B-I
adjunctive	I-I
therapy	I-I
are	O
warranted	O
.	O


The	O
study	O
recruited	O
successive	B-P
patients	I-P
with	I-P
unresectable	I-P
grade	I-P
I/II	I-P
head	I-P
and	I-P
neck	I-P
cancer	I-P
who	I-P
were	I-P
not	I-P
suitable	I-P
for	I-P
irradiation	I-I
treatment	I-I
(	I-P
T	I-P
any	I-P
N3	I-P
or	I-P
T4	I-P
N2C	I-P
)	I-P
,	I-P
metastatic	I-P
or	I-P
previously	I-P
irradiated	I-P
.	I-P


A	B-P
total	I-P
of	I-P
170	I-P
patients	I-P
were	I-P
included	I-P
in	I-P
the	I-P
study	I-P
.	I-P


)	O
bolus	O
days	O
1-4	O
and	O
1000	O
mg/m	O
(	O
2	O
)	O
/24	O
h	O
5-FU	O
in	O
a	O
4-h	O
infusion	O
on	O
days	O
1-4	O
.	O


The	O
overall	B-OUT
response	I-OUT
rate	I-OUT
(	I-OUT
RR	I-OUT
)	I-OUT
based	O
on	O
the	O
evaluable	O
patients	O
was	O
48/74	O
(	O
65	O
%	O
,	O
95	O
%	O
confidence	O
interval	O
(	O
CI	O
)	O
54-75	O
%	O
)	O
;	O
The	O
RR	B-OUT
based	I-OUT
on	I-OUT
an	I-OUT
intent-to-treat	I-OUT
analysis	I-OUT
was	O
57	O
%	O
,	O
95	O
%	O
CI	O
47-67	O
%	O
;	O
Median	B-OUT
survival	I-OUT
was	O
13	O
months	O
;	O
There	O
were	O
50	O
episodes	O
of	O
granulocytopenia	B-OUT
grade	I-OUT
IV	I-OUT
and	O
15	O
of	O
febrile	B-OUT
neutropenia	I-OUT
per	O
316	O
cycles	O
.	O


CONCLUSION	O
In	O
this	O
study	B-I
,	I-I
cariprazine	I-I
3-12mg/day	O
was	O
effective	O
and	O
generally	O
well	O
tolerated	O
in	O
the	O
treatment	O
of	O
manic	O
and	O
mixed	O
episodes	O
associated	O
with	O
bipolar	O
I	O
disorder	O
.	O


Twenty-four	B-P
patients	I-P
with	I-P
chronic	I-P
arthritis	I-P
[	I-P
20	I-P
with	I-P
rheumatoid	I-P
arthritis	I-P
(	I-P
RA	I-P
)	I-P
and	I-P
4	I-P
with	I-P
psoriatic	I-P
arthritis	I-P
(	I-P
PsA	I-P
)	I-P
]	I-P
were	O
divided	O
into	O
2	B-I
groups	I-I
(	I-I
10	I-I
RA	I-I
,	I-I
2	I-I
PsA	I-I
)	I-I
and	I-I
randomly	I-I
given	I-I
CysA	I-I
5	I-I
mg/kg	I-I
daily	I-I
or	I-I
hydroxychloroquine	I-I
(	I-I
OH-Chlor	I-I
)	I-I
6	I-I
mg/kg	I-I
daily	I-I
in	I-I
divided	I-I
doses	I-I
.	I-I


METHODS	O
The	O
cohort	O
included	O
81	B-P
patients	I-P
undergoing	I-P
diagnostic	I-P
or	I-P
therapeutic	I-P
bronchoscopy	I-P
under	I-P
propofol	I-I
sedation	I-I
that	O
were	O
prospectively	B-I
randomized	I-I
to	I-I
guide	I-I
the	I-I
depth	I-OUT
of	I-OUT
sedation	I-OUT
by	I-I
BIS	I-I
monitoring	I-I
(	I-I
BIS	I-I
group	I-I
;	I-I
n	I-I
=	I-I
40	I-I
)	I-I
or	I-I
conventional	I-I
monitoring	I-I
(	I-I
control	I-I
group	I-I
;	I-I
n	I-I
=	I-I
41	I-I
)	I-I
.	I-I


CONCLUSIONS	O
Clomipramine	O
and	O
desipramine	O
are	O
differentially	O
effective	O
in	O
treating	O
the	O
obsessive-compulsive	B-OUT
and	I-OUT
core	I-OUT
symptoms	I-OUT
in	O
autistic	O
disorder	O
.	O


Biological	O
links	O
between	O
compulsions	O
and	O
stereotyped	O
,	O
repetitive	O
behaviors	O
in	O
autistic	O
disorder	O
should	O
be	O
explored	O
.	O


The	O
results	O
indicated	O
that	O
amprenavir	B-OUT
plasma	I-OUT
concentrations	I-OUT
were	O
decreased	O
by	O
saquinavir	B-I
soft	O
gel	O
capsule	O
(	O
by	O
32	O
%	O
for	O
area	O
under	O
the	O
concentration-time	B-OUT
curve	I-OUT
at	I-OUT
steady	I-OUT
state	I-OUT
[	O
AUC	O
(	O
ss	O
)	O
]	O
and	O
37	O
%	O
for	O
peak	B-OUT
plasma	I-OUT
concentration	I-OUT
at	I-OUT
steady	I-OUT
state	I-OUT
[	O
C	O
(	O
max	O
,	O
ss	O
)	O
]	O
)	O
and	O
increased	O
by	O
indinavir	B-I
(	O
33	O
%	O
for	O
AUC	O
(	O
ss	O
)	O
)	O
.	O


Treatment	O
effects	O
of	O
eptifibatide	B-I
in	O
planned	O
coronary	O
stent	O
implantation	O
in	O
patients	B-P
with	I-P
chronic	I-P
kidney	I-P
disease	I-P
(	O
ESPRIT	O
Trial	O
)	O
.	O


The	O
role	O
of	O
platelet	B-I
glycoprotein	I-I
IIb/IIIa	I-I
inhibitor	I-I
therapy	I-I
in	O
patients	B-P
with	I-P
mild	I-P
renal	I-P
impairment	I-P
is	O
not	O
well	O
characterized	O
.	O


Patients	B-P
were	I-P
randomly	I-P
assigned	I-P
to	I-P
placebo	I-I
or	I-I
eptifibatide	I-I
as	I-I
an	I-I
adjunct	I-I
to	I-I
stent	I-I
implantation	I-I
(	I-I
1,755	I-I
with	I-I
CrCl	I-I
>	I-I
or	I-I
=60	I-I
ml/min	I-I
and	I-I
289	I-I
with	I-I
CrCl	I-I
<	I-I
60	I-I
ml/min	I-I
)	I-I
.	O


During	O
the	O
postoperative	O
period	O
,	O
the	O
patients	O
were	O
assessed	O
for	O
the	O
occurrence	B-OUT
and	I-OUT
severity	I-OUT
of	I-OUT
pruritus	I-OUT
(	O
classified	O
as	O
absent	O
,	O
mild	O
,	O
moderate	O
,	O
or	O
severe	O
)	O
or	O
other	B-OUT
untoward	I-OUT
symptoms	I-OUT
.	I-OUT


The	O
additional	O
NMES	O
application	O
in	O
the	O
treatment	O
could	O
bring	O
more	O
improvements	O
in	O
the	O
distal	O
motor	O
functions	O
and	O
faster	O
rehabilitation	O
progress	O
.	O


We	O
studied	O
nine	B-P
subjects	I-P
(	I-P
eight	I-P
men	I-P
and	I-P
one	I-P
woman	I-P
;	I-P
mean	I-P
age+/-SD	I-P
:	I-P
31.3+/-11.0	I-P
yr	I-P
)	I-P
with	I-P
mild	I-P
intermittent	I-P
allergic	I-P
asthma	I-P
,	I-P
never	I-P
treated	I-P
with	I-P
regular	I-P
beta2-agonists	I-P
or	I-P
inhaled	I-P
corticosteroids	I-P
.	I-P


Quick	B-I
change	I-I
versus	I-I
double	I-I
pump	I-I
while	O
changing	O
the	O
infusion	O
of	O
inotropes	O
:	O
an	O
experimental	O
study	O
.	O


The	O
data	O
were	O
registered	O
in	O
an	O
Excel	O
spreadsheet	O
and	O
analysed	O
with	O
SAS	O
.	O


RESULTS	O
The	B-P
sample	I-P
comprised	I-P
30	I-P
patients	I-P
of	I-P
age	I-P
between	I-P
1	I-P
and	I-P
27	I-P
months	I-P
,	I-P
of	I-P
whom	I-P
13	I-P
(	I-P
43	I-P
%	I-P
)	I-P
were	I-P
male	I-P
.	I-P


The	O
characteristics	O
of	O
the	O
patients	O
of	O
the	O
two	O
groups	O
did	O
not	O
differ	O
significantly	O
.	O


The	O
hypothyroid	B-P
men	I-P
all	O
had	O
elevated	O
basal	B-OUT
and	I-OUT
TRH-stimulated	I-OUT
TSH	I-OUT
levels	I-OUT
.	I-OUT


The	O
PRL	O
response	O
to	O
TRH	O
was	O
lower	O
in	O
both	O
group	O
I	O
and	O
group	O
II	O
obese	O
men	O
than	O
in	O
normal	O
controls	O
and	O
was	O
similar	O
between	O
group	O
I	O
and	O
group	O
II	O
.	O


Reducing	O
blood	B-OUT
loss	I-OUT
at	O
open	B-I
myomectomy	I-I
using	O
triple	B-I
tourniquets	I-I
:	I-I
a	O
randomised	O
controlled	O
trial	O
.	O


DESIGN	O
A	O
randomised	O
controlled	O
trial	O
.	O


SETTING	O
Two	B-P
University	I-P
teaching	I-P
hospitals	I-P
.	I-P


MAIN	O
OUTCOME	O
MEASURES	O
Intra-operative	B-OUT
blood	I-OUT
loss	I-OUT
,	I-OUT
post-operative	I-OUT
blood	I-OUT
loss	I-OUT
,	I-OUT
blood	I-OUT
transfusion	I-OUT
rates	I-OUT
,	I-OUT
operative	I-OUT
morbidity	I-OUT
,	I-OUT
uterine	I-OUT
blood	I-OUT
flow	I-OUT
and	I-OUT
ovarian	I-OUT
function	I-OUT
.	I-OUT


Day	O
two	O
serum	B-OUT
FSH	I-OUT
concentrations	I-OUT
after	O
surgery	O
were	O
unchanged	B-OUT
(	O
P=	O
0.45	O
)	O
,	O
compared	O
with	O
baseline	O
values	O
.	O


ORs	O
for	O
predicting	O
hip	O
fracture	O
were	O
:	O
previous	B-OUT
fracture	I-OUT
,	O
2.31	O
(	O
95	O
%	O
CI	O
1.31-4.08	O
)	O
;	O
low	B-OUT
body	I-OUT
weight	I-OUT
(	O
<	O
58	O
kg	O
)	O
,	O
2.20	O
(	O
95	O
%	O
CI	O
1.28-3.77	O
)	O
;	O
maternal	B-OUT
history	I-OUT
of	I-OUT
hip	I-OUT
fracture	I-OUT
,	O
1.68	O
(	O
95	O
%	O
CI	O
0.85-3.31	O
)	O
;	O
a	B-OUT
fall	I-OUT
in	I-OUT
the	I-OUT
last	I-OUT
12	I-OUT
months	I-OUT
,	O
2.92	O
(	O
95	O
%	O
CI	O
1.70-5.01	O
)	O
;	O
and	O
age	B-OUT
(	O
per	O
year	O
increase	O
)	O
,	O
1.09	O
(	O
95	O
%	O
CI	O
1.04-1.13	O
)	O
.	O


This	O
study	O
used	O
a	O
randomized	O
controlled	O
trial	O
to	O
evaluate	O
the	O
efficacy	B-OUT
of	O
RIT	O
on	O
elicited	O
and	O
spontaneous	O
imitation	B-OUT
skills	I-OUT
in	O
21	B-P
young	I-P
children	I-P
with	I-P
autism	I-P
.	I-P


[	O
Potentiation	O
of	O
the	O
effect	O
of	O
non-depolarizing	O
muscle	B-P
relaxants	I-P
by	O
acylaminopenicillins	B-I
.	I-I


The	O
shortest	B-OUT
time	I-OUT
of	O
the	O
control	O
periods	O
was	O
8.6	O
min	O
and	O
the	O
maximum	O
time	O
was	O
32.6	O
min	O
.	O


Pairwise	O
comparisons	O
showed	O
the	O
mitomycin	O
protocol	O
with	O
short-term	O
intensive	O
(	O
weekly	O
)	O
combined	O
with	O
long-term	O
maintenance	O
instillation	O
to	O
have	O
a	O
highly	O
beneficial	B-OUT
effect	I-OUT
compared	O
to	O
long-term	O
maintenance	O
instillation	O
only	O
especially	O
for	O
patients	O
entering	O
the	O
study	O
with	O
recurrent	O
tumors	O
(	O
RR	O
=	O
0.06	O
,	O
95	O
%	O
CI	O
:	O
[	O
0.008	O
,	O
0.506	O
]	O
.	O


CONCLUSION	O
These	O
results	O
show	O
that	O
intensive	B-OUT
therapeutic	I-OUT
instillation	I-OUT
may	O
have	O
an	O
advantage	O
over	O
less	O
intensive	O
,	O
prophylactic	O
regimens	O
.	O


Diet	B-I
interventions	I-I
that	O
maximize	O
eating	O
behavior	O
self-efficacy	O
may	O
therefore	O
improve	O
weight	O
loss	O
outcomes	O
.	O


In	O
the	O
combined	O
cohort	O
,	O
individuals	O
losing	O
the	O
most	O
weight	O
reported	O
improvements	O
in	O
eating	B-OUT
behavior	I-OUT
self-efficacy	I-OUT
,	O
whereas	O
those	O
achieving	O
less	O
weight	B-OUT
loss	I-OUT
reported	O
decrements	O
in	O
eating	B-OUT
behavior	I-OUT
self-efficacy	I-OUT
.	I-OUT


While	O
GL	O
does	O
not	O
appear	O
to	O
influence	O
eating	O
behavior	O
self-efficacy	O
,	O
lesser	O
amounts	O
of	O
weight	O
loss	O
on	O
provided-food	B-I
energy	I-I
restricted	I-I
diets	I-I
may	O
deter	O
successful	O
maintenance	O
of	O
weight	O
loss	O
by	O
attenuating	O
improvements	O
in	O
eating	O
behavior	O
self-efficacy	O
.	O


The	O
lag	B-OUT
times	I-OUT
(	O
mean	O
42	O
(	O
SD	O
11	O
)	O
s	O
and	O
44	O
(	O
16	O
)	O
s	O
)	O
,	O
maximum	B-OUT
block	I-OUT
(	O
99	O
(	O
2	O
)	O
%	O
and	O
98	O
(	O
3	O
)	O
%	O
)	O
and	O
intubating	B-OUT
conditions	I-OUT
at	I-OUT
60	I-OUT
s	I-OUT
(	O
good-to-excellent	O
in	O
86	O
%	O
and	O
84	O
%	O
of	O
patients	O
)	O
were	O
similar	O
for	O
rapacuronium	O
and	O
rocuronium	O
,	O
respectively	O
.	O


METHODS	O
Five	B-P
adult	I-P
male	I-P
long-term	I-P
survivors	I-P
of	I-P
childhood	I-P
brain	I-P
tumours	I-P
(	I-P
median	I-P
age	I-P
21.8	I-P
years	I-P
(	I-P
18.4-26.7	I-P
)	I-P
;	I-P
13.7	I-P
years	I-P
(	I-P
11.4-15.7	I-P
)	I-P
post-radiotherapy	I-P
,	I-P
>	I-P
30Gy	I-P
)	I-P
and	I-P
five	I-P
matched	I-P
controls	I-P
were	I-P
studied	I-P
.	I-P


All	O
studies	O
were	O
conducted	O
in	O
a	O
random	O
fashion	O
.	O


RESULTS	O
Significantly	B-OUT
lower	I-OUT
peak	I-OUT
and	I-OUT
area	I-OUT
under	I-OUT
the	I-OUT
curve	I-OUT
(	I-OUT
AUC	I-OUT
)	I-OUT
GH	I-OUT
concentrations	I-OUT
occurred	O
in	O
the	O
irradiated	O
group	O
using	O
0.15	O
microg/kg	O
(	O
median	O
peak	O
Irradiated	O
,	O
4	O
.	O


In	O
irradiated	O
subjects	O
there	O
was	O
an	O
incremental	O
rise	B-OUT
in	I-OUT
GH	I-OUT
output	I-OUT
with	O
increasing	O
doses	O
of	O
GHRH	B-I
(	I-I
1-29	I-I
)	I-I
NH	I-I
(	I-I
2	I-I
)	I-I
(	I-I
median	I-I
AUC	O
:	O
122mU/l.min	O
vs	O
179mU/l.min	O
vs	O
268mU/l.min	O
;	O
P=0.007	O
)	O
reflecting	O
altered	O
pituitary	B-OUT
sensitivity	I-OUT
and	I-OUT
reduced	I-OUT
responsiveness	I-OUT
.	I-OUT


Eberconazole	B-I
1	O
%	O
cream	O
is	O
an	O
effective	B-OUT
and	I-OUT
safe	I-OUT
alternative	O
for	O
dermatophytosis	O
treatment	O
:	O
multicenter	O
,	O
randomized	O
,	O
double-blind	O
,	O
comparative	O
trial	O
with	O
miconazole	B-I
2	O
%	O
cream	O
.	O


No	O
differences	O
between	O
the	O
two	O
arms	O
,	O
either	O
as	O
regards	O
the	O
duration	B-OUT
of	I-OUT
disease-free	I-OUT
survival	I-OUT
or	I-OUT
overall	I-OUT
survival	I-OUT
,	O
were	O
noted	O
in	O
the	O
group	O
with	O
more	O
than	O
one	O
invaded	O
lymph	O
node	O
whatever	O
the	O
number	O
of	O
invaded	O
lymph	O
nodes	O
.	O


This	O
study	O
demonstrates	O
for	O
the	O
first	O
time	O
that	O
the	O
efficiency	O
of	O
TIL	B-I
in	O
stage	O
III	O
melanoma	O
(	O
AJCC	O
)	O
is	O
directly	O
related	O
to	O
the	O
number	O
of	O
invaded	O
lymph	O
nodes	O
,	O
indicating	O
that	O
tumor	O
burden	O
might	O
be	O
a	O
crucial	O
factor	O
in	O
the	O
efficacy	O
and/or	O
in	O
vitro	O
expansion	O
of	O
T	O
cells	O
specific	O
for	O
autologous	O
tumor	O
antigen	O
,	O
a	O
finding	O
which	O
could	O
be	O
of	O
value	O
in	O
future	O
vaccine	O
development	O
for	O
the	O
treatment	O
of	O
melanoma	O
.	O


The	O
Dispatcher-Assisted	O
Randomized	O
Trial	O
(	O
DART	O
)	O
was	O
designed	O
to	O
compare	O
2	O
types	O
of	O
dispatcher	B-OUT
cardiopulmonary	I-OUT
(	I-OUT
CPR	I-OUT
)	I-OUT
instruction	I-OUT
,	O
but	O
not	O
intended	O
to	O
affect	O
the	O
proportion	O
of	O
arrest	O
victims	O
that	O
received	O
bystander	O
CPR	O
.	O


CONCLUSIONS	O
Odds	B-OUT
of	I-OUT
bystander	I-OUT
CPR	I-OUT
were	O
higher	O
during	O
the	O
trial	O
,	O
an	O
increase	O
related	O
to	O
higher	O
likelihood	O
of	O
DA-CPR	B-OUT
.	I-OUT


Incidence	O
of	O
infectious	B-OUT
symptoms	I-OUT
after	I-P
radiation	I-I
therapy	I-I
for	I-P
breast	I-P
cancer	I-P
.	I-P


Although	O
statistically	O
not	O
significant	O
the	O
preoperatively	B-I
irradiated	I-I
patients	O
also	O
had	O
a	O
higher	O
morbidity	B-OUT
than	O
those	O
treated	O
with	O
surgery	B-I
alone	O
.	O


An	O
explanation	O
for	O
the	O
increased	O
morbidity	B-OUT
seems	O
to	O
be	O
that	O
the	O
volume	O
of	O
lung	O
tissue	O
,	O
encompassed	O
within	O
the	O
full-dose	O
target	O
volume	O
,	O
is	O
the	O
crucial	O
factor	O
.	O


This	O
volume	O
was	O
considerable	O
in	O
the	O
preoperatively	B-I
treated	I-I
patients	O
but	O
kept	O
at	O
a	O
minimum	O
in	O
the	O
postoperative	B-I
group	O
.	O


Types	O
of	O
parent	B-I
verbal	I-I
responsiveness	I-I
that	O
predict	O
language	O
in	O
young	B-P
children	I-P
with	I-P
autism	I-P
spectrum	I-P
disorder	I-P
.	I-P


A	O
four-point	O
categorized	O
scale	O
(	O
1=poor	O
,	O
2=fair	O
,	O
3=good	O
,	O
4=excellent	O
)	O
was	O
used	O
.	O


Unscheduled	B-OUT
maintenance	I-OUT
events	I-OUT
and	I-OUT
the	I-OUT
presence	I-OUT
of	I-OUT
fungal	I-OUT
colonization	I-OUT
were	O
also	O
recorded	O
.	O


Main	O
reasons	O
for	O
dropouts	O
and	O
discontinuation	O
were	O
fractured	B-OUT
dentures	I-OUT
and	I-OUT
patient	I-OUT
dissatisfaction	I-OUT
.	I-OUT


Fungal	B-OUT
colonization	I-OUT
was	O
the	O
most	O
commonly	O
observed	O
problem	O
and	O
was	O
the	O
only	O
reason	O
of	O
failure	O
at	O
12	O
months	O
.	O


METHODS	O
We	O
constructed	O
tissue	O
microarrays	O
(	O
TMAs	O
)	O
from	O
available	O
pathological	O
material	O
from	O
1113	B-P
patients	I-P
participating	I-P
in	O
two	O
randomized	O
clinical	O
trials	O
comparing	O
endocrine	B-I
therapy	I-I
alone	I-I
versus	I-I
chemo-endocrine	I-I
therapy	I-I
in	I-I
node-negative	I-P
breast	I-P
cancer	I-P
.	I-P


>	O
1	O
%	O
positive	O
tumor	O
cell	O
nuclei	O
)	O
in	O
80.1	O
%	O
(	O
880/1092	O
)	O
.	O


CONCLUSIONS	O
Interpretation	O
of	O
the	O
prognostic	O
significance	O
of	O
p53	B-OUT
expression	I-OUT
requires	O
knowledge	O
of	O
concurrent	O
expression	B-OUT
of	I-OUT
ER	I-OUT
.	I-OUT


TRIAL	O
REGISTRATION	O
Current	O
Controlled	O
Trials	O
ACTRN12607000037404	O
(	O
Trial	O
VIII	O
)	O
and	O
ACTRN12607000029493	O
(	O
Trial	O
IX	O
)	O
.	O


RESULTS	O
During	O
the	O
6-week	O
recruitment	O
period	O
,	O
57	B-P
children	I-P
from	I-P
28	I-P
states	I-P
satisfied	I-P
all	I-P
eligibility	I-P
criteria	I-P
and	O
were	O
randomly	O
assigned	O
to	O
1.3	O
grams	O
of	O
omega-3	B-I
fatty	I-I
acids	I-I
or	I-I
an	I-I
identical	I-I
placebo	I-I
daily	O
for	O
6	O
weeks	O
.	O


Children	O
in	O
the	O
omega-3	B-I
fatty	I-I
acid	I-I
group	O
had	O
a	O
greater	O
reduction	O
in	O
hyperactivity	B-OUT
(	O
-5.3	O
points	O
)	O
compared	O
to	O
the	O
placebo	B-I
group	O
(	O
-2.6	O
points	O
)	O
,	O
but	O
the	O
difference	O
was	O
not	O
statistically	O
significant	O
(	O
1.9-point	O
greater	O
improvement	O
in	O
the	O
omega-3	B-I
group	I-I
,	O
95	O
%	O
CI	O
=	O
-2.2	O
to	O
5.2	O
)	O
.	O


Adverse	B-OUT
events	I-OUT
were	O
rare	O
and	O
not	O
associated	O
with	O
omega-3	B-I
fatty	I-I
acids	I-I
.	I-I


Participant	O
feedback	B-OUT
was	O
positive	O
.	O


CONCLUSION	O
Internet-based	O
,	O
randomized	O
controlled	O
trials	O
of	O
therapies	O
in	O
children	B-P
with	I-P
ASD	I-P
are	O
feasible	O
and	O
may	O
lead	O
to	O
marked	O
reductions	O
in	O
the	O
time	O
and	O
cost	O
of	O
completing	O
trials	O
.	O


There	O
was	O
no	O
significant	O
difference	O
between	O
the	O
groups	B-P
regarding	I-P
pain	I-OUT
intensity	I-OUT
and	I-OUT
escape	I-OUT
medication	I-OUT
.	I-OUT


Ultracision	B-I
versus	I-I
electrocautery	I-I
in	O
performing	O
modified	O
radical	O
mastectomy	O
and	O
axillary	O
lymph	O
node	O
dissection	O
for	O
breast	B-P
cancer	I-P
:	I-P
a	O
prospective	O
randomized	O
control	O
trial	O
.	O


BACKGROUND	O
Treatment	O
for	O
breast	O
cancer	O
has	O
improved	O
dramatically	O
over	O
the	O
decades	O
.	O


Patients	B-P
were	I-P
randomized	I-P
in	I-P
two	I-P
groups	I-P
:	I-P
group	I-P
A	I-P
(	I-P
n	I-P
=	I-P
20	I-P
)	I-P
underwent	I-P
modified	I-I
radical	I-I
mastectomy	I-I
using	I-I
ultracision	I-I
(	I-I
UC	I-I
)	I-I
and	I-P
group	I-P
B	I-P
(	I-P
n	I-P
=	I-P
20	I-P
)	I-P
with	I-P
the	I-P
conventional	I-I
electrocautery	I-I
(	I-I
EC	I-I
)	I-I
method	I-I
.	I-I


The	B-OUT
mean	I-OUT
volume	I-OUT
of	I-OUT
drainage	I-OUT
from	I-OUT
the	I-OUT
axilla	I-OUT
in	O
the	O
EC	O
group	O
was	O
significantly	O
higher	O
than	O
UC	O
group	O
[	O
489.5	O
versus	O
188.1	O
mls	O
(	O
p	O
<	O
0.001	O
)	O
]	O
.	O


In	O
doing	O
so	O
,	O
the	O
use	O
of	O
this	O
technology	O
enable	O
us	O
to	O
discharge	O
patients	O
earlier	O
without	O
significant	O
morbidities	O
.	O


Secondary	O
outcome	O
measures	O
were	O
analgesic	B-OUT
onset	I-OUT
time	I-OUT
,	I-OUT
pain	I-OUT
relief	I-OUT
after	I-OUT
the	I-OUT
operation	I-OUT
and	I-OUT
residual	I-OUT
motor	I-OUT
blockade	I-OUT
.	I-OUT


RESULTS	O
The	O
proportion	O
of	O
children	O
with	O
effective	O
analgesia	O
during	O
the	O
operation	O
was	O
similar	O
among	O
groups	O
.	O


There	O
were	O
no	O
significant	O
differences	O
in	O
the	O
number	O
of	O
patients	O
receiving	O
rescue	O
analgesia	O
after	O
surgery	O
.	O


Fifty	B-P
two	I-P
patients	I-P
entered	I-P
the	I-P
trial	I-P
,	I-P
and	I-P
12	I-P
were	I-P
withdrawn	I-P
.	I-P


[	O
Therapeutic	O
value	O
of	O
a	O
combination	O
of	O
trimetazidine	B-I
with	O
a	O
calcium	O
inhibitor	O
in	O
the	O
treatment	O
of	O
chronic	B-P
coronary	I-P
insufficiency	I-P
]	I-P
.	O


This	O
study	O
shows	O
that	O
the	O
addition	O
of	O
trimetazidine	O
to	O
a	O
calcium	O
antagonist	O
brings	O
a	O
valuable	O
improvement	O
in	O
therapeutic	O
results	O
.	O


Colorectal	B-P
carcinoma	I-P
is	O
one	O
of	O
the	O
most	O
common	O
malignancies	O
in	O
the	O
world	O
,	O
and	O
its	O
incidence	O
has	O
increased	O
in	O
recent	O
years	O
.	O


The	O
exon	O
12	O
genotype	O
was	O
not	O
associated	O
with	O
sex	O
or	O
age	O
.	O


The	O
distribution	O
of	O
HIF-1alpha	B-OUT
genotypes	I-OUT
in	O
colorectal	B-P
cancer	I-P
patients	I-P
was	O
100	O
C/C	O
(	O
100	O
%	O
)	O
,	O
0	O
C/T	O
(	O
0	O
%	O
)	O
,	O
and	O
0	O
T/T	O
(	O
0	O
%	O
)	O
.	O


Cox	O
proportional	O
hazard	O
ratio	O
estimates	O
for	O
selected	O
baseline	O
covariates	O
showed	O
a	O
significantly	O
increased	O
risk	O
of	O
cardiovascular	O
events	O
by	O
age	O
(	O
p=0.0459	O
)	O
and	O
systolic	O
blood	O
pressure	O
(	O
p=0.0061	O
)	O
.	O


Reducing	O
the	O
psychological	B-OUT
distress	I-OUT
of	O
family	B-P
caregivers	I-P
of	I-P
home	I-P
based	I-P
palliative	I-P
care	I-P
patients	I-P
:	I-P
longer	O
term	O
effects	O
from	O
a	O
randomised	O
controlled	O
trial	O
.	O


RESULTS	O
Recruitment	B-P
to	I-P
the	I-P
one	I-P
visit	I-P
condition	I-P
was	I-P
57	I-P
,	I-P
the	I-P
two	I-P
visit	I-P
condition	I-P
93	I-P
,	I-P
and	I-P
the	I-P
control	I-P
148	I-P
.	I-P


Cardiovascular	O
complications	O
categorized	O
as	O
impaired	O
arterial	O
circulation	O
including	O
ischemic	B-OUT
heart	I-OUT
disease	I-OUT
,	I-OUT
venous	I-OUT
thromboembolism	I-OUT
,	I-OUT
cardiac	I-OUT
incompensation	I-OUT
and	I-OUT
cerebral	I-OUT
depression	I-OUT
were	O
found	O
to	O
be	O
equally	O
frequent	O
following	O
the	O
two	O
different	O
forms	O
of	O
treatment	O
.	O


SETTING	O
University	B-P
Hospital	I-P
.	I-P


Collateral	B-OUT
flow	I-OUT
index	I-OUT
(	I-OUT
CFI	I-OUT
)	I-OUT
without	I-OUT
iCSO	I-OUT
,	I-OUT
that	I-OUT
is	O
,	O
the	O
ratio	O
between	O
mean	O
distal	O
coronary	O
occlusive	O
(	O
Poccl	O
)	O
and	O
mean	O
aortic	O
pressure	O
(	O
Pao	O
)	O
both	O
minus	O
central	O
venous	O
pressure	O
.	O


Using	O
more	O
ecologically	O
valid	O
stimulus	O
situations	O
than	O
the	O
traditional	O
LED	O
in	O
the	O
dark	O
,	O
we	O
performed	O
two	O
experiments	O
.	O


We	O
measured	O
the	O
accuracy	B-OUT
and	I-OUT
precision	I-OUT
of	O
the	O
observers	O
'	O
absolute-	O
and	O
relative-direction	O
judgments	O
.	O


We	O
found	O
that	O
(	O
a	O
)	O
relative-direction	O
judgments	O
were	O
precise	O
and	O
independent	O
of	O
phoria	O
,	O
and	O
(	O
b	O
)	O
monocular	O
absolute-direction	O
judgments	O
were	O
inaccurate	B-OUT
,	O
and	O
the	O
magnitude	O
of	O
the	O
inaccuracy	B-OUT
was	O
predictable	O
from	O
the	O
magnitude	O
of	O
phoria	O
.	O


METHODS	O
In	B-P
this	I-P
open-label	I-P
,	I-P
phase	I-P
3	I-P
,	I-P
randomised	I-P
controlled	I-P
trial	I-P
conducted	I-P
in	I-P
101	I-P
centres	I-P
in	I-P
19	I-P
countries	I-P
,	I-P
we	I-P
enrolled	I-P
patients	I-P
aged	I-P
18	I-P
years	I-P
or	I-P
older	I-P
with	I-P
histologically	I-P
or	I-P
cytologically	I-P
confirmed	I-P
HNSCC	I-P
that	I-P
was	I-P
recurrent	I-P
,	I-P
metastatic	I-P
,	I-P
or	I-P
both	I-P
who	I-P
had	I-P
progressed	I-P
on	I-P
or	I-P
after	I-P
first-line	I-P
platinum-based	I-P
therapy	I-P
,	I-P
were	I-P
not	I-P
amenable	I-P
for	I-P
salvage	I-P
surgery	I-P
or	I-P
radiotherapy	I-P
,	I-P
and	I-P
who	I-P
had	I-P
an	I-P
Eastern	I-P
Cooperative	I-P
Oncology	I-P
Group	I-P
(	I-P
ECOG	I-P
)	I-P
performance	I-P
status	I-P
of	I-P
0	I-P
or	I-P
1	I-P
.	I-P


We	O
randomly	O
assigned	O
eligible	O
patients	O
in	O
a	O
2:1	O
ratio	O
to	O
receive	O
oral	B-I
afatinib	I-I
(	I-I
40	I-I
mg/day	I-I
)	I-I
or	I-I
intravenous	I-I
methotrexate	I-I
(	I-I
40	I-I
mg/m	I-I
(	I-I
2	I-I
)	I-I
per	I-I
week	I-I
)	I-I
,	O
stratified	O
by	O
ECOG	O
performance	O
status	O
and	O
previous	O
EGFR-targeted	O
antibody	O
therapy	O
for	O
recurrent	O
or	O
metastatic	O
disease	O
.	O


The	O
primary	O
endpoint	O
was	O
progression-free	B-OUT
survival	I-OUT
as	O
assessed	O
by	O
an	O
independent	O
,	O
central	O
imaging	O
review	O
committee	O
.	O


INTERPRETATION	B-I
Afatinib	O
was	O
associated	O
with	O
significant	O
improvements	B-OUT
in	I-OUT
progression-free	I-OUT
survival	O
and	O
had	O
a	O
manageable	O
safety	O
profile	O
.	O


No	O
effect	O
of	O
Na	B-I
intake	O
on	O
blood	B-OUT
pressure	I-OUT
was	O
identified	O
in	O
either	O
whites	B-P
or	O
blacks	B-P
.	I-P


The	O
half-life	B-OUT
(	I-OUT
T1/2	I-OUT
)	I-OUT
with	O
decreasing	O
Na	B-I
intake	O
to	O
10	O
mmol/d	O
was	O
1.08	O
days	O
in	O
whites	O
and	O
1.65	O
days	O
in	O
blacks	O
(	O
p	O
=	O
not	O
significant	O
[	O
NS	O
]	O
)	O
.	O


The	O
data	O
showed	O
that	O
T1/2	B-OUT
increases	I-OUT
with	O
increasing	O
Na	B-I
intake	O
and	O
is	O
,	O
therefore	O
,	O
dose-dependent	O
or	O
"	O
zero	O
"	O
order	O
.	O


American	O
Psychiatric	O
Association	O
,	O
Arlington	O
,	O
2013	O
)	O
.	O


The	O
Impact	O
of	O
Pupillary	B-I
Dilation	I-I
on	O
Intraocular	O
Pressure	O
and	O
Anterior	O
Segment	O
Morphology	O
in	O
Subjects	B-P
with	I-P
and	I-P
without	I-P
Pseudoexfoliation	I-P
.	I-P


Of	B-P
the	I-P
129	I-P
eyes	I-P
;	I-P
31	I-P
had	I-P
pseudoexfoliation	I-P
syndrome	I-P
(	I-P
PXS	I-P
)	I-P
,	I-P
37	I-P
had	I-P
pseudoexfoliation	I-P
glaucoma	I-P
(	I-P
PXG	I-P
)	I-P
,	I-P
31	I-P
eyes	I-P
were	I-P
the	I-P
fellow	I-P
eyes	I-P
of	I-P
subjects	I-P
with	I-P
unilateral	I-P
pseudoexfoliation	I-P
syndrome	I-P
(	I-P
subclinical	I-P
PXS	I-P
)	I-P
and	I-P
30	I-P
eyes	I-P
were	I-P
the	I-P
eyes	I-P
of	I-P
subjects	I-P
without	I-P
PXS	I-P
(	I-P
controls	I-P
)	I-P
.	I-P


ANIMALS	O
Five	B-P
male	I-P
Holstein-Friesian	I-P
calves	I-P
(	I-P
8-15	I-P
days	I-P
of	I-P
age	I-P
)	I-P
.	I-P


Abomasal	B-OUT
emptying	I-OUT
rate	I-OUT
after	O
injection	O
of	O
low-dose	O
gentamicin	O
was	O
similar	O
to	O
that	O
of	O
control	O
.	O


The	O
applicability	O
of	O
this	O
definition	O
,	O
and	O
of	O
related	O
surrogate	O
endpoint	O
criteria	O
,	O
is	O
discussed	O
,	O
with	O
emphasis	B-P
on	I-P
cancer	I-P
and	I-P
AIDS	I-P
research	I-P
settings	I-P
.	I-P


Auxiliary	B-I
variables	I-I
will	O
very	O
frequently	O
be	O
available	O
,	O
and	O
they	O
may	O
be	O
able	O
to	O
be	O
used	O
without	O
making	O
additional	O
strong	O
assumptions	O
.	O


RESULTS	O
The	O
effect	O
of	B-I
donepezil	I-I
treatment	O
on	O
EF	O
was	O
examined	O
.	O


CONCLUSIONS	O
Octreotide	B-I
therapy	I-I
reduces	O
liver	B-OUT
volumes	I-OUT
in	O
patients	O
with	O
ADPKD	O
and	O
is	O
safe	O
.	O


Hence	O
,	O
the	O
aim	O
of	O
the	O
present	O
study	O
was	O
to	O
examine	O
the	O
relative	O
effects	O
of	O
RRR-AT	O
and	O
all-rac-AT	O
on	O
plasma	O
antioxidant	O
levels	O
and	O
LDL	O
oxidation	O
in	O
healthy	B-P
persons	I-P
in	O
a	O
dose-response	O
study	O
.	O


Phase	O
contrast	O
and	O
scanning	O
electron	O
microscopes	O
were	O
used	O
to	O
score	B-OUT
cell	I-OUT
quantity	I-OUT
,	I-OUT
morphology	I-OUT
and	I-OUT
cell	I-OUT
attachment	I-OUT
.	I-OUT


The	O
data	O
were	O
statistically	B-OUT
analyzed	I-OUT
by	O
one	O
way	O
ANOVA	B-OUT
with	I-OUT
Post	I-OUT
Hoc	I-OUT
Tukey	I-OUT
HSD	I-OUT
test	I-OUT
(	O
p	O
=	O
0.05	O
)	O
.	O


Glass	O
ionomer	O
cement	O
with	O
10	O
%	O
bioactive	O
glass	O
showed	O
better	B-OUT
adhesion	I-OUT
and	I-OUT
spreading	I-OUT
of	I-OUT
cells	I-OUT
than	O
glass	O
ionomer	O
cement	O
with	O
0.01	O
%	O
collagen	O
.	O


Nine	O
dogs	O
in	O
each	O
group	O
experienced	O
at	O
least	O
one	O
serious	B-OUT
adverse	I-OUT
event	O
.	O


Fifty-four	B-P
untreated	I-P
,	I-P
mildly	I-P
hypertensive	I-P
men	I-P
whose	I-P
daily	I-P
alcohol	I-P
consumption	I-P
was	I-P
>	I-P
or	I-P
=	I-P
28	I-P
ml	I-P
ethanol	I-P
and	I-P
who	I-P
drank	I-P
at	I-P
least	I-P
4	I-P
times	I-P
per	I-P
week	I-P
took	O
part	O
in	O
a	O
randomized	O
,	O
controlled	O
crossover	O
trial	O
.	O


The	O
self-reported	B-OUT
alcohol	I-OUT
consumption	I-OUT
was	O
56.1	O
+/-	O
3.6	O
(	O
SEM	O
)	O
ml/day	O
during	O
the	O
usual	O
alcohol	O
drinking	O
period	O
and	O
26.1	O
+/-	O
3.0	O
ml/day	O
during	O
the	O
period	O
of	O
reduced	O
alcohol	O
consumption	O
.	O


BACKGROUND	O
As	O
renin-angiotensin	O
system	O
(	O
RAS	O
)	O
activity	O
may	O
affect	O
the	O
severity	O
of	O
oxidative	O
stress	O
and	O
inflammatory	O
markers	O
,	O
we	O
assessed	O
the	O
effects	O
of	O
enalapril	B-I
(	I-I
E	I-I
)	I-I
and/or	I-I
losartan	I-I
(	O
L	O
)	O
on	O
these	O
markers	O
in	O
renal	B-P
transplant	I-P
recipients	I-P
with	I-P
RAS	I-P
polymorphisms	I-P
.	I-P


It	O
was	O
shown	O
that	O
a	O
6-month	O
course	O
of	O
treatment	O
with	O
afala	B-I
at	I-I
a	I-I
dose	I-I
of	I-I
2	I-I
tablets	I-I
4	I-I
times	I-I
a	I-I
day	I-I
resulted	O
in	O
a	O
significant	O
reduction	O
in	O
the	O
severity	O
of	O
urinary	O
disorders	O
,	O
estimated	O
by	O
total	O
IPSS	O
score	O
,	O
relative	O
to	O
baseline	O
values	O
and	O
compared	O
to	O
placebo	B-I
therapy	O
.	O


Minor	B-OUT
omental	I-OUT
injuries	I-OUT
occurred	O
in	O
a	O
small	O
percentage	O
of	O
each	O
group	O
,	O
while	O
serious	O
complications	O
occurred	O
once	O
in	O
each	O
group	O
.	O


We	O
aimed	O
to	O
study	O
whether	O
the	O
use	O
of	O
risperidone	B-I
in	O
comparison	O
with	O
placebo	B-I
improved	O
functioning	O
in	O
children	B-P
with	I-P
autism	I-P
with	O
regard	O
to	O
behavior	O
(	O
aggressiveness	O
,	O
hyperactivity	O
,	O
irritability	O
)	O
,	O
social	O
and	O
emotional	O
responsiveness	O
,	O
and	O
communication	O
skills	O
.	O


Risperidone	B-I
was	O
associated	O
with	O
increased	O
appetite	B-OUT
and	I-OUT
a	I-OUT
mild	I-OUT
weight	I-OUT
gain	I-OUT
,	I-OUT
mild	I-OUT
sedation	I-OUT
in	I-OUT
20	I-OUT
%	I-OUT
,	I-OUT
and	I-OUT
transient	I-OUT
dyskinesias	I-OUT
in	O
three	O
children	O
.	O


STUDY	O
DESIGN	O
Randomized	O
clinical	O
trial	O
.	O


Outcomes	O
evaluated	O
over	O
a	O
12-month	O
period	O
included	O
:	O
self-reported	B-OUT
measures	I-OUT
of	I-OUT
back	I-OUT
pain	I-OUT
,	I-OUT
back	I-OUT
pain	I-OUT
disability	I-OUT
level	I-OUT
,	I-OUT
physical	I-OUT
health	I-OUT
,	I-OUT
mental	I-OUT
health	I-OUT
,	I-OUT
and	I-OUT
administrative	I-OUT
measures	I-OUT
of	I-OUT
recurrence	I-OUT
,	I-OUT
lost	I-OUT
work	I-OUT
time	I-OUT
,	I-OUT
and	I-OUT
medical	I-OUT
care	I-OUT
utilization	I-OUT
.	I-OUT


The	O
only	O
occupational	O
variable	O
found	O
to	O
influence	O
was	O
plant	O
group	O
whereby	O
service	O
parts	O
operations	O
workers	O
in	O
the	O
back	O
support	O
plus	O
education	O
group	O
experienced	O
a	O
lower	O
likelihood	O
of	O
WR-LBD	B-OUT
recurrence	I-OUT
.	I-OUT


OBJECTIVES	O
To	O
study	O
the	O
magnitude	B-OUT
of	I-OUT
differences	I-OUT
in	I-OUT
tumour	I-OUT
unidimensional	I-OUT
(	I-OUT
1D	I-OUT
)	I-OUT
,	I-OUT
bidimensional	I-OUT
(	I-OUT
2D	I-OUT
)	I-OUT
and	I-OUT
volumetric	I-OUT
(	I-OUT
VOL	I-OUT
)	I-OUT
measurements	I-OUT
determined	O
from	O
computed	O
tomography	O
(	O
CT	O
)	O
images	O
reconstructed	O
at	O
5	O
,	O
2.5	O
and	O
1.25	O
mm	O
slice	O
intervals	O
.	O


Many	O
children	B-P
with	I-P
Autism	I-P
Spectrum	I-P
Disorders	I-P
(	I-P
ASD	I-P
)	I-P
participate	O
in	O
social	O
skills	O
or	O
Theory	B-I
of	I-I
Mind	I-I
(	I-I
ToM	I-I
)	I-I
treatments	I-I
.	I-I


The	O
results	O
showed	O
that	O
,	O
compared	O
to	O
controls	O
,	O
the	O
treated	O
children	O
with	O
ASD	B-OUT
improved	I-OUT
in	O
their	B-OUT
conceptual	I-OUT
ToM	I-OUT
skills	I-OUT
,	O
but	O
their	B-OUT
elementary	I-OUT
understanding	I-OUT
,	I-OUT
self	I-OUT
reported	I-OUT
empathic	I-OUT
skills	I-OUT
or	I-OUT
parent	I-OUT
reported	I-OUT
social	I-OUT
behaviour	I-OUT
did	O
not	O
improve	O
.	O


Arginine	B-I
vasopressin	I-I
dissociates	O
the	O
diuresis	B-OUT
and	I-OUT
natriuresis	I-OUT
due	O
to	O
atrial	O
natriuretic	O
factor	O
in	O
man	B-P
.	I-P


Atrial	B-I
natriuretic	I-I
factor	I-I
15	I-I
pmol	I-I
kg-1	I-I
min-1	I-I
or	I-I
placebo	I-I
(	O
P	O
)	O
was	O
concomitantly	O
administered	O
against	O
a	O
background	O
infusion	O
of	O
either	O
AVP	B-I
0.003	I-I
pmol	I-I
kg-1	I-I
min-1	I-I
or	I-I
P	I-I
;	I-I
thus	O
the	O
combinations	O
P	B-I
+	I-I
P	I-I
,	I-I
AVP	I-I
+	O
P	O
,	O
P	B-I
+	I-I
ANF	I-I
and	I-I
AVP	I-I
+	I-I
ANF	I-I
were	O
studied	O
.	O


Arginine	B-I
vasopressin	I-I
reduced	O
V	B-OUT
(	O
-58	O
%	O
)	O
and	O
CH2O	B-OUT
(	O
-68	O
%	O
)	O
but	O
did	O
not	O
alter	O
UNaV	B-OUT
or	I-OUT
Ccr	I-OUT
.	I-OUT


Pulse	O
oximeter	O
perfusion	O
index	O
as	O
an	O
early	O
indicator	O
of	O
sympathectomy	O
after	O
epidural	O
anesthesia	O
.	O


Ameliorating	B-OUT
intrusive	I-OUT
memories	I-OUT
of	I-OUT
distressing	I-OUT
experiences	I-OUT
using	O
computerized	B-I
reappraisal	I-I
training	I-I
.	I-I


Could	O
changing	O
reappraisals	O
following	O
a	O
stressful	O
event	O
reduce	O
the	O
emergence	O
of	O
PTSD	O
symptoms	O
?	O
The	O
present	O
proof-of-principle	O
study	O
examined	O
whether	O
a	O
nonexplicit	B-I
,	I-I
systematic	I-I
computerized	I-I
training	I-I
in	O
reappraisal	O
style	O
following	B-P
a	I-P
stressful	I-P
event	I-P
(	I-P
a	I-P
highly	I-P
distressing	I-P
film	I-P
)	I-P
could	O
reduce	O
intrusive	O
memories	O
of	O
the	O
film	O
,	O
and	O
symptoms	O
associated	O
with	O
posttraumatic	O
distress	O
over	O
the	O
subsequent	O
week	O
.	O


The	O
training	O
targeted	O
self-efficacy	O
beliefs	O
and	O
reappraisals	O
of	O
secondary	O
emotions	O
(	O
emotions	O
in	O
response	O
to	O
the	O
emotional	O
reactions	O
elicited	O
by	O
the	O
film	O
)	O
.	O


Leukocyte-mediated	O
reperfusion	O
injury	O
is	O
partly	O
responsible	O
for	O
decreased	O
graft	B-OUT
function	I-OUT
after	O
prolonged	O
graft	O
ischemia	O
.	O


To	O
determine	O
the	O
efficacy	B-OUT
and	I-OUT
safety	I-OUT
of	O
leukocyte-depleted	B-I
reperfusion	I-I
,	O
20	B-P
patients	I-P
were	I-P
enrolled	I-P
in	I-P
a	I-P
randomized	I-P
,	I-P
double-blind	I-P
clinical	I-P
trial	I-P
to	I-P
be	I-P
treated	I-P
with	I-P
either	I-P
warm	I-I
whole	I-I
blood	I-I
reperfusion	I-I
(	I-P
group	I-P
I	I-P
;	I-P
n	I-P
=	I-P
9	I-P
)	I-P
or	I-I
warm	I-I
leukocyte-depleted	I-I
blood	I-I
reperfusion	I-I
(	I-P
group	I-P
II	I-P
;	I-P
n	I-P
=	I-P
11	I-P
)	I-P
.	I-P


Coronary	B-OUT
sinus	I-OUT
release	I-OUT
of	I-OUT
creatinine	I-OUT
phosphokinase-MB	I-OUT
5	I-OUT
minutes	I-OUT
after	I-OUT
reperfusion	I-OUT
was	O
significantly	O
less	O
in	O
group	O
II	O
(	O
1.65	O
EU/min	O
)	O
than	O
in	O
group	O
I	O
(	O
3.83	O
units/min	O
;	O
p	O
=	O
0.05	O
)	O
.	O


All	O
hearts	B-OUT
functioned	I-OUT
adequately	O
in	O
both	O
groups	O
.	O


This	O
randomised	O
,	O
double-blind	O
,	O
placebo-controlled	O
study	O
was	O
designed	O
to	O
evaluate	O
the	O
ability	O
of	O
the	O
orally	O
administered	O
matrix	B-I
metalloproteinase	I-I
inhibitor	I-I
,	I-I
marimastat	I-I
,	O
to	O
prolong	O
survival	B-OUT
in	O
patients	B-P
with	I-P
non-resectable	I-P
gastric	I-P
and	I-P
gastro-oesophageal	I-P
adenocarcinoma	I-P
.	I-P


Three	B-P
hundred	I-P
and	I-P
sixty-nine	I-P
patients	I-P
with	I-P
histological	I-P
proof	I-P
of	I-P
adenocarcinoma	I-P
,	I-P
who	I-P
had	I-P
received	I-P
no	I-P
more	I-P
than	I-P
a	I-P
single	I-P
regimen	I-P
of	I-P
5-fluorouracil-based	I-I
chemotherapy	I-I
,	O
were	O
randomised	O
to	O
receive	O
either	O
marimastat	B-I
(	I-I
10	I-I
mg	I-I
b.d	I-I
.	I-I


The	O
median	B-OUT
survival	I-OUT
was	O
138	O
days	O
for	O
placebo	B-I
and	O
160	O
days	O
for	O
marimastat	B-I
,	O
with	O
2-year	O
survival	O
of	O
3	O
%	O
and	O
9	O
%	O
respectively	O
.	O


This	O
benefit	O
increased	O
with	O
2	O
years	O
additional	O
follow-up	O
(	O
P=0.006	O
,	O
hazard	O
ratio=1.68	O
(	O
1.16-2.44	O
)	O
)	O
,	O
with	O
2-year	B-OUT
survival	I-OUT
of	O
5	O
%	O
and	O
18	O
%	O
respectively	O
.	O


This	O
is	O
one	O
of	O
the	O
first	O
demonstrations	O
of	O
a	O
therapeutic	O
benefit	O
for	O
a	O
matrix	O
metalloproteinase	O
inhibitor	O
in	O
cancer	O
patients	O
.	O


The	O
greatest	O
benefit	O
was	O
observed	O
in	O
patients	B-P
who	I-P
had	I-P
previously	I-P
received	I-P
chemotherapy	I-I
.	I-I


METHODS	O
AND	O
MATERIALS	O
Between	B-P
1995	I-P
and	I-P
1996	I-P
,	I-P
100	I-P
patients	I-P
were	I-P
randomized	I-I
to	I-P
receive	I-P
a	I-P
prophylactic	I-P
therapy	I-P
for	I-P
prevention	I-P
of	I-P
heterotopic	I-P
ossification	I-P
.	I-P


Heterotopic	B-OUT
ossification	I-OUT
was	I-OUT
scored	I-OUT
according	I-OUT
to	I-OUT
the	I-OUT
Brooker	I-OUT
Grading	I-OUT
system	I-OUT
.	I-OUT


In	O
the	O
untreated	O
historical	O
control	O
group	O
the	O
incidence	O
of	O
heterotopic	B-OUT
ossification	I-OUT
was	O
65	O
%	O
(	B-OUT
Brooker	I-OUT
Score	I-OUT
I	O
:	O
26	O
%	O
;	O
II	O
:	O
15	O
%	O
;	O
III	O
:	O
19	O
%	O
;	O
IV	O
:	O
5	O
%	O
)	O
.	O


The	B-P
diagnosis	I-P
included	I-P
acute	I-P
lymphoblastic	I-P
leukemia	I-P
(	I-P
ALL	I-P
)	I-P
(	I-P
n	I-P
=	I-P
27	I-P
)	I-P
,	I-P
neuroblastoma	I-P
(	I-P
n	I-P
=	I-P
29	I-P
)	I-P
,	I-P
and	I-P
miscellaneous	I-P
solid	I-P
tumors	I-P
(	I-P
n	I-P
=	I-P
18	I-P
)	I-P
.	I-P


All	O
patients	O
survived	B-OUT
PBSCT	I-P
.	I-P


The	O
median	B-OUT
numbers	I-OUT
of	I-OUT
transfused	I-OUT
mononuclear	I-OUT
cells	I-OUT
(	I-OUT
MNC	I-OUT
)	I-OUT
,	I-OUT
CD34	I-OUT
(	I-OUT
+	I-OUT
)	I-OUT
cells	I-OUT
,	I-OUT
and	I-OUT
CFU-GM	I-OUT
were	O
,	O
respectively	O
,	O
4.5	O
(	O
range	O
,	O
1	O
to	O
19	O
)	O
x	O
10	O
(	O
8	O
)	O
/kg	O
,	O
8.0	O
(	O
1.1	O
to	O
25	O
)	O
x	O
10	O
(	O
6	O
)	O
/kg	O
,	O
and	O
3.7	O
(	O
1.2	O
to	O
23	O
)	O
x	O
10	O
(	O
5	O
)	O
/kg	O
in	O
the	O
treatment	O
group	O
(	O
n	O
=	O
30	O
)	O
and	O
2.9	O
(	O
0.8	O
to	O
21	O
)	O
x	O
10	O
(	O
8	O
)	O
/kg	O
,	O
6.3	O
(	O
1.1	O
to	O
34	O
)	O
x	O
10	O
(	O
6	O
)	O
/kg	O
,	O
and	O
5.5	O
(	O
1.3	O
to	O
37	O
)	O
x	O
10	O
(	O
5	O
)	O
/kg	O
,	O
respectively	O
,	O
in	O
the	O
control	O
group	O
(	O
n	O
=	O
28	O
)	O
,	O
with	O
no	O
significant	O
difference	O
.	O


There	O
were	O
24	O
atherosclerotic	B-OUT
deaths	I-OUT
in	O
the	O
drug	O
treatment	O
group	O
(	O
21.8	O
%	O
)	O
and	O
23	O
in	O
the	O
placebo	B-I
group	O
(	O
19.0	O
%	O
)	O
.	O


There	O
were	O
22	O
patients	O
in	O
the	O
drug	O
treatment	O
group	O
(	O
20.0	O
%	O
)	O
and	O
29	O
patients	O
in	O
the	O
placebo	O
group	O
(	O
24.0	O
%	O
)	O
with	O
opposite-side	B-OUT
amputations	I-OUT
.	I-OUT


Survival	O
curve	O
analyses	O
revealed	O
little	O
difference	O
between	O
these	O
groups	O
for	O
major	B-OUT
vascular	I-OUT
end	I-OUT
points	I-OUT
,	I-OUT
total	I-OUT
mortality	I-OUT
,	I-OUT
all	I-OUT
amputations	I-OUT
,	I-OUT
or	I-OUT
myocardial	I-OUT
infarctions	I-OUT
.	I-OUT


Studies	O
of	O
vector-parasite	O
relations	O
of	O
Wuchereria	O
bancrofti	O
suggest	O
that	O
a	O
reduction	O
in	O
the	O
microfilarial	O
reservoir	O
by	O
mass	O
chemotherapy	B-I
may	O
interrupt	O
transmission	O
and	O
thereby	O
eliminate	O
infection	O
.	O


The	O
rate	B-OUT
of	I-OUT
leg	I-OUT
oedema	I-OUT
was	O
not	O
altered	O
,	O
but	O
the	O
frequency	B-OUT
of	I-OUT
advanced	I-OUT
hydroceles	I-OUT
decreased	O
by	O
47	O
%	O
with	O
combined	O
therapy	O
and	O
56	O
%	O
with	O
diethylcarbamazine	B-I
alone	O
.	O


Exposure	B-OUT
to	I-OUT
infective	I-OUT
third-stage	I-OUT
larvae	I-OUT
decreased	O
in	O
all	O
monitored	O
five	O
communities	O
.	O


Transmission	O
was	O
almost	O
interrupted	O
in	O
two	O
communities	O
treated	O
with	O
combined	O
therapy	O
.	O


We	O
have	O
measured	O
the	O
capacity	O
of	O
the	O
sodium-potassium	B-I
pump	I-I
,	O
as	O
assessed	O
by	O
86rubidium	O
uptake	O
and	O
the	O
number	O
of	O
[	O
3H	O
]	O
-ouabain	O
binding	O
sites	O
on	O
white	O
blood	O
cells	O
,	O
in	O
children	B-P
aged	I-P
9-11	I-P
years	I-P
,	I-P
partly	I-P
cross-sectionally	I-P
and	I-P
partly	I-P
longitudinally	I-P
after	I-P
a	I-P
physical	I-I
training	I-I
programme	I-I
.	I-I


After	O
adjustment	O
for	O
differences	O
in	O
sexual	O
maturation	O
the	O
observed	O
significant	O
difference	O
disappeared	O
.	O


Important	O
correlates	O
of	O
pump	B-I
activity	I-I
were	O
height	O
,	O
plasma	O
glucose	O
,	O
and	O
physical	O
fitness	O
.	O


OBJECTIVE	O
To	O
evaluate	O
the	O
effect	O
of	O
modified	O
CIMT	B-I
on	O
improving	O
paretic	O
arm	O
function	O
in	O
poststroke	B-P
patients	I-P
during	O
a	O
subacute	O
rehabilitation	O
period	O
.	O


OBJECTIVE	O
Consumption	O
of	O
soy	O
protein	O
has	O
recently	O
been	O
shown	O
to	O
improve	O
the	O
blood	B-OUT
lipid	I-OUT
levels	I-OUT
in	O
nondiabetic	O
subjects	O
.	O


RESEARCH	O
DESIGN	O
AND	O
METHODS	O
Twenty	B-P
type	I-P
2	I-P
diabetic	I-P
subjects	I-P
participated	I-P
in	I-P
a	I-P
crossover	I-P
trial	I-P
.	I-P


The	O
percentage	O
mean	O
treatment	O
difference	O
between	O
Abalon	B-I
and	O
placebo	B-I
demonstrated	O
significantly	O
lower	O
mean	O
values	O
after	O
Abalon	B-I
for	O
LDL	B-OUT
cholesterol	I-OUT
(	O
10	O
+/-	O
15	O
%	O
,	O
P	O
<	O
0.05	O
)	O
,	O
LDL/UHDL	B-OUT
ratio	I-OUT
(	O
12	O
+/-	O
18	O
%	O
,	O
P	O
<	O
0.05	O
)	O
,	O
apolipoprotein	B-OUT
(	O
apo	O
)	O
B100	O
(	O
30	O
+/-	O
38	O
%	O
,	O
P	O
<	O
0.01	O
)	O
,	O
triglycerides	B-OUT
(	O
22	O
+/-	O
10	O
%	O
,	O
P	O
<	O
0.05	O
)	O
,	O
and	O
homocysteine	B-OUT
(	O
14	O
+/-	O
21	O
%	O
,	O
P	O
<	O
0.01	O
)	O
,	O
whereas	O
the	O
total	B-OUT
cholesterol	I-OUT
value	I-OUT
tended	O
to	O
be	O
less	O
significant	O
but	O
still	O
lower	O
(	O
8	O
+/-	O
15	O
%	O
,	O
P	O
<	O
0.08	O
)	O
.	O


CONCLUSIONS	O
These	O
results	O
indicate	O
beneficial	O
effects	O
of	O
dietary	O
supplementation	O
with	O
Abalon	B-I
on	O
cardiovascular	B-OUT
risk	I-OUT
markers	I-OUT
in	O
type	B-P
2	I-P
diabetic	I-P
subjects	I-P
.	I-P


Ordinary	O
least	O
squares	O
regressions	O
were	O
used	O
to	O
estimate	O
the	O
effect	O
of	O
the	O
program	O
on	O
costs	B-OUT
for	I-OUT
Medicaid	I-OUT
PCS/waiver	I-OUT
services	I-OUT
and	O
other	O
Medicaid	B-OUT
services	I-OUT
,	O
while	O
controlling	O
for	O
consumers	O
'	O
preenrollment	O
characteristics	O
and	O
preenrollment	O
Medicaid	O
spending	O
.	O


Higher	O
costs	B-OUT
for	I-OUT
personal	I-OUT
care/waiver	I-OUT
services	I-OUT
were	O
partially	O
offset	O
by	O
savings	O
in	O
other	O
Medicaid	O
services	O
,	O
particularly	O
those	O
related	O
to	O
long-term	O
care	O
.	O


Only	O
in	O
Arkansas	O
did	O
the	O
treatment-control	O
difference	O
in	O
total	O
cost	B-OUT
shrink	I-OUT
over	I-OUT
time-to	I-OUT
less	O
than	O
5	O
percent	O
(	O
and	O
statistically	O
insignificant	O
)	O
in	O
year	O
2	O
.	O


Captopril	B-I
,	O
but	O
not	O
quinapril	O
,	O
increased	O
excretion	O
of	O
prostacyclin	B-OUT
metabolite	I-OUT
(	O
217	O
+/-	O
50	O
vs.	O
135	O
+/-	O
21	O
pg/mg	O
Cr	O
base	O
line	O
,	O
P	O
<	O
.05	O
)	O
.	O


Reducing	O
blood	B-OUT
loss	I-OUT
in	O
simultaneous	B-P
bilateral	I-P
total	I-P
knee	I-P
arthroplasty	I-P
:	I-P
combined	O
intravenous-intra-articular	O
tranexamic	B-I
acid	I-I
administration	O
.	O


A	O
prospective	O
randomized	O
controlled	O
trial	O
.	O


RESULTS	O
Median	O
postoperative	O
volume	B-OUT
of	I-OUT
drained	I-OUT
blood	I-OUT
was	O
lower	O
in	O
the	O
group	O
receiving	O
TXA	B-I
(	O
500.00	O
mL	O
)	O
than	O
in	O
control	O
subjects	O
(	O
900.00	O
mL	O
)	O
(	O
p	O
<	O
0.05	O
)	O
[	O
95	O
%	O
CI	O
(	O
-525.00	O
)	O
to	O
(	O
-300.00	O
)	O
]	O
.	O


CONCLUSIONS	O
This	O
prospective	O
randomized	O
study	O
showed	O
that	O
during	O
simultaneous	O
bilateral	O
TKA	O
,	O
TXA	B-I
reduced	O
blood	B-OUT
loss	I-OUT
with	O
negligible	O
side	B-OUT
effects	I-OUT
.	I-OUT


A	O
comparison	O
of	O
the	O
systemic	O
bioactivity	O
of	O
inhaled	O
budesonide	B-I
and	O
fluticasone	B-I
propionate	I-I
in	O
normal	B-P
subjects	I-P
.	I-P


Bioavailability	B-OUT
of	O
omega-3	B-I
essential	I-I
fatty	I-I
acids	I-I
from	I-P
perilla	I-I
seed	I-I
oil	I-I
.	I-I


PURPOSE	O
We	O
assessed	O
the	O
impact	O
of	O
hexaminolevulinate	B-I
fluorescence	I-I
cystoscopic	I-I
detection	I-I
of	O
papillary	O
,	O
nonmuscle	O
invasive	O
bladder	O
cancer	O
on	O
the	O
long-term	B-OUT
recurrence	I-OUT
rate	I-OUT
.	I-OUT


MATERIALS	O
AND	O
METHODS	O
Long-term	B-P
followup	I-P
was	I-P
assessed	I-P
in	I-P
551	I-P
participants	I-P
enrolled	I-P
in	I-P
a	I-P
prospective	I-P
,	I-P
randomized	I-P
study	I-P
of	I-P
fluorescence	I-I
cystoscopy	I-I
for	I-I
Ta	I-I
or	I-I
T1	I-I
urothelial	I-I
bladder	I-I
cancer	I-I
.	I-I


In	O
the	O
original	O
study	O
280	B-P
patients	I-P
in	I-P
the	I-P
white	I-I
light	I-I
cystoscopy	I-I
group	I-P
and	O
271	B-P
in	I-P
the	I-P
fluorescence	I-I
cystoscopy	I-I
group	I-P
were	I-P
followed	I-P
with	I-P
cystoscopy	I-I
for	O
3	O
,	O
6	O
and	O
9	O
months	O
after	O
initial	O
resection	O
or	O
until	O
recurrence	O
.	O


A	O
study	O
extension	O
protocol	O
was	O
done	O
for	O
long-term	O
followup	O
of	O
these	O
patients	O
.	O


Cystectomy	B-I
was	O
done	O
in	O
22	O
of	O
280	O
cases	O
(	O
7.9	O
%	O
)	O
in	O
the	O
white	B-I
light	I-I
group	O
and	O
in	O
13	O
of	O
the	O
271	O
(	O
4.8	O
%	O
)	O
in	O
the	O
fluorescence	B-I
group	O
(	O
p	O
=	O
0.16	O
)	O
.	O


CONCLUSIONS	O
Hexaminolevulinate	B-I
fluorescence	I-I
cystoscopy	I-I
significantly	O
improves	O
long-term	B-OUT
bladder	I-OUT
cancer	I-OUT
time	I-OUT
to	I-OUT
recurrence	I-OUT
with	O
a	O
trend	O
toward	O
improved	O
bladder	O
preservation	O
.	O


After	O
12	O
months	O
,	O
a	O
significant	O
reduction	O
in	O
HbA1c	B-OUT
was	O
observed	O
in	O
the	O
nateglinide	O
group	O
,	O
whereas	O
a	O
significant	O
increase	O
of	O
HbA1c	B-OUT
was	O
observed	O
in	O
the	O
untreated	O
group	O
.	O


Two	O
clinically	O
meaningful	O
improvement	O
categories	O
were	O
assessed	O
,	O
including	O
1	B-OUT
)	I-OUT
3-point	I-OUT
or	I-OUT
greater	I-OUT
baseline	I-OUT
to	I-OUT
end	I-OUT
point	I-OUT
total	I-OUT
I-PSS	I-OUT
improvement	I-OUT
and	I-OUT
2	I-OUT
)	I-OUT
25	I-OUT
%	I-OUT
or	I-OUT
greater	I-OUT
baseline	I-OUT
to	I-OUT
end	I-OUT
point	I-OUT
total	I-OUT
I-PSS	I-OUT
improvement	I-OUT
.	I-OUT


OBJECTIVE	O
To	O
evaluate	O
the	O
cardiorespiratory	B-OUT
effects	I-OUT
of	O
IV	O
administration	O
of	O
propofol	B-I
(	O
4	O
mg/kg	O
)	O
,	O
ketamine	B-I
hydrochloride	I-I
and	I-I
propofol	I-I
(	O
2	O
mg/kg	O
each	O
;	O
K-P	O
)	O
,	O
or	O
ketamine	B-I
hydrochloride	I-I
(	O
5	O
mg/kg	O
)	O
and	O
diazepam	B-I
(	O
0.2	O
mg/kg	O
;	O
K-D	O
)	O
before	O
and	O
after	O
induction	O
of	O
anesthesia	B-I
(	O
IoA	O
)	O
in	O
dogs	B-P
sedated	I-P
with	I-P
acepromazine	I-I
maleate	I-I
and	I-P
oxymorphone	I-I
hydrochloride	I-I
.	I-I


Propofol	O
decreased	O
mean	B-OUT
arterial	I-OUT
blood	I-OUT
pressure	I-OUT
and	I-OUT
systemic	I-OUT
vascular	I-OUT
resistance	I-OUT
immediately	O
after	O
IoA	O
but	O
did	O
not	O
change	O
heart	B-OUT
rate	I-OUT
,	I-OUT
cardiac	I-OUT
output	I-OUT
,	I-OUT
or	I-OUT
oxygen	I-OUT
delivery	I-OUT
.	I-OUT


Supplemental	O
100	O
%	O
oxygen	O
should	O
be	O
provided	O
during	O
IoA	O
with	O
all	O
3	O
treatments	O
.	O


CONCLUSION	O
Our	O
findings	O
indicate	O
that	O
most	O
participants	O
are	O
willing	O
to	O
publicly	B-OUT
release	I-OUT
their	O
genomic	O
data	O
;	O
however	O
,	O
a	O
significant	O
portion	O
prefers	O
restricted	B-OUT
release	I-OUT
.	I-OUT


Using	O
data	O
from	O
the	O
Cholesterol	O
Lowering	O
Atherosclerosis	O
Study	O
(	O
CLAS	O
)	O
,	O
we	O
explored	O
the	O
association	O
of	O
self-selected	O
supplementary	O
antioxidant	B-I
vitamin	I-I
intake	O
on	O
the	O
rate	O
of	O
progression	O
of	O
early	B-P
preintrusive	I-P
atherosclerosis	I-P
.	I-P


Within	O
the	O
placebo	B-I
group	O
,	O
less	B-OUT
carotid	I-OUT
IMT	I-OUT
progression	I-OUT
was	O
found	O
for	O
high	O
supplementary	O
vitamin	B-I
E	I-I
users	O
when	O
compared	O
with	O
low	O
vitamin	B-I
E	I-I
users	O
(	O
0.008	O
versus	O
0.023	O
mm/y	O
,	O
P	O
=	O
.03	O
)	O
.	O


Repetitive	B-I
transcranial	I-I
magnetic	I-I
stimulation	I-I
(	I-I
rTMS	I-I
)	I-I
is	O
a	O
safe	O
and	O
efficacious	O
technique	O
when	O
targeting	O
specific	O
areas	O
of	O
cortical	O
dysfunction	O
in	O
major	O
depressive	O
disorder	O
,	O
and	O
a	O
similar	O
approach	O
could	O
yield	O
therapeutic	O
benefits	O
in	O
ASD	O
,	O
if	O
applied	O
to	O
relevant	O
cortical	O
regions	O
.	O


A	O
RANDOMIZED	O
CONTROL	O
STUDY	O
.	O


BACKGROUND	O
Major	O
liver	O
resection	O
is	O
associated	O
with	O
haemodynamic	O
,	O
hepatic	O
and	O
renal	O
changes	O
as	O
a	O
result	O
of	O
the	O
procedure	O
.	O


Doppler	B-OUT
corrected	I-OUT
flow	I-OUT
time	I-OUT
(	I-OUT
FTc	I-OUT
)	I-OUT
between	O
groups	O
were	O
comparable	O
(	O
P	O
>	O
0.05	O
)	O
.	O


METHODS	O
Forty-two	B-P
patients	I-P
scheduled	I-P
for	I-P
elective	I-P
CS	I-P
were	O
randomly	O
divided	O
into	O
3	O
equal	O
groups	O
,	O
and	O
received	O
2-CP	B-I
,	I-I
2-CP	I-I
+	I-I
epinephrine	I-I
(	O
Epi	O
,	O
5	O
micrograms.ml-1	O
)	O
or	O
2	B-I
%	I-I
lidocaine	I-I
(	I-I
Lido	I-I
)	I-I
with	I-I
Epi	I-I
for	O
LEA	O
.	O


The	O
Lido	O
+	O
Epi	O
group	O
used	O
significantly	O
less	B-OUT
morphine	I-OUT
(	O
P	O
=	O
0.01	O
)	O
compared	O
to	O
either	O
of	O
the	O
2-CP	B-I
groups	O
with	O
no	O
significant	O
difference	O
between	O
the	O
2-CP	B-I
groups	O
.	O


CONCLUSION	O
Analgesic	B-OUT
efficacy	I-OUT
of	O
EM	B-I
is	O
decreased	O
when	O
2-CP	B-I
is	O
used	O
for	O
LEA	O
compared	O
to	O
when	O
Lido	B-I
+	I-I
Epi	I-I
is	O
used	O
.	O


Cognitive	O
function	O
was	O
recorded	O
on	O
the	O
day	O
of	O
surgery	O
using	O
the	O
Mini-Mental	B-I
State	I-I
Examination	I-I
(	O
MMSE	O
)	O
and	O
24	O
and	O
48	O
hours	O
postoperatively	O
using	O
the	O
Telephone	B-OUT
Interview	I-OUT
of	I-OUT
Cognitive	I-OUT
Status	I-OUT
(	I-OUT
TICS	I-OUT
)	I-OUT
.	I-OUT


The	O
results	O
of	O
this	O
investigation	O
indicate	O
that	O
the	O
sedation	O
regimen	O
of	O
propofol	B-I
alone	O
has	O
the	O
least	O
impact	O
on	O
postprocedure	B-OUT
cognitive	I-OUT
function	I-OUT
.	I-OUT


UNLABELLED	O
Coronary	O
heart	O
disease	O
(	O
CHD	O
)	O
is	O
the	O
leading	O
cause	O
of	O
morbidity	O
and	O
mortality	O
across	O
the	O
entire	O
world	O
,	O
in	O
which	O
reversion	O
of	O
angina	O
or	O
improvement	O
of	O
ECG	O
remains	O
an	O
unrealistic	O
therapeutic	O
option	O
for	O
most	O
patients	O
,	O
suggesting	O
that	O
microvascular	O
dysfunction	O
or	O
impaired	O
oxygen	O
delivery	O
might	O
be	O
critical	O
factors	O
in	O
CHD	O
.	O


This	O
research	O
article	O
,	O
thus	O
presents	O
the	O
rationale	O
basis	O
,	O
clinical	O
and	O
experimental	O
,	O
for	O
the	O
first	O
therapeutic	O
innovation	O
addressing	O
the	O
role	O
of	O
red	O
blood	O
cell	O
(	O
RBC	O
)	O
H/K	O
and	O
O2/CO2	O
exchanges	O
in	O
CHD	O
.	O


All	B-P
patients	I-P
had	I-P
serial	I-P
clinical	I-P
evaluation	I-P
,	I-P
Ion	I-P
Transport	I-P
Studies	I-P
,	I-P
ECGs	I-P
and	I-P
non-invasive	I-P
aortic	I-P
waveform	I-P
and	I-P
cardiovascular	I-P
hemodynamic	I-P
recordings	I-P
.	I-P


Double	O
blind	O
comparison	O
of	O
Iomeprol	B-I
350	I-I
and	I-I
Iopamidol	I-I
340	I-I
in	O
intravenous	B-I
digital	I-I
subtraction	I-I
angiography	I-I
for	I-P
peripheral	I-P
vascular	I-P
disease	I-P
.	I-P


A	O
comparison	O
between	O
oral	O
ciprofloxacin	B-I
and	O
intra-peritoneal	B-I
vancomycin	I-I
and	O
gentamicin	B-I
in	O
the	O
treatment	O
of	O
CAPD	B-OUT
peritonitis	I-OUT
.	I-OUT


Staphylococcal	O
species	O
accounted	O
for	O
40	O
%	O
of	O
the	O
isolates	O
with	O
an	O
equal	O
incidence	O
of	O
Staphylococcus	B-OUT
aureus	I-OUT
and	O
coagulase	B-OUT
negative	I-OUT
staphylococci	I-OUT
.	I-OUT


Although	O
,	O
overall	O
,	O
there	O
was	O
no	O
significant	O
difference	O
between	O
the	O
regimens	O
in	O
outcome	O
,	O
ciprofloxacin	B-I
was	O
significantly	O
less	O
effective	B-OUT
when	O
peritonitis	O
was	O
due	O
to	O
coagulase	O
negative	O
staphylococci	O
.	O


bolus	O
of	O
750	O
mg	O
m	O
(	O
-2	O
)	O
.	O


IFN-beta	B-I
was	O
injected	O
intramuscularly	O
three	O
times	O
weekly	O
at	O
9	O
M	O
IU	O
.	O


Treatment	O
continued	O
for	O
52	O
weeks	O
,	O
or	O
until	O
disease	B-OUT
progression	I-OUT
or	O
intolerable	B-OUT
toxicity	I-OUT
.	I-OUT


The	O
only	O
grade	B-OUT
IV	I-OUT
toxicity	I-OUT
observed	O
was	O
neutropenia	O
(	O
two	O
patients	O
per	O
group	O
)	O
.	O


The	O
overall	B-OUT
median	I-OUT
survival	I-OUT
of	O
the	O
entire	O
group	O
was	O
13.2	O
months	O
.	O


In	O
the	O
FAM	B-I
arm	O
there	O
were	O
3	O
(	O
18	O
%	O
)	O
responders	O
(	O
2	O
CR	O
and	O
1	O
PR	O
)	O
,	O
7	O
(	O
41	O
%	O
)	O
SD	O
and	O
7	O
(	O
41	O
%	O
)	O
PD	O
,	O
versus	O
O	O
responders	O
,	O
5	O
(	O
31	O
%	O
)	O
SD	O
and	O
11	O
(	O
69	O
%	O
)	O
PD	O
in	O
the	O
5-FU	O
plus	O
BCNU	O
arm	O
.	O


We	O
developed	O
suppositories	B-I
and	I-I
ointment	I-I
with	I-I
30	I-I
%	I-I
free	I-I
fatty	I-I
acid	I-I
(	I-I
FFA	I-I
)	I-I
extract	I-I
from	I-I
omega-3	I-I
fish	I-I
oil	I-I
.	I-I


Peripheral	O
intravenous	B-OUT
line	I-OUT
survival	I-OUT
and	O
phlebitis	B-OUT
prevention	O
in	O
patients	B-P
receiving	I-P
intravenous	I-P
antibiotics	I-I
:	I-I
heparin/hydrocortisone	O
versus	O
in-line	O
filters	O
.	O


antibiotics	B-P
.	I-P


A	O
two-filter	B-I
model	I-I
for	O
frequency	B-OUT
discrimination	I-OUT
.	I-OUT


SETTING	O
Pediatric	B-P
emergency	I-P
service	I-P
of	I-P
a	I-P
large	I-P
teaching	I-P
hospital	I-P
.	I-P


Effect	O
of	O
the	O
dietary	O
approaches	O
to	O
stop	O
hypertension	O
diet	O
and	O
reduced	O
sodium	O
intake	O
on	O
blood	O
pressure	O
control	O
.	O


Eight	O
patients	O
(	O
14.4	O
%	O
)	O
in	O
CsA	O
group	O
required	O
a	O
drug	O
conversion	O
but	O
none	O
in	O
FK506	O
group	O
.	O


CONCLUSION	O
For	O
HBV-carrying	B-P
renal	I-P
transplant	I-P
recipients	I-P
,	O
FK506	B-I
as	O
the	O
primary	O
choice	O
of	O
immunosuppressant	O
can	O
be	O
more	O
effective	O
and	O
safer	O
than	O
CsA	O
.	O


RESULTS	O
Rabeprazole	B-OUT
clearance	I-OUT
was	O
lower	O
in	O
CYP2C19	O
PMs	O
than	O
in	O
EMs	O
(	O
with	O
average	O
values	O
of	O
10.7	O
vs.	O
16.8	O
l	O
h	O
(	O
-1	O
)	O
in	O
PMs	O
and	O
EMs	O
,	O
respectively	O
)	O
,	O
resulting	O
in	O
higher	O
plasma	O
levels	O
in	O
the	O
former	O
group	O
.	O


The	O
predicted	B-OUT
gastrin-time	I-OUT
profile	I-OUT
showed	O
a	O
higher	O
response	O
in	O
CYP2C19	O
PMs	O
than	O
in	O
EMs	O
on	O
days	O
4	O
and	O
7	O
.	O


Helicobacter	B-OUT
pylori	I-OUT
was	I-OUT
eradicated	I-OUT
in	O
all	O
CYP2C19	O
PMs	O
except	O
in	O
one	O
patient	O
infected	O
by	O
a	O
resistant	O
strain	O
.	O


High-pressure	B-I
,	I-I
rapid-inflation	I-I
pneumatic	I-I
compression	I-I
improves	O
venous	O
hemodynamics	O
in	O
healthy	B-P
volunteers	I-P
and	I-P
patients	I-P
who	I-P
are	I-P
post-thrombotic	I-P
.	I-P


There	O
were	O
three	O
responses	O
among	O
77	O
patients	O
crossed	O
over	O
to	O
mitoxantrone	B-I
after	O
initial	O
treatment	O
with	O
doxorubicin	B-I
.	I-I


The	B-OUT
major	I-OUT
dose-limiting	I-OUT
toxicity	I-OUT
for	O
both	O
drugs	O
was	O
leukopenia	B-OUT
.	I-OUT


Compared	O
with	O
doxorubicin	B-I
it	O
appears	O
to	O
be	O
marginally	B-OUT
less	I-OUT
active	I-OUT
and	I-OUT
significantly	I-OUT
less	I-OUT
toxic	I-OUT
.	I-OUT


Participants	B-P
were	I-P
adolescent	I-P
girls	I-P
and	I-P
boys	I-P
(	I-P
N	I-P
=	I-P
878	I-P
)	I-P
aged	I-P
11-15	I-P
years	I-P
on	I-P
entry	I-P
.	I-P


The	O
pattern	O
of	O
findings	O
was	O
similar	O
for	O
most	O
subgroups	O
defined	O
by	O
gender	O
and	O
study	O
condition	O
.	O


OBJECTIVE	O
We	O
investigated	O
whether	O
micronutrients	B-I
given	O
acutely	O
following	O
the	O
Christchurch	B-P
earthquakes	O
continued	O
to	O
confer	O
benefit	O
1	O
year	O
following	O
the	O
treatment	O
.	O


METHODS	O
Sixty-four	B-P
adults	I-P
from	I-P
the	I-P
original	I-P
91	I-P
participants	I-P
experiencing	I-P
heightened	I-P
anxiety	I-P
or	I-P
stress	I-P
2-3	I-P
months	I-P
following	I-P
the	I-P
22nd	I-P
February	I-P
2011	I-P
earthquake	I-P
and	I-P
who	I-P
had	I-P
been	I-P
randomized	I-P
to	I-P
receive	I-P
three	I-I
different	I-I
doses	I-I
of	I-I
micronutrients	I-I
completed	I-P
on-line	I-P
questionnaires	I-P
assessing	I-P
mood	I-OUT
,	I-OUT
anxiety	I-OUT
,	I-OUT
stress	I-OUT
,	I-OUT
and	I-OUT
symptoms	I-OUT
associated	I-OUT
with	I-OUT
post-traumatic	I-OUT
stress	I-OUT
disorder	I-OUT
1	I-P
year	I-P
after	I-P
completing	I-P
the	I-P
initial	I-P
study	I-P
.	I-P


Twenty-one	B-P
out	I-P
of	I-P
29	I-P
nonrandomized	I-P
controls	I-P
who	I-P
did	I-P
not	I-P
receive	I-P
the	I-P
treatment	I-P
also	I-P
completed	I-P
the	I-P
questionnaires	I-P
.	O


RESULTS	O
Both	O
the	O
treated	O
and	O
control	O
groups	O
experienced	O
significant	O
improvement	O
in	O
psychological	B-OUT
functioning	I-OUT
compared	O
with	O
end-of-trial	O
.	O


Those	O
who	O
stayed	O
on	O
micronutrients	O
through	O
to	O
follow-up	O
or	O
stopped	O
all	O
treatment	O
reported	O
better	O
psychological	B-OUT
functioning	I-OUT
than	O
those	O
who	O
switched	O
to	O
other	O
treatments	O
including	O
medications	O
.	O


Six-	B-P
to	I-P
13-year-olds	I-P
(	I-P
N	I-P
=	I-P
126	I-P
)	I-P
viewed	I-I
a	I-I
sad	I-I
film	I-I
and	I-I
were	I-I
instructed	I-I
to	I-I
reappraise	I-I
the	I-I
importance	I-I
,	I-I
reappraise	I-I
the	I-I
outcome	I-I
,	I-I
or	I-I
ruminate	I-I
about	I-I
the	I-I
sad	I-I
events	I-I
;	I-I
another	I-I
group	I-I
received	I-I
no	I-I
regulation	I-I
instructions	I-I
.	I-I


Children	B-P
viewed	O
an	O
educational	B-I
film	I-I
,	O
and	O
memory	O
for	O
this	O
was	O
later	O
assessed	O
.	O


As	O
predicted	O
,	O
reappraisal	O
strategies	O
more	O
effectively	O
attenuated	O
children	B-OUT
's	I-OUT
self-reported	I-OUT
emotional	I-OUT
processing	I-OUT
.	I-OUT


Superior	O
efficacy	O
of	O
clopidogrel	B-I
plus	I-I
acetylsalicylic	I-I
acid	I-I
compared	O
with	O
extended-release	B-I
dipyridamole	I-I
plus	I-I
acetylsalicylic	I-I
acid	I-I
in	O
preventing	O
arterial	O
thrombogenesis	O
in	O
healthy	B-P
volunteers	I-P
.	I-P


INTRODUCTION	O
Recent	O
ex	O
vivo	O
platelet	O
aggregometry	O
data	O
indicate	O
that	O
clopidogrel	B-I
75	O
mg/day	O
plus	B-I
acetylsalicylic	I-I
acid	I-I
(	I-I
ASA	I-I
)	I-I
75	O
mg/day	O
is	O
a	O
more	O
potent	O
antiplatelet	O
regimen	O
than	O
the	O
marketed	O
combination	O
of	O
dipyridamole+ASA	B-I
.	I-I


MATERIALS	O
AND	O
METHODS	O
This	O
was	O
a	O
randomized	O
,	O
double-blind	O
,	O
placebo-controlled	O
,	O
crossover	O
study	O
.	O


Few	O
studies	O
have	O
evaluated	O
the	O
impact	O
of	O
maintenance	O
immunosuppression	O
on	O
blood	O
humoral	O
parameters	O
.	O


MATERIAL/METHODS	O
We	O
performed	O
a	O
post-hoc	O
analysis	O
on	O
307	B-P
kidney	I-P
transplant	I-P
recipients	I-P
included	I-P
in	I-P
a	I-P
prospective	I-P
randomized	I-P
trial	I-P
comparing	I-P
tacrolimus/mycophenolate	I-I
mofetil	I-I
(	I-I
Tac/MMF	I-I
)	I-I
vs.	I-I
cyclosporine/azathioprine	I-I
(	I-I
CsA/AZA	I-I
)	I-I
,	O
both	O
used	O
with	O
antithymocyte	B-I
globulin	I-I
induction	I-I
and	O
steroids	B-I
.	I-I


More	O
patients	O
sensitized	O
at	O
baseline	O
became	O
non-sensitized	O
at	O
M12	O
with	O
Tac/MMF	O
than	O
with	O
CsA/AZA	O
.	O


It	O
is	O
recommended	O
that	O
in	O
nephrectomies	O
undertaken	O
for	O
primary	B-P
renal	I-P
cell	I-P
carcinoma	I-P
at	O
least	O
one	O
random	O
block	O
of	O
renal	O
cortex	O
should	O
be	O
examined	B-I
to	O
confirm	O
or	O
exclude	O
intraglomerular	O
metastases	O
.	O


A	O
pilot	B-I
group	I-I
therapy	I-I
for	O
functional	B-P
memory	I-P
disorder	I-P
.	I-P


An	O
in	O
vitro	O
comparative	O
analysis	O
:	O
scanning	O
electron	O
microscopy	O
of	O
dentin/restoration	O
interfaces	O
.	O


Each	B-P
group	I-P
was	O
restored	O
with	O
one	O
of	O
ten	B-I
different	I-I
restorative	I-I
techniques	I-I
.	I-I


Five	O
tooth	O
sections	O
from	O
the	O
dentin	O
bonding	O
resin	O
groups	O
were	O
allowed	O
to	O
dry	O
at	O
20	O
degrees	O
C	O
for	O
24h	O
.	O


All	O
tooth	O
specimens	O
were	O
sputter-coated	B-I
with	I-I
gold	I-I
for	O
4	O
min	O
and	O
examined	O
using	O
a	O
scanning	O
electron	O
microscope	O
.	O


OBJECTIVE	O
The	O
efficacy	B-OUT
of	O
topical	B-I
anesthesia	I-I
during	O
retinopathy	B-P
of	I-P
prematurity	I-P
(	I-P
ROP	I-P
)	I-P
screening	O
has	O
been	O
a	O
controversial	O
issue	O
.	O


Wilcoxon	O
signed-ranks	O
test	O
was	O
used	O
to	O
pair	B-OUT
pain	I-OUT
scores	I-OUT
.	O


After	B-OUT
6	I-OUT
months	I-OUT
,	I-OUT
mean	I-OUT
serum	O
25	O
(	O
OH	O
)	O
D	O
increased	O
to	O
53	O
nmol/l	O
with	O
800	O
IU/day	O
,	O
to	O
50.5	O
nmol/l	O
with	O
100,000	O
IU/3	O
months	O
,	O
and	O
to	O
29.1	B-I
nmol/l	I-I
with	I-I
advised	I-I
sunlight	I-I
exposure	I-I
(	I-I
supplementation	I-I
vs	O
sunshine	B-OUT
p	I-OUT
<	I-OUT
0.001	I-OUT
)	I-OUT
.	O


CONCLUSION	B-I
Vitamin	I-I
D	O
supplementation	B-I
is	I-I
more	I-I
effective	I-I
than	I-I
advised	I-I
sunlight	O
exposure	O
for	O
treating	B-P
vitamin	I-P
D	I-P
deficiency	I-P
in	I-P
non-western	O
immigrants	O
.	O


Using	O
a	O
novel	O
wound	O
model	O
to	O
investigate	O
the	O
healing	B-OUT
properties	I-OUT
of	O
products	O
for	O
superficial	O
wounds	O
.	O


Best	O
results	O
were	O
obtained	O
for	O
the	O
polyurethane	O
and	O
hydrocolloid	O
products	O
,	O
which	O
had	O
high	B-OUT
mean	I-OUT
scores	I-OUT
close	O
to	O
the	O
maximum	O
of	O
10	O
.	O


Histological	B-OUT
examination	I-OUT
of	I-OUT
biopsies	I-OUT
taken	O
from	O
the	O
abrasions	O
of	O
two	O
volunteers	O
showed	O
the	O
dermis	B-OUT
remained	I-OUT
intact	I-OUT
,	O
making	O
the	O
model	O
highly	O
suitable	O
for	O
the	O
study	O
of	O
superficial	O
wounds	O
.	O


Supplemental	O
1alpha-hydroxycholecalciferol	O
(	O
1alpha-OHD3	O
)	O
has	O
been	O
shown	O
to	O
have	O
qualitatively	O
similar	O
and	O
quantitatively	O
additive	O
effects	O
to	O
exogenous	O
phytase	O
.	O


Two	O
experiments	O
were	O
conducted	O
from	O
0	O
to	O
35	O
d	O
in	O
floor	O
pens	O
to	O
determine	O
the	O
additive	O
effect	O
of	O
phytase	B-I
and	I-I
1alpha-OHD3	I-I
when	O
supplemented	O
to	O
Ca-	B-I
and	I-I
P-deficient	I-I
diets	I-I
.	I-I


Therefore	O
,	O
85	B-P
HCC	I-P
patients	I-P
after	I-P
transcatheter	I-I
arterial	I-I
chemoembolization	I-I
and	I-P
radiofrequency	I-I
ablation	I-I
therapy	I-I
were	I-P
randomized	I-P
to	I-P
immunotherapy	I-I
group	I-P
and	I-P
no	I-I
adjuvant	I-I
therapy	I-I
group	I-P
.	I-P


After	O
CIK	B-I
cell	I-I
infusions	O
,	O
the	O
percentages	B-OUT
of	I-OUT
CD3+	I-OUT
,	I-OUT
CD4+	I-OUT
,	I-OUT
CD56+	I-OUT
,	I-OUT
CD3+CD56+	I-OUT
cells	I-OUT
,	I-OUT
and	I-OUT
CD4+/CD8+	I-OUT
ratio	I-OUT
increased	O
from	O
68.6+/-11.0	O
%	O
,	O
31.1+/-9.0	O
%	O
,	O
15.6+/-7.9	O
%	O
,	O
5.2+/-3.1	O
%	O
,	O
and	O
1.1+/-0.5	O
to	O
70.7+/-10.1	O
%	O
,	O
33.5+/-8.0	O
%	O
,	O
18.4+/-9.4	O
%	O
,	O
5.9+/-2.8	O
%	O
,	O
and	O
1.3+/-0.7	O
,	O
respectively	O
(	O
P	O
<	O
0.05	O
)	O
;	O
whereas	O
the	O
percentage	B-OUT
of	I-OUT
CD8	I-OUT
cells	I-OUT
decreased	O
from	O
31.1+/-7.8	O
%	O
to	O
28.6+/-8.3	O
%	O
(	O
P	O
<	O
0.05	O
)	O
.	O


CONCLUSIONS	O
Vilazodone	B-I
had	O
no	O
significant	O
effect	O
on	O
cardiac	B-OUT
repolarization	I-OUT
,	I-OUT
heart	I-OUT
rate	I-OUT
,	I-OUT
PR	I-OUT
or	I-OUT
QRS	I-OUT
interval	I-OUT
duration	I-OUT
,	I-OUT
or	I-OUT
ECG	I-OUT
morphology	I-OUT
in	O
healthy	B-P
adult	I-P
participants	I-P
.	I-P


During	O
the	O
second	O
and	O
third	O
periods	O
,	O
the	O
patient	O
received	O
3	O
X	O
2	O
inhalations	O
of	O
drug	O
or	O
placebo	B-I
in	O
a	O
cross-over	O
design	O
.	O


The	O
medical	O
staff	O
was	O
blind	O
to	O
the	O
nature	O
of	O
the	O
aerosol	O
(	B-I
drug	I-I
or	O
placebo	B-I
)	I-I
,	O
which	O
was	O
given	O
in	O
random	O
order	O
.	O


The	O
run-in	O
clinical	O
score	O
was	O
high	O
.	O


On	O
the	O
basis	O
of	O
these	O
examinations	O
,	O
the	O
authors	O
identified	O
64	B-P
women	I-P
who	I-P
had	I-P
at	I-P
least	I-P
one	I-P
ruptured	I-P
implant	I-P
at	I-P
the	I-P
first	I-P
magnetic	I-P
resonance	I-P
imaging	I-P
examination	I-P
and	O
,	O
for	O
comparison	O
,	O
all	O
women	O
who	O
had	O
intact	O
implants	O
at	O
both	O
examinations	O
(	O
n	O
=	O
98	O
)	O
.	O


The	O
difference	O
in	O
rates	O
of	O
pancreatitis	B-OUT
between	O
the	O
two	O
groups	O
was	O
1.7	O
%	O
:	O
95	O
%	O
CI	O
[	O
-4.8	O
%	O
,	O
8.2	O
%	O
]	O
.	O


CONCLUSIONS	O
The	O
type	O
of	O
current	B-I
used	O
when	O
performing	O
endoscopic	B-I
sphincterotomy	I-I
does	O
not	O
appear	O
to	O
alter	O
the	O
risk	O
of	O
post-ERCP	O
pancreatitis	O
.	O


The	O
selection	O
of	O
electrosurgical	B-I
current	I-I
for	O
biliary	O
endoscopic	B-I
sphincterotomy	I-I
should	O
be	O
based	O
on	O
endoscopist	O
preference	O
.	O


UNLABELLED	O
On	O
December	O
12	O
,	O
2014	O
,	O
the	O
U.S.	O
Food	O
and	O
Drug	O
Administration	O
(	O
FDA	O
)	O
approved	O
ramucirumab	B-I
for	O
use	O
in	O
combination	O
with	O
docetaxel	B-I
for	O
the	O
treatment	O
of	O
patients	B-P
with	I-P
metastatic	I-P
non-small	I-P
cell	I-P
lung	I-P
cancer	I-P
(	I-P
NSCLC	I-P
)	I-P
with	I-P
disease	I-P
progression	I-P
on	I-P
or	I-P
after	I-P
platinum-based	I-P
chemotherapy	I-P
.	I-P


Patients	O
who	O
received	O
ramucirumab	O
in	O
combination	O
with	O
docetaxel	O
had	O
improved	B-OUT
OS	I-OUT
(	O
hazard	O
ratio	O
[	O
HR	O
]	O
:	O
0.86	O
;	O
95	O
%	O
confidence	O
interval	O
[	O
CI	O
]	O
:	O
0.75	O
,	O
0.98	O
)	O
.	O


Median	B-OUT
OS	I-OUT
was	O
10.5	O
months	O
on	O
the	O
ramucirumab	O
plus	O
docetaxel	O
arm	O
versus	O
9.1	O
months	O
on	O
the	O
placebo	O
plus	O
docetaxel	O
arm	O
.	O


An	O
oxytocin-induced	O
facilitation	O
of	O
neural	B-OUT
and	I-OUT
emotional	I-OUT
responses	I-OUT
to	I-OUT
social	I-OUT
touch	I-OUT
correlates	O
inversely	O
with	O
autism	B-P
traits	I-P
.	I-P


In-person	O
recall	O
data	O
were	O
combined	O
for	O
comparison	O
with	O
the	O
telephone	O
recalls	O
.	O


Thirty-four	B-P
elderly	I-P
outpatients	I-P
meeting	I-P
Petersen	I-P
's	I-P
MCI	I-P
criteria	I-P
were	O
randomly	O
assigned	O
to	O
receive	B-I
10	I-I
sessions	I-I
of	I-I
either	I-I
active	I-I
TMS	I-I
or	I-I
sham	I-I
,	I-I
10	I-I
Hz	I-I
rTMS	I-I
at	I-I
110	I-I
%	I-I
of	I-I
motor	I-I
threshold	I-I
,	I-I
2,000	I-I
pulses	I-I
per	I-I
session	I-I
.	I-I


ANOVA	O
on	O
the	O
primary	O
efficacy	O
measure	O
,	O
the	B-OUT
Rivermead	I-OUT
Behavioural	I-OUT
Memory	I-OUT
Test	I-OUT
,	O
revealed	O
a	O
significant	O
group-by-time	O
interaction	O
(	O
p	O
=	O
0.05	O
)	O
,	O
favoring	O
the	O
active	O
group	O
.	O


Both	O
the	O
median	B-OUT
number	I-OUT
of	I-OUT
angina	I-OUT
attacks	I-OUT
per	I-OUT
week	I-OUT
and	I-OUT
the	I-OUT
median	I-OUT
number	I-OUT
of	I-OUT
nitroglycerin	I-OUT
(	I-OUT
NTG	I-OUT
)	I-OUT
tablets	I-OUT
consumed/week	I-OUT
were	O
significantly	O
reduced	O
after	O
amlodipine	B-I
(	O
mean	O
daily	O
dose	O
of	O
8.6	O
mg	O
)	O
when	O
compared	O
with	O
baseline	O
(	O
p	O
<	O
0.05	O
)	O
.	O


[	O
GISSI-2	O
;	O
the	O
beginning	O
of	O
the	O
end	O
or	O
the	O
end	O
of	O
the	O
beginning	O
for	O
tissue	B-I
plasminogen	I-I
activator	O
in	O
acute	B-OUT
myocardial	I-OUT
infarct	I-OUT
?	O
]	O
.	O


[	O
Diphtheria	O
antitoxin	O
level	O
2	O
years	O
after	O
booster	B-I
vaccination	I-I
]	I-I
.	O


After	O
one	O
and	O
two	O
years	O
7	B-P
%	I-P
and	I-P
8	I-P
%	I-P
of	I-P
the	I-P
subjects	I-P
had	O
diphtheria	B-OUT
antitoxin	I-OUT
level	I-OUT
below	O
0.01	O
I.U./ml	O
.	O


Elevated	O
concentration	O
of	O
placental	O
growth	O
factor	O
(	O
PlGF	O
)	O
and	O
long	O
term	O
risk	O
in	O
patients	B-P
with	I-P
acute	I-P
coronary	I-P
syndrome	I-P
in	I-P
the	I-P
PROVE	I-P
IT-TIMI	I-P
22	I-P
trial	I-P
.	I-P


PlGF	B-OUT
was	O
measured	O
at	O
baseline	O
(	B-P
n	I-P
=	I-P
3,761	I-P
)	I-P
and	O
at	O
four-months	O
(	O
n	O
=	O
3,369	O
)	O
in	O
patients	B-P
randomized	I-P
to	I-P
atorvastatin	I-I
80	I-I
mg	I-I
or	I-I
pravastatin	I-I
40	I-I
mg	I-I
after	I-I
ACS	I-I
in	I-P
the	O
PROVE	O
IT-TIMI	O
22	O
trial	O
.	O


The	O
primary	O
endpoint	O
was	O
death	B-OUT
,	I-OUT
myocardial	I-OUT
infarction	I-OUT
(	I-OUT
MI	I-OUT
)	I-OUT
,	I-OUT
unstable	I-OUT
angina	I-OUT
,	I-OUT
revascularization	I-OUT
or	I-OUT
stroke	I-OUT
(	O
mean	O
follow-up	O
24	O
months	O
)	O
.	O


The	O
risk	B-OUT
of	I-OUT
death	I-OUT
or	I-OUT
MI	I-OUT
was	O
also	O
higher	O
in	O
patients	B-P
with	I-P
elevated	I-P
baseline	I-P
PlGF	I-P
(	O
Q1	O
vs.	O
Q5	O
:	O
7.0	O
vs.	O
11.6	O
%	O
,	O
p	O
=	O
0.029	O
)	O
.	O


Adjusting	O
for	O
baseline	O
characteristics	O
and	O
risk	O
factors	O
,	O
elevated	O
baseline	O
PlGF	O
was	O
independently	O
associated	O
with	O
the	O
risk	O
of	O
the	O
primary	O
endpoint	O
(	O
adjusted-HR	O
for	O
Q5	O
vs.	O
Q1	O
1.45	O
;	O
95	O
%	O
CI	O
1.16-1.83	O
;	O
p	O
=	O
0.001	O
)	O
.	O


Elevated	O
PlGF	O
at	O
four	O
months	O
was	O
associated	O
with	O
higher	O
risk	B-OUT
of	I-OUT
death	I-OUT
or	I-OUT
MI	I-OUT
(	O
Adjusted	O
HR	O
Q5	O
vs.	O
Q1	O
2.79	O
,	O
95	O
%	O
CI	O
:	O
1.37-5.68	O
;	O
p	O
=	O
0.005	O
)	O
,	O
and	O
higher	O
risk	O
of	O
the	O
primary	O
endpoint	O
(	O
Adjusted	O
HR	O
Q5	O
vs.	O
Q1	O
1.78	O
,	O
95	O
%	O
CI	O
:	O
1.26-2.51	O
;	O
p	O
=	O
0.001	O
)	O
.	O


The	O
between-treatment	O
differences	O
were	O
significant	O
for	O
many	O
of	O
the	O
scores	O
particularly	O
in	O
the	O
first	O
24	O
weeks	O
of	O
treatment	O
.	O


The	O
results	O
of	O
the	O
aspirin	B-I
trial	O
are	O
reported	O
here	O
.	O


Dental	O
study	O
casts	O
,	O
lateral	O
and	O
postero-anterior	O
cephalograms	O
were	O
taken	O
before	O
treatment	O
,	O
after	O
the	O
distraction	O
phase	O
and	O
at	O
12-month	O
follow	O
up	O
.	O


Relapse	B-OUT
was	O
not	O
significant	O
and	O
at	O
follow	O
up	O
the	O
significant	O
increase	O
in	O
distance	O
was	O
sustained	O
.	O


Tipping	O
of	O
the	O
maxillary	O
segments	O
and	O
increases	O
in	O
the	O
retention	B-OUT
period	I-OUT
are	O
equal	O
in	O
both	O
groups	O
.	O


The	O
median	O
survival	O
is	O
less	O
than	O
10	O
months	O
,	O
and	O
less	O
than	O
10	O
percent	O
of	O
patients	O
survive	O
for	O
5	O
years	O
.	O


Recent	O
studies	O
have	O
suggested	O
that	O
combined	B-I
chemotherapy	I-I
and	I-I
radiation	I-I
therapy	I-I
may	O
result	O
in	O
improved	O
survival	O
.	O


The	O
trial	O
was	O
stopped	O
after	O
the	O
accumulated	O
results	O
in	O
121	B-P
patients	I-P
demonstrated	I-P
a	I-P
significant	I-P
advantage	I-P
for	I-P
survival	I-P
in	I-P
the	I-P
patients	I-P
who	I-P
received	I-P
chemotherapy	I-I
and	I-I
radiation	I-I
therapy	I-I
.	I-I


Extrapyramidal	B-OUT
effects	I-OUT
were	O
evident	O
for	O
all	O
doses	O
of	O
haloperidol	B-I
,	O
but	O
absent	O
for	O
the	O
lower	O
doses	O
of	O
sertindole	B-I
.	I-I


Forty-two	B-P
students	I-P
with	I-P
autism	I-P
,	I-P
varying	I-P
in	I-P
age	I-P
and	I-P
expressive	I-P
communication	I-P
ability	I-P
,	I-P
were	I-P
randomly	I-P
assigned	I-P
to	I-P
the	I-P
experimental	I-P
conditions	I-P
.	I-P


Attitude	B-P
certainty	I-P
has	O
been	O
the	O
subject	O
of	O
considerable	O
attention	O
in	O
the	O
attitudes	O
and	O
persuasion	O
literature	O
.	O


BCG	O
protection	O
varies	O
and	O
in	O
some	O
places	O
(	O
nearest	O
the	O
equator	O
)	O
is	O
low	O
or	O
absent	O
.	O


Understanding	O
this	O
variation	O
can	O
inform	O
the	O
efforts	O
to	O
develop	O
new	O
vaccines	O
against	O
tuberculosis	O
.	O


Two	O
main	O
hypotheses	O
are	O
used	O
to	O
explain	O
this	O
variation	O
:	O
under	O
masking	O
,	O
new	O
vaccines	O
are	O
unlikely	O
to	O
increase	O
protection	B-OUT
;	I-OUT
under	O
blocking	O
new	O
vaccines	O
have	O
a	O
greater	O
potential	O
to	O
be	O
effective	O
when	O
BCG	O
is	O
not	O
.	O


For	O
revaccination	B-OUT
at	I-OUT
school	I-OUT
age	I-OUT
,	O
protection	O
was	O
modest	O
in	O
Salvador	O
(	O
19	O
%	O
,	O
95	O
%	O
CI	O
3-33	O
%	O
,	O
p=0.022	O
)	O
and	O
absent	O
in	O
Manaus	O
(	O
1	O
%	O
,	O
95	O
%	O
CI	O
to	O
27-23	O
%	O
,	O
p=0.932	O
)	O
.	O


Vaccine	B-OUT
efficacy	I-OUT
for	O
neonatal	O
vaccination	O
was	O
similar	O
in	O
Salvador	O
(	O
40	O
%	O
,	O
95	O
%	O
CI	O
22-54	O
%	O
,	O
p	O
<	O
0.001	O
)	O
and	O
Manaus	O
(	O
36	O
%	O
,	O
95	O
%	O
CI	O
11-53	O
%	O
,	O
p=0.008	O
)	O
.	O


New	O
tuberculosis	O
vaccines	O
that	O
overcome	O
or	O
by	O
pass	O
this	O
blocking	O
effect	O
could	O
confer	O
protection	O
in	O
situations	O
where	O
BCG	O
is	O
not	O
protective	O
.	O


A	O
double-blind	O
placebo-controlled	B-I
pilot	O
study	O
of	O
olanzapine	B-I
in	O
childhood/adolescent	B-P
pervasive	I-P
developmental	I-P
disorder	I-P
.	I-P


This	O
is	O
the	O
first	O
placebo-controlled	B-I
trial	O
of	O
olanzapine	B-I
in	O
the	O
treatment	O
of	O
children	O
and	O
adolescents	O
with	O
PDD	O
.	O


Additional	O
studies	O
are	O
needed	O
to	O
determine	O
the	O
efficacy	O
and	O
safety	O
of	O
olanzapine	O
in	O
the	O
treatment	O
of	O
children	O
with	O
PDD	O
.	O


State-Trait	B-OUT
Anxiety	I-OUT
Inventory	I-OUT
(	I-OUT
STAI	I-OUT
)	I-OUT
and	I-OUT
the	I-OUT
Short	I-OUT
Form-36	I-OUT
(	I-OUT
SF-36	I-OUT
)	I-OUT
were	O
administered	O
at	O
study	O
inclusion	O
,	O
after	O
1	O
,	O
6	O
months	O
.	O


However	O
,	O
compared	O
to	O
control	B-OUT
,	O
AP	O
[	O
+2	O
mmHg	O
,	O
95	O
%	O
confidence	O
interval	O
(	O
CI	O
)	O
0.36-4.36	O
;	O
p	O
=	O
0.01	O
]	O
and	B-OUT
AIx	O
(	O
+6	O
%	O
,	O
95	O
%	O
CI	O
1.24-10.1	O
;	O
p	O
=	O
0.02	O
)	O
increased	O
,	O
and	B-OUT
time	I-OUT
to	I-OUT
maximum	I-OUT
P	I-OUT
ex	O
(	O
a	O
component	O
of	O
reservoir	O
function	O
related	O
to	O
timing	O
of	O
peak	O
aortic	O
in-flow	O
)	O
decreased	O
(	O
-7	O
ms	O
,	O
95	O
%	O
CI	O
-15.4	O
to	O
2.03	O
;	O
p	O
=	O
0.01	O
)	O
compared	O
to	O
control	O
.	O


Effects	B-OUT
of	O
telmisartan	B-I
and	I-I
enalapril	I-I
on	O
renoprotection	O
in	O
patients	B-P
with	I-P
mild	I-P
to	I-P
moderate	I-P
chronic	I-P
kidney	I-P
disease	I-P
.	I-P


The	O
aim	O
of	O
this	O
study	O
was	O
to	O
compare	O
the	O
chronic	O
effects	O
of	O
telmisartan	B-I
and	O
enalapril	B-I
on	O
proteinuria	O
,	O
urinary	B-OUT
liver-type	I-OUT
fatty	I-OUT
acid-binding	I-OUT
protein	I-OUT
(	I-OUT
L-FABP	I-OUT
)	I-OUT
and	O
endothelin	B-OUT
(	I-OUT
ET	I-OUT
)	I-OUT
-1	I-OUT
levels	I-OUT
in	O
patients	B-P
with	I-P
mild	I-P
CKD	I-P
.	I-P


We	O
measured	O
blood	B-OUT
pressure	I-OUT
,	I-OUT
serum	I-OUT
creatinine	I-OUT
,	I-OUT
eGFR	I-OUT
,	I-OUT
urinary	I-OUT
protein	I-OUT
,	I-OUT
L-FABP	I-OUT
and	I-OUT
ET-1	I-OUT
before	O
the	O
start	O
of	O
treatment	O
and	O
6	O
and	O
12	O
months	O
after	O
the	O
start	O
of	O
treatment	O
.	O


CONCLUSIONS	O
The	O
study	O
results	O
suggest	O
that	O
telmisartan	B-I
results	O
in	O
a	O
greater	O
reduction	O
of	O
urinary	B-OUT
markers	I-OUT
than	O
does	O
enalapril	B-I
and	O
that	O
this	O
effect	O
occurs	O
by	O
a	O
mechanism	O
independent	O
of	O
blood	O
pressure	O
reduction	O
.	O


Acute	O
elevations	O
in	O
intraocular	B-OUT
pressure	I-OUT
(	I-OUT
IOP	I-OUT
)	I-OUT
commonly	O
follow	O
extracapsular	O
cataract	O
extraction	O
and	O
lens	O
implant	O
in	O
glaucoma	B-P
patients	I-P
.	I-P


Acamprosate	B-I
appears	O
to	O
decrease	B-OUT
alcohol	I-OUT
intake	I-OUT
in	O
weaned	B-P
alcoholics	I-P
.	I-P


Untoward	O
effects	O
of	O
fenfluramine	B-I
in	O
autistic	B-P
children	I-P
.	I-P


Medication	O
was	O
administered	O
in	O
a	O
double-blind	O
,	O
placebo-controlled	B-I
cross-over	O
study	O
.	O


Traumatic	B-P
brain	I-P
injury-related	I-P
attention	I-OUT
deficits	I-OUT
:	I-OUT
treatment	O
outcomes	B-OUT
with	O
lisdexamfetamine	B-I
dimesylate	I-I
(	I-I
Vyvanse	I-I
)	I-I
.	I-I


BACKGROUND	O
AND	O
OBJECTIVES	O
Attention	O
deficits	O
are	O
often	O
among	O
the	O
most	O
persistent	O
and	O
debilitating	O
impairments	O
resulting	O
from	O
traumatic	O
brain	O
injury	O
(	O
TBI	O
)	O
.	O


Avenues	O
for	O
further	O
research	O
and	O
treatment	O
applications	O
in	O
this	O
area	O
are	O
discussed	O
.	O


There	O
is	O
experimental	O
evidence	O
to	O
suggest	O
that	O
hypercholesterolaemia	O
may	O
play	O
a	O
pathogenetic	O
role	O
in	O
progressive	B-P
glomerular	I-P
injury	I-P
.	I-P


Patients	O
were	O
randomly	O
assigned	O
in	O
a	O
single-blind	O
fashion	O
to	O
treatment	O
with	O
either	O
lovastatin	B-I
,	I-I
an	I-I
HMG	I-I
CoA	I-I
reductase	I-I
inhibitor	I-I
(	O
n	O
=	O
16	O
;	O
mean	O
dose	O
30.0	O
+/-	O
12.6	O
mg/day	O
)	O
or	O
placebo	B-I
(	O
n	O
=	O
18	O
)	O
for	O
2	O
years	O
.	O


Lp	B-OUT
(	I-OUT
a	I-OUT
)	I-OUT
showed	O
no	B-OUT
significant	I-OUT
change	O
in	O
both	O
groups	O
.	O


Regression	O
analysis	O
identified	O
that	B-P
younger	I-P
subjects	I-P
with	I-P
higher	I-P
baseline	I-P
weight	I-P
z-score	O
were	O
at	O
highest	O
risk	O
for	O
weight	O
gain	O
.	O


We	O
have	O
compared	O
this	O
method	O
with	O
two	O
other	O
methods	O
based	O
on	O
ultrasonic	O
waves	O
to	O
identify	O
the	O
IJV	O
and	O
the	O
carotid	O
artery	O
(	O
CA	O
)	O
(	O
even	O
in	O
atypical	O
positions	O
)	O
.	O


We	O
employed	O
an	B-I
ultrasound	I-I
Doppler	I-I
device	I-I
in	I-I
group	I-I
II	I-I
and	I-I
a	I-I
real-time	I-I
ultrasonograph	I-I
in	I-I
group	I-I
III	I-I
.	I-I


One	O
patient	O
(	O
group	O
I	O
)	O
displayed	O
a	O
hematoma	B-OUT
following	O
inadvertent	O
puncture	O
of	O
the	O
CA	O
.	O


Comparison	O
of	O
the	O
evolutional	B-OUT
process	I-OUT
of	O
children	B-P
with	I-P
autism	I-P
spectrum	I-P
disorders	I-P
in	O
different	O
language	B-I
therapeutic	I-I
interventions	I-I
.	I-I


It	O
was	O
used	O
the	O
Autism	B-OUT
Behavior	I-OUT
Checklist	I-OUT
(	I-OUT
ABC	I-OUT
)	I-OUT
to	I-I
interview	I-I
the	I-I
mothers	I-I
,	I-I
and	I-I
the	I-I
Sample	I-OUT
of	I-OUT
Vocal	I-OUT
Behavior	I-OUT
(	I-OUT
SVB	I-OUT
)	I-OUT
,	I-I
in	I-I
three	I-I
occasions	I-I
:	I-I
at	I-I
the	I-I
beginning	I-I
of	I-I
the	I-I
intervention	I-I
process	I-I
(	I-I
time	I-I
0	I-I
)	I-I
,	I-I
six	I-I
months	I-I
later	I-I
(	I-I
time	I-I
1	I-I
)	I-I
and	I-I
12	I-I
months	I-I
later	I-I
(	I-I
time	I-I
2	I-I
)	I-I
.	I-I


The	O
performance	O
of	O
children	B-P
with	I-P
Asperger	I-P
syndrome	I-P
was	O
considered	O
more	O
positive	O
when	O
compared	O
to	O
that	O
of	O
children	B-P
with	I-P
autism	I-P
.	I-P


BACKGROUND	O
Unstuck	B-I
and	I-I
On	I-I
Target	I-I
(	I-I
UOT	I-I
)	I-I
is	O
an	O
executive	B-I
function	I-I
(	I-I
EF	I-I
)	I-I
intervention	I-I
for	O
children	B-P
with	I-P
autism	I-P
spectrum	I-P
disorders	I-P
(	I-P
ASD	I-P
)	I-P
targeting	O
insistence	O
on	O
sameness	O
,	O
flexibility	O
,	O
goal-setting	O
,	O
and	O
planning	O
through	O
a	O
cognitive-behavioral	O
program	O
of	O
self-regulatory	O
scripts	O
,	O
guided/faded	O
practice	O
,	O
and	O
visual/verbal	O
cueing	O
.	O


Children	O
in	O
both	O
groups	O
improved	O
with	O
intervention	O
,	O
but	O
mean	O
change	O
scores	O
from	O
pre-	O
to	O
postintervention	O
indicated	O
significantly	O
greater	O
improvements	B-I
for	I-I
UOT	I-I
than	I-I
SS	O
groups	B-OUT
in	I-OUT
:	I-OUT
problem-solving	I-OUT
,	I-OUT
flexibility	I-OUT
,	I-OUT
and	I-OUT
planning/organizing	I-OUT
.	O


CONCLUSIONS	O
These	O
data	O
support	O
the	O
effectiveness	O
of	O
the	O
first	O
contextually-based	O
EF	O
intervention	B-P
for	I-P
children	I-P
with	I-I
ASD	I-I
.	O


DESIGN	O
AND	O
METHODS	O
The	O
Migraine-Specific	B-OUT
Questionnaire	I-OUT
(	I-OUT
MSQ	I-OUT
,	O
version	O
2.1	O
)	O
was	O
used	O
to	O
assess	O
the	O
effect	O
of	O
TPM	B-I
100	O
mg/d	O
on	O
the	O
functionality	O
and	O
HRQoL	O
of	O
randomized	O
intent-to-treat	B-P
(	I-P
ITT	I-P
)	I-P
and	I-P
study-completer	I-P
populations	I-P
pooled	O
from	O
three	O
randomized	O
,	O
double-blind	O
,	O
placebo-controlled	O
trials	O
.	O


The	O
HS-60	B-I
and	O
HS-30	B-I
heifers	O
were	O
limited-fed	O
to	O
gain	O
0.9	O
kg/d	O
,	O
and	O
the	O
LS-30	B-I
heifers	O
had	O
ad	O
libitum	O
access	O
to	O
the	O
diet	O
.	O


A	O
comparison	O
of	O
the	O
laryngeal	B-I
tube-S	I-I
and	O
Proseal	B-I
laryngeal	I-I
mask	I-I
during	O
outpatient	B-P
surgical	I-P
procedures	I-P
.	I-P


Airway	B-OUT
seal	I-OUT
pressure	I-OUT
(	O
cm	O
H	O
(	O
2	O
)	O
O	O
)	O
for	O
LTS	O
and	O
PLMA	O
was	O
20	O
+/-	O
8.6	O
and	O
24.1	O
+/-	O
10.8	O
,	O
respectively	O
(	O
P	O
=	O
0.04	O
)	O
.	O


CONCLUSIONS	O
Both	O
devices	O
provide	O
a	O
secure	O
airway	O
,	O
are	O
similar	O
in	O
clinical	O
utility	O
and	O
are	O
easy	O
to	O
insert	O
.	O


A	O
total	O
of	O
88	O
tumors	O
(	O
9.3+/-3.2	O
)	O
(	O
5.0-14.5	O
)	O
cm	O
in	O
diameter	O
were	O
detected	O
,	O
and	O
the	O
largest	O
tumor	O
in	O
a	O
specific	O
patients	B-P
with	I-P
multiple	I-P
lesions	I-P
was	O
selected	O
for	O
observation	O
.	O


The	O
positive	O
predictive	O
and	O
negative	O
predictive	O
values	O
for	O
IAN	B-P
patients	I-P
were	O
77	O
%	O
and	O
60	O
%	O
,	O
respectively	O
.	O


There	O
were	O
statistically	O
significant	O
differences	O
in	O
the	O
distribution	O
of	O
age	O
,	O
duration	O
of	O
injury	O
,	O
cause	O
of	O
injury	O
,	O
presence	O
of	O
neuropathic	O
pain	O
,	O
presence	O
of	O
trigger	O
pain	O
,	O
and	O
degree	O
of	O
injury	O
between	O
the	B-P
IAN	I-P
and	I-P
LN	I-P
patient	I-P
populations	I-P
.	I-P


OBJECTIVE	O
To	O
evaluate	O
the	O
effect	O
of	O
finasteride	B-I
on	O
serum	O
androst-4-ene-3,17-dione	O
(	O
androstenedione	O
)	O
and	O
its	O
association	O
with	O
prostate	O
cancer	O
risk	O
among	O
subjects	B-P
who	I-P
participated	I-P
in	I-P
the	I-P
Prostate	I-P
Cancer	I-P
Prevention	I-P
Trial	I-P
.	I-P


RESULTS	O
We	O
observed	O
a	O
22	O
%	O
increase	O
in	B-OUT
androstenedione	I-OUT
levels	O
compared	O
with	O
the	O
baseline	O
values	O
in	B-P
subjects	I-P
who	I-P
were	I-P
treated	I-P
with	I-OUT
finasteride	I-OUT
for	I-P
3	I-P
years	I-P
.	O


CONCLUSION	O
The	O
results	O
of	O
this	O
nested	O
case-control	O
study	O
confirm	O
that	B-I
finasteride	I-I
blocks	O
the	O
conversion	O
of	O
testosterone	O
to	O
dihydrotestosterone	O
(	O
DHT	O
)	O
and	O
of	O
androstenedione	O
to	O
5α-androstanedione-3,17-dione	O
,	O
which	O
also	O
leads	O
to	O
the	O
reduction	O
of	O
DHT	O
formation	O
.	O


Median	B-OUT
survival	I-OUT
time	I-OUT
to	I-OUT
extubation	I-OUT
was	O
similar	O
between	O
the	O
groups	O
(	O
T	O
67	O
h	O
[	O
95	O
%	O
CI	O
51	O
,	O
84	O
]	O
vs	O
P	O
52	O
h	O
[	O
95	O
%	O
CI	O
43	O
,	O
65	O
]	O
;	O
P	O
=	O
0.4	O
)	O
,	O
and	O
similar	O
numbers	O
were	O
extubated	O
by	O
96	O
h	O
(	O
T	O
69	O
%	O
vs	O
P	O
77	O
%	O
;	O
difference	O
-8	O
%	O
,	O
95	O
%	O
CI	O
-28	O
,	O
13	O
%	O
)	O
.	O


Morphine	O
and	O
midazolam	O
exposure	O
was	O
similar	O
,	O
with	B-OUT
low	I-OUT
pain	I-OUT
scores	I-OUT
in	O
both	O
groups	O
(	O
mean	O
percentage	O
of	O
time	O
with	B-OUT
a	I-OUT
pain	I-OUT
score	I-OUT
>	O
5/20	O
during	O
the	O
5	O
days	O
:	O
T	O
13	O
%	O
vs	O
P	O
11	O
%	O
,	O
difference	O
in	O
means	O
2.8	O
[	O
95	O
%	O
CI	O
-1.8	O
,	O
7.6	O
]	O
,	O
P	O
=	O
0.20	O
)	O
.	O


RESULTS	O
Six	B-P
hundred	I-P
eighty-eight	I-P
patients	I-P
were	I-P
enrolled	I-P
.	I-P


Neutropenia	B-OUT
and	I-OUT
thrombocytopenia	I-OUT
grade	I-OUT
>	I-OUT
or	I-OUT
=	I-OUT
3	I-OUT
were	O
observed	O
in	O
40	O
%	O
and	O
15	O
%	O
in	O
the	O
experimental	O
arm	O
versus	O
30	O
%	O
and	O
12	O
%	O
in	O
the	O
control	O
arm	O
.	O


A	O
cognitive-behavioral	B-I
intervention	I-I
for	O
emotion	O
regulation	O
in	O
adults	B-P
with	I-P
high-functioning	I-P
autism	I-P
spectrum	I-P
disorders	I-P
:	I-P
study	O
protocol	O
for	O
a	O
randomized	O
controlled	O
trial	O
.	O


Some	O
studies	O
have	O
reported	O
the	O
efficacy	O
of	O
cognitive-behavioral	B-I
therapy	I-I
(	I-I
CBT	I-I
)	I-I
in	O
improving	O
emotion-regulation	O
among	O
children	B-P
with	I-P
ASD	I-P
.	I-P


The	B-P
participants	I-P
will	I-P
be	I-P
60	I-P
adults	I-P
with	I-P
ASD	I-P
;	I-P
30	I-P
will	I-P
be	I-P
assigned	I-P
to	I-P
a	I-P
CBT	I-I
group	I-P
and	I-P
30	I-P
to	I-P
a	I-P
waitlist	I-I
control	I-I
group	I-I
.	I-I


All	O
will	O
be	O
administered	O
during	O
the	O
pre-	O
and	O
post-intervention	O
,	O
and	O
12	O
week	O
follow-up	O
periods	O
.	O


The	O
CBT	O
group	O
will	O
receive	O
group	O
therapy	O
over	O
an	O
8	O
week	O
period	O
(	O
one	O
session	O
per	O
week	O
)	O
with	O
each	O
session	O
lasting	O
approximately	O
100	O
minutes	O
.	O


Group	O
therapy	O
will	O
consist	O
of	O
four	O
or	O
five	O
adults	O
with	O
ASD	O
and	O
two	O
psychologists	O
.	O


LDL	O
,	O
isolated	O
before	O
and	O
after	O
treatment	O
was	O
subjected	O
to	O
copper-catalysed	O
lipid	O
peroxidation	O
.	O


AIMS	O
To	O
verify	O
the	O
preliminary	O
results	O
with	O
EPI-NO	B-I
in	O
a	O
prospective	O
randomised	O
trial	O
.	O


We	O
found	O
no	O
significant	O
differences	O
between	O
the	O
two	B-P
groups	I-P
regarding	O
incidence	B-OUT
of	I-OUT
perineal	I-OUT
tears	I-OUT
,	I-OUT
duration	I-OUT
of	I-OUT
second	I-OUT
stage	I-OUT
of	I-OUT
labour	I-OUT
,	I-OUT
use	I-OUT
of	I-OUT
pain	I-OUT
relief	I-OUT
and	I-OUT
rate	I-OUT
of	I-OUT
vaginal	I-OUT
infection	I-OUT
.	I-OUT


Induction	B-OUT
deaths	I-OUT
were	O
comparable	O
at	O
9	O
%	O
(	O
ALL-2	O
)	O
versus	O
7	O
%	O
(	O
L-20	O
)	O
.	O


We	O
used	O
fixed	O
effects	O
models	O
to	O
evaluate	O
associations	O
with	O
measures	O
of	O
temperature	O
that	O
were	O
adjusted	O
for	O
time-varying	O
covariates	O
.	O


Papular	B-P
urticaria	I-P
(	I-P
PU	I-P
)	I-P
is	O
among	O
the	O
commonest	O
skin	O
ailments	O
in	O
children	O
.	O


The	O
predischarge	O
angiogram	O
showed	O
the	O
presence	B-OUT
of	I-OUT
TIMI	I-OUT
3	I-OUT
flow	I-OUT
in	O
96	O
%	O
of	O
patients	O
who	O
received	O
PCI	O
and	O
65	O
%	O
of	O
patients	O
who	O
received	O
SK	O
(	O
P	O
<	O
.001	O
)	O
.	O


A	O
composite	O
of	O
in-hospital	B-OUT
death	I-OUT
,	I-OUT
reinfarction	I-OUT
,	I-OUT
severe	I-OUT
heart	I-OUT
failure	I-OUT
,	I-OUT
stroke	I-OUT
,	I-OUT
and	I-OUT
major	I-OUT
bleeding	I-OUT
occurred	O
in	O
15	O
%	O
of	O
patients	O
who	O
received	O
PCI	O
and	O
21	O
%	O
of	O
patients	O
who	O
received	O
SK	O
(	O
P	O
=.4	O
)	O
.	O


The	O
study	O
was	O
performed	O
by	O
collaboration	O
with	O
The	O
National	O
Institute	O
of	O
Research	O
and	O
Development	O
in	O
Pathology	O
and	O
Biomedical	O
Sciences-	O
"	O
V.	O
Babes	O
"	O
-Bucharest	O
.	O


RESEARCH	O
DESIGN	O
AND	O
METHODS	O
We	O
compared	O
the	O
cost-benefits	B-OUT
of	O
the	O
two	O
methods	O
using	O
a	O
randomized	O
,	O
prospective	O
,	O
6-month	O
,	O
crossover	O
design	O
in	O
10	B-P
adult	I-P
type	I-P
I	I-P
diabetic	I-P
patients	I-P
.	I-P


RESULTS	O
When	O
judged	O
on	O
the	O
last	O
month	O
of	O
IP	O
versus	O
SC	O
periods	O
in	O
the	O
nine	O
patients	O
who	O
completed	O
the	O
study	O
,	O
metabolic	B-OUT
data	I-OUT
showed	O
better	O
glycemic	B-OUT
control	I-OUT
(	O
HbA1c	O
:	O
7.2	O
+/-	O
0.2	O
IP	O
vs.	O
8.5	O
+/-	O
0.7	O
%	O
SC	O
,	O
mean	O
+/-	O
SE	O
,	O
P	O
=	O
0.02	O
)	O
,	O
reduced	B-OUT
glycemic	I-OUT
fluctuations	I-OUT
(	O
SD	O
of	O
capillary	O
glucose	O
values	O
:	O
3.4	O
+/-	O
0.2	O
IP	O
vs.	O
4.6	O
+/-	O
0.2	O
mM	O
SC	O
,	O
P	O
<	O
0.01	O
)	O
,	O
and	O
fewer	O
mild	B-OUT
hypoglycemic	I-OUT
events	I-OUT
(	O
5.7	O
+/-	O
2.0	O
IP	O
vs.	O
10.0	O
+/-	O
3.1	O
events/month	O
SC	O
,	O
P	O
=	O
0.02	O
)	O
.	O


In	O
addition	O
,	O
longer-term	O
,	O
larger-scale	O
,	O
and	O
comparative	O
evaluation	O
is	O
required	O
.	O


Long-term	O
follow-up	O
of	O
the	O
Stockholm	O
randomized	O
trials	O
of	O
postoperative	B-I
radiation	I-I
therapy	I-I
versus	I-I
adjuvant	I-I
chemotherapy	I-I
among	O
'high	B-P
risk	I-P
'	I-P
pre-	I-P
and	I-P
postmenopausal	I-P
breast	I-P
cancer	I-P
patients	I-P
.	I-P


RESULTS	O
The	B-P
Pa	I-P
group	I-P
(	I-P
n	I-P
=	I-P
101	I-P
)	I-P
had	I-P
a	I-P
clearly	I-P
lower	I-OUT
incidence	I-OUT
of	I-OUT
both	I-OUT
local	I-OUT
and	I-OUT
systemic	I-OUT
adverse	I-OUT
events	I-OUT
than	I-P
the	I-P
Pw	I-P
group	I-P
(	I-P
n	I-P
=	I-P
100	I-P
)	I-P
.	I-P


CONCLUSION	O
The	O
presently	O
studied	O
diphtheria	O
,	O
tetanus	O
,	O
acellular	O
pertussis-H.	O
influenzae	O
b	O
vaccine	O
conjugated	O
to	O
tetanus	B-I
toxoid	I-I
combination	I-I
was	O
at	O
least	O
as	O
immunogenic	O
as	O
the	O
diphtheria	B-I
,	I-I
tetanus	I-I
,	I-I
whole	I-I
cell	I-I
pertussis-H.	I-I
influenzae	I-I
b	I-I
vaccine	I-I
conjugated	I-I
to	I-I
tetanus	I-I
toxoid	I-I
combination	I-I
,	O
with	O
a	O
significantly	O
better	O
safety	O
profile	O
.	O


[	B-I
Intra-arterial	I-I
(	I-I
5-FU/FA	I-I
and	I-I
FUDR	I-I
)	I-I
versus	I-I
systemic	I-I
chemotherapy	I-I
(	I-I
5-FU/FA	I-I
)	I-I
of	O
non-resectable	B-OUT
colorectal	I-OUT
liver	I-OUT
metastases	I-OUT
]	I-OUT
.	O


5-FU/FA	B-I
chemotherapy	I-I
for	O
the	O
treatment	O
of	O
unresectable	B-P
colorectal	I-P
liver	I-P
metastases	I-P
was	O
compared	O
in	O
a	O
prospective	O
randomized	O
clinical	O
trial	O
.	O


The	O
response	B-OUT
rate	I-OUT
after	O
HAI	B-I
treatment	O
was	O
significantly	O
higher	O
as	O
compared	O
to	O
i.v	O
.	O


Mean	O
weight	B-OUT
gain	I-OUT
was	O
2.0	O
kg	O
on	O
aripiprazole	O
and	O
0.8	O
kg	O
on	O
placebo	O
at	O
week	O
8	O
.	O


The	O
Overlay	O
Ref	O
technique	O
may	O
facilitate	O
the	O
procedure	O
for	O
implanting	O
left	O
ventricular	O
(	O
LV	O
)	O
pacing	O
leads	O
to	O
deliver	O
CRT	B-I
.	I-I


Mean	B-OUT
total	I-OUT
fluoroscopy	I-OUT
times	I-OUT
were	I-I
:	I-I
Overlay	I-I
Ref	O
group	O
,	O
13.6	O
±	O
4.3	O
min	O
;	O
control	O
group	O
,	O
23.8	O
±	O
15.7	O
min	O
;	O
p=0.007	O
.	B-OUT


CONCLUSION	O
These	O
results	O
indicate	O
that	O
higher	O
plasma	O
FGF23	O
levels	O
are	O
associated	O
with	O
lower	O
BMI	O
and	O
dyslipidemia	B-I
in	I-I
dialysis	I-I
patients	I-P
.	O


The	O
secondary	O
outcomes	O
are	O
an	O
additional	O
measure	B-OUT
of	I-OUT
pain	I-OUT
relief	I-OUT
,	I-OUT
maternal	I-OUT
sedation	I-OUT
,	I-OUT
nausea	I-OUT
and	I-OUT
vomiting	I-OUT
,	I-OUT
maternal	I-OUT
oxygen	I-OUT
saturation	I-OUT
,	I-OUT
satisfaction	I-OUT
with	I-OUT
analgesia	I-OUT
,	I-OUT
whether	I-OUT
method	I-OUT
of	I-OUT
analgesia	I-OUT
would	I-OUT
be	I-OUT
used	I-OUT
again	I-OUT
,	I-OUT
use	I-OUT
of	I-OUT
Entonox	I-OUT
,	I-OUT
umbilical	I-OUT
arterial	I-OUT
and	I-OUT
venous	I-OUT
pH	I-OUT
,	I-OUT
fetal	I-OUT
heart	I-OUT
rate	I-OUT
,	I-OUT
meconium	I-OUT
staining	I-OUT
,	I-OUT
time	I-OUT
from	I-OUT
delivery	I-OUT
to	I-OUT
first	I-OUT
breath	I-OUT
,	I-OUT
Apgar	I-OUT
scores	I-OUT
at	I-OUT
5	I-OUT
mins	I-OUT
,	I-OUT
naloxone	I-OUT
requirement	I-OUT
,	I-OUT
transfer	I-OUT
to	I-OUT
neonatal	I-OUT
intensive	I-OUT
care	I-OUT
unit	I-OUT
,	I-OUT
neonatal	I-OUT
haemoglobin	I-OUT
oxygen	I-OUT
saturation	I-OUT
at	I-OUT
30	I-OUT
,	I-OUT
60	I-OUT
,	I-OUT
90	I-OUT
,	I-OUT
and	I-OUT
120	I-OUT
mins	I-OUT
after	I-OUT
delivery	I-OUT
,	I-OUT
and	I-OUT
neonatal	I-OUT
sedation	I-OUT
and	I-OUT
feeding	I-OUT
behaviour	I-OUT
during	I-OUT
first	I-OUT
2	I-OUT
hours	I-OUT
.	I-OUT


DISCUSSION	O
If	O
the	O
trial	O
demonstrates	O
that	O
diamorphine	B-I
provides	O
better	O
analgesia	O
with	O
fewer	O
side	O
effects	O
in	O
mother	B-P
and	I-P
neonate	I-P
this	O
could	O
lead	O
to	O
a	O
change	O
in	O
national	O
practice	O
and	O
result	O
in	O
diamorphine	B-I
becoming	O
the	O
preferred	O
intramuscular	O
opioid	B-I
for	O
analgesia	O
in	O
labour	O
.	O


Aloe	B-I
vera	I-I
gel	I-I
and	O
cesarean	B-OUT
wound	I-OUT
healing	I-OUT
;	I-OUT
a	O
randomized	O
controlled	O
clinical	O
trial	O
.	O


Also	O
,	O
a	O
significant	O
difference	O
was	O
observed	O
between	O
the	O
two	O
groups	O
with	O
respect	O
to	O
the	B-OUT
wound	I-OUT
healing	I-OUT
score	I-OUT
24	I-OUT
hours	I-OUT
after	I-OUT
the	I-OUT
operation	I-OUT
(	O
P=0.003	O
)	O
.	O


[	B-I
Mitoxantrone	I-I
(	I-I
MTX	I-I
)	I-I
versus	I-I
mitomycin	I-I
C	I-I
(	I-I
MMC	I-I
)	I-I
in	O
the	O
ablative	O
treatment	O
of	B-P
Ta	I-P
,	I-P
T1	I-P
superficial	I-P
bladder	I-P
tumors	I-P
.	I-P


We	O
can	O
conclude	O
from	O
the	O
results	O
of	O
the	O
present	O
study	O
that	O
Mitoxantrone	B-I
is	O
a	O
useful	O
agent	O
for	O
ablation	O
therapy	O
of	O
superficial	B-P
bladder	I-P
tumors	I-P
,	O
although	O
the	O
high	O
incidence	O
of	O
severe	O
side	B-OUT
effects	I-OUT
warrants	O
its	O
limited	O
use	O
and	O
at	O
high	O
dilutions	O
.	O


The	O
efficacy	B-OUT
and	I-OUT
safety	I-OUT
of	O
simultaneous	O
transurethral	B-I
GreenLight	I-I
photoselective	I-I
vaporization	I-I
of	O
bladder	O
tumor	O
and	O
prostate	O
in	O
patients	B-P
with	I-P
bladder	I-P
tumor	I-P
and	I-P
lower	I-P
urinary	I-P
tract	I-P
symptoms	I-P
.	I-P


The	O
rates	B-OUT
of	I-OUT
recurrence	I-OUT
,	I-OUT
progression	I-OUT
and	I-OUT
tumor	I-OUT
recurrence	I-OUT
of	I-OUT
bladder	I-OUT
neck/prostatic	I-OUT
fossa	I-OUT
were	O
16.0	O
,	O
4.0	O
and	O
4.0	O
%	O
in	O
the	O
simultaneous	O
resection	O
group	O
,	O
and	O
18.9	O
,	O
5.4	O
and	O
8.1	O
%	O
in	O
the	O
group	O
PVBT	O
,	O
respectively	O
.	O


PVBT/PVP	B-I
can	O
be	O
performed	O
effectively	O
and	O
safely	O
in	O
patients	B-P
with	I-P
bladder	I-P
tumor	I-P
and	I-P
BPH	I-P
.	I-P


PURPOSE	O
This	O
study	O
was	O
designed	O
to	O
evaluate	O
the	O
clinical	O
role	O
of	O
rHuEPO	O
in	O
reducing	O
symptomatic	B-OUT
anemia	I-OUT
in	O
patients	B-P
with	I-P
advanced	I-P
cancer	I-P
who	I-P
were	I-P
receiving	I-P
myelosuppressive	I-P
chemotherapy	I-P
(	I-P
excluding	I-P
cisplatin	I-P
)	I-P
.	I-P


for	B-I
30	I-I
min	I-I
,	I-I
once	I-I
every	I-I
other	I-I
day	I-I
,	I-I
and	I-I
those	I-I
of	I-I
medication	I-I
group	I-I
were	I-I
treated	I-I
with	I-I
oral	I-I
administration	I-I
of	I-I
hydroxyl-chloroquine	I-I
(	I-I
6	I-I
mg/kg	I-I
per	I-I
day	I-I
)	I-I
,	I-I
oral	I-I
transfer	I-I
agent	I-I
liquid	I-I
,	I-I
Vit	I-I
B1	I-I
,	I-I
Vit	I-I
B2	I-I
,	I-I
Vit	I-I
C	I-I
,	I-I
fish-liver	I-I
oil	I-I
,	I-I
one	I-I
tablet/time	I-I
,	I-I
t.i.d.	I-I
,	O
and	B-I
pilocarpine	I-I
(	I-I
20	I-I
mg/d	I-I
)	I-I
,	I-I
continuously	I-I
for	I-I
2	I-I
months	I-I
.	O


The	O
other	O
intervention	O
group	O
were	O
also	O
given	O
a	O
health	B-I
check	I-I
and	I-I
written	I-I
feedback	I-I
;	I-I
in	I-I
addition	I-I
,	I-I
they	I-I
were	I-I
given	I-I
the	I-I
opportunity	I-I
to	I-I
attend	I-I
their	I-I
general	I-I
practitioner	I-I
to	I-I
discuss	I-I
preventive	I-I
health	I-I
.	I-I


CONCLUSION	O
There	O
was	O
considerable	O
interest	O
in	O
participating	O
in	O
health	O
promotion	O
.	O


Long-term	O
follow	O
up	O
is	O
needed	O
to	O
determine	O
effects	O
and	O
side	O
effects	O
of	O
health	B-I
checks	I-I
and	O
health	O
talks	O
.	O


Analgesia	B-OUT
lasted	O
longer	O
in	O
the	O
bupivacaine-clonidine	B-I
group	O
(	O
139.4	O
+/-	O
31	O
min	O
)	O
compared	O
with	O
the	O
bupivacaine-fentanyl	B-I
group	O
(	O
127.9	O
+/-	O
48	O
min	O
)	O
(	O
P	O
=	O
0.42	O
)	O
.	O


CROP	B-I
(	I-I
cytosine	I-I
arabinoside	I-I
,	I-I
daunorubicin	I-I
,	I-I
vincristine	I-I
,	I-I
prednisolone	I-I
)	I-I
produced	O
CR	O
in	O
41	O
%	O
of	O
patients	O
,	O
7	O
and	O
3	O
(	B-I
cytosine	I-I
arabinoside	I-I
,	I-I
daunorubicin	I-I
)	I-I
in	O
42	O
%	O
and	O
7	O
and	O
3	O
plus	B-I
hydroxyurea	I-I
in	O
52	O
%	O
.	O


Measurement	O
of	O
repeatability	O
and	O
plaque	O
removal	O
.	O


Topical	B-I
fibronectin	I-I
therapy	I-I
for	O
treatment	O
of	O
a	O
patient	B-P
with	I-P
chronic	I-OUT
stasis	I-OUT
ulcers	I-OUT
.	I-OUT


During	O
post-operative	O
adjuvant	O
therapy	O
,	O
4/48	O
(	O
8	O
%	O
)	O
anastrozole	B-I
and	O
25/49	O
(	O
51	O
%	O
)	O
tamoxifen	B-I
patients	O
experienced	O
recurrence	B-OUT
.	I-OUT


There	O
was	O
a	O
significant	O
increase	O
in	O
overall	B-OUT
survival	I-OUT
with	O
anastrozole	B-I
(	O
0.21	O
;	O
0.05-0.96	O
;	O
P	O
=	O
0.0436	O
)	O
and	O
there	O
were	O
2/48	O
(	O
4	O
%	O
)	O
and	O
10/49	O
(	O
20	O
%	O
)	O
deaths	B-OUT
with	O
anastrozole	B-I
and	I-I
tamoxifen	I-I
,	O
respectively	O
.	O


Over	O
the	O
5.4	O
years	O
of	O
median	O
follow-up	O
,	O
simvastatin	O
produced	O
changes	O
in	O
total	B-OUT
cholesterol	I-OUT
,	I-OUT
low	I-OUT
density	I-OUT
lipoprotein	I-OUT
(	I-OUT
LDL	I-OUT
)	I-OUT
cholesterol	I-OUT
,	O
and	O
high	B-OUT
density	I-OUT
lipoprotein	I-OUT
(	I-OUT
HDL	I-OUT
)	I-OUT
cholesterol	I-OUT
of	O
-25	O
%	O
,	O
-35	O
%	O
,	O
and	O
+8	O
%	O
,	O
respectively	O
,	O
with	O
minimal	O
adverse	B-OUT
effects	I-OUT
.	I-OUT


The	O
lungs	O
were	O
ventilated	O
to	O
normocapnia	O
.	O


The	O
first	O
flow	O
measurements	O
were	O
performed	O
approximately	O
1	O
h	O
after	O
induction	O
of	O
anaesthesia	O
.	O


Serum	B-OUT
hemoglobin	I-OUT
was	O
measured	O
before	O
and	O
after	O
surgery	O
,	O
and	O
the	O
following	O
day	O
.	O


resected	O
prostate	O
was	O
calculated	O
(	O
2.65	O
versus	O
4.65	O
gm	O
.	O


Treatment	O
with	O
enalapril	O
significantly	O
reduced	O
plasma	B-OUT
angiotensin	I-OUT
II	I-OUT
levels	I-OUT
and	I-OUT
supine	I-OUT
blood	I-OUT
pressure	I-OUT
compared	O
with	O
placebo	O
.	O


The	O
2	B-P
treatment	I-P
groups	I-P
were	O
well	O
matched	O
.	O


Anthropometric	O
indices	O
of	O
Gambian	B-P
children	I-P
after	O
one	O
or	O
three	O
annual	O
rounds	O
of	O
mass	B-I
drug	I-I
administration	I-I
with	O
azithromycin	B-I
for	O
trachoma	B-P
control	O
.	O


BACKGROUND	O
Mass	O
drug	O
administration	O
(	O
MDA	O
)	O
with	O
azithromycin	B-I
,	O
carried	O
out	O
for	O
the	O
control	O
of	O
blinding	O
trachoma	O
,	O
has	O
been	O
linked	O
to	O
reduced	O
mortality	O
in	O
children	B-P
.	I-P


RESULTS	O
No	O
significant	B-OUT
differences	I-OUT
in	O
mean	B-OUT
height-for-age	I-OUT
,	I-OUT
weight-for-age	I-OUT
or	I-OUT
weight-for-height	I-OUT
z	I-OUT
scores	I-OUT
were	O
found	O
between	O
the	O
annual	O
MDA	O
and	O
single	O
MDA	O
arms	O
,	O
nor	O
was	O
there	O
a	O
significant	B-OUT
reduction	I-OUT
in	O
prevalence	B-OUT
of	I-OUT
stunting	I-OUT
,	I-OUT
wasting	I-OUT
or	I-OUT
underweight	I-OUT
between	O
arms	O
.	O


PURPOSE	O
To	O
verify	O
the	O
efficacy	O
to	O
obtain	O
mydriasis	O
and	O
cardiovascular	O
safety	O
of	O
Mydriasert	B-I
(	I-I
ophthalmic	I-I
insert	I-I
containing	I-I
tropicamide	I-I
and	I-I
phenylephrine	I-I
)	I-I
in	O
diabetic	B-P
and	I-P
nondiabetic	I-P
patients	I-P
undergoing	I-P
retinal	I-P
angiography	I-P
by	I-P
comparing	I-P
it	I-P
with	I-P
usually	I-P
administered	I-P
eyedrops	I-P
(	I-I
tropicamide	I-I
1	I-I
%	I-I
and	I-I
phenylephrine	I-I
10	I-I
%	I-I
)	I-I
.	O


There	O
was	O
no	O
significant	O
between-group	O
difference	O
in	O
mean	B-OUT
heart	I-OUT
rate	I-OUT
or	I-OUT
systolic	I-OUT
and	I-OUT
diastolic	I-OUT
blood	I-OUT
pressure	I-OUT
at	O
any	O
of	O
the	O
time	O
points	O
.	O


Infants	O
also	O
received	O
a	O
prebiotic	B-I
galacto-oligosaccharide	I-I
or	I-I
placebo	I-I
.	I-I


RESULTS	O
Of	B-P
the	I-P
1018	I-P
intent-to-treat	I-P
infants	I-P
,	I-P
891	I-P
(	I-P
88	I-P
%	I-P
)	I-P
attended	I-P
the	I-P
5-year	I-P
visit	I-P
.	I-P


Sodium	O
removal	O
estimated	O
from	O
pre-	O
and	O
postplasma	O
concentrations	O
correlated	O
well	O
with	O
removal	O
measured	O
by	O
conductivity	O
monitoring	O
as	O
ionic	B-OUT
mass	I-OUT
balance	I-OUT
(	O
R2	O
0.66	O
,	O
p	O
<	O
0.0001	O
)	O
.	O


Here	O
we	O
report	O
effects	O
of	O
endocrine	B-I
treatment	I-I
withdrawal	O
on	O
BMD	O
,	O
bone	O
turnover	O
markers	O
(	O
BTM	O
)	O
and	O
fracture	O
rates	O
.	O


Following	O
treatment	O
withdrawal	O
,	O
the	O
differences	O
in	O
BMD	O
observed	O
between	O
the	O
two	O
endocrine	O
strategies	O
were	O
partially	O
reversed	O
.	O


A	O
similar	O
pattern	O
of	O
changes	O
was	O
observed	O
at	O
the	O
hip	O
.	O


Corresponding	O
inverse	B-OUT
changes	I-OUT
in	I-OUT
BTM	I-OUT
were	O
seen	O
,	O
with	O
an	O
increase	O
following	O
tamoxifen	O
withdrawal	O
and	O
a	O
reduction	O
after	O
exemestane	O
.	O


A	O
higher	O
number	B-OUT
of	I-OUT
fractures	I-OUT
occurred	I-OUT
during	O
exemestane	B-I
treatment	O
,	O
but	O
fracture	B-OUT
rates	I-OUT
were	O
similar	O
after	O
treatment	O
withdrawal	O
.	O


Ongoing	O
monitoring	O
of	O
BMD	O
is	O
therefore	O
not	O
routinely	O
required	O
.	O


The	O
levels	B-OUT
of	I-OUT
P-selectin	I-OUT
,	I-OUT
tPA	I-OUT
antigen	I-OUT
,	I-OUT
and	I-OUT
PAI-1	I-OUT
activity	I-OUT
were	O
all	O
significantly	B-OUT
higher	I-OUT
in	O
stroke	O
patients	O
compared	O
with	O
controls	O
(	O
all	O
p	O
<	O
0.0001	O
)	O
;	O
the	O
level	B-OUT
of	I-OUT
tPA	I-OUT
activity	I-OUT
was	O
significantly	O
lower	O
in	O
patients	O
than	O
that	O
in	O
controls	O
(	O
p	O
<	O
0.0001	O
)	O
.	O


Neither	O
hyperamylasemia	B-OUT
nor	I-OUT
pancreatitis	I-OUT
was	O
preventable	O
when	O
glucagon	B-I
was	O
used	O
.	O


Esophageal	B-P
variceal	I-P
hemorrhage	I-P
(	I-P
EVH	I-P
)	I-P
is	O
a	O
serious	O
and	O
expensive	O
sequela	O
of	O
chronic	O
liver	O
disease	O
,	O
leading	O
to	O
increased	O
utilization	O
of	O
resources	O
.	O


EL	O
and	O
ES	O
had	O
similar	O
cost/variceal	B-OUT
rebleeding	I-OUT
prevented	O
(	O
$	O
28,678	O
vs.	O
$	O
29,093	O
)	O
and	O
cost/survival	B-OUT
(	O
$	O
27,313	O
vs.	O
$	O
23,804	O
)	O
.	O


The	O
total	B-OUT
length	I-OUT
of	I-OUT
hospital	I-OUT
stay	I-OUT
,	I-OUT
time	I-OUT
to	I-OUT
ambulation	I-OUT
,	I-OUT
and	I-OUT
time	I-OUT
to	I-OUT
oral	I-OUT
nutrition	I-OUT
were	O
recorded	O
.	O


Methods	O
Patients	B-P
randomized	O
to	O
a	O
single	O
IV	O
infusion	O
of	O
zoledronic	B-I
acid	I-I
5	O
mg	O
or	O
risedronate	B-I
(	O
5	O
mg/day	O
)	O
and	O
stratified	O
based	O
on	O
glucocorticoids	B-I
duration	O
[	O
treatment	O
(	O
>	O
3	O
months	O
)	O
and	O
prevention	O
(	O
≤	O
3	O
months	O
)	O
subpopulations	B-P
]	I-P
were	I-P
subgrouped	I-P
by	I-P
age	I-P
;	I-P
gender	I-P
;	I-P
menopausal	I-P
status	I-P
in	I-P
women	I-P
;	I-P
dose	I-P
and	I-P
duration	I-P
of	I-I
prednisone	I-I
during	I-P
the	I-P
trial	I-P
;	I-P
and	I-P
baseline	I-P
serum	I-P
25-OH	I-P
vitamin	I-P
D	I-P
,	I-P
LS	I-P
BMD	I-P
T-score	I-P
,	I-P
creatinine	I-P
clearance	I-P
,	I-P
and	I-P
concomitant	I-P
medication	I-P
use	I-P
.	O


Comparison	O
of	O
antihypertensives	B-OUT
after	O
coronary	B-P
artery	I-P
surgery	I-P
.	I-P


These	O
results	O
suggest	O
that	O
the	O
hemodynamic	B-OUT
effects	I-OUT
of	O
the	O
3	O
drugs	O
are	O
similar	O
within	O
the	O
first	O
30	O
min	O
.	O


The	O
pharmacokinetics	B-OUT
of	O
perindopril	B-I
and	O
its	O
active	O
metabolite	O
perindoprilat	O
and	O
the	O
time	B-OUT
course	I-OUT
of	I-OUT
angiotensin	I-OUT
converting	I-OUT
enzyme	I-OUT
inhibition	I-OUT
were	O
studied	O
for	O
72	O
h	O
following	O
the	O
last	O
dose	O
of	O
treatment	O
in	O
the	O
two	B-P
appropriate	I-P
groups	I-P
.	I-P


Enrolled	O
patients	O
received	O
trimethoprim-sulfamethoxazole	B-I
(	O
n	O
=	O
85	O
)	O
or	O
ciprofloxacin	B-I
(	O
n	O
=	O
85	O
)	O
for	O
10	O
days	O
.	O


Combined	O
hospital	B-OUT
death	I-OUT
and	I-OUT
additional	I-OUT
antibiotic	I-OUT
prescription	I-OUT
rates	I-OUT
were	O
similar	O
in	O
the	O
2	O
groups	O
(	O
16.4	O
%	O
vs	O
15.3	O
%	O
for	O
trimethoprim-sulfamethoxazole	O
group	O
vs	O
ciprofloxacin	O
group	O
;	O
difference	O
,	O
1.1	O
%	O
;	O
95	O
%	O
confidence	O
interval	O
[	O
CI	O
]	O
-9.8	O
%	O
to	O
12.0	O
%	O
;	O
P	O
=	O
.832	O
)	O
.	O


The	O
need	B-OUT
for	I-OUT
an	I-OUT
additional	I-OUT
antibiotic	I-OUT
course	I-OUT
was	O
observed	O
in	O
8	O
patients	O
in	O
the	O
trimethoprim-sulfamethoxazole	B-I
group	O
and	O
5	O
patients	O
in	O
the	O
ciprofloxacin	O
group	O
(	O
difference	O
,	O
2.3	O
%	O
;	O
95	O
%	O
CI	O
,	O
-5.4	O
to	O
10.0	O
;	O
P	O
=	O
.549	O
)	O
.	O


Platelet	O
function	O
was	O
measured	O
in	O
20	B-P
healthy	I-P
men	I-P
during	O
11	O
days	O
of	O
aspirin	B-I
or	I-I
clopidogrel	I-I
intake	O
,	O
using	O
light	O
transmission	O
aggregometry	O
(	O
LTA	O
)	O
and	O
the	O
Platelet	O
Function	O
Analyzer	O
100	O
(	O
PFA-100	O
)	O
.	O


Clopidogrel	B-OUT
intake	I-OUT
was	O
best	O
shown	O
by	O
ADP	O
induced	O
aggregation	O
.	O


The	O
results	O
of	O
our	O
pilot	O
study	O
suggested	O
that	O
a	O
dose	O
of	O
5000	O
IU	O
administered	O
intramuscularly	O
three	O
times	O
per	O
week	O
for	O
four	O
weeks	O
was	O
more	O
effective	O
than	O
the	O
lower	O
doses	O
given	O
in	O
past	O
trials	O
.	O


The	O
primary	O
outcome	O
-	O
death	B-OUT
or	I-OUT
chronic	I-OUT
lung	I-OUT
disease	I-OUT
at	O
36	O
weeks	O
'	O
postmenstrual	O
age	O
-	O
occurred	O
in	O
significantly	O
fewer	O
infants	O
in	O
the	O
vitamin	O
A	O
group	O
than	O
in	O
the	O
control	O
group	O
(	O
55	O
percent	O
vs.	O
62	O
percent	O
;	O
relative	O
risk	O
,	O
0.89	O
;	O
95	O
percent	O
confidence	O
interval	O
,	O
0.80	O
to	O
0.99	O
)	O
.	O


The	O
proportion	B-OUT
of	I-OUT
infants	I-OUT
with	I-OUT
serum	I-OUT
retinol	I-OUT
values	I-OUT
below	O
20	O
microg	O
per	O
deciliter	O
(	O
0.70	O
micromol	O
per	O
liter	O
)	O
was	O
lower	O
in	O
the	O
vitamin	O
A	O
group	O
than	O
in	O
the	O
control	O
group	O
(	O
25	O
percent	O
vs.	O
54	O
percent	O
,	O
P	O
<	O
0.001	O
)	O
.	O


(	O
ABSTRACT	O
TRUNCATED	O
AT	O
250	O
WORDS	O
)	O


TRIAL	O
REGISTRY	O
Japan	O
Primary	O
Registries	O
Network	O
;	O
No	O
.	O


Covariance	B-I
analysis	I-I
in	I-P
generalized	I-P
linear	I-P
measurement	I-P
error	I-P
models	I-P
.	I-P


In	O
randomized	O
studies	O
,	O
simple	O
techniques	O
exist	O
for	O
testing	O
for	O
a	O
treatment	O
effect	O
.	O


A	O
randomized	O
study	O
comparing	O
levofloxacin	B-I
,	I-I
omeprazole	I-I
,	I-I
nitazoxanide	I-I
,	O
and	O
doxycycline	B-I
versus	O
triple	B-I
therapy	I-I
for	O
the	O
eradication	O
of	O
Helicobacter	B-OUT
pylori	I-OUT
.	I-OUT


perviridis	B-I
:	I-I
B.	I-I
rapa	I-I
)	I-I
with	O
the	O
aim	O
to	O
investigate	O
the	O
effects	O
of	O
this	O
juice	O
mixture	O
on	O
anthropometric	B-OUT
data	I-OUT
,	I-OUT
blood	I-OUT
parameters	I-OUT
,	O
and	O
dietary	O
intake	O
differences	O
.	O


Twenty-two	B-P
maturity-onset	I-P
type	I-P
diabetics	I-P
treated	I-P
with	I-P
oral	I-I
hypoglycaemic	I-I
agents	I-I
entered	O
a	O
single-blind	O
crossover	O
study	O
using	O
placebo	B-I
(	O
periods	O
A	O
and	O
C	O
,	O
2	O
months	O
each	O
)	O
and	O
clofibrate	B-I
(	O
2	O
g/day	O
;	O
period	O
B	O
;	O
2	O
months	O
)	O
.	O


2	O
.	O


Ropinirole	B-I
as	O
a	O
treatment	O
of	O
restless	B-P
legs	I-P
syndrome	I-P
in	I-P
patients	I-P
on	I-P
chronic	I-P
hemodialysis	I-P
:	I-P
an	O
open	O
randomized	O
crossover	O
trial	O
versus	O
levodopa	B-I
sustained	I-I
release	I-I
.	I-I


METHODS	O
Eleven	B-P
patients	I-P
(	I-P
7	I-P
men	I-P
,	I-P
4	I-P
women	I-P
)	I-P
were	I-P
enrolled	I-P
in	I-P
the	I-P
study	I-P
.	I-P


Ropinirole	B-I
was	O
superior	O
to	O
levodopa	B-I
SR	I-I
in	O
reducing	O
6-item	O
IRLS	O
scores	O
(	O
P	O
<	O
0.001	O
)	O
and	O
in	O
increasing	O
sleep	B-OUT
time	I-OUT
(	O
P	O
<	O
0.001	O
)	O
.	O


There	O
was	O
no	O
significant	O
carryover	B-OUT
or	I-OUT
period	I-OUT
effect	I-OUT
for	O
any	O
outcome	O
measure	O
.	O


RESULTS	O
After	O
3	O
doses	O
of	O
the	O
OPV	B-I
(	I-I
HDC	I-I
)	I-I
vaccine	I-I
,	O
the	O
systemic	B-OUT
reactions	I-OUT
were	O
mild	O
.	O


A	O
randomized	O
crossover	O
study	O
comparing	O
patient	O
preference	O
for	O
tamsulosin	B-I
and	I-I
silodosin	I-I
in	O
patients	B-P
with	I-P
lower	I-P
urinary	I-P
tract	I-P
symptoms	I-P
associated	I-P
with	I-P
benign	I-P
prostatic	I-P
hyperplasia	I-P
.	I-P


A	O
major	O
reason	O
for	O
preference	O
of	O
either	O
drug	O
was	O
'good	B-OUT
efficacy	I-OUT
'	I-OUT
.	I-OUT


DESIGN	O
Phase	O
II	O
,	O
prospective	O
,	O
randomized	O
,	O
assessor-blind	O
,	O
multicenter	O
,	O
dose-finding	O
,	O
noninferiority	O
study	O
.	O


Among	O
women	O
with	O
fewer	O
than	O
six	O
menses	O
per	O
year	O
,	O
the	B-OUT
cumulative	I-OUT
ovulation	I-OUT
rates	I-OUT
over	O
three	O
cycles	O
were	O
comparable	O
in	O
the	B-I
anastrozole	I-I
5	O
mg	O
(	O
52.4	O
%	O
)	O
and	O
CC	O
50	O
mg/d	O
(	O
42.3	O
%	O
)	O
groups	O
.	O


The	O
aim	O
of	O
the	O
study	O
was	O
to	O
assess	O
the	O
feasibility	B-OUT
and	I-OUT
effectiveness	I-OUT
of	O
different	O
modes	O
of	O
HIT	O
in	O
cardiac	O
rehabilitation	O
.	O


Peak	B-OUT
VO2	O
increased	O
from	O
34.7	O
±	O
7.3	O
to	O
39.0	O
±	O
8.0	O
ml/kg/min	O
,	O
32.7	O
±	O
6.5	O
to	O
36.0	O
±	O
6.2	O
ml/kg/min	O
,	O
and	O
34.4	O
±	O
4.8	O
to	O
37.2	O
±	O
5.2	O
ml/kg/min	O
in	O
TE	O
,	O
GE	O
,	O
and	O
HE	O
,	O
respectively	O
.	O


CONCLUSION	O
HIT	O
was	O
efficiently	O
performed	O
in	B-OUT
three	I-OUT
settings	I-OUT
of	I-OUT
cardiac	I-OUT
rehabilitation	I-OUT
,	I-OUT
with	I-OUT
respect	I-OUT
to	I-OUT
target	I-OUT
exercise	I-OUT
intensity	O
,	O
exercise	O
attendance	O
,	O
and	B-OUT
increase	I-OUT
in	I-OUT
peak	I-OUT
VO2	O
.	O


These	O
results	O
appear	O
to	O
justify	O
long-term	O
studies	O
of	O
levobunolol	B-I
for	O
the	O
treatment	O
of	O
increased	O
intraocular	B-OUT
pressure	I-OUT
.	I-OUT


AIM	O
To	O
compare	O
the	O
effectiveness	B-OUT
of	I-OUT
treatment	I-OUT
of	O
peri-implantitis	O
with	O
a	O
novel	O
ultrasonic	O
device	O
,	O
the	O
Vector	B-I
system	I-I
,	O
with	O
that	O
of	O
subgingival	O
debridement	O
with	O
carbon	O
fiber	O
curettes	O
.	O


The	B-P
patients	I-P
were	O
followed	O
for	O
one	O
year	O
.	O


After	O
multivariate	O
analysis	O
,	O
the	O
following	O
variables	O
were	O
found	O
to	O
be	O
independent	O
predictors	O
of	O
spasm	O
:	O
radial	O
artery	O
diameter	O
(	O
RD	O
)	O
/height	O
index	O
(	O
p	O
=	O
0.005	O
)	O
,	O
RD/BSA	O
index	O
(	O
p	O
=	O
0.012	O
)	O
,	O
and	O
sheath	O
outer	O
diameter	O
(	O
OD	O
)	O
/RD	O
index	O
(	O
p	O
=	O
0.024	O
)	O
.	O


A	O
total	O
of	O
1,615	B-P
angiographic	I-P
readings	I-P
in	I-P
240	I-P
patients	I-P
with	I-P
acute	I-P
myocardial	I-P
infarction	I-P
were	O
analyzed	O
from	O
a	O
randomized	O
trial	O
of	O
intravenous	B-I
anistreplase	I-I
(	I-I
Eminase	I-I
)	I-I
,	I-I
also	I-I
known	I-I
as	I-I
anisoylated	I-I
plasminogen	I-I
streptokinase	I-I
activator	I-I
complex	I-I
(	I-I
APSAC	I-I
)	I-I
,	O
versus	O
intracoronary	O
streptokinase	B-I
.	I-I


All	O
of	O
these	O
changes	O
in	O
flow	O
were	O
statistically	O
more	O
common	O
for	O
the	O
circumflex	O
coronary	O
artery	O
and	O
early	O
treatment	O
(	O
less	O
than	O
4	O
h	O
)	O
,	O
but	O
did	O
not	O
differ	O
for	O
anistreplase	B-I
or	O
streptokinase	B-I
.	I-I


Any	O
angiographic	O
assessment	O
of	O
thrombolytic	B-I
drug	I-I
efficacy	O
should	O
take	O
these	O
variations	O
as	O
well	O
as	O
interobserver	O
variability	O
into	O
account	O
.	O


This	O
retrospective	O
multi-centre	O
study	O
aims	O
to	O
determine	O
the	O
outcome	O
following	O
colonic	O
stenting	O
for	O
large	O
bowel	O
obstruction	O
and	O
identify	O
factors	O
associated	O
with	O
successful	O
intervention	O
.	O


ASA	O
grade	O
≥3	O
predicted	O
a	O
worse	B-OUT
clinical	I-OUT
outcome	I-OUT
(	O
OR	O
0.43	O
,	O
P	O
=	O
0.04	O
)	O
.	O


The	B-OUT
cumulative	I-OUT
rate	I-OUT
of	I-OUT
HIV	I-OUT
transmission	I-OUT
or	O
death	O
at	O
12	O
months	O
was	O
10·2	O
%	O
(	O
95	O
%	O
CI	O
7·6-13·6	O
%	O
)	O
in	O
the	O
triple	O
antiretroviral	O
group	O
compared	O
with	O
16·0	O
%	O
(	B-I
12·7-20·0	I-I
%	I-I
)	I-I
in	O
the	O
zidovudine	B-I
and	I-I
single-dose	I-I
nevirapine	O
group	O
(	O
p=0·017	O
)	O
.	O


The	B-OUT
incidence	I-OUT
of	I-OUT
laboratory	I-OUT
and	I-OUT
clinical	I-OUT
serious	O
adverse	O
events	O
in	O
both	O
mothers	O
and	O
their	O
babies	O
was	O
similar	O
between	O
groups	O
.	O


INTERPRETATION	O
Triple	O
antiretroviral	O
prophylaxis	O
during	O
pregnancy	B-OUT
and	O
breastfeeding	B-OUT
is	I-OUT
safe	I-OUT
and	I-OUT
reduces	I-OUT
the	I-OUT
risk	I-OUT
of	I-OUT
HIV	O
transmission	O
to	O
infants	O
.	O


Between	O
groups	O
2	O
and	O
3	O
,	O
there	O
were	O
significant	O
differences	O
at	O
two	O
and	O
four	O
weeks	O
.	O


CONCLUSIONS	O
and	O
CLINICAL	O
IMPLICATIONS	O
The	O
use	O
of	O
NovaMin	O
powder	O
and	O
NovaMin-containing	O
toothpaste	O
for	O
hypersensitivity	O
reduction	O
is	O
more	O
effective	O
than	O
the	O
use	O
of	O
a	O
desensitizing	O
toothpaste	O
containing	O
potassium	O
nitrate	O
and	O
fluoride	O
.	O


Cardiovascular	B-OUT
safety	I-OUT
and	I-OUT
gastrointestinal	I-OUT
tolerability	I-OUT
of	O
etoricoxib	B-I
vs	I-I
diclofenac	I-I
in	O
a	O
randomized	O
controlled	O
clinical	O
trial	O
(	O
The	O
MEDAL	O
study	O
)	O
.	O


CONCLUSIONS	O
The	O
cap	B-I
technique	I-I
with	O
submucosa	O
injection	O
and	O
the	O
ligation	B-I
technique	I-I
without	O
submucosa	O
injection	O
are	O
similar	O
with	O
respect	O
to	O
efficacy	O
and	O
safety	O
for	O
endoscopic	O
resection	O
of	O
early	O
stage	O
esophageal	O
cancers	O
.	O


Bone	B-OUT
strength	I-OUT
was	O
measured	O
weekly	O
by	O
quantitative	O
ultrasound	O
measurement	O
of	O
tibial	B-OUT
bone	I-OUT
speed	I-OUT
of	I-OUT
sound	I-OUT
(	O
SOS	O
)	O
.	O


PURPOSE	O
Combined-modality	B-I
treatment	I-I
is	O
standard	O
treatment	O
for	O
patients	B-P
with	I-P
clinical	I-P
stage	I-P
I/II	I-P
Hodgkin	I-P
lymphoma	I-P
(	I-P
HL	I-P
)	I-P
.	I-P


No	O
difference	O
was	O
found	O
between	O
the	O
two	O
anesthetic	O
techniques	O
in	O
the	O
incidence	B-OUT
of	I-OUT
nausea	I-OUT
,	I-OUT
vomiting	I-OUT
,	I-OUT
or	I-OUT
both	I-OUT
during	O
the	O
first	O
24	O
hr	O
after	O
operation	O
.	O


The	O
overall	O
incidence	B-OUT
was	O
62	O
and	O
67	O
%	O
for	O
air-O2	O
and	O
N2O-O2	O
groups	O
,	O
respectively	O
.	O


It	O
is	O
concluded	O
that	O
nitrous	B-I
oxide	I-I
does	O
not	O
contribute	O
to	O
the	O
occurrence	O
of	O
nausea	B-OUT
or	I-OUT
vomiting	I-OUT
after	O
isoflurane	O
anesthesia	O
for	O
gynecologic	O
laparotomies	O
.	O


The	O
primary	O
outcome	O
was	O
the	O
between-group	O
difference	O
in	O
improvement	O
in	O
pain	B-OUT
at	O
2	O
hours	O
following	O
the	O
most	O
recent	O
ingestion	O
of	O
the	O
study	O
drug	O
,	O
relative	O
to	O
the	O
time	O
of	O
phone	O
contact	O
after	O
ED	O
discharge	O
.	O


CONCLUSIONS	O
Both	O
medications	O
decreased	B-OUT
NRS	I-OUT
pain	I-OUT
scores	I-OUT
by	O
approximately	O
50	O
%	O
.	O


These	O
findings	O
should	O
be	O
regarded	O
as	O
tentative	O
and	O
require	O
independent	O
validation	O
in	O
similar	O
and	O
other	O
acute	O
pain	O
models	O
.	O


One	B-P
hundred	I-P
and	I-P
twenty	I-P
four	I-P
randomly	I-P
selected	I-P
patients	I-P
with	I-P
DBU	I-P
were	O
included	O
in	O
this	O
prospective	O
study	O
.	O


The	B-I
detection	I-I
of	I-I
Helicobacter	I-I
pylori	I-I
(	I-I
HP	I-I
)	I-I
in	I-I
the	I-I
stomach	I-I
and	I-I
duodenum	I-I
was	I-I
carried	I-I
out	I-I
with	I-I
Giemsa	I-I
(	I-I
using	I-I
standard	I-I
visual	I-I
analogue	I-I
scale	I-I
)	I-I
,	I-I
rapid	I-I
urease	I-I
test	I-I
(	I-I
standard	I-I
Jatrox-HP	I-I
test	I-I
,	I-I
Rohm	I-I
Pharma	I-I
,	I-I
Germany	I-I
)	I-I
,	I-I
and	I-I
polymerase	I-I
chain	I-I
reaction	I-I
(	I-I
PCR	I-I
)	I-I
to	I-I
detect	I-I
the	I-I
specific	I-I
fragment	I-I
of	I-I
ureC	I-I
HP	I-I
gene	I-I
(	I-I
Helicopol	I-I
II	I-I
,	I-I
Lytech	I-I
,	I-I
Russia	I-I
)	I-I
.	O


SPEM	O
is	O
a	O
multicenter	B-P
randomized	O
double-blind	O
study	O
performed	O
to	O
test	O
the	O
acute	B-OUT
and	I-OUT
chronic	I-OUT
electrophysiological	I-OUT
behavior	I-OUT
of	O
three	O
different	O
ventricular	B-P
leads	I-P
:	I-P
(	O
1	O
)	O
an	B-I
ion	I-I
exchange	I-I
membrane	I-I
with	I-I
30-microgram	I-I
dexamethasone	I-I
elution	I-I
in	I-I
a	I-I
contoured	I-I
activated	I-I
carbon	I-I
tip	I-I
lead	I-I
(	O
Membrane	O
1400T	O
,	O
30	O
patients	O
)	O
;	O
(	O
2	O
)	O
the	B-I
same	I-I
lead	I-I
design	I-I
without	I-I
steroid	I-I
(	O
Membrane	O
1401T	O
,	O
24	O
patients	O
)	O
;	O
and	O
(	O
3	O
)	O
the	B-I
same	I-I
lead	I-I
design	I-I
without	I-I
steroid	I-I
or	I-I
membrane	I-I
(	O
control	O
group	O
,	O
27	O
patients	O
)	O
.	O


Implant	O
threshold	O
(	O
chronaxie	O
=	O
0.413	O
+/-	O
0.280	O
ms	O
,	O
rheobase	O
=	O
0.264	O
+/-	O
0.099	O
V	O
)	O
,	O
signal	O
amplitude	O
(	O
13.45	O
+/-	O
5.87	O
mV	O
)	O
,	O
and	O
slew	O
rate	O
(	O
2.05	O
+/-	O
1.38	O
V/s	O
)	O
reveal	O
no	O
significant	O
differences	O
.	O


RESULTS	O
Thirty-six	B-P
Nellore	I-P
sheep	I-P
were	O
randomly	O
divided	O
into	O
four	O
groups	O
of	O
nine	O
animals	O
each	O
using	O
a	O
balanced	O
,	O
completely	O
randomised	O
design	O
.	O


The	O
animals	O
in	O
group	O
1	O
(	O
RDN0	O
)	O
were	O
fed	O
with	O
ad	B-I
libitum	I-I
FMS	I-I
.	I-I


NCE	B-OUT
decreased	I-OUT
linearly	O
(	O
P	O
<	O
0.05	O
)	O
as	O
the	O
level	B-OUT
of	I-OUT
RDN	I-OUT
increased	I-OUT
.	O


A	O
1.5-year	O
follow-up	O
of	O
an	O
Internet-based	B-I
intervention	I-I
for	O
complicated	O
grief	O
.	O


UNLABELLED	O
Dramatic	O
effects	O
on	O
autistic	B-OUT
behaviour	I-OUT
after	O
repeated	O
injections	O
of	O
the	O
gastrointestinal	O
hormone	O
secretin	B-I
have	O
been	O
referred	O
in	O
a	O
number	O
of	O
case	O
reports	O
.	O


Although	O
controlled	O
studies	O
on	O
the	O
effect	O
of	O
mainly	O
one	O
single	O
dose	O
have	O
not	O
documented	O
any	O
effect	O
,	O
many	O
children	B-P
still	O
continue	O
to	O
receive	O
secretin	B-I
.	I-I


Six	B-P
children	I-P
enrolled	I-P
in	O
a	O
double-blind	O
,	O
placebo-controlled	O
crossover	O
study	O
in	O
which	O
each	O
child	O
was	O
its	O
own	O
control	O
.	O


Interventional	O
study	O
to	O
strengthen	O
the	O
health	O
promoting	O
behaviours	O
of	O
pregnant	B-P
women	I-P
to	O
prevent	O
anaemia	O
in	O
southern	B-P
India	I-P
.	I-P


METHODS	O
Forty-eight	B-P
nurses	I-P
with	I-P
critical	I-P
care	I-P
experience	I-P
volunteered	I-P
to	I-P
take	I-P
part	I-P
in	I-P
this	I-P
randomized	I-P
,	I-P
blinded	I-P
,	I-P
controlled	I-P
study	I-P
conducted	I-P
in	I-P
the	I-P
simulation	I-P
centre	I-P
of	I-P
an	I-P
urban	I-P
hospital	I-P
.	I-P


They	O
assisted	O
in	O
the	O
management	O
of	O
a	O
simulated	B-P
patient	I-P
with	I-P
septic	I-P
shock	I-P
.	I-P


Vasopressor	B-I
infusions	I-I
were	O
prepared	O
either	O
by	O
diluting	B-I
concentrated	I-I
drugs	I-I
from	I-I
ampoules	I-I
or	O
were	O
provided	O
in	O
syringes	B-I
pre-filled	I-I
beforehand	O
by	O
an	O
intensive	O
care	O
unit	O
resident	O
.	O


Silicone	O
Study	O
report	O
11	O
.	O


DESIGN	O
Prospective	O
,	O
randomized	O
,	O
multicentered	O
surgical	O
trial	O
.	O


Both	B-P
cohorts	I-P
consisted	I-P
of	I-P
eyes	I-P
that	I-P
had	I-P
and	I-P
had	I-P
not	I-P
undergone	I-P
vitrectomy	I-P
for	I-P
PVR	I-P
(	O
groups	O
1	O
and	O
2	O
,	O
respectively	O
)	O
before	O
randomization	O
.	O


Compared	O
with	O
oil-retained	O
eyes	O
,	O
oil-removed	O
eyes	O
had	O
higher	O
rates	B-OUT
of	I-OUT
complete	I-OUT
posterior	I-OUT
attachment	I-OUT
(	I-OUT
P	I-OUT
=	I-OUT
.01	I-OUT
)	I-OUT
and	I-OUT
of	I-OUT
a	I-OUT
visual	I-OUT
acuity	I-OUT
of	I-OUT
5/200	I-OUT
or	I-OUT
better	I-OUT
(	I-OUT
P	I-OUT
<	I-OUT
.001	I-OUT
)	I-OUT
and	I-OUT
less	I-OUT
keratopathy	I-OUT
(	O
P	O
<	O
.05	O
)	O
.	O


RATIONAL	O
Autism	O
is	O
associated	O
with	O
activation	O
of	O
the	O
inflammatory	O
response	O
system	O
.	O


RESULTS	O
Significant	O
time	O
×	O
treatment	O
interaction	O
was	O
observed	B-OUT
for	I-OUT
Irritability	I-OUT
(	O
F	O
(	O
1.658	O
,	O
63.021	O
)	O
=	O
13.580	O
,	O
P	B-OUT
<	I-OUT
0.001	I-OUT
)	I-OUT
,	I-OUT
Lethargy/Social	I-OUT
Withdrawal	O
(	O
F	O
(	O
1.948	O
,	O
74.032	O
)	O
=	O
16.811	O
,	O
P	B-OUT
<	I-OUT
0.001	I-OUT
)	I-OUT
,	I-OUT
and	I-OUT
Stereotypic	O
Behavior	O
(	O
F	O
(	O
1.742	O
,	O
66.198	O
)	O
=	O
12.104	O
,	O
P	B-OUT
<	I-OUT
0.001	I-OUT
)	I-OUT
,	I-OUT
but	I-OUT
not	I-OUT
for	I-OUT
Hyperactivity/Noncompliance	O
(	O
F	O
(	O
2.564	O
,	O
97.424	B-OUT
)	I-OUT
=	I-OUT
1.469	I-OUT
,	I-OUT
P	I-OUT
=	I-OUT
0.232	I-OUT
)	I-OUT
,	O
and	O
Inappropriate	O
Speech	O
subscales	O
(	O
F	O
(	O
1.607	O
,	O
61.075	O
)	O
=	O
0.173	O
,	O
P	B-I
=	I-I
0.794	I-I
)	I-I
.	O


Complete	B-I
response	O
was	O
achieved	O
by	O
four	O
(	O
20	O
%	O
)	O
patients	O
in	O
the	O
placebo	O
group	O
and	O
11	O
(	O
55	O
%	O
)	O
patients	O
in	O
the	B-OUT
celecoxib	I-OUT
group	O
(	O
χ	O
(	O
2	O
)	O
(	O
1	O
)	O
=	O
5.227	O
,	O
P	O
=	O
0.022	O
)	O
.	O


CONCLUSIONS	O
Combination	O
of	B-OUT
risperidone	I-OUT
and	I-OUT
celecoxib	I-OUT
was	I-OUT
superior	I-OUT
to	I-OUT
risperidone	I-OUT
alone	I-P
in	I-P
treating	I-P
irritability	O
,	O
social	O
withdrawal	O
,	O
and	O
stereotypy	O
of	O
children	O
with	O
autism	O
.	O


PURPOSE	O
To	O
evaluate	O
oral	B-I
ondansetron	I-I
in	O
the	O
prevention	O
of	O
total-body	B-P
irradiation	I-P
(	I-P
TBI	I-P
)	I-P
-induced	I-P
nausea	I-P
and	I-P
vomiting	I-P
.	I-P


METHODS	O
Twenty	B-P
patients	I-P
who	I-P
received	I-P
4	I-P
days	I-P
of	I-P
TBI	I-P
as	I-P
part	I-P
of	I-P
their	I-P
preparative	I-P
regimen	I-P
before	I-P
bone	I-P
marrow	I-P
transplantation	I-P
were	O
randomized	O
to	O
receive	O
either	O
8-mg	O
oral	B-I
doses	I-I
of	I-I
ondansetron	I-I
or	I-I
placebo	I-I
.	I-I


The	O
intervention	O
did	O
result	O
in	O
less	O
self-reported	O
sedentary	O
screen	O
time	O
,	O
although	O
these	O
results	O
are	O
likely	O
biased	O
by	O
social	O
desirability	O
.	O


Design	O
and	O
methods	O
of	O
a	O
double	O
blind	O
randomized	O
placebo-controlled	B-I
trial	O
of	O
extended-release	B-I
naltrexone	I-I
for	O
alcohol	B-P
dependent	I-P
and	I-P
hazardous	I-P
drinking	I-P
prisoners	I-P
with	I-P
HIV	I-P
who	I-P
are	I-P
transitioning	I-P
to	I-P
the	I-P
community	I-P
.	I-P


METHODS	O
A	O
randomized	O
double-blind	O
,	O
placebo-controlled	B-I
trial	O
of	O
XR-NTX	B-I
to	O
improve	O
HIV	O
treatment	O
outcomes	O
via	O
reducing	O
relapse	B-OUT
to	I-OUT
alcohol	I-OUT
use	O
after	O
prison	O
release	O
for	O
HIV-infected	O
hazardous	O
drinking	O
and	O
alcohol	B-P
dependent	I-P
prisoners	I-P
is	O
discussed	O
.	O


RESULTS	O
Acceptability	B-OUT
of	O
study	O
participation	O
is	O
high	O
with	O
86	O
%	O
of	O
those	O
referred	O
who	O
met	O
eligibility	O
criteria	O
and	O
85	O
%	O
of	O
those	O
who	O
were	O
able	O
to	O
receive	O
injections	O
prior	O
to	O
release	O
accepted	O
injections	O
,	O
yet	O
important	O
implementation	O
issues	O
are	O
identified	O
and	O
addressed	O
during	O
the	O
study	O
and	O
are	O
discussed	O
in	O
this	O
paper	O
.	O


All	O
patients	O
had	O
access	B-I
to	I-I
patient-controlled	I-I
analgesia	I-I
with	I-I
intravenous	I-I
morphine	I-I
.	O


Pain	B-OUT
severity	I-OUT
decreased	O
by	O
66	O
%	O
with	O
gabapentin	B-I
compared	O
to	O
33	O
%	O
with	O
placebo	B-I
.	I-I


Relative	O
to	O
matched	O
controls	O
,	O
children	O
with	O
ASD	O
did	O
not	O
exhibit	O
deficits	O
in	O
object-oriented	B-OUT
intention	I-OUT
understanding	I-OUT
.	I-OUT


Results	O
suggest	O
that	O
children	B-P
with	I-P
ASD	I-P
have	O
intact	O
object-oriented	B-OUT
intention	I-OUT
understanding	I-OUT
abilities	O
,	O
and	O
are	O
able	O
to	O
use	O
social-communicative	O
cues	O
to	O
understand	O
intention	O
.	O


The	O
high	O
number	O
of	O
self-initiated	B-OUT
questions	I-OUT
during	O
follow-up	O
indicates	O
that	O
both	O
groups	O
maintained	O
this	O
skill	O
.	O


Implications	O
of	O
the	O
results	O
and	O
directions	O
for	O
future	O
research	O
are	O
discussed	O
.	O


Conservative	B-I
treatment	I-I
of	O
plantar	B-P
fasciitis	I-P
.	I-P


A	O
prospective	O
study	O
.	O


PURPOSE	O
To	O
evaluate	O
and	O
compare	O
total	B-OUT
body	I-OUT
weight	I-OUT
(	I-OUT
TBW	I-OUT
)	I-OUT
,	I-OUT
lean	I-OUT
body	I-OUT
weight	I-OUT
(	I-OUT
LBW	I-OUT
)	I-OUT
,	I-OUT
and	I-OUT
estimated	I-OUT
blood	I-OUT
volume	I-OUT
(	I-OUT
BV	I-OUT
)	I-OUT
for	O
the	O
adjustment	O
of	O
the	O
iodine	B-I
dose	I-I
required	O
for	O
contrast	O
material-enhanced	O
multidetector	O
computed	O
tomography	O
(	O
CT	O
)	O
of	O
the	O
aorta	O
and	O
liver	O
.	O


One	B-P
hundred	I-P
twenty	I-P
patients	I-P
(	I-P
54	I-P
men	I-P
,	I-P
66	I-P
women	I-P
;	I-P
mean	I-P
age	I-P
,	I-P
64.1	I-P
years	I-P
;	I-P
range	I-P
,	I-P
19-88	I-P
years	I-P
)	I-P
who	I-P
underwent	I-P
multidetector	I-I
CT	I-I
of	I-P
the	I-P
upper	I-P
abdomen	I-P
were	O
randomized	O
into	O
three	O
groups	O
of	O
40	O
patients	O
each	O
:	O
(	O
a	O
)	O
TBW	O
group	O
(	O
0.6	O
g	O
of	O
iodine	B-I
per	O
kilogram	O
of	O
TBW	O
)	O
,	O
(	O
b	O
)	O
LBW	O
group	O
(	O
0.821	O
g	O
of	O
iodine	B-I
per	O
kilogram	O
of	O
LBW	O
)	O
,	O
and	O
(	O
c	O
)	O
BV	O
group	O
(	O
men	O
,	O
8.6	O
g	O
of	O
iodine	B-I
per	O
liter	O
of	O
BV	O
;	O
women	O
,	O
9.9	O
g	O
of	O
iodine	O
per	O
liter	O
of	O
BV	O
)	O
.	O


RESULTS	O
In	O
the	O
portal	O
venous	O
phase	O
,	O
correlation	B-OUT
coefficients	I-OUT
for	O
the	O
correlation	B-OUT
of	I-OUT
change	I-OUT
in	I-OUT
CT	I-OUT
number	I-OUT
per	I-OUT
gram	I-OUT
of	O
iodine	B-I
with	O
TBW	B-OUT
for	O
the	O
aorta	O
and	O
liver	O
were	O
-0.71	O
and	O
-0.79	O
,	O
respectively	O
,	O
in	O
the	O
TBW	O
group	O
;	O
-0.80	O
and	O
-0.86	O
,	O
respectively	O
,	O
in	O
the	O
LBW	O
group	O
;	O
and	O
-0.68	O
and	O
-0.66	O
,	O
respectively	O
,	O
in	O
the	O
BV	O
group	O
.	O


Pimecrolimus	B-I
cream	I-I
1	O
%	O
vs.	O
betamethasone	B-I
17-valerate	I-I
0.1	O
%	O
cream	O
in	O
the	O
treatment	O
of	O
seborrhoeic	O
dermatitis	O
.	O


This	O
difference	O
was	O
statistically	O
significant	O
.	O


MPA	O
was	O
given	O
orally	O
as	O
tablets	O
,	O
as	O
a	O
dose	O
of	O
500	O
mg	O
b.i.d	O
.	O


for	O
6	O
months	O
.	O


Subjective	B-OUT
parameters	I-OUT
also	O
showed	O
more	O
improvement	O
in	O
the	O
MPA	B-I
group	O
than	O
in	O
the	O
patients	O
given	O
CT	O
alone	O
.	O


Combination	O
treatment	O
resulted	O
in	O
no	O
significant	O
differences	B-OUT
in	I-OUT
appetite	I-OUT
or	I-OUT
weight	I-OUT
compared	O
with	O
megestrol	B-I
acetate	I-I
alone	O
.	O


CONCLUSION	O
In	O
the	O
doses	O
and	O
schedules	O
we	O
studied	O
,	O
megestrol	B-I
acetate	I-I
provided	O
superior	O
anorexia	O
palliation	O
among	O
advanced	B-P
cancer	I-P
patients	I-P
compared	O
with	O
dronabinol	B-I
alone	O
.	O


The	B-OUT
time	I-OUT
of	I-OUT
mechanical	I-OUT
ventilation	I-OUT
was	O
also	O
monitored	O
.	O


Patients	B-P
were	I-P
assessed	I-P
for	I-P
complications	I-OUT
,	I-OUT
mortality	I-OUT
,	I-OUT
tube	I-OUT
function	I-OUT
,	I-OUT
and	I-OUT
cost	I-OUT
.	I-OUT


Groups	B-P
were	I-P
equally	I-P
matched	I-P
for	I-P
indications	I-P
and	I-P
underlying	I-P
disease	I-P
.	I-P


METHODS	O
Placebo	B-I
or	I-I
RRV-TV	I-I
(	O
titre	O
4x10	O
(	O
5	O
)	O
plaque-forming	O
units	O
)	O
was	O
given	O
to	O
infants	B-P
at	I-P
ages	I-P
2	I-P
,	I-P
3	I-P
,	I-P
and	I-P
5	I-P
months	I-P
.	I-P


226	O
episodes	O
were	O
included	O
in	O
the	O
primary	O
efficacy	B-OUT
analysis	O
of	O
fully	O
vaccinated	O
children	O
(	O
54	O
among	O
1128	O
RRV-TV	O
recipients	O
,	O
172	O
among	O
1145	O
placebo	O
recipients	O
;	O
vaccine	O
efficacy	O
68	O
%	O
[	O
57-76	O
]	O
)	O
.	O


100	O
episodes	O
were	O
severe	O
,	O
eight	O
in	O
RRV-TV	B-I
recipients	O
and	O
92	O
in	O
placebo	O
recipients	O
(	O
vaccine	O
efficacy	O
91	O
%	O
[	O
82-96	O
]	O
)	O
.	O


Comparison	B-P
of	I-P
nasal	I-OUT
deposition	I-OUT
and	I-OUT
clearance	I-OUT
of	I-OUT
aerosol	I-OUT
generated	O
by	O
nebulizer	B-I
and	I-I
an	I-I
aqueous	I-I
spray	I-I
pump	I-I
.	I-I


The	O
analgesic	B-OUT
effect	I-OUT
of	O
1,2,6-IP3	O
was	O
evaluated	O
in	O
a	O
double-blind	O
,	O
randomized	O
study	O
in	O
24	B-P
patients	I-P
undergoing	I-P
cholecystectomy	I-I
.	I-I


Postoperative	B-OUT
pain	I-OUT
(	I-OUT
visual	I-OUT
analog	I-OUT
pain	I-OUT
scale	I-OUT
;	I-OUT
VAS	I-OUT
)	I-OUT
and	I-OUT
opiate	I-OUT
analgesic	I-OUT
requirements	I-OUT
(	I-OUT
ketobemidon	I-OUT
)	I-OUT
were	O
evaluated	O
during	O
five	O
postoperative	O
days	O
.	O


No	O
drug-related	B-OUT
side	I-OUT
effects	I-OUT
were	O
observed	O
.	O


Although	O
continuous	O
positive	O
airway	O
pressure	O
(	O
CPAP	O
)	O
therapy	O
using	O
a	O
face	O
mask	O
is	O
known	O
to	O
improve	O
oxygenation	O
,	O
the	O
intrapulmonary	O
shunt	O
reduction	O
remains	O
unsettled	O
.	O


After	O
screening	O
for	O
exclusion	O
,	O
only	B-P
55	I-P
patients	I-P
were	I-P
included	I-P
in	O
the	O
first	O
3-hour	O
investigation	O
period	O
.	O


However	O
,	O
there	O
was	O
no	O
significant	O
difference	O
between	O
the	O
two	O
groups	O
in	O
24-hour	O
hospital	O
mortality	O
.	O


Knowledge	O
regarding	O
these	O
genes	O
and	O
the	O
advantages	O
and	O
limitations	O
of	O
genetic	O
testing	O
is	O
limited	O
.	O


Actual	O
uptake	O
of	O
BRCA1	B-OUT
testing	I-OUT
is	O
reported	O
with	O
a	O
six	O
year	O
follow-up	O
.	O


CONCLUSIONS	O
There	O
is	O
strong	O
interest	O
in	O
BRCA1	O
testing	O
.	O


Unexpected	O
random	O
urinary	O
protein	O
:	O
creatinine	O
ratio	O
results-limitations	O
of	O
the	O
pyrocatechol	B-I
violet-dye	I-I
method	I-I
.	I-I


CONCLUSIONS	O
Random	O
urinary	O
PrCr	O
was	O
overestimated	O
in	O
dilute	O
urine	O
when	B-I
tested	I-I
using	I-I
a	I-I
common	I-I
pyrocatechol	I-I
violet	O
dye-based	O
method	O
.	O


This	O
effect	O
was	O
reduced	O
in	O
cohorts	O
when	O
pyrogallol	O
red	O
assays	O
were	O
used	O
.	O


Physical	O
exertion	O
(	O
RPE	O
)	O
reflects	O
the	O
balance	O
between	O
physical	O
work	O
demands	O
and	O
physical	O
capacity	O
of	O
the	O
individual	O
.	O


METHODS	O
200	B-P
female	I-P
healthcare	I-P
workers	I-P
(	I-P
age	I-P
:	I-P
42.0	I-P
,	I-P
body	I-P
mass	I-P
index	I-P
:	I-P
24.1	I-P
,	I-P
average	I-P
pain	I-P
intensity	I-P
:	I-P
3.1	I-P
on	I-P
a	I-P
scale	I-P
of	I-P
0	I-P
to	I-P
10	I-P
,	I-P
average	I-P
WRPE	I-P
:	I-P
3.6	I-P
on	I-P
a	I-P
scale	I-P
of	I-P
0	I-P
to	I-P
10	I-P
)	I-P
from	I-P
18	I-P
departments	I-P
at	I-P
three	I-P
participating	I-P
hospitals	I-P
.	I-P


RESULTS	O
2.2	O
(	O
SD	O
:	O
1.1	O
)	O
and	O
1.0	O
(	O
SD	O
:	O
1.2	O
)	O
training	O
sessions	O
were	O
performed	O
per	O
week	O
in	O
WORK	O
and	O
HOME	O
,	O
respectively	B-OUT
.	I-OUT


Within-group	B-OUT
effect	I-OUT
size	I-OUT
(	I-OUT
Cohen	I-OUT
's	I-OUT
d	I-OUT
)	I-OUT
in	O
WORK	O
and	O
HOME	O
was	O
0.43	O
and	O
0.13	O
,	O
respectively	O
.	O


It	O
can	O
also	O
correlate	O
with	O
gamma-aminobutyric	O
acid	O
(	O
GABA	O
)	O
-homocarnosine	O
interaction	O
,	O
with	O
possible	O
anticonvulsive	O
effects	O
.	O


We	O
investigated	O
31	B-P
children	I-P
with	I-P
autistic	I-P
spectrum	I-P
disorders	I-P
in	I-P
an	I-P
8-week	I-P
,	I-P
double-blinded	I-P
study	I-P
to	O
determine	O
if	O
800	O
mg	O
L-carnosine	B-I
daily	O
would	O
result	O
in	O
observable	O
changes	O
versus	O
placebo	B-I
.	I-I


Seventy-five	B-P
participants	I-P
,	I-P
25	I-P
per	I-P
group	I-P
,	I-P
completed	I-P
the	I-P
study	I-P
.	I-P


Based	O
on	O
these	O
findings	O
,	O
the	O
use	O
of	O
VRE	O
in	O
the	O
treatment	O
of	O
FOF	O
was	O
supported	O
in	O
this	O
controlled	O
study	O
,	O
suggesting	O
that	O
experiences	O
in	O
the	O
virtual	O
world	O
can	O
change	O
experiences	O
in	O
the	O
real	O
world	O
.	O


DESIGN	O
Prospective	O
,	O
observer-blinded	O
,	O
randomized	O
clinical	O
trial	O
.	O


INTERVENTIONS	O
Ropivacaine	B-I
hydrochloride	I-I
administered	I-I
at	I-I
the	I-I
conclusion	I-I
of	I-I
surgery	I-I
as	I-I
LAI	I-I
by	I-I
the	I-I
surgeon	I-I
(	O
n	O
=	O
25	O
)	O
or	B-I
as	I-I
ultrasonography-guided	I-I
BRSB	I-I
by	I-I
the	I-I
anesthesiologist	I-I
(	O
n	O
=	O
27	O
)	O
.	O


These	O
observations	O
suggest	O
that	O
dairy	O
food	O
can	O
be	O
included	O
as	O
part	O
of	O
a	O
normal	O
healthy	O
diet	O
without	O
increasing	B-OUT
cardio-metabolic	I-OUT
risk	O
.	O


TRIAL	O
REGISTRATION	O
NUMBER	O
ACTRN12612000574842	O
.	O


Seven-star	B-I
needle	I-I
stimulation	I-I
improves	O
language	B-OUT
and	I-OUT
social	I-OUT
interaction	I-OUT
of	O
children	B-P
with	I-P
autistic	I-P
spectrum	I-P
disorders	I-P
.	I-P


Children	O
in	O
the	O
treatment	B-P
group	I-P
underwent	O
30	O
sessions	O
of	O
stimulation	O
over	O
6	O
weeks	O
,	O
while	O
children	O
in	O
the	O
control	B-P
group	I-P
were	O
on	O
a	O
waiting	O
list	O
and	O
did	O
not	O
receive	O
treatment	O
during	O
this	O
period	O
of	O
time	O
.	O


Verapamil	B-I
,	O
although	O
primarily	O
known	O
as	O
a	O
calcium	O
channel	O
blocker	O
,	O
also	O
has	O
PKC	O
inhibitory	O
activity	O
.	O


Therefore	O
,	O
we	O
investigated	O
verapamil	B-I
,	I-I
used	I-I
alone	I-I
or	I-I
as	I-I
an	I-I
adjunctive	I-I
treatment	I-I
,	O
in	O
manic	B-P
patients	I-P
who	I-P
did	I-P
not	I-P
respond	I-P
to	I-P
an	I-P
initial	I-P
adequate	I-P
trial	I-P
of	I-P
lithium	I-I
.	I-I


The	O
addition	B-I
of	O
PVO	B-I
during	I-I
MIRE	I-I
resulted	O
in	O
a	O
significant	O
increase	O
in	O
PC	B-OUT
.	I-OUT


METHOD	O
Treatment-seeking	B-P
,	I-P
alcohol-dependent	I-P
individuals	I-P
entering	I-P
the	I-P
Combining	I-P
Pharmacotherapies	I-P
and	I-P
Behavioral	I-P
Interventions	I-P
for	I-P
Alcohol	I-P
Dependence	I-P
(	I-P
COMBINE	I-P
)	I-P
Study	I-P
(	I-P
N	I-P
=	I-P
1,372	I-P
;	I-P
69	I-P
%	I-P
men	I-P
)	I-P
completed	O
the	O
ADS	O
,	O
diagnostic	O
interviews	O
,	O
and	O
other	O
measures	O
before	O
randomization	O
.	O


CONCLUSIONS	O
The	O
ADS	O
reflected	O
variation	O
in	O
symptom	O
severity	O
but	O
did	O
not	O
adequately	O
identify	O
physiological	O
dependence	O
or	O
withdrawal	O
in	O
treatment-seeking	B-P
individuals	I-P
with	I-P
DSM-IV	I-P
alcohol	I-P
dependence	I-P
.	I-P


Buspirone	O
is	O
a	O
5-HT	O
(	O
1A	O
)	O
receptor	O
agonist	O
with	O
antiaggressive	O
effects	O
increasing	O
prosocial	O
behaviors	O
.	O


The	O
patients	O
were	O
assessed	O
at	O
baseline	O
,	O
week	O
4	O
,	O
and	O
week	O
8	O
using	O
the	O
Aberrant	O
Behavior	O
Checklist-Community	O
Rating	O
Scale	O
.	O


The	O
mean	O
dose	O
of	O
buspirone	O
was	O
6.7	O
(	O
SD	O
2.7	O
)	O
mg/day	O
.	O


Irritability	B-OUT
subscale	I-OUT
score	I-OUT
significantly	O
decreased	O
during	O
this	O
trial	O
in	O
both	O
groups	O
(	O
buspirone	O
group	O
:	O
declined	O
from	O
25.7	O
[	O
SD	O
5.7	O
]	O
to	O
16.3	O
[	O
SD	O
8.5	O
]	O
;	O
placebo	O
group	O
:	O
declined	O
from	O
24.7	O
[	O
SD	O
7.6	O
]	O
to	O
18.2	O
[	O
SD	O
7.7	O
]	O
)	O
.	O


Intravenously	B-I
administered	I-I
histamine	I-I
increases	I-P
choroidal	I-P
but	I-P
not	I-P
retinal	I-P
blood	I-P
flow	I-P
.	I-P


The	O
results	O
of	O
the	O
treatment	O
of	O
1022	B-P
ovarian	I-P
cancers	I-P
were	O
reviewed	O
and	O
the	O
problems	O
of	O
prophylactic	B-I
chemotherapy	I-I
,	O
a	O
second	O
look	O
operation	O
and	O
the	O
maintenance	O
of	O
the	O
remission	O
were	O
studied	O
.	O


In	O
ovarian	B-P
cancers	I-P
of	I-P
stage	I-P
1	I-P
and	I-P
stage	I-P
2	I-P
,	O
a	O
post-operative	B-I
prophylactic	I-I
chemotherapy	I-I
is	O
useful	O
only	O
in	O
cases	O
with	O
tumor	O
cells	O
in	O
the	O
secretions	O
of	O
the	O
pouch	O
of	O
Douglas	O
or	O
in	O
the	O
ascites	O
and	O
in	O
cases	O
where	O
a	O
sensitivity	O
to	O
the	O
chemotherapy	O
can	O
be	O
assumed	O
.	O


Radical	O
operation	O
during	O
the	O
remission	O
appears	O
to	O
be	O
very	O
important	O
for	O
survival	B-OUT
of	O
the	O
patient	O
.	O


For	O
the	O
maintenance	O
of	O
the	O
remission	O
continuous	O
chemotherapy	B-I
for	O
at	O
least	O
2	O
years	O
following	O
treatment	O
by	O
operation	O
and	O
radiotherapy	B-I
is	O
necessary	O
.	O


Testing	B-P
Italian	I-P
(	I-P
IT	I-P
)	I-P
and	I-P
US	I-P
American	I-P
(	I-P
US	I-P
)	I-P
adults	I-P
,	O
we	O
found	O
that	O
IT	O
participants	O
processed	O
information	B-OUT
more	I-OUT
holistically	I-OUT
and	I-OUT
had	I-OUT
a	I-OUT
higher	I-OUT
chronic	I-OUT
level	I-OUT
of	I-OUT
FOI	I-OUT
than	O
US	O
participants	O
;	O
furthermore	O
,	O
the	O
manipulation	O
of	O
FOI	B-OUT
affected	I-OUT
context	I-OUT
sensitivity	I-OUT
more	O
for	O
IT	O
than	O
for	O
US	B-P
participants	I-P
.	I-P


Postbaseline	O
psychiatric	B-OUT
hospitalization	O
rate	O
was	O
low	O
for	O
both	O
groups	O
(	O
7.6	O
%	O
for	O
LAI	B-I
,	O
9.2	O
%	O
for	O
oral	O
)	O
,	O
but	O
mean	O
hospitalization	O
duration	O
was	O
significantly	O
longer	O
for	O
oral	O
patients	O
(	O
1.80	O
days	O
[	O
20	O
for	O
those	O
hospitalized	O
]	O
vs	O
0.43	O
days	O
[	O
6	O
for	O
those	O
hospitalized	O
]	O
,	O
P	O
=	O
0.02	O
)	O
.	O


Design	O
and	O
implementation	O
of	O
the	O
TRACIA	O
:	O
intracoronary	O
autologous	O
transplant	O
of	O
bone	O
marrow-derived	O
stem	O
cells	O
for	O
acute	B-P
ST	I-P
elevation	I-P
myocardial	I-P
infarction	I-P
.	I-P


RESULTS	O
Of	O
all	O
the	O
subjects	O
assessed	O
,	O
FA-specific	B-OUT
IgE	I-OUT
was	O
detected	O
in	O
only	O
two	O
asthmatics	O
,	O
and	O
their	O
IgE	O
levels	O
of	O
FA	O
were	O
low	O
(	O
0.42	O
and	O
0.46	O
UA/ml	O
)	O
.	O


One	O
of	O
the	O
two	O
patients	O
with	O
FA-specific	O
IgE	O
had	O
severe	B-OUT
asthma	I-OUT
and	I-OUT
frequent	I-OUT
symptoms	I-OUT
of	I-OUT
mucosal	I-OUT
irritation	I-OUT
,	O
but	O
the	O
other	O
had	O
mild	B-OUT
asthma	I-OUT
and	I-OUT
only	I-OUT
rare	I-OUT
symptoms	I-OUT
of	I-OUT
mucosal	I-OUT
irritation	I-OUT
.	I-OUT


CONCLUSIONS	O
The	O
prevalence	O
of	O
IgE	B-OUT
sensitization	I-OUT
to	O
FA	O
appears	O
very	O
low	O
in	O
Japanese	B-P
children	I-P
,	O
whether	O
or	O
not	O
they	O
have	O
asthma	O
.	O


A	O
comparative	B-OUT
study	I-OUT
of	I-OUT
the	I-OUT
pharmacokinetics	I-OUT
of	O
ibuprofen	B-I
arginate	I-I
versus	I-I
dexibuprofen	I-I
in	O
healthy	B-P
volunteers	I-P
.	I-P


CONCLUSION	B-I
Aloe	I-I
vera	I-I
possesses	O
an	O
antiinflammatory	O
effect	O
on	O
UV-induced	O
erythemas	O
.	O


A	O
randomized	O
,	O
double-blind	O
,	O
placebo-controlled	B-I
study	O
of	O
the	O
efficacy	B-OUT
and	I-OUT
safety	I-OUT
of	O
2	O
doses	O
of	O
vortioxetine	B-I
in	O
adults	B-P
with	I-P
major	I-P
depressive	I-P
disorder	I-P
.	I-P


AIMS	O
Diuretic	B-I
therapy	O
is	O
conventionally	O
used	O
to	O
treat	O
oedema	B-P
in	I-P
patients	I-P
with	I-P
hypoxic	I-P
cor	I-P
pulmonale	I-P
.	I-P


This	O
condition	O
is	O
associated	O
with	O
activation	O
of	O
the	O
renin	O
angiotensin	O
system	O
(	O
RAS	O
)	O
with	O
elevated	O
levels	O
of	O
angiotensin	O
II	O
(	O
ANG	O
II	O
)	O
,	O
a	O
potent	O
pulmonary	O
pressor	O
agent	O
.	O


We	O
explored	O
the	O
hypothesis	O
that	O
RAS	O
activation	O
by	O
diuretic	O
therapy	O
might	O
therefore	O
worsen	O
hypoxic	O
pulmonary	O
vasoconstriction	O
via	O
the	O
effects	O
of	O
ANG	O
II	O
on	O
the	O
pulmonary	O
vascular	O
bed	O
.	O


METHODS	O
Eight	B-P
normal	I-P
volunteers	I-P
were	I-P
studied	I-P
on	O
2	O
separate	O
days	O
.	O


They	O
either	O
received	O
40	B-I
mg	I-I
frusemide	I-I
daily	I-I
or	I-I
placebo	I-I
for	O
4	O
days	O
and	O
were	O
then	O
rendered	O
hypoxaemic	O
,	O
by	O
breathing	O
an	O
N2/O2	O
mixture	O
for	O
20	O
min	O
to	O
achieve	O
an	O
SaO2	O
of	O
85-90	O
%	O
adjusted	O
for	O
a	O
further	O
20	O
min	O
to	O
achieve	O
an	O
SaO2	O
of	O
75-80	O
%	O
.	O


In	O
contrast	O
to	O
its	O
effect	O
on	O
the	O
pulmonary	O
vasculature	O
prior	O
treatment	O
with	O
frusemide	B-I
did	O
not	O
significantly	O
alter	O
systemic	B-OUT
haemodynamic	I-OUT
parameters	I-OUT
either	O
at	O
baseline	O
or	O
during	O
hypoxia	O
.	O


CONCLUSIONS	O
Thus	O
,	O
prior	O
treatment	O
with	O
frusemide	B-I
increased	O
baseline	O
pulmonary	B-OUT
vascular	I-OUT
resistance	I-OUT
and	O
significantly	O
augmented	O
the	O
hypoxaemic	B-OUT
pulmonary	I-OUT
vascular	I-OUT
response	I-OUT
in	O
additive	O
fashion	O
.	O


Plasma	B-OUT
dilution	I-OUT
and	O
the	O
rate	O
of	O
infusion	O
of	O
Ringer	B-I
's	I-I
solution	I-I
.	I-I


Based	O
on	O
these	O
experiments	O
,	O
nomograms	O
were	O
constructed	O
from	O
which	O
the	O
rate	O
of	O
infusion	O
of	O
Ringer	B-I
's	I-I
solution	I-I
and	O
the	O
infusion	O
time	O
required	O
to	O
obtain	O
a	O
defined	O
plasma	O
dilution	O
in	O
both	O
males	O
and	O
females	O
can	O
be	O
estimated	O
together	O
with	O
the	O
infusion	O
rate	O
needed	O
to	O
maintain	O
the	O
dilution	O
at	O
the	O
level	O
reached	O
.	O


A	O
double-blind	O
comparative	O
study	O
of	O
ofloxacin	B-I
otic	I-I
drops	I-I
versus	O
neomycin-polymyxin	B-I
B-hydrocortisone	I-I
otic	I-I
drops	I-I
in	O
the	O
medical	O
treatment	O
of	O
chronic	B-P
suppurative	I-P
otitis	I-P
media	I-P
.	I-P


Significantly	O
fewer	O
patients	O
(	O
seven	O
per	O
cent	O
versus	O
29	O
per	O
cent	O
,	O
p	O
=	O
0.04	O
)	O
in	O
the	O
ofloxacin	O
group	O
had	B-OUT
active	I-OUT
disease	I-OUT
at	O
the	O
end	O
of	O
the	O
two-week	O
treatment	O
.	O


BACKGROUND	O
Self-efficacy	B-OUT
has	O
been	O
found	O
to	O
be	O
an	O
important	O
precondition	O
for	O
behavioral	O
change	O
in	O
sedentary	B-P
people	I-P
.	I-P


CONCLUSIONS	O
Adding	O
a	O
15-minute	O
self-efficacy	O
coaching	O
at	O
the	O
start	O
of	O
a	O
lifestyle	B-I
PA	I-I
program	I-I
is	O
a	O
promising	O
strategy	O
to	O
enhance	O
the	O
intervention	O
effects	O
on	O
PA	B-OUT
behavior	I-OUT
,	I-OUT
self-efficacy	I-OUT
beliefs	I-OUT
,	I-OUT
and	I-OUT
program	I-OUT
adherence	I-OUT
.	I-OUT


A	B-P
total	I-P
of	I-P
282	I-P
participants	I-P
(	I-P
100	I-P
women	I-P
,	I-P
182	I-P
men	I-P
)	I-P
with	I-P
substance	I-P
use	I-P
disorders	I-P
were	I-P
included	I-P
in	I-P
this	I-P
secondary	I-P
analysis	I-P
.	I-P


A	O
randomized	O
controlled	O
design	O
was	O
employed	O
to	O
evaluate	O
a	O
social	B-I
skills	I-I
intervention	I-I
for	O
children	B-P
with	I-P
pervasive	I-P
developmental	I-P
disorders	I-P
.	I-P


Treatment	O
consisted	O
of	O
a	O
16-week	O
group	B-I
intervention	I-I
designed	I-I
to	I-I
teach	I-I
appropriate	I-I
social	I-I
behavior	I-I
.	I-I


Between	O
group	O
comparisons	O
showed	O
that	O
children	O
in	O
treatment	O
were	O
rated	O
as	O
improved	O
on	O
the	O
primary	B-OUT
outcome	I-OUT
measure	I-OUT
,	I-OUT
(	I-OUT
unblinded	I-OUT
parent	I-OUT
report	I-OUT
)	I-OUT
,	O
but	O
not	O
on	O
the	O
secondary	O
outcome	O
measure	O
,	O
a	O
parent	B-OUT
questionnaire	I-OUT
.	I-OUT


This	O
study	O
aimed	O
to	O
extend	O
previous	O
work	O
using	O
the	O
D-C	B-I
model	I-I
of	I-I
job	I-I
strain	I-I
to	O
predict	O
caregiver	B-OUT
burden	I-OUT
and	O
satisfaction	B-OUT
in	O
the	O
informal	B-P
caregivers	I-P
of	I-P
patients	I-P
with	I-P
heart	I-P
failure	I-P
.	I-P


All	O
patients	O
,	O
irrespective	O
of	O
training	O
form	O
,	O
were	O
able	O
to	O
exercise	O
to	O
maximal	O
intensity	O
(	O
80-90	O
%	O
of	O
estimated	O
maximal	O
heart	O
rate	O
)	O
.	O


The	O
cardiovascular	B-OUT
condition	I-OUT
improved	O
significantly	O
and	O
similarly	O
in	O
the	O
two	O
groups	O
.	O


DESIGN	O
Prospective	O
,	O
randomized	O
,	O
controlled	O
,	O
unblinded	O
study	O
.	O


SETTING	O
A	O
mixed	O
medical/surgical	O
ICU	O
in	O
a	O
university	O
hospital	O
.	O


Seventeen	O
individuals	O
had	O
approximal	O
surfaces	O
with	O
consistently	O
high	O
or	O
consistently	O
low	O
S.	B-OUT
mutans	I-OUT
levels	I-OUT
.	I-OUT


The	O
polyps	B-OUT
were	I-OUT
completely	I-OUT
removed	I-OUT
in	O
61	O
out	O
of	O
62	O
(	O
98	O
%	O
)	O
women	O
assigned	O
to	O
morcellation	B-I
compared	O
with	O
49	O
out	O
of	O
59	O
(	O
83	O
%	O
)	O
women	O
treated	O
with	O
electrosurgical	B-I
resection	I-I
(	O
odds	O
ratio	O
12.5	O
;	O
95	O
%	O
confidence	O
interval	O
[	O
CI	O
]	O
1.5-100.6	O
;	O
P=.02	O
)	O
.	O


CONCLUSION	O
In	O
comparison	O
to	O
electrosurgical	B-I
resection	I-I
during	O
hysteroscopic	O
polypectomy	O
,	O
morcellation	B-I
was	O
significantly	O
quicker	B-OUT
,	O
less	O
painful	B-OUT
,	O
more	O
acceptable	B-OUT
to	O
women	O
,	O
and	O
more	O
likely	O
to	O
completely	B-OUT
remove	I-OUT
endometrial	I-OUT
polyps	I-OUT
compared	O
with	O
electrosurgical	B-I
resection	I-I
.	I-I


min	O
(	O
-1	O
)	O
)	O
was	O
infused	O
from	O
the	O
end	O
of	O
anesthesia	B-I
to	O
15	O
min	O
after	O
extubation	B-I
.	I-I


Untreated	O
controls	O
at	O
the	O
2	O
intervals	O
showed	O
a	O
mean	O
decrease	B-OUT
in	I-OUT
sensitivity	I-OUT
to	I-OUT
cold	I-OUT
of	O
3.6	O
degrees	O
C	O
and	O
4.1	O
degrees	O
C.	O
Statistical	O
analysis	O
showed	O
type	O
of	O
composite	O
cement	O
to	O
be	O
a	O
significant	O
factor	O
.	O


Effects	O
of	O
repetitive	B-I
transcranial	I-I
magnetic	I-I
stimulation	I-I
in	O
performing	O
eye-hand	O
integration	O
tasks	O
:	O
four	O
preliminary	O
studies	O
with	O
children	B-P
showing	I-P
low-functioning	I-P
autism	I-P
.	I-P


OBJECTIVE	O
To	O
compare	O
18-month	O
outcomes	O
of	O
N-terminal	O
BNP-guided	O
vs	O
symptom-guided	O
heart	O
failure	O
therapy	O
.	O


The	O
effects	O
of	O
peer	B-I
counseling	I-I
on	O
smoking	O
cessation	B-OUT
and	O
reduction	O
.	O


Infant	B-OUT
birth	I-OUT
weight	I-OUT
increases	O
with	O
both	O
smoking	O
cessation	O
and	O
smoking	O
reduction	O
,	O
suggesting	O
that	O
peer	B-I
counseling	I-I
intervention	I-I
programs	I-I
may	O
improve	O
newborn	B-OUT
health	I-OUT
despite	O
their	O
failure	O
to	O
affect	O
smoking	O
cessation	O
.	O


Sixty	B-P
patients	I-P
with	I-P
peptic	I-P
ulcer	I-P
(	I-P
gastric	I-P
,	I-P
32	I-P
patients	I-P
;	I-P
duodenal	I-P
,	I-P
28	I-P
patients	I-P
)	I-P
who	I-P
had	I-P
a	I-P
history	I-P
of	I-P
ulcer	I-P
recurrence	I-P
were	O
randomly	O
assigned	O
to	O
dual	O
therapy	O
with	O
amoxycillin	B-I
(	O
500	O
mg	O
three	O
times	O
daily	O
for	O
2	O
weeks	O
)	O
and	O
omeprazole	B-I
(	O
20	O
mg	O
once	O
daily	O
for	O
8	O
weeks	O
)	O
or	O
to	O
triple	O
therapy	O
with	O
metronidazole	B-I
(	O
500	O
mg	O
twice	O
daily	O
for	O
2	O
weeks	O
)	O
plus	B-I
amoxycillin	I-I
and	I-I
omeprazole	I-I
,	O
given	O
in	O
the	O
same	O
dosages	O
as	O
dual	O
therapy	O
.	O


On	O
an	O
intention-to-treat	O
basis	O
,	O
the	B-OUT
difference	I-OUT
between	I-OUT
the	I-OUT
groups	I-OUT
in	I-OUT
the	I-OUT
rate	I-OUT
of	I-OUT
H.	I-OUT
pylori	I-OUT
eradication	I-OUT
was	I-OUT
marginally	I-OUT
significant	I-OUT
(	O
P	O
=	O
0.06	O
[	O
0.028-0.512	O
]	O
)	O
.	O


Triple	B-OUT
therapy	I-OUT
with	I-OUT
metronidazole	I-OUT
,	I-OUT
amoxycillin	I-OUT
,	I-OUT
and	I-OUT
omeprazole	I-OUT
was	I-OUT
significantly	I-OUT
more	I-OUT
effective	I-OUT
for	I-OUT
the	I-OUT
eradication	I-OUT
of	I-OUT
H.	I-OUT
pylori	I-OUT
than	I-OUT
dual	I-OUT
therapy	I-OUT
with	I-OUT
amoxycillin	I-OUT
and	I-OUT
omeprazole	I-OUT
alone	I-OUT
.	I-OUT


BACKGROUND	O
Chronic	B-I
kidney	I-I
disease	I-I
(	I-I
CKD	I-I
)	I-I
is	O
associated	O
with	O
increased	O
mortality	B-OUT
in	O
patients	B-P
with	I-P
heart	I-I
failure	I-I
(	I-I
HF	I-I
)	I-I
.	I-I


Matched	B-OUT
HR	I-OUT
for	I-OUT
cardiovascular	I-OUT
and	I-OUT
HF	I-OUT
hospitalization	I-OUT
were	O
respectively	O
1.17	O
(	O
95	O
%	O
CI	O
,	O
1.06-1.28	O
,	O
P	O
=	O
0.002	O
)	O
and	O
1.28	O
(	O
95	O
%	O
CI	O
,	O
1.13-1.45	O
,	O
P	O
<	O
0.0001	O
)	O
.	O


They	B-P
were	I-P
all	I-P
exposed	I-P
to	I-P
environmental	I-P
factors	I-P
such	I-P
as	I-P
routine	I-P
use	I-P
of	I-P
video	I-P
monitors	I-P
or	I-P
air	I-P
conditioning	I-P
.	I-P


DESIGN	O
Eighty-three	B-P
technically	I-P
successful	I-P
PTA	I-I
procedures	I-P
were	I-P
studied	I-P
.	I-P


RESULTS	O
There	O
was	O
continuing	O
TBPI	B-OUT
improvement	O
over	O
1	O
month	O
in	O
patients	O
given	O
saline	B-I
following	O
PTA	O
.	O


In	O
patients	O
given	O
GTN	B-I
,	O
peak	B-OUT
TBPI	I-OUT
was	O
achieved	O
by	O
1	O
week	O
,	O
and	O
corresponded	O
with	O
the	O
TBPI	B-OUT
observed	O
immediately	O
following	O
GTN	B-I
administration	O
.	O


Restenosis	B-OUT
occurred	O
in	O
27	O
(	O
33	O
%	O
)	O
patients	O
,	O
and	O
was	O
significantly	O
more	O
frequent	O
following	O
the	O
procedures	O
for	O
rest	O
pain	O
or	O
ulceration	O
,	O
or	O
where	O
a	O
TBPI	B-OUT
increase	O
of	O
more	O
than	O
0.15	O
by	O
1	O
week	O
was	O
observed	O
.	O


BACKGROUND	O
Previous	O
research	O
has	O
demonstrated	O
the	O
efficacy	B-OUT
of	O
an	O
interactive	B-I
expert	I-I
system	I-I
intervention	I-I
for	O
smoking	O
cessation	O
for	O
a	O
general	B-P
population	I-P
.	I-P


METHODS	O
Four	O
interventions	O
were	O
compared	O
:	O
(	O
a	O
)	O
the	B-I
interactive	I-I
expert	I-I
system	I-I
intervention	I-I
;	I-I
(	O
b	O
)	O
the	O
expert	B-I
system	I-I
intervention	I-I
plus	I-I
counselor	I-I
calls	I-I
;	I-I
(	O
c	O
)	O
the	B-I
expert	I-I
system	I-I
intervention	I-I
plus	I-I
the	I-I
stimulus	I-I
control	I-I
computer	I-I
;	I-I
and	O
(	O
d	O
)	O
an	O
assessment	B-I
only	I-I
condition	I-I
.	I-I


RESULTS	O
Thirty-eight	B-P
percent	I-P
were	I-P
in	I-P
the	I-P
precontemplation	I-P
stage	I-P
,	I-P
45	I-P
%	I-P
in	I-P
the	I-P
contemplation	I-P
stage	I-P
,	I-P
and	I-P
only	I-P
17	I-P
%	I-P
in	I-P
the	I-P
preparation	I-P
stage	I-P
.	I-P


CONCLUSIONS	O
The	O
enhanced	O
conditions	O
failed	O
to	O
outperform	B-OUT
the	O
expert	B-OUT
system	I-OUT
alone	O
.	O


PATIENTS	O
AND	O
METHODS	O
We	B-P
used	I-P
data	I-P
from	I-P
EORTC	I-P
22881-10882	I-P
trial	I-P
,	I-P
with	I-P
median	I-P
follow-up	I-P
of	I-P
77.4	I-P
months	I-P
.	I-P


During	O
and	O
following	O
cancer	O
treatment	O
,	O
children	B-P
describe	O
school	O
related	O
problems	O
,	O
reduced	O
physical	O
fitness	O
,	O
and	O
problems	O
related	O
to	O
interaction	O
with	O
peers	O
.	O


METHODS/DESIGN	O
The	O
RESPECT	O
study	O
is	O
a	O
nationwide	B-P
population-based	O
prospective	O
,	O
controlled	O
,	O
mixed-methods	O
intervention	O
study	O
looking	O
at	O
children	B-P
aged	I-P
6-18	I-P
years	I-P
newly	I-P
diagnosed	I-P
with	I-P
cancer	I-P
in	I-P
eastern	I-P
Denmark	I-P
(	I-P
n=120	I-P
)	I-P
and	I-P
a	I-P
matched	I-P
control	I-P
group	I-P
in	I-P
western	I-P
Denmark	I-P
(	I-P
n=120	I-P
)	I-P
.	I-P


Secondary	O
endpoints	O
are	O
quality	B-OUT
of	I-OUT
life	I-OUT
measured	I-OUT
by	I-OUT
validated	I-OUT
questionnaires	I-OUT
and	I-OUT
interviews	I-OUT
,	I-OUT
and	I-OUT
physical	I-OUT
performance	I-OUT
.	I-OUT


The	O
patients	B-P
are	O
tested	O
at	O
diagnosis	O
,	O
at	O
3	O
and	O
6	O
months	O
after	O
diagnosis	O
,	O
and	O
one	O
year	O
after	O
the	O
cessation	O
of	O
treatment	O
.	O


For	O
children	B-P
with	I-P
cancer	I-P
,	O
RESPECT	O
contributes	O
to	O
expanding	O
knowledge	O
on	O
rehabilitation	O
that	O
can	O
also	O
facilitate	O
rehabilitation	O
of	O
other	O
children	O
undergoing	O
hospitalization	O
for	O
long-term	O
illness	O
.	O


Analgesia	O
was	O
initiated	B-I
with	I-I
intrathecal	I-I
bupivacaine	I-I
0.25	I-I
%	I-I
1	I-I
mL	I-I
+	I-I
sufentanil	I-I
5	I-I
microg	I-I
in	I-I
the	I-I
combined	I-I
spinal-epidural	I-I
group	I-I
(	I-I
n	I-I
=	I-I
54	I-I
)	I-I
,	I-I
and	I-I
with	I-I
bupivacaine	I-I
0.125	I-I
%	I-I
+	I-I
epinephrine	I-I
2.5	I-I
microg	I-I
mL	I-I
(	I-I
-1	I-I
)	I-I
+	I-I
sufentanil	I-I
7.5	I-I
microg	I-I
in	I-I
the	I-I
epidural	I-I
group	I-I
(	I-I
n	I-I
=	I-I
59	I-I
)	I-I
.	I-I


The	B-P
characteristics	I-OUT
of	I-OUT
labour	I-OUT
were	I-P
similar	I-P
in	I-P
both	I-P
groups	I-P
.	I-P


Effects	O
of	O
bench	B-I
step	I-I
exercise	I-I
intervention	I-I
on	O
work	B-OUT
ability	I-OUT
in	O
terms	O
of	O
cardiovascular	B-OUT
risk	O
factors	O
and	O
oxidative	O
stress	O
:	O
a	O
randomized	O
controlled	O
study	O
.	O


These	O
results	O
suggest	O
that	O
a	O
bench	B-I
step	I-I
exercise	I-I
may	O
improve	O
work	B-OUT
ability	I-OUT
by	O
reducing	O
cardiovascular	O
risk	O
factors	O
and	O
oxidative	O
stress	O
.	O


This	O
study	O
explored	O
the	O
feasibility	O
and	O
effects	O
of	O
humour-related	B-I
interventions	O
for	O
mentally	B-P
ill	I-P
adults	I-P
.	I-P


The	O
National	O
Cancer	O
Institute	O
of	O
Canada	O
Clinical	O
Trials	O
Group	O
.	O


PATIENTS	O
AND	O
METHODS	O
Ninety-nine	B-P
eligible	I-P
patients	I-P
with	I-P
T2	I-P
to	I-P
T4b	I-P
transitional	I-P
cell	I-P
bladder	I-P
cancer	I-P
participated	I-P
,	I-P
64	I-P
%	I-P
with	I-P
cT3b	I-P
or	I-P
cT4	I-P
.	I-P


The	O
pelvic	B-OUT
relapse	I-OUT
rate	I-OUT
in	O
the	O
two	O
groups	O
was	O
significantly	O
reduced	O
by	O
concurrent	B-I
cisplatin	I-I
(	O
P	O
=	O
.038	O
,	O
log-rank	O
test	O
)	O
and	O
this	O
effect	O
was	O
preserved	O
in	O
a	O
stepwise	O
Cox	O
regression	O
model	O
of	O
prognostic	O
factors	O
(	O
hazards	O
ratio	O
,	O
0.50	O
;	O
90	O
%	O
confidence	O
interval	O
[	O
CI	O
]	O
,	O
0.29	O
to	O
0.86	O
;	O
P	O
=	O
.036	O
)	O
.	O


The	O
changes	B-OUT
in	I-OUT
BMD	I-OUT
between	O
the	O
6th	O
and	O
12th	O
months	O
were	O
0	O
.	O


34	O
+/-	O
2.24	O
and	O
-1.73	O
+/-	O
3.25	O
%	O
at	O
the	O
lumbar	B-OUT
spine	I-OUT
and	I-OUT
the	I-OUT
femoral	I-OUT
neck	I-OUT
,	O
respectively	O
.	O


The	O
examinations	O
indicate	O
in	O
general	O
the	O
difficulty	O
of	O
the	O
judgement	O
of	O
efficacy	O
of	O
non-medicamentous	B-I
therapeutic	I-I
measures	O
in	O
connection	O
with	O
a	O
rational	O
dose-reduced	O
long-term	O
therapy	O
with	O
antihypertensive	O
drugs	O
.	O


[	O
It	O
is	O
difficult	O
to	O
predict	O
the	O
effect	O
of	O
minoxidil	B-I
liniment	I-I
on	O
hair	B-OUT
loss	I-OUT
in	I-P
men	I-P
]	I-P
.	O


Different	O
prognostic	O
factors	O
and	O
SLN	O
tumor	O
burden	O
were	O
recorded	O
.	O


Additional	O
positive	O
non-SLN	O
after	O
CLND	O
,	O
and	O
disease	O
outcome	O
were	O
evaluated	O
.	O


RESULTS	O
Of	O
381	B-P
patients	I-P
who	I-P
underwent	I-P
SLN	I-P
biopsy	I-P
,	I-P
103	I-P
(	I-P
27	I-P
%	I-P
)	I-P
were	I-P
positive	I-P
.	I-P


Double	O
blockade	O
decreased	O
lung	B-OUT
volume-to-heart	I-OUT
rate	I-OUT
variability	I-OUT
transfer	I-OUT
function	I-OUT
magnitude	I-OUT
(	O
P	O
<	O
0.007	O
)	O
and	O
increased	O
phase	B-OUT
angle	I-OUT
(	O
P	O
<	O
0.02	O
)	O
without	O
age	O
effects	O
or	O
age-drug	O
interactions	O
.	O


BACKGROUND	O
Given	O
the	O
prevalence	O
of	O
cardiovascular	O
disease	O
and	O
the	O
high	O
rates	O
of	O
depression	O
among	O
cardiac	B-P
patients	I-P
,	O
there	O
is	O
a	O
need	O
to	O
develop	O
practical	O
ways	O
to	O
identify	O
this	O
population	O
and	O
provide	O
pragmatic	O
general-practitioner-based	B-I
interventions	I-I
for	O
managing	O
depression	O
as	O
a	O
comorbid	O
condition	O
.	O


Elevated	O
scores	O
were	O
associated	O
with	O
being	O
younger	O
,	O
female	O
,	O
divorced	O
or	O
separated	O
,	O
not	O
employed	O
,	O
living	O
alone	O
,	O
having	O
a	O
lower	O
level	O
of	O
education	O
,	O
and	O
having	O
poorer	O
health	O
and	O
quality	O
of	O
life	O
.	O


Evaluation	O
of	O
different	O
inhaled	B-I
combination	I-I
therapies	I-I
(	I-I
EDICT	I-I
)	I-I
:	I-I
a	O
randomised	O
,	O
double-blind	O
comparison	O
of	O
Seretide	B-I
(	O
50/250	O
microg	O
bd	O
Diskus	B-I
vs.	I-I
formoterol	I-I
(	O
12	O
microg	O
bd	O
)	O
and	O
budesonide	B-I
(	O
800	O
microg	O
bd	O
)	O
given	O
concurrently	O
(	O
both	O
via	O
Turbuhaler	O
)	O
in	O
patients	B-P
with	I-P
moderate-to-severe	I-P
asthma	I-P
.	I-P


Four	B-P
hundred	I-P
two	I-P
patients	I-P
with	I-P
suspected	I-P
myocardial	I-P
infarction	I-P
seen	I-P
within	I-P
6	I-P
hours	I-P
of	I-P
the	I-P
onset	I-P
of	I-P
symptoms	I-P
entered	O
a	O
double-blind	O
randomized	O
trial	O
of	O
lidocaine	B-I
vs	I-I
placebo	I-I
.	I-I


The	O
mean	B-OUT
plasma	I-OUT
lidocaine	I-OUT
level	I-OUT
of	O
patients	O
on	O
beta-blocking	O
agents	O
was	O
no	O
different	O
from	O
that	O
in	O
patients	O
not	O
on	O
beta	O
blocking	O
agents	O
.	O


There	O
were	O
no	O
significant	O
differences	O
(	O
P	O
=	O
0.3626	O
)	O
in	O
the	O
prevaccination	B-OUT
anti-Hib	I-OUT
geometric	I-OUT
mean	I-OUT
concentration	I-OUT
(	I-OUT
GMC	I-OUT
)	I-OUT
among	O
the	O
three	O
Hib	O
groups	O
.	O


METHODS	O
In	O
this	O
single-center	B-P
,	I-P
randomized	I-P
,	I-P
double-blind	I-P
,	I-P
placebo-controlled	I-I
,	I-P
crossover	I-P
,	I-P
two-arm	I-P
study	I-P
,	I-P
40	I-P
patients	I-P
with	I-P
persistent	I-P
AR	I-P
were	I-P
randomized	I-P
to	O
receive	O
either	O
montelukast	B-I
and/or	I-I
levocetirizine	I-I
or	I-I
placebo	I-I
(	O
n	O
=	O
20	O
)	O
or	O
to	O
receive	O
treatment	O
with	O
montelukast	B-I
and/or	I-I
desloratadine	I-I
or	O
placebo	B-I
(	O
n	O
=	O
20	O
)	O
.	O


Nasal	B-OUT
eosinophilia	I-OUT
and	I-OUT
concentration	I-OUT
of	I-OUT
sICAM-1	I-OUT
in	I-OUT
peripheral	I-OUT
blood	I-OUT
were	O
assessed	O
before	O
and	O
on	O
the	O
last	O
day	O
of	O
each	O
treatment	O
period	O
.	O


Effects	O
of	O
a	O
caregiver	B-I
intervention	I-I
on	O
negative	O
caregiver	B-P
appraisals	O
of	O
behavior	O
problems	O
in	O
patients	B-P
with	I-P
Alzheimer	I-P
's	I-P
disease	I-P
:	I-P
results	O
of	O
a	O
randomized	O
trial	O
.	O


The	O
authors	B-P
assessed	O
CLEMs	O
twice	O
in	O
a	O
counterbalanced	O
design	O
.	O


In	O
the	O
control	B-P
(	I-P
symmetric	I-P
)	I-P
condition	I-P
,	O
each	O
participant	B-P
sat	O
in	O
a	O
completely	B-I
symmetrical	I-I
position	I-I
facing	O
a	O
wall	O
devoid	O
of	O
any	O
asymmetrical	O
features	O
.	O


The	O
AQ-J	B-I
had	O
satisfactory	B-OUT
internal	I-OUT
consistency	I-OUT
reliability	I-OUT
(	O
Cronbach	O
's	O
alpha	O
>	O
0.70	O
in	O
the	O
two	O
groups	O
)	O
,	O
test-retest	B-OUT
reliability	I-OUT
,	I-OUT
and	I-OUT
discriminant	I-OUT
validity	I-OUT
[	O
i.e	O
.	O


The	O
effects	O
of	O
a	O
24-h	O
psychological	B-I
training	I-I
program	I-I
on	O
attitudes	B-OUT
,	I-OUT
communication	I-OUT
skills	I-OUT
and	I-OUT
occupational	I-OUT
stress	I-OUT
in	O
oncology	O
:	O
a	O
randomised	O
study	O
.	O


Safety	O
and	O
possible	O
effects	O
of	O
low-intensity	B-I
resistance	I-I
training	I-I
associated	O
with	O
partial	O
blood	O
flow	O
restriction	O
in	O
polymyositis	B-P
and	I-P
dermatomyositis	I-P
.	I-P


RESULTS	O
The	O
BFR	B-I
training	O
program	O
was	O
effective	O
in	O
increasing	O
the	O
maximal	B-OUT
dynamic	I-OUT
strength	I-OUT
in	O
both	O
the	O
leg-press	B-I
(	O
19.6	O
%	O
,	O
P	O
<	O
0.001	O
)	O
and	O
knee-extension	B-OUT
exercises	I-OUT
(	O
25.2	O
%	O
P	O
<	O
0.001	O
)	O
,	O
as	O
well	O
as	O
in	O
the	O
timed-stands	B-OUT
(	O
15.1	O
%	O
,	O
P	O
<	O
0.001	O
)	O
and	O
timed-up-and-go	B-OUT
test	I-OUT
(	O
-4.5	O
%	O
,	O
P	O
=0.002	O
)	O
.	O


Laboratory	B-OUT
parameters	I-OUT
(	I-OUT
creatine	I-OUT
kinase	I-OUT
and	I-OUT
aldolase	I-OUT
)	I-OUT
were	O
also	O
unchanged	O
(	O
P	O
>	O
0.05	O
)	O
after	O
the	O
intervention	O
.	O


TRIAL	O
REGISTRATION	O
Clinicaltrials.gov	O
NCT01501019	O
.	O


RESULTS	O
Fatigue	B-OUT
did	O
not	O
significantly	O
correlate	O
with	O
any	O
of	O
the	O
neuropsychological	O
outcome	O
measures	O
at	O
baseline	O
or	O
after	O
treatment	O
.	O


CONCLUSIONS	O
Cognitive	O
functioning	O
in	O
MS	O
is	O
independent	O
of	O
fatigue	O
.	O


CONCLUSION	O
Homeopathic	O
vital	O
force	O
ratings	O
reflect	O
better	O
perceived	O
mental	O
function	O
,	O
energy	O
,	O
and	O
positive	O
dimensions	O
of	O
the	O
individual	O
,	O
beyond	O
absence	O
of	O
disease	O
.	O


First-line	B-I
cisplatin	I-I
with	I-I
docetaxel	I-I
or	I-I
vinorelbine	I-I
in	O
patients	B-P
with	I-P
advanced	I-P
non-small-cell	I-P
lung	I-P
cancer	I-P
:	I-P
a	O
quality	B-P
of	I-P
life	I-P
directed	I-P
phase	I-P
II	I-P
randomized	I-P
trial	I-P
of	I-P
Gruppo	I-P
Oncologico	I-P
Italia	I-P
Meridionale	I-P
.	I-P


The	O
impact	O
of	O
these	O
regimens	O
on	O
patients	O
'	O
QoL	O
as	O
well	O
as	O
symptoms	B-OUT
control	I-OUT
and	I-OUT
type	I-OUT
and	O
grading	O
chemo-related	O
side-effects	B-OUT
has	O
been	O
compared	O
prospectically	O
.	O


Baseline	O
mean	O
scores	O
and	O
rates	O
at	O
which	O
pts	O
failed	O
to	O
complete	O
QoL	O
assessment	O
were	O
similar	O
in	O
the	O
two	O
arms	O
.	O


OBJECTIVES	O
To	O
establish	O
the	O
effect	O
of	O
the	O
atypical	O
neuroleptic	O
clozapine	B-I
on	O
chorea	O
,	O
voluntary	O
motor	O
performance	O
,	O
and	O
functional	O
disability	O
in	O
patients	B-P
with	I-P
Huntington	I-P
's	I-P
disease	I-P
.	I-P


Twelve	O
patients	O
already	O
used	O
other	O
neuroleptic	O
medication	O
,	O
which	O
was	O
kept	O
unchanged	O
during	O
the	O
trial	O
period	O
.	O


RESULTS	O
Clozapine	B-I
tended	O
to	O
reduce	O
chorea	B-OUT
in	O
neuroleptic	O
naive	O
patients	O
only	O
(	O
AIMS	O
)	O
;	O
improvement	O
seemed	O
more	O
pronounced	O
in	O
patients	O
receiving	O
higher	O
doses	O
of	O
clozapine	O
.	O


Other	O
measures	B-OUT
of	I-OUT
chorea	I-OUT
(	I-OUT
UHDRS	I-OUT
chorea	I-OUT
score	I-OUT
,	I-OUT
video	I-OUT
ratings	I-OUT
)	I-OUT
showed	O
no	O
improvement	O
.	O


Because	O
adverse	O
reactions	O
are	O
often	O
encountered	O
,	O
clozapine	B-I
should	O
be	O
used	O
with	O
restraint	O
in	O
this	O
patient	O
group	O
.	O


Patients	O
were	O
randomly	O
assigned	O
to	O
one	O
of	O
five	O
groups	O
.	O


BACKGROUND	O
No	O
study	O
has	O
yet	O
assessed	O
the	O
impact	O
of	O
physicians	O
'	O
skills	O
acquisition	O
after	O
a	O
communication	B-I
skills	I-I
training	I-I
programme	I-I
on	O
the	O
evolution	O
of	O
patients	B-P
'	I-P
anxiety	O
following	O
a	O
medical	O
consultation	O
.	O


Consultations	O
with	O
a	O
cancer	O
patient	O
were	O
recorded	O
.	O


0.45	O
)	O
,	O
1.07	O
(	O
0.21	O
)	O
,	O
1.13	O
(	O
0.30	O
)	O
and	O
1.02	O
(	O
0.27	O
)	O
.	O


The	O
response	O
of	O
neuropathic	B-OUT
pain	I-OUT
and	I-OUT
pain	I-OUT
in	I-OUT
complex	I-OUT
regional	I-OUT
pain	I-OUT
syndrome	I-OUT
I	I-P
to	O
carbamazepine	B-I
and	O
sustained-release	B-I
morphine	I-I
in	O
patients	B-P
pretreated	I-P
with	I-P
spinal	I-I
cord	I-I
stimulation	I-I
:	I-I
a	O
double-blinded	O
randomized	O
study	O
.	O


Forty-three	B-P
patients	I-P
with	I-P
peripheral	I-P
neuropathic	I-P
pain	I-P
,	I-P
exclusively	I-P
pain	I-P
reduced	I-P
by	I-P
spinal	I-I
cord	I-I
stimulation	I-I
(	I-I
SCS	I-I
)	I-I
,	I-P
were	I-P
switched	I-P
into	I-P
a	I-P
painful	I-P
state	I-P
after	I-P
SCS	I-I
inactivation	I-P
.	I-P


The	O
pain	B-OUT
intensity	I-OUT
was	O
rated	O
on	O
a	O
numeric	B-OUT
analog	I-OUT
scale	I-OUT
.	I-OUT


Hypertensive	B-P
patients	I-P
were	O
randomly	O
assigned	O
to	O
receive	O
5	B-I
mg	I-I
of	I-I
enalapril	I-I
(	I-P
n	I-P
=	I-P
50	I-P
)	I-P
or	I-P
10	I-I
mg	I-I
of	I-I
lisinopril	I-I
(	I-P
n	I-P
=	I-P
47	I-P
)	I-P
daily	I-P
.	I-P


During	O
the	O
first	O
week	O
of	O
treatment	O
,	O
the	O
goal	O
of	O
diastolic	B-OUT
BP	I-OUT
of	O
less	O
than	O
90	O
mmHg	O
was	O
reached	O
by	O
40	O
%	O
of	O
the	O
enalapril	B-I
group	O
and	O
62	O
%	O
of	O
the	O
lisinopril	B-I
group	O
;	O
by	O
the	O
end	O
of	O
the	O
titration	O
period	O
,	O
98	O
%	O
and	O
96	O
%	O
,	O
respectively	O
,	O
had	O
achieved	O
the	O
BP	B-OUT
goal	I-OUT
.	I-OUT


Formoterol	O
caused	O
a	O
significantly	O
higher	O
tremor	B-OUT
score	I-OUT
and	O
a	O
larger	O
drop	O
in	O
S-potassium	B-OUT
than	O
salmeterol	O
at	O
the	O
highest	O
doses	O
.	O


The	O
immature	O
immune	O
system	O
of	O
preterm	B-P
neonates	I-P
puts	O
them	O
at	O
higher	O
risk	O
of	O
neonatal	O
sepsis	O
.	O


Secondary	O
outcomes	O
were	O
the	O
incidence	B-OUT
of	I-OUT
positive	I-OUT
blood	I-OUT
cultures	I-OUT
,	I-OUT
necrotising	I-OUT
enterocolitis	I-OUT
(	I-OUT
NEC	I-OUT
)	I-OUT
stage	I-OUT
II	I-OUT
or	I-OUT
III	I-OUT
,	I-OUT
or	I-OUT
death	I-OUT
,	I-OUT
and	I-OUT
the	I-OUT
duration	I-OUT
of	I-OUT
hospital	I-OUT
stay	I-OUT
.	I-OUT


Further	O
research	O
involving	O
a	O
larger	O
,	O
more	O
heterogeneous	O
sample	O
is	O
recommended	O
.	O


mTOR	B-OUT
signaling	I-OUT
was	O
assessed	O
by	O
immunoblotting	B-I
from	I-I
repeated	I-I
muscle	I-I
biopsy	I-I
samples	I-I
.	I-I


Mixed	B-OUT
muscle	I-OUT
fractional	I-OUT
synthetic	I-OUT
rate	I-OUT
(	I-OUT
FSR	I-OUT
)	I-OUT
was	O
measured	O
using	O
stable	O
isotope	O
techniques	O
.	O


Serum	B-OUT
concentrations	I-OUT
of	I-OUT
total	I-OUT
drug	I-OUT
(	I-OUT
enalapril	I-OUT
+	I-OUT
enalaprilat	I-OUT
,	I-OUT
its	I-OUT
active	I-OUT
metabolite	I-OUT
)	I-OUT
during	O
the	O
day	O
and	O
night	O
trials	O
did	O
not	O
differ	O
significantly	O
at	O
any	O
time	O
.	O


Internet-based	B-I
Mindfulness	I-I
Meditation	I-I
for	O
Cognition	O
and	O
Mood	B-OUT
in	O
Older	B-P
Adults	I-P
:	I-P
A	O
Pilot	O
Study	O
.	O


DESIGN	O
The	O
study	O
was	O
a	O
randomized	O
,	O
controlled	O
trial	O
(	O
RCT	O
)	O
,	O
a	O
pilot	O
study	O
,	O
with	O
participants	B-P
randomized	O
either	O
to	O
the	O
meditation	B-I
group	O
or	O
the	O
education	B-I
group	O
.	O


INTERVENTION	O
Participants	O
in	O
both	O
groups	O
took	O
part	O
in	O
a	O
1-h	B-I
online	I-I
session	I-I
each	I-I
week	I-I
for	I-I
6	I-I
wk	I-I
,	I-I
with	I-I
30	I-I
min	I-I
of	I-I
daily	I-I
home	I-I
practice	I-I
.	I-I


Acceptability	B-OUT
was	O
high	O
for	O
the	O
interventions	O
,	O
based	O
on	O
above-average	O
scores	O
on	O
the	O
client	O
satisfaction	O
questionnaire	O
.	O


The	O
IMMI	B-I
participants	O
completed	O
(	O
1	O
)	O
4.25	O
±	O
2.4	O
sessions	O
,	O
with	O
a	O
range	O
of	O
0-6	O
;	O
(	O
2	O
)	O
604	O
±	O
506	O
home-practice	O
minutes	O
,	O
with	O
a	O
range	O
0-1432	O
;	O
and	O
(	O
3	O
)	O
21.3	O
±	O
15.5	O
d	O
of	O
practice	O
,	O
with	O
a	O
range	O
of	O
0-46	O
.	O


The	O
intervention	O
and	O
control	O
formats	O
were	O
both	O
feasible	O
,	O
and	O
the	O
control	O
group	O
was	O
appropriate	O
.	O


SETTING	O
The	O
study	O
was	O
performed	O
in	O
General	B-P
Clinical	I-P
Research	I-P
Centers	I-P
at	I-P
two	I-P
University	I-P
Hospitals	I-P
.	I-P


SUBJECTS	O
Forty-one	B-P
subjects	I-P
with	I-P
T2DM	I-P
were	O
treated	O
with	O
metformin	B-I
or	O
diet	B-I
,	O
having	O
good	O
glycemic	O
control	O
with	O
glycosylated	O
hemoglobin	O
values	O
of	O
6.2-7.5	O
%	O
.	O


RESULTS	O
There	O
were	O
small	O
and	O
comparable	O
reductions	O
in	O
glycosylated	B-OUT
hemoglobin	I-OUT
in	O
both	O
groups	O
over	O
3	O
months	O
.	O


Serum	B-OUT
total	I-OUT
cholesterol	I-OUT
did	I-OUT
not	I-OUT
change	I-OUT
significantly	O
in	O
both	O
groups	O
.	O


The	O
serum	B-OUT
LDL	I-OUT
level	I-OUT
decreased	I-OUT
by	O
6.2	O
%	O
and	O
11.8	O
%	O
,	O
respectively	O
.	O


Overall	O
,	O
faropenem	B-I
daloxate	I-I
was	O
at	O
least	O
as	O
effective	O
clinically	B-OUT
and	I-OUT
bacteriologically	I-OUT
as	O
cefuroxime	B-I
axetil	I-I
and	O
was	O
well	O
tolerated	B-OUT
.	I-OUT


Eighty	B-P
children	I-P
,	I-P
3-17	I-P
years	I-P
of	I-P
age	I-P
,	I-P
with	I-P
autism	I-P
or	I-P
Asperger	I-P
syndrome	I-P
and	I-P
mild	I-P
to	I-P
severe	I-P
distress	I-P
in	I-P
the	I-P
presence	I-P
of	I-P
some	I-P
sounds	I-P
,	O
were	O
randomly	O
allocated	O
to	O
two	O
groups	O
.	O


Significant	O
improvements	O
in	O
behavior	B-OUT
and	I-OUT
severity	I-OUT
of	I-OUT
autism	I-OUT
were	O
maintained	O
for	O
12	O
months	O
by	O
both	O
groups	O
.	O


Informal	O
data	O
suggested	O
that	O
a	O
range	B-OUT
of	I-OUT
abnormal	I-OUT
responses	I-OUT
to	O
sound	B-OUT
and	I-OUT
other	I-OUT
sensory	I-OUT
abnormalities	I-OUT
may	O
also	O
have	O
improved	O
.	O


BACKGROUND	O
In	O
the	O
treatment	O
of	O
reflux	O
oesophagitis	O
,	O
H2-receptor	O
antagonists	O
are	O
still	O
widely	O
used	O
in	O
spite	O
of	O
the	O
apparent	O
higher	O
efficacy	O
of	O
proton	O
pump	O
inhibitors	O
.	O


The	O
assessment	B-I
strategy	I-I
developed	O
is	O
implemented	O
in	O
a	O
RCT	O
of	O
risperidone	B-I
(	O
McDougle	O
et	O
al.	O
,	O
2000	O
)	O
for	O
which	O
the	O
design	O
and	O
other	O
methodological	O
challenges	O
are	O
described	O
elsewhere	O
(	O
Scahill	O
et	O
al.	O
,	O
2000	O
)	O
.	O


MATERIALS	O
AND	O
METHODS	O
Twenty-four	B-P
subjects	I-P
,	I-P
each	I-P
requiring	I-P
a	I-P
nonmolar	I-P
extraction	I-P
and	I-P
delayed	I-P
implant	I-P
placement	I-P
,	O
were	O
randomly	O
selected	O
to	O
receive	O
ridge	B-I
preservation	I-I
treatment	I-I
with	I-I
either	I-I
an	I-I
allograft	I-I
in	I-I
an	I-I
experimental	I-I
putty	I-I
carrier	I-I
plus	I-I
a	I-I
calcium	I-I
sulfate	I-I
barrier	I-I
(	I-I
PUT	I-I
)	I-I
or	I-I
a	I-I
bovine-derived	I-I
xenograft	I-I
(	I-I
BDX	I-I
)	I-I
plus	I-I
a	I-I
collagen	I-I
membrane	I-I
.	I-I


DISCUSSION	O
Greater	O
vital	B-OUT
bone	I-OUT
fill	I-OUT
in	O
the	O
PUT	B-I
group	O
may	O
be	O
attributable	O
to	O
earlier	O
and	O
greater	O
vascular	O
invasion	O
of	O
the	O
carrier	O
material	O
.	O


CONCLUSIONS	O
Allograft	O
mixed	O
with	O
an	O
experimental	O
putty	O
carrier	O
produced	O
significantly	O
more	O
vital	O
bone	O
fill	O
than	O
did	O
the	O
use	O
of	O
a	O
xenograft	B-I
with	O
no	O
carrier	O
material	O
.	O


Ridge	B-OUT
width	I-OUT
and	I-OUT
height	I-OUT
dimensions	I-OUT
were	O
similarly	O
preserved	O
with	O
both	O
graft	O
materials	O
.	O


Day	O
14	O
reductions	O
were	O
22.2	O
%	O
for	O
Colgate	O
Cavity	O
Protection	O
,	O
29.1	O
%	O
for	O
Regimen	O
One	O
,	O
and	O
34.4	O
%	O
for	O
Regimen	O
Two	B-OUT
.	I-OUT


Reductions	B-OUT
for	O
Regimen	O
One	O
and	O
Regimen	O
Two	O
were	O
significantly	O
greater	O
compared	O
to	O
Regimen	O
Three	O
,	O
the	O
negative	O
control	O
,	O
at	O
each	O
time	O
period	O
(	O
p	O
<	O
0.01	O
)	O
,	O
and	O
those	O
for	O
Regimen	O
Two	O
were	O
significantly	O
greater	O
compared	O
to	O
Regimen	O
One	O
on	O
days	O
2	O
and	O
14	O
(	O
p	O
<	O
0.05	O
)	O
and	O
directionally	O
more	O
effective	O
on	O
day	O
5	O
(	O
p	O
=	O
0.0673	O
)	O
.	O


No	O
significant	O
differences	O
were	O
found	O
between	O
the	O
groups	O
in	O
the	O
changes	O
in	B-OUT
5-m	I-OUT
and	I-OUT
10-m	I-OUT
sprint	I-OUT
time	I-OUT
from	O
pre-	O
to	O
posttraining	O
.	O


Epirubicin	O
alone	O
failed	O
to	O
induce	O
changes	B-OUT
in	I-OUT
VEGF	I-OUT
expression	I-OUT
(	O
P	O
=	O
0.54	O
)	O
,	O
while	O
the	O
addition	O
of	O
tamoxifen	B-I
to	I-I
epirubicin	I-I
resulted	O
in	O
a	O
significant	O
reduction	O
in	O
VEGF	B-OUT
expression	I-OUT
(	O
P	O
<	O
0.001	O
)	O
.	O


METHODS/DESIGN	O
A	O
prospective	O
,	O
randomised	O
,	O
double-blind	O
,	O
placebo-controlled	B-I
,	O
stepped	O
wedge	O
design	O
will	O
be	O
employed	O
at	O
a	B-P
single	I-P
centre	I-P
(	I-P
Bristol	I-P
,	I-P
UK	I-P
)	I-P
.	I-P


Eighty	B-P
patients	I-P
with	I-P
progressive	I-P
MS	I-P
will	I-P
be	I-P
recruited	I-P
;	I-P
60	I-P
will	I-P
have	I-P
secondary	I-P
progressive	I-P
disease	I-P
(	I-P
SPMS	I-P
)	I-P
but	I-P
a	I-P
subset	I-P
(	I-P
n	I-P
=	I-P
20	I-P
)	I-P
will	I-P
have	I-P
primary	I-P
progressive	I-P
disease	I-P
(	I-P
PPMS	I-P
)	I-P
.	I-P


Participants	O
will	O
be	O
followed	O
up	O
for	O
a	O
further	O
year	O
following	O
the	O
final	O
intervention	O
.	O


Operative	B-OUT
time	I-OUT
was	O
significantly	O
shorter	O
in	O
the	O
thermal	O
destruction	O
group	O
(	O
24	O
+/-	O
4	O
minutes	O
vs	O
37	O
+/-	O
6	O
minutes	O
)	O
.	O


Intraoperative	B-OUT
blood	I-OUT
loss	I-OUT
was	O
significantly	O
lower	O
in	O
the	O
thermal	O
destruction	O
group	O
(	O
7.2	O
+/-	O
2.8	O
mL	O
vs	O
89	O
+/-	O
38	O
mL	O
)	O
.	O


Discharge	B-OUT
time	I-OUT
,	I-OUT
complication	I-OUT
rate	I-OUT
,	I-OUT
and	I-OUT
resumption	I-OUT
of	I-OUT
normal	I-OUT
activity	I-OUT
were	O
not	O
significantly	O
different	O
between	O
the	O
two	O
groups	O
.	O


Infants	O
nursed	O
with	O
a	O
postural	O
support	O
roll	O
either	O
with	O
or	O
without	O
a	O
postural	O
support	O
nappy	O
demonstrated	O
improved	O
shoulder	B-OUT
posture	I-OUT
to	O
term	O
equivalent	O
age	O
.	O


Changes	O
of	O
gastric	B-OUT
drainage	I-OUT
volume	I-OUT
,	I-OUT
therapeutic	I-OUT
times	I-OUT
and	I-OUT
cured	I-OUT
rate	I-OUT
were	O
investigated	O
in	O
the	O
3	O
groups	O
.	O


The	O
cured	B-OUT
rate	I-OUT
was	O
100.0	O
%	O
and	O
the	O
therapeutic	B-OUT
times	I-OUT
was	O
(	O
7.24	O
+/-	O
3.87	O
)	O
in	O
the	O
group	O
A	O
,	O
66.7	O
%	O
,	O
(	O
9.83	O
+/-	O
4.60	O
)	O
times	O
in	O
the	O
group	O
B	O
and	O
75.0	O
%	O
,	O
(	O
15.25	O
+/-	O
3.81	O
)	O
times	O
in	O
the	O
group	O
C	O
,	O
with	O
significant	O
differences	O
in	O
the	O
cured	B-OUT
rate	I-OUT
and	I-OUT
the	I-OUT
therapeutic	I-OUT
times	I-OUT
among	O
the	O
3	O
groups	O
(	O
P	O
<	O
0.05	O
,	O
P	O
<	O
0.01	O
)	O
.	O


Control	O
subjects	O
received	O
two	O
brief	O
"	B-I
check-in	I-I
"	I-I
telephone	I-I
calls	I-I
during	O
this	O
6-month	O
period	O
.	O


CONCLUSION	O
A	O
structured	O
,	O
multicomponent	O
skills	O
training	O
intervention	O
that	O
targeted	O
CG	O
self-care	O
behaviors	O
as	O
one	O
of	O
five	O
target	O
areas	O
,	O
improved	O
self-reported	B-OUT
health	I-OUT
status	I-OUT
,	O
and	O
decreased	O
burden	B-OUT
and	O
bother	O
in	O
racially	B-P
and	I-P
ethnically	I-P
diverse	I-P
CGs	I-P
of	I-P
people	I-P
with	I-P
dementia	I-P
.	I-P


Two	B-P
of	I-P
the	I-P
3	I-P
subjects	I-P
in	I-P
the	I-P
MCT	I-I
oil	I-I
group	I-P
with	O
evidence	O
of	O
the	O
metabolic	O
syndrome	O
at	O
baseline	O
did	O
not	O
have	O
metabolic	O
syndrome	O
at	O
endpoint	O
.	O


RESULTS	O
DHA	O
supplementation	O
increased	B-OUT
the	O
DHA	B-OUT
concentration	I-OUT
in	I-OUT
plasma	I-OUT
by	O
76	O
%	O
(	O
P	O
<	O
0.0001	O
)	O
and	O
the	O
proportion	B-OUT
in	I-OUT
erythrocyte	I-OUT
lipids	I-OUT
by	O
58	O
%	O
(	O
P	O
<	O
0.0001	O
)	O
.	O


In	O
addition	O
,	O
the	O
LDL	B-OUT
cholesterol	I-OUT
:	I-OUT
apolipoprotein	I-OUT
B	I-OUT
ratio	I-OUT
was	O
3.1	O
%	O
higher	O
with	O
DHA	O
treatment	O
than	O
with	O
placebo	B-I
(	O
P	O
=	O
0.04	O
)	O
,	O
which	O
suggested	O
an	O
increase	B-OUT
in	I-OUT
LDL	I-OUT
size	I-OUT
.	I-OUT


It	O
is	O
suggested	O
that	O
DHA	B-I
down-regulates	O
the	O
expression	O
of	O
the	O
LDL	O
receptor	O
.	O


1	O
.	O


Systolic	O
time	O
intervals	O
were	O
sensitive	O
and	O
specific	O
for	O
isoprenaline-induced	O
effects	O
,	O
PEP	O
and	O
QS2c-measurements	O
had	O
high	O
reproducibility	O
.	O


Cross-over	O
effects	O
of	O
a	O
dopamine	B-I
agonist	I-I
and	I-I
an	I-I
antagonist	I-I
]	I-I
.	O


Therefore	O
,	O
we	O
tested	O
the	O
hypothesis	O
that	O
two	O
dopaminergic	B-I
(	I-I
DA	I-I
)	I-I
drugs	I-I
have	O
a	O
similar	O
5-HT	O
effect	O
underlying	O
the	O
therapeutic	O
efficiency	O
.	O


The	O
dosages	O
of	O
platelet	B-I
5-HT	I-I
and	I-I
serum	I-I
prolactin	I-I
were	O
carried	O
out	O
at	O
the	O
beginning	O
and	O
at	O
the	O
end	O
of	O
every	O
phase	O
of	O
treatment	O
(	O
active	O
or	O
placebo	B-I
)	I-I
with	O
radioenzymology	O
and	O
radioimmunoassay	O
methods	O
respectively	O
.	O


This	O
order	O
effect	O
could	O
be	O
explained	O
by	O
a	O
remanent	O
effect	O
of	O
amisulpride	O
after	O
6	O
wash-out	O
weeks	O
.	O


Rapeseed	B-I
and	I-I
soybean	I-I
products	I-I
as	O
protein	O
sources	O
for	O
growing	B-P
turkeys	I-P
of	I-P
different	I-P
ages	I-P
.	I-P


Onset	B-OUT
of	I-OUT
action	I-OUT
of	O
ciclesonide	B-I
once	O
daily	O
in	O
the	O
treatment	O
of	O
seasonal	O
allergic	O
rhinitis	O
.	O


Safety	B-OUT
and	O
efficacy	B-OUT
of	O
a	O
low	O
molecular	O
weight	O
heparin	O
(	O
Logiparin	O
)	O
versus	O
dextran	O
as	O
prophylaxis	O
against	O
thrombosis	B-OUT
after	O
total	B-P
hip	I-P
replacement	I-P
.	I-P


The	O
XaI	O
activity	O
was	O
less	O
than	O
or	O
equal	O
to	O
0.24	O
XaI	O
units/ml	O
and	O
the	O
IIaI	O
activity	O
less	O
than	O
or	O
equal	O
to	O
0.043	O
IIaI	O
mu/ml	O
.	O


No	O
accumulation	O
of	O
the	O
activities	O
were	O
seen	O
.	O


Based	O
on	O
these	O
data	O
,	O
an	O
open	O
,	O
randomized	O
controlled	O
trial	O
was	O
started	O
.	O


The	O
patients	B-P
were	O
randomly	O
assigned	O
to	O
receive	O
standard	B-I
care	I-I
or	I-I
transfusions	I-I
to	O
reduce	O
the	O
hemoglobin	O
S	O
concentration	O
to	O
less	O
than	O
30	O
percent	O
of	O
the	O
total	O
hemoglobin	O
concentration	O
.	O


The	O
incidence	O
of	O
stroke	O
(	O
cerebral	O
infarction	O
or	O
intracranial	O
hemorrhage	O
)	O
was	O
compared	O
between	O
the	O
two	O
groups	O
.	O


A	O
stimulation	O
of	O
NOLD	B-OUT
was	O
observed	O
only	O
when	O
plasma	B-OUT
AA	I-OUT
levels	I-OUT
were	O
increased	O
(	O
study	O
III	O
;	O
1.23	O
+/-	O
0.03	O
mumol/kg.min	O
,	O
P	O
<	O
0.01	O
versus	O
basal	O
)	O
.	O


Adverse	O
effects	O
on	O
blood	O
pressure	O
,	O
electrolytes	O
,	O
and	O
aldosterone	O
levels	O
,	O
seen	O
with	O
another	O
drug	O
in	O
this	O
class	O
,	O
have	O
not	O
been	O
noted	O
in	O
studies	O
of	O
anacetrapib	B-I
to	O
date	O
.	O


Eligible	B-P
patients	I-P
at	I-P
National	I-P
Cholesterol	I-P
Education	I-P
Program-Adult	I-P
Treatment	I-P
Panel	I-P
III	I-P
LDL-C	I-OUT
treatment	I-P
goal	I-P
on	I-P
a	I-P
statin	I-P
,	I-P
with	I-P
or	I-P
without	I-P
other	I-P
lipid-modifying	I-P
medications	I-P
,	O
are	O
treated	O
with	O
anacetrapib	B-I
,	O
100	O
mg	O
,	O
or	O
placebo	B-I
for	O
18	O
months	O
,	O
followed	O
by	O
a	O
3-month	O
,	O
poststudy	O
follow-up	O
.	O


The	O
primary	O
end	O
points	O
are	O
percent	B-OUT
change	I-OUT
from	I-OUT
baseline	I-OUT
in	I-OUT
LDL-C	I-OUT
and	I-OUT
the	I-OUT
safety	I-OUT
and	I-OUT
tolerability	I-OUT
of	I-OUT
anacetrapib	I-OUT
.	I-OUT


The	O
CARS	B-OUT
scores	I-OUT
of	O
both	O
groups	O
declined	O
after	O
the	O
treatment	O
.	O


METHODS/DESIGN	O
This	O
is	O
to	O
be	O
a	O
randomized	O
controlled	O
feasibility	O
trial	O
recruiting	O
50	B-P
individuals	I-P
with	I-P
upper-limb	I-P
motor	I-P
impairment	I-P
after	I-P
stroke	I-P
.	I-P


Participants	B-P
allocated	O
to	O
the	O
control	O
group	O
will	O
receive	O
arm	B-I
therapy	I-I
in	O
accordance	O
with	O
usual	O
care	O
.	O


Recruitment	B-OUT
,	I-OUT
adherence	I-OUT
,	I-OUT
withdrawals	I-OUT
,	I-OUT
adverse	I-OUT
events	I-OUT
(	I-OUT
AEs	I-OUT
)	I-OUT
,	I-OUT
and	I-OUT
completeness	I-OUT
of	I-OUT
data	I-OUT
will	O
be	O
recorded	O
and	O
reported	O
.	O


Standard	B-I
versus	O
extended	B-I
lymphadenectomy	I-I
in	O
radical	O
pancreatoduodenectomy	O
for	O
ductal	O
adenocarcinoma	O
of	O
the	O
head	O
of	O
the	O
pancreas	O
:	O
long-term	O
results	O
of	O
a	O
Japanese	O
multicenter	O
randomized	O
controlled	O
trial	O
.	O


Demographic	B-P
and	I-P
histopathological	I-P
characteristics	I-P
of	I-P
the	I-P
two	I-P
groups	I-P
were	I-P
similar	I-P
.	I-P


Effects	O
of	O
weight	B-I
reduction	I-I
interventions	I-I
by	O
community	O
pharmacists	O
.	O


MAIN	O
OUTCOME	O
MEASURE	O
Weight	B-OUT
changes	I-OUT
.	I-OUT


Prospective	O
,	O
randomized	O
comparison	O
of	O
transperitoneal	B-I
versus	I-I
retroperitoneal	I-I
laparoscopic	I-I
adrenalectomy	I-I
.	I-I


Median	O
adrenal	B-OUT
mass	I-OUT
size	I-OUT
was	O
2.7	O
cm	O
(	O
range	O
1	O
to	O
9	O
)	O
in	O
the	O
TLA	O
group	O
and	O
2.6	O
cm	O
(	O
range	O
0.5	O
to	O
6	O
)	O
in	O
the	O
RLA	O
group	O
(	O
p	O
=	O
0.83	O
)	O
.	O


Fourteen	B-P
patients	I-P
with	I-P
paired	I-P
intrabony	I-P
periodontal	I-P
defects	I-P
of	I-P
≥	I-P
4	I-P
mm	I-P
participated	I-P
in	O
this	O
split-mouth	O
design	O
study	O
.	O


However	O
,	O
the	O
present	O
data	O
can	O
not	O
exclude	O
the	O
possibility	O
that	O
the	O
neuroendocrine	O
changes	O
reflect	O
nonspecific	O
stress	O
responses	O
or	O
changes	O
in	O
pituitary	O
blood	O
flow	O
.	O


In	O
addition	O
,	O
blood	O
cardioplegic	O
solution	O
samples	O
were	O
collected	O
in	O
Group	O
I	O
from	O
the	O
lines	O
proximal	O
and	O
distal	O
to	O
the	O
filter	O
during	O
first	O
and	O
last	O
administration	O
.	O


Recovery	O
after	O
anesthesia	O
,	O
with	O
special	O
focus	O
on	O
postoperative	O
nausea	O
and	O
vomiting	O
(	O
PONV	O
)	O
,	O
was	O
assessed	O
.	O


Memory	B-I
aids	I-I
in	O
longitudinal	O
health	O
surveys	O
:	O
results	O
from	O
a	O
field	O
experiment	O
.	O


Differences	O
in	O
reporting	O
levels	O
were	O
particularly	O
striking	O
during	O
the	O
first	O
six	O
to	O
12	O
weeks	O
of	O
the	O
survey	O
,	O
for	O
symptoms	O
related	O
to	O
acute	O
,	O
transitory	O
illness	O
,	O
and	O
among	O
minorities	O
and	O
the	O
lower	O
socioeconomic	O
groups	O
.	O


AIM	O
To	O
assess	O
in	O
a	O
randomized	O
study	O
the	O
patient-centred	B-OUT
outcome	I-OUT
of	O
two	O
guided	O
surgery	B-I
systems	O
(	B-I
mucosa	I-I
or	I-I
bone	I-I
supported	I-I
)	I-I
compared	O
to	O
conventional	B-I
implant	I-I
placement	I-I
,	O
in	O
fully	B-P
edentulous	I-P
patients	I-P
.	I-P


MATERIAL	O
AND	O
METHODS	O
Fifty-nine	B-P
patients	I-P
(	I-P
72	I-P
jaws	I-P
)	I-P
with	I-P
edentulous	I-P
maxillas	I-P
and/	I-P
or	I-P
mandibles	I-P
,	I-P
were	I-P
consecutively	I-P
recruited	I-P
and	I-P
randomly	I-P
assigned	I-P
to	O
one	O
of	O
the	O
treatment	O
groups	O
.	O


For	O
the	O
HRQOLI-instrument	B-OUT
,	O
a	O
significant	O
difference	O
was	O
found	O
between	O
the	O
Materialise	B-I
Mucosa	I-I
and	O
Materialise	B-I
Bone	I-I
group	O
at	O
day	O
1	O
(	O
p	O
=	O
0.02	O
)	O
and	O
day	O
2	O
(	O
p	O
=	O
0.01	O
)	O
.	O


However	O
there	O
was	O
a	O
tendency	O
for	O
patients	O
treated	O
with	O
conventional	O
flapped	O
implant	O
placement	O
to	O
experience	O
the	O
pain	O
for	O
a	O
longer	O
period	O
of	O
time	O
.	O


RESULTS	O
Of	O
the	O
469	B-P
patients	I-P
,	I-P
255	I-P
(	I-P
54.4	I-P
%	I-P
)	I-P
were	I-P
female	I-P
and	I-P
214	I-P
(	I-P
45.6	I-P
%	I-P
)	I-P
were	I-P
male	I-P
.	I-P


The	O
number	B-OUT
of	I-OUT
patients	I-OUT
who	I-OUT
discontinued	I-OUT
treatment	I-OUT
due	I-OUT
to	I-OUT
an	I-OUT
unsatisfactory	I-OUT
analgesic	I-OUT
response	I-OUT
was	O
significantly	O
less	O
in	O
the	O
HI2	O
group	O
(	O
2	O
;	O
1.3	O
%	O
)	O
than	O
in	O
the	O
CA	O
group	O
(	O
12	O
;	O
7.5	O
%	O
)	O
(	O
P	O
=	O
0.008	O
)	O
.	O


There	O
were	O
no	O
significant	O
differences	O
in	O
the	O
number	B-OUT
of	I-OUT
patients	I-OUT
experiencing	I-OUT
adverse	I-OUT
events	I-OUT
in	O
the	O
HI2	O
(	O
127	O
;	O
83	O
%	O
)	O
,	O
HI1	B-I
(	O
124	O
;	O
79.5	O
%	O
)	O
,	O
and	O
CA	B-I
(	O
129	O
;	O
80.6	O
%	O
)	O
groups	O
.	O


Cytokine	B-OUT
levels	I-OUT
and	I-OUT
systemic	I-OUT
toxicity	I-OUT
in	O
patients	B-P
undergoing	I-P
isolated	I-I
limb	I-I
perfusion	I-I
with	I-I
high-dose	I-I
tumor	I-I
necrosis	I-I
factor	I-I
,	I-I
interferon	I-I
gamma	I-I
,	I-I
and	I-I
melphalan	I-I
.	I-I


PURPOSE	O
Isolated	B-I
limb	I-I
perfusion	I-I
(	I-I
ILP	I-I
)	I-I
with	I-I
tumor	I-I
necrosis	I-I
factor	I-I
(	I-I
TNF	I-I
)	I-I
,	I-I
interferon	I-I
gamma	I-I
,	I-I
and	I-I
melphalan	I-I
(	I-I
M	I-I
)	I-I
has	O
been	O
reported	O
to	O
result	O
in	O
high	O
response	B-OUT
rates	I-OUT
for	O
extremity	O
melanoma	O
and	O
sarcoma	O
.	O


Cytokine	O
levels	O
in	O
the	O
perfusate	O
and	O
systemic	O
circulation	O
during	O
and	O
after	O
ILP	O
were	O
measured	O
by	O
enzyme-linked	B-I
immunosorbent	I-I
assay	I-I
.	I-I


Hypotension	B-OUT
that	I-OUT
required	I-OUT
vasopressor	I-OUT
support	I-OUT
occurred	O
in	O
six	O
of	O
six	O
patients	O
with	O
evidence	O
of	O
a	O
leak	O
(	O
>	O
or	O
=	O
1	O
%	O
)	O
and	O
zero	O
of	O
six	O
patients	O
without	O
a	O
leak	O
(	O
<	O
1	O
%	O
)	O
.	O


OBJECTIVES	O
To	O
evaluate	O
the	O
applicability	O
of	O
magnetic	B-I
resonance	I-I
imaging	I-I
(	I-I
MRI	I-I
)	I-I
as	O
a	O
method	O
for	O
monitoring	O
the	O
activity	O
of	O
otospongiotic	O
lesions	O
before	O
and	O
after	O
clinical	O
treatment	O
.	O


The	O
emergence	O
of	O
behavioral	O
control	O
in	O
some	O
instances	O
seemed	O
to	O
be	O
marked	O
by	O
reduction	O
of	O
complexity	O
of	O
the	O
impulse	O
response	O
to	O
one	O
dominated	O
by	O
the	O
zeroth-order	O
lag	O
,	O
leading	O
to	O
dynamically	O
simpler	O
responses	O
compared	O
to	O
control	O
.	O


The	O
efficacy	B-OUT
and	I-OUT
safety	I-OUT
of	O
lamotrigine	B-I
and	I-I
carbamazepine	I-I
as	O
monotherapy	O
in	O
patients	B-P
with	I-P
untreated	I-P
,	I-P
newly	I-P
diagnosed	I-P
or	I-P
recurrent	I-P
partial	I-P
and/or	I-P
generalised	I-P
tonic-clonic	I-P
seizures	I-P
,	O
were	O
compared	O
in	O
a	O
randomised	O
,	O
open	O
,	O
multicentre	O
study	O
.	O


Patients	O
received	O
24	O
weeks	O
'	O
treatment	O
with	O
oral	B-I
lamotrigine	I-I
100	I-I
mg	I-I
(	I-I
LTG	I-I
100	I-I
,	I-I
n	I-I
=	I-I
115	I-I
)	I-I
or	I-I
200	I-I
mg	I-I
(	I-I
LTG	I-I
200	I-I
,	I-I
n	I-I
=	I-I
111	I-I
)	I-I
or	I-I
carbamazepine	I-I
600	I-I
mg	I-I
(	I-I
CBZ	I-I
600	O
,	O
n	O
=	O
117	O
)	O
.	O


Both	O
dosage	O
regimens	O
of	O
lamotrigine	B-I
were	O
well	O
tolerated	B-OUT
.	I-OUT


Similarly	O
,	O
a	O
greater	O
proportion	O
of	O
the	O
CBZ	B-I
600	O
group	O
required	O
a	O
change	O
in	O
dose	O
,	O
47	O
%	O
versus	O
20	O
%	O
(	B-I
LTG	I-I
100	O
)	O
and	O
17	O
%	O
(	B-I
LTG	I-I
200	O
)	O
or	O
withdrew	O
completely	O
due	O
to	O
adverse	B-OUT
experiences	I-OUT
,	O
10.3	O
%	O
versus	O
4.3	O
%	O
(	B-I
LTG	I-I
100	O
)	O
and	O
4.5	O
%	O
(	B-I
LTG	I-I
200	O
)	O
.	O


Overall	O
lamotrigine	B-I
appeared	O
equally	O
effective	O
but	O
better	O
tolerated	O
compared	O
with	O
carbamazepine	B-I
.	I-I


Prediction	O
of	O
gestational	O
diabetes	O
mellitus	O
in	O
the	O
first	B-P
trimester	I-P
,	O
comparison	O
of	O
fasting	O
plasma	O
glucose	O
,	O
two-step	O
and	O
one-step	O
methods	O
:	O
a	O
prospective	O
randomized	O
controlled	O
trial	O
.	O


The	O
effect	O
of	O
intravenous	O
lidocaine	B-I
on	O
QT	B-OUT
changes	I-OUT
during	O
tracheal	B-P
intubation	I-P
.	I-P


There	O
were	O
no	O
significant	O
differences	O
in	O
TDR	B-OUT
either	O
between	O
or	O
within	O
the	O
groups	O
.	O


To	O
minimize	O
the	O
consequence	O
of	O
haemorrhage	O
,	O
we	O
performed	O
every	O
rigid	O
bronchoscopy	B-I
,	I-I
placing	I-I
a	I-I
non	I-I
inflated	I-I
Fogarty	I-I
balloon	I-I
and	I-I
a	I-I
rigid	I-I
aspirator	I-I
(	I-I
diameter	I-I
4	I-I
mm	I-I
)	I-I
in	I-I
lobar	I-I
bronchus	I-I
near	I-I
the	I-I
biopsy	I-I
segment	I-I
.	I-I


CONCLUSION	O
The	O
use	O
of	O
large	O
biopsy	O
forceps	O
to	O
perform	O
TBLB	O
via	O
rigid	O
bronchoscope	O
can	O
significantly	O
increase	O
diagnostic	O
yield	O
in	O
the	O
pathological	O
diagnosis	O
of	O
diffuse	B-P
infiltrative	I-P
lung	I-P
disease	I-P
.	I-P


Although	B-I
EACA	I-I
and	I-I
HOE	I-I
140	I-I
decreased	I-OUT
fibrinolysis	I-OUT
and	I-OUT
EACA	I-OUT
attenuated	I-OUT
blood	I-OUT
loss	I-OUT
,	O
these	O
treatments	O
did	O
not	O
reduce	O
the	O
proportion	O
of	O
patients	O
transfused	O
.	O


Results	O
were	O
similar	O
for	O
pedometer	B-OUT
measured	I-OUT
physical	I-OUT
activity	I-OUT
,	O
with	O
a	O
significant	O
overall	O
increase	B-OUT
in	I-OUT
steps/day	I-OUT
from	O
baseline	O
to	O
follow-up	O
,	O
but	O
no	O
between	O
arm	O
difference	O
in	O
change	O
.	O


The	O
measurement	O
and	O
quantification	O
of	O
saccadic	O
eye	O
movements	O
is	O
a	O
powerful	O
tool	O
for	O
assessing	O
sensory	O
,	O
motor	O
,	O
and	O
cognitive	O
function	O
.	O


This	O
study	O
,	O
therefore	O
,	O
tested	O
the	O
hypothesis	O
that	O
children	B-P
with	I-P
fetal	I-P
alcohol	I-P
spectrum	I-P
disorder	I-P
(	I-P
FASD	I-P
)	I-P
will	O
exhibit	O
deficits	O
in	O
the	O
accuracy	O
of	O
saccades	O
.	O


METHODS	O
A	B-P
group	I-P
of	I-P
children	I-P
with	I-P
FASD	I-P
(	I-P
n	I-P
=	I-P
27	I-P
)	I-P
between	I-P
the	I-P
ages	I-P
of	I-P
8	I-P
and	I-P
16	I-P
and	I-P
typically	I-P
developing	I-P
control	I-P
children	I-P
(	I-P
n	I-P
=	I-P
27	I-P
)	I-P
matched	I-P
for	I-P
age	I-P
and	I-P
sex	I-P
,	O
completed	O
3	B-I
saccadic	I-I
eye	I-I
movement	I-I
tasks	I-I
of	I-I
increasing	I-I
difficulty	I-I
.	I-I


METHODS	O
Patients	B-P
with	I-P
stages	I-P
II	I-P
and	I-P
IIIA/B	I-P
non-small-cell	I-P
lung	I-P
cancer	I-P
received	O
induction	O
paclitaxel	B-I
225	O
mg/m2	O
intravenously	O
(	O
IV	O
)	O
and	O
carboplatin	B-I
area	O
under	O
the	O
curve	O
(	O
AUC	O
)	O
6	O
both	O
days	O
1	O
and	O
22	O
,	O
followed	O
by	O
concurrent	O
weekly	O
paclitaxel	B-I
(	O
50	O
mg/m2	O
)	O
and	O
carboplatin	B-I
(	O
AUC	O
2	O
)	O
,	O
with	O
hyperfractionated	B-I
radiation	I-I
therapy	I-I
(	O
69.6	O
Gy	O
at	O
1.2	O
Gy	O
BID	O
)	O
.	O


Patients	O
were	O
randomly	O
assigned	O
to	O
amifostine	B-I
(	O
AM	O
)	O
500	O
mg	O
IV	O
four	O
times	O
per	O
week	O
or	O
no-AM	O
during	O
chemoradiotherapy	O
.	O


Prospective	O
comparison	O
of	O
the	O
value	O
of	O
brushings	B-I
before	I-I
and	I-I
after	I-I
biopsy	I-I
in	O
the	O
endoscopic	O
diagnosis	O
of	O
gastroesophageal	B-P
malignancy	I-P
.	I-P


In	O
45	O
%	O
of	O
trials	O
a	O
stop	O
signal	O
was	O
presented	O
after	O
the	O
go	O
signal	O
,	O
to	O
which	O
subjects	O
were	O
asked	O
to	O
stop	O
the	O
movement	O
as	O
rapidly	O
as	O
possible	O
.	O


CONCLUSION	O
The	O
use	O
of	O
either	O
face	O
mask	O
during	O
PPV	O
in	O
the	O
delivery	O
room	O
yields	B-OUT
similar	I-OUT
mask	I-P
leak	I-P
in	I-P
preterm	I-P
infants	I-P
<	I-P
33	I-P
weeks	I-P
gestational	I-P
age	O
.	O


In	O
the	O
latter	O
patients	O
the	O
ratio	O
of	O
emissions	B-OUT
from	O
the	O
graft	O
over	O
reference	O
fell	O
significantly	O
on	O
starting	O
ASA	B-I
+	I-I
DPM	I-I
,	O
suggesting	O
a	O
net	O
loss	O
of	O
platelets	O
from	O
the	O
graft	O
.	O


Primary	O
end	O
points	O
of	O
effectiveness	O
(	O
three	O
parameters	O
)	O
and	O
secondary	O
end	O
points	O
of	O
safety	O
during	O
ESD	O
and	O
after	O
return	O
to	O
the	O
ward	O
were	O
compared	O
between	O
the	O
groups	O
.	O


The	O
FB	O
group	O
had	O
excessive	O
amounts	B-OUT
of	I-OUT
omission	I-OUT
and	I-OUT
commission	I-OUT
errors	I-OUT
,	O
a	O
greater	O
response	B-OUT
time	I-OUT
mean	I-OUT
(	O
i.e.	O
,	O
slower	O
to	O
respond	O
)	O
and	O
had	O
greater	O
variance	B-OUT
around	I-OUT
their	I-OUT
mean	I-OUT
response	I-OUT
time	I-OUT
.	I-OUT


OBJECTIVE	O
The	O
aim	O
of	O
the	O
study	O
was	O
to	O
assess	O
the	O
effects	O
of	O
two	B-I
estroprogestins	I-I
(	I-I
EPs	I-I
)	I-I
,	I-I
ethinyl-estradiol	I-I
(	I-I
EE	I-I
)	I-I
30	I-I
mcg/drospirenone	I-I
(	I-I
DRSP	I-I
)	I-I
3	I-I
mg	I-I
,	I-I
and	I-I
ethinyl-estradiol	I-I
(	I-I
EE	I-I
)	I-I
30	I-I
mcg/chlormadinone	I-I
acetate	I-I
(	I-I
CMA	I-I
)	I-I
2	I-I
mg	I-I
,	O
both	O
on	O
increased	O
serum	B-OUT
androgen	I-OUT
levels	I-OUT
and	O
on	O
several	O
skin	B-OUT
parameters	I-OUT
in	O
women	B-P
affected	I-P
by	I-P
mild	I-P
to	I-P
severe	I-P
acne	I-P
and	I-P
polycystic	I-P
ovary	I-P
syndrome	I-P
(	I-P
PCOS	I-P
)	I-P
.	I-P


METHODS	O
Fifty-nine	B-P
women	I-P
were	I-P
randomized	I-P
to	O
receive	O
EE/DRSP	B-I
(	O
n	O
=	O
32	O
)	O
or	O
EE/CMA	B-I
(	O
n	O
=	O
27	O
)	O
for	O
six	O
months	O
.	O


Parecoxib	B-I
for	O
analgesia	B-P
after	I-P
craniotomy	I-P
.	I-P


However	O
,	O
overall	O
,	O
it	O
had	O
only	O
minimal	O
impact	O
on	O
postoperative	B-OUT
analgesia	I-OUT
.	I-OUT


CONCLUSIONS	O
We	O
found	O
only	O
limited	O
evidence	O
to	O
support	O
parecoxib	O
as	O
an	O
analgesic	O
after	O
craniotomy	O
.	O


To	O
that	O
end	O
,	O
participants	O
completed	O
two	B-I
cooperative	I-I
tasks	I-I
with	I-I
a	I-I
confederate	I-I
,	O
which	O
allowed	O
us	O
to	O
measure	O
linguistic	B-OUT
alignment	I-OUT
with	I-OUT
the	I-OUT
confederate	I-OUT
in	O
terms	O
of	O
lexical	B-OUT
choice	I-OUT
,	I-OUT
syntactic	I-OUT
structure	I-OUT
and	I-OUT
spatial	I-OUT
frame	I-OUT
of	I-OUT
reference	I-OUT
.	I-OUT


CONCLUSION	O
Use	O
of	O
CEE	O
results	O
in	O
a	O
modest	O
but	O
statistically	O
significant	O
increase	O
in	O
mammographic	B-OUT
density	I-OUT
that	O
is	O
sustained	O
over	O
at	O
least	O
a	O
2-year	O
period	O
.	O


The	O
long-term	O
effect	O
of	O
oxandrolone	B-I
on	O
hepatic	O
acute	O
phase	O
proteins	O
in	O
severely	B-P
burned	I-P
children	I-P
.	I-P


Levels	O
of	O
constitutive	O
proteins	O
and	O
acute	O
phase	O
proteins	O
were	O
measured	O
at	O
admission	O
;	O
at	O
discharge	O
;	O
and	O
at	O
6	O
,	O
9	O
,	O
and	O
12	O
months	O
after	O
burn	O
.	O


Hence	O
the	O
current	O
trial	O
was	O
conducted	O
with	O
the	O
objective	O
to	O
show	O
the	O
therapeutic	O
equivalence	O
of	O
two	O
treatments	O
(	B-I
placebo	I-I
and	O
amoxycillin	B-I
)	I-I
for	O
children	B-P
presenting	I-P
with	I-P
non-severe	I-P
pneumonia	I-P
with	I-P
wheeze	I-P
,	I-P
who	I-P
have	I-P
persistent	I-P
fast	I-P
breathing	I-P
after	I-P
nebulisation	I-P
with	I-P
salbutamol	I-P
,	I-P
and	I-P
have	I-P
normal	I-P
chest	I-P
radiograph	I-P
.	I-P


PRINCIPAL	O
FINDINGS	O
We	O
randomized	O
836	B-P
cases	I-P
in	I-P
placebo	I-P
and	I-P
835	I-P
in	I-P
amoxycillin	I-P
group	I-P
.	I-P


TRIAL	O
REGISTRATION	O
ClinicalTrials.gov	O
NCT00407394	O
.	O


For	O
all	O
patients	O
,	O
baseline	O
TEI	O
index	O
was	O
a	O
predictor	O
of	O
worsened	B-OUT
outcome	I-OUT
.	I-OUT


Only	O
children	B-P
treated	I-P
with	I-P
carvedilol	I-I
showed	O
a	O
significant	O
decrease	O
in	O
systolic	B-OUT
SI	I-OUT
(	O
P	O
B	O
0.0001	O
)	O
,	O
diastolic	B-OUT
SI	I-OUT
(	O
P	O
B	O
0.0001	O
)	O
,	O
and	O
TEI	B-OUT
index	I-OUT
(	O
P	O
=	O
0.02	O
)	O
.	O


Arm	O
function	O
was	O
evaluated	O
pretraining	O
and	O
posttraining	O
by	O
Fugl-Meyer	B-OUT
assessment	I-OUT
(	I-OUT
FM	I-OUT
)	I-OUT
,	I-OUT
maximal	I-OUT
reach	I-OUT
distance	I-OUT
,	I-OUT
Stroke	I-OUT
Upper	I-OUT
Limb	I-OUT
Capacity	I-OUT
Scale	I-OUT
(	I-OUT
SULCS	I-OUT
)	I-OUT
,	I-OUT
and	I-OUT
arm	I-OUT
pain	I-OUT
via	I-OUT
Visual	I-OUT
Analogue	I-OUT
Scale	I-OUT
,	O
in	O
addition	O
to	O
perceived	O
motivation	O
by	O
Intrinsic	O
Motivation	O
Inventory	O
posttraining	O
.	O


The	O
AS	O
group	O
reported	O
higher	B-OUT
interest/enjoyment	I-OUT
during	O
training	O
than	O
the	O
CON	O
group	O
.	O


BACKGROUND	O
AND	O
AIMS	O
Studies	O
investigating	O
hyperbaric	B-I
oxygen	I-I
treatment	I-I
(	I-I
HBOT	I-I
)	I-I
to	O
improve	O
outcome	O
in	O
burns	O
have	O
been	O
inconclusive	O
.	O


In	O
this	O
study	O
,	O
we	O
aimed	O
to	O
characterize	O
early	B-P
thermal	I-P
burns	I-P
injury	I-P
in	I-P
adult	I-P
patients	I-P
with	I-P
<	I-P
40	I-P
%	I-P
total	I-P
body	I-P
surface	I-P
area	I-P
(	I-P
TBSA	I-P
)	I-P
and	O
to	O
determine	O
the	O
effects	O
of	O
HBOT	B-I
administered	O
within	O
24	O
h	O
to	O
48	O
h	O
of	O
a	O
burn	O
injury	O
.	O


Two	B-I
HBOT	I-I
patients	I-P
and	I-P
four	I-P
control	I-P
patients	I-P
developed	I-OUT
positive	I-OUT
bacterial	I-OUT
cultures	I-OUT
.	O


Inflammatory	B-OUT
markers	I-OUT
were	O
significantly	O
increased	O
at	O
24	O
h	O
in	O
patients	O
with	O
<	O
40	O
%	O
TBSA	O
burn	O
.	O


[	O
Postoperative	O
analgesia	O
:	O
peridural	B-I
morphine	I-I
versus	O
sublingual	B-I
buprenorphine	I-I
.	I-I


Comparative	O
clinical	O
study	O
]	O
.	O


However	O
,	O
the	O
necessity	O
to	O
administer	O
buprenorphine	B-I
more	O
frequently	O
after	O
the	O
sixth	O
hour	O
and	O
the	O
consequent	O
increase	O
in	O
side	B-OUT
effects	I-OUT
,	O
lead	O
us	O
to	O
believe	O
that	O
the	O
method	O
used	O
for	O
group	B-P
A	I-P
patients	I-P
is	O
more	O
advantageous	O
.	O


Randomized	O
,	O
placebo-controlled	B-I
,	O
crossover	O
study	O
of	O
methylphenidate	B-I
for	O
attention-deficit/hyperactivity	O
disorder	O
symptoms	O
in	B-P
preschoolers	I-P
with	I-P
developmental	I-P
disorders	I-P
.	I-P


The	O
primary	O
outcome	O
measure	O
was	O
the	O
Diagnostic	B-OUT
and	I-OUT
Statistical	I-OUT
Manual	I-OUT
of	I-OUT
Mental	I-OUT
Disorders	I-OUT
,	I-OUT
4	I-OUT
(	I-OUT
th	I-OUT
)	I-OUT
edition	I-OUT
(	I-OUT
DSM-IV	I-OUT
)	I-OUT
ADHD	I-OUT
subscale	I-OUT
of	I-OUT
the	I-OUT
Conners	I-OUT
'	I-OUT
Parent	I-OUT
Rating	I-OUT
Scale-Revised	I-OUT
(	O
CPRS-R-DSM-IV-ADHD	O
)	O
.	O


The	O
CPRS-R-DSM-IV-ADHD	B-OUT
subscale	I-OUT
was	O
significant	O
for	O
the	O
PDD	B-P
subgroup	I-P
(	O
p	O
=	O
0.005	O
,	O
Cohen	O
d	O
=	O
0.97	O
)	O
and	O
marginally	O
significant	O
for	O
the	O
entire	O
DD	O
sample	O
(	O
p	O
=	O
0.08	O
,	O
Cohen	O
d	O
=	O
0.50	O
)	O
.	O


CONCLUSION	O
The	O
predominant	O
direction	O
of	O
response	O
in	O
these	O
preschoolers	B-P
with	I-P
both	I-P
ADHD	I-P
and	I-P
PDD/ID	I-P
favored	O
MPH	B-I
,	O
even	O
though	O
the	O
response	O
was	O
more	O
subtle	O
and	O
variable	O
than	O
in	O
older	O
and	O
typically	O
developing	O
children	O
.	O


IMPORTANCE	O
Disruptive	O
behavior	O
is	O
common	O
in	O
children	B-P
with	I-P
autism	I-P
spectrum	I-P
disorder	I-P
.	I-P


TRIAL	O
REGISTRATION	O
clinicaltrials.gov	O
Identifier	O
:	O
NCT01233414	O
.	O


During	O
aortic	O
cross-clamping	O
dopexamine	B-I
was	O
a	O
useful	O
agent	O
in	O
improving	O
splanchnic	B-OUT
blood	I-OUT
flow	I-OUT
,	I-OUT
cardiac	I-OUT
index	I-OUT
venous	I-OUT
saturation	I-OUT
.	I-OUT


Also	O
,	O
since	O
the	O
drug	O
produces	O
dose	O
related	O
hemodynamic	O
changes	O
of	O
rapid	O
onset	O
and	O
reversibility	O
,	O
it	O
is	O
possible	O
to	O
interrupt	O
the	O
infusion	O
before	O
aortic	O
declamping	O
to	O
avoid	O
the	O
decrease	O
in	O
the	O
intramucosal	O
pH	O
value	O
.	O


METHOD	O
In	O
a	O
parallel	B-P
groups	I-P
design	I-P
,	I-P
12	I-P
children	I-P
with	I-P
DSM-IV	I-P
autistic	I-P
disorder	I-P
(	I-P
mean	I-P
age	I-P
7.8+/-2.1	I-P
years	I-P
)	I-P
were	I-P
randomized	I-P
to	O
6	O
weeks	O
of	O
open	B-I
treatment	I-I
with	I-I
olanzapine	I-I
or	I-I
haloperidol	I-I
.	I-I


CONCLUSIONS	O
The	O
findings	O
suggest	O
that	O
olanzapine	B-I
is	O
a	O
promising	O
treatment	B-OUT
for	O
children	B-P
with	I-P
autistic	I-P
disorder	I-P
.	I-P


BACKGROUND	O
Iron	O
deficiency	O
anemia	O
is	O
a	O
common	O
complication	O
in	O
patients	B-P
with	I-P
chronic	I-P
kidney	I-P
disease	I-P
(	I-P
CKD	I-P
)	I-P
.	I-P


The	O
main	O
objective	O
of	O
this	O
study	O
was	O
to	O
assess	O
the	O
safety	B-OUT
of	O
ferumoxytol	B-I
for	O
the	O
treatment	O
of	O
patients	B-P
with	I-P
CKD	I-P
stages	I-P
1	I-P
to	I-P
5	I-P
and	I-P
5D	I-P
.	I-P


Serious	B-OUT
adverse	I-OUT
events	I-OUT
occurred	O
in	O
21	O
patients	O
(	O
2.9	O
%	O
)	O
after	O
ferumoxytol	B-I
and	O
13	O
patients	O
(	O
1.8	O
%	O
)	O
after	O
placebo	B-I
.	I-I


CONCLUSIONS	O
Ferumoxytol	B-I
is	O
well	O
tolerated	B-OUT
and	O
has	O
a	O
safety	B-OUT
profile	I-OUT
similar	O
to	O
placebo	B-I
in	O
anemic	B-P
patients	I-P
with	I-P
CKD	I-P
stages	I-P
1	I-P
to	I-P
5	I-P
and	I-P
5D	I-P
.	I-P


Changes	O
in	O
hemodynamic	B-OUT
response	O
to	O
tasks	O
were	O
not	O
accompanied	O
by	O
consistent	O
changes	O
in	O
cognitive	B-OUT
performance	I-OUT
.	I-OUT


Adenosinergic	B-I
mechanisms	I-I
contribute	O
to	O
individual	B-P
differences	I-P
in	I-P
sleep	I-P
deprivation-induced	I-P
changes	O
in	O
neurobehavioral	O
function	O
and	O
brain	O
rhythmic	O
activity	O
.	O


Future	O
therapeutic	O
directions	O
for	O
factor	O
Xa	O
inhibition	O
in	O
the	O
prophylaxis	O
and	O
treatment	O
of	O
thrombotic	B-P
disorders	I-P
.	I-P


Current	O
investigations	O
that	O
are	O
under	O
way	O
or	O
completed	O
evaluate	O
the	O
efficacy	B-OUT
and	I-OUT
safety	I-OUT
of	O
fondaparinux	O
for	O
the	O
management	O
of	O
various	O
thrombotic	O
diseases	O
.	O


For	O
the	O
prevention	O
of	O
VTE	O
,	O
fondaparinux	B-I
has	O
been	O
studied	O
as	O
extended	O
prophylaxis	O
following	O
hip	O
fracture	O
surgery	O
(	O
PENTHIFRA	O
Plus	O
)	O
,	O
for	O
use	O
in	O
high-risk	O
abdominal	O
surgical	O
patients	O
(	O
PEGASUS	O
and	O
APOLLO	O
)	O
,	O
and	O
for	O
use	O
in	O
medical	O
patients	O
(	O
ARTEMIS	O
)	O
.	O


Studies	O
evaluating	O
fondaparinux	B-I
for	O
the	O
treatment	O
of	O
VTE	O
are	O
part	O
of	O
the	O
large	O
MATISSE	O
clinical	O
program	O
(	O
MATISSE	O
DVT	O
and	O
MATISSE	O
PE	O
)	O
.	O


Researchers	O
evaluated	O
whether	O
a	O
new	O
device	O
might	O
decrease	O
the	O
time	B-OUT
required	I-OUT
for	I-OUT
catheter	I-OUT
insertion	I-OUT
,	I-OUT
increase	I-OUT
the	I-OUT
likelihood	I-OUT
of	I-OUT
inserting	I-OUT
the	I-OUT
catheter	I-OUT
on	I-OUT
the	I-OUT
first	I-OUT
attempt	I-OUT
(	I-OUT
improved	I-OUT
accuracy	I-OUT
)	I-OUT
,	O
and	O
reduce	B-OUT
patient	I-OUT
discomfort	I-OUT
.	I-OUT


RESULTS	O
Of	O
the	O
1380	B-P
families	I-P
approached	I-P
,	I-P
313	I-P
were	I-P
enrolled	I-P
,	I-P
263	I-P
were	I-P
excluded	I-P
because	I-P
we	I-P
could	I-P
not	I-P
find	I-P
or	I-P
contact	I-P
a	I-P
family	I-P
member	I-P
(	I-P
FDR	I-P
or	I-P
parent	I-P
)	I-P
,	I-P
331	I-P
did	I-P
not	I-P
have	I-P
eligible	I-P
family	I-P
members	I-P
,	I-P
and	I-P
473	I-P
refused	I-P
.	I-P


Studies	O
2	O
and	O
3	O
were	O
designed	O
as	O
cross-over	O
studies	O
intended	O
to	O
investigate	O
drug	B-OUT
consumption	I-OUT
.	I-OUT


58	O
%	O
of	O
the	O
patients	O
opted	O
to	O
continuetreatment	B-OUT
with	O
lansoprazole	B-I
,	O
compared	O
with	O
only	O
25	O
%	O
in	O
the	O
case	O
of	O
esomeprazole	B-I
.	O


The	O
LKSS	B-OUT
was	O
assessed	O
before	O
treatment	O
,	O
10	O
days	O
of	O
treatment	O
,	O
by	O
the	O
end	O
of	O
the	O
treatment	O
,	O
and	O
1	O
month	O
after	O
treatment	O
.	O


Thirteen	O
cases	O
were	O
clinically	O
controlled	O
,	O
with	O
11	O
markedly	O
effective	O
,	O
6	O
effective	O
,	O
and	O
1	O
ineffective	O
in	O
the	O
treatment	O
group	O
,	O
while	O
5	O
cases	O
were	O
clinically	O
controlled	O
,	O
with	O
11	O
markedly	O
effective	O
,	O
10	O
effective	O
,	O
and	O
4	O
ineffective	O
in	O
the	O
control	O
group	O
.	O


Nasal	O
sprays	O
were	O
well	O
tolerated	B-OUT
and	O
there	O
was	O
no	O
evidence	O
of	O
increased	O
side	B-OUT
effects	I-OUT
resulting	O
from	O
oxytocin	B-I
administration	O
.	O


Patients	B-P
(	I-P
N	I-P
=	I-P
96	I-P
;	I-P
5-17	I-P
years	I-P
)	I-P
,	O
received	B-I
risperidone	I-I
(	I-I
low-dose	I-I
:	I-I
0.125	I-I
mg/day	I-I
[	I-I
20	I-I
to	I-I
<	I-I
45	I-I
kg	I-I
]	I-I
,	I-I
0.175	I-I
mg/day	I-I
[	I-I
>	I-I
45	I-I
kg	I-I
]	I-I
or	I-I
high-dose	I-I
:	I-I
1.25	I-I
mg/day	I-I
[	I-I
20	I-I
to	I-I
<	I-I
45	I-I
kg	I-I
]	I-I
,	I-I
1.75	I-I
mg/day	I-I
[	I-I
>	I-I
45	I-I
kg	I-I
]	I-I
)	I-I
or	O
placebo	O
.	O


Using	O
Z	B-I
rather	I-I
than	I-I
P	I-I
could	O
save	O
busy	O
cancer	O
centres	O
time	O
and	O
improve	O
patient	B-OUT
satisfaction	I-OUT
.	I-OUT


Sixty-three	B-P
women	I-P
with	I-P
evidence	I-P
of	I-P
underlying	I-P
hypertensive	I-P
disease	I-P
were	I-P
followed	I-P
prospectively	O
throughout	O
pregnancy	O
.	O


INTRODUCTION	O
The	O
aim	O
of	O
the	O
study	O
is	O
to	O
test	O
whether	O
nizatidine	B-I
delivered	O
via	O
a	O
unique	O
bimodal	O
pulsatile-controlled	O
release	O
system	O
,	O
nizatidine	B-I
controlled	I-I
release	I-I
(	I-I
CR	I-I
)	I-I
,	O
accelerates	O
gastric	B-OUT
emptying	I-OUT
in	O
patients	B-P
with	I-P
gastroesophageal	I-P
reflux	I-P
disease	I-P
(	I-P
GERD	I-P
)	I-P
.	I-P


All	B-P
the	I-P
84	I-P
patients	I-P
were	I-P
classified	I-P
at	I-P
baseline	I-P
with	I-P
DGE	I-OUT
(	I-P
gastric	I-P
retention	I-P
>	I-P
6.3	I-P
%	I-P
at	I-P
4	I-P
hours	I-P
)	I-P
or	I-P
normal	I-OUT
gastric	I-OUT
emptying	I-OUT
.	I-OUT


CONCLUSIONS	O
Nizatidine	B-I
CR	I-I
(	O
150	O
and	O
300	O
mg	O
)	O
significantly	O
enhanced	O
gastric	B-OUT
emptying	I-OUT
of	O
a	O
standard	O
meal	O
in	O
patients	B-P
with	I-P
GERD	I-P
with	I-P
DGE	I-P
.	I-P


DESIGN	O
Single	O
blind	O
randomized	O
clinical	O
trial	O
.	O


INTERVENTIONS	O
Patient	B-I
education	I-I
(	I-I
PE	I-I
)	I-I
.	I-I


RESULTS	O
No	O
significant	O
between	O
group	O
differences	O
were	O
found	O
for	O
WOMAC	B-OUT
pain	I-OUT
over	O
the	O
16-month	O
follow-up	O
.	O


No	O
significant	O
differences	O
were	O
found	O
for	O
WOMAC	B-OUT
stiffness	I-OUT
,	O
the	O
SF-36	O
subscales	O
or	O
the	O
activity	O
scale	O
.	O


METHOD	O
To	O
make	O
further	O
advances	O
in	O
untangling	O
this	O
chicken-and-egg	O
question	O
,	O
we	O
employed	O
autoregressive	O
cross-lagged	O
modeling	O
over	O
4	O
time	O
points	O
in	O
a	O
sample	O
of	O
149	B-P
depressive	I-P
patients	I-P
receiving	I-P
supportive-expressive	I-I
psychotherapy	I-I
or	I-I
clinical	I-I
management	I-I
combined	I-I
with	I-I
pharmacotherapy	I-I
or	I-I
clinical	I-I
management	I-I
combined	I-I
with	I-I
placebo	I-I
.	I-I


Additionally	O
,	O
alliance	B-OUT
,	O
but	O
not	O
symptoms	B-OUT
,	O
predicted	O
subsequent	B-OUT
alliance	I-OUT
levels	I-OUT
.	I-OUT


BACKGROUND	O
Laparoscopic	B-I
cholecystectomy	I-I
(	I-I
LC	I-I
)	I-I
has	O
become	O
the	O
treatment	O
of	O
choice	O
for	O
elective	B-I
cholecystectomy	I-I
,	O
but	O
controversy	O
persists	O
over	O
use	O
of	O
this	O
approach	O
in	O
the	O
treatment	O
of	O
acute	B-P
cholecystitis	I-P
.	I-P


METHODS	O
63	B-P
of	I-P
68	I-P
consecutive	I-P
patients	I-P
who	I-P
met	I-P
criteria	I-P
for	I-P
acute	I-P
cholecystitis	I-P
were	I-P
randomly	I-P
assigned	I-P
OC	I-I
(	I-P
31	I-P
patients	I-P
)	I-P
or	I-P
LC	I-I
(	I-P
32	I-P
patients	I-P
)	I-P
.	I-P


METHODS	O
Eight	B-P
healthy	I-P
subjects	I-P
underwent	I-P
esophageal	I-P
manometry	I-P
using	I-P
a	I-P
10-lumen	I-I
sleeve	I-I
assembly	I-I
during	I-I
placebo	I-I
or	I-I
loxiglumide	I-I
(	I-P
10	I-P
mg/kg/h	I-P
)	I-P
in	I-P
a	O
randomized	O
double-blind	O
order	O
.	O


Loxiglumide	O
significantly	O
reduced	O
the	O
number	O
of	O
TLESRs	B-OUT
,	O
from	O
11.5	O
(	O
5.8-18.3	O
)	O
to	O
6.0	O
(	O
3.3-14.3	O
)	O
during	O
the	O
total	O
recording	O
period	O
of	O
1	O
h	O
,	O
and	O
from	O
5.5	O
(	O
4.25-7.5	O
)	O
to	O
2.0	O
(	O
0.5-6.8	O
)	O
during	O
the	O
first	O
15	O
min	O
.	O


The	O
number	B-OUT
of	I-OUT
common	I-OUT
cavities	I-OUT
was	O
significantly	O
decreased	O
by	O
loxiglumide	O
,	O
from	O
8.0	O
(	O
4.0-20.0	O
)	O
to	O
5.0	O
(	O
2.0-7.8	O
)	O
.	O


TLESRs	B-OUT
represented	O
the	O
main	O
mechanism	O
(	O
60	O
%	O
during	O
placebo	O
,	O
74	O
%	O
during	O
loxiglumide	O
)	O
underlying	O
common	O
cavities	O
,	O
followed	O
by	O
swallow-induced	O
relaxation	O
.	O


CONCLUSIONS	O
Loxiglumide	O
significantly	O
reduces	O
the	O
number	O
of	O
TLESRs	B-OUT
triggered	O
by	O
gastric	O
distension	O
without	O
interfering	O
with	O
swallow-related	O
relaxation	O
of	O
the	O
lower	O
esophageal	O
sphincter	O
,	O
suggesting	O
the	O
involvement	O
of	O
CCKA	O
receptors	O
in	O
the	O
reflex	O
pathway	O
mediating	O
TLESRs	O
.	O


RESULTS	O
A	O
total	O
of	O
three	O
cases	O
(	O
1.8	O
%	O
)	O
in	O
study	O
group	O
and	O
four	O
cases	O
(	O
3	O
%	O
)	O
in	O
control	O
group	O
developed	O
DVT	O
.	O


This	O
difference	B-OUT
was	I-OUT
statistically	I-OUT
insignificant	I-OUT
(	O
P	O
>	O
0.05	O
)	O
.	O


We	O
present	O
data	O
regarding	O
551	B-P
women	I-P
who	I-P
had	I-P
colposcopy	I-I
in	I-P
Wales	I-P
for	I-P
a	I-P
low-grade	I-P
cytological	I-P
abnormality	I-P
and	I-P
who	I-P
were	I-P
followed	I-P
through	I-P
Cervical	I-P
Screening	I-P
Wales	I-P
for	I-P
subsequent	I-P
CIN	I-P
.	I-P


Thus	O
,	O
three	O
groups	O
were	O
formed	O
(	O
n	O
=	O
10	O
)	O
according	O
to	O
the	O
adhesive	O
system	O
employed	O
:	O
All-Bond	B-I
2	I-I
(	I-I
TE3	I-I
)	I-I
+	I-I
resin	I-I
cement	I-I
post	I-I
(	I-I
rcp	I-I
)	I-I
+	I-I
Duo-link	I-I
(	I-I
Dl	I-I
)	I-I
;	I-I
One-Step	I-I
Plus	I-I
(	I-I
TE2	I-I
)	I-I
+	I-I
rcp	I-I
+	I-I
Dl	I-I
;	I-I
Tyrian/One-Step	I-I
Plus	I-I
(	I-I
SE	I-I
)	I-I
+	I-I
rcp	I-I
+	I-I
Dl	I-I
.	I-I


Bilateral	B-I
transversus	I-I
abdominis	I-I
plane	I-I
block	I-I
does	O
not	O
decrease	O
postoperative	O
pain	O
after	O
laparoscopic	O
cholecystectomy	O
when	O
compared	O
with	O
local	B-I
anesthetic	I-I
infiltration	I-I
of	I-I
trocar	I-I
insertion	I-I
sites	I-I
.	I-I


After	O
exclusions	O
,	O
data	O
were	O
analyzed	O
on	O
39	O
patients	O
in	O
group	O
T	O
(	O
bilateral	O
TAP	B-I
block	I-I
)	I-I
and	O
35	O
patients	O
in	O
group	O
I	O
(	O
infiltration	O
)	O
.	O


There	O
was	O
no	O
statistically	B-OUT
significant	I-OUT
difference	I-OUT
in	O
pain	B-OUT
scores	I-OUT
on	I-OUT
the	I-OUT
numeric	I-OUT
analog	I-OUT
scale	I-OUT
(	O
0-10	O
)	O
between	O
the	O
groups	O
at	O
4	O
hrs	O
after	O
surgery	O
(	O
P	O
=	O
0.18	O
)	O
or	O
during	O
the	O
24	O
hrs	O
after	O
surgery	O
(	O
P	O
=	O
0.23	O
)	O
.	O


Early	B-OUT
specific	I-OUT
intervention	I-OUT
to	I-OUT
improve	I-OUT
the	I-OUT
autonomy	I-OUT
of	I-OUT
elderly	I-OUT
patients	I-OUT
seems	I-OUT
an	I-OUT
attractive	I-OUT
solution	I-OUT
that	O
could	O
be	O
assessed	O
by	O
randomized	O
controlled	O
trial	O
.	O


Above	O
all	O
,	O
our	O
results	O
should	O
also	O
serve	O
as	O
a	O
basis	O
for	O
further	O
controlled	O
randomized	O
studies	O
in	O
this	O
setting	O
.	O


A	O
sixty-day	O
feeding	O
trial	O
was	O
carried	O
out	O
to	O
elucidate	O
the	O
effect	O
of	O
dietary	B-I
pyridoxine	I-I
(	I-I
PN	I-I
)	I-I
on	O
hemato-immunological	B-OUT
parameters	I-OUT
in	O
Labeo	B-P
rohita	I-P
fingerlings	I-P
exposed	I-P
to	I-P
an	I-P
elevated	I-P
temperature	I-P
(	I-P
ET	I-P
)	I-P
of	I-P
33	I-P
°C	I-P
.	I-P


Two	B-P
hundred	I-P
and	I-P
seventy	I-P
fingerlings	I-P
(	I-P
6.71	I-P
±	I-P
0.32	I-P
g	I-P
)	I-P
were	O
randomly	O
distributed	O
into	B-I
six	I-I
treatments	I-I
in	I-I
triplicates	I-I
(	O
15	O
fish/tank	O
)	O
.	O


Also	B-OUT
,	I-OUT
serum	I-OUT
albumin	I-OUT
,	I-OUT
globulin	I-OUT
and	I-OUT
lysozyme	I-OUT
activity	I-OUT
were	O
found	O
significantly	O
(	O
p	O
<	O
0.05	O
)	O
higher	O
in	O
PN-fed	O
groups	O
.	O


All	O
patients	O
received	O
monthly	O
0.5-mg	O
ranibizumab	B-I
intravitreal	I-I
injections	I-I
for	O
3	O
months	O
,	O
after	O
which	O
monthly	O
injections	O
were	O
administered	O
in	O
accordance	O
with	O
the	O
standard	O
of	O
care	O
.	O


The	O
scores	B-OUT
from	I-OUT
5-items	I-OUT
questionnaires	I-OUT
and	I-OUT
6-items	I-OUT
clinical	I-OUT
score	I-OUT
were	O
significantly	O
associated	O
with	O
the	O
physician-diagnosed	O
groups	O
(	O
i.e.	O
,	O
controlled	O
,	O
partly	O
controlled	O
and	O
uncontrolled	O
groups	O
)	O
.	O


Twenty-nine	B-P
patients	I-P
with	I-P
mycologically	I-P
proven	I-P
tinea	I-P
pedis	I-P
were	O
randomly	O
allocated	O
to	O
oral	O
treatment	O
with	O
either	O
ketoconazole	B-I
200	I-I
mg	I-I
daily	I-I
or	I-I
griseofulvin	I-I
1	I-I
g	I-I
daily	O
for	O
a	O
period	O
of	O
up	O
to	O
8	O
weeks	O
.	O


Complete	B-OUT
response	I-OUT
after	O
controlling	O
for	O
hepatitis	O
C	O
virus	O
was	O
similar	O
(	O
relative	O
risk=1.19	O
;	O
95	O
%	O
confidence	O
interval=0.89-1.60	O
)	O
.	O


There	O
was	O
a	O
marginally	O
significant	O
difference	O
in	O
the	O
sustained	B-OUT
virological	I-OUT
response	I-OUT
between	O
IVDUs	O
(	O
46.6	O
%	O
)	O
and	O
non-IVDUs	O
(	O
34.6	O
%	O
)	O
(	O
relative	O
risk=1.35	O
;	O
95	O
%	O
confidence	O
interval=1.00-1.81	O
)	O
,	O
also	O
disappearing	O
after	O
adjusting	O
for	O
genotype	O
.	O


Therefore	O
,	O
it	O
is	O
no	O
longer	O
justifiable	O
to	O
withhold	O
treatment	O
to	O
chronic	B-OUT
hepatitis	I-OUT
C	I-OUT
patients	I-P
who	I-P
use	I-P
intravenous	I-P
drugs	I-P
.	I-P


Thus	O
,	O
treatment	O
with	O
single-chamber	B-I
atrial	I-I
pacing	I-I
is	O
safe	B-OUT
and	O
can	O
be	O
recommended	O
to	O
patients	B-P
with	I-P
sick	I-P
sinus	I-P
syndrome	I-P
without	O
bundle-branch	O
block	O
.	O


Eighty-eight	B-P
postmenopausal	I-P
women	I-P
with	I-P
metastatic	I-P
breast	I-P
cancer	I-P
,	I-P
in	I-P
whom	I-P
estrogen	I-P
receptors	I-P
(	I-P
ER	I-P
)	I-P
were	I-P
positive	I-P
or	I-P
unknown	I-P
,	O
were	O
treated	O
on	O
a	O
controlled	O
trial	O
to	O
determine	O
the	O
effectiveness	B-OUT
of	O
tamoxifen	B-I
and	I-I
to	I-I
assess	I-I
the	I-I
therapeutic	I-OUT
advantage	I-OUT
of	I-I
sequentially	I-I
adding	I-I
low-dose	I-I
cyclophosphamide-methotrexate-5-fluorouracil	I-I
(	I-I
CMF	I-I
)	I-I
chemotherapy	I-I
in	I-I
tamoxifen	I-I
responders	I-I
.	I-I


Patients	B-P
with	I-P
known	I-P
ER	I-P
negative	I-P
status	I-P
were	I-P
not	I-P
studied	I-P
.	I-P


MAIN	O
OUTCOME	O
MEASURE	O
(	O
S	O
)	O
Delta	B-OUT
"	I-OUT
stage-of-change	I-OUT
"	I-OUT
and	I-OUT
rate	I-OUT
of	I-OUT
maintained	I-OUT
cessation	I-OUT
at	O
12	O
months	O
post	O
follow-up	O
.	O


A	O
prospective	O
randomized	O
study	O
of	O
transurethral	B-I
resection	I-I
of	I-I
the	I-I
prostate	I-I
and	I-I
transurethral	I-I
vaporization	I-I
of	I-I
the	I-I
prostate	I-I
as	O
a	O
therapeutic	O
alternative	O
in	O
the	O
management	O
of	O
men	B-P
with	I-P
BPH	I-P
.	I-P


Mean	B-OUT
prostatic	I-OUT
volume	I-OUT
at	O
3	O
months	O
decreased	O
from	O
51.7	O
to	O
26.2	O
g	O
,	O
a	O
49.3	O
%	O
reduction	O
.	O


In	O
the	O
TUVP	O
group	O
,	O
none	O
of	O
the	O
patients	O
required	O
blood	B-OUT
transfusions	I-OUT
or	O
developed	O
clinical	B-OUT
transurethral	I-OUT
resection	I-OUT
syndrome	I-OUT
.	I-OUT


It	O
appears	O
to	O
be	O
an	O
effective	O
treatment	O
for	O
BPH	O
;	O
however	O
,	O
long-term	O
results	O
should	O
be	O
evaluated	O
.	O


Carotid	O
sinus	O
syndrome	O
:	O
a	O
modifiable	O
risk	O
factor	O
for	O
nonaccidental	B-OUT
falls	I-OUT
in	I-P
older	I-P
adults	I-P
(	O
SAFE	O
PACE	O
)	O
.	O


Falls	B-OUT
(	I-OUT
without	I-OUT
loss	I-OUT
of	I-OUT
consciousness	I-OUT
)	I-OUT
were	O
reduced	O
by	O
two-thirds	O
:	O
controls	O
reported	O
669	O
falls	O
(	O
mean	O
9.3	O
;	O
range	O
0	O
to	O
89	O
)	O
,	O
and	O
paced	O
patients	O
216	O
falls	O
(	O
mean	O
4.1	O
;	O
range	O
0	O
to	O
29	O
)	O
.	O


Thus	O
,	O
paced	O
patients	O
were	O
significantly	O
less	O
likely	O
to	O
fall	B-OUT
(	O
odds	O
ratio	O
0.42	O
;	O
95	O
%	O
confidence	O
interval	O
:	O
0.23	O
,	O
0.75	O
)	O
than	O
were	O
controls	O
.	O


Adverse	O
events	O
leading	O
to	O
withdrawal	O
were	O
few	O
(	O
n	O
=	O
0	O
perindopril	O
,	O
n	O
=	O
4	O
placebo	O
)	O
.	O


The	O
following	O
factors	O
were	O
negatively	O
associated	O
with	O
fruit	B-OUT
consumption	I-OUT
:	I-OUT
family	I-OUT
income	I-OUT
higher	I-OUT
than	I-OUT
four	I-OUT
minimum	I-OUT
wages	I-OUT
,	O
(	O
p=0.024	O
)	O
,	O
lower	B-OUT
paternal	I-OUT
educational	I-OUT
level	I-OUT
(	O
p=0.03	O
)	O
,	O
and	O
lower	B-OUT
fruit	I-OUT
consumption	I-OUT
at	I-OUT
12-16	I-OUT
months	I-OUT
(	O
p=0.002	O
)	O
.	O


This	O
study	O
investigated	O
the	O
effects	O
of	O
deep	B-I
pressure	I-I
on	O
arousal	O
and	O
anxiety	O
reduction	O
in	O
autism	O
with	O
Grandin	B-I
's	I-I
Hug	I-I
Machine	I-I
,	O
a	O
device	O
that	O
allows	O
self-administration	O
of	O
lateral	O
body	O
pressure	O
.	O


In	O
each	O
case	O
in	O
the	O
first	O
group	O
two	O
catheters	B-I
were	O
tied	O
together	O
and	O
introduced	O
transcervically	O
into	O
the	O
uterine	O
cavity	O
after	O
delivery	O
of	O
the	O
placenta	O
.	O


Intrauterine	B-I
catheter-tip	I-I
transducers	I-I
can	O
be	O
used	O
reliably	O
to	O
measure	O
uterine	B-OUT
activity	I-OUT
in	O
the	O
third	B-P
stage	I-P
of	I-P
labour	I-P
although	O
there	O
may	O
be	O
minor	O
contraction	O
by	O
contraction	O
differences	O
in	O
recordings	O
of	O
individual	B-OUT
active	I-OUT
pressures	I-OUT
.	I-OUT


Sub-Tenon	B-I
's	I-I
capsule	I-I
anesthesia	I-I
for	O
anterior	O
segment	O
surgery	O
avoids	O
the	O
risks	O
of	O
retrobulbar	B-I
and	O
peribulbar	O
injections	O
.	O


Pre-	B-OUT
and	I-OUT
postinjection	I-OUT
IOP	I-OUT
for	O
retrobulbar	B-I
and	O
1-QST	B-I
patients	O
were	O
similar	O
.	O


Complete	B-OUT
akinesia	I-OUT
was	O
achieved	O
in	O
41	O
%	O
with	O
1-QST	B-I
and	O
in	O
69	O
%	O
of	O
retrobulbar	O
patients	O
.	O


In	O
the	O
majority	O
of	O
patients	O
(	O
80	O
%	O
)	O
,	O
therapeutic	B-OUT
response	I-OUT
was	O
lost	O
within	O
30	O
minutes	O
following	O
discontinuation	O
of	O
esmolol	B-I
infusion	O
,	O
a	O
finding	O
indicative	O
of	O
rapid	O
reversal	O
of	O
beta-adrenoceptor	O
blockade	O
.	O


Inflammatory	O
pathways	O
in	O
RA	O
negatively	O
affect	O
vascular	O
physiology	O
and	O
promote	O
metabolic	O
disturbances	O
that	O
contribute	O
to	O
CVD	O
.	O


RA	O
disease	O
activity	O
was	O
assessed	O
with	B-OUT
the	I-OUT
28-Joint	I-OUT
Count	I-OUT
Disease	I-OUT
Activity	I-OUT
Score	I-OUT
(	I-OUT
DAS-28	I-OUT
)	I-OUT
C-reactive	I-OUT
protein	I-OUT
(	I-OUT
CRP	I-OUT
)	I-OUT
and	I-OUT
the	I-OUT
Short	I-OUT
Form	I-OUT
(	I-OUT
36	I-OUT
)	I-OUT
Health	I-OUT
Survey	I-OUT
quality	I-OUT
of	I-OUT
life	I-OUT
questionnaire	I-OUT
.	O


Further	B-I
,	I-I
pioglitazone	I-I
significantly	O
reduced	B-OUT
RA	I-OUT
disease	I-OUT
activity	I-OUT
(	I-OUT
P=0.02	I-OUT
)	I-OUT
and	I-OUT
CRP	I-OUT
levels	I-OUT
(	O
P=0.001	O
)	O
,	O
while	O
improving	O
lipid	O
profiles	O
.	O


In	O
the	O
G-CSF	B-I
group	O
,	O
the	O
duration	B-OUT
of	I-OUT
neutropenia	I-OUT
was	O
significantly	O
shorter	O
and	O
the	O
frequency	O
of	O
documented	O
infection	O
was	O
significantly	O
decreased	O
.	O


The	O
incidence	B-OUT
of	I-OUT
ARDS	I-OUT
due	I-OUT
to	I-OUT
pulmonary	I-OUT
infection	I-OUT
per	I-OUT
case	I-OUT
was	O
25.4	O
%	O
and	O
was	O
significantly	O
higher	O
in	O
the	O
G-CSF	B-I
group	O
(	O
p	O
<	O
0.025	O
,	O
chi2	O
test	O
)	O
.	O


Fourteen	O
events	O
occurred	O
in	O
5198	O
exposures	O
(	O
0.27	O
%	O
)	O
to	O
nifedipine	B-I
and	O
24	O
events	O
in	O
5402	O
exposures	O
(	O
0.44	O
%	O
)	O
to	O
other	O
active	O
drug	O
controls	O
.	O


Unadjusted	B-OUT
odds	I-OUT
ratios	I-OUT
for	O
nifedipine	O
versus	O
controls	O
were	O
0.49	O
(	O
95	O
%	O
confidence	O
interval	O
[	O
CI	O
]	O
,	O
0.22-1.09	O
)	O
for	O
definitive	B-OUT
events	I-OUT
(	I-OUT
death	I-OUT
,	I-OUT
nonfatal	I-OUT
myocardial	I-OUT
infarction	I-OUT
or	I-OUT
stroke	I-OUT
,	I-OUT
revascularization	I-OUT
procedure	I-OUT
)	I-OUT
and	O
0.61	O
(	O
95	O
%	O
CI	O
,	O
0.31-1.17	O
)	O
for	O
all	B-OUT
events	I-OUT
(	I-OUT
definitive	I-OUT
plus	I-OUT
increased	I-OUT
angina	I-OUT
)	I-OUT
.	I-OUT


The	O
odds	B-OUT
ratio	I-OUT
for	I-OUT
nifedipine	I-OUT
monotherapy	I-OUT
(	O
sustained-	O
or	O
extended-release	O
in	O
91	O
%	O
of	O
exposures	O
)	O
was	O
nonsignificantly	O
higher	O
for	O
definitive	O
and	O
all	O
events	O
(	O
odds	O
ratio	O
,	O
1.40	O
;	O
95	O
%	O
CI	O
,	O
0.49-4.03	O
and	O
odds	O
ratio	O
,	O
1.39	O
;	O
95	O
%	O
CI	O
,	O
0.59-3.32	O
,	O
respectively	O
)	O
.	O


In	O
the	O
intervention	O
group	O
,	O
42	O
women	O
(	O
33	O
%	O
)	O
conceived	O
,	O
of	O
which	O
29	O
pregnancies	O
were	O
ongoing	O
(	O
23	O
%	O
)	O
.	O


R/S	O
≥	O
0.5	O
criterion	O
:	O
Present	O
in	O
47	O
cases	B-I
:	I-I
6	I-I
of	I-I
lateral	I-I
MI	I-I
,	I-I
39	I-I
of	I-I
inferolateral	I-I
MI	O
,	O
2	O
of	O
inferior	O
MI	O
.	O


Diclofensine	B-I
inhibits	O
the	O
uptake	O
of	O
serotonin	O
,	O
noradrenaline	O
and	O
dopamine	O
.	O


Findings	O
suggest	O
that	O
a	O
50	O
mg	O
daily	O
dose	O
of	O
diclofensine	B-I
would	O
be	O
sufficient	O
for	O
the	O
majority	O
of	O
the	O
patients	O
.	O


While	O
the	O
efficacy	B-OUT
index	I-OUT
of	O
the	O
two	O
drugs	O
was	O
similar	O
(	O
approximately	O
60	O
%	O
)	O
,	O
they	O
differed	O
greatly	O
in	O
their	O
profile	B-OUT
of	I-OUT
side-effects	I-OUT
.	I-OUT


A	O
double-blind	O
,	O
placebo-controlled	B-I
trial	O
of	O
nefazodone	B-I
in	O
the	O
treatment	O
of	O
patients	B-P
hospitalized	I-P
for	I-P
major	I-P
depression	I-P
.	I-P


BACKGROUND	O
There	O
are	O
few	O
published	O
placebo-controlled	B-I
clinical	O
trials	O
demonstrating	O
the	O
efficacy	O
of	O
the	O
newer	O
antidepressants	O
in	O
markedly	B-P
or	I-P
severely	I-P
depressed	I-P
hospitalized	I-P
patients	I-P
.	I-P


RESULTS	O
Nefazodone	O
treatment	O
resulted	O
in	O
a	O
significant	O
reduction	O
(	O
p	O
<	O
.01	O
)	O
of	O
the	O
17-item	B-OUT
Hamilton	I-OUT
Rating	I-OUT
Scale	I-OUT
for	I-OUT
Depression	I-OUT
(	O
HAM-D-17	O
)	O
total	O
score	O
compared	O
with	O
placebo	B-I
from	O
the	O
end	O
of	O
the	O
first	O
treatment	O
week	O
through	O
the	O
end	O
of	O
the	O
study	O
(	O
-12.2	O
nefazodone	B-I
vs.	O
-7.7	O
placebo	B-I
)	I-I
.	O


Significantly	O
more	O
patients	O
treated	O
with	O
nefazodone	B-I
(	O
36	O
%	O
)	O
than	O
placebo-treated	B-I
patients	O
(	O
14	O
%	O
)	O
had	O
a	O
HAM-D-17	B-OUT
score	I-OUT
<	O
or	O
=	O
10	O
at	O
the	O
end	O
of	O
treatment	O
(	O
p	O
=	O
.004	O
)	O
.	O


MATERIALS	O
AND	O
METHODS	O
Three	B-P
hundred	I-P
consecutive	I-P
patients	I-P
scheduled	I-P
for	I-P
US-guided	I-P
TPB	I-P
were	O
randomized	O
1:1:1	O
to	O
receive	O
PI	B-I
administration	O
of	O
5	O
g	O
2.5	O
%	O
lidocaine	B-I
gel	I-I
10	O
minutes	O
before	O
TPB	O
(	O
Group	O
1	O
)	O
,	O
or	O
a	O
mixture	O
of	O
5	B-I
g	I-I
2.5	I-I
%	I-I
lidocaine	I-I
gel	I-I
and	I-I
0.3	I-I
%	I-I
ketorolac	I-I
tromethamine	I-I
solution	I-I
1	I-I
hour	I-I
before	I-I
TPB	I-I
(	O
Group	O
2	O
)	O
,	O
or	O
5	B-I
g	I-I
2.5	I-I
%	I-I
lidocaine	I-I
and	I-I
2.5	I-I
%	I-I
prilocaine	I-I
cream	I-I
20	I-I
minutes	I-I
before	I-I
TPB	I-I
(	O
Group	O
3	O
)	O
.	O


The	O
0-to-10	B-OUT
points	I-OUT
visual	I-OUT
analogue	I-OUT
scale	I-OUT
(	I-OUT
VAS	I-OUT
)	I-OUT
was	O
used	O
for	O
assessing	O
pain	O
at	O
probe	O
insertion	O
and	O
movements	O
(	O
VAS-1	O
)	O
,	O
at	O
prostate	O
sampling	O
(	O
VAS-2	O
)	O
,	O
and	O
maximal	O
procedural	O
pain	O
(	O
MPP	O
)	O
.	O


Interestingly	O
,	O
letrozole	B-I
was	O
effective	O
even	O
in	O
marginally	O
ER+	O
tumors	O
and	O
,	O
unlike	O
tamoxifen	O
,	O
consistently	O
reduced	O
the	O
expression	B-OUT
from	I-OUT
estrogen-regulated	I-OUT
genes	I-OUT
(	O
progesterone	O
receptor	O
and	O
trefoil	O
factor	O
1	O
)	O
.	O


Furthermore	O
,	O
when	O
analyzed	O
by	O
Ki67	O
immunohistochemistry	O
,	O
letrozole	O
was	O
significantly	O
more	O
effective	O
than	O
tamoxifen	O
in	O
reducing	O
tumor	B-OUT
proliferation	I-OUT
(	O
P=0.0009	O
)	O
.	O


In	O
the	O
exercise	B-I
therapy	I-I
group	O
the	O
percentage	O
of	O
patients	O
with	O
sickness	B-OUT
absence	I-OUT
was	O
higher	O
and	O
the	O
duration	B-OUT
of	I-OUT
absence	I-OUT
was	O
longer	O
than	O
in	O
the	O
placebo	B-I
and	O
usual	B-I
care	I-I
groups	O
,	O
but	O
these	O
differences	O
were	O
not	O
significant	O
.	O


CONCLUSIONS	O
Exercise	B-I
therapy	I-I
for	O
patients	B-P
with	I-P
acute	I-P
low	I-P
back	I-P
pain	I-P
does	O
not	O
reduce	O
sickness	B-OUT
absence	I-OUT
.	I-OUT


The	O
median	B-OUT
duration	I-OUT
of	I-OUT
response	I-OUT
for	O
tamoxifen	B-I
(	O
20	O
months	O
)	O
was	O
longer	O
than	O
that	O
for	O
surgical	B-I
oophorectomy	I-I
(	O
7	O
months	O
)	O
,	O
but	O
this	O
did	O
not	O
achieve	O
statistical	O
significance	O
(	O
P	O
=	O
.056	O
)	O
.	O


Toxicity	B-OUT
was	O
greater	O
in	O
those	O
undergoing	O
oophorectomy	O
,	O
though	O
both	B-OUT
treatments	I-OUT
were	I-OUT
well	I-OUT
tolerated	I-OUT
.	I-OUT


OBJECTIVE	O
To	O
compare	O
the	O
effect	O
of	O
ethinyl	B-I
estradiol	I-I
20	I-I
microg/drospirenone	I-I
3	I-I
mg	I-I
(	O
EE	O
20	O
microg/DRSP	O
3	O
mg	O
)	O
administered	O
according	O
to	O
a	O
24/4	O
regimen	O
with	O
ethinyl	B-I
estradiol	I-I
20	I-I
microg/desogestrel	I-I
150	O
microg	O
(	O
EE	O
20	O
microg/DSG	O
150	O
microg	O
)	O
administered	O
according	O
to	O
the	O
conventional	O
21/7	O
regimen	O
on	O
lipid	O
,	O
carbohydrate	O
and	O
hemostatic	O
parameters	O
.	O


SETTING	O
The	B-P
medical	I-P
intensive	I-P
care	I-P
unit	I-P
(	I-P
ICU	I-P
)	I-P
of	I-P
a	I-P
university	I-P
hospital	I-P
located	I-P
in	I-P
a	I-P
large	I-P
metropolitan	I-P
area	I-P
.	I-P


PATIENTS	O
A	B-P
total	I-P
of	I-P
100	I-P
patients	I-P
who	I-P
were	I-P
admitted	I-P
to	I-P
the	I-P
medical	I-P
ICU	I-P
,	I-P
required	I-P
arterial	I-P
line	I-P
monitoring	I-P
for	I-P
clinical	I-P
purposes	I-P
,	I-P
and	I-P
were	I-P
managed	I-P
by	I-P
the	I-P
ICU	I-P
medical	I-P
service	I-P
.	I-P


MEASUREMENTS	O
AND	O
MAIN	O
RESULTS	O
Data	O
gathered	O
included	O
:	O
age	O
;	O
gender	O
;	O
ICU	O
discharge	O
status	O
;	O
the	O
duration	B-OUT
of	I-OUT
ICU	I-OUT
stay	I-OUT
;	I-OUT
time	I-OUT
in	I-OUT
the	I-OUT
study	I-OUT
;	I-OUT
volume	I-OUT
of	I-OUT
all	I-OUT
blood	I-OUT
drawn	I-OUT
,	I-OUT
discarded	I-OUT
,	I-OUT
or	I-OUT
lost	I-OUT
due	I-OUT
to	I-OUT
leakage	I-OUT
;	I-OUT
hemoglobin	I-OUT
concentrations	I-OUT
;	I-OUT
blood	I-OUT
transfusions	I-OUT
;	I-OUT
and	I-OUT
accidental	I-OUT
needle	I-OUT
injuries	I-OUT
.	I-OUT


The	O
blood	B-I
conservation	I-I
system	I-I
did	O
not	O
alter	O
or	O
interfere	O
with	O
pressure	B-OUT
waveforms	I-OUT
.	I-OUT


On	O
Days	O
-2	O
,	O
7	O
,	O
14	O
,	O
21	O
,	O
and	O
28	O
,	O
each	O
cat	O
was	O
infested	O
with	O
100	O
adult	O
C.	O
felis	O
from	O
the	O
Kansas	B-P
1	I-P
flea	I-P
strain	I-P
.	I-P


At	O
21	O
and	O
28	O
days	O
after	O
treatment	O
,	O
none	O
of	O
the	O
formulations	O
killed	O
significant	O
numbers	B-OUT
of	I-OUT
fleas	I-OUT
as	O
compared	O
to	O
controls	O
within	O
6	O
hours	O
of	O
infestation	O
.	O


This	O
study	O
demonstrates	O
that	O
the	O
speed	O
of	O
kill	O
of	O
residual	O
flea	B-OUT
products	I-OUT
on	O
cats	B-P
decreases	O
throughout	O
the	O
month	O
following	O
application	O
.	O


Basal	B-OUT
levels	I-OUT
of	I-OUT
plasma	I-OUT
B-TG	I-OUT
and	I-OUT
PF4	I-OUT
and	O
the	O
maximal	O
amplitude	B-OUT
of	I-OUT
ADP-induced	I-OUT
platelet	I-OUT
aggregation	I-OUT
were	O
abnormally	O
high	O
in	O
TIA	O
patients	O
.	O


Risk	O
of	O
anterior	B-P
cruciate	I-P
ligament	I-P
fatigue	I-P
failure	I-P
is	I-P
increased	O
by	O
limited	O
internal	O
femoral	O
rotation	O
during	O
in	O
vitro	O
repeated	O
pivot	O
landings	O
.	O


MPA	B-I
:	I-I
in	O
this	O
group	O
,	O
89	O
%	O
of	O
responders	O
still	O
showed	O
a	O
benefit	O
at	O
week	O
24	O
,	O
compared	O
with	O
45	O
%	O
in	O
the	O
megestrol	B-I
group	O
(	O
P	O
=	O
0.03	O
)	O
.	O


depot	O
MPA	B-I
injections	O
provides	O
significant	O
and	O
long-lasting	O
relief	B-OUT
from	O
postmenopausal	B-OUT
hot	I-OUT
flashes	I-OUT
in	O
patients	B-P
with	I-P
a	I-P
history	I-P
of	I-P
breast	I-P
cancer	I-P
,	O
offering	O
an	O
alternative	O
to	O
estrogen	O
replacement	O
therapy	O
or	O
prolonged	O
administration	O
of	O
oral	O
megestrol	B-I
.	I-I


This	O
research	O
will	O
have	O
two	O
potential	O
benefits	O
in	O
the	O
sense	O
of	O
helping	B-P
children	I-P
with	I-P
autism	I-P
and	O
protecting	O
the	O
endangered	O
species	O
.	O


The	O
remainder	O
made	O
an	O
uncomplicated	B-OUT
recovery	I-OUT
.	I-OUT


Intramuscular	O
phenobarbitone	O
is	O
well	O
absorbed	O
in	O
children	B-P
with	I-P
severe	I-P
malaria	I-P
;	I-P
the	O
optimum	O
prophylactic	O
anticonvulsant	O
dose	O
remains	O
to	O
be	O
determined	O
.	O


A	O
randomized	O
comparison	O
of	O
parecoxib/valdecoxib	B-I
and	O
placebo	B-I
for	O
the	O
prevention	O
of	O
cystoid	O
macular	O
edema	O
after	O
scleral	B-P
buckling	I-P
surgery	I-P
.	I-P


There	O
was	O
no	O
evidence	O
of	O
a	O
difference	O
between	O
COX	O
2	O
inhibitor	O
and	O
placebo	O
groups	O
in	O
the	O
incidence	B-OUT
of	I-OUT
edema	I-OUT
,	I-OUT
retinal	I-OUT
thickness	I-OUT
or	I-OUT
visual	I-OUT
outcome	I-OUT
.	I-OUT


CONCLUSIONS	O
The	O
rate	O
of	O
cystoid	O
macular	O
edema	O
after	O
scleral	O
buckling	O
surgery	O
is	O
low	O
and	O
is	O
not	O
influenced	O
by	O
prophylactic	O
use	O
of	O
valdecoxib	B-I
.	I-I


BACKGROUND	O
AND	O
PURPOSE	O
Prolonged	O
wakefulness	O
impairs	O
sustained	O
vigilant	B-OUT
attention	I-OUT
,	O
measured	O
with	O
the	O
psychomotor	B-OUT
vigilance	I-OUT
task	I-OUT
(	I-OUT
PVT	I-OUT
)	I-OUT
,	O
and	O
induces	O
a	O
compensatory	O
increase	O
in	O
sleep	O
intensity	O
in	O
recovery	O
sleep	O
,	O
quantified	O
by	O
slow-wave	B-OUT
activity	I-OUT
(	I-OUT
SWA	I-OUT
)	I-OUT
in	O
the	O
sleep	B-OUT
electroencephalogram	I-OUT
(	I-OUT
EEG	I-OUT
)	I-OUT
.	O


CONCLUSIONS	O
AND	O
IMPLICATIONS	O
Common	O
genetic	O
variation	O
of	O
ADORA2A	O
is	O
an	O
important	O
determinant	O
of	B-OUT
psychomotor	I-OUT
vigilance	I-OUT
in	O
rested	O
and	O
sleep-deprived	O
state	O
.	O


Cone	O
biopsy	O
:	O
has	O
endocervical	B-I
sampling	I-I
a	O
role	O
?	O
OBJECTIVE	O
To	O
investigate	O
the	O
sensitivity	O
,	O
specificity	O
and	O
predictive	O
value	O
of	O
endocervical	B-I
sampling	I-I
in	O
women	B-P
with	I-P
abnormal	I-P
cervical	I-P
smears	I-P
.	I-P


MAIN	O
OUTCOME	O
MEASURES	O
Cytology	B-OUT
and	I-OUT
histology	I-OUT
results	I-OUT
from	I-OUT
endocervical	I-OUT
sampling	I-OUT
compared	I-OUT
with	I-OUT
cone	I-OUT
biopsy	I-OUT
histology	I-OUT
.	I-OUT


Fifty-one	O
(	O
64.6	O
%	O
)	O
of	O
these	O
adverse	B-OUT
events	I-OUT
occurred	O
in	O
patients	O
treated	O
with	O
FLOX	B-I
and	O
28	O
(	O
35.4	O
%	O
)	O
in	O
those	O
treated	O
with	O
FL	O
(	O
P	O
<	O
.01	O
)	O
.	O


Effects	O
of	O
glucocorticoids	B-I
on	O
energy	B-OUT
metabolism	I-OUT
and	O
food	B-OUT
intake	I-OUT
in	O
humans	B-P
.	I-P


Energy	B-OUT
metabolism	I-OUT
was	O
measured	O
by	O
indirect	O
calorimetry	O
and	O
food	B-OUT
intake	I-OUT
by	O
an	O
automated	O
food-selection	O
system	O
.	O


Immune	B-OUT
status	I-OUT
of	I-P
infants	I-P
fed	I-P
soy-based	I-I
formulas	I-I
with	I-P
or	I-P
without	I-P
added	I-I
nucleotides	I-I
for	I-P
1	I-P
year	I-P
:	I-P
part	O
2	O
:	O
immune	O
cell	O
populations	O
.	O


Nucleotides	B-I
added	O
to	O
milk-based	O
formula	O
benefit	O
infant	O
immune	O
status	O
,	O
but	O
reports	O
of	O
the	O
immunologic	B-OUT
effects	I-OUT
of	O
adding	O
nucleotides	B-I
to	O
soy-based	B-I
formula	I-I
are	O
not	O
available	O
.	O


None	O
of	O
the	O
cell	B-OUT
populations	I-OUT
differed	O
between	O
infants	B-P
fed	I-P
soy	I-P
formula	I-P
versus	O
soy	O
plus	O
nucleotides	B-I
.	I-I


RESULTS	O
Biofilm	B-OUT
,	I-OUT
250	I-OUT
Mum	I-OUT
thick	I-OUT
,	O
was	O
observed	O
with	O
CLSM	O
on	O
the	O
polished	O
acrylic	O
surface	O
.	O


Significantly	O
less	O
bacterial	B-OUT
accumulation	I-OUT
was	O
observed	O
on	O
the	O
crowns	O
coated	O
with	O
bonding	O
agent	O
,	O
whereas	O
no	O
biofilm	B-OUT
was	O
observed	O
on	O
the	O
crowns	O
coated	O
with	O
liquid	O
polish	O
(	O
P	O
<	O
.001	O
)	O
.	O


Irrespective	O
of	O
MIC	O
and	O
dose	O
of	O
mefloquine	O
,	O
parasitaemia	O
cleared	O
in	O
all	O
subjects	O
in	O
96	O
h	O
or	O
less	O
.	O


Additional	O
measurements	O
such	O
as	O
change	O
in	O
urinary	B-OUT
potassium	I-OUT
level	I-OUT
,	I-OUT
capsule	I-OUT
count	I-OUT
,	I-OUT
client	I-OUT
self	I-OUT
report	I-OUT
and	I-OUT
physician	I-OUT
estimate	I-OUT
of	I-OUT
adherence	I-OUT
were	O
recorded	O
.	O


PURPOSE	O
We	O
determined	O
the	O
prognostic	O
value	O
of	O
carcinoembryonic	O
antigen	O
(	O
CEA	O
)	O
clearance	O
after	O
tumor	B-I
resection	I-I
with	O
serial	O
evaluation	O
of	O
postoperative	O
CEA	O
levels	O
in	O
rectal	B-P
cancer	I-P
.	I-P


METHODS	O
Between	B-P
1994	I-P
and	I-P
2004	I-P
,	I-P
we	I-P
retrospectively	I-P
reviewed	I-P
122	I-P
patients	I-P
with	I-P
rectal	I-P
cancer	I-P
whose	I-P
serum	I-OUT
CEA	I-OUT
levels	I-OUT
were	I-P
measured	I-P
on	I-P
the	I-P
preoperative	I-P
day	I-P
and	I-P
postoperative	I-P
days	I-P
7	I-P
and	I-P
30	I-P
.	I-P


Vitamin	B-I
C	I-I
and	O
acute	O
illness	O
in	O
Navajo	B-P
school	I-P
children	I-P
.	I-P


PURPOSE	O
The	O
purpose	O
was	O
to	O
assess	B-OUT
the	I-OUT
incidence	I-OUT
and	I-OUT
clinical	I-OUT
manifestations	I-OUT
of	O
radiation-induced	O
brachial	O
plexopathy	O
in	O
breast	B-P
cancer	I-P
patients	I-P
,	I-P
treated	I-P
according	I-P
to	I-P
the	I-P
Danish	I-P
Breast	I-P
Cancer	I-P
Cooperative	I-P
Group	I-P
protocols	I-P
.	I-P


METHODS	O
AND	O
MATERIALS	O
One	B-P
hundred	I-P
and	I-P
sixty-one	I-P
recurrence-free	I-P
breast	I-P
cancer	I-P
patients	I-P
were	I-P
examined	I-P
for	I-P
radiation-induced	I-P
brachial	I-P
plexopathy	I-P
after	I-P
a	I-P
median	I-P
follow-up	I-P
period	I-P
of	I-P
50	I-P
months	I-P
(	I-P
13-99	I-P
months	I-P
)	I-P
.	I-P


One	O
hundred	O
twenty-eight	O
patients	O
were	O
treated	O
with	O
postoperative	B-I
radiotherapy	I-I
with	I-I
50	I-I
Gy	I-I
in	O
25	O
daily	O
fractions	O
over	O
5	O
weeks	O
.	O


Fractions	O
of	O
2	O
Gy	O
or	O
less	O
are	O
advisable	O
.	O


Both	O
SQ29,852	B-I
(	O
mean	O
dose	O
15.0	O
+/-	O
5.1	O
mg/day	O
)	O
and	O
atenolol	B-I
(	O
mean	O
dose	O
37.5	O
+/-	O
18.5	O
mg/day	O
)	O
significantly	O
decreased	O
both	O
systolic	B-OUT
and	I-OUT
diastolic	I-OUT
blood	I-OUT
pressures	I-OUT
.	I-OUT


There	O
were	O
no	O
significant	O
changes	O
in	O
serum	B-OUT
lipids	I-OUT
,	I-OUT
apolipoproteins	I-OUT
,	I-OUT
lipoproteins	I-OUT
or	I-OUT
atherosclerotic	I-OUT
indices	I-OUT
after	O
both	O
SQ29,852	B-I
and	O
atenolol	B-I
.	I-I


There	O
were	O
also	O
no	B-OUT
significant	I-OUT
inter-group	I-OUT
differences	I-OUT
.	I-OUT


Entomological	O
determinants	O
of	O
insecticide-treated	O
bed	O
net	O
effectiveness	B-OUT
in	O
Western	B-P
Myanmar	I-P
.	I-P


BACKGROUND	O
In	O
a	O
large	O
cluster	O
randomized	O
control	O
trial	O
of	O
insecticide-treated	B-I
bed	I-I
nets	I-I
(	I-I
ITN	I-I
)	I-I
in	O
Western	B-P
Myanmar	I-P
the	O
malaria	O
protective	B-OUT
effect	I-OUT
of	O
ITN	B-I
was	O
found	O
to	O
be	O
highly	O
variable	O
and	O
,	O
in	O
aggregate	O
,	O
the	O
effect	O
was	O
not	O
statistically	O
significant	O
.	O


A	O
total	O
of	O
916	B-P
person	I-P
nights	I-P
yielded	I-P
3,009	I-P
female	I-P
anopheline	I-P
mosquitoes	I-P
between	I-P
6	I-P
pm	I-P
and	I-P
6	I-P
am	I-P
.	I-P


Overall	O
51	O
%	O
(	O
1447/2837	O
)	O
of	O
all	O
bites	B-OUT
recorded	I-OUT
were	O
between	O
6	O
pm	O
and	O
8	O
pm	O
.	O


A	B-P
large	I-P
proportion	I-OUT
of	I-OUT
children	I-OUT
were	O
not	O
sleeping	B-OUT
under	O
an	O
ITN	B-I
during	O
peak	B-OUT
biting	I-OUT
times	I-OUT
.	I-OUT


The	O
limited	O
efficacy	B-OUT
of	O
ITN	B-I
in	O
this	O
area	O
of	O
Western	B-P
Myanmar	I-P
may	O
be	O
explained	O
by	O
the	O
biting	O
behaviour	O
of	O
the	O
prevalent	O
Anopheles	O
mosquito	O
vectors	O
in	O
this	O
area	O
.	O


STUDY	O
OBJECTIVES	O
To	O
examine	O
potential	O
threats	O
to	O
internal	O
and	O
external	O
study	O
validity	O
caused	O
by	O
differential	B-P
patient	I-P
withdrawal	I-P
from	I-P
a	I-P
randomized	I-P
controlled	I-P
trial	I-P
evaluating	I-P
pharmacist	I-P
management	I-P
of	I-P
hypertension	I-P
,	I-P
to	I-P
compare	I-P
the	I-P
characteristics	I-P
of	I-P
patients	I-P
who	I-P
withdrew	I-P
with	I-P
those	I-P
of	I-P
patients	I-P
who	I-P
completed	I-P
the	I-P
study	I-P
,	I-P
and	I-P
to	I-P
identify	I-P
characteristics	I-P
that	I-P
predispose	I-P
patients	I-P
to	I-P
withdraw	I-P
from	I-P
hypertension	I-P
management	I-P
.	I-P


PATIENTS	O
Four	B-P
hundred	I-P
sixty-three	I-P
patients	I-P
with	I-P
a	I-P
diagnosis	I-P
of	I-P
hypertension	I-P
and	I-P
a	I-P
last	I-P
documented	I-P
systolic	I-P
blood	I-P
pressure	I-P
of	I-P
160	I-P
mm	I-P
Hg	I-P
or	I-P
greater	I-P
and/or	I-P
diastolic	I-P
blood	I-P
pressure	I-P
of	I-P
100	I-P
mm	I-P
Hg	I-P
or	I-P
greater	I-P
.	I-P


METHODS	O
Patients	B-P
with	I-P
type	I-P
2	I-P
diabetes	I-P
,	I-P
mild-to-moderate	I-P
hypertension	I-P
(	I-P
diastolic	I-P
blood	I-P
pressure	I-P
85-105	I-P
mmHg	I-P
,	I-P
systolic	I-P
blood	I-P
pressure	I-P
<	I-P
160	I-P
mmHg	I-P
,	I-P
and	I-P
24-hour	I-P
mean	I-P
systolic	I-P
blood	I-P
pressure	I-P
>	I-P
130	I-P
mmHg	I-P
)	I-P
,	I-P
and	I-P
microalbuminuria	I-P
were	O
randomized	O
to	O
1	O
year	O
of	O
doubleblind	O
treatment	O
with	O
fixed-dose	B-I
manidipine/delapril	I-I
(	O
n=54	O
)	O
or	O
losartan/hydrochlorothiazide	B-I
(	I-I
HCTZ	I-I
)	I-I
(	O
n=56	O
)	O
.	O


Glycemia	B-OUT
over	O
the	O
1-year	O
study	O
was	O
largely	O
unaffected	O
;	O
the	O
blood	B-OUT
glucose	I-OUT
concentration	I-OUT
was	O
reduced	O
from	O
baseline	O
with	O
manidipine/delapril	B-I
,	O
although	O
not	O
statistically	O
significant	O
(	O
mean	O
change	O
-0.2	O
mmol/L	O
,	O
P=0.064	O
)	O
.	O


from	O
the	O
ratio	O
of	O
detection	O
rate	O
(	O
prevalence	O
of	O
screen-detected	O
cases	O
)	O
and	O
expected	O
incidence	O
(	O
cumulative	O
risk	O
)	O
.	O


A	O
lower	O
PSA	B-OUT
cut-off	I-OUT
level	I-OUT
of	O
3	O
ng/ml	O
used	O
in	O
Sweden	O
and	O
The	O
Netherlands	O
prolonged	O
the	O
mean	O
lead-time	O
by	O
approximately	O
1	O
year	O
.	O


CONCLUSION	O
The	O
lead-time	O
for	O
prostate	O
cancer	O
found	O
in	O
ERSPC	O
substantially	O
exceeded	O
that	O
found	O
for	O
breast	O
,	O
cervical	O
and	O
colorectal	O
cancer	O
screening	O
.	O


One	O
round	O
of	O
prostate	O
cancer	O
screening	O
can	O
advance	O
clinical	O
diagnosis	O
by	O
4-8	O
years	O
.	O


OBJECTIVE	O
Our	O
aim	O
was	O
to	O
evaluate	O
the	O
hypothesis	O
that	O
testosterone	B-I
treatment	I-I
and	O
a	O
nutritional	B-I
supplement	I-I
have	O
additive	O
benefits	O
.	O


RESULTS	O
In	O
subjects	O
receiving	O
combined	B-I
testosterone	I-I
and	I-I
nutritional	I-I
supplements	I-I
(	O
n	O
=	O
11	O
)	O
,	O
there	O
were	O
no	O
hospital	B-OUT
admissions	I-OUT
,	O
whereas	O
there	O
were	O
9	O
admissions	O
(	O
2	O
elective	O
)	O
in	O
13	O
subjects	O
in	O
the	O
no-treatment	B-I
group	O
,	O
4	O
in	O
the	O
testosterone-treated	B-I
group	O
(	O
n	O
=	O
12	O
)	O
,	O
and	O
5	O
in	O
the	O
supplement-treated	B-I
group	O
(	O
n	O
=	O
13	O
)	O
;	O
P	O
=	O
0.06	O
with	O
no-treatment	O
compared	O
with	O
combined	O
treatment	O
.	O


BACKGROUND	O
We	O
evaluated	O
the	O
antithrombotic	O
effects	O
of	O
statins	B-I
and	O
angiotensin-converting	B-I
enzyme	I-I
inhibitor	I-I
(	I-I
ACEI	I-I
)	I-I
drugs	I-I
in	O
patients	B-P
with	I-P
coronary	I-P
artery	I-P
disease	I-P
(	I-P
CAD	I-P
)	I-P
.	I-P


Rates	B-OUT
of	I-OUT
prothrombin	I-OUT
and	I-OUT
factor	I-OUT
V	I-OUT
activation	I-OUT
(	I-OUT
FVa	I-OUT
)	I-OUT
,	I-OUT
fibrinogen	I-OUT
(	I-OUT
Fbg	I-OUT
)	I-OUT
cleavage	I-OUT
and	I-OUT
FVa	I-OUT
inactivation	I-OUT
showed	O
that	O
both	O
quinapril	O
and	O
atorvastatin	O
decreased	O
the	O
rates	O
of	O
:	O
formation	B-OUT
of	I-OUT
thrombin	I-OUT
B-chain	I-OUT
(	O
by	O
30.6	O
%	O
,	O
P=0.007	O
;	O
and	O
by	O
34.3	O
%	O
,	O
P=0.003	O
)	O
,	O
formation	B-OUT
of	I-OUT
thrombin-antithrombin	I-OUT
complexes	I-OUT
(	O
by	O
30.4	O
%	O
,	O
P=0.0002	O
;	O
and	O
by	O
40	O
%	O
,	O
P=0.001	O
)	O
,	O
FV	B-OUT
activation	I-OUT
(	O
by	O
19.1	O
%	O
,	O
P=0.03	O
;	O
and	O
by	O
21.8	O
%	O
,	O
P=0.005	O
)	O
and	O
Fbg	B-OUT
depletion	I-OUT
(	O
by	O
29.2	O
%	O
,	O
P=0.004	O
;	O
and	O
by	O
32.7	O
%	O
,	O
P=0.001	O
)	O
.	O


Atorvastatin	O
alone	O
accelerated	O
FVa	B-OUT
inactivation	I-OUT
(	O
P=0.005	O
)	O
.	O


CONCLUSIONS	O
In	O
CAD	B-P
patients	I-P
,	O
atorvastatin	O
and	O
quinapril	O
slowed	O
blood	O
clotting	O
at	O
the	O
site	O
of	O
microvascular	O
injury	O
after	O
28	O
days	O
of	O
therapy	O
.	O


Computer	B-I
Decision	I-I
Support	I-I
Changes	O
Physician	B-P
Practice	I-OUT
But	O
Not	O
Knowledge	B-OUT
Regarding	O
Autism	B-P
Spectrum	I-P
Disorders	I-P
.	I-P


The	O
Eastern	B-P
Cooperative	I-P
Oncology	I-P
Group	I-P
experience	O
with	O
cyclophosphamide	B-I
,	I-I
adriamycin	I-I
,	I-I
and	I-I
5-fluorouracil	I-I
(	I-I
CAF	I-I
)	I-I
in	O
patients	B-P
with	I-P
metastatic	I-P
breast	I-P
cancer	I-P
.	I-P


These	O
differences	O
ceased	O
,	O
however	O
,	O
to	O
be	O
statistically	O
significant	O
in	O
logistic	O
models	O
.	O


The	O
instruction	O
to	O
refrain	B-I
from	I-I
blinking	I-I
affects	O
auditory	B-OUT
P3	I-OUT
and	I-OUT
N1	I-OUT
amplitudes	I-OUT
.	I-OUT


Often	O
subjects	O
have	O
been	O
instructed	O
to	O
refrain	B-I
from	I-I
blinking	I-I
lest	O
their	O
evoked	O
EEG	O
potentials	O
should	O
be	O
distorted	O
.	O


We	O
studied	O
whether	O
these	O
very	O
instructions	O
have	O
any	O
impact	O
on	O
P3	B-OUT
amplitude	I-OUT
.	I-OUT


Target	O
tones	O
evoked	O
larger	O
P3s	B-OUT
than	O
non-targets	O
in	O
the	O
latter	O
group	O
but	O
not	O
in	O
the	O
former	O
,	O
in	O
particular	O
not	O
in	O
those	O
subjects	O
that	O
actually	O
blinked	O
rarely	O
.	O


These	O
discrepancies	O
could	O
be	O
largely	O
resolved	O
by	O
the	O
instructional	O
variable	O
,	O
in	O
conjunction	O
with	O
different	O
tone	B-OUT
intensities	I-OUT
.	I-OUT


PARTICIPANTS	O
84	B-P
elementary	I-P
school	I-P
children	I-P
,	I-P
mean	I-P
age	I-P
6.8	I-P
years	I-P
.	I-P


RESULTS	O
Controlling	O
for	O
baseline	O
age	O
,	O
developmental	B-OUT
quotient	I-OUT
(	I-OUT
DQ	I-OUT
)	I-OUT
and	I-OUT
language	I-OUT
;	I-OUT
rates	I-OUT
of	I-OUT
initiations	I-OUT
and	I-OUT
PECS	I-OUT
usage	I-OUT
increased	O
significantly	O
immediately	O
post-treatment	O
(	O
Odds	O
Ratio	O
(	O
OR	O
)	O
of	O
being	O
in	O
a	O
higher	O
ordinal	O
rate	O
category	O
2.72	O
,	O
95	O
%	O
confidence	O
interval	O
1.22-6.09	O
,	O
p	O
<	O
.05	O
and	O
OR	O
3.90	O
(	O
95	O
%	O
CI	O
1.75-8.68	O
)	O
,	O
p	O
<	O
.001	O
,	O
respectively	O
)	O
.	O


PATIENTS	O
AND	O
METHODS	O
Forty-eight	B-P
patients	I-P
were	I-P
randomized	I-P
to	O
receive	O
:	O
FA	B-I
(	O
25	O
mg/m2	O
iv	O
bolus	O
days	O
1	O
to	O
3	O
)	O
,	O
followed	O
by	O
5-FU	B-I
(	O
750	O
mg/m2	O
iv	O
bolus	O
days	O
1	O
to	O
3	O
)	O
,	O
arm	O
A	O
;	O
or	O
FA	B-I
(	O
25	O
mg/m2	O
iv	O
bolus	O
days	O
1	O
to	O
3	O
)	O
,	O
followed	O
by	O
5-FU	B-I
(	O
750	O
mg/m2	O
iv	O
bolus	O
days	O
1	O
to	O
3	O
)	O
plus	O
IFO	B-I
(	O
2,000	O
mg/m2	O
in	O
1000	O
mL	O
5	O
%	O
dextrose	O
in	O
a	O
2-hr	O
infusion	O
,	O
days	O
1	O
to	O
3	O
)	O
,	O
arm	O
B.	O
Mesna	O
was	O
added	O
during	O
and	O
after	O
IFO	O
to	O
prevent	O
hemorrhagic	O
cystitis	O
.	O


RESULTS	O
Forty-five	B-P
patients	I-P
were	I-P
assessable	I-P
for	I-P
response	I-P
:	I-P
in	O
arm	O
A	O
,	O
5	O
patients	O
achieved	O
a	O
partial	B-OUT
response	I-OUT
(	O
overall	O
response	O
,	O
25	O
%	O
)	O
,	O
and	O
in	O
arm	O
B	O
,	O
2	O
patients	O
achieved	O
a	O
complete	B-OUT
and	O
1	O
a	O
partial	B-OUT
response	I-OUT
(	O
overall	O
response	O
,	O
12	O
%	O
)	O
.	O


BACKGROUND	O
Because	O
the	O
response	O
to	O
treatment	O
is	O
limited	O
,	O
patients	B-P
with	I-P
metastatic	I-P
renal	I-P
cell	I-P
carcinoma	I-P
(	I-P
mRCC	I-P
)	I-P
typically	O
receive	O
multiple	O
treatments	O
.	O


Fifty-four	B-P
patients	I-P
had	I-P
sufficient	I-P
tumor	I-P
cells	I-P
for	I-P
comet	I-P
analysis	I-P
at	O
1	O
min	O
and	O
26	O
at	O
both	O
1	O
and	O
2	O
min	O
.	O


RESULTS	O
There	O
was	O
a	O
significant	O
correlation	O
between	O
the	O
1-	O
and	O
2-min	O
MTM	O
(	O
slope	O
=	O
0.77	O
+/-	O
0.03	O
)	O
.	O


In	O
contrast	O
to	O
alkaline	B-OUT
phosphatase	I-OUT
,	O
a	O
fall	O
in	O
inflammatory	O
activity	O
stimulated	O
and	O
impairment	O
of	O
functional	B-OUT
capacity	I-OUT
significantly	O
decreased	O
osteocalcin	O
levels	O
in	O
patients	B-P
with	I-P
RA	I-P
.	I-P


ChiCTR-TRC-11001761	O
.	O


In	O
conclusion	O
,	O
although	B-I
6	I-I
mg/kg	I-I
ATG	O
applied	O
in	O
haploidentical	O
transplantation	O
decreased	B-OUT
the	I-OUT
risk	I-OUT
of	I-OUT
EBV	I-OUT
reactivation	I-OUT
compared	I-I
with	I-I
10	I-I
mg/kg	I-I
ATG	O
,	O
this	O
treatment	O
exposes	O
patients	O
to	O
a	B-OUT
higher	I-OUT
risk	I-OUT
for	I-OUT
severe	I-OUT
acute	I-OUT
GVHD	O
.	O


To	O
assess	O
the	O
effect	O
of	O
DUP	O
on	O
the	B-OUT
neuropsychological	I-OUT
status	I-OUT
of	O
the	O
patients	O
,	O
a	O
linear	O
mixed-effect	O
model	O
was	O
fitted	O
to	O
each	O
neuropsychological	O
dimension	O
.	O


RESULTS	O
At	O
Week	O
144	O
,	O
virologic	B-OUT
suppression	I-OUT
was	O
achieved	O
in	O
72	O
%	O
(	B-I
COBI	I-I
)	I-I
and	O
74	O
%	O
(	B-I
RTV	I-I
)	I-I
of	O
patients	O
.	O


Efficacy	B-OUT
and	I-OUT
cost-effectiveness	I-OUT
of	O
an	O
experimental	O
short-term	O
inpatient	B-I
Dialectical	I-I
Behavior	I-I
Therapy	I-I
(	I-I
DBT	I-I
)	I-I
program	O
:	O
study	O
protocol	O
for	O
a	O
randomized	O
controlled	O
trial	O
.	O


DBT	O
is	O
the	O
treatment	O
model	O
with	O
the	O
largest	O
number	O
of	O
published	O
research	O
articles	O
showing	O
effectiveness	O
.	O


The	O
primary	O
outcome	O
is	O
the	B-OUT
number	I-OUT
of	I-OUT
suicide	I-OUT
attempts/self-harming	I-OUT
acts	I-OUT
.	O


Secondary	O
outcomes	O
are	B-OUT
severity	I-OUT
of	I-OUT
other	I-OUT
borderline	I-OUT
complaints	I-OUT
,	I-OUT
quality	I-OUT
of	I-OUT
life	I-OUT
,	I-OUT
general	I-OUT
psychopathological	I-OUT
symptoms	I-OUT
and	I-OUT
health	I-OUT
care	I-OUT
utilization	I-OUT
and	I-OUT
productivity	I-OUT
costs	I-OUT
.	O


PATIENT	O
(	O
S	O
)	O
Sixty-one	B-P
patients	I-P
were	O
randomly	O
assigned	O
into	O
two	B-I
letrozole	I-I
and	I-I
gonadotropin-treated	I-I
groups	O
.	O


Neither	O
increase	O
nor	O
decrease	O
was	O
statistically	O
significant	O
.	O


In	O
a	O
previous	O
study	O
it	O
was	O
demonstrated	O
that	O
patients	O
with	O
multiallergy	O
hyposensitized	O
with	O
combined	O
allergen	O
extracts	O
showed	O
a	O
statistically	O
significant	O
increase	O
in	O
IgG	B-OUT
anti-IgG	I-OUT
titres	I-OUT
during	O
treatment	O
.	O


The	O
increase	O
failed	O
to	O
appear	O
in	O
the	O
present	O
patients	O
allergic	O
only	O
to	O
pollen	O
and	O
treated	O
with	O
purified	O
allergen	O
extracts	O
.	O


It	O
is	O
therefore	O
suggested	O
that	O
a	O
multiallergic	O
condition	O
and	O
the	O
combination	O
and/or	O
purification	O
of	O
allergen	O
extracts	O
administered	O
during	O
hyposensitization	O
may	O
influence	O
the	O
production	O
of	O
IgG	B-OUT
anti-	I-OUT
IgG	I-OUT
antibodies	I-OUT
.	I-OUT


METHODS	O
Some	B-P
204	I-P
patients	I-P
with	I-P
mid	I-P
and	I-P
low	I-P
rectal	I-P
adenocarcinomas	I-P
were	I-P
allocated	I-P
randomly	I-P
to	I-P
open	I-I
(	I-P
103	I-P
)	I-P
or	I-I
laparoscopic	I-I
(	I-I
101	I-I
)	I-I
surgery	I-I
.	I-I


The	O
primary	O
outcome	O
variables	O
were	O
direct	B-OUT
and	I-OUT
indirect	I-OUT
costs	I-OUT
of	I-OUT
treatment	I-OUT
and	I-OUT
PD	I-OUT
severity	I-OUT
.	I-OUT


The	O
pharmacological	O
and	O
CBT	O
interventions	O
were	O
associated	O
with	O
a	O
greater	O
clinical	B-OUT
improvement	I-OUT
compared	O
with	O
usual	O
care	O
at	O
posttest	O
.	O


BACKGROUND	O
Intake	O
of	O
fish	O
and	O
long-chain	O
n-3	O
fatty	O
acids	O
has	O
been	O
of	O
wide	O
interest	O
due	O
to	O
their	O
beneficial	O
effects	O
on	O
cardiovascular	O
risk	O
factors	O
and	O
lower	O
coronary	B-P
heart	I-P
disease	I-P
(	I-P
CHD	I-P
)	I-P
risk	O
.	O


Inclusion	B-P
criteria	I-P
were	I-P
myocardial	I-P
infarction	I-P
or	I-P
unstable	I-P
ischemic	I-P
attack	I-P
,	I-P
age	I-P
under	I-P
70	I-P
years	I-P
,	I-P
use	I-P
of	I-P
betablockers	I-P
and	I-P
presence	I-P
of	I-P
sinus	I-P
rhythm	I-P
.	I-P


Serum	B-OUT
total	I-OUT
triglyceride	I-OUT
concentration	I-OUT
did	O
not	O
significantly	O
change	O
.	O


However	O
,	O
when	O
only	O
the	O
last	O
50	O
patients	O
were	O
analyzed	O
,	O
we	O
found	O
no	O
difference	O
in	O
procedure	B-OUT
time	I-OUT
between	O
the	O
groups	O
,	O
probably	O
related	O
to	O
the	O
learning	O
curve	O
of	O
the	O
operators	O
.	O


However	O
,	O
the	O
guidebook	O
was	O
seldom	O
used	O
as	O
it	O
had	O
been	O
intended	O
during	O
consultations	O
.	O


Patients	O
felt	O
constrained	O
by	O
time	O
limits	O
and	O
consultants	O
did	O
not	O
actively	O
encourage	O
guidebook	O
use	O
.	O


Using	O
Centers	O
for	O
Disease	O
Control	O
(	O
CDC	O
)	O
standardized	O
scores	O
,	O
both	O
weight	B-OUT
and	I-OUT
body	I-OUT
mass	I-OUT
index	I-OUT
(	I-OUT
BMI	I-OUT
)	I-OUT
increased	O
with	O
risperidone	B-I
during	O
the	O
acute	O
trial	O
(	O
0.5	O
and	O
0.6	O
SDs	O
,	O
respectively	O
,	O
for	O
risperidone	B-I
;	I-I
0.0	O
and	O
0.1	O
SDs	O
,	O
respectively	O
,	O
for	O
placebo	B-I
)	I-I
and	O
into	O
open-label	O
extension	O
(	O
0.19	O
and	O
0.16	O
SDs	O
,	O
respectively	O
)	O
,	O
although	O
the	O
amount	O
of	O
gain	O
decelerated	O
with	O
time	O
.	O


A	O
multi-center	O
,	O
randomized	O
,	O
controlled	O
trial	O
of	O
parenteral	B-I
nutrition	I-I
titrated	O
to	O
resting	O
energy	O
expenditure	O
in	O
children	B-P
undergoing	I-P
hematopoietic	I-P
stem	I-P
cell	I-P
transplantation	I-P
(	I-P
"	I-P
PNTREE	I-P
"	I-P
)	I-P
:	I-P
rationale	O
and	O
design	O
.	O


DESIGN	O
AND	O
HYPOTHESIS	O
We	O
hypothesize	O
that	O
changes	O
in	O
body	O
composition	O
affect	O
REE	O
during	O
HSCT	O
,	O
and	O
that	O
standard	O
nutritional	O
support	O
may	O
lead	O
to	O
overfeeding	O
.	O


METHODS	O
Seventy	B-P
patients	I-P
with	I-P
impaired	I-P
left	I-P
ventricular	I-P
function	I-P
[	I-P
left	I-P
ventricular	I-P
ejection	I-P
fraction	I-P
(	I-P
LVEF	I-P
)	I-P
<	I-P
35	I-P
%	I-P
]	I-P
undergoing	I-P
on-pump	I-P
CABG	I-P
were	I-P
enrolled	I-P
.	I-P


Safety	B-OUT
and	I-OUT
efficacy	I-OUT
of	I-OUT
thymopentin	I-OUT
in	O
zidovudine	B-P
(	I-P
AZT	I-P
)	I-P
-treated	I-P
asymptomatic	I-P
HIV-infected	I-P
subjects	I-P
with	I-P
200-500	I-P
CD4	I-P
cells/mm3	I-P
:	I-P
a	O
double-blind	O
placebo-controlled	O
trial	O
.	O


In	O
stratum	O
I	O
(	O
mean	O
,	O
16	O
months	O
AZT	O
at	O
entry	O
)	O
two	O
AIDS	B-OUT
or	I-OUT
death	I-OUT
events	I-OUT
occurred	O
in	O
thymopentin	O
and	O
10	O
in	O
placebo	O
recipients	O
(	O
p	O
=	O
0.024	O
;	O
relative	O
risk	O
(	O
RR	O
)	O
estimate	O
,	O
4.9	O
[	O
95	O
%	O
confidence	O
limit	O
(	O
CI	O
)	O
,	O
1.1	O
to	O
22.2	O
]	O
)	O
.	O


In	O
contrast	O
,	O
placebo-treated	O
subjects	O
with	O
little	O
prior	O
AZT	O
experience	O
had	O
low	O
progression	O
rates	O
;	O
these	O
were	O
not	O
significantly	O
changed	O
by	O
thymopentin	O
treatment	O
.	O


There	O
was	O
no	O
increase	O
in	O
the	O
incidence	O
of	O
adverse	B-OUT
reactions	I-OUT
with	O
thymopentin	O
.	O


Atrial	B-OUT
remodeling	I-OUT
after	O
mitral	B-I
valve	I-I
surgery	I-I
in	O
patients	B-P
with	I-P
permanent	I-P
atrial	I-P
fibrillation	I-P
.	I-P


BACKGROUND	O
Mitral	O
valve	O
pathology	O
is	O
frequently	O
associated	O
with	O
auricular	O
dilatation	O
and	O
atrial	O
fibrillation	O
.	O


Robotic	B-I
therapy	I-I
:	I-I
a	O
novel	O
approach	O
in	O
upper-limb	B-OUT
neurorehabilitation	I-OUT
after	O
stroke	B-P
.	I-P


Fewer	O
studies	O
have	O
examined	O
whether	O
changes	O
in	O
cognition	O
are	O
associated	O
with	O
changes	O
in	O
social	B-OUT
functioning	I-OUT
.	I-OUT


Children	B-P
's	I-P
gains	O
in	O
cognitive	B-OUT
ability	I-OUT
were	O
modestly	O
associated	O
with	O
independent	B-OUT
assessors	I-OUT
'	I-OUT
and	I-OUT
teachers	I-OUT
'	I-OUT
evaluations	I-OUT
of	I-OUT
social	I-OUT
functioning	I-OUT
but	O
were	O
not	O
associated	O
with	O
changes	O
in	O
parent	B-OUT
ratings	I-OUT
.	I-OUT


Naltrexone	B-I
treatment	O
failed	O
to	O
produce	O
significant	B-OUT
changes	I-OUT
in	O
social	B-OUT
behavior	I-OUT
,	O
but	O
it	O
did	O
reduce	B-OUT
irritability	I-OUT
and	I-OUT
target	I-OUT
scores	I-OUT
on	I-OUT
behavior	I-OUT
checklists	I-OUT
.	I-OUT


No	O
differences	O
were	O
found	O
in	O
either	O
DM	B-OUT
intake	I-OUT
or	I-OUT
actual	I-OUT
milk	I-OUT
yield	I-OUT
between	O
the	O
WCGF-L	O
and	O
WCGF-DL	O
treatments	O
,	O
indicating	O
that	O
prepartum	O
diets	O
did	O
not	O
influence	O
lactational	O
performance	O
.	O


Therefore	O
,	O
the	O
infrared	O
LED	O
irradiation	B-OUT
during	I-OUT
treadmill	I-OUT
training	I-OUT
can	I-OUT
improve	I-OUT
maximal	I-OUT
performance	I-OUT
and	I-P
post-exercise	I-P
recovery	O
in	O
postmenopausal	O
women	O
.	O


The	O
tablet	O
device	O
participants	O
scored	O
an	O
average	O
of	O
15.48	O
points	O
,	O
while	O
the	O
audio	O
device	O
participants	O
scored	O
an	O
average	O
of	O
268	O
points	O
.	O


RESULTS	O
The	B-P
trial	I-P
was	I-P
planned	I-P
for	I-P
150	I-P
patients	I-P
,	I-P
but	I-P
was	I-P
halted	I-P
after	I-P
75	I-P
patients	I-P
when	I-P
planned	I-P
interim	I-P
analysis	I-P
showed	I-P
that	I-P
SILS	I-I
patients	I-P
had	I-P
more	I-P
postoperative	I-OUT
pain	I-OUT
(	O
pain	O
score	O
:	O
4.4	O
±	O
1.6	O
vs	O
3.5	O
±	O
1.5	O
;	O
p	O
=	O
0.01	O
)	O
and	O
higher	B-OUT
inpatient	I-OUT
opiate	I-OUT
usage	I-OUT
(	O
hydromorphone	O
use	O
:	O
3.9	O
±	O
1.9	O
mg	O
vs	O
2.8	O
±	O
1.7	O
mg	O
;	O
p	O
=	O
0.01	O
)	O
than	O
3-port	O
laparoscopy	B-OUT
.	I-OUT


METHODS	O
AND	O
RESULTS	O
To	O
compare	O
and	O
contrast	O
the	O
relative	O
importance	O
of	O
C-reactive	B-OUT
protein	I-OUT
(	I-OUT
CRP	I-OUT
)	I-OUT
,	I-OUT
homocysteine	I-OUT
,	I-OUT
and	I-OUT
lipids	I-OUT
as	O
long-term	O
predictors	O
of	O
SCD	O
,	O
we	O
performed	O
a	O
prospective	O
,	O
nested	O
,	O
case-control	O
analysis	O
involving	O
97	B-P
cases	I-P
of	I-P
SCD	I-P
among	I-P
apparently	I-P
healthy	I-P
men	I-P
enrolled	I-P
in	I-P
the	I-P
Physician	I-P
's	I-P
Health	I-P
Study	I-P
.	I-P


It	O
has	O
become	O
evident	O
that	O
elevated	O
plasma	O
norepinephrine	O
levels	O
are	O
directly	O
related	O
to	O
prognosis	O
;	O
patients	O
with	O
levels	O
>	O
900	O
pg/ml	O
have	O
a	O
poor	O
prognosis	O
and	O
shortened	O
life	O
expectancy	O
.	O


A	O
higher	O
percentage	O
of	O
patients	O
in	O
the	O
intervention	O
group	O
,	O
relative	O
to	O
the	O
control	O
group	O
,	O
were	O
able	O
to	O
reduce	O
the	O
use	B-OUT
of	I-OUT
antihypertensive	I-OUT
medications	I-OUT
(	O
31	O
vs.	O
8	O
%	O
,	O
P	O
<	O
0.0001	O
)	O
,	O
and	O
fewer	O
patients	O
in	O
this	O
group	O
required	O
additional	B-OUT
medications	I-OUT
or	O
increases	O
in	O
dosage	O
relative	O
to	O
the	O
controls	O
(	O
11	O
vs.	O
28	O
%	O
,	O
P	O
=	O
0.03	O
)	O
.	O


DESIGN	O
Randomized	O
controlled	O
trial	O
with	O
attention-matched	O
controls	O
and	O
blinded	O
assessments	O
.	O


SETTING	O
Community	O
.	O


PARTICIPANTS	O
Stroke	B-P
survivors	I-P
(	I-P
N=35	I-P
;	I-P
22	I-P
men	I-P
;	I-P
mean	I-P
age	I-P
,	I-P
66.9±12.7y	I-P
)	I-P
.	I-P


From	O
a	O
baseline	O
average	O
of	O
640.7±99.6min/d	B-OUT
,	I-OUT
daily	I-OUT
sitting	I-OUT
time	I-OUT
reduced	O
on	O
average	O
by	O
30±50.6min/d	O
(	O
95	O
%	O
confidence	O
interval	O
[	O
CI	O
]	O
,	O
5.8-54.6	O
)	O
in	O
the	O
intervention	O
group	O
and	O
40.4±92.5min/d	O
in	B-I
the	I-I
control	I-I
group	O
(	O
95	O
%	O
CI	O
,	O
13.0-93.8	O
)	O
.	O


CONCLUSIONS	O
Our	O
protocol	O
was	O
both	O
safe	O
and	O
feasible	O
.	O


The	B-OUT
key	I-OUT
finding	I-OUT
of	I-OUT
this	I-OUT
study	I-OUT
was	I-OUT
the	I-OUT
significant	I-OUT
lowering	I-OUT
of	I-OUT
pH	I-OUT
in	I-OUT
the	I-OUT
umbilical	I-OUT
cord	I-OUT
vein	I-OUT
(	I-OUT
7.31	I-OUT
+/-	I-OUT
0.04	I-OUT
)	I-OUT
and	I-OUT
artery	I-OUT
(	I-OUT
7.21	I-OUT
+/-	I-OUT
0.06	I-OUT
)	I-OUT
in	I-OUT
the	I-OUT
glucose-infused	I-OUT
group	I-OUT
when	I-OUT
compared	I-OUT
with	I-OUT
the	I-OUT
non-glucose	I-OUT
infusion	I-OUT
groups	I-OUT
(	I-OUT
p	I-OUT
less	I-OUT
than	I-OUT
0.05	I-OUT
)	I-OUT
.	I-OUT


Thus	B-OUT
acute	I-OUT
maternal	I-OUT
glucose	I-OUT
infusion	I-OUT
in	I-OUT
normal	I-OUT
patients	I-OUT
can	I-OUT
cause	I-OUT
fetal	I-OUT
hyperglycemia	I-OUT
,	I-OUT
metabolic	I-OUT
acidosis	I-OUT
,	I-OUT
and	I-OUT
neonatal	I-OUT
hypoglycemia	I-OUT
.	I-OUT


These	B-OUT
findings	I-OUT
may	I-OUT
be	I-OUT
of	I-OUT
particular	I-OUT
clinical	I-OUT
importance	I-OUT
when	I-OUT
fetal	I-OUT
distress	I-OUT
or	I-OUT
fetal	I-OUT
hypoxemia	I-OUT
is	I-OUT
due	I-OUT
to	I-OUT
other	I-OUT
perinatal	I-OUT
events	I-OUT
.	I-OUT


METHODS	O
Patients	B-P
undergoing	I-P
Wise-pattern	I-P
breast	I-P
reduction	I-P
or	I-P
abdominal	I-P
procedures	I-P
had	O
paired	O
incisions	O
randomly	O
assigned	O
to	O
Steri-Strip	B-I
S	I-I
or	I-I
suture	I-I
closure	I-I
.	I-I


Complication	B-OUT
rates	I-OUT
did	O
not	O
differ	O
between	O
closure	O
types	O
.	O


One	O
surgeon	O
rated	O
breast	O
Steri-Strip	O
S	O
scars	O
worse	O
than	O
suture	O
scars	O
(	O
4.3	O
versus	O
3.7	O
;	O
p	O
=	O
0.014	O
)	O
.	O


CONCLUSIONS	O
Steri-Strip	B-I
S	I-I
permits	O
faster	O
wound	B-OUT
closure	I-OUT
than	O
suture	B-I
.	I-I


Correlation	O
between	O
in	O
vivo	O
humoral	O
and	O
in	O
vitro	O
cellular	O
immune	O
responses	O
following	O
immunization	O
with	O
hepatitis	B-I
B	I-I
surface	I-I
antigen	I-I
(	I-I
HBsAg	I-I
)	I-I
vaccines	I-I
.	I-I


To	O
study	O
the	O
regulation	O
of	O
the	O
human	B-P
immune	I-P
response	I-P
to	I-P
hepatitis	I-I
B	I-I
surface	I-I
antigen	I-I
(	I-I
HBsAg	I-I
)	I-I
we	O
have	O
carefully	O
monitored	O
the	O
in	O
vivo	O
humoral	O
and	O
in	O
vitro	O
cellular	O
immune	O
responses	O
to	O
HBsAg	O
in	O
50	B-P
subjects	I-P
receiving	I-P
four	I-P
doses	I-P
of	I-P
hepatitis	I-I
B	I-I
vaccine	I-I
according	I-P
to	I-P
a	I-P
0	I-P
,	I-P
1	I-P
,	I-P
2	I-P
,	I-P
12	I-P
month	I-P
vaccination	I-P
scheme	I-P
.	I-P


The	O
effects	O
of	O
sex	O
,	O
the	O
menstrual	O
cycle	O
,	O
oral	O
contraceptives	O
,	O
pregnancy	O
,	O
and	O
the	O
menopause	O
on	O
skin	O
perfusion	O
in	O
healthy	B-P
women	I-P
and	O
in	O
patients	B-P
with	I-P
Raynaud	I-P
's	I-P
phenomenon	I-P
suggest	O
a	O
role	O
of	O
female	O
sex	O
hormones	O
.	O


There	O
were	O
no	O
significant	O
differences	O
in	O
the	O
test	B-OUT
results	I-OUT
after	O
placebo	O
and	O
after	O
progesterone	O
.	O


(	O
ABSTRACT	O
TRUNCATED	O
AT	O
250	O
WORDS	O
)	O


The	O
carotid	O
artery	O
was	O
cannulated	O
to	O
monitor	O
the	O
arterial	B-OUT
pressure	I-OUT
and	O
to	O
take	O
samples	O
for	O
arterial	B-OUT
gas	I-OUT
measurements	I-OUT
.	I-OUT


CONCLUSIONS	O
We	O
conclude	O
that	O
the	O
intraoperative	O
use	O
of	O
remifentanil	B-I
in	O
the	O
rat	O
reduces	O
the	O
MAC	O
of	O
isoflurane	O
,	O
and	O
that	O
this	O
anaesthetic	O
sparing	O
effect	O
is	O
dose-dependent	O
and	O
similar	O
to	O
that	O
produced	O
by	O
fentanyl	O
at	O
the	O
doses	O
tested	O
.	O


Most	O
people	O
may	O
already	O
have	O
diet-related	B-I
CRC	I-I
prevention	I-I
beliefs	I-I
and	O
having	O
them	O
is	O
associated	O
with	O
a	O
more	O
healthful	B-OUT
dietary	I-OUT
intake	I-OUT
.	I-OUT


Interferon	B-I
was	O
administered	O
as	O
induction	O
treatment	O
(	O
3	O
Mu/day	O
)	O
and	O
then	O
as	O
maintenance	O
therapy	O
(	O
3	O
Mu	O
three	O
times	O
a	O
week	O
)	O
.	O


Under	O
short	O
general	O
anesthesia	O
or	O
sedation	O
,	O
100	B-P
to	I-P
200	I-P
U	I-P
of	I-P
Dysport	I-I
(	I-P
Polish	I-P
patients	I-P
)	I-P
or	I-P
Botox	I-I
(	I-P
U.S.	I-P
patients	I-P
)	I-P
was	O
injected	O
through	O
a	O
cystoscope	O
into	O
20	O
to	O
30	O
sites	O
submucosally	O
in	O
the	O
trigone	O
and	O
floor	O
of	O
the	O
bladder	O
.	O


Patients	O
were	O
evaluated	O
with	O
the	O
O'Leary-Sant	B-OUT
validated	I-OUT
IC	I-OUT
questionnaire	I-OUT
or	I-OUT
with	I-OUT
voiding	I-OUT
charts	I-OUT
and	I-OUT
a	I-OUT
visual	I-OUT
analog	I-OUT
pain	I-OUT
scale	I-OUT
1	O
month	O
postoperatively	O
and	O
at	O
subsequent	O
3-month	O
intervals	O
.	O


Follow-ups	O
were	O
at	O
weeks	O
6	O
,	O
12	O
,	O
24	O
,	O
and	O
at	O
1-2	O
years	O
posttreatment	O
.	O


Significant	B-OUT
treatment	I-OUT
effects	I-OUT
were	O
found	O
on	O
all	O
measures	O
at	O
posttreatment	O
.	O


The	O
improvement	B-OUT
rate	I-OUT
was	O
49	O
%	O
at	O
week	O
6	O
;	O
it	O
rose	O
to	O
80	O
%	O
by	O
week	O
12	O
,	O
85	O
%	O
by	O
week	O
24	O
,	O
and	O
83	O
%	O
by	O
the	O
1-2-year	O
follow-up	O
.	O


METHODS	O
The	O
HF-ACTION	O
trial	O
was	O
a	O
prospective	O
,	O
randomized	O
trial	O
of	O
exercise	B-I
therapy	I-I
vs	I-I
usual	I-I
care	I-I
in	O
2331	B-P
patients	I-P
with	I-P
HFREF	I-P
.	I-P


Over	O
a	O
median	O
follow-up	O
of	O
30	O
months	O
,	O
the	O
primary	O
outcome	O
of	B-OUT
all-cause	I-OUT
mortality	I-OUT
or	I-OUT
all-cause	I-OUT
hospitalization	I-OUT
occurred	O
in	O
78	O
%	O
of	O
those	O
with	O
anemia	O
and	O
64	O
%	O
in	O
those	O
without	O
(	O
P	O
<	O
0.001	O
)	O
.	O


Efficacy	O
and	O
safety	O
of	O
azithromycin	B-I
and	I-I
doxycycline	I-I
for	O
the	O
treatment	O
of	O
moderate	B-P
acne	I-P
vulgaris	I-P
were	O
evaluated	O
(	B-P
240	I-P
patients	I-P
)	I-P
in	I-P
both	I-P
intention-to-treat	I-P
and	I-P
per-protocol	I-P
populations	I-P
.	I-P


Reduction	O
in	O
the	O
number	B-OUT
of	I-OUT
lesions	I-OUT
was	O
similar	O
with	O
both	O
azithromycin	B-I
and	I-I
doxycycline	I-I
treatments	I-I
(	O
27	O
+/-	O
12	O
and	O
30	O
+/-	O
12	O
,	O
respectively	O
)	O
in	O
both	O
groups	O
.	O


Recombinant	B-I
human	I-I
granulocyte	I-I
and	I-I
granulocyte-macrophage	I-I
colony-stimulating	I-I
factor	I-I
(	I-I
G-CSF	I-I
and	I-I
GM-CSF	I-I
)	I-I
administered	O
following	O
cytotoxic	B-I
chemotherapy	I-I
have	O
a	O
similar	O
ability	O
to	O
mobilize	O
peripheral	O
blood	O
stem	O
cells	O
.	O


Primary	O
endpoints	O
of	O
the	O
study	O
were	O
the	O
number	B-OUT
of	I-OUT
CD34+	I-OUT
cells	I-OUT
harvested	I-OUT
per	I-OUT
kg	I-OUT
body	I-OUT
weight	I-OUT
on	I-OUT
the	I-OUT
occasion	I-OUT
of	I-OUT
six	I-OUT
consecutive	I-OUT
leukaphereses	I-OUT
and	O
the	O
time	B-OUT
needed	I-OUT
for	I-OUT
hematological	I-OUT
reconstitution	I-OUT
following	I-OUT
autografting	I-OUT
.	I-OUT


Reasons	O
for	O
discontinuation	O
of	O
part	O
I	O
included	O
loss	B-OUT
of	I-OUT
efficacy	I-OUT
(	O
N=5	O
)	O
and	O
adverse	B-OUT
effects	I-OUT
(	O
N=1	O
)	O
.	O


An	O
objective	O
response	O
to	O
treatment	O
was	O
observed	O
in	O
48	O
per	O
cent	O
of	O
the	O
patients	O
of	O
the	O
group	O
I	O
and	O
60	O
per	O
cent	O
of	O
the	O
group	O
II	O
.	O


BACKGROUND	O
It	O
has	O
been	O
postulated	O
from	O
virologic	O
studies	O
that	O
herpesvirus	O
infection	O
could	O
play	O
a	O
role	O
in	O
the	O
progression	O
of	O
MS.	O
METHODS	O
Patients	B-P
were	I-P
eligible	I-P
for	I-P
the	I-P
study	I-P
if	I-P
they	I-P
had	I-P
had	I-P
two	I-P
or	I-P
more	I-P
MS	I-P
relapses	I-P
in	I-P
the	I-P
2-year	I-P
period	I-P
before	I-P
enrollment	I-P
.	I-P


Pharmacokinetic-pharmacodynamic	B-OUT
modelling	I-OUT
of	O
the	O
antihistaminic	B-P
(	I-P
H1	I-P
)	I-P
effect	I-P
of	I-P
bilastine	I-I
.	I-I


METHODS	O
The	O
pharmacokinetic	O
model	O
was	O
developed	O
from	O
different	O
single-dose	O
and	O
multiple-dose	O
studies	O
.	O


In	B-P
the	I-P
single-dose	I-P
studies	I-P
,	I-P
a	I-P
total	I-P
of	I-P
183	I-P
subjects	I-P
received	I-P
oral	I-P
doses	I-P
of	I-P
bilastine	I-I
2.5	O
,	O
5	O
,	O
10	O
,	O
20	O
,	O
50	O
,	O
100	O
,	O
120	O
,	O
160	O
,	O
200	O
and	O
220	O
mg	O
.	O


Twelve	B-P
patients	I-P
were	I-P
randomly	I-P
assigned	I-P
to	O
four	O
groups	O
with	O
different	O
rhG-CSF	B-I
therapy	I-I
schedules	I-I
.	I-I


The	O
value	O
for	O
the	O
area	O
under	O
the	O
concentration-time	B-OUT
curve	I-OUT
of	O
rhG-CSF	B-OUT
on	O
the	O
day	O
of	O
neutrophilia	O
was	O
lower	O
than	O
that	O
on	O
the	O
day	O
of	O
neutropenia	O
(	O
P	O
<	O
0.05	O
)	O
.	O


Our	O
results	O
suggest	O
that	O
the	O
fall	O
in	O
serum	B-OUT
G-CSF	I-OUT
levels	I-OUT
during	O
rhG-CSF	B-I
therapy	I-I
may	O
result	O
from	O
increased	O
clearance	O
and/or	O
decreased	O
absorption	O
of	O
rhG-CSF	B-I
,	O
two	O
processes	O
related	O
to	O
circulating	O
neutrophil	O
counts	O
.	O


The	O
overall	B-OUT
cumulative	I-OUT
infarction	I-OUT
rate	I-OUT
was	O
somewhat	O
higher	O
in	O
patients	O
assigned	O
to	O
surgery	B-I
(	O
36	O
%	O
)	O
than	O
in	O
medical	O
patients	O
(	O
31	O
%	O
)	O
(	O
p	O
=	O
0.13	O
)	O
due	O
to	O
perioperative	O
infarctions	O
(	O
13	O
%	O
)	O
and	O
an	O
accelerated	B-OUT
infarction	I-OUT
rate	I-OUT
after	O
the	O
fifth	O
year	O
of	O
follow-up	O
(	O
average	O
,	O
2.4	O
%	O
/yr	O
in	O
the	O
surgical	O
group	O
versus	O
1.4	O
%	O
/yr	O
in	O
the	O
medical	O
group	O
)	O
.	O


According	O
to	O
the	O
Cox	O
model	O
,	O
the	O
estimated	B-OUT
risk	I-OUT
of	I-OUT
death	I-OUT
after	I-OUT
infarction	I-OUT
was	O
59	O
%	O
lower	O
in	O
surgical	O
than	O
in	O
medical	O
patients	O
(	O
p	O
less	O
than	O
0.0001	O
)	O
.	O


The	O
reduction	B-OUT
in	O
postinfarction	B-OUT
mortality	I-OUT
with	O
surgery	O
was	O
most	O
striking	O
in	O
the	O
first	O
month	O
after	O
the	O
event	O
:	O
99	O
%	O
in	O
the	O
first	O
month	O
(	O
p	O
less	O
than	O
0.0001	O
)	O
and	O
49	O
%	O
subsequently	O
(	O
p	O
less	O
than	O
0.0001	O
)	O
.	O


Exclusion	O
of	O
perioperative	O
infarctions	O
did	O
not	O
alter	O
the	O
findings	O
.	O


A	O
chinese	O
mind-body	O
exercise	O
improves	O
self-control	B-OUT
of	O
children	B-P
with	I-P
autism	I-P
:	I-P
a	O
randomized	O
controlled	O
trial	O
.	O


In	O
addition	O
,	O
the	O
experimental	O
group	O
showed	O
enhanced	B-OUT
EEG	I-OUT
activity	I-OUT
in	O
the	O
anterior	O
cingulate	O
cortex	O
,	O
a	O
region	O
that	O
mediates	O
self-control	O
,	O
whereas	O
the	O
PMR	O
group	O
did	O
not	O
.	O


This	O
analysis	O
is	O
based	O
upon	O
publicly	O
available	O
evidence	O
presented	O
in	O
a	O
complaint	O
of	O
research	O
misconduct	O
filed	O
with	O
the	O
Office	O
of	O
Research	O
Integrity	O
of	O
the	O
Department	O
of	O
Health	O
and	O
Human	O
Services	O
.	O


The	O
overall	B-OUT
survival	I-OUT
rate	I-OUT
at	O
three	O
years	O
was	O
also	O
very	O
similar	O
in	O
the	O
two	O
groups	O
(	O
86	O
percent	O
in	O
the	O
laparoscopic-surgery	O
group	O
and	O
85	O
percent	O
in	O
the	O
open-colectomy	O
group	O
;	O
P=0.51	O
;	O
hazard	B-OUT
ratio	I-OUT
for	I-OUT
death	I-OUT
in	O
the	O
laparoscopic-surgery	O
group	O
,	O
0.91	O
;	O
95	O
percent	O
confidence	O
interval	O
,	O
0.68	O
to	O
1.21	O
)	O
,	O
with	O
no	O
significant	O
difference	O
between	O
groups	O
in	O
the	O
time	B-OUT
to	I-OUT
recurrence	I-OUT
or	I-OUT
overall	I-OUT
survival	I-OUT
for	O
patients	O
with	O
any	O
stage	O
of	O
cancer	O
.	O


The	O
rates	B-OUT
of	I-OUT
intraoperative	I-OUT
complications	I-OUT
,	I-OUT
30-day	I-OUT
postoperative	I-OUT
mortality	I-OUT
,	I-OUT
complications	I-OUT
at	I-OUT
discharge	I-OUT
and	I-OUT
60	I-OUT
days	I-OUT
,	I-OUT
hospital	I-OUT
readmission	I-OUT
,	I-OUT
and	I-OUT
reoperation	I-OUT
were	O
very	O
similar	O
between	O
groups	O
.	O


CONCLUSIONS	O
In	O
this	O
multi-institutional	O
study	O
,	O
the	O
rates	B-OUT
of	I-OUT
recurrent	I-OUT
cancer	I-OUT
were	O
similar	O
after	O
laparoscopically	B-I
assisted	I-I
colectomy	I-I
and	O
open	B-I
colectomy	I-I
,	O
suggesting	O
that	O
the	O
laparoscopic	O
approach	O
is	O
an	O
acceptable	O
alternative	O
to	O
open	O
surgery	O
for	O
colon	O
cancer	O
.	O


We	O
measured	O
DR	B-OUT
curves	I-OUT
of	I-OUT
PaO2/FIO2	I-OUT
versus	I-OUT
the	I-OUT
inhaled	I-OUT
NO	I-OUT
dose	I-OUT
at	O
regular	O
intervals	O
.	O


METHODS	O
We	O
studied	O
50	B-P
children	I-P
undergoing	I-P
laparoscopy	I-P
for	I-P
diagnostic	I-P
and	I-P
therapeutic	I-P
purposes	I-P
.	I-P


Their	B-P
ages	I-P
ranged	I-P
from	I-P
3	I-P
to	I-P
13	I-P
years	I-P
,	I-P
and	I-P
all	I-P
belonged	I-P
to	I-P
American	I-P
Society	I-P
of	I-P
Anesthesiologists	I-P
(	I-P
ASA	I-P
)	I-P
class	I-P
I	I-P
or	I-P
II	I-P
.	I-P


Given	O
the	O
necessarily	O
invasive	O
nature	O
of	O
caudal	O
block	O
,	O
we	O
suggest	O
the	O
combined	O
use	O
of	O
diclofenac	B-I
suppository	I-I
with	O
local	O
anesthetic	B-I
infiltration	I-I
at	O
port	O
sites	O
as	O
a	O
useful	O
and	O
more	O
economical	O
alternative	O
for	O
analgesia	O
following	O
pediatric	O
laparoscopy	O
.	O


Forearm	B-OUT
bone	I-OUT
density	I-OUT
(	I-OUT
BMDprox	I-OUT
)	I-OUT
increased	O
with	O
2.94	O
%	O
(	O
p	O
=	O
0.006	O
)	O
in	O
women	O
who	O
were	O
prescribed	O
levonorgestrel	O
,	O
which	O
was	O
in	O
contrast	O
to	O
stable	O
values	O
in	O
those	O
prescribed	O
depot-medroxy-progesterone	B-I
acetate	I-I
;	I-I
group	O
difference	O
at	O
6	O
months	O
for	O
BMDprox	B-OUT
3.4	O
%	O
(	O
95	O
%	O
CI	O
1.3	O
,	O
5.5	O
;	O
p	O
=	O
0.025	O
)	O
and	O
BMDdist	B-OUT
4.1	O
%	O
(	O
95	O
%	O
CI	O
-	O
1.3	O
,	O
9.6	O
;	O
p	O
=	O
0.077	O
)	O
.	O


The	O
findings	O
suggest	O
an	O
increase	O
in	O
bone	B-OUT
density	I-OUT
during	O
treatment	O
with	O
levonorgestrel	B-I
and	O
stable	O
values	O
during	O
short-term	O
administration	O
of	O
DMPA	B-I
,	O
in	O
standard	O
clinical	O
doses	O
for	O
contraception	O
.	O


Dosing	O
was	O
continued	O
for	O
8	O
consecutive	O
days	O
on	O
each	O
treatment	O
with	O
an	O
intervening	O
wash-out	O
period	O
of	O
1	O
week	O
.	O


Similarly	O
for	O
anaerobic	B-OUT
bacterial	I-OUT
counts	I-OUT
,	O
92	O
%	O
and	O
88	O
%	O
maximum	O
reductions	O
were	O
recorded	O
on	O
Day	O
1	O
and	O
Day	O
8	O
,	O
which	O
again	O
were	O
significantly	O
lower	O
than	O
placebo	O
for	O
up	O
to	O
3	O
hours	O
post-dose	O
.	O


Logistic	O
regression	O
analysis	O
confirmed	O
that	O
TDM	O
independently	O
reduced	O
the	O
incidence	B-OUT
of	I-OUT
nephrotoxicity	I-OUT
in	O
this	O
patient	O
population	O
.	O


On	O
the	O
basis	O
of	O
this	O
reduced	O
nephrotoxicity	B-OUT
,	O
a	O
incremental	B-OUT
cost	I-OUT
of	O
$	O
435	O
per	O
case	O
of	O
nephrotoxicity	O
prevented	O
was	O
found	O
for	O
vancomycin	B-I
serum	O
concentration	O
monitoring	O
.	O


METHODS/DESIGN	O
A	B-P
total	I-P
of	I-P
210	I-P
participants	I-P
with	I-P
low	I-P
back	I-P
pain	I-P
lasting	I-P
at	I-P
least	I-P
3	I-P
months	I-P
will	I-P
be	I-P
recruited	I-P
from	I-P
primary	I-P
care	I-P
clinics	I-P
of	I-P
a	I-P
large	I-P
healthcare	I-P
system	I-P
based	I-P
in	I-P
Seattle	I-P
.	I-P


They	O
will	O
be	O
randomized	O
in	O
a	O
2:2:1	O
ratio	O
to	O
receive	O
12	B-I
weekly	I-I
yoga	I-I
classes	I-I
,	I-I
12	I-I
weekly	I-I
conventional	I-I
therapeutic	I-I
exercise	I-I
classes	I-I
of	I-I
comparable	I-I
physical	I-I
exertion	I-I
,	I-I
or	I-I
a	I-I
self-care	I-I
book	I-I
.	I-I


One	O
month	O
post-transplantation	O
,	O
357	B-P
patients	I-P
were	O
randomized	O
to	O
receive	O
standard-dose	B-I
cyclosporine	I-I
(	I-I
sCsA	I-I
,	O
n	O
=	O
179	O
)	O
or	O
reduced-dose	B-I
cyclosporine	I-I
(	I-I
rCsA	I-I
,	O
n	O
=	O
178	O
)	O
.	O


Hydrofluoroalkane-134a	B-I
(	I-I
HFA	I-I
)	I-I
,	O
a	O
non-ozone-depleting	O
propellant	O
,	O
has	O
been	O
used	O
to	O
reformulate	O
albuterol	O
(	O
HFA	O
albuterol	O
)	O
.	O


Safety	B-OUT
and	I-OUT
efficacy	I-OUT
were	O
compared	O
over	O
the	O
first	O
12	O
weeks	O
of	O
the	O
yearlong	O
trial	O
between	O
patients	O
who	O
had	O
remained	O
on	O
CFC	O
albuterol	O
and	O
those	O
who	O
had	O
been	O
switched	O
to	O
HFA	O
albuterol	O
.	O


Efficacy	O
of	O
artemisinin-based	B-I
combination	I-I
treatments	I-I
of	O
uncomplicated	O
falciparum	O
malaria	O
in	O
under-five-year-old	B-P
Nigerian	I-P
children	I-P
.	I-P


OBJECTIVE	O
To	O
determine	O
whether	O
lower	O
rates	O
or	O
incomplete	O
resection	O
of	O
cervical	B-P
intraepithelial	I-P
neoplasia	I-P
(	I-P
CIN	I-P
)	I-P
may	O
be	O
achieved	O
by	O
needle	B-I
excision	I-I
of	I-I
the	I-I
transformation	I-I
zone	I-I
(	I-I
NETZ	I-I
)	I-I
than	I-I
with	I-I
loop	I-I
excision	I-I
(	I-I
LLETZ	I-I
)	I-I
.	I-I


METHODS	O
Women	O
were	O
randomised	O
to	O
receive	O
either	O
LLETZ	B-I
or	I-I
NETZ	I-I
.	I-I


More	O
women	O
in	O
the	O
NETZ	B-I
arm	O
had	O
clear	B-OUT
histological	I-OUT
margins	I-OUT
(	O
84.8	O
%	O
vs	O
75	O
%	O
,	O
(	O
P=	O
0.03	O
)	O
.	O


The	O
median	B-OUT
volume	I-OUT
of	I-OUT
specimens	I-OUT
in	O
the	O
NETZ	O
arm	O
was	O
739	O
mm	O
(	O
3	O
)	O
larger	O
(	O
P=	O
0.33	O
)	O
and	O
they	O
were	O
less	B-OUT
likely	I-OUT
to	I-OUT
be	I-OUT
removed	I-OUT
in	O
multiple	O
pieces	O
(	O
2.5	O
%	O
vs	O
29.5	O
%	O
,	O
RR	O
0.09	O
,	O
95	O
%	O
CI	O
0.04	O
to	O
0.20	O
)	O
.	O


Needle	O
excision	O
took	O
longer	B-OUT
to	I-OUT
perform	I-OUT
(	I-OUT
median	I-OUT
treatment	I-OUT
time	I-OUT
210	O
vs	O
90	O
seconds	O
,	O
P	O
<	O
0.0001	O
)	O
and	O
surgeons	O
more	O
often	O
reported	B-OUT
the	I-OUT
procedure	I-OUT
as	I-OUT
'difficult	I-OUT
'	I-OUT
(	O
9.5	O
%	O
vs	O
3.0	O
%	O
,	O
RR	O
=	O
3.17	O
%	O
,	O
95	O
%	O
CI	O
1.33	O
to	O
7.58	O
)	O
.	O


The	O
first	O
study	O
assessed	O
the	O
effects	O
of	O
incremental	O
doses	O
of	O
GH	O
(	O
0.5	O
,	O
1.0	O
,	O
2.0	O
IU/day	O
for	O
1	O
wk	O
each	O
)	O
on	O
insulin-like	O
growth	O
factor	O
I	O
(	O
IGF-I	O
)	O
levels	O
during	O
each	O
estrogen	B-I
treatment	I-I
phase	O
.	O


PATIENTS	O
AND	O
METHODS	O
In	O
a	O
randomized	O
crossover	O
study	O
,	O
26	B-P
patients	I-P
undergoing	I-P
bilateral	I-P
lower	I-P
third	I-P
molar	I-P
surgery	I-P
at	I-P
two	I-P
visits	I-P
had	O
patient-controlled	O
sedation	O
with	O
1	O
mg	O
midazolam	B-I
increments	O
at	O
1-minute	B-I
or	O
3-minute	B-I
intervals	I-I
at	O
one	O
visit	O
and	O
the	O
alternative	O
at	O
the	O
other	O
visit	O
.	O


CONCLUSION	O
A	O
significant	O
majority	O
preferred	O
the	O
sedation	O
technique	O
with	O
1-minute	O
increment	O
intervals	O
(	O
chi	O
2	O
=	O
4.6	O
;	O
P	O
<	O
.05	O
)	O
.	O


Eligibility	O
for	O
acute	O
beta-blocker	O
therapy	O
was	O
determined	O
on	O
the	O
basis	O
of	O
readily	O
available	O
,	O
noninvasive	O
tests	O
.	O


There	O
was	O
no	O
significant	O
difference	O
in	O
the	O
incidence	B-OUT
of	I-OUT
congestive	I-OUT
heart	I-OUT
failure	I-OUT
between	O
propranolol-	B-I
and	O
placebo-treated	B-I
groups	O
.	O


There	O
was	O
no	O
significant	O
difference	O
in	O
mortality	B-OUT
between	O
the	O
2	O
groups	O
during	O
an	O
average	O
of	O
36	O
months	O
'	O
follow-up	O
.	O


METHODS	O
Twenty-two	B-P
volunteers	I-P
over	I-P
60	I-P
years	I-P
of	I-P
age	I-P
participated	O
in	O
the	O
present	O
study	O
.	O


Each	O
subjects-either	O
inactive	O
or	O
active-performed	O
two	B-I
treadmill	I-I
tests	I-I
at	O
two-days	O
interval	O
,	O
to	O
measure	O
maximal	O
and	O
submaximal	O
responses	O
to	O
exercise	O
,	O
respectively	O
.	O


[	O
Management	O
of	O
the	O
perineal	O
wounds	O
after	O
abdominoperineal	O
resection	O
:	O
simple	B-I
drainage	I-I
only	O
or	O
with	O
continuous	B-I
irrigation	I-I
?	O
]	O
.	O


Perineal	O
wound	O
healing	O
was	O
taken	O
as	O
endpoint	O
of	O
this	O
study	O
.	O


RESULTS	O
A	O
total	O
of	O
74	B-P
patients	I-P
were	I-P
enrolled	I-P
in	I-P
present	I-P
study	I-P
,	O
with	O
37	O
patients	O
in	O
each	O
arm	O
,	O
and	O
there	O
were	O
12	O
cases	O
and	O
10	O
cases	O
who	O
received	O
preoperative	O
radiation	O
therapy	O
,	O
respectively	O
.	O


The	O
incidence	B-OUT
of	I-OUT
major	I-OUT
complication	I-OUT
was	O
significantly	O
lower	O
in	O
arm	O
A	O
(	O
5.4	O
%	O
vs.21.6	O
%	O
,	O
P	O
=	O
0.042	O
)	O
.	O


Patients	O
received	O
preoperative	O
radiation	O
therapy	O
had	O
significantly	O
higher	O
rate	B-OUT
of	I-OUT
minor	I-OUT
complications	I-OUT
than	O
patients	O
underwent	O
surgery	O
only	O
(	O
18.2	O
%	O
vs.	O
3.9	O
%	O
,	O
P	O
=	O
0.039	O
)	O
.	O


Moderate	O
CRI	O
is	O
defined	O
as	O
estimated	O
glomerular	O
filtration	O
rate	O
(	O
GFR	O
)	O
of	O
30	O
to	O
59.9	O
mL/min/1.73	O
m2	O
at	O
baseline	O
.	O


Among	O
399	B-P
study	I-P
subjects	I-P
,	O
the	O
rate	B-OUT
of	I-OUT
change	I-OUT
in	I-OUT
renal	I-OUT
function	I-OUT
in	O
the	O
gemfibrozil	B-I
group	O
during	O
a	O
median	O
of	O
61	O
months	O
was	O
not	O
significantly	O
different	O
from	O
that	O
in	O
the	O
placebo	B-I
group	O
(	O
0.49	O
mL/min/1.73	O
m2/y	O
faster	O
;	O
95	O
%	O
confidence	O
interval	O
,	O
0.09	O
slower	O
to	O
1.09	O
faster	O
;	O
P	O
=	O
0.10	O
)	O
.	O


An	O
analysis	O
of	O
available	O
space	O
was	O
made	O
by	O
evaluating	O
the	O
pre-treatment	O
dental	O
casts	O
of	O
all	O
patients	O
included	O
in	O
the	O
study	O
.	O


Intervention	O
in	O
children	B-P
with	I-P
Developmental	I-P
Coordination	I-P
Disorder	I-P
:	I-P
the	O
role	O
of	O
parents	B-I
and	I-I
teachers	I-I
.	I-I


AIMS	O
The	O
study	O
aimed	O
to	O
determine	O
the	O
extent	O
to	O
which	O
parents	B-I
and	I-I
teachers	I-I
,	O
with	O
guidance	O
,	O
can	O
assist	O
in	O
the	O
management	O
of	O
children	B-P
with	I-P
DCD	I-P
;	I-P
whether	O
children	B-P
with	I-P
DCD	I-P
are	O
helped	O
in	O
this	O
way	O
and	O
how	O
this	O
may	O
contribute	O
to	O
our	O
understanding	O
of	O
the	O
condition	O
.	O


It	O
is	O
possible	O
that	O
the	O
children	O
who	O
did	O
not	O
improve	O
have	O
difficulties	O
that	O
are	O
of	O
a	O
more	O
complex	O
type	O
which	O
require	O
more	O
specialist	B-I
therapy	I-I
to	O
meet	O
their	O
need	O
.	O


In	O
the	O
second-line	O
treatment	O
of	O
advanced	O
breast	O
carcinoma	O
,	O
fulvestrant	O
was	O
shown	O
previously	O
to	O
be	O
as	O
effective	O
as	O
the	O
third-generation	O
aromatase	O
inhibitor	O
,	O
anastrozole	O
,	O
in	O
terms	O
of	O
time	O
to	O
disease	O
progression	O
and	O
objective	O
response	O
rates	O
.	O


The	O
authors	O
reported	O
the	O
overall	B-OUT
survival	I-OUT
results	O
from	O
these	O
studies	O
.	O


The	O
median	B-OUT
overall	I-OUT
survival	I-OUT
was	O
similar	O
between	O
treatments	O
,	O
being	O
27.4	O
months	O
and	O
27.7	O
months	O
in	O
fulvestrant	B-I
and	O
anastrozole-treated	B-I
patients	O
,	O
respectively	O
(	O
hazards	O
ratio	O
,	O
0.98	O
;	O
95	O
%	O
confidence	O
interval	O
,	O
0.84-1.15	O
;	O
P	O
=	O
0.809	O
)	O
.	O


Fulvestrant	O
continued	O
to	O
be	O
well	O
tolerated	O
,	O
and	O
was	O
associated	O
with	O
a	O
significantly	O
lower	O
incidence	B-OUT
of	I-OUT
joint	I-OUT
disorders	I-OUT
compared	O
with	O
anastrozole	O
(	O
P	O
=	O
0.0234	O
)	O
.	O


CONCLUSIONS	O
The	O
current	O
analysis	O
showed	O
that	O
fulvestrant	B-I
was	O
similar	O
to	O
anastrozole	O
with	O
respect	O
to	O
overall	O
survival	O
in	O
the	O
second-line	O
treatment	O
of	O
postmenopausal	B-P
women	I-P
with	I-P
advanced	I-P
breast	I-P
carcinoma	I-P
.	I-P


The	O
DCCT	O
proved	O
that	O
intensive	B-I
treatment	I-I
reduced	O
the	O
risks	O
of	O
retinopathy	B-OUT
,	I-OUT
nephropathy	I-OUT
,	I-OUT
and	I-OUT
neuropathy	I-OUT
by	O
35	O
%	O
to	O
90	O
%	O
compared	O
with	O
conventional	O
treatment	O
.	O


Intensive	B-I
treatment	I-I
was	O
most	O
effective	O
when	O
begun	O
early	O
,	O
before	O
complications	O
were	O
detectable	O
.	O


With	O
advancing	O
HIV-1	O
disease	O
there	O
is	O
Th1	O
to	O
Th2	O
cytokine	O
switching	O
.	O


All	O
patients	O
on	O
oral	O
therapy	O
overall	O
had	O
greater	B-OUT
relief	I-OUT
than	O
patients	O
using	O
topical	O
steroids	O
.	O


OBJECTIVES	O
To	O
compare	O
the	O
tolerance	O
,	O
adherence	O
and	O
effectiveness	O
of	O
two	O
approaches	O
for	O
the	O
treatment	O
of	O
latent	O
tuberculosis	O
infection	O
(	O
LTBI	O
)	O
:	O
6	O
months	O
of	O
isoniazid	B-I
(	I-I
6H	I-I
)	I-I
vs.	O
3	O
months	O
of	O
isoniazid	B-I
plus	I-I
rifampicin	I-I
(	I-I
3RH	I-I
)	I-I
.	I-I


Effectiveness	O
was	O
evaluated	O
at	O
5	O
years	O
.	O


Comparison	O
of	O
antiresorptive	O
activities	O
of	O
ipriflavone	B-I
,	O
an	O
isoflavone	B-I
derivative	I-I
,	O
and	O
elcatonin	B-I
,	O
an	O
eel	B-I
carbocalcitonin	I-I
.	I-I


Thirty	B-P
postmenopausal	I-P
women	I-P
with	I-P
reduced	I-P
bone	I-P
mineral	I-P
density	I-P
were	I-P
divided	I-P
randomly	I-P
into	I-P
two	I-P
groups	I-P
based	I-P
on	I-P
the	I-P
chronological	I-P
sequence	I-P
of	I-P
their	I-P
first	I-P
visit	I-P
to	I-P
the	I-P
Osteoporosis	I-P
Clinic	I-P
of	I-P
Katsuragi	I-P
Hospital	I-P
.	I-P


RESULTS	O
For	O
the	O
first	O
surveillance	O
test	B-OUT
,	I-OUT
risk	I-OUT
of	I-OUT
non-attendance	I-OUT
was	O
significantly	O
higher	O
in	B-P
younger	I-P
women	I-P
,	I-P
those	I-P
without	I-P
post-secondary	I-P
education	I-P
,	I-P
and	I-P
non-users	I-P
of	I-P
prescribed	I-P
contraception	I-P
.	O


Breathlessness	O
and	O
psychiatric	O
morbidity	O
in	O
chronic	B-P
bronchitis	I-P
and	I-P
emphysema	I-P
:	I-P
a	O
study	O
of	O
psychotherapeutic	B-I
management	I-I
.	I-I


[	O
Clinical	O
benefits	O
of	O
normothermic	B-I
cardiopulmonary	I-I
bypass	I-I
on	O
postoperative	O
systemic	O
metabolism	O
]	O
.	O


The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
evaluate	O
the	O
effects	O
of	O
TENS	B-I
on	O
the	O
following	O
issues	O
in	O
patients	B-P
who	I-P
have	I-P
early-stage	I-OUT
osteoarthritis	I-OUT
of	I-OUT
the	I-OUT
knee	I-OUT
:	I-OUT
(	I-OUT
1	I-OUT
)	I-OUT
pain	I-OUT
reduction	I-OUT
;	I-OUT
(	I-OUT
2	I-OUT
)	I-OUT
subjective	I-OUT
and	I-OUT
(	I-OUT
3	I-OUT
)	I-OUT
objective	I-OUT
functional	I-OUT
improvements	I-OUT
;	I-OUT
(	I-OUT
4	I-OUT
)	I-OUT
quality-of-life	I-OUT
(	I-OUT
QOL	I-OUT
)	I-OUT
measure	I-OUT
improvements	I-OUT
;	I-OUT
and	I-OUT
(	I-OUT
5	I-OUT
)	I-OUT
isokinetic	I-OUT
strength	I-OUT
.	I-OUT


Differential	O
effects	O
of	O
vitamin	B-I
K1	I-I
on	O
AFP	O
and	O
DCP	O
levels	O
in	O
patients	B-P
with	I-P
unresectable	I-P
HCC	I-P
and	I-P
in	I-P
HCC	I-P
cell	I-P
lines	I-P
.	I-P


EXPERIMENTAL	O
DESIGN	O
HCC	B-P
patients	I-P
who	I-P
had	I-P
both	I-P
elevated	I-P
AFP	I-P
and	I-P
DCP	I-P
were	I-P
included	I-P
.	I-P


CONCLUSIONS	O
Vitamin	B-I
K1	I-I
was	O
non-toxic	O
at	O
high	O
doses	O
,	O
strongly	O
inhibited	O
plasma	O
DCP	O
levels	O
,	O
but	O
weakly	O
suppressed	O
AFP	O
levels	O
.	O


PARTICIPANTS	O
Forty-nine	B-P
volunteers	I-P
who	I-P
passed	I-P
the	I-P
initial	I-P
assessment	I-P
for	I-P
recurrent	I-P
aphthous	I-P
stomatitis	I-P
entered	I-P
a	I-P
pretrial	I-P
phase	I-P
in	I-P
which	I-P
their	I-P
eligibility	I-P
for	I-P
the	I-P
trial	I-P
phase	I-P
of	I-P
the	I-P
study	I-P
was	I-P
assessed	I-P
.	I-P


The	O
remaining	O
26	B-P
subjects	I-P
were	O
randomized	O
to	O
placebo	O
or	O
treatment	O
.	O


Six	O
subjects	O
withdrew	O
because	O
of	O
adverse	O
effects	O
,	O
and	O
1	O
was	O
unavailable	O
for	O
follow-up	O
.	O


Patients	O
taking	O
placebo	B-I
reported	O
no	B-OUT
improvement	I-OUT
in	O
these	O
variables	O
.	O


Larger	O
studies	O
are	O
needed	O
to	O
expand	O
upon	O
these	O
findings	O
.	O


AIM	O
To	O
assess	O
tolerability	B-OUT
and	O
study	O
,	O
bile	B-OUT
acid	I-OUT
metabolism	I-OUT
in	O
a	O
phase	O
1	O
trial	O
with	O
the	O
selective	O
ileal	O
bile	O
acid	O
transporter	O
inhibitor	O
A4250	O
.	O


The	O
primary	O
bile	O
acids	O
cholic	O
and	O
chenodeoxycholic	O
acids	O
constituted	O
the	O
majority	B-OUT
of	I-OUT
faecal	I-OUT
bile	O
acids	O
in	O
the	O
A4250-treated	O
groups	O
.	O


Evaluation	O
of	O
three	B-I
dosage-prediction	I-I
methods	O
for	O
initial	O
in-hospital	O
stabilization	O
of	O
warfarin	O
therapy	O
.	O


We	O
manipulated	O
three	O
visual	O
cues	O
:	O
gaze	O
direction	O
,	O
emotional	O
expression	O
,	O
and	O
pointing	O
gesture	O
,	O
while	O
participants	B-P
performed	O
either	O
emotion	O
or	O
gaze	O
direction	O
judgments	O
.	O


Norasept	B-I
II	I-I
Study	O
Investigators	O
.	O


BACKGROUND	O
As	O
the	O
proportion	O
of	O
the	O
population	O
that	O
is	O
older	O
continues	O
to	O
rise	O
,	O
infection	O
in	O
older	B-P
people	I-P
has	O
become	O
an	O
important	O
healthcare	O
problem	O
.	O


RESULTS	O
Data	O
were	O
available	O
for	O
930	B-P
patients	I-P
.	I-P


This	O
is	O
another	O
factor	O
to	O
be	O
considered	O
in	O
assessing	O
the	O
risk	O
of	O
certain	O
foods	O
to	O
food-allergic	B-P
consumers	I-P
and	O
adds	O
another	O
dimension	O
to	O
clinical	O
,	O
research	O
and	O
regulatory	O
practice	O
.	O


BACKGROUND	O
Little	O
evidence	O
exists	O
to	O
indicate	O
whether	O
community	O
psychiatric	O
nurses	O
can	O
achieve	O
the	O
results	O
reported	O
by	O
expert	O
cognitive-behavioural	B-I
therapists	I-I
in	O
patients	B-P
with	I-P
schizophrenia	I-P
.	I-P


Sixty-three	B-P
infertility	I-P
patients	I-P
had	O
bilateral	O
pelvic	O
sidewall	O
adhesions	O
removed	O
at	O
laparotomy	O
.	O


Significantly	O
more	O
adhesions	B-OUT
were	O
observed	O
at	O
laparoscopy	O
on	O
the	O
control	O
pelvic	O
sidewalls	O
(	O
48	O
of	O
63	O
,	O
76	O
%	O
)	O
than	O
on	O
the	O
treated	O
sides	O
(	O
26	O
of	O
63	O
,	O
41	O
%	O
)	O
(	O
P	O
less	O
than	O
.0001	O
)	O
.	O


Comparisons	O
of	O
itraconazole	B-I
alone	I-I
and	O
itraconazole	B-I
with	I-I
simultaneous	I-I
ddI	I-I
were	O
performed	O
on	O
days	O
1	O
and	O
15	O
.	O


Apart	O
from	O
the	O
dialyzer	O
,	O
the	O
dialysis	O
prescription	O
remained	O
unchanged	O
.	O


RESULTS	O
Twenty-five	B-P
patients	I-P
received	O
101	O
cycles	O
of	O
therapy	O
(	O
median	O
two	O
cycles	O
,	O
range	O
1-15	O
)	O
.	O


Food	O
had	O
no	O
significant	O
effect	O
on	O
irinotecan	B-I
pharmacokinetics	O
.	O


No	O
association	O
was	O
found	O
between	O
the	O
UGT1A1*28	O
genotype	O
and	O
the	O
risk	O
of	O
severe	B-OUT
irinotecan-induced	I-OUT
toxicity	I-OUT
.	I-OUT


When	O
enoximone	B-I
is	O
acutely	O
administered	O
to	O
patients	B-P
with	I-P
stable	I-P
angina	I-P
and	I-P
angiographically	I-P
proven	I-P
relevant	I-P
coronary	I-P
stenosis	I-P
i.v	I-P
.	I-P


Similar	O
observations	O
were	O
found	O
when	O
the	O
drug	O
was	O
injected	O
in	O
the	O
diseased	O
coronary	O
arteries	O
in	O
a	O
small	O
dose	O
(	O
0.075	O
mg/kg	O
)	O
so	O
that	O
peripheral	B-OUT
effects	I-OUT
were	O
not	O
present	O
.	O


POPULATION	O
Two	B-P
hundred	I-P
and	I-P
twenty-four	I-P
women	I-P
at	I-P
12	I-P
to	I-P
20	I-P
weeks	I-P
of	I-P
gestation	I-P
.	I-P


The	O
course	O
of	O
misoprostol	B-I
was	O
repeated	O
if	O
the	O
woman	O
did	O
not	O
abort	O
within	O
24	O
hours	O
.	O


There	O
was	O
no	O
difference	O
in	O
the	B-OUT
median	I-OUT
induction-to-abortion	I-OUT
interval	I-OUT
(	O
sublingual	O
:	O
13.8	O
hours	O
;	O
vaginal	O
:	O
12.0	O
hours	O
)	O
.	O


Our	O
aim	O
,	O
therefore	O
,	O
was	O
to	O
ascertain	O
whether	O
pioglitazone	B-I
reduces	O
macrovascular	B-OUT
morbidity	I-OUT
and	O
mortality	B-OUT
in	O
high-risk	B-P
patients	I-P
with	I-P
type	I-P
2	I-P
diabetes	I-P
.	I-P


Analysis	O
was	O
by	O
intention	O
to	O
treat	O
.	O


This	O
study	O
is	O
registered	O
as	O
an	O
International	O
Standard	O
Randomised	O
Controlled	O
Trial	O
,	O
number	O
ISRCTN	O
NCT00174993	O
.	O


The	O
average	O
time	O
of	O
observation	O
was	O
34.5	O
months	O
.	O


RESULTS	B-P
Three	I-P
participants	I-P
dropped	I-P
out	I-P
and	I-P
seven	I-OUT
died	I-OUT
(	O
five	O
in	O
the	O
intervention	O
and	O
two	O
in	O
the	O
control	O
group	O
,	O
P=0.28	O
)	O
.	O


Oral	O
magnesium	B-I
supplementation	I-I
in	O
children	B-P
with	I-P
cystic	I-P
fibrosis	I-P
improves	O
clinical	B-OUT
and	I-OUT
functional	I-OUT
variables	I-OUT
:	I-OUT
a	O
double-blind	O
,	O
randomized	O
,	O
placebo-controlled	O
crossover	O
trial	O
.	O


DESIGN	O
This	O
double-blind	O
,	O
randomized	O
,	O
placebo-controlled	O
crossover	O
study	O
included	O
44	B-P
CF	I-P
patients	I-P
(	I-P
aged	I-P
7-19	I-P
y	I-P
;	I-P
20	I-P
males	I-P
)	I-P
who	I-P
were	I-P
randomly	I-P
assigned	I-P
to	I-P
receive	I-P
magnesium	I-I
(	I-P
n	I-P
=	I-P
22	I-P
;	I-P
300	I-P
mg/d	I-P
)	I-P
or	I-P
placebo	I-I
(	I-P
n	I-P
=	I-P
22	I-P
)	I-P
for	I-P
8	I-P
wk	I-P
with	I-P
a	I-P
4-wk	I-P
washout	I-P
period	I-P
between	I-P
trials	I-P
.	I-P


The	O
duration	B-OUT
of	I-OUT
neutropenia	I-OUT
(	O
less	O
than	O
0.5	O
x	O
10	O
(	O
9	O
)	O
/L	O
)	O
was	O
similar	O
between	O
controls	O
(	O
median	O
22.5	O
days	O
)	O
and	O
patients	O
treated	O
with	O
lithium	B-I
(	O
median	O
24	O
days	O
)	O
.	O


It	O
is	O
reported	O
about	O
a	O
synthetic	B-I
secretin	I-I
(	I-I
Hoe	I-I
069	I-I
+	I-I
depot	I-I
component	I-I
)	I-I
given	O
prophylactically	O
to	O
100	B-P
patients	I-P
postoperatively	I-P
.	I-P


Statin	B-I
treatment	I-I
withdrawal	I-I
in	O
ischemic	B-P
stroke	I-P
:	I-P
a	O
controlled	O
randomized	O
study	O
.	O


BACKGROUND	O
Pretreatment	O
with	O
statins	O
has	O
been	O
shown	O
to	O
reduce	O
brain	O
injury	O
in	O
cerebral	O
ischemia	O
.	O


Are	O
'leaky	B-OUT
gut	I-OUT
'	I-OUT
and	O
behavior	B-OUT
associated	O
with	O
gluten	B-I
and	I-I
dairy	I-I
containing	O
diet	O
in	O
children	B-P
with	I-P
autism	I-P
spectrum	I-P
disorders	I-P
?	O
OBJECTIVES	O
Studies	O
have	O
suggested	O
a	O
link	O
between	O
diet	O
and	O
behavior	B-OUT
in	O
children	B-P
with	I-P
autism	I-P
spectrum	I-P
disorders	I-P
(	I-P
ASDs	I-P
)	I-P
.	I-P


An	O
association	O
between	O
diet	O
type	O
,	O
intestinal	B-OUT
permeability	I-OUT
(	I-OUT
IP	I-OUT
)	I-OUT
(	I-OUT
'leaky	I-OUT
gut	I-OUT
'	I-OUT
)	I-OUT
,	O
and	O
behavior	B-OUT
has	O
been	O
long	O
proposed	O
but	O
not	O
substantiated	O
.	O


DISCUSSION	O
Our	O
study	O
although	O
underpowered	O
to	O
show	O
small	O
differences	O
does	O
not	O
support	O
an	O
association	O
between	O
dietary	O
gluten/milk	O
,	O
IP	B-OUT
,	O
and	O
behavioral	B-OUT
changes	I-OUT
in	O
subjects	B-P
with	I-P
ASD	I-P
.	I-P


Objectively	O
maximum	O
active	O
extension	O
,	O
flexion	O
and	O
abduction	O
of	O
the	O
shoulder	O
,	O
and	O
subjectively	O
pain	O
stiffness	O
movement	O
and	O
function	O
were	O
measured	O
at	O
0	O
and	O
2	O
weeks	O
.	O


OBJECTIVES	O
To	O
compare	O
the	O
efficacy	O
and	O
safety	O
of	O
R-salbutamol	B-I
cream	I-I
0.5	O
%	O
vs.	B-I
placebo	I-I
on	O
DLE	O
lesions	O
in	O
a	O
multicentre	O
,	O
double-blinded	O
,	O
randomized	O
,	O
placebo-controlled	O
phase	O
II	O
trial	O
.	O


METHODS	O
Thirty-seven	B-P
patients	I-P
with	I-P
at	I-P
least	I-P
one	I-P
newly	I-P
developed	I-P
DLE	I-P
lesion	I-P
were	O
randomized	B-I
-	I-I
19	I-I
to	I-I
the	I-I
R-salbutamol	I-I
cream	I-I
0.5	I-I
%	I-I
and	I-I
18	I-I
to	I-I
placebo	I-I
-	I-I
and	I-I
treated	I-I
twice	I-I
daily	I-I
for	I-I
8	I-I
weeks	I-I
.	I-I


RESULTS	O
The	O
mean	O
area	O
under	O
the	O
curve	O
of	O
improvement	O
for	O
scaling/hypertrophy	B-OUT
,	I-OUT
pain	I-OUT
,	I-OUT
itching	I-OUT
and	I-OUT
global	I-OUT
patient	I-OUT
assessment	I-OUT
was	O
significantly	O
better	O
for	O
the	O
actively	O
treated	O
patients	O
as	O
compared	O
with	O
placebo	B-I
(	O
scaling/hypertrophy	O
,	O
P	O
=	O
0.0262	O
;	O
pain	O
,	O
P	O
=	O
0.0238	O
;	O
itching	O
,	O
P	O
=	O
0.0135	O
;	O
global	O
patient	O
assessment	O
,	O
P	O
=	O
0.045	O
)	O
.	O


Patients	O
who	O
did	O
not	O
improve	O
after	O
6	O
weeks	O
of	O
this	O
treatment	O
were	O
randomly	O
assigned	O
to	O
one	O
of	O
the	O
three	O
haloperidol	B-I
levels	O
for	O
another	O
6	O
weeks	O
.	O


The	O
improvement	O
was	O
defined	O
as	O
at	O
least	O
50	O
percent	O
reduction	O
of	O
the	O
Brief	B-OUT
Psychiatric	I-OUT
Rating	I-OUT
Scale	I-OUT
(	I-OUT
BPRS	I-OUT
)	I-OUT
total	I-OUT
score	I-OUT
.	I-OUT


These	O
results	O
suggest	O
that	O
the	O
haloperidol	B-I
doses	O
used	O
in	O
clinical	O
practice	O
may	O
be	O
higher	O
than	O
necessary	O
.	O


A	O
phase	O
III	O
clinical	O
trial	O
of	O
exercise	B-I
modalities	O
on	O
treatment	O
side-effects	O
in	O
men	B-P
receiving	I-P
therapy	I-P
for	I-P
prostate	I-P
cancer	I-P
.	I-P


As	O
this	O
project	O
is	O
much	O
longer	O
term	O
than	O
previous	O
investigations	O
in	O
the	O
area	O
of	O
exercise	B-I
and	O
cancer	O
,	O
we	O
will	O
gain	O
knowledge	O
as	O
to	O
the	O
continuing	O
effects	O
of	O
exercise	O
in	O
this	O
patient	O
population	O
specifically	O
targeting	O
bone	B-OUT
density	I-OUT
,	I-OUT
cardiovascular	I-OUT
function	I-OUT
,	I-OUT
lean	I-OUT
and	I-OUT
fat	I-OUT
mass	I-OUT
,	I-OUT
physical	I-OUT
function	I-OUT
and	I-OUT
falls	I-OUT
risk	I-OUT
as	O
primary	O
study	O
endpoints	O
.	O


CLINICAL	O
TRIAL	O
REGISTRY	O
A	O
Phase	O
III	O
clinical	O
trial	O
of	O
exercise	O
modalities	O
on	O
treatment	O
side-effects	O
in	O
men	O
receiving	O
therapy	O
for	O
prostate	O
cancer	O
;	O
ACTRN12609000200280	O
.	O


BACKGROUND	O
Long-term	O
data	O
from	O
randomised	O
trials	O
on	O
the	O
consequences	O
of	O
treatment	O
with	O
a	O
protease	B-I
inhibitor	I-I
(	I-I
PI	I-I
)	I-I
,	I-I
non-nucleoside	I-I
reverse	I-I
transcriptase	I-I
inhibitor	I-I
(	I-I
NNRTI	I-I
)	I-I
,	I-I
or	I-I
both	I-I
are	I-I
lacking	I-I
.	I-I


Analyses	O
were	O
by	O
intention-to-treat	O
.	O


Mean	B-OUT
change	I-OUT
in	I-OUT
CD4	I-OUT
cell	I-OUT
count	I-OUT
at	O
or	O
after	O
32	O
months	O
was	O
+234	O
cells	O
per	O
mm3	O
and	O
+227	O
cells	O
per	O
mm3	O
for	O
the	O
three-class	O
and	O
the	O
combined	O
two-class	O
strategies	O
(	O
p=0.62	O
)	O
,	O
respectively	O
.	O


Of	O
the	O
patients	B-P
treated	I-P
with	I-P
photons	I-I
45.7	O
%	O
had	O
severe	O
reactions	B-OUT
in	I-OUT
the	I-OUT
bladder	I-OUT
compared	O
with	O
10.6	O
%	O
after	O
neutron	B-I
therapy	I-I
(	O
p	O
less	O
than	O
0.001	O
)	O
.	O


Thalidomide	B-I
:	I-I
an	O
alternative	O
therapy	O
for	O
treatment	B-OUT
of	I-OUT
apthous	I-OUT
ulcers	I-OUT
(	I-P
canker	I-P
sores	I-P
)	I-P
.	I-P


SETTING	O
El	B-P
Minia	I-P
University	I-P
Hospital	I-P
,	I-P
El	I-P
Minia	I-P
,	I-P
Egypt	I-P
.	I-P


PATIENTS	O
AND	O
METHODS	O
Two-hundred	B-P
pregnant	I-P
women	I-P
with	I-P
stillbirth	I-P
,	I-P
unfavorable	I-P
cervix	I-P
and	I-P
scarred	I-P
uterus	I-P
were	O
recruited	O
into	O
this	O
study	O
.	O


RESULTS	O
Time	B-OUT
from	I-OUT
balloon	I-OUT
insertion	I-OUT
to	I-OUT
expulsion	I-OUT
and	O
from	O
balloon	B-OUT
insertion	I-OUT
to	I-OUT
delivery	I-OUT
was	O
significantly	O
shorter	O
in	O
Foley	O
's	O
catheter	O
group	O
.	O


CONCLUSIONS	O
Foley	B-I
's	I-I
catheter	I-I
and	O
Cook	B-I
cervical	I-I
ripening	O
balloon	O
are	O
comparable	O
regarding	O
efficacy	B-OUT
and	I-OUT
safety	I-OUT
profile	I-OUT
when	O
used	O
to	O
ripen	O
the	O
cervix	O
in	O
pregnant	B-P
women	I-P
with	I-P
stillbirth	I-P
,	I-P
unfavorable	I-P
cervix	I-P
and	I-P
scarred	I-P
uterus	I-P
.	I-P


METHOD	B-I
Mecamylamine	I-I
,	O
because	O
of	O
its	O
safety	O
record	O
in	O
children	O
with	O
other	O
disorders	O
,	O
was	O
chosen	O
for	O
this	O
first	O
exploration	B-P
.	I-P


Is	O
the	O
orientation	O
of	O
the	O
apical	B-P
defibrillation	I-P
paddle	I-P
of	I-P
importance	I-P
during	O
manual	B-I
external	I-I
defibrillation	I-I
?	O
OBJECTIVE	O
Transthoracic	B-OUT
impedance	I-OUT
(	I-OUT
TTI	I-OUT
)	I-OUT
is	O
a	O
factor	O
determining	O
the	O
magnitude	O
of	O
the	O
transmyocardial	O
current	O
during	O
external	B-I
defibrillation	I-I
.	I-I


Basal	B-OUT
CRT	I-OUT
2	I-OUT
was	O
0.643	O
(	O
0.033	O
)	O
s	O
in	O
non-TIPS	O
and	O
0.825	O
(	O
0.076	O
)	O
s	O
in	O
TIPS	O
patients	O
(	O
p	O
<	O
0.02	O
)	O
.	O


There	O
was	O
no	O
alteration	O
in	O
psychometric	B-OUT
function	I-OUT
in	O
non-TIPS	O
patients	O
after	O
glutamine	O
when	O
LOLA	B-I
was	O
given	O
but	O
when	O
placebo	B-I
was	O
given	O
,	O
glutamine	O
caused	O
prolongation	O
of	O
CRT	B-OUT
(	O
p=0.02	O
)	O
.	O


STUDY	O
DESIGN	O
Forty	B-P
emergency	I-P
patients	I-P
participated	I-P
,	I-P
and	I-P
each	I-P
had	I-P
a	I-P
clinical	I-P
diagnosis	I-P
of	I-P
an	I-P
irreversible	I-P
pulpitis	I-P
.	I-P


Patients	O
randomly	O
received	B-I
a	I-I
7-day	I-I
oral	I-I
dose	I-I
(	I-I
28	I-I
capsules	I-I
,	I-I
500	I-I
mg	I-I
each	I-I
,	I-I
to	I-I
be	I-I
taken	I-I
every	I-I
6	I-I
hours	I-I
)	I-I
of	I-I
either	I-I
penicillin	I-I
or	I-I
a	I-I
placebo	I-I
control	I-I
in	I-I
a	I-I
double-blind	I-I
manner	I-I
.	I-I


CONCLUSIONS	O
Blepharitis	B-I
therapy	I-I
with	I-I
the	I-I
antiseptic	I-I
bibrocathol	O
2	O
%	O
in	O
this	O
trial	O
was	O
highly	O
efficacious	O
and	O
safe	O
.	O


The	O
aim	O
of	O
the	O
present	O
study	O
was	O
to	O
examine	O
plaque	B-OUT
characteristics	I-OUT
by	O
B-mode	B-I
ultrasound	I-I
in	O
the	O
previous	O
intervention	O
study	O
,	O
and	O
also	O
to	O
investigate	O
the	O
relationship	O
between	O
plaque	B-OUT
characteristics	I-OUT
at	O
baseline	O
and	O
cardiovascular	B-OUT
events	I-OUT
during	O
the	O
6-year	O
follow-up	O
in	O
the	O
two	O
randomization	O
groups	O
.	O


Side	O
effects	O
,	O
mainly	O
diarrhea	B-OUT
,	O
occurred	O
in	O
15	O
percent	O
of	O
the	O
patients	O
given	O
antibiotics	B-I
.	I-I


DESIGN/METHODS	O
Prospective	O
randomized	O
,	O
controlled	O
trial	O
.	O


Topically	O
applied	O
fluorides	O
have	O
been	O
successfully	O
used	O
to	O
inhibit	O
the	O
formation	O
of	O
dental	O
caries	O
in	O
this	O
population	O
.	O


The	O
intraoral	B-I
fluoride-releasing	I-I
system	I-I
(	I-I
IFRS	I-I
)	I-I
containing	I-I
a	I-I
sodium	I-I
fluoride	I-I
core	I-I
is	O
a	O
newly	O
developed	O
,	O
sustained-release	O
,	O
passive	O
drug	O
delivery	O
system	O
that	O
does	O
not	O
require	O
patient	O
involvement	O
except	O
for	O
periodic	O
replacement	O
,	O
thus	O
reducing	O
the	O
effect	O
of	O
patient	O
compliance	O
on	O
its	O
effectiveness	O
in	O
dental	O
caries	O
prevention	O
.	O


Twenty-two	B-P
head	I-P
and	I-P
neck	I-P
cancer	I-P
patients	I-P
from	I-P
U.	I-P
T.	I-P
M.	I-P
D.	I-P
Anderson	I-P
Cancer	I-P
Center	I-P
,	I-P
with	I-P
radiation-induced	I-P
xerostomia	I-P
,	O
were	O
entered	O
into	O
a	O
pilot	O
study	O
to	O
contrast	O
the	O
daily	O
home	O
use	O
of	O
a	O
0.4	O
%	O
stannous	O
fluoride-gel-containing	B-I
tray	I-I
(	O
control	O
group	O
)	O
to	O
IFRS	B-I
(	O
study	O
group	O
)	O
with	O
respect	O
to	O
tolerability	O
and	O
adherence	O
,	O
and	O
to	O
obtain	O
information	O
on	O
relative	O
caries	O
preventive	O
efficacy	O
.	O


Triple	B-I
combination	I-I
as	I-I
adjuvant	I-I
to	I-I
cryotherapy	I-I
in	O
the	O
treatment	B-OUT
of	I-OUT
solar	I-OUT
lentigines	I-OUT
:	I-OUT
investigator-blinded	O
,	O
randomized	O
clinical	O
trial	O
.	O


OBJECTIVE	O
Autosomal	B-P
dominant	I-P
polycystic	I-P
kidney	I-P
disease	I-P
(	I-P
ADPKD	I-P
)	I-P
is	O
progressive	O
,	O
resulting	O
in	O
end-stage	B-P
kidney	I-P
failure	I-P
in	I-P
most	I-P
patients	I-P
.	I-P


Trial	O
visits	O
were	O
conducted	O
every	O
3	O
months	O
,	O
assessing	O
kidney	B-OUT
function	I-OUT
by	O
estimated	O
glomerular	B-OUT
filtration	I-OUT
rate	I-OUT
and	I-OUT
24	I-OUT
h	I-OUT
urine	I-OUT
creatinine	I-OUT
clearance	I-OUT
and	I-OUT
urinary	I-OUT
protein	I-OUT
excretion	I-OUT
.	I-OUT


This	O
effect	O
was	O
not	O
seen	O
in	O
the	O
supplemented	O
group	O
.	O


Systematic	O
data	O
on	O
the	O
long-term	O
course	O
of	O
and	O
therapeutic	O
options	O
for	O
these	O
consequences	O
are	O
limited	O
.	O


The	B-P
control	I-P
group	I-P
consisted	I-P
of	I-P
patients	I-P
who	I-P
received	I-P
no	I-I
specific	I-I
training	I-I
.	I-I


During	O
in-patient	O
rehabilitation	O
,	O
the	O
results	B-OUT
of	I-OUT
a	I-OUT
comprehensive	I-OUT
neuropsychological	I-OUT
test	I-OUT
battery	I-OUT
improved	O
significantly	O
in	O
all	O
three	O
groups	O
,	O
and	O
no	O
specific	O
intervention	O
effects	O
were	O
identified	O
.	O


SUBJECTS	O
AND	O
SETTINGS	O
we	O
randomized	O
patients	B-P
aged	I-P
75	I-P
years	I-P
and	I-P
older	I-P
on	I-P
four	I-P
or	I-P
more	I-P
medicines	I-P
who	I-P
had	I-P
been	I-P
discharged	I-P
from	I-P
three	I-P
acute	I-P
general	I-P
and	I-P
one	I-P
long-stay	I-P
hospital	I-P
to	I-P
a	I-P
pharmacy	I-P
intervention	I-P
or	I-P
usual	I-P
care	I-P
.	I-P


In	O
this	O
prospective	O
study	O
,	O
14	B-P
patients	I-P
with	I-P
colonic	I-P
cancer	I-P
were	O
randomly	O
assigned	O
to	O
undergo	O
a	O
6-hour	O
stable	O
isotope	B-I
infusion	I-I
study	O
(	O
3	O
hours	O
of	O
fasting	B-I
followed	O
by	O
3-hour	O
infusions	O
of	O
amino	B-I
acids	I-I
,	I-I
Travasol	I-I
[	O
Baxter	O
,	O
Montreal	O
,	O
Canada	O
]	O
10	O
%	O
at	O
0.02	O
mL.kg	O
(	O
-1	O
)	O
.min	O
(	O
-1	O
)	O
,	O
with	B-I
or	I-I
without	I-I
glucose	I-I
at	O
4	O
mg.kg	O
(	O
-1	O
)	O
.min	O
(	O
-1	O
)	O
)	O
on	O
the	O
second	O
day	O
after	O
colorectal	O
surgery	O
.	O


The	O
administration	O
of	O
amino	B-I
acids	I-I
increased	O
protein	B-OUT
balance	I-OUT
from	O
-16+/-4	O
micromol.kg	O
(	O
-1	O
)	O
.h	O
(	O
-1	O
)	O
in	O
the	O
fasted	O
state	O
to	O
16+/-3	O
micromol.kg	O
(	O
-1	O
)	O
.h	O
(	O
-1	O
)	O
.	O


The	O
effects	O
of	O
esmolol	B-I
,	O
an	O
ultrashort-acting	O
beta	O
blocker	O
,	O
and	O
verapamil	B-I
were	O
compared	O
in	O
controlling	O
ventricular	B-OUT
response	I-OUT
in	O
45	B-P
patients	I-P
with	I-P
atrial	I-P
fibrillation	I-P
or	I-P
atrial	I-P
flutter	I-P
,	I-P
in	I-P
a	I-P
randomized	I-P
,	I-P
parallel	I-P
,	I-P
open-label	I-P
study	I-P
.	I-P


Patients	O
received	O
local	B-I
applications	I-I
of	I-I
ointments	I-I
containing	I-I
5	I-I
%	I-I
lignocaine	I-I
(	I-I
n=28	I-I
)	I-I
,	I-I
0.5	I-I
%	I-I
minoxidil	I-I
(	O
n=36	O
)	O
,	O
or	B-I
both	I-I
(	O
n=26	O
)	O
.	O


RESULTS	O
Rates	B-OUT
of	I-OUT
complete	I-OUT
healing	I-OUT
of	I-OUT
fissure	I-OUT
were	O
similar	O
in	O
the	O
three	O
groups	O
(	B-I
lignocaine	I-I
alone	O
8/27	O
,	O
minoxidil	B-I
alone	O
10/34	O
,	O
combination	O
7/22	O
;	O
p=ns	O
)	O
.	O


CONCLUSION	O
Combination	O
treatment	O
with	O
minoxidil	B-I
and	O
lignocaine	B-I
helps	O
in	O
faster	O
healing	O
of	O
anal	O
fissures	O
and	O
provides	O
better	O
symptomatic	O
relief	O
than	O
either	O
drug	O
alone	O
.	O


In	B-P
addition	I-P
,	I-P
986	I-P
breast	I-P
cancer	I-P
and	I-P
442	I-P
colorectal	I-P
cancer	I-P
(	I-P
CRC	I-P
)	I-P
cases	I-P
were	I-P
studied	I-P
.	I-P


The	O
mutation	B-OUT
contributed	O
significantly	O
to	O
younger	O
age	O
(	O
≤55	O
years	O
)	O
at	O
onset	O
and	O
high	O
prostate-specific	O
antigen	O
(	O
PSA	O
;	O
≥20	O
ng/mL	O
)	O
at	O
diagnosis	O
.	O


No	O
statistically	O
significant	O
evidence	O
for	O
a	O
contribution	B-OUT
in	I-OUT
CRC	I-OUT
risk	I-OUT
was	O
detected	O
,	O
but	O
a	O
suggestive	O
role	O
for	O
the	O
mutation	O
was	O
observed	O
in	O
familial	O
BRCA1/2-negative	O
breast	O
cancer	O
.	O


In	O
part	O
B	B-I
,	I-I
cediranib	I-I
30	O
mg/day	O
appeared	O
to	O
be	O
the	O
most	O
sustainable	O
for	O
chronic	O
dosing	B-I
.	I-I


CONCLUSION	O
No	O
implant	O
or	O
surgical	O
technique	O
is	O
superior	O
to	O
any	O
other	O
under	O
all	O
circumstances	O
for	O
distal	O
femoral	O
fracture	O
.	O


Participants	B-P
were	O
also	O
more	O
likely	O
to	O
report	O
that	O
the	O
tailored	B-I
expert	I-I
system	I-I
was	O
personally	B-OUT
relevant	I-OUT
,	I-OUT
helpful	I-OUT
,	I-OUT
and	I-OUT
easy	I-OUT
to	I-OUT
understand	I-OUT
.	I-OUT


However	O
,	O
clearance	B-OUT
rates	I-OUT
at	O
week	O
52	O
were	O
significantly	O
different	O
:	O
43	O
%	O
for	O
R1	O
and	O
88	O
%	O
for	O
R2	O
(	O
95	O
%	O
CI	O
for	O
difference	O
:	O
11	O
%	O
to	O
68	O
%	O
,	O
p	O
=	O
0.02	O
)	O
.	O


CONCLUSION	O
Five	O
weeks	O
of	O
5	O
%	O
imiquimod	B-I
cream	O
once	O
daily	O
with	O
a	O
1-week	O
interval	O
was	O
more	O
effective	B-OUT
but	O
as	O
well	B-OUT
tolerated	I-OUT
as	O
the	O
8-week	O
alternate	O
week	O
regimen	O
for	O
sBCC	B-P
.	I-P


They	O
consumed	O
less	O
vitamin	B-OUT
D	I-OUT
from	I-OUT
supplements	I-OUT
(	O
2.15	O
(	O
sd	O
5.24	O
)	O
μg/d	O
(	O
86	O
(	O
sd	O
210	O
)	O
IU/d	O
)	O
v.	O
4.55	O
(	O
sd	O
8.48	O
)	O
μg/d	O
(	O
188	O
(	O
sd	O
344	O
)	O
IU/d	O
)	O
,	O
P	O
=	O
0.003	O
)	O
.	O


From	O
these	O
six	O
items	O
,	O
a	O
composite	O
score	O
of	O
≤	O
2.25	O
demonstrated	O
≥89	B-OUT
%	I-OUT
sensitivity	I-OUT
but	I-OUT
≤35	I-OUT
%	I-OUT
specificity	I-OUT
for	O
VDI	O
.	O


BACKGROUND	O
Myoclonic	O
movements	O
are	O
a	O
common	O
problem	O
in	O
unpremedicated	O
patients	B-P
during	I-P
induction	I-P
of	I-P
anesthesia	I-P
with	I-P
etomidate	I-P
.	I-P


The	O
differences	O
are	O
statistically	O
significant	O
.	O


Midlife	B-P
women	I-P
online	O
:	O
evaluation	O
of	O
an	O
internet-based	O
program	O
to	O
prevent	O
unintended	O
pregnancy	O
&	O
STIs	O
.	O


METHODS	O
A	O
randomized	O
controlled	O
trial	O
of	O
an	O
Internet-based	B-I
multimedia	I-I
program	I-I
to	O
reduce	O
risk	O
of	O
unintended	O
pregnancy	O
and	O
STIs	O
among	O
midlife	B-P
women	I-P
was	I-P
conducted	I-P
with	I-P
164	I-P
women	I-P
ages	I-P
40-55	I-P
years	I-P
of	I-P
age	I-P
.	I-P


Implications	O
for	O
future	O
research	O
and	O
intervention	O
development	O
are	O
presented	O
.	O


Enhanced	B-OUT
bioavailability	I-OUT
of	I-OUT
zeaxanthin	I-OUT
in	O
a	O
milk-based	O
formulation	O
of	O
wolfberry	O
(	O
Gou	O
Qi	O
Zi	O
;	O
Fructus	O
barbarum	O
L.	O
)	O
.	O


Results	O
showed	O
that	O
triacylglycerol-rich	B-OUT
lipoprotein	I-OUT
zeaxanthin	I-OUT
peaked	I-OUT
at	O
6	O
h	O
post-ingestion	O
for	O
all	O
formulations	O
.	O


Eradication	B-OUT
was	O
determined	O
by	O
a	O
13C-urea	O
breath	O
test	O
6	O
months	O
and	O
2	O
years	O
after	O
the	O
first	O
visit	O
.	O


Consumer-directed	O
care	O
for	O
beneficiaries	B-P
with	I-P
mental	I-P
illness	I-P
:	I-P
lessons	O
from	O
New	O
Jersey	O
's	O
Cash	O
and	O
Counseling	O
program	O
.	O


For	O
most	O
outcome	O
measures	O
the	O
CCDE	O
program	O
demonstrated	O
a	O
positive	B-OUT
effect	I-OUT
after	O
baseline	O
characteristics	O
were	O
controlled	O
for	O
.	O


Differences	O
between	O
the	O
two	O
groups	O
were	O
significant	O
(	O
p	O
less	O
than	O
0.05	O
)	O
.	O


This	O
sustained	O
secretion	O
of	O
both	O
GH	B-OUT
and	I-OUT
PRL	I-OUT
in	O
uremia	O
could	O
be	O
attributed	O
to	O
reduced	O
kidney	O
clearance	O
.	O


Does	O
cognition	O
predict	O
treatment	O
response	O
and	O
remission	O
in	O
psychotherapy	B-I
for	O
late-life	B-P
depression	I-P
?	O
OBJECTIVES	O
To	O
identify	O
cognitive	O
predictors	O
of	O
geriatric	B-P
depression	I-P
treatment	O
outcome	O
.	O


We	O
examined	O
cognitive	O
predictors	O
to	O
identify	O
treatment	O
responders	O
(	O
i.e.	O
,	O
HAM-D	B-OUT
scores	I-OUT
reduced	O
by	O
≥50	O
%	O
)	O
and	O
remitters	O
(	O
i.e.	O
,	O
post-treatment	O
HAM-D	O
score	O
≤10	O
)	O
.	O


No	O
other	O
cognitive	O
or	O
health	O
variables	O
predicted	B-OUT
psychotherapy	I-OUT
outcomes	O
in	O
the	O
decision	O
trees	O
.	O


Malnutrition	O
and	O
immunosupression	O
make	O
patients	O
highly	O
susceptible	O
to	O
postoperative	O
infections	O
and	O
complications	O
.	O


OBJECTIVES	O
Compare	O
two	O
immunoenhanced	B-I
enteral	I-I
nutritions	I-I
with	O
a	O
control	O
diet	O
,	O
and	O
evaluate	O
the	O
effect	O
in	O
postoperative	B-OUT
infections	I-OUT
,	I-OUT
length	I-OUT
of	I-OUT
stay	I-OUT
and	I-OUT
inflammatory	I-OUT
markers	I-OUT
.	I-OUT


PATIENTS	O
A	B-P
population	I-P
of	I-P
44	I-P
patients	I-P
with	I-P
oral	I-P
and	I-P
laryngeal	I-P
cancer	I-P
was	I-P
enrolled	I-P
in	I-P
a	I-P
randomized	I-P
trial	I-P
.	I-P


No	O
significant	O
intergroup	O
differences	O
in	O
the	O
trend	O
of	O
the	O
two	B-OUT
plasma	I-OUT
proteins	I-OUT
(	I-OUT
albumin	I-OUT
,	I-OUT
transferrin	I-OUT
)	I-OUT
,	I-OUT
lymphocytes	I-OUT
,	I-OUT
weight	I-OUT
,	I-OUT
IL-6	I-OUT
,	I-OUT
CPR	I-OUT
and	I-OUT
TNFalpha	I-OUT
were	O
detected	O
.	O


The	O
control	O
group	O
showed	O
the	O
highest	O
levels	O
of	O
TNFalpha	B-OUT
at	O
the	O
fourteenth	O
postoperative	O
day	O
.	O


CONCLUSIONS	O
Immunoenhanced	B-I
enteral	I-I
nutrition	I-I
formulas	I-I
improved	O
the	O
infection	B-OUT
rate	I-OUT
in	O
the	O
postoperative	O
of	O
head	B-P
and	I-P
neck	I-P
cancer	I-P
patients	I-P
.	I-P


The	O
usefulness	O
of	O
caffeine	B-I
,	I-I
metoclopramide	I-I
and	I-I
pyridoxine	I-I
as	O
adjuncts	O
to	O
tolfenamic	B-I
acid	I-I
was	O
tested	O
in	O
acute	B-OUT
migraine	I-OUT
attacks	I-OUT
in	I-P
ten	I-P
patients	I-P
.	I-P


CONCLUSIONS	O
These	O
data	O
suggest	O
that	O
different	O
patterns	O
of	O
allelic	B-OUT
deletion	I-OUT
may	O
be	O
acquired	O
during	O
cancer	O
progression	O
to	O
metastases	O
.	O


Accelerated	O
approval	O
was	O
based	O
on	O
demonstration	O
of	O
a	O
beneficial	O
effect	O
on	O
progression-free	O
survival	O
(	O
PFS	O
)	O
.	O


Patients	B-P
receiving	I-P
panitumumab	I-I
in	O
combination	O
with	O
bevacizumab	B-I
and	I-I
chemotherapy	I-I
experienced	O
a	O
higher	O
incidence	O
of	O
death	B-OUT
(	O
9	O
%	O
versus	O
4	O
%	O
)	O
and	O
a	O
higher	O
risk	O
for	O
grade	B-OUT
3	I-OUT
and	I-OUT
4	I-OUT
toxicities	I-OUT
than	O
patients	B-P
receiving	I-P
bevacizumab	I-I
and	I-I
chemotherapy	I-I
alone	I-I
.	I-I


Grade	B-OUT
3	I-OUT
and	I-OUT
4	I-OUT
AEs	I-OUT
occurring	O
more	O
commonly	O
in	O
panitumumab-treated	B-I
patients	O
included	O
rash/acneiform	B-OUT
dermatitis	I-OUT
,	I-OUT
diarrhea	I-OUT
,	I-OUT
dehydration	I-OUT
,	I-OUT
primarily	I-OUT
resulting	I-OUT
from	I-OUT
diarrhea	I-OUT
,	I-OUT
hypokalemia	I-OUT
,	I-OUT
stomatitis/mucositis	I-OUT
,	I-OUT
and	I-OUT
pulmonary	I-OUT
embolism	I-OUT
.	I-OUT


Patients	B-P
were	I-P
followed	I-P
clinically	I-P
at	I-P
months	I-P
1	I-P
,	I-P
3	I-P
,	I-P
6	I-P
,	I-P
12	I-P
,	I-P
18	I-P
,	I-P
and	I-P
24	I-P
after	I-P
the	I-P
diagnosis	I-P
of	I-P
DVT	I-P
.	I-P


Based	O
upon	O
the	O
VPS	O
,	O
PTS	O
was	O
scored	O
as	O
absent	O
(	O
score	O
<	O
3	O
or	O
3	O
without	O
objective	O
criteria	O
)	O
,	O
mild	O
to	O
moderate	O
(	O
score	O
≥3	O
with	O
1	O
objective	O
criteria	O
)	O
,	O
or	O
severe	O
(	O
score	O
≥4	O
)	O
.	O


Effect	O
of	O
ozone	B-I
application	I-I
on	O
the	O
resin-dentin	B-OUT
microtensile	I-OUT
bond	I-OUT
strength	I-OUT
.	I-OUT


Forty	B-P
human	I-P
third	I-P
molars	I-P
were	O
divided	O
into	O
four	O
groups	O
:	O
Group	O
1	O
,	O
not	B-I
treated	I-I
with	I-I
ozone	I-I
;	I-I
Group	O
2	O
,	O
ozone	B-I
application	I-I
followed	I-I
by	I-I
acid	I-I
etching	I-I
;	I-I
Group	O
3	O
,	O
acid	B-I
etching	I-I
followed	I-I
by	I-I
ozone	I-I
application	I-I
;	I-I
and	O
Group	O
4	O
,	O
ozone	B-I
and	I-I
application	I-I
of	I-I
sodium	I-I
ascorbate	I-I
.	O


All	O
beams	O
that	O
fractured	O
were	O
analyzed	O
under	O
stereomicroscopy	O
(	O
40×	O
)	O
.	O


The	O
use	O
of	O
ozone	O
in	O
Group	O
2	O
resulted	O
in	O
lower	B-OUT
values	I-OUT
of	I-OUT
μTBS	O
in	O
all	O
conditions	O
evaluated	O
.	O


The	O
predominant	B-OUT
failure	I-OUT
mode	O
was	O
adhesive	O
.	O


CONCLUSIONS	O
Clindamycin	B-I
vaginal	O
cream	O
therapy	O
was	O
associated	O
with	O
significantly	O
prolonged	O
gestation	O
and	O
reduced	O
cost	O
of	O
neonatal	O
care	O
in	O
women	B-P
with	I-P
BV	I-P
.	I-P


OBJECTIVE	O
To	O
observe	O
the	O
effects	O
of	O
Shuxuening	B-I
Injection	I-I
(	I-I
SI	I-I
)	I-I
on	O
the	O
levels	O
of	O
serum	B-OUT
matrix	I-OUT
metalloproteinase-9	I-OUT
(	I-OUT
MMP-9	I-OUT
)	I-OUT
and	O
tissue	B-OUT
inhibitor	I-OUT
of	I-OUT
metalloproteinase	I-OUT
(	I-OUT
TIMP-1	I-OUT
)	I-OUT
in	O
acute	B-P
exacerbated	I-P
chronic	I-P
obstructive	I-P
pulmonary	I-P
disease	I-P
(	I-P
COPD	I-P
)	I-P
patients	I-P
.	I-P


The	O
levels	B-OUT
of	I-OUT
serum	I-OUT
MMP-9	I-OUT
and	I-OUT
TIMP-1	I-OUT
were	O
detected	O
using	O
ELISA	O
before	O
and	O
after	O
treatment	O
,	O
and	O
compared	O
with	O
20	O
healthy	O
subjects	O
as	O
the	O
control	O
.	O


One	O
of	O
its	O
mechanisms	O
might	O
be	O
correlated	O
with	O
lowering	O
the	O
serum	O
levels	O
of	O
MMP-9	O
and	O
TIMP-1	O
,	O
and	O
correcting	O
the	O
imbalance	O
of	O
MMP-9/TIMP-1	O
.	O


We	O
analyzed	O
598	B-P
patients	I-P
who	I-P
received	I-P
at	I-P
least	I-P
one	I-P
dose	I-P
of	I-P
trial	I-P
medication	I-P
.	I-P


Overall	B-OUT
response	I-OUT
rates	I-OUT
were	O
similar	O
in	O
patients	O
treated	O
intravenously	O
or	O
subcutaneously	O
.	O


The	O
clinical	O
trial	O
is	O
registered	O
at	O
eudract.ema.europa.eu	O
as	O
n.	O
2010-019173-16	O
.	O


Primary	O
non-resectable	O
liver	O
malignancies	O
show	O
the	O
best	O
results	O
after	O
chemoembolisation	O
(	O
Frankfurt	O
method	O
)	O
.	O


We	O
tested	O
whether	O
coping	O
was	O
a	O
mediator	O
and	O
for	O
moderated	O
mediation	O
,	O
and	O
(	O
post-hoc	O
)	O
subgroup	O
treatment	O
effects	O
on	O
coping	O
.	O


RESULTS	B-P
Data	I-P
were	I-P
available	I-P
for	I-P
187	I-P
carers	I-P
(	I-P
71.9	I-P
%	I-P
)	I-P
for	O
the	O
mediation	O
analysis	O
.	O


The	O
prospective	O
randomized	O
controlled	O
study	O
consisted	O
of	O
two	O
groups	O
.	O


Concerning	O
the	O
69-month	B-OUT
survival	I-OUT
rate	I-OUT
,	O
a	O
better	O
result	O
was	O
observed	O
in	O
the	O
MMC	B-I
+	I-I
HCFU	I-I
group	O
than	O
in	O
the	O
MMC	B-I
only	I-I
group	O
(	O
generalized	O
Wilcoxon	O
test	O
:	O
p	O
less	O
than	O
0.05	O
)	O
.	O


METHODS	O
Eyes	B-P
were	O
randomized	O
to	O
receive	O
sham	B-I
injections	I-I
plus	I-I
prompt	I-I
laser	I-I
,	I-I
intravitreal	I-I
ranibizumab	I-I
injections	I-I
plus	I-I
prompt	I-I
laser	I-I
,	I-I
intravitreal	I-I
ranibizumab	I-I
injections	I-I
plus	I-I
deferred	I-I
laser	I-I
,	I-I
or	I-I
intravitreal	I-I
triamcinolone	I-I
acetonide	I-I
injections	I-I
plus	I-I
prompt	I-I
laser	I-I
up	O
to	O
every	O
16	O
weeks	O
with	O
sham	O
injections	O
intermittently	O
.	O


RESULTS	O
The	O
PKVP	O
loop	O
achieved	O
a	O
fast	O
and	O
sharp	O
cutting	O
action	O
similar	O
to	O
that	O
with	O
the	O
traditional	O
TURP	O
loop	O
.	O


CONCLUSION	O
PKVP	B-I
achieved	O
comparable	O
results	O
to	O
traditional	O
TURP	B-I
and	O
was	O
an	O
effective	B-OUT
and	I-OUT
safe	I-OUT
procedure	O
.	O


The	O
patients	B-P
have	I-P
been	I-P
divided	I-P
into	I-P
two	I-P
groups	I-P
according	I-P
to	I-P
ST-T	I-P
changes	I-P
during	I-P
chest	I-P
pain	I-P
:	I-P
29	I-P
with	I-P
ST	I-P
elevation	I-P
(	I-P
group	I-P
A	I-P
)	I-P
and	I-P
41	I-P
with	I-P
other	I-P
repolarization	I-P
abnormalities	I-P
(	I-P
group	I-P
B	I-P
)	I-P
.	I-P


Treatment	O
was	O
then	O
randomized	O
in	O
each	O
group	O
.	O


Because	O
the	O
aim	O
of	O
prostate	O
cancer	O
detection	O
is	O
to	O
find	O
cancers	O
at	O
an	O
early	O
,	O
potentially	O
curable	O
stage	O
,	O
it	O
is	O
of	O
major	O
interest	O
that	O
71.8	O
%	O
of	O
evaluable	O
cancers	O
were	O
clinical	O
stage	O
B	O
;	O
8.4	O
%	O
and	O
10.7	O
%	O
were	O
stages	O
C1	O
and	O
C2	O
,	O
respectively	O
;	O
only	O
9.2	O
%	O
were	O
stage	O
D	O
(	O
metastatic	O
)	O
at	O
first	O
visit	O
while	O
none	O
was	O
at	O
stage	O
D	O
at	O
follow-up	O
visits	O
.	O


Injury	B-OUT
and	I-OUT
illness	I-OUT
costs	I-OUT
in	O
the	O
Certified	O
Safe	O
Farm	O
study	O
.	O


CONCLUSIONS	O
Results	O
suggest	O
that	O
farmers	O
receiving	O
the	O
intervention	B-I
had	O
lower	O
health	B-OUT
care	I-OUT
costs	I-OUT
for	O
occupational	O
injuries	O
and	O
illnesses	O
than	O
control	B-I
farmers	O
.	O


Morphology	O
of	O
the	O
postoperative	B-P
blebs	I-P
suggests	O
that	O
increased	O
filtration	O
results	O
in	O
lower	O
intraocular	B-OUT
pressure	I-OUT
in	O
the	O
5-FU	B-I
group	I-P
.	I-P


The	O
level	O
of	O
impairment	O
for	O
each	O
component	O
literacy	O
skill	O
was	O
examined	O
for	O
CwPLI	O
and	O
CwSLI	O
.	O


Patients	O
in	O
the	O
conventional	B-I
treatment	I-I
group	I-I
(	O
n=119	O
)	O
were	O
not	O
given	O
insulin	B-I
unless	O
glucose	B-OUT
levels	I-OUT
were	O
greater	O
than	O
11.1	O
m	O
mol/l	O
(	O
200mg/dl	O
)	O
.	O


Both	O
groups	O
were	O
treated	O
with	O
insulin	B-I
infusion	O
to	O
maintain	O
normoglycemia	O
after	O
leaving	O
NICU	O
.	O


The	O
second	O
outcomes	O
including	O
ICU	B-OUT
infection	I-OUT
rate	I-OUT
,	I-OUT
duration	I-OUT
of	I-OUT
ICU	I-OUT
stay	I-OUT
,	I-OUT
in-hospital	I-OUT
mortality	I-OUT
rate	I-OUT
and	I-OUT
neurologic	I-OUT
outcome	I-OUT
at	O
6	O
months	O
follow-up	O
.	O


The	O
days	B-OUT
stay	I-OUT
in	I-OUT
NICU	I-OUT
was	O
shorter	O
in	O
intensive	B-I
insulin	I-I
control	I-I
group	I-I
than	O
that	O
in	O
conventional	B-I
therapy	I-I
group	I-I
[	O
4.2	O
days	O
vs.	O
5.6	O
days	O
(	O
medians	O
)	O
P	O
<	O
0.05	O
]	O
.	O


The	O
neurologic	B-OUT
outcome	I-OUT
according	O
to	O
Glasgow	B-OUT
Outcome	I-OUT
Score	I-OUT
(	I-OUT
GOS	I-OUT
)	I-OUT
at	O
6	O
months	O
(	O
GOS	O
5	O
and	O
4	O
)	O
was	O
better	O
in	O
the	O
intensive	B-I
insulin	I-I
therapy	I-I
group	O
(	O
34	O
of	O
117	O
,	O
29.1	O
%	O
)	O
than	O
that	O
in	O
the	O
conventional	B-I
therapy	I-I
group	O
(	O
26	O
of	O
116	O
,	O
22.4	O
%	O
,	O
P	O
<	O
0.05	O
)	O
.	O


Social	O
stories	O
:	O
mechanisms	O
of	O
effectiveness	O
in	O
increasing	O
game	B-I
play	I-I
skills	I-I
in	O
children	B-P
diagnosed	I-P
with	I-P
autism	I-P
spectrum	I-P
disorder	I-P
using	O
a	O
pretest	O
posttest	O
repeated	O
measures	O
randomized	O
control	O
group	O
design	O
.	O


A	O
parallel	O
set	O
of	O
analyses	O
was	O
conducted	O
on	O
partners	B-OUT
'	I-OUT
depression	I-OUT
and	I-OUT
anxiety	I-OUT
data	I-OUT
.	I-OUT


DISCUSSION	O
Findings	O
from	O
this	O
study	O
support	O
that	O
these	O
telephone-delivered	O
psychosocial	O
interventions	O
were	O
effective	B-OUT
for	O
decreasing	O
symptoms	B-OUT
of	I-OUT
depression	I-OUT
and	I-OUT
anxiety	I-OUT
to	O
improve	O
psychological	B-OUT
quality	I-OUT
of	I-OUT
life	I-OUT
when	O
compared	O
to	O
an	O
AC	O
group	O
.	O


Brief	O
report	O
:	O
a	O
pilot	O
study	O
of	O
auditory	B-OUT
integration	I-OUT
training	I-I
in	O
autism	B-P
.	I-P


White	O
coat	O
effect	O
detected	O
using	O
self-monitoring	B-I
of	I-I
blood	I-I
pressure	I-I
at	I-I
home	I-I
:	I-I
comparison	O
with	O
ambulatory	O
blood	O
pressure	O
.	O


Hypertensive	B-P
patients	I-P
were	O
randomized	O
to	O
measure	O
HBP	B-I
for	O
2	O
weeks	O
or	O
ABP	B-I
for	O
24	O
h.	O
The	O
alternative	O
measurement	O
was	O
then	O
performed	O
.	O


Subjects	B-P
with	I-P
a	I-P
difference	I-P
of	I-P
>	I-P
or	I-P
=	I-P
20	I-P
mm	I-P
Hg	I-P
systolic	I-P
or	I-P
>	I-P
or	I-P
=	I-P
10	I-P
mm	I-P
Hg	I-P
diastolic	I-P
BP	I-P
between	I-P
CBP	I-P
and	I-P
awake	I-P
ABP	I-I
or	I-P
CBP	I-I
and	I-P
HBP	I-I
,	O
were	O
classified	O
as	O
clinic	O
reactors	O
.	O


The	O
proportion	O
of	O
patients	O
classified	O
as	O
clinic	B-OUT
reactors	I-OUT
was	O
identical	O
using	O
the	O
HBP	B-I
or	O
the	O
ABP	B-I
method	O
(	O
25.9	O
%	O
)	O
.	O


METHOD	O
Forty	B-P
individuals	I-P
comprised	I-P
the	I-P
simulating	I-P
and	I-P
control	I-P
group	I-P
and	O
all	O
participants	O
were	O
randomly	B-I
assigned	I-I
to	I-I
the	I-I
simulating	I-I
and	I-I
control	I-I
groups	I-I
.	I-I


Twenty	B-P
memory-impaired	I-P
patients	I-P
,	I-P
all	I-P
of	I-P
whom	I-P
had	I-P
been	I-P
diagnosed	I-P
as	I-P
suffering	I-P
from	I-P
a	I-P
memory	I-P
impairment	I-P
following	I-P
acquired	I-P
brain	I-P
damage	I-P
,	I-P
participated	I-P
as	I-P
the	I-P
memory-impaired	I-P
control	I-P
group	I-P
.	I-P


The	B-I
simulation	I-I
group	I-I
was	I-I
directed	I-I
to	I-I
imitate	I-I
a	I-I
person	I-I
with	I-I
a	I-I
memory	I-I
impairment	I-I
.	I-I


CONCLUSION	O
It	O
is	O
suggested	O
that	O
these	O
two	O
tests	O
,	O
when	O
administered	O
jointly	O
,	O
might	O
be	O
of	O
use	O
in	O
clinical	O
settings	O
to	O
assist	O
in	O
the	O
detection	O
of	O
malingerers	O
.	O


In	O
the	O
matched	O
groups	O
,	O
there	O
was	O
no	O
difference	B-OUT
between	I-OUT
adverse	I-OUT
event	I-OUT
rates	O
in	O
patients	O
treated	O
with	O
β-blockers	O
and	O
those	O
who	O
were	O
not	O
.	O


The	O
number	O
of	O
patients	O
requiring	B-OUT
intraoperative	I-OUT
blood	I-OUT
product	I-OUT
use	O
was	O
significantly	O
higher	O
among	O
β-blocker-treated	O
patients	O
(	O
p=0.004	O
)	O
.	O


CONCLUSIONS	O
A	O
rational	O
for	O
preoperative	O
β-blockade	O
exists	O
.	O


The	O
objectives	O
of	O
this	O
pilot	O
study	O
were	O
1	O
)	O
to	O
examine	O
possible	O
effects	O
of	O
secretin	B-I
infusions	O
on	O
sleep-wake	O
state	O
organization	O
in	O
children	B-P
with	I-P
autism	I-P
,	I-P
and	I-P
2	I-P
)	I-P
to	I-P
assess	I-P
the	I-P
feasibility	I-P
of	I-P
home	I-P
recordings	I-P
using	I-P
time-lapse	I-P
videosomnography	I-P
in	I-P
children	I-P
with	I-P
autism	I-P
.	I-P


One	O
trial	O
,	O
the	O
UC	O
Irvine	O
study	O
,	O
assessed	O
the	O
effects	O
of	O
porcine	B-I
secretin	I-I
vs.	I-I
saline	I-I
infusions	I-I
on	O
children	O
's	O
behavior	B-OUT
,	I-OUT
language	I-OUT
and	O
IQ	B-OUT
.	I-OUT


Dexmedetomidine	B-I
infusion	O
for	O
maintenance	O
of	O
anesthesia	O
in	O
patients	B-P
undergoing	I-P
abdominal	I-P
hysterectomy	I-P
.	I-P


The	O
usefulness	O
of	O
intravenous	O
dexmedetomidine	B-I
infusion	O
for	O
maintenance	O
of	O
anesthesia	O
was	O
studied	O
in	O
patients	B-P
anesthetized	I-P
with	I-P
thiopental	I-P
,	I-P
fentanyl	I-P
,	I-P
nitrous	I-P
oxide	I-P
,	I-P
and	I-P
oxygen	I-P
.	I-P


Isoflurane	O
was	O
added	O
as	O
needed	O
.	O


The	O
infusion	O
was	O
started	O
with	O
an	O
initial	O
dose	O
given	O
over	O
10	O
min	O
before	O
the	O
induction	O
of	O
anesthesia	O
;	O
at	O
induction	O
the	O
maintenance	O
rate	O
was	O
begun	O
and	O
continued	O
until	O
closure	O
of	O
the	O
abdominal	O
fascia	O
.	O


The	O
heart	B-OUT
rate	I-OUT
response	I-OUT
to	I-OUT
endotracheal	I-OUT
intubation	I-OUT
was	I-OUT
significantly	I-OUT
blunted	I-OUT
.	I-OUT


PURPOSE/OBJECTIVE	O
This	O
is	O
a	O
prospective	O
comparison	O
of	O
weekly	O
cisplatin	B-I
to	O
weekly	O
paclitaxel	B-I
as	O
concurrent	O
chemotherapy	O
with	O
standard	B-I
radiotherapy	I-I
for	O
locally	O
advanced	B-P
cervical	I-P
carcinoma	I-P
.	I-P


Both	O
types	O
of	O
radiation	O
techniques	O
lowered	O
the	O
incidence	B-OUT
of	I-OUT
loco-regional	I-OUT
recurrences	I-OUT
significantly	O
,	O
but	O
had	O
no	O
significant	O
influence	O
on	O
the	O
overall	B-OUT
survival	I-OUT
.	I-OUT


Results	O
of	O
a	O
prospective	O
randomized	O
study	O
of	O
hepatic	B-I
artery	I-I
infusion	I-I
with	I-I
5-fluorouracil	I-I
versus	I-I
intravenous	I-I
5-fluorouracil	I-I
in	O
patients	B-P
with	I-P
hepatic	I-P
metastases	I-P
from	I-P
colorectal	I-P
cancer	I-P
:	I-P
A	O
Central	O
Oncology	O
Group	O
study	O
.	O


[	O
Risk	O
factors	O
for	O
atherosclerotic	O
disease	O
from	O
the	O
Japanese	B-P
Elderly	I-I
Diabetes	I-I
Intervention	I-I
Trial	I-P
(	I-P
J-EDIT	I-P
)	I-P
]	I-P
.	O


METHODS	O
Forty-nine	B-P
patients	I-P
were	I-P
assigned	I-P
to	I-P
receive	I-P
UDCA	I-I
(	I-P
450	I-P
mg/day	I-P
)	I-P
over	I-P
a	I-P
period	I-P
of	I-P
6	I-P
months	I-P
and	I-P
52	I-P
to	I-P
receive	I-P
no	I-I
treatment	I-I
.	I-I


RESULTS	O
In	O
the	O
UDCA	B-I
group	O
,	O
serum	B-OUT
ALT	I-OUT
and	I-OUT
GGT	I-OUT
levels	I-OUT
significantly	O
improved	O
.	O


ALT	B-OUT
values	I-OUT
decreased	O
from	O
pre-treatment	O
levels	O
of	O
157.0	O
+/-	O
62.6	O
IU/l	O
to	O
82.5	O
+/-	O
46.4	O
IU/l	O
(	O
P	O
<	O
0.05	O
)	O
,	O
and	O
GGT	O
fell	O
from	O
141.3	O
+/-	O
86.2	O
IU/l	O
to	O
66.0	O
+/-	O
49.5	O
IU/l	O
(	O
P	O
<	O
0.001	O
)	O
.	O


CONCLUSION	O
Although	O
our	O
encouraging	O
preliminary	O
results	O
must	O
be	O
validated	O
by	O
double-blind	O
histological	O
trials	O
,	O
UDCA	B-I
may	O
be	O
an	O
alternative	O
treatment	O
for	O
patients	B-P
who	I-P
fail	I-P
to	I-P
respond	I-P
to	I-P
interferon	I-I
therapy	I-I
.	I-I


The	O
effect	O
of	O
prophylactic	B-I
calcium	I-I
and	I-I
magnesium	I-I
infusions	I-I
on	O
the	O
incidence	O
of	O
neurotoxicity	O
and	O
clinical	O
outcome	O
of	O
oxaliplatin-based	O
systemic	O
treatment	O
in	O
advanced	B-P
colorectal	I-P
cancer	I-P
patients	I-P
.	I-P


Patients	O
were	O
retrospectively	O
divided	O
into	O
two	B-I
groups	I-I
:	I-I
patients	I-I
in	I-I
the	I-I
Ca/Mg	I-I
(	I-I
+	I-I
)	I-I
group	I-I
received	I-I
Ca/Mg	I-I
at	I-I
least	I-I
during	I-I
their	I-I
first	I-I
treatment	I-I
cycle	I-I
,	I-I
and	I-I
patients	I-I
in	I-I
the	I-I
Ca/Mg	I-I
(	I-I
-	I-I
)	I-I
group	I-I
did	I-I
not	I-I
.	I-I


Clinicians	O
may	O
apply	O
the	O
results	O
of	O
this	O
study	O
when	O
considering	O
treatment	O
options	O
for	O
facial	B-P
acne	I-P
and	I-P
seborrhea	I-P
.	I-P


Biventricular	O
pacing	O
improves	O
cardiac	B-OUT
function	I-OUT
and	O
prevents	O
further	O
left	B-OUT
atrial	I-OUT
remodeling	I-OUT
in	O
patients	B-P
with	I-P
symptomatic	I-P
atrial	I-P
fibrillation	I-P
after	I-P
atrioventricular	I-P
node	I-P
ablation	I-P
.	I-P


BACKGROUND	O
Randomized	O
trials	O
have	O
demonstrated	O
benefits	O
of	O
biventricular	B-I
(	I-I
BiV	I-I
)	I-I
pacing	I-I
in	O
patients	B-P
with	I-P
advanced	I-P
heart	I-P
failure	I-P
,	I-P
intraventricular	I-P
conduction	I-P
delay	I-P
,	I-P
and	I-P
atrial	I-P
fibrillation	I-P
(	I-P
AF	I-P
)	I-P
post-atrioventricular	I-P
(	I-P
AV	I-P
)	I-P
node	I-P
ablation	I-P
.	I-P


Interventricular	B-OUT
dyssynchrony	I-OUT
significantly	O
decreased	O
with	O
BiV	O
compared	O
with	O
RV	O
pacing	O
.	O


RESULTS	O
Patients	B-P
with	I-P
non-eosinophilic	I-P
asthma	I-P
had	O
absence	B-OUT
of	I-OUT
eosinophils	I-OUT
in	I-OUT
the	I-OUT
mucosa	I-OUT
(	O
median	O
4.4	O
cells/mm	O
(	O
2	O
)	O
vs	O
23	O
cells/mm	O
(	O
2	O
)	O
in	O
eosinophilic	O
asthma	O
and	O
0	O
cells/mm	O
(	O
2	O
)	O
in	O
normal	O
controls	O
;	O
p	O
=	O
0.03	O
)	O
and	O
normal	O
subepithelial	B-OUT
layer	I-OUT
thickness	I-OUT
(	O
5.8	O
microm	O
vs	O
10.3	O
microm	O
in	O
eosinophilic	O
asthma	O
and	O
5.1	O
microm	O
in	O
controls	O
,	O
p	O
=	O
0.002	O
)	O
.	O


Compared	O
with	O
placebo	O
,	O
8	O
weeks	O
of	O
treatment	O
with	O
inhaled	O
mometasone	O
led	O
to	O
less	O
improvement	B-OUT
in	O
methacholine	B-OUT
PC	I-OUT
(	I-OUT
20	I-OUT
)	I-OUT
(	O
0.5	O
vs	O
5.5	O
doubling	O
concentrations	O
,	O
95	O
%	O
CI	O
of	O
difference	O
1.1	O
to	O
9.1	O
;	O
p	O
=	O
0.018	O
)	O
and	O
asthma	B-OUT
quality	I-OUT
of	I-OUT
life	I-OUT
(	O
0.2	O
vs	O
1.0	O
points	O
,	O
95	O
%	O
CI	O
of	O
difference	O
0.27	O
to	O
1.43	O
;	O
p	O
=	O
0.008	O
)	O
.	O


The	O
present	O
study	O
was	O
designed	O
to	O
compare	O
the	O
efficacy	B-OUT
and	I-OUT
safety	I-OUT
of	O
10	O
%	O
HES	O
130/0.4	O
and	O
10	O
%	O
HES	O
200/0.5	O
.	O


RESULTS	O
Equivalent	B-OUT
volumes	I-OUT
of	I-OUT
investigational	I-OUT
medication	I-OUT
were	O
infused	O
until	O
24	O
hours	O
after	O
the	O
first	O
administration	O
(	O
1577	O
vs.	O
1540	O
mL	O
;	O
treatment	O
difference	O
37	O
[	O
-150	O
;	O
223	O
]	O
mL	O
;	O
P	O
<	O
0.0001	O
for	O
equivalence	O
)	O
.	O


Whereas	O
standard	B-OUT
laboratory	I-OUT
tests	I-OUT
of	I-OUT
coagulation	I-OUT
were	O
comparable	O
between	O
groups	O
,	O
von	B-OUT
Willebrand	I-OUT
factor	I-OUT
activity	I-OUT
on	O
the	O
first	O
postoperative	O
morning	O
tended	O
to	O
be	O
higher	O
following	O
treatment	O
with	O
10	O
%	O
HES	O
130/0.4	O
as	O
compared	O
to	O
10	O
%	O
HES	O
200/0.5	O
(	O
P=0.025	O
)	O
with	O
this	O
difference	O
being	O
statistically	O
significant	O
only	O
in	O
the	O
per-protocol	O
analysis	O
(	O
P=0.02	O
)	O
.	O


Compared	O
with	O
ETT	B-OUT
,	I-OUT
index	I-OUT
testing	I-OUT
costs	I-OUT
were	O
higher	O
for	O
exercise	O
MPI	O
(	O
P	O
<	O
0.001	O
)	O
,	O
whereas	O
downstream	O
procedural	O
costs	O
were	O
slightly	O
lower	O
(	O
P=0.0008	O
)	O
.	O


The	O
control	O
group	O
received	B-I
usual	I-I
services	I-I
throughout	I-I
the	I-I
study	I-I
while	O
the	O
intervention	O
group	O
also	O
received	B-I
a	I-I
theory-based	I-I
educational	I-I
program	I-I
on	I-I
colorectal	I-I
cancer	I-I
screening	I-I
plus	I-I
a	I-I
reminder	I-I
call	I-I
.	I-I


Screening	B-OUT
behavior	I-OUT
,	O
the	O
main	O
outcome	O
,	O
was	O
assessed	O
4	O
months	O
after	O
randomization	O
.	O


Patients	B-P
were	I-P
ineligible	I-P
if	I-P
they	I-P
had	I-P
uncontrolled	I-P
hypertension	I-P
,	I-P
recent	I-P
myocardial	I-P
infarction	I-P
,	I-P
haematological	I-P
disorders	I-P
or	I-P
a	I-P
history	I-P
of	I-P
seizures	I-P
.	I-P


Double-blind	O
placebo-controlled	B-I
comparison	O
of	O
the	O
analgesic	B-OUT
effects	I-OUT
of	O
single	O
doses	O
of	O
lornoxicam	B-I
and	I-I
aspirin	I-I
in	O
patients	B-P
with	I-P
postoperative	I-P
dental	I-P
pain	I-P
.	I-P


All	O
indices	O
of	O
efficacy	B-OUT
showed	O
similar	O
results	O
,	O
all	O
active	O
treatments	O
being	O
associated	O
with	O
highly	O
significant	O
(	O
P	O
less	O
than	O
0.0001	O
)	O
reductions	B-OUT
in	I-OUT
pain	I-OUT
during	O
the	O
study	O
period	O
.	O


Lornoxicam	O
was	O
very	O
well	B-OUT
tolerated	I-OUT
at	O
all	O
three	O
doses	O
studied	O
,	O
with	O
no	O
adverse	B-OUT
events	I-OUT
definitely	O
attributable	O
to	O
its	O
administration	O
.	O


Anesthesia	B-I
induction	I-I
and	O
perioperative	O
management	O
followed	O
the	O
same	O
protocols	O
in	O
the	O
two	O
groups	O
,	O
and	O
in	O
UTI	O
group	O
,	O
patients	O
received	B-I
5000	I-I
U/kg	I-I
UTI	I-I
while	O
those	O
in	O
the	O
control	O
group	O
were	O
given	O
the	O
same	O
volume	O
of	O
saline	O
.	O


The	O
bronchoalveoar	B-OUT
lavage	I-OUT
fluid	I-OUT
(	I-OUT
BAFL	I-OUT
)	I-OUT
was	O
also	O
collected	O
at	O
T	O
(	O
1	O
)	O
and	O
T	O
(	O
2	O
)	O
for	O
IL-6	O
and	O
IL-8	O
detection	O
.	O


In	O
the	O
treatment	O
group	O
compared	O
to	O
the	O
control	O
group	O
,	O
mean	O
changes	O
on	O
the	O
ABC	B-OUT
total	I-OUT
score	I-OUT
and	I-OUT
subscales	I-OUT
were	O
similar	O
except	O
a	O
greater	O
number	O
of	O
children	O
improved	O
in	O
irritability	O
(	O
p	O
=	O
0.0311	O
)	O
.	O


Changes	O
in	O
performance	O
were	O
compared	O
by	O
repeated	O
measures	O
ANOVA	B-OUT
.	I-OUT


RESULTS	O
Twenty-nine	B-P
boys	I-P
and	I-P
9	I-P
girls	I-P
with	I-P
autism	I-P
and	I-P
severe	I-P
behavioral	I-P
disturbance	I-P
and	I-P
a	I-P
mental	I-P
age	I-P
>	I-P
or=18	I-P
months	I-P
completed	I-P
the	I-P
cognitive	I-P
part	I-P
of	I-P
the	I-P
study	I-P
.	I-P


The	O
study	O
was	O
randomized	O
and	O
double	O
blinded	O
.	O


RESULTS	O
In	O
the	O
IV	O
group	O
there	O
was	O
a	O
slight	O
but	O
significant	O
increase	O
in	O
p	B-OUT
(	I-OUT
a	I-OUT
)	I-OUT
CO2	I-OUT
after	O
5	O
,	O
10	O
,	O
and	O
15	O
min	O
compared	O
with	O
the	O
IM	O
group	O
(	O
5.2	O
vs.	O
4.8	O
,	O
5.4	O
,	O
vs.	O
5.0	O
and	O
5.5	O
vs.	O
5.1	O
kPa	O
,	O
respectively	O
)	O
.	O


The	O
IV	O
group	O
had	O
a	O
significantly	O
faster	O
onset	B-OUT
of	I-OUT
analgesic	I-OUT
effect	I-OUT
than	O
the	O
IM	O
group	O
(	O
5	O
vs.	O
20	O
min	O
)	O
.	O


Patients	O
in	O
the	O
IV	O
group	O
were	O
slightly	O
more	O
sedated	B-OUT
than	O
the	O
IM	O
group	O
5	O
and	O
10	O
min	O
after	O
morphine	O
.	O


IV	O
morphine	B-I
even	O
at	O
a	O
dose	O
as	O
high	O
as	O
10	O
mg	O
IV	O
is	O
well	O
tolerated	B-OUT
if	O
there	O
is	O
a	O
certain	O
level	O
of	O
pain	O
at	O
its	O
administration	O
.	O


BACKGROUND	O
The	O
objective	O
was	O
to	O
evaluate	O
efficacy	O
and	O
safety	O
of	O
rapid	O
,	O
large-dose	B-I
intravenous	I-I
(	I-I
IV	I-I
)	I-I
administration	I-I
of	I-I
ferric	I-I
carboxymaltose	I-I
compared	O
to	O
oral	B-I
iron	I-I
in	O
correcting	O
iron	O
deficiency	O
anemia	O
due	O
to	O
heavy	O
uterine	O
bleeding	O
.	O


RESULTS	O
Compared	O
to	O
those	O
assigned	O
to	O
ferrous	B-I
sulfate	I-I
,	O
more	O
patients	O
assigned	O
to	O
ferric	B-I
carboxymaltose	I-I
responded	O
with	O
a	O
hemoglobin	B-OUT
(	I-OUT
Hb	I-OUT
)	I-OUT
increase	O
of	O
2.0	O
g/dL	O
or	O
more	O
(	O
82	O
%	O
vs.	O
62	O
%	O
,	O
95	O
%	O
confidence	O
interval	O
for	O
treatment	O
difference	O
12.2-28.3	O
,	O
p	O
<	O
0.001	O
)	O
,	O
more	O
achieved	O
a	O
3.0	O
g/dL	O
or	O
more	O
increase	O
(	O
53	O
%	O
vs.	O
36	O
%	O
,	O
p	O
<	O
0.001	O
)	O
,	O
and	O
more	O
achieved	O
correction	B-OUT
(	O
Hb	O
>	O
or=	O
12	O
g/dL	O
)	O
of	O
anemia	O
(	O
73	O
%	O
vs.	O
50	O
%	O
,	O
p	O
<	O
0.001	O
)	O
.	O


CONCLUSIONS	O
RFA	O
is	O
more	O
effective	O
in	O
the	O
treatment	O
of	O
HCC	O
compared	B-I
to	O
PLA	O
for	O
lesions	O
≥	O
21	O
mm	O
.	O


Participants	B-P
were	I-P
recruited	I-P
largely	I-P
during	I-P
the	I-P
era	I-P
prior	I-P
to	I-P
highly	I-P
active	I-P
antiretroviral	I-P
therapy	I-P
(	I-P
HAART	I-P
;	I-P
1992-1997	I-P
)	I-P
.	I-P


RESULTS	O
Men	B-P
in	I-P
the	I-P
CBSM	I-P
group	I-P
maintained	O
previously	O
observed	O
effects	O
on	O
depressive	B-OUT
symptoms	I-OUT
and	I-OUT
perceived	I-OUT
social	I-OUT
support	I-OUT
.	I-OUT


The	O
trial	O
,	O
amended	O
from	O
a	O
larger	O
factorial	O
design	O
,	O
was	O
terminated	O
early	O
due	O
to	O
slow	O
recruitment	O
.	O


Both	O
regimens	O
remain	O
as	O
reasonable	O
treatment	O
options	O
.	O


The	O
first	O
group	O
was	O
treated	O
by	O
standard	B-I
ESWL	I-I
and	O
included	O
54	O
patients	O
.	O


Effects	O
of	O
inhaled	B-I
treprostinil	I-I
on	O
exercise	O
capacity	O
,	O
functional	O
class	O
,	O
and	O
echocardiographic	O
and	O
hemodynamic	O
data	O
were	O
evaluated	O
.	O


Based	O
on	O
these	O
early	O
data	O
,	O
further	O
study	O
of	O
inhaled	B-I
treprostinil	I-I
appears	O
warranted	B-P
in	I-P
pediatric	I-P
patients	I-P
with	I-P
PAH	O
.	O


Registry	O
information	O
from	O
the	O
last	O
9	O
years	O
was	O
used	O
to	O
identify	O
3,585	B-P
women	I-P
who	I-P
met	I-P
the	I-P
study	I-P
criteria	I-P
with	I-P
respect	I-P
to	I-P
age	I-P
,	I-P
stage	I-P
,	I-P
and	I-P
previous	I-P
therapy	I-P
.	I-P


Efficacy	B-OUT
of	O
chlorhexidine	B-I
gluconate	I-I
use	O
in	O
the	O
prevention	O
of	O
perirectal	O
infections	O
in	O
patients	B-P
with	I-P
acute	I-P
leukemia	I-P
.	I-P


The	O
frequency	O
of	O
rectal	B-OUT
infections	I-OUT
is	O
increased	O
in	O
patients	B-P
with	I-P
acute	I-P
leukemia	I-P
.	I-P


Complications	O
associated	O
with	O
rectal	O
lesions	O
may	O
be	O
severe	O
enough	O
to	O
cause	O
life-threatening	O
septicemia	O
.	O


No	O
significant	O
difference	O
was	O
seen	O
in	O
the	O
occurrence	B-OUT
of	I-OUT
perirectal	I-OUT
infections	I-OUT
(	O
p	O
=	O
0.35	O
)	O
or	O
skin	B-OUT
breakdown	I-OUT
(	O
p	O
=	O
0.18	O
)	O
between	O
the	O
two	O
groups	O
.	O


BACKGROUND	O
This	O
study	O
examines	O
socio-demographic	O
determinants	O
of	O
participation	O
in	O
a	O
population-based	O
randomized	O
controlled	O
trial	O
that	O
proved	O
that	O
oral	B-I
visual	I-I
inspection	I-I
was	O
effective	O
in	O
reducing	O
oral	B-OUT
cancer	I-OUT
mortality	I-OUT
in	I-P
high-risk	I-P
individuals	I-P
in	I-P
India	I-P
.	I-P


CONCLUSIONS	O
In	O
summary	O
,	O
adequate	O
coverage	O
can	O
be	O
obtained	O
in	O
population-based	B-I
oral	I-I
screening	I-I
in	O
developing	O
countries	O
.	O


Mechanical	B-OUT
efficiency	I-OUT
,	I-OUT
oxygen	I-OUT
uptake	I-OUT
,	I-OUT
heart	I-OUT
rate	I-OUT
,	I-OUT
timing	I-OUT
parameters	I-OUT
and	I-OUT
stroke	I-OUT
angles	I-OUT
were	I-I
measured	I-I
.	I-I


INTERPRETATION	O
A	O
low-intensity	O
,	O
7-week	O
training	O
protocol	O
has	O
a	O
beneficial	O
effect	O
on	O
the	O
mechanical	B-OUT
efficiency	I-OUT
and	I-OUT
metabolic	I-OUT
cost	I-OUT
of	O
wheelchair	O
propulsion	O
in	O
able-bodied	B-P
participants	I-P
.	I-P


This	O
was	O
a	O
12-week	O
randomized	O
,	O
double-blind	O
,	O
placebo-controlled	B-I
trial	O
.	O


However	O
,	O
it	O
has	O
never	O
been	O
used	O
for	O
digital	O
blocks	O
.	O


No	O
postoperative	B-OUT
neurocognitive	I-OUT
dysfunction	I-OUT
was	O
identified	O
.	O


Effects	O
of	O
weight-bearing	B-I
versus	I-I
nonweight-bearing	I-I
exercise	I-I
on	O
function	B-OUT
,	I-OUT
walking	I-OUT
speed	I-OUT
,	I-OUT
and	I-OUT
position	I-OUT
sense	I-OUT
in	O
participants	B-P
with	I-P
knee	I-P
osteoarthritis	I-P
:	I-P
a	O
randomized	O
controlled	O
trial	O
.	O


OBJECTIVE	O
To	O
investigate	O
whether	O
weight-bearing	B-I
(	I-I
WB	I-I
)	I-I
exercise	I-I
enhances	O
functional	B-OUT
capacity	I-OUT
to	O
a	O
greater	O
extent	O
than	O
nonweight-bearing	B-I
(	I-I
NWB	I-I
)	I-I
exercise	I-I
in	O
participants	B-P
with	I-P
knee	I-P
osteoarthritis	I-P
.	I-P


SETTING	O
Kinesiology	O
laboratory	O
.	O


Resource	O
use	O
was	O
identified	O
,	O
quantified	O
,	O
and	O
valued	O
for	O
direct	O
and	O
indirect	O
hospital	O
costs	O
and	O
for	O
societal	O
costs	O
.	O


CONCLUSION	B-OUT
Hemiarthroplasty	I-OUT
was	I-OUT
a	I-OUT
cost-effective	O
treatment	O
.	O


Weight	B-OUT
loss	I-OUT
≥	I-OUT
5	I-OUT
%	I-OUT
was	O
reported	O
for	O
64	O
of	O
179	O
(	B-I
35.8	I-I
%	I-I
)	I-I
zonisamide-treated	I-I
children	O
.	O


No	O
consistent	O
correlations	O
between	B-OUT
weight	I-OUT
loss	I-OUT
and	I-OUT
skeletal	I-OUT
development	I-OUT
or	I-OUT
sexual	I-OUT
maturation	I-OUT
were	O
observed	O
.	O


Using	O
the	O
chi2-test	O
for	O
overall	O
association	O
,	O
this	O
difference	O
was	O
statistically	O
highly	O
significant	O
(	O
p	O
=	O
0.002	O
)	O
.	O


The	O
effect	O
of	O
recombinant	B-I
human	I-I
erythropoietin	I-I
(	I-I
rHu-EPO	I-I
)	I-I
treatment	I-I
.	I-I


The	O
treatment	O
was	O
continued	O
till	O
the	O
hematocrit	B-OUT
level	I-OUT
reached	O
30	O
%	O
.	O


Presented	O
results	O
indicate	O
that	O
chronic	B-P
hemodialysis	I-P
patients	I-P
have	O
significantly	O
diminished	O
lymphocyte	B-OUT
number	I-OUT
.	I-OUT


Clinical	O
outcomes	O
measured	O
included	O
total	B-OUT
energy	I-OUT
intake	I-OUT
and	I-OUT
growth	I-OUT
over	I-OUT
the	I-OUT
first	I-OUT
six	I-OUT
postnatal	I-OUT
weeks	I-OUT
,	I-OUT
sepsis	I-OUT
incidence	I-OUT
,	I-OUT
liver	I-OUT
function	I-OUT
,	I-OUT
milk	I-OUT
tolerance	I-OUT
,	I-OUT
duration	I-OUT
of	I-OUT
respiratory	I-OUT
support	I-OUT
,	I-OUT
duration	I-OUT
of	I-OUT
hospital	I-OUT
stay	I-OUT
and	I-OUT
complication	I-OUT
incidence	I-OUT
.	I-OUT


03	O
;	O
tolerated	B-OUT
full	I-OUT
milk	I-OUT
feeds	I-OUT
(	O
165	O
ml/kg/day	O
)	O
earlier	O
,	O
mean	O
difference	O
-11.2	O
(	O
CI	O
-19	O
,	O
-3	O
)	O
days	O
,	O
p	O
=	O
0.03	O
;	O
reduced	O
requirement	B-OUT
for	I-OUT
supplemental	I-OUT
oxygen	I-OUT
,	O
mean	O
difference	O
-22.4	O
(	O
CI-41.5	O
,	O
-3.3	O
)	O
days	O
,	O
p	O
=	O
0.02	O
;	O
and	O
were	O
discharged	B-OUT
home	I-OUT
earlier	O
,	O
mean	O
difference	O
-22.1	O
(	O
CI	O
-42.1	O
,	O
-2.2	O
)	O
days	O
,	O
p	O
=	O
0.04	O
.	O


We	O
used	O
standardized	O
behavioral	O
measures	O
of	O
the	O
primary	O
and	O
secondary	O
features	O
of	O
autism	O
,	O
including	O
the	O
Autism	O
Behavior	O
Checklist	O
,	O
to	O
assess	O
the	O
degree	O
of	O
impairment	O
at	O
base	O
line	O
and	O
over	O
the	O
course	O
of	O
a	O
four-week	O
period	O
after	O
treatment	O
.	O


Thus	O
,	O
56	B-P
children	I-P
(	I-P
28	I-P
in	I-P
each	I-P
group	I-P
)	I-P
completed	I-P
the	I-P
study	I-P
.	I-P


Monitoring	O
of	O
the	O
central	B-OUT
pulse	I-OUT
pressure	I-OUT
is	O
useful	O
for	O
detecting	O
cardiac	O
overload	O
during	O
antiadrenergic	O
treatment	O
:	O
the	B-P
Japan	I-P
Morning	I-P
Surge	I-P
1	I-P
study	I-P
.	I-P


RESULTS	O
In	O
the	O
added	O
treatment	O
group	O
,	O
the	O
brachial	B-OUT
systolic	I-OUT
blood	I-OUT
pressure	I-OUT
was	O
successfully	O
reduced	O
,	O
but	O
the	O
central	B-OUT
PP	I-OUT
increased	O
significantly	O
,	O
whereas	O
the	O
other	O
blood	O
pressure	O
parameters	O
did	O
not	O
change	O
from	O
the	O
baseline	O
.	O


CONCLUSION	O
This	O
study	O
showed	O
that	O
the	O
central	B-OUT
PP	I-OUT
measurement	I-OUT
may	O
be	O
more	O
important	O
to	O
assess	O
cardiac	O
load	O
than	O
the	O
brachial	O
PP	O
during	O
antiadrenergic	B-I
treatment	I-I
.	I-I


The	B-P
median	I-P
age	I-P
of	I-P
the	I-P
sixteen	I-P
patients	I-P
was	I-P
50	I-P
years	I-P
(	I-P
range	I-P
30-64	I-P
)	I-P
.	I-P


Patients	O
were	O
randomly	O
divided	O
in	O
two	O
groups	O
:	O
In	O
group	O
1	O
(	O
n	O
=	O
41	O
)	O
postmenopausal	O
women	O
received	O
oral	B-I
risedronate	I-I
(	O
35	O
mg/week	O
)	O
,	O
calcium	B-I
(	O
1,000	O
mg/day	O
)	O
,	O
and	O
vitamin	B-I
D	I-I
(	O
400	O
IU/day	O
)	O
for	O
12	O
months	O
.	O


Bone	B-OUT
mineral	I-OUT
density	I-OUT
(	I-OUT
BMD	I-OUT
)	I-OUT
of	I-OUT
lumbar	I-OUT
spine	I-OUT
(	I-OUT
L1-L4	I-OUT
)	I-OUT
and	I-OUT
proximal	I-OUT
femur	I-OUT
were	O
determined	O
using	O
dual	O
X-ray	O
absorptiometry	O
at	O
baseline	O
and	O
after	O
one	O
year	O
.	O


In	O
group	O
2	O
,	O
however	O
,	O
the	O
level	B-OUT
of	I-OUT
serum	I-OUT
cytokines	I-OUT
did	O
not	O
change	O
after	O
three	O
and	O
6	O
months	O
.	O


In	O
conclusion	O
,	O
hypnosis	B-I
improves	O
IBS	B-OUT
symptoms	I-OUT
through	O
reductions	O
in	O
psychological	B-OUT
distress	I-OUT
and	I-OUT
somatization	I-OUT
.	I-OUT


Systolic	B-OUT
blood	I-OUT
pressure	I-OUT
was	I-OUT
lower	I-OUT
in	O
the	O
group	O
that	O
received	O
nicotine	O
(	O
105	O
(	O
SD	O
3	O
)	O
versus	O
122	O
(	O
SD	O
3	O
)	O
;	O
P	O
<	O
0.001	O
)	O
,	O
but	O
there	O
was	O
no	B-OUT
difference	I-OUT
in	I-OUT
diastolic	I-OUT
blood	I-OUT
pressure	I-OUT
or	I-OUT
heart	I-OUT
rate	I-OUT
.	I-OUT


4	O
.	O


5	O
.	O


CONTEXT	O
Postoperative	O
nausea	O
and	O
vomiting	O
remains	O
a	O
clinically	O
important	O
problem	O
after	O
strabismus	B-P
surgery	I-P
in	I-P
children	I-P
.	I-P


At	O
an	O
individual	O
initial	O
visit	O
the	O
12	O
volunteers	O
were	O
introduced	O
to	O
the	O
needle	B-I
sensation	I-I
by	O
having	O
a	O
needle	O
inserted	O
into	O
the	O
point	O
LI	O
11	O
.	O


SESSION	O
A	O
A	O
short	B-I
acupuncture	I-I
needle	I-I
,	O
(	O
Seirin	O
no	O
3	O
,	O
&	O
emptyv	O
;	O
0.20x15	O
mm	O
)	O
was	O
inserted	O
perpendicular	O
into	O
the	O
earpoint	O
,	O
Lu	O
1	O
,	O
in	O
the	O
left	O
inferior	O
hemi-conchae	O
.	O


A	O
significant	O
decrease	O
in	O
the	O
heart	B-OUT
rate	I-OUT
frequency	I-OUT
(	O
P	O
<	O
0.05	O
)	O
at	O
the	O
end	O
of	O
the	O
post-stimulation	O
period	O
was	O
also	O
demonstrated	O
.	O


The	O
effect	O
of	O
three	O
times	O
daily	O
oral	O
ondansetron	O
in	O
preventing	O
postoperative	B-OUT
nausea	I-OUT
and	I-OUT
vomiting	I-OUT
was	O
investigated	O
in	O
two	O
randomized	O
,	O
double-blind	O
,	O
placebo-controlled	B-I
,	O
multi-centre	O
studies	O
.	O


Ondansetron	B-I
8	O
mg	O
three	O
times	O
daily	O
was	O
also	O
significantly	O
better	O
than	O
placebo	O
in	O
the	O
second	O
study	O
.	O


Enrollment	O
of	O
racial	B-P
and	I-P
ethnic	I-P
minorities	I-P
in	I-P
the	I-P
Prostate	I-P
,	I-P
Lung	I-P
,	I-P
Colorectal	I-P
and	I-P
Ovarian	I-P
Cancer	I-P
Screening	I-P
Trial	I-P
.	I-P


METHODS	O
The	O
Prostate	B-I
,	I-I
Colorectal	I-I
,	I-I
Lung	I-I
and	I-I
Ovarian	I-I
(	I-I
PLCO	I-I
)	I-I
Cancer	I-I
Screening	I-I
Trial	O
is	O
a	O
multicenter	O
randomized	O
trial	O
designed	O
to	O
evaluate	O
the	O
effectiveness	B-P
of	I-P
screening	I-I
for	I-I
the	I-I
PLCO	I-I
cancers	I-I
.	I-I


This	O
compares	O
to	O
an	O
age-eligible	O
population	O
in	O
the	O
combined	O
catchment	O
areas	O
of	O
the	O
PLCO	B-P
centers	I-P
that	I-P
was	I-P
14.0	I-P
%	I-P
black	I-P
,	I-P
2.9	I-P
%	I-P
Hispanic	I-P
and	I-P
5.4	I-P
%	I-P
Asian	I-P
,	I-P
and	I-P
an	I-P
age-eligible	I-P
population	I-P
across	I-P
the	I-P
U.S.	I-P
that	I-P
was	I-P
9.5	I-P
%	I-P
black	I-P
,	I-P
6.5	I-P
%	I-P
Hispanic	I-P
and	I-P
3.0	I-P
%	I-P
Asian	I-P
.	I-P


However	O
,	O
validation	O
of	O
the	O
usefulness	O
of	O
psychological	B-I
strategies	I-I
is	O
limited	O
in	O
the	O
literature	O
.	O


In	O
the	O
diclofenac	B-I
group	O
,	O
it	O
was	O
2.2	O
and	O
0.95	O
mg/min	O
,	O
respectively	O
(	O
p	O
less	O
than	O
0.01	O
)	O
.	O


Measurement	B-OUT
of	I-OUT
serum	I-OUT
bile	I-OUT
acids	I-OUT
in	O
32	B-P
patients	I-P
(	I-P
18	I-P
ursodeoxycholic	I-I
acid	I-I
,	I-P
14	I-P
placebo	I-I
)	I-I
indicated	O
that	O
at	O
2	O
yr	O
,	O
ursodeoxycholic	B-I
acid	I-I
comprised	O
65	O
%	O
of	O
serum	O
bile	O
acids	O
in	O
the	O
treated	O
group	O
and	O
7	O
%	O
in	O
the	O
placebo	B-I
group	I-P
.	I-P


CYP21	B-I
PCR	I-I
products	O
were	O
subjected	O
to	O
ligase	O
detection	O
reaction	O
,	O
simultaneously	O
analyzing	O
9	O
CYP21	O
mutations	O
;	O
PCR	O
products	O
of	O
other	O
genes	O
were	O
subjected	O
to	O
direct	O
gel	O
analysis	O
.	O


Ten	O
full-term	O
affected	O
neonates	O
showed	O
a	O
wide	B-OUT
range	I-OUT
of	I-OUT
17-OHP	I-OUT
levels	I-OUT
(	O
15-1400	O
nmol/L	O
)	O
.	O


CYP21	B-OUT
heterozygote	I-OUT
frequency	I-OUT
for	I-OUT
classic	I-OUT
mutations	I-OUT
is	O
higher	O
than	O
expected	O
based	O
on	O
genotype	O
compared	O
with	O
that	O
predicted	O
by	O
hormonal	O
newborn	B-P
screening	O
.	O


They	O
accounted	B-P
for	I-P
60	I-P
%	I-P
of	I-P
the	I-P
2392	I-P
children	I-P
(	I-P
aged	I-P
0-7	I-P
years	I-P
)	I-P
who	I-P
had	I-P
been	I-P
enrolled	I-P
in	I-P
a	I-P
nutrition	I-I
intervention	I-I
study	I-P
during	I-P
1969-77	I-P
.	I-P


We	O
estimated	O
annual	O
income	O
,	O
hours	O
worked	O
,	O
and	O
average	O
hourly	O
wages	O
from	O
all	O
economic	O
activities	O
.	O


A	O
dose-ranging	O
study	O
of	O
pramipexole	B-I
for	O
the	O
symptomatic	O
treatment	O
of	O
restless	B-P
legs	I-P
syndrome	I-P
:	I-P
polysomnographic	O
evaluation	O
of	O
periodic	B-OUT
leg	I-OUT
movements	I-OUT
and	O
sleep	O
disturbance	O
.	O


Data	O
from	O
107	B-P
patients	I-P
were	O
included	O
in	O
the	O
intent-to-treat	O
(	O
ITT	O
)	O
analysis	O
.	O


PURPOSE	O
Radiation	B-I
Therapy	I-I
Oncology	I-I
Group	I-I
(	I-I
RTOG	I-I
)	I-I
9508	I-I
showed	O
a	O
survival	O
advantage	O
for	O
patients	B-P
with	I-P
1	I-P
but	I-P
not	I-P
2	I-P
or	I-P
3	I-P
brain	I-P
metastasis	I-P
(	I-P
BM	I-P
)	I-P
treated	O
with	O
whole-brain	B-I
radiation	I-I
therapy	I-I
(	I-I
WBRT	I-I
)	I-I
and	I-I
stereotactic	I-I
radiosurgery	I-I
(	I-I
SRS	I-I
)	I-I
versus	I-I
WBRT	I-I
alone	I-I
.	I-I


Our	O
hypothesis	O
was	O
that	O
if	O
the	O
data	O
from	O
RTOG	B-I
9508	I-I
were	O
poststratified	O
by	O
the	O
GPA	O
,	O
the	O
conclusions	O
may	O
vary	O
.	O


METHODS	O
AND	O
MATERIALS	O
In	O
this	O
analysis	O
,	O
252	B-P
of	I-P
the	I-P
331	I-P
patients	I-P
were	I-P
evaluable	I-P
by	I-P
GPA	I-P
.	I-P


RESULTS	O
The	O
fundamental	O
conclusions	O
of	O
the	O
primary	O
analysis	O
were	O
confirmed	O
in	O
that	O
there	O
was	O
no	O
survival	B-OUT
benefit	I-OUT
overall	O
for	O
patients	O
with	O
1	O
to	O
3	O
metastases	O
;	O
however	O
,	O
there	O
was	O
a	O
benefit	O
for	O
the	O
subset	O
of	O
patients	O
with	O
GPA	O
3.5	O
to	O
4.0	O
(	O
median	O
survival	O
time	O
[	O
MST	O
]	O
for	O
WBRT	B-I
+	I-I
SRS	I-I
vs	O
WBRT	O
alone	O
was	O
21.0	O
versus	O
10.3	O
months	O
,	O
P=.05	O
)	O
regardless	O
of	O
the	O
number	O
of	O
metastases	O
.	O


Lanthanum	B-I
carbonate	I-I
(	I-I
Fosrenol	I-I
)	I-I
efficacy	I-OUT
and	I-OUT
tolerability	I-OUT
in	O
the	O
treatment	O
of	O
hyperphosphatemic	B-P
patients	I-P
with	I-P
end-stage	I-P
renal	I-P
disease	I-P
.	I-P


AIMS	O
High	O
serum	O
phosphorus	O
levels	O
are	O
a	O
common	O
problem	O
in	O
patients	B-P
receiving	I-P
long-term	I-P
dialysis	I-P
treatment	I-P
.	I-P


Lanthanum	B-I
carbonate	I-I
(	I-I
Fosrenol	I-I
)	I-I
is	O
a	O
new	O
non-aluminum	O
,	O
non-calcium	O
phosphate	O
binder	O
developed	O
for	O
the	O
treatment	O
of	O
hyperphosphatemia	O
in	O
patients	B-P
with	I-P
end-stage	I-P
renal	I-P
disease	I-P
(	I-P
ESRD	I-P
)	I-P
.	I-P


Ca	B-OUT
x	I-OUT
P	I-OUT
product	I-OUT
levels	I-OUT
were	O
also	O
significantly	O
lower	O
in	O
the	O
lanthanum	B-I
carbonate	I-I
group	O
at	O
the	O
end	O
of	O
randomized	O
treatment	O
(	O
p	O
<	O
0.001	O
)	O
.	O


GOAL	O
The	O
aim	O
of	O
this	O
analysis	O
was	O
to	O
determine	O
whether	O
patients	B-P
'	I-P
demographic	I-P
variables	I-P
affect	O
the	O
efficacy	O
of	O
imiquimod	B-I
5	I-I
%	I-I
cream	I-I
versus	O
vehicle	B-I
cream	I-I
for	O
the	O
treatment	O
of	O
external	B-P
genital	I-P
and	I-P
perianal	I-P
warts	I-P
.	I-P


We	O
examined	O
the	O
effect	O
of	O
prior	O
treatment	O
history	O
on	O
the	O
outcome	B-OUT
of	I-OUT
pharmacotherapy	I-OUT
of	O
MDpsy	B-P
in	I-P
patients	I-P
who	I-P
participated	I-P
in	I-P
the	I-P
STOPD-PD	I-P
study	I-P
,	I-P
a	I-P
randomized	I-P
,	I-P
double-blind	I-P
,	I-P
clinical	I-P
trial	I-P
comparing	I-P
a	I-P
combination	O
of	O
olanzapine	B-I
plus	I-I
sertraline	I-I
vs.	I-I
olanzapine	I-I
plus	I-I
placebo	I-I
.	I-I


Similar	O
to	O
patients	O
with	O
major	O
depression	O
,	O
these	O
results	O
emphasize	O
the	O
impact	B-OUT
of	I-OUT
prior	I-OUT
pharmacotherapy	I-OUT
on	O
treatment	B-OUT
outcomes	I-OUT
in	O
patients	B-P
with	I-P
MDpsy	I-P
.	I-P


All	B-P
patients	I-P
received	I-P
protocol-based	I-I
systemic	I-I
and	I-I
intrathecal	I-I
chemotherapy	I-I
.	I-I


RESULTS	O
Relapses	B-OUT
occurred	O
in	O
21	O
(	O
43	O
%	O
)	O
of	O
49	O
patients	O
,	O
predominantly	O
in	O
the	O
CNS	O
(	O
71	O
%	O
)	O
and	O
bone	O
marrow	O
(	O
52	O
%	O
)	O
.	O


The	O
3-year	B-OUT
event-free	I-OUT
survival	I-OUT
+/-	O
SE	O
for	O
all	O
patients	O
with	O
CNS+	O
disease	O
was	O
45	O
%	O
+/-	O
7	O
%	O
.	O


Randomized	O
trial	O
of	O
an	O
allogeneic	B-I
melanoma	I-I
lysate	I-I
vaccine	I-I
with	I-I
low-dose	I-I
interferon	I-I
Alfa-2b	I-I
compared	O
with	O
high-dose	B-I
interferon	I-I
Alfa-2b	I-I
for	O
Resected	B-P
stage	I-P
III	I-P
cutaneous	I-P
melanoma	I-P
.	I-P


METHOD	O
Seventeen	B-P
children	I-P
,	I-P
ages	I-P
6	I-P
to	I-P
9	I-P
,	I-P
with	I-P
a	I-P
diagnosis	I-P
of	I-P
ASD	I-P
were	I-P
randomly	I-P
assigned	I-P
to	I-P
the	I-P
music	I-I
therapy	I-I
group	I-I
(	I-I
MTG	I-I
)	I-I
or	I-P
the	I-P
no-music	I-I
social	I-I
skills	I-I
group	I-I
(	I-I
SSG	I-I
)	I-I
.	I-I


CONCLUSIONS	O
The	O
results	O
of	O
this	O
study	O
support	O
further	O
research	O
on	O
the	O
use	O
of	O
music	O
therapy	O
group	O
interventions	O
for	O
social	B-OUT
skills	I-OUT
in	O
children	B-P
with	I-P
ASD	I-P
.	I-P


To	O
determine	O
whether	O
Pgp	O
inhibition	O
improves	O
treatment	O
outcome	O
in	O
CML-BP	O
,	O
the	O
Southwest	O
Oncology	O
Group	O
performed	O
a	O
randomized	B-I
,	I-I
controlled	I-I
trial	I-I
testing	I-I
the	I-I
benefit	I-I
of	I-I
the	I-I
Pgp	I-I
modulator	I-I
,	I-I
cyclosporin	I-I
A	I-I
(	I-I
CsA	I-I
)	I-I
.	I-I


Seventy-three	B-P
eligible	I-P
patients	I-P
were	O
assigned	B-I
to	I-I
treatment	I-I
with	I-I
cytarabine	I-I
and	I-I
infusional	I-I
daunorubicin	I-I
with	I-I
or	I-I
without	I-I
intravenous	I-I
CsA	I-I
.	I-I


However	O
,	O
the	O
mechanism	O
underlying	O
these	O
androgenic	O
actions	O
has	O
remained	O
relatively	O
unknown	O
.	O


Most	O
notably	O
,	O
occlusion	O
of	O
flow	O
in	O
the	O
microvasculature	O
causes	O
the	O
acute	O
pain	O
crises	O
[	O
3	O
]	O
that	O
are	O
the	O
commonest	O
cause	O
for	O
patients	B-P
with	I-P
SCD	I-P
to	I-P
seek	O
medical	O
attention	O
[	O
4	O
]	O
and	O
major	O
determinants	O
of	O
their	O
quality	B-P
of	I-P
life	I-P
[	O
5	O
]	O
.	O


A	O
Phase	O
I	O
clinical	O
study	O
demonstrated	O
that	O
a	O
single	O
oral	O
dose	O
of	O
PPS	B-I
increased	O
microvascular	B-OUT
blood	I-OUT
flow	I-OUT
in	O
patients	O
with	O
SCD	O
.	O


A	O
Phase	O
II	O
clinical	O
study	O
that	O
was	O
not	O
completed	O
documented	O
that	O
daily	O
oral	O
doses	O
of	O
PPS	B-I
administered	O
for	O
8	O
weeks	O
lowered	O
plasma	B-OUT
levels	I-OUT
of	I-OUT
sVCAM-1	I-OUT
and	O
tended	O
to	O
improve	O
microvascular	B-OUT
blood	I-OUT
flow	I-OUT
in	O
patients	O
with	O
SCD	O
.	O


BACKGROUND	O
An	O
imbalance	O
in	O
the	O
excitatory/inhibitory	O
systems	O
with	O
abnormalities	O
in	O
the	O
glutamatergic	O
pathways	O
has	O
been	O
implicated	O
in	O
the	O
pathophysiology	O
of	O
autism	O
.	O


The	O
goal	O
of	O
this	O
pilot	O
study	O
was	O
to	O
assess	O
the	O
feasibility	O
of	O
using	O
oral	B-I
N-acetylcysteine	I-I
(	I-I
NAC	I-I
)	I-I
,	O
a	O
glutamatergic	O
modulator	O
and	O
an	O
antioxidant	O
,	O
in	O
the	O
treatment	O
of	O
behavioral	O
disturbance	O
in	O
children	B-P
with	I-P
autism	I-P
.	I-P


METHODS	O
This	O
was	O
a	O
12-week	O
,	O
double-blind	O
,	O
randomized	O
,	O
placebo-controlled	B-I
study	O
of	O
NAC	B-I
in	I-P
children	I-P
with	I-P
autistic	I-P
disorder	I-P
.	I-P


The	O
primary	O
behavioral	O
measure	O
(	B-OUT
Aberrant	I-OUT
Behavior	I-OUT
Checklist	I-OUT
[	I-OUT
ABC	I-OUT
]	I-OUT
irritability	I-OUT
subscale	I-OUT
)	I-OUT
and	O
safety	O
measures	O
were	O
performed	O
at	O
baseline	O
and	O
4	O
,	O
8	O
,	O
and	O
12	O
weeks	O
.	O


Compared	O
with	O
placebo	B-I
,	I-I
NAC	I-I
resulted	O
in	O
significant	O
improvements	O
on	O
ABC	B-OUT
irritability	I-OUT
subscale	I-OUT
(	O
F	O
=	O
6.80	O
;	O
p	O
<	O
.001	O
;	O
d	O
=	O
.96	O
)	O
.	O


RESULTS	O
Baseline	O
characteristics	O
were	O
similar	O
between	O
the	O
two	O
groups	O
.	O


Although	O
pre-course	B-OUT
scores	I-OUT
were	O
similar	O
(	O
student-directed	O
25.3	O
(	O
7.3	O
)	O
;	O
structured	O
24.8	O
(	O
7.5	O
)	O
)	O
the	O
structured	O
approach	O
resulted	O
in	O
higher	O
post-course	B-OUT
scores	I-OUT
in	O
comparison	O
with	O
the	O
student-directed	O
approach	O
(	O
student-directed	O
41.8	O
(	O
9.4	O
)	O
;	O
structured	O
53.8	O
(	O
8.8	O
)	O
;	O
p	O
<	O
0.01	O
)	O
.	O


One-year	B-OUT
and	I-OUT
4-year	I-OUT
overall	I-OUT
survival	I-OUT
rates	I-OUT
in	O
the	O
PRE	O
group	O
were	O
100	O
%	O
and	O
86	O
%	O
respectively	O
and	O
100	O
%	O
and	O
60	O
%	O
in	O
the	O
POST	O
group	O
(	O
p	O
=	O
0.520	O
)	O
.	O


Supplementation	O
with	O
larger	O
ARA	B-I
doses	I-I
added	I-I
to	I-I
DHA	I-I
may	O
therefore	O
mitigate	O
social	O
impairment	O
.	O


To	O
examine	O
underlying	O
mechanisms	O
underlying	O
the	O
effect	O
of	O
our	O
supplementation	O
regimen	O
,	O
we	O
examined	O
plasma	B-OUT
levels	I-OUT
of	I-OUT
antioxidants	I-OUT
transferrin	I-OUT
and	I-OUT
superoxide	I-OUT
dismutase	I-OUT
,	O
which	O
are	O
useful	O
markers	O
of	O
signal	O
transduction	O
.	O


These	O
results	O
suggest	O
that	O
even	O
widely	O
accepted	O
best	O
practices	O
for	O
survey	O
methods	O
deserve	O
scrutiny	O
when	O
applied	O
to	O
special	O
subpopulations	O
.	O


Controlled	O
study	O
on	O
the	O
therapeutic	B-OUT
efficacy	I-OUT
of	O
propionyl-L-carnitine	O
in	O
patients	B-P
with	I-P
congestive	I-P
heart	I-P
failure	I-P
.	I-P


In	O
a	O
randomized	O
study	O
of	O
patients	B-P
undergoing	I-P
Caesarean	I-P
section	I-P
,	I-P
either	I-P
enflurane	I-I
(	I-P
mean	I-P
0.24	I-P
MAC-h	I-P
)	I-P
or	I-P
halothane	I-I
(	I-P
mean	I-P
0.23	I-P
MAC-h	I-P
)	I-P
and	I-P
50	I-I
%	I-I
nitrous	I-I
oxide	I-I
in	I-I
oxygen	I-I
were	O
administered	O
to	O
women	B-P
(	I-P
n	I-P
=	I-P
12	I-P
)	I-P
with	I-P
severe	I-P
pre-eclampsia-eclampsia	I-P
and	I-P
to	I-P
16	I-P
healthy	I-P
pregnant	I-P
patients	I-P
with	I-P
normal	I-P
renal	I-P
and	I-P
hepatic	I-P
function	I-P
.	I-P


Primary	O
care	O
physician	O
and	O
gynecologist	O
visits	O
increased	O
the	O
likelihood	O
of	O
a	O
subsequent	B-OUT
mammogram	I-OUT
for	O
women	O
in	O
all	O
intervention	O
groups	O
.	O


CONCLUSIONS	O
Telephone	B-I
contact	I-I
by	O
regular	O
health	O
plan	O
staff	O
was	O
more	O
successful	O
than	O
publicity	O
in	O
encouraging	O
continued	O
participation	B-OUT
in	O
mammography	B-OUT
screening	I-OUT
in	O
women	O
enrolled	O
in	O
a	O
group-model	O
managed	O
health	O
care	O
plan	O
.	O


The	O
Gonorrhea	O
Treatment	O
Study	O
Group	O
.	O


The	O
overall	B-OUT
cure	I-OUT
rates	I-OUT
were	O
96	O
percent	O
for	O
the	O
400-mg	O
dose	O
of	O
cefixime	B-I
(	O
89	O
of	O
93	O
patients	O
)	O
(	O
95	O
percent	O
confidence	O
interval	O
,	O
93.5	O
percent	O
to	O
97.8	O
percent	O
)	O
;	O
98	O
percent	O
for	O
the	O
800-mg	O
dose	O
of	O
cefixime	B-I
(	O
86	O
of	O
88	O
patients	O
)	O
(	O
95	O
percent	O
confidence	O
interval	O
,	O
94.6	O
percent	O
to	O
100	O
percent	O
)	O
;	O
and	O
98	O
percent	O
for	O
ceftriaxone	B-I
(	O
92	O
of	O
94	O
patients	O
)	O
(	O
95	O
percent	O
confidence	O
interval	O
,	O
94.9	O
to	O
100	O
percent	O
)	O
.	O


In	O
conclusion	O
,	O
intra-arterial	O
and	O
intravenous	O
heparin	O
administration	O
provide	O
comparable	O
efficacy	O
in	O
preventing	O
RAO	O
,	O
favoring	O
a	O
probable	O
systemically	O
mediated	O
mechanism	O
of	O
action	O
,	O
rather	O
than	O
a	O
local	O
effect	O
.	O


Continuous	O
application	O
of	O
transdermal	B-I
nitroglycerin	I-I
appears	O
to	O
result	O
in	O
tolerance	B-OUT
to	I-OUT
the	I-OUT
antianginal	I-OUT
effect	I-OUT
.	I-OUT


Exercise	B-OUT
time	I-OUT
to	I-OUT
onset	I-OUT
of	I-OUT
angina	I-OUT
,	I-OUT
total	I-OUT
exercise	I-OUT
duration	I-OUT
and	I-OUT
time	I-OUT
to	I-OUT
1	I-OUT
mm	I-OUT
ST	I-OUT
segment	I-OUT
depression	I-OUT
were	O
all	O
significantly	O
increased	O
after	O
initial	O
application	O
during	O
the	O
continuous	O
and	O
intermittent	O
treatment	O
periods	O
.	O


These	O
increases	O
were	O
maintained	O
after	O
1	O
week	O
of	O
intermittent	O
but	O
not	O
continuous	O
treatment	O
.	O


The	B-OUT
number	I-OUT
of	I-OUT
follicles	I-OUT
⩾11mm	I-OUT
was	O
slightly	O
higher	O
after	B-I
corifollitropin	I-I
alfa	I-I
compared	O
with	O
daily	O
rFSH	O
at	O
stimulation	O
day	O
8	O
(	O
difference	O
,	O
1.2	O
;	O
95	O
%	O
confidence	O
interval	O
(	O
CI	O
)	O
0.5-1.8	O
;	O
P	O
<	O
0.01	O
)	O
and	O
on	O
the	O
day	O
of	O
HCG	O
injection	O
(	O
difference	O
,	O
2.1	O
;	O
95	O
%	O
CI	O
1.4-2.8	O
;	O
P	O
<	O
0.01	O
)	O
.	O


In	O
a	O
10-week	O
,	O
randomized	O
,	O
double-blind	O
,	O
parallel-group	O
,	O
placebo-controlled	B-I
clinical	O
trial	O
,	O
44	B-P
outpatients	I-P
of	I-P
both	I-P
genders	I-P
aged	I-P
4-12	I-P
years	I-P
with	I-P
a	I-P
diagnosis	I-P
of	I-P
AD	I-P
and	I-P
a	I-P
score	I-P
of	I-P
≥12	I-P
on	I-P
the	I-P
Aberrant	I-P
Behavior	I-P
Checklist-Community	I-P
(	I-P
ABC-C	I-P
)	I-P
irritability	I-P
subscale	I-P
were	I-P
included	I-OUT
.	I-OUT


B-domain	B-I
deleted	I-I
recombinant	I-I
factor	I-I
VIII	I-I
preparations	I-I
are	O
bioequivalent	O
to	O
a	O
monoclonal	O
antibody	O
purified	O
plasma-derived	O
factor	O
VIII	O
concentrate	O
:	O
a	O
randomized	O
,	O
three-way	O
crossover	O
study	O
.	O


OBJECTIVE	O
The	O
primary	O
objective	O
of	O
this	O
three-way	O
crossover-design	O
study	O
was	O
to	O
compare	O
the	O
pharmacokinetic	B-P
(	I-P
PK	I-P
)	I-P
parameters	O
of	O
two	O
BDDrFVIII	B-I
formulations	I-I
(	I-I
one	I-I
reconstituted	I-I
with	I-I
5	I-I
mL	I-I
of	I-I
sterile	I-I
water	I-I
,	I-I
the	I-I
other	I-I
reconstituted	I-I
with	I-I
4	I-I
mL	I-I
sodium	I-I
chloride	I-I
0.9	I-I
%	I-I
USP	I-I
)	I-I
with	O
those	O
of	O
a	O
plasma-derived	O
,	O
full-length	B-I
FVIII	I-I
preparation	I-I
(	I-I
Hemofil	I-I
M	I-I
)	I-I
in	I-P
patients	I-P
with	I-P
haemophilia	I-P
A	I-P
to	O
determine	O
bioequivalence	O
.	O


National	O
Institute	O
of	O
Child	O
Health	O
and	O
Human	O
Development	O
Neonatal	O
Research	O
Network	O
.	O


BACKGROUND	O
Nosocomial	B-OUT
infections	I-OUT
are	O
a	O
major	O
cause	O
of	O
morbidity	O
and	O
mortality	O
in	O
premature	B-P
infants	I-P
.	I-P


Photodynamic	B-I
therapy	I-I
with	I-I
5-aminolaevulinic	I-I
acid	I-I
or	I-I
placebo	I-I
for	O
recalcitrant	B-P
foot	I-OUT
and	I-OUT
hand	I-OUT
warts	I-OUT
:	I-OUT
randomised	O
double-blind	O
trial	O
.	O


BACKGROUND	O
Photodynamic	B-I
therapy	I-I
(	I-I
PDT	I-I
)	I-I
with	I-I
topical	I-I
5-aminolaevulinic	I-I
acid	I-I
(	I-I
ALA	I-I
)	I-I
followed	I-I
by	I-I
irradiation	I-I
with	I-I
incoherent	I-I
light	I-I
(	I-I
ALA-PDT	I-I
)	I-I
for	O
recalcitrant	O
warts	O
have	O
had	O
beneficial	O
results	O
.	O


In	O
week	O
18	O
,	O
the	O
median	B-OUT
relative	I-OUT
reduction	I-OUT
in	I-OUT
wart	I-OUT
area	I-OUT
was	O
100	O
%	O
in	O
the	O
ALA-PDT	B-I
group	O
(	O
100	O
%	O
,	O
57	O
%	O
)	O
versus	O
71	O
%	O
(	O
100	O
%	O
,	O
0	O
)	O
in	O
the	O
placebo-PDT	B-I
arm	O
(	O
p=0.008	O
)	O
.	O


Significantly	O
more	O
ALA-PDT	B-I
warts	O
were	O
graded	O
at	O
a	O
higher	B-OUT
pain	I-OUT
intensity	I-OUT
after	O
treatment	O
than	O
placebo-PDT	B-I
warts	O
.	O


We	O
sought	O
to	O
determine	O
whether	O
plasma	O
EBV-DNA	O
could	O
serve	O
as	O
a	O
surrogate	O
for	O
EBER-ISH	B-OUT
and	O
to	O
explore	O
its	O
prognostic	O
utility	O
in	O
HL	O
.	O


Specimens	B-P
from	I-P
the	I-P
Cancer	I-P
Cooperative	I-P
Intergroup	I-P
Trial	I-P
E2496	I-P
were	O
used	O
to	O
compare	B-I
pretreatment	I-I
plasma	I-I
EBV-DNA	I-I
quantification	I-I
with	I-I
EBV	I-I
tumor	I-OUT
status	I-OUT
by	I-I
EBER-ISH	I-OUT
.	I-OUT


Pretreatment	O
and	O
month	O
6	B-P
plasma	I-P
specimens	I-P
were	O
designated	O
EBV	O
(	O
-	O
)	O
or	O
EBV	O
(	O
+	O
)	O
by	O
this	O
cutoff	O
.	O


The	O
efficacy	B-OUT
and	I-OUT
safety	I-OUT
of	O
three	O
oral	B-I
fluoroquinolones	I-I
(	I-I
lomefloxacin	I-I
,	I-I
levofloxacin	I-I
,	I-I
and	I-I
ciprofloxacin	I-I
)	I-I
for	O
the	O
treatment	O
of	O
chronic	O
osteomyelitis	O
were	O
analyzed	O
.	O


Lomefloxacin	O
was	O
effective	O
therapy	O
for	O
five	O
of	O
seven	O
(	O
71	O
%	O
)	O
patients	O
,	O
and	O
ciprofloxacin	O
was	O
effective	O
therapy	O
for	O
two	O
of	O
five	O
patients	O
(	O
40	O
%	O
)	O
.	O


Effects	O
of	O
application	O
in	O
spring	O
of	O
urea	B-I
fertiliser	I-I
on	O
aspects	O
of	O
reproductive	O
performance	O
of	O
pasture-fed	B-P
dairy	I-P
cows	I-P
.	I-P


Similar	O
generous	O
pasture	O
allowances	O
were	O
offered	O
to	O
both	O
groups	O
.	O


The	O
interval	B-OUT
from	I-OUT
calving	I-OUT
to	I-OUT
first	I-OUT
ovulation	I-OUT
tended	O
(	O
p=0.10	O
)	O
to	O
be	O
lower	O
and	O
the	O
diameter	B-OUT
of	I-OUT
the	I-OUT
dominant	I-OUT
follicle	I-OUT
of	I-OUT
the	I-OUT
oestrous	I-OUT
cycle	I-OUT
at	I-OUT
which	I-OUT
cows	I-OUT
conceived	I-OUT
was	O
greater	O
(	O
p=0.02	O
)	O
in	O
Control	O
than	O
High-N	O
cows	O
.	O


CONCLUSIONS	O
The	O
use	O
of	O
large	O
amounts	O
of	O
urea	B-I
fertiliser	I-I
during	O
spring	O
and	O
the	O
consequent	O
increases	O
in	O
concentrations	B-OUT
of	I-OUT
CP	I-OUT
in	I-OUT
pasture	I-OUT
and	I-OUT
urea	I-OUT
in	I-OUT
serum	I-OUT
did	O
not	O
negatively	O
affect	O
any	O
of	O
the	O
parameters	O
of	O
reproductive	B-OUT
performance	I-OUT
of	O
pasture-fed	B-P
dairy	I-P
cows	I-P
that	O
were	O
assessed	O
in	O
this	O
study	O
.	O


Walking	B-OUT
time	I-OUT
in	I-OUT
seconds	I-OUT
,	I-OUT
number	I-OUT
of	I-OUT
steps	I-OUT
,	I-OUT
frequency	I-OUT
of	I-OUT
lateral	I-OUT
line	I-OUT
stepping-over	I-OUT
,	I-OUT
and	I-OUT
stops	I-OUT
were	O
recorded	O
.	O


We	O
,	O
therefore	O
,	O
suggest	O
that	O
the	O
choice	O
of	O
the	O
attention-splitting	O
task	O
in	O
dual-task	O
gait	O
assessment	O
among	O
older	B-P
adults	I-P
must	O
be	O
made	O
carefully	O
.	O


METHODS	O
We	O
conducted	O
a	O
randomized	O
,	O
placebo-controlled	B-I
trial	O
at	O
eight	O
centers	O
to	O
evaluate	O
etanercept	B-I
for	O
the	O
maintenance	O
of	O
remission	O
in	B-P
180	I-P
patients	I-P
with	I-P
Wegener	I-P
's	I-P
granulomatosis	I-P
.	I-P


There	O
were	O
no	O
significant	O
differences	O
between	O
the	O
etanercept	B-I
and	O
control	O
groups	O
in	O
the	O
rates	B-OUT
of	I-OUT
sustained	I-OUT
remission	I-OUT
(	O
69.7	O
percent	O
vs.	O
75.3	O
percent	O
,	O
P=0.39	O
)	O
,	O
sustained	O
periods	O
of	O
low-level	B-OUT
disease	I-OUT
activity	I-OUT
(	O
86.5	O
percent	O
vs.	O
90.6	O
percent	O
,	O
P=0.32	O
)	O
,	O
or	O
the	O
time	O
required	O
to	O
achieve	O
those	O
measures	O
.	O


CONCLUSIONS	O
Etanercept	B-I
is	O
not	O
effective	O
for	O
the	O
maintenance	B-OUT
of	I-OUT
remission	I-OUT
in	I-P
patients	I-P
with	I-P
Wegener	I-P
's	I-P
granulomatosis	I-P
.	I-P


Tirasemtiv	B-I
was	O
given	O
as	O
a	O
single	O
daily	O
dose	O
up	O
to	O
375	O
mg	O
for	O
two	O
weeks	O
,	O
with	O
and	O
without	O
concomitant	O
riluzole	O
.	O


Safety	B-OUT
and	I-OUT
tolerability	I-OUT
were	O
assessed	O
,	O
as	O
well	O
as	O
measures	B-OUT
of	I-OUT
function	I-OUT
,	I-OUT
muscle	I-OUT
strength	I-OUT
and	I-OUT
endurance	I-OUT
.	I-OUT


[	O
Effectiveness	O
of	O
adjuvant	B-I
hormone	I-I
therapy	I-I
in	O
breast	O
cancer	O
]	O
.	O


METHODS	O
Patients	B-P
of	I-P
non-small	I-P
cell	I-P
lung	I-P
cancer	I-P
(	I-P
NSCLC	I-P
)	I-P
treated	I-P
with	I-P
chemotherapy	I-I
with	I-I
or	I-I
without	I-I
Endostar	I-I
were	O
observed	O
.	O


The	O
amount	O
of	O
activated	O
CECs	O
was	O
detected	O
by	O
flow	O
cytometry	O
,	O
and	O
the	O
expression	O
of	O
survivin	O
mRNA	O
was	O
determined	O
by	O
real-time	O
polymerase	O
chain	O
reaction	O
(	O
PCR	O
)	O
.	O


We	O
conducted	O
a	O
double-blind	O
,	O
randomized	O
,	O
placebo-controlled	B-I
trial	O
in	O
40	B-P
patients	I-P
to	I-P
evaluate	I-P
the	I-P
need	I-P
for	I-P
antibiotics	I-P
in	I-P
acute	I-P
exacerbations	I-P
of	I-P
chronic	I-P
bronchitis	I-P
.	I-P


Arterial	B-OUT
blood	I-OUT
gases	I-OUT
,	I-OUT
spirometric	I-OUT
tests	I-OUT
,	I-OUT
bacteriologic	I-OUT
evaluation	I-OUT
of	I-OUT
sputum	I-OUT
,	I-OUT
and	I-OUT
patient	I-OUT
and	I-OUT
physician	I-OUT
evaluation	I-OUT
of	I-OUT
the	I-OUT
severity	I-OUT
of	I-OUT
illness	I-OUT
were	O
assessed	O
at	O
the	O
beginning	O
and	O
end	O
of	O
the	O
study	O
.	O


METHODS	O
Over	O
a	O
6-year	B-P
period	I-P
,	I-P
patients	I-P
with	I-P
persistent	I-P
H.	I-P
pylori	I-P
infection	I-P
following	I-P
omeprazole-clarithromycin-amoxicillin	I-I
eradication	I-P
therapy	I-P
were	O
randomized	O
to	O
receive	O
omeprazole	B-I
,	I-I
20	I-I
mg	I-I
twice	I-I
daily	I-I
,	I-I
bismuth	I-I
,	I-I
120	I-I
mg	I-I
four	I-I
times	I-I
daily	I-I
,	I-I
metronidazole	I-I
,	I-I
500	I-I
mg	I-I
twice	I-I
daily	I-I
,	I-I
and	I-I
either	I-I
tetracycline	I-I
,	I-I
500	I-I
mg	I-I
four	I-I
times	I-I
daily	I-I
,	I-I
or	I-I
clarithromycin	I-I
,	I-I
500	I-I
mg	I-I
twice	I-I
daily	I-I
,	O
given	O
for	O
7	O
days	O
.	O


On	O
intention-to-treat	O
analysis	O
,	O
eradication	B-OUT
was	O
achieved	O
in	O
41	O
of	O
the	O
49	O
patients	O
(	O
84	O
%	O
;	O
95	O
%	O
confidence	O
interval	O
,	O
70.4-92.7	O
%	O
)	O
and	O
27	O
of	O
the	O
46	O
patients	O
(	O
59	O
%	O
;	O
95	O
%	O
confidence	O
interval	O
,	O
43.3-73.0	O
%	O
)	O
of	O
the	O
tetracycline-	O
and	O
clarithromycin-containing	O
groups	O
,	O
respectively	O
(	O
P=0.007	O
)	O
.	O


The	B-I
aerosol	I-I
was	I-I
administered	I-I
via	I-I
a	I-I
pneumatic	I-I
nebulizer	I-I
once	I-I
a	I-I
day	I-I
for	I-I
5	I-I
days	I-I
.	I-I


The	O
present	O
study	O
aimed	O
to	O
assess	O
the	O
effects	O
of	O
thymostimulin	B-I
in	O
patients	B-P
with	I-P
different	I-P
degrees	I-P
of	I-P
immunodepression	I-P
,	O
by	O
evaluating	O
both	O
the	O
incidence	B-OUT
of	I-OUT
postoperative	I-OUT
infections	I-OUT
and	O
the	O
changes	B-OUT
induced	I-OUT
in	O
various	O
immunological	B-OUT
parameters	I-OUT
.	I-OUT


The	O
advantages	O
were	O
evident	O
in	O
hypo-anergic	O
subjects	O
both	O
with	O
regard	O
to	O
the	O
frequency	B-OUT
of	I-OUT
early	I-OUT
postoperative	I-OUT
infections	I-OUT
,	O
and	O
with	O
regard	O
to	O
immunological	B-OUT
parameters	I-OUT
.	I-OUT


Activator	B-I
protein-1	I-I
(	I-I
AP-1	I-I
)	I-I
signalling	O
in	O
human	B-P
atherosclerosis	I-P
:	I-P
results	O
of	O
a	O
systematic	O
evaluation	O
and	O
intervention	O
study	O
.	O


Animal	O
studies	O
implicate	O
the	O
AP-1	B-I
(	I-I
activator	I-I
protein-1	I-I
)	I-I
pro-inflammatory	O
pathway	O
as	O
a	O
promising	O
target	O
in	O
the	O
treatment	O
of	O
atherosclerotic	B-P
disease	I-P
.	I-P


It	O
is	O
,	O
however	O
,	O
unclear	O
whether	O
these	O
observations	O
apply	O
to	O
human	B-P
atherosclerosis	I-P
.	I-P


BACKGROUND	O
AND	O
OBJECTIVE	O
Acute	O
intermittent	O
porphyria	O
is	O
an	O
autosomal	O
dominant	O
disorder	O
caused	O
by	O
deficient	O
activity	O
of	O
the	O
third	O
enzyme	O
in	O
the	O
haem	O
biosynthetic	O
pathway	O
,	O
porphobilinogen	O
deaminase	O
.	O


Recently	O
,	O
a	O
new	O
form	O
of	O
treatment	O
based	O
on	O
porphobilinogen	B-I
deaminase	I-I
enzyme	I-I
replacement	I-I
therapy	I-I
has	O
been	O
shown	O
to	O
be	O
effective	O
in	O
an	O
acute	O
intermittent	O
porphyria	O
mouse	O
model	O
which	O
,	O
during	O
phenobarbital	O
(	O
phenobarbitone	O
)	O
induction	O
of	O
haem	O
biosynthesis	O
,	O
mimics	O
the	O
biochemical	O
pattern	O
of	O
acute	O
porphyric	O
attacks	O
.	O


The	O
washout	O
period	O
between	O
Parts	O
A	O
and	O
B	O
was	O
2	O
weeks	O
.	O


Urinary	B-OUT
porphobilinogen	I-OUT
,	I-OUT
5-aminolevulinic	I-OUT
acid	I-OUT
and	I-OUT
porphyrin	I-OUT
concentrations	I-OUT
,	O
as	O
well	O
as	O
plasma	B-OUT
porphyrin	I-OUT
concentrations	I-OUT
,	O
were	O
analysed	O
using	O
standard	O
methods	O
.	O


The	O
corresponding	B-OUT
concentrations	I-OUT
of	I-OUT
metabolites	I-OUT
in	I-OUT
the	I-OUT
urine	I-OUT
reflected	O
the	O
pattern	O
observed	O
in	O
the	O
plasma	O
.	O


Analgesia	B-OUT
was	O
supplemented	O
whenever	O
the	O
pain	B-OUT
score	I-OUT
was	O
>	O
or	O
=	O
4	O
.	O


In	O
colorectal	O
cancer	O
,	O
BRAF	O
mutation	O
is	O
associated	O
with	O
microsatellite	O
instability	O
(	O
MSI	O
)	O
,	O
and	O
typically	O
predicts	O
inferior	O
prognosis	O
.	O


We	O
examined	O
the	O
effect	O
of	O
BRAF	O
mutation	O
on	O
survival	O
and	O
treatment	O
efficacy	O
in	O
patients	B-P
with	I-P
stage	I-P
III	I-P
colon	I-P
cancer	I-P
.	I-P


Among	O
patients	O
with	O
BRAF-mutated	O
tumors	O
,	O
a	O
nonsignificant	O
trend	O
toward	O
improved	O
OS	B-OUT
was	O
observed	O
for	O
IFL	B-I
versus	O
FU/LV	B-I
arm	O
(	O
multivariate	O
HR	O
=	O
0.52	O
;	O
95	O
%	O
CI	O
:	O
0.25-1.10	O
)	O
.	O


TRIAL	O
REGISTRATION	O
Australian	B-P
New	I-P
Zealand	I-P
Clinical	I-P
Trials	I-P
Registry	I-P
ACTRN12610000087055	O
.	O


A	O
subgroup	O
of	O
11	O
subjects	O
(	O
6	O
female	O
,	O
5	O
male	O
;	O
age	O
28.9	O
±	O
9.9	O
years	O
)	O
returned	O
after	O
12	O
hours	O
when	O
this	O
protocol	O
was	O
repeated	O
.	O


The	B-OUT
upper	I-OUT
tarsal	I-OUT
conjunctiva	I-OUT
was	I-OUT
more	I-OUT
sensitive	I-OUT
than	O
the	O
lower	O
tarsal	O
conjunctiva	O
(	O
P	O
=	O
0.04	O
)	O
.	O


Central	B-OUT
retinal	I-OUT
thickness	I-OUT
decreased	O
significantly	O
in	O
both	O
groups	O
(	O
P	O
<	O
0.001	O
,	O
Tukey	O
test	O
)	O
,	O
without	O
significant	O
difference	O
between	O
the	O
two	O
groups	O
at	O
any	O
time	O
point	O
.	O


Epiretinal	B-OUT
membrane	I-OUT
recurred	O
in	O
5.1	O
%	O
of	O
eyes	O
in	O
the	O
Standard-group	O
and	O
in	O
7.5	O
%	O
of	O
eyes	O
in	O
the	O
NVS-group	O
(	O
Fisher	O
's	O
exact	O
test	O
,	O
P	O
=	O
1.000	O
)	O
.	O


Frequent	B-OUT
adverse	I-OUT
reactions	I-OUT
were	O
gynecomastia	B-OUT
and	I-OUT
breast	I-OUT
pain	I-OUT
.	I-OUT


Serum	B-OUT
concentrations	I-OUT
of	I-OUT
LH	I-OUT
,	I-OUT
testosterone	I-OUT
and	I-OUT
estradiol	I-OUT
increased	I-OUT
significantly	I-OUT
after	O
treatment	O
.	O


After	O
24	O
weeks	O
treatment	O
,	O
simvastatin	B-I
induced	O
a	O
37	O
%	O
reduction	O
in	O
cholesterol	B-OUT
plasma	I-OUT
levels	I-OUT
,	O
a	O
9	O
%	O
increase	O
of	O
HDL	B-OUT
and	O
a	O
16	O
%	O
reduction	O
of	O
LDL	B-OUT
.	I-OUT


Gemfibrozil	B-I
induced	O
a	O
20	O
%	O
reduction	O
in	O
plasma	B-OUT
triglycerides	I-OUT
and	O
a	O
13	O
%	O
decrease	O
in	O
plasma	B-OUT
cholesterol	I-OUT
,	O
with	O
a	O
significant	O
19	O
%	O
increase	O
in	O
HDL	B-OUT
and	O
a	O
11	O
%	O
reduction	O
in	O
LDL	B-OUT
.	I-OUT


N-9	B-OUT
concentration	I-OUT
in	I-OUT
the	I-OUT
gel	I-OUT
(	O
2.5	O
%	O
or	O
5.0	O
%	O
)	O
was	O
not	O
related	O
to	O
the	O
findings	O
.	O


The	O
nature	O
of	O
placebo	B-I
response	O
in	O
clinical	O
studies	O
of	O
major	B-P
depressive	I-P
disorder	I-P
.	I-P


STUDY	O
SELECTION	O
Relevant	O
abstracts	O
were	O
identified	O
in	O
PubMed	O
,	O
including	O
clinical	O
trials	O
,	O
quantitative	O
studies	O
,	O
and	O
qualitative	O
research	O
.	O


Initial	O
studies	O
have	O
demonstrated	O
that	O
persons	O
performing	O
Nordic	B-I
Walking	I-I
are	O
able	O
to	O
exercise	O
longer	O
and	O
harder	O
compared	O
to	O
normal	O
walking	O
thereby	O
increasing	O
their	O
cardiovascular	O
metabolism	O
.	O


In	O
addition	O
we	O
investigate	O
whether	O
there	O
is	O
an	O
increase	O
in	O
the	O
cardiovascular	O
metabolism	O
in	O
persons	B-P
performing	I-P
supervised	I-I
Nordic	I-I
Walking	I-I
compared	O
to	O
persons	B-P
who	I-P
are	I-P
advised	I-I
to	I-I
stay	I-I
active	I-I
.	I-I


This	O
study	O
has	O
shown	O
the	O
superiority	B-I
of	O
LH	O
compared	B-I
to	I-I
hCG	O
in	O
supporting	B-I
FSH-induced	I-OUT
follicular	I-OUT
development	I-OUT
in	I-P
HH	I-P
women	O
.	O


Effect	O
of	O
L-carnitine	B-I
on	O
myocardial	O
metabolism	O
:	O
results	O
of	O
a	O
balanced	O
,	O
placebo-controlled	O
,	O
double-blind	O
study	O
in	O
patients	B-P
undergoing	I-P
open	I-P
heart	I-P
surgery	I-P
.	I-P


Seventeen	B-P
subjects	I-P
underwent	I-P
mitral	I-I
valve	I-I
replacement	I-I
and	I-P
19	I-P
patients	I-P
coronary	I-I
artery	I-I
bypass	I-I
grafting	I-I
.	I-I


The	O
post-ischaemic	O
functional	O
recovery	O
of	O
the	O
heart	O
was	O
assessed	O
by	O
clinical	O
parameters	O
,	O
as	O
well	O
as	O
by	O
biochemical	O
and	O
ultrastructure	O
evaluations	O
on	O
biopsy	O
specimens	O
.	O


In	O
patients	O
with	O
mitral	O
valve	O
replacement	O
,	O
L-carnitine	B-I
therapy	I-I
was	O
associated	O
with	O
significantly	O
higher	O
concentrations	O
of	O
pyruvate	B-OUT
,	I-OUT
ATP	I-OUT
and	I-OUT
creatine	I-OUT
phosphate	I-OUT
in	O
papillary	O
muscle	O
.	O


However	O
,	O
it	O
can	O
not	O
be	O
concluded	O
that	O
L-carnitine	O
provides	O
an	O
advantageous	B-OUT
support	I-OUT
therapy	I-OUT
for	O
well-compensated	O
patients	B-P
requiring	I-P
cardiac	I-P
surgery	I-P
.	I-P


A	O
brief	B-I
adherence	I-I
intervention	I-I
that	O
improved	O
glycemic	B-OUT
control	I-OUT
:	I-OUT
mediation	O
by	O
patterns	O
of	O
adherence	O
.	O


CONCLUSIONS	O
The	O
study	O
treatment	O
experience/familiarity	O
greatly	O
influenced	O
the	O
follow-up	O
treatment	O
:	O
those	O
who	O
had	O
received	O
parent	O
training	O
reported	O
seeking	O
it	O
,	O
whereas	O
those	O
who	O
had	O
not	O
received	O
it	O
tended	O
not	O
to	O
seek	O
it	O
.	O


These	O
results	O
lend	O
support	O
to	O
the	O
feasibility	O
of	O
a	O
cognitive-behavioral	B-OUT
,	I-OUT
school-based	I-OUT
prevention	I-OUT
program	I-OUT
for	O
students	O
'	O
distress-coping	O
enhancement	O
.	O


Therapy-associated	B-OUT
relief	I-OUT
of	O
symptoms	O
was	O
paralleled	O
by	O
substantial	B-OUT
gains	I-OUT
in	O
HRQoL	O
,	O
which	O
continued	O
to	O
stabilize	O
post-treatment	O
.	B-I


Death	B-OUT
associated	I-OUT
with	I-OUT
a	I-OUT
fungal	I-OUT
or	I-OUT
bacterial	I-OUT
infection	I-OUT
occurred	I-OUT
between	I-OUT
day	I-OUT
30	I-OUT
and	I-OUT
day	I-OUT
365	I-OUT
after	O
transplantation	B-I
in	O
9	O
marrow	B-I
recipients	O
and	O
no	O
blood	B-I
stem	I-I
cell	I-I
recipients	O
(	O
P	O
=.008	O
)	O
.	O


A	O
randomized	O
,	O
controlled	O
trial	O
of	O
wax-matrix	B-I
sustained-release	I-I
niacin	I-I
in	O
hypercholesterolemia	B-OUT
.	I-OUT


Smaller	O
improvements	O
were	O
seen	O
in	O
high-density	B-OUT
lipoprotein	I-OUT
cholesterol	I-OUT
and	I-OUT
triglyceride	I-OUT
levels	I-OUT
.	I-OUT


The	O
dropout	B-OUT
rate	I-OUT
due	O
to	O
side	B-OUT
effects	I-OUT
was	O
only	O
3.4	O
%	O
and	O
was	O
coupled	O
with	O
good	O
medication	O
compliance	O
.	O


After	O
2	O
weeks	O
on	O
placebo	B-I
the	O
patients	O
were	O
assigned	O
at	O
random	O
to	O
4	O
groups	O
:	O
group	O
P	B-I
--	I-I
placebo	I-I
,	O
group	O
L	O
--	O
0.1	O
mg.	O
,	O
group	O
M	O
--	O
0.2	O
mg.	O
and	O
group	O
H	O
--	O
0.4	O
mg.	O
of	O
YM617	B-I
.	I-I


Residual	B-OUT
urine	I-OUT
volume	I-OUT
was	O
significantly	O
decreased	O
in	O
groups	O
L	O
,	O
M	O
and	O
H	O
after	O
instillation	O
of	O
saline	O
into	O
the	O
bladder	O
(	O
p	O
less	O
than	O
0.01	O
)	O
but	O
not	O
in	O
group	O
P.	O
The	O
maximum	B-OUT
and	I-OUT
average	I-OUT
flow	I-OUT
rates	I-OUT
were	O
significantly	O
increased	O
in	O
groups	O
L	O
,	O
M	O
and	O
H	O
(	O
p	O
less	O
than	O
0.01	O
)	O
but	O
not	O
in	O
group	O
P.	O
Average	B-OUT
flow	I-OUT
rate	I-OUT
showed	O
significant	O
differences	O
between	O
groups	O
M	O
or	O
H	O
versus	O
group	O
P.	O
Neither	O
orthostatic	B-OUT
hypotension	I-OUT
nor	O
a	O
decrease	O
in	O
blood	B-OUT
pressure	I-OUT
was	O
noted	O
.	O


Adverse	O
side	O
effects	O
and	O
changes	O
in	O
laboratory	O
data	O
were	O
all	O
slight	O
and	O
disappeared	O
when	O
the	O
second	O
tests	O
were	O
performed	O
.	O


The	O
psychopharmacology	O
of	O
saccadic	O
distractibility	O
is	O
less	O
well	O
understood	O
,	O
but	O
is	O
relevant	O
both	O
to	O
interpreting	O
patient	O
studies	O
and	O
to	O
establishing	O
the	O
neurological	O
basis	O
of	O
their	O
findings	O
.	O


Our	O
results	B-OUT
also	I-OUT
suggest	I-OUT
that	I-OUT
other	I-OUT
studies	I-OUT
in	I-OUT
this	I-OUT
field	I-OUT
,	I-OUT
particularly	I-OUT
those	I-OUT
using	I-OUT
parallel	I-OUT
groups	I-OUT
design	I-OUT
,	I-OUT
should	I-OUT
take	I-OUT
account	I-OUT
of	I-OUT
practice	I-OUT
effects	I-OUT
.	I-OUT


CONCLUSION	O
Ibuprofen	B-I
is	O
a	O
potent	O
antipyretic	B-OUT
agent	O
and	O
is	O
a	O
safe	B-OUT
alternative	O
for	O
the	O
selected	O
febrile	B-P
child	I-P
who	O
may	O
benefit	O
from	O
antipyretic	O
medication	O
but	O
who	O
either	O
can	O
not	O
take	O
or	O
does	O
not	O
achieve	O
satisfactory	O
antipyresis	B-OUT
with	O
acetaminophen	B-I
.	I-I


The	O
frequencies	O
of	O
predictions	O
of	O
drug	O
efficacy	O
and	O
of	O
adverse	O
drug	O
effects	O
during	O
the	O
initial	O
drug	O
titration	O
were	O
tabulated	O
for	O
all	O
486	B-P
randomized	I-P
subjects	I-P
.	I-P


Patients	O
received	O
long-term	O
treatment	O
with	O
the	O
first	O
antiarrhythmic	O
drug	O
that	O
was	O
predicted	O
to	O
be	O
effective	O
on	O
the	O
basis	O
of	O
drug	O
testing	O
.	O


The	O
actuarial	B-OUT
probability	I-OUT
of	I-OUT
a	I-OUT
recurrence	I-OUT
of	I-OUT
arrhythmia	I-OUT
after	O
a	O
prediction	O
of	O
drug	O
efficacy	O
by	O
either	O
strategy	O
was	O
significantly	B-OUT
lower	I-OUT
for	O
patients	O
treated	O
with	O
sotalol	O
than	O
for	O
patients	O
treated	O
with	O
the	O
other	O
drugs	O
(	O
risk	O
ratio	O
,	O
0.43	O
;	O
95	O
percent	O
confidence	O
interval	O
,	O
0.29	O
to	O
0.62	O
;	O
P	O
<	O
0.001	O
)	O
.	O


This	O
combination	O
also	O
seemed	O
to	O
be	O
associated	O
with	O
the	O
longest	O
response	O
duration	O
.	O


Patients	O
and	O
therapists	O
were	O
blinded	O
to	O
the	O
type	O
of	O
TBS	B-I
.	I-I


The	O
impact	O
of	B-I
imatinib	I-I
dose	O
on	O
response	O
rates	O
and	O
survival	O
in	B-P
older	I-P
patients	I-P
with	I-P
chronic	I-P
myeloid	I-P
leukemia	I-P
in	I-P
chronic	I-P
phase	I-P
has	O
not	O
been	O
studied	O
well	O
.	O


We	O
suggest	O
that	O
the	O
optimal	O
dose	O
for	O
older	O
patients	O
is	O
higher	O
than	O
400	O
mg/day	O
.	O


ARIES	O
(	O
Avastin	O
Regimens	O
:	O
Investigation	O
of	O
Effectiveness	O
and	O
Safety	O
)	O
,	O
a	O
prospective	O
observational	O
cohort	O
study	O
,	O
evaluated	O
outcomes	O
in	O
a	O
large	O
,	O
community-based	O
population	O
of	O
patients	B-P
with	I-P
first-line	I-P
NSCLC	I-P
.	I-P


Placebo-controlled	O
study	O
of	O
oral	B-I
enoximone	I-I
in	O
congestive	O
heart	O
failure	O
with	O
initial	B-OUT
and	I-OUT
final	I-OUT
intravenous	I-OUT
hemodynamic	I-OUT
evaluation	I-OUT
.	I-OUT


(	O
ABSTRACT	O
TRUNCATED	O
AT	O
250	O
WORDS	O
)	O


A	O
randomized	O
clinical	O
trial	O
of	O
St.	O
John	O
's	O
wort	O
for	O
smoking	B-OUT
cessation	I-OUT
.	I-OUT


Self-reported	O
smoking	B-OUT
abstinence	I-OUT
was	O
biochemically	O
confirmed	O
with	O
expired	B-OUT
air	I-OUT
carbon	I-OUT
monoxide	I-OUT
.	I-OUT


The	B-P
study	I-P
dropout	I-P
rate	I-P
was	I-P
high	I-P
(	I-P
43	I-P
%	I-P
)	I-P
.	I-P


SJW	B-I
did	O
not	O
attenuate	O
withdrawal	B-OUT
symptoms	I-OUT
among	O
abstinent	O
subjects	O
.	O


CONCLUSIONS	O
In	O
this	O
randomized	O
trial	O
,	O
SJW	B-I
did	O
not	O
increase	O
smoking	O
abstinence	B-OUT
rates	O
.	O


Our	O
data	O
,	O
in	O
combination	O
with	O
data	O
from	O
other	O
studies	O
,	O
suggest	O
that	O
SJW	O
has	O
little	O
role	O
in	O
the	O
treatment	O
of	O
tobacco	B-P
dependence	I-P
.	I-P


BACKGROUND	O
Allogeneic	B-I
hematopoietic	I-I
stem-cell	I-I
transplantation	I-I
is	O
a	O
widely	O
used	O
,	O
cost-intensive	O
procedure	O
.	O


Multivariable	B-OUT
analysis	I-OUT
evaluated	O
the	O
association	O
between	O
costs	B-OUT
and	I-OUT
patient	I-OUT
's	I-OUT
pretransplant	I-OUT
status	I-OUT
and	I-OUT
transplant-related	I-OUT
complications	I-OUT
.	I-OUT


The	O
major	O
cost	O
driver	O
was	O
hospital	O
days	O
.	O


CONCLUSION	O
Our	O
data	O
highlight	O
the	O
discrepancy	O
between	O
the	O
Diagnosis	O
Related	O
Group	O
prospective	O
payment	O
system	O
and	O
actual	B-OUT
costs	I-OUT
.	I-OUT


PURPOSE	O
To	O
compare	O
lesion	O
anatomical	O
responses	O
to	O
ranibizumab	B-I
versus	O
verteporfin	B-I
photodynamic	I-I
therapy	I-I
(	I-I
PDT	I-I
)	I-I
in	O
the	O
ANCHOR	O
(	O
Anti-VEGF	O
Antibody	O
for	O
the	O
Treatment	O
of	O
Predominantly	B-P
Classic	I-P
Choroidal	I-P
Neovascularization	I-P
[	I-P
CNV	I-P
]	I-P
in	I-P
Age-Related	I-P
Macular	I-P
Degeneration	I-P
)	I-P
study	O
.	O


METHODS	O
In	O
this	O
2-year	O
,	O
Phase	O
III	O
,	O
randomized	O
,	O
multicenter	O
,	O
double-masked	O
trial	O
,	O
423	B-P
patients	I-P
received	I-P
ranibizumab	I-I
(	I-P
0.3	I-P
or	I-P
0.5	I-P
mg	I-P
)	I-P
monthly	I-P
+	I-P
sham	I-I
PDT	I-I
or	I-I
PDT	I-I
+	I-I
monthly	I-P
sham	I-I
injection	I-I
.	I-I


Main	O
outcome	O
measures	O
included	O
mean	O
change	O
from	O
baseline	O
at	O
Months	O
12	O
and	O
24	O
for	O
area	O
of	O
classic	O
CNV	O
and	O
total	O
area	O
of	O
leakage	O
from	O
CNV	O
.	O


CONCLUSION	O
Differences	O
between	O
the	O
PDT	B-I
and	O
the	O
ranibizumab	B-I
groups	O
in	O
lesion	O
anatomical	O
outcomes	O
were	O
early	O
,	O
sustained	O
,	O
and	O
favored	O
ranibizumab	B-I
.	I-I


CONCLUSION	O
(	O
S	O
)	O
Lengthening	O
of	O
triptorelin	B-I
administration	O
intervals	O
from	O
4	O
weeks	O
to	O
6	O
weeks	O
is	O
effective	O
in	O
maintaining	O
a	O
hypoestrogenic	B-OUT
state	I-OUT
.	I-OUT


Patients	O
were	O
more	O
compliant	B-OUT
with	O
triptorelin	B-I
than	O
danazol	B-I
.	I-I


Thus	O
,	O
triptorelin	B-I
injection	O
every	O
6	O
weeks	O
is	O
more	O
cost-effective	O
than	O
conventional	O
regimens	O
.	O


Safety	B-OUT
and	I-OUT
efficacy	I-OUT
of	O
a	O
new	B-I
3.3	I-I
g	I-I
b.i.d	I-I
.	I-I


METHODS	O
In	O
a	O
double-blind	O
,	O
multicenter	B-P
study	I-P
patients	I-P
with	I-P
symptoms	I-P
of	I-P
acute	I-P
UC	I-P
and	I-P
a	I-P
baseline	I-P
Modified	I-P
Mayo	I-P
Disease	I-P
Activity	I-P
Index	I-P
(	I-P
MMDAI	I-P
)	I-P
score	I-P
between	I-P
6	I-P
and	I-P
10	I-P
,	I-P
inclusive	I-P
,	I-P
with	I-P
a	I-P
subscale	I-P
rating	I-P
of	I-P
>	I-P
or	I-P
=2	I-P
for	I-P
both	I-P
rectal	I-P
bleeding	I-P
and	I-P
mucosal	I-P
appearance	I-P
were	O
randomized	O
to	O
receive	O
3.3	O
g	O
of	O
balsalazide	B-I
or	I-I
placebo	I-I
tablets	O
twice	O
daily	O
for	O
8	O
weeks	O
.	O


Safety	O
assessments	O
were	O
conducted	O
from	O
baseline	O
through	O
2-weeks	O
post-treatment	O
.	O


RESULTS	O
A	B-P
total	I-P
of	I-P
249	I-P
patients	I-P
(	I-P
166	I-P
balsalazide	I-I
,	I-P
83	I-P
placebo	I-I
)	I-I
received	O
at	O
least	O
1	O
dose	O
of	O
study	O
medication	O
.	O


Naltrexone	B-I
in	I-P
autistic	I-P
children	I-P
:	I-P
behavioral	O
symptoms	O
and	O
attentional	O
learning	O
.	O


Forty-one	B-P
children	I-P
,	I-P
all	I-P
inpatients	I-P
,	I-P
ages	I-P
2.9	I-P
to	I-P
7.8	I-P
years	I-P
,	I-P
completed	I-P
the	I-P
study	I-P
.	I-P


RESULTS	O
Subjects	O
in	O
the	O
CM	O
(	O
attendance	O
)	O
and	O
in	O
the	O
CM	O
(	O
weight	O
)	O
group	O
lost	O
a	B-OUT
mean	I-OUT
of	O
1.16	O
kg	O
and	O
1.23	O
kg	O
,	O
respectively	O
,	O
while	O
subjects	O
in	O
the	O
CON	B-OUT
gained	I-OUT
a	O
mean	O
of	O
0.68	O
kg	O
.	O


Subjects	O
receiving	O
CM	O
(	O
behavior	O
)	O
,	O
lost	O
a	O
mean	O
of	O
2.54	O
kg	O
,	O
which	O
was	O
a	O
significant	B-OUT
weight	I-OUT
loss	I-OUT
compared	O
to	O
the	O
control	O
period	O
.	O


In	O
this	O
study	O
,	O
we	O
review	O
theoretical	O
and	O
empirical	O
literature	O
regarding	O
designs	O
that	O
account	O
for	O
such	O
effects	O
in	O
medical	O
research	O
,	O
and	O
consider	O
the	O
appropriateness	O
of	O
these	O
designs	O
to	O
health	B-P
education	I-P
research	I-P
.	I-P


Several	O
predictors	O
of	O
format	O
preference	O
were	O
also	O
identified	O
,	O
with	O
important	O
implications	O
for	O
targeting	O
disease-management	O
education	O
to	O
this	O
population	O
.	O


In	O
the	O
placebo	B-I
group	O
FEV1	B-OUT
decreased	O
by	O
0.33	O
+/-	O
0.20	O
L	O
after	O
6	O
wk	O
(	O
p	O
<	O
0.001	O
)	O
.	O


A	O
statistically	O
significant	O
linear	O
trend	O
of	O
an	O
increase	B-OUT
in	I-OUT
calcium	I-OUT
absorption	I-OUT
adjusted	O
for	O
age	O
and	O
body	O
mass	O
index	O
with	O
increasing	B-I
vitamin	I-I
D₃	O
dose	O
or	O
serum	O
25	O
(	O
OH	O
)	O
D	O
concentration	O
was	O
observed	O
.	O


CONCLUSIONS	O
No	O
evidence	O
of	O
a	O
threshold	O
of	O
calcium	O
absorption	O
was	O
found	O
with	O
a	O
serum	O
25	O
(	O
OH	O
)	O
D	O
range	O
from	O
40	O
to	B-OUT
130	I-OUT
nmol/L	I-OUT
.	I-OUT


OBJECTIVES	O
To	O
determine	O
the	O
effectiveness	B-OUT
of	O
around-the-clock	O
(	O
ATC	O
)	O
analgesic	O
administration	O
,	O
with	O
or	O
without	O
nurse	O
coaching	O
,	O
compared	O
with	O
standard	O
care	O
with	O
as	O
needed	O
(	O
PRN	O
)	O
dosing	O
in	O
children	B-P
undergoing	I-P
outpatient	I-P
tonsillectomy	I-P
.	I-P


Nurse	O
coaching	O
does	O
not	O
impact	O
parent	O
's	O
adherence	O
to	O
ATC	O
dosing	O
.	O


Use	O
of	O
activated	O
charcoal	O
in	O
a	O
simulated	O
poisoning	B-P
with	I-P
acetaminophen	I-P
:	I-P
a	O
new	O
loading	O
dose	O
for	O
N-acetylcysteine	B-I
?	O
STUDY	O
OBJECTIVES	O
To	O
investigate	O
the	O
ability	O
of	O
a	O
supranormal	O
dose	O
of	O
N-acetylcysteine	B-I
to	O
overcome	O
the	O
effects	O
of	O
activated	O
charcoal	O
on	O
N-acetylcysteine	O
bioavailability	O
and	O
to	O
determine	O
the	O
effects	O
of	O
activated	O
charcoal	O
on	O
serum	O
acetaminophen	O
levels	O
.	O


During	O
phase	O
I	O
(	O
control	O
)	O
,	O
subjects	O
ingested	O
3	B-I
g	I-I
acetaminophen	I-I
,	O
followed	O
one	B-I
hour	I-I
later	I-I
by	I-I
the	I-I
normal	I-I
loading	I-I
dose	I-I
of	I-I
N-acetylcysteine	I-I
(	O
140	O
mg/kg	O
)	O
.	O


A	O
serum	B-OUT
acetaminophen	I-OUT
level	I-OUT
was	O
measured	O
at	O
four	O
hours	O
.	O


RESULTS	O
The	O
area	B-OUT
under	I-OUT
the	I-OUT
curve	I-OUT
for	I-OUT
N-acetylcysteine	I-OUT
was	O
significantly	O
higher	O
for	O
phase	O
II	O
than	O
phase	O
I	O
(	O
P	O
<	O
.05	O
,	O
two-tailed	O
paired	O
t-test	O
)	O
.	O


In	O
addition	O
to	O
this	O
,	O
enhanced	O
azithromycin	B-I
penetration	O
from	O
plasma	O
into	O
bronchial	O
secretion	O
and	O
lung	O
tissue	O
was	O
evidenced	O
by	O
the	O
increase	O
in	O
the	O
ratio	B-OUT
of	I-OUT
AUC	I-OUT
(	I-OUT
bronchial	I-OUT
washing	I-OUT
)	I-OUT
versus	I-OUT
AUC	I-OUT
(	I-OUT
plasma	I-OUT
)	I-OUT
(	O
2.96	O
vs	O
5.27	O
at	O
500	O
and	O
1000	O
mg	O
,	O
respectively	O
)	O
and	O
AUC	B-OUT
(	I-OUT
lung	I-OUT
)	I-OUT
versus	I-OUT
AUC	I-OUT
(	I-OUT
plasma	I-OUT
)	I-OUT
(	O
64.35	O
vs	O
97.73	O
at	O
500	O
and	O
1000	O
mg	O
,	O
respectively	O
)	O
.	O


Total	B-OUT
and	I-OUT
Partial	I-OUT
Prevalence	I-OUT
of	I-OUT
Cancer	I-OUT
Across	I-P
Kerman	I-P
Province	I-P
,	I-P
Iran	I-P
,	I-P
in	I-P
2014	I-P
,	O
Using	O
an	O
Adapted	O
Generalized	O
Network	O
Scale-Up	O
Method	O
.	O


The	O
aim	O
of	O
the	O
present	O
study	O
was	O
to	O
estimate	O
total	O
and	O
partial	O
prevalence	B-OUT
of	I-OUT
cancer	I-OUT
in	O
southeastern	O
Iran	O
using	O
an	O
adapted	O
version	O
of	O
the	O
generalized	O
network	O
scale-up	O
method	O
.	O


Serum	B-OUT
lutein	I-OUT
and	I-OUT
zeaxanthin	I-OUT
concentrations	I-OUT
and	O
macular	B-OUT
pigment	I-OUT
densities	I-OUT
were	O
obtained	O
at	O
baseline	O
,	O
day	O
45	O
and	O
day	O
90	O
.	O


BACKGROUND	O
Ulcerative	O
colitis	O
(	O
UC	O
)	O
is	O
a	O
chronic	O
relapsing	O
and	O
remitting	O
idiopathic	O
inflammatory	O
bowel	O
disorder	O
.	O


AIM	O
To	O
evaluate	O
once-daily	O
mesalamine	B-I
(	I-I
mesalazine	I-I
)	I-I
granules	I-I
(	I-I
MG	I-I
)	I-I
for	O
maintenance	O
of	O
remission	O
of	O
UC	O
.	O


METHODS	O
Randomized	O
,	O
double-blind	O
,	O
placebo-controlled	O
trial	O
of	O
patients	B-P
(	I-P
n=209	I-P
MG	I-P
,	I-P
n=96	I-P
placebo	I-P
)	I-P
with	I-P
UC	I-P
in	I-P
remission	I-P
[	I-OUT
revised	I-OUT
Sutherland	I-OUT
Disease	I-OUT
Activity	I-OUT
Index	I-OUT
(	I-OUT
SDAI	I-OUT
)	I-OUT
rectal	I-P
bleeding=0	I-P
,	I-P
mucosal	I-P
appearance	I-P
<	I-P
2	I-P
]	I-P
who	I-P
took	I-P
MG	I-I
1.5	I-I
g	I-I
or	I-I
placebo	I-I
once-daily	I-I
for	I-I
up	I-I
to	I-I
6	I-I
months	I-I
.	I-I


A	O
randomized	O
phase	O
III	O
study	O
.	O


BACKGROUND	O
Pneumatic	B-I
compression	I-I
is	O
a	O
frequently	O
prescribed	O
physical	O
therapy	O
for	O
patients	B-P
affected	I-P
by	I-P
postmastectomy	I-P
lymphedema	I-P
but	O
,	O
despite	O
its	O
wide	O
use	O
,	O
its	O
efficacy	O
has	O
not	O
been	O
demonstrated	O
in	O
phase	O
III	O
studies	O
.	O


The	O
patients	O
in	O
both	O
groups	O
were	O
instructed	O
as	O
to	O
the	O
prophylactic	O
hygienic	O
care	O
of	O
the	O
limb	O
.	O


RESULTS	O
Eighty	B-P
patients	I-P
entered	O
the	O
study	O
.	O


To	O
determine	O
the	O
safety	O
and	O
efficacy	O
of	O
a	O
new	O
,	O
non-contact	B-I
,	I-I
kilohertz	I-I
ultrasound	I-I
therapy	I-I
for	O
the	O
healing	O
of	O
recalcitrant	B-OUT
diabetic	I-OUT
foot	I-OUT
ulcers	I-OUT
-	O
as	O
well	O
as	O
to	O
evaluate	O
the	O
impact	O
on	O
total	O
closure	O
and	O
quantitative	O
bacterial	O
cultures	O
and	O
the	O
effect	O
on	O
healing	O
of	O
various	O
levels	O
of	O
sharp/surgical	O
debridement	O
-	O
a	O
randomized	O
,	O
double-blinded	O
,	O
sham-controlled	O
,	O
multicenter	B-P
study	I-P
was	I-P
conducted	I-P
in	I-P
hospital-based	I-P
and	I-P
private	I-P
wound	I-P
care	I-P
clinics	I-P
.	I-P


The	O
ultrasound	B-I
treatment	I-I
was	O
easy	O
to	O
use	O
and	O
no	O
difference	O
in	O
the	O
number	O
and	O
type	O
of	O
adverse	B-OUT
events	I-OUT
between	O
the	O
two	O
treatment	O
groups	O
was	O
noted	O
.	O


PURPOSE	O
With	O
advances	O
in	O
imaging	O
and	O
radiotherapy	O
,	O
the	O
prognostic	O
value	O
of	O
skull-base	O
invasion	O
in	O
nasopharyngeal	O
carcinoma	O
(	O
NPC	O
)	O
needs	O
to	O
be	O
reassessed	O
.	O


PATIENTS	O
AND	O
MATERIALS	O
We	O
retrospectively	B-P
reviewed	I-P
749	I-P
patients	I-P
who	I-P
underwent	I-P
MRI	I-I
and	I-I
were	I-I
subsequently	I-I
histologically	I-I
diagnosed	I-I
with	I-I
nondisseminated	I-I
NPC	I-I
and	I-I
treated	I-I
with	I-I
IMRT	I-I
.	I-I


RESULTS	O
MRI-detected	O
skull-base	O
invasion	O
was	O
not	O
found	O
to	O
be	O
an	O
independent	O
prognostic	O
factor	O
for	O
overall	B-OUT
survival	I-OUT
(	I-OUT
OS	I-OUT
)	I-OUT
,	I-OUT
distant	I-OUT
metastasis-free	I-OUT
survival	I-OUT
(	I-OUT
DMFS	I-OUT
)	I-OUT
,	I-OUT
local	I-OUT
relapse-free	I-OUT
survival	I-OUT
(	I-OUT
LRFS	I-OUT
)	I-OUT
,	I-OUT
or	I-OUT
disease-free	I-OUT
survival	I-OUT
(	I-OUT
DFS	I-OUT
;	I-OUT
p	O
>	O
0.05	O
for	O
all	O
)	O
.	O


The	B-OUT
5-year	I-OUT
OS	I-OUT
,	I-OUT
DMFS	I-OUT
,	I-OUT
LRFS	I-OUT
,	I-OUT
and	I-OUT
DFS	I-OUT
rates	I-OUT
in	O
the	O
classification	O
of	O
skull-base	O
invasion	O
in	O
NPC	O
were	O
83	O
vs.	O
67	O
%	O
,	O
85	O
vs.75	O
%	O
,	O
95	O
vs.	O
88	O
%	O
,	O
and	O
76	O
vs.	O
62	O
%	O
,	O
respectively	O
(	O
p	O
<	O
0.05	O
for	O
all	O
)	O
.	O


However	O
,	O
classification	O
according	O
to	O
the	O
site	O
of	O
invasion	O
has	O
prognostic	O
value	B-P
.	I-P


[	B-P
Local	I-P
treatment	I-P
of	I-P
periarthropathies	I-P
with	O
the	O
5-HT3-receptor-antagonist	B-I
tropisetron	I-I
]	I-I
.	O


Finding	O
alternatives	O
to	O
these	O
agents	O
in	O
the	O
local	O
treatment	O
of	O
the	O
disease	O
therefore	O
seems	O
desirable	O
.	O


These	O
findings	O
demonstrate	O
that	O
a	O
local	B-OUT
injection	I-OUT
of	I-OUT
5	I-OUT
mg	I-OUT
tropisetron	I-OUT
does	O
represent	O
an	O
alternative	O
to	O
the	O
local	O
treatment	O
with	O
corticosteriods	B-I
plus	I-I
local	I-I
anesthetics	I-I
.	I-I


MATERIALS	O
AND	O
METHODS	O
This	O
study	O
involved	O
prospective	O
randomization	O
of	O
82	B-P
patients	I-P
in	I-P
a	I-P
"	I-P
traditional	I-P
"	I-P
and	I-P
a	I-P
"	I-I
fast-track	I-I
"	I-I
treatment	I-P
arm	I-P
.	I-P


There	O
was	O
also	O
no	O
significant	O
difference	O
in	O
patient	O
's	O
and	O
surgeon	O
's	O
assessment	O
of	O
their	O
experience	O
.	O


Complications	B-OUT
and	I-OUT
recovery	I-OUT
characteristics	I-OUT
also	O
did	O
not	O
show	O
any	O
significant	O
difference	O
.	O


There	O
are	O
no	B-OUT
differences	I-OUT
in	O
terms	O
of	O
overall	B-OUT
survival	I-OUT
and	I-OUT
distant	I-OUT
disease-free	I-OUT
survival	I-OUT
.	I-OUT


PURPOSE	O
Endotracheal	O
suctioning	O
causes	O
significant	O
lung	O
derecruitment	O
.	O


MATERIAL	O
AND	O
METHODS	O
Randomized	O
crossover	O
study	O
examining	O
20	B-P
patients	I-P
postcardiac	I-OUT
surgery	I-P
.	I-P


There	O
were	O
no	O
statistically	O
significant	O
differences	O
in	O
the	O
other	O
respiratory	O
parameters	O
.	O


RESULTS	O
A	O
repeated	O
measures	O
analysis	O
of	O
variance	O
indicated	O
no	O
significant	O
differences	O
between	O
groups	O
or	O
between	O
baseline	O
,	O
intervention	O
,	O
and	O
withdrawal	O
conditions	O
.	O


This	O
study	O
is	O
the	O
first	O
clinical	O
trial	O
to	O
evaluate	O
continuous	B-I
microneedle-based	I-I
drug	I-I
infusion	I-I
,	O
device	O
wearability	O
,	O
and	O
intradermal	O
microneedle	O
insulin	O
kinetics	O
over	O
a	O
multi-day	O
(	O
72	O
h	O
)	O
wear	O
period	O
.	O


Twenty-eight	B-P
patients	I-P
were	I-P
randomized	I-P
and	O
exposed	O
to	O
trial	O
product	O
,	O
and	B-P
23	I-P
completed	I-P
the	I-P
study	I-I
.	I-I


Analyses	O
of	O
secondary	B-OUT
PK	I-OUT
endpoints	I-OUT
corresponded	O
with	O
the	O
primary	O
endpoint	O
findings	B-OUT
.	I-OUT


Bisphosphonates	B-I
are	O
used	O
in	O
oncology	O
as	O
a	O
means	O
of	O
decreasing	O
complications	O
due	O
to	O
bone	B-P
metastases	I-P
,	O
in	O
association	O
with	O
anticancer	O
treatment	O
,	O
especially	O
in	O
patients	O
with	O
breast	O
cancer	O
,	O
prostate	O
cancer	O
and	O
myeloma	O
.	O


PURPOSE	O
This	O
study	O
was	O
undertaken	O
to	O
compare	O
the	O
effectiveness	B-OUT
of	O
oral	O
diazepam	B-I
and	I-I
midazolam	I-I
in	O
sedating	B-P
autistic	I-P
patients	I-P
during	I-P
dental	I-P
treatment	I-P
.	I-P


BACKGROUND	O
There	O
is	O
emerging	O
research	O
detailing	O
the	O
relationship	O
between	O
balance/gait/falls	O
and	O
cognition	O
.	O


Our	O
underlying	O
hypothesis	O
is	O
that	O
cognitive	O
function	O
and	O
frontal	O
lobe	O
connections	O
with	O
the	O
basal	O
ganglia	O
and	O
brainstem	O
posture/locomotor	O
centers	O
are	O
responsible	O
for	O
postural	O
deficits	O
in	O
people	B-P
with	I-P
Parkinson	I-P
's	I-P
disease	I-P
and	O
play	O
a	O
role	O
in	O
rehabilitation	O
efficacy	O
.	O


DISCUSSION	O
The	O
results	O
from	O
this	O
study	O
will	O
further	O
our	O
understanding	O
of	O
the	O
relationship	O
between	O
cognition	O
and	O
mobility	O
with	O
a	O
focus	O
on	O
brain	O
circuitry	O
as	O
it	O
relates	O
to	O
rehabilitation	O
potential	O
.	O


In	O
the	O
second	O
group	O
,	O
CT	B-I
colonography	I-I
was	I-I
performed	I-I
after	I-I
a	I-I
reduced	I-I
bowel	I-I
preparation	I-I
,	O
with	O
the	O
oral	O
contrast	O
medium	O
for	O
residue	O
tagging	O
being	O
administered	O
only	O
on	O
the	O
day	O
of	O
the	O
investigation	O
.	O


The	O
development	O
of	O
a	O
web-	B-I
and	I-I
a	I-I
print-based	I-I
decision	I-I
aid	I-I
for	O
prostate	B-OUT
cancer	I-OUT
screening	I-OUT
.	I-OUT


The	O
booklet	O
was	O
adapted	O
from	O
two	O
previous	O
versions	O
evaluated	O
in	O
randomized	B-I
controlled	I-I
trials	I-I
(	I-I
RCTs	I-I
)	I-I
and	O
the	O
website	B-I
was	O
created	O
to	O
closely	O
match	O
the	O
content	O
of	O
the	O
revised	O
booklet	O
.	O


The	O
tools	O
were	O
also	O
reviewed	O
by	O
a	O
plain	O
language	O
expert	O
and	O
the	O
interdisciplinary	O
research	O
team	O
.	O


A	O
parent-mediated	B-I
intervention	I-I
to	O
increase	O
responsive	B-OUT
parental	I-OUT
behaviors	I-OUT
and	I-OUT
child	I-OUT
communication	I-OUT
in	O
children	B-P
with	I-P
ASD	I-P
:	I-P
a	O
randomized	O
clinical	O
trial	O
.	O


Results	O
showed	O
a	O
significant	O
treatment	O
effect	O
of	O
FPI	B-I
on	O
responsive	B-OUT
parental	I-OUT
behaviors	I-OUT
.	I-OUT


Early	B-OUT
recovery	I-OUT
(	I-OUT
eye	I-OUT
opening	I-OUT
,	I-OUT
orientation	I-OUT
and	I-OUT
sitting	I-OUT
)	I-OUT
was	O
slower	O
in	O
both	O
eltanolone	O
groups	O
compared	O
to	O
the	O
thiopental	O
group	O
(	O
P	O
<	O
0.01	O
)	O
.	O


(	O
ABSTRACT	O
TRUNCATED	O
AT	O
250	O
WORDS	O
)	O


Milk	B-OUT
production	I-OUT
in	O
cows	B-P
with	I-P
endotoxin-induced	I-I
mastitis	I-I
treated	O
with	O
isotonic	B-I
or	I-I
hypertonic	I-I
sodium	I-I
chloride	I-I
solution	I-I
.	I-I


Thus	B-P
,	I-P
autism	I-P
in	I-P
Oman	I-P
is	O
associated	O
with	O
decreased	O
antioxidant	O
resources	O
and	O
decreased	O
methylation	O
capacity	O
,	O
in	O
conjunction	O
with	O
elevated	B-I
hair	I-I
levels	I-I
of	I-I
mercury	I-I
.	O


Before	O
PTCA	O
,	O
19	O
ischemic	O
episodes	O
were	O
present	O
in	O
10	O
(	O
33	O
%	O
)	O
of	O
30	B-P
patients	I-P
.	I-P


Many	O
children	B-P
with	I-P
childhood-onset	I-P
obsessive-compulsive	I-P
disorder	I-P
(	I-P
OCD	I-P
)	I-P
fail	O
to	O
respond	O
adequately	O
to	O
standard	O
therapies	O
.	O


This	O
study	O
examined	O
the	O
efficacy	O
of	O
riluzole	B-I
,	O
a	O
glutamatergic	O
modulator	O
,	O
as	O
an	O
adjunctive	O
therapy	O
for	O
children	B-P
with	I-P
treatment-resistant	I-P
OCD	I-P
.	I-P


In	O
a	O
12-week	O
,	O
double-blind	O
,	O
placebo-controlled	B-I
study	O
,	O
60	B-P
treatment-resistant	I-P
children	I-P
and	I-P
adolescents	I-P
(	I-P
mean	I-P
age=14.5	I-P
±	I-P
2.4	I-P
years	I-P
)	I-P
,	I-P
with	I-P
moderate	I-P
to	I-P
severe	I-P
OCD	I-P
(	I-P
mean	I-P
Children	I-P
's	I-P
Yale-Brown	I-P
Obsessive-Compulsive	I-P
Scale	I-P
(	I-P
CY-BOCS	I-P
)	I-P
=28.2	I-P
±	I-P
3.7	I-P
)	I-P
,	I-P
17	I-P
of	I-P
whom	I-P
also	I-P
had	I-P
concomitant	I-P
autism	I-P
spectrum	I-P
disorder	I-P
,	O
were	O
randomized	O
to	O
receive	B-I
riluzole	I-I
(	I-I
final	I-I
dose	I-I
of	I-I
100	I-I
mg/day	I-I
)	I-I
or	I-I
placebo	I-I
in	O
addition	O
to	O
the	O
existing	O
treatment	O
regimen	B-P
.	I-P


Riluzole	O
was	O
fairly	O
well	B-OUT
tolerated	I-OUT
,	O
although	O
it	O
was	O
associated	O
with	O
one	O
case	O
of	B-OUT
pancreatitis	I-OUT
and	O
five	O
instances	O
of	O
slight	O
increases	O
in	B-OUT
transaminases	I-OUT
.	O


All	O
subjects	O
showed	O
significant	O
reductions	O
in	B-OUT
CY-BOCS	I-OUT
scores	I-OUT
during	O
treatment	O
;	O
however	O
,	O
there	O
was	O
no	O
significant	O
difference	O
between	O
placebo	O
and	O
riluzole	O
on	O
any	O
of	O
the	O
primary	O
or	O
secondary	O
outcome	O
measures	O
.	O


However	O
,	O
future	O
studies	O
may	O
show	O
benefits	O
for	O
less	O
treatment-refractory	B-P
children	I-P
with	I-P
fewer	I-P
concomitant	I-P
medications	I-P
.	O


[	O
Observation	O
on	O
therapeutic	O
effect	O
of	O
picking	O
therapy	O
on	O
Graves	B-P
'	I-P
disease	I-P
]	I-P
.	O


After	O
treatment	O
,	O
serum	B-OUT
TT3	I-OUT
,	I-OUT
TT4	I-OUT
,	I-OUT
FT3	I-OUT
,	I-OUT
FT4	I-OUT
and	I-OUT
S-TSH	I-OUT
contents	I-OUT
had	O
very	O
significant	O
change	O
in	O
the	O
two	O
groups	O
(	O
P	O
<	O
0.01	O
)	O
,	O
TRAb	O
had	O
very	O
significant	O
change	O
in	O
the	O
treatment	O
group	O
(	O
P	O
<	O
0.01	O
)	O
and	O
no	O
significant	O
change	O
in	O
the	O
control	O
group	O
(	O
P	O
>	O
0.05	O
)	O
there	O
were	O
significant	O
differences	O
in	O
decrease	O
of	O
TT3	B-OUT
,	I-OUT
FT3	I-OUT
,	I-OUT
TRAb	I-OUT
(	O
P	O
<	O
0.05	O
)	O
and	O
no	O
significant	O
difference	O
in	O
decrease	O
of	O
TT4	B-OUT
,	I-OUT
FT4	I-OUT
and	I-OUT
increase	I-OUT
of	I-OUT
S-TSH	I-OUT
between	O
the	O
two	O
groups	O
(	O
P	O
>	O
0.05	O
)	O
.	O


CONCLUSION	O
Pricking	O
therapy	O
has	O
a	O
definite	O
therapeutic	O
effect	O
on	O
Graves	B-P
'	I-P
disease	I-P
,	O
which	O
is	O
carried	O
out	O
through	O
regulating	O
thyroid	O
function	O
.	O


The	O
intervention	O
group	O
showed	O
a	O
significant	O
improvement	B-OUT
in	O
mood	B-OUT
status	I-OUT
and	I-OUT
quality	I-OUT
of	I-OUT
life	I-OUT
over	O
time	O
compared	O
with	O
their	O
counterparts	O
in	O
the	O
control	O
group	O
.	O


Calcium	O
supplementation	O
was	O
associated	O
(	O
P	O
<	O
0.05	O
)	O
with	O
increased	O
aBMD	B-OUT
compared	O
with	O
placebo	O
,	O
adjusted	O
for	O
age	O
,	O
height	O
,	O
and	O
weight	O
at	O
the	O
following	O
time	O
points	O
from	O
baseline	O
:	O
total	O
hip	O
,	O
6	O
months	O
(	O
1.9	O
%	O
)	O
,	O
12	O
months	O
(	O
1.6	O
%	O
)	O
,	O
and	O
18	O
months	O
(	O
2.4	O
%	O
)	O
;	O
lumbar	O
spine	O
,	O
12	O
months	O
(	O
1.0	O
%	O
)	O
;	O
femoral	O
neck	O
,	O
6	O
months	O
(	O
1.9	O
%	O
)	O
.	O


Adjusted	B-OUT
total	I-OUT
body	I-OUT
bone	I-OUT
mineral	I-OUT
content	I-OUT
was	O
higher	O
in	O
the	O
calcium	O
group	O
at	O
6	O
months	O
(	O
2.0	O
%	O
)	O
,	O
12	O
months	O
(	O
2.5	O
%	O
)	O
,	O
18	O
months	O
(	O
4.6	O
%	O
)	O
,	O
and	O
24	O
months	O
(	O
3.7	O
%	O
)	O
,	O
respectively	O
(	O
all	O
P	O
<	O
0.001	O
)	O
.	O


A	O
subset	O
of	O
92	B-P
patients	I-P
with	I-P
C4	I-P
disease	I-P
were	O
prospectively	O
randomized	O
,	O
and	O
ambulatory	O
venous	O
pressure	O
(	O
AVP	O
)	O
was	O
determined	O
preoperatively	O
and	O
postoperatively	O
.	O


Of	O
the	O
832	O
patients	O
undergoing	O
SEPS	B-I
,	O
460	O
(	O
55	O
%	O
)	O
underwent	O
saphenous	B-I
vein	I-I
ligation	I-I
and	I-I
stripping	I-I
at	O
the	O
same	O
operation	O
.	O


Logistic	O
regression	O
models	O
indicated	O
that	O
positive	O
affect	O
was	O
associated	O
with	O
increased	O
and	O
negative	O
affect	O
was	O
associated	O
with	O
decreased	O
overall	O
and	O
leisure	B-OUT
activity	I-OUT
.	I-OUT


Older	O
,	O
married	O
,	O
and	O
employed	O
women	O
were	O
more	O
likely	O
to	O
engage	O
in	O
household/occupational	B-OUT
activity	I-OUT
,	O
whereas	O
women	O
who	O
perceived	O
their	O
risk	O
for	O
breast	O
cancer	O
as	O
high	O
were	O
less	O
likely	O
.	O


More	O
educated	O
women	O
and	O
those	O
with	O
higher	O
perceived	O
risk	O
were	O
more	O
likely	O
to	O
engage	O
in	O
leisure	B-OUT
activity	I-OUT
,	O
and	O
married	O
women	O
were	O
less	O
likely	O
.	O


These	O
results	O
suggest	O
a	O
need	O
to	O
increase	B-I
activity	I-I
levels	I-I
in	O
women	B-P
at	I-P
moderate	I-P
risk	I-P
for	I-P
breast	I-P
cancer	I-P
,	O
provide	O
variables	O
upon	O
which	O
interventions	O
can	O
be	O
tailored	O
to	O
promote	O
activity	O
,	O
and	O
point	O
to	O
psychological	O
benefits	O
of	O
activity	O
in	O
this	O
population	O
.	O


Subjectively	O
,	O
the	O
children	B-P
enjoyed	O
whole	O
body	O
vibration	O
which	O
was	O
easy	B-OUT
to	O
integrate	O
into	O
the	O
behavioural	O
programme	O
.	O


Each	O
subject	O
received	O
a	O
15	B-I
mg	I-I
oral	I-I
dose	I-I
of	I-I
BMS-181101	I-I
twice	I-I
a	I-I
day	I-I
(	O
q	O
12	O
h	O
)	O
for	O
11	O
days	O
and	O
a	O
morning	B-I
dose	I-I
of	I-I
BMS-181101	I-I
on	I-I
day	I-I
12	I-I
.	I-I


Serial	B-OUT
blood	I-OUT
samples	I-OUT
were	O
collected	O
up	O
to	O
12	O
h	O
on	O
days	O
6	O
and	O
12	O
following	O
the	O
administration	O
of	O
the	O
morning	O
dose	O
.	O


HPV16	B-OUT
(	O
59.9	O
%	O
)	O
,	O
HPV31	B-OUT
(	O
18.1	O
%	O
)	O
,	O
HPV52	B-OUT
(	O
14.8	O
%	O
)	O
,	O
HPV51	B-OUT
(	O
14.0	O
%	O
)	O
,	O
and	O
HPV18	B-OUT
(	O
13.2	O
%	O
)	O
were	O
the	O
five	O
most	O
common	O
HPV	O
genotypes	O
detected	O
.	O


IMPACT	O
In	O
populations	O
vaccinated	O
against	O
HPV16	B-I
(	I-I
and	I-I
HPV18	I-I
)	I-I
,	O
the	O
median	O
age	O
of	O
CIN3	O
in	O
women	O
with	O
ASCUS	O
and	O
LSIL	O
cytology	O
should	O
shift	O
to	O
older	O
ages	O
,	O
possibly	O
permitting	O
later	O
age	O
at	O
first	O
screening	O
.	O


The	O
mean	O
breathing	O
patterns	O
of	O
seven	B-P
normal	I-P
,	I-P
healthy	I-P
male	I-P
subjects	I-P
and	I-P
eight	I-P
male	I-P
patients	I-P
who	I-P
had	I-P
undergone	I-P
upper	I-P
abdominal	I-P
surgery	I-P
2-4	I-P
days	I-P
previously	I-P
were	O
studied	O
breathing	O
through	O
a	B-I
mouthpiece	I-I
fitted	I-I
in	I-I
random	I-I
order	I-I
with	I-I
a	I-I
5	I-I
,	I-I
6	I-I
,	I-I
7	I-I
,	I-I
8	I-I
,	I-I
or	I-I
15	I-I
mm	I-I
diameter	I-I
(	I-I
17	I-I
mm	I-I
long	I-I
)	I-I
resistor	I-I
.	I-I


With	O
the	O
15	O
mm	O
aperture	O
,	O
the	O
patients	O
had	O
a	O
greater	O
breathing	B-OUT
frequency	I-OUT
(	I-OUT
f	I-OUT
)	I-OUT
than	O
did	O
the	O
normal	O
subjects	O
(	O
21	O
+/-	O
5	O
[	O
SD	O
]	O
vs.	O
14	O
+/-	O
4	O
breaths/min	O
,	O
P	O
less	O
than	O
0.01	O
)	O
as	O
well	O
as	O
a	O
smaller	O
mean	B-OUT
tidal	I-OUT
volume	I-OUT
(	I-OUT
VT	I-OUT
)	I-OUT
.	I-OUT


Their	O
improvemments	O
were	O
significantly	O
greater	B-OUT
on	O
methandienone	B-I
than	O
on	O
placebo	B-I
;	I-I
their	O
body	B-OUT
weights	I-OUT
rose	I-OUT
(	O
though	O
this	O
seemed	O
to	O
be	O
associated	O
with	O
water	O
retention	O
)	O
;	O
and	O
systolic	B-OUT
blood	I-OUT
pressure	I-OUT
rose	I-OUT
significantly	O
.	O


Anabolic	B-I
steroids	I-I
are	O
effective	O
only	O
when	O
given	O
combination	O
with	O
exercise	O
and	O
high-protein	O
diet	O
.	O


We	O
deprecate	O
their	O
use	O
in	O
athletics	O
but	O
can	O
suggest	O
no	O
way	O
of	O
stopping	O
it	O
.	O


Only	O
three	O
patients	O
(	O
7.3	O
%	O
)	O
had	O
symptoms	O
suggestive	O
of	O
hypomania	B-OUT
,	O
and	O
only	O
one	O
patient	O
stopped	O
treatment	O
because	O
of	O
a	O
rapid	B-OUT
mood	I-OUT
swing	I-OUT
into	I-OUT
depression	I-OUT
.	I-OUT


Short-term	O
effect	O
of	O
pitavastatin	B-I
on	O
the	O
reactive	B-OUT
hyperemic	I-OUT
index	I-OUT
in	O
post-menopausal	B-P
women	I-P
with	I-P
high	I-P
levels	I-P
in	I-P
serum	I-P
LDL-cholesterol	I-P
.	I-P


The	O
improvements	O
found	O
in	O
higher-level	B-OUT
social	I-OUT
cognition	I-OUT
encourage	O
further	O
studies	O
into	O
the	O
therapeutic	O
potential	O
of	O
oxytocin	O
in	O
schizophrenia	B-P
.	I-P


The	B-OUT
OPG	I-OUT
,	I-OUT
RANKL	I-OUT
,	I-OUT
and	I-OUT
vWF	I-OUT
levels	I-OUT
were	I-I
measured	I-I
at	I-I
T0	I-I
,	I-I
T10	I-I
,	I-I
and	I-I
T180	I-I
of	I-I
HD	I-I
session	I-I
after	I-I
each	I-I
period	I-I
of	I-I
evaluation	I-I
.	O


CONCLUSIONS	O
Impact	B-I
of	I-I
heparin	I-I
on	O
endothelial	O
cells	O
and	O
simultaneously	O
on	O
OPG/RANK/RANKL	O
axis	O
reinforces	O
the	O
presumption	O
of	O
the	O
pathophysiological	O
linkage	O
between	O
bone	O
mineralization	O
and	O
endothelial	O
dysfunction	B-P
in	I-P
end-stage	I-P
renal	I-P
disease	I-P
.	O


The	O
subjects	O
walked	B-I
5	I-I
d/week	I-I
for	I-I
15	I-I
weeks	I-I
at	I-I
65	I-I
%	I-I
of	I-I
their	I-I
maximal	I-I
aerobic	I-I
power	I-I
expending	I-I
300	I-I
kcal	I-I
(	I-I
1255	I-I
kJ	I-I
)	I-I
in	I-I
exercise	I-I
in	I-I
one	I-I
(	I-I
Group	I-I
S1	I-I
)	I-I
or	I-I
two	I-I
daily	I-I
sessions	I-I
(	I-I
Group	I-I
S2	I-I
)	I-I
.	I-I


VO	B-OUT
(	I-OUT
2max	I-OUT
)	I-OUT
was	I-I
measured	I-I
in	I-I
a	I-I
direct	I-I
maximal	I-I
treadmill	I-I
test	I-I
.	I-I


Effects	O
of	O
electro-acupuncture	B-I
on	O
T	B-OUT
cell	I-OUT
subpopulations	I-OUT
,	I-OUT
NK	I-OUT
activity	I-OUT
,	I-OUT
humoral	I-OUT
immunity	I-OUT
and	I-OUT
leukocyte	I-OUT
count	I-OUT
in	I-P
patients	I-P
undergoing	I-P
chemotherapy	I-P
.	I-P


CONCLUSION	O
Electro-acupuncture	B-I
may	O
reduce	O
immunologic	B-OUT
damage	I-OUT
caused	O
by	O
chemotherapy	B-I
,	O
thus	O
it	O
can	O
be	O
used	O
as	O
the	O
auxiliary	O
therapy	O
for	O
patients	B-P
undergoing	I-P
chemotherapy	I-I
.	I-I


Efficacy	B-OUT
and	O
safety	B-OUT
relative	O
to	O
placebo	B-I
of	O
an	O
oral	O
formulation	O
of	O
cetirizine	B-I
and	O
sustained-release	O
pseudoephedrine	B-I
in	O
the	O
management	B-OUT
of	I-OUT
nasal	I-OUT
congestion	I-OUT
.	I-OUT


METHODS	O
Twenty-four	B-P
patients	I-P
with	I-P
perennial	I-P
rhinitis	I-P
due	I-P
to	I-P
house-dust-mite	I-P
(	I-P
HDM	I-P
)	I-P
allergy	I-P
were	I-P
recruited	I-P
in	O
this	O
crossover	O
study	O
.	O


Immediately	O
after	O
the	O
first	O
dose	O
of	O
each	O
medication	O
(	O
day	O
1	O
)	O
,	O
nasal	B-OUT
congestion	I-OUT
and	O
related	B-OUT
symptoms	I-OUT
were	O
assessed	O
during	O
a	O
7-h	O
challenge	O
with	O
HDM	O
feces	O
,	O
with	O
the	O
Vienna	O
Challenge	O
Chamber	O
(	O
VCC	O
)	O
,	O
to	O
investigate	O
onset	O
of	O
action	O
of	O
the	O
preparation	O
.	O


Both	O
medications	O
were	O
well	O
tolerated	B-OUT
,	O
and	O
no	O
serious	O
adverse	B-OUT
events	I-OUT
occurred	O
during	O
the	O
study	O
.	O


CONCLUSIONS	O
In	O
this	O
study	O
,	O
cetirizine/PSE	B-I
relieved	O
nasal	B-OUT
congestion	I-OUT
and	O
other	O
objective	O
and	O
subjective	O
symptoms	B-OUT
to	O
a	O
significantly	O
greater	O
extent	O
than	O
placebo	O
.	O


METHODS	O
Children	B-P
with	I-P
autism	I-P
and	I-P
typically	I-P
developed	I-P
children	I-P
participated	I-P
in	O
one	O
of	O
two	O
experiments	O
.	O


Safety	O
,	O
immunogenicity	O
and	O
the	O
influence	O
of	O
seasonal	O
influenza	O
vaccination	O
and	O
antibody	O
cross-reactivity	O
with	O
a	O
seasonal	O
H1N1	O
strain	O
was	O
assessed	O
.	O


RESULTS	O
A	O
single	O
vaccination	O
with	O
either	O
dose	O
induced	O
substantial	O
increases	O
in	B-OUT
H1N1	I-OUT
A/California/07/2009	I-OUT
hemagglutination	I-OUT
inhibition	I-OUT
(	I-OUT
HI	I-OUT
)	I-OUT
and	I-OUT
neutralizing	I-OUT
(	I-OUT
MN	I-OUT
)	I-OUT
antibody	I-OUT
titers	I-OUT
in	O
both	O
adult	O
and	O
elderly	O
subjects	O
.	O


Both	B-OUT
HI	I-OUT
and	I-OUT
MN	I-OUT
antibodies	I-OUT
persisted	O
for	O
≥	O
6	O
months	O
post-vaccination	O
.	O


The	O
taste	O
and	O
consumption	O
of	O
glucose	O
can	O
also	O
relieve	O
physical	O
pain	O
,	O
and	O
the	O
purpose	O
of	O
the	O
current	O
study	O
was	O
to	O
examine	O
whether	O
it	O
might	O
also	O
reduce	O
the	O
negative	B-OUT
emotional	I-OUT
effects	I-OUT
of	I-OUT
ostracism	I-OUT
.	I-OUT


Clinical	B-OUT
efficacy	I-OUT
was	O
determined	O
by	O
pneumatic	O
otoscopy	O
and	O
tympanometric	O
testing	O
3	O
to	O
5	O
,	O
11	O
to	O
14	O
,	O
and	O
22	O
to	O
26	O
days	O
after	O
the	O
initiation	O
of	O
therapy	O
.	O


Taste	B-OUT
acceptability	I-OUT
was	O
highest	O
for	O
CEC	B-I
and	O
lowest	O
for	O
this	O
formulation	O
of	O
CAE	B-I
.	I-I


Significantly	O
more	O
patients	O
in	O
the	O
AMX-CL	B-I
group	O
than	O
in	O
the	O
CAE	B-I
or	O
CEC	B-I
group	O
had	O
a	O
side	B-OUT
effect	I-OUT
,	I-OUT
primarily	I-OUT
diarrhea	I-OUT
,	I-OUT
vomiting	I-OUT
,	I-OUT
or	I-OUT
diaper	I-OUT
rash	I-OUT
.	I-OUT


We	O
conclude	O
that	O
CAE	O
suspension	O
has	O
greater	O
clinical	B-OUT
efficacy	I-OUT
than	O
CEC	O
and	O
fewer	O
side	B-OUT
effects	I-OUT
than	O
AMX-CL	B-I
.	I-I


These	O
results	O
suggest	O
that	O
the	O
shear-induced	O
pathway	O
of	O
aspirin-treated	B-I
platelets	O
is	O
more	O
vulnerable	O
to	O
cardiopulmonary	O
bypass	O
than	O
the	O
pathway	O
in	O
normal	O
platelets	O
and	O
causes	O
severe	O
impairment	O
of	O
hemostasis	O
afterward	O
.	O


Direct	B-I
renin	I-I
inhibition	I-I
improves	O
parasympathetic	O
function	O
in	O
diabetes	B-P
.	I-P


Autonomic	B-OUT
function	I-OUT
was	O
assessed	O
by	O
power	O
spectral	O
analysis	O
and	O
RR-variation	O
during	O
deep	O
breathing	O
[	O
i.e	O
.	O


The	O
MCR	O
and	O
E/I	O
ratio	O
assess	O
parasympathetic	O
function	O
.	O


Randomised	O
controlled	O
trial	O
of	O
graded	B-I
exercise	I-I
in	O
patients	B-P
with	I-P
the	I-P
chronic	I-OUT
fatigue	I-OUT
syndrome	I-OUT
.	I-OUT


SUBJECTS	O
66	B-P
patients	I-P
with	I-P
the	I-P
chronic	I-P
fatigue	I-P
syndrome	I-P
who	I-P
had	I-P
neither	I-P
a	I-P
psychiatric	I-P
disorder	I-P
nor	I-P
appreciable	I-P
sleep	I-P
disturbance	I-P
.	I-P


Three	B-P
months	I-P
after	I-P
surgery	I-P
,	O
the	O
patients	O
were	O
asked	O
about	O
symptomatic	B-OUT
relief	I-OUT
and	I-OUT
intervals	I-OUT
between	I-OUT
the	I-OUT
operation	I-OUT
and	I-OUT
return	I-OUT
to	I-OUT
their	I-OUT
daily	I-OUT
activities	I-OUT
and	I-OUT
work	I-OUT
,	I-OUT
and	I-OUT
examined	I-OUT
for	I-OUT
scar	I-OUT
tenderness	I-OUT
and	I-OUT
esthetic	I-OUT
outcome	I-OUT
.	I-OUT


PARTICIPANTS	O
Thirty-four	B-P
eyes	I-P
of	I-P
32	I-P
patients	I-P
with	I-P
chronic	I-P
CSC	I-P
with	I-P
>	I-P
6	I-P
months	I-P
'	I-P
duration	I-P
of	I-P
symptoms	I-P
or	I-P
recurrent	I-P
CSC	I-P
were	I-P
randomly	I-P
placed	I-P
into	I-P
the	I-P
low-fluence	I-P
PDT	I-P
group	I-P
(	I-P
n	I-P
=	I-P
18	I-P
)	I-P
or	I-P
the	I-P
ranibizumab	I-P
group	I-P
(	I-P
n	I-P
=	I-P
16	I-P
)	I-P
.	I-P


Secondary	O
outcomes	O
included	O
the	O
mean	B-OUT
changes	I-OUT
in	I-OUT
logarithm	I-OUT
of	I-OUT
the	I-OUT
minimum	I-OUT
angle	I-OUT
of	I-OUT
resolution	I-OUT
best-corrected	I-OUT
visual	I-OUT
acuity	I-OUT
(	I-OUT
BCVA	I-OUT
)	I-OUT
,	I-OUT
central	I-OUT
retinal	I-OUT
thickness	I-OUT
(	I-OUT
CRT	I-OUT
)	I-OUT
,	O
and	O
angiographic	B-OUT
findings	I-OUT
from	O
baseline	O
to	O
12	O
months	O
.	O


CONCLUSIONS	O
This	O
study	O
represents	O
the	O
overall	O
superiority	O
of	O
low-fluence	O
PDT	O
compared	O
with	O
intravitreal	O
ranibizumab	O
in	O
the	O
treatment	O
of	O
chronic	O
CSC	O
.	O


Efficacy	B-OUT
was	O
evaluated	O
using	O
the	O
caregiver-rated	O
Aberrant	B-OUT
Behavior	I-OUT
Checklist	I-OUT
Irritability	I-OUT
subscale	I-OUT
(	I-OUT
primary	I-OUT
efficacy	I-OUT
measure	I-OUT
)	I-OUT
and	I-OUT
the	I-OUT
clinician-rated	I-OUT
Clinical	I-OUT
Global	I-OUT
Impressions-Improvement	I-OUT
score	I-OUT
.	I-OUT


All	O
aripiprazole	B-I
doses	O
demonstrated	O
significantly	O
greater	O
improvements	B-OUT
in	I-OUT
mean	I-OUT
Clinical	I-OUT
Global	I-OUT
Impressions-Improvement	I-OUT
score	I-OUT
than	O
placebo	B-I
at	O
week	O
8	O
.	O


There	O
were	O
two	O
serious	B-OUT
adverse	I-OUT
events	I-OUT
:	I-OUT
presyncope	I-OUT
(	O
5	O
mg/day	O
)	O
and	O
aggression	B-OUT
(	O
10	O
mg/day	O
)	O
.	O


At	O
week	O
8	O
,	O
mean	O
weight	B-OUT
change	I-OUT
(	O
last	O
observation	O
carried	O
forward	O
)	O
was	O
as	O
follows	O
:	O
placebo	O
+0.3	O
kg	O
,	O
aripiprazole	B-I
5	O
mg/day	O
+1.3	O
kg	O
,	O
10	O
mg/day	O
+1.3	O
kg	O
,	O
and	O
15	O
mg/day	O
+1.5	O
kg	O
;	O
all	O
p	O
<	O
.05	O
versus	O
placebo	B-I
.	I-I


The	O
participants	O
reported	O
their	O
daily	B-OUT
emotional	I-OUT
experiences	I-OUT
,	O
by	O
completing	O
questionnaires	B-OUT
relating	I-OUT
to	I-OUT
sensory	I-OUT
and	I-OUT
social	I-OUT
pleasure	I-OUT
.	I-OUT


In	O
this	O
task	O
,	O
pleasure	O
typically	O
decreases	O
with	O
decreasing	O
contrast	O
of	O
the	O
positive	O
images	O
displayed	O
.	O


BACKGROUND	O
Colonization	O
patterns	O
,	O
especially	O
by	O
anaerobic	O
flora	O
,	O
may	O
play	O
an	O
important	O
role	O
in	O
neonatal	B-P
gut	I-P
function	I-P
.	I-P


METHODS	O
To	O
study	O
the	O
ability	O
of	O
Lactobacillus	B-I
GG	I-I
(	I-I
LGG	I-I
)	I-I
to	O
colonize	B-OUT
the	I-OUT
neonatal	I-OUT
gut	I-OUT
and	I-OUT
modify	I-OUT
its	I-OUT
microbial	I-OUT
ecology	I-OUT
,	O
a	O
prospective	O
,	O
randomized	O
study	O
was	O
performed	O
in	O
71	B-P
preterm	I-P
infants	I-P
of	I-P
less	I-P
than	I-P
2000	I-P
g	I-P
birth	I-P
weight	I-P
.	I-P


Infants	B-P
less	I-P
than	I-P
1500	I-P
g	I-P
(	O
24	O
treated	O
,	O
15	O
control	O
)	O
received	O
10	O
(	O
9	O
)	O
LGG	B-I
orally	O
twice	O
daily	O
for	O
21	O
days	O
.	O


Mean	B-OUT
log	I-OUT
CFU	I-OUT
of	I-OUT
Gram	I-OUT
(	I-OUT
-	I-OUT
)	I-OUT
bacteria	I-OUT
did	O
not	O
change	O
in	O
treated	O
infants	O
weighing	O
less	O
than	O
1500	O
g.	O
However	O
,	O
Gram	B-OUT
(	I-OUT
+	I-OUT
)	I-OUT
mean	I-OUT
log	I-OUT
CFU	I-OUT
showed	O
a	O
significant	O
increase	O
on	O
day	O
21	O
(	O
6.1	O
+/-	O
0.9	O
)	O
compared	O
with	O
day	O
0	O
(	O
3.5	O
+/-	O
0.9	O
)	O
(	O
P	O
<	O
0.05	O
)	O
.	O


The	O
results	O
suggest	O
that	O
PRP-P	B-I
is	O
both	O
well	B-OUT
tolerated	I-OUT
clinically	I-OUT
and	I-OUT
has	I-OUT
greater	I-OUT
immunogenicity	I-OUT
than	O
PRP	O
.	O


The	O
subjects	O
were	O
randomly	O
assigned	O
to	O
three	O
groups	O
each	O
having	O
a	O
different	O
procedure	O
of	O
requesting	O
the	O
completion	O
of	O
the	O
survey	O
and	O
providing	O
the	O
questionnaires	O
:	O
(	O
1	O
)	O
Postal	B-I
Group	I-I
,	I-I
(	I-I
2	I-I
)	I-I
Telephone	I-I
Group	I-I
,	I-I
and	I-I
(	I-I
3	I-I
)	I-I
Face-to-face	I-I
Group	I-I
.	I-I


Safety	B-OUT
,	I-OUT
tolerability	I-OUT
,	I-OUT
and	I-OUT
changes	I-OUT
in	I-OUT
amyloid	I-OUT
beta	I-OUT
concentrations	I-OUT
after	O
administration	O
of	O
a	O
gamma-secretase	B-I
inhibitor	I-I
in	O
volunteers	B-P
.	I-P


Adverse	B-OUT
events	I-OUT
reported	O
by	O
subjects	O
taking	O
5-mg	O
,	O
20-mg	O
,	O
or	O
40-mg	O
doses	O
were	O
similar	O
to	O
those	O
reported	O
by	O
subjects	B-P
taking	I-P
placebo	I-P
.	I-P


Two	O
of	O
7	O
subjects	O
taking	O
50	O
mg/day	O
experienced	O
adverse	O
events	O
that	O
may	O
have	O
been	O
drug	O
related	O
.	O


At	O
the	O
onset	O
of	O
the	O
study	O
as	O
well	O
as	O
after	O
2	O
and	O
4	O
weeks	O
,	O
the	O
following	O
criteria	O
were	O
analyzed	O
:	O
HAMD	O
,	O
B-L	O
,	O
CGI	O
,	O
and	O
vegetative	O
symptoms	O
.	O


A	O
randomized	O
controlled	O
trial	O
.	O


Both	B-P
groups	I-P
were	I-P
homogeneous	I-P
regarding	I-P
age	I-P
,	I-P
sex	I-P
distribution	I-P
,	I-P
etiology	I-P
of	I-P
liver	I-P
cirrhosis	I-P
,	I-P
history	I-P
of	I-P
previous	I-P
complications	I-P
,	I-P
clinical	I-P
status	I-P
,	I-P
liver	I-P
and	I-P
renal	I-P
function	I-P
,	I-P
modified	I-P
Child	I-P
's	I-P
score	I-P
,	I-P
and	I-P
nutritional	I-P
status	I-P
at	I-P
admission	I-P
.	I-P


Mortality	B-OUT
rate	I-OUT
while	I-OUT
in	I-OUT
the	I-OUT
hospital	I-OUT
was	O
lower	O
in	O
patients	O
on	O
enteral	O
feeding	O
than	O
in	O
controls	O
(	O
12	O
%	O
vs	O
47	O
%	O
)	O
.	O


The	O
primary	O
outcome	O
measures	O
were	O
the	O
score	O
on	O
the	O
Irritability	O
subscale	O
of	O
the	O
Aberrant	O
Behavior	O
Checklist	O
and	O
the	O
rating	O
on	O
the	O
Clinical	O
Global	O
Impressions	O
-	O
Improvement	O
(	O
CGI-I	O
)	O
scale	O
at	O
eight	O
weeks	O
.	O


However	O
,	O
a	O
subgroup	O
of	O
26	O
%	O
responded	O
with	O
more	O
than	O
25	O
%	O
reduction	B-OUT
of	I-OUT
ADHD	I-OUT
symptoms	I-OUT
and	O
a	O
drop	B-OUT
of	I-OUT
CGI	I-OUT
scores	I-OUT
to	O
the	O
near-normal	O
range	O
.	O


BACKGROUND	O
Daclizumab	B-I
,	O
a	O
humanised	O
monoclonal	O
antibody	O
,	O
modulates	O
interleukin-2	O
signalling	O
by	O
blocking	O
the	O
α	O
subunit	O
(	O
CD25	O
)	O
of	O
the	O
interleukin-2	O
receptor	O
.	O


Analysis	O
was	O
by	O
intention	O
to	O
treat	O
.	O


One	O
patient	B-I
given	I-I
daclizumab	I-I
HYP	O
150	O
mg	O
who	O
was	O
recovering	O
from	O
a	B-OUT
serious	I-OUT
rash	O
died	O
because	O
of	O
local	O
complication	O
of	O
a	O
psoas	O
abscess	O
.	O


In	O
a	O
cross-over	O
double-blind	O
study	O
,	O
three	O
dosages	O
of	O
naltrexone	O
(	O
0.5	O
,	O
1	O
and	O
2	O
mg/kg/day	O
)	O
and	O
placebo	O
were	O
compared	O
.	O


The	O
clinical	B-OUT
efficacy	I-OUT
of	O
the	O
prostacyclin	B-I
analogue	I-I
iloprost	I-I
was	O
studied	O
during	O
a	O
2	O
week	O
treatment	O
and	O
6	O
month	O
follow-up	O
period	O
in	O
103	B-P
patients	I-P
with	I-P
ischaemic	I-P
ulcers	I-P
who	I-P
were	I-P
randomised	I-P
to	I-P
receive	I-P
active	I-I
treatment	I-I
or	I-I
placebo	I-I
.	I-I


Responders	O
were	O
defined	O
as	O
those	O
patients	O
who	O
achieved	O
healing	O
of	O
at	O
least	O
one	O
third	O
of	O
the	O
ulcer	O
area	O
during	O
the	O
study	O
period	O
.	O


Brief	O
report	O
:	O
autistic	B-P
children	I-P
's	I-P
attentiveness	I-OUT
and	I-OUT
responsivity	I-OUT
improve	O
after	O
touch	B-I
therapy	I-I
.	I-I


In	O
12	O
patients	O
,	O
teeth	O
were	O
treated	O
with	O
surgical	O
debridement	O
(	O
DEBR	O
)	O
alone	O
and	O
not	O
splinted	O
.	O


DEBR	O
alone	O
showed	O
reductions	B-OUT
in	I-OUT
tooth	I-OUT
mobility	I-OUT
and	I-OUT
PPD	I-OUT
and	O
a	O
significantly	O
smaller	B-OUT
gain	I-OUT
in	O
CPAL	B-OUT
than	O
in	O
presplint	O
teeth	O
treated	O
with	O
BRG	O
.	O


[	O
Combined	O
preoperative	B-I
xeloda	I-I
and	I-I
radiotherapy	I-I
for	O
lower	B-P
rectal	I-P
cancer	I-P
]	I-P
.	O


Multifaceted	B-I
support	I-I
to	O
improve	O
clinical	O
decision	O
making	O
in	O
diabetes	O
care	O
:	O
a	O
randomized	O
controlled	O
trial	O
in	O
general	O
practice	O
.	O


Discussion	B-OUT
of	I-OUT
problems	I-OUT
with	I-OUT
medication	I-OUT
showed	O
a	O
near	O
significant	O
trend	O
towards	O
increased	O
benefit	O
for	O
the	O
intervention	O
group	O
(	O
1.52	O
;	O
0.99-2.32	O
)	O
.	O


The	O
evolving	O
clinical	O
status	O
of	O
patients	B-P
after	I-P
a	I-P
myocardial	I-P
infarction	I-P
:	I-P
the	O
importance	O
of	O
post-hospital	B-I
data	I-I
for	O
mortality	O
prediction	O
.	O


Studies	O
predicting	O
mortality	O
after	O
myocardial	B-P
infarction	I-P
(	I-P
MI	I-P
)	I-P
usually	O
rely	O
on	O
in-hospital	B-I
data	I-I
,	O
and	O
combine	O
patients	B-P
admitted	I-P
for	I-P
the	I-P
first	I-P
MI	I-P
with	I-P
recurrent	I-P
MI	I-P
patients	I-P
.	I-P


Most	O
importantly	O
,	O
a	O
distinct	O
gradient	O
within	O
each	O
class	O
of	O
the	O
in-hospital	B-I
data	I-I
only	O
system	O
was	O
created	O
by	O
the	O
addition	O
of	O
the	O
post-hospital	B-I
data	I-I
.	I-I


Quality	B-OUT
of	I-OUT
life	I-OUT
.	I-OUT


RESULTS	O
The	O
GMC	O
of	O
non-and-low	B-P
response	I-P
children	I-P
in	O
group	O
A	O
(	O
before	O
booster	O
)	O
,	O
group	O
B	O
(	O
after	O
1	O
dose	O
booster	O
)	O
and	O
group	O
C	O
(	O
after	O
3	O
dose	O
booster	O
)	O
were	O
18.66	O
mIUml	O
,	O
88.82	O
mIU/ml	O
,	O
178.24	O
mIU/ml	O
respectively	O
;	O
the	O
proportion	O
of	O
non-responders	O
in	O
three	O
groups	O
were	O
20.4	O
%	O
,	O
9.1	O
%	O
,	O
1.9	O
%	O
respectively	O
.	O


In	O
contrast	O
to	O
this	O
,	O
gamma-glutamyl	B-OUT
transferase	I-OUT
(	I-OUT
GGT	I-OUT
)	I-OUT
activity	I-OUT
increased	O
by	O
2,4	O
times	O
during	O
5-days	O
therapy	B-I
with	I-I
the	I-I
lipid	I-I
emulsions	I-I
mentioned	O
above	O
(	O
SMOF	O
lipid	O
:	O
21,9	O
to	O
52,9	O
U/L	O
,	O
Lipofundin	O
:	O
from	O
32,5	O
to	O
79,6	O
U/L	O
)	O
.	O


Further	O
,	O
sprint	B-OUT
times	I-OUT
again	O
tended	O
to	O
be	O
slower	O
in	O
the	O
CODS-SS	B-I
trial	O
compared	O
with	O
the	O
CODS-CON	B-I
across	O
all	O
sprint	O
variables	O
,	O
with	O
a	O
significantly	O
slower	O
(	O
P	O
<	O
0.05	O
)	O
BST	O
recorded	O
for	O
set	O
3	O
after	O
static	O
stretching	O
.	O


Many	O
kinds	O
of	O
blood	B-I
purifying	I-I
technologies	I-I
have	O
been	O
applied	O
to	O
the	O
treatment	O
of	O
critically	B-P
ill	I-P
patients	I-P
since	O
1979	O
when	O
plasma	O
exchange	O
with	O
hollow-fiber	O
membranes	O
was	O
developed	O
.	O


These	O
technologies	O
have	O
been	O
applied	O
not	O
only	O
to	O
the	O
removal	O
of	O
toxic	O
substances	O
,	O
but	O
also	O
to	O
the	O
treatment	O
of	O
objective	O
diseases	O
and	O
the	O
removal	O
of	O
the	O
factors	O
relating	O
to	O
the	O
associated	O
inflammation	O
.	O


This	O
article	O
summarizes	O
these	O
methods	O
and	O
their	O
efficacies	O
for	O
critically	B-P
ill	I-P
patients	I-P
,	I-P
especially	I-P
those	I-P
with	I-P
severe	I-P
sepsis	I-P
.	I-P


Attempts	O
have	O
been	O
made	O
to	O
remove	O
endotoxin	O
,	O
the	O
main	O
cause	O
of	O
sepsis	O
,	O
from	O
the	O
circulation	O
using	O
polymyxin	B-I
B	I-I
immobilized	I-I
fiber	I-I
,	I-I
charcoal	I-I
hemoperfusion	I-I
,	O
and	O
plasma	B-I
or	I-I
whole	I-I
blood	I-I
exchange	I-I
.	I-I


Yohimbine	B-I
in	O
neurally	B-P
mediated	I-P
syncope	I-P
.	I-P


Eight	B-P
previously	I-P
characterized	I-P
patients	I-P
with	I-P
recurrent	I-P
NMS	I-P
(	I-P
five	I-P
females	I-P
and	I-P
three	I-P
males	I-P
;	I-P
34+/-2	I-P
yr	I-P
)	I-P
were	I-P
recruited	I-P
from	I-P
the	I-P
Vanderbilt	I-P
Syncope	I-P
Unit	I-P
and	O
eight	B-P
age-matched	I-P
controls	I-P
underwent	O
initial	O
administration	O
of	O
clonidine	B-I
(	I-I
CLO	I-I
)	I-I
or	I-I
yohimbine	I-I
(	O
YHO	O
)	O
.	O


Yohimbine-induced	O
enhancement	O
of	O
sympathetic	O
tone	O
in	O
patients	B-P
with	I-P
NMS	I-P
improves	O
orthostatic	O
tolerance	O
and	O
raises	O
the	O
possibility	O
that	O
this	O
drug	O
may	O
be	O
a	O
useful	O
agent	O
in	O
the	O
treatment	O
of	O
NMS	O
.	O


On	O
the	O
third	O
day	O
of	O
GnRH-a	B-I
administration	O
,	O
119	B-P
patients	I-P
were	O
randomized	O
in	O
three	O
groups	O
to	O
receive	O
daily	O
fixed	O
doses	O
of	O
300	O
IU	O
of	O
rFSH	B-I
(	O
group	O
A	O
,	O
n	O
=	O
38	O
)	O
,	O
or	O
450	O
IU	O
of	O
rFSH	B-I
(	O
group	O
B	O
,	O
n	O
=	O
39	O
)	O
,	O
or	O
600	O
IU	O
of	O
rFSH	B-I
(	O
group	O
C	O
,	O
n	O
=	O
42	O
)	O
.	O


MAIN	O
OUTCOME	O
MEASURE	O
(	O
S	O
)	O
Peak	B-OUT
E	I-OUT
(	I-OUT
2	I-OUT
)	I-OUT
levels	I-OUT
,	I-OUT
days	I-OUT
of	I-OUT
stimulation	I-OUT
with	I-OUT
rFSH	I-OUT
,	I-OUT
total	I-OUT
rFSH	I-OUT
dosage	I-OUT
,	I-OUT
total	I-OUT
number	I-OUT
of	I-OUT
oocytes	I-OUT
retrieved	I-OUT
,	I-OUT
M2	I-OUT
oocytes	I-OUT
retrieved	I-OUT
,	I-OUT
total	I-OUT
number	I-OUT
of	I-OUT
embryos	I-OUT
,	I-OUT
number	I-OUT
of	I-OUT
embryos	I-OUT
transferred	I-OUT
,	I-OUT
number	I-OUT
of	I-OUT
Grade-1	I-OUT
embryos	I-OUT
transferred	I-OUT
,	I-OUT
clinical	I-OUT
pregnancy	I-OUT
rate	I-OUT
(	I-OUT
positive	I-OUT
fetal	I-OUT
cardiac	I-OUT
activity	I-OUT
)	I-OUT
,	I-OUT
and	I-OUT
cancellation	I-OUT
rates	I-OUT
of	I-OUT
stimulation	I-OUT
and	I-OUT
embryo	I-OUT
transfer	I-OUT
.	I-OUT


Neostigmine	B-I
and	O
edrophonium	B-I
antagonism	O
of	O
moderate	O
neuromuscular	O
block	O
induced	O
by	O
pancuronium	O
or	O
tubocurarine	O
.	O


Only	O
seven	O
of	O
20	B-P
patients	I-P
who	I-P
received	I-P
edrophonium	I-P
demonstrated	O
adequate	O
recovery	O
30	O
min	O
after	O
antagonism	O
.	O


This	O
study	O
was	O
aimed	O
to	O
investigate	O
the	O
effects	O
of	O
water	B-I
extracts	I-I
of	I-I
Graptopetalum	I-I
paraguayense	I-I
(	I-I
WGP	I-I
,	I-I
4	I-I
g/d	I-I
)	I-I
on	O
blood	B-OUT
pressure	I-OUT
,	I-OUT
blood	I-OUT
glucose	I-OUT
level	I-OUT
,	I-OUT
and	I-OUT
lipid	I-OUT
profiles	I-OUT
in	O
subjects	B-P
with	I-P
metabolic	I-P
syndrome	I-P
(	I-P
MS	I-P
)	I-P
.	I-P


Blood	B-OUT
pressure	I-OUT
,	I-OUT
FG	I-OUT
,	I-OUT
and	I-OUT
lipid	I-OUT
profiles	I-OUT
were	O
significantly	O
correlated	O
with	O
antioxidant	O
enzymes	O
activities	O
after	O
supplementation	O
(	O
P	O
<	O
0.05	O
)	O
.	O


Further	O
,	O
powerful	O
and	O
controlled	O
studies	O
are	O
needed	O
to	O
elucidate	O
the	O
best	O
treatment	O
strategies	O
for	O
H.	O
pylori	O
eradication	O
in	O
this	O
age	O
group	O
.	O


[	B-I
Rilmenidine	I-I
sympatholytic	O
activity	O
preserves	O
mental	B-OUT
and	I-OUT
orthostatic	I-OUT
sympathetic	I-OUT
response	I-OUT
and	O
epinephrine	B-OUT
secretion	I-OUT
]	I-OUT
.	O


The	O
patients	O
were	O
operated	B-I
with	I-I
envelope	I-I
flap	I-I
on	I-I
one	I-I
side	I-I
and	I-I
triangular	I-I
flap	I-I
on	I-I
the	I-I
other	I-I
side	I-I
.	I-I


METHODS	O
Three	B-P
hundred	I-P
fourteen	I-P
patients	I-P
with	I-P
grades	I-P
2	I-P
or	I-P
3	I-P
esophageal	I-P
varices	I-P
(	I-P
Child	I-P
A	I-P
and	I-P
B/C	I-P
:	I-P
218	I-P
and	I-P
96	I-P
)	I-P
were	O
enrolled	O
.	O


In	O
a	O
Cox	O
model	O
,	O
the	O
presence	O
of	O
tense	O
ascites	O
(	O
relative	O
risk	O
3.4	O
,	O
95	O
%	O
confidence	O
interval	O
,	O
CI	O
2.5-5.9	O
)	O
and	O
a	O
prior	O
history	O
of	O
hemorrhage	O
(	O
relative	O
risk	O
4.4	O
,	O
95	O
%	O
CI	O
2.6-7.5	O
)	O
were	O
independent	O
predictors	O
of	O
variceal	B-OUT
hemorrhage	I-OUT
.	I-OUT


CONCLUSIONS	O
Despite	O
the	O
advent	O
of	O
effective	O
drugs	O
and	O
endoscopic	B-I
therapy	I-I
for	O
variceal	O
bleeding	O
,	O
about	O
a	O
quarter	O
of	O
deaths	B-OUT
occur	O
very	O
early	O
after	O
bleeding	O
onset	O
,	O
confirming	O
the	O
need	O
for	O
rapid	O
specific	O
management	O
.	O


The	O
pioglitazone	B-I
group	O
had	O
significantly	O
higher	O
HbA	B-OUT
(	I-OUT
1c	I-OUT
)	I-OUT
values	O
compared	O
with	O
the	O
glimepiride	B-I
group	O
after	O
12	O
weeks	O
of	O
therapy	O
(	O
8.66	O
%	O
vs	O
7.80	O
%	O
;	O
P	O
=	O
0.007	O
)	O
but	O
had	O
significantly	O
lower	O
values	O
after	O
52	O
weeks	O
(	O
7.46	O
%	O
vs	O
7.77	O
%	O
;	O
P	O
=	O
0.027	O
)	O
.	O


Pioglitazone	B-I
therapy	O
was	O
associated	O
with	O
significant	O
increases	O
in	O
insulin	B-OUT
sensitivity	I-OUT
(	I-OUT
reduced	I-OUT
insulin	I-OUT
resistance	I-OUT
)	I-OUT
,	O
whereas	O
glimepiride	B-I
had	O
no	O
effect	O
.	O


METHODS	O
This	O
prospective	O
,	O
randomized	O
,	O
controlled	O
trial	O
was	O
designed	O
to	O
show	O
that	O
the	O
use	O
of	O
barbed	B-I
suture	I-I
in	O
dermal	B-P
closure	I-P
of	I-P
the	I-P
Pfannenstiel	I-P
incision	I-P
during	I-P
nonemergent	I-P
cesarean	I-P
delivery	I-P
surgery	I-P
produces	I-P
scar	O
cosmesis	O
at	O
5	O
weeks	O
that	O
is	O
no	O
worse	O
than	O
that	O
observed	O
with	O
conventional	B-I
closure	I-I
using	O
3-0	B-I
polydioxanone	I-I
suture	I-I
.	I-I


Use	O
of	O
ketorolac	B-I
is	O
associated	O
with	O
decreased	O
pneumonia	O
following	O
rib	B-P
fractures	I-P
.	I-P


The	O
rates	B-OUT
of	I-OUT
acute	I-OUT
kidney	I-OUT
injury	I-OUT
,	I-OUT
gastrointestinal	I-OUT
hemorrhage	I-OUT
,	I-OUT
and	I-OUT
fracture	I-OUT
nonunion	I-OUT
were	O
not	O
different	O
.	O


CONCLUSIONS	O
Early	O
administration	O
of	O
ketorolac	B-I
to	O
patients	B-P
with	I-P
rib	I-P
fractures	I-P
is	O
associated	O
with	O
a	O
decreased	O
likelihood	O
of	O
pneumonia	B-OUT
,	O
without	O
apparent	O
risks	O
.	O


Only	O
minor	B-OUT
side-effects	I-OUT
were	O
reported	O
.	O


Patients	O
were	O
randomized	O
to	O
receive	O
a	O
clear	B-I
liquid	I-I
diet	I-I
and	I-I
the	I-I
PEG	I-I
4L	I-I
regimen	I-I
(	I-P
106	I-P
patients	I-P
)	I-P
or	O
the	O
low	B-I
residue	I-I
test	I-I
meals	I-I
and	I-I
the	I-I
PEG	I-I
4L	I-I
regimen	I-I
(	I-I
TM-PEG	I-I
4L	O
,	O
108	O
patients	O
)	O
.	O


RESULTS	O
No	O
significant	O
differences	O
were	O
observed	O
between	O
the	O
treatment	O
groups	O
according	O
to	O
the	O
Ottawa	B-OUT
cleansing	I-OUT
scale	I-OUT
findings	O
(	O
PEG	O
4L	O
:	O
2.97	O
vs	O
TM-PEG	O
4L	O
:	O
2.46	O
,	O
P	O
=	O
0.063	O
)	O
.	O


Children	O
in	O
the	O
experimental	O
group	O
were	O
enrolled	O
in	O
day	O
care	O
and	O
their	O
parents	B-I
and	I-I
child	I-I
care	I-I
workers	I-I
received	I-I
a	I-I
12-week	I-I
intervention	I-I
consisting	I-I
of	I-I
lectures	I-I
and	I-I
on-site	I-I
consultations	I-I
to	I-I
day-care	I-I
centers	I-I
.	I-I


Comparing	O
antipsychotic	O
treatments	O
for	O
schizophrenia	B-P
:	I-P
a	O
health	O
state	O
approach	O
.	O


The	O
overall	O
impact	O
of	O
first	O
and	O
second	O
generation	O
antipsychotics	B-I
on	O
quality	B-OUT
of	I-OUT
life	I-OUT
and	I-OUT
symptoms	I-OUT
of	O
people	B-P
with	I-P
schizophrenia	I-OUT
remains	O
controversial	O
.	O


We	O
applied	O
K-means	O
clustering	O
to	O
the	O
data	O
to	O
create	O
discrete	O
groupings	O
of	O
patients	O
with	O
symptom	B-OUT
and	I-OUT
side	I-OUT
effect	I-OUT
characteristics	I-OUT
that	O
were	O
then	O
validated	O
using	O
quality	B-OUT
of	I-OUT
life	I-OUT
measures	I-OUT
.	I-OUT


This	O
study	O
evaluates	O
the	O
effects	O
of	O
two	O
Chinese	B-I
herbal	I-I
formulae	I-I
[	I-I
Cure-allergic-rhinitis	I-I
Syrup	I-I
(	I-I
CS	I-I
)	I-I
and	I-I
Yu-ping-feng	I-I
San	I-I
(	I-I
YS	I-I
)	I-I
]	I-I
in	O
treating	O
undergraduate	B-P
nursing	I-P
students	I-P
with	I-P
allergic	I-P
rhinitis	I-P
over	I-P
a	I-P
3-month	I-P
follow-up	I-P
,	O
when	O
compared	O
to	O
a	O
placebo	O
control	O
group	O
.	O


It	O
also	O
significantly	O
reduced	O
(	O
P	O
<	O
0.05	O
)	O
the	O
endoscopic	B-OUT
ultrasonography	I-OUT
score	I-OUT
on	O
the	O
gastric	O
wall	O
surface	O
(	O
score	O
4	O
,	O
14	O
%	O
)	O
in	O
comparison	O
with	O
that	O
observed	O
for	O
treatment	O
A	O
(	O
3	O
%	O
)	O
.	O


OBJECTIVE	O
The	O
objective	O
of	O
this	O
study	O
was	O
to	O
assess	O
the	O
performance	O
of	O
three	B-I
staging	I-I
systems	I-I
[	I-I
Okuda	I-I
,	I-I
Cancer	I-I
of	I-I
the	I-I
Liver	I-I
Italian	I-I
Program	I-I
(	I-I
CLIP	I-I
)	I-I
and	I-I
Barcelona	I-I
Clinic	I-I
Liver	I-I
Cancer	I-I
group	I-I
(	I-I
BCLC	I-I
)	I-I
]	I-I
,	O
for	O
predicting	O
survival	B-OUT
in	O
patients	B-P
with	I-P
hepatocellular	I-P
carcinoma	I-P
(	I-P
HCC	I-P
)	I-P
and	O
to	O
explore	O
how	O
to	O
improve	O
prognostic	O
classification	O
among	O
French	B-P
patients	I-P
with	I-P
HCC	I-P
whose	I-P
main	I-P
etiology	I-P
is	I-P
alcoholic	I-P
cirrhosis	I-P
.	I-P


To	O
explore	O
how	O
to	O
improve	O
classifications	O
,	O
univariate	O
and	O
multivariate	O
Cox	O
model	O
analyses	O
were	O
carried	O
out	O
.	O


RESULTS	O
The	O
pooled	O
database	O
included	B-P
538	I-P
patients	I-OUT
.	I-OUT


World	B-OUT
Health	I-OUT
Organization	I-OUT
performance	I-OUT
status	I-OUT
(	I-OUT
WHO	I-OUT
PS	I-OUT
)	I-OUT
for	I-I
CLIP	I-I
or	I-I
alpha-fetoprotein	I-I
for	O
BCLC	O
allowed	O
a	B-OUT
significant	I-OUT
improvement	I-OUT
of	I-OUT
prognostic	I-OUT
information	I-OUT
.	O


A	O
standard	O
general	O
anesthesia	O
procedure	O
including	O
sufentanil	O
was	O
used	O
.	O


In	O
conclusion	O
,	O
administering	O
ketamine	B-I
at	O
the	O
end	O
of	O
surgery	O
is	O
more	O
effective	O
in	O
reducing	O
morphine	B-OUT
consumption	I-OUT
than	O
it	O
is	O
when	O
given	O
before	O
surgery	O
.	O


A	O
randomized	O
double	O
blind	O
placebo	B-I
controlled	O
clinical	O
trial	O
of	O
N-Acetylcysteine	B-I
added	I-I
to	I-I
risperidone	I-I
for	O
treating	O
autistic	B-P
disorders	I-P
.	I-P


RESULTS	O
The	B-OUT
mean	I-OUT
score	I-OUT
of	I-OUT
irritability	I-OUT
in	O
the	B-I
NAC+risperidone	I-I
and	I-I
placebo+risperidone	I-I
groups	O
at	O
baseline	O
was	O
13.2	O
(	O
5.3	O
)	O
and	O
16.7	O
(	O
7.8	O
)	O
,	O
respectively	O
.	O


There	O
was	O
no	B-OUT
fatal	I-OUT
adverse	I-OUT
effect	I-OUT
.	O


CONCLUSIONS	B-I
Risperidone	I-I
plus	I-I
NAC	I-I
more	O
than	O
risperidone	O
plus	O
placebo	O
decreased	B-OUT
irritability	I-OUT
in	I-P
children	I-P
and	I-P
adolescents	I-P
with	I-P
ASD	I-P
.	O


The	O
registration	O
number	O
of	O
this	O
trial	O
was	O
IRCT201106103930N6	O
.	O


Four	O
of	O
the	O
forty-eight	B-P
women	I-P
treated	I-P
with	I-P
intraperitoneal	I-I
phosphorus	I-I
required	O
surgical	B-OUT
reexploration	I-OUT
for	I-OUT
intestinal	I-OUT
obstruction	I-OUT
or	I-OUT
bowel	I-OUT
injury	I-OUT
.	I-OUT


Twenty-one	O
women	O
died	B-OUT
of	O
their	O
disease	O
.	O


The	O
5-year	B-OUT
actuarial	I-OUT
survival	I-OUT
was	O
78	O
%	O
.	O


BACKGROUND	O
We	O
previously	O
reported	O
urinary	O
podocytes	O
to	O
be	O
a	O
marker	O
of	O
glomerular	O
injury	O
.	O


The	O
aim	O
of	O
the	O
present	O
study	O
was	O
to	O
determine	O
whether	O
cerivastatin	B-I
,	O
a	O
newly	O
developed	O
,	O
potent	O
synthetic	O
statin	O
,	O
affects	O
proteinuria	O
and	O
urinary	O
podocyte	O
excretion	O
in	O
patients	B-P
with	I-P
chronic	I-P
glomerulonephritis	I-P
(	I-P
CGN	I-P
)	I-P
.	O


Subjects	B-P
comprised	I-P
24	I-P
men	I-P
and	I-P
16	I-P
women	I-P
,	I-P
with	I-P
a	I-P
mean	I-P
age	I-P
of	I-P
40.8+/-14.4	I-P
years	I-P
;	I-P
27	I-P
had	I-P
IgA	I-P
nephropathy	I-P
and	I-P
13	I-P
had	I-P
non-IgA	I-P
proliferative	I-P
glomerulonephritis	I-P
.	I-P


The	O
differences	O
between	O
the	O
cerivastatin	O
group	O
and	O
the	O
placebo	O
group	O
were	O
significant	O
(	O
cholesterol	O
,	O
P	O
<	O
0.001	O
;	O
LDL-cholesterol	B-OUT
,	O
P	O
<	O
0.001	O
;	O
triglycerides	B-OUT
,	O
P	O
<	O
0.05	O
;	O
HDL-cholesterol	B-OUT
,	O
P	O
<	O
0.001	O
;	O
urinary	B-OUT
protein	I-OUT
,	O
P	O
<	O
0.01	O
;	O
and	O
urinary	B-OUT
podocytes	I-OUT
,	O
P	O
<	O
0.01	O
)	O
.	O


BACKGROUND	O
Amlodipine	B-I
besylate	I-I
has	O
been	O
used	O
in	O
Korea	O
for	O
the	O
treatment	O
of	O
hypertension	O
for	O
>	O
17	O
years	O
,	O
with	O
well-established	O
efficacy	O
and	O
tolerability	O
.	O


Amlodipine	B-I
camsylate	I-I
is	O
a	O
newer	O
formulation	O
developed	O
for	O
generic	O
use	O
.	O


Patients	O
were	O
randomly	B-I
assigned	I-I
to	I-I
receive	I-I
oral	I-I
treatment	I-I
with	I-I
amlodipine	I-I
camsylate	I-I
or	I-I
amlodipine	I-I
besylate	I-I
.	I-I


All	O
patients	B-P
received	I-P
peritoneal	I-P
or	I-P
hemodialysis	I-P
treatment	I-P
concurrently	I-P
with	O
the	O
study	O
drug	O
.	O


Patients	O
performed	O
under	O
general	O
anesthesia	O
(	O
n	O
=	O
35	O
)	O
were	O
separated	O
as	O
a	O
nasogastric	O
tube	O
for	O
visualization	O
of	O
the	O
esophagus	O
was	O
used	O
.	O


SUBJECTS	O
AND	O
INTERVENTIONS	O
Seventy-three	B-P
patients	I-P
with	I-P
steroid-sensitive	I-P
idiopathic	I-P
NS	I-P
admitted	I-P
to	I-P
the	I-P
study	I-P
were	O
randomly	O
assigned	O
to	O
cyclophosphamide	B-I
(	O
2.5	O
mg/kg/day	O
)	O
for	O
8	O
weeks	O
or	O
CsA	B-I
(	O
5	O
mg/kg/day	O
in	O
adults	O
,	O
6	O
mg/kg/day	O
in	O
children	O
)	O
for	O
9	O
months	O
,	O
tapered	O
off	O
by	O
25	O
%	O
every	O
month	O
until	O
complete	O
discontinuation	O
at	O
month	O
12	O
.	O


We	O
designed	O
a	O
randomized	O
phase	O
II	O
study	O
to	O
evaluate	O
and	O
compare	O
the	O
activity	O
and	O
safety	O
profile	O
of	O
the	O
combination	B-I
versus	I-I
single-agent	I-I
TMZ	I-I
in	O
patients	B-P
with	I-P
advanced	I-P
melanoma	I-P
.	I-P


RESULTS	O
Tumor	B-OUT
responses	I-OUT
(	O
complete	O
and	O
partial	O
responses	O
)	O
were	O
seen	O
in	O
16	O
patients	O
(	O
26	O
%	O
)	O
in	O
arm	O
A	O
and	O
19	O
patients	O
(	O
29	O
%	O
)	O
in	O
arm	O
B	O
.	O


The	O
median	B-OUT
time	I-OUT
to	I-OUT
progression	I-OUT
(	I-OUT
TTP	I-OUT
)	I-OUT
was	O
3.8	O
months	O
in	O
arm	O
A	O
and	O
5.8	O
months	O
in	O
arm	O
B	O
.	O


The	O
test	O
toothpastes	O
were	O
:	O
1	O
)	O
a	B-I
low	I-I
abrasion	I-I
paste	I-I
containing	I-I
0.8	I-I
%	I-I
sodium	I-I
monofluorophosphate	I-I
(	I-I
MFP	I-I
)	I-I
,	O
and	O
2	O
)	O
a	B-I
paste	I-I
containing	I-I
3	I-I
%	I-I
sodium	I-I
trimetaphosphate	I-I
(	I-I
TMP	I-I
)	I-I
.	I-I


All	O
three	B-P
groups	I-P
of	I-P
children	I-P
showed	O
some	O
improvement	O
in	O
oral	B-OUT
hygiene	I-OUT
and	I-OUT
in	I-OUT
gingival	I-OUT
health	I-OUT
,	O
but	O
there	O
were	O
no	O
significant	O
differences	O
between	O
the	O
groups	O
.	O


Although	O
polycythemia	B-P
vera	I-P
and	I-P
the	I-P
other	I-P
myeloproliferative	I-P
diseases	I-P
are	O
relatively	O
uncommon	O
,	O
the	O
PVSG	O
was	O
able	O
to	B-P
accumulate	I-P
well	I-P
over	I-P
1,000	I-P
patients	I-P
with	I-P
these	I-P
various	I-P
disorders	I-P
and	O
to	O
study	O
them	O
according	O
to	O
a	O
total	O
of	O
15	O
different	O
protocols	O
.	O


INTERVENTION	O
(	O
S	O
)	O
Metaphase	O
II	O
oocytes	O
were	O
divided	O
into	O
groups	O
A	O
and	O
B	O
,	O
vitrified	B-I
with	I-I
and	I-I
without	I-I
cumulus	I-I
cells	I-I
,	O
respectively	O
.	O


Clinical	B-OUT
scores	I-OUT
were	O
significantly	O
improved	O
(	O
P	O
less	O
than	O
.01	O
)	O
at	O
ten	O
and	O
30	O
minutes	O
following	O
the	O
treatment	O
with	O
racemic	B-I
epinephrine	I-I
but	O
not	O
at	O
120	O
minutes	O
.	O


Polycystic	O
ovary	O
syndrome	O
and	O
cardiovascular	O
risk	O
in	O
young	B-P
patients	I-P
treated	I-P
with	I-P
drospirenone-ethinylestradiol	I-I
or	I-I
contraceptive	I-I
vaginal	I-I
ring	I-I
.	I-I


PATIENT	O
(	O
S	O
)	O
Thirty-seven	B-P
women	I-P
with	I-P
polycystic	I-P
ovary	I-P
syndrome	I-P
(	I-P
PCOS	I-P
)	I-P
were	O
randomly	O
submitted	O
to	O
drospirenone+ethinylestradiol	B-I
(	O
group	O
I	O
;	O
n=19	O
)	O
or	B-I
combined	I-I
contraceptive	I-I
vaginal	I-I
ring	I-I
(	O
group	O
II	O
;	O
n=18	O
)	O
therapy	B-I
.	I-I


INTERVENTION	O
(	O
S	O
)	O
The	O
effect	O
of	O
treatments	O
was	O
assessed	O
after	O
6	B-I
months	I-I
of	I-I
therapy	I-I
.	I-I


MAIN	O
OUTCOME	O
MEASURE	O
(	O
S	O
)	O
Utero-ovarian	B-OUT
ultrasound	I-OUT
analysis	I-OUT
and	I-OUT
color	I-OUT
Doppler	I-OUT
evaluation	I-OUT
of	I-OUT
uterine	I-OUT
and	I-OUT
stromal	I-OUT
ovarian	I-OUT
arteries	I-OUT
.	I-OUT


In	O
addition	O
,	O
analysis	B-OUT
of	I-OUT
brachial	I-OUT
artery	I-OUT
flow-mediated	I-OUT
vasodilatation	I-OUT
and	I-OUT
24-hour	I-OUT
ambulatory	I-OUT
blood	I-OUT
pressure	I-OUT
monitoring	I-OUT
were	O
performed	O
.	O


RESULT	O
(	O
S	O
)	O
Both	O
treatments	O
improved	O
hirsutism	B-OUT
,	I-OUT
hyperandrogenemia	I-OUT
,	I-OUT
and	I-OUT
ultrasound	I-OUT
and	I-OUT
color	I-OUT
Doppler	I-OUT
ovarian	I-OUT
parameters	I-OUT
.	I-OUT


In	O
these	O
patients	O
with	O
normal	O
or	O
near-normal	O
resting	O
left	O
ventricular	O
function	O
,	O
neither	O
drug	O
induced	O
depression	O
of	O
left	O
ventricular	O
function	O
.	O


In	O
26	B-P
patients	I-P
with	I-P
chronic	I-P
angina	I-P
pectoris	I-P
receiving	O
acebutolol	B-I
under	O
double-blind	O
,	O
placebo-controlled	B-I
conditions	O
,	O
gated	O
(	O
equilibrium	O
)	O
myocardial	O
blood	O
pool	O
imaging	O
using	O
red	O
blood	O
cells	O
labeled	O
with	O
technetium	O
99m	O
showed	O
acebutolol	B-I
to	O
have	O
no	O
clinically	O
significant	O
negative	O
effect	O
on	O
left	O
ventricular	O
performance	O
at	O
rest	O
or	O
during	O
supine	O
bicycle	O
exercise	O
.	O


RESULTS	O
The	O
total	B-OUT
effective	I-OUT
rate	I-OUT
was	O
86.7	O
%	O
in	O
the	O
EA	B-I
plus	I-I
behavior	I-I
therapy	I-I
group	O
which	O
was	O
better	O
than	O
56.7	O
%	O
of	O
the	O
behavior	O
therapy	O
group	O
,	O
and	O
had	O
significant	O
enhancement	O
in	O
sensation	B-OUT
,	I-OUT
association	I-OUT
,	I-OUT
body	I-OUT
,	I-OUT
and	I-OUT
ability	I-OUT
of	I-OUT
self-care	I-OUT
(	O
P	O
<	O
0.05	O
)	O
and	O
was	O
better	O
than	O
the	O
behavior	O
therapy	O
group	O
in	O
sensation	B-OUT
,	I-OUT
body	I-OUT
and	I-OUT
self-care	I-OUT
factors	I-OUT
,	O
with	O
no	O
significantly	O
improvement	O
in	O
the	O
scores	O
of	O
PPVT	B-OUT
in	O
the	O
two	O
groups	O
(	O
P	O
>	O
0.05	O
)	O
.	O


Early	O
intervention	O
for	O
autism	O
with	O
a	O
parent-delivered	B-I
Qigong	I-I
massage	I-I
program	I-I
:	I-I
a	O
randomized	O
controlled	O
trial	O
.	O


Final	O
analysis	O
of	O
the	O
UKLG	O
LY02	O
trial	O
comparing	O
6-8	O
cycles	O
of	O
CHOP	B-I
with	O
3	O
cycles	O
of	B-I
CHOP	I-I
followed	I-I
by	I-I
a	I-I
BEAM	I-I
autograft	I-I
in	O
patients	B-P
<	I-P
65	I-P
years	I-P
with	I-P
poor	I-P
prognosis	I-P
histologically	I-P
aggressive	I-P
NHL	I-P
.	I-P


This	O
trial	O
involved	O
457	B-P
patients	I-P
and	O
sought	O
to	O
assess	O
the	O
value	O
of	O
early	O
intensification	O
with	O
autologous	O
transplantation	O
in	O
patients	B-P
with	I-P
poor	I-P
prognosis	I-P
histologically	I-P
aggressive	I-P
non-Hodgkin	I-P
lymphoma	I-P
(	I-P
NHL	I-P
)	I-P
showing	I-P
a	I-P
response	I-P
to	I-P
initial	I-P
CHOP	I-I
(	I-I
cyclophosphamide	I-I
,	I-I
doxorubicin	I-I
,	I-I
vincristine	I-I
,	I-I
prednisolone	I-I
)	I-I
chemotherapy	I-I
.	I-I


Randomization	O
was	O
made	O
at	O
the	O
time	O
of	O
diagnosis	O
with	O
223	O
assigned	O
to	O
continuing	O
CHOP	B-I
and	O
234	O
to	O
3	O
cycles	O
of	O
CHOP	B-I
followed	I-I
by	I-I
a	I-I
BEAM	I-I
(	I-I
carmustine	I-I
,	I-I
etoposide	I-I
,	I-I
cytarabine	I-I
,	I-I
melphalan	I-I
)	I-I
autograft	I-I
.	I-I


Analysis	O
was	O
on	O
an	O
intention	O
to	O
treat	O
basis	O
.	O


Of	O
the	O
patients	O
who	O
attained	O
CR	O
and	O
subsequently	O
relapsed	B-OUT
,	O
there	O
were	O
no	O
long-term	B-OUT
survivors	I-OUT
in	O
the	O
autograft	O
recipients	O
compared	O
to	O
46	O
%	O
of	O
the	O
continuing	O
CHOP	B-I
recipients	O
(	O
P	O
=	O
0.0008	O
)	O
.	O


We	O
monitored	O
self-reported	B-OUT
abstinence	I-OUT
and	I-OUT
end-expired	I-OUT
air	I-OUT
carbon	I-OUT
monoxide	I-OUT
(	I-OUT
CO	I-OUT
)	I-OUT
.	I-OUT


These	O
results	O
document	O
ways	O
in	O
which	O
smoking	O
cessation	O
strategies	O
can	O
be	O
personalized	O
based	O
on	O
levels	B-OUT
of	I-OUT
nicotine	I-OUT
dependence	I-OUT
,	I-OUT
genotype	I-OUT
scores	I-OUT
and	I-OUT
CO	I-OUT
monitoring	I-OUT
.	I-OUT


These	O
assessments	O
,	O
taken	O
together	O
,	O
can	O
help	O
match	O
most	O
smokers	B-P
with	O
optimal	O
NRT	B-I
doses	O
and	O
help	O
rapidly	O
identify	O
some	O
who	O
may	O
be	O
better	O
treated	O
using	O
other	O
methods	O
.	O


The	O
images	O
were	O
further	O
converted	O
into	O
a	O
standard	O
uniform	O
brain	O
format	O
in	O
which	O
the	O
mean	O
data	O
of	O
all	O
11	O
subjects	O
were	O
obtained	O
.	O


Especially	O
important	O
is	O
the	O
fact	O
that	O
the	O
thalamus	O
is	O
activated	O
by	O
nicotine	B-I
.	I-I


OBJECTIVE	O
The	O
purpose	O
of	O
this	O
split-face	O
randomized	O
prospective	O
open-label	O
trial	O
was	O
to	O
determine	O
the	O
effectiveness	O
of	O
sequential	B-I
erbium	I-I
:	I-I
yttrium-aluminum-garnet	I-I
(	I-I
Er	I-I
:	I-I
YAG	I-I
)	I-I
laser	I-I
versus	I-I
intense	I-I
pulsed	I-I
light	I-I
(	I-I
IPL	I-I
)	I-I
for	O
the	O
treatment	O
of	O
mild	B-P
to	I-P
moderate	I-P
facial	I-P
photodamage	I-P
.	I-P


RESULTS	O
Ten	B-P
female	I-P
subjects	I-P
with	I-P
mild	I-P
to	I-P
moderate	I-P
facial	I-P
photodamage	I-P
were	O
treated	O
with	O
one	O
pass	O
of	O
either	O
IPL	O
or	O
Er	O
:	O
YAG	O
in	O
a	O
split-face	O
fashion	O
.	O


Randomized	O
controlled	O
trial	O
of	O
parental	B-I
responsiveness	I-I
intervention	I-I
for	O
toddlers	B-P
at	I-P
high	I-P
risk	I-P
for	I-P
autism	I-P
.	I-P


BACKGROUND	O
Analgesics	O
are	O
an	O
essential	O
component	O
of	O
the	O
treatment	O
of	O
cancer-associated	O
pain	O
.	O


METHODS	O
This	O
23-day	O
,	O
prospective	O
,	O
double-blind	O
,	O
randomized	O
,	O
parallel-group	O
study	O
was	O
conducted	O
at	O
3	O
Colombian	O
centers	O
:	O
University	O
Libre	O
,	O
Social	O
Security	O
Institute	O
,	O
and	O
General	O
Hospital	O
of	O
Medellín	O
,	O
Cali	O
,	O
Colombia	O
.	B-P


RESULTS	O
Of	O
the	B-P
121	I-P
patients	I-P
who	I-P
participated	I-P
,	O
59	O
received	B-I
C/A	I-I
and	O
62	O
received	B-I
H/A	I-I
.	I-P


At	O
baseline	O
,	O
88	O
%	O
of	O
the	O
patients	O
described	O
their	B-OUT
pain	I-OUT
intensity	I-OUT
as	O
moderate	O
;	O
12	O
%	O
,	O
severe	O
.	O


In	O
patients	O
with	B-I
H/A	I-I
,	O
pain	B-OUT
was	O
reported	O
as	O
absent	O
or	O
mild	O
in	O
56	O
%	O
of	O
patients	O
at	O
the	O
starting	O
dosage	O
of	O
25/2500	O
mg/d	O
;	O
an	O
additional	O
15	O
%	O
of	O
the	O
patients	O
responded	O
to	O
the	O
double	O
dosage	O
;	O
the	O
remaining	O
29	O
%	O
of	O
patients	O
did	O
not	O
experience	O
any	B-OUT
pain	I-OUT
relief	I-OUT
.	O


PATIENTS	O
AND	O
METHODS	O
Patients	B-P
with	I-P
advanced	I-P
cancer	I-P
with	I-P
a	I-P
fatigue	I-P
score	I-P
of	I-P
≥	I-P
4	I-P
out	I-P
of	I-P
10	I-P
on	I-P
the	I-P
Edmonton	I-P
Symptom	I-P
Assessment	I-P
Scale	I-P
(	I-P
ESAS	I-P
)	I-P
were	O
randomly	O
assigned	O
to	O
one	O
of	O
the	O
following	O
four	O
groups	O
:	O
MP+NTI	O
,	O
PL+NTI	O
,	O
MP	O
+	B-I
control	I-I
telephone	I-I
intervention	I-I
(	O
CTI	O
)	O
,	O
and	O
PL+CTI	B-I
.	I-I


All	O
children	O
will	O
complete	O
assessments	O
at	O
baseline	O
,	O
post-intervention	O
and	O
3-months	O
follow-up	O
.	O


If	O
Mindlight	B-I
turns	O
out	O
to	O
be	O
effective	O
,	O
it	O
could	O
be	O
an	O
important	O
contribution	O
to	O
the	O
already	O
existing	O
interventions	O
for	O
anxiety	O
in	O
children	O
with	O
an	O
ASD	O
.	O


Mindlight	B-I
could	O
then	O
be	O
implemented	O
as	O
an	O
evidence-based	O
treatment	O
for	O
anxiety	B-OUT
symptoms	I-OUT
in	O
children	B-P
with	I-P
an	I-P
ASD	I-P
in	O
mental	O
health	O
institutes	O
and	O
special	O
education	O
schools	O
.	O


At	O
this	O
exercise	O
training	O
that	O
lasted	O
for	O
20	O
min	O
the	O
acute	B-OUT
response	I-OUT
of	I-OUT
heart	I-OUT
rate	I-OUT
,	I-OUT
blood	I-OUT
pressure	I-OUT
,	I-OUT
rate-pressure	I-OUT
product	I-OUT
,	I-OUT
glucose	I-OUT
,	I-OUT
lactate	I-OUT
and	I-OUT
catecholamines	I-OUT
was	O
measured	O
.	O


No	O
significant	O
changes	B-OUT
in	O
baseline	O
parameters	O
occurred	O
in	O
the	O
control	O
group	O
.	O


Atypical	B-I
social	I-I
modulation	I-I
of	O
imitation	O
in	O
autism	B-P
spectrum	I-P
conditions	I-P
.	I-P


Naltrexone	B-I
,	I-I
1.0	I-I
mg/kg	I-I
,	I-I
was	I-I
given	I-I
daily	I-I
in	I-I
a	I-I
randomized	I-I
,	I-I
double-blind	I-I
,	I-I
placebo-controlled	I-I
crossover	I-I
design	I-I
.	I-I


CONCLUSIONS	O
Naltrexone	B-I
offers	O
promise	O
as	O
an	O
agent	O
for	O
modest	O
improvement	O
of	O
behavior	B-OUT
and	O
social	B-OUT
communication	I-OUT
in	O
young	B-P
children	I-P
with	I-P
autism	I-P
.	I-P


Patients	O
also	O
received	O
oral	B-I
prednisone	I-I
5	I-I
mg	I-I
twice	I-I
daily	I-I
.	I-I


The	O
primary	O
end	O
point	O
was	O
overall	B-OUT
survival	I-OUT
(	O
OS	O
)	O
;	O
secondary	O
end	O
points	O
included	O
progression-free	B-OUT
survival	I-OUT
(	I-OUT
PFS	I-OUT
)	I-OUT
.	O


PFS	B-OUT
was	O
significantly	O
improved	O
in	O
the	O
sunitinib	O
arm	O
(	O
median	O
5.6	O
v	O
4.1	O
months	O
;	O
HR	O
,	O
0.725	O
;	O
95	O
%	O
CI	O
,	O
0.591	O
to	O
0.890	O
;	O
stratified	O
log-rank	O
test	O
,	O
P	O
<	O
.001	O
)	O
.	O


Toxicity	B-OUT
and	I-OUT
rates	I-OUT
of	I-OUT
discontinuations	I-OUT
because	I-OUT
of	I-OUT
adverse	I-OUT
events	I-OUT
(	O
AEs	O
;	O
27	O
%	O
v	O
7	O
%	O
)	O
were	O
greater	O
with	O
sunitinib	O
than	O
placebo	O
.	O


CONCLUSION	O
The	O
addition	O
of	O
sunitinib	O
to	O
prednisone	O
did	O
not	O
improve	O
OS	B-OUT
compared	O
with	O
placebo	O
in	O
docetaxel-refractory	O
mCRPC	O
.	O


After	O
17	O
d	O
of	O
dosing	O
,	O
>	O
90	O
%	O
of	O
steady	O
state	O
concentrations	B-OUT
were	O
reached	O
,	O
which	O
was	O
compatible	O
with	O
an	O
effective	O
half-life	O
for	O
accumulation	O
of	O
5	O
d.	O
The	O
terminal	B-OUT
elimination	I-OUT
half-life	I-OUT
was	O
12	O
+/-	O
7	O
d	O
(	O
n	O
=	O
20	O
)	O
.	O


Zeaxanthin	B-I
was	O
well	O
tolerated	O
.	O


CONCLUSION	O
Long-term	O
oral	O
intake	O
of	O
1	O
and	O
10	O
mg	O
zeaxanthin	B-I
as	O
beadlets	O
increases	O
plasma	B-OUT
zeaxanthin	I-OUT
concentrations	I-OUT
approximately	O
4-	O
and	O
20-fold	O
,	O
respectively	O
.	O


METHODS	O
Age-matched	B-P
boys	I-P
with	I-P
ADHD	I-P
(	I-P
18	I-P
)	I-P
,	I-P
ASD	I-P
(	I-P
19	I-P
)	I-P
and	I-P
healthy	I-P
controls	I-P
(	I-P
25	I-P
)	I-P
were	O
compared	B-I
with	I-I
fMRI	I-I
during	I-I
a	I-I
stop	I-I
task	I-I
measuring	I-I
motor	I-OUT
inhibition	I-OUT
.	I-OUT


7	O
%	O
)	O
recipients	O
for	O
subjects	O
receiving	O
5	O
µg	O
or	O
25	O
µg	O
of	O
VLP	O
immunotherapy/dose	O
(	O
71	O
%	O
±	O
s.e.m	O
.	O


Of	B-P
52	I-P
protocol	I-P
compliant	I-P
placebo	I-P
immunotherapy	I-P
recipients	I-P
in	I-P
Wenzhou	O
,	O
37	O
were	O
disease	O
free	O
at	O
two	O
months	O
,	O
and	O
a	O
further	O
8	O
had	B-OUT
>	I-OUT
50	I-OUT
%	I-OUT
disease	I-OUT
reduction	I-OUT
.	I-OUT


Extracorporeal	B-I
shock	I-I
wave	I-I
therapy	I-I
(	I-I
ESWT	I-I
)	I-I
in	O
patients	B-P
with	I-P
chronic	I-P
proximal	I-P
plantar	I-P
fasciitis	I-P
:	I-P
a	O
2-year	O
follow-up	O
.	O


MBCT	B-I
appears	O
to	O
be	O
a	O
valid	O
form	O
of	O
intervention	O
for	O
children	B-P
with	I-P
autism	I-P
.	I-P


To	O
test	O
the	O
effectiveness	O
of	O
a	O
special	B-I
health	I-I
care	I-I
program	I-I
for	O
adolescent	B-P
mothers	I-P
(	I-P
17	I-P
years	I-P
old	I-P
or	I-P
younger	I-P
)	I-P
and	I-P
their	I-P
infants	I-P
,	I-P
243	I-P
mother-infant	I-P
pairs	I-P
were	I-P
randomly	I-P
assigned	I-P
to	O
one	O
of	O
two	B-P
groups	I-P
.	I-P


In	O
spite	O
of	O
the	O
high	O
dropout	O
rate	O
,	O
91	O
%	O
of	O
the	O
mothers	O
were	O
located	O
for	O
the	O
18	O
month	O
follow-up	O
interview	O
.	O


Mothers	O
in	O
the	O
special	B-I
care	I-I
program	I-I
who	O
continued	O
to	O
attend	O
clinic	O
used	B-OUT
the	I-OUT
emergency	I-OUT
room	I-OUT
less	I-OUT
than	O
the	O
mothers	O
who	O
continued	O
to	O
attend	O
in	O
the	O
control	O
group	O
.	O


These	O
results	O
suggest	O
that	O
a	O
comprehensive	B-I
health	I-I
care	I-I
program	I-I
is	O
one	O
way	O
to	O
bring	O
about	O
better	O
outcomes	O
for	O
both	O
adolescent	O
mothers	O
and	O
their	O
infants	O
.	O


Patients	O
demonstrated	O
a	O
modest	O
improvement	O
in	O
PFS	B-OUT
but	O
no	O
improvement	O
in	O
OS	B-OUT
compared	O
with	O
children	O
with	O
low-grade	O
gliomas	O
who	O
were	O
treated	O
with	O
contemporary	O
chemotherapy-alone	O
approaches	O
.	O


Blood	O
was	O
drawn	O
on	O
day	O
1	O
of	O
each	O
cycle	O
for	O
CA125	O
and	O
,	O
in	O
a	O
substudy	O
of	O
randomized	O
patients	O
,	O
for	O
markers	O
of	O
coagulation	O
activation	O
and	O
angiogenesis	O
.	O


Two	O
patients	O
experienced	B-OUT
VTE	I-OUT
several	O
days	O
after	O
discontinuing	O
study	O
drug	O
.	O


DESIGN	O
Single-blind	O
,	O
randomized	O
,	O
controlled	O
trial	O
with	O
a	O
3-month	O
follow-up	O
.	O


SETTING	O
Outpatient	B-P
physiotherapy	I-P
departments	I-P
in	I-P
hospital	I-P
and	I-P
university	I-P
settings	I-P
.	I-P


Variability	O
in	O
isochronous	B-I
tapping	I-I
:	I-I
higher	O
order	O
dependencies	O
as	O
a	O
function	O
of	O
intertap	O
interval	O
.	O


This	O
fact	O
has	O
largely	O
been	O
ignored	O
by	O
the	O
timing	O
literature	O
,	O
one	O
reason	O
probably	O
being	O
that	O
influential	O
timing	O
models	O
assume	O
random	O
variability	O
.	O


These	O
breaks	O
correspond	O
to	O
qualitative	O
changes	O
in	O
performance	O
for	O
other	O
temporal	O
tasks	O
,	O
which	O
suggests	O
common	O
timing	O
processes	O
across	O
modalities	O
and	O
tasks	O
.	O


In	O
a	O
randomized	O
,	O
placebo	O
controlled	O
trial	O
,	O
eleven	B-P
healthy	I-P
volunteers	I-P
were	O
studied	O
during	O
4	O
separate	O
study	O
periods	O
of	O
4	O
days	O
each	O
.	O


Primary	B-OUT
hemostasis	I-OUT
was	O
assessed	O
with	O
a	O
platelet	O
function	O
analyser	O
(	O
PFA-100	O
)	O
,	O
which	O
measures	O
the	B-OUT
closure	I-OUT
time	I-OUT
(	I-OUT
CT	I-OUT
)	I-OUT
of	I-OUT
a	I-OUT
collagen-	I-OUT
and	I-OUT
epinephrine-coated	I-OUT
pore	I-OUT
by	I-OUT
aggregating	I-OUT
platelets	I-OUT
in	I-OUT
flowing	I-OUT
blood	I-OUT
.	I-OUT


)	O
plus	O
tobramycin	B-I
3	O
mg/kg	O
per	O
day	O
(	O
1.5	O
mg/kg	O
b.i.d.	O
)	O
.	O


Initial	O
antibacterial	B-I
therapy	I-I
was	O
successful	B-OUT
(	I-OUT
apyrexia	I-OUT
at	O
72	O
h	O
,	O
without	O
antibiotic	O
change	O
)	O
more	O
frequently	O
(	O
P	O
=	O
0.008	O
)	O
with	O
the	O
regimen	O
containing	O
piperacillin/tazobactam	B-I
(	O
54.4	O
%	O
)	O
than	O
with	O
the	O
one	O
including	O
ceftazidime	B-I
(	O
37.6	O
%	O
)	O
.	O


METHODS/DESIGN	O
This	O
trial	O
is	O
a	O
two	O
arm	O
,	O
single-blind	O
,	O
randomized	O
controlled	O
feasibility	O
trial	O
within	O
in-patient	O
stroke	O
rehabilitation	O
.	O


For	O
quantitative	O
analysis	O
of	O
this	O
prostaglandin	O
metabolite	O
and	O
the	O
stable-isotope	O
dilution	O
techniqe	O
of	O
selected	B-I
ion	I-I
monitoring	I-I
(	O
SIM	O
)	O
is	O
employed	O
using	O
gas-liquid	O
chromatography-mass	O
spectrometry	O
.	O


The	O
preparation	O
of	O
the	O
bis	B-I
(	I-I
D3-methyloxime	I-I
)	I-I
,	I-I
bis-methyl	I-I
ester	I-I
of	I-I
PGE-M	I-I
containing	O
a	O
tritium	O
tracer	O
in	O
position	O
2	O
which	O
was	O
used	O
as	O
internal	O
standard	O
for	O
the	O
SIM	O
method	O
is	O
described	O
.	O


No	O
significant	O
difference	O
in	O
excretion	O
of	O
PGE-M	O
between	O
the	O
sexes	B-P
was	I-P
observed	I-P
in	I-P
the	I-P
pre-pubertal	I-P
age-grou	I-P
(	I-P
male	I-P
:	I-P
2.9	I-P
+/-	I-P
0.8	I-P
mug/24	I-P
hours	I-P
,	I-P
n=5	I-P
;	I-P
female	I-P
:	I-P
3.1	I-P
+/-	I-P
0.9	I-P
mug/24	I-P
hours	I-P
,	I-P
n=5	I-P
)	I-P
or	I-P
in	I-P
the	I-P
age-group	I-P
of	I-P
45-80	I-P
years	I-P
(	I-P
male	I-P
:	I-P
9.3	I-P
+/-	I-P
1.1	I-P
mug/24	I-P
hours	I-P
,	I-P
n=21	I-P
;	I-P
female	I-P
:	I-P
7.3	I-P
+/-	I-P
0.9	I-P
mug/24	I-P
hours	I-P
,	I-P
n=12	I-P
)	I-P
.	I-P


Satraplatin	B-I
is	O
a	O
novel	O
oral	O
platinum	B-I
(	O
IV	O
)	O
complex	O
that	O
shows	O
activity	O
against	O
hormone-refractory	B-P
prostate	I-P
cancer	I-P
(	I-P
HRPC	I-P
)	I-P
in	O
cisplatin-resistant	B-I
human	O
tumor	O
lines	O
in	O
phase	O
I	O
and	O
phase	O
II	O
trials	O
.	O


Eligibility	O
criteria	O
included	O
pathological	O
proof	O
of	O
prostate	B-P
cancer	I-P
,	O
documented	O
progression	O
despite	O
prior	O
hormonal	O
manipulation	O
,	O
WHO	O
PS	O
0-2	O
,	O
and	O
no	O
daily	O
intake	O
of	O
narcotic	B-I
analgesics	I-I
.	I-I


Compliance	O
was	O
excellent	O
.	O


Progression-free	B-OUT
survival	I-OUT
was	O
5.2	O
months	O
(	O
95	O
%	O
CI	O
:	O
2.8-13.7	O
)	O
on	O
the	O
satraplatin	B-I
plus	O
prednisone	B-I
arm	O
as	O
compared	O
to	O
2.5	O
months	O
(	O
95	O
%	O
CI	O
:	O
2.1-	O
4.7	O
)	O
on	O
the	O
prednisone	B-I
alone	O
arm	O
(	O
HR	O
=	O
0.50	O
,	O
95	O
%	O
CI	O
:	O
0.28-0.92	O
)	O
.	O


A	O
randomised	O
,	O
controlled	O
study	O
of	O
dietary	B-I
intervention	I-I
in	O
autistic	B-P
syndromes	I-P
.	I-P


In	O
these	O
syndromes	O
urinary	O
peptide	O
abnormalities	O
,	O
derived	O
from	O
gluten	O
,	O
gliadin	O
,	O
and	O
casein	O
,	O
are	O
reported	O
.	O


Toxicity	B-OUT
was	O
mainly	O
limited	O
to	O
WHO	O
grades	O
1	O
or	O
2	O
.	O


Assays	O
using	O
blasts	O
from	O
a	O
subset	O
of	B-P
40	I-P
patients	I-P
treated	O
with	O
T	O
plus	O
E	O
on	O
this	O
study	O
showed	O
that	B-OUT
AMLs	I-OUT
with	I-OUT
a	I-OUT
RASGRP1/APTX	I-OUT
ratio	I-OUT
of	O
more	O
than	O
5.2	O
had	O
a	O
78	O
%	O
CR	O
rate	O
and	O
negative	O
predictive	O
value	O
87	O
%	O
.	O


However	O
,	O
identification	O
of	O
patients	B-P
at	I-P
risk	I-P
for	I-P
CI-AKI	I-P
is	O
challenging	O
.	O


Each	O
test	O
condition	O
included	O
five	O
matched	O
pairs	O
of	O
sheep	O
tibiae	O
.	O


In	O
doing	O
this	O
,	O
one-third	B-I
of	I-I
the	I-I
total	I-I
length	I-I
of	I-I
the	I-I
bone	I-I
was	I-I
removed	I-I
in	O
each	O
of	O
the	O
following	O
specimens	O
to	O
include	O
(	O
1a	O
)	O
30	O
percent	O
of	O
the	O
cross-sectional	O
area	O
of	O
the	O
total	O
bone	O
,	O
(	O
1b	O
)	O
37	O
percent	O
of	O
the	O
cross-sectional	O
area	O
of	O
the	O
total	O
bone	O
,	O
and	O
(	O
1c	O
)	O
50	O
percent	O
of	O
the	O
cross-sectional	O
area	O
of	O
the	O
total	O
bone	O
.	O


The	O
initial	O
complete	B-OUT
response	I-OUT
rate	I-OUT
(	I-OUT
CR	I-OUT
)	I-OUT
was	O
79	O
%	O
.	O


Implant	B-OUT
failure	I-OUT
with	I-OUT
revision	I-OUT
surgery	I-OUT
was	O
necessary	O
in	O
2	O
patients	O
after	O
an	O
additional	O
adequate	O
trauma	O
.	O


Nasal	O
allergic	O
inflammation	O
enhances	O
bone-marrow	O
eosinophil	O
production	O
,	O
mainly	O
via	O
IL-5	O
,	O
and	O
rhinitis	O
patients	O
have	O
increased	O
airway	O
inflammation	O
during	O
the	O
pollen	O
season	O
.	O


SAR	B-P
patients	I-P
were	I-P
identified	I-P
by	I-P
history	I-P
,	I-P
skin-prick	I-P
test	I-P
and	I-P
specific	I-P
IgE	I-P
.	I-P


RESULTS	O
Nasal	O
allergen	O
challenge	O
led	O
to	O
an	O
increase	O
in	O
sputum	B-OUT
ECP	I-OUT
(	O
pre	O
=	O
60	O
+/-	O
12	O
,	O
post	O
=	O
212	O
+/-	O
63	O
micro	O
g/L	O
,	O
P	O
=	O
0.02	O
vs.	O
placebo	O
)	O
,	O
and	O
sICAM	B-OUT
(	O
4.8	O
+/-	O
2.7	O
to	O
6.5	O
+/-	O
2.9	O
ng/mL	O
,	O
P	O
=	O
0.02	O
vs.	O
placebo	O
)	O
,	O
whereas	O
IL-10	B-OUT
decreased	O
after	O
provocation	O
(	O
44	O
+/-	O
11	O
to	O
29	O
+/-	O
6	O
pg/mL	O
,	O
P	O
=	O
0.06	O
vs.	O
placebo	O
)	O
.	O


Sputum	B-OUT
IL-5	I-OUT
was	O
undetectable	O
in	O
all	O
patients	O
.	O


This	O
study	O
was	O
conducted	O
to	O
determine	O
the	O
efficacy	O
and	O
safety	O
of	O
once-daily	B-I
MMX	I-I
mesalamine	I-I
compared	O
with	O
twice-daily	B-I
delayed-release	I-I
mesalamine	I-I
(	I-I
Asacol	I-I
;	I-I
Warner	I-I
Chilcott	I-I
,	I-I
Dublin	I-I
,	I-I
Ireland	I-I
)	I-I
for	O
maintaining	O
endoscopic	O
remission	O
in	O
patients	O
with	O
UC	O
.	O


METHODS	O
A	O
multicenter	O
,	O
randomized	O
,	O
double-blind	O
,	O
6-month	O
,	O
active-control	O
trial	O
was	O
conducted	O
to	O
assess	O
the	O
non-inferiority	O
of	B-I
once-daily	I-I
MMX	I-I
mesalamine	I-I
2.4	O
g/day	O
compared	O
with	B-I
twice-daily	I-I
delayed-release	I-I
mesalamine	I-I
at	I-I
a	I-I
total	I-I
daily	I-I
dose	I-I
of	I-I
1.6	I-I
g/day	I-I
in	O
patients	O
with	O
UC	O
in	O
endoscopic	O
remission	O
.	O


Initial	O
substance	O
use	O
predicted	O
an	O
increase	O
in	O
the	O
number	B-OUT
of	I-OUT
substance	I-OUT
using	I-OUT
friends	I-OUT
over	I-OUT
time	I-OUT
,	O
indicating	O
an	O
effect	O
of	O
selection	O
,	O
and	O
the	O
initial	O
number	O
of	O
substance	O
using	O
friends	O
predicted	O
substance	B-OUT
use	I-OUT
progression	O
,	O
providing	O
evidence	O
of	O
socialization	O
.	O


Ten	B-P
undernourished	I-P
patients	I-P
receiving	I-P
total	I-P
parenteral	I-P
nutrition	I-P
and	I-P
undergoing	I-P
major	I-P
intestinal	I-P
surgery	I-P
were	O
restarted	O
on	O
intravenous	O
feeds	O
identical	O
to	O
their	O
pre-operative	O
regimens	O
within	O
24	O
h	O
of	O
their	O
operation	O
.	O


Five	O
,	O
chosen	O
at	O
random	O
,	O
received	O
post-operatively	O
1-2	B-I
units	I-I
insulin/kg	I-I
body	I-I
weight/24	I-I
h	I-I
with	I-I
their	I-I
feed	I-I
,	O
while	O
the	O
other	O
five	O
received	B-I
the	I-I
feed	I-I
only	I-I
.	I-I


Changes	O
in	O
dietary	O
stage	O
of	O
change	O
were	O
associated	O
with	O
decreases	B-OUT
in	I-OUT
fat	I-OUT
intake	I-OUT
and	I-OUT
increases	I-OUT
in	I-OUT
fiber	I-OUT
,	I-OUT
fruit	I-OUT
and	I-OUT
vegetable	I-OUT
intake	I-OUT
.	I-OUT


Stage	O
of	O
change	O
appears	O
to	O
be	O
useful	O
for	O
understanding	O
mediators	O
of	O
health	O
promotion	O
intervention	O
effectiveness	O
.	O


All	O
subjects	O
participated	O
in	O
three	O
separate	O
experiments	O
comparing	O
one	O
drug	O
(	O
5	O
mg	O
d	B-I
,	I-I
l-amphetamine	I-I
,	O
5	O
mg	O
diazepam	B-I
or	O
10	O
mg	O
diazepam	B-I
)	I-I
to	O
placebo	B-I
.	I-I


Each	O
experiment	O
consisted	O
of	O
nine	O
sessions	O
:	O
On	O
the	O
first	O
four	O
sessions	O
subjects	O
sampled	O
two	O
color-coded	O
capsules	O
on	O
alternate	O
sessions	O
and	O
on	O
the	O
following	O
five	O
sessions	O
they	O
chose	O
and	O
ingested	O
the	O
capsule	O
they	O
preferred	O
.	O


Subjects	O
in	O
all	O
three	O
groups	O
chose	O
5	O
mg	O
diazepam	B-I
as	O
often	O
as	O
placebo	O
but	O
preferred	O
placebo	B-I
to	O
10	O
mg	O
diazepam	B-I
.	I-I


In	O
contrast	O
,	O
they	O
chose	O
amphetamine	B-I
either	O
as	O
often	O
as	O
or	O
more	O
often	O
than	O
placebo	B-I
.	I-I


(	O
ABSTRACT	O
TRUNCATED	O
AT	O
250	O
WORDS	O
)	O


CONCLUSIONS	O
The	O
higher	O
than	O
manufacturer	O
's	O
cut-off	O
for	O
Kalon	O
ELISA	O
modestly	O
reduced	O
the	O
rate	O
of	O
false-positive	B-OUT
test	I-OUT
results	I-OUT
,	O
but	O
also	O
increased	O
false	B-OUT
negatives	I-OUT
.	I-OUT


22	B-P
patients	I-P
received	I-P
immunotherapy	I-I
10	I-P
days	I-P
before	I-P
surgery	I-P
,	I-P
whereas	I-P
the	I-P
remaining	I-P
21	I-P
control	I-P
patients	I-P
received	I-P
no	I-I
immune	I-I
stimulation	I-I
.	I-I


A	O
decrease	O
was	O
found	O
in	O
the	O
number	B-OUT
of	I-OUT
blood	I-OUT
monocytes	I-OUT
and	I-OUT
the	I-OUT
number	I-OUT
of	I-OUT
monocytes	I-OUT
capable	I-OUT
of	I-OUT
transforming	I-OUT
into	I-OUT
active	I-OUT
macrophages	I-OUT
,	O
indicating	O
a	O
possible	O
sequestration	O
of	O
these	O
cells	O
in	O
the	O
tissues	O
.	O


3	O
.	O


The	O
results	O
suggest	O
that	O
the	O
ketorolac-warfarin	O
interaction	O
is	O
unlikely	O
to	O
be	O
of	O
major	O
clinical	O
significance	O
;	O
however	O
,	O
combined	O
use	O
of	O
ketorolac	B-I
and	O
warfarin	B-I
in	O
patients	O
should	O
be	O
undertaken	O
with	O
due	O
caution	O
and	O
appropriate	O
monitoring	O
.	O


METHODS	O
The	O
randomised	O
controlled	O
study	O
was	O
embedded	O
in	O
the	O
obligatory	O
advanced	O
life	O
support	O
(	O
ALS	O
)	O
course	O
for	O
final-year	B-P
medical	I-P
students	I-P
.	I-P


The	O
well-trained	O
group	O
was	O
measured	O
once	O
in	O
the	O
respiration	O
chamber	O
for	O
36	O
h	O
according	O
to	O
the	O
same	O
protocol	O
.	O


Use	O
of	O
the	O
oral	O
neuraminidase	B-I
inhibitor	I-I
oseltamivir	I-I
in	O
experimental	B-P
human	I-P
influenza	I-P
:	I-P
randomized	O
controlled	O
trials	O
for	O
prevention	O
and	O
treatment	O
.	O


OBJECTIVE	O
To	O
determine	O
the	O
safety	B-OUT
,	I-OUT
tolerability	I-OUT
,	I-OUT
and	I-OUT
antiviral	I-OUT
activity	I-OUT
of	O
oral	O
neuraminidase	O
inhibitor	O
oseltamivir	O
(	O
GS4104/Ro64-0796	O
)	O
for	O
prevention	O
and	O
the	O
early	O
treatment	B-P
of	I-P
influenza	I-P
in	I-P
experimentally	I-P
infected	I-P
humans	I-P
.	I-P


All	O
regimens	O
were	O
continued	O
for	O
5	O
days	O
.	O


RESULTS	O
In	O
the	O
prophylaxis	O
study	O
,	O
8	O
(	O
67	O
%	O
)	O
of	O
12	O
placebo	O
and	O
8	O
(	O
38	O
%	O
)	O
of	O
21	O
oseltamivir	O
recipients	O
became	O
infected	B-OUT
(	O
P	O
=	O
.16	O
;	O
efficacy	O
,	O
61	O
%	O
)	O
;	O
6	O
(	O
50	O
%	O
)	O
placebo	O
compared	O
with	O
0	O
oseltamivir	O
recipients	O
shed	O
virus	O
(	O
P	O
<	O
.001	O
;	O
efficacy	O
,	O
100	O
%	O
)	O
,	O
and	O
33	O
%	O
of	O
placebo	O
but	O
no	O
oseltamivir	O
recipient	O
had	O
infection-related	O
respiratory	O
illness	O
(	O
P	O
<	O
.01	O
)	O
.	O


Among	O
infected	O
subjects	O
in	O
the	O
treatment	O
study	O
(	O
n	O
=	O
69	O
)	O
,	O
the	O
viral	B-OUT
titer	I-OUT
area	I-OUT
under	I-OUT
the	I-OUT
curve	I-OUT
of	O
the	O
combined	O
oseltamivir	O
groups	O
(	O
n	O
=	O
56	O
)	O
was	O
lower	O
(	O
median	O
[	O
interquartile	O
range	O
[	O
IQR	O
]	O
]	O
,	O
80	O
[	O
23-151	O
]	O
vs	O
273	O
[	O
79-306	O
]	O
log10	O
tissue	O
culture-infective	O
doses50	O
per	O
milliliter	O
x	O
hour	O
;	O
P	O
=	O
.02	O
)	O
than	O
the	O
placebo	O
group	O
(	O
n	O
=	O
13	O
)	O
,	O
and	O
the	O
median	B-OUT
(	I-OUT
IQR	I-OUT
)	I-OUT
duration	I-OUT
of	I-OUT
viral	I-OUT
shedding	I-OUT
with	O
therapy	O
was	O
reduced	O
from	O
107	O
(	O
83-131	O
)	O
to	O
58	O
(	O
35-59	O
)	O
hours	O
(	O
P	O
=	O
.003	O
)	O
.	O


Clinical	B-OUT
efficacy	I-OUT
of	O
antazoline	B-I
in	O
rapid	B-OUT
cardioversion	I-OUT
of	I-OUT
paroxysmal	I-OUT
atrial	I-OUT
fibrillation	I-OUT
--	I-OUT
a	I-OUT
protocol	O
of	O
a	O
single	O
center	O
,	O
randomized	O
,	O
double-blind	O
,	O
placebo-controlled	O
study	O
(	O
the	O
AnPAF	O
Study	O
)	O
.	O


Subjects	O
who	O
fulfill	O
selection	O
criteria	O
will	O
be	O
randomly	O
assigned	O
to	O
receive	O
intravenously	O
either	O
antazoline	B-I
or	O
placebo	B-I
in	O
divided	O
doses	O
and	O
observed	O
for	O
1.5	O
hours	O
after	O
conversion	O
to	O
sinus	O
rhythm	O
or	O
after	O
the	O
last	O
i.v	O
.	O


A	O
sample	B-P
size	I-P
of	I-P
80	I-P
patients	I-P
was	I-P
calculated	I-P
based	O
on	O
the	O
following	O
assumptions	O
:	O
two-tailed	O
test	O
,	O
a	O
type	O
I	O
error	O
of	O
0.01	O
,	O
a	O
power	O
of	O
90	O
%	O
,	O
efficacy	B-OUT
of	O
placebo	B-I
5	O
%	O
,	O
efficacy	O
of	O
antazoline	B-I
50	O
%	O
and	O
20	O
%	O
drop-out	O
rate	O
to	O
fulfill	O
the	O
criteria	O
of	O
intention-to-treat	O
analysis	O
.	O


The	O
use	O
of	O
effective	B-I
instructional	I-I
strategies	I-I
in	O
small	O
groups	O
was	O
investigated	O
to	O
determine	O
learning	O
effects	O
for	O
24	B-P
elementary	I-P
age	I-P
students	I-P
with	I-P
autism	I-P
and	I-P
developmental	I-P
disabilities	I-P
.	I-P


Thirty-minute	O
language	O
groups	O
were	O
targeted	O
to	O
teach	O
receptive	O
and	O
expressive	O
skills	O
using	O
pictures	O
and	O
common	O
objects	O
across	O
five	O
categories	O
(	O
e.g.	O
,	O
household	O
items	O
,	O
foods	O
)	O
.	O


Results	O
showed	O
increased	B-OUT
opportunities	I-OUT
to	I-OUT
respond	I-OUT
,	I-OUT
increased	I-OUT
levels	I-OUT
of	I-OUT
responding	I-OUT
and	I-OUT
academic	I-OUT
engagement	I-OUT
,	I-OUT
higher	I-OUT
gains	I-OUT
on	I-OUT
weekly	I-OUT
criterion-referenced	I-OUT
pre-	I-OUT
and	I-OUT
posttests	I-OUT
,	I-OUT
and	I-OUT
decreased	I-OUT
passive	I-OUT
and	I-OUT
inappropriate	I-OUT
student	I-OUT
behavior	I-OUT
during	O
interventions	O
.	O


No	O
randomized	O
studies	O
have	O
been	O
published	O
,	O
however	O
,	O
comparing	O
the	O
outcome	O
of	O
conventional	O
fingerpacking	O
with	O
the	O
outcome	O
of	O
pressurization	O
of	O
the	O
cement	O
prior	O
to	O
cup	O
insertion	O
.	O


Baseline	O
attention	O
was	O
then	O
used	O
to	O
separate	O
low	O
and	O
high	O
attenders	O
.	O


Appropriate	O
technical	O
support	O
and	O
training	O
must	O
be	O
ensured	O
to	O
address	O
equipment	O
maintenance	O
.	O


Side	O
branch	O
occlusion	O
with	O
everolimus-eluting	B-I
and	I-I
paclitaxel-eluting	I-I
stents	I-I
:	I-I
three-year	O
results	O
from	O
the	O
SPIRIT	O
III	O
randomised	O
trial	O
.	O


AIMS	O
AND	O
METHODS	O
The	O
rates	O
of	O
side	O
branch	O
occlusion	O
and	O
subsequent	O
periprocedural	O
MI	O
during	O
everolimus-eluting	B-I
stent	I-I
(	I-I
EES	I-I
)	I-I
and	O
paclitaxel-eluting	B-I
stent	I-I
(	I-I
PES	I-I
)	I-I
placement	O
were	O
examined	O
in	O
the	O
randomised	O
SPIRIT	O
III	O
trial	O
.	O


Patients	B-P
treated	I-P
with	I-P
EES	I-I
rather	I-P
than	I-P
PES	I-I
were	O
less	O
likely	O
to	O
develop	O
side	B-OUT
branch	I-OUT
occlusion	I-OUT
during	O
stent	O
placement	O
,	O
contributing	O
to	O
lower	O
rates	O
of	O
periprocedural	O
MI	O
with	O
EES	B-I
compared	O
to	O
PES	B-I
.	I-I


However	B-OUT
,	I-OUT
recognition	I-OUT
of	I-OUT
symptoms	I-OUT
associated	O
with	O
gynecologic	O
cancers	O
was	O
consistently	O
higher	O
among	O
providers	O
who	O
reported	O
using	O
CDC	O
materials	O
.	O


Gastroscopy	O
was	O
performed	O
48	O
hours	O
before	O
and	O
24	O
hours	O
after	O
the	O
dogs	O
ran	O
300	O
miles	O
.	O


Compared	O
with	O
high-dose	O
famotidine	B-I
,	I-I
omeprazole	I-I
significantly	O
decreased	O
the	O
severity	B-OUT
(	O
0.4	O
versus	O
1.2	O
,	O
P	O
=	O
.0002	O
)	O
and	O
prevalence	B-OUT
(	O
2/23	O
versus	O
7/21	O
,	O
P	O
=	O
.049	O
)	O
of	O
gastric	B-OUT
lesions	I-OUT
.	I-OUT


The	O
percentage	B-OUT
of	I-OUT
heartburn-free	I-OUT
days	I-OUT
was	O
significantly	O
higher	O
with	O
esomeprazole	B-I
40	O
mg	O
(	O
63	O
%	O
,	O
66	O
%	O
)	O
or	O
20	O
mg	O
(	O
63	O
%	O
,	O
68	O
%	O
)	O
than	O
with	O
placebo	B-I
(	O
46	O
%	O
,	O
36	O
%	O
;	O
P	O
<	O
or	O
=	O
0.001	O
)	O
in	O
each	O
of	O
the	O
two	O
studies	O
.	O


The	O
spectrum	B-OUT
and	I-OUT
frequency	I-OUT
of	I-OUT
adverse	I-OUT
events	I-OUT
with	O
esomeprazole	B-I
were	O
similar	O
to	O
those	O
with	O
placebo	B-I
.	I-I


During	O
the	O
study	O
,	O
the	O
horses	O
were	O
monitored	O
for	O
general	O
health	O
,	O
lameness	O
,	O
and	O
swelling	O
around	O
the	O
injection	O
area	O
.	O


Radiographs	O
were	O
taken	O
biweekly	O
to	O
evaluate	O
bony	O
fusion	O
.	O


Slab	O
sections	O
of	O
the	O
PIJ	O
were	O
evaluated	O
grossly	O
and	O
radiographically	O
for	O
bony	O
fusion	O
.	O


Based	B-OUT
on	I-OUT
this	I-OUT
study	I-OUT
,	I-OUT
chemical	I-OUT
arthrodesis	I-OUT
can	I-OUT
not	I-OUT
be	I-OUT
advocated	I-OUT
in	I-OUT
clinical	I-OUT
cases	I-OUT
because	I-OUT
of	I-OUT
the	I-OUT
high	I-OUT
complication	I-OUT
rate	I-OUT
and	I-OUT
lack	I-OUT
of	I-OUT
bony	I-OUT
fusion	I-OUT
.	I-OUT


Economic	O
analysis	O
will	O
determine	O
appropriate	O
measures	B-OUT
of	I-OUT
generic	I-OUT
health	I-OUT
and	I-OUT
resource	I-OUT
use	I-OUT
categories	I-OUT
for	I-OUT
cost-effectiveness	I-OUT
analysis	I-OUT
.	I-OUT


ETHICS	O
AND	O
DISSEMINATION	O
National	O
Health	O
Service	O
Ethics	O
Approval	O
(	O
NHS	O
;	O
ref	O
11/YH/0340	O
)	O
for	O
the	O
trial	O
protocol	O
has	O
been	O
obtained	O
along	O
with	O
NHS	O
Research	O
and	O
Development	O
permission	O
from	O
Leeds	O
and	O
York	O
Partnership	O
NHS	O
Foundation	O
Trust	O
.	O


This	O
kind	O
of	O
lexically	B-I
induced	I-I
perceptual	I-OUT
learning	I-OUT
enables	O
people	B-P
to	O
adjust	O
to	O
the	O
variations	O
in	O
utterances	O
due	O
to	O
talker-specific	O
characteristics	O
,	O
such	O
as	O
individual	O
identity	O
and	O
dialect	O
.	O


Information	O
on	O
demographic	B-OUT
,	I-OUT
indications	I-OUT
for	I-OUT
extraction	I-OUT
,	I-OUT
and	I-OUT
development	I-OUT
of	I-OUT
alveolar	I-OUT
osteitis	I-OUT
were	O
obtained	O
and	O
analyzed	O
.	O


RESULTS	O
The	O
demographic	B-OUT
and	I-OUT
other	I-OUT
baseline	I-OUT
parameters	I-OUT
such	I-OUT
as	I-OUT
indications	I-OUT
for	I-OUT
extractions	I-OUT
were	O
comparable	O
among	O
the	O
study	O
groups	O
(	O
p	O
>	O
0.05	O
)	O
.	O


OUTCOME	O
MEASURES	O
Severity	B-OUT
of	I-OUT
gagging	I-OUT
was	O
rated	O
on	O
a	O
visual-analogue	O
scale	O
.	O


The	O
three	O
scales	O
,	O
Physiological	O
Tension	O
,	O
Physical	O
Assessment	O
,	O
and	O
Cognitive	O
Tension	O
,	O
demonstrated	O
adequate	O
internal	O
consistency	O
with	O
KR20	O
reliability	O
coefficients	O
of	O
.89	O
,	O
.95	O
,	O
and	O
.81	O
,	O
respectively	O
.	O


Recommendations	O
were	O
made	O
for	O
future	O
research	O
on	O
the	O
inventory	O
.	O


Combined	B-I
modality	I-I
therapy	I-I
in	O
advanced	O
Hodgkin	O
's	O
disease	O
:	O
a	B-P
report	I-P
on	I-P
218	I-P
patients	I-P
with	I-P
a	I-P
median	I-P
follow-up	I-P
of	I-P
eight	I-P
years	I-P
.	I-P


Patients	O
in	O
complete	O
remission	O
(	O
CR	O
)	O
received	O
20	O
Gy	O
to	O
the	O
involved	O
field	O
and	O
40	O
Gy	O
to	O
the	O
spleen	O
.	O


The	O
actuarial	B-OUT
survival	I-OUT
curves	I-OUT
were	O
performed	O
according	O
to	O
Kaplan	O
and	O
Meier	O
.	O


However	O
,	O
analysis	O
of	O
total	B-OUT
relapses	I-OUT
revealed	O
that	O
patients	O
treated	O
with	O
ABVD/OPP	B-I
had	O
a	O
significantly	O
higher	O
likelihood	O
of	O
achieving	O
a	O
second	B-OUT
CR	I-OUT
compared	O
to	O
patients	B-P
who	I-P
entered	I-P
the	I-P
ABVD/MOPP	I-I
arm	I-P
.	I-P


The	O
steepness	O
parameter	O
was	O
somewhat	O
higher	O
in	O
the	O
logistic	O
model	O
,	O
also	O
resulting	O
in	O
a	O
slightly	O
lower	O
D	O
(	O
50	O
)	O
.	O


A	O
shortened	O
versus	O
standard	O
matched	O
postpartum	B-I
magnesium	I-I
sulphate	I-I
regimen	I-I
in	O
the	O
treatment	O
of	O
eclampsia	B-P
:	I-P
a	O
randomised	O
controlled	O
trial	O
.	O


Safety	O
and	O
acceptability	O
of	O
cellulose	B-I
sulfate	I-I
as	O
a	O
vaginal	O
microbicide	O
in	O
HIV-infected	B-P
women	I-P
.	I-P


Women	O
and	O
men	O
found	O
the	O
gel	O
highly	O
acceptable	O
.	O


Little	O
is	O
known	O
about	O
the	O
volume	O
of	O
injected	O
intra-articular	O
saline	B-I
solution	I-I
that	O
is	O
needed	O
to	O
effectively	O
rule	O
in	O
or	O
rule	O
out	O
a	O
traumatic	O
arthrotomy	O
of	O
the	O
knee	O
.	O


The	O
purpose	O
of	O
the	O
present	O
study	O
was	O
to	O
determine	O
the	O
appropriate	B-OUT
volume	I-OUT
and	O
needle	B-OUT
location	I-OUT
for	O
the	O
diagnosis	O
of	O
a	O
traumatic	O
knee	O
arthrotomy	O
and	O
to	O
assess	O
the	O
effect	B-OUT
of	O
associated	B-OUT
variables	I-OUT
,	O
including	O
knee	B-OUT
circumference	I-OUT
,	I-OUT
body	I-OUT
mass	I-OUT
index	I-OUT
,	I-OUT
and	I-OUT
sex	I-OUT
.	I-OUT


An	O
inferomedial	B-OUT
injection	I-OUT
location	I-OUT
requires	O
significantly	B-OUT
less	I-OUT
fluid	I-OUT
than	O
a	O
superomedial	B-OUT
injection	I-OUT
location	I-OUT
does	O
for	O
the	O
diagnosis	O
of	O
inferolateral	O
arthrotomies	O
of	O
the	O
knee	O
.	O


The	O
treatment	O
effect	O
of	O
grass	O
AIT	O
during	O
the	O
follow-up	O
year	O
and	O
the	O
previous	O
three	O
treatment	O
years	O
was	O
similar	O
.	O


The	O
effect	O
increased	B-OUT
with	O
increasing	O
grass	O
pollen	O
exposure	O
.	O


The	O
effects	O
of	O
parental	B-I
components	I-I
in	O
a	O
trauma-focused	B-I
cognitive	I-I
behavioral	I-I
based	I-I
therapy	I-I
for	O
children	B-P
exposed	I-P
to	I-P
interparental	I-P
violence	I-P
:	I-P
study	O
protocol	O
for	O
a	O
randomized	O
controlled	O
trial	O
.	O


Participants	B-P
(	I-P
N	I-P
=	I-P
100	I-P
)	I-P
are	I-P
children	I-P
(	I-P
4-12	I-P
years	I-P
)	I-P
,	I-P
and	I-P
their	I-P
parents	I-P
,	I-P
who	I-P
have	I-P
been	I-P
exposed	I-P
to	I-P
interparental	I-P
violence	I-P
.	O


Data	O
are	O
collected	O
three	O
times	O
:	O
before	O
and	O
after	O
the	O
program	O
and	O
six	O
months	O
later	O
.	O


RESULTS	O
The	B-P
age	I-P
of	I-P
the	I-P
patients	I-P
ranged	I-P
from	I-P
32	I-P
to	I-P
98	I-P
years	I-P
(	I-P
mean	I-P
,	I-P
80.8	I-P
years	I-P
)	I-P
,	I-P
and	I-P
65	I-P
patients	I-P
had	I-P
a	I-P
history	I-P
of	I-P
coronary	I-P
artery	I-P
disease	I-P
.	I-P


Majority	B-OUT
of	I-OUT
myocardial	I-OUT
infarctions	I-OUT
were	O
asymptomatic	O
or	O
unrecognized	O
.	O


Interest	O
in	O
equivalence	O
trials	O
has	O
been	O
increasing	O
for	O
many	O
years	O
,	O
though	O
the	O
methodology	O
which	O
has	O
been	O
developed	O
for	O
such	O
trials	O
is	O
mainly	O
for	O
uncensored	O
data	O
.	O


OBJECTIVE	O
This	O
study	O
was	O
designed	O
to	O
compare	O
with	O
placebo	B-I
the	O
dose-response	O
effect	O
of	O
cyclical	O
doses	O
of	O
the	O
C21	B-I
progestogen	I-I
,	I-I
medroxyprogesterone	I-I
acetate	I-I
(	O
MPA	O
)	O
on	O
blood	O
pressure	O
(	O
BP	O
)	O
when	O
administered	O
to	O
normotensive	B-P
postmenopausal	I-P
women	I-P
receiving	I-P
a	I-P
fixed	I-P
mid-range	I-P
daily	I-P
dose	I-P
of	I-P
conjugated	I-I
equine	I-I
oestrogen	I-I
(	I-I
CEE	I-I
)	I-I
.	I-I


The	O
four	O
blinded	O
treatments	O
were	O
MPA	B-I
2.5	I-I
mg	I-I
,	I-I
MPA	I-I
5	I-I
mg	I-I
,	I-I
MPA	I-I
10	I-I
mg	I-I
and	I-I
matching	I-I
placebo	I-I
,	I-I
taken	I-I
for	I-I
the	I-I
last	I-I
14	I-I
days	I-I
of	I-I
each	I-I
28	I-I
day	I-I
treatment	I-I
cycle	I-I
.	I-I


CEE	O
0.625	O
mg	O
was	O
also	O
administered	O
once	O
daily	O
as	O
open	O
labelled	O
tablets	O
to	O
all	O
subjects	O
throughout	O
the	O
study	O
.	O


Atomoxetine	B-I
alone	O
or	O
combined	O
with	O
fluoxetine	B-I
for	O
treating	O
ADHD	B-P
with	I-P
comorbid	I-P
depressive	I-P
or	I-P
anxiety	I-P
symptoms	I-P
.	I-P


Completion	B-OUT
rates	I-OUT
for	O
the	O
two	O
groups	O
were	O
similar	O
,	O
as	O
were	O
discontinuation	B-OUT
rates	I-OUT
for	O
adverse	B-OUT
events	I-OUT
.	I-OUT


Children	O
were	O
randomly	O
assigned	O
to	O
haloperidol-placebo-haloperidol	B-I
or	I-I
placebo-haloperidol-placebo	I-I
treatment	O
sequences	O
.	O


Statistically	O
,	O
haloperidol	B-I
was	O
significantly	O
superior	O
to	O
placebo	B-I
in	O
reducing	O
behavioral	B-OUT
symptoms	I-OUT
.	I-OUT


PURPOSE	O
The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
compare	B-OUT
the	I-OUT
outcome	I-OUT
of	I-OUT
stapled	I-OUT
hemorrhoidopexy	I-OUT
(	I-I
SH	I-I
group	I-I
)	I-I
performed	O
using	O
a	O
circular	O
stapler	O
with	O
that	O
of	O
the	O
Milligan-Morgan	B-I
technique	I-I
(	I-I
MM	I-I
group	I-I
)	I-I
.	I-I


Social	O
robots	O
as	O
embedded	O
reinforcers	O
of	O
social	B-P
behavior	I-P
in	I-P
children	I-P
with	I-P
autism	I-P
.	I-P


Children	O
spoke	O
more	O
in	O
general	O
,	O
and	O
directed	O
more	O
speech	O
to	O
the	O
adult	O
confederate	O
,	O
when	O
the	O
interaction	O
partner	O
was	O
a	O
robot	O
,	O
as	O
compared	O
to	O
a	O
human	O
or	O
computer	O
game	O
interaction	O
partner	O
.	O


This	O
study	O
provides	O
the	O
largest	O
demonstration	O
of	O
social	O
human-robot	O
interaction	O
in	O
children	O
with	O
autism	O
to	O
date	O
.	O


Human	B-I
recombinant	I-I
GM-CSF	I-I
in	O
allogeneic	O
bone	O
marrow	O
transplantation	O
for	O
leukaemia	O
:	O
double-blind	O
placebo	O
controlled	O
trial	O
.	O


The	O
tumor	O
growth	O
pattern	O
according	O
to	O
Jass	O
and	O
the	O
extent	O
of	O
tumor	B-I
budding	I-I
were	O
analyzed	O
in	O
patients	B-P
with	I-P
American	I-P
Joint	I-P
Committee	I-P
on	I-P
Cancer/Union	I-P
for	I-P
International	I-P
Cancer	I-P
Control	I-P
(	I-P
AJCC/UICC	I-P
)	I-P
stage	I-P
II	I-P
disease	I-P
.	I-P


RESULTS	O
Whereas	O
population	B-OUT
and	I-OUT
sperm	I-OUT
characteristics	I-OUT
were	O
comparable	O
in	O
both	O
groups	O
,	O
the	O
number	B-OUT
of	I-OUT
follicles	I-OUT
≥	O
14	O
mm	O
in	O
diameter	O
(	O
P	O
<	O
0.007	O
)	O
and	B-OUT
serum	I-OUT
estradiol	I-OUT
levels	I-OUT
(	O
P	O
<	O
0.001	O
)	O
on	O
the	O
day	O
of	B-I
hCG	I-I
were	O
lower	O
in	O
the	O
Early	O
versus	O
the	O
Late	B-I
hCG	I-I
groups	O
.	O


Early	O
intervention	O
for	O
autism	O
spectrum	O
disorder	O
(	O
ASD	O
)	O
tends	O
to	O
focus	O
on	O
enhancing	O
social-communication	O
skills	O
.	O


How	O
well	O
do	O
blood	B-OUT
folate	I-OUT
concentrations	I-OUT
predict	O
dietary	B-I
folate	I-I
intakes	I-I
in	O
a	O
sample	O
of	O
Canadian	B-P
lactating	I-P
women	I-P
exposed	I-P
to	I-P
high	I-P
levels	I-P
of	I-P
folate	I-P
?	O
An	O
observational	O
study	O
.	O


Folic	O
acid	O
fortification	O
has	O
produced	O
a	O
dramatic	O
increase	O
in	O
blood	O
folate	O
concentrations	O
among	O
reproductive	O
age	O
women	O
,	O
and	O
a	O
reduction	O
in	O
neural	O
tube	O
defect	O
(	O
NTD	O
)	O
-affected	O
pregnancies	O
.	O


METHODS	O
The	O
relationship	O
between	O
blood	B-OUT
folate	I-OUT
concentrations	I-OUT
and	O
dietary	B-OUT
folate	I-OUT
intakes	I-OUT
,	O
determined	O
by	O
weighed	B-I
food	I-I
records	I-I
,	O
were	O
assessed	O
in	O
a	O
sample	B-P
of	I-P
predominantly	I-P
university-educated	I-P
lactating	I-P
women	I-P
(	I-P
32	I-P
+/-	I-P
4	I-P
yr	I-P
)	I-P
at	I-P
4-	I-P
(	I-P
n	I-P
=	I-P
53	I-P
)	I-P
and	I-P
16-wk	I-P
postpartum	I-P
(	I-P
n	I-P
=	I-P
55	I-P
)	I-P
.	I-P


The	O
mean	O
RBC	B-OUT
folate	I-OUT
concentration	I-OUT
of	O
women	O
consuming	O
151-410	O
microg/d	O
of	O
synthetic	O
folate	O
(	O
2nd	O
quartile	O
of	O
intake	O
)	O
did	O
not	O
differ	O
from	O
that	O
of	O
women	O
consuming	O
>	O
410	O
microg/d	O
(	O
3rd	O
and	O
4th	O
quartile	O
)	O
.	O


Until	O
data	O
from	O
such	O
studies	O
are	O
available	O
,	O
women	O
planning	O
a	O
pregnancy	O
should	O
continue	O
to	O
consume	O
a	O
daily	O
folic	B-I
acid	I-I
supplement	I-I
of	O
400	O
microg	O
.	O


A	O
randomized	O
clinical	O
trial	O
.	O


The	O
vertical	B-OUT
clinical	I-OUT
attachment	I-OUT
level	I-OUT
(	I-OUT
CAL-v	I-OUT
)	I-OUT
gain	I-OUT
was	O
statistically	O
significant	O
only	O
for	O
the	O
OFD-group	O
.	O


This	O
study	O
enrolled	O
patients	B-P
with	I-P
symptomatic	I-P
,	I-P
smoking-related	I-P
COPD	I-P
,	O
randomized	O
to	O
receive	O
sibenadet	B-I
or	I-I
placebo	I-I
for	O
a	O
52-week	O
treatment	O
period	O
.	O


inpatient	B-OUT
hospital	I-OUT
care	I-OUT
)	I-OUT
.	O


Regression	O
analyses	O
suggested	O
that	O
targeting	B-I
different	I-I
beliefs	I-I
for	O
those	O
donors	O
who	O
had	O
and	O
had	O
not	O
reacted	O
would	O
yield	O
most	O
benefit	O
in	O
bolstering	O
donors	O
'	O
intentions	O
to	O
remain	O
donating	O
.	O


Fifty-six	O
patients	O
received	O
an	O
oral	B-I
dosage	I-I
of	I-I
50	I-I
mg/kg	I-I
of	I-I
aminocaproic	I-I
acid	I-I
every	O
4	O
hours	O
for	O
5	O
days	O
,	O
up	O
to	O
a	O
maximum	O
of	O
30	O
g	O
daily	O
,	O
and	O
56	O
patients	O
received	O
an	O
oral	B-I
dosage	I-I
of	I-I
40	I-I
mg	I-I
of	I-I
prednisone	I-I
daily	I-I
(	O
adjusted	O
for	O
weight	O
)	O
in	O
two	O
divided	O
doses	O
.	O


BACKGROUND	O
Hyperbaric	B-I
oxygen	I-I
(	I-I
HBO	I-I
)	I-I
attenuates	O
lipopolysaccharide	O
(	O
LPS	O
)	O
-induced	O
acute	B-P
lung	I-P
injury	I-P
.	I-P


All	O
rats	B-P
were	O
maintained	O
for	O
6	O
h	O
and	O
then	O
sacrificed	O
with	O
a	O
high-dose	B-I
pentobarbital	I-I
injection	I-I
.	I-I


RESULTS	O
Histological	B-OUT
analysis	I-OUT
,	I-OUT
PMNs/alveoli	I-OUT
ratio	I-OUT
,	I-OUT
and	I-OUT
wet/dry	I-OUT
weight	I-OUT
ratio	I-OUT
measurements	I-OUT
demonstrated	O
that	O
LPS	O
caused	O
significant	O
lung	O
injury	O
and	O
HBO	O
and/or	O
hemin	O
significantly	O
attenuated	O
this	O
LPS-induced	O
lung	O
injury	O
.	O


Increased	O
pulmonary	O
iNOS	B-OUT
expression	I-OUT
and	I-OUT
NO	I-OUT
production	I-OUT
were	O
associated	O
with	O
lung	O
injury	O
.	O


The	O
prevalence	O
of	O
minor	B-OUT
RAS	I-OUT
in	I-OUT
the	I-OUT
experimental	I-OUT
phase	I-OUT
decreased	I-OUT
significantly	I-OUT
in	O
both	O
groups	O
compared	O
with	O
the	O
run-in	O
phase	O
to	O
a	O
similar	O
extent	O
,	O
without	O
intergroup	O
differences	O
.	O


There	O
is	O
evidence	O
to	O
suggest	O
accelerated	B-P
bone	I-OUT
loss	I-OUT
following	I-P
estrogen	I-P
cessation	I-P
.	I-P


Bone	B-OUT
turnover	I-OUT
markers	I-OUT
and	I-OUT
bone	I-OUT
density	I-OUT
(	I-OUT
BMD	I-OUT
)	I-OUT
were	O
measured	O
throughout	O
the	O
study	O
.	O


Training	B-I
groups	I-I
participated	I-I
in	I-I
a	I-I
9	I-I
wk	I-I
program	I-I
,	I-I
3	I-I
d.wk-1	I-I
.	I-I


Subjects	B-I
assigned	I-I
to	I-I
HCT	I-I
exercised	I-I
on	I-I
a	I-I
9	I-I
station	I-I
circuit	I-I
,	I-I
completing	I-I
3	I-I
circuits.d-1	I-I
.	I-I


For	O
all	O
three	O
training	O
groups	O
,	O
the	O
increase	O
in	O
VO2max	B-OUT
was	O
associated	O
with	O
increases	O
in	O
SVmax	B-OUT
and	I-OUT
COmax	I-OUT
(	O
P	O
less	O
than	O
0.05	O
for	O
both	O
)	O
.	O


Effects	O
of	O
skin-to-skin	B-I
contact	I-I
on	O
autonomic	B-OUT
pain	I-OUT
responses	I-OUT
in	O
preterm	B-P
infants	I-P
.	I-P


Beat-to-beat	O
heart	O
rate	O
(	O
HR	O
)	O
and	O
spectral	O
power	O
analysis	O
of	O
heart	O
rate	O
variability	O
,	O
low	O
frequency	O
power	O
(	O
LF	O
)	O
,	O
high	O
frequency	O
power	O
(	O
HF	O
)	O
,	O
and	O
LF/HF	O
ratio	O
were	O
measured	O
in	O
26	B-P
infants	I-P
.	I-P


During	O
Heel	O
Stick	O
,	O
LF	B-OUT
and	O
HF	B-OUT
were	O
significantly	O
higher	O
in	O
IC	O
than	O
in	O
KC30	B-I
.	I-I


Disc	B-I
coablation	I-I
and	I-I
epidural	I-I
injection	I-I
of	I-I
steroids	I-I
:	I-I
a	O
comparison	O
of	O
strategies	O
in	O
the	O
treatment	O
of	O
mechanical	B-P
spinal	I-P
discogenic	I-P
pain	I-P
.	I-P


Comparison	O
of	O
the	O
data	O
indicated	O
an	O
improvement	O
of	O
average	B-OUT
VAS	I-OUT
when	O
relaxed	O
for	O
both	O
groups	O
(	O
p	O
<	O
0.01	O
)	O
,	O
while	O
after	O
slight-moderate	O
strain	O
,	O
this	O
value	O
was	O
significant	O
only	O
after	O
coablation	B-I
(	O
p	O
<	O
0.001	O
)	O
.	O


[	O
Effect	O
of	O
acupuncture	B-I
on	O
T-lymphocyte	B-OUT
and	I-OUT
its	I-OUT
subsets	I-OUT
from	O
the	O
peripheral	O
blood	O
of	O
patients	B-P
with	I-P
malignant	I-P
neoplasm	I-P
]	I-P
.	O


Effect	O
of	O
acupuncture	B-I
on	O
the	O
T-lymphocyte	B-OUT
and	O
its	O
subsets	B-OUT
from	O
the	O
peripheral	O
blood	O
of	O
patients	B-P
with	I-P
malignant	I-P
neoplasm	I-P
has	O
been	O
researched	O
in	O
this	O
study	O
.	O


48	B-P
healthy	I-P
adults	I-P
were	I-P
also	I-P
studied	I-P
as	I-P
normal	I-P
control	I-P
group	I-P
.	I-P


The	O
results	O
showed	O
that	O
the	O
percentages	B-OUT
of	I-OUT
OKT3+	I-OUT
,	I-OUT
OKT4+	I-OUT
,	I-OUT
OKT8+	I-OUT
cells	I-OUT
in	I-OUT
the	I-OUT
peripheral	I-OUT
blood	I-OUT
of	O
the	O
51	O
patients	O
were	O
lower	O
than	O
those	O
of	O
the	O
normal	O
adults	O
respectively	O
.	O


Spoken	O
communication	O
was	O
assessed	O
in	O
a	O
rigorous	O
test	O
of	O
generalization	O
at	O
pretreatment	O
,	O
posttreatment	O
,	O
and	O
6-month	O
follow-up	O
periods	O
.	O


This	O
prospective	O
,	O
randomized	O
,	O
double-blind	O
,	O
placebo-controlled	O
study	O
evaluated	O
the	O
effect	O
of	O
dexmedetomidine	B-I
(	I-I
DEX	I-I
)	I-I
for	O
reducing	O
the	O
incidence	O
and	O
severity	O
of	O
propofol	O
injection	O
pain	O
.	O


Patients	O
in	O
groups	O
II	O
,	O
III	O
,	O
and	O
IV	O
received	O
DEX	B-I
0.25	I-I
µg/kg	I-I
,	I-I
0.5	I-I
µg/kg	I-I
,	I-I
or	I-I
1.0	I-I
µg/kg	I-I
,	I-I
respectively	I-I
,	I-I
mixed	I-I
with	I-I
isotonic	I-I
saline	I-I
immediately	I-I
before	I-I
propofol	I-I
injection	I-I
.	O


Propofol	B-I
consisted	I-I
of	I-I
1	I-I
%	I-I
long-chain	I-I
triglyceride	I-I
propofol	I-I
(	I-I
2.5	I-I
mg/kg	I-I
)	I-I
injected	I-I
at	I-I
1	I-I
mL/s	I-I
.	O


RESULTS	O
Median	O
propofol	B-OUT
injection	I-OUT
pain	I-OUT
score	I-OUT
was	O
0.00	O
(	O
IQR	O
0.00-3.00	O
)	O
in	O
patients	O
who	O
received	O
1.0	O
µg/kg	O
DEX	O
5	O
min	O
before	O
the	O
propofol	O
injection	O
(	O
group	O
VII	O
)	O
,	O
and	O
only	O
1	O
patient	O
(	O
of	O
30	O
)	O
in	O
this	O
group	O
received	O
a	O
pain	O
score	O
>	O
2	O
.	O


A	O
pilot	O
study	O
of	O
a	O
low-tilt	O
biphasic	O
waveform	O
for	O
transvenous	O
cardioversion	O
of	O
atrial	B-P
fibrillation	I-P
:	I-P
improved	O
efficacy	B-OUT
compared	O
with	O
conventional	O
capacitor-based	O
waveforms	O
in	O
patients	O
.	O


Defibrillation	O
electrodes	O
were	O
positioned	O
in	O
the	O
right	O
atrial	O
appendage	O
and	O
distal	O
coronary	O
sinus	O
.	O


RESULTS	O
The	O
low-tilt	B-I
waveform	I-I
produced	O
successful	O
termination	B-OUT
of	I-OUT
persistent	I-OUT
AF	I-OUT
at	O
a	O
mean	O
voltage	O
of	O
223	O
V	O
(	O
8.2	O
J	O
)	O
versus	O
270	O
V	O
(	O
6.7	O
J	O
)	O
with	O
the	O
conventional	B-I
waveform	I-I
(	O
P	O
=	O
0.002	O
for	O
voltage	O
,	O
P	O
=	O
ns	O
for	O
energy	O
)	O
.	O


In	O
patients	B-P
with	I-P
induced	I-P
AF	I-P
the	O
mean	B-OUT
voltage	I-OUT
for	O
the	O
low-tilt	O
waveform	O
was	O
91V	O
(	O
1.6	O
J	O
)	O
and	O
for	O
the	O
conventional	O
waveform	O
was	O
158	O
V	O
(	O
2.0	O
J	O
)	O
(	O
P	O
=	O
0.005	O
for	O
voltage	O
,	O
P	O
=	O
ns	O
for	O
energy	O
)	O
.	O


In	O
our	O
opinion	O
,	O
PKRP	B-I
makes	O
a	O
promising	O
treatment	O
for	O
BPH	O
with	O
its	O
advantages	O
,	O
such	O
as	O
early	O
removal	O
of	O
postoperative	O
urethral	O
catheter	O
,	O
a	O
shorter	O
hospital	O
stay	O
and	O
the	O
absence	O
of	O
TUR	O
syndrome	O
risk	O
.	O


The	O
hydration	O
status	O
was	O
assessed	O
with	O
USG	O
and	O
body	O
mass	O
measures	O
and	O
urine	O
volume	O
collections	O
.	O


Pretrial	B-OUT
USG	I-OUT
was	O
1.022	O
±	O
0.001	O
in	O
the	O
HYPO	O
trial	O
and	O
decreased	O
<	O
1.020	O
by	O
45	O
minutes	O
(	O
1.013	O
±	O
0.003	O
)	O
.	O


This	O
study	O
demonstrated	B-P
that	I-P
mildly	I-P
HYPO	I-P
subjects	O
could	O
reach	O
euhydration	O
within	O
45	O
minutes	O
of	O
the	O
ingestion	O
of	O
600	B-I
ml	O
of	O
W	O
or	O
a	O
combination	O
of	O
salt	B-I
and	O
CES	O
solutions	O
.	O


Following	O
this	O
practice	O
will	O
minimize	O
the	O
incidence	O
of	O
starting	O
a	O
practice	O
or	O
competition	O
hypohydrated	O
.	O


OBJECTIVE	O
To	O
assess	O
efficacy	O
and	O
safety	O
of	O
once-daily	O
8	O
or	O
12	O
mg	O
perampanel	B-I
,	O
a	O
noncompetitive	O
α-amino-3-hydroxy-5-methyl-4-isoxazole-propionic	O
acid	O
(	O
AMPA	O
)	O
receptor	O
antagonist	O
,	O
when	O
added	O
to	O
concomitant	O
antiepileptic	O
drugs	O
(	O
AEDs	O
)	O
in	O
the	O
treatment	O
of	O
drug-resistant	O
partial-onset	O
seizures	O
.	O
